Effects of Drugs On Clinical Laboratory Tests DS Young

Effects of
Drugs on
Clinical Laboratory Tests
D. S. Young, D. W. Thomas, R. B. Friedman and L. C. Pestaner
This compilation of effects of drugs on laboratory action of drugs in humans. We should emphasize
tests has been developed from a computer-file of that we believe that the present list should be used
information that has been used to assist the as a guide for the interpretation of results. It
interpretation of abnormal test results in the should not be thought of as providing the correct
laboratories of the Clinical Pathology Department explanation for any abnormal data in any given
of the Clinical Center, National Institutes of situation. fh disease for which a drug was
Health. The computerized list contains entries of administered should al*ays be considered initially
both the normal physiological response to thera- as a source of abnormal results. Underlying disease
peutic drugs, as well as the effects of overdoses. processes and the concomitant administration of
We have not attempted a complete differentiation other drugs may have considerable influence on
between the two types of effects, nor have we the apparent action of one drug, so that the
separated rare effects from those that are common. reported effects of the drug may not occur or may
While most physicians are aware of the major be modified.
physiological or pharmacological effects of thera- Our file of effects of drugs on laboratory tests
peutic drugs on laboratory tests, many do not known as CLAUDE (computer list of anticipated and
know the minor effects of even some of the most unintended drug effects) is being expanded con-
widely used drugs. Few patient-care physicians tinually. This publication lists the first 9000
are aware of the possible influence of dngs entries into the system. rfhe entries are not
administered to patients on the analytical pro- necessarily the most important but represent the
cedures used to measure constituents of body results of our initial search of the literature.
fluids in the clinical laboratory. In the present Already many additional effects have been docu-
publication we include many common and less mented and these will be included in a later
common effects of drugs on laboratory tests that publication. We have expanded upon our original
have been reported in the literature. As source intention of including the effects of drugs only to
material we have used several recent books that include other factors that should be considered for
have been concerned with drug interactions as proper understanding of the significance of labora-
well as many publications on the clinical pharma- tory data. For example, we cite the modifying
cology and pathology of individual drugs. In most influences of certain foods, the menstrual cycle and
cases the effects have been observed in humans menopause in women, and the effects of activity
but we have included some findings from animal and change of posture in subjects from whom
studies when these have appeared to have some blood is obtained. These factors are often over-
relevance to the understanding of the mode of looked in the interpretation of laboratory data, yet
can alter the results of several tests to such an
extent that erroneous conclusions may be drawn
From the Clinical Pathology Department, Clinical Center,
about the state of health of an individual. It
National Institutes of Health, Bethesda, Maryland 20014. should be noted that several chemical compounds
CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972 1041

are listed as if they were drugs when these are not file consists of three lines, one each for the authors,
normally ingested by patients. Some of these corn- the title of the article, and the journal citation.
pounds are used as laboratory reagents and their It should be noted that entries have been made in
interfering effects arise from contamination of some cases to simplify the search procedure
glassware or an inappropriate use in the laboratory. rather than because we believe that a particular
The structure of the computer-file has been fluid, for example, should be used for analysis.
described in some detail (Young, D.S., Friedman, Thus, most hormone analyses in blood are listed
R.B., Thomas, D.W., in preparation) and will not under “P” for plasma. Glucose and potassium are
be discussed here. The two most common mdi- listed under “5” for serum when we prefer to
cations for using the computer-file are to determine make the analyses in plasma, and for glucose with
all the actions of one drug and to identify all the an added antiglycolytic agent.
drugs that may modify a particular laboratory In everyday use we differentiate interferences
test. To facilitate these applications with the affecting the methods in use in our laboratory
present publication we have prepared it under five from those in use elsewhere. In this publication we
major headings. do not subdivide methodological effects. As we
began to develop the file we felt it justifiable to
Generic/proprietary name directory of drugs
Abbreviation and short-form directory include “no effect” entries when these were
Alphabetic listing of effects by generic names of drugs reported. It was apparent that, because of the
Alphabetic listing of effects by laboratory test large number of effects of most drugs, it would be
Reference file
of value to eliminate drugs as possible causes of
The generic name directory lists all the headings changes of laboratory data. We have therefore
under which drug effects are entered into the corn- included appropriate entries to indicate that
puter-file. When the file is used in conjunction certain drugs have no pharmacological effects on
with the computer it is possible to make a search certain measurements, or on the tests when
on the basis of a proprietary name. If a proprietary particular analytical methods are used.
name is typed into the system the computer In most cases we have only entered effects as
responds by printing the “header” line that described by the cited authors, but in some cases
includes generic name and brand names. It is then we have interpreted their data to include the
possible to make a search using the correct generic modifications that could have been anticipated
name. had other tests been performed.
Because the file structure precludes the use of With the entry of so much data into the corn-
descriptions of unlimited length for the various puter-file it is inevitable that some typographical
entries, e.g., type of body-fluid, mechanism of and transcription errors have been made. We
effect, and occasionally English-language explana- would be grateful if readers noticing such errors
tion of the reported effect, we have had to abbre- could send their comments to us. We welcome
viate some of the entries. The abbreviations used suggestions as to how this compilation could be
throughout the text are summarized in the short- improved to provi4e the maximum amount of
form directory. Th two listings of drug effects information for laboratory scientists and physi-
are similar in structure. The generic name of the cians. Please address all correspondence to
drug (or abbreviation) is followed by a letter
Dr. D. S. Young
indicating the type of body fluid. This is closely Bldg. 10, Rm. 4N-309
followed by the test-name and the designation of National Institutes of Health
“mc,” “Dec,” or “Z” to indicate whether the Bethesda, Md. 20014
value is increased, decreased, or unaffected by the
drug. The letters V and M are used to indicate No reprints of this article will be available from
whether the listed effect is of physiological the authors. Copies may be purchased at a cost
(pharmacological) or analytical origin. The En- of $4 each from
glish-language description of the effect is followed
Executive Director, AACC
by a number indicating the number of the reference P.O. Box 15053
in the reference file. Each entry in the reference Winston-Salem, N. C. 27103
1042 CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

USE OF THE DIRECTORIES
The effects of drugs on laboratory tests are con- pound, etc., listed in the first column. The fourth
tamed in two listings. The first is sorted alpha- column contains an entry of M” or ‘V.
‘ ‘ If ‘M,”‘ “ ‘
betically by generic drug name. The second con- the effect was probably due to the analytical
tains the same information but is sorted alpha- procedure. If “V,” the effect occurred in the
betically by laboratory test. The format is the patient because of the pharmacological action of
same for both. the drug. The fifth colunm is an explanation of the
The first entry is the drug, chemical, or modi- effect. The final column lists a reference number.
fying condition. The second column consists of The reference directory includes-under the same
abbreviated entries for the fluid analyzed. The number-the authors, title, and journal citation of
single letter entry is explained in the abbreviation an article in which this effect was mentioned. The
and short-form directory. The third column con- abbreyiation and short-form directory lists all
tains the test made and whether the result was the nonconventional abbreviations used through-
increased, decreased, or unaffected by the corn- out this publication.
INDEX
1041 Introduction and Use of the Directories
1043 Acknowledgments
1044 Generic/Proprietary Drug Name Directory
1060 Abbreviation and Short-Form Directory
1063 Alphabetic Listing by Drug Name
1 166 Alphabetic Listing by Laboratory Test
1269 References
Acknowledgments
Many people have contributed to this publica- the data contributed by them have not yet been
tion by suggestions, verification of data, entry of incorporated into the published list). We have
information into the computer files, and assistance received assistance from Eli Lilly and Company,
in programming. In particular we would like to Knoll Pharmaceutical Company, J. B. Roerig
thank Dr. H. R. Gralnick, Dr. N. Gochman, (Pfizer), Abbott Laboratories, Armour Pharma-
Dr. A. E. Horvath, and Dr. D. P. Tschudy for ceutical Company, Riker Laboratories, Winthrop
reviewing data. D. F. L. Mitchell and Dr. D. C. Laboratories, Merck Sharpe and Dohme, G. D.
Cannon also gave assistance in obtaining back- Searle, Lakeside Laboratories, E. IL Squibb &
ground information. Mrs. Betty Smith, Mrs. Sons, Wyeth Laboratories, Smith Kline and
Carolyn Grubbs, and Mr. Douglas Ireland entered French, Upjohn Company, Syntex, Bristol Labora-
much of the data and Mr. J. F. Pestaner provided tories, Ciba-Geigy, U.S.V. Pharmaceutical Corp.,
valuable advice in programming. Miss Silja Meret Wallace Pharmaceuticals, and Schering Corp.
assisted with the proofreading. We are also grateful to Dr. J. F. Gallelli and the
We would like to acknowledge the cooperation of staff of the Clinical Center Pharmacy for their
several pharmaceutical houses (although much of help and encouragement.

ACETANINOPUEN*(XCDRIN) (BRONO SELTZER) (RONILAR) (TENPRA) (TYLENOL) (VANQUISH) (FEBROLIN) (PARAFON) (NYQUIL) (APANIDE)
ACETANILID*
ACETATES*(SODIUN ACETATE) (AZINONIUM ACETATE)
ACETAZOLAMIDE* (DIAMOX) (ACETAZOLAMIDE SODIUM) (DIAMOX PARNTERAL) (DIANOX SODIUN)
ACETOACETATE* (ACETOACETIC ACID)
AC!TOHEXANIDE* (DYNELOR)
ACETOHYDROXANIC AC*(ACETOHYDROXANIC ACID) (AHA)
CETONE*
ACETOPHENAZINE*(ACE1OPHBNAZINF NALEATE) (TINDAL)
ACETDPHENETIDIN* (PHENACETIN) (CODZMPERIL) (EDRISAL) (ENPIRIN) (FIORINAL) (PHENAPHEN) (SONA) (TETREX-APC)
ACETOPHENONE* (DROXONE)
ACETRIZOATE* (ACETRIZOATE SODIUM WITH POLYVINYLPYHROLIDONE) (SALPIX) (UROKON) (IODOPAQUE) (TRIIODTRAST)
ACETYLAMINOPHENOL* (N-ACETYL-P-ANINOPHENOL)
ACETYLGLUCOSAMINE* (N -ACETYLGLUCOSANINE)
ACETYLPENIC ILLA MI NE*
ACETYLPHENYLH!DRAZ* (ACETYLPHENYLHYDRAZIN)
ACETYLSALICYLIC AC* (ACETYLSALICYLIC ACID) (ASPIRIN) (BUFFERIN) (SALICYLATE) (ENPIPIN) (SALICYLIC ACID) (SALICYLAMIDE)
ACETYLSALICYLIC AC*(MEASURIN)
ACETYLSULFANILAMIDE* (52 ACETYLSULFANILANIDE)
ACETYLTRY PTOPHA N*
ACIDS*(HYDROCHLORIC ACID) (SULFUEIC ACID) (NITRIC ACID) (ACETIC ACID) (PHOSPHORIC ACID) (OXALIC ACID*) (BORIC ACID*)
ACRIFLAVINE*
ACTINOMYCIN (CACTINOMYCIN) (DACTINOMYCIN*)
AD IPIODONE*
AJMALI NE* (GILUBYTNAL)
ALANINE*
ALBUNIN,HUNAN*(ALBUMIN, NORMAL SERUM) (ALBUMIN) (ALBUSPAN) (ALBUMINATE) (ALBUNISOL) (PROSERUM)
ALCOHOLS (ETHANOL*) (METHANOL*) (ISOPROPANOL*) (BENZYL ALCOHOL*) (AMYL ALCOHOL*) (PROPYL ALCOHOL) (BUTYL ALCOHOL)
AL DOS T E ROME *
ALDRIN*
ALKALINE ANTACIDS*(DUCON) (ALUMINUM HYDROXIDE) (MAGNESIUM HYDROXIDE) (CALCIUM CARBONATE) (DICARBOSIL)
ALKALINE URINE*
ALKYLA MINES (BROMPHENIRA NINE*) (CHLORPHENIEANINE*) (DEXBROMPHENIRAMINE) (DEXCHLORPIIENIRAMINE) (DI NETANE) (DISOMER)
ALKYLAMINES (DIMETHINDENE) (PHENIRAMINE) (TPIPROLIDINE) (POLARAMINE) (FORHISTAL) (TRIMETON) (ACTIDIL)
ALLANTOIN*
ALLOPURINOL* (ZYLOPRIN) (APURIN)
ALOIN*
ALPHA-ADRENERGIC AGENTS (GUANOXAN*) (GUANOCLOR*)
ALPHA-ADPENERGIC AGENTS (PHENTOLANINE*) (TOLAZOLINE*) (PHENOXYBENZAMINE*) (AZAPETINF.) (PIPEROXAN) (DIBOZANE)
ALUMINUM NICOTINATE* (NICALEX)
ALUMINUM SALTS* (ALUMINUM NICOTINATE*) (ALUMINUM HYDROXIDE) (ALUMINUM ACETATE)
AMANTADINE* (AMANTADINE HYDROCHLORIDE) (SYMNETREL)
ANBULATION*(MUSCULAB EXERCISE*)
ANEBICIDES (CARBARSONE*) (IODOCHLORHYDROXYQUIN*) (DIIODOHYDEOXYQUIN*) (TETPACYCLINE*) (ERYTHROMYCIN*)
AMEBICIDES (FURAPROMIDIUN*)
AMEBICIDES (PARONOMYCIN*) (EMETINE) (CHLOROQUINE*) (PECAC) (CHINIOFON*) (DILOXANIDE) (DEHYDROENETINE*)
ANILORIDE* (AMILORIDE HYDROCHLORIDE) (MK-870) (AMIPPAMIDINE) (IDANOE)
ANIN ACIDS* (ALANINE*) (GLUTATHIONE) (ASPARAGINE*) (METHIONINE*) (VALINE*) (TYROSINE*) (PROTEIN HYDROLYSATE)
AMINO ACIDS* (ERGOTHIONI NE*) (SEPINE) (HISTIDINE*) (FIBP.IN HYDROLYSATZ*) (CYSTEI NE*) (LACOTEIN)
ANI NO ACIDS* (LEUCINE*) (TRY? TOPHAN*) (PHENYLALANI NE*) (LYSI NE*) (GLYCINE*) (GLUTANINE*) (GLUTAMIC ACID*) (HISTA NINE*)
ANINOBENZOIC ACID* (P-AMINOBENZOIC ACID) (PARA-AMINOBENZOIC ACID) (PABA)
AMINOCAPROIC AC1D*(AMICAR) (EACA) (EPSILON-AMINOCAPPOIC ACID)
AM INOGLUTETHI MIDE*
ANINOSLYCOSIDES (STPEPTOMYCIN*) (GENTAMICIN*) (KANAMYCIN*) (NEOMYCIN*) (PARO?IOMYCIN*)
AMINOHIPPURIC ACID*(P-AMINOHIPPURIC ACID) (PARA-AMINOHIPPURIC ACID) (PAH) (AMINOHIPPURATE SODIUM)
AMINOMETHYLCYCLOHEX*(ANINONETHYLCYCLOHEXANE)
AMINOPHEN AZONE*
AMINOPHENOL* (P-A MI NOPHENOL)
AMINOPHYLLINE*(AMINODUR) (DAINITE) (HYDRYLLIN) (LIXAMINOL) (MUDRANE) (QUINAMM) (SONOPHYLLIN)
AMINOPYRINE*(BICAMPHORATE) (PYRANIDON) (AMIDOPYRINE)
AMINOSALICYLIC AC* (ANINOSALICYLIC ACID) (AMINOSALICYLATE) (PAMISYL) (REZIPAS) (PASCA) (PASKALIUN) (PASNA)
A N INOT H IA ZO LE *
AMITRIPTYLINE*(AMITRIPTYLINE HYDROCHLORIDE) (ELAVIL) (ETRAFON) (TRIAVIL)
AMMONIA*
AMNONIUM SALTS*(AMMONIUM CHLORIDE*) (AMCHLOB) (ANMONIUM OXALATE*) (AMMONIUM NITRATE*) (ANNONIUM BROMIDE)
ANMONIUM SALTS*(AMNONItJM IONS*) (ANMONIA*)
AMOBARBITAL* (ANYTAL) (TUINAL) (AMOBARBITAL SODIUM) (ANYTAL SODIUM)
AMODIAQUINE* (ANODIAQUINE HYDROCHLORIDE) (CANOQUIN HYDROCHLORIDE) (MIAQUIN)
AMPHENONE*(AMPHENONE B)
AMPHETAMINES*(AMPHETAMINE PHOSPHATE) (AMPHETAMINE SULFATE) (BENZEDRINE) (METHANPHETAMINE*) (DEXTROANPHTAMINE*)
AMPHETAMINES* (BENZPHETAMINE)
AMPHOTERICIN B* (FUNGIZONE) (NYSTECLIN)
AMPICILLIN* (A MCILL) (OMNI PEN) (PENDRITIN) (POLYCILLIN) (PRINCIPEN) (SUPEN) (ALPEN) (TOTACILLI N) (ACILLINE)
AMYGDAL IN S*
AMYL ALCOHOL*
AMYL NITRITE*
ANABOLIC STEROIDS*(NORETHANDROLONE*) (FLUOXYMESTERONE*) (NETHANDROSTENOLONE*) (OXYMETHOLONE*) (STANOZOLOL*) (ANDROGENS*)
ANABOLIC STEROIDS* (OXANDROLONE*) (ETHYLESTRENOL*) (METHYLTESTOSTEBONE*) (TESTOSTERONE*) (N ANDROLON E*) (N ETHANDRIOL)
AN ALEPTICS (AMPHETAIINES*) (CAFFEINE*) (DEXTROA MPHETAMINE*) (DOXAPRAM*) (ETHAMIVAN*) (METHA MPHETAMI NE*) (METHYLPHENIDATE*)
ANALEPTICS (LOBELINE) (PRETHCAMIDE)
ANALEPTICS (NIKETHAMIDE*) (PENTYLENETETRAZOL*) (PICROTOXIN) (AMINOPHYLLINE*) (AMIPHENAZOLE) (BEMEGRIDE)
ANALGESICS* (ACETAMINOPHEN*) (ACETOPHENETIDIN*) (ANTIPYRINE*) (ANINOPYRINE*) (DIPYRONE*) (MEFENAMIC ACID*)
ANALGESICS* (CODEINE*) (ETHOHEPTAZINE) (PROPOXYPHENE*) (ACETYLSALICYLIC ACID*) (SALICYLAMIDE) (ACETANILID*)
ANCROD*(ARVIN)
ANDPOGENS*(ANDROID) (FORMATBIX) (GLUKOR) (ORA-TESTRYL) (TESTOSTERONE*) (ANABOLIC STEROIDS*) (ANDROSTERONE*)
ANDROGENS* (DROMOSTA NOLONE*) (FLUOXYMESTERONE*) (TESTOLACTONE*) (METHYLTESTOS TERONE*) (NORETHANDROLONE)
ANDROG ENS* (MESTEROLONE) (METHENOLONE) (METHANDROSTENOLONE*) (NANDROLONE*) (OXYMETHOLONE*) (STANOLONE)
ANDBOGENS* (STANOZOLOL*) (ETHYLESTRENOL*) (METHANDRIOL*) (OXANDROLONE*) (BOLASTERONE) (NORTESTOSTERONE*)
A NDROSTERONE*
ANESTHESIA (SPINAL ANESTHESIA*) (ANESTHETIC AGENTS*)

ANESTHETIC AGENTS* (ETHER*) (HALOTHANE*) (NETHOXYFLURANZ*) (CHLOROFORM*) (CYCLOPROPANE*) (ETHTLENE*) (KF.TAMI NE)
ANESTHETIC AGENTS*(ETHYL CHLOPIDE*) (FLUROXEN!*) (TRICHLOROETHYLENE*) (VINYL !THER*) (THIOPENTAL*) (NITROUS OXIDE*)
ANESTHETIC AG!NTS* (METHOHEXITAL) (HYDROXYDIONE) (DPOPERIDOL) (NITROUS OXIDE*) (HALOPROPANE) (CXC LOHEXYLAMINE)
ANGIOGRAPRIC AGENTS (DIATRIZOATE*) (IOTHALAMATE*)
ANGIOTENSIN* (ANGIOTENSIN AMIDE) (HYPERTENSIN)
ANILERIDINE*(APODOL) (LERITINE) (ANILERIDINE HYDROCHLORIDE) (ANILEPIDINE PHOSPHATE)
ANILINE* (AMINOBENZENE)
ANISINDIONE* (MIRADON)
ANTACIDS* (ALKALINE ANTACIDS*) (BICARBONAT!S*)
ANTACIDS*(SODIUN BICAP.BONATE*) (CALCIUM CARBONATE) (CALCIUM PHOSPHATE) (ALUMINUM HYDROXIDE) (MAGNESIUM SALTS*)
ANTAZOLI NE* (ANTAZOLINE PRO SPRATE) (VASOCON-A) (ANTISTINE PHOSPHATE)
ANTHELMINTHICS (METRIFONATE*) (MALE FERN*) (DICHLOROPHEN) (LUCANTHONE*) (NICLOSAMIDE*)
ANTHELMINTICS (ANTIMONY COMPOUNDS*) (ASPIDIUN OLEOR!SIN*) (BEPHENIUM) (DIETHYLCARBAMAZIN!*) (HEXYLBESORCINOL)
ANTHELMINTICS (HYCANTHONE*) (NICLOSAMIDE) (PIPERAZINE*) (PYRVINIUM PAMOATE*) (QUINACRINE*) (STIBOPHEN*)
ANTHELPENTICS (SURAMIN*) (TETRACHLOROETHYLENE) (THIABENDAZOLE*) (DITHIAZINE*) (METHYLPOSANILINE) (NIPIDAZOLE*)
ANTHRAQUINONE* (ANTHRAQUINONE DERIVATIVES) (CASCARA*) (DANTHRON*) (DOXIDAN)
ANTIANGI NAL AGENTS (NITROGLYCEPIN*) (ANINOPHYLLINE*) (AMYL NITRITE*) (ERTTHRITYL TETRANITRATE) (I SOSOBBI DE DINITRATE*)
ANTIANGINAL AGENTS (PAPAVERINE*) (PFNTAERYTHRITOL TETRANITRATE) (PERITRATE) (PBRHEXILENE*)
ANTIANXIETY AGENTS (BUCLIZINE) (BENACTYZINE) (ECTYLUREA*) (DOXEPIN*)
ANTIAN XIFTY AGENTS (CHLOPDIAZEPOX IDE*) (CHLORMEZANONE*) (DIAZEPAM*) (HYDROXPMENAMATE) (NEP HENOXALDNE*)
ANTIANXIETY AGENTS (NEPROBAMATE*) (OXANAMIDE) (OXAZEPAN*) (PHENAGLYCODOL*) (TYBAMATE) (HYDROXYZINE*)
ANTIARRHYTHNIC AGENTS (EPINEPHR INE* (ISOPROTERENOL*) (NETHOXAMINE)
ANTIARRHYTHMIC AGENTS(DIGITALIS*) (Q(JINIDINE*) (PROCAINAMIDE*) (LIDOCA INE*) (DIPHENYLHYDANTOIN*) (PROPRANOLOL*)
ANTIBIOTICS* (CHLORAMPHENICOL*) (PENICILLIN*) (CEPHALOSPORINS) (ERYTHROMYCIN*) (TETRACYCLINE*)
ANTIBIOTICS* (LINCOMYCIN*) (COLI STIN*) (POLYMYXIN B*) (PARONONYCIN*) (GENTAMICIN*) (DEMETHYLCHLORTETRACYCLINE*)
ANTIBIOTICS* (OLEANDONYCIN*) (TROLEANDOMYCIN) (TYROTHRICIN*) (VANCOMTIN*) (BACITRACIN*) (CLINDAMYCIN*)
ANTIBIOTICS * (POLYMIXI N*) (BACIT RACIN*) (GENTANICIN*) (GRAMICIDIN) (LINCOMYCIN*)
ANTIBIOTICS* (STREPTOMYCIN*) (KANAMYCIN*) (METHENAMINE*) (NALIDIXIC ACID*) (NEOMYCIN*) (NOVOBIOCIN*)
ANTICHOLINERGIC AGENTS (ATROPINE*) (SCOPOLAMINE) (NETHANTHELINE) (OXYPHENONIUN)
ANTICHOLINESTERA SES (ORGANOPHOSPHOR US INSECTICIDES*) (PYRIDOSTIGMINE) (A MBENONIUM) (EDROPHONI UN)
ANTICHOLINESTERASES (PHYSOSTIGMINE*) (NEOSTIGMINE*) (ECHOTHIOPHATE*) (ISOFLUROPHATE*) (DEMECARIUM*)
ANTICOAGULANTS* (CITRATES*) (OXALATES*) (FLUORIDES*) (LIQUOID*) (ANCBOD*)
ANTICO AGULANTS* (HEPARIN*) (COUMARIN DERIVATIVES*) (INDANDIONE DERIVATIVE S*) (EDTA*) (BISHYDROXYCOUMARI N*) (ANISINDIONE*)
ANTICOAGULANTS* (WARFARIN*) (ETHYL BISCOUNACETATE*) (PHENPROCOUNON) (ACENOCOUMA RI N) (PHENINDION!*) (DIPHENADIONE)
ANTICONVtJLSANTS* (BARBITURATES*) (PRIMIDONE*) (HYDANTOINS*) (SUCCINIMIDES*) (OXAZOLIDINEDIONES) (ACETAZOLAMIDE*)
ANTICONVtJLSANTS*(BROMIDLS*) (PHENACEMIDE*) (MEPROBAMATE*) (PARALDEHYDE*) (QUINACRINE*) (DIAZEPAM*) (PHENETURIDE*)
ANTICONVULSANTS* (SULTHIAME*) (CARBANAZEPINE*) (PA RA NETHADIONE*) (TRINETHADIONE*)
ANTIDEPRESSANTS (TRICYCLIC ANTIDEPRESSANTS) (MAO INHIBITORS*) (METHTLPHENIDATE*) (AMPHETAMINES*)
ANTIDIABETIC AGENTS (ACETOHEXAMIDE*) (METHEXANIDE*) (TOLAZANIDE*) (TOLCYCLAMIDE)
ANTIDIABETIC AGENTS (SULFONYLUREAS*) (PHENFORMIN*) (INSULIN*) (NK-27O*) (GLTMIDINE*) (GLYBURIDE*)
ANTIDIABETIC AGENTS (TOLBUTAMIDE*) (CARBUTAMIDE*) (CHLORPROPAMIDE*) (METFORMIN*) (BUFORMIN*) (BIGUANIDES)
ANTIDIARREALS (BISMUTH SALTS*) (KAOLIN*) (OPIUM TINCTURE) (PECTIN) (POLYCAP.BOPHIL) (CREMONTCIN*) (DONNAGEL)
ANTIDIARREALS (CRENOSUXIMIDE*) (DIPHENOXYLATE) (FURAZOLIDON!*) (KAOMYCIN) (LACTOBACILLUS*) (PAREGORIC)
ANTIDIARREALS (PAREPECTOLIN) (POLYMAGMA) (POMALIN) (SORBOQUEL)
ANTIDIURETICS (VASOPRESSIN*) (THIAZIDES*)
ANTIFUNGAL AGENTS* (AMPHOTERICIN B*) (ACRISORCIN) (CANDICIDIN) (GRISEOFULVIN*) (BYDROXYSTILBAMIDINE) (TOLNAFTATE)
ANTIFUNGAL AGENTS* (IODOCHLORHYDROXYQUIN*) (UNDECYLENIC ACID) (HEXACHLOROBENZENE*) (FLUOROCTTOSINE*)
ANTIFUNGAL AGENTS* (NYSTATIN*) (POTASSIUM IODIDE*) (SPOROSTACIN) (BENZOIC ACID) (CARBOL-FUCHSIN) (GENTIAN VIOLET)
ANTIHISTA MINES* (ETHANOLAMINES) (ETHYLENEDIAMINES) (ALKYLA NINES) (PHENOTHIAZINES*) (CYPROHEPTIDIN E*)
ANTIHISTAMINES* (PHENINDAMINE) (BROMODIPHENHYDRAMINE) (DIPHENYLPYRALINE) (ROTOXANINE) (PIPERAZINES*)
ANTIHISTANINES* (TRIPROLIDINE) (CHLORPHENIRAMINE*)
ANTIHY PERTEN SIVE AGENTS (GUANET HIDINE*) (HYDRALAZI N!*) (MEBUTANATE) (MECAMYLAMINE*) (NETHYLDOPA*) (PAR GYLINE*)
ANTIHYPERTENSIVE AGENTS (GUANOCLOR*) (VERATRUN) (SYPOSINGOPINE*)
ANTIHYPE9TNSIVE AGENTS (GUANOXAN*) (MINOXIDIL*) (PENTOLINIUM*) (PHENOXYBENZANINE*) (DESERPIDINE*) (BETHANIDINE*)
ANTIHYPERTENSIVE AGENTS (TRIMETHAPHAN) (RAUWOLFIA*) (CLONIDINE*) (THIOCYANATES*) (NITRITES*) (NITRATES*)
ANTILYMPHOCYTE* (ANTILYNPHOCYTE GLOBULIN)
ANTIIIALAP IA LS* (AMODIAQUI NE*) (CHLOROGUANIDE*) (CHLOROQUINE*) (HYDROXYCHLOROQUINE*) (PRIMAQUI NE*)
ANTINALARIALS’ (PT RINRTHAMINE*) (QUINACRINE*) (QUININE*) (PENTAQUINE*) (CYCLOGUANIL) (TRIMETHOPBIM*) (QUINOCIDE*)
ANTIMONY CONPOUNDS* (ANTIMONY POTASSIUM TABTRATE)
ANTI NEOPLASTIC* (ANTINEOPLASTIC DRUGS) (MITHRAMYCIN*) (BUSULFAN*) (CHLORAMBUCIL*) (CYCLOPHOSPHAMIDE*)
ANTINEOPLASTIC* (NECHLORETHAMINE*) (MELPHALAN*) (PIPOBROMAN*) (THIOTEPA*) (TRIETHYL!NEMELAMINE*)
ANTINEOPLASTIC* (PROCARBAZINE*) (QUINACRINE*) (VINBLASTINE*) (VINCRISTI NE*) (ANDBOGENS*) (PROGESTOGENS*)
ANTINEOPLASTIC* (RADIOACTIVE AGENTS*) (HEXANETHYLMELA MINE*) (ANTILYMPHOCYTE GLOBULIN*)
ANTINEOPLASTIC* (THIOGUANINE*) (DACTINONYCIN*) (HYDROXTUREA*) (URETHAN*) (PREDNISONE*)
ANTINEOPLASTIC* (URACIL MUSTARD*) (CYTARBINE*) (FLUOROURACIL*) (MERCAPTOPURINE*) (PIETHOTREXATE*)
ANTIPROTOZOA L AGENTS (SURA MIN*) (PENTAMIDINE*) (MELARSOPROL*) (MELARSONYL*) (ANTIMONY COMPOUNDS*)
ANTIPSYCHOTIC AGENTS (PHENOTHIAZINES*) (THIOXANTHINES) (BUTYROPHENONES) (FLUROTHYL) (LITHIUM CARBONATE*) (MOLINDONE*)
ANTIPYRETICS* (ACETAMINOPHEN*) (ACETOPHENETIDIN*) (ACBTANILID*) (ACETYLSALICYLIC ACID*) (ANTI PYRINE*)
ANTIPYRINE*(ANALGESTNE) (ANODYNINE) (SEDANTINE) (PHENAZONE)
ANTIR HEUMATIC AGENTS (ACETYLSALICYLIC ACID*) (OXYPHENBUTAZONE*) (PHENYLBUTAZONE*) (INDOMETHACI N*)
ANTIRHEUMATIC AGENTS (HYDROXYCHLOROQUINE SULFATE*) (GOLD SALTS*)
ANTISEPTICS* (ACRIFLAVINE*)
ANTISEPTICS* (QUATERNABY AMMONIUM COMPOUNDS*) (PHENOLIC COMPOUNDS*) (BORIC ACID*) (HYDROGEN PEROXIDE*)
AN TISEPTICS* (ETHANOL*) (ISOPROPA NOL*) (HYPOCHLORITES*) (IODINE COMPOUNDS) (MERCURY COMPOUNDS*) (SILVER COMPOUNDS*)
ANTISPASMODICS (BELLADONNA ALKALOIDS*) (QUATERNART ANMONIUM COMPOUNDS*) (ALVERINE) (DICYCLOMINE)
ANTISP ASMODICS (METHIXENE) (OX! PHENCYCLIMINE)
ANTITflYROID AGENTS (CAPBIMAZOLE*) (METHYLTHIOURACIL*) (DINITROPHENOL*) (AMINOTHIAZOLE*) (AMINOTRIAZOLE*)
ANTITHYROID AGENTS (CABBUTANIDZ*) (THIAMAZOLE*) (THIOCYANATBS*)
ANTITHYROID AGENTS (PROPYLTHIOURACIL*) (THIOURACIL*) (METHIMAZOLE*) (POTASSIUM PERCHLORATE*) (AMPHENONE*)
ANTITHYROID AGENTS (RADIOACTIVE IODINE*) (LUGOL’S IODINE*) (POTASSIUM IODIDE*) (SODIUM IODIDE)
ANTITRICHOMONAL AGENTS (METRONIDAZOLE*) (DIIODOHYDROXYQUIN*) (IODOCHLORHYDROXYQUIN*) (POVIDONE-IODINE*)
ANTITRICHONONAL AGENTS (TRICLOBISONIUM) (TPICOFUPON) (AVC) (CARBARSONE*)
ANTITRYPANOSOMAL AGENTS (MELARSOPROL*) (NELARSONYL*) (NITROFUR AZONE*) (PENTANINIDINE*) (SURA MIN*)
ANTITRYPANOSONAL AGENTS (TRYPARSAMIDE*) (NIFURTIMOX*)
ANTITUBERCULOSIS AGENTS (AMINOSALICYLIC ACID*) (CYCLOSERINE*) (ETHAMBUTOL*) (ETRIONAMIDE*) (ISONIAZID*)
ANTITUBERCULOSIS AGENTS (KANAMYCIN*) (PYBAZINAMIDE*) (STREPTOMYCIN*) (VIOMYCIN*) (RIFAMPIN*) (CAPREOMYCIN*)
ANTITUBERCULOSIS AGENTS (PPOTHIONAMIDE*) (MORPHAZINAMIDE*) (TIOCAPLIDE*) (PYRAZINOIC ACID*)
ANTITUSSIVES (LEVOPROPOXYPHENE) (NOSCAPINE) (PIPAZETHATE) (COUGH MEDICINES*)
ANTITUSSIVES (NARCOT ICS*) (BENZONATATE) (CHLOPHEDIA NOL) (DEXTROMETHORPHAN*) (j YCER XL GUAIACOLATE*)
ANTIVIRAL AGENTS (AMANTADINE*) (IDOXURIDINE*) (NETHISAZONE) (CYTARAGINE*) (INTERFERONS)

AORTOGRAPHIC AGENTS (DIATRIZOATE*) (IOTHALAMATE*)
APOMORPHINE*
APRONA L*
ARABINOSE*
ARGININE*(ARGININE HYDROCHLORIDE) (ARGININE GLUTAMATE) (B-GENE) (MODUMATE)
ARSENICALS* (ARSENIC) (AR SPRE NAMI NE) (SULFARSPHENA MI NE) (NEOARSPHENANINE) (STO VARSOL) (CARBARSONE*) (TRYPARSAMIDE*)
ARSENICALS* (NEOSALVA RSAN*) (POTA SSI UN ARSENITE) (FOWLER ‘ S SOLUTION) (MAPHARSEN) (ARSINE) (NELARSONYL*) (MELARSOPROL*)
A RS ENOB EN Z EN ES*
ASCORBIC ACID*(VITANIN C) (ASCORBATE SODIUM) (CECON) (CEVALIN) (CE-VI-SOL) (LIQUI-CEE) (CENOLATE)
ASPARAGINASE*(L-ASPARAGINASE) (CRASNITIN)
ASPARAGINE*
ASPIDIUM* (ASPIDIUM OLEORESIN)
ATROPINE* (ATROPINE SULFATE) (BUCLADIN) (ENURETROL) (ORALEN) (PRYDON) (PRYDONNAL) (ATROPINE METHYLNITRATE)
AZA DRUGS* (AZASERINE*) (AZATHIOPRINE*) (AZATHYNINE*) (AZAURIDINE*)
AZASERINE*
AZATHIOPRINE* (INURAN)
AZATHYNINE*
AZAURIDINE*
AZOSULFAMIDE*
AZtJRESIN*(DIAGNEX BLUE)
B-HYDROXYAMINOBUTYR* (B-HYDROXYAMINOBUTYRATE)
B-HYDROXYBUT!R ATE*
BACITRACIN* (BACIMYCIN) (BACITRACIN ZINC) (COBTISPORIN) (EPIMYCIN) (NEO-POLYCIN) (POLYSPORIN) (BACIGUENT)
BACTERIAL CONTAM* (BACTERIAL CONTAMINATION)
BACTERIURIA*
BA NANA S*
BARBITURATES* (ALLOBARBITAL) (BUTETHAL) (HEXETHAL) (HEXOBARBITAL) (METHITURAL) (METHOHEXITAL) (THI AMYLAL*)
BARBITURATES*(AMOBARBITAL*) (BUTABARBITAL*) (PROBARBITAL) (VINBARBITAL*) (PENTOBARBITAL) (SECOBARBITAL*)
BARBITURATES* (APROBARBITAL) (HEPTABARBITAL*) (ALLOBARBITAL) (BARBITAL) (NEPHORBARBITAL) (METHARBITAL)
BARBI TURATES* (METBOPHENOBARBITAL*) (PHENOBARBITA L*) (THIOPENTAL*) (CYCLOBARBITAL) (TALBUTAL*) (QUIN ALBARBITAL*)
BARIUM SALTS* (BARIUM SULFATE) (ESOPHOTRAST) (BARIUM*)
BCG VACCINE*
BED REST* (RECUMBENCY*)
BEETS *
BELLADONNA* (BELLADONNA ALKALOIDS) (BELLADONNA EXTRACT) (BELLADONNA LEAF) (HYOSCYANINE) (ATROPINE*)

BENDROFLUNETHIAZIDE* (NATURETIN)
BENZALKONI UN CHLORIDE (AMINO-CERV) (BIOTRES) (IONAX) (IONIL) (MEDICONET) (NTZ) (SPOROSTACIN) (ZEPRIRAN CHLORIDE)
BENZENE* (BENZOL)
BENZIODARONE* (CARDIVIX)
BEN ZOCAINE*
BENZODIAZ EPINES (CHLORDIAZE POXIDE*) (DIAZEPAM*) (NITRAZEPAM*) (OXAZEPA N*) (NEDEZEPAN) (FLURAZEPAM*) (DIBENZEPIN)
BENZONORPHANS* (PHENAZOCINE*) (CYCLAZOC IN!)
BENZYL ALCOHOL*
BERYLLIUM SALTS*
BETA-ADRENERGIC* (BETA-ADRENERGIC AGENTS) (ISOPROTERENOL*) (PROPRANOLOL*) (OXYPR.ENOLOL) (ALPRENOLOL) (BUNOLOL)
BETA-ADRENERGIC* (BUTOXANINE) (LEVARTERENOL*)
BETA-A DRENERGIC* (P1 NDOLOL) (ISOPHENETHANOL) (DEXPROPR ANOL) (PRACTOLOL) (NETHOXA MINE) (BUTIDRINE) (PRONETHALOL)
BETANETHASONE* (CELESTONE) (BETAMETHASONE ACETATE) (CELESTONE SOLUSPAN) (BETANETHASONE VALERATE) (VALISONE)
BETAZOLE* (BETAZOLE HYDROCHLORIDE) (HISTALOG)
BETHANECHOL*(NYOCHOLINE) (URECHOLINE)
BETHANIDINE*
BEVERA GES (COFFEE*) (ETHANOL*) (TEA*) (CO COA*)
BICARBONATES* (SODIUM BICARBONATE)
BIGUANIDES (PHENFORNIN*) (METFORNIN*) (BUFORNIN*)
BILE SALTS* (BILE*) (CHENODEOXYCHOLIC ACID*) (DEHYDROCHOLIC ACID*)
BILIRUBIN*
BI LI VERDI N*
BISACODYL* (DULCOLAX)
BISCOUMACETATE*(ETHYL BISCOUMACETATE) (TRONEXAN)
BISHYDROXYCOUMARIN* (DICUMAROL) (DICOUMARIN)
BISMUTH SALTS* (BISMUTH OXTIODIDE) (BISMUTH OXYIODOGALLATE) (BISMUTH SUBNITRATE*) (BISNUTH SUBCARBONATE) (BISNUTH*)
BISMUTH SUBNITRATE*
BISULFITES* (SODIUM BISULFITE)
BLOOD GROUP*
BLOOD TRANSFUSIONS*
BLOOD*
BORIC ACID*(SODIUM BORATE)
BOXIDI NE*
BRETYLIUN*(BRETYLIUM TOSYLATE) (DARENTHIN)
BROMATE*(POTASSIUN BROMATE)
BROMELAINS* (ANANASE)
BRONIDES* (SODIUM BROMIDE) (POTASSIUM BROMIDE) (ANNONIUM BROMIDE) (CALCIUM BROMIDE) (NEUROSINE)
BRONISOVALUN* (BRONISOVAL)
BROMPHENIRANINES (BROMPHENIRAMINE NALEATE) (DINETANE)
BROMSULFALEIN* (BSP) (SULFOBROMOPHTHALEIN)
BRONCUODILATORS (EPI NEPHRINE*) (EPHEDRINE*) (ETHYLNOREPINEPHRINE) (ISOPROTERENOL*) (NETHOXYPRENAMINE)
BRONCHODILATORS (PROTOKYLOL) (PSEUDOEPHEDRINE) (THEOPHYLLINE DERIVATIVES*)
BRONCHOGRAPHIC AGENTS (LIPIODOL*) (PROPYLIODONE*)
BUFORNI N*
BUNAMIODYL* (ORABILEX) (BILl-ORAL) (ORABILIX) (TRIODAN)
BUSULFAN* (NYLERAN)
BUTABARBITAL*
BUTAPERAZINE* (BUTAPERAZINE MALEATE) (REPOISE MALEATE)
BUTYROPHENONES (HALOPERIDOL*) (TRIFLUPERI DOL*) (DROPERIDOL) (FR-33)
CADNIUN*(CADNIUN SULFIDE) (CADMIUM CARBONATE) (CADMIUM OXIDE)
CAERULIN*
CAFFEINE* (CAFFEINE SODIUM 5ENZ OAT!)
CALCIFEROL*
CALCITONIN*
CALCIUM CABBINIDE*(CITRATED CALCIUM CARBINIDE) (TEMPOSIL)

CALCIUM SALTS* (CALCIUM CARBIMIDE*) (CALCIUM CHLORIDE*) (CALCIUM GLUCONATE*) (CALCIUM BROMIDE) (CALCIUM LEVULINATE)
CALCIUM SALTS* (CALCIUM HYDROXIDE) (CALCIUM CARBONATE) (CALCIUM LACTATE) (CALCIUM PHOSPHATE) (CALCIUN*)
CAPREOMYCIN* (CAPREOMYCIN SULFATE) (CAPASTAT)
CARBACRYLANINE RES*(CARBACRYLAMINE RESIN)
CARBAMAZEPINE* (TEGRETOL)
CARBANIDE*
CA R BA P SONE*
CAPBENICILLIN*(CARBENICILLIN DISODIUM) (PYOPEN) (GEOCILLIN)
CARBENOXOLONE* (CARBE NOXOLONE SODIUM) (BIOGASTRONE) (DUOGASTRONE)
CAPBIMAZOLE* (NEOMERCAZOLE)
CARBON DISULFIDE*
CARBON MONOXIDE*
CARBON TETRACHLOH* (CARBON TETRACHLORIDE) (TETRACHLORONETHANE)
CARBONIC ANHYDRASE INHIBITORS (ACETAZOLAMIDE*) (DICHLORPHENANIDE*) (ETHOXZOLAMID!*) (METHAZOLAMIDE*)
CARBRONAL* (CARBITAL)
CARBUTAMIDE*
CARINAMIDE* (STATICIN)
CAR OT E NE *
CARPHENAZINE* (CARPHENAZINE NALEATE) (PROKETAZINE) (CARFENAZINE)
CARROTS*
CASCARA* (CASCARA SAGRADA) (CAS-EVAC)
CASTOR OIL*
CATEC HOLS*
CATHARTICS* (ANTHRAQUINONE*) (ALOIN*)
CATHARTICS* (PHENOLPHTHALEIN*) (BISACODYL*) (OXYPHENISATIN*) (CASCABA*) (CASTOR OIL*) (SENNA*) (DANTHRON*)
CELLULOSE ACETATE* (CELLULOSE ACETATE RESIN CONTAINERS)
CEPHALEXIN*(KEFLEX) (CEPOR) (CEPOREX) (CEPOREXINE) (KEFORAL) (ORACEF)
CEPHALORIDINE* (LORIDINE)
CEPHALOSPOPINS (CEPHALORIDI NE*) (CEPHALOTHIN*) (C!PHALEXIN*) (CEPHALOGLYCIN)
CEPRALOTHIN* (KEFLIN) (CEPHALOTHIN SODIUM)
CHELATING AGENTS (EDTA*) (DIMERCAPROL*) (PENICILLAMIN E*) (DEFEROXAMINE*) (ACETYLPENICILLAMINE*)
CH ENODEOXYCHOLIC* (CHENO DEOXYCHOLIC ACID)
CHINIOPON* (QUINOXYL) (YATREN)
CHLORAL BETAINE* (BETA-CHLOR)
CHLORAL HYDRATE* (AQUACHLORAL) (FELSULES) (KESSODRATE) (NORTEC) (RECTULES) (HYDRAL) (LYCORAL) (SOMNOS)
CBLORAL* (CHLORAL DERIVATIVES) (CRLORAL BETAINE*) (CHLORAL HYDRATE*) (TPICHLOROETHANOL) (PETRICHLORAL)
CHLOPAL* (TRICHLOROETHYL PHOSPHATE) (CHLOROBUTANOL*)
CHLORAMBUCIL* (LEUKERAN)
CRLOPAMPHENICOL* (CHLORAMPHENICOL PALMITATE) (CHLORAMPHENICOL SODIUM SUCCINAT!) (AMPHICOL) (CHLOROMYCETIN) (MYCHEL)
CHLORATE* (POTASSIUM CBLORATE*)
CHLORDANE*
CHLORDIAZEPOXIDE*(CHLORDIAZEPOXIDE HYDROCHLORIDE) (LIBRIUM) (LIBRAX) (LIBRITARS)
CHLORIDE SALTS* (CHLORIDE)
CHLORINATED INSECT* (CHLORINATED INSECTICIDES*) (DDT) (HCH) (DIELDRIN) (NETOXYCHLOR) (CHLOROPHENOTHANE*)
CHLORINATED INSECT*(CHLORDANE*) (HEPTACHLOR*) (TOXAPRENE)
CHLORINE*
CHLORNADINONE*(CHLORNADINONE ACETATE) (LORMIN) (LUTERAN) (LUTORAL)
CHLORMEPODIN* (NEOHYDRIN)
CHLOPMEZANONE* (TRANCOPAL)
CHLOROBUTANOL* (CHLOPETONE)
CHLOROFORN* (TRICHLOROMETHANE)
CHLOPOGUANIDE* (CHLOROGUANIDE HYDROCHLORIDE) (PALUDRINE)
CHLOROPHENOTHANE* (DDT) (DICOPHANE)
CHLOBOPHENYLANINE* (P-CHLOROPHENYLANINE) (FENCLONINE)
CHLOROQUINE*(CHLOROQUINE HYDROCHLORIDE) (ABALEN PHOSPHATE) (CHLOROQUINE PHOSPHATE) (ARALEN HYDROCHLORIDE) (AVOCHLOR)
CHLOROTHIAZIDE*(ALDOCLOR) (DIUPRES) (DIURIL) (CHLOROTHIAZID! SODIUM) (SODIUM DIURIL)
CHLORPHEN lB ANINE* (CHLOBPHENIRA MINE MALEAT!) (ALLEREST) (ORNADE) (TELDRIN) (HISTA- SPAN) (CHLOR-T RI MET ON)
CHLORPROMAZINE*(THORAZINE) (CHLOPPROMAZINE HYDROCHLORIDE) (THORAZINE HYDROCHLORIDE) (LARGACTIL) (MEGAPHEN)
CHLORPROPAMIDE* (DIABINESE)
CHLORPROTHIXENE* (TARACTAN)
CHLORTETRACYCLINE* (CHLORTETRACYCLINE CALCIUM) (CHLORTETRACYCLINE HYDROCHLORIDE) (AUREOMYCIN)
CHLORTHALIDONE* (HYGROTON)
CHLORZOXAZONE* (PARAFON FORTE) (PARAFLEX)
CHOCOLATE*
CHOLANGIOGRAPHIC AGENTS (DIATRIZOATE*) (IODIPAMIDE*) (IOGLYCAMIDE)
CHOLECYSTOGRAPHIC AGENTS (DIATRIZOATE*) (IOPANOIC ACID*) (IPODATE*) (BUNANIODYL*) (I000ALPHIONIC ACID*) (IOPHENDYLATE*)
CHOLECYSTOGRAPHIC AGENTS (IOPHENOXIC ACID*) (PHENOBUTIODIL) (IOBENZAMIC ACID) (IODOPH THALEIN)
CHOLERETICS*
CHOLESTA NOL*
CH OLESTEPOL*
CHOLESTYRANINE* (CHOLESTYRAMINE PESIN) (QUESTRAN) (CUENID)
CHOLINERGICS*(METBACHOLINE*) (BETHANECHOL*)
CHR YSAROBIN*
CINCHOPHEN* (NEOCINCHOPHEN) (ATOPHAN)
CITRATES*(SODIUN CITRATE) (CITRATED WHOLE HUMAN BLOOD) (SHOHL’S SOLUTION)
CLINDAMYCIN*(CLEOCIN) (CLININYCIN)
CLIOQUINOL (CHINIOFORM) (CHLORIODOHYDROXYQUINOLINE) (ENTEROQUINOL) (ENTRIN) (ENTEROSEPTOL) (ENTEROVIOFORM)
CLOFIBRATE*(ATRONID-S) (REGELAN) (CHLOROPHENOXYISOBUTYRATE) (CPIB)
CLOMIPHENE* (CLONID) (CLONIPHENE CITRATE)
CLONIDINE* (CLONIDINE HYDROCHLORIDE) (CATAPRES) (CATAPRESAN)
CLOPAMID!* (BRINALDIX)
CLOPENTHIXOL*
CLOREXOLONE*(NEFROLAN)
CLOXACILLIN* (CLOXACILLIN SODIU?! NONOHYDRATE) (TEGOPEN)
COAL TAR* (COAL TAR DERIVATIVES) (BALNETAR) (POLYTAR) (SUPERTAH) (TAR DISTILLATE) (TARBONIS) (TARSUM) (ZETAR)
COBALT SALTS*(COBALTOUS CHLORIDE)
COCOA*
CODEINE*(CODEINE PHOSPHATE) (CODEINE SULFATE)
COFFEE* (CAPFEINE*)
COLCHICINE (COLBENENIDE) (SALPACINE)

COLD AGGLUTININS*
COLESTIPOL*
COLISTIMETHATE* (COLISTINETHATE SODIUM) (COLY-MYCIN)
COLISTIN* (COLISTIN SULFATE) (COLY-MYCIN)
CONGO RED*
CONTACT WITH CLOT*(DELAYED SEPARATION OF SERUM) (STANDING OF SAMPLE)
COPPER*(COPPER SALTS) (CUPPIC IONS) (COPPER COMPOUNDS) (COPPER SULFATE)
CORK STOPPERS*
COPTICOST!ROIDS* (DEXAMETHASONE*) (MEDRYSONE) (METHYLPREDNISOLONE)
COPT!COSTEBOIDS* (FLUDROCORTISONE*) (FLURANDRENOLIDE) (FLUMETHASONE) (FLUOCINOLONE) (FLUOROMETHOLONE)
CORTICOSTEROIDS* (PREDNISONE*) (PREDNISOLONE*) (GLUCOCORTICOIDS*) (MINERALOCORTICOIDS*) (DOCA*) (MEPREDNI SON!)
CORTICOTROPIN* (ADRENOCOPTICOTROPHIC HORMONE) (ACTH) (ACTHAR) (HP ACTHAR GEL) (SYNACTHEN) (ACTEST) (CORTIGEL)
CORTISONE*(CORTISONE ACETATE) (CORTONE ACETATE) (NEOSONE)
COUGH MEDICINES*
CDUMARIN* (COUMARIN DPIVATIVES) (ACENOCOUMAROL) (BI SHYDROXYCOUMARIN*) (BISCOUMAC!TATE*) (WARFARIN*)
CR E AT I NE *
CREATI NINE*
CRENOMYCIN*
C P EOSOTE*
CRESOL* (LYSOL*)
T1341*(STEROID MIXTURE IN CRENOPHOP EL)
CYANATE*
CYANIDES*
CYCLIC AMP* (3’ ,5’-ADENOSINE NONOPHOSPHATE)
CYCLOHEXIMIDE*
CYCLOLEUCINE*
CYCLOPHOSPHAMIDE* (CYTOXAN) (ENDOXAN)
C YCL OPRO PA N
CYCLOSERINE* (SEROMYCIN) (OXAMYCIN)
CYCLOTHIAZI DE* (ANHYDRON)
CYPPOHFPTIDINF* (CYPROHEPTIDINE HYDROCHLORIDE) (PERIACTIN)
CYPROTERONE9CYPROTEBONE ACETATE)
CYSTEINN*
CYTARABINE* (CYTOSAR) (CYTOSINE ARABINOSIDE) (ABA-C)
DACTINONYCIN* (COSMEGEN) (ACTINOMYCIN D)
DANDRUFF MEDICATION* (IOQUIN*) (SELENIUM SULFIDE) (CADMIUM SULFIDE*)
DANTHRON* (DANIVAC) (DORBANE)
DECAMETHONIUM* (DECANETHONIU N IODIDE) (SYNCURINE) (EULISSIN)
DEFEROXAMIN E* (DEFERO XAMINE NESYLATE) (DESFERYL)
DEHYDROCHOLIC ACID* (DEHYDROCHOLATE SODIUM) (DECHOLIN)
DBHYDBOEM ETIN E*
DEMECARIUM* (DEMECARIUM BROMIDE) (HUMORSOL)
DENFCLOCYCLINE* (DEMECLOCYCLIN1 HYDROCHLORIDE) (DECLONYCIN)
DEMETHYLCHLORTFTRAC* (DEMETHYLCHLORT ETRACYCLINE)
DERMATOLOGIC AGENTS (ALUMINUM SALTS*) (BORIC ACID*) (CALCIUM SALTS*) (ETHANOL*) (ISOPROPANOL*) (CAMPHOR)
DERMATOLOGIC AGENTS (ANMONIATED MERCURY OINTMENT) (CADMIUM SULFID!*) (SELENIUM SULFIDE) (MINERAL OIL*)
DERMATOLOGIC AGENTS (SILVER CON POUNDS) (MENTHOL*) (COLLODION) (POLYETHYLENE) (COVERMARK) (SULFAPYRIDINE*) (SULFONES*)
DESERPIDINE*(HARNONYL) (ENDURONYL)
DES IPPANINE * (DESIPRA MI NE HYDROCHLORIDE) (NORPRANIN) (PERTOFRANE)
DESSICATED THYROID*
DETER GE NT S *
DEXAMETHASONE* (DECADRON) (DECAGESIC) (DRONACTIN) (GAMNACORTEN) (HEXADROL) (DERONIL) (DEXANETH) (MAXIDEX)
DEXTRAN* (LM) (RHEONACRODEX) (DEXTRAN ‘40) (DEXTRAN 70)
DEXTROAMPHETAMINE* (DEXTROAMPHETAMINE PHOSPHATE*) (DEXTROAMPHETAMINE SULFATE*) (DBXEDRIN)
DEXTRONETHORPHAN* (DEXTROMETHORPHAN HYDROBROMIDE) (RONILAR)
DEXT ROMO BA MI DE*
DEXTROTHYROXINE* (SODIUM DEXTROTHYROXINE) (DETHYRONA) (CHOLOXIN)
DIANINODIPHENYLSULF*(DIAMINODIPHENYLSUL!ONE) (DIANINODIPHENYL SULFONE) (DDS) (DAPSON!)
OIAPAM IDE*
DIAPRIM*
DIATPIZOATE*(DIATBIZOATE MEGLUNINE) (CARDIOGRAFIN) (ASTROGRAFIN) (HYPAQUE) (RENOGRAFIN) (RENOVIST) (SINOGRAFIN)
DIAZEPAM* (VALIUM)
DIAZI NON*
DIAZOXIDE* (HYPRSTAT) (EUDIMEN!)
DICHLORALPHENAZONE* (WELLDOPM)
DICHLORPFIENAMIDE* (DAPANIDE) (ORATROL)
DICLOXACILLIN*(DICLOXACILLIN SODIUM MONOHYDRATE) (DYNAPEN) (PATHOCIL) (VERACILLIN)
DIELDRIN*
DIETHIAZ INE *
DIETHYLCARBAMAZINE* (DIETHYLCARBAMAZINE CITRATE) (BANOCIDE) (HETRAZAN) (NOTEZINE)
DIETHYLPROPION* (DIETHYLPROPION HYDROCHLORIDE) (TENUATE) (TEPANIL)
DIETHYLSTILBESTROL* (DI ETHYLSTILBESTPOL DIPROSPHATE) (DIETHYLSTILB!STROL DIPROPIONATE) (STILBETIN) (ST ILPHOSTROL)
DIFLUOROPHOS?HATE*
DIGITALIS*(DIGITALIS GLYCOSIDES) (LANATOSIDE C) (DIGITORA) (PIL-DIGIS)
T)IGITALIS*(DIGTTALIS LEAF) (DIGITOXIN*) (ACETYLDIGITOXIN) (DESLANOSID!) (DIGOXIN*) (GITALIN) (OUBAIN)
D!GITONIN*
DIGITOXIN*(DIGITALINE) (MYODIGIN) (PURODIGIN) (CRYSTODIGIN)
DIGOXIN* (LANOXIN)
DIHYDROTACHYSTFROL* (HYTAKEROL)
DIHYDROXYACiTONE*
DIIODOCAFEINE* (DIIODOCAFFEINE HYDRIODIDE) (IODOCAFFEINE) (CAFFEDRIN)
DIIODOHYDROXYQUIF* (DI000QUIN) (NOEBIQUIN) (YODOXIN) (FLORAQUIN)
DIIODOQUINOLINE (ANOEBINDON) (AMOEQUIN)
DIMERCAPROL*(BAL) (BRITISH ANTILEWISITE) (BAL IN OIL) (2,3 DINERCAPTOPROPANOL)
DI METHI STE RONE*
DINFTHYLTUBOCURAP*(DINETHYLTUBOCURARINE IODIDE) (METUBINE IODIDE)
DINITROPHENOL*(2,L4-DINITROPHENOL)
DIPHENHYDRAMINE*(DIPHENHYDRAMINE HYDROCHLORIDE) (BENADRYL) (HISTA-SED)
DIPHENYLHYDANTOIN*(DIPHENYLHYDANTOIN SODIUM) (DILANTIN) (DI-PHENYL) (EKKO) (MEBROIN) (PHELANTIN) (TOIN UNICELLES)
DIPHPNYLHYDANTOIN* (PHENYTOIN)

DIPROTIZOATE* (SODIUM DIPROTIZOATE) (M!OKON)
DIPYRIDAMOLE*
DIPYRONE* (DINETHIONE) (KEY-PYRONE) (NARON!) (PYRILGIN)
DISULFIRAM* (ANTABUSE) (TETRAETHYLTHIURAM DISULFIDE)
DITHIAZINE* (DITHIAZINE IODIDE) (DELVEX) (PART!L) (TELMID) (ANELNID)
DITHIOERYTHRITOL*
DIURETICS*(AMINOPHYLLINE*) (ACETAZOLAMIDE*) (M!PCURIAL DIURETICS*) (THIAZIDES*) (CHLORTHALIDONE*) (QUINETHAZONE*)
DIURETICS*(CLOPANIDE*) (DIAPAMIDP*) (TRIFLOCIN*) (AMILORIDE*) (DICHLORPHENANID!*) (METHAZOLAMIDE*) (ETHOXZOLAMIDE*)
DIURETICS*(ETHACPYNIC ACID*) (SPIRONOLACTON!*) (TRIANTEREN!*) (FUROSENIDE*) (MEFRUSID!*) (SC 16102*) (NETOLAZONF*)
DIURETICS* (QUINETHAZONE*) (CLOREXOLONE*)
DIURNAL VAFIATION*(CIRCADIAN RHYTHM)
DOAN’S PILLS*(DOAN’S KIDNEY PILLS)
DOCA* (DESOXYCORTICOSTEPONE ACETATE) (DESOXYCORTICOSTERONE PIVALATE) (CORTATE) (CORTINAQ) (PERCORTEN)
DOPAMI NEt
DOXAPRAM* (DOXAPRAN HYDROCHLORIDE) (DOPRAN)
DOXEPINt (DOXEPIN HYDROCHLORIDE) (SINEQUAN)
DOXYCYCLINTt (VIBRAMYCIN) (DOXYCYCLINE HYCLATE) (DOXYCYCLINE MONOHYDRATE)
DROMOSTANOLONE* (DRONOSTANOLON! PROPIONATE) (DROLBAN) (MASTEPONE)
DYDPOGESTERONE* (DUPHASTON) (GYNOREST)
CHOTHIOPHATE*(ECHOTHIOPHATE IODIDE) (PHOSPHOLINE IODIDE)
ECTYLUREA* (LEVANIL) (NOSTYN)
EDTA*(ENDRATE) (EDATHAMIL) (DISODIUM EDETATE) (CALCIUM DISODIUN ED?TATE) (CALCIUM DISODIUN VERSENATE) (VERSENE)
EGG PL A NT *
ELECTROCAUTERY*
ENODINt
FNZYMIC PREPARATIONS (TR!PSIN*) (FIBRINOLYSINt) (HYALURONIDASE) (PANCBEOZYMIN*) (STREPTOKINASE*) (TRASYLOLt)
EPHEDRINE* (EPHEDRINE SULFATE) (EPHEDRINE HYDROCHLORIDE)
EPINEPHRINE* (EPINEPHRINE HYDROCHLORIDE) (EPINEPRRIN! BITARTRATE) (ADRENALIN) (ADRENALI N CHLORIDE) (ASNOLIN)
EPI NEPHRI NE* (SUS-PHRINE) (NEDIHALER -EPI) (VAPONEFRIN)
ERECT POSTURE*(ERECT) (STANDING) (UPRIGHT POSTURE) (DEPENDENCY OF ARM)
EPGOTHIONINE*
ERYTHROMYCIN*(ERYTHROCIN) (ILOTYCIN) (PEDIAMYCIN) (ERYTHROMYCIN ESTOLATE) (ILOSONE) (BRISTAMYCIN)
ESTRADIOL*(ESTFADIOL BENZOATE) (ESTPADIOL CYPIONATE) (ESTRADIOL VALERATE) (ESTRADIOL DIPROPIONATE) (AQUADIOL) (PROGYNON)
ESTROGENS* (ESTPADIOL*) (ESTRONE*) (ESTRIOL) (DIETHYLSTILB!STROL*) (BENZESTROL) (CHLOROTRIANIS!NE) (DIENESTROL)
ESTROGENS*(HEXESTROL) (METHALLENESTRIL) (PROMETHSTROL) .(OGEN)
ESTPOGENS* (MILPREM) (PREMARIN*) (AMNESTROGEN) (MEREST) (MENRIUM) (MESTBANOL*) (ETHINYLESTRADIOL*) (QUINESTROL)
ESTRONE*(ESTRONE PIPERAZINE SULFATE) (ESTRONE SODIUM SULFATE) (OGEN) (NOBESTIN) (ESTRUGENONE) (ESTRUSOL) (NENFORMON)
ESTRONE* (THEE LIN)
ETHACRYNIC ACID*(FDECRIN) (ETRACRYNATE SODIUM) (EDECRIN SODIUM) (LYOVAC)
ETHAMBUTOL* (ETHANBUTOL HYDROCHLORIDE) (NYAMBUTOL)
ETHAMIVAN*(NMIVAN) (ETAMIVAN)
ETHANOL* (ALCOHOL) (BEER) (WINE) (WHISKEY) (BRANDY) (SHERRY) (RUBBING ALCOHOL)
ETHANOLAMINES (DIPHEN}iYDRAMINE*) (CARBINOXAMINE) (CHLORPHENOXAMINE) (DOXYLAMINE) (ROTOXAMINE) (DIPHENYLPYRALINE)
ETHCHLORVYNOL* (PLACIDYL) (ETRCHLOROVYNOL)
ETHER* (ETHER ANESTHESIA) (ETHYL ETHER) (DIETHYL ETHER)
ETHINAMATEt (VALMID)
ETHINYLESTRADIOL*(ESTINYL) (FENINONE) (LYNORAL) (NOVESTROL) (PALONYL) (ESTE3D) (ETICYLOL)
ETHIODOL*(ETHIODIZED OIL)
ETHIONAMIDE* (TRECATOR)
FTHOSUXINIDE* (ZARONTIN)
ETHOTOIN* (PEGANONE)
ETEOXAZENE* (SERENIUN)
ETHOXAZOLAMIDE*(CARDRASE) (ETHAMIDE)
ETHYL CHLORIDE*
ETHYLENE GLYCOL*
ETHYLENE*
ETHYLENEDIAMINES (TRIPELENNANINE*) (ANTAZOLINE*) (PHENINDAMINE) (METHAPYRILENE) (PYRILAMINE) (CHLOROTHEN)
ETHYLESTRENOL*(NAXIBOLIN) (ORGABOLIN)
ETHYNODIOL* (ETHYNODIOL DIAC!TATE) (DEMULEN) (OVULEN)
ETIOCHOLANOLONE*
ETRYPTAMINE* (NON AS!)
EVANS BLUE*
EXPECTORANTS (GLYCERYL GUAIACOLATEt) (IODINATED GLYCERIN*) (HYDR.IODIC ACID SYRUP) (SYRUP OF IPECAC) (BENYLIN)
EXPECTORANTS (INHALANTS) (ACETYLCYSTEINE) (MUCOMYST) (ANMONIUM CHLORIDE*) (ALEVAIRE) (GLYCERIN) (AMBENYL)
EXPECTORANTS (PANCREATIC DORNASE) (SODIUM IODIDEt) (POTASSIUM IODIDE*) (PROPYLENE GLYCOL) (TERPIN HYDRATE) (ACTIFED)
FATTY FOODS*
FAVA BEANS*
FENFLURA MINE* (FENFLURA MI NE HYDROCHLORIDE) (PONDEREX)
FENOXY PRO PA ZINE*
FENTANYL*(FENTANYL CITRATE) (INNOVAR) (SUBLIMAZE)
FERPICYANIDE*
FERROUS SALTS (FERROUS CARBONATE) (FERROUS ASCORBINATE*)
FERROUS SALTS (IRON SALTS*) (DXTPIFERPON) (FERROUS GLUCONATE) (FERROUS SULFATE) (FERROCHOLINATE) (FERROUS FUMARATE)
FIBRIN HYDROLYSATE* (FIBRIN HYDROLYSATE PREPARATION FOR HYPERALIM!NTATION)
FIBRINOLYSIN*(HUMAN FIBRINOLYSIN) (THRONBOLYSIN)
FILTER PAPER*
FISHt
FLAVASPIDIC ACID*
FLORA NTYRONE*
FLORAQUI Nt
FLUDROCORTISONE* (FLUDROCORTISONE ACETATE) (F-CORTEF ACETATE) (FLORINEF ACETATE)
FLUFENAMIC ACIDt
FLUMETHIAZIDE* (RAUTRAX)
FLUORESCEIN*(FLUORESCEIN POTASSIUM) (FLUORESCEIN SODIUM) (FLUORESCITE)
FLUORIDES* (SODIUM FLUORIDE)
FLU OROBORATE*
FLUOROCYTOSINE* (5-FL UOROCYTOSINE)
FLUOROPYRINIDI NEt
FLUOROURACIL* (FLUOROPLEX)
FLUOXYMESTERONE* (HALOTESTIN) (ORA-TESTRYL) (ULTANDREN)

FLUPHENAZINEt (FLUPHENAZINE ENANTHATE) (PROLIXINE ENANTHATE) (FLUPHENAZINE HYDROCHLORIDE) (PERMITIL) (PROLIXINE)
?LUPAZEPAM*(FLUBAZEPAN HYDROCHLORIDE) (DALMANE)
FLUROXENE* (FLUOPONAP)
FOLIC ACIDt(FOLATE SODIUM) (FOLVITE) (FOLVITE SODIUM) (FILIBON) (HENAFERBIN) (IBERET) (TOLFRINIC) (VITACREST)
FOOD (TRTJIT) (FISH*) (MEAT*) (VEGETABLES) (CHOCOLATE*) (NETRECAL*) (FATTY FOODS*) (WALNUTSt) (NON-FASTING STATE) (MEALS*)
FOOD (PHYLLOERYTHPOGEN*)
FORMALDEHYDEt
ORNALINt
FRUCTOSE’ (LEVULOSE)
FRUIT (BANANAS*) (PLUMS*) (RHUBARB*) (PINEAPPLES*)
FUMAGILLINt
FURALTADONE* (ALTAFUR) (FURMETHONOL)
FURA PROMI DI UMt
FURAZOLIDONE* (TRICOFURON) (FUROXONE) (FUROXONE LIQUID)
FURAZOLIU Mt
FUP.OSENIDEt (LASIX) (FRUSENIDE)
FUSIDIC ACID*
GALACTOSANIN!*
GA LA CTOSN *
GALLAMINE*(GALLAMINE TRIETHIODIDE) (FLAXEDIL)

GANGLIONIC BLOCKING*(GANGLIONIC BLOCKING DRUGS) (HEXAMETHONIUM) (MECAMYLAMINE*) (PEMPIDINE*)
GARGLESt (MOUTH WASHES)
GASTROENTEROGRAPHIC AGENTS (DIATRIZOATE*) (BARIUM SULFATE*)
GENTAMICIN *(GENTAMICIN SULFATE) (GAPAMYCIN)
GENTISIC ACID*
GLASSWARE* (CONTAMINATION OF GLASSWARE)
GLAUCARUBIN*
GLOBULINt
GLUCAG ON*
GLUOCOPTICOIDSt (PAPA METHASONE*) (FLUPREDNISOLONE) (DEXAMETHASONE*) (BETAMETHASONE*) (FLUDROC ORTI SONE*)
GLUCOCORTICOI DS* (TRIANCINOLON E*) (PREDNISONE*) (PREDNISOLONE*) (METHYLPREDNISOLONE)
GLUCOSAMINE*
GLUCOS Et(DEXTPOSE)
GL UCOS ULFONE* (GLUCOSULPONE SODI UN) (PROMIN)
GLUCURONIC ACID*(GLUCONATES) (FERROUS GLUCONATE) (POTASSIUM GLUCONATE) (GLUCURONIDES) (GLUCOSIDES)
GLUTAMIC ACID* (SODIUM GLUTAMATE) (ARGININE GLUTAMATE*) (GLUTAVENE) (GLUTAMIC ACID HYDROCHLORIDE)
GLUTANINE*
GLUTARIMIDE* (PHENYL-ETHYLGLUTARIMIDE)
GLUTATRIONE*
GLUTETHINIDE* (DORIDEN)
GLYBURIDE*(GLYBENCLAMIDE) (GLIBENCLANIDE) (HB 419) (USAN) (DAONIL) (DIABETA) (EUGLUCON)
GLYCEPALDEB YDE*
GLYCEPIC ACIDt
GLYCERYL GUAIACOLAT*(GLYCEPYL GUAIACOLATE) (ROBITUSSIN) (2/G)
GL YCINE*
GLYCOCYA MIDI NEt
GLYCOCYANINEt (GUANIDINO ACETIC ACID)
GLYCOPYR?OLAT!* (ROBINUL)
GLYMIDINE* (GONDAFON) (GLYCODIAZINE)
GOLDt (GOLD SODIUM THIOSULFATE) (GOLD SALTS) (AUROTHIOGLUCOSE) (SOLGANAL) (GOLD SODIUM THIOMALATE) (MYOCHRYSINE)
GONADOTROPIN* (CHORIONIC GONADTROPIN) (HCG) (ANTUITRIN 5) (APL) (FOLLUTEIN) (PREGNYL) (RIOGON)
GRISEOFULVIN*(FULVICIN) (GRIFULVIN) (GRISACTIN)
GROWTH HORNONE*(HUMAN GROWTH HORMONE) (HGH)
GUANCYDINE*
GUANETHIDINE*(GUANETHIDINE SULFATE) (ISMELIN SULFATE) (ISMELIN) (GUANOCHLOR*) (GUANOXAN*)
GUANID INE*
GUANINE*
GUANOCHLOR* (GUANOCLOR)
GUANOXAN*
HAIR LACQUEP*
HALOFENATEt (MK-185)
HALOGEN CON POUNDS* (CHLORIDE SALTS*) (FLUORIDES*) (BROMIDES*) (IODIDES*)
HALOPERIDOL* (HALDOL)
HALOTHANE* (FLUOTHANE)
HEAT*(ROOM TEMPERATUREt) (AMBIENT TEMPERATURE)
HEAVY METALS (MERCURY*) (ARSENIC*) (LEAD*)
HEMATIN*
HEMOGLOBINt (HEMOLYSIS*)
HEMOLYSIS* (HENOGLOBIN*)
HEPARIN*(HEPARIN SODIUM) (LIPO-HEPIN) (PANHEPRIN) (DEPO-HEPARIN SODIUM) (HEPATHROM) (LIQUAEMIN SODIUM)
HEPTABAFBITAL* (MEDOMIN)
HEPTA CHLOR*
HETACILLINt (PENPLENUM) (VERSAPEN)
HEXACHLOROBENZENE*(GAMMA BENZENE HEXACHLORIDE) (KWELL)
HEXAMETHYLMELANINE*(NC 13875)
HEXOSA MINEt (GLUCOSA MI NEt) (GALAC TOSAMINE*) (ACETYLGLUCOSAMINE*)
HIPPURAN *(SODIUM IODOHIPPUPATE)
FiIPPURIC ACID*
HISTAMINEt (HISTAMINE PHOSPHATE)
HISTIDINEt
HOMOGENTISIC ACIDt
HYCANTHON!* (HYCANTHONE NESY LATE)
HYDANTOINS*(DIPHENYLHYbANTOIN*) (NEPHENYTOINt) (ETHOTOIN*) (ALBUTOIN)
HYDRALAZINE*(HYDPALAZINE HYDROCHLORIDE) (APRESOLINE) (SERPASIL) (APRESOLINE HYDROCHLORIDE) (HYDRALLAZINE)
HYDRAZINE* (HYDRAZINE DERIVATIVES) (I SOCARBOXAZID*) (NIALANIDE*) (PHENELZINE*)
HYDROCHLOROTHIAZIDE* (ALDACTAZIDE) (BUTIZIDE) (ESIDRIX) (ESIMIL) (DYAZIDE) (HYDRODIURIL) (HYDROPES) (SER-AP-ES) (ORETIC)
HYDROCORTISCNEt (CORTI SOL) (HYDROCORTI SON! ACETATE) (H YDROCORTISONE CYPIONATE) (HYDROCORTAMATE) (HYDROCORTONE)
HYDROCYANIC ACID*(HCN) (PRUSSIC ACID)
HYDOFLUMETHIAZIDEt (SALURON) (SALUTENSIN)
HYDROGEN PEROXIDEt
1050 CLINiCAL CHEMISTRY, Vol. 18, No. 10, 1972

HYDROGEN SULFIDE*
HYDROQUINONE* (ELDOPAQU E) (ELDOQUIN) (DERMA-BLANCH) (MONO BENZONE) (BENOQU IN)
HYDPOXYACETANIDE*
HYDROXYAMINOBUTYRIC* (BETA-HYDROXY-GANMA-ANINOBUTYBIC ACID)
HYDPOXYCHLOROQUINE* (HYDROXYCHLOPOQUINE SULFATE) (PLAQUERIL SULFATE)
HYDROXYHEXANIDE*
HYDROXYQU INOLI NEt
HYDROXYUREA* (HYDREA)
HYDROXYZINE* (HYDROXYZINE HYDROCHLORIDE) (ATARAX) (CARTRAX) (ENARAX) (MARAX) (VISTARIL) (HYDROXYZINE PAMOATE)
HYPEROSNOTIC AGENTS (GLYCERIN) (NANNITOL*) (UPEA*)
HYPERVENTILATIO Nt
HY?OCHLORI TES*(SODIUM HYPOCHLOR IT!) (ZONITE) (OXYCHLOROSENE) (CLORPACTIN)
HYPOLIPIDENIC AGENTS (BOXIDINE*) (MK-185*)
HYPOLIPIDEMIC AGENTS (CHOLESTYRAMINE*) (CLOFIBRATE*) (DEXTROTHYROXINE*) (ESTROGENS*) (NICOTINIC ACIDt) (SITOSTERCL*)
HYSTEROSALPINGOGRAPHIC AGENTS (DIATRIZOAT!t) (LIPIODOL*) (ACETRIZOATE*) (IODIPANIDE*)
I.N.INJECTIONSt(INTPAMUSCULAR INJECTION)
I B UTE N A Ct
ICTEROGENINt
IDOXURI DINE* (DEN DRI D) (HERPLEX LIQUIFILM) (STOXIL)
IMIPRPIMINE* (IMIPRANINE HYDROCHLORIDE) (TOPRANIL)
IMMUNE SERA*(ANTITOXINS)
1MM UNOSUPPRESSANTS (AZATHIOPRINE*) (PREDNISONE*) (CYCLOPHOSPHAMIDE*) (ANTILYMPHOCT! GLOBULINt)
INDANDIONES* (INDANDIONE DERIVATIVES) (ANISINDIONE*) (DIPHENADIONE) (PHENINDIONE*) (DIPAXIN)
INDICAN* (INDOXYL SULFATE)
INDIGOTINDISULFONt(INDIGOTINDISULFONATE) (INDIGO CARMINE)
INDOCYANINE GREEN* (CAR DIO-GRE!N)
INDOLEt
INDOLEACETIC ACID*
INDOLEPROPIONIC ACt (INDOLEPROPIONIC ACID)
INDOMETHACIN* (INDOCIN)
INOSITOLt (HEXAHYDROXYCYCLOHEXANE)
INSECTICIDES*(CRLORINATED INSECTICIDES*) (ORGANOPHOSPHORUS INSECTICIDES*) (ALDRIN*) (DIELDRIN*) (LINDANE*) (DIAZINON*)
INSECTICIDNS* (ROTENONE*)
INSULIN*(ILETIN) (ULTRALENTE) (NPH ILETIN) (SEMILENTE) (PROTAMIN! ZINC AND ILETIN)
INULINt
IODIDES*(IODATES*) (SODIUM IODIDE) (POTASSIUM IODIDE*)
IODINATED GLYCERIN* (ORGAN lOIN)
IODINE COMPOUNDS (IODINE SOLUTION) (IODINE TINCTURE) (POVIDONE-IODINEt) (UNDECOYLIUM*) (LIPIODOL*) (ETHIODOLt)
IODINE CONTAIN DPUG*(IODINE CONTAINING DRUGS) (ORGANIDIN) (DYCLONINE HYDROCHLORIDE)
IODIPAMIDEt (CHOLOGRAFIN) (IODIPA MID! MEGLUMINE) (SODIUM IODIPAMIDE) (BILIGRAFIN) (RADIOSELECTA N)
IODOALPHIONIC ACID* (PRIODAX)
IODOCASEIN*
IODOCHLORHYDROXYQU*(IODOCHLORHYDROXYQUIN) (I000CHLORHYDROXYQUINOLINE) (CLIOQUINOL) (VIOFORM) (ENTEBO-VIOFORM)
*
IODOPYRAET*(DIODRAST) (PYLtJNBRINE) (PYELOMBRINE) (DIODONE) (PERIODIL) (PYELOSIL) (UROGRAF) (VASIODONE)

I000PYRINE* (ANTIPYRINE IODIDE)
IODOTHIOURACIL*(5-IODOTHIOURACIL) (ITRUMIL) (IOTHIOURACL)
ION EXCHANGE PESIN*(CARBACRYLAMIN! RESINt) (POLYSTYRENE SULFONATE*)
IOPANOIC ACID* (TELEPAQUE) (CHOLADINE) (CI STOTEL) (COLEPAX) (FELOMBRINE) (IODOPANOIC ACI D) (TELETRAST)
IOPHENDYLATE* (PANTOPAQUE)
IOPHENOXIC ACIDt (TERIDAX) (TRILONBRINE) (TRILOSHADE)
IOPYDONE*
IOQUIN*
IOTHALA NATE* (IOTHALA MATE MEGLUNINE) (CONB AT) (ANGIO-CONRAY) (CONRAY-400) (SODIUM IOTHALAMATE) (IOTHALAMIC ACID)
IPODATE* (IPODATE CALCIUM) (IPODATE SODIUM) (ORAGRAFIN) (SOLU-BILOPTIN)
IPRINDOLE* (PRONDOL)
IPRONIAZID* (MAPSILID)
IRON DEXTRAN* (IMFERON) (IRON SORBITEX) (JECTOFER)
IRON SALTS* (FERROUS SULFATE) (FERROUS GLUCONATE) (FERROUS FUMARATE) (FEERIC AMNONIUM CITRATE) (IRON SORBITOL)
ISOCARBOXA ZID* (MARPLA N)
ISOFLUROPHATEt (PLO P0 PR YL)
ISONIAZID*(ISONICOTINIC ACID HYDRAZIDE) (NYDRAZID) (NICONYL) (TYVID) (HYZYD) (TEEBACONIN) (NICOZIDE) (RINI’ON)
I SOPROPANIDE* (I SOPPOPANIDE IODIDE) (T!RIMIDE) (PRIAMIDE) (DARBID) (ORNA DE) (TUSS-ORNADE)
ISOPPOPANOL* (ISOPROPYL ALCOHOL)
ISOPROTERENOL*(ISOPROTERENDL HYDROCHLORIDE) (AEROLONE) (DUOHALER) (ISUPPEL) (MEDIHALER-ISO) (NORISODRINE) (IPRENOL)
ISOPROTERENOLt(PROTERNOL) (ISOPROTEPENOL SULFATE) (ISOPRENALINE) (ISOPROPYLNORADRENALINE)
ISOSORBIDE*(ISOSOPBIDE DINITRATE) (ISORDIL) (SORBITRATE)
I SOSOR BITOL*
KANAMYCIN*(KANAMYCIN SULFATE) (KANTREX)
KAOLIN *(KAOLIN MIXTURE) (KAOP!CTATE)
KERATOLYTIC AGENTS (ANTHRALIN) (BICHLORACETIC ACID) (TRICHLOPAC!TIC ACID) (CANTHARIDIN) (CARBON DIOXIDE SNOW)
KERATOLYTIC AGENTS (CHRYSAROBIN*) (COAL TARt) (CRESOL*) (ICHTHAMMOL) (LIQUID NITROGEN) (PHENOLS*)
KERATOLYTIC AGENTS (PODOPHYLLUM) (RESORCINOLt) (SALICYLIC ACID) (PIGMENTATION AGENTS)
K ER OS EN
KETONE BODIES* (ACETONE*) (ACETOACETATE*) (HYDROXYBUTYR ATE)
LACTATE*(SODIUM LACTATE)
LACTATION*
LACTOBACILLtJS*(LACTOBACILLUS ACIDO?HILUS) (BACID) (LACTINEX)
LACTOSN*
*
LAXATIVES* (BISACODYL*) (CASCARA*) (CASTOR OIL*) (DANTHRONt) (GLYCERIN SUPPOSITORIES) (OXYPHENISATIN*)

LAXATIVESt (DIOCTYL SODIUM SULFOSUCCINATE) (COLACE) (SURFAK) (DIONEDICONE) (DOXINATE) (LAXINATE)
LAXATI VESt (PHENOLPRTHALEIN*) (SENNA*) (CAPROXYNETHYLCELLULOSE) (PLANTAGO) (PSYLLIUM) (MINER AL OILt)
LEAD*(LEAD SALTS) (LEAD CARBONATE) (LEAD CHROMATE) (LEAD OXIDE)
LEPROSTATIC AGENTS (ACETOSULFONE) (DAPSONE) (SULFOXONE*) (SULFONES*) (DIANINODIPHENYLSULFONEt)
LEUCINE*
LEVARTER ENOLt (LEVA RTEPENDL BITABTR ATE) (LEVOPHED BIT ARTRATE) (NORADRENALINE) (LEVOPHED) (NOREPINEPHPIN !*)
LEVODOPAt(DIHYDROXYPHENYLALANINE) (L DOPA) (BROCADOPA) (LEVODOPAMINE) (DOPAR) (LARODOPA) (DOPAIDAN)
LEVONEPPOMAZINE*
LEVOTH YROXINE* (LETTER) (TITROID) (SY NTHPOID) (LEVAXIN) (ELTROXIN)

LICORICE*(AMMONIUM GLYCYRPHIZATE)
LIDOCAINEt(LIDOCAINE HYDROCHLORIDE) (XYLOCAINE)
LIGHTt
LINCONYCINt(LINCOMYCIN HYDROCHLORIDE NONOHYDRATE) (LINCOCIN)
LINDANE*
LINOLEAMIDE* (N- (ALPHA-NETHYLBENZYL) LINOLEAMIDE)
LIOTHYRONINE*(LIOTHYRONINE SODIUM) (CYTOMEL)
LIOTRIX* (EUTHROID) (THYROLAR)
LIPENIA*
LIPI000Lt (IODIZIED OIL) (VISCIODOL)
L IP OC BROM Et
LIPONUL*(COTTONSEED OIL EMULSION INJECTION)
LIQUOID*(SODIUM POLYANETHOLSULFONATE)
LITHIUM* (LITHIUM CARBONATE*) (ESKALITH) (LITHANE) (LITHONATE)
LOCAL ANESTHETICS*(LIDOCAINE*) (BENZOCAINE*) (PRILOCAINE*) (PROCAINEt) (NEPIVACAINE) (TETRACAINS*)
LOCAL ANESTHETICS*(PROCAINAMIDE*) (CYCLOMETHYCAINE)
LUCANTHONE* (MIRACIL D) (NILODIN)
LUGOL’S IODINEt
LYMPHANGIOGRAPHIC AGENTS (ETHIODOL*)
LYSERGIC ACIDt(LYSEBGIC ACID DIETHYLANIDE) (DESEPIL) (LSD) (LYSERGIDE)
LYSINEt (LYSIN! MONOHYDROCHLORIDE)
LY S OL*
MAFENIDE* (MAPENIDE ACETATE) (NAFENIDE HYDROCHLORIDE*) (SULFAMYLON) (MAFENIDE ACETATE CREAM)
MAGNESIUM SALTS*(NAGNESIUN CARBONATE) (MAGNESIUM PHOSPHATE) (MAGNESIUM HYDROXIDE) (MAGNESIUM OXIDE) (MAGNESIUM SULFATE)
MAGNESIUM SALTS*(NILK OF MAGNESIA)
MALE !ERN*
MALIC ACID*
MALONIC ACID*
NALTOSE*
MANDELIC ACID*
MANGANESE SALTS* (MANGANESE DIOXIDE)
MANNITOL* (OSMITROL)
MANNO SEt
MAO INHIBITORS*(IPRONIAZID*) (PHENIPRAZINEt) (ETRYPTAMINE*) (PARGYLINE*) (PROCARBAZINE*) (NEBANAZINE*)
MAO INHIBITORS*(ISOCARBOXAZID*) (NIALAMIDEt) (PHENELZINE*) (TPANYLCYPROMINt*) (MONOAMINE OXIDASE INHIBITORS)
MAO INHIBITORS*(NEBANAZINE*)
MARIHUANAt (CANNABIS) (TETRAHYDROCANNABINOL)
MAR 0 PH! Nt
MDA* (3, ‘4-METHYLENEDIOXYAMPHETAMINE)
MEALS*(NON-PASTING STATE) (FOOD*)
MEASLES VACCINE*
NEAT*
NEBA NA ZI NEt
MECAMYLAMINEt (MECANYLAMINE HYDROCHLORIDE) (INVERSINE HYDROCHLORIDE)
MECHLORETHANINE* (NECHLORETHANINE HYDROCHLORIDE) (MUSTARGEN)
MEDROXYPROGESTERONEt (MEDROXYPROGESTERONE ACETATE)
MEFENAMIC ACIDt(PONSTEL)
NFFBUSI DE*
MEGFSTROL* (NEGESTROL ACETATE)
MELA NI Nt (MELANOGEN)
MELARSONYL*(NELARSONYL POTASSIUM) (TRIMELARSAN)
MELARSOPROLt(NEL B) (NELARSEN OXIDE BAL) (ARSOBAL)
NELPHALAN*(ALKERAN) (L-SARCOLYSIN) (CB 3025)
MENOPAUSE*
MENSTRUATION*
ME NT BOLt
MEPACRINE*(MEPACRINE HYDROCHLORIDE)
NEPAZINEt (PACATAL)
MEPERIDINE* (NEPEPIDINE HYDROCHLORIDE) (DENEROL) (PETHIDINE) (DOLANTIN) (DOLANTOL) (EUDOLAL)
NEPHENESIN*(MEPHENESIN CARBAMATE) (TOLSERAM) (DIOLOXOL) (TOLAX) (TOLSEROL) (MYANESIN)
MEPHENOXALONE* (TREPIDONE)
MEPHENYTOINt (NESANTOIN)
MEPROBAMATE* (EQUANIL) (NILTOWN) (ARCOBAN) (MEPROMON CMC) (VIOBANATE)
MERALLURIDE*(M!PALLURIDE SODIUM) (MERCUHYDRIN)
NERCAPTONERIN*(MERCAPTOMERIN SODIUM) (THIONERIN)
MERCAPTOPURINEt (6 NERCAPTOPURINE) (PURINETHOL)
MERCURIAL DIURETICS* (MERCUMATILIN) (NERBAPHEN) (MERCUPRIN) (DIURGIN)
MERCURIAL DIURETICS*(MEPSALYL*) (MEBALLURIDE*) (MERCAPTOMERIN*) (CHLORNERODIN*) (MERCUROPHYLLIN) (MERETHOXYLINE)
MER CU ROC H RO ME t
MERCURY COMPOUNDS* (MERCURIAL DI OR ETICSt) (NITBOMEPSOL) (PHENYLMERCURIC ACETATE) (PHENYLMERCURIC NITRATE) (M!RTHIOLATE*)
MERCURY CONPOUNDS*(THIMEROSAL) (MERCURIC IODIDE) (AMMONIATED MERCURY OINTMENT) (SULFUR OINTMENTS) (NERCUROCHROM!*)
NERSALYL*
NERTHIOLATE*
NESORIDAZINE* (SERENTIL)
MESTRANOL*(ENOVID) (NORINYL) (ORTHO-NOVUM) (OVULEN)
METAHEXA MIDE*
NETALS* (LEAD*) (MERCURY COMPOUNDS*) (NICKEL*)
MET A ND IE *
META PROTERENOL*
METAXALONE* (SKELAXIN)
METFORNINt
METHACHOLINE*(METHACHOLINE CHLORIDE) (MECHOLYL CHLORIDE) (MECHOLYL BROMIDE)
N!THACYCLINE* (METHACYCLINE HYDROCHLORIDE) (RONDO NYMIN)
METHADONE*(NETHADONE HYDROCHLORIDE) (DOLOPHINE) (ANIDONE) (BUTALGIN) (DIADONE) (NIADONE) (PHYSEPTONE) (POLAMIDONE)
METHAMPHETAMINE*(METHAMPHETAMINE HYDROCHLORIDE) (DESOXYN) (SYNDROX) (EFROXINE) (METHEDRINE) (NOROI)IN)
LIETHANPYRONE*
NETHANDRIOL*(ANDRODIOL) (MAD) (NEOSTENE) (STENEDIOL)
NETHANDROSTENOLONE* (DIANABOL)
METHANOLt (METHYL ALCOHOL) (WOOD ALCOHOL) (COLUNBIAN SPIRIT)
NETHAPYRILINE*(N!THAPYPILINE HYDROCHLORIDE)

METHAQUALONE*(METHAQUALONE HYDROCHLORIDE) (QUAALUDE) (SOPOR) (PAREST) (SOMNAFAC)
METHARBITAL* (GEMONIL)
NETHAZOLAMIDE (NEPTAZONE)
METHENAMINEt (METHENAMINE MANDELATE) (METHENANIN! HIPPURATE) (MANDELAMINE) (‘JRITONE) (HIPREX) (MANDACON)
METHICILLIN*(STAPHCILLIN) (METHICILLIN SODIUM)
METHIMAZOLE* (TAPAZ OLE)
METHIODOL* (NETHI000L SODIUM) (SKIODAN) (RETROPAQUE)
METHIONINE*
NETHOCARBANOL* (ROBAXIN)
METHOPHENOBARBITAL*
METHOTREXATE* (METHOTREXATE SODIUM) (AMETHOPTERIN)
N!THOTRIMEPRAZINE* (LEVOPROME)
METHOXSALEN* (MELOXINE) (OXSORALEN)
METHOXYFLURANE* (PENTHRANE)
METHSUXINIDE* (CELONTIN)
METHYCLOTHIAZIDE* (ENDURON)
METH YLBROMIDE*
METHYLCHOLINE*
METHYLDOPA*(METHYLDOPATE HYDROCHLORIDE) (ALDOCLOR) (ALDOMET) (ALDORIL) (ALDOMET ESTER HYDROCHLORIDE)
METHYLENE BLUE*
METHYLPHENIDATE* (METHYLPHENIDATE HYDROCHLORIDE) (RITALIN HYDROCHLORIDE)
METH YLPROMAZINE*
METHYLTESTOSTERONEt ( META NDRE N) (NEO-HOMBREOL M) (ORETON N) (ANDROID)
METH!LTHIOURACIL* (METHIACIL) (THIMECIL)
NETHYLTRYPTOPHA Nt
NETHYPRYLONt (NOLUDAR) (METHYPRYLONE)
NETHYSERGIDE*(METHYSERGID! MALEATE) (SANSERT) (DESERIL)
METOLAZONE* (ZAROXOLYN)
METRECAL*
METRI FONATEt
NETRIZOATE* (ISOPAQUE) (METRIOSIL) (RONPACON) (TRIOSIL)
METRONIDAZOLE* (FLAGYL)
METYRAPONE*(METOPIRONE) (METYRAPONE TARTRATE) (METOPIRONE TARTRATE)
MICR OBUTA NOL*
MINERAL OIL*
MI NERALOCORTICOIDS (H!DROCORTISONE*) (CORTISONE*) (PREDNI SOLONEt) (PREDNISONE*) (FLUDROCORTISONE*)
NINOXI DI Lt
MITHRAMYCIN* (MITHRACIN)
MITOMYCIN Ct
MITOTANE*(O,P-DDD) (LYSORDEN)
MK-270t
MONOFLUOROSULPHON* (MONOFLUOROSULPHONATE)
NORPHAZ INAMIDE*
NORPHINE*(MORPHINE SULFATE) (MORPHINE CHLORIDE)
MOUTH WASHES*
MUSCLE RELAXANTS (NEPHENSIN*) (METHOCARBAMOLt) (STYRANATE) (CHLORZOXAZONE*) (CARISOPRODOL)
MUST LE RELAXANTS (ORPHENADRINE) (ETHOPROPAZINE) (LEVODOPA*) (BULBOCAPNINE)
MUSCLE RELAXANTS (TRIHEXYPHENIDYL) (BIPERIDEN) (CYCRIMINE) (PROCYCLIDINE) (BENZTROPINE) (CHLORPHENOXAMINE)
MUSTARD GAS*
MYELOGRAPHIC AGENTS (IOPHENDYLATE*) (METRIODOL*)
MYOGLOBIN*
NAFCILLIN* (NAFCILLIN SODIUM) (UNIPEN)
NAFENOPINt
NALIDIXIC ACID*(NEGGRAM)
NALORPHINE* (NALLINE)
NANDROLONE* (NANDROLONE PHENPROPIONATE) (DURABOLIN)
NAPHTHALENE* (NAPHTHALIN) (TAR CAMPHOR)
NAPHT BOLt
NAPHTHOXYACETIC ACt (B-NAPHTHOXYACETIC ACID)
NARCOTIC ANTAGONISTS (NALORPHINE*) (LEVALLORPHAN) (PENTAZOCINEt)
NARCOTICS* (HYDROCODONE) (HEROIN) (METOPON) (OXYCODONE) (NALORPHINE*) (NALOXONE) (APOMORPHINE*) (PHENAZOCINE*)
NARCOTICS* (LEVORPHANOL) (METHA DONE*) (METHOTRIMEPRAZINE*) (OXYMORPHONE) (PENTAZOCINE*) (PIMINODINE) (CODEINE*)
NARCOTICS* (MORPHINE*) (NEPERIDI NEt) (ALPHAPRODINE) (ANILERIDINE*) (FENTANYLt) (HYDROMORPHONE) (ETHYLMORPHINE)
NARCOTICS* (PROPOXYPHENEt) (OPIATES*)
NEO-LOPAX*
NEOMYCIN*(NEONYCIN SULFATE) (MYCIFRADIN) (MYCIGUENT) (NEOBIOTIC) (NEO-CORTEF)(NEOSPORIN) (EPIMYCIN) (FRAMYCETIN)
NEOSALVARSAN*
NEOSTYGMINEt (NEOSTIGMI NE BROMIDE) (PROSTIGNIN BRONI DE)
NESSLER’S REAGENT*
NEUROMUSCULAR*(NEUROMUSCULAR BLOCKING AGENTS) (CURARE) (SUCCINYLCHOLINE*) (TUBOCURARINE*) (GALLAMINE*) (DECAMETHONIUM*)
NIAGARA SKY BLUEt
NIALAMIDE* (NIAMID)
NICKEL* (NICKEL CARBONYL)
NICOTINA MIDEt
NICOTI NEt
NICOTINIC ACID* (NICOTINA MIDE*) (NIACIN) (ADENOCREST) (ADENOLIN) (MENIC) (NICO-SPAN) (NICOTINEX) (RAGUS) (VASTRAN) (NICALEX)
NICOTINIC ACID*(NICOTINYL ALCOHOL) (RONIACOL)
NIFURTIMOX* (BAYER 2502)
NIKETHANIDEt (CORAMINE)
NIRIDAZOLE* (ANBILHAR)
NITRATES*(BISMUTH SUBNITRATE) (ISOSORBIDE DINITRATE) (NANNITOL HEXANITRATE) (TROLNITRATE) (PENTAERYTHRITOL TETRANITRATE)
NITRAZ EP ANt (MOG A DON)
NITRIC ACID*
NITRITES *(AMYL NITRITEt) (SODIUM NITRITE) (NITROGLYCERIN*)
NITROBENZENE*
NITROFURA NS* (NITROFURA NTOI Nt) (NI TROFURAZONE*) (FURAZOLIDONE*) (TRICOFURON) (NITROFURAL)
NITROFURANTOIN* (FURADANTIN) (MACRODA NTIN) (NITREX) (STERI-NED) (TRANTOIN)
NITROPURAZONE*(FURACIN) (DYNAZONE) (ELDEZOL)
NITROGEN OXIDES* (NITRIC OXIDE) (NITROUS OXIDEt) (NITRIC DIOXIDE) (NITROGEN TRIOXIDE) (NITROGEN PENTOXIDE)
NITROGLYCERIN* (ANGIBID) (NITROGLYN) (NITRONG) (NITROSPAN) (GLYCERYL TRINITRATE)

NITROUS OXIDE*
NOREPINEPHRINEt(NORADRENALINE) (LEVARTERENOLt)
N0ETHANDROLONE* (NILEVAR)
NORETHANDROSTENOLt (NORETHANDROSTENOLONE)
NOBETHINDRONEt (GESTEST) (NOPINYL) (NORLESTRIN) (ORTHO-NOVUM) (NORLUTIN) (NORETHINDRONE ACETATE) (NORLUTATE)
NORETHISTERONEt
NOPNTHYNODREL* (ENOVID-B)
NOR T!S P05 T!R ONE *
NORTPIPTYLINE*(NORTRIPTYLINE HYDROCHLORIDE) (AVENTYL)
NOVOBIOCINt (NOVOBIOCIN CALCIUM) (NOVOBIOCIN SODIUM) (ALBAMYCI N) (PANALBA)
NSD 3004*
NUCLEOPROTEIN 5*
NUTRITIONAL AGENTS (NON-FASTING STATE*) (FOOD) (FAT EMULSION) (LIPONULt) (METRECALt) (LIPENIAt)
NYSTATI Nt (ACHPOSTATIN) (DECLOSTATIN) (MYCOSTATIN) (NYSTA) (TETREX) (NILSTAT)
OLEANDOMYCINt (OLEANDOMYCI N PHOSPHATE) (TRIACETYLOLEANDOMYCIN) (TAO) (TROLEANDOMYCIN) (CYCLAMYCIN) (MATROMYCI N)
OPIATES*(MOPPHINE*) (CODEINEt) (NEPEBIDINEt) (PAPAVERETUM) (DIBYDROMORPHINONE) (NETHYLDIHYDROMORPHINONE)
OPIATESt (OXYMORPHONE) (DIHYDROCODEINE)
ORAL :ONTRACEPTIVE*(ESTROGEN*) (PROGESTOGENt) (OVULEN) (DEMULEN) (PROVEST) (NORINYL) (ORTHO-NOVUM)
OPAL CONTRACEPTIVE* (NORLESTRIN) (ENOVID) (OVRAL) (C-QUENS) (ORACON) (NORQUEN) (ENOVID-E) (ORTHO-NOVUM SQ)
ORAL PESINSt
ORGANIC IODIDES (IODOALPHIONIC ACIDt) (IOPANOIC ACIDt)
OP.GANOPHOSPHORUSt (ORGANOPH OSPHORUS IN SECTICIDES) (METASYSTOX) (EKATIN) (FOLITHION) (LEBAYCID) (DIPTEHEX)
ORGANOPHOSPHORUS*(ALDRINt) (DIELERINt) (ENDRIN) (TELODRIN) (DFP) (MIPAFOX) (TABUN) (SARIN) (SOMAN) (PARAOXON)
ORGANOPHOSPHORUSt (PA BATh ONt) (THIOPHOS) (EPN) (MALATHION) (TEPP) (OMPA) (SCHRADA N) (ECHOTHIOPHATEt)
OROTIC ACIDt
OS MOTIC D IU RETICS (UREA*) (MANNITOLt) (UREAPHIL) (UREVERT) (OSNITROL) (ISO-SORBI TOL*) (GLUCOSEt) (SUC ROSEt)
OVULATI ONt
OXACILLINt (OXACILLI N SODIUM) (PROSTAPULIN)
OXALATESt(POTASSIJM OXALATEt) (AMMONIUM OXALATE*) (SODIUM OXALATE*) (OXALIC ACID)
OXALOACET *
OXANDROLONEt (ANAVAR)
OXAZEPAMt (SERAX)
OXAZOLIDINEDIONES (TRINETHADIONEt) (PARANETHADIONE*)
OXYMETHOLONEt (ADROYD) (ANADROL)
OXYPHENBUTAZONEt (TANDEARIL)
OXYPHENISATIN* (OXYPHENISATIN ACETATE) (PRULET) (EVASOF) (HYDROLOSE) (SYNCELAX) (URBALAX) (yb-LAX) (ISOCRIN) (DIALOSE)
OXYTETRACYCLIN!*(TERRA-CORTRIL) (OXYTETRACYCLINE CALCIUM) (OXYTETRACYCLINE HYDROCHLORIDE) (TERRAMYCIN) (TERRASTATIN)
PA I Nt
PAMAQUINEt(PAMAQUINE NAPHTHOATE) (PLASNOQUINE)
PA NCREOZY MI Nt
PANTOT HEN YL ALCOHOLt
PAPAVERINEt (PAPAVERINE HYDROCHLORIDE) (CERESPAN) (PAVABID) (VASOSPAN) (BLUPAV)
PARABROMDYLAMINE*(PARABRONDYLAMINE NALEATE) (DIMETANE)
PARALDEHYDN* (PAPAL)
PARAMETHADIONEt (PARADIONE)
PARAMETHASONEt (PARAMETHASONE ACETATE) (HALDRONE) (STENNEX)
PARASYMPATHOMINETIC ANINES*
PARATHION*
PARATHYROID EXTRACT* (PAROIDIN) (PARATHYROID INJECTION)
PARGYLINEt (PARGYLINE HYDROCHLORIDE) (EUTONYL)
PAROMOMYCIN t (PAROMOMYCIN SULFATE) (HUMATIN)
PECAZINEt
PENPIDINE*
PENETRAMATE*(PENETRANATE HYDRIIODIDE) (LEOCILLIN) (NEOPENIL) (ESTONYCIN) (!STOPEN)
PENICILLANINEt (CUPRIMINE)
PENICILLINt(AMPICILLINt) (METHICILLINt) (OXACILLINt) (CARBENICILLINt) (PHENOXYMETHYL PENICILLIN) (PHENETHICILLINt)
PENICILLIN*(PENICILLIN G) (CLOXACILLIN*) (DICLOXACILLINt) (NAFCILLIN*) (HETACILLIN*)
PENTAGASTRINt (PEPTAVLON)
PENTAMIDINE (PENTAMIDINE ISETHIONATE) (LOMIDINE)
PENTA QU INEt
PENTAZOCI NEt (TALWIN) (FOBTRAL) (P ENTA ZOCINE HYDROCHLORIDE) (PENTAZOCINE LACTATE) (FORTRALIN) (SOSEGON) (SOSIGON)
PENTOLINIUM*
PENTYLENETETRAZOL* (METRAZOL) (CENALENE-M) (CARDIA ZOL)
PERCHLORATE* (POTASSIUM PERCHLORATE)
PERHEXILENE*(PERHEXILEN! MALEATE) (PREXID)
PERIODATEt
PERMANGANATEt(POTASSIUM PERNANGANATE)
PEROXIDE* (HYDROGEN PEROXIDEt)
PERPHENAZINEt (TRILA EON)
PHENACEMIDE* (PHENURONE) (PHENYLACETYLUREA)
PHENAGLYCODOLt (DAVO-TRAN) (ULTRA N)
PHENAZOCINE*(PHENAZOCINE HYDROBRONIDE) (PRINADOL)
PHENAZOPYRIDINE*(PHENAZOPYRIDINE HYDROCHLORIDE) (AZO-NANDELAMINE) (DOLONIL) (DONNASEP) (PYRIDIUM) (THIOSULFIL)
PHENBLZINEt (PHENELZINE SULFATE) (NARDIL)
PHENETHICILLINt (SYNCILLIN)
PHENETURIDEt (PHENYLETHYLACETYL UREA)
PHENFORMINt (DBI) (PHENPORNIN HYDROCHLORIDE)
PHENINDIONEt(DANILONE) (HEDULIN) (ERIDIONE) (DINDEVAN)
PHENIODOL*
PHENIPRAZINEt (CATRON)
PHENMETRAZINEt (PHENMETRAZINE HYDROCHLORIDE) (PRELUDIN)
PHENOBARBITALt (BARBIPIL) (BARBITA) (ESK ABARB) (HYPNETTE) (LIXOPHEN) (SOLUBARB) (PHENOBARTITAL SODIUM) (LUMINAL)
PHENOLIC CONPOUN DS (PHENOLS*) (HEXACHLOROPHENE) (PHISOHEXt) (CHLOROTHYNOL) (CREOSOTEt) (CRESOLt)
PHENOLPHTHALEIN* (AGORAL) (CAROID) (EVAC-U-GEN) (KONDREMUL) (NOVALAX) (PHENOLAX)
PHFNOLSt (PHENOL DERIVATIVES) (LIQUIFIED PHENOL) (PHENOLATED CALAMINE LOTION) (CARBOLIC ACID)
PHRNOTHIAZINES* (CARPHENAZINEt) (FLUPEIENAZINEt) (VERPHENAZINEt) (PROCHLORPBRAZINEt) (TRIFLUOPERAZINE*)
PHENOTHIAZINES*(CHLOFPRONAZINEt) (NESORIDAZINE*) (THIORIDAZINEt) (ACETOPHENAZINE*) (BUTAPERIZINE*)
PHENOTHIAZINESt (PRONETHAZINEt) (PROPIOMAZINE) (PRONAZINEt) (TRIFLUOPERAZINE*) (NETHOTRINEPRAZINEt) (TRIFLUPRONAZINE*)
PHENOTHIAZINESt(THIOPROPAZATE*) (PIPERACETAZINE*) (METHDILAZINE) (TRIMEPRAZINEt)
PHENOXYBENZAMINEt (DIBENZYLINE)

PHENSUXIMIDEt (NILONTIN)
PHENTOLANINE*(PHENTOLANINE MESYLATE) (PHENTOLAMINE HYDROCHLORIDE) (REGITINE)
PHENYLALANINE*
PHENYLUTAZONE*(BUTAZOLIDIN) (STERAZOLIDIN) (BUTAZOLIDIN ALKA)
PHENYLENEDIAMINEt
PHENYLHYDRAZINE*
PH ENYLI NDANDIONE*
PHENYLISOPROPYLHYD* (BETA-PHENYLISOPROPYLBYDRAZINE) (CATRON)
PH ENYL PROPANOLAMINE*
PHENYLPYRAZOLONE DERIVATIVES (PHENYLBUTAZONEt) (ANTIPYRINEt) (AMINOPYRINE*) (DIPYRONEt)
PHENYLPYRUVIC ACID*
PHENYLSALICYLATEt
PHENYLTHIOU REA*
PHENYRAMIDOLt(ANALEXIN) (PHENYRANIDOL HYDORCHLORIDE)
Ht
PH LORI DZI Nt
PHOSPHATESt (HYPER-PHO5-K)
PHOSPHO SODAt
PHOSPHORUS* (ELEMENTAL PHOSPHORUS) (RED PHOSPHORUS) (YELLOW PHOSPHORUS)
PBYLLOERYTHRINOGENt(GREEN VEGETABLES)
PHYSOSTIGMINEt (PHYSOSTIGNINE SA LICYLATE) (PHYSOSTIGNINE SULFATE) (ESROMIOTIN) (ISOPTO-ESERINS)
PHYTONADIONEt(AQUANEPHYTON) (KONAKION) (MEPHYTON) (VITAMIN Ki)
PICRIC ACID*
PIDH (1-(2-PYRIMINIDINYL)-14-ININO-1,Lt-DIHYDROPYRIDINE HYDROCHLORIDE)
PIGMENTATION AGENTS (SUNTAN OIL*) (HYDROQUINONE*) (METHOXSALEN*) (TRIO XSALENt)
PILOCARPINEt (PILOCARPI NE HYDROCHLORIDE) (PILOCARPINE NITRATE)
PINEA PPLESt
PINK CAPSULES*
P1 PAMAZINEt
PIPERACETAZINEt (QUID!)
PIPERAZINESt (CHLORCYCLIZINE) (CYCLIZINE) (MECLIZINE)
PIPERAZINES*(PIPERAZINE CALCIUM EDETATE) (PIPERAZINE CITRATE) (PIPERAZINE PHOSPHATE) (PERIN) (ANTEPAR) (PIPIZAN)
PIPERIDINES*(MEPERIDINE*) (ANILERIDINEt) (ALPHAPRODINE)
PIPOBROMANt (VERCYTE)
PLANTA INSt
PLA SNOQUI Nt
PLUMS*
POLIOMYELITIS VACt(POLIOMYELITIS VACCINE)
POLYMYXIN B*(POLYNYXIN) (POLYMYXIN B SULFATE) (AEROSPORIN)
POLYSTYRENE SULFON*(SODIUM POLYSTYRENE SULFONATE) (KAYEXALATE) (CATION-EXCHANGE RESINS) (ION EXCHANGE RESINt)
POLYTHIAZIDE* (RENESE)
PORPHY RINSt
POSTERIOR PITUITARY* (PITUITRIN)
POTASSIUM AMINOBENZ*(POTASSIUM P-ANINOBENZOATE)
POTA SSIUM CELORI DEt (DI ASAL) (KAOCHLOR) (K-LOR) (KAY-CIEL)
POTASSIUM IODIDE*(MUDRANE) (PIMA) (SYNATE-N) (THEOKIN)
POTASSIUM SALTS*(POTASSIUN BROMIDE) (POTASSIUM PERMANGANATE)
POTASSIUM SALTS*(POTASSIUM CHLORATE*) (POTASSIUM P-AMINOBENZOATEt) (POTASSIUM PERCHLORATE*)
POTASSIUM SALTSt(POTASSIUM CHLORIDE*) (POTASSIUM GLUCONATEt) (POTASSIUM IODIDE*) (POTASSIUM OXALATE*)
POVIDONE-IODINEt (BETADINE) (ISODINE)
PREDNISOLONE* (DELTA-CORTEF) (HYDELTRASOL) (PREDNISOLONEACETATE) (METICORTELONE) (PREDNI SOLONETEBUTATE) (OTOBIONE)
PR!DNISONE* (ANT HRALGEN) (BETAPAR) (DELTA -DOME) (DELTA SON!) (STERAZOLIDIN) (DELTRA) (METICORTEN) (PARACORT)
PREGNANCY*
PREMARIN* (CONJUGATED ESTROGENS)
PRILOCAINE* (PRILOCAINE HYDROCHLORIDE) (CITANEST)
PRIMAQUINEt (PRIMAQUINE PHOSPHATE)
PRIMIDONE* (MYSOLINE)
PROBENECIDt (BENEMID) (COLBENEMID)
PROBUCOLt (DH-581) (BIPHENABID)
PROCAINAMIDE*(PROCAINANIDE HYDROCHLORIDE) (PRONESTYL)
PROCAINEt(ANUCAINE) (NOVOCAINE) (PROCAINE HYDROCHLORIDE)
PROCARBAZINE* (PROCARBAZINE HYDROCHLORIDE) (MATULANE) (NATULAN)
PROCHLORPERAZINE* (COMPAZINE) (ESKATROL) (PROCHLORPERAZINE EDISYLATE) (PROCI1LORPERAZINE MALEATE)
PROCYCLIDINEt(KENADRIN)
PROGESTERONE* (GESTEROL) (LIPO-LUTIN) (PROLUTON)
PROGESTINt (CHLORNADI NONEt) (DIMETHISTERONEt) (NORGESTREL) (HYDROXYPROGESTERONE) (DY DROGESTERONEt) (ETHI STERONE)
PPOGESTIN*(CYPPOTERONE*) (ACETOPHENONE)
PROGFSTIN* (MEDROXYPROGESTERONEt) (ETHYNODIOLt) (NOR ETHINDRONE*) (NORET HYNODREL*) (MEGESTROL ACETATE) (PROGESTOGEN)
PROGUANIL*
*
PROMAZINEt (PROMAZINE HYDROCHLORIDE) (SPARINE)

PROMETHAZINEt (PROMETHAZINE HYDROCHLORIDE) (MEPERGAN) (PHENERGAN)
PROPOXYPHENEt (PROPOXYPHENE HYDROCHLORIDE) (DARVON)
PROPRANOLOLt(PROPRANOLOL HYDROCHLORIDE) (INDERAL)
PROPYLIODONEt (DIONSIL)
PROPYLTHIOURACILt (PROP AC IL)
PROPYNYL-CYCLOHEXt (PROPYNYL-CYCLOHEXANOL CARBAM ATE)
PROSTATE PALPATION*(PROSTATIC PALPATION) (PROSTATIC MASSAGE)
PROTAMINEt (PROTAMINE SULFATE)
PROTEINt(HIGH PROTEIN DIET) (HIGH MEAT DIET)
PROTEINURIAt
PROTHIONA MI DEt
PROTOCATECHUIC ACIDt
PROTOZOACIDES (PENTAMIDINEt)
PROTRIPTYLINE*(PROTRIPTYLINE HYDROCHLORIDE) (VIVANTIL)
PSPt (PHENOLSULFONPHTHALEIN) (PHENOL RED)
PSYCHOTOGENIC DRUGS (N ESCALINE) (LYSERGIC ACID DIETHYLAMIDEt) (MARIHUANAt)
PYELOGPAPHIC AGENTS (DIATRIZOATE*) (IOTHALAMATEt)
PYRATHIAZINEt
PYRAZINAMIDEt(ALDINAMIDE) (TEBRAZID) (PZA)

PYPAZINOIC ACIDt
PYRAZOLONESt (PYRAZOLONE DERIVATIVES) (AMINOPYRINE*) (ANTIPYBINE*) (NIFENAZONE) (MONOPHENYLBUTAZONE)
PYRIDOXINEt
PYRIDYLCAPBINOL*(BETA PYRIDYLCAFRINOL) (B-PYRIDYLCARBINOL) (NICOTINYL ALCOHOL) (RONIACOL TIMESPAN)
PYRIMETHMINEt (DARAPPIM)
PYBOGA LLOLt
PYROGENt (3ACTERIAL ENDOTOXIN)
PYPUVATE* (PYRUVIC ACID)
PYRVINIUM PAMOATE* (‘OVAN) (VANQUIN)
QUATERNAPY* (MEPENZOLATE) (NETUSCOPOLANINE) (PENTAPIVERIDE) (PROPANTHELINE) (VALETHANATE) (ANISOTROPINE)
QUATERNARYt (MET’IANTHELINE) (DIPHEMANIL) (GLYCOPYRROLATE*) (HEXOCYCLIUN) (HONATROPINE) (ISOPROPAMIDE*)
QUATERNARYt(OXYPHENUNIUM) (PENTHIENATE) (PIPENZOLATE) (POLDINE) (TRIDHEXETHYL)
QUATERNAPYt(QUARTEPNARY AMMONIUM COMPOUNDS) (BEPHENIUM) (BENZALKONIUM) (BENZETHONIUM) (CETYLPYRIDINIUM)
QUINACRINE*(QUINACRINE HYDROCHLORIDE) (ATABRINE) (MEPACRINE HYDROCHLORIDE) (ATEBRIN)
QUINALBARBITP.Lt
QUINAZOLINES*
QUINETHAZONE* (HYDROMOX)
QUINIDINEt(QUINAGLUTE) (CARDIOQUIN) (QUINIDEX)
QtY INID INE* (QUINIDINE GLUCONATE) (QUINIDINE SULFATE) (QUINIDINE POLYGALACTURONATE) (QUINIDINE HYDROCHLORIDE)
QUININE IODOBISt (QUININE IODOBISMUTHATE) (BI-IOCHINOL) (BISMOSALVAN)
QUININEt (QUININE SULFATE) (QUINAMM) (QUININE DIHYDROCHLORIDE)
QUI NOd DE*
RADIOACTIVE IODINE*(SODIUN IODIDE 1131) (IODOTOPE) (ORIODIDE-131) (RADIOCAPS-131) (THERIODIDE-131) (TRACERVIAL-131)
RADIOACTIVEt(PADIOACTIVE AGENTS) (IRRADIATION) (X-RAY THERAPY) (RADIOACTIVE IODINE*) (SODIUM PHOSPHATE P32*)
PADIOGRAPHIC* (BARIUM SULFATEt) (DIATPIZOATEt) (IODIPAMIDEt) (LIPIODOLt) (IODOPYRACET*) (IOPANOIC ACIDt) (ADIPIODONEt)
RADIOGRAPHIC* (IOPHENDYLA TEt) (IOTHALANATE*) (IPODATEt) (NETHIODOL*) (ETHIODOLt) (PROPYLIODONEt) (IOGLYCAMATE) (IOPYDONEt)
RADIOGPAPHIC* (RADIOGRAPHIC CONTRAST MEDIA) (BADIOPAQUE MEDIA) (ACETRIZOATE*) (GALLBLADDER DYES) (PHENIODOLt) *
RAUWOLFIA*(AJMALINEt) (RESERPILINE) (SERPENTINE)

RAUWOL!IAt(RAUWOLFIA ALKALOIDS) (ALSEROXYLON) (RESERPINEt) (DESERPIDINEt) (RESCINNAMINE) (SYPOSINGOPINEt)
RECUMBENCYt (BED REST*) (LYING DOWN)
RED DYED DRUGS* (TETRAIODOFLUORESCEIN*)
RED DYED FOODt(TETRAIODOFLUORESCEINt)
RESERPINEt (BUTISERPINE) (DIUPRES) (ENDUPONYL) (HYDROVRFS) (RAUZIDE) (RENESE-R) (REGROTON) (SERPASIL) (RAURINE) (RAULOYDIN)
RESORCINt
PESOBCINOL* (RESORCINOL MONACETATE) (EUBESOL) (CARFUSIN) (CENAC) (FUSINOL) (KONED) (RESULIN) (RETAFEN)
RHUBARB*
RIBOFLAVINt(VITAMIN B2)
P 13055*
RIFAMPINt (RIFAMYCIN) (RINACTAN) (PIMACTANE) (RIPADIN) (PIFOLDIN) (RIFAMPICIN)
RISTOCETIN* (PISTOCETIN A) (RISTOCETIN B) (SPONTIN)
ROOM TEMPERATUREt(ANBIENT TEMPERATURE)
POT EN ON
SALICYLAZOSULFAPYRt (SALICYLAZOSULFAPYRIDINE) (AZULFIDINE) (SALAZOPYR IN)
SALINEt (SODIUM CHLORIDE)
SALIVAt
SALOL*
SANTONINt
SAUEPKPAUTt
SC- 161 02* (5-ETHOXYETHYL-2-AMINO-4-AZIDO-6-PHENYLPYRI MIDINE)
SCABICIDES (B!NZYL BENZOATE) (CHLOROPHENOTHANE*) (CROTANITON) (GAMMA BENZENE HEXACHLORIDE*)
SECOBA BBITAL* (SECONAL) (TUIN AL)
SECRETINt
SEDATIVE-HYPNOTICS (BARBITURATES*) (CHLORAL DERIVATIVES*) (ETHCHLORVYNOL*) (ETHINAMATE*)
SEDATIVE-HYPNOTICS (CHLORDIAZEPOXIDE*) (DIAZEPANt) (NITRAZEPAM*) (OXAZEPAM*) (METHYPRYLON*) (FLURAZEPAM*)
SEDATIVE-HYPNOTICS (DICHLORALPHENAZONE*)
SEDATIVE-HYPNOTICS (GLUTETHIMIDE*) (METHAQUALONEt) (CARBROMALt) (PARALDEHYDEt) (BROMIDES*)
SEDATIVE-HYPNOTICS (URETHANt) (HEDONAL) (APRONALt) (NEPROBAMATE*) (BROMISOVALUN*)
SEDOPM ID* (ALL YL- ISOPROPYL-ACETY LCARBAMIDE)
SENNA* (SENOKOT) (APERENS) (CASAFRU) (GLYSENNID)
SERINFt
SERUNt (COMPARED WITH PLASMA) (CLOTTING) (CLOTTING OF SAMPLE)
SIALOGRAPHIC AGENTS (LIPIODOLt) (ETHIODOLt)
SILVER*(SILVER SALTS) (SILVER NITRATE) (SILVER COMPOUNDS)
SINOGRAPHIC AGENTS (LIPIODOL*)
SITOSTEROL* (CYTELLIN)
S KA TO LEt
SKELETAL MUSCLE RELAXANTS (CARISOPRODOL) (CHLORPHENESIN) (CHLORZOXAZONEt) (MEPHENESINt) (METAXALONEt) (NETHOCARBANOLt)
SKELETAL MUSCLE RELAXANTS (ORPHENADRINE CITRATE) (CHLORDIAZEPOXIDE*) (DIAZEPAMt) (MEPROBANATEt)
SLEEPt
SMALLPOX VACCINEt
SNOKING* (NICOTINE*) (TOBACCO SMOKE*)
SODIUM NITROPRUSSIt (SODIUM NITROPRUSSIDE)
SODIUM PHOS P32t(SODIUM PHOSPHATE P32) (PHOSPHOTOPE)
SODIUM SALTS*(SODIUM BROMIDE) (SODIUM IODIDE) (SODIUM PHOSPHATE P32*)
SODIUNt(SODIUM PHYTATF*) (SODIUM SULFATE*) (SALINEt) (SODIUM CHLORIDEt*)
SODIUNt(SODIUM SALTSt) (SODIUM NITROPRUSSIDEt) (SODIUM BICARBONATEt) (SODIUM IPODATEt) (SODIUM OXALATEt)
SPECTI NOMYCIN* (SPECTINOMYCIN DIHYDROCHLORIDE PENTAHYDRATE) (TROBICIN)
SPINAL ANESTHESIA*
SPIRONOLACTONE*(ALDACTAZIDE) (ALDACTONE)
SPLENOPORTOGRAPHIC AGENTS (DIATPIZOATE*)
STANOZOLOLt (WINSTROL)
STI BOCAPTATE*
STIBOPHENt (FUADIN)
STI LBESTROLt
STORAGE OF SAMPLE*(STORAGE OF SERUM) (STABILITY OF SAMPLE)
STREPTOKINASEt(STREPTOKINASE-STREPTODORNASE) (VARIDASE) (KABIKINASE) (STREPTASE)
STREPTOM YCINt
STREPTOZOTOCI Nt
STPONTIUM*
STRYCHNINEt

SUCCINIMIDESt(ETHOSUXIMIDE*) (METHSUXIMIDEt) (PHENSUXIMIDE*)
SUCCINYLCHOLIN’!* (SUCCINYLCHOLIN! CHLORIDE) (ANECTINE) (QUELICIN) (SUCOSTRIN) (SUXINYL CHLORIDE) (SCOLIN!)
SUCCINYLSULFATHIAZ*(SUCCINYLSULFATHIAZOLE) (CRENOSUXIDINE) (SULFASUXIDINE)
SULFACETANIDE*(SULFACETAMIDE SODIUM) (UROSULFON) (SULAMYD)
SULFADIAZ INEt (SULA MYD) (SULFADIAZINE SODIUM)
SULFADIMETHOXINEt (NADRIBON)
SULFADINIDINEt
SULFA FURAZOLEt
SULFAGUANIDINEt
SULPAMERAZINEt(SULFAMEPAZINE SODIUM)
SULFAMETHIZOLE*(AZOTREX) (MESULFIN) (SULADYNE) (THIOSULFIL)
SULFAMETHOXAZOLE* (GANTANOL)
SULFANETHOXYPYRID* (SULFAMETHOXYPYPIDAZINE) (KYNEX) (MIDICEL)
SULFANILA MIDEt
S UL? A PH ENA ZOL E*
SULFAPYRIDINEt
SULFA PTH BOLt
SULFATES* (FERROUS SULFATE) (PROTAMINE SULFATE) (SODIUM SULFATEt)
SULFATHI AZOLEt
SULFHYDRYL CONPS*(SULFHYDRYL COMPOUNDS) (SULFHYDRYL GROUPS)
SULFINPYRAZONE*(ANTURANE)
SULFISOXAZOLEt (SOSOL) (GANTRISIN) (ENTUSI L) (ACETYL SULFISOXAZOLE) (SULPISOXAZOL! DIOLA MINE)
SUL?ONAMIDESt(PARA-NITROSULFATHIAZOLE) (PHTHALYLSULFACETANIDE) (PHTHALYLSULFATHIAZOLE) (SALICIYLAZOSULFAPYRIDINE*)
SULFONAMIDES*(SUCCINYLSULFATHIAZOLE*) (MAFENIDEt) (SULFANILAMIDE*) (SULFAPHENAZOLEt) (ACETYLSULFANILAMIDE*)
SULFONANIDESt (SULFACETAMIDEt) (SULFACHLOROPYRIDAZINE) (SULFADIAZINEt) (SULFA MERAZINEt) (SULFANTHIDOLE)
SULFONAMIDES*(SULFAMETHAZINE) (SULFAMETHIZOLEt) (SULFANETHOXAZOLE*) (SULFAPYRIDINE*) (SULFATHIAZOLE)
SULFONAMIDESt(SULFISOMIDINE) (SULFISOXAZOLE*) (SULFADIMETHOXINEt) (SULFANETER) (SULPAMETHOXYPYRIDAZINEt)
SULFONEMETHANEt (SULFONAL)
SULFONESt (DIANINODIPHENYLSULFONE*) (ACETOSULFON!) (SULFOXONEt) (THIAZOLSULFONE*) (GLUCOSULFONE*)
SULFONESt (SULFETRONE) (DADDS)
SULPONETHYLNETHANE* (TRIONAL)
SULFONYLUREAS*(HYDROXYHEXANID!t) (CARBUTAMIDEt) (METAHEXANIDE*)
SULFONYLUREASt (ORAL HYPOGLYCEMIC AGENTS) (ACETOHEXAMIDEt) (CHLORPROPAMIDE*) (TOLAZAMIDEt) (TOLBUTA MIDEt) (GLYBURIDE*)
SULFOXONEt(SULFOXONE SODIUM) (DIASONE SODIUM)
SULTHIANE* (CONADIL) (OSPOLOT)
SUNTAN OIL*
SURANIN* (SURAMIN SODIUM) (ANTRYPOL) (BAYER-2O5) (GERNANIN) (MORANYL) (NAPHURIDE SODIUM)
SWEET POTATOESt
SYMPATHOMINETIC DRUGS (CYCLOPENTANINE) (PROPYLHEXEDRINE) (F!NFLURAMINE*)
SYNPATHOMIMETIC DRUGS (EPHEDRINEt) (PHENYLPROPANOLAMINE*) (MEPHENTERMINE) (CHLORPHENTERMINE) (TUAMINOHEPTANE)
SYMPATHOMINETIC DRUGS (NYLIDRIN) (ISOXSUPRINE) (METHOXYPHENANINE) (METHOXANINE) (AMPHETAMINE*) (METHAMPHETAMINE*)
SYNPATHOMIMETIC DRUGS (PHENYLETHYLAMINE) (EPINEPHRINEt) (NOREPINEPRRINE*) (DOPANINEt) (NORDEFRIN) (ISOPROTERENOL*)
SYNPATHOMINETIC DRUGS (PROTOKYLOL) (METAPPOTER!NOL*) (NETARAMINOL) (PHENYLEPHRIN!) (TYRANINE) (HYDROXYAMPHETANINE)
SYROSINGOPINE* (SINGOSER?)
TALBUTALt (LOTUSATE)
TAR TB A TES t
TEAt
TESTOLACTONEt (TESLAC)
TESTOSTERONEt (ANDROID) (DESATRIC) (ESTRATEST) (GERAMINE) (GLUTEST) (ORETON) (TESTOSTERONE PROPIONATE)
TETRACAINEt
TETRACHLOROTHYRONt (TETRACHLOROTHYPONINE)
TETRACOSACTRIN* (SYN ACTHEN) (CORTROSYN)
TETRACYCLINEt (ACHROMYCIN) (PANMYCIN) (STECLIN) (TETRACYM) (TETREX) (BRISTACYCLINE) (SUMYCIN) (TETRACYCLINE HYDROCHLORIDE)
TETRACYCLI NEt (CHLORTETRACYCLIN 5*) (DEMECLOCYCLINE*) (DOXYCYCLI NEt) (METHACYCLINE*) (OXYTETRACYCLINE*)
TETRACYCLINEt (ROLITETRACYCLINE)
TETRAIODOFLUORESCE* (TETRAIODOFLUORESCEIN) (ERYTHEOSINE)
TETRAIODOPHT HALEINt
TETRA LINt
TETRIDAZ-Bt
THALLIUNt
THENALIDINE*(THENALIDINE TARTRATE)
THEOPHYLLINEt (THEOPHYLLINE DERIVATIVES) (AMINOPHYLLINE) (DYPHYLLINE) (OXTRIPHYLLINE) (ELIXOPHYLLIN) (SYNOPHYLATE)
THIABENDAZOLEt (MINTEZOL)
THIACETAZONEt (PANRONE) (TIBIONE)
THIAMAZOLEt
THIAMYL SODIUM*
THIAZIDES*(CHLOROTHIAZIDE*) (HYDROCHLOROTHIAZIDES*) (BENZTHIAZIDE) (HYDROFLUMETHIAZIDEt) (BENDROPLUNETHIAZIDE*)
THIAZIDESt (HYDROBENZTHIAZIDE)
THIAZIDESt (M!THYCLOTHIAZIDE*) (TRICHLORNETHIAZIDE*) (POLYTHIAZIDEt) (CYCLOTHIAZIDEt) (FLUMETHIAZIDEt)
THIAZOLSULFONE* (PROM IZOLE)
THIOCYANATFS*
THIOGLYCOLATEt (AMMONIUM THIOGLYCOLATE)
THIOGUANINE*
THIOLSt
THIOPENTALt (PENTOT HAL)
THIOPROPAZATE* (THIOPROPAZATE HYDROCHLORIDE) (DARTAL)
THIOR IDAZI NEt (MELLARIL) (THIOBIDAZINE HYDROCHLORIDE)
THIOSEMICARBAZONES* (AMITHIOZONE) (THIACETAZONEt)
THIOTEPA* (TRIETHYLEN ETHIOPHOSPHORAMIDE)
THIOTHIXENE* (NAVANE)
THIOUR ACIL*
THIOUREAt
THIOXANTHINES (CHLORPROTHIXENEt) (THIOTHIXENEt) (CLOPENTRIXOL) (FLUPENTHIXOL)
THYMOL* (THYMOL-ISOPROPANOL)
THYROID*(DESSICATED THYROIDt) (THYROID EXTRACT) (THYROID PREPARATIONS) (LEVOTHYROXINE*) (THYRAR) (PROLOID) (LIOTRIX*)
THYROID* (THYROTROPHIN) (THYTROPAF1) (THYROXIN FRACTION) (DESSICATED THYROIDt)
THYROTROPIN* (TSH) (THYTROPAR)
THYROTROPIN-RELEA St (TB YROTROPIN-RELEASING HORMONE) (TRH)
TINt
TIOCAR LIDEt

TO3ACCO SNOKEt
TOLAZAMIDEt (TOLl NASE)
TOLAZOLINE*(TOLAZOLINE HYDROCHLORIDE) (PRISCOLINE HYDROCHLORIDE)
TOLBUTAMIDEt (ORINASE)
TOLONIUM* (BLUTENE)
TOLUIDINE BLUFt
TOOTH PA STEt
TOURNIQUET* (USE OF TUURNIQUET) (VENOUS STASIS) (CIRCULATORY STASIS)
TRANQUILIZERS (CHLORPROMAZINEt) (CHORDIAZEPOXIDEt) (MEPBOBAMATEt) (PPOMAZINE*) (BESERPINEt) (DIAZEPANt)
TPANQUILIZERS (OXAZEPANt) (NEPROBAMATEt) (TYBAMATE) (HYDROXYZINE*) (PROMETHIAZINEt) (DIPHENYLHYDRAMINE)
TPANYLCYPROMINE*(TRANYLCYPRONINE SULFATE) (PARNATE SULFATE)
TB ASYLOLt
TRIAMCINOLONEt(TRIAMCINOLONE ACETONIDE) (TRIANCINOLONE DIACETATE) (TRIAMCINOLONE HEXACETONIDE) (ARISTOCORT) (ARISTOPAN)
TRIAMTEPNNE* (DYPENIUM) (DYAZIDE)
TP.ICELORNETHIAZID!*(METAHYDRIN) (NAQUA)
TRICHLOPOETHYLENE* (TRILENE) (TPIMAR)
TRICHLO?OETHYLPHOS* (TRICHLOROETHYL PHOSPHATE)
TRICYCLIC ANTIDEPRESSANTS (IMIPPAMINEt) (ANITRYPTILINEt) (DESIPRAMINE*) (DOXEPINt) (NORTRIPTYLINE*) (PROTRIPTYLINE*)
TPICYCLIC ANTIDEPRESSANTS (OPIPRANOL) (TRIMIPRANINE) (MONOCHLORIMIPRAMINE)
TRIETHYLENEMELAMINFt (TEN)
TRIFLOCIN*
TRI YL(JOPERAZINE* (TRIFLUOPEPAZINE HYDROCHLORIDE) (STELAZ IN!)
TRIFLUPERIDOLt (TRIPERIDOL)
TPIFLUPROMAZINE*(TRIPLUPROMAZINE HYDROCHLORIDE) (VESPPIN)
TRII000THYRONINEt (THYROLAR) (LIOTHYRONINE*) (TERTPOXI N) (CYTOMEL)
TRIMEPRAZINEt (TRINEPRAZI NE TARTRATE) (TEMERIL)
TPINETHADION!t (TRIDIONE)
TRINETHOPRIMt (TRINETHOPRIM/SULFAMETHOXAZOLE COMBINATION) (SYRAPRIN)
TRIMETHYLENEMELAN*(TPIMETHYLENE MELANIN!)
TRINETOZINEt
TRI NITROTOLUENEt (TNT)
TB 10 XA El N Ft
TRIOXSAL!Nt (TRISORALEN)
TBIP!LENNAMINFt(TRIPLEL!NNAMINR CITRATE) (TRIPELENNAMINE HYDROCHLORIDE) (PYRIBENZAMINE)
TRONETHA MINEt (TRIS HYDROXYNETHYL ANINCEETHANE) (TROMETAMOL) (T HAM) (THIS ANI NO) (TRIZMA)
TRYPAN BLUEt
TPYPARSANIDE*
TRYPSINt (TPYPSIN-CHYMOTPYPSIN) (CHYMORAL)
TR YPTAMINEt
TRY PT OPH A Nt
TRYPTOPHAN-THIOLt
TUBOCURARINEt (TUBOCURARINE HYDROCHLORIDE)
TURPENTINE* (GUM TURPENTINE) (OIL OF TURPENTINE)
TYROSINE*
TYR OCR RICIN*
UNDZCOYLIUNt (UNDECOYLIUM CHLORIDE-IODINE) (VIRAC)
UPACIL NUSTARD*
UREA DERIVATIVES (APPONALt) (BROMISOVALUM*) (CARBROMALt)
U?EAt(UREA FOR INJECTION) (UPEAPHIL) (UP! VERT)
URETHAN* (URETHANE) (ETHYL CARBA MATE)
URIC ACID*
URICOSURIC AGENTS (ALLOPURINOLt)
URICOSURIC AGENTS (CAPINAMID!*) (PROBENECID*) (SULFINPYRAZONE*) (PHENYLBUTAZONE*) (OXYPHENBUTAZONEt)
URINE PRESERVATIVES (FORMALINt) (FORMALDEHYDEt) (THYNOL*) (TOLUENE) (CHLOROFORN*) (ANTIBIOTICSt) (BORIC ACIDt)
UBOBILINt
UPOGRAPHIC AGENTS (DIATRIZOATEt) (IOTHALA!ATE*) (ACETRIZOAT!*) (DIPROTIZOATE*)
UP OKINASE*
VACCINES (CHOLERA VACCINE) (DIPHTHERIA VACCINE) (MEASLES VACCINEt) (INFLUENZA VACCINE) (RABIES VACCINE)
VACCINES (SMALLPOX VACCINEt) (IMMUNE SERA*) (BCG VACCINEt) (TYPHOID VACCINE) (POLIOMYMLITIS VAC*)
VAGINAL POWDEPt
VALINE*
VANCOMYCIN*(VANCONYCIN HYDROCHLORIDE) (VANCOCIN)
VANILL At
VANILLIC ACID*
VANILLIN*
VASODILATORS (AZAPETI NE) (TOLAZOLAZINE*) (CYCLANDELATE) (ISOXSUPRINE HCL) (NICOTINIC ACI D*) (NIC OTINYL ALCOHOL)
VASODILATORS (NYLIDRIN HCL) (PHENOXYBENZAMINE*) (PH!NTOLAMINFt) (ETHAVERINE)
VASOPRESSIN*(VASOPRESSIN TANNATE) (PITRESSIN) (PITRESSIN TANNATE) (LYPRESSIN) (POSTERIOR PITUITARY*)
VASOPRESSORS (METHAMPHETAMIN!*) (EPHEDRINEt) (MEPHENTERMINE) (LEVARTERENOL*) (EPINEPHRINE*) (METARAMINOL) (ANGIOTENSIN AMID!)
VASOPEESSORS (METHOXAMINE)
VEGETABLES (BEETSt) (SWEET POTATOES*) (FAVA BEANS*) (EGG PLANT*) (SAUERKRAUT*) (CARROTS*)
VIN3ARBITALt (DELVINAL)
VINBLASTINEt(VINBLASTINE SULFATE) (VELBAN)
VINCRIS’PINEt(VINCRISTINE SULFATE) (ONCOVIN)
VINYL ETHER*(VINETRENE)
VIOMYCINt(VIOMYCIN SULFATE) (VINACTANE SULFATE) (VIOCIN SULFATE)
VITAMIN At(ACON) (ALPHALIN) (ANATOL) (AQUASOL A) (A-SOL) (DISPATABS) (DISPA’TATE) (VIO-A) (VI-ALPHA) (ALPHA-TOCOPHEROL)
VITAMIN Bt(VITANIN B COMPLEX)
VITAMIN B12*(CYANOCOBALAMIN) (BERUBIGEN) (REDISOL) (RUBRAMIN) (SYTOBEX) (LIVER INJECTION) (PERNAEMON)
VITAMIN D*(CALCIFEROLt) (DIHYDPOTACHYSTEROL*)
VITAMIN Dt(ERGOCALCIFEROL) (VITAMIN D2) (CHOLECALCIFEROL) (VITAMIN D3) (DELTALIN) (DRISDOL) (DERATOL) (GELTABS)
VITAMIN #{128}*(ALPHA_TOCOPHEROL)
VITAMIN Kt (MENADIOL SODIUM DIPHOSPHATE) (MENADIONE) (MENADIONE SODIUM BISULFITE) (PHYTONADIONE*) (VITAMIN KS)
VITAMIN PREPSt(DAYALETS) (VITAMIN Nt) (VITAMIN At) (VITAMIN Bt) (VITAMIN B12t)
VITAMIN PR!PSt (VITAMIN At) (VITAMIN Bt) (ASCORBIC AMIDt) (VITAMIN Dt) (VITAMIN Kt) (NICOTINIC ACID*) (RIBOFLAVINt)
VNA*(VANILLOYL NANDELIC ACID) (VANILNANDELIC ACID) (VANILLYLMANDELIC ACID)
W_235L4*
WALNUTSt
WARVARI Nt (WARFAPIN SODI UN) (WARFARIN POTASSIUM) (COUNADIN SODIUM) (PANWARFIN) (ATHRONBIN K) (PROTHONADIN)
X-RAY THERAPY*
105$ CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

XANTHINESt (AMISOME’RADINE) (CHLORAZA NIL)
XANTHI NESt (CA FFEINE*) (TREOBROMINE) (THEOPHYLLINEt) (ATRENOL) (BRONKOTABS) (HOL!DYL) (TETRAL) (TH FOBID)
XANTHOPHYLL*
XY LITOLt
XYLOSEt
XYLULOSEt (XYLUKETOSE)
ZINC SALTS*
ZOXAZOLAMINEt (FLEXIN)
1 1 -OXYSTEROIDSt (1 1 -HYDROXYCORTI COSTEROIDS) (1 1-HYDRO XYSTEROIDS)
5-HYDROXYINDOLEACETt (5-HYDROXYINDOLEACETIC ACID)
5-HYDROXYTRY PTA NI NEt (5-HYDROXYTBYPTAMINE CREATININE SULTATE)

A.P. ALKALINE PHOSPHATAS!
ABNORM ABNORMALITY
ABSOPP ABSORPTION
AC ACID
ACCJN ACCT1TMULTION
ACT ACTING
ACTH ADRENOCORTICOTROPI C HORMONE
ACTTV ACTIVITY
AD9 ANTIDIURETIC HORMONE
ADfIN ADMINISTRATION
AGGRE AGGREGATION
AGNO3 SILV’R NITRATE
AICAB AMINO-U-IMIDAZOLE-5-CARBOXAMIDE RIBOTIDE
ALA AMINOLRVULINIC ACID
ALB ALBUMIN
PILE ALKALINE
AMA AMERICAN MEDICAL ASSOCIATION
ANT AMOUNT
ANTICOAG ANTICOAGULANT
APP APPLIED
APPROX APPROXIMATELY
ASSOC ASSOCIATED
AT? ADENOSINE TRIPHOSPHAT!
B WHOLE BLOOD OR BETA (AS APPROPRIATE)
BCG BROMCPESOL GREEN (EXCEPT IN BCG VACCINE)
BEI BUTANOL EXTRACTABLE IODINE
BILl BILIRUBIN
BIND BINDING
BLEED BLEEDING
RN BONE MARROW
B!R BASAL METABOLIC RATE
BND BOUND
35? BPOMSULFOPHTHALEIN
C CEREBROSPINAL FLUID
CA CALCIUM
CA OX CALCIUM OXALATE
CASOU CALCIUM SULFATE
CHEM C9EMICAL
CHRON CHRONIC
CIRO CIPCULATING
CL CHLORIDE
CBS CENTRAL NERVOUS SYSTEM
CC’MPET OMPETITION
COMP COMPOUND
CONT CATrC:OL_OMETRYL TRANSFERASE
CONC CONCENTRATION OR CONCENTRATED
CONJUG CONJUGATED OR CONJUGATION (AS APPROPRIATE)
CORTICOSTEP COPTICOSTERONE
CPK CREATINE PHOSPHOKINASE
CVS CARDIOVASCULAR SYSTEM
DEC DECREASED
DET DEFICIENCY
DEG DEGREES (CENTRIGPADE)
DEGEN DEGENERATION
DEP DEPENDENT
DEPRESS DEPRESSION
DERIV DPRIVATIVE
DFVEL DEVELOPMENT
DFT’ DIALYZABLE FREE THYROXIN?
DIP? DIFETBENT
DIP DIRECT
DIST DISTURBANCE
DISTILL DISTILLATION
DMABA DIMETHYLAMINOBENZALDEHYDE
DNPH DINITPOPHENYLHYDRAZINE
DOPA DIHYDROXYPHENYLALANINE
E ERYTHPOCYT!
EC? EXTAC!LLULAR FLUID
EDTA FTHYLENEDIAMINETETRAACETIC ACID
EGDT ERYTHPOCTYE GLUTAMIC-OXALOACETIC TRANSAMINASE
ENZ ENZYME
EQtJIV EQUIVALENT
EPPF EFRECTIVE RENAL PLASMA FLOW
ESP ESPECIALLY
EXIST EXISTING
EXPTL EXPERIMENTAL
P FECAL
RE IRON
FFCL3 FEPRIC CHLORIDE
FECN TERRICYANIDE
FIGLU FORMIMINOGLUTAMIC ACID
FLDORFS FLUORESCENCE
PRIG REFRIGERATOR
FSH TOLLICLE STIMULATING HORMONE
FIT FREE THYROXINE INDEX
G GRAM
G.I. GASTRO-INTESTINAL
G-6-PD GLUCOSE-6-PHOSPHATE DEHYDROGENASE
GFR GLOMERULAR FILTRATION PATE
GGTP GAMMA-GLUTAMYL TRANSPEPTIDASE

GLC GAS LIQUID CHROMATOGRAPHY
GLOB GLOBULIN
GLU OX GLUCOSE OXIDASE
GLUCUR GLUCURONIDE
GTT GLUCOSE TOLERANCE TEST
H HOUR OR HYDROGEN (AS APPROPRIATE)
HABA HYDROXYAZOBENZENE BENZOIC ACID
HBD HYDROXYBUTYRIC DEHYDPOGENASE
HCG HUMAN CHOPIONIC GONADOTBOPIN
HCL HYDROCHLORIC ACID
HCO3 BICARBONATE
HEM HEMOLYTIC
HG MERCURY
HGB HEMOGLOBIN
HMPG HYDROXY-METHOXY-PHENYL GLYCOL
HPF HIGH POWER FIELD
HPG HUMAN PITUITARY GONADOTROPIN
HVE HIGH VOLTAGE ELECTROPHORESIS
H2O WATER
I IODINE
I 131 IODINE 131
I.M. INTRAMUSCULAR
I.V. INTRAVENOUS
lCD ISOCITRIC DEHYDROGENASE
IGA IMNUNOGLOBULIN IGA
IGG IMMUNOGLOBULIN IGG
1GM IMNUNOGLOBULIN 1GM
IMMED IMMEDIATE
IMMUNOL IMMUNOLOGICAL
IMPAIR IMPAIRED OR IMPAIRMENT (AS APPROPRIATE)
INC INCREASED
INFARCT INFARCTION
INFECT INFECTIOUS
INGEST INGESTION
INHIB INHIBITION
INJECT INJECTION
lET INTESTINAL
ISOENZ ISOENZYM!S
12 IODINE
K POTASSIUM
KG KILOGRAM
K3 VITAMIN K3
K4 VITAMIN KR
L-B LIEBERMANN-BURCHARD
LAB LABORATORY
LDH LACTIC DEHYDROGENASE
LE LUPUS ERYTHEMATOSUS
LFT LIVER FUNCTION TESTS
LH LUTEINIZING HORMONE
N METHODOLOGICAL EFFECT
M NT MOLECULAR WEIGHT
MAO MONOAMINE OXIDASE
MAX MAXIMUM
MCHC MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION
MCV MEAN CORPUSCULAR VOLUME
MEAS MEASURED
NECH MECHANISM
MEG MEGALOBLASTIC
NENST MENSTRUATING
METAB METABOLISM
METH METHOD
METHENOGLOB METHEMOGLOBIN
MG MILLIGRAM OR MAGNESIUM (AS APPROPRIATE)
MIN MINUTE OR MINIMAL (AS APPROPRIATE)
ML MILLILITER
MM MILLIMETER OR MILLIMOLES (AS APPROPRIATE)
NO MONTH
MOD MODERATE(LY) OR MODIFIED (AS APPROPRIATE)
N METHOD IN USE AT NIH
NA SODIUM
NEFA NON ESTERIFIED FATTY ACIDS(FREE FATTY ACIDS)
NEG NEGATIVE
NH3 AMMONIA
NHI4 AMMONIUM
NH4CL AMMONIUM CHLORIDE
NIT OX NITROUS OXIDE
NORM NORMAL
NORNET NORMETANEPHRINE
NPN NON PROTEIN NITROGEN
0 OTHER FLUID OR IN VIVO PHYSIOLOGICAL TEST
OCCAS OCCASIONAL (LY))
OCT ORNITHINE CARBIMYL TRANSFERASE
OH HYDROXY
P PLASMA
PABA PARA-AMINO BENZOIC ACID
PAR PAPA-AMINO HIPPURIC ACID
PANCREAT PANCREATIC
PARADOX PARADOXICAL
PHI PROTEIN-BOUND IODINE
PEP PHOSPHOENOL PYRUVATE

PF.RIPH PERIPHERAL
PGH PITUITARY GONADOTROPIN
PHARMACOL PHARMACOLOGICAL
PHOS PHOSPHATASE
PHYSIO PHYSIOLOGICAL
PIT PITUITARY
P05 POSITIVE
P014 PHOSPHATE
PPM PARTS PER MILLION
PRECIP PRECIPITATION
PREG PREGNANT
PREP PREPARATION
PROB PROBABLE
PROC PROCEDURE
PROD PRODUCED
PROSTAT PROSTATIC
PROT PROTEIN
PROX PROXIMAL
PSP PHENOLSULFONPHTHALEIN
PTS PATIENTS
PTT PARTIAL THROMBOPLASTIN TIME
PULN PULMONARY
QUANT QUANTITATIVE
B INDICATES NUMBER IN REFERENCE FILE
RBC RED BLOOD CELL
REACT REACTION
RED. REDUCING
RL RELATIVE
RESP RESPIRATORY OR RESPIRATION (AS APPROPRIATE)
S SERUM
S.G. SPECIFIC GRAVITY
SATIS SATISFACTORY
SEC SECONDARY
SENS SENSITIVITY
SGOT SERUM GLUTAMIC-OXALACETIC TRANSAMINASE
SGPT SERUM GLUTAMIC-PYRUVIC TRANSAMINASE
SIG SIGNIFICANT
SL SLIGHT
SMA SEQUENTIAL MULTIPLE ANALYZER
SOLN SOLUTION
STIM STIMULATION
STRUCT STRUCTURE
SUBST SUBSTANCE
I OBTAINED UNDER TEST CONDITIONS
TBG THYROXINE BINDING GLOBULIN
TBPA THYROXINE BINDING PREALBUMIN
TCA TRICRLOROACETIC ACID OR TRICARBOXYLIC ACID (AS APPROPRIATE)
TECH TECHNIQUE
TEMP TEMPORARY OR TEMPERATURE (AS APPROPRIATE)
THRU THROUGH
TIBC TOTAL IRON-BINDING CAPACITY
TLC THIN LAYER CHROMATOGRAPHY
TNG TUBULAR MAXIMUM (GLUCOSE)
TREAT TREATMENT
TSH THYROID STIMULATING HORMONE
T3 TRIIODOTHYRONINE
CR THYROXINE
U URINE OR UNITS (AS APPROPRIATE)
U.N. UREA NITROGEN
UDP UPIDINE DIPHOSPHAT!
UG MICROGRAM
UIBC UNSATURATED IRON BINDING CAPACITY
UV ULTRAVIOLET
V PHYSIOLOGICAL OR PHARMACOLOGICAL EFFECT
VASODIL VASODILATATION
VENT VENTILATION
VMA VANILLYLMANDELIC ACID
VOL VOLUME
V WHITE CELL
WBC WHITE BLOOD CELL
WKS WEEKS
X TIMES
YR YEAR
Z NO EFFECT
ZNSOL4 ZINC SULFATE
2-PG 2-PHOSPHOGLYCERATE
2,3 DPG 2,3-DIPHOSPHOGLYCERATE
2ND SECONDARY
3-PG 3-PHOSPHOGLYCEPATE
5 HIAA 5-HYDROXYINDOLE ACETIC ACID
5HT 5-HYDROXYTRYPTAMIN!
* INDICATES ENTRIES UNDER THIS HEADING
? INDICATES ‘POSSIBLE’ OR ‘UNKNOWN’

ACETA N INOPREN B HEMOGLOBIN DEC V ANEMI A/PAN CYTOPE NIA BOO 26
AC ETA MINOPHEN B METREMOGLOBIN INC V MAY BARELY CAUSE HENOLYSIS B 03 84
ACETAM INOP HEN B NEUTROPHILS DEC V MAY CAUSE NEUTROPENIA/PANCYTOPENIA RO38L$
ACETAMINOPHEN B RED CELL COUNT DEC V NAY CAUSE HENOLYTIC ANEMIA P06 20
ACETAMINOPREN B WHITE CELL COUNT DEC V NAY AFFECT BONE NARROW FUNCTION/PANCYTOPENIA RO591
AC ETA MINOPHEN P PROTHROMBIN TINE INC V DEPRESSES CLOTTING FACTOR SYNTHESIS 30137
ACETAMINOPREN S BILIRUBIN INC V HEPATIC DAMAGE REPORTED WITH OVERDOSE B0797
ACETA MINOPHEN S CREATININE INC V REVERSIBLE TUBULAR NECROSIS REPORTED RO137
ACETAMINOPHEN S DIRECT BILIRUBIN INC V HEPATIC NECROSIS WITH DOSE OF 105 REPORTED RO137
ACETA N INOPHE N S GLUCOSE DEC V REPORTED EFFECT OF NETABOLITE P0 251
ACETANINOPHEN S ICTERIC INDEX INC V MAY CAUSE HEPATIC TOXICITY RO620
ACETA NINOPHEN S SGOT INC V REPATIC NECROSIS WITH DOSE OF 10 G REPORTED 0 137
ACETAMINOPH EN S SGPT INC V HEPATIC NECROSIS WITH DOSE OF 10 G REPORTED 30137
ACETA N INOPREN S UREA NITROGEN INC V REVERSIBLE TUBULAR NECROSIS REPORTED 30137
ACETA MI NOPH EN S URIC ACID INC N FALSELY HIGH VALUES WITH PHOSPHOTUNGSTATE METHODS RO370
ACETA N INO PREN U CATECROLANINES Z V NO EFFECT WITH SHORT TERM INGESTION 2.6 G/DAY P0236
ACETAMINOPHEN U EPINEPHRINE Z V NO EFFECT WITH SHORT TERM INGESTION 2.6 G/DAY B 0236
ACETAMINOPHEN U NOREPINEPHRINE Z V NO EFFECT WITH SHORT TERN INGESTION 2.6 G/DAY RO236
AC ETAMINOPHEN U PROTEIN INC V RENAL DAMAGE MAY OCCUR 30137
ACETAMINOPHEN U SULFATE DEC V REDUCES INCREASED OUTPUT OF RHEUMATOIDS R0810
ACETAMINOPHEN U URIC ACID INC N FALSELY HIGH VALUES WITH PHOSPHOTUNGSTATE METHODS 30370
ACETAMINOPHEN U URINALYSIS BILE INC V HEPATIC NECROSIS MAY OCCUR WITH DOSE OF 1 G RO137
ACETA MINOPHEN U URINALYSIS CASTS INC V RENAL DAMAGE DUE TO HENOLYSIS/ANURIA B 0384
ACETAMINO PHEN U URINALYSIS CELLS INC V NAY BE MARKED INC IN RENAL TUBULAR CELLS RO384
ACETAMINOPHEN U URINALYSIS METREMOGLOB INC V RENAL DAMAGE DUE TO HEMOLYSIS P0 384
ACETANINOPHEN U URINALYSIS PROTEIN INC V NEPUROTOXIC EFFECT OF DRUG RO137
PLCETA MINOPREN U URINALYSIS RBC/HPF INC V RENAL DAMAGE DUE TO HEMOLYSIS 30384
ACETANINOPHEN U VOLUME DEC V INC TRANSPORT OF WATER IN DIABETES INSIPIDUS RO384
ACETAM INOPHEN U 11 OH CORTICOSTEROIDS Z V NO EFFECT WITH SHORT TERN INGESTION 2.6 G/DAY P02 36
ACETANINOPHEN U 17 KETOSTEROIDS Z V NO EFFECT WITH SHORT TERN INGESTION 2.6 G/DAY R0236
ACETAMINOPREN U 17 OH CORTICOSTEROIDS Z V NO EFFECT WITH SHORT TERM INGESTION 2.6 G/DAY B 02 36
ACETANILID B ERYTHROCYTE SURVIVAL DEC V DUE TO HEMOLYSIS P0384
ACETANILID B HEINZ-BODY FORMATION P05 V OCCURS INITIALLY PRIOR TO OVERT HEMOLYSIS P0518
ACETAN ILID B HENATOCRIT DEC V HENOLYTIC ANEMIA 3 0656
ACETANILID B HEMOGLOBIN DEC V RENOLYTIC ANEMIA RO656
ACETAN ILID B METHEMOGLOBIN INC V INTRAVASCULAR HEMOLYSIS RO656
ACETANILID B RED CELL COUNT DEC V RENOLYTIC ANEMIA/AGRANULOCYTOSIS P0658
ACETANILID B RETICULOCYTES INC V OCCURS DURING RECOVERY FROM HENOLYSIS R0518
ACETA NIL ID B SULFHEMOGLOBIN INC V HEMOLYTIC ANEMIA IN ACUTE POISONING P03 84
AC ETA NILID B WHITE CELL COUNT DEC V LEUKOPENI A ROSS 3
ACETANILID E REDUCED GLUTATHIONE DEC V SHARP FALL BEFORE OVERT HEMOLYSIS 30518
ACETANILID P HEMOGLOBIN INC V OCCURS WITH MARKED HEMOLYSIS P05 18
ACETANILID S BILIPUBIN INC V HENOLYSIS WITH G-6-PD DEFICIENCY RO620
ACETANILID S DIRECT BILIRUBIN INC V HEMOLYSIS WITH G-6-PD DEFICIENCY P062 0
ACETANILID S HAPTOGLOBIN DEC V HEMOLYSIS WITH G-6-PD DEFICIENCY R0620
ACETANILID U PROTEIN INC V HEMOLYSIS NAY CAUSE RENAL DAMAGE B 0384
ACETAN IL ID U SUGAR INC N ACTS AS REDUCING SUBSTANCE WITH BENEDICT’S REAGENT R0654
ACETANILID U URINALYSIS CASTS INC V DUE TO HEMOLYSIS AND RENAL DAMAGE RO38L4
ACETANILID U URINALYSIS HEMOGLOBIN INC V OCCURS WITH HEMOLYSIS R0518
ACETA N ILID U URINALYSIS NETHEMOGLOB INC V DUE TO HENOLYSIS AND PENAL DAMAGE RO 38 ‘4
ACETANILID U URINALYSIS PROTEIN INC V DUE TO RENAL DAMAGE WITH HEMOLYSIS P0 3 814
ACETANILID U URINALYSIS RBC/HPF INC V DUE TO HENOLYSIS AND RENAL DAMAGE P03 814
AC ETAN IL ID U URINALYSIS SUGAR INC N ACTS AS REDUCING AGENT WITH NON-SPECIFIC TESTS P03 55
ACETANILID U 5 OH INDOLFACETIC ACID INC N FALSE P05 NITROSONAPHTHOL,NO EFFECT QUANT TEST P07 37
AC ETA T ES B PH INC V ALKALINIZING ACTION DUE TO RAPID METABOLISM P03 814
ACETATES U ACETOACETATE INC N MAY INTERFERE WITH GERHARDT FECL3 PROCEDURE RO1LI3
AC ETAZ OLA MID! B HEMOGLOBIN DEC V ANEMIA DUE TO PANCYTOPENIA/AGRANULOCYTOSIS 30620
ACETA ZOLA N IDE B LE CELL PREP P05 V MAY PRODUCE LE-LIKE SYNDROME R09O7
ACETAZOLAMI DE B PH DEC V DUE TO INHIBITION OF CARBONIC ANHYDRASE R0620
ACETAZOLAMIDE B PLATELET COUNT DEC V MAY CAUSE PANCYTOPENIA WITH APLASTIC ANEMIA RO564
ACETAZOLA MI OS B BED CELL COUNT DEC V MAY CAUSE PANCYTOPENIA/AGRANULOCYTOSIS P0520
ACETAZOLAMIDE B WHITE CELL COUNT DEC V LEUKOPENIA/AGRAN ULOCYTOSIS P0 728
ACETAZOLAMI DE P AMMONIA INC V ?DIVERTS NH3 FROM KIDNEY TO GENERAL CIRCULATION P0 356
ACETAZ OLA MID! S BILIPUBIN INC V SINGLE CASE OF CHOLESTATIC JAUNDICE REPORTED P 0555
ACETAZOLAMIDE S CALCIUM DEC V DEFECTIVE CA AND P04 REABSORPTION CAN BE INDUCED P02014
ACETAZOLA MID! S CHLORIDE INC V LOSS OF HCO3 BY CARBONIC ANRYDRASE INHIBITION R0299
ACETAZOLAMIDE S CO2 CONTENT DEC V CARBONIC ANHYDRAS! INHIBITION IN RENAL TUBULES RO2OL4
ACETAZOLA MID! S GLUCOSE INC V SEEN IN PREDIABETICS AND IF HYPOGLYCEMIC AGENTS RO559
AC!TAZ OLANI DE S PBI DEC V INHIBITS IODINATION OF TYROSINE IN TBG 30004
ACETAZOLA MID! S PBI Z V REPORTED TO HAVE NO CLINICAL EFFECT P0 2 55
AC ETAZOLA MID! S PHOSPHATE DEC V DEFECTIVE CA AND P014 REABSORPTION CAN BE INDUCED R 0204
ACETAZOLA MID! S POTASSIUM DEC V DIURETIC ACTION,CARBONIC ANHYDRASE INHIBITION P02014
ACETAZOLANIDE S UREA NITROGEN INC V MAY OCCUR WITH PROLONGED TREATMENT RO596
ACETAZOLANIDE S URIC ACID INC V DECREASED URATE CLEARANCE P0 2 99
ACETAZOLA NIDE U AMMONIA DEC V INCREASED ALKALINITY 903814
ACETAZOL AM IDE U BICARBONATE INC V INHIBITION OF CARBONIC ANHYDRASE P0 384
ACETAZOLA MID! U CALCIUM INC V INHIBITS TUBULAR REABSORPTION P07 23
ACETAZOLAMIDE U CITRATE DEC V ALTERATION OF ACID BASE STATUS, DIURESIS R0723
ACETAZ OLA MID! U PHOSPHATE INC V INHIBITS TUBULAR REABSORPTION P02014
ACETAZOLAMIDE U POTASSIUM INC V DIURETIC ACTION P03 84
ACETA ZOLA MIDE U PSP EXCRETION DEC V INC URINE FLOW P0 299
ACETAZOLAMI DE U SODIUM INC V DIURETIC ACTION P 03 84
ACETAZOLAMIDE U TITRATABLE ACIDITY DEC V INCREASED ALKALINITY P0 384
AC!TAZ OLA MID! U URIC ACID DEC V INHIBITION OF TUBULAR SECRETION OF ‘IRATE P02 99
ACETAZOLAMID! U URINALYSIS CRYSTALS INC N PRESENCE OF DRUG P02 99
ACETAZOLAMI DE U URINALYSIS PH INC V INHIBITION OF CARBONIC ANHYDPASE 30384
ACETAZOLAMIDE U URINALYSIS PROTEIN INC N MAKES URINE HIGHLY ALKALINE, CAUSES FALSE POSITIVE 90039
ACETAZOLAMI DE U UROBILINOGEN INC V EXCRETION INCREASED BY ALKALINIZATION OF URINE 30666
ACETAZOLANIDE U 17 K!TOGENIC STEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION R0133
ACETAZOLAMID! U 17 KETOSTEROIDS Z N MIN INTERFERENCE WITH ZIMMERMAN REACTION IN VITRO R0133

ACETAZOLAMIDE U 17 OH COPTICOSTEROIDS INC N IN VITRO INTERFERENCE WITH GLENN-NELSON METHOD R0299
ACETCAC ElATE S CREATININE INC N INTERFERES - GRAFNETTER AND AUTOANALYZER METHODS R0546
ACFTOAC?TATE S C?EATININE Z N NO EFFECT ON METHOD OF POLAR AND METCOFF R05146
ACTOACET ATE S SALICYLATE INC N 50 MG/100ML GIVE EQUIV OF 1 MG/100ML BY TRiNDER R06O6
A C El OAC ETATE S SGOT INC N INTERFERENCE IN DIAZONIUM END POINT REACTIONS RO027
ACETO ACETATE S URIC ACID INC V INHIBITS TUBULAR SECRETION OF URATE R0377
ACET OACET ATE U PHENYLKETONES POS M RED/RED-BROWN WITH FECL3, NO EFFECT PHENISTIX P0239
A CLTO ACET A TI U PHOSPHATE INC V INHIBITS TUBULAR REABSORPTION P02814
ACETOACETATE U URIC ACID DEC V INHIBITS TUBULAR SECRETION OF URATE P0377
AC TOHPXAMIDE B HEMATOCRIT DEC V MAY CAUSE ANEMIA AND HENOLYSIS IF G-6-PD DEFICIENCY P0298
ACETOHEXAMIDE B HEMOGLOBIN DEC V MAY CAUSE ANEMIA AND HEMOLYSIS IF G-6-PD DEFICIENCY P0 298
ACETOHEX.MIDE B PLATELET COUNT DEC V THRONBOCYTOPENIA AND APLASTIC ANEMIA REPORTED EO620
ACETOHEXAMIDE B RED CELL COUNT DEC V NAY CAUSE HEMOLYTIC ANEMIA R0298
ACTOhEXAM IDE B WHITE CELL COUNT DEC V LEUKOPENIA AND APLASTIC ANEMIA REPORTED R0620
ACFTOHEXAMIDE F UPOBILINOGEN DEC V THEORETICALLY IF CHOLESTASIS OCCURS P0026
ACET OHEXAMIDE P PPOTHP.OMBIN TIME INC V OCCURS IF FAILURE TO EXCRETE BILE SALTS P0026
ACETOHEXANIDE S ALKALINE PHOSPHATASE INC V MAY CAUSE INTRAHEPATIC CHOLESTATIC JAUNDICE P0204
ACETOHFXAMIDE S BILIRUBIN INC V MAY CAUSE INTRAHEPATIC CHOLESTATIC JAUNDICE P0204
AC ETOHEXAMIDE S BSP RETENTION INC V MAY CAUSE INTEAHEPATIC CHOLESTATIC JAUNDICE P0204
ACTOHEXAMIDE S CEPHALIN FLOCCULATION INC V NAY CAUSE INTRAHEPATIC CHOLESTATIC JAUNDICE P0620
AC E C HEXAM IDE S CHOLESTEROL INC V NAY CAUSE INTRAHEPATIC CHOLESTATIC JAUNDICE R0596
ACET OHEXA !IDk S DIRECT BILIPUBIN INC V MAY CAUSE HEMOLYTIC ANEMIA P0 298
AC!TO HEX AM IDE S GLUCOSE DEC V SULFONYLUPEA DERIVATIVE PROMOTES INSULIN SECRETION R6204
ACETOHEXAM IDE S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P02 98
ACEr0HEx ‘MIDE S SGOT INC V MAY CAUSE INTPAHEPATIC CHOLESTATIC JAUNDICE HO 596
ACETOHEXAMIDL S SGPT INC V MAY CAUSE INTRAHEPATIC CHOLESTATIC JAUNDICE P0596
ACETOHEXAMIDE S THYMOL TURBIDITY INC V MAY CAUSE INTRAHEPATIC CHOLESTATIC JAUNDICE P0620
PLCETOHEXANIDE S UREA NITROGEN INC N CHEN. STRUCT. CAUSES TO BE MEAS. BY DIACETYL REACT. P0204
ACETOREXAMIDE S URIC ACID DEC V MILD URICOSURIC ACTION P1018
C IT 0 H EXA N IDE S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS P0492
ACETOHEXAMIDE U BILIPUBIN INC V MAY CAUSE INTRAHEPATIC CHOLESTATIC JAUNDICE HO 620
ACTOHEXANIDE U URIC ACID INC V URICOSURIC ACTION P0404
ACETOHEXAMIDE U URINALYSIS BILE INC V NAY CAUSE INTRAHEPATIC CHOLESTATIC JAUNDICE R0620
ACET OHEXANIDE U UROBILINOGEN DEC V THEORETICAL EFFECT IF CHOLESTASIS P0026
ACETOHYDROXAMIC AC S UREA NITROGEN DEC V INHIBITION OF UREASE (LIMITED IN VIVO EFFECT) P0906
ACETONE S CREATININE INC M INTERFERES WITH JAFFE METHOD HO 546
ACETONE S UREA NITROGEN INC M TURBIDITY IN NESSLERIZATION PROCEDURES R0436
A C ET ONE U BOGEN TEST PUS N REACTS AS IF ETHANOL P 0368
AC ONE Ii UROBILINOGEN INC M MAY PRODUCE SIMILAR COLOR IN REACTION HO 620
ACETOPHENA ZI NE B PLATELET COUNT DEC V AGRANULOCYTOSIS OR APLASTIC ANEMIA P0026
ACETOPHENAZ INE B RED CELL COUNT DEC V POSSIBLE APLASTIC ANEMIA RC620
ACETOPRENA ZINE B WHITE CELL COUNT DEC V TRANSITORY LEUKOPENIA OR AGRANULOCYTOSIS R0026
ACET OPHENA LINE S ALKALINE PHOSPHATASE INC V CHOLESTATIC HEPATITIS WITH OBSTRUCTION P0620
ACETOPHENAZINE S BILIRUBIN INC V CHOLESTASIS WITH INTPAHEPATIC OBSTRUCTION H 0355
ACETOPHENA 2IINE S BSP RETENTION INC V CHOLESTASIS WITH INTPAHEPATIC OBSTRUCTION P0620
ACETOPHENALINE S CEPHALIN FLOCCULATION INC V CHOLESTASIS WITH INTRAHEPATIC OBSTRUCTION P0620
ACETOPHE NAZINE S CHOLESTEROL INC V CHOLESTASIS WITH INTRAHEPATIC OBSTRUCTION P0767
ACTF OPI!ENAZINE S SGCT INC V CHOLESTASIS WITH INTRAHEPATIC OBSTRUCTION R0620
ACEIOPHENA ZINE S SGPT INC V CHOLESTASIS WITH INTRAHEPATIC OBSTRUCTION P0620
ACETOPHENAZINE S THYMOL TURBIDITY INC V CHOLESTASIS WITH INTPAHEPATIC OBSTRUCTION P0620
ACETOPHENA ZINE U BILIRUBIN INC V CHOLESTASIS WITH INTRAHEPATIC OBSTRUCTION P0620
ACT OPHENAZI NE U URINALYSIS BILE INC V CHOLESTASIS WITH INTRAHEPATIC OBSTRUCTION P0620
ACETOPHENETI DI N B ERYTHROCYTE SURVIVAL DEC V ASSOCIATED WITH DRUG INDUCED HEMOLYSIS R0384
ACETOPHE NETIDIN B HEINZ-BODY FORMATION P05 V OCCURS INITIALLY PRIOR TO OVERT HEMOLYSIS P05 18
ACETOPHENETIDI N B HEMATOCRIT DEC V HEMOLYTIC ANEMIA P0240
ACET OP HE NE TIDIN B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA P 0240
ACETOPHENETIDI N B MCV INC V MACROCYTIC ANEMIA (NAY OCCUR OCCASIONALLY) P060 7
ACETOPHENETIJIN B METHEMOGLOBIN INC V HEMOLYTIC ANEMIA PC 128
ACETOPHENETIDIN B PERIPHERAL SMEAR V PYKNO-SCHISTO-,SPHEROCYTES, HEINZ BODIES ETC P0252
ACETOPHENETIDIN B PLATELET COUNT DEC V HENOLYTIC OP APLASTIC ANEMIA P04 35
ACET OPHENETIDI N B RED CELL COUNT DEC V HENOLYTIC ANEMIA P0 240
ACETOPHENETIDI N B PETICULOCYTES INC V RESPONSE TO HENOLYSIS DURING RECOVERY R0252
ACFTOPHENETIDIN B SULFHEMOGLOBIN INC V HEMOLYSIS MAY OCCUR FREQUENTLY PC 3142
AC ETOPHENETI DI N B WHITE CELL COUNT DEC V MAY CAUSE APLASTIC ANEMIA OR PANCYTOPENIA P0620
ACETOPHENETIDIN C PROTEIN INC N REACTS AS IF PHENOL WITH FOLIN-CIOCALTEU REAGENT P0907
ACITOPHENETIDI N E REDUCED GLUTATHIONE DEC V SHARP FALL PRIOR TO OVERT HEMOLYSIS P05 18
ACETOPHFNETIDI N P HEMOGLOBIN INC V MAY OCCUR WITH HEMOLYSIS R0518
ACETOPHENETIDIN P PROTHROMBIN TIME INC V TRANSIENT INCREASES REPORTED P0657
ACETOPHENETIDIN S ALKALINE PHOSPHATASE INC V MAY CAUSE HEPATIC TOXICITY P0620
ACETOPHENETIDIN S BILIRUBIN INC V RARE CASE OF HEPATIC TOXICITY REPORTED P0384
ACETOPHENETIDIN S BSP RETENTION INC V MAY CAUSE HEPATIC TOXICITY P0620
ACET OPHENETIDI N S COONBS TEST P05 V IMMUNOLOGICAL RESPONSE TO DRUG HO 104
ACETOPHENETI DIN S CREATININE INC V MAY CAUSE AZOTEMIA R0620
ACETOPHENETIDI N S DIRECT BILIRUBIN INC V MAY CAUSE HENOLYTIC ANEMIA P0636
ACET OPH NETIDIN S DIRECT COONBS TEST POS V AUTOINMUNE PHENOMENON(OCCURS AFTER SEVERAL MONTHS) P04 18
ACETOPHENETIDIN S IRON INC V MAY OCCUR WITH CHRONIC HEMOLYSIS P0657
ACETOPHENETIDIN S NPN INC V NAY CAUSE AZOTEMIA P0620
A C ETO PH 1 NE T I D I N S SGOT INC V MAY CAUSE HEPATIC TOXICITY P0620
ACETOPHENETIDI N S SGPT INC V MAY CAUSE HEPATIC TOXICITY P0620
ACETOPHENETIDIN S SULFA AS SULFANILAMIDE INC M INTERFERES WITH ANALYTICAL PROCEDURE P 0356
ACET OP HENETIDIN S UREA NITROGEN INC V MAY CAUSE AZOTEMIA P0620
ACETOPHENETIDI N S URIC ACID INC N MEASURED AS URIC ACID BY SMA 12/60 METHOD P0876
ACETOPHENETIDIN U PHENYLKETONES P05 N RED FADING WITH FECL3, PINK/RED PHENISTIX P023 9
ACET OPHE NETID IN U PROTEIN INC V HEMOLYSIS MAY CAUSE RENAL DAMAGE P0384
ACETO#{176}HENETIDIN U SUGAR INC N FALSE POSITIVE WITH BENEDICT’S TEST P0383
ACET OPHENETIDI N U URIC ACID INC N MEASURED AS URIC ACID BY SMA 12/60 METHOD P0876
ACETOPHENETIDIN U URINALYSIS BILE INC V NAY CAUSE HEPATIC TOXICITY P0620
ACET OPHENETIDIN U URINALYSIS CASTS INC V NAY OCCUR IF INTRAVASCULAR HEMOLYSIS R0384
ACETOPHENETIDIN U URINALYSIS CELLS INC V NAY BE MARKED INC IN RENAL TUBULAR CELLS P0384
ACETOPHFNETIDI N U URINALYSIS COLOR INC M PINK-RED COLORATION DUE TO METABOLITE P0299

ACETOP HE NET ID IN U URINALYSIS COLOR INC V MAY CAUSE HEMATURIA (RED-BROWN COLOR) P06 57
AC ETOPH ENETIDI N U URINALYSIS HEMOGLOBIN INC V OCCURS WITH MARKED HEMOLYSIS 30518
ACETOPHENET IDIN U URINALYSIS METHEMOGLOB INC V FREE METHENOGLOBIN MAY OCCUR WITH HEMOLYSIS 303814
ACETOPHENETIDIN U URINALYSIS PROTEIN INC V NAY OCCUR IF INTRAVASCULAR HEMOLYSIS 30 3 8L
ACETOPHENETIDIN U URINALYSIS PBC/HPF INC V HEMOLYSIS NAY CAUSE OLIGURIA OR ANURIA 30384
AC ETOPHENETI DIN U 5 OH INDOLEACETIC ACID INC N FALSE POSITIVE WITH SCREENING PROCEDURES P04 17
ACETOP HEN ONE U 17 KETOGENIC STEROIDS INC H INTERFERES IN MEASUREMENT BY ZIMMERMAN NETHOD 30907
ACETOP HENONE U 17 KETOSTEROIDS INC N INTERFERES IN MEASUREMENT BY ZIMMERMAN METHOD P0907
ACETPIZOATF S I 131 UPTAKE DEC V DUE TO IODINE COMPONENT OF MATERIAL P0 595
ACETR IZOATE S PBI INC M BUT DOES NOT AFFECT TL4 (EFFECT LASTS 2 TO 14 WEEKS) P0839
ACETRIZOATE U GFR DEC V WHEN 70% INJECTED FOP AORTOGRAPHY P0020
ACETRIZOA TE U PAH CLEARANCE DEC V WHEN 70% INJECTED FOR AORTOGRAPHY R0020
ACETYLA MI NO PHENOL S GLUCOSE INC N AT 1 MNOL/L AFFECTS SMA 12/60 METHOD 30876
ACETYLANINOPHENOL S SGOT INC M AT THERAPEUTIC CONC MAY AFFECT SNA 12/60 METHOD 30876
ACETYLAMINOPHFNOL S URIC ACID INC N REACTS AS IF URIC ACID WITH SMA 12/60 METHOD 30876
ACETYLAMINOPHENOL U URIC ACID INC N REACTS AS IF URIC ACID WITH SMA 12/60 METHOD 90876
ACETYLGLUCOSAMINE T PROTEIN INC N SLIGHT REACTION WTIH FOLIN-CIOCALTEU REAGENT P04140
ACETYLPENICILLANINE S COPPER DEC V ELIMINATION OF HEAVY METALS IN CASES OF HG POISON P0511
ACETYLPENICILLANINE S MERCURY INC V MOBILIZATION OF HG IN CASE OF POISONING P0511
ACETYLPENICILLAN IRE U MERCURY INC V ELIMINATION OF HEAVY METALS IN CASES OF HG POISON P0511
ACETYLPHENY LHYDPAZ B HENATOCRIT DEC V MAY CAUSE HEMOLYTIC ANEMIA H 06 20
ACETYLPHENYLHYDR AZ B HEMOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P 0620
ACETYLPHE NYLHYDRAZ B RED CELL COUNT DEC V MAY CAUSE HEMOLYTIC ANEMIA P06 20
ACETYLPHENYLHYDRAZ S BILIRUBIN INC V MAY CAUSE HENOLYTIC ANEMIA R0620
ACETYLPHE NY LHYDRAZ S DIRECT BILIRUBIN INC V MAY CAUSE HEMOLYTIC ANEMIA P06 20
AC ETYLPHZNYLH YDRAZ S HAPTOGLOBIN DEC V NAY CAUSE HENOLYTIC ANEMIA R062O
ACETYLSALICYLIC AC B BLEEDING TIME INC V ALSO INHIBITS PLATELET GLYCOLYSIS R0326
ACETYLSALICYLIC AC B EOSINOPHILS DEC V MAY CAUSE APLASTIC ANEMIA OH PANCYTOPENIA RO928
ACETYLSALICYLIC AC B ERYTHROCYTE SURVIVAL DEC V LARGE DOSES INCREASE DESTRUCTION 303814
ACETYLSALICYLIC AC B FACTOR VII DEC V ACTS LIKE BISHYDROXYCOUMAPIN 303814
ACETYLSALICYLIC AC B HEINZ-BODY FORMATION P05 V OCCUR INTIALLY BUT DISAPPEAR WITH HEMOLYSIS 90518
ACETYLSALICYLIC AC B HEMATOCPIT DEC V DEPRESSES BONE NARROW, G.I. BLEEDING, HEM ANEMIA P02 40
ACETYLSALICYLIC AC B HEMOGLOBIN DEC V DEPRESSES HONE MARROW, G.I. BLEEDING, HEM ANEMIA 30240
ACETYLSALICYLIC AC B METHENOGLOBIN INC V MAY CAUSE HENOLYSIS WITH G-6-PD DEFICIENCY 90926
ACETYLSALICYLIC AC B PCO2 DEC V IN TOXICITY WITH INC RESP RATE AND PULM VENT HO 384
ACETYLSALICYLIC AC B PH DEC V NAY CAUSE ACIDOSIS LATER (RESP AND METABOLIC) P0 620
ACETYLSALICYLIC AC B PH INC V INITIAL RESPIRATORY ALKALOSIS 30957
ACETYLSALICYLIC AC B PLATELET AGGREG DEC V INHIBITS RELEASE OF ADP FROM PLATELETS RO384
ACETYLSALICYLIC AC B PLATELET COUNT DEC V DECREASED PLATELET SURVIVAL TINE, MAY BE PURPUPA R0920
ACETYLSALICYLIC AC B RED CELL COUNT DEC V HENOLYSIS/G-6-PD DEF./GI HEMORRHAGE/DIR BM DEPRESS ROe 4 L4
ACETYLSALICYLIC AC B HETICULOCYTES INC V RESPONSE DUPING RECOVERY FROM HEMOLYSIS R0518
ACETYLSALICYLIC AC B SEDIMENTATION RATE DEC V IF ELEVATED REDUCES TOWARD NORMAL VALUE R038L1
ACETYLSALICYLIC AC B SEDIMENTATION RATE INC V OCCURS IN SOME PATIENTS (REVERSIBLE) 903814
ACETYLSALICYLIC AC B WHITE CELL COUNT DEC V DEPRESSES LEUKOCYTOSIS OF ACUTE RHEUMATIC FEVER HO 989
ACETYLSALICYLIC AC C PROTEIN INC N FALSE POSITIVE WITH FOLIN-CIOCALTEU REAGENT 91026
ACETYLSALICYLIC AC E REDUCED GLUTATHIONE DEC V OCCURS INITIALLY BEFORE OVERT HEMOLYSIS P0518
ACETYLSALICYLIC AC F COLOR INC V RED OP BLACK DUE TO GASTROINTESTINAL BLEEDING 30620
ACETYLSALICYLIC AC F OCCULT BLOOD P05 V IN OVER 70% PATIENTS WREN MORE THAN 3G/DAY GIVER R 09714
ACETYLSALICYLIC AC 0 BNP INC V REPORTED METABOLIC EFFECT POS 96
ACETYLSALICYLIC AC P FIBRINOGEN INC V ASSOC WITH INC SEDIMENTATION RATE HO 384
ACETYLSALICYLIC AC P HEMOGLOBIN INC V OCCURS WITH HENOLYTIC ANEMIA P05 18
ACETYLSALICYLIC AC P PROTHROMBIN TINE DEC V SMALL DOSE EFFECT P0620
ACETYLSALICYLIC AC P PROTHROMBIN TIME INC V LARGE DOSE EFFECT (DEC SYNTHESIS OF CLOT FACTORS) HO 270
ACETYLSALICYLIC AC P TSH DEC V DEC RELEASE AFTER ADMINISTRATION 30657
ACETYLSALICYLIC AC P 17 OH COBTICOSTEPOIDS INC V LARGE DOSES STIMULATE ADPENOCORTICAL ACTIVITY R0881
ACETYLSALICYLIC AC S ACETOACETATE INC V DUE TO LATE METABOLIC ACIDOSIS AND RENAL IMPAIR R0384
ACETYLSALICYLIC AC S ALBUMIN DEC N DECREASED DYE BINDING CAPACITIY RO907
ACETYLSALICYLIC AC S ALDOLASE INC V EXPTL EFFECT SEEN IN RABBITS WITH PROLONGED USE ROB 06
ACETYLSALICYLIC AC S ALKALINE PHOSPHATASE INC V PROLONGED USE MAY CAUSE HEPATIC TOXICITY HO 573
ACETYLSALICYLIC AC S AMYLASE INC V SINGLE CASE REPORTED Ri 001
ACETYLSALICYLIC AC S BARBITURATE INC N NAY INTERFERE WITH UV SPECTROPHOTONETRY 901814
ACETYLSALICYLIC AC S BILIRUBIN INC V COMPETITION FOR ALBUMIN BINDING R0426
ACETYLSALICYLIC AC S CALCIUM DEC N DEPRESSES FLUORESCENCE OF CALCEIN METHOD HO 644
ACETYLSALICYLIC AC S CHOLESTEROL DEC V DOSES OVER SG REPORTED TO HAVE EFFECT 30384
ACETYLSALICYLIC AC S CHOLESTEROL INC N ALLEGED EFFECT (BUT ALSO NO EFFECT AT 3OMG/100NL) P04 36
ACETYLSALICYLIC AC S CO2 CONTENT DEC V INITIAL ACIDOSIS WITH EXCESSIVE DOSES R0299
ACETYLSALICYLIC AC S CO2 CONTENT INC V LATER ALTERATION OF ACID BASE BALANCE 302014
ACETYLSALICYLIC AC S DIRECT BILIRUBIN INC V OCCURS WITH HEMOLYTIC ANEMIA P 09 07
ACETYLSALICYLIC AC S FREE THYROXINE INC V INTERFERES WITH BINDING TO TBG AND TBPA HO 565
ACETYLSALICYLIC AC S FREE TRIIODOTHYRONINE INC V INTERFERES WITH BINDING TO TBG P 0565
ACETYLSALICYLIC AC S GLUCOSE DEC V IN DIABETICS AND IF TOXIC DOSES INGESTED R0299
ACETYLSALICYLIC AC S GLUCOSE INC V INC ABSOPP. AND STEROID RELEASE INHIBITS TCA CYCLE R0907
ACETYLSALICYLIC AC S GLUCOSE Z N AT 10 NG/100NL NO EFFECT ON GLU OX OF GOCHNAN P0370
ACETYLSALICYLIC AC S GLUCOSE Z N AT 10 MG/100ML NO EFFECT ALKALINE FERRICYANIDE BC 370
ACETYLSALICYLIC AC S I 131 UPTAKE DEC V WITH LARGE DOSES AND CHRONIC ADMINISTRATION 30408
ACETYLSALICYLIC AC S IRON DEC V NAY BE MARKEDLY REDUCED WITH LARGE DOSES HO 384
ACETYLSALICYLIC AC S KETONES DEC V INC OXIDATION OF KETONE BODIES IN DIABETICS P03 814
ACETYLSALICYLIC AC S KETONES INC V DUE TO INDUCED ACIDOSIS R0368
ACETYLSALICYLIC AC S LACTATE INC V DUE TO LATE METABOLIC ACIDOSIS AND RENAL IMPAIR P03 814
ACETYLSALICYLIC AC S LACTIC DEHYDROGENASE INC V EXPTL EFFECT SEEN IN RABBITS WITH PROLONGED USE P0 806
ACETYLSALICYLIC AC S NEFA DEC V INC FATTY ACID OXIDATION, DECREASED LIPOGENESIS H 0384
ACETYLSALICYLIC AC S PHI DEC V COMPETES FOR TBPA ALSO UNCOUPLES PHOSPHOHYLATION HO 299
ACETYLSALICYLIC AC S PHOSPHOLIPIDS DEC V INC FATTY ACID OXIDATION, DEC LIPOGENESIS P 03 84
ACETYLSALICYLIC AC S POTASSIUM DEC V DIURETIC ACTION, RESPIRATORY ALKALOSIS RO204
ACETYLSALICYLIC AC S PYPUVATE INC V DUE TO LATE METABOLIC ACIDOSIS AND PENAL IMPAIR HO 3814
ACETYLSALICYLIC AC S SALICYLATE INC V DUE TO INGESTION OF COMPOUND HO 36 8
ACETYLSALICYLIC AC S SGOT INC V PROLONGED ADMIN. NAY CAUSE HEPATIC TOXICITY HO 573
ACETYLSALICYLIC AC S SGPT INC V PROLONGED USE NAY CAUSE HEPATIC TOXICITY P02 99
ACETYLSALICYLIC AC S THYROXINE (T14) DEC V DISPLACES THYROXINE FROM BINDING SITES (TBPA) 30907
ACETYLSALICYLIC AC S T3 UPTAKE INC V RED CELL UPTAKE AFFECTED ALSO AFFECTS RESIN TEST P02 99

ACETYLSALICYLIC AC S UREA NITROGEN INC V MAY HAVE NEPHROTOXIC EFFECT R0955
ACETYLSALICYLIC AC S UREA NITROGEN Z M NO EFFECT ON BERTHELOT PROCEDURE P05 10
ACETYLSALICYLIC AC S URIC ACID DEC V MILD URICOSURIC ACTION (LARGE DOSE EFFECT) R0204
ACETYLSALICYLIC AC S URIC ACID INC N ACTS AS REDUCING SUBST WITH NON-SPECIFIC METHODS R04 17
ACETYLSALICYLIC AC S URIC ACID INC V SMALL DOSE EFFECT P 05 96
ACETYLSALICYLIC AC S URIC ACID INC V LOW DOSES REDUCE PENAL EXCRETION OF URIC ACID P1001
ACETYLSALICYLIC AC S URIC ACID Z M NO EFFECT ON METHODS USING URICASE ROll 1
ACETYLSALICYLIC AC S 5-NUCLEOTIDASE INC V REVEPSIBLE HEPATOTOXICITY WITH PROLONGED ADMIN. P0806
ACETYLSALICYLIC AC U ACETOACETATE INC N REACTS WITH GERHARDT FECL3 PROCEDURE P 1001
ACETYLSALICYLIC AC U ACETOACETATE INC V ACIDOTIC RESPONSE ESP IN CHILDREN P0368
ACETYLSALICYLIC AC U ALKALINE PHOSPHATASE INC V DUE TO NEPHROTOXIC EFFECT OF DRUG P07 58
ACETYLSALICYLIC AC U ALPHA AMINO NITROGEN INC V INHIBTION OF REABSORPTION, INC PROTEIN CATABOLISM P038 4
ACETYLSALICYLIC AC U AMINO ACIDS INC V TWO FOLD INCREASE AFTER 1.6G IN NORMALS P0 30 1
ACETYLSALICYLIC AC U ASCORBIC ACID INC V REPORTED EFFECT P0246
ACETYLSALICYLIC AC U BICARBONATE INC V RESPONSE TO HESP ALKALOSIS OF EARLY TOXICITY P0 384
ACETYLSALICYLIC AC U CATECHOLAMINES INC N INTERFERING FLUORESCENCE IN MANY PROCEDURES P05 96
ACETYLSALICYLIC AC U CATECHOLAMINES Z N NO EFFECT ON FLUOROMETHIC CHOUT PROCEDURE HO 2 36
ACETYLSALICYLIC AC U CATECHOLAMINES Z V NO EFFECT WITH SHORT TERN INGESTION 2.6 G/DAY P0236
ACETYLSALICYLIC AC U DORA SCREEN TEST P05 M LIGHT AMBER COLOR PRODUCED P0 802
ACETYLSALICYLIC AC U EPINEPHPINE Z V NO EFFECT WITH SHORT TERN INGESTION 2.6 G/DAY P0236
ACETYLSALICYLIC AC U FOUCHET TEST P05 N PRODUCES PURPLE COLOR P0143
ACETYLSALICYLIC AC U GFR DEC V NEPHHOTOXICITY OF DRUG OCCURRING ACUTELY P0087
ACETYLSALICYLIC AC U GLUCOSE DEC N GLUCOSE OXIDASE METHODS INHIBITED BY GENTISIC ACID HO 317
.ACETYLSALICYLIC AC U GLUCOSE INC V INHIBITS LIVER AND MUSCLE GLYCOGEN SYNTHESIS R0384
ACETYLSALICYLIC AC U HOMOGENTISIC ACID INC N INTERFERES WITH MEASUREMENT PROCEDURE P0356
ACETYLSALICYLIC AC U KETONES DEC V INC OXIDATION OF KETONE BODIES IN DIABETICS P0 3814
ACETYLSALICYLIC AC U KETONES INC M REDDISH COLOR WITH GERHARDT’S TEST P0299
ACETYLSALICYLIC AC U LACTIC DEHYDROGENASE INC V RENAL IRRITATION & DESQUAMATION OF EPITHELIAL CELLS R0758
ACETYLSALICYLIC AC U LEUCINE AMINOPEPTIDASE DEC V DUE TO ANTIFIBRINOLYTIC ACTION RO758
ACETYLSALICYLIC AC U NITROGEN INC V EFFECT OBSERVED IN ADULTS P0881
ACETYLSALICYLIC AC U NOHEPINEPHRINE Z V NO EFFECT WITH SHORT TERM INGESTION 2.6 G/DAY R0236
ACETYLSALICYLIC AC U PHENYLKETONES P05 N PURPLE WITH FECL3, PURPLE WITH PHENISTIX P0299
ACETYLSALICYLIC AC U PHOSPHATE INC V INHIBITS TUBULAR REABSORPTION P0384
ACETYLSALICYLIC AC U POTASSIUM INC V DIRECT EFFECT ON RENAL TUBULES P0 384
ACETYLSALICYLIC AC U PROTEIN INC N INTERFERENCE WITH FOLIN-CIOCALTEU REACTION P 1001
ACETYLSALICYLIC AC U PROTEIN INC V MAY CAUSE NEPHROTOXICITY R0417
ACETYLSALICYLIC AC U PSP EXCRETION DEC V COMPETES WITH PSP FOR EXCRETION P1001
ACETYLSALICYLIC AC U SODIUM INC V RESPONSE TO RESP ALKALOSIS OF EARLY TOXICITY R0384
ACETYLSALICYLIC AC U SUGAR INC N FALSE POSITIVE WITH CLINITEST OH BENEDICT’S HO 299
ACETYLSALICYLIC AC U TAURINE DEC V REDUCES ELEVATED CONC IN RHEUMATOID PATIENTS P0810
ACETYLSALICYLIC AC U URIC ACID DEC V LOW DOSES EFFECT P1001
ACETYLSALICYLIC AC U URIC ACID INC N ACTS AS REDUCING SUBST WITH NON-SPECIFIC METHODS P014 17
ACETYLSALICYLIC AC U URIC ACID INC V HIGH DOSE EFFECT (GREATER THAN 3 G DAILY) HO 299
ACETYLSALICYLIC AC U URINALYSIS CASTS INC V OCCURS WITH POISONING P03 68
ACETYLSALICYLIC AC U URINALYSIS CELLS INC V TUBULAR EPITRELIAL CELLS INC INITALLY, NAY PERSIST R038L4
ACETYLSALICYLIC AC U UPINALYSIS GLUCOSE DEC V MAY REDUCE HYPERGLYCEMIA, GLYCOSUPIA IN DIABETES P038 4
ACETYLSALICYLIC AC U URINALYSIS GLUCOSE INC V DUE TO HYPERGLYCEMIA HO 384
ACETYLSALICYLIC AC II UHI NALYSIS HEMOGLOBIN INC V OCCURS WITH SEVERE RENOLYTIC ANEMIA R0518
ACETYLSALICYLIC AC U URINALYSIS KETONES DEC V BY INC OXIDATION OF KETONE BODIES IN DIABETICS P03 84
ACETYLSALICYLIC AC U URINALYSIS KETONES INC V ACIDOTIC RESPONSE ESP IN CHILDREN P03 68
ACETYLSALICYLIC AC U URINALYSIS PROTEIN INC V MAY CAUSE NEPHROTOXICITY P 04 17
ACETYLSALICYLIC AC U URINALYSIS RBC/HPF INC V INITIAL EFFECT ALWAYS, MAY PERSIST P0 384
ACETYLSALICYLIC AC U URINALYSIS SUGAR INC N CONJUGATE NAY REACT WITH BENEDICT’S P0(436
ACETYLSALICYLIC AC U URINALYSIS WBC/HPF INC V OCCURS WITH POISONING P0 3 68
ACETYLSALICYLIC AC U VMA INC N INTERFERES WITH FLUORO-,COLORIMETPIC PROCEDURES P0155
ACETYLSALICYLIC AC U VOLUME INC V DEC RENAL TUBULAR REABSORPTION HO 3814
ACETYLSALICYLIC AC U XYLOSE EXCRETION DEC V AFFECTS RENAL ELIMINATION P0523
ACETYLSALICYLIC AC U 11 OH CORTICOSTEROIDS Z N NO EFFECT ON FLUORONETRIC MATTINGLY METHOD P0236
ACETYLSALICYLIC AC U 11 OH CORTICOSTEHOIDS Z V NO EFFECT WITH SHORT TERN INGESTION 2.6 G/DAY P0236
ACETYLSALICYLIC AC U 17 KETOSTEROIDS Z N NO EFFECT ON ZIMMERMAN PROCEDURE P0 236
ACETYLSALICYLIC AC U 17 KETOSTEROIDS Z V NO EFFECT WITH SHORT TERN INGESTION 2.6 G/DAY P0236
ACETYLSALICYLIC AC U 17 OH CORTICOSTEROIDS DEC N CONJUGATE INHIBITS B-GLUCURONIDASE, DOSE> 4.8 G/DAY P0236
ACETYLSALICYLIC AC U 17 OH CORTICOSTEROIDS Z N NO EFFECT ON POHTEH-SILBER PROCEDURE HO 236
ACETYLSALICYLIC AC U 17 OH CORTICOSTEHOIDS Z V NO EFFECT WITH SHORT TERM INGESTION 2.6 G/DAY HO 236
ACETYLSALICYLIC AC W ASCORBIC ACID DEC V PROLONGED ADMIN DECREASES CONC IN BUFFY COAT P0326
ACETYLSULFANIL AMID! B HEMOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P0518
ACETYLSULFA NILAMIDE B RED CELL COUNT DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0518
ACETYLTPYPTOPH AN T THYPTOPHAN INC N MEASURED AS SAME BY SPIES/CHAMBERS METHOD P03 99
ACIDS B WHITE CELL COUNT INC V RESPONSE TO INGESTION P03 68
ACIDS U PROTEIN INC V INGESTION NAY CAUSE SEVERE RENAL DAMAGE P036 8
ACIDS U URINALYSIS CASTS INC V PENAL DAMAGE FOLLOWING INGESTION P0368
ACIDS U URINALYSIS HEMOGLOBIN INC V RENAL DAMAGE FOLLOWING INGESTION P0368
ACIDS U URINALYSIS PROTEIN INC V RENAL DAMAGE FOLLOWING INGESTION P0368
ACRIFLAVI NE U POHPHYRINS INC N PRODUCE FLUORESCENCE H 1001
ACRIFL AVINE U URINALYSIS BILE INC N PRODUCES YELLOW COLORWHEN URINE SHAKEN HO 143
ACRIFLAVINE U URINALYSIS COLOR INC N GREENISH FLUORESCENCE P0 663
ACHIFLAVINE U UHOBILIN INC N PRODUCES YELLOW-GREEN FLUORESCENCE P04 36
ADIPI000NE S BSP RETENTION INC V REPORTED WITHOUT EVIDENCE OF LIVER DAMAGE P0596
ADIPIODONE S CHOLINESTERASE DEC V FAIRLY POWERFUL INHIBITOR R0567
ADIPI000NE S I 131 UPTAKE DEC V DUE TO IODINE COMPONENT OF MATERIAL P0 596
ADIPIODONE S PBI INC N CONTAINS IODINE R05 96
AJMALINE F UHOBILINOGEN DEC V INTRAHEPATIC CHOLESTASIS BOO 88
AJNALINE 0 GASTRIC JUICE HCL INC V STRONG STIMULANT ACTION P0596
AJMALINE P CATECHOLAMINES INC V RELEASE OF STORED NOREPINEPHRINE P0596
AJNAL! NE S ALKALINE PHOSPHATASE INC V INTRAHEPATIC CHOLESTASIS P0088
AJMALINE S BILIRUBIN INC V INTRAREPATIC CHOLESTASIS P0088
AJMALINE S SGOT INC V INTHAHEPATIC CHOLESTASIS P0088
AJ N AL IN! S SGPT INC V INTRAHEPATIC CHOLESTASIS P0088
AJNALINE S THYMOL TURBIDITY INC V INTRAHEPATIC CHOLESTASIS RO088
AJ MALINE U HMPG INC V RELEASE OF STORED NOREPINEPHPINE P0596

AJNALINE U URINALYSIS BILE INC V INTRAHEPATIC CHOLESTASIS R0088
AJMALINE U UROBILINOGEN DEC V INTRAHEPATIC CHOLESTASIS ROOB8
AJMALINE U VMA INC V RELEASE OF STORED NOREPINEPHHINE R0596
ALANINE S UREA NITROGEN Z N NO EFFECT ON BERTHELOT REACTION P0510
ALANI NE U PHOSPHATE INC V INHIBITS TUBULAR REABSORPTION P02 84
ALBUMIN C PROTEIN DEC M TURBIDITY < GLOBULINS WITH SULFOSALICYLIC ACID P 06 20
ALBUMI N S TRYMOL TURBIDITY INC M IF HIGH P0620
ALBUMIN, HUMAN S ALKALINE PHOSPHATAS! INC V PLACENTAL A.P. IF FROM PITMAN-MOORE OR PARKE-DAVIS P04 17
ALBUMI N, HUMAN S PBI INC V CAUSES EFFECT IF IODINATED P 09 07
AL DOST ER ONE S CHLORIDE DEC V HYPOKALEMIC HYPOCHLORENIC ALKALOSIS NAY OCCUR RO3 814
AL DOSTERONE S CO2 CONTENT INC V METABOLIC ALKALOSIS HO 299
ALDOSTERONE S POTASSIUM DEC V HYPOKALEMIC HYPOCHLOREMIC ALKALOSIS NAY OCCUR 90384
AL DOST FR ONE U MAGNESIUM INC V MAGNESIUM EXCRETION INCREASED TO SAME EXTENT AS K P 0965
AL DOS T ER ON E U PH INC V EXCHANGED WITH K ION FOR NA ION P03 84
ALDOST ERONE U POTASSIUM INC V CONSERVATION OF NA WITH INCREASED K LOSS P0965
AL DO ST EHO NE U SODIUM DEC V DUE TO HORMONAL ACTION H 0965
A LD OS T ER 0 NE U URINALYSIS PH INC V H AND K IONS EXCHANGED FOR NA ION O384
ALDRIN S CHOLINESTERASE DEC V IN VITRO 6.0% DEC AT 1X1O-4 N H 0362
A LD RI N S LACTIC DEHYDROGENASE DEC V IN VITRO 4.5% DEC AT 1X1O-L4 N P 03 62
ALKALINE ANTACIDS F COLOR DEC N WHITE DISCOLORATION OP SPECKLING P062 0
ALKALINE ANTACIDS S CALCIUM DEC V INHIBITION OF ABSORPTION HO 620
ALKALINE ANTACIDS S CALCIUM INC V THEORETICAL POSSIBILITY WITH ABSOPP OF CA SALTS HO 883
ALKALINE ANTACIDS S CREATININ! DEC V MAY CAUSE MILK-ALKALI SYNDROME 90596
ALKALINE ANTACIDS S MAGNESIUM INC V THEORETICAL POSSIBILITY P0883
ALKALINE ANTACIDS S PHOSPHATE DEC V THEORETICAL POSSIBILITY HO 883
ALKALINE ANTACIDS S UREA NITROGEN INC V PROLONGED USE NAY CAUSE NEPHROTOXICITY HO 596
ALKALINE URINE U URINALYSIS PROTEIN INC N HIGHLY BUFFERED URINE NAY AFFECT COMBISTIX P0620
ALLA NTOIN S UREA NITROGEN INC N REACTS WITH XANTHYDROL IN METHOD OF POSSE P0143 6
ALLOPURINOL B EOSINOPHILS INC V MAY CAUSE SEVERE SENSITIVITY REACTION P066 5
ALLOPU RI NOL B HENATOCRIT DEC V PARE CASE OF ANEMIA REPORTED ROO26
ALLOPURINOL B HEMOGLOBIN DEC V PARE CASE OP ANEMIA REPORTED HO 026
ALLOPUR INOL B PLATELET COUNT DEC V RARE POTENTIALLY DANGEROUS COMPLICATION 30378
ALLOPURI NOL B RED CELL COUNT DEC V RAPE CASE OF ANEMIA NAY OCCUR HO 026
ALLOP UP INOL B RETICULOCYTES INC V NILD(MAY B! ASSOCIATED WITH OTHER DRUGS) HO 166
ALLOPURI NOL B WHITE CELL COUNT DEC V HYPERSENSI TIVITY REACTION (OFTEN TRANSIENT) P0620
ALLOPURINOL B WHITE CELL COUNT INC V HYPERSENSITIVITY REACTION OCCURS WITH FEVER P06 20
ALLOPURI NOL P PROTHROMBIN TIME INC V PATIENTS ON COUNAPINS (UNCONFIRMED CLINICALLY) P096 0
ALLOPURINOL S ALKALINE PHOSPHATASE INC V REVERSIBLE CLINICAL HEPATOTOXICITY NOTED P0204
ALLOPUHINOL S ALLOXANTHINE INC V ACCUMULATES WITH CHRONIC ADMINISTRATION P03 84
ALLOPUP INOL S BILIRUBIN INC V REPORTED IN RENAL FAILURE ALSO IN OTHER PATIENTS P0 585
ALLOPtYRINOL S BSP RETENTION INC V ASSOCIATED WITH REVERSIBLE HEPATOTOXICITY P08 143
ALLOPURINOL S CHOLESTEROL DEC V HEPATOTOXIC EFFECT P0596
A LL OP U R INOL S GLUCOSE DEC V HEPATOTOXIC EFFECT 90596
ALLOPURI NOL S HYPOXANTHINE INC V INHIBITS XANTHINE OXIDASE (SLIGHT INC ONLY) P0 026
ALLOPURINOL S lCD INC V PEVEPSIBLE CLINICAL HEPATOTOXICITY REPORTED HO 596
ALLOPU RI NOL S IRON DEC V 40% REDUCTION IN ONE WEEK (ACCUMULATES IN LIVER) R 01466
ALLOPURINOL S SGOT INC V REVERSIBLE CLINICAL HEPATOTOXICITY REPORTED P0596
ALLOPURINOL S SGPT INC V REVERSIBLE CLINICAL HEPATOTOXICITY REPORTED HO 596
ALLOPURINOL S UREA NITROGEN INC V AZOTENIA AS SENSITIVITY REACTION IN 2 CASES 30665
ALLOPURINOL S URIC ACID DEC V INHIBITION OF XANTHINE OXIDASE 90299
A LLOPU RI NOL S XANTHINE INC V INHIBITS XANTHINE OXIDASE (SLIGHT INC ONLY) P0026
ALLOPUR INOL U HYPOXANTHINE INC V INHIBITS XANTHINE OXIDASE BOO 26
ALLOPU PINOL U URIC ACID DEC V INHIBITION OF XANTHINE OXIDASE P02 99
ALLOPUP INOL U URINALYSIS BILE INC V HEPATOTOXIC EFFECT R0596
ALLOPLIPINOL U URINALYSIS PBC/HPF INC V ASSOCIATED WITH SEVERE SENSITIVITY REACTION P0665
ALLOPU P1 NOL U URINALYSIS WBC/HP! INC V ASSOCIATED WITH SEVERE SENSITIVITY REACTION P06 65
ALLOPU RINOL U UROBILIN INC V TRANSIENT INCREASES REPORTED 0657
ALLOPURINOL U XANTRINE CALCULI POS V RARE SIDE EFFECT P 03 95
ALLOPUPINOL U XANTHINE INC V INHIBITS XANTHINE OXIDASE P00 26
ALOIN U URINALYSIS COLOR INC N RED-BROWN/YELLOW PINK(ALKALINE) ,YELLOW BROWN(ACID) P0620
ALUMINUM NICOTINATE S CHOLESTEROL DEC V THERAPEUTIC INTENT THHOUGH NICOTINIC ACID RELEASE P00140
ALUMINUM NICOTINATE S GLUCOSE INC V PRODUCES CARBOHYDRATE INTOLERANCE OVER LONG TERM P05147
ALUMINUM NICOTINATE S URIC ACID INC V NAY INCREASE URIC ACID TO PRODUCE GOUT R00(4O
ALUMINUM SALTS F COLOR DEC N WHITE DISCOLORATION OP SPECKLING P06 20
ALUMINUM SALTS S PHOSPHATE DEC V BINDING OF PHOSPHATE IN G.I.TRACT R1001
ALUMINUM SALTS U DIAGNEX BLUE EXCRETION INC V HEAVY METAL DISPLACEMENT OF DIAGNEX BLUE P1001
ALUMINUM SALTS U PHOSPHATE DEC V DEC ABSORPTION AND EXCRETION P00 26
ANANTADINE S SGOT INC V REPORTED EFFECT NO MECHANISM DISCUSSED 30620
AMBULATION F CALCIUM DEC V AFTER SEVERAL WEEKS BED REST(GRADUAL EFFECT) R01471
AMBULATION P PENIN INC V ACTIVITY INCREASED BY MOD TO SEVERE EXERCISE 90062
AMBULATION S ALKALINE PHOSPHATASE INC V FOLLOWING PROLONGED BED REST(?INC BONE FORMATION) P0147 1
AMBULATION S CALCIUM DEC V FOLLOWING SEVERAL WEEKS OF BED PEST HO 47 1
AMBULATION S NYOGLOBIN INC V FOLLOWS PHYSICAL EXERTION P0462
AMBULATION S THYROXINE (T4) DEC V TRANSIENT? DUE TO INC CELLULAR UTILIZATION HO 266
AMBULATION U CALCIUM DEC V FOLLOWING SEVERAL WEEKS OF BED REST P0147 1
AMBULATION U HYDROXYPROLINE DEC V FOLLOWING SEVERAL WEEKS OF BED PEST P 047 1
AMBULATION U MYOGLOBIN INC V FOLLOWS PHYSICAL EXERTION P0462
AMILORIDE S C02 CONTENT DEC V REDUCES ALKALOSIS INDUCED BY OTHER DIURETICS ROO5O
ANILORIDE S POTASSIUM INC V ALSO INHIBITS KALURESIS CAUSED BY THIAZIDES 907714
A MILORI DE S UREA NITROGEN INC V MAY OCCUR WITH EXCESSIVE SALURESIS 90557
AM ILOR IDE U CHLORIDE INC V DIURETIC ACTION HO 38(4
AMILOPIDE U POTASSIUM DEC V NAY OCCUR EVEN IF MARKED SODIUM LOSS 303 814
AM ILOR IDE U SODIUM INC V DIURETIC ACTION 30 173
AMILORIDE U URINALYSIS PH INC V MODERATE INCREASE SOMETIMES OBSERVED 90384
AMINO ACIDS E ATP DEC V ASSOCIATED WITH LOW SERUM PHOSPHATE 90938
AMINO ACIDS E FRUCTOSE-6-P DEC V ASSOCIATED WITH LOW SERUM PHOSPHATE P0938
AMINO ACIDS E GLUCOSE-6-P014 DEC V ASSOCIATED WITH LOW SERUM PHOSPHATE RO938
AMINO ACIDS E PEP DEC V ASSOCIATED WITH LOW SERUM PHOSPHATE 90938
AMINO ACIDS E 2-PG DEC V ASSOCIATED WITH LOW SERUM PHOSPHATE P0938
AMINO ACIDS E 2,3 DPG DEC V ASSOCIATED WITH LOW SERUM PHOSPHATE P09 38

AMINO ACIDS E 3-PG DEC V ASSOCIATED WITH LOW SERUM PHOSPHATE P0938
AMINO ACIDS p INSULIN INC V ? DUE TO ACTION ON BETA CELLS P049 1
AMINO ACIDS S GASTRIN INC V OPAL FEEDING PRODUCES UP TO TENFOLD INCREASE RO55O
AMINO ACIDS S GLUCOSE INC V AS RESULT OF I.V. INFUSION P03 49
AMINO ACIDS S PHOSPHATE DEC V IF GIVEN I.V. HYPEHALIMETATION P0 93 8
AMINO ACIDS S UREA NITROGEN INC N MAY REACT WITH BEPTHELOT IF UPEASE NOT USED P0179
AMINO ACIDS S UREA NITROGEN INC V AS RESULT OF I.V. INFUSION HO 349
AMINO ACIDS U URINALYSIS SUGAR INC N FALSE POSITIVE CAUSED BY SOME WITH BENEDICT’S P02 99
AMINOBENZOIC ACID B HEMATOCRIT DEC V INDUCES MALABSORPTION AND MEGALOBLASTIC ANEMIA P0716
ANINOBENZOIC ACID B HEMOGLOBIN DEC V INDUCES NALABSORPTION AND MEGALOBLASTIC ANEMIA P07 16
AMINOBENZOIC ACID B MCV INC V INDUCES MALABSORPTION AND MEGALOBLASTIC ANEMIA P07 16
AMINOBENZOIC ACID B PH DEC V ACIDOSIS FROM USE OP FREE AD REPORTED P0384
ANINOBENZOIC ACID B PLATELET COUNT DEC V INDUCES NALABSORPTION AND MEGALOBLASTIC ANEMIA P0932
ANINOBENZOIC ACID B RED CELL COUNT DEC V INDUCES MALABSOPPTION AND MEGALOBLASTIC ANEMIA P07 16
AMINOBENZOIC ACID S I 131 UPTAKE DEC V MAY IMPAIR UPTAKE P0596
AMINOBENZOIC ACID S PBI DEC V INHIBITS IODINATION OF TYPOSINE IN TBG R0004
AMINOBENZOIC ACID S SALICYLATE INC V BY COMPETING FOR GLYCINE FOR CONJUGATION P03814
AMINOBENZOIC ACID S SGOT INC V TOXIC HEPATITIS REPORTED 30384
AMINOBENZOIC ACID S SULFA AS SULFANILAMIDE INC N MEASURED AS IF SULFONAMIDE P0384
AMINOBENZOIC ACID U PAH CLEARANCE INC N MEASURED AS IF PAR P0779
AMINOBENZOIC ACID U PHENYLKETONES P05 N GREEN WITH FECL3 P0239
AMINOCAPPOIC ACID S POTASSIUM INC V REPORTED EFFECT ESP IF RENAL FUNCTION IMPAIRED P0014 1
AMINOCAPROIC ACID U AMINO ACIDS INC N REACTS WITH NINHYDRIN MEASURED AS AMINO ACID P1 015
ANINOCAPROIC ACID U LEUCINE AMINOPEPTIDASE DEC V DUE TO ANTIFIBRINOLYTIC ACTION P0758
AMINOGLUTETHIMIDE B WHITE CELL COUNT DEC V MAY CAUSE LEUKOPENIA P0620
AMINOGLUTETHIMIDE S I 131 UPTAKE DEC V REPORTED EFFECT HO 596
ANI NOGLUTETHIMIDE S PBI DEC V INHIBITS IODINATION OF TYPOSINE IN TBG P0004
AMINOGLUTETHINIDE U 17 KETOSTEROIDS DEC V INHIBITS STEROID BIOSYNTHESIS R0359
AMINOGLUTETHINIDE U 17 OH CORTICOSTEHOIDS DEC V INHIBITS STEROID BIOSYNTHESIS RO359
AMINOHIPPURIC ACID S CREATININE INC N CHROMOGENICITY IN COLOR REACTION P0907
AMINOHIPPURIC ACID S SULFA AS SULFANILANIDE INC N MEASURED AS IF SULFONAMIDE P0779
AMI NON ETHYLCYCLO HEX U LEUCINE ANINOPEPTIDASE DEC V DUE TO ANTIFIBRINOLYTIC ACTION P0758
AMINOPHENAZONE U CREATINE INC V REPORTED EFFECT P0 596
AMINOPHENAZONE U NITROGEN INC V REPORTED EFFECT P05 96
AMINOPHENAZONE U PHOSPHATE INC V REPORTED EFFECT HO 596
AMI NOPHENOL S BILIRUBIN INC N AT 1 NMOL/L AFFECTS SMA 12/60 METHOD P0876
AMINOPHENOL S CALCIUM INC N AT 0.1 NNOL/L AFFECTS SNA 12/60 METHOD P0876
ANI NOPHENOL S GLUCOSE INC N AT 1 MMOL/L AFFECTS SMA 12/60 METHOD P0876
AMINOPHENOL S SCOT INC N AT 1 NMOL/L AFFECTS SMA 12/60 METHOD P0876
AMI NOPHENOL S UREA NITROGEN INC N NAY REACT IN BERTHELOT PROCEDURE P0510
AMINOPHENOL S URIC ACID INC N AT 1 MMOL/L AFFECTS SNA 12/60 AND HENRY METHODS P0876
AMINOPHYLLINE B COAGULATION TIME DEC V REPORTED EFFECT R0384
AMINOPHYLLINE F OCCULT BLOOD P05 V HENATEMESIS MAY OCCUR EARLY WITH POISONING P0657
ANINOPHYLLINE P CATECHOLAMINES INC V RESPONSE TO I.V. THERAPEUTIC DOSE P0059
AMINOPHYLLINE S URIC ACID INC M REACTS AS IF URIC ACID IN METHOD OF BITTNFR R07 214
ANINOPHYLLINE U EPINFPHRINE INC V THREEFOLD INCREASE IN RESPONSE TO I.V. DOSE P00 59
AMINOPHYLLI NE U NOPEPINEPHPINE INC V TWOFOLD INCREASE IN RESPONSE TO I.V. DOSE P0059
AMINOPHYLLINE U URINALYSIS PROTEIN INC V INC IN RENAL DISEASE (OCCURS EARLY WITH POISONING) RO299
AMINOPYHINE B HEINZ-BODY FORMATION P05 V OCCURS INITIALLY BEFORE OVERT HENOLYSIS P05 18
AMINOPYRINE B HENATOCRIT DEC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS HO 2 40
AMINOPYRINE B HEMOGLOBIN DEC V HENOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS P0240
AMINOPYRINE B PLATELET COUNT DEC V MAY CAUSE HEMOLYTIC OR APLASTIC ANEMIA R1O23
ANINOPYRINE B RED CELL COUNT DEC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS P02140
ANINOPYRINE B RETICULOCYTES INC V MAY OCCUR DURING RECOVERY FROM HEMOLYSIS R0S 18
AMINOPYRINE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS,OCCURS WITHIN MINUTES P1023
ANINOPYRINE E REDUCED GLUTATHIONE DEC V SHARP FALL BEFORE OVERT HEMOLYSIS P0518
AMINOPYRINE P HEMOGLOBIN INC V MAY OCCUR WITH MARKED HEMOLYSIS R0518
AMI NOPYRINE P PROTHROMBIN TIME INC V OBSERVED IN NAN AND EXPTL ANIMALS P0620
AMINOPYRINE P VOLUME INC V FLUID RETENTION MAY OCCUR P0657
AMINOPYPINE S BILIPUBIN INC V HEMOLYSIS IN G-6-PD DEFICIENCY P0079
AMINOPYRINE S CHOLESTEROL INC N INTERFERES WITH MEASUREMENT PROCEDURE P0(436
A MI NOPYRI NE S DIRECT BILIRUBIN INC V MAY CAUSE HENOLYTIC ANEMIA P0620
AMINOPYP IN! S GAMMA GLOBULIN INC V SPECIFIC ANTIBODIES TO DRUG MAY DEVELOP P0583
AMINOPYRINE S HAPTOGLOBIN DEC V NAY CAUSE HEMOLYTIC ANEMIA P0620
AMINOPYRINE S SCOT INC V LIVER DAMAGE UP TO HEPATIC NECROSIS SEEN R0657
AMINOPYRINE S SGPT INC V LIVER DAMAGE UP TO HEPATIC NECROSIS SEEN P0657
AMINOPYRINE S UREA NITROGEN INC V RARE SUGGESTION OF NEPHROTOXIC ACTION RO657
AMINOPYRINE U GLUCARIC ACID INC V AS RESULT OF HEPATIC ENZYME INDUCTION R0596
AMINO PYHINE U PORPHYRINS INC V STIMULATES FORMATION OF ALA-SYNTHETASE P03 84
AMINOPYRINE U URINALYSIS COLOR INC N RED BROWN P0620
AMI NOPYRINE U URINALYSIS HEMOGLOBIN INC V MAY OCCUR WITH MARKED REMOLYSIS P05 18
AMINOPYHINE U URINALYSIS PROTEIN INC V NEPHROTOXICITY REPORTED HO 657
AMINOPYRINE U URINALYSIS RBC/HPF INC V RARE N!PHROTOXICITY REPORTED P0657
ANINOSALICYLIC AC B EOSINOPHILS INC V HYPERSENSITIVITY REACTION HO 4214
ANINOSALICYLIC AC B HENATOCHIT DEC V HEMOLYTIC ANEMIA/NEGkLOBLASTIC ANEMIA P02140
AMINDSALICYLIC AC B HEMOGLOBIN DEC V HEMOLYTIC ANENIA/NEGALOBLASTIC ANEMIA P0240
AMINOSALICYLIC AC B LE CELL PREP PUS V NAY PRODUCE LE-LIKE SYNDROME P06 22
AMINOSALICYLIC AC B LYMPHOCYTES INC V MAY PRODUCE SYNDROME LIKE INFECTIOUS MONONUCLEOSIS HO 3 84
ANINOSALICYLIC AC B MCV INC V IF MEGALOBLASTIC ANEMIA OCCURS P0976
AMINOSALICYLIC AC B METHEMOGLOBIN INC V MAY CAUSE HEMOLYTIC ANEMIA P0026
ANINOSALICYLIC AC B NEUTROPHILS DEC V IF SEVERE MEGALOBLASTIC ANEMIA OCCURS P0976
AMINOSALICYLIC AC B PERIPHERAL SMEAR V ATYPICAL LYMPHOCYTES WITH EOSINOPHILIA P0657
ANINOSALICYLIC AC B PH DEC V NOD STRONG ACID, LOSS OF FIXED CATION = ACIDOSIS P0 384
AMINOSALICYLIC AC B PLATELET COUNT DEC V MAY OCCUR WITH SEVERE NEGALOBLASTIC ANEMIA HO 976
AMINOSALICYLIC AC B RED CELL COUNT DEC V HEMOLYTIC ANEMIA/MEGALOBLASTIC ANEMIA P0 240
AMINOSALICYLIC AC B WHITE CELL COUNT DEC V LEUKOPENIA BUT NO CASES OF AGPANULOCYTOSIS P065 8
AMINOSALICYLIC AC B WHITE CELL COUNT INC V MAINLY DUE TO EOSINOPHILIA DUE TO HYPERSENSITIVITY HO 620
AMINOSALICYLIC AC C PROTEIN INC N REACTS AS PHENOL IF FOLIN-CIOCALTEU REACTION USED P0907
AMINOSALICYLIC AC F OCCULT BLOOD P05 V REVERSIBLE GASTHITIS CAUSED BY DRUG HO 384
AMINOSALICYLIC AC F UROBILINOGEN DEC V PALE STOOLS MAY OCCUR IF CHOLESTASIS P04 77

AMINOSALICYLIC AC P PPOTHROMBIN TIME INC V DRUG SUPPRESSES FORMATION OF PROTHROMBIN P0763
ANINOSALICYLIC AC S ALKALINE PHOSPHATASE INC V REVERSIBLE CHOLESTASIS MAY OCCUR 301477
AMINOSALICYLIC AC S ANYLASE INC V MAY CAUSE ACUTE PANCREATITIS P0384
AMINOSALICYLIC AC S BILIRUBIN INC V REVERSIBLE CHOLESTASIS CAUSED BY DRUG P0091
AMINOSALICYLIC AC S BSP RETENTION INC V REVERSIBLE CHOLESTASIS CAUSED BY DRUG P0715
AMINOSALICYLIC AC S CEPHALIN FLOCCULATION INC V REVERSIBLE CHOLESTASIS CAUSED BY DRUG RO715
AMINOSALICYLIC AC S CHOLESTEROL DEC V AS EFFECTIVE AS NEOMYCIN, MECHANISM OBSCURE P0579
ANINOSALICYLIC AC S DIRECT BILIRUBIN INC V REVERSIBLE CHOLESTASIS CAUSED BY DRUG P0091
AMINOSALICYLIC AC S DIRECT COOMBS TEST POS V IMMUNOLOGICAL RESPONSE TO DRUG 30118
AMINOSALICYLIC AC S FOLATE DEC V MAY OCCUR WITH PROTRACTED THERAPY P0657
AMINOSALICYLIC AC S GLUCOSE DEC V MAY CAUSE LOWERING IN DIABETICS 90596
AMINOSALICYLIC AC S GLUCOSE INC N AT 1 MNOL/L AFFECTS SMA 12/60 METHOD 30876
ANINOSALICYLIC AC S GLUCOSE INC V HYPERGLYCEMIA REPORTED WITH PROTRACTED THERAPY P0676
AMINOSALICYLIC AC S GUANASE INC V MAY CAUSE CYTOTOXIC HEPATOCELLULAR DAMAGE P0079
ANINOSALICYLIC AC S HAPTOGLOBIN DEC V EFFECT OF HEMOLYTIC ANEMIA RO24O
ANINOSALICYLIC AC S I 131 UPTAKE DEC V MAY CAUSE GOITROUS HYPOTHYROIDISM RO736
ANINOSALICYLIC AC S lCD INC V NAY CAUSE CYTOTOXIC HEPATOCELLULAR DAMAGE P0079
AMINOSALICYLIC AC S OCT INC V MAY CAUSE CYTOTOXIC HEPATOCELLULAR DAMAGE P0079
AMINOSALICYLIC AC S PBI DEC V INHIBITS IODINATION OF TYROSINE IN TBG R0848
AMINOSALICYLIC AC S POTASSIUM DEC V DUE TO ACTION ON RENAL TUBULES OR VOMITING P0637
AMINOSALICYLIC AC S SGOT INC N AT 1 NNOL/L AFFECTS SMA 12/60 METHOD P0876
ANINOSALICYLIC AC S SGOT INC V NAY CAUSE CYTOTOXIC HEPATOCELLULAR DAMAGE ROO79
AMINOSALICYLIC AC S SGPT INC V MAY CAUSE CYTOTOXIC HEPATOCELLULAR DAMAGE P0079
ANINOSALICYLIC AC S SULFA AS SULFANILAMIDE INC VERY SLIGHT EFFECT, MEASURED AS IF SULFA P0779
AMINOSALICYLIC AC S THYMOL TURBIDITY INC V LIVER DAMAGE MAY OCCUR WITH 10% MORTALITY P0736
AMINOSALICYLIC AC S THYROXINE (TIl) DEC MAY CAUSE GOITROUS HYPOTHYROIDISM 30736
AMINOSALICYLIC AC S UREA NITROGEN INC N REACTS AS UREA WITH DIMETHYLAMINOBENZALDEHYDE RO9O7
AMINOSALICYLIC AC S VITAMIN B12 DEC V IMPAIRS ABSORPTION R0975
AMINOSALICYLIC AC U AICAH INC V OCCURS WITH VITAMIN 812 DEFICIENCY P0976
AMINOSALICYLIC AC U FIGLU INC V OCCURS WITH VITAMIN B12 DEFICIENCY RO976
AMINOSALICYLIC AC U GLUCOSE INC V GLYCOSURIA REPORTED WITH PROTRACTED THERAPY RO676
AMINOSALICYLIC AC U METHYLMALONATE INC V OCCURS WITH VITAMIN B12 DEFICIENCY P0976
ANINOSALICYLIC AC U PAR CLEARANCE INC M VERY SLIGHT EFFECT, MEASURED AS IF PAll RO779
AMINOSALICYLIC AC U PRENYLKETONES P05 N RED-BROWN WITH FECL3, PINK TO PURPLE PHENISTIX RO239
AMINOSALICYLIC AC U PORPHOBILINOGEN INC N REACTS WITH EHRLICH’S REAGENT RO65LI
AMINOSALICYLIC AC U PROTEIN INC V MAY OCCUR AS RESULT OF NEPHROTOXICITY P0677
AMINOSALICYLIC AC U SUGAR INC N ACTS AS REDUCING AGENT WITH BENEDICT’S REAGENT P0044
ANINOSALICYLIC AC U URINALYSIS BILE INC V HEPATOTOXICITY P0620
AMINOSALICYLIC AC U URINALYSIS COLOR INC N ABNORMAL COLOR (NOT DISTINCTIVE) RO122
AMINOSALICYLIC AC U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG 90299
AMINOSALICYLIC AC U URINALYSIS PROTEIN INC N REACTS WITH FOLIN-CIOCALTEU OF LOWRY PROCEDURE 30355
AMINOSALICYLIC AC U URINALYSIS PROTEIN INC V MAY CAUSE NEPHROTOXICITY RO355
ANINOSALICYLIC AC U URINALYSIS BBC/HPF INC V BLEEDING CAUSED BY DRUG P0355
AMINOSALICYLIC AC U URINALYSIS SUGAR INC N ACTS AS REDUCING AGENT WITH NON-SPECIFIC METHODS P0355
ANINOSALICYLIC AC U UHOBILINOGEN INC N REACTS WITH EHRLICH’S REAGENT (YELLOW COLOR) R0081
AMINOSALICYLIC AC U VITAMIN B12 DEC V OCCURS WITH VITAMIN B12 DEFICIENCY P0976
AMINOSALICYLIC AC U VMA INC M REACTS WITH DIAZO REAGENT IF USED P0030
ANINOSALICYLIC AC U XYLOSE EXCRETION DEC V 2X NORMAL DOSE PRODUCED REVERSIBLE EFFCT ON ABSORP R0993
ANINOTHIAZOLE S BILIRUBIN INC V JAUNDICE WITH FEBRILE REACTIONS P0384
AMINOTHIAZOLE S PBI DEC V INHIBITS IODINATION OF TYPOSINE IN TBG P00014
ANITRIPTYLINE B RED CELL COUNT DEC V PARE TRANSIENT AGPANULOCYTOSIS ROO26
AMITHIPTYLINE B WRIT! CELL COUNT DEC V LEUKOPENIA/AGPANULOCYTOSIS NAY OCCUR 30063
AMITRIPTYLINE S ALKALINE PHOSPHATASE INC V PARE CASES OF CHOLESTASIS (TRANSIENT) P0673
AMITRIPTYLINE S BILIRUBIN INC V RAPE CASES OF TRANSIENT CHOLESTASIS 90673
AMITRIPTYLINE S BSP RETENTION INC V DUE TO TRANSIENT CHOLESTASIS P0620
AMITRIPTYLINE S CEPHALIN FLOCCULATION INC V RARE CASES OF TRANSIENT CHOLESTASIS P0620
AMITRIPTYLINE S SGOT INC V HARE CASES OF TRANSIENT CHOLESTASIS P0673
AMITRIPTYLINE S SGPT INC V PARE CASES OF TRANSIENT CHOLESTASIS 30673
AMITRIPTYLINE S TRYMOL TURBIDITY INC V RARE CASES OF TRANSIENT CHOLESTASIS R062O
AMITRIPTYLINE U URINALYSIS BILE INC V DUE TO TRANSIENT CHOLESTASIS R062O
ANITRIPTYLINE U URINALYSIS COLOR INC N GREENISH-BLUE COLOR RO299
AMITRIPTYLINE U VOLUME DEC V NAY CAUSE URINARY RETENTION ROO26
AMMONIA P ALPHA AMINO NITROGEN INC N UNLESS REMOVED DURING ANALYTIC PROCEDURE RO1436
AMMONIA U ALPHA AMINO NITROGEN INC N UNLESS REMOVED DURING ANALYTIC PROCEDURE P01436
AMMONIA U AMINOLEVULINIC ACID INC N IF NO PRELIMINARY SEPARATION P0779
AMNONIUM CHLORIDE B PH DEC V FOLLOWING ADMINISTRATIONS (METABOLIC ACIDOSIS) P0620
AMMONIUM CHLORIDE S CHLORIDE INC V ADDED CHLORIDE AND METABOLIC ACIDOSIS R0620
AMMONIUM CHLORIDE S POTASSIUM DEC V PERPETUATES POTSSIUM DEFICIENCY, CATION LESS P0520
AMMONIUM CHLORIDE S SODIUM DEC V CATION LOSS AS EXCESS CHLORIDE EXCRETED P0204
AMNONIUM CHLORIDE U CHLORIDE INC V DIURETIC ACTION 90384
ANMONIUM CHLORIDE U POTASSIUM INC V DIURETIC ACTION AND HYPERCHLOREMIC ACIDOSIS P03814
ANNONIUN CHLORIDE U SODIUM INC V DIURETIC ACTION P0384
AMNONIUM IONS S PROTEIN DEC N CUPRIC ANMONIUN COMPLEX FOPMED(CU AVAILABILITY DEC) P0436
AMNONIUN NITRATE B METHENOGLOBIN INC V MAY CAUSE HEMOLYTIC ANEMIA R0658
AMMONIUM OXALATE B PH DEC N ALTERS ACID-BASE BALANCE IF USED AS ANTICOAGULANT RO620
AMMONIUM SALTS P AMMONIA INC N INCREASED BLOOD LEVELS R0356
ANMONIUM SALTS S MAGNESIUM Z V NO EFFECT OBSERVED IN SPITE OF URINARY CHANGE R0617
AMMONIUM SALTS S UREA NITROGEN INC N IF UREASE USED AND AMMONIA MEASURED RO1436
AMMONIUM SALTS U MAGNESIUM INC V DIURETIC ACTION OBSERVED WITH ACIDOSIS P0617
AMNONIUN SALTS U UROBILINOGEN DEC V ACIDIFICATION OF URINE DECREASES EXCRETION RO666
AMMONIUM SALTS U VOLUME INC V DIURETIC ACTION OF ACID FORMING SALT P03814
ANOBARBITAL P PHOTHPOMBIN TIME DEC V ANTAGONIZES ACTION OF COUMARINS (ENZ INDUCTION) RO787
ANOBARBITAL S BSP RETENTION INC V PROBABLY NON-SPECIFIC EFFECT ON CELLS 30958
AMODIAQUINE B WHITE CELL COUNT DEC V REPORTED EFFECT(ANA - BLOOD DYSCRASIA COMMITTEE) P0620
ANODIAQUINE S ALKALINE PHOSPHATASE INC V REPORTED REPATOTOXICITY P0620
AMODIAQUINE S BILIPUBIN INC V REPORTED EFFECT 90620
AMODIAQUINE S BSP RETENTION INC V REPORTED HEPATOTOXICITY P0620
AMODIAQUINE S CEPHALIN FLOCCULATION INC V REPORTED HEPATOTOXICITY R062O
AMODIAQUINE S lCD INC V REPORTED HEPATOTOXICITY P0620
AMODIAQUINE S SGOT INC V REPORTED HEPATOTOXICITY P0620
CLINICAL CHEMISTRY, Volt 18, No. 10, 1972 1069

ANODIAQUINE S SGPT INC V REPORTED HEPATOTOXICITY R0620
AMODIAQUINE S THYMOL TURBIDITY INC V REPORTED HEPATOTOXICITY P0620
ANODIAQUINE U URINALYSIS BILE INC V REPORTED HEPATOTOXICITY P0620
AMPHENONE S I 131 UPTAKE DEC V REPORTED EFFECT RO255
ANPHENDN! S PBI DEC V INHIBITS IODINATION OF TYROSINE IN TBG P0004
AMPHETAMINES B HEMATOCHIT DEC V HEMOLYTIC ANEMIA (DEPENDS ON PRIOR SENSITIVITY) P02140
AMPHETAMINES B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA (DEPENDS ON PRIOR SENSITIVITY) P02140
AMPHETAMINS B MYELOBLASTS INC V NYELOBLASTIC LEUKEMIA P0100
AMPHETAMINES B PROMYELOBLASTS INC V MYELOBLASTIC LEUKEMIA P0100
AMPHETAMINES B RED CELL COUNT DEC V HENOLYTIC ANEMIA (DEPENDS ON PRIOR SENSITIVITY) P0240
AMPHETAMINES B WHITE CELL COUNT INC V MYELOBLASTIC LEUMIA P0100
AMPHETAMINES 0 BNR INC V METABOLIC EFFECT OF DRUGS P0596
AMPHETAMINES S NEFA INC V BUT DOES NOT MODIFY CARBOHYDRATE UTILIZATION P0384
AMPH!TAMTNES U 17 KETOSTEROIDS Z N NO EFFECT ON ZIMMERMAN REACTION P0133
AMPHETAMINES U 17 OH CORTICOSTEHOIDS Z N NO EFFECT ON GLENN-NELSON PROCEDURE P0133
AMPHOTEHICIN B B HEMATOCRIT DEC V BONE NARROW DEPRESSION WITH HEMOLYTIC ANEMIA P09145
AM?HOTERICIN B B HEMOGLOBIN DEC V BONE NARROW DEPRESSION WITH HEMOLYTIC ANEMIA P09145
AMPHOTERICIN B B PLATELET COUNT DEC V BONE MARROW DEPRESSION WITH HENOLYTIC ANEMIA R09145
AMPHOTEPICIN B B RED CELL COUNT DEC V BONE NARROW DEPRESSION WITH HEMOLYTIC ANEMIA P09145
AMPHOTERICIN B F OCCULT BLOOD P05 V MELENA AND HEMORRHAGIC GASTHOENTERITIS R0026
AMPP.OTEPICIN B D ERPF DEC V OCCURS IN HIGH PERCENTAGE OF PATIENTS P0026
AMPHOTERICIN B S ALKALINE PHOSPHATASE INC V DUE TO HEPATOCELLULAP DYSFUNCTION P0620
AMPROTEHICIN B S BILIPUBIN INC V MAY CAUSE HEPATOCELLULAR DYSFUNCTION 30384
AMPHOTERICIN B S BSP RETENTION INC V DUE TO HEPATOCELLULAR DYSFUNCTION H0620
AMPHOTERICIN B S CEPHALIN LOCCULATI0N INC V DUE TO HEPATOCELLULAR DYSFUNCTION P0620
ANPHOTERICIN B S CPK INC V RHABDONYOLYSIS CAUSED BY SEVERE HYPOKALEMIA P0285
AMPHOTERICIN B S CREATININE INC V NEPHROTOXIC EFFECT P0620
PIMPHOTEHICIN B S lCD INC V DUE TO HEPATOCELLULAR DYSFUNCTION R0620
AMPHOTERICIN B S MAGNESIUM DEC V (OCCASIONAL) ASSOCIATED WITH TOXIC EFFECT OF DRUG P0038
AMPHOTERICIN B S NPN INC V NEPHPOTOXIC EFFECT R0620
AMPHOTERICIN B S POTASSIUM DEC V (FREQUENT) ASSOCIATED WITH RENAL DAMAGE P0038
AMPHOTERICIN B S POTASSIUM INC V NAY OCCUR WITH PENAL TOXICITY P0170
AMPROTERICIN B S SGOT INC V HEPATOTOXICITY REPORTED P0620
AMPHOTERICIN B S SGPT INC V HEPATOTOXICITY REPORTED P0620
AMPHOTERICIN B S SODIUM DEC V SIGNIFICANT EFFECT EVEN IN NORMAL SUBJECTS RO17O
AMPHOTERICIN B S THYMOL TURBIDITY INC V DUE TO REPATOCELLULAR DYSFUNCTION P0620
AMPHOTERICIN B S UREA NITROGEN INC V NEPHROTOXIC EFFECT P0620
AMPHOTERICIN B U CPEATININ! CLEARANCE DEC V NEPHROTOXICITY EFFECT (DECREASE UP TO 36%) P0170
AMPHOTEPICIN B U GFP DEC V OCCURS IN HIGH PERCENTAGE OF PATIENTS P0026
AMPHOTEPICIN B U MAGNESIUM INC V FOLLOWING I.V. INFUSION FOR 2 HOURS P0657
AMPHOTERICIN B U MYOGLOBIN INC V CAUSED BY RHABDOMYOLYSIS P0285
AMPHOTERICIN B U PROTEIN INC V NEPHROTOXIC EFFECT P0299
AMPHOTERICIN B U URINALYSIS BILE INC V REPORTED HEPATOTOXICITY P0620
ANPROTERICIN B U URINALYSIS CASTS INC V GRANULAR AND HYALINE CASTS WITH TOXICITY P0026
AMPHOTERICIN B U URINALYSIS HEMOGLOBIN INC V NEPHROTOXICITY, BLEEDING ACTUALLY CAUSED BY DRUG P0299
ANPUOTERICIN B U URINALYSIS PROTEIN INC V NEPHROTOXICITY RO299
AMPHOTERICIN B U URINALYSIS RBC/HPF INC V NEPHROTOXICITY R0299
ANPICILLIN B ROSINOPHILS INC V ALLERGIC REACTION P0424
AMPICILLIN B MONOCYTES INC V ASSOCIATED WITH AGRANULOCYTOSIS P0390
ANPICILLIN B WHITE CELL COUNT DEC V LEUKOPENIA P0390
AMPICILLIN B WHITE CELL COUNT INC V MAINLY DUE TO EOSINOPHILIA OF HYPERSENSITIVITY P0620
AMICILLIN P CATECHOLAMINES INC N CONC SOLUTIONS CAUSE STRIKING FLUORESCENCE P0188
AMPICILLIN S CEPHALIN FLOCCULATION INC N ALTERS TINE OF FLOCCULATION R0541
AMPICILLIN S CPK INC V PROBABLE EFFECT OF I.N. INJECTION P0541
AMPICILLIN S FOLATE DEC N INHIBITS GROWTH OF L. CASEI RO91O
AMPICILLIN S SCOT INC V PROBABLE EFFECT OF I.M. INJECTION RO541
AMPICILLIN S SGPT INC V PROBABLE EFFECT OF I.M. INJECTION P05141
ANPICILLIN U AMINO ACIDS INC M PRESENCE OF DRUG AS ADDITIONAL SPOT P0749
AMPICILLIN U PROTEIN INC V NECROSIS OF TUBULES DUE TO NEPHHOTOXICITY P0916
ANPICILLIN U URINALYSIS CASTS INC V OCCURS AS RESULT OF NEPHROTOXICITY P0916
ANPICILLIN U URINALYSIS CRYSTALS INC N PRESENCE OF DRUG MAXIMAL AT PH 5 P0749
AMPICILLIN U URINALYSIS HEMOGLOBIN INC V OCCURS AS RESULT OF NEPHROTOXICITY R0916
AMPICILLIN Ti URINALYSIS PROTEIN INC V NECROSIS OF TUBULES DUE TO NEPHROTOXICITY P0916
AMPICILLIN U URINALYSIS RBC/HPF INC V NECROSIS OF TUBULES DUE TO NEPHROTOXICITY P0916
AMPICILLIN U UPINALYSIS WBC/HPF INC V NECROSIS OF TUBULES DUE TO NEPHROTOXICITY P0916
ANYGDALINS U URINALYSIS SUGAR INC N MEASURED AS REDUCING AGENTS WITH BENEDICT’S P0620
AMYL ALCOHOL B METHEMOGLOBIN INC V NAY CAUSE HENOLYSIS FOLLOWING INGESTION P0368
AMYL ALCOHOL F OCCULT BLOOD P05 V MAY CAUSE GASTROINTESTINAL HEMORRHAGE P0368
AMYL ALCOHOL S SGPT INC V MAY CAUSE LIVER DAMAGE IF INGESTED P0368
AMYL ALCOHOL 1’ URINALYSIS GLUCOSE INC V ASSOCIATED WITH RENAL DAMAGE P0368
AMYL NITRITE B NETHEMOGLOBIN INC V HEMOLYTIC ANEMIA P0656
AMYL NITRITE B RED CELL COUNT DEC V HEMOLYTIC ANEMIA (SLIGHT OP MARKED EFFECT) R0656
AMYL NITRITE B RETICULOCYTES INC V HEMOLYTIC ANEMIA (UP TO 15%) RO656
AMYL NITRITE F UROBILINOGEN INC V IF HENOLYTIC ANEMIA OCCURS P0656
AMYL NITRITE P HEMOGLOBIN INC V IF INTRAVASCULAR HENOLYSIS OCCURS P0656
AMYL NITRITE S BILIPUBIN INC V WITH INCREASED HENOLYSIS P0656
AMYL NITRITE U UROBILINOGEN INC V LESS RELIABLE INDEX THAN FECAL IF HENOLYSIS OCCURS P0656
ANABOLIC STEROIDS B FACTOR V INC V METABOLIC EFFECT R0072
ANABOLIC STEROIDS B FACTOR VII INC V METABOLIC EFFECT R0072
ANABOLIC STEROIDS B FACTOR X INC V METABOLIC EFFECT P0072
ANABOLIC STEROIDS P FIBRINOGEN DEC V METABOLIC EFFECT R0O72
ANABOLIC STEROIDS P PLASMINOGEN INC V METABOLIC EFFECT P0072
ANABOLIC STEROIDS P PROTHRONBIN TINE DEC V INC PROTHROMBIN AS METABOLIC EFFECT P06814
ANABOLIC STEROIDS P PROTHPOMBIN TIME INC V EXAGGERATED RESPONSE TO ANTICOAGULANTS REPORTED P01467
ANABOLIC STEROIDS S ALKALINE PHOSPHATASE INC V CHOLESTATIC SYNDROME 90384
ANABOLIC STEROIDS S BETA-GLUCURONIDASE INC V METABOLIC EFFECT R0O72
ANABOLIC STEROIDS S BILIRUBIN INC V CHOLESTATIC SYNDROME P0299
ANABOLIC STEROIDS S BSP RETENTION INC V CHOLESTATIC SYNDROME RO299
ANABOLIC STEROIDS S CALCIUM INC V POSITIVE EFFECT ON CALCIUM RETENTION P0021
ANABOLIC STEROIDS S CEPHALIN FLOCCULATION INC V DUE TO CHOLESTATIC SYNDROME P0596

ANABOLIC STEROIDS S CHOLESTEROL INC V CHOLESTATIC PHENOMENON 30596
ANABOLIC STEROIDS S CORTISOL BINDING GLOB INC V METABOLIC EFFECT P007 2
ANABOLIC STEROIDS S DIRECT BILIRUBIN INC V CHOLESTATIC SYNDROME P0 620
ANABOLIC STEROIDS S ERYTHROPOIETIN INC V METABOLIC EFFECT P0072
ANABOLIC STEROIDS S GLUCOSE DEC V ANABOLIC EFFECT IN FASTING STATE HO 596
ANABOLIC STEROIDS S GUANASE INC V DUE TO CHOLESTATIC SYNDROME 30596
ANABOLIC STEROIDS S HAPTOGLOBIN INC V METABOLIC EFFECT 90072
ANABOLIC STEROIDS S lCD INC V DUE TO CHOLESTATIC SYNDROME P05 96
ANABOLIC STEROIDS S PBI DEC V REDUCES CONCENTRATION OF CIRCULATING TBG HO 004
ANABOLIC STEROIDS S PHOSPHATE INC V AUGMENTS PHOSPHATE RETENTION P0204
ANABOLIC STEROIDS S PROTEIN INC V ASSOCIATED WITH INCREASED PROTEIN SYNTHESIS RO211
ANABOLIC STEROIDS S SGOT INC V CHOLESTATIC SYNDROME (I NTRAHEPATIC CHOLESTASIS) P0596
ANABOLIC STEROIDS S SGPT INC V CHOLESTATIC SYNDROME (INTRAHEPATIC CHOLESTASIS) HO 5 96
ANABOLIC STEROIDS S SODIUM INC V NINERALOCORTICOID EFFECT WITH RETENTION P0620
ANABOLIC STEROIDS S TBG DEC V DIRECT EFFECT OF DRUG R0001$
ANABOLIC STEROIDS S TBPA INC V METABOLIC EFFECT P0072
ANABOLIC STEROIDS S THYMOL TURBIDITY INC V DUE TO CHOLESTATIC SYNDROME R0596
ANABOLIC STEROIDS S TRYPSIN INHIBITOR INC V METABOLIC EFFECT 90072
ANABOLIC STEROIDS S UREA NITROGEN INC V IMPROVES NITROGEN BALANCE 902014
ANABOLIC STEROIDS S URIC ACID INC V IMPROVES NITROGEN BALANCE HO 6 20
ANABOLIC STEROIDS S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS P04 92
ANABOLIC STEROIDS U CREATINE DEC V ANABOLIC EFFECT P03 55
ANABOLIC STEROIDS U CREATININE DEC V ANABOLIC EFFECT 30355
ANABOLIC STEROIDS U URINALYSIS BILE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE 30384
ANALGESICS B NETHEMOGLOBIN INC V MAY CAUSE INTRAVASCULAR HEMOLYSIS P0910
ANALGESICS S CPK INC V MAY CAUSE EFFECT IF INJECTED I.M. P0 080
ANCPOD P FIBRINOGEN DEC V CONVERTS TO FIBRIN SHREDS R07L42
AN DROG EN S B HEMATOCRIT INC V ASSOCIATED WITH INCREASED WELL BEING P0026
ANDROGE MS B RED CELL COUNT INC V MAY PRODUCE EPYTHROCYTEMIA (INCS WELL-BEING) P00 26
ANDROGENS P COPTICOSTEROIDS DEC V MAY CAUSE CHOLESTATIC SYNDROME RO355
ANDROGENS S ACID PHOSPHATASE TOTAL INC V EFFECT OF HORMONE IN FEMALES HO 299
ANDROG ENS S ALKALINE PHOSPHATASE INC V MAY CAUSE CHOLESTATIC SYNDROME 30299
ANDROGENS S BILIRUBIN INC V MAY CAUSE CHOLESTATIC SYNDROME P0 299
A N DROG ENS S BSP RETENTION INC V MAY CAUSE CHOLESTATIC SYNDROME H 02 99
ANDPO GEMS S CALCIUM INC V POSITIVE EFFECT ON CALCIUM RETENTION 30021
A NDROG ENS S CEPHALIN FLOCCULATION INC V CHOLESTATIC PHENOMENON 90620
AN DR OGENS S CERULOPLASMIN INC V HORMONAL EFFECT RO079
A NDHOG ENS S CHLORIDE INC V NAY CAUSE SALT AND WATER RETENTION P03814
ANDROGENS S CHOLESTEROL DEC V DECREASED SYNTHESIS 91001
A N DR OG! MS S CHOLESTEROL INC V CHOLESTATIC PHENOMENON RD 596
AN D HO C EN S S DIRECT BILIRUBIN INC V NAY CAUSE CHOLESTATIC SYNDROME P06 20
ANDROGE NS S GLUCOSE DEC V ANABOLIC EFFECT IN FASTING STATE R0596
ANDPOGENS S GUANASE INC V CHOLESTATIC PHENOMENON R06 20
A ND P OG ENS S I 131 UPTAKE Z V NO EFFECT ON UPTAKE REPORTED HO 596
ANDPOG ENS S lCD INC V CHOLESTATIC PHENOMENON P 062 0
AN DRO GE MS S PBI DEC V REDUCED SYNTHESIS OF TBG HO 596
ANDROGENS S PHOSPHATE INC V AUGMENTS PHOSPHATE BALANCE P0204
ANDROGENS S PROTEIN INC V ASSOCIATED WITH INCREASED PROTEIN SYNTHESIS 30211
A NDROG ENS S SGOT INC V MAY CAUSE CHOLESTATIC SYNDROME HO 596
ANDRO GEMS S SGPT INC V MAY CAUSE CHOLESTATIC SYNDRCME P0 596
A N DROG ENS S SODIUM INC V MINERALOCORTICOID EFFECT WITH INC RETENTION 0O21
AN DRO GEM S S TBG DEC V DIRECT EFFECT OF DRUG 30004
A ND HOG E MS S THYNOL TURBIDITY INC V CHOLESTATIC PHENOMENON P06 20
AN DR OG ENS S UREA NITROGEN INC V AUGMENTS NITROGEN BALANCE P02 04
ANDROGENS S URIC ACID INC V AUGMENTS NITROGEN BALANCE 90620
A ND HOG ENS S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS 90492
ANDROGENS U CREATINE DEC V ANABOLIC EFFECT HO 355
ANDROGENS U CREATININE DEC V ANABOLIC EFFECT P02 99
ANDROGENS U URINALYSIS BILE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE HO 384
A ND POST EHON E S CHOLESTEROL DEC V THERAPEUTIC EFFECT 90355
ANESTHETIC AGENTS P PPOTHROMBIN TINE INC V OBSERVED EFFECT P04 67
ANESTHETIC AGENTS S PHOSPHATE DEC V OBSERVED AFTER ANESTHESIA 90355
AN GIOTENS IN P ALDOSTERONE INC V INC OF 14 TIMES NORMAL AFTER I.V. FOR 1 HOUR R0331
ANGIOTENSIN P EPINEPHRINE DEC V DEC SLIGHTLY LESS THAN NOREPINEPHRINE INC P1030
ANGIOTENS IN P ERPF DEC V MARKED DEC FOLLOWING ADMINISTRATION 90657
A MG lOT ENSIN P NOREPINEPHRINE INC V OF SANE MAGNITUDE AS IF NOREPINEPHBINE GIVEN 31030
ANGIOTENSIN P RENIN DEC V CAUSES DEC IN NORMALS WHEN GIVEN I.V. P033 1
A NGIOTENS IN P VOLUME DEC V PROMOTES LOSS OF PROTEIN-FREE FILTRATE TO TISSUES P0384
ANGIOTENSIN S PROTEIN INC V RENOCONCENTHATION EFFECT HO 38 (4
ANGIOTENSIN S SODIUM INC V DUE TO SALT RETAINING ACTION OF ALDOSTERONE 90384
ANGI OTENSIN S URIC ACID INC V REDUCED URATE CLEARANCE IF GIVEN I.V. P03 24
ANGIOTENS IN U GFR DEC V VASOCONSTRICTIVE EFFECT IN KIDNEY HO 384
ANGIOTEMSIN U SODIUM DEC V DUE TO EFFECT ON RENAL TUBULES P03 84
A N G 10 TE MS I N U URIC ACID CLEARANCE DEC V LARGE DECREASE FOLLOWING ADMINISTRATION P06 57
A NGIOTENSIN U URIC ACID DEC V DECREASES URATE EXCRETION AND RENAL PLASMA FLOW P0324
ANGIOTENS IN U VMA Z V EPINEPHRINE DEC COMPENSATES FOR NOREPINEPHRINE INC R1O3O
ANGIOTENSIN U VOLUME DEC V VASOCONSTRICTIVE EFFECT IN KIDNEY HO 3814
ANILERIDINE U VMA INC N INTERFERES WITH PISANO PROCEDURE P0299
ANILINE B METHEMOGLOBIN INC V OCCURS AS RESULT OF INTRAVASCULAR HENOLYSIS B 03 68
ANILINE U URINALYSIS COLOR INC V BROWN COLOR DUE TO INTRAVASCULAR HEMOLYSIS HO 368
ANILINE U URINALYSIS METHEMOGLOB INC V DUE TO INTRAVASCULAR HEMOLYSIS P03 68
ANI SI NDIONE U URINALYSIS COLOR INC N ORANGE (ALKALINE) , PINK-RED-BROWN (ACID) R0620
ANTACIDS B PH INC V NAY CAUSE OCCASIONAL METABOLIC ALKALOSIS R0026
ANTACIDS S CALCIUM INC V NAY OCCUR IF CA CONTAINING PREPARATIONS P0657
ANTAZOLINE B PLATELET COUNT DEC V THRONBOCYTOPENIA (IMMUNOLOGICALLY I NDUCED) P0 932
ANTAZOLINE B WHITE CELL COUNT DEC V LEUKOPENI A P0932
ANTHRAQUINONE F COLOR INC N BROWNISH STAINING P06 20
ANTHRA QUI NONE U PSP EXCRETION INC M INTERFERENCE BY COLOR OF COMPOUND ROSS 1
ANTRRAQUINONE U URINALYSIS COLOR INC N PINK, RED, PURPLE, ORANGE & RUST P06 54
ANTIBI OTICS P UROBILINOGEN DEC V INHIBIT G.I.TPACT FLORA HO 355

ANTIBI OTICS P PROTHROMBIN TIME INC V DECREASED SYNTHESIS OF VIT K BY G.I. TRACT Ri 001
ANTIBIOTICS S CALCIUM Z N NO EFFECT ON FLUORESCENCE OF CALCEIN P06 144
ANTIBIOTICS S PBI Z V NO EFFECT OBSERVED P0255
ANTIBIOTICS U UROBILINOGEN DEC V INHIBIT G.I.TRACT FLORA P03 56
ANTICOAGULANTS B COAGULATION TIME INC V THERAPEUTIC INTENT P06 20
ANTICOAGULANTS F COLOR INC V RED TO BLACK DUE TO INTERNAL BLEEDING R0620
ANTICOAGULANTS P PROTHROMBIN TINE INC V THERAPEUTIC INTENT P06 20
ANTICO AGULANTS S PBI Z V NO EFFECT OBSERVED P0255
ANTICONVULSANTS B HEMATOCRIT DEC V MAY CAUSE MEGALOBLASTIC/APLASTIC ANEMIA HO791
ANTICONVULSANTS B HEMOGLOBIN DEC V MAY CAUSE NEGALOBLASTIC/APLASTIC ANEMIA H 07 9 1
ANTICONVU LSANTS B MCV INC V MAY CAUSE MEGALOBLASTIC/APLASTIC ANEMIA HO 976
ANTICONVULSANTS B NEUTBOPHILS DEC V MAY OCCUR WITHOUT EFFECT ON WHITE CELL COUNT P0467
ANTICONVULSANTS B PLATELET COUNT DEC V MAY OCCUR WITH SEVERE MEGALOBLASTIC ANEMIA P0976
ANTICONVULSANTS B WHITE CELL COUNT DEC V MAY OCCUR WITH SEVERE NEGALOBLASTIC ANEMIA P0976
ANTICONVULS ANTS E EGOT DEC V IN TREATED PATIENTS COMPARED WITH CONTROLS P07 68
ATICONVULSANTS S ALKALINE PHOSPHATASE INC V OCCURS IN 214% CHILDREN (90% BONY ORIGIN) R0473
A NTICONVULSANTS S CALCIUM DEC V FOUND IN 30% CHILDREN ON PROLONGED THERAPY P 0473
ANTICONVULSANTS S FOLATE DEC V NAY CAUSE MEGALOBLASTIC ANEMIA H0791
ANTICONVULSANTS S VITAMIN B12 DEC V SIC LOWER THAN NORMAL CONTROLS HO 657
A NTICONVULSANTS S 25 OH-VITAMIN D DEC V PROBABLY DUE TO INC METABOLISM OF VITAMIN D P040 9
ANTICONVULS ANTS U AICAP INC V OCCURS WITH MEGALOBLASTIC ANEMIA R0976
ANTICONVULSANTS U AMINOLEVULINIC ACID INC V REPORTED IN ONE CHILD P0657
ANTICONVULS ANTS U FIGLU INC V OCCURS WITH MEGALOBLASTIC ANEMIA R0976
ANTICONVLILSANTS U GLUCARIC ACID INC V OCCURS IN 914 % CHILDREN (REPATIC ENZYME INDUCTION) RO1473
ANTICONVULS ANTS U PORPHOBILINOGEN INC V DRUG RELATED EFFECT REPORTED IN ONE CHILD P0657
ANTICONVULSANTS U UROPORPHYRIN INC V DRUG RELATED EFFECT REPORTED IN ONE CHILD P06 57
ANTIFUNGAL AGENTS S ALKALINE PHOSPHATASE INC V HEPATOTOXICITY NAY OCCUR P03 55
ANTIFUNGAL AGENTS S BILIRUBIN INC V HEPATOTOXIC EFFECT HO 3SS
ANTIFUNGAL AGENTS S BSP RETENTION INC V HEPATOTOXIC EFFECT MAY IMPEDE CLEARANCE P0355
ANTIFUNGAL AGENTS S SGOT INC V HEPATOTOXICITY NAY OCCUR RO 3S
ANTIFUNGAL AGENTS S SGPT INC V HEPATOTOXICITY MAY OCCUR P0355
ANTIFUNGAL AGENTS U URINALYSIS BILE INC V HEPATOTOXICITY MAY OCCUR H0355
ANTIHI STANI NES P PROTHHOMBIN TIME DEC V ACCELERATE METABOLISM OF ANTICOAGULANTS P0620
ANTIHISTAMINES S I 131 UPTAKE DEC V UNCOMMON REPORTED EFFECT P0596
ANTIHISTAMINES S PBI Z V PROBABLY EXERT NO CLINICALLY SIGNIFICANT EFFECT HO 255
ANTILYNPHOCYTE B PLATELET COUNT DEC V OBSERVED LESS COMMONLY WITH OTHER IMNUNOSUPRESSANTS P0893
ANTIMALARIALS B HEINZ-BODY FORMATION P05 V OCCURS PRIOR TO OVERT HEMOLYSIS P05 18
ANTIMALARIALS B HEMATOCRIT DEC V MAY CAUSE HEMOLYTIC ANEMIA P0518
ANTIMALARIALS B HEMOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P05 18
ANTIMALAPIALS B NETHEMOGLOBIN INC V MAY CAUSE HEMOLYTIC ANEMIA R0518
ANTIMALA RIA LS B RED CELL COUNT DEC V MAY CAUSE HEMOLYTIC ANEMIA P0518
ANTI MALARIAL S B PETICULOCYTES INC V OCCURS DURING RECOVERY FROM HENOLYSIS P05 18
ANTIMALARIALS 3 REDUCED GLUTATHIONE DEC V OCCURS PRIOR TO OVERT HENOLYSIS H0518
ANTIMALARIALS P HEMOGLOBIN INC V OCCURS WITH MARKED HEMOLYSIS P05 18
ANTINALAPIALS S BILIRUBIN INC V MAY CAUSE HEMOLYTIC ANEMIA P05 18
ANTIMALARIALS S DIRECT BILIRUBIN INC V MAY CAUSE HEMOLYTIC ANEMIA RO51 8
ANTIMALARIALS U URINALYSIS HEMOGLOBIN INC V NAY OCCUR WITH MARKED HEMOLYSIS P05 18
ANTIMONY COMPOUNDS B PLATELET COUNT DEC V THRONBOCYTOPENIA P06 20
ANTIMONY COMPOUNDS B RED CELL COUNT DEC V PANCYTOPENIA/MAY CAUSE HEMOLYTIC ANEMIA P06 20
ANTIMONY COMPOUNDS S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT HO 596
ANTIMONY COMPOUNDS S BILIRUBIN INC V HEPATOTOXIC EFFECT P0596
ANTIMONY COMPOUNDS S BSP RETENTION INC V HEPATOTOXIC EFFECT P0596
ANTIMONY COMPOUNDS S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT H 0596
ANTIMONY COMPOUNDS S CHOLESTEROL DEC V HEPATOTOXIC EFFECT P0596
ANTIMONY COMPOUNDS S GLUCOSE DEC V HEPATOTOXIC EFFECT P0596
ANTIMONY COMPOUNDS S GUANASE INC V HEPATOTOXIC EFFECT P0 596
ANTIMONY COMPOUNDS S lCD INC V HEPATOTOXIC EFFECT P096
ANTIMONY COMPOUNDS S SCOT INC V HEPATOTOXIC EFFECT HO 596
ANTIMONY COMPOUNDS S SGPT INC V HEPATOTOXIC EFFECT H 05 96
ANTIMONY COMPOUNDS S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT R0596
ANTIMONY COMPOUNDS S UREA NITROGEN INC V NEPHPOTOXIC EFFECT (COMMON AT THERAPEUTIC DOSES) P0299
ANTIMONY COMPOUNDS U PROTEIN INC V NEPHROTOXIC EFFECT HO 299
ANTIMONY COMPOUNDS U URINALYSIS BILE INC V HEPATOTOXICITY P0620
ANTIMONY COMPOUNDS U URINALYSIS CASTS INC V NEPHROTOXIC EFFECT P06 20
ANTIMONY COMPOUNDS U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT R0299
ANTINEOPLASTIC B PLATELET COUNT DEC V MAY CAUSE APLASTIC ANEMIA P0620
ANTINEOPLASTIC B RED CELL COUNT DEC V MAY CAUSE APLASTIC ANEMIA RO62O
ANTI NEOPLASTIC B WHITE CELL COUNT DEC V OFTEN THERAPEUTIC INTENT 30620
ANTINEOPLASTIC S URIC ACID INC V DESTRUCTION OF NUCLEOPHOTEIN P00 42
ANTIPYRETICS B HEINZ-BODY FORMATION PUS V OCCURS PRIOR TO OVERT HEMOLYSIS P05 18
ANTIPYRETICS B HENATOCRIT DEC V MAY CAUSE HENOLYTIC ANEMIA P05 18
ANTIPYRETICS B HEMOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA R0518
ANTIPYRETICS B RED CELL COUNT DEC V NAY CAUSE HEMOLYTIC ANEMIA P05 18
ANTIPYRETICS B PETICULOCYTES INC V OCCURS DUPING RECOVERY FROM HEMOLYSIS P0518
ANTIPYRETICS I REDUCED GLUTATHIONE DEC V SHARP FALL BEFORE OVERT HEMOLYSIS P05 18
ANTIPYPETICS P HEMOGLOBIN INC V MAY OCCUR WITH NARKEDHEMOLYSIS ROS 18
ANTIPYPETICS S BILIRUBIN INC V OCCURS WITH HEMOLYTIC ANEMIA P0518
ANTIPYRETICS S DIRECT BILIRUBIN INC V OCCURS WITH HEMOLYTIC ANEMIA P05 18
ANTIPYRETICS U PORPHYRINS INC V REPORTED EFFECT P03 55
ANTIPYRETICS U URINALYSIS HEMOGLOBIN INC V OCCURS WITH MARKED HENOLYSIS R0518
ANTIPYPINE B HEINZ-BODY FORMATION P05 V OCCURS INITIALLY PRIOR TO HEMOLYSIS P05 18
ANTIPYRINE B HENATOCRIT DEC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS P0 240
ANTIPYRINE B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS P02140
ANT IPYRINE B NETHENOGLOBIN INC V INCREASE SELDOM OCCURS P0384
ANTIPYRINE B NEUTROPHILS DEC V MYELOTOXIC ACTION OF DRUGS P0657
ANTIPYHINE B PLATELET COUNT DEC V ASSOCIATED WITH HENOLYTIC ANEMIA P0657
ANTIPYRINE B RED CELL COUNT DEC V HENOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS R02140
ANTIPYRINE B RETICULOCYTES INC V OCCURS WITH HENOLYTIC ANEMIA (RECOVERY) P0240
ANTIPYRINE B WHITE CELL COUNT DEC V LEUKOPENIA/AGRANULOCYTOSIS P0657
ANTIPYRINE F UROBILINOGEN INC V OCCURS WITH HEMOLYTIC ANEMIA HO 240

ANTIPYRINE P METHEMALBUMIN INC V OCCURS WITH INTRAVASCULAR HEMOLYSIS P0240
ANTIPYRINE P PPOTHROMBIN TIME DEC V OBSERVED IN MAN AND EXPTL ANIMALS P0657
ANTIPYRINE P PROTHROMBIN TIME INC V PATIENTS ON COUNARINS 90657
ANTIPYHINE S BARBITURATE INC N EXTRACTION PROPERTIES OF FREE FORM SIMILAR P0936
ANTIPYPINE 5 BILIPUBIN INC V HENOLYSIS IN G-6-PD DEFICIENCY 90079
ANTIPYRINE S GLUCOSE INC V SEVERE HYPERGLYCEMIA UNRESPONSIVE TO INSULIN P0657
ANTIPYRINE U ACETOACETATE INC N INTERFERES WITH FERRIC CHLORIDE TEST HO65L4
ANTIPYPINE U PHENYLKETONES P05 N RED FADING WITH FECL3, PINK TO RED PHENISTIX P0239
ANTIPYPINE U URINALYSIS CELLS INC V RENAL ACTION OF DRUG RO988
ANTIPYRINE U URINALYSIS COLOR INC M RED BROWN (GREEN IN REFLECTED LIGHT) 90620
ANTIPYPINE U URINALYSIS GLUCOSE INC V RENAL ACTION OF DRUG P0988
ANTIPYRINE U URINALYSIS HEMOGLOBIN INC V OCCURS WITH MARKED HEMOLYSIS P0518
ANTIPYPINE U URINALYSIS PROTEIN INC V RENAL ACTION OF DRUG RO988
ANTIPYRINE U URINALYSIS SUGAR INC N ACTS AS REDUCING AGENT P0654
ANTIPYRINE U UROBILINOGEN INC N PRODUCES SIMILAR COLOR WITH EHRLICHS R1001
ANTIPYRINE U UROBILINOGEN INC V OCCURS WITH HEMOLYTIC ANEMIA P02140
ANTISEPTICS S PBI INC N IF CONTAIN IODINE AND USED TO CLEAN SKIN R0255
APONOPPHINE B PCO2 INC V NAY DEPRESS RESPIRATION P03814
APHONAL B PLATELET COUNT DEC V IMMUNOLOGICAL MECHANISM 90657
APRONAL U PORPHYRINS INC V NAY PRECIPITATE ATTACK OF ACUTE PORPHYRIA 90657
ARABINOSE U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S P01436
ARGININE B PH DEC V CHLORIDE SALT TENDS TO CAUSE ACIDOSIS R0O26
APGININE P AMMONIA DEC V CAPABLE OF REACTING WITH AMMONIA R05314
ARGININE P GROWTH HORMONE INC V EFFECT ALSO SHOWN BY PROTEIN MEALS RO759
ARGININE P INSULIN INC V SLIGHT EFFECT AND METABOLISM BY TISSUES P0311
ARGININE S CPEATINE INC V INCORPORATED INTO UREA CYCLE P0026
ARGININE S CREATININE INC N IF METHOD OF VOGES-PROSKAUER USED P01436
ARGININE S CPEATININE INC V INCORPORATED INTO UREA CYCLE P0026
ARGININE S GLUCOSE INC V SLIGHT INC IN NORMALS , MORE IN DIABETICS P0890
ARGININE S UREA NITROGEN INC V INCORPORATED INTO UREA CYCLE P0026
APGININE S UREA NITROGEN Z N NO EFFECT ON BERTHELOT REACTION RO51O
APSENICALS B EOSINOPHILS INC V UP TO 50% OBSERVED IN ONE CASE, OTHERS 10-20% RO41S
ARSENICALS B HEINZ-BODY FORMATION P05 V SOME MAY CAUSE HEMOLYTIC ANEMIA P0104
ARSENICALS B HENATOCPIT DEC V PANCYTOPENIA P0240
APSENICALS B HEMOGLOBIN DEC V NEGALOBLASTIC ANEMIA/PANCYTOPENIA 30240
ARSENICALS B PLATELET COUNT DEC V PANCYTOPENIA P0240
ARSENICALS B RED CELL COUNT DEC V NEGALOBLASTIC ANEMIA/PANCYTOPENIA P0240
ARSENICALS B RETICULOCYTES INC V VALUES OBSERVED RANGING UP TO 18% 90415
ARSENICALS B WHITE CELL COUNT DEC V PANCYTOPENIA P0240
ARSENICALS F OCCULT BLOOD P05 V OBSERVED IN SEVERAL CASES WITH POISONING 90415
APSENICALS S ALKALINE PHOSPHATASE DEC N APSENATES APE INHIBITORS OF ENZYME IN LAB PHOCS P0929
ARSENICALS S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT (CHOLESTASIS/CHOLANGIOLITIS) P0596
ARSENICALS S BILIRUBIN INC V HEPATOTOXIC EFFECT (CHOLESTASIS/CHOLANGIOLITIS) R0596
ARSENICALS S BSP RETENTION INC V HEPATOTOXIC EFFECT (CHOLESTASIS/CHOLANGIOLITIS) P0596
ARSENICALS S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT (CHOLESTASIS/CHOLANGIOLITIS) P0596
ARSENICALS S CHOLESTEROL INC V HEPATOTOXIC EFFECT (MAY BE VERY HIGH) P0596
ARSENICALS S CREATININE INC V NEPHROTOXICITY (COMMON WITH THERAPEUTIC DOSES) P0355
ARSENICALS S FOLATE DEC V MEGALOBLASTIC ANEMIA AFTER POWLER’S SOLN P0657
APSENICALS S GLUCOSE DEC V REPATOTOXIC EFFECT P0596
ARSENICALS S GUANASE INC V HEPATOTOXIC EFFECT R0596
APSENICALS S lCD INC V HEPATOTOXIC EFFECT 90990
ARSENICALS S NPN INC V NEPHPOTOXICITY (COMMON WITH THERAPEUTIC DOSES) P0355
ARSENICALS S SGOT INC V HEPATOTOXIC EFFECT (CHOLESTASIS/CHOLANGIOLITIS) P0596
ARSENICALS S SGPT INC V REPATOTOXIC EFFECT (CHOLESTASIS/CHOLANGIOLITIS) RO596
APSENICALS S THYNOL TURBIDITY INC V HEPATOTOXIC EFFECT P0596
APSENICALS S UREA NITROGEN INC V NEPHROTOXIC EFFECT (COMMON WITH THERAPEUTIC DOSES) P0384
ARSENICALS U PPOTEIN INC V NEPHPOTOXIC EFFECT R0299
APSENICALS U URINALYSIS BILE INC V HEPATOTOXICITY (CHOLESTASIS/CHOLANGIOLITIS) P0620
ARSENICALS U URINALYSIS CASTS INC V NEPHROTOXIC EFFECT 90620
ARSENICALS U URINALYSIS HEMOGLOBIN INC V MAY BE MARKED HENATURIA 30368
ARSENICALS U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT 90299
APSENICALS U URINALYSIS RBC/HPF INC V NEPHROTOXICITY WITH TUBULAR NECROSIS R0384
ARSENOBENZENES B PLATELET COUNT DEC V THROMBOCYTOPENIA P0620
ASCORBIC ACID C PROTEIN Z N NO EFFECT ON FOLIN-CIOCALTEU PROCEDURE 31026
ASCORBIC ACID F OCCULT BLOOD MEG N INTERFERES WITH ANALYTIC METHODS R0620
ASCORBIC ACID P CATECHOLANINES INC N CONC SOLUTIONS CAUSE STRIKING FLUORESCENCE 30188
ASCORBIC ACID S BILIRUBIN INC N AT THERAPEUTIC CONC NAY AFFECT SMA 12/60 METHOD P0876
ASCORBIC ACID S CHOLESTEROL DEC V TENDS TO FALL IN PEOPLE UNDER 25 WHEN 1G/DAY GIVEN P0892
ASCORBIC ACID S CHOLESTEROL INC V WHEN ATHEROSCLEROTIC, ?MOBILIZATION FROM ARTERIES P0892
ASCORBIC ACID S CPEATININE INC N CHRONOGENICITY IN COLOR PEACTION(ACTS AS RED.AGENT) P0299
ASCORBIC ACID S CREATININE Z N NO EFFECT ON METHOD OF POLAR AND METCOFF P0546
ASCORBIC ACID S GLUCOSE DEC N SLIGHT EFFECT WITH COUPLED GLUCOSE OXIDASE METHOD RO37O
ASCORBIC ACID S GLUCOSE INC N AT 1 MMOL/L AFFECTS SMA 12/60 METHOD 90876
ASCORBIC ACID S GLUCOSE INC N AFFECTS ALKLAINE FEPRICYANIDE METHODS P0370
ASCORBIC ACID S LACTIC DEHYDROGENASE DEC N AT THERAPEUTIC CONC NAY DEPRESS SMA 12/60 VALUE P0876
ASCORBIC ACID S PHENYLALANINE DEC V REDUCES ELEVATED LEVEL OF PREMATURE INFANTS P0384
ASCORBIC ACID S SCOT INC N AT 1 MMOL/L AFFECTS SMA 12/60 METHOD P0876
ASCORBIC ACID S TRIGLYCERIDES DEC V EFFECT OBSERVED IN ATHEROSCLEROTIC PATIENTS RO884
ASCORBIC ACID S TYHOSINE DEC V REDUCES ELEVATED LEVEL IN PREMATURE INFANTS P03814
ASCORBIC ACID S URIC ACID INC N MEASURED AS REDUCING SUBSTANCE P02014
ASCORBIC ACID T PROTEIN INC N REACTS WITH FOLIN-CIOCALTEU OF LOWRY PROCEDURE P0213
ASCORBIC ACID U CREATININE INC N ACTS AS REDUCING AGENT P0042
ASCORBIC ACID U GLUCOSE DEC N IMPAIRED ‘C OLOR DEVEL OF CHROMOGEN IN GLU OX NETH R0299
ASCORBIC ACID U PORPHOBILINOGEN DEC N INHIBITION OF COLOR DEVELOP IF NO PRIOR SEPARATION P0322
ASCORBIC ACID U SUGAR INC N FALSE POSITIVE WITH BENEDICT’S AND CLINITEST P0299
ASCORBIC ACID U URIC ACID INC N MEASURED AS REDUCING SUBSTANCE P0436
ASCORBIC ACID U URINALYSIS GLUCOSE DEC N NAY INHIBIT TESTAPE AND CLINISTIX R09O7
ASCORBIC ACID U URINALYSIS HEMOGLOBIN DEC N IN LARGE AMOUNTS INHIBITS GUAIAC TEST RO299
ASCORBIC ACID U UPOBILINOGEN DEC V LOWERED PM REDUCES EXCRETION P0666
ASCORBIC ACID U 17 OH COPTICOSTEROIDS INC N INTERFERES WITH METHOD OF REDDY RO417

ASPARAGINASE B FACTOR V DEC V DIMINISHED HEPATIC SYNTHESIS HC18O
ASPARAGINASE B FACTOR VII DEC V DIMINISHED HEPATIC SYNTHESIS P0180
ASPARAGINASE B FACTOR VIII DEC V DIMINISHED HEPATIC SYNTHiSIS P0180
ASPARAGINASE B GRANULOCYTES DEC V SLIGHT REDUCTION (NOT )OSE DEPENDENT) P0705
ASPARAGINASE P HEMATOCRIT DEC V MAY CAUSE ANEMIA PC 1427
ASPARAGINASE B HEMOGLOBIN DEC V NAY CAUSE ANEMIA R0L427
ASPARAGINASE B LYMPHOCYTES DEC V SLIGHT REDUCTION (NOT DOSE DEPENDENT) P0705
ASPARAGINASE B PLATELET COUNT DEC V MAY CAUSE BONE MARROW DEPRESSION PC75
ASARAGINASE B THRONBIN TIME INC V OCCURS WITH DECREASED FIBRINOGEN CONCENTRATION R0705
ASPARAGINASE B WHITE CELL COUNT DEC V MILD EFFECT IN UP TO 25 PATIEJTS P0705
AS PA RAGIN A SE P AMMONIA INC V MA! BE MARKED,?ASSOC WITH ABNORMAL LIVER FUNCTION H 0 4147
ASPARAGINASE P FIBRINOGEN DEC V MARKED EFFECT IN ALMOST ALL PATIENTS P0705
ASPARAGINASE P INSULIN DEC V ?DUE TO DEC PRODUCTION WITH DEC PROTEIN SYNTHESIS P18Q
AS PA RAGINASE P PROTHROMBIN TIME INC V DIMINISHED SYNTHESIS OF PROTHRONBIN BY LIVER RC 180
ASPAPAGINA SE S ALBUMIN DEC V HEPATOTOXICITY (OBSERVED IN 80% PATIENTS) P0705
ASPAPAGINASE S ALKALINE PHOSPHATASE INC V NAY CAUSE HEPATOTOXICITY (FREQUENT) P0427
ASPARAGINASE S ALPHA2-GLOBULIN DEC V DEC TO 70% OF CONTROL AT 2 WEEKS P0705
ASPARAGINA SE S AMYLASE INC V MAY CAUSE PANCREATIC TOXICITY R0427
ASPAHAGINASE S BETA-GLOBULIN DEC V DEC TO 70 Of CONTROL AT 2 WEEKS P0705
ASPARAGINASE S BETA-LIPOPROTEINS DEC V OBSERVED IN UNUSUAL HYPEPLIPIDMIC RESPONSE P0705
ASPARAGINASE S BETA1A-GLOBULIN DEC V DIMINISHED HEPATIC SYNTHESIS R 070S
ASPAPAGINASE S BETA2-GLYCOPHOTEIN DEC V DIMINISHEi) HEPATIC SYNTHESIS P0705
ASP AR AGINASE S BILIRUBIN INC V UP TO 4MG/1C’)NL (DOSE RELAThO EFFECT) R07C5
ASPARAGINASE S BSP RETENTION INC V HEPATOTOXICITY (USUALLY MILD) R0427
ASPARAGINASE S CALCIUM DEC V OBSERVED IN 6C (?DUE TO HY?OALBUNINENIA) P07 05
ASPARAGINA SE S CEPHALIN FLOCCULATION INC V HEPATOTOXICITY P0427
ASPARAGI NASE S CERULOPLASMIN DEC V DIMINISHED HEPATIC SYNTHESIS P0705
ASPARAGINASE S CHOLESTEROL DEC V HEPATOTOXICITY (EFFECT MARKED) B 0427
ASPARAGINASE S CHOLESTEROL INC V UNUSUAL REPONSE IN SOME PATIENTS P0705
AS PARAGINASE S CHYLONICHONS INC V OBSERVED IN UNUSUAL HYPERLIPIDENIC RESPONSE P0705
ASPARAGINA SE S GAMMA GLOBULIN INC V INC CONTINUOUSLY TO 170% OF MEAN AT 4 WEEKS P0705
ASPAHAGINASE S GLUCOSE INC V MAY BE HYPEROSNOTC NONKETOTIC HYPERGLYCEMIA HO 180
ASPARAGINASE S INMUNOGLOBULIN IGA INC V INCREASED HEPATIC SYNTHESIS P0705
ASPAPAGINASE S IMMUNOGLOBULIN IGG INC V INCREASED HEPATIC SYNTHESIS P0705
ASP AR AGINASE S IMMUNOGLOBULIN 1GM INC V INCREASED HEATIC SYNTHESIS R0705
ASPARAGINA SE S LIPOPPOTEIN LIPASE DEC V OBSERVED IN UNUSUAL HYPERLIPIDENIC RESPONSE P0705
ASPAPAGINASE S LIPOPPOTEINS DEC V POSSIBLE DEPRESSED SYNTHESIS 201427
ASPARAGINASE S PHOSPHOLIPIDS DEC V PARALLEL DECREASE IN CHOLESTEEOL HO 70 5
ASPARAGINA SE S PHOSPHOLIPIDS INC V RARE RESPONSE AFTER INITIAL HYPOLIPIDEMIA H 0705
ASPARAGINASE S PREBETA-LIPOPROTEINS INC V OBSERVED IN UNUSUAL HYPERLIPIDEMIC RESPONSE P0705
ASPARAGINASE S SCOT INC V HEPATOTOXICITY P01427
ASPARAGINASE S SGPT INC V HEPATOTOXICITY P 0427
ASPARAGINA SE S THYMOL TURBIDITY INC V HEPATOTOXICITY P01427
ASPARAGI NASE S TOTAL LIPIDS DEC V PARALLEL DECPLASE IN CHOLESTEROL P0705
ASPARAGINASE S TOTAL LIPIDS INC V RAPE RESPONSE AFTER INITIAL HYPOLIPIDENIA P0705
ASPARAGINASE S TRANSFEHPIN DEC V REPORTED EFFECT R0705
ASPARAGINASE S TRIGLYCERIDES DEC V NOTED AFTER FIRST WEEK IN SOME PATIENTS P070 5
ASPAPAGINA SE S TRIGLYCERIDES INC V RARE RESPONSE AFTER INITIAL HYPOLIPIDEMIA P 0705
ASPARA GINASE S UREA NITROGEN INC V OCCURS IN 50% SUBJECTS (PEERENAL ORIGIN) RC427
ASPA RAGINA SE S 5-NUCLEOTIDASE INC V OBSERVED IN UP TO 25% PATIENTS P0705
ASPARAGIN ASE U CALCIUM INC V ATYPICAL R2.SPONSE BUT OBSERVED IN SOME P0705
ASPARAGINASE U NITROGEN INC V EFFECT GREATEST IN RESPONDERS TO THERAPY PC 705
ASPARAGINA SE U PHOSPHATE INC V RESPONSE IN ALL TREATED PATIENTS R0705
ASPAR AGINASE U PROTEIN INC V TRANSIENT EFFECT FOR FEW DAYS P0705
ASPARAGINASE U URIC ACID INC V MARKED RESPONSE IF LYSIS OP TISSUES R0705
ASPARAGINASE U URINALYSIS PROTEIN INC V TRANSIENT SLIGHT EFFECT FOR FEW DAYS P0705
ASPARAGINE P AMMONIA INC V POTENTIAL SOURCE OF AMMONIA P05314
ASPARAGINE S UREA NITROGEN INC N BLUE COLOR WITH BERTHELOT’S REAGENT R0530
ASPIDIUM S ALKALINE PHOSPHATASE INC V MAY CAUSE HEPATIC TOXICITY R3620
ASPIDIUN S BILIRUBIN INC V NAY CAUSE HEPATIC TOXICITY R0299
ASPIDIUM S BSP RETENTION INC V MAY CAUSE HEPAIIC TOXICITY PC 299
ASPI DIUM S CEPHALIN FLOCCULATION INC V MAY CAUSE HEPATIC TOXICITY PC 620
ASPIDIUM S SGOT INC V MAY CAUSE HEPATIC TOXICITY P C 620
ASPIDIUN S SGPT INC V MAY CAUSE HEPATIC TOXICITY RC623
ASPIDIUM S THYMOL TURBIDITY INC V MAY CAUSE HEPATIC TOXICITY P0620
ASPID IUN U URINALYSIS BILE INC V NAY CUASE HEPATIC TOXICITY P0620
ASPIDIUM U URINALYSIS SUGAR INC N ACTS AS REDUCING AGENT P0299
ATROPINE B WHITE CELL COUNT INC V MAY CAUSE LEUKOCYTOSIS (EFFECT IN CHILDREN) BC 026
A T HO 21 NE 0 GASTRIC JUICE HCL DEC V VOLUME ALSO REDUCED P0384
ATROPINE S BARBITURATE INC N FALSE P05 SCRIEN TEST WITH HG COMPLEX FOH B C 183
ATROPI NE S GLUCOSE DEC V POSSIBLE SLIGHT FALL IF GIVEN AS PRENEDICATION P0643
ATROPINE U PSP EXCRETION DEC V INTERFERES WITH SECRETION BY TUBULES B 0779
AIROPINE U VOLUME DEC V VERY LARGE DOSES CAUSE RELEASE OF ADH P0384
AZA DRUGS S BSP RETENTION INC V MAY CAUSE HEPATOTOXICITY P0355
AZASERINE S SGOT INC V MAY CAUSE HEPATOTOXICITY BC 990
AZASERINE S SGPT INC V MAY CAUSE HEPAIOTOXICITY P0990
AZATHIOPHINE B NEUTROPHILS DEC V DRUG RELATED LEUKOPENIA (CURED BY CESSATION) P022
AZATHIOPPINE B PLATELET COUNT DEC V PlAY CAUSE BONE MARROW DEPRESSION P 0860
AZATHIOPRINE B RED CELL COUNT DEC V BONE MARROW DEPEESSION WITH ANEMIA P0026
AZATHIOPRINE B RETICULOCYTES DEC V GRADUAL REDUCTION OBSERVED P05 19
AZATHIOPRINE B WHITE CELL COUNT DEC N LOW COUNT BY COULTER 5, ?DUE TO FRAGILE CELLS #{163}0598
AZAT HIOPPINE B WHITE CELL COUNT DEC V OPUG RELATED LEUKOPENIA (PROBABLE EFFECT) PC 86
AZATHIOPRINE F FAT INC V MAY OCCASIONALLY CAUSE STEATOHPHEA PCi 467
AZAT HIOPPINE P PROTHEOMBIN TIME DEC V MAY CAUSE HEPATOTOXICIIY F C 893
AZATHIOPHINE S ALBUMIN DEC V MAY CAUSE HEPATOTOXICITY HO 893
AZATHIOPRINE S ALKALINE PIIOSPHATASE DEC V IMPROVES BILIARY EXCRETION IN BILIAHY CIRRHOSIS PC 799
AZATHIOPRINE S ALKALINE PHOSPHATASE INC V MAY BE VERY HIGd, LIVER DAMAGE OR BILIARY STASIS B 0467
AZA?HIOPPINE S AMYLASE INC V UNUSUAL SIDE EFFECT BUT MAY CAUSE PANCREATITIS PC 1467
AZATHIOPRINE S BILIRUBIN INC V MAY CAUSE HEPATOTOXICITY (NOT USUALLY VERY HIGH) P0893
AZATHIOPHINE S CHOLESTEROL DEC V IMPROVES BILIARY EXCRETION IN BILIARY CIRRHOSIS RC799

AZATHIOPRINE S IMNUNOGLOBULIN 1GM DEC V REDUCED WHEN BILIARY CIRRHOSIS TREATED 90799
TtZATHIOPPINE S SGOT INC V MAY CAUSE HEPATOTOXICITY HO 8 93
AZATHIOPRINE S SGPT INC V MAY CAUSE HEPATOTOXICITY HO 893
AZATHIOPRINE S URIC ACID DEC V IN PATIENTS WITH GOUT DECREASES CONCENTRATION P0888
AZATHIOPR INE S URIC ACID INC V RAPID DESTRUCT OF TISSUES AND NUCLEIC AC CATABOLISM R03814
AZATHIOPRINE U URIC ACID DEC V IN PATIENTS WITH GOUT REDUCES EXCRETION P08 88
AZATHYMINE S URIC ACID INC V DUE TO TISSUE DESTRUCTION P0620
AZAURIDINE S URIC ACID INC V DUE TO TISSUE DESTRUCTION P0620
AZAUPIDINE U OROTIC ACID INC V METABOLIC EFFECT NAY CAUSE CRYSTALLURIA H 0092
AZAURIDINE U URINALYSIS CRYSTALS INC V MAY OCCUR DUE TO RESPONSE TO TISSUE DESTRUCTION P0092
AZOSULFAMIDE S SULFA AS SULPANILAMIDE INC N SLIGHT EFFECT, MEASURED AS IF SULFONAMIDE P077 9
AZOSULFA MIDE U PAR CLEARANCE INC N SLIGHT EFFECT ONLY, MEASURED AS IF PAH HO 779
AZURESIN U URINALYSIS COLOR INC N BLUE OR GREEN FOR A FEW DAYS AFTER TEST P04 17
B- HYDROXYANINOBUTYR U AMINO ACIDS INC N FALSE POSITIVE NINHYDRIN REACTING SPOT 90811
B-HYDPOXYBU TYRATE S URIC ACID INC V INHIBITS TUBULAR SECRETION OF URAT! HO 377
B- H YDH OXY BUTYR AT E U URIC ACID DEC V INHIBITS TUBULAR SECRETION OF URATE 90377
BACITHACIN S UREA NITROGEN INC V PENAL TOXICITY (ESPECIALLY IF GIVEN I.V.) HO 384
BACITR ACIN U PROTEIN INC V MAY CAUSE NEPHPOTOXICITY RO 35
BACITRACIN U URINALYSIS CASTS INC V NEPHHOTOXIC EFFECT (CYLINDPURIA NAY OCCUR) 90620
BACITR ACIN U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG HO 2 99
BACITRACIN U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT P02 99
BACITRACIN U URINALYSIS RBC/HPF INC V ACTUAL BLEEDING CAUSED BY DRUG P02 99
BACTERIAL CONTAM S CEPHALIN FLOCCULATION INC N IF REAGENT CONTAMINATED TURBIDITY MEASURED P 1001
BACTERIAL CONTAM U UREA NITROGEN DEC N RAPID EVOLUTION OF NH3 CHANGES PH, LOSS OF NH3 P014 36
BACTERIURIA U BETA-GLUCURONIDASE INC V HIGH ACTIVITY POSSIBLE WITH BACTERIAL CONTAMINATION P07 58
BACTERIURIA U CATALASE INC V INFECTED URINES HAVE ACTIVITY P0758
BACTER IUR IA U URINALYSIS HEMOGLOBIN INC N FALSE POSITIVE WITH HENATEST R1001
BANANAS U CATECHOLAMINES INC N CATECHOLS IN BANANAS 90234
BANANAS U UROBILINOGEN INC N 5HIAA PRODUCED REACTS WITH EHRLICH’S REAGENT R01436
BANANAS U VNA INC N METABOLITES INTERFERE WITH ANALYSIS HO 3 55
BANANAS U 14-RYDROXYBENZOIC ACID INC V POSSIBLE EFFECT OF BACTERIAL METABOLISM P0858
BANANAS U 5 OH INDOLEACETIC ACID INC N INDOLES IN BANANAS P02 34
BARBITURATES B COPROPORPHYRIN INC V MAY PRECIPITATE ACUTE CUTANEOUS PORPHYRIA RO371
BARBITURATES B HEMATOCRIT DEC V MAY CAUSE NEGALOBLASTIC ANEMIA 90 976
BARBITURATES B HEMOGLOBIN DEC V NAY CAUSE MEGALOBLASTIC ANEMIA RO976
BARBITURATES B MCV INC V MAY CAUSE NEGALOBLASTIC ANEMIA P09 76
BA RBITURA TES B PCO2 INC V RESPIRATORY DEPRESSANT P03 814
BARBITURATES B PLATELET COUNT DEC V THROMBOCYTOPENIA P06 20
BARBITURATES B P02 DEC V SLIGHT DEC DURING SLEEP WITH HYPNOTIC DOSE R0384
BARBITURATES B PROTOPORPHYRIN INC V MAY PRECIPITATE ACUTE CUTANEOUS POPPHYHIA RO371
BARBITURA TES B RED CELL COUNT DEC V APLASTIC OR MEGALOBLASTIC ANEMIA P0620
BARBITURATES B WHITE CELL COUNT DEC V LEUKOPENIA 30952
BARBITURATES F COPPOPORPHYPIN INC V MAY PRECIPITATE ACUTE PORPHYRIA 90371
BARBITURATES F PHOTOPORPHYRIN INC V NAY PRECIPITATE ACUTE PORPHYRIA HO 37 1
BARBITURATES 0 GASTRIC JUICE HCL DEC V SECRETION SLIGHTLY DEPRESSED P03 84
BARBITURATES 0 GASTRIC JUICE PEPSIN DEC V SECRETION SLIGHTLY DEPRESSED P03 84
BARBITURATES P AMMONIA INC V IMPAIRED METABOLISM IN DOGS P093 1
BARBITURATES P PROTHROMBIN TINE DEC V METAB OF COUNARINS ENHANCED (ENZ INDUCT IN LIVER) P03 87
BARBITURATES P PROTHROMBIN TIME INC V THEORETICALLY IF CHOLESTASIS OCCURS HO 620
BAHBITURA TES S ALKALINE PHOSPHATASE INC V RAPE CASE OF HEPATOTOXICITY P0114
BARBITURATES S BILIRUBIN DEC V INDUCES GLUCURONYL THANSFERASE IN NEWBORN INFANTS RO4 17
BA RBITUPA TES S BILIRUBIN INC V HARE CASES OF JAUNDICE FOLLOWING USE 90114
BARBITURATES S BSP RETENTION DEC V INC CONJUGATION WITH GLUTATHIONE 303814
BARBI TURATES S BSP RETENTION INC V MAY INCREASE RETENTION IF GIVEN WITHIN 21$H P0383
BARBITURATES S CALCIUM Z N NO EFFECT ON FLUORESCENCE OF CALCEIN HO 644
BARBITURATES S CPK INC V OCCUPS WITH POISONING, PROBABLE MUSCLE ORIGIN P 1008
BARBITURATES S CREATININE INC V SHOCK AND RENAL FAILURE IN INTOXICATION 906514
BARBITURATES S FOLATE DEC V MAY CAUSE MEGALOBLASTIC ANEMIA (IMPAIRS ABSORP) P0976
BARBITURATES S I 131 UPTAKE INC V ? DUE TO ENZYME INDUCTION P0 596
BARBITURATES S SGOT INC V OCCURS WITH POISONING, PROBABLE MUSCLE ORIGIN H 1008
BARBITURATES S SGPT INC V OCCURS WITH POISONING, PROBABLE MUSCLE ORIGIN P1008
BARBITURATES U AICAR INC V OCCURS IF MEGALOBLASTIC ANEMIA P0976
BARBITURATES U ANINOLEVULINIC ACID INC V MAY PRECIPITATE ACUTE PORPHYRIA HO 37 1
BARBITURA TES U COPROPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P037 1
BARBITURATES U FIGLU INC V OCCURS IF NEGALOBLASTIC ANEMIA P0976
BARBITURATES U GLUCARIC ACID INC V AS RESULT OF HEPATIC ENZYME INDUCTION HO 596
BARBI TURA TES U PORPHOBILINOGEN INC V MAY PRECIPITATE ACUTE PORPHYRIA R0371
BARBITURATES U UROPOPPHYRIN INC V NAY PRECIPITATE ACUTE PORPHYRIA HO 37 1
BARBITURATES U 17 KETOSTEPOIDS Z N NO INTERFERENCE WITH ZIMMERMAN PROCEDURE P0236
BARBITURATES U 17 KETOSTEROIDS Z V SHORT TERM INGESTION PRODUCES NO EFFECT P0236
BARBITURATES U 17 OH CORTICOSTEROIDS DEC V CHRONIC INGESTION NETAB DIVERTED TO 6-B-OH-COPTISOL P0 236
BARBITURATES U 17 OH CORTICOSTEPOIDS Z N NO INTERFERENCE WITH POPTER-SILBER PROCEDURE 90236
BARBITURATES U 17 OH COBTICOSTEPOIDS Z V NO EFFECT WITH SHORT TERM INGESTION P 100 1
BARIUM U MAGNESIUM INC N MEASURED BY FLUOROMETRIC METHOD OF SCHACHTER 90923
BARIUM SALTS F OCCULT BLOOD P05 V NAY CAUSE SEVERE G.I. TRACT HEMORRHAGE HO 384
BARIUM SALTS S P51 INC N OCCASIONALLY CONTAMINATED WITH INORGANIC IODINE P0255
BARIUM SALTS S SCOT INC V SEVERE LIVER DAMAGE IF TANNIC ACID IN ENEMA P00 26
BARIUM SALTS S SGPT INC V SEVERE LIVER DAMAGE IF TANNIC ACID IN ENEMA P002 6
BARIUM SALTS U DIAGNEX BLUE EXCRETION INC V HEAVY METAL DISPLACEMENT OF DIAGNEX BLUE P1001
BCG VACCINE S GAMMA GLOBULIN DEC V ASSOC WITH SEVERE REACTION R0657
BED REST F CALCIUM INC V UP TO 70 MEQ/DAY IN HEALTHY MALES HO ($7 1
BED REST PHOSPHATE INC V SLIGHT EFFECT ONLY HO471
BED REST S CALCIUM INC V INCREASE OF APPROX 0.1 MEQ/L HO 147 1
BED REST S PHOSPHATE INC V INCUPTOO.5NG/100ML H 0147 1
BED REST U CALCIUM INC V UP TO 50 MEQ/DAY IN HEALTHY MALES HO 47 1
BED PEST U HYDROXYPPOLINE INC V MAXIMAL DURING SECOND MONTH BED PEST RO1471
BED PEST U MAGNESIUM INC V SLIGHT EFFECT ONLY R0471
BED REST U NITROGEN INC V NEGATIVE NITROGEN BALANCE (OVER I G/DAY) 30471
BED REST U PHOSPHATE INC V INC OF APPPOX 200 MG/DAY HO 47 1
BEETS U URINALYSIS COLOR INC N RED DUE TO ANTHOCYANINS AND OTHER PIGMENTS P06 20

BELLADONNA B WHITE CELL COUNT INC V MAY CAUSE LEUKOCYTOSIS 90026
BENDPO?LUNETHIAZIDE S CALCIUM INC V DUE TO INC CONC OF PROTEIN DUE TO TEMP NA DEPLETION P0720
BENDROFLUMETHIAZIDE S C02 CONTENT INC V METABOLIC ALKALOSIS 90325
BENDROFLUMETHIAZIDE S OSMOLALITY DEC V DUE TO HYPONATREMIA P0325
BENDROFLUNETHIAZIDE S POTASSIUM DEC V MARKED DIURETIC RESPONSE P0325
BENDPOFLUNETHIAZIDE S SODIUM DEC V MAY CAUSE HYPONATREMIA DUE TO K DEPLETION R0325
BENDHOFL’JMETHIAZIDE S URIC ACID INC V INHIBITION OF TUBULAR SECRETION OF URATE P0404
BENDROTLUNETHIAZIDE U CALCIUM DEC V IMPAIRED EXCRETION MAY OCCUR WITH THIAZIDES RO72O
BFNDROLUNETHIAZIDE U CITRATE DEC V UP TO 30% DECREASE OBSERVED P0657
PENZENE B HEMOGLOBIN DEC V DUE TO APLASTIC ANEMIA P0384
BENZEN! B PLATELET COUNT DEC V PROBABLE MYELOTOXIC EFFECT (COMMON) P0658
BENZENE B RED CELL COUNT DEC V MILD MACROCYTIC ANEMIA /APLASTIC ANEMIA R0658
BENZENE B WHITE CELL COUNT DEC V PROBABLE MYELOTOXIC EFFECT (USUALLY LATE) P0658
BENZENE B WHITE CELL COUNT INC V LYM?HOCYTIC OR POLYMORPHONUCLEAP EARLY HO384
BENZENE S GLUCOSE DEC V TOXIC EFFECT P0620
BENZENE U URINALYSIS COLOR INC N RED BROWN R0620
BENZIODARONE S ALKALINE PHOSPHATASE INC V MAY CAUSE HEPATIC TOXICITY R0620
BENZIODAPONE S BILIRUBIN INC V NAY CAUSE HEPATIC TOXICITY R0620
BENZIODAPONE S BSP RETENTION INC V MAY CAUSE HEPATIC TOXICITY P0620
BENZ IODA HONE S CEPHALIN FLOCCULATION INC V MAY CAUSE HEPATIC TOXICITY R0620
BENZI ODARONE S I 131 UPTAKE DEC V DUE TO IODINE COMPONENT OF DRUG P0596
BENZIODA ROWE S PBI INC N CONTAINS 46% IODINE R0004
BENZI ODA HONE S SCOT INC V NAY CAUSE HEPATIC TOXICITY P0620
BEN ZIODA HONE S SGPT INC V MAY CAUSE HEPATIC TOXICITY P0620
BENZI ODA RONE S THYMOL TURBIDITY INC V MAY CAUSE HEPATIC TOXICITY P0620
BENZIODARONE S URIC ACID DEC V STIMULATES SECRETION OF URATE P0388
BENZI ODA HONE U URIC ACID INC V STIMULATES SECRETION OF URATE P0388
BENZIODARONF U URINALYSIS BILE INC V MAY CAUSE HEPATIC TOXICITY 30620
BENZOCAINE B HEMATOCRIT DEC V MAY CAUSE HEMOLYSIS P0121
BENZOCAINE P HEMOGLOBIN DEC V NAY CAUSE HENOLYSIS P0121
BENEOCAINE B NETHENOGLOBIN INC V HEMOLYSIS R0121
BENZOCAINE B RED CELL COUNT DEC V NAY CAUSE HEMOLYSIS P0121
ENZYL ALCOHOL S GLUCOSE INC V USED AS SALINE PRESERVATIVE, EFFECT IN MICE?HUNANS P0067
BERYLLIUM SALTS S ALKALINE PHOSPHATASE DEC N INHIBITORS OF ENZYME IN LABORATORY PROCEDURES R0929
BERYLLIUM SALTS S URIC ACID INC V NEPHROPATHY ASSOC WITH DEC EXCRETION PER NEPHPON P0520
BERYLLIUM SALTS U URIC ACID DEC V NEPHROPATHY ASSOC WITH DEC EXCRETION PEP NEPHRON P0520
BETA-A DRENERGIC S GLUCOSE INC V MASKS SPURIOUS HYPOGLYCEMIA FROM INSULIN OVERDOSE P0355
BETA-A DRENE PG IC U VOLUME DEC V ANTIDIURETIC EFFECT MEDIATED CENTRALLY P0835
BETA NETHA SONE P 17 OH COPTICOSTEPOIDS INC V SLIGHT EFFECT, ABSORBED THROUGH SKIN 30026
BET ANET H ASO NE S POTASSIUM DEC V OCCURS INFREQUENTLY P0026
BETAMETHA SONE S SODIUM INC V OCCURS INFREQUENTLY WITH EDEMA P0026
BET A NET H ASO NE U POTASSIUM INC V OCCURS INFREQUENTLY P0062
BETA MET HA SOME U 17 KETOSTEROIDS DEC V FEEDBACK PITUITARY SUPPRESSION OF ACTH P0356
B ET AN ETH AS ONE U 17 OH COPTICOSTEROIDS INC V SLIGHT INC, MAY BE ABSORBED THROUGH SKIN R0026
BETAZ OLE 0 GASTRIC JUICE HCL INC V USED TO STIMULATE SECRETION P0026
BETH A NEC HOL S AMYLASE INC V MAY CAUSE INC SECRETION, SPASM OF SPHINCTER OF ODDI P0250
BET HA NEC HOL S BILIRUBIN INC V IMPAIRED EXCRETION DUE TO SPASM 0? SPHINCTER P02014
B ETH A N ECH OL S BSP RETENTION INC V IMPAIRED EXCRETION DUE TO SPASM OF SPHINCTER RO204
BET HANECHOL S LIPASE INC V MAY CAUSE INC SECRETION, SPASM OF SPHINCTER OF ODDI P0250
BETI1ANECHOL S SGOT INC V IMPAIRED EXCRETION DUE TO SPASM OF SPINCTEP P0204
BETHAN ID IMP S CREATININE INC V EFFECT REPORTED IN ONE PATIENT R09O2
BETHA NI DIN! U NOREPINEPHRINE DEC V REPORTED EFFECT P0417
BICARBONATES S CHLORIDE DEC V INDUCES METABOLIC ALKALOSIS P02014
BICARBONATES S CO2 CONTENT INC V INDUCES METABOLIC ALKALOSIS R0204
BICARBONATES S POTASSIUM DEC V INDUCES METABOLIC ALKALOSIS RO2014
BICARBONA TES S SODIUM INC V INDUCES METABOLIC ALKALOSIS P0204
BI CARBON ATFS U CALCIUM DEC V PROTECTS SKELETON FROM REABSORPTION OF P04 P0077
BICARBONATES U PHOSPHATE INC V POSSIBLE COMPETITION FOR SANE EXCRETORY MECHANISM P0284
81 LE U PSP EXCRETION INC N INTERFERING COLOR P0620
BILE U URINALYSIS COLOR INC N GREEN COLOR WITH OXIDIZED BILE ON STANDING RO143
BILE SALTS S CHOLESTEROL INC V AUGMENT CHOLESTEROL POOL P0204
BILE SALTS U UROBILINOGEN INC N CONVERTED TO ACIDS, PRODUCE TURBIDITY P0436
BILIRUBIN B HEMOGLOBIN INC M IN HIGH CONCS AFFECTS OXY-HEMOGLOBIN METHODS P0779
BILIHUBIN P AMMONIA Z N NO EFFECT ON MEASUREMENT PROCEDURE P0530
BILIRUBIN S ALBUMIN DEC N IF HABA, METHYL ORANGE, OR BIURET METHODS USED P0576
BILIRUBIN S ALBUMIN Z M NO EFFECT IF BROMOCRESOL GREEN USED IN METHOD R0576
BILIRtIBIN S CALCIUM DEC N IF CALCEIN TITRATION USED P0017
BILIRUBIN S CALCIUM INC N IF HIGH MAY CONFUSE EDTA TITRATION END-POINT P0436
BILIRUBIN S CHOLESTEROL INC N INTERFERES WITH DIRECT PROCEDURES P0355
BILIRUBIN S GLUCOSE DEC N EFFECT CAN BE AVOIDED BY USING SOMOGYI FILTRATE P0436
BILIPtIBIN S GLUCOSE INC N NAY HAVE MARKED EFFECT ON 0-TOLUIDINE METHOD P1009
BILIRUBIN S IRON Z N NO EFFECT ON IRON MEASUREMENT P0779
BILIRUBIN S PROTEIN INC N NO EFFECT UP TO 29 MG/100ML P0436
BILIRUBIN S SALICYLATE Z N UP TO 20 MG/100ML NO EFFECT ON TRINDER PROCEDURE P0606
BILIRUBIN S SCOT INC N INTERFERENCE IN DIAZONIUM END POINT REACTIONS P0027
BILIPUBIN S THYMOL TURBIDITY Z N NO EFFECT UP TO 14 MG/100NL P0436
BILIR UB IN S TIBC Z M NO EFFECT ON MEASUREMENT P0779
BILIRUBIN S UREA NITROGEN Z N NO EFFECT ON BEPTHELOT REACTION HO51O
BILIR UBIN S ZNSOL& TURBIDITY Z N PHOB SAME NON-INTERFERENCE AS WITH THYNOL TURBIDITY P0436
BILIPUBIN U PHENYLKETONES P05 N BLUE-GREEN WITH FECL3 P0239
BILIRUBIN U URINALYSIS COLOR INC N YELLOWISH FOAM P0663
BILIPUBIN U UROBILINOGEN INC N PRODUCES GREEN COLOR DUE TO BILIVEPDIN P01436
BILIVERDIN U URINALYSIS COLOR INC N GREENISH FOAM P0663
BILIVEPDIN U UPOBILINOGEN INC N NAY PRODUCE GREEN COLOR P0436
P1 SACODYL F FAT INC V NAY CAUSE STEATORPHEA IF PROTRACTED INGESTION P0993
BISACODYL S POTASSIUM DEC V ASSOC WITH STEATORHHEA IF USED IN EXCESS P0993
B! SCOUMAC ETATE S URIC ACID DEC V URICOSURIC ACTION P0404
BISCOUMACETATE U URIC ACID INC V URICOSURIC ACTION P014014
BISHYDPOXYCOUMAPIN B CLOTTING TIME INC V SLIGHT EFFECT IN GLASS, GREATER IN SILICONE P0384
BISHYDPOXYCOUMARIN B FACTOR IX DEC V DOSE RELATED EFFECT P0384

BISHYDPOXYCOUMAPIN B FACTOR VII DEC V DOSE RELATED EFFECT R0384
BISHYDROXYCOUMARIN B FACTOR X DEC V DOSE RELATED EFFECT P0384
BISHYDROXYCOUMAHIN B PLATELET ADHESIVENESS DEC V RELATED TO DOSE 90384
BISHYDPOXYCOUMARIN B PLATELET AGGREG INC V IN RESPONSE TO ADP RO384
BISHYDROXYCOUMARIN B RECALCIFICATION TIME INC V EFFECT ON CITRATED PLASMA 30384
BISHYDROXYCOUMARIN B RED CELL COUNT DEC V MAY CAUSE ANEMIA (AMA-BLOOD DYSCRASIAS COMMITTEE) 90658
BISHYDROXYCOUNAPIN B SEDIMENTATION RATE Z V UNALTERED BY COUMARINS P03814
BISHYDPOXYCO$JMAPIN B WHITE CELL COUNT DEC V REPORTED EFFECT (AMA-BLOOD DYSCRASIAS COMMITTEE) R0658
BISHYDPOXYCOUMAPIN P PHOTHRONBIN TINE INC V DOSE RELATED EFFECT P0384
BISHYDROXYCOUMARIN S LACTIC DEHYDROGENASE INC V NAY BE HIGH ENOUGH TO SIMULATE MYOCARDIAL INFARCT P0079
BISHYDROXYCOUMAPIN S SCOT INC V NAY SIMULATE NYOCARDIAL INFARCT (GREATER THAN GPT) P0079
BISHYDROXYCOUMARIN S SGPT INC V MAY BE HIGH ENOUGH TO SIMULATE MYOCARDIAL INFARCT P0079
BISHYDROXYCOUMAPIN S T3 UPTAKE INC V RED CELL UPTAKE AFFECTED 901814
BISHYDROXYCOUNARIN S URIC ACID DEC V URICOSURIC ACTION P0039
BISHYDROXYCOUMARIN U URIC ACID INC V UPICOSURIC ACTION ROL&04
BISMUTH B WHITE CELL COUNT DEC V NAY CAUSE APLASTIC ANENIA/AGPANULOCYTOSIS P0620
BISMUTH S ALKALINE PHOSPHATASE INC V HEPATOTOXICITY P0620
BISMUTH S BILIRUBIN INC V HEPATOTOXICITY P0620
BISMUTH S BSP RETENTION INC V HEPATOTOXICITY R0620
BISMUTH S CEPHALIN FLOCCULATION INC V HEPATOTOXICITY P0620
BISMUTH S SGOT INC V HEPATOTOXICITY 90620
BISMUTH S SGPT INC V HEPATOTOXICITY P0620
BISMUTH S THYMOL TURBIDITY INC V HEPATOTOXICITY P0620
BISMUTH U URINALYSIS BILE INC V HEPATOTOXICITY P0620
BISMUTH SALTS F COLOR INC N BLACKENS OP DISCOLORS STOOL WITH SC ORALLY P0620
BISMUTH SALTS S AMINO ACIDS INC V TOXICITY EFFECT P0299
BISMUTH SALTS S BISMUTH INC V MEASURABLE IN POISONING 90557
BISMUTH SALTS S P81 INC V MANY BISMUTH SALTS CONTAIN IODINE R00014
BISMUTH SALTS S UREA NITROGEN INC V NAY CAUSE RENAL FAILURE H0657
BISMUTH SALTS U AMINO ACIDS INC V MAY PRODUCE FANCONI SYNDROME WITH POISONING R0657
BISMUTH SALTS U BISMUTH INC V MEASURABLE WITH POISONING P0657
BISMUTH SALTS U PHOSPHATE INC V FANCONI SYNDROME WITH POISONING 90657
BISMUTH SALTS U PROTEIN INC V NEPHROTOXIC EFFECT RO299
BISMUTH SALTS U URINALYSIS GLUCOSE INC V MAY PRODUCE FANCONI SYNDROME WITH POISONING P0657
BISMUTH SALTS U URINALYSIS HEMOGLOBIN INC V MAY CAUSE SEVERE RENAL DAMAGE R0657
BISMUTH SALTS U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT 30299
BISMUTH SALTS U URINALYSIS RBC/HPF INC V NAY CAUSE SEVERE RENAL DAMAGE RO657
BISMUTH SALTS U URINALYSIS SUGAR INC N INTERFERES WITH BENEDICT’S REACTION 90299
BISMUTH SUBNITRATE B METHEMOGLOBIN INC V NAY CAUSE HEMOLYTIC ANEMIA 90658
BISULFITES S INDOCYANINE GREEN DEC N AS CONTAMINANT OF HEPARIN NAY REDUCE PEAK 90026
BLOOD U URINALYSIS COLOR INC V SMOKY RED TO BROWN DUE TO HEMATURIA R0663
BLOOD GROUP S ALKALINE PHOSPHATASE INC V 0 SECRETOR SUBJECTS - HIGHEST INTESTINAL COMPONENT P0969
BLOOD TRANSFUSIONS B PH DEC V IF MASSIVE TRANSFUSIONS GIVEN RO596
BLOOD TRANSFUSIONS P PHTHALAT!S P05 V WHEN BLOOD STORED FOR FEW DAYS IN PLASTIC PACK R0614
RLOOD TRANSFUSIONS S CITRATE INC V IF CITRATED BLOOD USED P0596
BLOOD TRANSFUSIONS S IRON INC V IF FREQUENT MAY CAUSE HEMOCHPONATOSIS 30596
BLOOD TRANSFUSIONS S POTASSIUM INC V MAY OCCUR WITH RELEASE FROM RBC P0596
BLOOD TRANSFUSIONS S UREA NITROGEN INC V CATABOLISM OF INFUSED PROTEIN P0299
BLOOD TRANSFUSIONS S URIC ACID INC V CATABOLISM OF INFUSED BLOOD CELLS R0355
BLOOD TRANSFUSIONS U URINALYSIS HEMOGLOBIN INC V MAY OCCUR ESP WITH FROZEN GLYCEROLIZED BLOOD P0596
BORIC ACID F OCCULT BLOOD P05 V TOXICITY EFFECT 90620
BORIC ACID S BILIRUBIN INC V TOXICITY EFFECT WITH HEPATOMEGALY P0368
BORIC ACID S CHLORIDE INC V TOXICITY EFFECT (WITH ACUTE TUBULAR NECROSIS) 90620
BORIC ACID S POTASSIUM INC V TOXICITY EFFECT WITH ACUTE TUBULAR NECROSIS 302014
BORIC ACID S SODIUM INC V TOXICITY EFFECT 30620
BORIC ACID S UREA NITROGEN INC V TOXICITY EFFECT WITH ACUTE TUBULAR NECROSIS P02011
BORIC ACID U URINALYSIS PROTEIN INC V DUE TO RENAL DAMAGE R0368
BOXIDINE S CHOLESTEROL DEC V INHIBITS TRANSFORM OF 7-DEHYDROCHOLESTEHOL HO351
BOXIDINE S UREA NITROGEN INC V POSSIBLE RELATIONSHIP TO TUMOR DESTRUCTION RO351
BOXIDINE S 7-DEHYDROCHOLESTEROL INC V INHIBITS TRANSFORMATION TO CHOLESTEROL 90351
BRETYLIUM P PPOTHROMBIN TIME INC V ENHANCES ANTICOAGULANT ACTIVITY P0384
BROMATE B HEMOGLOBIN DEC V MAY CAUSE HEMOLYSIS P03814
BRONATE B METHEMOGLOBIN INC V MAY CAUSE HENOLYSIS 903814
BRONATE B RED CELL COUNT DEC V MAY CAUSE HENOLYSIS 303814
BRONATE S UREA NITROGEN INC V ANURIA AND AZOTEMIA MAY OCCUR WITHIN HOURS P0368
BROMATE U URINALYSIS CASTS INC V DUE TO PENAL DAMAGE P0368
BROMATE U URINALYSIS PROTEIN INC V DUE TO PENAL DAMAGE RO368
BROMATE U URINALYSIS RBC/HPF INC V DUE TO RENAL DAMAGE P0368
BPOMELAINS P PROTHROMBIN TIME INC V EFFECT OBSERVED OVER 48 PERIOD IN ANIMALS P0026
BROMIDES F OCCULT BLOOD P05 N INTERFERES WITH BENZIDINE TEST P0355
BROMIDES S BROMIDE INC V CONC MEASURABLE WITH THERAPEUTIC DOSES RO657
BROMIDES S CHLORIDE DEC V REVERSIBLE HALIDE DYSEQUILIBRATION P0204
BROMIDES S CHLORIDE INC N MEASURED AS CL MERCURIMETRIC, ELECTROMETRIC METHODS P0436
BROMIDES S CHOLESTEROL INC N INTERFERES WITH ZLATKIS-ZAK METHOD (UP TO 10%) R0777
BROMIDES S PBI INC N NAY BE CONTAMINATED WITH IODINE P0355
BROMIDES U CHLORIDE INC N BROMIDE MEASURED AS CHLORIDE 90355
BROMIDES U URINALYSIS HEMOGLOBIN INC N INTERFERES WITH GUAIAC AND BENZIDINE TESTS R1001
BROMISOVALUN S BROMIDE INC V METABOLITE (CONC MAY EXCEED 25 MEQ/L) P03814
BROMISOVALUM S CHLORIDE INC N METABOLITE MAY BE MEASURED AS CHLORIDE P0384
BROMSULFALEIN S ALKALINE PHOSPHATASE INC N INTERFERES WITH BESSEY PROCEDURE R0192
BROMSULFALEIN S CALCIUM INC M NAY INTERFERE WITH COLORIMETRIC PROCEDURES P0654
BROMSULFALEIN S CHEATINEINC N PRESENCE OF INTERFERING COLOR 30620
BRONSULFALEIN S CHEATININE INC N PRESENCE OF INTERFERING COLOR 90620
BROMSULFALEIN S I 131 UPTAKE Z V NO EFFECT ON UPTAKE REPORTED 90596
BPOMSULFALEIN S PHI INC M ORGANIC IODIDE CONTAMINATION OF SOME BSP SOLNS R0738
BRONSULFALEIN S PROTEIN INC N COLOR AUGMENTATION WITH ALKALINE BIUPET RO181
BRONSULFALEIN U PSP EXCRETION INC N DEVELOPMENT OF COLOR AT ALKALINE PH 91001
BROMSULFALEIN U URINALYSIS ACETONE INC N DEVELOPMENT OF COLOR AT ALKALINE PH (ROTHERA TEST) 91001
BRONSULFALEIN U URINALYSIS COLOR INC N RED IN ALKALINE URINE RO88O
BROMSULFALEIN U UROBILINOGEN INC N COLOR DEVELOPMENT WITH EHRLICH’S ALDEHYDE 51001

BPONSUL’ALPI N U UROBILINOGEN INC V PRESENCE OF BSP IN URINE AND LIVER DISEASE P02 99
BROMSULFALEIN U VNA INC N OCCURS UNLESS COMPLETELY EXTRACTED P0030
BUFORNIN S GLUCOSE DEC V THERAPEUTIC INTENT P0657
BUFOHMIN S LACTATE INC V RISES BUT NOT USUALLY TO LEVEL OF ACIDOSIS R0657
BUNAMIODYL S BILIPUBIN INC V COMPETITION FOR HEPATIC UPTAKE OF UNCONJUGATED RO1O8
BUNAMIODYL S BsP RETENTION INC V COMPET. FOR HEPATO-CELLULAR PROTEIN BINDING SITES P0101
PU NAN IODYL S PHI INC V EFFECT UP TO 2 MONTHS (AFFECTS TIl AT HIGH CONCS) HO 191
BUNAMIODYL U CHEATININE CLEARANCE DEC V AT DOSE OF .5G; OCCURRED WITHOUT LIVER EFFECT 90980
PU NANIODYL U URINALYSIS PROTEIN INC N AFFECTS TURBIDITY TESTS FOR UP TO 3 DAYS P0020
BUSULFAN B HEMATOCRIT DEC V PANCYTOPENIA/HEMOLYTIC ANEMIA P014 67
B US ULFA N B HEMOGLOBIN DEC V PANCYTOPENIA/HEMOLYTIC ANEMIA P0467
PU SULFA N B PLATELET COUNT DEC V PANCYTOPENIA/THRONBOCYTOPENIA 901467
BUS ULFA N B RED CELL COUNT DEC V PANCYTOPENIA/HEMOLYTIC ANEMIA P01467
B U SUL FA N B WHITE CELL COUNT DEC V PANCYTOPENIA/LEUKOPENIA RO6S 7
BUS UL F AN S BILIRUBIN INC V OCCURS WITH HENOLYTIC ANEMIA P0467
BUSULFAN S UPEA NITROGEN INC V RENAL DAMAGE MAY OCCUR FROM UPATE DEPOSITION P0384
BUS UL F AN S URIC ACID INC V AS A RESULT OF TISSUE DESTRUCTION 90620
BUTABAPHITAL P PROTHHOMBIN TINE DEC V DEC RESPONSE TO ANTICOAGULANTS (ENZ INDUCTION) P0886
BUTAPERAZINE B HFMATOCRIT DEC V TRANSITORY ANEMIA HO 026
BUTAPERAZINE B HEMOGLOBIN DEC V TRANSITORY ANEMIA REPORTED R0026
BUTAPERAZINE B RED CELL COUNT DEC V TRANSITORY ANEMIA HO 026
BUTAPERAZ INE B WHITE CELL COUNT DEC V TRANSITORY LEUKOPENIA P0026
BUTAPEPAZINE S BILIPUBIN INC V CHOLESTATIC HEPATITIS WITH OBSTRUCTION P0026
BUTAPERAZINE S SGOT INC V CHOLESTATIC HEPATITIS WITH OBSTRUCTION P00 26
BUTAPEPAZINE S SGPT INC V CHOLESTATIC HEPATITIS WITH OBSTRUCTION 90026
CADMIUM S BILIRUBIN INC V MAY OCCUR EVEN FOLLOWING RESPIRATORY EXPOSURE HO 368
CADMIUM S URIC ACID DEC V GENERALIZED IMPAIRMENT OF PROX TUBULAR FUNCTION P0006
CADMIUM U MAGNESIUM INC N MEASURED IN FLUORONETRIC METHOD OF SCHACHTSR P09 23
CA D MI U N U PROTEIN INC V GENERALIZED IMPAIRMENT OF PPOX TUBULAR FUNCTION P0006
CADMIUM U URIC ACID INC V GENERALIZED IMPAIRMENT OF PROX TUBULAR FUNCTION P0006
CADMIUM U URINALYSIS PROTEIN INC V GENERALIZED IMPAIRMENT OF PROX TUBULAR FUNCTION P0006
CAEHULIN P GLUCAGON INC V AFTER I.V. INFUSION IN NORMALS P03 12
CAERULIN S GLUCOSE INC V SLIGHT EFFECT AFTER I.V. INFUSION P0312
CAFFEI NE 0 BMR INC V METABOLIC EFFECT OF DRUG (TEMPORARY EFFECT) HO 596
CAFFEINE 0 GASTRIC JUICE HCL INC V EFFECT OF I.V. INFUSION, ALSO IF GIVEN ORALLY P0209
CAFFEINE 0 GASTRIC JUICE PEPSIN INC V EFFECT OF I.V. INFUSION, ALSO IF GIVEN ORALLY RO209
CAFFEINE P PROTHPONBIN TIME DEC V OBSERVED IN PATIENTS RECEIVING ANTICOAGULANTS HO 620
CAFFEINE P 3,5-AMP INC V INHIBITS PHOSPHODIESTERASE INCS LIPOLYSIS P0429
CAFFE IRE S BILIRUBIN DEC N ALLEGED LOWER VALUES WHEN USED AS COUPLING AGENT HO 299
CAFFEINE S DIRECT BILIRUBIN DEC N ALLEGED LOWER VALUES IF USED AS COUPLING AGENT P03 56
CAFFEINE S GLUCOSE INC V EFFECT IN ORDER OF 10 NG/100ML ONLY HO 202
CAFFEINE S GLUCOSE TOLERANCE INC V DEC OF GLUCOSE AT 30 AND 60 MINUTES P03 16
CAFFEINE S NEFA INC V 220 MG RAISED NEFA BY APPROX 30% HO 516
CA FEEl NE U CREATINE INC V ACTS ON INTERMEDIARY METABOLISM H 03 814
CAFFEINE U DIAGNEX BLUE EXCRETION DEC V AS NA BENZOATE SALT; LOW GASTRIC ACIDITY P0 299
CAF’EINE U URIC ACID INC N REDUCTION OF PHOSPHOTUNGSTATE BY METABOLITES RO182
CAFFEI NE U URINALYSIS CELLS INC V NAY CAUSE MARKED INC IN RENAL TUBULAR CELLS HO 384
CAFFEINE U URINALYSIS RBC/HPF INC V DAILY ADMIN CAUSES MODERATE INCREASE P06 57
CAFFEINE U VMA INC N INTERFERENCE WITH METHOD REPORTED RO355
CAFFEINE U VOLUME INC V DIURETIC ACTION RO384
CALCIFEROL S CALCIUM INC V ENHANCES ABSORPTION FROM G.I. TRACT H 0204
CALCIFEROL S PHOSPHATE INC V BETTER ABSORPTION AND UTILIZATION HO 204
CALCIFEROL U CALCIUM INC V AS RESULT OF INC ABSORPTION P02 04
CALCITONIN S CALCIUM DEC V DEC OF GREATER THAN 0.5 MEQ/L OBSERVED HO 406
CALCITONIN S PHOSPHATE DEC V DUE TO URINARY LOSS P03 84
CALCITONIN U CALCIUM INC V ACTS INDEPENDENTLY OF PAPATHYROID P0 406
CALCITONIN U MAGNESIUM INC V ACTS INDEPENDENTLY OF PARATHYROID P0406
CALCITON IN U PHOSPHATE INC V ACTS INDEPENDENTLY OF PARATHYROID R0406
CALCITONIN U POTASSIUM INC V ACTS INDEPENDENTLY OF PARATHYHOID R0406
CALCITON IN U SODIUM INC V ACTS INDEPENDENTLY OF PARATHYROID HO 107
CALCITONIN U URINALYSIS CASTS INC V POSSIBLE NEPHROTOXIC EFFECT (INC GRANULAR CASTS) P04 19
CALCITONIN U URINALYSIS CELLS INC V POSSIBLE NEPHROTOXIC EFFECT (INC EPITHELIAL CELLS) P04 19
CALCIUM S POTASSIUM INC N EMISSION SPECTRUM NAY INTERFERE P062 0
CALCIUM S SODIUM INC N EMISSION SPECTRUM MAY INTERFERE R 0620
CALCIUM CARBIMIDE U OXALATE DEC N INHIBITS ENZYMATIC PROCEDURE FOP MEASUREMENT H 1022
CALCIUM CHLORIDE B PH DEC V IS AN ACIDIFYING SALT P06 20
CALCIUM GLUCONATE S MAGNESIUM DEC N FALSE DECREASE IF MEASURED BY TITAN-YELLOW 90031
CALCIUM GLUCONATE U MAGNESIUM DEC N FALSE DECREASE IF MEASURED BY TITAN-YELLOW P0 03 1
CALCIUM GLUCONATE U 17 OH COFTICOSTEHOIDS DEC N REDUCED VALUE REPORTED IN A SINGLE CASE HO 1614
CALCIUM SALTS S CALCIUM INC N POSSIBLE CONTAMINATION OF DISTILLED WATER P1 001
CALCIUM SALTS S CALCIUM INC V DIRECT EFFECT OF INCREASED GUT ABSORPTION R0O26
CALCIUM SALTS S MAGNESIUM DEC V COMPETES FOP ABSORPTION FROM GUT AND TUBULES P003 1
CALCIUM SALTS S UREA NITROGEN INC V AZOTEMIA WITH MILK-ALKALI SYNDROME P03 814
CALCIUM SALTS U CALCIUM INC N POSSIBLE CONTAMINATION OF DISTILLED WATER H 1001
CALCIUM SALTS U CALCIUM INC V INC EXCRETION WITH LARGE ORAL DOSES HO 384
CALCIUM SALTS U DIAGNEX BLUE EXCRETION INC V HEAVY METAL DISPLACEMENT FROM RESIN P06 20
CAPPEOMYCIN B EOSINOPHILS INC V ALLERGIC REACTION (NAY BE UP TO 35%) HO 156
CA P P E0 MY C I N B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA OF HYPERSENSITIVITY P062 0
CAPREOM YC IN S BSP RETENTION INC V TRANSIENT INCREASE IN 5% SUBJECTS P0657
CAPREOMYCIN S CREATININE INC V N!PHROTOXIC EFFECT H06 20
CAPREOM YC IN S NPN INC V NEPHROTOXIC EFFECT P06 20
CAPREOMYCI N S UREA NITROGEN INC V NEPHROTOXIC EFFECT (IN 6% SUBJECTS) H 0384
CAPREOMYCIN S URIC ACID INC V NEPHROTOXIC EFFECT ASSOCIATED WITH HYPEPURICEMIA P014 33
CAPREOMYCIN U PROTEIN INC V NEPHHOTOXIC EFFECT (TRANSIENT) P0299
CAPPEOMYCIN U URINALYSIS CASTS INC V NEPHPOTOXIC EFFECT (USUALLY GRANULAR CASTS) R0620
CAPPEON YCIN U URINALYSIS PROTEIN INC V NEPHHOTOXIC EFFECT (TRANSIENT) HO 299
CARBACRYLANINE RES S POTASSIUM INC V PART OF RESIN IS IN FORM OF POTASSIUM SALT P0620
CARBACRYLAMINE RES S SODIUM DEC V CATION-EXCHANGE WITH REDUCED G.I.THACT ABSORPTION R0620
CARBA MAZE PINE B HENATOCRIT DEC V PANCYTOPENIA HO 278
CAPBAM AZ EPIN E B HEMOGLOBIN DEC V PANCYTOPENIA P0 278

CARBANAZEPINE B PLATELET COUNT DEC V THROMBOCYTOPENIA MAY OCCUR AFTER 1 YP(IMMUNOLOGIC) P0278
CARBAMAZEPINE B RED CELL COUNT DEC V PANCYTOPENIA P0278
CARBAMAZEPINE B WHITE CELL COUNT DEC V PANCYTOPENIA (LEUKOPENIA IN 15% PATIENTS) P0278
CARBANAZEPINE S ALKALINE PHOSPRATASE INC V CHOLESTATIC AND HEPATOCELLULAR DAMAGE P0762
CARBAMAZEPINE S BILIRUBIN INC V CHOLESTATIC AND HEPATOCELLULAR DAMAGE P0762
CARBAMAZEPINE S BSP RETENTION INC V CHOLESTATIC AND HEPATOCELLULA! DAMAGE P0417
CAPBAMAZEPINE S SCOT INC V CHOLESTATIC AND HEPATOCELLULAR DAMAGE P0762
CARBAMAZEPIN! S SGPT INC V CHOLESTATIC AND HEPATOCELLULAR DAMAGE P0762
CAPBAMAZEPINE S UREA NITROGEN INC V MAY CAUSE KIDNEY DYSFUNCTION P0026
CARBAMAZEPINE S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS R01492
CAPBAMAZEPINE U GLUCOSE INC V SINGLE CASE OF GLYCOSURIA REPORTED P01117
CARBAMAZEPINE U URINALYSIS GLUCOSE INC V SINGLE CASE OF GLYCOSURIA REPORTED RO1417
CARBANIDE B PLATELET COUNT DEC V REPORTED EFFECT (AMA-BLOOD DYSCRASIAS COMMITTEE) R0658
CARBARSONE S SGOT INC V MAY CAUSE HEPATITIS/LIVER NECROSIS P0026
CARBARSONE S SGPT INC V MAY CAUSE HEPATITIS/LIVER NECROSIS P0026
CARBARSONE U PROTEIN INC V NEPHROTOXIC EFFECT P0299
CARBARSONE U URINALYSIS PROTEIN INC V NEPHPOTOXIC EFFECT R0299
CARBENICILLIN B CLOTTING TINE INC V REPORTED EFFECT P0966
CARBENICILLIN B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA REPORTED P0467
CARBENICILLIN B NEUTROPHILS DEC V NEUTROPENIA REPORTED OCCASIONALLY RO1467
CARBENICILLIN B PLATELET COUNT DEC V OCCASIONALLY THROMBOCYTOPENIA NAY OCCUR P01467
CARBENICILLIN B FED CELL COUNT DEC V RENOLYTIC ANEMIA REPORTED R0467
CARBENICILLIN B WHITE CELL COUNT DEC V LEUKOPENIA MAY OCCUR INFREQUENTLY P01467
CARBENICILLIN P PROTRRONBIN TIME INC V EFFECT OBSERVED ESPECIALLY IN UREMICS R0467
CARBENICILLIN S ALKALINE PHOSPHATASE INC V TRANSIENT ELEVATIONS REPORTED R03814
CARBENICILLIN S CPK INC V PROBABLY DUE TO TRAUMA OF I.M. INJECTION 90541
CARBENICILLIN S LACTIC DEHYDROGENASE INC V TRANSIENT ELEVATIONS REPORTED R03814
CARBENICILLIN S SCOT INC V EFFECT OF DRUG? HEPATOTOXIC H0355
CAPBENICILLIN S SGPT INC V ELEVATION REPORTED ? DUE TO HEPATOTOXICITY P01467
CARBENOXOLONE S ALDOLASE INC V DUE TO HYPOKALENIC MYOPATHY 90074
CARBENOXOLONE S BILIRUBIN INC V POSSIBLE HEPATOTOXIC EFFECT OF DRUG P0669
CARBENOXOLONE S BSP RETENTION INC V REVERSIBLE HEPATOTOXIC EFFECT P0669
CARB!NOXOLONE S CALCIUM DEC V ALDOSTERONE LIKE EFFECT OF DRUG !0669
CARBENOXOLONE S CO2 CONTENT INC V HYPOKALEMIC ALKALOSIS R0669
CARBENOXOLONE S POTASSIUM DEC V ALDOSTERONE LIKE EFFECT P0336
CARBENOXOLONE S SCOT INC V ASSOC WITH MYOPATHY 30669
CARBENOXOLONE S SGPT INC V ASSOC WITH MYOPATHY P0669
CARBENOXOLONE S UREA NITROGEN INC V DUE TO NEPHP0PATHY WITH HYPOKALENIA R00714
CARBENOXOLONE S 5-NUCLEOTIDASE INC V POSSIBLE DIRECT HEPATOTOXICITY OF DRUG P0669
CAPBENOXOLONE U CREATININE CLEARANCE DEC V DUE TO NEPHROPATHT P0669
CARBENOXOLONE U NYOGLOBIN INC V MYOPATHY FOLLOWING HYPOKALEMIA 30669
CARBENOXOLONE U POTASSIUM INC V ALDOSTERONE LIKE EFFECT P0669
CARBENOXOLONE U PROTEIN INC V DUE TO NYOGLOBINURIA AND NEPHPOPATHY 90669
CARBENOXOLONE U SPECIFIC GRAVITY DEC V IMPAIRED CONCENTRATION WITH HYPOKALEMIA P0669
CARBENOXOLONE U URINALYSIS PH INC V IMPAIRED ACIDIFICATION WITH HYPOKALEMIA P0669
CAPBENOXOLONE U URINALYSIS PROTEIN INC V DUE TO NYOGLOBIN AND NEPHROPATHY P0669
CARBENOXOLONE U URINALYSIS S.C. DEC V IMPAIRED ABILITY TO C3NCENTPATE WITH LOW K P0669
CARBIMAZOLE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS P0165
CARBIMAZOLE S I 131 UPTAKE Z V NO EFFECT ON UPTAKE BY THYROID 30596
CARBIMAZOLE S PHI DEC V INHIBITS IODINATION OF TYROSINE IN TBG R00014
CARBON DISULFIDE B EOSINOPHILS INC V OCCASIONAL RESPONSE P0368
CARBON DISULFIDE B HEMATOCRIT DEC V HYPOCHROMIC ANEMIA COMMON 902514
CARBON DISULFIDE B HEMOGLOBIN DEC V HYPOCHROMIC ANEMIA COMMON P0254
CARBON DISULFIDE B LYMPHOCYTES INC V EFFECT USUALLY SLIGHT IN POISONING P0368
CARBON DISULFIDE B MONOCYTES INC V OCCURS IN 25% CASES REGARDLESS OF DURATION P0254
CARBON DISULFIDE 0 GASTRIC JUICE HCL DEC V FREQUENT;ALSO HIGH INCIDENCE CHRONIC GASTRITIS P02514
CARBON DISULFIDE S ALBUMIN DEC V EFFECT GREATER THAN ON TOTAL PROTEIN P0254
CARBON DISULFIDE S CHOLESTEROL DEC V IN PEOPLE WITH EXPOSURE TO 37 PPM FOR 5.7 YEARS R0254
CARBON DISULFIDE S CHOLESTEROL ESTERS DEC V WHILE CHOLESTEROL WAS INCREASED P0083
CARBON DISULFIDE S CHOLESTEROL INC V WITH OTHER LFT NORMAL ON CHRONIC EXPOSURE P0083
CARBON DISULFIDE S CHOLINESTEPASE DEC V NOT USUALLY SEVERE ENOUGH TO PRODUCE SYMPTOMS P0368
CARBON DISULFIDE S PROTEIN DEC V EFFECT SLIGHT P0254
CARBON DISULFIDE S UREA NITROGEN INC V RENAL IMPAIRMENT OBSERVED P0254
CARBON DISULFIDE U PROTEIN INC V MANIFESTATION OF RENAL DAMAGE P0254
CARBON DISULFIDE U URINALYSIS HEMOGLOBIN INC V MANIFESTATION OF RENAL DAMAGE P0254
CARBON DISULFIDE U URINALYSIS PROTEIN INC V MANIFESTATION OF RENAL DAMAGE P0254
CARBON DISULFIDE U URINALYSIS RBC/HPF INC V MANIFESTATION OP PENAL DAMAGE P02514
CARBON DISULFIDE U 17 KETOSTEROIDS DEC V REDUCTION IN RELATION TO TIME OF EXPOSURE P0254
CARBON DISULFIDE U 17 OH CORTICOSTEPOIDS DEC V REDUCTION IN RELATION TO TIME OF EXPOSURE P02511
CARBON MONOXIDE B CARBOXYHEMOGLOBIN INC V DUE TO PRESENCE OF CARBON MONOXIDE P0368
CARBON MONOXIDE S SGOT INC V ASSOC WITH HEPATOMEGALY R0368
CARBON MONOXIDE U URINALYSIS PROTEIN INC V ASSOC WITH OLIGURIA AND RENAL DAMAGE P0368
CARBON TETRACHLOR B PLATELET COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0658
CARBON TETRACHLOH B RED CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0658
CARBON TETRACHLOR B WHITE CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) R0658
CARBON TETRACHLOP F OCCULT BLOOD P05 V HEMATEMESIS IF INGESTED P0384
CARBON TETRACHLOP S AMYLASE INC V PANCPEATITIS OCEUPS RARELY R0384
CARBON TETRACHLOR S BILIRUBIN INC V HEPATOTOXIC EFFECT P0620
CARBON TETRACHLOH S BSP RETENTION INC V REDUCED HEPATIC BLOOD FLOW AND LIVER DAMAGE P0376
CARBON TETRACHLOR S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT P0620
CARBON TETRACHLOR S GLUCOSE DEC V HEPATOTOXIC EFFECT P0620
CARBON TETRACHLOP S lCD INC . V MAY BE EXTENSIVE HEPATIC NECROSIS RO990
CARBON TETRACHLOR S SCOT INC V MAY B! EXTENSIVE HEPATIC NECROSIS P0990
CARBON TETRACHLOP S SGPT INC V NAY BE EXTENSIVE H!PATIC NECROSIS 90990
CARBON TETRACHLOP S TRYNOL TURBIDITY INC V HEPATOTOXIC EFFECT P0620
CARBON TETPACHLOP U CATECHOLAMINES INC N SPURIOUS RESULTS 90112
CARBON TETPACHLOP U PROTEIN INC V NEPHROTOXIC EFFECT P0299
CARBON TETRACHLOP U SUGAR INC V DUE TO HEPATIC AND RENAL DAMAGE P0620
CARBON TETRACHLOP U URINALYSIS BILE INC V HEPATOTOXIC EFFECT P0620
CARBON TETRACHLOR U URINALYSIS COLOR INC V RED BROWN DUE TO HEMATURIA R0620

CARBON T!TRACHLOR U URINALYSIS GLUCOSE INC V DUE TO HEPATIC AND RENAL DAMAGE P0620
CARBON TETRACHLOP U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT H0299
CARBRONAL S BHOMIDN INC V METABOLITE CONC MAY EXCEED 25 MEQ/L 903814
CARBROMAL S CHLORIDE INC M BROMIDE AS METABOLITE MAY BE NEASUPED AS CL P03814
CARBROMAL S CPK INC V OCCURS WITH POISONING, PROBABLE MUSCLE ORIGIN 91008
CARBROMAL S DIRECT COOMBS TEST P05 V UNUSUAL CAUSE OF HEMOLYTIC ANEMIA 90636
CAPBPOMAL S INDIRECT COONBS TEST P05 V UNUSUAL CAUSE OF HENOLYTIC ANEMIA P0636
CARBROMAL S SCOT INC V OCCURS WITH POISONING, PROBABLE MUSCLE ORIGIN 91008
CARBROMAL S SGPT INC V OCCURS WITH POISONING, PROBABLE MUSCLE ORIGIN P1008
CARBROMAL U POHPHYRINS INC V MAY PRECIPITATE ATTACK OF ACUTE PORPHYRIA P0596
CARBUTAMIDE B PLATELET COUNT DEC V MAY CAUSE APLASTIC ANEMIA OR THROMBOCYTOPENIA 91000
CARBUTANIDE B WHITE CELL COUNT DEC V LEUKOPENIA/AGRANULOCYTOSIS P1000
CARBUTAMID! S ALKALINE PHOSPHATASE INC V HEPATOTOXICITY 90620
CARBUTAMIDE S BILIRUBIN INC V HEPATOTOXICITY P0620
CARBUTANIDE S BSP RETENTION INC V HEPATOTOXICITY P0620
CARBUTAMIDE S CHOLESTEROL DEC V HEPATOTOXICITY P0620
CARBUTAMIDE S CREATININE INC V NEPHROTOXIC EFFECT RO62O
CARBUTAMIDE S GLUCOSE DEC V HEPATOTOXICITY P0620
CARBUTAMIDE S I 131 UPTAKE DEC V SUBSTANTIAL EFFECT OBSERVED IN ELDERLY P0255
CARBUTAMID! S NEFA INC V REPORTED TO CAUSE HYPERLIPEMIA P0596
CARBUTAMIDE S NPN INC V NEPHPOTOXIC EFFECT P0520
CARBUTAMIDE S PHI DEC V INHIBITS IODINATION OF TYROSINE IN TBG P0004
CARBUTAMIDE S SGOT INC V HEPATOTOXICITY P0620
CAPBUTAMIDE S SGPT INC V HEPATOTOXICITY R062O
CARBUTAMIDE S UREA NITROGEN INC V NEPHROTOXIC EFFECT 90620
CARBUTAMIDE U PROTEIN INC V NEPHROTOXIC EFFECT RO96LI
CARBUTAMIDE U URINALYSIS PILE INC V HEPATOTOXICITY P0620
CARBUTAMIDE U URINALYSIS PROTEIN INC V NEPHPOTOXIC EFFECT P0964
CARINAMIDE U PSP EXCRETION DEC V INHIBITS SECRETION P0299
CAPINAMIDE U URINALYSIS PROTEIN INC N PRODUCES PRECIPITATE WITH ACID TESTS 90143
CARINAMIDE U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S R0436
CAROTENE S BILIHUBIN INC N COLOR MAY INTERFERE WITH DIRECT METHODS P0299
CAROTENE S ICTEPIC INDEX INC M INTERFERING BACKGROUND COLOR P0355
CARPHENAZINE S BILIRUBIN INC V PROBABLE CHOLESTATIC EFFECT (REVERSIBLE) P0620
CARPHENAZINE S BSP RETENTION INC V PROBABLE CHOLESTATIC EFFECT (REVERSIBLE) 30620
CARPHENAZINE S CEPHALIN FLOCCULATION INC V PROBABLE CHOLESTATIC EFFECT (REVERSIBLE) P0620
CARPHENAZINE S SGOT INC V PROBABLE CHOLESTATIC EFFECT (REVERSIBLE) P0620
CARPHENAZINE S SGPT INC V PROBABLE CHOLESTATIC EFFECT (REVERSIBLE) RO620
CARPHENAZINE S THYMOL TURBIDITY INC V PROBABLE CHOLESTATIC EFFECT (REVERSIBLE) P0620
CARPHENAZINE U URINALYSIS BILE INC V PROBABLE CHOLESTATIC EFFECT (REVERSIBLE) P0620
CARROTS S BILIRUBIN INC N COLOR MAY BE MISINTERPRETED P0356
CARROTS S DIRECT BILIRUBIN INC N COLOR MAY BE MISINTERPRETED P0356
CARROTS S ICTERIC INDEX INC N COLOR MAY BE MISINTERPRETED 90355
CARROTS U URINALYSIS COLOR INC N YELLOW COLOR SOLUBLE IN PETROLEUM ETHER P0620
CASCARA U PORPHOBILINOGEN INC N COLOR EXTRACTABLE INTO CHLOROFORM P0436
CASCARA U PSP EXCRETION INC N CONVERTED TO ANTHRAQUINONE-G.I. TRACT (RED COLOR) P0233
CASCARA U URINALYSIS COLOR INC N BROWN (ACID),YEL-PINK(ALKALINE)BLACK ON STANDING P0299
CASCARA U UROBILINOGEN INC N REACTS WITH EHRLICH’ S REAGENT 901436
CASTOR OIL U URINALYSIS CELLS INC V MULTINUCLEATED GIANT CELLS IN 50% PATIENTS RO657
CATEHOLS S GLUCOSE DEC N NAY INHIBIT GLU OX PROCEDURES RO436
CATHARTICS S ALBUMIN DEC V RARE PROTEIN-LOSING GASTROENTEROPATHY 90384
CATHAPTICS S POTASSIUM DEC V EXCESSIVE USE MAY CAUSE HYPOKALENIA 90384
CATHAPTICS S PROTEIN DEC V RARE PROTEIN LOSING GASTROENTEROPATHY 90384
CATHARTICS S SODIUM DEC V EXCESSIVE USE NAY CAUSE NA DEPLETION P03814
CATHAPTICS U POTASSIUM INC V SECONDARY ALDOSTERONISN IF BLOOD VOLUME REDUCED P03814
CELLULOSE ACETATE S THYROXINE (T4) INC N DUE TO PHTHALATES AS PLASTICIZEP IN CONTAINERS 90822
CELLULOSE ACETATE S TRIIODOTHYRONINE (T3) INC N INHIBITS BINDING OF T4 TO TBG P0822
CEPHALEXIN B EOSINOPHILS INC V ALLERGIC RESPONSE P0736
CEPHALEXIN S DIRECT COOMBS TEST P05 V INCIDENCE LOW R0309
CEPHALOPIDINE B EOSINOPHILS INC V MAY BE UP TO 10% IN 1% PEOPLE RO298
CEPHALORIDIN! B HEMATOCRIT DEC V MAY CAUSE ANEMIA P0026
CEPHALORIDINE B HEMOGLOBIN DEC V MAY CAUSE ANEMIA R0026
CEPHALORIDINE B RED CELL COUNT DEC V NAY CAUSE ANEMIA P0026
CEPHALOHIDINE B WHITE CELL COUNT DEC V MAY CAUSE NEUTROPENIA/LEUKOPENIA R0298
CEPHALOPIDINE P PROTHROMBIN TIME INC V REPORTED EFFECT P0026
CEPHALORIDINE S ALKALINE PHOSPHATASE INC V MECHANISM NOT LISTED P01417
CEPHALORIDINE S CREATININE INC V NEPHROTOXIC ESP IF COMBINED WITH DIURETIC P0736
CEPHALORIDINE S DIRECT COOMBS TEST P05 V NO IMMUNOL RESPONSR(COMPLEX BINDS TO CELL-8% CASES) P0(418
CEPHALORIDINE S NPN INC V NEPHROTOXIC ESP IF COMBINED WITH DIURETIC P0736
CEPHALORIDINE S POTASSIUM INC V NAY OCCUR WITH NEPHROTOXICITY R0620
CEPHALORIDINE S SCOT INC V TRANSIENT SLIGHT RISE ?HEPATOTOXICITY P0298
CEPHALORIDINE S SGPT INC V TRANSIENT SLIGHT RISE ?HEPATOTOXICITY 90298
CEPHALORIDINE S UREA NITROGEN INC V HIGH DOSES, NEPHHOTOXICITY REPORTED P0029
CEPHALORIDINE U PROTEIN INC V MAY BE RESULT OF NEPUPOTOXICITY P01449
CEPHALOHIDINE U URINALYSIS CASTS INC V NEPHPOTOXICITY (HYALINE AND GRANULAR) 90298
CEPHALORIDINE U URINALYSIS GLUCOSE Z N WITH TESTAPE P0298
CEPHALOHIDINE U URINALYSIS PROTEIN INC N WEAK P05 WITH ALBUSTIX AT HIGH CONCS 90581
CEPHALOPIDINE U URINALYSIS PROTEIN INC N PRECIPITATE OCCURS WITH SULFOSALICYLIC ACID RO581
CEPHALORIDINE U URINALYSIS PROTEIN INC V NAY BE RESULT OF NEPHROTOXICITY 901449
CEPRALOPIDINE U URINALYSIS SUGAR INC M ABNORMAL DARK COLOR WITH BENEDICT’S B CLINITEST P0317
CEPHALORIDINE U VOLUME DEC V SUGGESTIVE OF NEPHROTOXICITY P0298
CEPHALOTHIN B POSINOPHILS INC V ALLERGIC RESPONSE P0651
CEPHALOTHIN B HENATOCRIT DEC V HEMOLYTIC ANEMIA 90392
CEPRALOTHIN B HEMOGLOBIN DEC V COOMBS POSITIVE HEMOLYTIC ANEMIA P0392
CEPHALOTHIN B NEUTROPHILS DEC V NEUTROPENIA OR LEUKOPENIA PARE P0021
CEPHALOTHIN B PLATELET COUNT DEC V INC RESISTANCE TO OSMOTIC FRAGILITY R0656
CEPHALOTHIN B RED CELL COUNT DEC V HEMOLYTIC ANEMIA P0392
CEPHALOTHIN B WHITE CELL COUNT DEC V HARE RESPONSE TO THERAPY P0620
CEPHALOTHIN B WHITE CELL COUNT INC V DUE TO ROSINOPHILIA OF HYPERSENSITIVITY P0620
CEPHALOTHIN S BILIRUBIN INC V MAY CAUSE HENOLYTIC ANEMIA 90393

CEPHALOTHIN S DIRECT BILIPUBIN INC V MAY CAUSE HEMOLYTIC ANEMIA P0393
CEPHALOTRIN S DIRECT COOMBS TEST P05 V NONINNUNOLOGIC PHENOMENON, COMPLEX BINDS TO CELL P01418
CEPHALOTHIN S SGPT INC V SINGLE CASE REPORTED P0657
CEPHALOTHIN S THYMOL TURBIDITY INC V REPORTED IN ALCOHOLIC PATIENT WITH CIRRHOSIS P0620
CEPHALOTHIN S UREA NITROGEN INC V RARE ELEVATION NOTED (POSSIBLE NEPHHOTOXICITY) P0298
CEPHALOTHIN U SUGAR INC N FALSE POSITIVE WITH COPPER REDUCTION PROCEDURES P0907
CEPHALOTHIN U URINALYSIS PROTEIN INC N WEAK POSITIVE WITH ALBUSTIX AT HIGH CONCS P0581
CEPHALOTHIN U URINALYSIS PROTEIN INC N PRECIPITATE OCCURS WITH SULFOSALICYLIC ACID P0581
CEPHALOTHIN U URINALYSIS PROTEIN INC V PARE EFFECT FOLLOWING I.V. INFUSION R0657
CEPHALOTHIN U URINALYSIS SUGAR INC N BROWN-BLACK COLOR WITH CLINITEST (FALSE POSITIVE) R0O1414
CHENODEOXYCHOLIC S ALKALINE PHOSPHATASE INC V MILD TRANSIENT ELEVATION OBSERVED P0248
CHENODEOXYCHOLIC S BETA-LIPOPROTEINS Z V NO EFFECT OBSERVED DURING TREAT OF GALLSTONES P02148
CHENODEOXYCHOLIC S CHOLESTEROL Z V NO EFFECT OBSERVED DURING TREAT OF GALLSTONES P02148
CHENODEOXYCHOLIC S SCOT INC V MILD TRANSIENT ELEVATION OBSERVED P02148
CHINIOFON S PHI INC M CONTAINS 27.5% IODINE P0004
CHINIOFON S SGPT INC V LARGE DOSES MAY OCCASIONALLY CAUSE HEPATIC DAMAGE P0384
CHLORAL S BILIPUBIN INC V PROBABLY NON-SPECIFIC EFFECT ON CELLS P0420
CHLOPAL S BSP RETENTION INC V PROBABLY NON-SPECIFIC EFFECT ON CELLS P01420
CHLORAL S URIC ACID INC N AFFECTS PHOSPHOTUNGSTATE REDUCTION METHODS P0596
CHLOHAL U PROTEIN INC V RENAL DAMAGE WITH HIGH CONCENTRATION P0384
CHLORAL U URINALYSIS PROTEIN INC V PAPENCHYMATOUS RENAL INJURY IN CHRONIC INTOXICATION P0384
CHLOHAL U URINALYSIS SUGAR INC N EXCRETED AS GLUCURONIDE FALSE P05 WITH BENEDICT’S 90299
CHLORAL BETAINE P PPOTHRONBIN TIME DEC V MAY DECREASE POTENCY OF COUMARIN ANTICOAGULANTS P0026
CHLOPAL BETAINE U URINALYSIS SUGAR INC M EXCRETED AS GLUCURONIDE, ACTS AS REDUCING SUBST P0356
CHLOPAL HYDRATE P PPOTHHONBIN TIME DEC V ACCELERATES RATE OF INACTIVATION OF COUNARINS P0620
CHLOHAL HYDRATE P PROTHROMBIN TIME INC V DISPLACES ANTICOAGULANTS FROM ALBUMIN P0886
CHLOPAL HYDRATE S UREA NITROGEN INC N REACTS WITH NESSLER REACTION P0907
CHLORAL HYDRATE U CATECHOLAMINES INC N INTERFERES WITH FLUOROMETRIC PROCEDURES P01417
CRLORAL HYDRATE U PORPHYRINS INC V MAY PRECIPITATE ATTACK OF ACUTE PORPHYRIA P0596
CHLORAL HYDRATE U URINALYSIS SUGAR INC N EXCRETED AS GLUCURONIDE, REDUCES BENEDICT’S R0596
CHLORAL HYDRATE U 17 OH COBTICOSTEROIDS INC N INTERFERES WITH POPTEP-SILBER REACTION P0907
CHLORAMBUCIL B LYMPHOCYTES DEC V MARKED DECREASE MAY OCCUR P01467
CRLOHANBUCIL B NEUTROPHILS DEC V SEVERE NEUTROPENIA MAY BE PRODUCED P0467
CHLOPAMBUCIL B PLATELET COUNT DEC V DOSE DEPENDENT BONE MARROW DEPRESSION P0026
CHLORAMBUCIL B RED CELL COUNT DEC V DOSE DEPENDENT BONE MARROW DEPRESSION P0026
CHLORANBUCIL B WHITE CELL COUNT DEC V NEUTROPENIA (DOSE RELATED) P0167
CHLORAMBUCIL S SGPT INC V OCCASIONAL HEPATOTOXICITY REPORTED P0384
CHLORAMPHENICOL B BOSINOPHILS INC V ALLERGIC REACTION P0424
CHLORANPHENICOL B HEMATOCRIT DEC V NORMALLY SLIGHT RESPONSE/MAY BE PANCYTOPENIA P0272
CULORAMPHENICOL B HEMOGLOBIN DEC V NORMALLY SLIGHT RESPONSE/MAY BE PANCYTOPENIA P0272
CHLOPAMPHENICOL B NETHEMOGLOBIN INC V NAY CAUSE HENOLYSIS IN G-6-PD DEFICIENCY P0926
CHLOPAMPHENICOL B NEUTROPHILS DEC V COMMON TOXIC REACTION/APLASTIC ANEMIA P0657
CHLORAMPHENICOL B PLATELET COUNT DEC V PANCYTOPENIA/APLASTIC ANEMIA P0272
CHLORAMPHENICOL B RED CELL COUNT DEC V DOSE RELATED RESPONSE USUAL/APLASTIC ANEMIA R0272
CHLORAMPHENICOL B HETICULOCYTES DEC V REVERSIBLE TOXIC REACTION OP PANCYTOPENIA P0656
CHLORAMPHENICOL B WRITE CELL COUNT DEC V PANCYTOPENIA/APLASTIC ANEMIA P0272
CHLOPAMPHENICOL B WHITE CELL COUNT INC V LEUKEMIA MAY OCCUR AS SEQUEL TO NARROW DEPRESSION P0026
CHLORAMPHENICOL C PROTEIN INC M SLIGHT EFFECT ON FOLIN-CIOCALTEU PROCEDURE P1026
HL0PA!PHENICOL F OCCULT BLOOD P05 V MAY BE C.I. HEMORRHAGE, WITH LOW PROTHROMBIN P0026
CHLOPANPHENICOL F UROBILINOGEN DEC V REDUCTION OF FLORA IN G.I. TRACT P0417
CHLORANPHENICOL P PHOTHROMBIN TIME INC V MAY CAUSE LOWERED PROTHROMBIN AND HEMORRHAGE P0270
CHLORAMPHENICOL S ALKALINE PHOSPHATASE INC V ?HEPATOTOXIC-CHOLESTATIC EFFECT P0596
CHLOPAMPHENICOL S BILIRUBIN INC V HEPATOTOXIC-CHOLESTATIC EFFECT P0596
CHLOPAMPHENICOL S BSP RETENTION INC V HEPATOTOXICITY P0596
CHLOPANPHENICOL S CEPHALIN FLOCCULATION INC V HEPATOTOXICITY P0596
CHLOPAMPHENICOL S FOLATE DEC N INHIBITS GROWTH OF L. CASEI P0910
CHLORAMPHENICOL S IRON INC V REVERSIBLE TOXIC REACTION P0736
CHLOHANPHENICOL S SCOT INC V HEPATOTOXIC-CHOLESTATIC EFTECT P0596
CHLORAMPHENICOL S SGPT INC V HEPATOTOXIC-CHOLESTATIC EFFECT P0596
CHLOHAMPHENICOL S THYMOL TURBIDITY INC V HEPATOTOXICITY P0596
CHLORAMPHENICOL S TIBC DEC V DECREASED UPTAKE BY ERYTHHOID TISSUE P0596
CHLORANPHENICOL S UREA NITROGEN DEC N INHIBITS BERTHELOT REACTION P0907
CHLOPAMPHENICOL S UREA NITROGEN INC N REACTS WITH NESSLER REAGENT P0907
CHLORANPHEN!COL S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS P0596
CHLORAMPHENICOL U URINALYSIS BILE INC V HEPATOTOXICITY 90620
CHLORANPHENICOL U URINALYSIS SUGAR INC M FALSE POSITIVE WITH COPPER REDUCTION PROCEDURES P0907
CHLORAMPHENICOL U UROBILINCG!N DEC V REDUCTION OF FLORA IN G.I. TRACT P01417
CHLORANPHENICOL U 17 KETOSTEROIDS INC N AFFECTS SOME METHODS BUT NOT MODIFIED REDDY METHOD P0417
CHLORATE B HEMOGLOBIN DEC V CAUSES HEMOLYSIS P03814
CHLORATE B METHENOGLOBIN INC V MAY CAUSE HEMOLYSIS P0384
CHLORATE B RED CELL COUNT DEC V DESTROYS CELLS ON ABSORPTION P0384
CHLORATE S PHI DEC V INTERFERES WITH TRAPPING OF IODIDE BY THYROID P00014
CHLOPDANE B PLATELET COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0658
CHLOPDANE B RED CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0658
CHLOPDANE B WHITE CELL COUNT DEC V PANCYTOPENIA (ANA-BLOQD DYSCPASIAS) P0658
CHLORDANE P PROTHRONBIN TIME DEC V INDUCES HEPATIC METABOLISM OF ANTICOAGULANTS P0384
CHLORDANE S BILIPUBIN INC V DUE TO HEPATOTOXICITY P0368
CHLORDANE S SGPT INC V DUE TO HEPATOTOXICITY P0368
CHLOHDIAZEPOXIDE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS REPORTED (LEUKOPENIA MORE COMMON) P0620
CHLORDIAZEPOXIDE F COPPOPORPHYPIN INC V MAY PRECIPITATE ACUTE PORPHYRIA RO371
CHLORDIAZEPOXIDP F PROTOPOPPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P0371
CHLORDIAZEPOXIDF F UPOBILINOGEN DEC V INFREQUENT CHOLESTATIC EFFECT RO477
CHLORDIAZEPOXIDE P PPOTHRONBIN TIME INC V ASSOC WITH FAILURE OF EXCRETION OF BILE SALTS P0477
CHLOFDIAZEPOXIDE P PROTHROMBIN TIME Z V DOES NOT AFFECT ACTION OF ADMINISTERED COUMARINS P0787
CHLOPDIAZEPOXIDE P WARFARIN INC N SPECTROPHOTOMETRIC METHOD SHOWS INTERFERENCE P0787
CHLORDIAZEPOXIDE S ALKALINE PHOSPHATASE INC V INFREQUENT CHOLESTATIC EFFECT P0596
CHLOBDIAZEPOXIDE S BILIRUBIN INC V INFREQUENT CHOLESTATIC EFFECT R0299
CHLOPDIAZEPOXIDE S PSP RETENTION INC V INFREQUENT CHOLESTATIC EFFECT R0477
CHLORDIAZEPOXIDE 5 CEPHALIN FLOCCULATION INC V INFREQUENT CIIOLESTATIC EFFECT P0620
CHLORDIAZEPOXIDF S I 131 UPTAKE DEC V ?ANTITHYHOID EFFECT P0075
CLiNICAL CHEMISTRY, Vol. 18, No. 10, 1972 1081

CHLORDIAZEPOXIDE S lCD INC V INFREQUENT CHOLESTATIC EFFECT R062O
CHLOPDIAZEPOXIDE S SGOT INC V MAY PRODUCE HEPATOTOXIC EFFECT P 0002
CULORDIAZEPOXIDE S SGPT INC V MAY PRODUCE HEPATOTOXIC EFFECT R0002
CHLORDIAZEPOXIDE S THYMOL TURBIDITY INC V INFREQUENT CHOLESTATIC EFFECT P0620
CHLORDIAZEPOXIDE S T3 UPTAKE DEC V ?ANTITHYROID EFFECT (RESIN TEST AFFECTED) P0075
CHLORD lAZE POXIDE U ANINOLEVULINIC ACID INC V NAY PRECIPITATE ACUTE PORPHYRIA P037 1
CHLORDIAZEPOXIDE U CATECHOLAMINES Z V NO EFFECT SHORT TERN INGESTION OF 30 MG/DAY P0236
CHLORDIAZEPOXIDE U COPROPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P 03 71
CRLORDIAZEPOXIDE U EPINEPHRINE Z V NO EFFECT SHORT TERM INGESTION OF 30 MG/DAY P02 36
CHLORD IAZEPOXIDE U NOPEPINEPHRINE Z V NO EFFECT SHORT TERN INGESTION OF 30 MG/DAY P0 236
CHLOBDIAZEPOXIDE U PORPHOBILINOGEN INC V MAY PRECIPITATE ACUTE PORPHYRIA P03 71
CHLOPDIAZEPOXIDE U PORPHYRINS INC V MAY PRECIPITATE ATTACK OF ACUTE PORPHYRIA P0596
CHLOPDIAZEPOXIDE U URINALYSIS BILE INC V HEPATOTOXIC EFFECT P062 0
CHLORDIAZEPOXIDE U UPOBILINOGEN DEC V INFREQUENT CHOLESTATIC EFFECT P01477
CHLORDIAZEPOXIDE U 11 OH COPTICOSTEROIDS Z V NO EFFECT SHORT TERM INGESTION 30 MG/DAY P02 36
CHLORDIAZEPOXIDE U 17 KETOGENIC STEROIDS DEC N INTERFERES WITH ZIMMERMAN REACTION P0907
CHLOBDIAZEPOXIDE U 17 KETOCENIC STEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION P0692
CHLOR DIAZEPOXIDE U 17 KETOSTEROIDS DEC N INTERFERES WITH ZIMMERMAN HEACTION(IN VITRO, VIVO) HO 133
CHLOPDIAZEPOXIDE U 17 KETOSTEROIDS Z M NO EFFECT ON ZIMMERMAN REACTION IF ADDED IN VITRO P0236
CHLORDIAZEPOXIDE U 17 KETOSTEPOIDS Z V NO EFFECT SHORT TERM INGESTION OF 30 MG/DAY HO 236
CHLOPD IAZEPOXIDE U 17 OH CORTICOSTEROIDS INC N INT ERFERES WITH POPTEP-SILBER REACTION (VITRO, VIVO) P0133
CHLOPDIAZEPOXIDE U 17 OH CORTICOSTEROIDS Z M NO EFFECT PORTER-SILBEH REACTION IF ADDED IN VITRO RO 236
CHLORDIAZEPOXIDE U 17 OH CORTICOSTEROIDS Z V NO EFFECT SHORT TERN INGESTION 30 MG/DAY HO 236
CHLORIDE SALTS S AMYLASE INC N CHLORIDE ENHANCES ENZYME ACTIVITY P0863
CHLORIDE SALTS S CHLORIDE INC V INCREASED ABSORPTION WITH INCREASED SERUM LEVELS HO 204
CHLORIDE SALTS S PHI INC N LABORATORY CONTAMINATION NAY CAUSE SIC EFFECT R0255
CHLORINATED INSECT E CHOLINESTEPASE INC V POWERFUL INHIBITOR OF ENZYME HO 130
CHLORINATED INSECT S ALDOLASE INC V PRESUMED DAMAGE OF LIVER CELLS HO 130
CHLORINATED INSECT S ALKALINE PHOSPHATASE INC V PRESUMED DAMAGE OF LIVER CELLS HO 130
CHLOPI NE S URIC ACID INC N IF STANDARDS MADE IN CONTAMINATED WATER P0183
CHLOP M ADINONE S PBI INC V DUE TO INCREASED BINDING GLOBULIN P0620
CHLOR NA DI NONE S TBG INC V THERAPEUTIC EFFECT P0620
CHLOR MADINONE U LH DEC V USUAL EFFECT IN NORMAL WOMEN P0900
C HLOHMERODI N S PHI DEC N FORMATION OF MERCURIAL IODIDE DUPING ANALYSIS P0233
CHLOPMERODIN U 17 KETOSTEROIDS DEC N POSSIBLE INTERFERENCE WITH ZIMMERMAN REACTION R0133
CHLOR NERODI N U 17 OH CORTICOSTEROIDS INC M POSSIBLE INTERFERENCE WITH PORTER-SILVER REACTION R0133
CHLOP NEZ ANONE S ALKALINE PHOSPHATASE INC V HEPATOTOXICITY P06 20
CHLOR MEZA NONE S BILIRUBIN INC V HEPATOTOXICITY P06 20
CR LOP MEZA NONE S CEPHALIN FLOCCULATION INC V HEPATOTOXICITY P062 0
CHLOP MEZA NONE S SCOT INC V REP ATOTOXICITY RO 620
C HL OP NEZ A NONE S SGPT INC V HEPATOTOXICITY P0620
CHLOR MEZANONE S THYMOL TURBIDITY INC V HEP ATOTOXICITY RO620
CHLOP MEZA NONE U URINALYSIS BILE INC V HEPATOTOXICITY R062O
CHLOROBUTANOL S UREA NITROGEN INC N FALSE INCREASE WITH DIRECT NESSLERIZATION P0436
CHLOROFORM S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT WITH NECROSIS P06 20
CHLOROFORM S PILIHUBIN INC V HEPATOTOXIC EFFECT WITH NECROSIS P0620
CHLOROFORM S BSP RETENTION INC V HEPATOTOXIC EFFECT WITH NECROSIS P0620
CHLOROFORM S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT WITH NECROSIS P0620
CHLOROFORM S CHOLESTEROL DEC V HEPATOTOXIC EFFECT WITH NECROSIS R0620
CHLOROFORM S GLUCOSE DEC V HEPATOTOXIC EFFECT WITH NECROSIS P06 20
CHLOROFORM S OCT INC V HEPATOTOXIC EFFECT WITH NECROSIS R0990
CHLOROFORM S SCOT INC V HEPATOTOXIC EFFECT WITH NECROSIS P062 0
CHLOROFOR N S SGPT INC V HEPATOTOXIC EFFECT WITH NECROSIS HO 6 20
CHLOROFORM S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT WITH NECROSIS P0620
CHLOROFORM U URINALYSIS SUGAR INC V POSITIVE WITH BENEDICT’S, FEHLING’S SOLNS P1001
CHLOPOGUA NIDE B NYELOCYTES INC V UP TO 10% IN PATIENTS WITH OVERT MALARIA RO384
CHLOPOGUANI DE S FOLATE DEC V ANTAGONISES FOLIC ACID P0026
CHLOROGUANIDE U URINALYSIS CASTS INC V NEPHROTOXIC EFFECT P06 20
CRLOROGUANIDE U URINALYSIS CELLS INC V MAY CAUSE TRANSIENT APPEARANCE OF EPITHELIAL CELLS P03 84
CHLOROGUANIDE U URINALYSIS HEMOGLOBIN INC V DRUG PRODUCES ACTUAL BLEEDING P0299
CHLOROGUANIDE U URINALYSIS PBC/HPF INC V DRUG PRODUCES ACTUAL BLEEDING P0299
CHLOROPHENOTHANE B PLATELET COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCPASIAS) P0658
CHLOROPHENOTHANE B RED CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P06 58
CHLOROPHENOTH ANE B WHITE CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0658
CHLOROPHENOTRANE 0 DEXAMETHASONE SUPPRESS Z V NORMAL IN SUBJECTS WITH OCCUPATIONAL EXPOSURE P0206
CHLOROPHENO THAN! P CORTISOL Z V OCCUPATIONAL EXPOSURE NO EFFECT P02 06
CHLOROPHENOTHA NE S BILIRUBIN DEC V EFFECT ON CONGENITAL NON-HEN. HYPERBILIRUBINENIA P0907
CHLOROPHENYLANINE U S OH INDOLEACETIC ACID DEC V INHIBITS. BIOSYNTHESIS OF SEROTONIN P023 1
CHLOPOQUINE B HEMATOCRIT DEC V G-6-PD HEMOLYTIC ANEMIA/PANCYTOPENIA P09 12
CHLOPOQUI NE B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS P09 12
CHLOROQU IN! B PLATELET COUNT DEC V PANCYTOPEN IA P0912
CRLOROQUI NE B RED CELL COUNT DEC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS P0912
CHLOROQUINE B WHITE CELL COUNT DEC V AGH ANULOCYTOS IS/PA NCYIOPE NIA P09 12
CHLOROQUI NE S BILIRUBIN INC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENCY P0467
CHLOROQUINE S SCOT INC V REPORTED EFFECT NO MECHANISM CITED HO 620
C HLOPOQUI NE U URINALYSIS COLOR INC N BROWN COLOR P0299
CHLOROQUINE U UROBILINOGEN INC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENCY P0467
CRLOROQUINE U UHOPORPHYRIN INC V TRANSIENT INC MAY OCCUR WITH CUTANEOUS PORPHYRIA P037 1
CHLOROTHI AZ IDE B HENATOCRIT DEC V PANCYTOPEN IA P0024
CHLOROTHIAZ IDE B HEMOGLOBIN DEC V PA NC YTOPEN IA ROO2LI
CHLOBOTHI AZI DE B LE CELL PREP P05 V MAY PRODUCE LE-LIKE SYNDROME P0910
CRLOROTHIAZIDE B NEUTROPHILS DEC V OCCASIONALLY OBSERVED HO 6 57
CHLOROTHIAZ IDE B PLATELET COUNT DEC V PANCYTOPENIA DUE TO APLASTIC ANEMIA MAY OCCUR P006 0
CHLOROTHIA ZIDE B RED CELL COUNT DEC V PANCYTOPENIA/APLASTIC ANEMIA R00 214
CHLOPOTHI AZ IDE B WHITE CELL COUNT DEC V LEUKOPENIA/PANCYTOPENIA ROO 214
CHLOROTHIAZIDE F CALCIUM DEC V ACCENTUATES POSITIVE CALCIUM BALANCE P06 57
CHLOROTHIAZIDE P AMMONIA INC V DECREASED POTASSIUM AND ALKALOSIS HO 356
CHLOPOTHIAZIDE P PROTHRONBIN TIME Z V DOES NOT AFFECT ACTION OF ADMINISTERED COUMAHINS P0787
CHLOROTHI AZ IDE S ALKALINE PHOSPHATASE INC V MAY CAUSE CHOLESTATIC JAUNDICE P0620
CHLOROTHIAZIDE S ANYLASE INC V INFREQUENT CONSEQUENCE OF THERAPY HO 117

CHLOROTHIAZIDE S BILIRUBIN INC V REPORTED TO CAUSE CHOLESTATIC JAUNDICE R0723
CHLOROTHIAZIDE S DSP RETENTION INC V MAY CAUSE CHOLESTATIC JAUNDICE P0620
CHLOHOTHIAZIDE S CALCIUM INC V IMPAIRED EXCRETION WITH CHRONIC ADMINISTRATION P0907
CHLOROTHIAZIDE S CEPRALIN FLOCCULATION INC V NAY CAUSE CHOLESTATIC JAUNDICE P0620
CHLOROTHIAZIDE S CHLORIDE INC V WITH PROLONGED THERAPY HYPERCHLOREMIC ALKALOSIS RO596
CHLOROTHIAZIDE S GLUCOSE INC V DIABETOGENIC PROPERTIES OF DRUG AFFECT GTT P0907
CHLOROTHIAZIDE S GLUCOSE TOLERANCE DEC V DIABETOGENIC-LIKE ACTION OF DRUG R0723
CHLOHOTHIAZIDE S POTASSIUM DEC V DIURETIC ACTION O907
CHLOPOTHIAZIDE S SCOT INC V MAY CAUSE CHOLESTATIC JAUNDICE P0620
CHLOPOTHIAZIDE S SGPT INC V MAY CAUSE CHOLESTATIC JAUNDICE P0620
CHLOPOTHIAZIDE S SODIUM DEC V MAY CAUSE HYPONATREMIA P0596
CHLOHOTHIAZIDE S THYMOL TURBIDITY INC V MAY CAUSE CHOLESTATIC JAUNDICE P0620
CHLOPOTHIAZIDE S URIC ACID DEC V IF GIVEN I.V. IN LARGE DOSES HAS URICOSURIC EFFECT P014011
CHLOROTHIAZIDE S URIC ACID INC V DECREASED URATE CLEARANCE P0907
CHLOHOTRIAZIDE S 5-NUCLEOTIDASE INC V MAY CAUSE CHOLESTATIC JAUNDICE P0620
CHLOPOTHIAZIDE U CALCIUM DEC V IMPAIRED EXCRETION WITH CHRONIC ADMINISTRATION RO907
CHLOROTHIAZIDE U CATECHOLAMINES Z N NO EFFECT ON FLUOPOMETRIC METHOD OF CROUT P0235
CHLOPOTHIAZIDE U CITRATE DEC V UP TO 30% DECREASE OBSERVED P0657
CHLOROTHIAZIDE U CREATININE CLEARANCE DEC V REPORTED EFFECT 30596
CHLOHOTHIAZIDE U GLUCOSE INC V DIABETOGENIC-LIKE ACTION OF DRUG AFFECTS GTT P0907
CHLOPOTHIAZIDE U PAH CLEARANCE DEC V COMPETITIVE INHIBITION OP SECRETION P014014
CHLOROTHIAZIDE U SODIUM INC V DIURETIC ACTION P0596
CHLOROTHIAZIDE U URIC ACID DEC V IMPAIRED CLEARANCE P0596
CHLOROTHIAZIDE U URIC ACID INC V IF GIVFN I.V. IN LARGE DOSES HAS URICOSURIC EFFECT 90404
CHLOHOTHIAZIDE U URINALYSIS BILE INC V MAY CAUSE CHOLESTATIC JAUNDICE P0620
CHLOHOTHIAZIDE U 17 KETOGENIC STEROIDS Z N PROB MIN INTERFERENCE WITH ZIMMERMAN REACTION P0907
CHLOHOTHIAZIDE U 17 KETOSTEPOIDS Z M MIN INTERFERENCE WITH ZIMMERMAN REACTION IN VITRO P0133
CHLOROTHIAZIDE U 17 OH COPTICOSTEROIDS INC N INTERFERES WITH PORTER-SILBEP REACTION IN VITRO P1001
CHLOHPHENIRAMINE B WHITE CELL COUNT DEC V LEUKOPENIA (AMA-BLOOD DYSCRASIAS) P0658
CHLORPRONAZINE B EOSINOPHILS INC V OFTEN PRECURSOR OF JAUNDICE P0657
CHLOPPROMAZINE B HEMATOCRIT DEC V HEMOLYTIC ANEMIA 90222
CHLOBPROMAZINE B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA P0222
CHLORPROMAZINE B MONOCYTES INC V OCCASIONALLY BEFORE AGRANULOCYTOSIS P0602
CHLORPROMAZINE B PLATELET COUNT DEC V ASSOC WITH PURPUPA AND PANCYTOPENIA 90026
CHLORPRONAZINE B RED CELL COUNT DEC V HEMOLYTIC ANEMIA 90222
CHLOBPPOMAZINE B WHITE CELL COUNT DEC V AGPANULOCYTOSIS/LEUKOPENIA/GRANULOCYTOPENIA RO602
CHLORPROMAZINE C PROTEIN INC N REACTS AS IF PHENOL WITH FOLIN-CIOCALTEU REAGENT 30907
CHLOPPROMAZINE F UROBILINOCEN DEC V PALE STOOLS, DUE TO CHOLESTASIS R0477
CHLORPHOMAZINE P CATECHOLAMINES INC V INC METABOLISM, DEC ORGAN UPTAKE OF NOPEPINEPHRINE P0355
CHLORPROMAZINE P ERPF INC V SLIGHT INC IN PENAL BLOOD FLOW 903814
CHLORPROMAZINE P GROWTH HORMONE DEC V PHOB INHIBITS SECRETION OF PIT. GROWTH HORMONE P0865
CHLORPROMAZINE P NOREPINEPHRINE INC V INCREASES METABOLISM, DECREASES ORGAN UPTAKE RO384
CHLORPROMAZINE P PROLACTIN INC V MARKED INC IN NORMALS IN 2 HOURS RO9143
CHLORPROMAZINE P PROTHROMBIN TIME INC V ASSOC WITH FAILURE OF EXCRETION OF BILE SALTS R01$77
CHLOPPBOMAZINE S ALKALINE PHOSPHATASE INC V HEPATIC SENSITIVITY TO DRUG (IN UP TO 2% PATIENTS) P0859
CHLOPPROMAZINE S BETA-GLUCUHONIDASE INC V RESULT OF TOXIC HEPATITIS 90990
CHLORPHOMAZINE S BILIRUBIN INC V SENSITIVITY REACTION (MAY CAUSE JAUNDICE IN INFANT) P0859
CHLOHPROMAZINE S BSP RETENTION INC V INDUCES TRANSIENT CHOLESTATIC HEPATITIS (1 CASE) P0271
CHLORPRONAZINE S CHOLESTEROL INC V ASSOC WITH HEPATOCANALICULAR CHOLESTATIC JAUNDICE P0079
CHLORPROMAZINE S COOMBS TEST P05 V IMMUNOLOGICAL RESPONSE TO DRUG R01418
CHLORPPOMAZINE S CPK INC V MAY BE DUE TO INJECTION ONLY (OCCURS IN 20%) P0645
CHLORPHOMAZINE S DIRECT BILIRUBIN INC V SENSITIVITY REACTION TO DRUG (IN UP TO 2% PATIENTS) 90859
CHLOPPROMAZINE S GLUCOSE INC V ABNORMALLY HIGH WITH REPEATED DOSES P014146
CHLOHPROMAZINE S GLUCOSE TOLEPANCE DEC V ABNORMAL CURVES IN 140% PATIENTS R0657
CHLORPRONAZINE S HAPTOGLOBIN DEC V HEMOLYTIC ANEMIA P0620
CHLOHPROMAZINE S lCD INC V MAY BE HYPERSENSITIVE REACTION P0990
CHLOHPHONAZINE S PBI DEC V MECHANISM OBSCURE (OBSERVED IF OVER 600MG GIVEN) P0004
CHLORPROMAZINE S PHI Z V NO EFFECT OBSERVED WITH NORMAL DOSES P0255
CHLORPROMAZINE S PHOSPHOLIPIDS INC V NAY CAUSE XANTHOMATOUS BILIARY CIRRHOSIS R01405
CHLOPPRONAZINE S SCOT INC V HEPATIC SENSITIVITY TO DRUG (IN UP TO 2% PATIENTS) P0859
CHLOPPROMAZINE S SGPT INC V NAY BE DAMAGE OF BILIARY CANALICULI R099O
CHLORPRONAZINE S THYROXINE (T14) DEC V INCREASED METABOLISM BY HEPATIC MICROSOMES 30907
CHLORPROMAZINE S URIC ACID DEC V URICOSURIC ACTION WITHIN 2-3 DAYS P0907
CHLOHPHOMAZINE S VITAMIN R12 DEC N POSSIBLE INHIB EFFECT ON SOME STRAINS E. GRACILIS RO657
CHLORPROMAZINZ T UREA NITROGEN INC N PRODUCES TURBIDITY WITH BEPTHELOT’S REAGENT R0530
CHLOPPROMAZINE U ESTROGENS INC V BLOCKS OVULATION, MAINTAINS DECIDUAL REACTION P03814
CHLORPRONAZINE U GONADOTROPINS DEC V BLOCKS OVULATION, MAINTAINS DECIDUAL REACTION P0384
CHLORPPOMAZINE U METANEPHPINES TOTAL INC N INTERFERENCE IN PISANO PROCEDURE 90125
CHLORPROMAZINE U PHENYLKETONES P05 N LIGHT PURPLE WITH FECL3, SAME WITH PHENISTIX RO239
CHLORPROMAZINE U PORPHOBILINOGEN INC N REACTS WITH EHRLICH’S ALDEHYDE REAGENT P1001
CHLORPPOMAZINE U PREGNANCY TESTS P05 N GIVES FALSE P05 WITH FROG, RABBIT AND IMMUNOL TEST R0907
CHLOHPROMAZINE U PROCESTINS DEC V BLOCKS OVULATION, MAINTAINS DECIDUAL REACTION P0384
CHLOPPROMAZINE U URIC ACID INC V URICOSUHIC ACTION REPORTED R0596
CHLORPPOMAZINE U URINALYSIS BILE INC N ALLEGED INTERFERENCE WITH BILI-LABSTIX P01417
CHLORPROMAZINE U URINALYSIS PROTEIN INC N AFFECTS TURBIDITY TESTS FOR UP TO 3 DAYS P0020
CHLORPPOMAZINE U UROBILINOGEN DEC V MAY B! CHOLESTASIS P01477
CHLORPPOMAZINE U UROBILINCGEN INC N REACTS WITH ERHLICH’S ALDEHYDE REAGENT P1001
CHLORPROMAZINE U VMA INC V INC METAB AND DEC ORGAN UPTAKE OF NOREPINEPHRINE P1001
CHLOPPROMAZINE U VOLUME INC V ?DEPRESSES ADH SECRETION OR WATER REABSORPTION R0384
CHLORPPONAZINE U 17 KETOGENIC STEROIDS INC N INTERFEPES WITH ZIMMERMAN REACTION R0907
CHLORPROMAZINE U 17 KETOSTEROIDS DEC V INHIBIT OF HYPOTHALAMUS AND DEC ACTH SECRETION HO359
CHLORPROMAZINE U 17 KETOSTEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION RO907
CULORPRONAZINE U 17 KETOSTEHOIDS INC V ALTERS STEROID METABOLISM P0133
CHLORPRONAZINE U 17 OH CORTICOSTEROIDS DEC V INHIBIT OF HYPOTHALAMUS AND DEC ACTH SECRETION P0359
CHLORPROMAZINE U 17 OH CORTICOSTEROIDS INC N INTERFERES WITH PORTER-SILBEP REACTION P0133
CHLORPPONAZINE U S OH INDOLEACETIC ACID DEC N INTERFERES WITH METHOD OF GOLDENBEPG P0374
CHLORPROPAMIDE B COPPOPORPHYRIN INC V MAY PRECIPITATE CUTANEOUS PORPHYRIA P0371
CHLOHPROPAMIDE B EOSINOPHILS INC V ALLERGIC RESPONSE P0424
CHLORPROPAMIDE B HEMATOCRIT DEC V MILD ANEMIA, HARE APLASTIC ANEMIA 90733
CHLORPROPANIDE B HEMOGLOBIN DEC V MILD ANEMIA, PARE APLASTIC ANEMIA P0733

CHLOHPHOPAMIDE B PLATELET COUNT DEC V THROMBOCYTOPENIA OR APLASTIC ANEMIA MAY OCCUR P0024
CHLORPROPANIDE B PROTOPORPHYRIN INC V NAY PRECIPITATE CUTANEOUS PORPHYRIA P0371
CHLOHPROPAMIDE B RED CELL COUNT DEC V MILD ANEMIA, RARE APLASTIC ANEMIA P0733
CHLOPPROPAMIDE B WHITE CELL COUNT DEC V AGPANULOCYTOSIS P0984
CHLORPROPAMIDE B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA OF HYPERSENSITIVITY P0620
CHLORPROPANIDE F COPROPORPHYRIN INC V MAY PRECIPITATE CUTANEOUS PORPHYRIA P0371
CHLORPROPAMIDF P OCCULT BLOOD P05 V ASSOCIATED WITH SEVERE DIARRHEA AND BLEEDING P0733
CHLORPROPAMIDE F PROTOPORPHYRIN INC V MAY PRECIPITATE CUTANEOUS PORPHYRIA P0371
CHLORPROPAM!DE F UROBILINOGEN DEC V PALE STOOLS DUE TO CHOLESTASIS(INFREQUENT) P01477
CHLORPROPAMIDE P INSULIN INC V EFFECT OBSERVED DUPING TOLERANCE TEST P0600
CHLOPPROPAMIDE P PPOTHROMBIN TIME INC V ASSOC WITH FAILURE OF EXCRETION OF BILE SALTS P01477
CHLOHPROPAMIDE S ALKALINE PHOSPHATASE INC V INFREQUENT INTPAHEPATIC CHOLESTASIS P01477
CHLOBPPOPAMIDE S BILIPUBIN INC V CHOLESTATIC JAUNDICE OF ALLERGIC NATURE MAY OCCUR R0417
CHLORPROPAMIDE S 135P RETENTION INC V INFREQUENT CHOLESTATIC EFFECT P01477
CHLOPPROPAMIDE S CEPHALIN FLOCCULATION INC V HEPATOCELLULAP DAMAGE, AFFECTS PROTEIN SYNTHESIS P0620
CHLOPPHOPAMIDE S CHOLESTEROL DEC V NAY INHIBIT HEPATIC SYNTHESIS (?ALSO ABSORPTION) P0596
CHLORPROPAMIDE S CHOLESTEROL INC V INFREQUENT CHOLESTATIC EFFECT P0477
CHLORPROPA!IDE S COOMBS TEST P05 V IMMUNOLOGICAL RESPONSE TO DRUG P01418
CHLORPROPAMIDE S GLUCOSE DEC V SULFONYLUREA DERIVATIVE PROMOTES INSULIN SECRETION P0733
CHLORPPOPAMIDE S GUANASE INC V MAY CAUSE CYTOTOXIC LIVER DAMAGE P0079
CHLORPROPAMIDE S OCT INC V MAY CAUSE CYTOTOXIC LIVER DAMAGE P0079
CHLORPROPAMIDE S PHI DEC V QUESTIONABLE EFFECT (MAY BE SLIGHT IN DIABETICS) P0004
CHLORPPOPAMIDE S SCOT INC V MAY CAUSE CYTOTOXIC LIVER DAMAGE P0079
CHLORPPOPAMIDE S SCPT INC V NAY CAUSE CYTOTOXIC LIVER DAMAGE P0079
CRLOHPPOPANIDE S SODIUM DEC V INDUCES INAPPROPRIATE ADH SECRETION P0979
CHLOPPPOPAMIDE S THYMOL TURBIDITY INC V MAY CAUSE CYTOTOXIC LIVER DAMAGE P0620
CRLOHPROPAMIDE S THYROXINE (TL4) DEC V DISPLACES THYROXINE FROM TBG RO907
CHLORPROPAMIDE S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS P01492
CHLOPPROPAMIDE U ADH INC V STIMULATES RELEASE FROM NEUPOHYPOPHYSIS P0357
CHLORPROPAMIDE U AMINOLEVULINIC ACID INC V MAY PRECIPITATE CUTANEOUS PORPHYRIA R0371
CRLOPPPOPANIDE U OSMOLALITY INC V IN PATIENTS WITH DIABETES INSIPIDUS P0840
CHLORPROPAMIDE U PORPHOBILINOGEN INC V MAY AGGRAVATE CUTANEOUS PORPHYRIA R0371
CHLORPROPANIDE U PROTEIN INC V NEPHROTOXIC EFFECT P09614
CHLORPPOPAMIDE U PROTOPORPHYRIN INC V NAY PRECIPITATE CUTANEOUS PORPHYRIA P0371
CHLORPROPAMIDE U URINALYSIS BILE INC V CHOLESTATIC JAUNDICE H0O29
CHLOPPROPAMIDE U URINALYSIS PROTEIN INC V NEPHHOTOXIC EFFECT P0964
CHLORPPOPAMIDE U UROBILINOGEN DEC V CHOLESTASIS MAY OCCUR INFREQUENTLY R0477
CHLOHPHOPAMIDE U UHOPORPHYRIN INC V MAY PRECIPITATE CUTANEOUS PORPHYRIA P0371
CHLOPPROPANIDE U VOLUME DEC V IN PATIENTS WITH DIABETES INSIPIDUS P0840
CRLOHPPOTHIXENE P LE CELL PREP P05 V MAY PRODUCE LE-LIKE SYNDROME P0910
CHLORPROTHIXENE B WHITE CELL COUNT DEC V POSSIBLE HEMATOLOGICAL DISORDER P0384
CHLORPROTHIXENE S ALKALINE PHOSPHATASE INC V HEPATOTOXICITY (REVERSIBLE) P0620
CHLOPPHOTHIXENE S PILIRUBIN INC V HEPATOTOXICITY (REVERSIBLE) P0620
CHLORPROTHIXENE S BSP RETENTION INC V MAY CAUSE HEPATOTOXICITY (REVERSIBLE) P0620
CHLORPROTHIXENE S CEPHALIN FLOCCULATION INC V MAY CAUSE HEPATOTOXICITY (REVERSIBLE) P0620
CHLORPROTHIXENE S SGOT INC V MAY CAUSE HEPATOTXICITY (REVERSIBLE) P0620
CHLORPROTHIXENE S SGPT INC V NAY CAUSE HEPATOTOXICITY (REVERSIBLE) P0620
CHLOPPROTHIXENE S THYNOL TURBIDITY INC V MAY CAUSE HEPATOTOXICITY (REVERSIBLE) P0620
tHLOPPROTRIXENE S URIC ACID DEC V URICOSUPIC EFFECT WITHIN 2-3 DAYS OF START OF DRUG P0907
CHLORPROTHIXENF U BILIRUBIN INC V MAY CAUSE HEPATOTOXICITY (REVERSIBLE) R0620
CHLOPPROTHIXENF U URIC ACID INC V URICOSURIC ACTION P0430
CHLOPPHOTHIXENE U URINALYSIS PILE INC V MAY CAUSE HEPATOTOXICITY (REVERSIBLE) P0355
CHLORTETRACYCLINE B PLATELET COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0658
CHLOPTETPACYCLINE P RED CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0658
CHLORTETRACYCLINE B WHITE CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCPASIAS) P0658
CHLOPTETRACYCLINE S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT WITH CENTHOLOBULAP NECROSIS R0355
CHLORTETRACYCLINE S BILIRUBIN INC V HEPATOTOXIC EFFECT WITH CENTROLOBULAR NECROSIS P0355
CHLORTETRACYCLINE S BSP RETENTION INC V HEPATOTOXIC EFFECT WITH CENTROLOBULAR NECROSIS P0654
CHLOHTETRACYCLINE S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT WITH CENTROLOBULAP NECROSIS P0355
CHLORTETRACYCLINE S CHOLESTEROL DEC V HEPATOTOXIC EFFECT WITH CENTROLOBULAP NECROSIS P0356
CHLOPTETRACYCLINE S NPN INC V EFFECT OBSERVED IN MALNOURISHED P03814
CHLORTETRACYCLINE S SGOT INC V HEPATOTOXIC EFFECT WITH CENTPOLOBULAH NECROSIS P0355
CHLOPTETRACYCLINE S SGPT INC V HEPATOTOXIC EFFECT WITH CENTHOLOBULAR NECROSIS P0355
CHLORTETRACYCLINE S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT WITH CENTROLOBULAR NECROSIS P0355
CHLOPTETRACYCLINE U CATECHOLAMINES INC N INTERFERENCE WITH FLUOPOMETRIC METHODS P0691
CHLORTETHACYCLINE U FOLATE INC V WITH DOSE OF 3G/DAY P03814
CHLOPTETRACYCLINE U N-METHYLNICOTINAMIDE INC V WITH DOSE OF 3G/DAY P0384
CHLOHTFTRACYCLINE U NITROGEN INC V EFFECT OBSERVED IN MALNOURISHED P0384
CHLORTETRACYCLINE U RIBOFLAVIN INC V WITH DOS! OF 3G/DAY R03814
CHLORTETRACYCLINE U URINALYSIS BILE INC V HEPATOTOXIC EFFECT WITH CENTROLOBULAP NECROSIS R0355
CHLORTETRACYCLINE U URINALYSIS SUGAR INC N ACTS AS REDUCING SUBSTANCE 90356
CHLOPTHALIDONE B NEUTHOPHILS DEC V FEW CASES REPORTED P0657
CHLORTHALIDONE B PLATELET COUNT DEC V ASSOCIATED WITH PARE AGRANULOCYTOSIS P0657
CHLORTHALIDONE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS R0537
CHLORTHALIDONE P ADH INC V SECRETED IN RESPONSE O HYPONATHENIA P0325
CHLOTHALIDONE P AMMONIA INC V PARTIALLY DUE TO DECRESED POTASSIUM AND ALKALOSIS P0036
CHLOPTHALIDONE P PROTHROMBIN TIME INC V PATIENTS ON COUMARINS P0656
CHLORTHALIDONE S AMYLASE INC V MAY PRECIPITATE ACUTE PANCPEATITIS R0503
CHLORTHALIDON! S CO2 CONTENT INC V METABOLIC ALKALOSIS IN SEVERE CASES P0325
CHLORTHALIDONT S CHEATININE INC V NEPHROTOXIC EFFECT R0596
CHLORTHALIDONE S GLUCOSE INC V DIABETOGENIC-LIKE ACTION AFFECTS PRE- OP DIABETIC P0033
CHLORTHALIDONE S GLUCOSE TOLERANCE DEC V DIABETOGENIC-LIKE ACTION OF DRUG P0723
CHLOHTHALIDONE S OSMOLALITY DEC V WITH ADH SECRETION IN RESPONSE TO DIURESIS P0325
CHLORTHALIDONE S POTASSIUM DEC V DIURETIC INDUCED DEPLETION R0355
CHLORTHALIDONE S SODIUM DEC V SEVERE HYPONATREMIA WITH K DEPLETION P0325
CHLORTHALIDONE S UREA NITROGEN INC V NEPHROTOXIC EFFECT P0021
CHLORTHALIDONE S URIC ACID INC V DECREASES URATE CLEARANCE P0159
CHLOPTHALIDONE U CHLORIDE INC V MAY PRODUCE MARKED DIURESIS P0657
CHLORTHALIDONE U GLUCOSE INC V DIABETOGENIC-LIKE ACTION OF DRUG AFFECTS GTT R0907
CHLORTHALIDONE U POTASSIUM INC V MAY PRODUCE MARKED DIURESIS P0657

CULORTHALIDONE U PROTEIN INC V NEPHPOTOXIC EFFECT RC355
CHLOPTHALIDONE U SODIUM INC , V MAY PRODUCE MARKED DIURISIS R0657
CHLCP.THALIDONE U URIC ACID DEC V DECREASED CLEARANCE P0596
CHLCFTHALIDONE U URINALYSIS GLUCOSE INC V DIABETOGENIC-LIKE ACTION OF DRUG AFFECTS GTT RO91C
CFLORTPALIDONE U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT P0355
CFLOBTHALIDONE U VOLUME INC V MAY PRODUCE MARKED DIURESIS P0657
CHLORTHALIDONE U 17 KETOSTEROIDS INC V ALLEGED INCREASED EXCRETION R0417
HLOFTHALIDONE U 17 OH COPTICOSTEROIDS INC V REPORTED EFFECT P0596
HLORZOXAZONE S ALKALINE PHOSPHATASE INC V PlAY CAUSE HEPATOTOXICITY P0620
CELORLOXAZ0N S BILIPUBIN INC V MAY CAUSE BEPATOTOXICITY P0620
HLCPZOXAZCNE S BSP PETENTION INC V MAY CAUSE HEPATOTOXICITY P0620
:ELoRzoxAzoNi S CEPHALIN FLOCCULATION INC V NAY CAUSE HEPATOTOXICITY R0620
CULOPZOXAZONE S SGOT INC V MAY CAUSE HEPATOTOXICITY RC620
CHLORZOXZONE S SGPT INC V MAY CAUSE HEPATOTOXICITY P0620
HLOPZOXAZONE S THYNOL TURBIDITY INC V MAY CAUSE HEPATOTOXICITY RC620
CHLORZOXAZONE U URINALYSIS BILE INC V MAY CAUSE HEPATOTOXICITY R0299
C1!Lo:ZoxAzoNE U URINALYSIS COLOR INC N PINK, RED. PURPLE OR RUST R0299
CHOCOLATT U VMA INC M CATECHOLS IN CHOCOLATE P0355
CHOLERETICS S BSP RETENTION INC V REPORTED EFFECT (?COMPETITION FOR EXCRETION) R0299
CHOLESTANOL S CHOLESTEROL INC N YIELDS YELLOW COLOR WITH ZLATKIS-ZAK METHOD P0436
CHOLESTEROL B SEDIMENTATION RATE INC N PROBABLY BY INCREASING VISCOSITY P0143
CHOLESTEROL P TESTOSTERONE INC M AT 1-20 UG AFFECTS COMPETITIVE BINDING METHOD P0269
HOLESTEROL P 11 OH CORTICOSTEROIDS INC N DUE TO NON-SPECIFIC FLUORESENCE P0389
CHOLESTYRANINE B HEMOGLOBIN DEC V IMPAIRS ABSORPTION OF IRON P0540
CHOLESTYPANINE . B WHITE CELL COUNT DEC V POSSIBLE RELATIONSHIP TO DRUG ADMINISTRATION P0467
CHOLESTYHAMINE P PPOTHHOMBIN TIME INC V COMBINES WITH BILE ACIDS (VIT K NOT ABSORBED) P0270
HOLESTYRANINE S ALPHA-TOCOPHEROL DEC V ?INHIBITS SYNTHESIS OF CARRIER LIPOPROTEIN P0978
CHOLESTYRAMINF S BETA-LIPOPROTEINS DEC V BUT DOES NOT AFFECT VERY LOW-DENSITY LIPOPROTEINS P0384
CHOLESTYRAMINE S BSP RETENTION INC V FEW CASES REPORTED PROB NOT HEPATOTOXICITY P0467
CHOLESTYHANINE S CHLORIDE INC V IS CHLORIDE SALT OF BASIC ANION EXCHANGE RESIN P1OC1
CHOLISTYRANINE
CHOLESTYRANINE
CIIOLESTYRAMINE
S
S
S
CHOLESTEROL
IRON DEC
PHOSPHOLIPIDS
DEC
DEC
V
V
V
THERAPEUTIC
IMPAIRS
THERAPEUTIC
GOAL
ABSORPTION
EFFECT
(?INC
OF
BIND
IRON
OF BILE
. SALTS IN GUT) P0465
P0540
P0596
CHOLESTYRAMINE S SCOT INC V FEW CASES REPORTED PROB NOT HEPATOTOXICITY P0467
CHOLLSTYRANINL S SGPT INC V FEW CASES REPORTED PPOB NOT HEPATOTOXICITY P0467
CHOLESTYRAMINE S THYROXINE (T14) DEC V DECREASED INTESTINAL ABSORPTION OF THYROXINE P0907
CHOLESTYRANINE S TOTAL LIPIDS DEC V LOWERS BILE ACIDS BY IONIC BINDING R0620
CI4OLESTYRANINE S TRIGLYCERIDES DEC V THERAPEUTIC EFFECT P0596
CHOLFSTYPANINT S TRIGLYCERIDES INC V MECHANISM OBSCURE (MAY OCCUR IN DIABETICS) P0504
CHOINSTYPAMINE S VITAMIN A Z V ABSORPTION NOT SIGNIFICANTLY IMPAIRED P0657
CEOLESTYRAMINE U CALCIUM INC V BINDS HEAVY METALS RC299
CH0LINrFGICS S ANYLASE INC V CAUSE SPASM OF SPHINCTER OF ODDI P0042
CHOLIt4TPGICS S BILIRUBIN INC V IMPAIRED EXCRETION DUE TO SPASM OF SPHINCTER P0204
CHOLINEP.GICS S HSP RETENTION INC V IMPAIRED EXCRETION DUE TO SPASM OF SPHINCTER P02014
CHOLINERGICS S LIPASE INC V IMPAIRED EXCRETION-SPASM OF SPHINCTER OP ODDI P0384
CHOLINERGICS S SGCT INC V IMPAIRED EXCRETION DUE TO SPASM OF SPHINCTER P02014
HPYSAROBIN U URINALYSIS COLOR INC N OXIDATION PRODUCT COLORS ALKALINE URINE RED RC384
CHPYSAROBIN U URINALYSIS PROTEIN INC V KIDNEY IRRITATION BY METABOLITE R0C26
CINCHOPHEN B WHITE CELL COUNT DEC V LEUKOPENIA OP AGRANULOCYTOSIS MAY OCCUR P0658
ZIN2HOPHEN S ALKALINE PHOSPHATASE INC V MAY CAUSE INTRAHEPATIC CHOLESTASIS P0620
CINHOPHFN S BILIRUBIN INC V NAY CAUSE HYPERSENSITIVE CHOLESTASIS R062C
CINCHOPHEN S BSP RETENTION INC V MAY CAUSE HEPATOTOXICITY (VIRAL-HEPATITIS LIKE) P0620
INCHOPHIN S CEPHALIN FLOCCULATION INC V NAY CAUSE HEPATOTOXICITY (VIRAL-HEPATITIS LIKE) P0620
CINCH0PHN S CHOLESTEROL INC V MAY CAUSE INTRAHEPATIC CHOLESTASIS P0405
CINCHOPHEN S SCOT INC V MAY CAUSE HEPATOTOXICITY (VIRAL-HEPATITIS LIKE) P0620
CINCHOPHEN S SGPT INC V NAY CAUSE HEPATOTOXICITY (VIRAL-HEPATITIS LIKE) P0620
CINCHOPHEN S THYNOL TURBIDITY INC V NAY CAUSE HEPATOTOXICITY (VIRAL-HEPATITIS LIKE) R0620
CINCHOPHEN S URIC ACID DEC V URICOSURIC ACTION P0620
CINCHOPHEN U URINALYSIS BILE INC V NAY CAUSE HEPATOTOXICITY (VIRAL-HEPATITIS LIKE) P0620
CINHOPHEN U URINALYSIS COLOR INC N RED BROWN P0620
CINCHOPHEN U URINALYSIS SUGAR INC M ACTS AS A REDUCING SUBSTANCE P0654
2ITPATFS B PH DEC N SIGNIFICANT EFFECT OF NA CITRATE AS ANTICOAGULANT R0181
CITRATES B PH DEC V SIGNIFICANT ACID SHIFT PRODUCED P0354
CITRATFS B PH INC V RESTORES BICARB RESERVE, MAY CAUSE ALKALOSIS P0026
CITRATES S AMYLASE DEC N INHIBITION OF ENZYME ACTIVITY P0635
TTRATFS S CALCIUM DEC V COMPLEXES CALCIUM P0620
CITRATES S HBD Z N NO EFFECT ON ACTIVITY P0779
CITHATES S IONIZED CALCIUM DEC V COMPLEXES CALCIUM (EFFECT OP TRANSFUSIONS) P0743
CITRATES S MAGNESIUM DEC V COMPLEXES MG (MAY OCCUR WITH BLOOD TRANSFUSIONS) P0094
ITRATTS S PH DC N IN VITRO ADDITION OF NA SALT TO PLASMA/SERUM P0035
ITRATaS S URIC ACID INC V ANTAGONISM OF UPICOSUPIC EFFECT P0355
CITATNS U URIC ACID DEC V ANTAGONISM OF UPICOSURIC EFFECT R0355
CITRAT?S U VOLUME INC V WEAK DIURETIC EFFECT R0026
CLTNDAMYCIN B EOSINOPHILS INC V OCCASIONAL ALLERGIC RESPONSE P0735
CLINDANYCIN B WHITE CELL COUNT DEC V MAY CAUSE AGRANULOCYTOSIS RC736
CLINDANYCIF S ALKALINE PHOSPHATASE INC V TRANSIENT ABNORMALITY NOTED P09149
CLINOAMYC:N S BILIRUBIN INC V OCCURS ESPECIALLY IF PREEXISTING LIVER DISEASE P0735
CLINDAMYCIr S SCOT INC V TRANSIENT ABNORMALITY NOTED P0949
CLNDAMYCIN S SGPT INC V MILD TRANSIENT RISES SEEN P0735
LIOQUINOL B NEUTROPHILS INC V TOXIC EFFECT REPORTED P0921
CLI000INOL S PBI INC N IS AN ORGANIC IODINE COMPOUND P0596
CLO?IBRAT 3 EUGLOBULIN LYSIS TIME DEC V REPORTED OBSERVATION P0657
LOFIBPATE P WHITE CELL COUNT DEC V MAY CAUSE LEUKOPENIA P0784
CLOF IPHATS ? BILE ACIDS DEC V AFTER TWO WEEKS TREATMENT SIGNIFICANT FALL P0668
CLOFIBRATE F NEUTRAL STEROIDS DEC V AFTER TWO WEEKS TREATMENT FALL OBSERVED P0668
CLOFIBTATE P FIERINOGEN DEC V REPORTED OBSERVATION IN SOME CASES RC195
CLOFIBSAT P PROTHHOMBIN TIME INC V DISPLACES ANTICOAGULANTS FROM BINDING PROTEIN RO7QJ
CLOFIBPAT S ACID PHOSPHATASE TOTAL INC V REPORTED EFFECT (?MECHANISM) P0299
:LoFIBRAT S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT R0620
CLOFIBRAT S ALPHA-TOCOPHEROL DEC V ?INHIBITS SYNTHESIS OF CARRIER LIPOPROTEIN P0978

CLOFIBRAT! S BETA-LIPOPROTEINS DEC V THERAPEUTIC EFFECT (MECHANISM DISPUTED) P0026
CLOTIBRATE S RILIRUBIN INC V HEPATOTOXIC EFFECT P0620
CLOFIBPAT! S BSP RETENTION INC V INTRAIIEPATIC CHOLESTASIS REPORTED HO 299
CLOFIBRATE S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT P06 20
CLOFIBRAT! S CHOLESTEPOL DEC V THERAPEUTIC GOAL (PROBABLY DIMINISHED SYNTHESIS) HO 141
CLOFIBRATE S CHOLESTEROL INC V PARADOX EFFECT IN PATIENTS WITH BILIARY CIRRHOSIS P0750
CLOFIBR ATE S CPK INC V ORIGINATES FROM SKELETAL MUSCLE (IN UP TO 15%) P0907
CLOFIBRATE S CREATININE INC V POSSIBLY DERIVED FROM MUSCLE DAMAGE (IN 15%) P0596
CLOFI BRAT! S GLUCOSE TOLERANCE INC V IMPROVEMENT REL TO DEC OF ABNORMAL TRIGLYCERIDES 90099
CLOFIBRATF S LACTIC DERYDROGENASE DEC V POSSIBLY DERIVED FROM MUSCLE DAMAGE P0 596
CL OF! B PATE S NEFA DEC V DISPLACEMENT FROM ALBUMIN HO 384
CLDFI BRAT! S PHOSPHOLIPIDS DEC V EFFECT LESS MARKED THAN WITH TRIGLYCERIDES HO 141
CLOFIBRATT S PREBETA-LIPOPPOTEINS DEC V THERAPEUTIC INTENT P0057
CLOFIBHATE S PROTEIN INC V REPORTED EFFECT, MECHANISM NOT DISCUSSED P068 3
CLOFIB PATE S SGOT INC V TRANSIENTLY ELEVATED DURING EARLY THERAPY R0099
CLOFIBRATE S SGPT INC V HEPATOTOXIC FFFECT P0620
CLOFIBRATE S TBG INC V INCREASES CONCENTRATION P 0907
CLOFI BRAT! S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT P0620
CLOFIBRATE S TOTAL LIPIDS DEC V NORMAL RESPONSE (NAY INCREASE IN DIABETICS) P0657
CLOFIBRATE S TRIGLYCERIDES DEC V INHIBITS TRANSFER FROM LIVER TO PLASMA R0141
CLOFIBP ATE S URIC ACID DEC V OCCURS IN ABOUT 10% (MAY OCCASIONALLY CAUSE GOUT) P00 16
CLOFIBPAT! U URIC ACID INC V WEAK TRANSIENT UPICOSUPIC EFFECT P0026
CLOFIBRATE U URINALYSIS BILE INC V HEPATOTOXIC EFFECT P06 20
CL OF! B PA TE U VNA DEC N DUE TO INTERFERING GLUCUPONIDES OF DRUG P08 12
CLOMIPHENE P ANDPOSTENEDION! INC V LIBERATES LH,ANTI-STEROID HORMONE EFFECT OF DRUG HO 193
CLONIPHENE P DEHYDROEPIANDROST 5014 INC V LIBERATES LH,ANTI-STEROID HORMONE EFFECT OF DRUG P0193
CLOMIPHENE P DEHYDROEPIANDROSTERONE INC V LIBERATES LFI,ANTI-STEROID HORMONE EFFECT OF DRUG HO 193
CLOMIPH EN! P ESTRADIOL INC V INC IN BOTH FOLLICLILAP AND LUTEAL PHASES OVER NORM R0783
CLOPIIPHENE P ESH INC V MAXIMUM INC OF 350% OF CONTROL IN MALES P0820
CLOMI PHENE P LH INC V UP TO 700% IN NORMAL MALES FOP FIRST 21 DAYS P0820
CLOMI PH EN! P PROGESTERONE INC V INC OVER NORMAL IN LUTEAL PHASE P0783
CLOMIP HEN! P TESTOSTERONE INC V LIBERATES LH,ANTI-STEROID HORMONE EFFECT OF DRUG HO 193
CLOMI PH EN! S 359 RETENTION INC V MAY CAUSE HEPATOTOXICITY P0 3 55
CLOMIPHEN! S CHOLESTEROL DEC V POSSIBLE INTERFERENCE WITH SYNTHESIS P00 26
CLOMI #{176}HENE U ESTROGENS INC V DUE TO ACTION ON HYPOTHALAMIC-PITUITARY AXIS P069 3
CLOMIPHENE U FSH INC V DUE TO ACTION ON HYPOTHALAMIC-PITUITARY AXIS P0693
CLOMIPHENE U LH INC V DUE TO ACTION ON HYPOTHALAMIC-PITUITARY AXIS R0693
CLDMIPHENE U TESTOSTERONE INC V LIBERATES LH,ANTI-STEPOID HORMONE EFFECT OF DRUG P0073
CLONIDINE 0 SALIVARY POTASSIUM INC V MECHANISM NOT DISCUSSED RO127
CLONIDINE 0 SALIVARY VOLUME DEC V MECHANISM NOT DISCUSSED HO 127
CLONID INE P RENIN DEC V DOSE RELATED EFFECT(2NDPY TO ACT OF CATECHOLANINES) 901455
CLONID!NE S ALKALINE PHOSPHATASE INC V SINGLE PROBABLE CASE OF TOXIC HEPATITIS P03 65
CLONID IN! S BILIRUBIN INC V TOXIC HEPATITIS REPORTED HO 365
CLONI DINE S BSP RETENTION INC V SINGLE PROBABLE CASE OF TOXIC HEPATITIS P03 65
CLONIDINE S CPK INC V TEMPORARY EFFECT OF UNKNOWN SIGNIFICANCE 90365
C LO NI DI NE S CREATININE INC V APPROXIMATELY 0. 1MG/i OOML Ri 016
CLONIDINE S INDIRECT COOMBS TEST P05 V MECHANISM NOT DISCUSSED RiO 16
CLONIDI N! S SCOT INC V SINGLE PROBABLE CASE OF TOXIC HEPATITIS HO 36 5
‘CLONIDINE S SGPT INC V SINGLE PROBABLE CASE OF TOXIC HEPATITIS HO 365
CLONI DI NE S SODIUM INC V PROBABLE DIRECT ACTION ON PENAL TUBULES P03 814
CLONIDINE S UREA NITROGEN INC V ASSOCIATED WITH DECREASED GER AT START OF THERAPY P0773
CLONID IN? U ALDOSTEPONE DEC V SECONDARY TO EFFECT ON RENIN P01455
CLONIDIN? U CATECHOLANINES DEC V DOSE RELATED EFFECT (PRIMARY ACTION OF DRUG) P01455
CLONIDINE U EPINEPHRINE DEC V PRIMARY ACTION OF DRUG P01455
CLONIDINE U NOP!PINEPHPINE DEC V DOSE RELATED EFFECT (PRIMARY ACTION OF DRUG) P0455
CLONID IN! U PAR CLEARANCE INC V NONSIGNIFICANT EFFECT IN HYPERTENSIVES P0 127
CLONI DINE U VMA DEC V DOSE RELATED EFFECT P014 55
CLOPAMIDE S GLUCOSE TOLERANCE DEC V POSSIBLE EFFECT OF HYPOKALEMIA P1002
CLOPAMIDE S POTASSIUM DEC V RESULT OF DIURETIC ACTION Ri 002
CLOPAN ID! U CHLORIDE INC V DIURETIC ACTION P076 1
CLOPA MID! U POTASSIUM INC V DIURETIC ACTION HO 76 1
CLOPAM IDE U SODIUM INC V DIURETIC ACTION (RAPID EFFECT) P076 1
CLOPA MID! U VOLUME INC V DIURETIC ACTION P076 1
CLOPENTHIXOL S GLUCOSE INC V GLYCOSFMIC EFFECT REPORTED RO657
CLOHEX OLONE S GLUCOSE INC V DIABETOGENIC ACTION P06 20
CLOPEXOLONE S POTASSIUM DEC V DIURETIC ACTION P06 57
CLOWEX OLON! S URIC ACID INC V OCCURS AS WITH THIAZIDE DRUGS P0657
CLOXAC’LLIN B EOSINOPHILS INC V HYPERSENSITIVITY RESPONSE P04 24
CLOXAC ILLIN B WHITE CELL COUNT DEC V MAY CAUSE LEUKOPENIA RO 620
CLOXACILLIN B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA OF HYPERSENSITIVITY P062 0
CLOXAC ILL IN S SCOT INC V FEW CASES REPORTED ?DUE TO I.M. INJECTION P00 26
CLOXACILLIN U 17 KETOSTEHOIDS INC N INTERFERES WITH ZIMMERMAN REACTION HO 907
COBALT SALTS S I 131 UPTAKE DEC V REPORTED EFFECT HO 596
COBALT SALTS S PBI DEC V CAUSE DECREASE, POSSIBLY TO EXTENT OF GOITER P03 84
CO CO A P CATECHOLAMINES INC V CATECHOLS PRESENT IN eOCOA HO 188
C 0 DEl N! B PCO2 INC V NAY CAUSE RESPIRATORY DEPRESSION P0384
CODEINE S AMYLASE INC V MAY CAUSE SPASM OF SPHINCTER OF ODDI HO 384
CODEINE S LACTIC DEHYDROGENASE INC V MAY CAUSE RISE IN INTPABILIAPY PRESSURE P0907
CODEINE S LIPASE INC V CAUSES SPASM OF SPHINCTER OF ODDI P0977
CODEINE 5 SCOT INC V MAY CAUSE RISE IN INTRABILIAPY PRESSURE HO 907
CODEINE S SGPT INC V NAY CAUSE RISE IN INTRABILIAPY PRESSURE R0907
COFFEE S NEFA INC V POSSIBLY DUE TO STRESS EFFECT P0657
COFFEE S URIC ACID INC N COMPONENT OF COFFEE MEASURED (METHOD OF BITTNER) P0724
COFFEE U UROBILINOGEN INC N ACETYLTRYPTOPHAN PRODUCED REACTS WITH ERRLICH’S HO (436
COFFEE U VNA INC N INTERFERENCE WITH NONSPECIFIC METHODS P07 13
COFFEE U U-HYDROXYBENZOIC ACID INC V POSSIBLE EFFECT OF BACTERIAL METABOLISM P08 58
COLCHICINE B HEMATOCRIT DEC V NEGALOBLASTIC ANEMIA(IMPAIPED ABSORP B12) HO 976
COLCHICINE B HEMOGLOBIN DEC V NEGALOBLASTIC ANENIA(IMPAIHED ABSOHP B12) P0976
C OLC HI C IN! B MCV INC V MEGALOBLASTIC ANEMIA WITH B12 DEFICIENCY P0976
COLCHICINE B PLATELET COUNT DEC V SELECTIVE THROMBOCYTOPENIA OR APLASTIC ANEMIA RO656

COLCHICINE B RED CELL COUNT DEC V MEGALOBLASTIC ANEMIA (IMPAIRED ABSORP B12) P0976
COLCHICINE B WHITE CELL COUNT DEC V LEUKOPENIA P0656
COLC HICINE B WHITE CELL COUNT INC V LEUKOCYTOSIS FOLLOWS INITIAL LEUKOPENIA P0 3814
COLCHICINE F OCCULT BLOOD P05 V TOXICITY EFFECT P0620
COLCHICI NE P PHOTHHOMBIN TIME DEC V PATIENTS ON COUMA PINS P0656
C0LC BIT IN! S ALKALINE PHOSPHATASE INC V POSSIBLE HEPATOTOXIC EFFECT P0596
COLCHICINE S BILIHUBIN INC V MAY CAUSE HEPATIC TOXICITY P0620
COLCHICINE S BSP RETENTION INC V MAY CAUSE HEPATIC TOXICITY P0620
COLCHICINE S CEPHALIN FLOCCULATION INC V MAY HAVE HEPATOTOXIC EFFECT P0620
COLC HICINE S CHOLESTEROL DEC V NAY HAVE HEPATOTOXIC EFFECT HO 804
COLCHICINE S SGOT INC V POSSIBLE HEPATOTOXIC EFFECT HO 596
COLC HICI NE S SGPT INC V POSSIBLE HEPATOTOXIC EFFECT HO 596
COLCHICINE S THYMOL TURBIDITY INC V MAY HAVE HEPATOTOXIC EFFECT H 0620
COLCHICINE S VITAMIN B12 DEC V IMPAIRS ABSORPTION P0 976
COLCHICI NE U AICAR INC V MEGALOBLASTIC ANEMIA WITH B12 DEFICIENCY P0976
COLCHICINE U FIGLU INC V MEGALOBLASTIC ANEMIA WITH B12 DEFICIENCY H 0976
COLC HICI NE U METHYLMALONATE INC V OCCURS WITH IMPAIRED ABSORPTION OF B12 P0976
COLC BICI NE U URINALYSIS BILE INC V MAY CAUSE HEPATOTOXICITY P0620
COLC HICINE U URINALYSIS HEMOGLOBIN INC V NAY CAUSE BLEEDING P0620
COLCHICINE U URINALYSIS RBC/HPF INC V MAY CAUSE BLEEDING P0620
CDLCHICINE U VITAMIN B12 DEC V OCCURS WITH IMPAIRED ABSORPTION OF B12 HO 976
COLC HICINE U XYLOSE EXCRETION DEC V DEC ABSORP FROM GUT, DISTURBS EPITHEL CELL FUNCTION H 0760
COLC HICINE U 17 OH COPTICOSTEROIDS INC N INTERFERES WITH PORTEP-SILBER REACTION P0907
COLD AGGLUTININS B HEMATOCHIT DEC M SPURIOUS NACROCYTOSIS DUE TO AGGLUTINATION P0732
COLD AGGLUTININS B MCHC INC N SPURIOUS NACROCYTOSIS DUE TO AGGLUTINATION R0732
COLD AGGLUTININS B MCVINC M SPURIOUS MACROCYTOSIS DUE TO AGGLUTINATION P0732
COLD AGGLUTININS B RED CELL COUNT DEC M SPURIOUS MACROCYTOSIS DUE TO AGGLUTINATION H 0732
COLE STIPOL S CHOLESTEROL DEC V THERAPEUTIC INTENT P0280
OLESTIPOL S TRIGLYCERIDES DEC V THERAPEUTIC INTENT H 02 80
CDLI STIMETHATE B WHITE CELL COUNT DEC V NEUTROPENIA/LEU KOPENI A/CPA NULOCYTOPENIA P0026
COLISTINETHA TE S CREATININE INC V NEPHHOTOXIC EFFECT (USUALLY REVERSIBLE) P0736
COLISTINET HATE S NPNINC V NEPHROTOXIC EFFECT (USUALLY REVERSIBLE) P0736
COLISTIM ETHA TE S UREA NITROGEN INC V NEPHROTOXIC EFFECT (USUALLY REVERSIBLE) R0620
COLISTIM ETHA TB U PROTEIN INC V COMMON NEPHROTOXIC EFFECT P0736
COLISTIMETHATE U URINALYSIS CASTS INC V NEPHROTOXIC EFFECT P0620
COLISTIM ETHA TB U URINALYSIS HEMOGLOBIN INC V COMMON NEPHHOTOXIC EFFECT P0736
COL ISTIMETH ATE U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT P0620
COLISTIMETHATE U URINALYSIS RBC/HPF INC V COMMON NEPHROTOXIC EFFECT P073 6
COLISTIN B WHITE CELL COUNT DEC V MAY CAUSE LEUKOPENIA/GPANULOCYTOPENIA R0620
OLISTIN S CREATININE INC V NEPHROTOXIC EFFECT (REVERSIBLE RENAL DAMAGE) R0620
COLISTIN S NPNINC V NEPHROTOXIC EFFECT (REVERSIBLE RENAL DAMAGE) R0620
C OL ISTI N S UREA NITROGEN INC V NEPHHOTOXIC EFFECT/MAY OCCUR AFTER LARGE DOSES P0620
COLISTIN U PROTEIN INC V NEPHROTOXIC EFFECT (REVERSIBLE RENAL DAMAGE) R0676
COLISTI N U URINALYSIS PROTEIN INC V NEPHPOTOXIC EFFECT (REVERSIBLE RENAL DAMAGE) P0676
CONGO RED U URINALYSIS COLOR INC V DYE NOT TAKEN UP. BY AMYLOID P 0026
CONTACT WITH CLOT P ALPHA AMINO NITROGEN INC N PROTEOLYSIS OCCURS EVEN IN REFRIGERATOR P0436
CONTACT WITH CLOT P AMMONIA INC M BREAKDOWN OF UREA IF DELAY IN ANALYSIS HO 355
CONTACT WITH CLOT S ACID PHOSPHATASE TOTAL DEC N LABILE AT ROOM TEMPERATURE P1001
CONTACT WITH CLOT S ALKALINE PHOSPHATASE DEC M REPORTED EFFECT ?TEMPERATURE OR STABILITY P100 1
CONTACT WITH CLOT S CALCIUM DEC N ABSORPTION BY CONTAINER P0355
CONTACT WITH CLOT S CALCIUM DEC N IF PROLONGED FACILITATES PASSAGE OF H20 FROM CELLS P0436
CONTACT WITH CLOT S CHLORIDE DEC N IF EXPOSED TO AIR WATER SHIFT FROM ERYTHROCYTES P0436
CONTACT WITH CLOT S CHOLESTEROL ESTERS INC M FREE DECS AT SANE TIME DUE TO ESTERASE ACTION P0436
CONTACT WITH CLOT S CO2 CONTENT DEC N PH SHIFT IN DRAWN BLOOD ALLOWS AT LEAST 5% DROP P0436
ONTACT WITH CLOT S GLUCOSE DEC N GLUCOSE METABOLISM BY CELLS P018 1
CONTACT WITH CLOT S GLUCOSE DEC M AT 4 DEGREES CHANGES 1-3 MG/1CCNL/HOUR P 0436
CONTACT WITH CLOT S LACTIC DEHYDROGENASE INC N HIGH INTRACELLULAR CONC OF LDH ACTIVITY P0436
CONTACT WITH CLOT S LITHIUM Z M NO EFFECT OBSERVED OVER 24 HOURS P0756
CONTACT WITH CLOT S PHOSPHATE INC N RELEASE FROM EHYTHROCYTES AND PLATELETS P0355
CONTACT WITH CLOT S POTASSIUM INC M RELEASE FROM ERYTHROCYTES AND PLATELETS RiCO 1
CONTACT WITH CLOT S URIC ACID Z N NO EFFECT 8H AT ROOM TEMP IF URICASE USED P0771
COPPER B HENATOCRIT DEC V WITH HEMOLYSIS OF COPPER TOXICITY R0124
COPPER B HEMOGLOBIN DEC V MAY BE MARKED DECREASE P0657
COPPER B METHEMOGLOBIN INC V MAY OCCUR WITH COPPER TOXICITY R0i24
COPPER B WHITE CELL COUNT INC V LEUKOCYTOSIS OBSERVED WITH POISONING P0657
COPPER B G-6-PD DEC V STRONGLY INHIBITED(NO ACTIVITY AT 100UM) IN VITRO P0135
COPPER B HEXOKINASE DEC V VERY SENSITIVE TO INHIBITION BY COPPER IN VITRO P0135
COPPER E PHOSPHOFHUCTOKINASE DEC V SEVEPLY AFFECTED IN VITRO P0135
COPPER E PHOSPHOGLYCERIC KINASE DEC V LESS MARKED INHIBITION IN VITRO P0 135
COPPER E PYBUVATE KINASE DEC V SEVERLY AFFECTED IN VITRO HO 135
COPPER E REDUCED GLUTATHIONE DEC V MARKED DECREASE WITH HEMOLYSIS OF TOXICITY R0124
TOPPER E 6-PG DEHYDROGENASE DEC V STRONGLY INHIBITED BY ADDITION OF COPPER HO 135
COPPER P HEMOGLOBIN INC V MAY OCCUR WITH HEMOLYSIS OF TOXICITY HO 124
COPPER P METHEMALBUNIN INC V OCCURS WITH ACUTE INTRAVASCULAR HEMOLYSIS P0124
COPPER S ACID PHOSPHATASE TOTAL DEC N CUPRIC IONS INHIBIT RED CELL ENZYME P092 9
COPPER S ARGINASE INC V INCREASED WHEN HENOLYTIC CRISIS OCCURS P01214
COPPER S BILIRUBIN INC V MARKED INCREASE WITH HEMOLYSIS OF TOXICITY HO 124
COPPER S BSP RETENTION INC V INCREASED WITH HENOLYTIC CRISIS P0 124
COPPER S CALCIUM INC N INTERFERES WITH EDTA TITRATION PROCEDURES P0436
COPPER S CEPHALIN FLOCCULATION INC V TRANSIENT EFFECT IN POISONING H 0657
COPPER S CEHULOPLASNIN INC V OBSERVED WITH COPPER POISONING P0657
COPPER S COPPER INC V MAY BE NORMAL IN TOXIC CASES WITH HEMOLYSIS P01214
COPPER S HAPTOGLOBIN DEC V MAY BE HEMOLYSIS WITH POISONING R0657
COPPER S LACTIC DEHYDROGENASE INC V TOXIC EFFECT, SHARP INCREASE WITH HEMOLYTIC CRISIS P0124
COPPER S PBIDEC N AS CONTAMINANT OF WATER MAY AFFECT ANALYSIS P064 1
COPPER S SGOT INC V TOXIC EFFECT, SHARP RISE WITH HENOLYTIC CRISIS PC 1214
COPPER S SGPT INC V TOXIC EFFECT, SHARP RISE WITH HEMOLYTIC CRISIS P0124
COPPER S SODIUM INC N MAY INTERFERE WITH FLAME PHOTOMETRY P0620
COPPER U COPPER INC V OBSERVED WITH POISONING P0657

COPPRR U URINALYSIS COLOR INC M BLUE DIAPERS (ALKALINE URINE ON COPPER FASTENINGS) P0161
COPPER U URINALYSIS HEMOGLOBIN INC N FALSE POSITIVE WITH GUAIAC AND BENZIDINE TESTS P0620
COPPER U URINALYSIS HEMOGLOBIN INC V MAY OCCUR WITH COPPER TOXICITY P0124
CORTICOSTEROIDS B RENATOCRIT DEC V MAY CAUSE G.I. BLEEDING WITH LOW FE STORES P01014
COPTICOSTEPOIDS B HEMOGLOBIN DEC V NAY CAUSE G.I. BLEEDING WITH LOW FE STORES P0104
COPTICOSTEHOIDS B RED CELL COUNT DEC V NAY CAUSE G.I. BLEEDING WITH LOW IRON STORES P0104
CORTICOSTEPOIDS B WHITE CELL COUNT DEC V MAY CAUSE LEUKOPENIA R0620
CORTICOSTEROIDS F OCCULT BLOOD P05 V MAY INCREASE INCIDENCE OF GASTRIC ULCERS HO1O14
CORTICOSTEPOIDS t GROWTH HORMONE DEC V SUPPRESSES SECRETION OF HORMONE P0657
CORTICOSTEPOIDS P PROTHRONBIN TIME DEC V ACCELERATE METABOLISM OF ANTICOAGtJLANTS P0620
CORTICOSTEROIDS P PROTHROMBIN TIME INC V ALLEGED POTENTIAON OF EFFECT OF ANTICOAGULANTS R01467
CORTICOSTEPOIDS P TSR DEC V USUAL RESPONSE IN PATIENTS ON STEROIDS R0596
COPTICOSTE?OIDS P VOLUME INC V EXPANSION OF ECF DUE TO WATER RETENTION P0384
CORTICOSTEROIDS S BILIRUBIN DEC V WHEN ELEVATED AS INCREASES BILE FLOW P0604
CORTICOSTEROIDS S CALCIUM DEC V ANTAGONIZES ACTION OF VITAMIN D AND PAPATHYROID P0026
COPTICOSTEROIDS S CHLORIDE DEC V METABOLIC ALKALOSIS WITH REDUCED CL REABSORPTION P0663
CORTICOST!ROIDS S CHLORIDE INC V NAY CAUSE RETENTION P0620
CORTICOSTEPOIDS S CHOLESTEROL INC N MANY STEROIDS REACT WITH FECL3 REAGENT P0436
CORTICOSTEROIDS S CHOLESTEROL INC V EFFECT OF PROLONGED HORMONE ACTION P0211
COPTICOSTEPOIDS S GLUCOSE INC V TENDS TO BE HIGH (AS IN CUSHING’S SYNDROME) R0384
CORTICOSTEHOIDS S OSMOLALITY INC V ASSOCIATED WITH NA AND CL RETENTION P0384
CORTICOSTEPOIDS S PHI DEC V IF CHRONIC ADMIN IN SMALL OP LARGE DOSES P0255
CORTICOSTEPOIDS S POTASSIUM DEC V MINEPALOCORTICOID EFFECT WITH INC RENAL EXCRETION P0021
COPTICOSTEROIDS S PROTEIN INC V PHYSIOLOGICAL DOSES PROMOTE PROTEIN SYNTHESIS P0211
COPTICOSTEROIDS S SODIUM INC V MAY CAUSE RETENTION P0620
COPTICOSTEROIDS S THYMOL TURBIDITY INC V PHYSIOLOGICAL DOSES INCREASE PROTEIN SYNTHESIS P0211
CORTICOSTEROIDS S URIC ACID DEC V PRODUCES NEGATIVE NITROGEN BALANCE P0620
CORTICOSTEROIDS S ZINC DEC V RAPID-SUSTAINED DROP IN BURN AND SURGICAL PATIENTS R0335
CORTICOSTEPOIDS U CALCIUM INC V METABOLIC EFFECT P0596
CORTICOSTEROIDS U CHLORIDE DEC V PROMOTES RETENTION (MINEPALOCORTICOID EFFECT) RO026
CORTICOSTEPOIDS U CREATININE INC V ASSOC WITH NEGATIVE NITROGEN BALANCE P0620
CORTICOSTEPOIDS U GLUCOSE INC V AS RESULT OF HYPERGLYCEMIA P0620
CORTICOST!POIDS U HYDROXYPROLINE INC V STIMULATE GROWTH IN CHILDREN P0657
COPTICOSTEROIDS U PROSPHATE INC V METABOLIC EFFECT P0596
CORTICOSTEPOIDS U POTASSIUM INC V PROMOTES EXCRETION (MINERALOCORTICOID EFFECT) P0026
CORTICOSTEHOIDS U SODIUM DEC V PROMOTES RETENTION (MINERALOCORTICOID EFFECT) P0026
COPTICOSTEROIDS U URINALYSIS GLUCOSE INC V AS RESULT OF HYPERGLYCEMIA P0620
COPTICOTROPIN B EOSINOPHILS DEC V STRIKING RESPONSE IN NORMALS P0384
CORTICOTROPIN B LYMPHOCYTES DEC V MARKED DROP OCCURS WITHIN 2 HOURS P0384
CORTICOTROPIN B RED CELL COUNT INC V ESP MARKED IF GIVEN TO ANEMICS P0384
CORTICOTHOPIN H RETICULOCYTES INC V !SP IF GIVEN TO ANENICS P0384
CORTICOTROPIN B WHITE CELL COUNT INC V SIGNIFICANT NEUTROPHILIC GRANULOCYTOSIS P0657
COPTICOTROPIN 0 BMR DEC V METABOLIC ACTION OF HORMONE P0596
CORTICOTROPIN 0 GASTRIC JUICE HCL INC V EFFECT 0’ PROTRACTED THERAPY P01467
CORTICOTROPIN P ALPHA AMINO NITROGEN INC V TISSUE AND PROTEIN CATABOLISM P0355
COR’TICOTROPIN P ANDROSTEPONE INC V HORMONAL EFFECT P0660
CORTICOTROPIN P CORTICOSTEROIDS INC V MAXIMUM RESPONSE SEEN AFTER 4 HOURS P0058
CORTICOTROPIN P CORTISOL INC V THERAPEUTIC INTENT P0467
COPTICOTROPIN P DEHYDROEPIANDPOSTERON! INC V HORMONAL E’FECT R0660
COPTICOTROPIN P PPOTHRONBIN TINE DEC V PATIENTS ON COUMARINS (MAY INDUCE ENZYMES) 90656
CORTICOTROPIN P PHOTHHOMBIN TIM! INC V PROLONGS ACTION OF ANTICOAGULANTS P0620
CORTICOTROPIN P VOLUME INC V MOD DOSES CAN CAUSE SALT AND WATER RETENTION P0467
COPTICOTROPIN P 11 OH CORTICOSTEPOIDS INC N DUE TO INC CHOLESTEROL WITH NON-SPECIFIC FLUORES P0389
CORTICOTROPIN S AMYLASE INC V INCREASE NAY BE MARKED (BOTH SHORT AND LONG TERM) 90196
CORTICOTROPIN S CHLORIDE DEC V MAY CAUSE HYPOCHLOPEMIC ALKALOSIS P0621
CORTICOTHOPIN S CHOLESTEROL DEC V ESTER CONCENTRATION REDUCED BY STIM OF ADRENAL P02014
CORTICOTROPIN S CHOLESTEROL ESTERS INC V INITIAL FALL THEN RISE ABOUT 10% R0621
COHTICOTROPIN S CHOLESTEROL INC V EFFECT OF HORMONE ACTION AFTER INITIAL FALL P0596
CORTICOTHOPIN S GLUCOSE INC V GLUCONEOGENESIS, INSULIN ANTAGONISM P1001
CORTICOTROPIN S GLUCOSE TOLERANCE DEC V CORTICOSTEROID IMPAIRMENT OF INSULIN SECRETION P0065
CORTICOTROPIN S I 131 UPTAKE DEC V ?EFFECT ON TSR - LASTS UP TO 8 DAYS P0408
CORTICOTROPIN S IRON DEC V DECREASE IN IRON BINDING GLOBULIN P1001
CORTICOTROPIN S PB! DEC V REDUCED THYROBINDING GLOBULIN P1001
CORTICOTROPIN S POTASSIUM DEC V INC URINARY EXCRETION (MINERALOCORTICOID EFFECT) P1001
CORTICOTROPIN S PROTEIN INC V PHYSIOLOGICAL DOSES PROMOTE PROTEIN SYNTHESIS P0211
COPTICOTROPIN S SODIUM INC V CAUSES RETENTION WITH EDEMA P0026
CORTICOTROPIN S TBC DEC V REDUCED SYNTHESIS P1001
CORTICOTROPIN S T9YMOL TURBIDITY INC V PHYSIOLOGICAL DOSE INCREASE PROTEIN SYNTHESIS P0211
COPTICOTROPIN S THYROXINE (T14) DEC V REDUCED THYROBINDING GLOBULIN P1001
CORTICOTROPIN S TIBC DEC V DECREASE IN IRON BINDING GLOBULIN P1001
CORTITOTROPIN S UIBC DEC V DECREASE IN IRON BINDING GLOBULIN P1001
CORTICOTROPIN S URIC ACID DEC V URICOSURIC ACTION P01404
CORTICOTROPIN U ALPHA AMINO NITROGEN INC V CATABOLISM OF BODY TISSUES R1001
CORTICOTPOPIN U AMINO ACIDS INC V CATABOLISM OF BODY TISSUES P1001
CORTIOTROPIN U CALCIUM INC V AVERAGE OR LARGE DOSES PROMOTE EXCRETION P0467
COPTICOTROPIN U ESTROGENS INC V HORMONAL EFFECT P0593
COPTICOTROPIN U GLUCOSE INC V INCREASED BLOOD GLUCOSE, REDUCED TMG P1001
COPTICOTROPIN U POTASSIUM INC V MOBILIZATION OF K FROM TISSUES P0384
CORTICOTROPIN U PRECNAN!DIOL INC V HORMONAL EFFECT P0593
CORTICOTROPIN U PROTEIN INC V NAY BE NEPHROTOXIC IN CHRONIC DISEASE P014145
CORTICOTROPIN U TESTOSTERONE INC V MODERATE EFFECT IN MEN P0798
CORTICOTHOPIN U URIC ACID INC V URICOSURIC ACTION P0404
CORTICOTROPIN U URINALYSIS GLUCOSE INC V INCREASED BLOOD GLUCOSE, REDUCED TMG P1001
CORTICOTHOPIN U URINALYSIS PROTEIN INC V NAY BE NEPHPOTOXIC IN CHRONIC DISEASE P01445
CORTICOTROPIN U 17 KETOSTEROIDS DEC V REDUCTION EVEN IF ORALLY OP TOPICALLY GIVEN P0138
COPTICOTHOPIN U 17 KETOSTEROIDS INC V STIMULATION OF ADRENAL P01417
CORTICOTROPIN U 17 OH COPTICOSTEBOIDS DEC V REDUCTION EVEN IF GIVEN ORALLY OR TOPICALLY P0138
CORTICOTPOPIN U 17 OH COHTICOSTEROIDS INC V MARKED RESPONSE TO I.V. INFUSION P0116
CORTICOTROPIN U 5 OH INDOLEACETIC ACID DEC V MECHANISM NOT DESCRIBED P0417
CORTISONE B NEUTROPHILS INC V SIGNIFICANT GRANULOCYTOSIS OBSERVED P03814

CORTISONE P COPTISOL INC V EFFECT LASTS FOP 214 HOURS AT LEAST P01490
CORTISONE P PROTHROMBIN TIME DEC V PATIENTS ON COUNAHINS P06146
CORTISONE S ALDOLASE INC V IN !XPTL ANIMALS ? OF MUSCLE ORIGIN P0990
CORTISONE S CALCIUM DEC V IF ELEVATED DUE TO SAPCOIDOSIS OR VITAMIN D P0026
CORTISONE S CHLORIDE DEC V MAY CAUSE HYPOCHLOREMIC ALKALOSIS P1028
CORTISONE S CHOLESTEROL ESTERS INC V INCREASE ABOUT 20% WITH VIGOROUS TREATMENT 31028
CORTISONE S CHOLESTEROL INC V INCREASE ABOUT 20% WITH VIGOROUS TREATMENT 91028
CORTISONE S GLUCOSE INC V GLUCONEOGENESIS RO596
CORTISONE S GLUCOSE TOLERANCE DEC V GLUCONEOGENESIS AND ANTI-INSULIN EFFECTS P0596
CORTISONE S I 131 UPTAKE DEC V PROBABLY DIMINISHES TSR SECRETION 30657
CORTISONE S IRON DEC V REDUCED SYNTHESIS OF TRANSF!RRIN 31001
CORTISONE S PB! DEC V INHIBITS IODINATION OF TYROSINE, ALSO HEMODILUTION 900014
CORTISONE S POTASSIUM DEC V MINEPALOCOPTICOID EFFECT P1001
CORTISONE S SCOT INC V MAY CONTRIBUTE TO LONG DURATION OF HEPATITIS 90596
CORTISONE S SGPT INC V MAY CONTRIBUTE TO LONG DURATION OF HEPATITIS RO596
CORTISONE S SODIUM INC V NINEPALOCOPTICOID EFFECT P1001
CORTISONE S TBG DEC V REDUCED SYNTHESIS 31001
CORTISONE S THYROXINE (T14) DEC V DECREASED SYNTHESIS O9O7
CORTISONE S TIBC DEC V REDUCED SYNTHESIS 0! TRANSFERPIN 31001
CORTISONE S TRANSFERRIN DEC V REDUCED SYNTHESIS 31001
CORTISONE U ALPHA AMINO NITROGEN INC V INCREASED TISSUE CATABOLISM 91001
CORTISONE U CHLORIDE DEC. V CAUSES RETENTION R0O26
CORTISONE U POTASSIUM INC V PROMOTES EXCRETION ROO26
CORTISONE U SODIUM DEC V CAUSES RETENTION ROO26
CORTISONE U URINALYSIS CELLS INC V INC NUMBER OBSERVED WITH LONG-TERM TREATMENT HO657
CORTISONE U 17 KETOGENIC STEROIDS INC V METABOLIC PRODUCTS R0596
CORTISONE U 17 KETOSTEROIDS DEC V PITUITARY SUPPRESSION OF ACTH 91001
CORTISONE U 17 OH CORTICOSTEBOIDS INC V MEASURING EXCRETORY PRODUCTS OF CORTISONE P1001
COUGH MEDICINES S PB! INC V SOME NAY CONTAIN IODIDES 90355
COUMAHIN S ALKALINE PHOSPHATASE INC V MAY CAUSE HEPATOTOXICITY P0990
COUMARIN S BILIHUBIN INC V MAY CAUSE HEPATOTOXICITY R0990
COUMAHIN S BSP RETENTION INC V MAY CAUSE HEPATOTOXICITY R099O
COUNARIN S CEPHALIN FLOCCULATION INC V MAY CAUSE HEPATOTOXICITY R0990
COUMARIN S SCOT INC V MAY CAUSE HEPATIC TOXICITY P0990
COUMARIN S SGPT INC V MAY CAUSE HEPATIC TOXICITY 30990
COUMARIN S THYNOL TURBIDITY INC V MAY CAUSE HEPATOTOXICITY P0990
COUMARIN S URIC ACID DEC V URICOSURIC EFFECT P0355
COUMAPIN U URIC ACID INC V URICOSURIC EFFECT P0355
COUNAPIN U URINALYSIS BILE INC V MAY CAUSE HEPATOTOXICITY 90990
COUMAPIN U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING MAY OCCUR WITH HIGH DOSES P0355
COUMAHIN U URINALYSIS PBC/HPF INC V ACTUAL BLEEDING MAY OCCUR WITH HIGH DOSES P0299
CREATINE S UREA NITROGEN INC N MAY REACT WITH BEPTHELOT IF UPEASE NOT USED O779
CREATININE S GLUCOSE INC N IF MEASURED BY ALK FERRICYANIDE REDUCTION P0750
CREATININE S GLUCOSE Z N NO EFFECT AT 100MG/100ML GLU OX O COCHRAN RO37O
CREATININE S UREA NITROGEN INC N INC CONCS AFFECT NESSLEHIZATION METHODS SLIGHTLY P01436
CPEATININ! S UREA NITROGEN Z N NO EFFECT ON BEPTHELOT PROCEDURE P0510
CREATININE U ALPHA AMINO NITROGEN Z N NO EFFECT IF DINITPOFLUOROBENZ!NE METHOD USED 90385
CREATININE U THORMAHLEN TEST P05 N LA1GE AMOUNTS GIVE BROWN COLOR 30929
CHEATININE U URINALYSIS SUGAR INC N ACTS LIKE REDUCING SUBSTANCE WITH BENEDICT’S 90620
CREMOMYCIN P PROTHROMBIN TINE INC V MAY CAUSE HYPOPROTHPOMBINENIA P0026
CPEMONYCIN S UREA NITROGEN INC V DEHYDRATION MAY SIMULATE RENAL DISEASE P0026
CREOSOTE U URINALYSIS COLOR INC M DARK GREEN P0620
CHESOL U URINALYSIS COLOR INC N DARK BROWN ON STANDING R062O
CRESOL U URINALYSIS SUGAR INC N EXCRETED AS GLUCURONIDE REACTS WITH BENEDICT’S P0197
CT1341 B PCO2 INC V POST-INDUCTION MEASUREMENT IN ARTERIAL BLOOD P0823
CT13(41 B P02 DEC V POST-INDUCTION MEASUREMENT IN ARTERIAL BLOOD P0823
CYANATE U ACETOACETATE INC N MAY PRODUCE INTERFERING COLOR WITH GERHARDT FECL3 90299
CYANIDES S ALKALINE PHOSPHATASE DEC N INHIBITORS OF ENZYME IN LABORATORY METHODS 30929
CYANIDES S PBI DEC V INHIBIT IODINATION OF TYROSINE IN TBG P00014
CYANIDES S URIC ACID DEC N URICASE IS SENSITIVE TO CYANIDE P01436
CYCLIC AMP P CORTISOL INC V HORMONAL ACTION R0319
CYCLIC AMP P GROWTH HORMONE INC V HORMONAL ACTION P0319
CYCLIC AMP P INSULIN INC V HORMONAL ACTION P0319
CYCLIC AMP S GLUCOSE INC V HORMONAL ACTION R0319
CYCLOHEXIMIDE B WHITE CELL COUNT DEC V LEUKOPENIA (AMA-BLOOD DYSCRASIAS) R0658
CYCLOLEUCINE U ARGININE INC V REVERSIBLE MARKED AMINOACIDURIA P0154
CYCLOLEUCINE U CYSTINE INC V REVERSIBLE MARKED AMINOACIDURIA P01514
CYCLOLEUCINE U LYSINE INC V REVERSIBLE MARKED AMINOACIDUPIA P01514
CYCLOPHOSPHAMIDE B PLATELET COUNT DEC V NAY CAUSE BONE MARROW DEPRESSION P0025
CYCLOPHOSPHAMIDE B WHITE CELL COUNT DEC V BONE MARROW DEPRESSION (REVERSIBLE LEUKOPENIA) P0025
CYCLOPHOSPHAMIDE F OCCULT BLOOD P05 V HEMORRHAGIC COLITIS REPORTED RO657
CYCLOPHOSPHAMIDE P PROTHROMBIN TIME INC V MAY CAUSE RYPOPROTHROMBINEMIA R0893
CYCLOPHOSPHAMIDE S ALBUMIN DEC V NAY CAUSE HEPATOTOXICITY P0893
CYCLOPHOSPHAMIDE S ALKALINE PHOSPHATASE INC V MAY CAUSE HEPATOTOXICITY P0520
CYCLOPHOSPHAMIDE S BILIRUBIN INC V MAY CAUSE HEPATOTOXICITY P0620
CYCLOPHOSPHAMID! S BSP RETENTION INC V MAY CAUSE HEPATOTOXICITY P0620
CYCLOPHOSPHAMIDE S CEPHALIN FLOCCULATION INC V NAY CAUSE HEPATOTOXICITY 90620
CYCLOPHOSPHAMIDE S CHOLESTEROL INC V SINGLE CASE OF DRUG INDUCED MYXEDENA P0207
CYCLOPHOSPHAMIDE S CHOLINESTEPASE DEC V CAUSES INHIBITION OF ACTIVITY R1027
CYCLOPHOSPHAMIDE S DIRECT COOMBS TEST P05 V MAY CAUSE HEMOLYTIC ANEMIA P0636
CYCLOPHOSPHAMIDE S I 131 UPTAKE DEC V SINGLE CASE OF DRUG INDUCED MYXEDENA 30207
CYCLOPHOSPHAMIDE S SCOT INC V MAY CAUSE HEPAT#{246}TOXICITY P0893
CYCLOPHOSPHAMIDE S SGPT INC . V NAY CAUSE HEPATOTOXICITY P0893
CYCLOPHOSPHAMIDE S THYMOL TURBIDITY INC V MAY CAUSE HEPATOTOXICITY 30620
CYCLOPHOSPHANIDE U URINALYSIS BILE INC V MAY CAUSE HEPATOPOXICITY P0620
CYCLOPHOSPHAMIDE U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG P0299
CYCLOPHOSPHAMIDE U URINALYSIS RBC/HPF INC V ACTUAL BLEEDING NAY BE CAUSED BY DRUG R0299
CYCLOPROPANE B BLEEDING TIME Z V ANESTHESIA HAS NO EFFECT RO3814
CYCLOPROPANE B CLOTTING TIME Z V ANESTHESIA HAS NO EFFECT R0384
CYCLOPROPANE B HEMATOCRIT INC V POSSIBLE EFFECT DUE TO DEC PLASMA VOLUME P0384

C Y L OPRO PA N B B PH DEC V MAY CAUSE METABOLIC ACIDOSIS P03 84
CYCLOPROPIN! B PLATELET COUNT Z V ANESTHESIA HAS NO EFFECT P0384
CYLOPROPANE B THROMBIN TIME Z V ANESTHESIA HAS NO EFFECT P0 384
CYCLOPPOP ANE 0 CAPILLARY FRAGILITY Z V ANESTHESIA HAS NO EFFECT R0384
CYCLOPHOPANE P CATECHOLAMINES INC V SIGNIFICANT INC. MAY REDUCE BLOOD TO KIDNEYS ETC P0026
CY CLO P POP AN B P FIBRINOCEN Z V ANESTHESIA HAS NO EFFECT P03 84
CYCL OP P OPA N! P PROTIIROMBIN TIME Z V ANESTHESIA HAS NO EFFECT P03814
CYCLOPROPANE S ALKALINE PHOSPHATASE INC V MAY CAUSE HEPATOTOXICITY (LASTS SEVERAL DAYS) P062 0
CYC LOP POP A NE S BILIRUBIN INC V MAY CAUSE HEPATOTOXICITY (LASTS SEVERAL DAYS) P0 620
CYCLOPPOPAN? S BSP RETENTION INC V NAY CAUSE HEPATOTOXICITY (LASTS SEVERAL DAYS) P0620
C YC LO PR OP A NE S CEPHALIN FLOCCULATION INC V MAY CAUSE HEPATOTOXICITY (LASTS SEVERAL DAYS) P0620
CYCLOPPOPANE S GLUCOSE INC V MODERATE WITH DEPLETION OF LIVER GLYCOGEN P0026
CYCLOPROPANE S INDOCYANINE GREEN INC V HEPATIC EXTRACTION IMPAIRED AFTER INJECTION P0384
CYCLOPROPANE S SCOT INC V MAY CAUSE HEPATOTOXICITY (LASTS SEVERAL DAYS) R0620
CYCLOPROPAN S SGPT INC V MAY CAUSE REPATOTOXICITY (LASTS SEVERAL DAYS) P0620
CYLOPROPANE S THYMOL TURBIDITY INC V MAY CAUSE HEPATOTOXICITY (LASTS SEVERAL DAYS) P06 20
CYCLOP? OP AN? U URINALYSIS BILE INC V MAY CAUSE HEPATOTOXICITY (LASTS SEVERAL DAYS) P06 20
CYCLOS ERI NE B HEMATOCRIT DEC V MAY CAUSE MEGALOBLASTIC ANEMIA P0976
CYCLOSEHIN! B HEMOGLOBIN DEC V MAY CAUSE MEGALOBLASTIC ANEMIA P0976
CYCLOSERINE B MCV INC V MAY CAUSE NEGALOBLASTIC ANEMIA R0976
CYCLOSEPINE B PLATELET COUNT DEC V MAY OCCUR WITH MEGALOBLASTIC ANEMIA P0976
CYCLOSERINE B RED CELL COUNT DEC V NAY CAUSE MEGALOBLASTIC ANEMIA p0976
CYCLOSERINE B WHITE CELL COUNT D’C V MAY OCCUR WITH MEGALOBLASTIC ANEMIA R0976
CYCLOSERIN! S ALKALINE PHOSPHATAS! INC V MAY CAUSE HEPATOTOXIC ITT HO 620
CYCLOSERI NE S BILIPUBIN INC V MAY CAUSE HEPATO TOXICITY P0620
CYCLOSER IN! S BSP RETENTION INC V NAY CAUSE HEPAT OTO XIC ITT P0620
CYCLOSEHI NE S CEPHALIN FLOCCULATION INC V NAY CAUSE HE PATOTOXICI TY P062 0
CYCLOSERINE S FOLAT! DEC V MAY CAUSE MEGALOBLASTIC ANEMIA R0976
CYCLOS ER! NE S SCOT INC V MAY CAUSE REPATOTOXICI TY P06 20
CYCLOSERINE S SGPT INC V MAY CAUSE HEPATOTOXIC ITT P0620
CYCLOS ERINE S THYMOL TURBIDITY INC V MAY CAUSE HEPATOTOXICITY R0620
CYCLOSERINE U AICAP INC V OCCURS WITH FOLIC ACID DEFICIENCY P0976
CYCLOSEPINE U FIGLU INC V OCCURS WITH FOLIC ACID DEFICIENCY P0976
CYCLOSERINE U URINALYSIS BILE INC V MAY CAUSE HEPATOTOXICITY P0620
CYCLOT HIAZIDE S URIC ACID INC V INHIBITION OF TUBULAR SECRETION OF URATE P04014
CY PROHEPTIDIN! S AMYLASE INC V MECHANISM NOT LISTED P04 17
CYPROHEPTIDINE S GLUCOSE DEC V SMALL DECREASE (10%), OFTEN NO CHANGE P04 17
CYPPOTERONE P ANDROSTENEDIONE INC V BY UP TO 450% IF ACETATE DERIVATIVE USED P0887
CY PROTEPONE P ESH Z V NO CHANGE FOLLOWING ORAL ADMINISTRATION R0887
C YP P OT ERO NE P LB Z V NO CHANGE FOLLOWING ORAL ADNINSTRATION P0887
CY PPOTERONE P TESTOSTERONE DEC V BY 20-40% (ANTIANDHOGENIC EFFECT) HO 887
CYSTEINE S GLUCOSE DEC N MAY AFFECT SOME GLU.OX PROCEDURES P0436
CYSTEINE S GLUCOSE INC N AT 1OMG/100ML AFFECTS ALKALINE FEPRICYANIDE P0370
CYSTEI NE S GLUCOSE Z N AT 1OMG/100ML NO EFFECT ON GLU OX OF GOCHMAN P03 70
CYSTEINE T PROTEIN INC N REACTS WITH FOLIN-CIOCALTEU OF LOWRY PROCEDURE P0213
CYTARABIN! B HEMOGLOBIN DEC V NAY CAUSE ANEMIA RO620
CYTAR A BINE B PLATELET COUNT DEC V DUE TO BONE MARROW DEPRESSION P0620
CYTARABINE B RED CELL COUNT DEC V MEGALOBLASTIC ANEMIA (RELATIVELY INFREQUENT) P0620
CYTARABIN! B WHIT! CELL COUNT DEC V AGRANULOCYTOSIS /LEUKOPENIA P0620
CYTARABINE S SGPT INC V HEPATOTOXIC EFFECT P03 84
DACTI NOMYCIN B HEMOGLOBIN DEC V MAY CAUSE ANEMIA R0026
DACTINOMYCIN B PLATELET COUNT DEC V THRO MBOCYTOPEN IA/PARC! TOPENIA P00 26
DACTI NOMYC!N B RED CELL COUNT DEC V ARMI A/PAN CYTOPENIA P0026
DACTINOMYCIN B RETICULOCYTES DEC V RETICULOCYTOPENIA/PANCYTOPE NIA HO 026
DACTI NOMYCIN B WHITE CELL COUNT DEC V LEUKOPENI A/PANCYTOPENIA P0026
DANDRUFF MEDICATION S PHI INC N IODINE CONTAMINATION (IN SON! PREPARATIONS) P0355
DA NTH RON U PSP EXCRETION INC N RED COLOR INTERFERES WITH PSP DETERMINATION P0 355
DANTHRON U URINALYSIS COLOR INC N RED COLORATION IN URINE P0355
DECA METHONIUM S P91 INC V CONTAINS 149.5% IODINE P0004
DEFEROX AMINE U IRON INC V PRIMARY AFFINITY FOR TRIVALENT IRON P0026
DEFEPOXA MINE U URINALYSIS COLOR INC N FORMS IRON CHELATE WITH REDDISH COLOR P0417
DEHYDPOCHOLIC ACID B HEMOGLOBIN DEC V MILD HEMOLYTIC ACTION IF INJECTED P0026
DEHYDROCHOLIC ACID S BSP RETENTION INC V HEPATIC UPTAKE OR BILIAPY EXCRETION IMPAIRED P0 417
DEHYDROCHOLIC ACID U VOLUME INC V MILD DIURETIC ACTION P0026
DEHYDROEMETINE S SCOT INC V POSSIBLY DUE TO GENERALIZED MYOSITIS HO 6 57
DEMECARIUM S CROLINESTEPASE DEC V THERAPEUTIC INTENT P0026
DEMECLOCYCLINE S CREATININE INC V DOSE RELATED N!PHROTOXICITY P0 572
DEMECLOCYCLINE S UREA NITROGEN INC V DOSE RELATED NBPHROTOXICITY P05 72
DMECLOCYCLINE U CATECHOLAMINES INC N PRODUCES INTERFERING FLUORESCENCE WITH ANALYSIS P0539
DEMECLOCYCLINE U PROTEIN INC V NEPHROTOXIC EFFECT P057 2
DEMECLOCYCLIN? U URINALYSIS PROTEIN INC V NE PH POTOXI CITY P0572
DEE ET BY LT H LO PT ET HAC U CATECHOLAMINES INC N INTERFERES WITH FLUOROMETRIC METHODS P02 33
DEE El H YLCHLO PT ET RAC U VOLUME INC V MAY CAUSE SYNDROME LIKE DIABETES INSIPIDUS P0736
DESERPIDINE B PLATELET COUNT DEC V POSSIBLE EFFECT AS RELATED COMPOUNDS CAUSE THIS P01467
DESIPRAMINE B BASOPHILS INC V MILD EFFECT NOTED IN SOME PATIENTS P0657
DESIPRAMINE B EOSINOPHILS DEC V AGRANULOCYTOSIS P0228
DESI PRAMI NE B BOSINOPHILS INC V ALLERGIC REACTION P0992
DESIPRA MINE B RED CELL COUNT DEC V TRANSIENT AGRANULOCYTOSIS (UP TO 25% REPORTED) P0026
DESIPPA MI NT B WHITE CELL COUNT DEC V MAY CAUSE AGRANULOCYTOSIS P062 0
D!SIPRAMtNE B WHITE CELL COUNT INC V DUE TO BOSINOPHILIA OF HYPERSENSITIVITY HO 620
DESI PRAMI NE S ALKALINE PHOSPHATASE INC V TRANSIENT CHOLESTASIS (PARE) P0620
DESIPR AMINE S BILIRUBIN INC V RAPE TRANSIENT CHOLESTASIS P04 17
D!SIPRA MINE S BSP RETENTION INC V HARE TRANSIENT CHOLESTASIS P06 20
D!SIPR AMINE S CEPHALIN FLOCCULATION INC V RAPE TRANSIENT C}PLESTASIS R0620
DESIPRA MINE S SCOT INC V PARE TRANSIENT CHOLESTASIS P0620
DESIPPAMTtNT S SGPT INC V RAPE TRANSIENT CHOLESTASIS HO 620
DESIPPAMIN! S THYMOL TURBIDITY INC V RARE TRANSIENT CHOLESTASIS P06 20
DESIPRAMINE U URINALYSIS BILE INC V RARE TRANSIENT CHOLESTASIS P0620
DF.SSICATED THYROID S PB! DEC V OBSERVED WITH SOME BATCHES (T14 CONVERTED TO T3) HO 233
DESSICATED THYROID S PHI INC V INCREASES BY 1-2 UG/100NL/DAY PER GRAIN GIVEN P0112

DESSICATED THYROID S THYROXINE (T14) INC V INCREASES BY 1-2 US/100ML/DAY PEP GRAIN GIVEN P0112
DETERGENTS S PHOSPHATE INC N CONTAMINATED GLASSWARE ETC 30620
DETERGENTS S SODIUM INC N CONTAMINATED GLASSWARE ETC 90620
DETERGENTS U PHENYLKETONES NEG N FALSE PEG RESULTS (BROWN COLOR) WITH ?ECL3 TEST P083 1
DEXA METHA SONE F OCCULT BLOOD POS V MAY AGGRAVATE PEPTIC ULCER AND CAUSE BLEEDING 901467
DEX A MET HA S ONE P COPTICOSTEROIDS DEC V EFFECT SEEN FOLLOWING MORNING IF GIVEN IN EVENING 30824
DEXAMETRA SONE P COPTICOTROPIN DEC V EFFECT MEASURED AFTER 9 HOURS P0058
DR XA MET H ASO NE S AMYLASE INC V MAY CAUSE PANCREATITIS AS SIDE EFFECT P04 67
DEXAMETHASONE S GLUCOSE INC V HORMONAL ACTION R0683
DEXANETHASONE S GLUCOSE TOLERANCE DEC V MAY IMPAIR CARBOHYDRATE TOLERANCE P01467
DEXA METHA SORE U ANDPOSTERONE DEC V SUPPRESSION OF ACTH 90653
DEX AM ET H ASO NE U CALCIUM INC V METABOLIC EFFECT 301467
DEX A MET HA S ONE U DEHYDROEPIANDROSTEPONE DEC V SUPPRESSION OF ACTH 90653
DEXAMETHASONE U ETIOCHOLANOLONE DEC V SUPPRESSION OF ACTH RO653
DR XA MET HA SO N! U POTASSIUM INC V METABOLIC EFFECT 90467
DEXANETHA SORE U SODIUM INC V MILD DIURESIS WITH NA LOSS MAY OCCUR INITIALLY 90026
DEXAMETHASONE U TESTOSTERONE DEC V SLIGHT EFFECT IN MEN 90798
DEX A ME TH A S ONE U URINALYSIS GLUCOSE INC V ASSOCIATED WITH HYPERGLYCEMIA 30467
DE XA MET HA SO NE U 17 KETOGENIC STEROIDS DEC V SUPPRESSION OF ACTH 90653
DEXA METHA SON! U 17 KETOSTEROIDS INC N AFFECTS METHOD OF REDDY (M!TABOLISM,1952) ?OU7O
DEXAMETHASONE U 17 OH CORTICOSTEPOIDS DEC V PITUITARY FEEDBACK WITH SUPPRESSION OF ACTH 9058L1
DEXAMETHASONE U 17 OH COFTICOSTEPOIDS INC M MEASURED AS ENDOGENOUS STEROIDS BY REDDY METHOD 30653
DEXTPAN B BLEEDING TIME INC V OBSERVED EFFECT BUT EXPLANATION UNCERTAIN P06 20
DEXT PA N B EACTOP IX DEC V SLIGHT EFFECT (MORE THAN HEMODILUTION) 90657
DEXTRAN B FACTOR V DEC V SLIGHT EFFECT (MOPE THAN HEMODILUTION) RO657
DEXTRAN B FACTOR VII DEC V DEC BY 50% IN NORMALS 30657
DEXTRAN B SEDIMENTATION RATE INC V DUE TO CELL AGGREGATING PROPERTIES 90620
DR XT PA N P FIBPINOGEN DEC V SLIGHT EFFECT (MORE THAN HEMODILUTION) P0657
DEXTRAN P VOLUME INC V HEMODYNAMIC EFTECT, ALSO INCREASES URINE PLOW RO38L4
DR XTRA N S BILIRUBIN INC N CAUSES TURBIDITY WITH METHANOL IN EVELYN-MALLOY P0907
DEXTRA N S CREATININE INC V BLOCKS TUBULES CAUSING RENAL FAILURE 90203
DEXTRAN S DIRECT BILIPUBIN INC N TURBIDITY DEVELOPS WITH EVELYN-MALLOY METHOD 902014
DEXTRA N S GLUCOSE INC M AFFECTS O-TOLUIDIN! PROCFDURE:TURBIDITY AT ACID PH 90907
DR XTR AN S IRON INC N CAUSES TURBIDITY WITH METHOD OF YOUNG-HICKS 90779
DEXTRA N S PROTEIN DEC V DUE TO HENODILUTION HO 596
DEXTRAN S PROTEIN INC N TURBIDITY EFFECT WITH BIURET REACTION 30907
DEXTPA N S UREA NITROGEN INC N REACTS AS IF UREA WITH DIMETHYLAMINOBENZALDEHYD! 90907
DEXTRAN S UREA NITROGEN INC V BLOCKS TUBULES CAUSING RENAL FAILURE P02 03
DEXTRAN S URIC ACID INC N REDUCES PHOSPHOTUNGSTATE .0596
DEXTRAN U INULIN CLEARANCE INC N INTERFERES WITH ANALYTICAL PROCEDURE 90657
DEXTRA N U SPECIFIC GRAVITY INC N HIGH MOLECULAR WEIGHT 30299
DEXTPAN U URINALYSIS S.G. INC N HIGH MOLECULAR WEIGHT 90299
DEXTRA N U VOLUME INC V HEMODYNAMIC EFFECT 303814
DEXTPOAMPHETAMINE P COPTICOSTEPOIDS INC V EFFECT MOST NAPKED IN EVENINGS P01 02
DEXTPOAMPHETAMINE S GLUCOSE INC V METABOLIC EFFECT 30620
DEXTROAMPHETAMIN E S PHI Z V APPEARS TO HAVE NO EFFECT HO 2 55
DEXTROAMPHETANINE U URINALYSIS GLUCOSE INC V WILL OCCUR IF HYPERGLYCEMIA 30520
DEXTRO METHORPHAN B PCO2 INC V HIGH DOSES MAY PRODUCE RESP DEPRESSION 90384
DEXTROMETHORPHAN B PLATELET COUNT DEC V THROMBOCYTOPENIA (AMA-BLOOD DYSCPASIAS) P06 58
DEXTHOMORAMIDE P EPINEPHRINE DEC V MECHANISM OBSCURE P014 96
DEXTROMOP AM IDE P NOREPINEPHRINE DEC V MECHANISM OBSCURE 301496
DEXTHOTHYROXINE P PROTHROMBIN TIME INC V INCS RECEPTOR SITE AFFINITY FOP ANTICOAGULANTS H 0885
DEXTR OTHY HO XIN! S BETA-LIPOPROTEINS DEC V THERAPEUTIC EFFECT P0026
DEXTROTHY POX INE S CHOLESTEROL DEC V THERAPEUTIC INTENT (ENHANCES EXCRETION) P04 17
DEXTROTHYROXINE S GLUCOSE INC V EFFECT SEEN IN DIABETICS P01417
DEXTROTHYROXI NE S I 131 UPTAKE Z V NO EFFECT REPORTED HO 596
DEXTROTHYROXINE S PB! INC V CONTAINS 65% IODINE(MAY CAUSE INC TO iO-25UG/100ML) P00014
DEXTROTHYROXINE S PHOSPHOLIPIDS DEC V THERAPEUTIC EFFECT HO 026
DEXTROTHYROXINE S THYROXINE (T14) INC V MECHANISM NOT DISCUSSED 30417
DEXTROTHY POXINE S TRIGLYCERIDES DEC V THERAPEUTIC EFFECT 90026
DEXTROTHYRO XINE S T3 UPTAKE INC V MECHANISM NOT DISCUSSED RO417
DEXTROTHY ROXINE U GLUCOSE INC V OCCURS DUE TO ELEVATION OF BLOOD SUGAR P014 17
DEXTROTHYRO XINE U URINALYSIS GLUCOSE INC V OCCURS DUE TO HYPERGLYCEMIA P01417
DIAMINODIPHENYLSULF B HEINZ-BODY FORMATION P05 V EARLY STAGE OF HEMOLYTIC ANEMIA 901014
DIAMINODIPHENYLSULF B HEMATOCRIT DEC V HENOLYSIS (HEMOLYTIC ANEMIA) P0451
DIA MINODIPHENYLSULF B HEMOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P0145 1
DIAMINODIPHENYLSULF B’ METHEMOGLOBIN INC V MAY CAUSE HEMOLYTIC ANEMIA P 01451
DIAMINODIPHENYLSULF B RED CELL COUNT DEC V MAY CAUSE HEMOLYTIC ANEMIA 90145 1
DIAMINODI PHENYLSULF B WHITE CELL COUNT DEC V AGRANULOCYTOSIS P0451
DIAPAMIDE S GLUCOSE INC V ALTERS GLUCOSE TOLERANCE 90609
DIAPANIDE S GLUCOSE TOLERANCE DEC V MODIFICATION OF GLUCOSE TOLERANCE P06 09
DIAPAMIDE S POTASSIUM DEC V DIURETIC ACTION HO 609
DIAPANIDE S URIC ACID INC V IMPAIRED EXCRETION P06 09
DIAPAMIDE U CHLORIDE INC V DIURETIC ACTION P 06 09
DIAPAMIDE U POTASSIUM INC V DIURETIC ACTION 90609
DIAPAMIDE U SODIUM INC V DIURETIC ACTION P0609
DIAPAMIDE U URINALYSIS GLUCOSE INC V RESULT OF MARKED HYPERGLYCEMIA 90609
DIAPAMIDE U VOLUME INC V DIURETIC ACTION 30609
DIAPRIM B WHITE CELL COUNT DEC V LEUKOPENIA 90656
DIATRIZOATE B VOLUME INC V HYPERTONICITY MAY OCCUR IN CHILDREN 90026
DIATRIZOATE S AMYLASE INC V BLOCKAGE OF PANCREATIC DUCT FOR 6-18 HOURS 90029
DIATRIZOATE S BEI Z N NO EFFECT REPORTED WITH HYPAQUE P02 55
DIATRIZOATE S CALCIUM DEC V ?DUE TO SMALL AMOUNT OF EDTA IN MEDIUM HO 5 60
DIATRIZOATE S I 131 UPTAKE DEC V DUE TO IODINE COMPONENT OF MATERIAL 90596
DIATRIZOATE S MAGNESIUM DEC V ?DUE TO SMALL AMOUNT OF EDTA IN MEDIUM 90560
DIATRIZOATE S PBI INC M BUT DOES NOT AFFECT T14, EFFECT LASTS 2-6 DAYS HO 83 9
DIATHIZOATE S SGOT INC V HAS CAUSED SEVERE MUSCLE SPASM AND RENAL FAILURE P062 1
DIATRIZOATE S UREA NITROGEN INC V HAS CAUSED ACUTE PENAL FAILURE WITH MYELOGPAPHY 90621
DIATRI ZOAT! S URIC ACID DEC V URICOSURIC EFFECT P06 80
DIATRIZOATE U PROTEIN INC N INTERFERES WITH SULFOSALICYLIC,NITR!C ACID TESTS 301475

DIATRIZOATE U SPECIFIC GRAVITY INC N PRESENCE OF HIGH MOLECULAR WEIGHT COMPOUND R0475
DIATRI ZOATE U URIC ACID INC V UPICOSUHIC EFFECT P0680
DIATPIZOATE U URINALYSIS PBC/HPF INC V HAS CAUSED ACUTE RENAL FAILURE WITH MYELOGRAPHY P0621
DIATRIZOAT! U URINALYSIS S.G. INC N PRESENCE OF HIGH MOLECULAR WEIGHT COMPOUND P0475
DIATRIZOATE U URINALYSIS SUGAR INC N AFFECTS COPPER REDUCTION TECHNIQUES DUE TO 12 P06514
DIAZ!PAN B NEUTPOPHILS DEC V TRANSITORY NEUTHOPENIA REPORTED P 0026
DIAZEPAM B WHITE CELL COUNT DEC V LEUKOPENIA P0789
DI A Z E PAM 0 GASTRIC JUICE HCL DEC V PRESUMED CENTRAL ACTION LASTS FOP 59 AFTER 10MG P0118
DIAZEPAM 0 GASTRIC JUICE VOLUME DEC V PRESUMED CENTRAL ACTION LASTS FOR 5H AFTER lONG HO 118
DI AZ F? A N S PILIPUBIN INC V PRESUMED HEPATIC TOXIC EFFECT Ri 001
DIAZEPAM S I 131 UPTAKE DEC V CONFLICTING REPORTS ? NO EFFECT HO 355
DI A Z B PA N S PHI Z V CONFLICTING REPORTS ? NO EFFECT R01417
DIAZEPAM S THYROXINE (T4) Z V CONFLICTING REPORTS ? NO EFFECT P014 17
DIAZEPAM S T3 UPTAKE DEC V RESIN TEST AFFECTED RO596
DIAZEPAM U CATECHOLANINES Z V NO EFFECT SHORT TERM INGESTION OF 15 MG/DAY P0236
DIAZEPAN U DOPA SCREEN TEST P05 N VERY SLIGHT PURPLE COLOR PRODUCED HO 802
DI A Z ! PA N U EPINLPHRINE Z V NO EFFECT SHORT TERM INGESTION OF 15 MG/DAY P0236
DIAZ!PAN U NOR!PIN!PHPINE Z V NO EFFECT SHORT TERN INGESTION OF 15 MG/DAY HO 2 36
DI A Z EPA N U 11 OH COPTICOSTEROIDS Z V NO EFFECT SHORT TERM INGESTION OF 15 MG/DAY P0236
DIAZEPAM U 17 KETOSTEROIDS Z V NO EFFECT SHORT TERM INGESTION OF 15 MG/DAY P02 36
DIAZEPAM U 17 OH COFTICOSTEPOIDS Z V NO EFFECT SHORT TERN INGESTION OF 15 MG/DAY P0236
DI AZINON S CHOLINESTERASE DEC V IN VITRO 8.2% DEC AT 1X1O-14 N HO 362
DIAZOXIDE B PLATELET COUNT DEC V IMMUNOLOGIC RESPONSE OCCURS FROM DAYS TO MONTHS P0967
DIAZOXIDE B WHITE CELL COUNT DEC V MAY CAUSE LEUROPENIA P0967
DI AZOXI DR P ERPE DEC V AFTER I.V. INJECT IMMEDIATE REDUCTION NOTED ROO49
DIAZOXIDF4 P PROTHHOMBIN TIME INC V DISPLACES ANTICOAGULANTS FROM ALBUMIN P0850
DIAZOXIDE P PENIN INC V EFFECT OBSERVED IN SOME HYPERTENSIVES HO 38 4
DI AZOXIDE P VOLUME INC V CAUSES SALT AND WATER RETENTION P03 84
DIAZOXIDE S CHLORIDE INC V MAY CAUSE SALT RETENTION H0384
DI AZOX IDE S GLUCOSE INC V INHIBITS INSULIN RELEASE, PEHIPH GLUC UTILIZATION HO 200
DIAZOX IDE S IMNUNOGLOBULIN IGG DEC V EFFECT MAY BE PERSISTENT ? MECHANISM P00 49
DIAZOXIDE S NEFA INC V SIGNIFICANT RISE OBSERVED AFTER OPAL OP I.V. ADMIN P0014 9
DI AZOXIDE S SODIUM INC V NAY CAUSE SALT RETENTION P03814
DIAZOXID! S URIC ACID INC V INHIBITION OF TUBULAR URIC ACID EXCRETION P050 1
DIAZOXIDE U BICARBONATE DEC V EFFECT NOT AS MARKED AS WITH SODIUM P004 9
DIAZOXIDE U CHLORIDE DEC V EFFECT OVER 28 OF 14MG/KG GIVEN I.V. OP ORALLY HO 50 1
DIAZOXIDE U CPEATININE CLEARANCE DEC V EFFECT OVER 2H OF 4MG/KG GIVEN I.V. P05 01
DIA ZOXIDE U GFR DEC V EFFECT OVER 2H OF 14MG/KG GIVEN I.V. P050 1
DIAZOXI DR U INULIN CLEARANCE DEC V EFFECT OVER 28 OF 4MG/KG GIVEN I.V. P050 1
DIAZOXIDE U OSMOLAP CLEARANCE DEC V EFFECT OVER 2H OF 4 MG/KG GIVEN I.V. RO501
DIAZOXIDE U PAH CLEARANCE DEC V EFFECT OVER 28 OF 4MG/KG GIVEN I.V. P050 1
DI AZO XIDE U POTASSIUM DEC V EFFECT OVER 2H OF 14MG/KG GIVEN I.V. HO 50 1
DIAZOX ID! U SODIUM DEC V EFFECT OVER 2H OF 4MG/KG GIVEN I.V. P050 1
D!AZOXIDE U URIC ACID CLEARANCE DEC V EFFECT OVER 2H OF 14MG/KG GIVEN I.V. P0 501
DIAZOX IDE U URIC ACID DEC V EFFECT OVER 2H 0! 4MG/KG GIVEN I.V. P050 1
DIAZOXIDE U URINALYSIS GLUCOSE INC V IF HYPERGLYCEMIA OCCURS P0200
DIAZOXIDE U URINALYSIS PH DEC V DUE TO DEC BICARBONATE EXCRETION P0049
DI A Z OX! DE U VOLUME DEC V EFFECT OVER 2H OF 4MG/KG GIVEN I.V. P0501
DICHLORALPHENAZON! F COPROPOPPHYRIN INC V MAT PRECIPITATE ACUTE PORPHYRIA P1005
01CR LOPALPH ERA ZONE P PROTOPOPPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA R0371
DICHLOFALPHENAZONE P PROTHROMBIN TIME DEC V ANTAGONIZES ACTION OF ADMINISTERED COUNARINS HO 787
DI CHLORAL PH ENAZ ONE U AMINOLEVULINIC ACID INC V MAY PRECIPITATE ACUTE PORPHYRIA P0371
DICHLDRALPHENAZONE U COPPOPORPHYPIN INC V MAY PRECIPITATE ACUTE PORPHYRIA HO 37 1
DICFILORALPHENAZONE U PORPHOBILINOGEN INC V NAY PRECIPITATE ACUTE PORPHYRIA HO 37 1
DICHLOPPHENAMIDE B PLATELET COUNT DEC V PROBABLE EFFECT (LIKE ACETAZOLAMIDE) P0026
DIC HLORPH ERA NI DE B WHITE CELL COUNT DEC V MAY CAUSE LEUKOPENIA P06 20
DICHLORPHENAMIDE S POTASSIUM DEC V DIURETIC ACTION (INHIBITS CARBONIC ANHYDRASE) P06 20
DICHLORPH!NA MIDE S SODIUM DEC V CATION LOSS AS EXCESS CHLORIDE IS EXCRETED P02 04
DICLOXACILLIN B BOSINOPHILS INC V MILD ALLERGIC RESPONSE P00 43
DICLOXACILLIN S CEPHALIN FLOCCULATION INC V MILD HEPATIC DYSFUNCTION NOTED P0043
DICLOXACILLIN S SGOT INC V MILD HEPATIC DYSFUNCTION OBSERVED P0043
DIELDRIN B WHITE CELL COUNT INC V MAY OCCUR IN ACUTE RESPONSE R0368
DI ELDPI N S CHOLINESTEPASE DEC V IN VITRO 7.2% DEC AT 1X10-4 N P03 62
DI!LDRIN S LACTIC DEHYDROGENASE DEC V IN VITRO 8.0% DEC AT 1X1O-4 N H 03 62
DIETHIAZINE B WHITE CELL COUNT DEC V NAY CAUSE LEUKOPENIA P062 0
DIETHYLCARBAMAZIN! B EOSINOPHILS INC V MAY INTENSIFY EOSINOPHILIA OF FILAHIAL INFECTION HO 384
DIETHYLCAPBAMAZINE B WHITE CELL COUNT INC V OFTEN MARKED LEUKOCYTOSIS MAXIMAL ON FOURTH DAY P0384
DIETHYLPPOPION B RED CELL COUNT DEC V MAY CAUSE BONE MARROW DEPRESSION P0047
DIETHYLPPOPION B WHITE CELL COUNT DEC V MARROW DEPRESSION WITH LEUKOPENIA/AGRANULOCYTOSIS P0650
DI!TBYLSTILRESTROL B PLATELET COUNT DEC V THPOMBOCYTOPENIA (AMA-BLOOD DYSCPASIAS) P0658
DIETHY LSTI LB!STROL F COPROPOPPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA P097 5
DI!THYLSTILB!STPOL F PHOTOPORPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA P0975
DIETHYLSTILBESTROL F UROPOHPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA P 0975
DI!THYLSTIL BESTROL 0 PROSTAT FLUID ACID PROS DEC V MARKEDLY LOWER IN BENIGN HYPEPTROPRY R0525
DIETHYLSTILB!STPOL P ?SH DEC V AT DOSES AFFECTING PIT-GONADAL AXIS P05 25
DI !TRYLSTILBESTPDL P LH DEC V AT DOSES AFFECTING PIT-GONADAL AXIS P05 25
DI!THYLSTILB!STPOL P TESTOSTERONE DEC V AT DOSES AFFECTING PITUITARY-GONADAL AXIS HO 525
DI ETHYLSTILP EST9OL S PHI INC V INCREASES CONCENTRATION OF CIRCULATING TBG P0004
DIETHYLSTI LBESTROL S TBG INC V DIRECT EFFECT OF DRUG P0004
DI !THYLSTILHESTEOL U COPROOPPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA P0975
DI!THYLSTILBESTR OL U UROPORPIIYRIN INC V NAY INDUCE PORPHYRIA CUTANEA TARDA RO 975
DI FLUOROPHOSPHATE S PB! DEC V INTERFERES WITH TRAPPING OF IODIDE BY THYROID R0004
DIGITALIS B !OSINOPHILS INC V ALLERGIC RESPONSE MAY BE LARGE WITH TOXICITY HO 42 14
DI G I T A LI S B PLATELET COUNT DEC V (RARE) PANCYTOPENIA/THROMBOCYTOPENIA P1017
DIGITALIS B RED CELL COUNT DEC V APLASTIC ANEMIA/PANCYTOPENIA R062O
DIGITALIS B WHITE CELL COUNT DEC V AGRANULOCYTOSIS/LEUKOPENIA P06 20
DIGITALIS B WHITE CELL COUNT INC V RARE LEUKOCYTOSIS P0620
DIGITALIS P PROTRROMBIN TIME DEC V ANIMAL EXPERIMENTS SUGGEST INC COAGULABILITY P0620
DIGITALIS S BARBITURATE Z N NO INTERFERENCE WITH UV ABSORPTION METHODS P0779
DIGITALIS S PHI Z V NO EFFECT OBSERVED P02 55

DIGITALIS S PROTEIN INC V IMPROVED HEPATIC FUNCTION AND DEC HYPOVOLENIA P0384
DIGITALIS U CHLORIDE INC V DIURETIC ACTION IN CARDIAC FAILURE 303814
DIGITALIS U GFR INC V IMPROVEMENT WITH RELIEF 0! EDEMA 90384
DIGITALIS U SODIUM INC V DIURETIC ACTION IN CARDIAC FAILURE 903814
DIGITALIS U VOLUME INC V DIURETIC ACTION IN CARDIAC FAILURE 903914
DIGITONIN S CHOLESTEROL INC N IF ?-TOLUENESULFONIC ACID REACTION USED RO36
DIGITOXIN B PLATELET COUNT DEC V PARE THROMBOCYTOPENIA (DUE TO IMMUNE MECHANISM) 31017
DIGITOXIN U CATECHOLANINES Z N NO EFFECT ON FLUOROMETPIC METHOD OF CROUT R0235
DIGITOXIN U 17 KETOGENIC STEROIDS INC M INTERFERES WITH ZIMMERMAN REACTION IN VITRO 90133
DIGITOXIN U 17 KETOSTEROIDS Z M NIN INTERFERENCE WITH ZIMMERMAN REACTION 30133
DIGITOXIN U 17 OH CORTICOSTEROIDS INC N MODERATE EFFECT WITH IN VITRO TEST 90417
DIGOXIN E POTASSIUM DEC V 6% DROP WITHIN 2 DAYS, AFFECTS MEMBRANE ATP-AS! 90527
DIGOXIN E SODIUM INC V 16% INC, DUE TO EFFECT ON MEMBRANE ATP-ASE 30527
DIGOXIN B WATER INC V SLIGHT EFFECT ONLY DUE TO ACTION ON MEMBRAN! P0527
DIGOXIN U 17 KETOSTEROIDS DEC N SLIGHT EFFECT ON ZIMMERMAN REACTION IN VITPO R0133
DIGOXIN U 17 OH CORTICOSTEROIDS INC N MODERATE EFFECT WITH IN VITRO TEST P01417
DIHYDROTACHYSTEROL S CALCIUM INC V WEAK ANTIRACHITIC ACTIVITY 30620
DIHYDROTACHYSTEPOL U CALCIUM INC V HYPERCALCIURIC EFFECT 90299
DIHYDROTACHYSTEROL U PHOSPHATE INC V DIURESIS ALMOST AS GREAT AS WITH VITAMIN D3 90026
DIHYDPOTACHYSTEROL U PROTEIN INC V MAY INDUCE INCREASED GLOMERULAR PERMEABILITY 90299
DIHYDROTACHYSTEROL U URINALYSIS PROTEIN INC N INCREASED GLONERULAR PERMEABILITY 90299
DIHYDPOXYACETONE S TRIGLYCERIDES INC N MEASURED AS GLYCEROL WITH ENZYMATIC METHODS P0779
DIIODOCAFFEINE S PHI INC V CONTAINS 66.5% IODINE RO00
DIIODOHYDROXYQUIN B RED CELL COUNT DEC V MAY CAUSE ANEMIA 90620
DIIODOHYDROXYQUIN B WHITE CELL COUNT DEC V MAY CAUSE LEUKOPENIA 90620
DIIODOHYDROXYQUIN S I 131 UPTAKE DEC V EFFECT LASTS FOB SEVERAL WEEKS 901417
DII000RYDROXYQUIN S PB! INC N CONTAINS 65% IODINE, EFFECT LASTS FOR SOME WEEKS 300014
DIIODOHYDROXTQUIN S SGPT INC V HEPATIC DAMAGE REPORTED IN ANIMALS 90384
DIIODOQUINOLINE S PB! INC N CONTAINS 67% IODINE P0004
DIMERCAPROL B HEMATOCRIT DEC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS 902140
DINERCAPROL B HEMOGLOBIN DEC V HENOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS 302140
DIMEPCAPPOL B METHEMOGLOBIN INC V MAY CAUSE HEMOLYSIS IN G-6-PD DEFICIENCY 90926
DIMEPCAPROL B PR DEC V NAY INDUCE METABOLIC ACIDOSIS 90026
DIMEHCAPROL B RED CELL COUNT DEC V HENOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS 90240
DIMEPCAPPOL B RETICULOCYTES INC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS RO24O
DIMERCAPROL P HEMOGLOBIN INC V OCCURS WITH INTRAVASCULAR HENOLYSIS 902140
DINERCAPROL P METHEMALBUMIN INC V OCCURS WITH INTRAVASCULAR HENOLYSIS 302140
DIMERCAPROL S BILIRUBIN INC V MAY CAUSE HENOLYSIS WITH G-6-PD DEFICIENCY 90079
DIMERCAPPOL S CO2 CONTENT DEC V ASSOCIATED WITH METABOLIC ACIDOSIS R0299
DIMERCAPROL S GLUCOSE DEC V AFTER INITIAL INCREASE 30620
DIMERCAPROL S GLUCOSE INC V INITIAL RESPONSE TO TOXIC DOSES 90620
DIMERCAPROL S HAPTOGLOBIN DEC V NAY CAUSE HEMOLYSIS 90079
DIMEPCAPPOL S I 131 UPTAKE DEC V ELEMENTAL IODINE TRAPPED IN THYROID P0620
DINEHCAPROL S LACTATE INC V ASSOC WITH METABOLIC ACIDOSIS R0O26
DIMEPCAPROL U ARSENIC INC V IF POISONING DUE TO ARSENIC 90026
DINERCAPROL U CALCIUM INC V EFFECTIVE BUT LESS GOOD THAN EDTA 90026
DIMERCAPROL U COPPER INC V IF CAUSE OF POISONING (PENICILLAMINE BETTER) P0026
DIMERCAPROL U GOLD INC V IF POISONING DUE TO GOLD R0O26
DIMERCAPROL U LEAD INC V IF POISONING DUE TO LEAD P0026
DIMERCAPPOL U MERCURY INC V IF POISONING DUE TO MERCURY 90026
DIMETHYLTUBOCUPAP S PBI INC V CONTAINS 35% IODINE 00O4
DINITROPHENOL B HEMOGLOBIN DEC V MAY CAUSE ANENIA/APLASTIC ANEMIA P0384
DINITROPHENOL B METHEMOGLOBIN INC V MAY CAUSE HEMOLYSIS/APLASTIC ANEMIA P0658
DINITROPHENOL B RED CELL COUNT DEC V NAY CAUSE ANEMIA/APLASTIC ANEMIA 903814
DINITROPHENOL B WHITE CELL COUNT DEC V NAY CAUSE AGRANULOCYTOSIS/APLASTIC ANEMIA 903814
DINITROPRENOL S BILIRUBIN INC V DUB TO TOXIC HEPATITIS 90368
DINITROPHENOL S PB! DEC V COMPETES WITH THYROXINE FOR TBG P0004
DINITPOPRENOL S SCOT INC V HEPATOTOXICITY WITH CENTPOLOBULAH NECROSIS P0384
DINITROPHENOL S SGPT INC V HEPATOTOXICITY WITH CENTROLOBULAP NECROSIS P03814
DINITROPHENOL S THYROXINE (T14) DEC V DISPLACED FROM BINDING SITES ON TBG P0907
DINITROPHENOL S UREA NITROGEN INC V REPORTED TO CAUSE RENAL DAMAGE P03814
DINITROPHENOL U PROTEIN INC V DUE TO NEPHROTOXICITY P0368
DINITPOPHENOL U URINALYSIS BILE INC V DUE TO HEPATOTOXICITY 90368
DINITROPHENOL U URINALYSIS CASTS INC V DUE TO TOXIC NEPHPITIS 90368
DINITROPHENOL U URINALYSIS COLOR INC V RED BROWN DUE TO HEMATUBIA 90620
DINITROPHENOL U URINALYSIS PROTEIN INC V DUE TO NEPRROTOXICITY P0368
DINITROPHENOL U URINALYSIS PBC/HPF INC V DUE TO TOXIC NEPHRITIS 30368
DIPHENHYDPAMINE B HEMATOCRIT DEC V HEMOLYTIC ANEMIA 90932
DIPHENHYDRANINE B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA 90932
DIPHENHYDPAMINE B RED CELL COUNT DEC V HENOLYTIC ANEMIA 90932
DIPHENHYDHAMIN! P AMMONIA DEC V REPORTED EFFECT IN EXOGENOUS NH3 TOXICITY P0533
DIPHENHYDRAMINE S BILIPUBIN INC V MAY OCCUR WITH HEMOLYTIC ANEMIA P0932
DIPHENHYDRANINE S HAPTOGLOBIN DEC V CONSEQUENCE OF HEMOLYTIC ANEMIA P0932
DIPRENHYDRAMINE U CATECHOLAMINES Z V NO EFFECT SHORT TERM INGESTION OF 150 MG/DAY P0236
DIPHENHYDRAMINE U EPINEPHRINE Z V NO EFFECT SHORT TERM INGESTION OF 150 MG/DAY P0236
DIPHENHYDRAMINE U NOPEPIN!PHPINE Z V NO EFFECT SHORT TERM INGESTION OF 150 MG/DAY P0236
DIPHENHYDHAMINE U 11 OH COBTICOSTEROIDS Z V NO EFFECT SHORT TERM INGESTION OF 150 MG/DAY P0236
DIPHENHYDRANIN! U 17 KETOSTEPOIDS Z V NO EFFECT SHORT TERM INGESTION OF 150 MG/DAY RO236
DIPHENHYDRANINE U 17 OH COBTICOSTEPOIDS I V NO EFFECT SHORT TERM INGESTION OF 150 MG/DAY RO236
DI?H!NYLHYDANTOIN B EOSINOPHILS INC V RAPE HYPERSENSITIVITY REACTION 801417
DIPHENYLHYDANTOIN B HEMATOCRIT DEC V MEGALOBLASTIC/HEMOLYTIC/APLASTIC ANENIA,PANCYTOPEN P0873
DIPHENYLHYDANTOIN B HEMOGLOBIN DEC V NEGALOBLASTIC/HEMOLYTIC/APLASTIC ANEMIA,PANCYTOPEN P0873
DIPHENYLMYDANTOIN B LE CELL PREP POS V REPORTED APPEARANCE OF LE CELLS P0596
DIPH!NYLHYDANTOIN B MCV INC V MAY OCCUR WITH NEGALOBLASTIC ANEMIA P0873
DIPHENYLHYDANTOIN B NETHEMOGLOBIN INC V OCCURS WITH HENOLYTIC ANEMIA P0596
DIPHENYLHYDANTOIN B NEUTROPHILS DEC V NEGALOBLASTIC/HEMOLYTIC/APLASTIC ANECIA,PANCYTOPEN P0025
DIPHENYLHYDANTOIN B PLATELET COUNT DEC V NEGALOBLASTIC/HEMOLYTIC/APLASTIC ANEMIA/PANCYTOPEN 90025
DIPHENYLHYDANTOIN B RED CELL COUNT DEC V MEGALOBLASTIC/HEMOLYTIC/APLASTIC ANEMIA/PANCYTOPEN P0873
DIPHENYLHYDANTOIN B WHITE CELL COUNT DEC V MEGALOBLASTIC/BEMOLYTIC/APLASTIC ANEMIA/PANCYTOPEN P0025
DIPHENYLHYDANTOIN B WHITE CELL COUNT INC V DUE TO BOSIWOPHILIA P0620

DI PH ENYLH YDA NTOI N E POLATE DEC V IMPAIRED DECONJUGATION OF POLYGLUTANATES IN GUT P09 10
DIPHENYLHYDANTOI N F COPPOPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P0371
DIPBENYLHYDANTOI N F PPOTOPORPHYPIN INC V MAY PRECIPITATE ACUTE PORPHYRIA HO 37 1
DIPH!NYLHYDANTOIN 0 DEXAMETHASON! SUPPRESS V ALTERS STEROID METABOLISM P014 17
DIPHFNYLHYDANTOI N P COPTICOSTEPOIDS INC V ALTERS STEROID METABOLISM P0959
DIPHENYLHYDANTOIN P COPTISOL DEC V CHRONIC ADMINISTRATION EFFECT IN CUSHINGS SYNDROME HO 596
DIPH? NYLHYDANTOIN P INSULIN DEC V REDUCES INSULIN RESPONSE TO GLUCOSE CHALLENGE R0613
DI PH?NYLHYDANTOTN P PROTHPOMBIN TIME INC V PATIENTS ON COUNAHINS WHICH INHIBIT ITS METABOLISM RO5 96
DIPHFNYLHYDANTOIN S ALKALINE PHOSPHATASE INC V HEPATOTOXICITY WITH CENTROLOBULAR NECROSIS HO 6 20
DI PHENYLHYDANTOIN S ALPHA2-GLOBULIN INC V RELATED TO DURATION OF THERAPY R0657
DIPHENYLHYDANTOIN S BARBITURATE DEC N NEGATIVE INTERFERENCE WITH DIPHENTLCAPBAZONE METH. P00 96
DI PHENYLBYDANTOIN S BILIPUBIN INC V RARE HYPERSENSITIVITY REACTION P014 17
DIPH!NYLHYDANTOIN S BSP RETENTION INC V DUE TO HYPERSENSITIVITY OR INTRAHEPATIC CHOLESTASIS P01417
DIPHENYLBYDANTOIN S CUPHALIN FLOCCULATION INC V HEPATOTOXICITY WITH CENTROLOBULAR NECROSIS P 06 20
DI?H!NYLHYDANTOIN S CERULOPLASMIN INC V EFFECT ON SYNTHESIS OF PROTEIN IN LIVER HO 907
DIPH!NYLHYDANTOI N S CHOLESTEROL INC V HEPATOTOXICITY WITH CENTROLOBULAH NECROSIS P09 55
DIPHEN YLHYDANTOIN S COOMBS TIST POS V IMMUNOLOGICAL RESPONSE TO DRUG P01418
DIPHENYLBYDANTOIN S FOLATE DEC V MAY CAUSE MEGALOBLASTIC ANEMIA (IMPAIRS ABSOPP) P0976
DIPH!NYLHYDANTOIN S FREE THYROXINE DEC V COMPETES WITH T14 FOP TBG, INC LIVER DEGRADATION P0004
DIPHENYLHYDANTOI N S GLUCOSE INC V INHIBITORY EFFECT ON INSULIN SECRETION P0241
DIPHENYLMYDANTOIN S GLUCOSE TOLERANCE DEC V DECREASES INSULIN EXCRETION P0596
DIPH! NYLHYDA NTOI N S IMMUNOGLOBULIN IGA DEC V OBSERVED IN 21% (MECHANISM NOT ELUCIDATED) 90889
DI PHENYLH YDANTOI N S PB! DEC V COMPETES WITH THYROXINE FOP BINDING SITES P01417
DIPHENYLBYDA NTOI N S SCOT INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P06 20
DIPHFNYLHYDANTOIN S SGPT INC V INTHAHEPATIC CHOLESTATIC JAUNDICE P062 0
DIPFIEN YLHYDANTOI N S THYMOL TURBIDITY INC V INTHAHEPATIC CHOLESTATIC JAUNDICE HO 620
DIPHFNYLHYDANTOIN S THYROXINE (TU) DEC V DISPLACES THYROXINE FROM BINDING SITES HO 90 7
DIPHEN YLHYDANTOIN S T3 UPTAKE INC V AFFECTS BOTH RESIN AND RED CELL UPTAKE P014 17
DIPHENYLHYDANTOI N T FOLAT! DEC N MILD DEPRESSANT EFFECT ON L. CASE! P06 57
DI?HENYLHYDANTOIN U AICAP INC V OCCURS WITH IMPAIRED ABSORPTION OF FOLIC ACID P0976
DIPHENYLHYDANTCI N U AMINOLEVULINIC ACID INC V NAY PRECIPITATE ACUTE PORPHYRIA P037 1
DIPHENYLHYD ANTO! N U COPPOPORPHYPIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P03 71
DIPH! NYLHYDA NTOI N U FIGLU INC V OCCURS WITH IMPAIRED ABSORPTION OF POLIC ACID P0976
DIPHENYLHYDANTOIN U GLUCOSE INC V OCCURS WTIH INHIBITION OF INSULIN SECRETION HO 241
DIPHENYLHYDA NTOIN U PORPHOBILINOGEN INC V NAY PRECIPITATE ACUTE PORPHYRIA HO 371
DI PHENYLHYDANTOIN U URINALYSIS BILE INC V HEPATOTOXICITY P062 0
DIPHENYLHYDA NTO! N U URINALYSIS COLOR INC N PINK,RED OP PRO-BROWN COLOR MAY OCCUR P0417
DIPHENYLHYDANTOIN U URINALYSIS GLUCOSE INC V OCCURS WITH HYPERGLYCEMIA P024 1
DIPHENYLHYDANTOI N U 17 KETOSTEPOIDS DEC V ALTERS STEROID METABOLISM RD 1417
DI PRENYLHYDA NTOI N U 17 OH CORTICOSTEROIDS DEC V WITH CHRONIC INGESTION CORTISOL= 6-B-OH COPTISOL P0981
DIPHENYLHYDANTOIN U 6 HYDPOXYCORTISOL INC V ALTERS STEROID METABOLISM HO 98 1
DIPROTIZOATE S I 131 UPTAKE DEC V DUE TO IODINE COMPONENT OF DRUG P0596
DIPPOTIZOATE S PB! INC N BUT DOES NOT AFFECT T4 (EFFECT FOP 1-2 WEEKS) HO 839
DIPYRIDA MOLE B PLATELET AGGREG DEC V WEAK INHIBITION OF ADENOSINE DEAMINASE P03 26
DIPYHIDAMOLE P PLATELET COUNT INC V POSSIBLY DUE TO ALTERATION OF TURNOVER P0326
DIPYPONE B HENATOCRIT DEC V HEMOLYTIC ANEMIA P0569
DIPYPONE B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA P0569
DIPYPONE p RED CELL COUNT DEC V HENOLYTIC ANEMIA P0 569
DI PT PORE B WHITE CELL COUNT DEC V LEUKOPENIA OP AGPANULOCYTOSIS P014 68
DIPYPONE F OCCULT BLOOD POS V MAY CAUSE GASTROINTESTINAL BLEEDING P0026
DIPYPON! P METHEMALBUMIN INC V OCCURS WITH HENOLYTIC ANEMIA P0569
DIPYPONE S BILIRUBIN INC V MAY CAUSE HEMOLYTIC ANEMIA P06 36
DIPYRONE S COONBS TEST P05 V IMMUNOLOGICAL RESPONSE TO DRUG HO 104
0!0 YR 0 NE S DIRECT BILIPUBIN INC V NAY CAUSE HEMOLYTIC ANEMIA HO 636
DIPYRONE S HAPTOBLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P0636
DIP YR 0 NE S UREA NITROGEN INC V REPORTED TO CAUSE ANURIA P0026
DIPYPONE U URINALYSIS GLUCOSE DEC N MAY CAUSE FALSE NEGATIVE WITH ENZYME TESTS HO 436
DISULFIHAN B ACETALDEHYDE INC V ETHANOL METABOLISM DIVERTED (10 TINES NORMAL CONC) HO 384
DISULFIRA N P PPOTHROMBIN TINE INC V INHIBITS METABOLISM OF COUMAPINS P080 1
DISULFIRAN S ALKALINE PHOSPHATASE INC V ONE POSSIBLE CASE OF CHOLESTASIS REPORTED P0467
DISULF IRA N S BILIRUBIN INC V ONE POSSIBLE CASE OF CHOLESTASIS REPORTED HO 1467
DISULFIPAM S I 131 UPTAKE DEC V UNCOMMON REPORTED EFFECT P0596
DISULFIRAM S PB! DEC V UNCOMMON REPORTED EFFECT HO 596
DISULFI HAM S SGPT INC V ONE CASE OP QUESTIONABLE CHOLESTASIS REPORTED P01467
DISULFIPAM U HMPG INC V INHIBTION OF ALDEHYDE DEHYDROGENASE P0 596
DISULFIPAM U VMA INC N ?INTEPFERENCE FROM ACETALDEHYDE FROM ETHANOL P014 17
DIT HIAZ IRE F COLOR INC N GREEN TO BLUE P06 20
DITHIAZINE S I 131 UPTAKE DEC V DUE TO IODINE COMPONENT OF DRUG P0596
DITHIAZINE S PHI INC N CONTAINS 214.5% IODINE P00014
DITHIAZIN! U URINALYSIS COLOR INC N BLUE P06 20
DITHIA ZINT U URINALYSIS PROTEIN INC N REACTS WITH FOLIN-CIOCALTRU OF LOWRY PROCEDURE P06514
DITHIAZINE U URINALYSIS PROTEIN INC V TRANSIENT PROTEINUPIA MAY OCCUR P0657
DITHIOERYTHHITOL T PROTEIN INC N REACTS WITH FOLIN-CIOCALTEU OF LOWRY PROCEDURE HO 2 13
DIURETICS B VOLUME DEC V MAY OCCUR IF RAPID DIURETIC ACTION P03 84
DIURETICS P PPOTHPOMBIN TINE DEC V IN PATIENTS PECEIVING-ANTICOAGULANTS P0620
DIURETICS S CHLORIDE DEC V DIURETIC ACTION IF EXCESSIVE P0620
DIURETICS S CPK INC V MAY OCCUR AS RESULT OF I.N. INJECTIONS P0080
DI U RET I CS S POTASSIUM DEC V LOSS IN URINE P0620
DIURETICS S SODIUM DEC V DIURETIC ACTION P0723
DIURETICS S UREA NITPOGEN INC V REDUCED CLEARANCE P072 3
DIURETICS S URIC ACID INC V REDUCED CLEARANCE P00142
DIURET ICS U GFR DEC V EFFECT ON CLEARANCES P07 23
DIURETICS U POTASSIUM INC V DIURETIC ACTION P0620
DIURETICS U PSP EXCRETION DEC V BLOCKING OF SECRETORY MECHANISM P0299
DI UPETIC S U UREA CLEARANCE INC V MAY BE OBSERVED AFTER USE OF DIURETICS P0143
DIURNAL VARIATION S IRON DEC V TOWARDS LATE AFTERNOON OP EVENING P0998
DIURNAL VARIATION S PB! INC V SMALL STATISTICALLY SIGNIFICANT EFFECT P02 55
DIURNAL VARIATION U UREA CLEARANCE DEC V CLEARANCE LEAST IN MORNING HO 143
DIURNAL VARIATION U URORILINOGEN INC V MAXIMUM EXCRETION IN AFTERNOON 90143
DOAN’S PILLS U URINALYSIS COLOR INC N GREENISH BLUE P06 20
1094 CLINICAL CHEM1STRY, Vol. 18, No. 10, 1972

DOCA S PB! DEC V INHIBITS IODINATION OF TYHOSIN! IN TRG P00014
DOCA S POTASSIUM DEC V OCCURS AS RESULT OF INCREASED EXCRETION P0026
DOCA S SODIUM INC V MAY CAUSE RETENTIONAND EDEMA P0026
DOCA U POTASSIUM INC V PROMOTES INCREASED URINARY ELIMINATION 90026
DOCA U SODIUM DEC V EXCHANGED WITH K ION P03814
DOCA U VOLUME INC V ASSOCIATED WITH POLYDIPSIA ALSO RO384
DOPAMINE U SODIUM INC V DIURETIC EFFECT 90595
DOXAPRAM B HEMATOCHIT DEC V NOTED POSTOPERATIVELY IN A FEW PATIENTS P0010
DOXAPRAM B HEMOGLOBIN DEC V NOTED POSTOPERATIVELY IN A FEW PATIENTS P0010
DOXAPPAM B RED CELL COUNT DEC V NOTED POSTOPERATIVELY IN A FEW PATIENTS 90620
DOXAPRAN B WHITE CELL COUNT DEC V FURTHER DEC NOTED IN PATIENT WITH LEUKOPENIA ROOlO
DOXAPRAM S UREA NITROGEN INC V ? NEPHPOTOXIC EFFECT P0299
DOXAPPAM U PROTEIN INC V NAY HAVE NE?HPOTOXIC EFFECT 90299
DOXAPRAM U URINALYSIS PROTEIN INC V ? NEPHHOTOXIC EFFECT 90299
DOXEPIN B WHITE CELL COUNT DEC V THEORETICAL POSSIBILITY DUE TO CLASS OF COMPOUND 90026
DOXEPIN S BILIRUBIN INC V THEORETICAL POSSIBILITY DUE TO CLASS OF COMPOUND P0026
DOXEPIN U URINALYSIS BILE INC V THEORETICAL POSSIBILITY DUE TO CLASS 0? COMPOUND P0026
DOXYCYCLINE B EOSINOPHILS INC V ALLERGIC RESPONSE REPORTED 907314
DOXYCYCLINE B PLATELET COUNT DEC V THROMBOCYTOPENIA REPORTED P0734
DOXYCYCLINE B WHITE CELL COUNT DEC V NEUTPOPENIA REPORTED 907314
DOXYCYCLINE S CREATININE INC V NEPHPOTOXIC EFFECT P07314
DOXYCYCLINE S SGOT INC V REPORTED EFFECT (?HEPATIC ORIGIN) 90026
DOXYCYCLINE S UREA NITROGEN INC V NEPHROTOXIC EFFECT 807314
DOXYCTCLINE U PROTEIN INC V NEPHROTOXIC EFFECT P0734
DOXYCYCLINE U URINALYSIS PROTEIN INC V NEPHROTOX!C EFFECT P0734
DPOMOSTANOLONE B HENATOCRIT INC V RESPONSE TO ANDROGENS 90026
DROMOSTANOLONE B HEMOGLOBIN INC V RESPONSE TO ANDHOGENS 90026
DPOMOSTANOLONE B RED CELL COUNT INC V RESPONSE TO ANDPOGENS P0026
DRONOSTANOLONE S CALCIUM DEC V MAY OCCUR WITH REGRESSION 30026
DROMOSTANOLONE S CALCIUM INC V USUALLY IF OSTEOLYTIC METASTASES 90026
DYDHOGESTERONE B WHITE CELL COUNT INC V MILD LEUKOCYTOSIS REPORTED 30026
ECHOTHIOPHATE E CHOLINESTEHASE DEC V DIRECT EFFECT OF DRUG P0913
ECTYLUPEA S ALKALINE PHOSPHATASE INC V MAY CAUSE CHOLESTASIS WITH CHOLANGIOLITIS P0620
ECTYLUPEA S BILIRUBIN INC V NAY CAUSE CHOLESTASIS WITH CHOLANGIOLITIS 90620
ECTYLUREA S BSP RETENTION INC V NAY CAUSE CHOLESTASIS WITH CHOLANGIOLITIS RO620
ECTYLUHEA S CEPHALIN FLOCCULATION INC V MAY CAUSE CHOLESTASIS WITH CHOLANGIOLITIS 90620
ECTYLUPEA S SGOT INC V MAY CAUSE CHOLESTASIS WITH CROLANGIOLITIS P0620
ECTYLUREA S SGPT INC V MAY CAUSE CHOLESTASIS WITH CHOLANGIOLITIS 90620
ECTYLUREA S THYMOL TURBIDITY INC V MAY CAUSE CHOLESTASIS WITH CROLANGIOLITIS P0620
ECTYLUREA U URINALYSIS BILE INC V NAY CAUSE CHOLESTASIS WITH CROLANGIOLITIS P0620
EDTA B HEMATOCPIT DEC V MAY OCCUR WITH PROLONGED THERAPY R0026
EDTA B HEMOGLOBIN DEC V MAY OCCUR WITH PROLONGED THERAPY 90026
EDTA B PH DEC N AFFECTS ACID-BASE BALANCE IF USED AS ANTICOAGULANT P0620
EDTA B PLATELET COUNT DEC V TRANSIENT BONE MARROW DEPRESSION P0026
EDTA B FED CELL COUNT DEC V TRANSIENT BONE MARROW DEPRESSION P0026
EDTA B WHITE CELL COUNT DEC V TRANSIENT BONE MARROW DEPRESSION P0026
EDIA P AMMONIA Z N SATISFACTORY AS ANTICOAGULANT 90215
EDTA P PROTHROMBIN TIME DEC V TRANSIENT FALL DURING ADMINISTRATION (WITHIN 12 H) P0620
EDTA P PROTHRONBIN TIME INC N WHEN USED AS ANTICOAGULANT 31029
EDTA S CALCIUM DEC N IF DETERMINED BY OXALATE OH OTHER PRECIP. TECH. P0907
EDTA S CALCIUM DEC V COMPLEXES CALCIUM BY CHELATION 90554
EDTA S CALCIUM Z N NO EFFECT ON FLAME PHOTOMETRIC METHODS 90596
EDTA S CHOLESTEROL DEC V REPORTED TO OCCUR IF GIVEN I.V. 901417
EDTA S CO2 CONTENT DEC N SIGNIFICANT ALTERATION OP PH IN DRAWN SAMPLE P01436
EDTA S CO2 CONTENT DEC V NEPHROTOXIC EFFECT (ESP CA EDTA) P0355
EDTA S CREATININE Z N NO EFFECT ON ANALYTICAL METHODS REPORTED 901436
EDTA S GLUCOSE INC N IF GREATER THAN 1 MG/NL AFFECT 0-TOLUIDINE P0221
EDTA S HBD Z N NO EFFECT ON ACTIVITY P0779
EDTA S IONIZED CALCIUM DEC V CHELATES CALCIUM H0026
EDTA S IRON DEC N INTERFERES WITH METHOD OF YOUNG-HICKS R0779
EDTA S NPN INC N THEORETICAL INC OF 7 MG/100ML AS ANTICOAGULANT P01436
EDTA S NPN INC V NEPHROTOXIC EFFECT (ESP CA !DTA) .0620
EDTA S PR DEC N IN VITRO ADDITION OF NA SALT TO PLASMA/SERUM P0035
EDTA S POTASSIUM DEC N REACTS WITH POTASSIUM 80620
ROTA S SCOT Z N NO EFFECT ON ACTIVITY 90825
ROTA S SORBITOL DEHYDROGENASE DEC N INHIBITORY EFFECT P0779
EDTA S TOTAL LIPIDS DEC V OCCURS IF ELEVATED LIPIDS AND GIVEN I.V. 901417
EDTA S UREA NITROGEN INC V NEPHHOTOXICITY (ESP CA ROTA) P0355
EDTA S UREA NITROGEN Z N NO EFFECT ON ANALYTICAL METHODS REPORTED 90436
EDTA U CADMIUM INC V IF POISONING DUE TO CADMIUM P0026
ROTA U CALCIUM INC V EXCRETION OF CHELATE 80026
ROTA U CHROMIUM INC V IF POISONING DUE TO CHROMIUM P0026
ROTA U COPPER INC V IF POISONING DUE TO COPPER O026
ROTA U GLUCOSE INC V REPORTED EFFECT. ?NECHANISM RO3814
EDTA U LEAD INC V IF POISONING DUE TO LEAD P0026
EDTA U MANGANESE INC V IF POISONING DUE TO MANGANESE P0026
ROTA U NICKEL INC V IF POISONING DUE TO NICKEL 30026
EDTA U POTASSIUM INC V OCCURS PARTICULARLY IF GIVEN I.V. P0417
EDTA U PROTEIN INC V NEPHROTOXIC EFFECT (ESP CA EDTA) P0026
EDTA U URINALYSIS CASTS INC V N!PHROTOXIC EFFECT (ESP CA EDTA) P0620
EOTA U URINALYSIS GLUCOSE INC V MAY CAUSE TUBULAR DAMAGE P0384
EDTA U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT (ESP CA ROTA) 90355
ROTA U URINALYSIS SUGAR INC M REDUCES BENEDICT’S REAGENT P0355
ROTA U ZINC INC V IF POISONING DUE TO ZINC 90026
EGGPLANT U 5 OH INDOLEACETIC ACID INC V AS RESULT OF HIGH CONTENT IN FOOD ROL&17
ELECTROCAUTERY S CPK INC V EFFECT OF MUSCLE DAMAGE P0355
ENODIN U URINALYSIS COLOR INC N PINK, RED, PURPLE & RUST COLOR P0355
EPHEDHINE S GLUCOSE INC V LESS EFFECTIVE THAN EPINEPHRINE P0384
EPHEDRINE U GLUCOSE INC V MAY CAUSE GLYCOSURIA 90299
EPHEOPINE U URINALYSIS GLUCOSE INC V INCREASED EXCRETION OF GLUCOSE 90299
CLINIcAL CHEMISTRY, Vol. 18, No. 10, 1972 1095

EPINEPHRINE B COAGULATION TIME DEC V PROBABLY DUE TO INCREASED ACTIVITY OF FACTOR V 90620
EPINEPHRINE B ROSINOPHILS DEC V MAY CAUSE EOSINOPENIA (DIRECT ACTION) RO4214
EPINEPHRINE B FACTOR V INC V TRANSIENT EFFECT P0596
FPINEPHRINE B RED CELL COUNT INC V DUE TO HEMOCONCENTRATION P0384
EPINEPHPINE B WHITE CELL COUNT INC V INITIALLY DUE TO LYMPHOCYTOSIS LATER NEUTROPHILIA P0894
EPINEPRHINE P ALPHA AMINO NITROGEN INC V METABOLIC EFFECT-GLUCONEOGENESIS P0111
EPINFPHPINE P CATECHOLAMINES INC V PRESENCE OF EPINEPHRINE RO235
EPINEPHRINE P ERPF DEC V MAY DEC UP TO 140% BUT NO EFFECT ON BLOOD PRESSURE P0384
EPINEPHPINE P HEMOGLOBIN Z V NO EFFECT OBSERVED WITH INCREASED BLOOD FLOW P01485
EPINEPURINE P VOLUME DEC V LOSS OF PROTEIN-FREE FLUID TO TISSUES P0384
EPINEPHRINE S BILIPUBIN INC N AT 1 MMOL/L AFFECTS SMA 12/60 METHOD P0876
FPINFPHPINE S CHOLESTEROL INC V METABOLIC EFFECT (INDIRECTLY THROUGH ACTH STIN) P0417
EPINEPHPINF S GLUCOSE INC N AT 10 MG/100ML AFFECTS ALKALINE FERRICYANIDE P0370
EPINEPHRINE S GLUCOSE INC M AT 1 MMOL/L AFFECTS SMA 12/60 METHOD P0876
EPINEPHRINE S GLUCOSE INC V CHARACTERISTIC ACTION OF HORMONE P0417
EPINEPHINE S GLUCOSE Z N AT 10 MG/100ML NO EFFECT GLU OX OF GOCHMAN P0370
EPINEPPRINE S IRON DEC V 1 ML 1% SOLN I.M. EFFECT FOP 6 HOUR P0105
EPINEPHRINE S LACTATE INC V MARKED EFFECT LIKE BETA-ADPENERGIC COMPS P0384
EPINEPHH!NE S LIPOPROTEINS INC V EFFECT ON LOW DENSITY COMPONENTS P0384
EPIN!PHPINE S !JEFA INC V TRANSIENT METABOLIC EFFECT P03814
EPINEPHRINE S PB! DEC V CAUSES RELEASE OF PB! FROM THYROID P0004
EPINEPHRIN! S PHOSPHATE DEC V INCREASED GLUC0NGENESIS ROO29
EPINEPHRINE S PHOSPHOLIPIDS INC V METABOLIC EFFECT P0384
EPINEPHPINE S POTASSIUM DEC V AFTER INITIAL RISE, DUE TO HORMONAL ACTION P0620
EPINEPHR!NE S POTASSIUM INC V INITIAL RISE ACCOMPANIES GLUCOSE MOBILIZATION R03814
EPINEPHRINE S PROTEIN INC V DUE TO HEMOCONCENTRATION P0384
EPINEPHRINE S SCOT INC N AT 1 MNOL/L AFECTS SMA 12/60 METHOD P0876
EPINEPHRINE S TBG INC V BINDING CAPACITY INC AFTER INFUSION ROSO9
EPINEPHRINE S URIC ACID INC N AT 1 MNOL/L AFFECTS SMA 12/60, HENRY METHODS P0876
!PINEPHRIN! S URIC ACID INC V RESULT OF VASOCONSTRICTION IN KIDNEY P01417
FPINEPHRINE T PROTEIN INC M REACTS WITH FOLIN-CIOCALTEU OF LOWRY PROCEDURE P0213
EPINEPHRIN! U AMINO ACIDS DEC V METABOLIC EFFECT ASSOCIATED WITH GLUCONEOGENESIS P0620
EPINEPHPINE U CHLORIDE DEC V WITH INC FILTRATION FRACTION P0384
EPINEPHRINE U GFP DEC V SLIGHT FALL AFTER I.M. INJECTION P0657
EPINEPHRINE U PHENYLKETONES P05 N GREEN IN HIGH CONENTRATIONS WITH FECL3 P0239
!PINEPHRIN! U POTASSIUM DEC V WITH INC FILTRATION FRACTION P0384
EPINR?HPINE U SODIUM DEC V WITH INC FILTRATION FRACTION P0384
EPINEPRRINE U URIC ACID CLEARANCE DEC V SHARP FALL FOLLOWING I.M. INJECTION P0657
EPINEPHPINE U VMA INC V MEASURED AS ENDOGENOUS COMPOUND R0417
EPINEPHPINE U VOLUME DEC V I.M. INJECTION CAUSES SHARP DEC P0657
ERECT POSTURE 3 HEMOGLOBIN INC V DUE TO REDISTRIBUTION OF BODY WATER P1001
ERECT POSTURE P ALDOSTERONE INC V INCREASES APPROX 6 TINES IF NORMAL DIET P0026
ERECT POSTURE P PENIN INC V INCREASES APPROX 2 TIMES IF NORMAL DIET P0026
ERECT POSTURE S PROTEIN INC V BY 0,75 G/100ML COMPARED WITH PEST ANO RECUMBENCY R0998
ERECT POSTURE U UREA CLEARANCE DEC V DECREASE OBSERVED AFTER RISING P0143
EPGOTHIONINE S GLUCOSE INC N AT 10 MG/100ML AFFECTS ALKALINE FERPICYANIDE P0370
EPGOTHIONINE S GLUCOSE Z N AT 10 MG/100ML NO EFFECT GLU OX OF GOCHNAN RO370
ERGOTHIONINE S URIC ACID INC N FALSELY HIGH VALUES WITH PHOSPHOTUNGSTATE METHODS P0370
EPGOTHIONINR U URIC ACID INC N FALSELY HIGH VALUES WITH PHOSPHOTUNGSTATE METHODS P0370
ERYTHPOMYCIN B EOSINOPHILS INC V ASSOC WITH HYPERSENSITIVITY REACTION P0623
EPYTHPONYCIN B WHITE CELL COUNT DEC V LEUKOPENIA OR NEUTROPENIA MAY OCCUR P0623
ERYTHPOMYCIN B WHITE CELL COUNT INC V LEUKOCYTOSIS OBSERVED P0623
EPYTHRONYCIN C PROTEIN Z N NO EFFECT ON FOLIN-CIOCALTEU PROCEDURE P1026
ERYTHROMYCIN F UROBILINOGEN DEC V NAY CAUSE CHOLESTASIS (REVERSIBLE) ROL&77
ERYTHROMYCIN P PROTHPOMB!N TIME INC V ASSOC WITH IMPAIRED AVAILABILITY OF BILE SALTS P0596
ERYTHPOMYCIN S ALKALINE PHOSPHATASE INC V MAY CAUSE INTRAHEPATIC CHOLESTASIS (REVEHStBLE) P0330
ERYTHPONYCIN S BILIRUBIN INC V CAUSES CHOLESTASIS IN APPROX 15% PATIENTS P0330
ERYTHPOMYCIN S BSP RETENTION INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P0029
ERTTHPOMYCIN S CEPHALIN FLOCCULATION INC V WEAK EFFECT DUE TO CHOLESTASIS P0477
EPYTHROM!CIN S CHOLESTEROL DEC V HEPATOTOXIC EFFECT P0596
EHYTHRONYCIN S DIRECT BILIRUBIN INC V REPORTED EFFECT 90620
ERYTHHOMYCIN S FOLATE DEC N INHIBITS GROWTH OF L. CASE! P0910
EPYTHROMTCIN S GLUCOSE DEC V HEPATOTOXIC EFFECT P0596
ERYTHHOMYCIN S SCOT INC N COLOPIMETHIC ASSAY IF DNPH OR DIAZONIUN SALT USED P0907
ERYTHPOMYCIN S SCOT INC V CAUSES HEPATIC TOXICITY IN SON! CASES P0330
ERYTHROMYCIN S SGPT INC N INTERFERES WITH COLOHIMETHIC PROCEDURES P0596
!RYTHROMYCIN S SGPT INC V MAY CAUSE HEPATIC TOXICITY RO33O
ERYTHROMYCIN S THYMOL TURBIDITY INC V WEAK EFFECT DUE TO CHOLESTASIS P0477
ERYTHROMYCIN U CATECHOLANINES INC N INTERFERES WITH FLUOHOMETPIC METHODS P0233
FRYTHPOMYCIN U URINALYSIS BILE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE 90029
ERTTHROMYCIN U UROBILINOGEN DEC V NAY OCCtYR WITH CHOLESTASIS P01477
!PYTHROMYCIN U 17 KETOSTEROIDS INC N INTERFERENCE WITH MEASURING PROCEDURE P0417
EPYTHROMYCIN U 17 OH CORTICOSTEPOIDS INC N REPORTED INTERFERENCE WITH MEASURING PROCEDURE P0417
ESTRADIOL P FSH DEC V RELATIVELY SLOWER THAN LH IN RESPONSE TO I.V. P1012
ESTRADIOL P LH DEC V IN RESPONSE TO I.V. INFUSION FOR SHORT DURATION P1012
ESTRAOIOL S ALKALINE PHOSPHATASE INC V OCCURS IN UP TO 50% CASES P0681
ESTRADIOL S BILIPUBIN INC V CHOLESTASIS NAY OCCUR P0620
ESTRAOIOL S BSP RETENTION INC V CHOLESTATIC EFFECT IN ALMOST ALL SUBJECTS P0681
ESTRADIOL S CEPHALIN FLOCCULATION INC V CHOLESTATIC EFFECT P0620
ESTRADIOL S PB! INC V INCREASES CONCENTRATION OF CIRCULATING TBG P0004
ESTHADIOL S SCOT INC V CHOLESTATIC EFFECT P0620
ESTHADIOL S SGPT INC V CHOLESTATIC EFFECT P0620
ESTRADIOL S TBG INC V DIRECT EFFECT OF DRUG 90004
ESTPAOIOL S THYMOL TURBIDITY INC V CHOLESTATIC EFFECT P0620
FSTRAOIOL S 5-NUCLEOTIDAS! INC V CHOLESTATIC EFFECT P0620
ESTRAOIOL U HPG EXCRETION DEC V IN OOPHOPECTOMIZED OR POSTNENOPAUSAL WOMEN P0934
ESTRADIOL U URINALYSIS BILE INC V CHOLESTATIC EFFECT P0620
ESTROGENS B ANGIOTFNSIN II INC V OCCURS WITHIN 5 DAYS, INC NAY BE 3 TIMES NORMAL P0174
ESTROGENS B COPHOPORPHYRIN INC V MAY PRECIPITATE PORPHYRIA ATTACK P0371
ESTROGENS B FACTOR II INC V REPORTED EFFECT P0134

ESTROGENS B FACTOR IX INC V ALTERED PROTEIN METABOLISM 90874
ESTROGENS B FACTOR VII INC V ALTERED PROTEIN METABOLISM 90874
ESTROG ENS B FACTOR X INC V SLIGHT EFFECT OBSERVED RO1 86
ESTROGENS B HEMATOCRIT DEC V NAY IMPAIR ABSORPTION OF FOLATE 90976
ESTROGENS B HEMOGLOBIN DEC V IMPAIRS ABSORPTION OF FOLATE HO 976
ESTROGENS B NCV INC V MEGALOBLASTIC ANEMIA 90976
ESTROGENS B PROTOPOPPHYHIN INC V MAY PRECIPITATE PORPHYRIA ATTACK P0 37 1
ESTROGENS B RED CELL COUNT DEC V MEGALOBLASTIC ANEMIA (IMPAIRS ABSORP OF FOLATE) HO 97 6
ESTROGENS F COPROPORPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA P0975
ESTROGENS F PROTOPORPHYHIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA HO 975
ESTROGENS F UHOPORPHYPIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA P0975
ESTROGENS 0 CERVICAL SECRETION INC V LEUCOPRHEA IN 20% WOMEN ON OPAL CONTRACEPTION 90629
ESTROGENS P ASCORBIC ACID DEC V EFFECT MARKED AT 2 WKS, < EFFECT IN PLATELETS H 05 06
ESTROGENS P CORTISOL INC V INCREASES CONC OF BINDING GLOBULIN 301417
ESTROG ENS P FIBBINOGEN INC V ALTERED LIVER METABOLISM P0 87 14
ESTROGENS P ESH DEC V HORMONAL EFFECT R0847
ESTROG ENS P GROWTH HORMONE INC V MODULATORS OF HIGH SECRETION IN NORMALS 306149
ESTROGENS P NON PHOT BOUND CORTISOL INC V HORMONAL ACTION 90417
ESTROGENS P PLASNINOGEN INC V ALTERED METABOLISM HO 8 714
ESTROGENS P PENIN ACTIVITY INC V DUE TO INCREASED SUBSTRATE HO 17 4
ESTROGENS P PENIN DEC V INHIBITION OF CIRC LEVEL BY ANGIOTENSIN 90174
ESTROGENS P RENIN SUBSTRATE INC V HORMONAL ACTION 90174
ESTROGENS P TESTOSTERONE INC V ALTERED METABOLISM HO 874
ESTROG ENS P VOLUME INC V RETENTION OF SALT AND WATER COMMON P065 7
ESTPOGE NS P 17 OH CORTICOSTEHOIDS INC V CAUSES STIMULATION OF PITUITARY ADRENAL AXIS HO 971
ESTROGENS S ALBUMIN DEC V METABOLIC CHANGES IN LIVER SYNTHESIS .0588
ESTROGENS S ALKALINE PHOSPHATASE INC V TRANSIENT INCREASES 2 TO 50% REPORTED HO 566
ESTROG ENS S ALPHA-L!POPROTEINS INC V METABOLIC EFFECT (ALMOST DOUBLED IN SOME STUDIES) P0072
ESTROGENS S ALPHA1-ANTITRYPSIN INC V METABOLIC EFFECT 90072
ESTROGENS S ALPHA2-MACPOGLOBULIN INC V METABOLIC EFFECT P007 2
ESTROGENS S ANT!THROMB!N I!! ACTIV DEC V ?PPEDISPOSING CAUSE OF THROMBOSIS R1O28
ESTROG ENS S BETA-GLUCURON!DASE INC V METABOLIC EFFECT P00 72
ESTROGENS S BETA-LIPOPROTEINS DEC V METABOLIC EFFECT (DECREASE OF 30%) P0072
ESTHOG ENS S BILIHUBIN INC V MAY CAUSE CHOLESTASIS (MAY BE HEPATOCELLULAR DEGEN) P06 20
ESTROGENS S BSP RETENTION INC V CHOLESTATIC EFFECT IN MOST CASES (DOSE RELATED) HO 68 1
ESTROGENS S C-REACTIVE PROTEIN INC V ALTERED LIVER METABOLISM HO 8 714
ESTROGENS S CALCIUM INC V POSITIVE EFFECT ON CALCIUM RETENTION HO 384
ESTROG ENS S CEPHALIN FLOCCULATION INC V MAY OCCUR WITH CHOLESTASIS P 0596
ESTROGENS S CERULOPLASMIN INC V BUT NO CHANGE IN CERULOPLASMIN ACTIVITY HO 6 140
ESTROGENS S CHLORIDE INC V MAY CAUSE SALT AND WATER RETENTION 903814
ESTROGENS S CHOLESTEROL DEC V REDUCES BY UP TO 18%:USED THERAPEUTICALLY P06 81
ESTROG ENS S CHOLINESTEPASE DEC V ALTERED LIVER METABOLISM 908714
ESTROGENS S COPPER INC V ASSOCIATED WITH INCREASED CEPULOPLASNIN P0 506
ESTROGENS S CORTICOSTEH BIND GLOB INC V METABOLIC EFFECT 90072
ESTROGENS S ELECTROPHOPETIC INDEX INC V INCREASES BINDING CAPACITY OF TBG RO997
ESTROG ENS S ESTROGEN BINDING GLOB INC V ALTERED LIVER METABOLISM HO 874
ESTROGENS S FOLATE DEC V MAY IMPAIR ABSORPTION 90976
ESTROGENS S FREE THYROXINE INC V INCREASES BINDING CAPACITY OF TBC HO 997
ESTROGENS S PT! INC V INCREASES BINDING CAPACITY OF TBG P0997
ESTROGENS S G-C COMPONENT INC V ALTERED METABOLISM 90072
ESTROGENS S GGTP Z V NO METABOLIC EFFECT 0O72
ESTROGENS S GLUCOSE INC V METABOLIC EFFECT 90467
ESTPOG ENS S GLUCOSE TOLERANCE DEC V EFFECT VARIABLE DEPENDING ON STRENGTH BO1417
ESTROGENS S GONADAL BINDING GLOB INC V METABOLIC EFFECT ROO72
ESTROG ENS S HAPTOGLOBIN DEC V ALTERED LIVER METABOLISM P08714
ESTROGENS S I 131 UPTAKE INC V INCREASED UPTAKE REPORTED RO596
ESTROG ENS S INMUNOGLOBULINS DEC V ALTERED LIVER METABOLISM 30 8714
ESTROGENS S IMMUNOGLOBUL!NS Z V NO METABOLIC EFFECT P00 72
ESTHOG ENS S LEUCINE ANINOPEPTIDASE INC V ALTERED METABOLISM P0072
ESTROGENS S LIPOPHOTEIN LIPASE DEC V METABOLIC EFFECT 90072
ESTROGENS S LIPOPROTEINS INC V IF VERY LOW DENSITY 90874
ESTROGENS S NAPHTHYLAMIDASE ISOENZ INC V METABOLIC EFFECT P0072
ESTROGENS S OROSOMUCOID DEC V ALTERED METABOLISM HO 1149
ESTROGENS S PSI INC V INCREASES BINDING CAPACITY OF TBG P0997
ESTROGENS S PHOSPHOLIPIDS INC V ALTERED METABOLISM P0 8714
ESTROGENS S PREBETA-LIPOPROTEINS INC V REPORTED EFFECT P03 814
ESTROGENS S PREGNANCY PROTEIN INC V METABOLIC EFFECT P0072
ESTROG ENS S PROTEIN DEC V ALTERED METABOLISM P08714
ESTROGENS S SCOT INC V MAY CAUSE CHOLESTASIS, HARE HEPATOCELLULAP DEGEN P0 596
ESTROG ENS S SCPT INC V MAY CAUSE CHOLESTASIS, RAPE HEPATOCELLULAP DEGEN P05 96
ESTROGENS S SIALIC ACID DEC V ALTERED METABOLISM P00 72
ESTROGENS S SODIUM INC V MAY CAUSE SALT AND WATER RETENTION P0384
ESTROGENS S TBG INC V INCREASES BINDING CAPACITY OF TBG P0997
ESTROG ENS S TBPA DEC V METABOLIC EFFECT 90072
ESTROGENS S THYMOL TURBIDITY INC V OCCURS WITH CHOLESTASIS 90596
ESTROGENS S THYROID BINDING RATIO DEC V INCREASES BINDING CAPACITY OF TBG HO 9 97
ESTROGENS S THYROXINE (T14) INC V INCREASES BINDING CAPACITY OF TBG 30112
ESTROGENS S TRANSFERRIN INC V ALTERED LIVER SYNTHESIS P06140
ESTROG ENS S TRIGLYCERIDES INC V ASSOC WITH INC VERY LOW DENSITY LIPOPPOTEINS P06 27
ESTROGENS S TRYPSIN INHIBITOR INC V METABOLIC EFFECT P0 072
ESTROG ENS S T3 UPTAKE DEC V INCREASES BINDING CAPACITY OF TBG P 0997
ESTROGENS S T4 (MURPHY-PATTER) INC V INCREASES BINDING CAPACITY OF TBG 90997
ESTROG ENS S ZINC INC V METABOLIC EFFECT P0148
ESTROGENS S 5-NUCLEOTIOASE INC V MAY CAUSE CHOLESTASIS HO 6 20
ESTROGENS U AICAR INC V OCCURS WITH MEGALOBLASTIC ANEMIA HO 976
ESTROGENS U AMINOLEVULINIC ACID INC V NAY PRECIPITATE PORPHYRIA ATTACK HO 371
ESTROG ENS U COPPOPOPPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA 80975
ESTROGENS U FIGLU INC V OCCURS WITH MEGALOBLASTIC ANEMIA P0976
ESTROGENS U PORPHOBILINOGEN INC V MAY PRECIPITATE PORPHYRIA ATTACK HO 37 1
ESTROGENS U URINALYSIS BILE INC V DUE TO CROLESTASIS P0620

ESTROGENS U UROPORPHYPIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA P0975
ESTROGENS U 17 KETOSTEROIDS DEC N INTERFERES WITH ZIMMERMAN REACTIONS P0355
ESTPOGENS U 17 OH COPTICOSTEROIDS DEC N INTERFERES WITH ZIMMERMAN REACTIONS P0654
ES TROGENS U 17 OH COPTICOSTEROIDS DEC V WITH CHRONIC INGESTION CORTISOL= 6-B-OH COHTISOL P05114
ESTROGENS U 6-HYDROXYCORTISOL INC V ALTERATION OF STEROID EXCRETORY PATTERN (LONG TERM) P0236
EST H ON F. S ALKALINE PHOSPHATASE INC V OCCURS IN UP TO 50% CASES P0681
EST HONE S BILIRUBIN INC V NAY CAUSE CHOLESTASIS R062O
EST HONE S BSP RETENTION INC V OCCURS IN ALMOST ALL CASES P0681
ESTR ONE S CEPHALIN FLOCCULATION INC V MAY CAUSE CHOLESTASIS P0620
ESTRONE S PB! INC V INCREASES CONCENTRATION OF CIRCULATING TBG P0004
ESTPONE S SCOT INC V MAY CAUSE CHOLESTASIS P0620
ESTRONE S SGPT INC V MAY CAUSE CHOLESTASIS H0620
ESTRONE S TBG INC V DIRECT EFFECT OF DRUG P0004
FSTRONE S THYNOL TURBIDITY INC V MAY CAUSE CHOLESTASIS P0620
EST HO NE U HPG EXCRETION DEC V IN OOPHOPECTOMIZLO OP POSTMENOPAUSAL WOMEN P09314
ESTRON E U URINALYSIS ;t INC V MAY CAUSE CHOLESTASIS RO620
ETHACRY NIC ACID B NEUTPOPHILS DEC V OCCASIONAL NEUTROPENIA OP AGRANULOCYTOSIS P0657
ETHACPYNIC ACID B PH INC V HYPOCHLOREMIC ALKALOSIS NAY OCCUR P0840
ETHACRYNIC ACID B PLATELET COUNT DEC V THROMBOCYTOPENIA REPORTED P0723
ETHACRYNIC AC I 0 B WHITE CELL COUNT DEC V AGPANULOCYTOSIS P0970
ETHACP YNIC ACID F OCCULT BLOOD P05 V ONE CASE REPORTED(26% IF GIVEN I.V. POSSIBLY) P0117
ETHAC PYNIC ACID P AMMONIA INC V ?DUE TO HYPOKALEMIA AND ALKALOSIS R01417
ETHACRYNIC ACID P CORTISOL Z V NO EFFECT OBSERVED WITH THERAPY R0657
ETHACRYNIC ACT U P INSULIN VEC V REDUCTION IN FASTING 8TATE NOTED 90657
ETHACRYNIC AC ID P PROTHROMBIN TIME INC V DISPLACEB COUMARIN9 FROM ALNUNIN P0850
ETHACRYNIC ACID S AMYLASE INC V IHOLATED CAPE OF ACUTE PANCREATITIS 901417
ET9ACBYNIC ACID S DILIRUBIN INC V CUOLENTASIN OR HEPATOCELLULAR DAMAUE P0840
ETHACRYNIC ACID S CHLORIDE DEC V DIURETIC ACTION (INFIXBITH TUBULAR REABBORPTTON) 90723
ETFIACRYNIC ACID S C02 CONTENT INC V ASSOC WITH HYPOCHLORENIC ALELORIB P0840
ETHACRYNIC ACID S GLUCOSE DEC V SYMPTOMATIC HYPOGLYCEMIA REPORTED 90840
ETHACR YNIC ACID S GLUCOSE INC V DIABETOORNIC PROPERTIES 90907
NT j A C P Y N I C ACID S GLUCOSE TOLERANCE DEC V DIARETOURNIC-LIKE ACTION 0? DRUG P0723
ETHACRYNIC ACID S POTASSIUM DEC V DIURETIC ACTION P0907
!T H A C R Y N IC ACID S SCOT INC V CHOLESTABIB NITH HEPATOCELLULAR DAMAGE P02149
ETFIACRYNIC ACID S BURP INC V CHOLESTA8IR WITH HEPATOCELLULAR DAMAGE 902149
ETFIACRYNIC ACID S SODIUM DEC V DIURETIC ACTXON 90620
ETFIACRYNIC ACID S UREA NITROGEN INC V MAY CAUHE DETERIORATION I? RENAL FUNCTION IMPAIRED 90029
ETFIACRYNIC ACID S URIC ACID DEC V IF GIVEN I,V. TN LARGE DOSES HAS URICO9URIC EFFECT 90895
ETUACHYNIC ACID S URIC ACID INC V DECREAPED URATE CLEARANCE WITH LOW DOSEP 90907
FEHACRYNIC ACID U CALCIUM INC V IMPAIRED REAPNORPTION 90723
ETUACRYNIC ACID U CHLORIDE INC V PRESENT AN MAJOR ANION 90384
FTUACR YNIC ACID U CORTIHOL DEC V ?DUE TO CHANGED SECRETION OR PENAL HANDLINH 90417
ETUACRYNIC AC! D U ULUCOSE INC V DIABETOQENIC PROPEPTIER 90907
ETHACR YNIC ACID U MAGNESIUM INC V INCREANE UP TO HEVEN TIMEP REPORTED 901417
ETH ACHY NIC ACID U POTASSIUM INC V MARKED DIURETIC RENPONBE MAY OCCUR 901417
ETHACR YNIC ACID U SODIUM INC THERAPEUTIC INTENT 90840
ETHACRYNIC ACID U URIC ACID DEC V DECREASED URATE CLEARANCE 90299
ETHACRYNIC ACID U URIC ACID INC I? 9IVEN I.V, TN LARGE DOPEB HAR URICOBURIC EFFECT 90895
ETHACRYNIC ACID U URINALYSIS GLUCOSE INC V DIABETOGENIC PROPERTIES 90907
ETHACRYNIC ACID U VOLUME INC V THERAPEUTIC INTENT 908140
N HA MB UT OL S DSP RETENTION INC V FEW CANES REPORTED 90657
ETHAMBUTOL S SOOT INC V DECREAMED LIVER FUNCTION REPORTED 90026
FT HA MB UT OL S BURT INC V DECREANED LIVER FUNCTION REPORTED 90026
ETH A MB U TOL S URIC ACID INC V REPORTED EFFECT, NO DETAILS GIVEN 90417
ETHAMI VAN B PCO2 DEC V INC DEPTH OF REP? AND IMPROVED RULM VENTILATION 90026
NT H A N 01. B COPROPORPHYRIN INC V MAY PRECIPITATE ATTACK OF PORPHYRIA 90371
ETHANOL B ETHANOL INC V PREHENCE OP ALCOHOL (RIOHEP IN PLAHMA THAN PC) 903814
ETHANOL U HEMATOCRIT DEC V MAY AFFECT FOLIC ACID AD9ORPTION AND UHAGE 90976
ETHANOL B UNMOULORIN DEC V MAY AFFECT FOLIC ACID A$PORPTION AND USAGE 90976
ETHANOL B METHANOL INC V COMPETITV TNHIMTTON OP ALCOHOL DEHYDHO9ENANE 90610
ETHANOL B PH DEC V CAUSEN LACTIC ACWOMIM 90176
ETHANOL B PLATELET COUNT DEC V TOXIC MARROW PUPPRENPYON, DUE TO CHRON ALCOHOLIHN 90176
ETHANOL B PROTOPORPHYRIN INC V NAY PRECIPITATE ATTACK OF PORPHYRIA 90371
ETHANOL B RED CELL COUNT DEC V MAY AFFECT FOLIC ACID ADSORPTION AND USAGE 90976
ETHA NOL C ETHANOL INC V UBUALLY AT LOWEP CONCENTRATION THAN IN BLOOD 90384
ETHANOL F CORROPORPHYRIN INC V MAY PPECIPITATE ATTACK OF PORPHYRIA 90371
ETH ANOL V RROTOPORPHYU!N INC V MAT PRECIPITATE ATTACK OF PORPHYRIA 90371
ETHANOL 0 BREATH ALCOHOL INC V PRENENCE OF INUENTED ALCOHOL 90384
ETH A NOL 0 GABTRIC JUICE HCL INC V PSYCHICALLY, RE?LEXLY AND THRU HIBTAMYNE/GANTRIN 903814
ETHANOL 0 GASTRIC JUICE PEPSIN DEC V UNLERN MAJOR PNYCN!C COMPONENT 90384
FT HA N 0 I. P CATECHOLI&MINEB INC V BLIURT INCREASE FOLLOWINO MODERATE DOMES 90051
ETHANOL P CORTISOL INC V EFFECT BEEN I? HIGH DOBEM GIVEN I,V, P01493
ETHANOL P PROTHHOMBTN TIME INC V WITH LARGE QUANTITIES AND ALCOHOLIHM 90620
ETHANOL S AMYLASE INC V DUE TO NTIMULATION OF’PANCREATIC SECRETION 80356
ETHANOL S BILIRUBIN D$C V DECREA9E PILl, IN INFANT I? GIVEN TO PREG, WOMAN 90582
ETH ANOL S C02 CONTENT DEC V CAUPE9 LACTIC ACYDOHIR 90706
ETHANOL S CPK INC V EFFECT NOTICED IN ALCOHOLICH AFTER ALCOHOL 901460
ETHANOL S FOLATE DEC V AFFECTS A$POPPTYON I? REVERE ALCOHOLISM 80976
ETHANOL S GGTP INC V BEEN WITH OTHER LFT9 NORMAL IN CHRONIC ALCOHOLISM 907914
ETHANOL S GLUCOSE DEC V REDUCED TO PILOW SO MU/100ML: EFFECT POP lIP TO 2149 80187
ETHANOL S GLUCOSE INC V TRANRIENT HYPERULYCEMIA IN DEVELOPING INTOXICATION 903814
ETHANOL S GLUCOSE TOLERANCE DEC V PORSIPLE DIMINISHED TISNUE UPTAKE 90279
ETHANOL S lCD INC V OCCURS WITHIN 14 HOURH IN NORMAL NUBJECTS 80372
ETHANOL S LACTATE INC V CAUSES LACTIC ACIDOBIB 90187
ETHANOL S LIPASE INC V CHEMICAL OR PHYNICAL PANCREATITIS 90355
ETHANOL S MAUNESIUM DEC V FOLLOWING ETHANOL INDUCED URINARY EXCRETION 90905
ETHANOL H NEFA INC V ALTERED METABOLISM WITH DEC FATTY ACID OXIDATION 90384
ETHANOL S OCT INC V OCCURP AT 15 HOURS IN NORMAL NUBJECT9 90372
ETHANOL S OSMOLALITY INC V OSMOTIC ACTIVITY OF ALCOHOL-MIN FROM OTHER BOURCEB 80785
ETHANOL S POTASSIUM DEC V INAPPROPRIATE SECRETION OF ADH IN BEER DRINKERN 90265
1098 CLINICAL CHEMISTRY, Vol. 18, No, 10, 1972

ETHANOL S SODIUM DEC V INAPPROPRIATE SECRETION OP ADH IN BEER DRINKERS P0265
ETHANOL S SODIUM INC V SLIGHTLY HIGHER AFTER HEAVY BEER DRINKING P0274
ETHANOL S TRIGLYCERIDES INC V INFUSION CAUSES INCREASED HEPATIC SYNTHESIS P01487
ETHANOL S URIC ACID INC V SEEN IN ACUTELY INTOXICATED AND IN RESPONSE TO DIET RO586
ETHANOL S VITAMIN B12 DEC V IMPAIRS ABSORPTION P0976
ETHANOL U AICAR INC V MAY OCCUR WITH FOLIC ACID OP B12 DEFICIENCY P0976
ETHANOL U ANINOLEVULINIC ACID INC V NAY PRECIPITATE ATTACK OF PORPHYRIA 90371
ETHANOL U COPROPORPHYRIN INC V MAY PRECIPITATE ATTACK OF PORPHYRIA RO371
ETHANOL U EPINEPHRINE INC V SLIGHT INCREASE FOLLOWING INGESTION P0051
ETHANOL U ETHANOL INC V AT EQUILIBRIUM APPPOX 130% BLOOD CONCENTRATION R03814
ETHANOL U FIGLU INC V MAY OCCUR WITH FOLIC ACID OR B12 DEFICIENCY HO976
ETHANOL U MAGNESIUM INC V INCREASED EXCRETION SEEN IN CHRONIC ALCOHOLICS P0905
ETHANOL U METHYLNALONATE INC V MAY OCCUR IF B12 DEFICIENCY P0976
ETHANOL U NOPEPINEPHHINE INC V SLIGHT INC (BUT LESS THAN EPINEPHRINE) 90051
ETHANOL U POHPHOBILINOGEN INC V MAY PRECIPITATE ATTACK OF PORPHYRIA RO371
ETHANOL U PORPHYRINS INC V INCREASED SYNTHESIS OF POPPHYRINS 31001
ETHANOL U URIC ACID DEC V MECHANISM OBSCURE 303814
ETHANOL U URINALYSIS COLOR DEC N DIURESIS INDUCED REDUCES COLOR 90U17
ETHANOL U UROPOPPHYRIN INC V MAY PRECIPITATE ATTACK OF PORPHYRIA 30371
ETHANOL U VOLUME INC V DIURETIC ACTION, INHIBITS PITUITARY ADH SECRETION P0384
ETHANOL U ZINC INC V IN ABSENCE OF EFFECT ON SERUM CONCENTRATION P0187
ETHANOL U 5 OH INDOLEACETIC ACID DEC V SEROTONIN METABOLISM DIVERTED TO 5 OH TPYPTOPHOL P0258
ETHCHLORVYNOL P PROTUROMBIN TIME DEC V DEC POTENCY OF COUMARIN ANTICOAGS (ENZ INDUCTION) P0498
ETHCHLORVYNOL S CPK INC V OCCURS WITH POISONING, PROBABLE MUSCLE ORIGIN P1008
ETHCHLORVYNOL S SCOT INC V OCCURS WITH POISONING, PROBABLE MUSCLE ORIGIN R1008
ETHCHLORVYNOL S SGPT INC V OCCURS WITH POISONING, PROBABLE MUSCLE ORIGIN P1008
ETHER B BLEEDING TINE Z V ANESTHESIA HAS NO EFFECT P03814
ETHER B CLOTTING TIME Z V NO EFFECT OF ANESTHESIA P0384
ETHER B PCO2 DEC V NAY BE SLIGHT EFFECT DURING ANESTHESIA R0384
ETHER B PH DEC V METABOLIC ACIDOSIS ESP IN CHILDREN P0026
ETHER B PLATELET COUNT Z V ANESTHESIA HAS NO EFFECT P0384
ETHER 0 CAPILLARY FRAGILITY Z V ANESTHESIA HAS NO EFFECT P03814
ETHER P ADH INC V EFFECT IN MODERATE TO DEEP ANESTHESIA RO3814
ETHER P CATECHOLAMINES INC V RESPONSE TO STRESS RO752
ETHER P CORTISOL INC V EFFECT OBSERVED IN MODERATE TO DEEP ANESTHESIA P0384
ETHER P EPINEPHRINE INC V RESPONSE TO STRESS R0752
ETHER P ERPF DEC V PROBABLY DUE TO PENAL VASOCONSTRICTION P0384
ETHER P INSULIN DEC V DUE TO RELEASE OF EPINEPHRIN! CAUSING INHIBITION P10114
ETHER P NOREPINEPHRINE INC V RESPONSE TO STRESS P0752
ETHER P PROTHROMBIN TINE Z V ANESTHESIA HAS NO EFFECT 90384
ETHER S ALKALINE PHOSPHATASE INC V HEPATIC DISTURBANCE (TRANSIENT) P0839
ETHER S BILIRUBIN INC V HEPATIC DISTURBANCE (TRANSIENT) 90839
ETHER S BSP RETENTION INC V HEPATIC DISTURBANCE (TRANSIENT) P0620
ETHER S CEPHALIN FLOCCULATION INC V HEPATIC DISTURBANCE (TRANSIENT) P0620
ETHER S GLUCOSE INC V METABOLIC EFFECT (TRANSIENT EFFECT) P1014
ETHER S LACTATE INC V METABOLIC EFFECT P10114
ETHER S PB! INC V CAUSES MOBILIZATION OF PBI STORES R00014
ETHER S PHOSPHATE DEC V REPORTED; NO MECHANISM CITED P03814
ETHER S PYRUVATE INC V METABOLIC EFFECT P10114
ETHER S SCOT INC V HEPATIC DISTURBANCE (TRANSIENT) P0839
ETHER S SGPT INC V HEPATIC DISTURBANCE (TRANSIENT) P0620
ETHER S THYNOL TURBIDITY INC V HEPATIC DISTURBANCE (TRANSIENT) 90620
ETHER S THYROXINE (T14) INC V EFFECT OBSERVED IN NOD TO DEEP ANESTHESIA RO384
ETHER U BOGEN TEST P05 N REACTS AS IF ETHANOL R0368
ETHER U GFR DEC V DUE TO PENAL VASOCONSTRICTION P0384
ETHER U GLUCOSE INC V DUE TO HYPERGLYCEMIA 90620
ETHER U URINALYSIS BILE INC V HEPATIC DISTURBANCE (TRANSIENT) P0620
ETHER U URINALYSIS GLUCOSE INC V FOLLOWS HYPERGLYCEMIA 90620
ETHER U VOLUME DEC V DUE TO VASOCONSTRICTION P0026
ETHINAMATE B PLATELET COUNT DEC V THHONBOCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0658
ETHINAMATE U URINALYSIS SUGAR INC N THEORETICAL EFFECT AS EXCRETED AS GLUCUPONIDE P0384
ETHINAMATE U 17 KETOSTEROIDS INC M INTERFERES WITH ZIMMERMAN REACTION P0133
ETHINAMATE U 17 OH CORTICOSTEROIDS INC N MINIMAL EFFECT WITH GLENN-NELSON METHOD 301417
ETHINYLESTRADIOL F CALCIUM DEC V DECREASE LESS MARKED THAN IN URINE P1016
ETHINYLESTRAOIOL F COPPOPOHPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA RO975
ET9INYL!STPADIOL F PROTOPORPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA P0975
ETHINYLESTHADIOL F UROPORPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TAPDA R0975
ETHINYLESTPADIOL P PROGESTERONE DEC V LUTEAL PHASE ALSO SHORTENED P01497
ETHINYLESTRADIOL P RENIN ACTIVITY INC V MEN AND WOMEN, INDEPENDENT OF DIET AND POSTURE 90657
ETHINYLESTHADIOL S ALBUMIN DEC V METABOLIC EFFECT #{216}1149
ETHINYLESTRADIOL S ALPHA-LIPOPROTEINS INC V MAY ALMOST DOUBLE IN SOME STUDIES P03814
ETHINYLESTRADIOL S BETA-LIPOPPOTEINS DEC V DECREASES BY UP TO 30% RO384
ETHINYLESTRADIOL S CALCIUM DEC V SIGNIFICANT FALL, ASSOCIATED WITH DEC ALBUMIN 91016
ETHINYLESTRADIOL S CAROTENE DEC V HORMONAL INFLUENCE 90352
ETHINYLESTPADIOL S CHOLESTEROL DEC V DECREASES BY UP TO 50% 903814
ETHINYLESTPADIOL S GLUCOSE TOLERANCE DEC V HORMONAL EFFECT P0683
ETHINYLESTRADIOL S HAPTOGLOBIN DEC V METABOLIC EFFECT P0149
ETHINYLESTRADIOL S OROSOMUCOIO DEC V METABOLIC EFFECT 901149
ETHINYLESTRADIOL S P81 INC V INCREASES CONCENTRATION OF CIRCULATING TBG R00014
ETHINYLESTRADIOL S PHOSPHATE DEC V DECREASE OF APPROXIMATELY 2 MG/100NL P0755
ETHINYLESTRADIOL S TBG INC V DIRECT EFFECT OF DRUG 900014
ETHINYLESTHADIOL S TYROSINE DEC V INDUCTION OF TYROSINR-TPANSANINASE BY STEROID P0796
ETHINYLESTRADIOL S VITAMIN A INC V DUE TO ALTERATION IN CONC OF BINDING GLOBULIN 90352
ETHINYLESTRADIOL U CALCIUM DEC V ASSOCIATED WITH DECREASED SERUM CONCENTRATION P1016
ETHINYLESTRADIOL U UPOPOPPHYRIN INC V MAY INDUCE PORPHYRIA CUTANFA TARDA 20975
ETHINYLESTRADIOL U 17 KETOSTEROIDS INC V TEMPORARY ENHANCED EXCRETION ON STOPPING DRUG 3069
ETHINYLESTPADIOL U 17 OH CORTICOSTEPOIDS INC V TEMPORARY ENHANCED EXCRETION ON STOPPING DRUG P0469
ETHIODOL S PB! INC N CONTAINS IODINE P0026
ETHIONAMIDE S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT P0620
ETHIONAMIDE S BILIRUBIN INC V HEPATOTOXICITY IN ABOUT 2% CASES 30417

ETHIONAMIDE S BSP RETENTION INC V HEPATOTOXIC EFFECT P06 20
ETHIONAMI DE S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT P0620
ETHIONA NIDE S GLUCOSE INC V HYPERGLYCEMIA REPORTED P0596
ETHIONANIDE S PHI DEC V ANTITHYPOID EFFECT AFTER SEVERAL WEEKS P014 17
ETHIONAMIDE S SGOT INC V INTRAHEPATIC CHOLESTATIC JAUNDICE HO 3814
ETHI ONA MIDE S SGPT INC V INTHAHEPATIC BILE DUCT DAMAGE, TOXIC HEPATITIS P0557
ETHIONAMIDE S THYMOL TURBIDITY INC V INTRAHEPATIC CHOLESTASIS P0620
ETUTONA MI OF S THYROXINE (T14) DEC V ANTITHYROID EFFECT AFTER SEVERAL WEEKS P04 17
ETHIONAMIDE U ALKALINE PHOSPHATASE DEC N INTERFERENCE WITH DETERMINATION PROCEDURE P0758
ETHIONANIDE U LACTIC DEHYDROGENASE DEC N INTERFERENCE WITH DETERMINATION PROCEDURE P0758
ETHIONAMIDE U URINALYS1S BILE INC V HEPATOTOXIC EFFECT P0620
ETHIONAMIDE U URINALYSIS GLUCOSE INC V DUE TO HYPERGLYCEMIA R0596
ETHOSUXIMIDE B EOSINOPHILS INC V RARE EOSINOPHILIA REPORTED P0026
ETHOSUXIMIDE B HEMATOCRIT DEC V APLASTIC ANEMIA P00 26
ETHOSUXIMIDE B HEMOGLOBIN DEC V APLASTIC ANEMIA P0026
ITHOSUXIMIDE B LE CELL PREP P05 V SEVERAL CASES OF LUPUS EHYTHEMATOSUS REPORTED P03814
ETHOSUXI NI DE B PLATELET COUNT DEC V APLASTIC ANEMIA/THPOBOCYTOPENIA/PANCYTOPENIA P0026
ETHOSUXIMIDE B RED CELL COUNT DEC V APLASTIC ANEMIA/PANCYTOPENIA P0620
ETHOSUXI MIDE B WHITE CELL COUNT DEC V APLASTIC ANEMIA/PANCYTOPENIA/LEUKOPENIA IN 10% P0026
ETHOSUXIMIDE S BILIRUBIN INC V RARE IDIOSYNCRATIC HEPATITIS REPORTED P0026
ETHOSUXIMIDE S CEPHALIN FLOCCULATION INC V RARE HEPATITIS REPORTED HO 620
ETHOS U XIMIDE S COOMBS TEST P05 V MECHANISM OBSCURE P04 18
ETHOSUXIMIDE S SGOT INC V INC IN ONE THIRD CASES P0657
ETHOSUXIMIDE S UREA NITROGEN INC V POSSIBLE REVERSIBLE NEPHROPATHY P00 26
ETHOSUXIMIDE U PROTEIN INC V POSSIBLE REVERSIBLE NEPHROPATHY HO 2 99
ETHOSUXIMIDE U URINALYSIS PROTEIN INC V POSSIBLE REVERSIBLE NEPHROPATHY P0299
ETHOTOIN B MCV INC V THEORETICAL EFFECT ON FOLIC ACID METABOLISM P0467
ET HOT OIN B RED CELL COUNT DEC V MAY CAUSE MARROW DEPRESS OP MEGALOBLASTIC ANEMIA P00 26
ETHOTOI N B WHITE CELL COUNT DEC V POSSIBLE BONE MARROW DEPRESSION P0026
ETHOTOIN S ALKALINE PHOSPHATASE INC V PROBABLE IDIOSYNCRATIC HEPATITIS P06 20
ETHOTOIN S BILIRUBIN INC V PROBABLE IDIOSYNCRATIC HEPATITIS 90620
ETHOTOIN S BSP RETENTION INC V PROBABLE IDIOSYNCRATIC HEPATITIS P0620
ETHOTOI N S CEPHALIN FLOCCULATION INC V HEPATOTOXICITY P0620
ETHOTOIN S SGOT INC V HEPATOTOXICITY P0620
ETHOTOI N S SGPT INC V HEPATOTOXICITY R062O
ETHOTOIN S THYMOL TURBIDITY INC V REPATOTOXICITY P0620
FT HOT OIN U URINALYSIS BILE INC V HEPATOTOXICITY P0620
ETHOX AZ EN F S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT P0620
FT HOX A ZE NE S BILIRUBIN INC M POSTULATED PRODUCTION OF COLOR WITH EHPLICH’S DIAZO P0029
ETHOXAZENE S BILIPUBIN INC V HEPATOTOXIC EFFECT P0299
ETHOXA ZEN! S BSP RETENTION INC M INCREASES ABSORBANCY IN TEST, FALSELY HIGH RESULT P04 17
ITHOXAZENE S BSP RETENTION INC V HEPATOTOXIC EFFECT P06514
ETHOXAZENE S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT P0620
ETHOXAZENE S SCOT INC V HEPATOTOXIC EFFECT H 0620
ETHOXAZENE S SGPT INC V HEPATOTOXIC EFFECT P06 20
ETHOXAZENE S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT P06 20
ETHOXAZENE U 9ILIRUBIN INC V HEPATOTOXIC EFFECT R0299
ETHOXAZENE U PORPHYHINS INC N FALSE POSITIVE WITH FLUORESCENT METHODS P1001
U PORPHYRINS INC V HEPATOTOXIC EFFECT P0299
ET HOX A ZR NE U PSP EXCRETION INC M PRODUCES INTERFERING BACKGROUND COLOR P0299
ETHOXAZENE U URINALYSIS BILE INC N ATYPICAL RED COLOR WITH BILI-LABSTIX AND ICTOTEST P04 17
El H OXA ZE NE U URINALYSIS BILE INC V HEPATOTOXIC EFFECT HO 620
ETHOXAZENE U URINALYSIS COLOR INC N RED,PINK, ORANGE & RUST COLORS P0654
FT HOXA ZOLA MIDE B PH DEC V NAY CAUSE METABOLIC ACIDOSIS P0 596
F.THOXAZOLANIDE B PLATELET COUNT DEC V THPOMBOCYTOPFNIA P0656
ETHOX AZOLAN IDE B WHITE CELL COUNT DEC V LEUKOPENIA P06 20
ETH OXAZOLAMIDE S POTASSIUM DEC V PROBABLE EFFECT (LIKE ACETAZOLAMIDE) P0026
ITHOXAZOLAM IDE S URIC ACID INC V DECREASES UHATE CLEARANCE P0596
ETHOXAZOLANIDE U URIC ACID DEC V DECREASES URATE CLEARANCE P0596
ETHYL CHLORIDE S BILIRUBIN INC V MAY CAUSE LIVER DAMAGE R0O26
ETHYL CHLORIDE S SCOT INC V MAY CAUSE LIVER DAMAGE P0026
ETHYL CHLORIDE S SGPT INC V MAY CAUSE LIVER DAMAGE P0026
FT HYLE NE S GLUCOSE INC V AFTER PROLONGED USE MAY BE MODERATE INC P00 26
ETHYLENE GLYCOL U URINALYSIS HEMOGLOBIN INC V DUE TO NEPHROTOXICITY P036 8
ETHYLENE GLYCOL U URINALYSIS PROTEIN INC V DUE TO NEPHROTOXICITY HO 368
ETHYLENE GLYCOL U URINALYSIS RBC/HPF INC V DUE TO NEPHROTOXICITY P036 8
FT HYL EST RE N 0 L P PLASMINOGEN INC V METABOLIC EFFECT P0072
ETHYL ESTRENOL S HAPTOBLOBIN INC V METABOLIC EFFECT P0072
ETHYLESTRENOL S SIALIC ACID INC V METABOLIC EFFECT P0072
FT H Y NO DI OL S TRIGLYCERIDES INC V DECREASED REMOVAL FROM CIRCULATION P0907
ETIOCHOLANOLONE B WHITE CELL COUNT INC V PYROGEN - INCREASES NUMBER OF GRANULOCYTES P06 57
ETPYPTAMINE U 17 KETOGENIC STEROIDS INC M INTERFERES WITH ZIMMERMAN REACTION P0133
ETRYPTAMINE U 17 OH CORTICOSTEPOIDS INC M GLUCURONIDE INTERFERES WITH ZIMMERMAN REACTION R0133
EVANS BLUE S P31 DEC V MECHANISM OBSCURE P0004
EVANS BLUE U URINALYSIS COLOR INC N BLUE COLOR DUE TO PRESENCE OF DYE P0143
FATTY FOODS S ALKALINE PHOSPHATASE INC V EFFECT MOST MARKED 4H AFTER MEAL IN 0 SECRETOPS P0969
FATTY FOODS S THYMOL TURBIDITY INC N LIPEMIA CAUSES FALSE HIGH VALUES DUE TO TURBIDITY P0356
FAVA BEANS B HEMATOCPIT DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
FAVA BEANS B HEMOGLOBIN DEC V MAY CAUSE HENOLYSIS WITH G-6-PD DEFICIENCY P0079
FAVA BEANS B RED CELL COUNT DEC V MAY CAUSE HENOLYSIS WITH G-6-PD DEFICIENCY P0079
FAVA BEANS S BILIRUBIN INC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
FAVA BEANS S DIRECT BILIRUBIN INC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
FENFLU TA MI NE P GROWTH HORMONE INC V ACTION ON BRAIN STIMULATING RELEASE P0582
FENFLUP AMINE S GLUCOSE DEC V DIRECT EFFECT, INCREASED GLUCOSE UPTAKE BY MUSCLE P09414
FENFLU HA MINE S KETONES INC V (AVERAGE INCREASE OF 57%) P07 25
?ENZLUR AMINE S TRIGLYCERIDES DEC V (NOT CONSTANT FINDING) P0907
FNOXY PROPAZINE S ALKALINE PHOSPHATASE INC V PRODUCED FATAL HEPATOTOXICITY P0657
FENOXY PROPAZIN! S BILIPUBIN INC V PRODUCED FATAL HEPATOTOXICITY P0657
FENOXY PROPAZINE S SCOT INC V PRODUCED FATAL HEPATOTOXICITY P0657
ENOXY PPOPAZINE S SGPT INC V PRODUCED FATAL HEPATOTOXICITY P06 57

TENTANYL P EPINEPHRINE INC V MECHANISM OBSCURE R01496
FENTANYL P NOREPINEPHBINE DEC V MECHANISM OBSCURE P014 96
FENTANYL S AMYLASE INC V MAY CAUSE SPASM OF SPHINCTER OF ODD! HO 026
FERRICYA RIDE U URINALYSIS HEMOGLOBIN INC M INTERFERES WITH BENZIDINE TEST HO 299
FERROUS ASCORBINATE S GLUCOSE TOLERANCE DEC V MECHANISM NOT REPORTED P04 17
FIBRIN HYDROLYSATE B HEMOGLOBIN DEC V ?DU! TO SEPTICENIA OP HYPOPHOSPHATENIA 30968
FIBRIN HYDROLYSATE P AMMONIA INC V DUE TO HIGH AMMONIA CONTENT OF SOLUTION P096 8
FIBRIN HYDPOLYSATE S PHOSPHATE DEC V INTRACELLULAR TRANSFER 30968
TIBRINOLYSIN S SGOT INC V SERUM HEPATITIS AS LATE COMPLICATION P 00 26
FIBRINOLYSIN S UREA NITROGEN INC V RENAL FAILURE REPORTED (RAPE COMPLICATION) 90026
FILTER PAPER P AMMONIA INC N ESP IF ACID-WASHED PAPER (ABSORBS N113 FROM AIR) P0181
FILTER PAPER S CALCIUM INC N ORDINARY PAPER CONTAINS HIGH CONCENTRATION HO 181
FILTER PAPER S NPN INC N IF CONTAINS AMMONIA AFFECTS SOME METHODS 90436
FILTER PAPER S TOTAL LIPIDS INC N IF LOW-FAT PAPER NOT USED IN SOME METHODS P0 181
FILTER PAPER U URINALYSIS HEMOGLOBIN INC N INTERFERES WITH BENZIDINE TEST 90143
FISH F OCCULT BLOOD P05 N AFFECT MOST METHODS IF NOT WITHHELD FOR 3 DAYS P0262
FLAVASPIDIC ACID S BILIRUBIN INC V INHIBITS UDP-GLUCUPONTL THANSFERASE P070 1
FLAVASPIDIC ACID S BSP RETENTION INC V COMPETITION FOR HEPATO-CELLULAR BINDING SITES 30701
FLAVASPIDIC ACID S DIRECT BILIRUBIN INC V INHIBITS UPTAKE OF BILIRUBIN BY LIVER CELLS HO 110
FLORA NTYRONE B FOSINOPHILS INC V IN PATIENTS WITH PREEXISTING LIVER DISEASE 30620
FL OR A NT YRON F B WHITE CELL COUNT INC V IN PATIENTS WITH PREEXISTING LIVER DISEASE P0620
FLORA NTY HONE S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT P06 20
FLOP A NT YRONE S BSP RETENTION INC V HEPATOTOXIC EFFECT H 0299
FLORA NTYRONE S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT RO620
FLORA NT YRO NE S SGOT INC V HEPATOTOXIC EFFECT P06 20
FLORA NTYPONE S SGPT INC V HEPATOTOXIC EFFECT 90620
FLOP ANTYPONE S THYNOL TURBIDITY INC V HEPATOTOXIC EFFECT P0620
FLORA NTY HONE U URINALYSIS BILE INC V HEPATOTOXIC EFFECT ROE 20
FLOPAQUIN S PBI INC N CONTAINS IODINE, EFFECT LASTS 2-4 WEEKS 3C112
FLUDHOCOPTISONE S POTASSIUM DEC V MAY CAUSE INCREASED URINARY EXCRETION 30026
FLUDROCOHTI SONE S SODIUM INC V MAY CAUSE SODIUM RETENTION AND EDEMA 90026
FLUDROCORTISONE U POTASSIUM INC V INCREASES URINARY ELIMINATION P00 26
FLUFENAMIC ACID S SCOT INC V TRANSIENT ELEVATION REPORTED P0667
FLUFENAMIC ACID S SGPT INC V TRANSIENT ELEVATION REPORTED 90657
FLUFENAMIC ACID U URINALYSIS BILE INC N PROBABLY DUE TO INTERFERING METABOLITE 9.0417
FLUMETHI AZIDE S URIC ACID INC V INHIBITION OF TUBULAR SECRETION OF URAT! 9014014
FLUORESCEI N U URINALYSIS COLOR INC M I.V. ADMINISTRATION MAY CAUSE YELLOW-ORANGE COLOR 90417
FLOOR ESCEIN U UROBILIN INC N PRODUCES YELLOW-GREEN FLUORESCENCE 90436
FLUORIDES B EOSINOPHILS INC V EOSINOPHILIA REPORTED AS ALLERGIC REACTION 30657
PLUORIDES B SEDIMENTATION RATE DEC N RETAPDS RATE WHEN COMPARED WITH HEPARIN 90143
FLUORIDES F CALCIUM DEC V REDUCES LOSS IN BONE DISORDERS P0384
FLUORIDES F OCCULT BLOOD P05 V IF LARGE ANT INGESTED MAY HEMORRHAGIC GASTRITIS H 0368
FLUORIDES P AMMONIA INC M CAUSE INCREASE IF USED AS ANTICOAGULANTS 90215
FLUORIDES S ACID PHOSPRATASE TOTAL DEC M ENZYME ACTIVITY INHIBITED BY FLUORIDE 30003
FLUORIDES S ACID PHOSPHATASE TOTAL DEC V IN VIVO INHIBITION OBSERVED 90338
FLUOPI DES S ALKALINE PHOSPHATASE DEC N INHIBITORY ACTION ON ENZYME P014 36
FLUORIDES S ALKALINE PHOSPHATASE DEC V IN VIVO INHIBITION WITH DOSES FOR FLUORIDATION HO 321
FLUORIDES S AMYLASE INC N EFFECT OF FLUORIDE, ACTIVATES ANYLAS! HO 929
FLUORIDES S CALCIUM DEC N MAY PRECIPITATE CALCIUM (FORMS INSOLUBLE SALT) HO 1436
FLUORIDES S C02 CONTENT DEC N ALTERATION OF PH WITH LOSS OF CO2 P 1001
FLUOP IDES S GLUCOSE INC N IF GREATER THAN 5 MG/ML AFFECTS 0-TOLUIDIN? 90221
FLUORIDES S LACTIC DEHYDHOGENASE DEC V IN VIVO INHIBITION WITH LOW DOSES P0338
FLUORIDES S PBI DEC V LARGE DOSES INTERFERE WITH 12 TRAPPING BY THYROID P00014
FLUORIDES S PB! Z V AT CONCS USED TO CAUSE FLUORIDATION OF WATER 90255
FLUORIDES S POTASSIUM INC N WITH INHIBITION OF PHOSPHORYLATION 301436
FLUORIDES S SGOT DEC V IN VIVO INHIBITION WITH LOW DOSES HO 33 8
FLUORIDES S SCOT INC N INC ACTIVITY OBSERVED WITH COLORIMETRIC METHOD P08 25
FLUORIDES S SODIUM INC N IF SALT OF FLUORIDE ‘0436
FLUOPI DES S UREA NITROGEN DEC N UREASE ACTIVITY INHIBITED BY FLUORIDE P01 91
F LU OH 08 OR ATE S PB! DEC V INTERFERES WITH TRAPPING OF IODIDE BY THYPOID HO 0014
FLUOPOCYTOSINE B WHITE CELL COUNT DEC V REPORTED EFFECT P0898
FLUOROC YTOSINE S ALKALINE PHOSPHATASE INC V REVERSIBLE HEPATOTOXICITY IN 10% P0 898
FLUOROC YTOSINE S BILIPUBIN INC V REVERSIBLE HEPATOTOXICITY IN 10% P0898
FLUOROCYTOSINE S CEPHALIN FLOCCULATION INC V REVERSIBLE HEPATOTOXICITY IN 10% P08 98
FLUOROCYTOSINE S SGOT INC V REVERSIBLE REPATOXICITY IN 10% 90898
FLUOROCYTOSINE S SGPT INC V REVERSIBLE HEPATOTOXICITY IN 10% P 0898
FLUOHOCYTOSINE S THYNOL TURBIDITY INC V REVERSIBLE HEPATOTOXICITY IN 10% HO 898
FLUOROPYRIMIDINE S PBI INC V MECHANISM OBSCURE P 0 004
FLUOROURACIL B PLATELET COUNT DEC V MAY CAUSE BONE MARROW DEPRESSION 30026
FLU OROU RACIL B RED CELL COUNT DEC V MAY CAUSE BONE NARROW DEPRESSION 90026
FLUOPOUPACIL B WHITE CELL COUNT DEC V NAY CAUSE BONE MARROW DEPRESSION 90026
FLUOROU HACIL S BILIHUBIN INC V SINGLE CASE REPORTED P014 17
FLUOROUPACIL S PB! Z V NO EFFECT OBSERVED 90255
FLUOPOURACIL U 5 OH INDOLEACETIC ACID INC V IN PATIENTS WITH CARCINOID DUE TO CELL DESTRUCTION 90417
FLUOXY MESTEPONE P PLASNINOGEN INC V METABOLIC EFFECT P0072
FLIJOXY MESTERONE S ALKALINE PHOSPHATASE INC V INTHAHEPATIC CHOLESTATIC JAUNDICE 90384
FLUOXY MESTERONE S BETA-GLUCUHONIDAS! INC V METABOLIC EFFECT R002
FLUOXYMESTE BONE S BILIRUBIN INC V INTRAHEPATIC CHOLESTATIC JAUNDICE 903814
FLUOXY NEST ERONE S BSP RETENTION INC V ? HEPATOTOXIC, CHOLESTATIC EFFECT 90355
FLUOXYMESTEPONE S HAPTOBLOBIN INC V METABOLIC EFFECT 90072
FLUOXY MESTEPON F S SGOT INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P03814
FLUOXY MESTE HONE S SGPT INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P03 814
FLUOXY MESTERONE U URINALYSIS BILE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE 90384
FLUPHENAZINE B WRITE CELL COUNT DEC V TRANSIENT LEUKOPENIA REPORTED P0026
FLUPH ENAZINE S ALKALINE PHOSPHATASE INC V HYPERSENSITIVITY RESPONSE RO620
FLUPHE NA ZINE S BILIPUBIN INC V HYPERSENSITIVITY RESPONSE P06 20
FLUPFIENAZINE S BSP RETENTION INC V HYPERSENSITIVITY RESPONSE P0620
FLUPHENAZINE S CEPRALIN FLOCCULATION INC V HYPERSEN5ITIVITY(MAYBE NORMAL WHEN OTHER TESTS NOT) P0620
FLUPHENAZINE S DIRECT BUIRUBIN INC V RELATIVELY HIGH COMPARED WITH TOTAL P03814
FLUPHENAZINE S SGOT INC V HYPERSENSITIVITY RESPONSE P0620

FLUPHENAZINE S SGPT INC V HYPERSENSITIVITY RESPONSE P0620
FLUPHENAZINE S THYMOL TURBIDITY INC V HYPERSENSITIVITY RESPONSE P0620
LUPHENAZINE U BILIRUB!N INC V HYPERSENSITIVITY RESPONSE P0620
FLUPHENAZINE U URINALYSIS RILE INC V HYPERSENSITIVITY RESPONSE P0620
FLU’AZEPAM S ALKALINE PHOSPHATASE INC V MAY CAUSE HEPATIC TOXICITY 90788
FLUPAZEPAM S BILIRUBIN INC V MAY CAUSE HEPATIC TOXICITY P0788
FLtJ?AZEPAM S BSP PETENTION INC V MAY CAUSE HEPATOTOXICITY P0788
FLURAZEPAM S CEPHALIN FLOCCULATION INC V MAY CAUSE HEPATOTOXICITY P0788
FLUPAZEPAM S DIRECT BILIPUBIN INC V NAY CAUSE HEPATIC TOXICITY P0788
PLURAZEPAM S SCOT INC V NAY CAUSE HEPATIC TOXICITY H0788
TLURAZEPAM S SGPT INC V MAY CAUSE HEPATIC TOXICITY P0788
FLURAZEPAM S THYMOL TURBIDITY INC V NAY CAUSE HEPATOTOXICITY , P0788
FLUPAZEPAM U URINALYSIS BILE INC V MAY CAUSE HEPATOTOXICITY P0788
FLUROXENE B BLEEDING TIME INC V PROLONGED DUPING ANESTHESIA, NORMAL IN 214H ROO26
FLUROXENE S BILIPUBIN INC V POTENTIALLY HEPATOTOXIC P0026
FLUPOXENE S BSP RETENTION INC V POTENTIALLY HEPATOTOXIC P0026
FLUROXENE S SCOT INC V POTENTIALLY HEPATOTOXIC RO026
FLUROXENE S SGPT INC V POTENTIALLY HEPATOTOXIC 90026
FOLIC ACID E VITAMIN P12 INC V DURING TREATMENT OF FOLATE DEFICIENT ANEMIA P01425
FORMALDEHYDE F OCCULT BLOOD P05 V INGESTION MAY CAUSE HEMATEMESIS P0368
FORMALDEHYDE S ACID PHOSPHATASE TOTAL DEC N STRONG INHIBITOR OF RED CELL ENZYMR P0929
FORMALDEHYDE S URIC ACID INC M IF ADDED TO STANDARDS INHIBITS UPICASE P0184
FORMALDEHYDE U BOGEN TEST P05 N REACTS AS IF ETHANOL 90368
FORMALDEHYDE U CATECHOLAMINES INC N INTERFERES WITH FLUOPONETRIC METHOD P0299
FORMALDEHYDE U CATECHOLAMINES INC N INTERFERES WITH PROCEDURES FOP ANALYSIS P0233
FORMALDEHYDE U PSP EXCRETION INC M PRODUCES INTERFERING COLOR REACTION P0233
FORMALDEHYDE U UREA NITROGEN DEC N INHIBITS UREASE (CAN NOT BE USED AS PRESERVATIVE) R0436
ORMALDEHYDE U URINALYSIS HEMOGLOBIN INC N INTERFERES WITH BENZIDINE TEST P0299
FORMALDEHYDE U tIPINALYSIS RBC/HBF INC V INGESTION MAY CAUSE HEMATURIA AND PENAL DAMAGE P0368
FORMALDEHYDE U URINALYSIS SUGAR INC N INTERFERES WITH BENEDICT’S REAGENT P0299
FORMALDEHYDE U UPOBILINOGEN INC N INTERFERES WITH COLOR REACTION P0233
FORMALIN U INDICAN DEC N PREVENTS OBERMEYER TEST REACTION P0143
FORMALIN U URINALYSIS BILE INC N MAY GIVE YELLOW RING WITH GMELIN TEST P0143
FOPMALIN U URINALYSIS CRYSTALS INC N UREA PRECIPITATION P0620
TORMALIN U URINALYSIS HEMOGLOBIN INC M REACTION WITH BENZIDINE P0620
FORNALIN U URINALYSIS SUGAR INC N MAY REDUCE FEHLINGS AND CLINITEST P0436
FORNALIN U UROBILINOGEN INC N INTERFERES WITH EHRLICHS REACTION P01143
FRUCTOSE B PH DEC V ASSOCIATED WITH LACTIC ACIDOSIS P0227
FRUCTOSE S ALPHA-KETOGLUTARATE INC V RISES MORE RAPIDLY THAN AFTER GLUCOSE R01476
FRUCTOSE S CITRATE INC V RISES MOPE RAPIDLY THAN AFTER GLUCOSE P01476
FRUCTOSE S CO2 CONTENT DEC V METABOLIC RESPONSE TO LARGE DOSE FRUCTOSE P0815
FRUCTOSE S CPEATININE INC M INTERFERENCE WITH JAFFE-REACTION P1001
FRUCTOSE S GLUCOSE DEC V MARKED FALL MAY OCCUR 1 HOUR AFTER I.V. FRUCTOSE P0815
FRUCTOSE S GLUCOSE INC M NON SPECIFICITY OF 0-TOLUIDINE, NEOCUPROINE, FECN P0750
FRUCTOSE S LACTATE INC V METABOLIC RESPONSE TO I.V. OR ORAL FRUCTOSE P0815
FRUCTOSE S PHOSPHATE DEC V PHOSPHORYLATION OCCURS AFTER I.V. INJECTION P0476
FRUCTOSE S PYPUVATE INC V RISES MORE RAPIDLY THAN AFTER GLUCOSE P0476
FRUCTOSE S TRIGLYCERIDES INC V OCCURS IN EXPTL ANIMALS, CONTRADICTORY IN HUMANS R01476
. FRUCTOSE S URIC ACID INC V FOLLOWING I.V. INFUSION: DOSE RELATED EFFECT P0907
FRUCTOSE U URIC ACID CLEARANCE INC V DOSE RELATED EFFECT P0815
FRUCTOSE U URIC ACID INC V DOSE RELATED EFFECT P0815
FRUCTOSE U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S P0436
FRUCTOSE U 17 OH CORTICOSTEROIDS INC N INTERFERES WITH POPTEP-SILBER REACTION P0907
FUMAGILLIN B WHITE CELL COUNT DEC V LEUKOPENIA (AMA-BLOOD DYSCRASIAS) 90658
FUPALTADONE B HEINZ-BODY FORMATION P05 V EARLY STAGE OF HEMOLYTIC ANEMIA P0104
FUPALTADONE B HEMATOCHIT DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
FUPALTADONE B HEMOGLOBIN DEC V NAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
FURALTADONE B RED CELL COUNT DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
FUPALTADONE B RETICULOCYTES INC V OCCURS WITH HEMOLYSIS P0079
FURALTADONE P METHENALBUMIN INC V MAY OCCUR WITH HENOLYSIS P0079
FUPALTADONE S BILIRUBIN INC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
FURALTADONE S HAPTOCLOBIN DEC V DUE TO HENOLYSIS P0079
FURAPHOMIDIUM P AMMONIA INC V OCCASIONAL INCREASE OBSERVED P0657
FURAZOLIDONE B HEINZ-BODY FORMATION P05 V EARLY STAGE OF HEMOLYTIC ANEMIA RO1O4
FURAZOLIDONE B HEMATOCRIT DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
FURAZOLIDONE B HEMOGLOBIN DEC V NAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
FURAZOLIDONE B METHEMOGLOBIN INC V MAY CAUSE HEMOLYSIS WITH C-6-PD DEFICIENCY P0926
FURAZOLIDONE B RED CELL COUNT DEC V NAY CAUSE HENOLYSIS WITH G-6-PD DEFICIENCY P0079
FURAZOLIDONE B PETICULOCYTES INC V OCCURS WITH HENOLYSIS P0079
FUPAZOLIDONE P METHEMALBUMIN INC V MAY OCCUR WITH HEMOLYSIS P0079
FURAZOLIDONE S BILIRUBIN INC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
FUPAZOLIDONE S HAPTOGLOBIN DEC V DUE TO HEMOLYSIS P0079
FUPAZOLIDONE U GLUCOSE INC N IF GIVEN IN VAGINAL POWDER ,GLUCOSE MAY BE PRESENT P0355
FUPAZOLIDONE U SUGAR INC N METABOLITES MAY GIVE FALSE POSITIVE WITH BENEDICT’S 901417
FUHAZOLIDONE U URINALYSIS COLOR INC N METABOLITES MAY PHODtTCE BROWN COLOR P0417
FUPAZOLIDONE U URINALYSIS GLUCOSE INC N DUE TO PRESENCE OF GLUCOSE IN VAGINAL POWDER P0355
FUPAZOLIUM U URINALYSIS COLOR INC M FED, PINK, PURPLE, ORANGE & RUST COLORS P0355
FUROSEMIDE B HEMATOCRIT DEC V MAY CAUSE ANEMIA P01452
FUROSEMIDE B HEMOGLOBIN DEC V MAY CAUSE ANEMIA P01452
FUROSEMIDE B PLATELET COUNT DEC V NAY BE ASSOCIATED WITH PURPURA P01452
FUROSEMIDE B RED CELL COUNT DEC V MAY CAUSE ANEMIA P01452
FUPOSEMID! B WHITE CELL COUNT DEC V MAY CAUSE LEUKOPENIA OH APLASTIC ANEMIA P0620
FUPOSEMIDE P AMMONIA INC V ACTS LIKE THIAZIDES CAUSES HYPOKALENIA & ALKALOSIS P0417
FUPOSEMIDE P INSULIN DEC V I.V. INJECTION EFFECT, LITTLE ON BLOOD SUGAR P0657
FUPOSENIDE S AMYLASE INC V NAY INDUCE MILD PANCREATITIS P0907
FUPOSEMIDE S CALCIUM DEC V DIURETIC ACTION (DIFF EFFECT HYDPOCHLORTHIAZIDE) P0146
FUROSEMIDE S CHLORIDE DEC V DIURETIC ACTION (INHIBITS TUBULAR REABSORPTION) P0021
FUPOSEMIDE S GLUCOSE INC V DIABETOGENIC-LIKE ACTION OF DRUG: AFFECTS GTT P0907
FUROSENIDE S GLUCOSE TOLERANCE DEC V DIABETOGENIC-LIKE ACTION OF DRUG P0723
FUPOSEMIDE S POTASSIUM DEC V DIURETIC ACTION P0907

FUROSEMIDE S SODIUM DEC V DIURETIC ACTION WITH SODIUM DEPLETION P002 1
FUPOSEMIDE S UREA NITROGEN INC V ?N!PHROTOXIC EFPECT(REVERSIBLE) USUALLY DEHYDRATION 90029
PUROSENIDE S URIC ACID INC V DECREASED URATE CLEARANCE 90907
FUROSEMIDE U CALCIUM INC V IMPAIRED REABSORPTION (INITIAL EFFECT ONLY) 90723
FUROS EMIDE U CHLORIDE INC V DIURETIC ACTION P01452
FUHOSEMIDE U GFR DEC V EXCESSIVE DIURESIS NAY CAUSE EFFECT O657
FUR OSE MIDE U GLUCOSE INC V DIABETOGENIC-LIKE ACTION OF DRUG 90907
FUR OSENIDE U POTASSIUM INC V DIURETIC ACTION 301452
EU P OS E M IDE U SODIUM INC V DIURETIC ACTION 052
FUROSEMI DE U URINALYSIS GLUCOSE INC V DUE TO HYPERGLYCEMIA 30907
FUROSE RIDE U VOLUME INC V DIURETIC ACTION 9.0452
FUSIDIC ACID P CORTISOL INC M INTERFERING FLUORESCENCE P014 90
GALACTOSANINE T PROTEIN INC N REACTS WITH FOLIN-CIOCALTRU OF LOWRY METHOD 301440
GALAC TOSE S GLUCOSE INC M MARKED EF!ECT ON !ECN, 0-TOLUIDINE METHODS 91009
C ALACTOSE U ESTRIOL DEC N INTERFERES WITH CLC METHOD R0830
GA tACT OS B U URINALYSIS SUGAR INC N GIVES POSITIVE WITH BENEDICT’ S 901436
G ALACTOSE U XYLOSE EXCRETION INC N INTERFERES WITH BROMOANILINE PROC IF OVER 2 G/100ML p0779
GALLA NINE S I 131 UPTAKE DEC V DUE TO IODINE COMPONENT OF DRUG 90596
GALLAMINE S PBI INC N ORGANIC IODINE CONTAMINATION 90 596
GA NGLIONIC BLOCKING 0 GASTRIC JUICE HCL DEC V VOLUME AND ACIDITY GENERALLY REDUCED 903814
GANGLIONIC BLOCKING P ERPF DEC V RETURNS TO NORMAL USUALLY WITHIN 2 HOURS 20384
GANGLIONIC BLOCKING U GFR DEC V RETURNS TO NORMAL USUALLY WITHIN 2 HOURS 903814
GA PG LBS S PB! INC N SOME MAY CONTAIN ORGANIC AND INORGANIC IODINE P03 55
GENTAMICIN B RED CELL COUNT DEC V MAY CAUSE ANEMIA P00 26
GENTAMICIN S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT 903814
GENTAMICIN S BILIRUBIN INC V AFFECTS LIVER FUNCTION 9 0026
GENTAMICIN S CREATININE INC V NEPHROTOXIC EFFECT 90596
GENTAMICIN S SCOT INC V MAY CAUSE H!PATOTOXICITY (OR DUE TO I.M. INJECTION) 90596
GENTAMICIN S SGPT INC V NAY CAUSE HEPATOTOXICITY 30596
GENTAMICIN S UREA NITROGEN INC V NEPHROTOXIC EFFECT WITH LARGE DOSES 90596
GENTA NICIN S URIC ACID INC V REPORTED EFFECT OF I.N. INJECTION PO45
GENTAMICIN U HEPARIN SULFATE INC V REACTS WITH HEPARIN TO FORM PRECIPITATE 90268
GENTANICIN U PROTEIN INC V NEPPROTOXIC EFFECT 90299
GENTAMICIN U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT 30299
GENTISIC ACID S GLUCOSE INC N FALSELY HIGH WITH ALKALINE FERPICYANIDE P0 3 70
GENTISIC ACID S GLUCOSE Z N HAS NO EFFECT ON CLU OX METHOD OF COCHNAN 90370
GENTISIC ACID S PBI DEC V COMPETES FOR BINDING WITH TBPA 90004
GENTISIC ACID S URIC ACID INC M FALSELY HIGH VALUES WITH PHOSPHOTUNGSTATE METHODS 90370
GENTISIC ACID U URIC ACID INC N FALSELY HIGH VALUES WITH PHOSPHOTDNGSTATE METHODS 30 370
GLASSWARE S CEPHALIN FLOCCULATION INC N IF HEAVY METALS. STRONG ACIDS PRESENT 91001
GLASSWARE S CHLORIDE INC N IF CHLORIDE PRESENT 91001
GLASSWARE S UREA NITROGEN DEC N IF MERCURY PRESENT AFFECTS NESSLERIZATION p1001
GLASSWARE U CHLORIDE INC N IF CHLORIDE PRESENT 91001
GLASSWARE U UREA NITROGEN DEC N IF MERCURY PRESENT AFFECTS NESSLERIZATION 91001
GLAUCARUBIN B WHITE CELL COUNT DEC V LEUKOPENIA 90620
GLOBULIN B SEDIMENTATION HATE INC V HIGH MOLECULAR WEIGHT PROTEINS CONTRIBUTE P0620
GLOBULIN C PROTEIN INC N COLOR EQUIV > ALBUMIN WITH FOLIN-CIOCALTEU P03143
GLUCAGON P GROWTH HORMONE INC V HORMONAL ACTION (POTENT STIMULANT) 90363
GLUCAGON P INSULIN INC V STIMULATES BETA CELLS OF PANCREAS 90817
GLUCA CON P PROTHROMBIN TIME INC V PATIENTS ON COUMAPINS 905143
C L UCA C ON S CALCIUM DEC V OCCURS 10 TO 20 MIN AFTER ADNIN IF HYPOGLYCEMIA P05 92
CL UCA CON S CHOLESTEROL DEC V REPORTED EFFECT. MECHANISM NOT LISTED HO 214 5
G LU CA C ON S GLUCOSE INC V COO NTERICT S HYPOCLYC EMIA B Y GLYCOG ENOLYSI S P0298
GLUCAGON S GLUCOSE TOLERANCE DEC V DECREASED INSULIN SENSITIVITY RO363
GLTJ C A C ON S POTASSIUM INC V IMNED. INC IN DOGS THEN FALL TO NORMAL OH LESS 90210
GLUCAGON S TOTAL LIPIDS DEC V TRANSFER OF LIPIDS TO PLATELETS HO 185
GLUCA CON S TRIGLYCERIDES DEC V TRANSFER OF LIPIDS TO PLATELETS 90185
CL U CA CON U GLUCOSE INC V MOBILIZES HEPATIC GLYCOCEN, CAUSES GLYCOSURIA P 0620
GLU CA CON U URINALYSIS GLUCOSE INC V MOBILIZES ENOUGH GLYCOGEN TO CAUSE CLYCOSURIA P0026
GLUCOCORTI COlDS B EOSINOPHILS DEC V REDUCED INFLAMMATORY RESPONSE P 0026
GLUCOCOHTICOIDS B LYMPHOCYTES DEC V ALSO DECREASE IN LYMPHOID TISSUE 30026
GLUCOCORTICOI DS B PLATELET COUNT INC V STIMULATE PRODUCTION 0! PLATELETS P 0 026
GLUCOCOPT IC OIDS B RED CELL COUNT INC V STIMULATE EHYTHROPOIESIS p0026
GLUCOCORTICOI DS 0 BNR DEC V METABOLIC ACTION OF HORMONES P0596
CL UCOCORTICOIDS S AMINO ACIDS INC V DUE TO BREAKDOWN OF TISSUE PROTEINS 30026
GLUCOCOPTICOID S S AMYLASE INC V WELL DOCUMENTED EARLY AND LATE PANCREATITIS P06 57
GLUCOCORTICOIDS S CALCIUM DEC V EFFECTIVE IF MYPERCALCEMIA DUE TO SARCOID,VITAMIN D P00 26
GLUCOC OPTICOIDS S GLUCOSE INC V DIABETOCENIC ACTION (INC GLUCONEOGENESIS) 20620
GLUCOCORTICOIDS S I 131 UPTAKE DEC V ASSOCIATED WITH REDUCED BNP 90596
GLUCOC OPT ICOIDS S PBI DEC V REDUCED AMOUNT OF TBG P03 55
GLUCOCORTICOIDS S POTASSIUM DEC V MAY CAUSE POTASSIUM LOSS 90026
CLUCOCOPTICOIDS S SODIUM INC V NAY CAUSE SODIUM RETENTION P 00 26
CLUCOCORTICOIDS U CALCIUM INC V PROMOTE RENAL EXCRETION 90026
CLUCOCORTICOIDS U URINALYSIS GLUCOSE INC V DUE TO HYPERGLYCEMIA 30620
GLUCOSA NINE S UREA NITROGEN Z N NO EFFECT ON BERTHELOT REACTION RO51O
GLUCOSAMINE T PROTEIN INC N REACTS WITH FOLIN-CIOCALTEU OF LOWRY METHOD P014140
GLUCOSAMINE U ANINOLEVULINIC ACID INC M IF NO PRELIMINARY SEPARATION PROCEDURE P 0779
CLUCOSE B SEDIMENTATION RATE DEC N HIGH BLOOD SUGAR LOWERS SED RATE HO 6 20
GLUCOSE P AMMONIA INC V MAY INCREASE AS GLUCOSE INCS IN CIRPHOTICS P04 17
GLUCOSE P GROWTH HORMONE INC V DELAYED RISE AFTER INITIAL SLIGHT FALL HO 14714
GLUCOSE P INSULIN INC V MARKED RISE IMMEDIATELY AFTER OPAL OR I.V. ADMIN. P1011
GLUCOSE S ALANINE INC V RISE RELATED TO GLUCONEOGENESIS AFTER LOAD 90397
GLUCOSE S AMINO ACIDS DEC V (SOME AFFECTED ONLY)-DEPOSITED IN MUSCLE P03 97
GLUCOSE S AHGININE DEC V PROBABLE MUSCLE UPTAKE R0397
GLUCOSE S CALCIUM DEC V NAY FALL BY 0.5 !EQ/L DUPING CTT P0592
GLUCOSE S CHLORIDE DEC V DILUTIONAL EFFECT WN INFUSED RO2 04
GLUCOSE S CREATININE INC N INTERFERES WITH JAFFE REACTION 90620
GLUCOSE S ISOLEUCINE DEC V PROBABLE MUSCLE UPTAKE P 03 97
GLUCOSE S LEUCINE DEC V PROBABLE MUSCLE UPTAKE 90397
GLUCOSE S NEFA DEC V EFFECT GREATER IN NORMALS THAN IN DIABETICS 907147

GLUCOSE S NEFA INC V DELAYED RISE 3 HOURS AFTER ADMINISTRATION P01474
GLUCOSE S OSMOLALITY INC N OSMOTICALLY ACTIVE CONSTITUENT IN SAMPLES P0 500
GLUCOSE S PHENYLALANINE DEC V PROBABLE MUSCLE UPTAKE P 03 97
GLUCOSE S PHOSPHATE DEC V DUPING CTT, LESS MARKED AND LONGER THAN CA P0592
GLUCOSE S POTASSIUM DEC V SHIFT INTRACELLULAPLY WREN INFUSION GIVEN P0880
GLUCOSE S SALICYLATE Z N UP TO 1000 MG/100ML NO EFFECT ON TRINDER METHOD P0606
GLUCOSE S THREONINE DC V PROBABLE MUSCLE UPTAKE HO 3 97
GLUCOSE S UREA NITROGEN DEC V PROTEIN SPARING EFFECT OF GLUCOSE AND HEMODILUTION H 100 1
GLUCOSE S URIC ACID DEC V INCREASED URATE CLEARANCE ALSO SEEN IN DIABETICS P0877
GLUCOSE S URIC ACID INC N REDUCING SUBSTANCE REACTS WITH PHOSPHOTUNGSTATE HO 204
GLUCOSE S VALINE DEC V PROBABLE MUSCLE UPTAKE P 03 97
GLUCOSE U ESTRIOL DEC M INTERFERENCE WITH GLC METHOD P08 30
GLUCOSE U INSULIN INC V OCCURS THREE HOURS AFTER GLUCOSE LOAD P0 803
GLUCOSE U OSMOLALITY INC M OSMOTICALLY ACTIVE CONSTITUENT IN SAMPLES P05 00
GLUCOSE U POTASSIUM DEC V AFTER ORAL GLUCOSE AND FALL IN SERUM CONC HO 454
GLUCOSE U URIC ACID INC V INFUSIONS HAVE URICOSURIC ACTION P0877
GLUCOSE U XYLOSF EXCRETION INC M INTERFERES WITH BHONOANILINE PROC IF OVER 2 G/100NL HO 779
GLUCOSE U 17 KF.TOGENIC STEPOIDS DEC M INTERFERES WITH NORYMBERSKI REACTION P09 07
GLUCOSE U 17 KETOSTEPOIDS DEC N INTERFERES WITH ZIMMERMAN REACTION P0907
GLUCOSE U 3-0-METHYL-D-GLUCOSE INC N SEVERAL METHODS WITHOUT REMOVAL O GLUCOSE P 03 40
CL UCOSULFONE B HEMATOCRIT DEC V HENOLYTIC ANEMIA HO 2 140
GLUC0SU LEONE B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA R024O
GLUCOSULFON E B METHEMOGLOBIN INC V HENOLYTIC ANEMIA P02 40
GLUCOSU LEONE B RED CELL COUNT DEC V HEMOLYTIC ANEMIA RO658
GLUCOSULFON! B SULFHEMOGLOBIN INC V HEMOLYTIC ANEMIA P065 8
GLUCOS ULFONE B WHITE CELL COUNT DEC V LEUKOPENIA HO 620
GLUCURONIC ACID S GLUCOSE INC N INTERFERES WITH SOME METHODS P0620
GLUCUPONIC ACID U URINALYSIS GLUCOSE Z N NO EFFECT ON CLINISTIX, LABSTIX METHODS HO 999
GLUCUPONIC ACID U URINALYSIS GLUCOSE Z M NO EFFECT ON TESTAPE P0999
GLUCURONIC ACID U URINALYSIS SUGAR INC N INTERFERES WITH BENEDICT’S, FEHLINGS, CLINITEST R0999
CLUTAMIC ACID B PH INC V NA SALT NAY CAUSE ALKALOSIS P0026
CLUTAMIC ACID P AMMONIA DEC V CAPABLE OF REACTING WITH AMMONIA P0534
GLUTAMIN! P AMMONIA INC V POTENTIAL SOURCE OF ADDITIONAL AMMONIA R0534
GLUTAMINE T UREA NITROGEN INC M BLUE COLOR WITH BEHTHELOTS REAGENT P05 30
GLUTAPIMID! S BARBITURATE Z N NO EFFECT ON UV ABSORPTION METHODS P0779
GLUTATHIONE S CREATININE Z N NO EFFECT ON METHOD OF POLAR AND METCOFF P05 146
GLUTATHIONE S GLUCOSE DEC N NAY AFFECT SOME GLU OX METHODS P04 36
GLUTATHI ONE S GLUCOSE INC N INTERFERES WITH NEOCUPROINE, ALK FECN METHODS P1009
GLUTATHIONE S GLUCOSE Z N AT 10 NG/100NL NO EFFECT GLU OX OF COCHRAN HO 370
GLUTATHION! S URIC ACID INC N ACTS AS REDUCING AGENT WITH PHOSPHOTUNGSTATE P01 84
CLUTETHIMIDE B MCV INC V MAY CAUSE MECALOBLASTIC ANEMIA R0384
GLUTETHIMI DR B METHENOGLOBIN INC V BLEEDING ASSOCIATED WITH OVERDOSAGE P0657
CL UTET HIM IDE B PLATELET COUNT DEC V THPOMBOCYTOPENIA OP APLASTIC ANEMIA P0026
GLUTETHI RIDE B RED CELL COUNT DEC V MAY CAUSE APLASTIC/MEGALOBLASTIC ANEMIA P0026
CL UTETRIMIDE B WHITE CELL COUNT DEC V MAY CAUSE APLASTIC ANEMIA P0026
GLUTFTHIMIDE F COPROPORPHYPIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P03 71
GL UTETHIN IDE F PROTOPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P037 1
GLUTETHIMID! P PPOTHROMBIN TINE DEC V INCS RATE OF DEGRADATION OF ADMINISTERED COUMARINS P0787
GLUTETHIMIDE P PROTHROMBIN TIME INC V EFFECT OBSERVED WITH OVEPDOSAGE P06 57
GLU TET H I MID F S BARBITURATE DEC N NEGATIVE INTERFERENCE WITH COLORIMETRIC METHOD P00 96
GLUTETHI MI DR U ANINOLEVULINIC ACID INC V MAY PRECIPITATE ACUTE PORPHYRIA P03 71
GLUTETHIMIDE U COPPOPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA Ho 371
GLUTETHIMIDE U POPPROBILINOGEN INC V MAY PRECIPITATE ACUTE PORPHYRIA P03 71
GLUTETHINIDE U PORPHYRINS INC V MAY PRECIPITATE ATTACK OF ACUTE PORPHYRIA P0596
GLUTETHIMIDE U 17 KETOGENIC STEROIDS Z N PROB NIN INTERFERENCE WITH ZIMNEPMAN REACTION P09 07
GLUTETHIMIDE U 17 KETOSTEROIDS Z N MIN INTERFERENCE WITH ZIMMERMAN REACTION IN VITRO P0 133
GLUTETHI MID! U 17 OH CORTICOSTEPOIDS INC N INTERFERES WITH MOD GLENN-NELSON PROCEDURE IN VITRO P0 133
GLYBUPIDE P INSULIN INC V SIGNIFICANT INCREASE REPORTED P0595
GLYBURIDE S GLUCOSE DEC V LONG ACTING SULFONYLUPRA = INSULIN SECRETION P0595
CLYBURIDE S GLUCOSE TOLERANCE INC V MARKED IMPROVEMENT NOTED P0595
GLYCERALDEHYDE S TRIGLYCERIDES INC N MEASURED AS GLYCEROL WITH ENZYMATIC PROCEDURES P0779
GLYCERIC ACID S LACTATE DEC N HIGH CONCS INTERFERE WITHH ENZYMATIC METHOD P0333
GLYCEPYL GUAIACOLAT U VMA INC N AFFECTS P-NITPONILINE IN INITIAL PART OF REACTION HO 233
GLYCERYL GUAIACOLAT U 5 OH INDOLEACETIC ACID INC N INTERFERES WITH NITPOSONAPHTHOL METHOD P0355
GLYCINE B MEGALOBLASTS INC V NAY PROVOKE OR ACCENTUATE MEGALOBLASTOSIS P079 1
GLYCI N! S ALKALINE PHOSPHATASE DEC N IF USED AS BUFFER IN LAB PROC AS COMPLEXES MG P0929
GLYCINF S GLYCINE INC V SIMILAR MARKED INC IN GOUTY AND NORMALS P1020
GLYCI NE S SEPINE INC V SIMILAR MARKED INC IN GOUTY AND NORMALS Ri 02 0
GLYCINE U AMINOLEVULINIC ACID INC N IF NO PRELIMINARY SEPARATION R0779
GLYCI NE U AMMONIA INC V SAME EXTENT IN GOUTY AND NORMAL SUBJECTS P1020
GLYCINE U GLYCINE INC V SIMILAR MARKED INC IN GOUTY AND NORMALS P1020
GLYCI NE U PHOSPHATE INC V INHIBITS TUBULAR REABSORPTION P02814
GLYCINE U SEPINE INC V SIMILAR MARKED INC IN GOUTY AND NORMALS H 1020
GLYCINE U URIC ACID INC V INC TUBULAR SECRETION ES? IN GOUTY SUBJECTS 91020
GLYCOCYAMIDINE S CREATININE INC N REACTS TO GIVE FALSE fl4C WITH JAFFE REAGENT P0907
GLYCOCYAMINE S CHEATININE INC N IF REACTION OF VOGES-PPOSKAUEP USED P0436
GLY CO PY P POL A TE S ALKALINE PHOSPHATASE INC V HEPATOTOXICITY P0620
GLYCOPYPPOLAT! S BILIRUBIN INC V HEPATOTOXICITY P0 620
GLYCOPY PROLATE S BSP RETENTION INC V HEPATOTOXICITY P06 20
CL YC OP Y RROI ATE S CEPHALIN FLOCCULATION INC V HEPATOTOXICITY P06 20
GLYCOPYPPOLATE S SGOT INC V HEPATOTOXICITY P0620
GLYCOPYRROLATE S SGPT INC V HEPATOTOXICITY P06 20
GLYCOPYRROLATE S THYNOL TURBIDITY INC V HEPATOTOXICITY P0620
GLYCOPYRROLATE U URINALYSIS BILE INC V HEPATOTOXICITY HO 620
GLYMIDI NE B SEDIMENTATION PATE INC V SLIGHT RISE IN MEAN PATE REPORTED P0657
GLYMIDINE S GLUCOSE DEC V PLASMA HALF-LIFE APPOXIMATELY 4 HOURS RO689
GOLD B EOSINOPHILS INC V TRANSIENT ALLERGIC RESPONSE P0933
GOLD a HEMATOCPIT DEC V APLASTIC ANEMIA P0933
GOLD B HEMOGLOBIN DEC V APLASTIC ANEMIA P0933
GOLD B PLATELET COUNT DEC V APLASTIC ANEMIA (THROMBOCYTOPENIA) P0933

COLD B RED CELL COUNT DEC V APLASTIC ANEMIA RO933
GOLD B WHITE CELL COUNT DEC V APLASTIC ANEMIA/LEUKOPENIA/AGRANULOCYTOSIS 30933
GOLD B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA OF HYPERSENSITIVITY 20620
COLD F OCCULT BLOOD P05 V ASSOC WITH THROMBOCYTOPENIA 90657
GOLD S ALKALINE PHOSPHATASE INC V PARE SIDE EFFECT WITH LIVER DAMAGE (REVERSIBLE) P0029
GOLD S BILIHUBIN INC V RARE SIDE EFFECT WITH LIVER DAMAGE P0657
GOLD S BSP RETENTION INC V HEPATOTOXICITY WITH CENTPOLOBULAP NECROSIS P0620
GOLD S CEPHALIN FLOCCULATION INC V HEPATOTOXICITY WITH CENTROLCBULAR NECROSIS 30620
GOLD S CHOLESTEROL INC V MAY CAUSE HYPERSENSITIVE CHOLESTASS 901405
GOLD S GAMMA GLOBULIN DEC V SINGLE CASE REPORTED 90657
GOLD S PBI DEC N INTERFERES WITH CHLORIC ACID, BARKER METHODS 90112
GOLD S SCOT INC V HFPATOTOXICITY WITH CENTPOLOBULAR NECROSIS 30620
GOLD S SGPT INC V HEPATOTOXICITY WITH C!NTPOLOBULAP NECROSIS P0620
GOLD S THYMOL TURBIDITY INC V HEPATOTOXICITY WITH CENTROLOBULAP NECROSIS 20620
GOLD U AMINOLEVULINIC ACID INC V OCCURS WITH PANMYELOPATHY 20384
GOLD U COPPOPOPPHYHIN INC V OCCURS WITH PANRYELOPATHY 203814
GOLD U PROTEIN INC V MAY CAUSE NEPHROTOXICITY 90657
GOLD U URINALYSIS BILE INC V HEPATOTOXICITY WITH CENTROLOBULAR NECROSIS P0620
GOLD U URINALYSIS HEMOGLOBIN INC V PRODUCES ACTUAL BLEEDING RO299
GOLD U URINALYSIS PROTEIN INC V NEPRROTOXIC EFFECT (AT LEAST IN 50% CASES) 90299
GOLD U URINALYSIS RBC/HPF INC V PRODUCES ACTUAL BLEEDING 90299
GONADOTROPIN U ANDROSTERONE INC V 150% INCRASE WHEN GIVEN TO NORMAL MEN 30845
GONADOTROPIN U ESTROGENS INC V HORMONAL ACTION 20593
GONADOTROPIN U ETIOCHOLANOLONE INC V 150% INCREASE WHEN GIVEN TO NORMAL MEN HC845
GONADOTROPIN U PREGNANEDIOL INC V HORMONAL ACTION 90593
GONADOTROPIN U PREGNANETRIOL INC V VARIABLE CHANGE WHEN GIVEN TO NORMAL MEN P0845
GONADOTPOPIN U TESTOSTERONE INC V MARKED EFFECT IN NORMAL MEN P0798
GONADOTPOPIN U 17 KETOSTEPOIDS INC V METABOLIC RESPONSE 908142
GONADOTROPIN U 17 OH COPTICOSTEPOIDS INC V HORMONAL ACTION 208142
GRISEOFULVIN B LE CELL PREP P05 V MAY PRODUCE LE-LIKE SYNDROME 20910
GRISEOFULVIN B LYMPHOCYTES INC V (RELATIVE LYMPHOCYTOSIS) R0657
GRISEOFULVIN B MONOCYTES INC V (RELATIVE NONOCYTOSIS) 30657
GPISEOFULVIN B PORPHYRINS INC V MAY PRECIPITATE ACUTE PORPHYRIA ATTACK 20736
GRISEOFULVIN B WHITE CELL COUNT DEC V MAY CAUSE LEUKOPENIA/NEUTROPENIA 30657
GRISEOFULVIN F COPROPOPPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA ATTACK 90371
GRISEOFULVIN F PROTOPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA ATTACK R0371
GRISEOFULVIN P PROTHROMBIN TINE DEC V INDUCES HEPATIC METABOLISM OF ANTICOAGULANTS RO237
GRISEOFULVIN S ALKALINE PHOSPHATASE INC V NAY BE HEPATOTOXIC 90596
GRISEOFULVIN S SGOT INC V MAY BE HEPATOTOXIC P0596
GRISEOFULVIN S SGPT INC V NAY BE HEPATOTOXIC P0596
GRISEOFULVIN S URIC ACID DEC V EFFECTIVE IN TREATMENT OF GOUT ?N!CHANISM 20972
GRISEOFULVIN U AMINOLEVULINIC ACID INC V MAY PRECIPITATE ACUTE PORPHYRIA ATTACK 90371
GPISEOFULVIN U COPHOPORPHYHIN INC V MAY PRECIPITATE ACUTE PORPHYRIA ATTACK P0371
GHISEOFULVIN U PORPHOBILINOGEN INC V MAY PRECIPITATE ACUTE PORPHYRIA ATTACK 90371
GRISEOFULVIN U PORPHYRINS INC V STIMULATES FORMATION OF ALA-SYNTHETASE 903814
GRISEOFULVIN U PROTEIN INC V MAY CAUSE NEPHPOTOXICITY 20198
GRISEOFULVIN U URINALYSIS CASTS INC V CYLINDRUPIA MAY OCCUR WITHOUT RENAL INSUFFICIENCY P0384
GPISEOFULVIN U URINALYSIS PROTEIN INC V ? NEPHROTOXIC EFFECT (TRANSIENT AND REVERSIBLE) P0299
GROWTH HORMONE P ALPHA AMINO NITROGEN DEC V INCREASED PERIPHERAL REMOVAL P0621
GROWTH HORMONE S GLUCOSE TOLERANCE DEC V REDUCES DISAPPEARANCE PATE AFTER I.V. GTT P0253
GROWTH HORMONE S NEFA INC V INDUCES LIPOLYSIS (?AT ADENYL CYCLAS! STEP) R0253
GROWTH HORMONE S PHOSPHATE INC V GRADUAL SLIGHT RISE - METABOLIC EFFECT P06149
GROWTH HORMONE S PROTEIN INC V ASSOCIATED WITH INCREASED PROTEIN SYNTHESIS P0211
GROWTH HORMONE S THYNOL TURBIDITY INC V INC PROTEIN SYNTHESIS 90211
GROWTH HORMONE S UREA NITBOGEN DEC V METABOLIC EFFECT R06U9
GROWTH HORMONE U CALCIUM INC V NORMAL METABOLIC RESPONSE 30649
GROWTH HORMONE U GLUCOSE INC V MAY CAUSE HYPERGLYCEMIA AND GLYCOSUPIA P0620
GROWTH HORMONE U HYDROXYPPOLINE INC V METABOLIC EFFECT 90384
GROWTH HORMONE U URINALYSIS GLUCOSE INC V OCCURS IF PRONOUNCED HYPERGLYCEMIA 20620
GUANCYDINE U SODIUM DEC V PROBABLE ACTION ON RENAL TUBULES P0962
GUANCYDINE U VOLUME DEC V PROBABLE ACTION ON PENAL TUBULES 90962
GUANETHIDINE 0 TYRAMINE TEST INC V INC RESPONSE TO TYRAMINE DUE TO MAO INHIBITION 30373
GUANETHIDINE P PROTHPOMBIN TIME INC V ENHANCES ANTICOAGULANT ACTIVITY 903814
GUANETHIDINE S CHLORIDE INC V SALT RETENTION ? DUE TO TUBULAR EFFECT 30384
GUANETHIDINE S GLUCOSE DEC V ANTIDIABETIC ACTIVITY (RISE ONCE STOP THERAPY) P0402
GUAN!THIDINE S GLUCOSE TOLERANCE INC V ANTIDIABETIC ACTIVITY (CHANGE AT END OF TREATMENT) P0402
GUANETHIDINE S SCOT INC V POSSIBLE MYOPATHIC COMPLICATION 90596
GUANETHIDINE S SGPT INC V POSSIBLE MYOPATHIC COMPLICATION P0596
GUANETHIDINE S SODIUM INC V SALT RETENTION ? DUE TO TUBULAR EFFECT 30384
GUANETHIDINE S UREA NITROGEN INC H DUE TO CHEN SIMILARITY TO UREA P0029
GUANETHIDINE S UREA NITROGEN INC V ASSOC WITH BLOOD PRESSURE REDUCTION, DEC BLOOD FLOW P0467
GUANETHIDINE U EPINEPHPINE INC V SLIGHT INCREASED OUTPUT REPORTED HO8OS
GUANETHIDINE U NOR!PINEPRRINE DEC V NON SIGNIFICANT DECREASE REPORTED P0805
GUANETHIDINE U VMA DEC V 30% REDUCTION SEEN IF GIVEN THERAPEUTICALLY 91006
GUANIDINE S CREATININE INC N IF REACTION OF VOCES-PROSKAUER USED 90436
GUANIDINE S UREA NITROGEN Z N NO EFFECT ON BERTHELOT REACTION 90510
GUANINE T PROTEIN INC N REACTS WITH FOLIN-CIOCALTEU OF LOWRY METHOD RO140
GUANOCHLOH S SCOT INC V POSSIBLE EFFECT ON LIVER 90596
GUANOCHLOP S SGPT INC V POSSIBLE EFFECT ON LIVER 90596
GUANOCHLOR S UREA NITROGEN INC V MAY DECREASE RENAL BLOOD FLOW 90299
GUANOXAN S ALKALINE PHOSPHATASE INC V MAY CAUSE HEPATIC TOXICITY 30620
GUANOXAN S BILIRUBIN INC V MAY CAUSE HEPATIC TOXICITY 062O
GUANOXAN S BSP RETENTION INC V MAY CAUSE HEPATIC TOXICITY P0347
GUANOXAN S CEPHALIN FLOCCULATION INC V NAY CAUSE HEPATIC TOXICITY 90620
GUANOXAN S SCOT INC V MAY CAUSE H!PATIC TOXICITY P0620
GUANOXAN S SGPT INC V MAY CAUSE HEPATIC TOXICITY 90620
GUANOXAN S THYMOL TURBIDITY INC V MAY CAUSE HEPATIC TOXICITY 30620
GUANOXAN S UREA NITROGEN INC V DUE TO DECREASED BLOOD FLOW RO596
GUANOXAN U NOREPINEPHRINE DEC V DECREASED OUTPUT REPORTED 20805
GUANOXAN U URINALYSIS BILE INC V MAY CAUSE HEPATIC TOXICITY P0620

HAIR LACQUER B WHITE CELL COUNT DEC V SOME MAY CAUSE LEUKOPENIA (AMA-BLOOD DYSCRASIAS) P0 658
HALOFENAT E S DFT14 INC V LOWERS BINDING TO TBG AND ALBUMIN P02 56
H ALOE EN ATE S FREE THYROXINE INC V INTERFERES WITH BINDING OF T14 TO TBG P06 714
HALO FE NATE S PHI DEC V INHIBITS BINDING OF T4 TO TBG P0674
HAL OFEN ATE S TBG Z V NO EFFECT OBSERVED AFTER 3 WEEKS P06714
HAL OF! NA TE S TBPA Z V NO EFFECT OBSERVED AFTER 3 WEEKS P0674
HA LOPE NA T F S THYROXINE (T14) DEC V INTERFERES WITH BINDING OF T4 TO TBG P0674
HA LOFE N ATE S TRIGLYCERIDES DEC V REDUCED BY UP TO 50% HO 674
HALOFENATE S T3 UPTAKE INC V RESIN UPTAKE INC BY 20% AFTER 3 WEEKS P06 74
HA LOPE NA TE S T14 (MURPHY-PATTEE) INC V SIGNIFICANT INCREASE OBSERVED P06714
H AL OFE N ATE S URIC ACID DEC V UHICOSURIC ACTION HO 674
HA L OF! NA TE U URIC ACID INC V EFFECT INDEPENDENT OF GFH P 06714
HALOPEPIDOL B RED CELL COUNT DEC V MAY CAUSE ANEMIA P0620
HA LOPERI DOL B WHITE CELL COUNT DEC V MAY CAUSE ANEMIA P06 20
HALOPERIDOL B WHITE CELL COUNT INC V RARELY REPORTED LEUKOCYTOSIS HO 026
HA LOPERIDOL S ALKALINE PHOSPHATASE INC V NAY CAUSE HEPATOCELLULAP CHANGES P0620
HALOPERIDOL S BILIHUBIN INC V MAY CAUSE HEPATOCELLULAR CHANGES P062 0
HALOPERIDOL S BSP RETENTION INC V MAY CAUSE HEPATOCELLULAR CHANGES P06 20
HALOPERIDOL S CEPHALIN FLOCCULATION INC V MAY CAUSE HEPATOCELLULAR CHANGES H 0620
HALOPERIDOL S CHOLESTEROL DEC V INHIBITS CHOLESTEROL BIOSYNTHESIS HO 6 20
HA LOPE RI DOL S DESMOSTEROL INC V FURTHER METABOLISM INHIBITED SO ACCUMULATES P03 814
HALOPER IDOL S GLUCOSE DEC V INSULIN LIKE ACTION OF DRUG REPORTED IN ONE CASE HO 1417
HALOPERI DOL S SCOT INC V NAY CAUSE HEPATOCELLULAP CHANCES HO 6 20
HALOPEH IDOL S SGPT INC V NAY CAUSE HEPATOCELLULAR CHANGES P06 20
HALOPERI DOL S THYMOL TURBIDITY INC V NAY CAUSE HEPATOCELLULAR CHANGES P0620
HALOPERIDOL U URINALYSIS BILE INC V MAY CAUSE HEPATOCELLULAR CHANGES HO 620
HALOTHA NE B WHITE CELL COUNT INC V ALLERGIC HYPERSENSITIVE RESPONSE P03814
HA LO TB AN! P EPPF DEC V UP TO 38% DEC REPORTED IN NORMALS P06 57
HALOTHA NE P GROWTH HORMONE INC V ?METABOLIC RESPONSE TO SURGICAL STRESS H0712
HAL OT HA N! S ALKALINE PHOSPHATASE INC V REVERSIBLE DEPRESSION OF LIVER FUNCTION 90861
HALOTHANE S BILIRUBIN INC V REVERSIBLE DEPRESSION OF LIVER FUNCTION P 0861
HA LOT HA NE S BSP RETENTION INC V REVERSIBLE DEPRESSION OF LIVER FUNCTION P0 86 1
H A LOTH A NE S CEPHALIN FLOCCULATION INC V REVERSIBLE DEPRESSION OF LIVER FUNCTION P06 20
HALOTHA NE S GLUCOSE INC V RESPONSE TO STRESS OF SURGERY 90712
HALOTHA NE S LACTIC DEHYDROGENASE INC V HEPATOTOXIC IN RARE CASES, ?IDIOSYNCPACY HO 861
HALOTHA NE S SCOT INC V ALLERGIC HEPATIC HYPERSENSITIVITY HO 86 1
HA LOTH A NE S SGPT INC V ALLERGIC HEPATIC HYPERSENSITIVITY H 086 1
HALOTHA NE S THYMOL TURBIDITY INC V ALLERGIC HEPATIC HYPERSENSITIVITY P06 20
HALOTHA NE U GFP DEC V UP TO 19% DEC REPORTED IN NORMALS P065 7
HA LOIN A NE U URINALYSIS BILE INC V ALLERGIC HEPATIC HYPERSENSITIVITY R062O
HE AT B PH INC N INC 0.015 PER DEGREE (MAY ALSO AFFECT BUFFERS) HO 181
HEAT S CEPHALIN FLOCCULATION INC N AS ROOM TEMPERATURE IS INCREASED P03 55
HE AT S PHENOL TURBIDITY INC N INCS GREATLY WITH CHANCE OF TEMPERATURE P0181
HEAT S THYNOL TURBIDITY DEC N AS ROOM TEMPERATURE IS INCREASED HO 181
HE AT S ZNSOL& TURBIDITY Z N LITTLE CHANGE WITH TEMPERATURE OBSERVED HO 181
HE MAT IN S AMINOLEVULINIC ACID DEC V IN A PATIENT WITH ACUTE INTERMITTENT PORPHYRIA RO131
HEMATIN S PORPHOBILINOGEN DEC V IN A PATIENT WITH ACUTE INTERMITTENT PORPHYRIA HO 131
HEMATIN U ANINOLEVULINIC ACID DEC V IN A PATIENT WITH ELEVATION DUE TO PORPHYRIA P0131
HEMATI N U PORPHOBILINOGEN DEC V IN A PATIENT WITH ELEVATION DUE TO PORPHYRIA R0131
HEMOGLOBIN P AMMONIA INC N SLIGHT INTERFERENCE WITH COLOR DEVELOPMENT HO 5 30
HEMOGLOBIN S ALBUMIN INC M IF NO BLANK WITH HABA DYE, SLIGHT EFFECT BCG P0670
HEMOGLOB IN S BILIRUBIN INC N PERCENTAGE OF UNCONJUGATED DECREASES WITH INC HGB HO 620
HEMOGLOBIN S CALCIUM DEC M INTERFERENCE WITH CALCEIN TITRATION P0017
HENOGLOB IN S CHOLESTEROL INC M INTERFERENCE WITH ZLATKIS-ZAK AND DIRECT METHODS HO 355
HEMOGL OBI N S DIRECT BILIPUBIN INC M OCCURS WITH DIRECT SPECTPOPHOTOMETHIC METHOD P01140
HEMOGLOBIN S GLUCOSE INC N MAY HAVE MARKED EFFECT WITH 0-TOLUIDINE Hi 009
HEMOGLOBIN S ICTERIC INDEX INC N CONTRIBUTES BACKGROUND COLOR P0184
HEMOGLOBIN S IRON Z N NO EFFECT UNLESS CONC GREATER THAN 500 MG/100ML R0779
HEMOGLOBIN S LIPASE DEC M INHIBITS LIPASE ACTIVITY P0530
HEMOGLOBIN S PROTEIN INC N 1 MG MEASURED AS EQUIVALENT TO 1.9 MG PROTEIN POLl 36
HEMOGLOB IN S SCOT INC N IF CHEATER THAN 25 NG/100NL HO 825
HEMOGLOBIN S THYMOL TURBIDITY Z N NO EFFECT UP TO CONC OF 14 NG/100ML P04 36
HEMOGLOBIN S TIBC Z M NO EFFECT ON MEASUREMENT P0779
HEMOGLOBIN S UREA NITROGEN INC M MAY AFFECT COLOR OF UREASE/BERTHELOT PROCEDURE P0779
HEMOGLOBIN S ZNSO14 TURBIDITY Z N PROB SAME NON-INTERFERENCE AS WITH THYMOL TURBIDITY HO 436
HENOGLOBI N U PORPHYRINS INC N AFFECTS UV ABSORPTION SCREEENING METHODS P0779
HEMOGLOBIN U PSP EXCRETION INC N INTERFERING COLOR R062O
HEMOGLOBI N U URINALYSIS COLOR INC N CLEAR RED TO REDDISH BROWN 90663
HEMOLYS IS P ALPHA AMINO NITROGEN INC N RELEASE OF GLUTATHIONE FROM EPYTHPOCYTES P014 36
H EMOLY S IS P AMMONIA INC N SOME INTERFERENCE WITH COLOR DEVELOPMENT P0355
HEMOLYSIS P COPTISOL INC N PPODUCESINTEPFEPENCE WITH FLUOPOMETPIC METHOD HO 490
HEMOLYSI S P INSULIN DEC N CAUSES DESTRUCTION OF HORMONE FOR RADIOIMMUNOASSAY HO 150
HENOLYSIS P PROTHROMBIN TIME Z N HAS NEGLIGIBLE EFFECT P0998
HEMOLYSIS P TESTOSTERONE INC N IF GREATER THAN 5 MC/100ML AFFECTS C-S METHOD P0269
HEMOLYSIS S ACID PHOSPHATASE TOTAL INC N ERYTHROCYTES CONTAIN CONSIDERABLE ACTIVITY 90779
HEMOLYSIS S ALBUMIN DEC N AFFECTS MEASUREMENT BY HABA, BIUPET, METHYL ORANGE HO 998
HEMOLYSIS S ALDOLASE INC M HIGH CONTENT IN ERYTHROCYTES AND PLATELETS HO 244
HEMOLYSIS S ALKALINE PHOSPHATASE INC N RBC CONC 6X SERUM SO EFFECT MINIMAL HO 436
HEMOLYSIS S AMYLASE INC N REPORTED EFFECT P0079
HEMOLYS IS S ARGINASE INC N RATIO OF 1000 TO 1 BETWEEN CELLS AND SERUM HO 181
HEMOLYSIS S BILIPUBIN DEC N METHENOGLOBIN FORMATION AFFECTS DIAZOTIZATION P06 34
HEMOLYSIS S BROMIDE INC N MAY CAUSE COLOR IN PROTEIN-FREE FILTRATE HO 181
HE MOLY S IS S BSP RETENTION INC M ABSORB OF HGB VARIES WITH PH (AFFECTS SOME PROCS) P0355
HENOLYSIS S CALCIUM DEC N INTERFERES WITH CALCEIN FLUORESCENCE METHODS P06 44
HEMOLYSIS S CEPULOPLASMIN DEC N MAY AFFECT LINEARITY OF REACTION CURVE P0779
HEMOLYSIS S CHLORIDE DEC N DILUTIONAL EFFECT P0620
HEMOLYS IS S CHOLESTEROL INC N VALUES HIGH BY 10% IF EXTRACTION NOT USED P0436
HEMOLYSIS S CPK Z M SLIGHT HEMOLYSIS HAS NO EFFECT R0779
HE MOLYSIS S CREATININE Z N MODERATE HEMOLYSIS HAS NO EFFECT P0907
HEMOLYSIS S DIRECT BILIRUBIN DEC N INTERFERENCE WITH DIRECT SPECTROPHOTONETRY R01436

HEMOLYSIS S ELECTROPHORESIS POS M MAY AUGMENT BETA, BETWEEN ALPHA2 AND BETA R0436
HEMOLYSIS S FRUCTOSE P014 ALDOLASE Z M SLIGHT HEMOLYSIS HAS NO EFFECT P0779
HENOLYSIS S GLUCOSE DEC N AFFECTS GLU OX AVOIDABLE BY SONOCYI FILTRATE P0436
HEMOLYSIS S GLUTAMATE DEHYDROGENASE Z N SLIGHT HEMOLYSIS HAS NO EFFECT P0779
HENOLYSIS S HBD INC M ERYTHPOCYTES CONTAIN LARGE AMOUNTS P0779
HEMOLYSIS S ICTERIC INDEX INC N PRESENCE OF HEMOGLOBIN PRODUCES RED COLOR HO1438
HEMOLYSIS S IRON INC N INTERFERES WITH COLORIMETRIC PROCEDURE P01439
HENOLYSIS S LACTATE INC N DUE TO METABOLIC ACTIVITY OP CELLS R0998
HEMOLYSIS S LACTIC DEHYDROGENASE INC N RELEASED FROM RBC’S AND PLATELETS H0355
HEMOLYSIS S LIPASE DEC N INHIBITION OF LIPASE ACTIVITY P01437
HEMOLYSIS S PBI DEC V IF MARKED, RBC’S CONTAIN NO 12 (DILUTION EFFECT) P0112
HEMOLYSIS S PHOSPHATE INC V RELEASED PROM RBC’S AND PLATELETS P0624
HEMOLYSIS S PHOSPHOHEXOSEISOMERASE Z N SMALL DEGREE HAS NO EFFECT P0998
HEMOLYSIS S PHOSPHOLIPIDS DEC N ORGANIC PHOSPHATE HYDROLYSES TO INOPGANIC P0998
HEMOLYSIS S POTASSIUM INC V RELEASED FROM RBC’S AND PLATELETS P0181
HEMOLYSIS S PROTEIN INC N ADDED PROTEIN MEASURED P0620
HEMOLYSIS S PYRUVATE INC N DUE TO METABOLIC ACTIVITY OF CELLS P0998
HENOLYSIS S SCOT INC V RELEASED FROM RBC’S AND PLATELETS P0620
HEMOLYSIS S SGPT INC V RELEASED ‘ROM PBS’S AND PLATELETS P0620
HEMOLYSIS S SODIUM DEC V DILUTION EFFECT P0620
HEMOLYSIS S SORBITOL DEHYDROCENASE Z N SLIGHT HEMOLYSIS HAS NO EFFECT P0779
HEMOLYSIS S UREA NITROGEN DEC N RED CELL CONC LESS THAN SERUM HO181
HEMOLYSIS S UREA NITROGEN INC N COLOR PRODUCED IN PROTEIN-FREE FILTRATES P0181
HENOLYSIS S URIC ACID INC N FALSE POSITIVE WITH GLUTATHIONE AND ERGOTHIONINE H0182
HENOLYSIS S URIC ACID Z N NO EFFECT IF MEASURED BY URICASE AND IS MODERATE P0771
HENOLYSIS U UROBILINOGEN INC V FURTHER METABOLISM OF HEMOGLOBIN P0620
HEPAPIN B CLOTTING TIME INC V CONCENTRATION RELATED EFFECT P0704
HEPARIN B FACTOR IX DEC V REPORTED EFFECT R0384
HEPAPIN B FACTOR V DEC V CONCENTRATION RELATED EFFECT P0384
HEPAPIN B FACTOR XI DEC V CONCENTRATION RELATED EFFECT P0384
HEPARIN B PLATELET COUNT DEC V REPORTED EFFECT FOLLOWING I.V. INFUSIONS 90656
HEPARIN B PTT INC V CONCENTRATION RELATED EFFECT P0704
HEPARIN B THRONBIN TIME INC V RELATED TO CONC OP CIRCULATING HEPARIN P0704
HEPAHIN B THRONBOPLASTIN CEN DEC V ABNORMAL RESPONSE (INHIBITION) P0384
BEPARIN P AMMONIA INC N CONTAINS VARIABLE AMOUNTS OF AMMONIUM SALTS 90181
HEPARIN P CORTICOSTEROIDS INC N IF CONTAMINATED BY IMPURITIES P0524
HEPARIN P INSULIN DEC M EFFECT IN HEPAPINIZED PLASMA AND SERUM R07O9
HEPAPIN P INSULIN INC N SPURIOUSLY RICH VALUES REPORTED FOP INMUNOASSAY H0O64
HEPAHIN P PPOTHROMBIN TIME INC V CONCENTRATION RELATED EFFECT P0704
HEPAPIN P TSH DEC V INTERFERES WITH THYROXINE BINDING TO PROTEIN P0502
HEPARIN S ALBUMIN INC M PROMOTES BINDING OF HABA DYE TO GLOBULINS HO907
HEPARIN S ANYLASE Z M NO EFFECT ON AMYLASE ACTIVITY P0998
HEPARIN S BSP RETENTION INC N COLOR INTENSITY INC IN SERUM, WAVELENGTH SHIFTED P0219
HEPARIN S CALCIUM DEC N INTERFERES WITH EDTA AND FLUOROMETRIC METHODS 91001
HEPARIN S CALCIUM INC M IF CA SALT USED MAY AFFECT RESULT P0998
HEPAHIN S CHOLESTEROL DEC V MECHANISM NOT DISCUSSED P0379
HEPARIN S CHOLESTEROL INC V REBOUND EFFECT OF CESSATION OF TREATMENT P01467
HEPAPIN S CPK DEC N REPORTED EFFECT P0079
HEPARIN S FREE THYROXINE INC V PROBABLE MODIFICATION OF THYROXINE BINDING RO655
HEPAHIN S GLUCOSE INC V SINGLE REPORT OF RISE OF 30 MC/100 ML P0219
HEPARIN S HBD DEC N SIGNIFICANT INACTIVATION P0779
HEPARIN S LIPOPROTEIN ELECTPOPHOR P05 N ALTERS ELECTPOPHORETIC PATTERN R0536
REPAHIN S LIPOPROTEIN LIPASE INC V RELEASE OF TISSUE LIPASE INTO PLASMA P03814
HEPARIN S NEFA INC V ALSO OCCURS WITH SITUATIONAL STRESSES P0998
HEPARIN S PHOSPHATE INC N PHOSPHATE CONTAMINATION OF HEPARIN REPORTED P0119
HEPAPIN S POTASSIUM INC V DECREASED RENAL EXCRETION P0384
HEPARIN S PHEBETA-LIPOPROTEINS DEC V NON-SUSTAINED RESPONSE TO SMALL I.V. INJECTION P0384
HEPARIN S SALICYLATE Z N NO EFFECT ON TRINDER PROCEDURE P0606
HEPAHIN S SCOT Z N NO EFFECT ON ACTIVITY 90825
HEPAHIN S SODIUM DEC V INC EXCRETION DUE TO ALDOSTEHONE SUPPRESSION P0620
HEPAPIN S SODIUM INC N IF NA SALT USED MAY AFFECT RESULT 90998
HEPARIN S THYNOL TURBIDITY INC N AFFECTS PHYSICO-CHEM PROPERTIES ALTERING TURBIDITY P0436
HEPAPIN S THYROXINE (T4) DEC V PROBABLE MODIFICATION OF THYROXINE BINDING P0813
HEPARIN S TRIGLYCERIDES DEC V PROMPT DEC WHEN SMALL DOSE GIVEN I.V. P0384
HEPAPIN S TRIIODOTHYRONINE (T3) INC V INTERFERES WITH THYROXINE BINDING TO PROTEIN P0502
HEPARIN S T3 UPTAKE INC V RED CELL UPTAKE INC, RESIN UNAFFECTED P0828
HEPAPIN S ZNSO4 TURBIDITY INC N AFFECTS PHYSICO-CHEMICAL PROPERTIES P01436
HEPAPIN U ALDOSTEBONE DEC V SUPPRESSED SECRETION WITH PROTRACTED TREATMENT P01467
HEPAPIN U SODIUM INC V DUE TO ALDOSTEHONE SUPPRESSION R02O4
HEPARIN U 5 OH INDOLEACETIC ACID DEC V REDUCTION IN SINGLE CASE CAPCINOID SYNDROME 90480
HEPTABARBITAL P PROTHROMBIN TIME DEC V INDUCES HEPATIC METABOLISM OF ANTICOACULANTS P0596
HEPTACHLOR S SCOT INC V LIVER DAMAGE OCCURS AS LATE EFFECT OF POISONING P0368
HEPTACHLOR S SGPT INC V LIVER DAMAGE OCCURS AS LATE EFFECT OF POISONING P0368
HETACILLIN B EOSINOPHILS INC V PROBABLY ALLERGIC RESPONSE P0467
HETACILLIN B PLATELET COUNT DEC V THPOMBOCYTOPENIA NAY OCCUR OCCASIONALLY P0467
HETACILLIN B RED CELL COUNT DEC V OCCASIONAL ANEMIA REPORTED WITH PENICILLINS P01467
HETACILLIN B WHITE CELL COUNT DEC V PROBABLY ALLERGIC RESPONSE (RARE) R0467
HETACILLIN F OCCULT BLOOD P05 V CAUSED BLEEDING WITH DOSE OF 14G HO2614
HETACILLIN S SCOT INC V OBSERVED WITH OTHER PENICILLINS (CAUSE?) P0467
HEXACHLOROBENZENE B PLATELET COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) 20658
HEXACHLOROBENZENE B RED CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) RO658
HEXACHLOROBENZENE B WHITE CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) 90658
HEXACHLOROBENZENE U PORPHYRINS INC V STIMULATES FORMATION OF ALA-SYNTHETASE P0384
HEXAMETHYLNELANINE B PLATELET COUNT DEC V MODERATE EFFECT IN A THIRD OF PATIENTS P0995
HEXAMETHYLNELAMINE B WHITE CELL COUNT DEC V MODERATE EFFECT IN HALF OF PATIENTS P0995
HEXOSANINE T PROTEIN INC M HEXOSAMINES, N-ACETYL-DERIVS AFFECT LOWRY METHOD R0097
HIPPURAN S PBI INC N BUT DOES NOT AFFECT T4 P0839
HIPPURIC ACID U URINALYSIS SUGAR INC N REDUCES BENEDICT’S SOLUTION P0299
HISTAMINE 0 GASTRIC JUICE HCL INC V USED DIAGNOSTICALLY P00 26
HISTAMINE 0 GASTRIC JUICE PEPSIN INC V EFFECT OCCURS WITH SECRETION OF ACID P0384

HISTAMINE S AMYLASE INC V SUBCUTANEOUS INJECT NAY CAUSE ACUTE PANCREATITIS P0 836
HISTAMINE S POTASSIUM INC V MARKED EFFECT OF I.V. INJECT (?INVOLVES G.I. TRACT) P 03814
HISTIDIN! S BILIRUBIN INC M REACTS WITH DIAZO REAGENT R01436
HISTIDIN! S UREA NITROGEN Z N NO EFFECT ON BERTHELOT REACTION P0510
HONOGENTISIC ACID U ANMONIACAL AGNO3 P05 N RAPID DARKENING OF SOLUTION P09 29
HOMOGENTISIC ACID U FECL3 TEST 205 N TRANSIENT BLUE COLOR HO 92 9
HOMOGENTISIC ACID U PHENYLKETONES P05 N BLUE/GREEN FADING WITH FECL3, NIL WITH PHENISTIX HO 239
ROMOGENTISIC ACID U PHENYLKETONES Z N NO EFFECT WITH PHENISTIX P 0239
HOMOGENTISIC ACID U URINALYSIS COLOR INC M BLACK (OCCURS WITH ALKAPTONURIA) P0663
HOMOGENTISIC ACID U URINALYSIS SUGAR INC N REDUCES BENEDICT’S SOLUTION H0299
HYCANTHON! S SGOT INC V TRANSIENT CHANGE IN LIVER FUNCTION H0026
HYCANTHONE S SGPT INC V TRANSIENT CHANGE IN LIVER FUNCTION P0026
HYDANTOINS B LE CELL PREP POS V NAY CAUSE APPEARANCE OF LE CELLS HO 596
HYDANTOINS B METHEMOGLOBIN INC V REPORTED EFFECT R0596
HYDANTOINS B PLATELET COUNT DEC V THROMBOCYTOPENIA (IMMUNOLOGICALLY INDUCED) P06 20
HYDANTOINS S ALKALINE PHOSPHATASE INC V SEVERE DELAYED HYPERSENSITIVITY REPORTED P0657
HYDANTOINS S BILIPUBIN INC V SEVERE DELAYED HYPERSENSITIVITY REPORTED P0657
HYDANTOINS S GAMMA GLOBULIN INC V OBSERVED IN CASES OF HYPERSENSITIVITY HO 657
HYDANTOINS S SGPT INC V SEVERE DELAYED HYPERSENSITIVITY REPORTED P0657
HYDPALAZINE B HEMATOCRIT DEC V MAY CAUSE HEMOLYTIC ANEMIA P0014
HYDRALAZINE B HEMOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA ROO 114
HYDPALAZINE B LE CELL PREP P05 V MORE COMMON IN SLOW ACETYLATORS HO 73 1
HYDPALAZINE B PLATELET COUNT DEC V PANCYTOPENIA NAY OCCUR WITH PURPUHA R00i4
HYDPALAZINE B RED CELL COUNT DEC V PANCYTOPENIA MAY OCCUR P00 14
HYDRALAZIN! B WHITE CELL COUNT DEC V AGRANULOCYTOSIS/PA NCYTOPENIA/LEUKOPENIA 90014
HYDPALAZINE F OCCULT BLOOD P05 V RARE GASTROINTESTINAL HEMORRHAGE P03 814
HYDRALAZINE 0 TYPAMINE TEST INC V INC RESPONSIVENESS H01417
HYDRALAZINE . S ANTINUCLEAR ANTIBODIES POS V MOPE COMMON IN SLOW ACETYLATORS P073 1
HYDRALAZINE S CALCIUM INC N AT 1 MMOL/L HAS SLIGHT EFFECT ON SMA 12/60 METHOD R0876
HYDPALAZINE S COONBS TEST P05 V MECHANISM OBSCURE P0418
HYDHALAZINE S GAMMA GLOBULIN INC V REPORTED FINDING HO 657
HYDRALAZINE S GLUCOSE INC M AT 1 MMOL/L AFFECTS SMA 12/60 METHOD P0876
HYDRALAZINE S SCOT INC N AT 1 NNOL/L AFFECTS SMA 12/60 METHOD H0876
PYDRALAZINE S UPIC ACID INC M AT 1 MMOL/L AFFECTS SMA 12/60 AND HENRY METHODS P0876
HYDRALAZINE S WASSERMAN REACTION P05 V FALSE POSITIVE REACTION REPORTED P06 57
HYDHALAZINE U CATECHOLAMINES INC N INTERFERES WITH SOME FLUOPOMETRIC METHODS P05 96
HYDRALAZIN! U CATECHOLAMINES Z N NO EFFECT ON FLUOROMETHIC METHOD OF CROUT HO 235
HYDRALAZINE U URINALYSIS HEMOGLOBIN INC V REPORTED FINDING 90657
HYDPALAZINE U URINALYSIS PROTEIN INC V REPORTED FINDING P06 57
HYDPALAZINE U URINALYSIS RBC/HPF INC V REPORTED FINDING P0657
HYDRALAZINE U 17 KETOGENIC STEROIDS INC N GLUCUPONIDE INTERFERES WITH ZIMMERMAN REACTION P09 07
HYDRALAZINE U 17 KETOSTEROIDS Z N NO SIGNIFICANT EFFECT WITH ZIMMERMAN REACTION HO 133
HYDRALAZINE U 17 OH CORTICOSTEROIDS DEC M IN VITRO EFFECT REPORTED MODIFIED GLENN-NELSON HO 133
HYDRAZINE S ALKALINE PHOSPHATASE INC V MAY CAUSE HEPATOTOXICITY P06 20
HYDHAZINE S BILIRUBIN INC V NAY CAUSE HEPATOTOXICITY H0620
HYDRAZIN! S BSP RETENTION INC V MAY CAUSE HEPATOTOXICITY HO 620
HYDPAZINE S CEPHALIN FLOCCULATION INC V MAY CAUSE HEPATOTOXICITY P0620
HYDHAZINE S GLUCOSE DEC V NAY POTENTIATE ACTION OF INSULIN IN DIABETICS HO 596
‘HYDPAZINE S SCOT INC V MAY CAUSE HEPATOTOXICITY 90620
HYDPAZINE S SGPT INC V NAY CAUSE HEPATOTOXICITY P0620
HYDPAZINE S THYMOL TURBIDITY INC V MAY CAUSE HEPATOTOXICITY P06 20
HYDRAZINE U METANEPHRINES TOTAL INC V MAY POTENTIATE ACTION OF DRUGS ON CNS R0596
HYDRAZIN! U NORMETANEPHHINE INC V MAY POTENTIATE ACTION OF DRUGS ON CNS RO596
HYDHAZIN! U URINALYSIS BILE INC V MAY CAUSE HEPATOTOXICITY P0620
HYDRAZINE U VMA DEC V MAY POTENTIATE ACTION OF DRUGS ON CNS HO 596
HYDRAZINE U 5 OH INDOLEACETIC ACID DEC V MAY POTENTIATE ACTION OF DRUGS ON CNS P0596
HYDHOCHLOPOTHIAZIDE B NEUTHOPHILS DEC V OCCASIONALLY OBSERVED P0 657
HYDROCHLOPOTHIAZIDE B PLATELET COUNT DEC V THROMBOCYTOPENIA REPORTED P0723
HYDROCHLOROTHIAZIDE B RED CELL COUNT DEC V APLASTIC ANEMIA MAY OCCUR HO 467
HYDPOCHLOROTHIAZIDE B WHITE CELL COUNT DEC V MAY CAUSE LEUKOPENIA/AGRANULOCYTOSIS P 026 1
HYDROCHLOPOTHIAZIDE F CALCIUM DEC V ACCENTUATES POSITIVE CALCIUM BALANCE P06 57
HYDPOHLOROTHIAZIDE P ADH INC V SECRETED IN RESPONSE TO HYPONATREMIA P0325
HYDROCHLOPOTHIAZIDE P INSULIN DEC V I.V. INJECTION HAS EFFECT WITH LITTLE ON SUGAR P0657
HYDROCHLOROTHIAZIDE S AMYLASE INC V ACUTE PANCREATITIS MAY OCCUR P0922
HYDHOCHLOPOTHIAZIDE S BILIHUBIN INC V CHOLESTATIC JAUNDICE REPORTED EFFECT OF THIAZIDES P0723
HYDROCHLOHOTHIAZIDE S CALCIUM INC V IMPAIRED EXCRETION (PROB ALSO RELEASED FROM BONE) 90907
HYDPOCHLOHOTHIAZIDE S CHLORIDE DEC V MAY CAUSE MARKED REDUCTION HO 325
HYOPOCHLOHOTHIAZIDE S CHLORIDE INC V HYPERCHLOREMIC ALKALOSIS WITH PROLONGED THERAPY P05 96
RYDROCHLOPOTHIAZIDF S C02 CONTENT INC V MAY CAUSE METABOLIC ALKALOSIS 90325
HYDPOCHLOROTHIAZIDE S GLUCOSE INC V DIABETOGENIC-LIKE ACTION OF DRUG P0 907
HYDPOCHLOROTHIAZIDE S GLUCOSE TOLERANCE DEC V DIABETOGENIC-LIKE ACTION OF DRUG P0723
HYDPOCHLOHOTHIAZIDE S OSMOLALITY DEC V DUE TO HYPONATRENIA OF DIURETIC ACTION HO 3 25
HYDHOCHLOPOTHIAZIDE S PBI DEC V MECHANISM OBSCURE H 00 014
HYDPOCHLOROTHIAZIDE S PHOSPHATE INC V ALTERED PARATHYROID METABOLISM P0 146
HYDPOCHLOPOTHIAZIDE S POTASSIUM DEC V DIURETIC ACTION P0907
HYDROCHLOROTHIAZIDE S SODIUM DEC V MAY CAUSE HYPONATPENIA HO 325
HYDPOCHLOROTHIAZIDE S UREA NITROGEN INC V MAY OCCUR WITH PROLONGED THERAPY P05 96
HYDPOCHLOHOTHIAZIDE S URIC ACID INC V DECREASED URATE CLEARANCE P0907
HYDPOCHLOROTHIAZIDE U CITRATE DEC V BY UP TO 30% REPORTED P08 149
HYDPOCHLOHOTHIAZIDE U CREATININE CLEARANCE DEC V REPORTED EFFECT P0 596
HYDROCHLOPOTHIAZIDE U GLUCOSE INC V DIABETOGENIC-LIKE ACTION OF DRUG HO 907
HYDROCHLOPOTHIAZIDE U PHOSPHATE INC V ALTERED PARATHYHOID METABOLISM R01i46
HYDPOCHLOROTHIAZIDE U SODIUM INC V DIUETIC ACTION OF DRUG HO 596
HYDROCHLOPOTHIAZIDE U URIC ACID DEC V DECREASED UHATE CLEARANCE P0596
HYDROCHLOROTHIAZIDE U URINALYSIS GLUCOSE INC V DUE TO HYPERGLYCEMIA IF PRODUCED H0907
HYDHOCORTISONE B EOSINOP9ILS DEC V STRIKING EFFECT IN NORMALS P03 84
HYDROCORTISON! P COPTISOL INC V EFFECT LASTS FOR AT LEAST 24 HOURS P0490
HYDROCORTISONE S CALCIUM Z M NO EFFECT ON FLUORESCENCE OF CALCEIN P061414
HYDPOCOPTISONE S CHLORIDE DEC V NAY CAUSE HYPOCHLORENIC HYPOKALENIC ALKALOSIS R0384
HYDROCOHTISONE S CHLORIDE INC V MAY CAUSE RETENTION AND EDEMA H0026

HYDPOCORTI SON! S C02 CONTENT INC V MAY CAUSE HYPOCRLOREMIC HYPOKALENIC ALKALOSIS P03 84
HYDROCORTISONE S PBI DEC V INHIBITS IODINATION OF TYROSINE IN TBG P0004
HYDROCORTI SONE S POTASSIUM DEC V PROMOTES URINARY ELIMINATION P0026
HYDROCOPTISONE S SODIUM INC V MAY CAUSE RETENTION AND EDEMA R0O26
HYDPOCOHTI S ONE U PAR CLEARANCE INC V INCREASES CFR R0384
HYDROCORTISONE U POTASSIUM INC V INCREASES ELIMINATION IN URINE P0026
HYDROCOHTISONE U SODIUM INC V ENHANCES EXCRETION RSP IF PRIOR LOADING 90384
HYDROCYANIC ACID B CYANMETHEMOGLOBIN INC V REACTS WITH METHEMOGLOBIN P03 84
HYDROFLU MET HIAZ IDE B HEMATOCHIT DEC V PANCYTOPENIA P 0991
HYDROFLUM ETHIAZI DR B HEMOGLOBIN DEC V PANCYTOPENIA P0991
HYDROFLUMETHIAZIDE B PLATELET COUNT DEC V PANCYTOPENIA OR THRONBOCYTOPENIA WITH PURPURA P099 1
HYDROFLUMETHIAZI DR B RED CELL COUNT DEC V PANCYTOPENIA, APLASTIC ANEMIA R0991
HYDHOFLUMETHIA ZID! B WHITE CELL COUNT DEC V PANCYTOPENIA, AGRANULOCYTOSIS OR APLASTIC ANEMIA P099 1
HYDROFLUMETHIAZI DR P AMMONIA INC V NAY OCCUR ESP IF PREEXISTING HEPATIC IMPAIRMENT P014 67
HYDROFLUMETHIA ZIDE S ALKALINE PHOSPHATASE INC V MAY CAUSE INTRAHEPATIC CHOLESTASIS HO 1467
HYDROPLUMETHIAZIDE S AMYLASE INC V OCCASIONAL COMPLICATION OF THERAPY P01467
HYDROPLUNET HIAZIDE S AMYLASS INC V ACUTE PANCREATITIS NAY OCCCUR WITH THIAZIDES 20467
HYDPOFLUMETHIAZIDE S BILIPUBIII INC V MAY CAUSE INTRAHEPATIC CHOLESTATIC JAUNDICE 90467
HYDROFLUNET HIA ZIDE S 859 RETENTION INC V NAY CAUSE INTRAHEPATIC CHOLESTASIS 201467
HYDROFLU MET HIAZ IDE S CHLORIDE DEC V DIURETIC ACTION P01167
HYDROFLUMETHIAZIDE S CO2 CONTENT INC V NAY CAUSE HYPOCHLORENIC ALKALOSIS 901467
HYDROFLUNETHIAZIDE S GLUCOSE INC V NAY OCCUR (SIMILAR ACTION TO OTHER THIAZIDES) P01467
HYDROFLUMETHIAZIDE S GLUCOSE TOLERANCE DEC V DIABETOGENIC LIKE ACTION OF DRUG ROLL 67
HYDROFLU MET HIAZ IDE S POTASSIUM DEC V DIURETIC ACTION HO 467
HYDROFLUMETHIAZI DR S SCOT INC V NAY CAUSE INTRAHEPATIC CHOLESTASIS P0467
HYDROFLUMETHIAZIDE S SGPT INC V MAY CAUSE INTRAHEPATIC CHOLESTASIS 30467
HYDROFLUMETHIAZI DR S SODIUM DEC V DIURETIC ACTION P0467
HYDPOFLUNETHIA ZIDE S UREA NITROGEN INC V MAY OCCUR ESP IF PREEXISTING RENAL DISEASE HO 1467
HYDROFLUNETHIAZI DE S URIC ACID INC V PROBABLY DUE TO IMPAIRED CLEARANCE P01467
HYDROFLUMETHIAZIDE U CHLORIDE INC V DIURETIC ACTION R0467
HYDHOFLUMETHIAZI DR U SODIUM INC V DIURETIC ACTION H0467
HYDROFLUNET HIAZIDE U URINALYSIS GLUCOSE INC V NAY OCCUR AS CONSEQUENCE OF HYPERGLYCEMIA 90467
HYDROGEN PEROXIDE U GLUCOSE INC N OXIDISES CHRONOGEN IN GLUCOSE OXIDASE TEST P02 99
HYDROGEN PEROXIDE U URINALYSIS GLUCOSE INC N OXIDISES CHROMOGEN IN GLUCOSE OXIDASE TESTS RO299
HYDROGEN SULFIDE U URINALYSIS CASTS INC V OCCURS DUE TO NEPPROTOXOCITY 90368
HYDROGEN SULFIDE U URINALYSIS HEMOGLOBIN INC V OCCURS DUE TO NEPHROTOXOCITY P0368
HYDROGEN SULFIDE U URINALYSIS PROTEIN INC V OCCURS DUE TO NEPHROTOXICITY 90368
HYDROGEN SULFIDE U URINALYSIS RBC/HPF INC V OCCURS WITH NEPHROTOXICITY(USUALLY MARKED) P0368
HYD ROQUINONE U CATECHOLANINES INC N REACTS LIKE EPINEPHRINE WITH NELSON-SHAW TEST RO16O
RYDROXYACETAMIDE S ALKALINE PHOSPHATAS! INC V HEPATOTOXICITY RO299
HYDROXYACETAMIDE S BILIRUBIN INC V HEPATOTOXICITY P0 620
HYDROXYACETANIDE S BSP RETENTION INC V REPATOTOXICITY R0620
HYDROXYACETAMIDE S CEPHALIN FLOCCULATION INC V HEPATOTOXICITY 90620
HYDROXYACETAMIDE S SCOT INC V TOXICITY EFFECT O620
HYDROXYACET AMID! S SGPT INC V TOXICITY EFFECT I062O
HYDROXYACETANIDE S THYMOL TURBIDITY INC V HEPATOTOXICITY P06 20
HYDPOXY ACETAMIDE U URINALYSIS BILE INC V HEPATOTOXICITY P0620
HYDROXYAMINOBUTY PlC U AMINO ACIDS INC N ADDITIONAL SPOT BY FIVE (?ALSO TLC) P08 11
HYDROXYCHLOPOQU IN! B PLATELET COUNT DEC V THHOMBOCYTOPENIA HO 754
HYDROXYCHLOROQUINE B RED CELL COUNT DEC V ANEMIA P06 20
HYDROXYCHLOHOQUI NE B WHITE CELL COUNT DEC V LEUKOPENIA P06 20
HYDROXYHEXAMIDE S GLUCOSE DEC V MILD EFFECT (STIMULATES RELEASE OF INSULIN) P1018
HYDHOXYHEXA MID! S URIC ACID DEC V MILD UPICOSURIC ACTION P1018
HY DROXYHEXA MID! U URIC ACID INC V MILD URICOSUPIC ACTION Hi 018
HYDROXYQUINOLINE S PBI INC M IN VAGINAL SUPPOSITORIES (OFTEN IODINATED) P0907
HYDROXYUPEA B PLATELET COUNT DEC V THRONBOCYTOPENIA RO026
HYDROXYUREA B RED CELL COUNT DEC V ANEMIA (MAY BE TRANSIENT MEGALOBLASTIC) P0026
HYDROXYUREA B WHITE CELL COUNT DEC V LEUKOPENIA MAY OCCUR 90657
HYDPOXYUPEA S URIC ACID INC V PROBABLE EFFECT OF CELL CATABOLISM HO 417
HYDROXYZINE P PROTHEONBIN TIME INC V PROLONGS ACTION OF ANTICOAGULANTS P1001
RYDROXYZINE S PBI Z V NO EFFECT WITH NORMAL DOSES P0255
HYDROXYZINE U 17 KETOGENIC STEROIDS INC M INTERFERES WITH ZIMMERMAN REACTION P0692
HYDROXYZINE U 17 KETOSTEROIDS Z N NO EFFECT REPORTED ON ZIMMERMAN REACTION HO 133
HYDROXYZINE U 17 OH COPTICOSTEROIDS INC M AFFECTS MODIFIED GLENN-NELSON METHOD 20133
HYDROXYZI NE U 17 OH CORTICOSTEROIDS INC N INTERFERES WITH POPTEP-SILBER REACTION 90654
HYPERVENTILATION B PH INC V DUE TO RESPIRATORY ALKALOSIS 908146
HYPERVENTILATION S IONIZED CALCIUM DEC V EFFECT OF RESPIRATORY ALKALOSIS P0846
HYPERVENTILATION S PHOSPHATE DEC V EFFECT 0? RESPIRATORY ALKALOSIS R08146
HYPOCHLOPITES F OCCULT BLOOD P05 V CORROSIVE ACTION ON G.I. TRACT IF SWALLOWED R0368
HYPOCHLOH ITES S PBI DEC V INTERFERES WITH TRAPPING OF IODIDE BY THYROID P0004
HYPOCHLORITRS U GLUCOSE INC N OXIDATION OF CHROMOGEN (O-TOLIDXNE) 90299
HYPOCHLOR ITES U URINALYSIS SUGAR INC N MAY CAUSE FALSE P05 WITH CLINISTIX RO 436
1.11. INJECTIONS S CPK INC V MUSCLE DAMAGE P0839
I.N.INJECTIONS S SCOT INC V MUSCLE DAMAGE HO 839
IBUFENAC F OCCULT BLOOD P05 V MAY CAUSE G.I. TRACT BLEEDING P0620
IBUFENAC S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT HO 620
IBUFENAC S BILIRUBIN INC V PROBABLE EFFECT AS BILIRUBIN CLEARANCE REDUCED RO1421
IBUFENAC S BSP RETENTION INC V HEPATOTOXIC EFFECT P0620
IBUFENAC S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT RO620
I B U FE N A C S SCOT INC V HEPATOTOXIC EFFECT H 0620
IBUFENAC S SGPT INC V HEPATOTOXIC EFFECT R0620
IBUFENAC S THYNOL TURBIDITY INC V HEPATOTOXIC EFFECT P06 20
IBUFENAC S URIC ACID INC V SIDE EFFECT SIMILAR TO THAT OF ASPIRIN R0620
IBUFENAC U URINALYSIS BILE INC V HEPATOTOXIC EFFECT P06 20
IBUFENAC U URINALYSIS GLUCOSE INC V AUGMENTATION OF DIABETIC GLYCOSUPIA SEEN 90657
ICTEHOGENIN S ALKALINE PHOSPHATASE INC V CAUSES INTHAHEPATIC CHOLESTASIS P00514
ICTEROGENIN S BILIRUBIN INC V CAUSES INTRAHEPATIC CHOLESTASIS P0054
ICTEPOGENIN S BSP RETENTION INC V CAUSES INTRAHEPATIC CHOLESTASIS 900514
ICTEROGENI N S CEPHALIN FLOCCULATION INC V CAUSES INTPAHEPATIC CHOLESTASIS 90054
ICTEPOGENIN S SCOT INC V CAUSES INTRAHEPATIC CHOLESTASIS 900514

ICTEPOGENIN S SGPT INC V CAUSES INTRAHEPATIC CHOLESTASIS P00514
ICTEROGENIN S THYNOL TURBIDITY INC V CAUSES INTRAHEPATIC CiJOLESTASIS P0054
ICTEROGENXN U URINALYSIS BILE INC V CAUSES INTRAHEPATIC CHOLESTASIS 90054
IDOXURIDINE B WHITE CELL COUNT DEC V EFFECT OF HIGH CONCENTRATION ONLY P0620
IDOXURIDINE S ALKALINE PHOSPHATASE INC V CHOLESTATIC JAUNDICE REPORTED IN ONE CASE P0259
IDOXURIDINE S BILIHUBIN INC V CHOLESTATIC JAUNDICE REPORTED IN ONE CASE P0259
IDOXURIDINE S SGOT INC V CHOLESTATIC JAUNDICE REPORTED IN ONE CASE H0259
IMIPPAMINE B FOSINOPHILS INC V ALLERGIC RESPONSE (MAY PRODUCE LOEFFLEP’S SYNDROME) P0857
IMIPRAMINE B WHITE CELL COUNT DEC V MAY CAUSE LEUKOPENIA/AGRANULOCYTOSIS P0857
INIPRAMINE B WHITE CELL COUNT INC V (TRANSIENT 1-6 HOURS) (POSSIBLY LOEFFLEP’S SYNDROME) P0857
IMIPRAMINE S ALKALINE PHOSPHATASE INC V MAY CAUSE CHOLESTATIC JAUNDICE HO512
INIPRAMINE S BILIRUBIN INC V MAY CAUSE CHOLESTATIC JAUNDICE 90512
INIPRANINE S BSP RETENTION INC V MAY CAUSE CHOLESTATIC JAUNDICE R06614
IMIPRAMINE S CHOLESTEROL INC V POSSIBLE CHOLESTATIC EFFECT R0767
IMIPPAMINE S GLUCOSE TOLERANCE DEC V PRELIMINARY OBSERVATIONS ONLY REPORTED R0O56
IMIPPAMINE S LACTIC DEHYDHOGENASE INC V MAY CAUSE CHOLSTATIC JAUNDICE 30512
IMIPRAMINE S PBI Z V NO EFFECT REPORTED WITH NORMAL DOSES P0255
IMIPRAMINE S SCOT INC V MAY CAUSE CHOLESTATIC JAUNDICE P0512
INIPPAMINE S SGPT INC V MAY CAUSE CHOLESTATIC JAUNDICE 30512
INIPRAMINE S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS RO1492
IMIPPAMINE T UREA NITROGEN INC N PRODUCES TURBIDITY WITH BERTHELOT’S REAGENT 30530
INIPRAMINE U BILIRUBIN INC V MAY CAUSE CHOLESTATIC JAUNDICE 30512
IMIPPAMINE U METANEPHPINES TOTAL INC N INTERFERENCE WITH PISANO METHOD P0125
IMIPRAMINE U URINALYSIS BILE INC V MAY CAUSE CHOLESTATIC JAUNDICE 20620
INIPPAMXNE U UROBILINOGEN INC V MAY CAUSE CHOLESTATIC JAUNDICE P0512
IMIPRAMINE U VMA DEC V APPROX. 30% DECREASE, BLOCK OF UPTAKE INTO CELLS P0428
IMIPRAMINE U 5 OH INDOLEACETIC ACID DEC V NAY DECREASE UPTO 50%:DEC CELL PERMEABILITY TO 5HT P0428
IMMUNE SEHA B PLATELET COUNT DEC V FALL OBSERVED SEVERAL DAYS AFTER INJECT H0657
IMMUNE SERA S UREA NITROGEN INC V NEPHHITIS MAY OCCUR WITH SERUM SICKNESS HO657
INDANDIONES B EOSINOPHILS INC V WITH OTHER SIGNS OF HYPERSENSITIVITY R0657
INDANDIONES B WHITE CELL COUNT DEC V WITH OTHER EVIDENCE OF HYPERSENSITIVITY P0620
INDANDIONES S !3ILIPUBIN INC V AS RESULT OF HYPERSENSITIVITY HO657
INDANDIONES S BSP RETENTION INC V MAY CAUSE HEPATOTOXICITY R0620
INDANDIONES S CEPHALIN FLOCCULATION INC V MAY CAUSE HEPATOTOXICITY R0620
INDANDIONES S SGOT INC V HEPATOCELLULAR DAMAGE WITH CHOLESTASIS P0620
INDANDIONES S SCPT INC V HEPATOCELLULAR DAMAGE WITH CHOLESTASIS P0620
INDANDIONES S THYMOL TURBIDITY INC V MAY CAUSE HEPATOTOXICITY P0620
INDANDIONES U URINALYSIS BILE INC V MAY CAUSE HEPATOTOXICITY P0620
INDANDIONES U URINALYSIS COLOR INC V MAY B! ORANGE TO RED IN COLOR P06514
INDANDIONES U URINALYSIS HEMOGLOBIN INC V MAY CAUSE HEMATUPIA - MANIFESTATION OF OVERDOSE P0355
INDANDIONES U UHINALYSIS RBC/HPF INC V NAY CAUSE HEMATURIA - MANIFESTATION OF OVERDOSE RO355
INDICAN S BILIPUBIN INC N MAY PRODUCE BROWN DIAZO COLOR IN UPEMIC SERUM P0436
INDICAN U OBERNAYER TEST P05 N PRODUCES BLUE COLOR(INDIGO BLUE)IN CHLOROFORM P0929
INDICAN U URINALYSIS COLOR INC N OCCURS IF INCREASED AND OXIDIZED ON STANDING P0143
INDICAN U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S P0663
INDICAN U UROBILINOGEN INC N PRODUCES YELLOW COLOR WITH EHRLICH’S REAGENT P01436
INDIGOTINDISULFON U URINALYSIS COLOR INC N COLOR USED TO MEASURE KIDNEY FUNCTION P0026
INDOCYANINE GREEN S I 131 UPTAKE DEC V CONTAINS IODINE, INHIBITS FURTHER UPTAKE HO596
INDOCYANINE GREEN S PHI INC M ORGANIC IODINE CONTAMINATION P0355
INDOLE T PROTEIN INC N REACTS WITH FOLIN-CIOCALTEU OF LOWRY METHOD P0440
INDOLE U UROBILINOGEN INC N PRODUCES RED COLOR WITH EHRLICH’S REAGENT P0436
INDOLEACETIC ACID S GLOBULIN INC N REACTS AS TRYPTOPHAN IN METHOD OF GOLDENBEHG 30375
INDOLEACETIC ACID T TRYPTOPHAN INC N MEASURED AS SAME AS SPIES/CHAMBERS METHOD P0399
INDOLEACETIC ACID U UROBILINOGEN INC N PRODUCES RED COLOR WTIH EHRLICH’S REAGENT P0436
INDOLEPROPIONIC AC T TRYPTOPHAN INC N MEASURED AS SANE AS SPIES/CHAMBERS,NETHOD P0399
INDONETHACIN B EOSINOPHILS DEC V OCCASIONAL EFFECT P0126
INDOMETHACIN B HENATOCRIT DEC V 2NDARY TO G.I.BLEED/AGPANULOCYTOSIS/PANCYTOPENIA RO12O
INDOMETHACIN B HEMOGLOBIN DEC V 2NDARY TO G.I.BLEED/AGRANULOCYTOSIS/PANCYTOPENIA P0120
INDOMETHACIN B NEUTROPHILS DEC V RARE NEUTROPENIA/MAY ALSO CAUSE APLASTIC ANEMIA RO3814
INDOMETHACIN B PLATELET COUNT DEC V RARE AGRANULOCYTOSIS/PANCYTOPENIA/APLASTIC ANEMIA RO786
INDOMETHACIN B RED CELL COUNT DEC V 2NDARY TO G.I.BLEED/AGRANULOCYTOSIS/PANCYTOPENIA P0120
INDONETHACIN B WHITE CELL COUNT DEC V AGRANULOCYTOSIS/PANCYTOPENIA P0786
INDOMETHACIN F OCCULT BLOOD P05 V MAY CAUSE ULCERATION OF STOMACH,DUODENUN, GUT H0648
INDOMETHACIN P PHOTHROMBIN TIME INC V DISPLACES ANTICOAGULANTS FROM BINDING PROTEIN P0682
INDOMETHACIN S ALKALINE PHOSPHATASE INC V CYTOTOXIC AND CHOLESTATIC LIVER DAMAGE P0521
INDOM!THACIN S AMYLASE INC V SINGLE CASE REPORTED (?CORRECT IMPLICATION) P0400
INDOMETHACIN S BILIRUBIN INC V CYTOTOXIC AND CHOLESTATIC TYPES OF LIVER DAMAGE 90521
INDOMETHACIN S BSP RETENTION INC V CYTOTOXIC AND CHOLESTATIC LIVER DAMAGE P0521
INDONETHACIN S CEPHALIN FLOCCULATION INC V CYTOTOXIC AND CHOLESTATIC LIVER DAMAGE RO521
INDOMETHACIN S DIRECT BILIPUBIN INC V CYTOTOXIC AND CHOLESTATIC LIVER DAMAGE RO521
INDOMETHACIN S GLUCOSE INC V HARE SIDE EFFECT P01417
INDOMETHACIN S HAPTOBLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA H0026
INDOMETHACIN S LIPASE INC V ASSOC WITH CHOLESTATI.C LIVER DAMAGE P0355
INDONETHACIN S SCOT INC V CYTOTOXIC AND CHOLESTATIC LIVER DAMAGE 90521
INDONETHACIN S SGPT INC V CYTOTOXIC AND CHOLESTATIC LIVER DAMAGE 30521
INDONETHACIN S THYMOL TURBIDITY INC V CYTOTOXIC AND CHOLESTATIC LIVER DAMAGE P0521
INDOMETHACIN S UREA NITROGEN INC V OCCASIONAL INC USUALLY TO UPPER NORMAL LIMIT HO659
INDOMETHACIN S URIC ACID DEC V OF SOME VALUE IN TREAT OF GOUTY ARTHRITIS RO378
INDONETHACIN S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS P0492
INDOMETHACIN U GLUCOSE INC V RARE SIDE EFFECT P0417
INDOMETHACIN U PROTEIN INC V REPORTED IN ONE PATIENT P0157
INDOMETHACIN U URINALYSIS BILE INC V CYTOTOXIC AND CHOLESTATIC LIVER DAMAGE P0029
INDOMETHACIN U URINALYSIS CASTS INC V GRANULAR CASTS IN ONE PATIENT 90157
INDOMETHACIN U URINALYSIS COLOR INC V INDIRECT RESULT OF HEPATIC TOXICITY, GREEN URINE P0320
INDONETHACIN U URINALYSIS GLUCOSE INC V AS RESULT OF RAPE HYPERGLYCEMIA P0(417
INDOMETHACIN U URINALYSIS HEMOGLOBIN INC V PRODUCES ACTUAL BLEEDING P0299
INDOMETHACIN U URINALYSIS PROTEIN INC V REPORTED IN ONE PATIENT H0157
INDOMETHACIN U URINALYSIS RBC/HPF INC V MAY CAUSE ACTUAL BLEEDING P0299
INDOMETHACIN U XYLOSE EXCRETION DEC V ?DUE TO INCREASED MOTILITY OF GUT R0523
INSECTICIDES S BILIPUBIN INC V MAY CAUSE HEMOLYTIC ANEMIA P0636

INSECTICIDES S CHOLINESTERASE DEC V DIRECT EFFECT OF DRUG P0913
INSECTICIDES S DIRECT COONBS TEST P05 V MAY CAUSE HEMOLYTIC ANEMIA HO 636
INSULIN P ALPHA AMINO NITROGEN DEC V INCREASED UPTAKE BY TISSUES R0355
IN S ULI N P CORTICOSTEROIDS INC V SIGNIFICANT EFFECT AT 4OMIN, MAXIMAL AT 6OMIN P0058
INSULIN P CORTICOTROPIN INC V RESPONSE TO STRESS R0662
INSULIN P EPINEPHRINE INC V STIMULATION OP ADRENAL MEDULLA, ?HY HYPOGLYCEMIA P0662
INSULIN S CHOLESTEROL DEC V THERAPEUTIC COAL P0907
INSULIN S CPK INC V IS AN ACTIVATOR OF ENZYME P02 08
I NS UL IN S GLUCOSE DEC V NATURAL ACTION OF HORMONE P0620
INSULI N S MAGNESIUM DEC V EFFECT SEEN IN TREATMENT OP DIABETIC COMA RO965
INSULIN S NEFA DEC V EFFECT SIMILAR IN NORMALS AND DIABETICS R0747
INSULI N S PHI INC V MECHANISM OBSCURE P0004
INSULIN S PHOSPHATE DEC V INCREASED PROSPHORYLATION OF GLUCOSE P1001
INSULI N S POTASSIUM DEC V THERAPEUTIC EFFECT, CAUSES INTRACELLULAR SHIFT HO 383
INSULIN S PROTEIN INC V ASSOCIATED WITH INCREASED PROTEIN SYNTHESIS P0211
INSULIN S THYMOL TURBIDITY INC V ASSOCIATED WITH INCREASED PROTEIN SYNTHESIS P0211
INSULIN U AMINO ACIDS DEC V METABOLIC EFFECTS HO 355
INSULIN U AMINO ACIDS INC V METABOLIC EFFECTS P0299
INSULIN U URINALYSIS KETONES INC V OCCURS ES? IF LOW LIVER GLYCOGEN STORES RO383
INSULIN U VNA INC V INCREASE AFTER INSULIN SHOCK, NONE WITH NORMAL DOSE HO 908
INULIN S OSMOLALITY INC V MASSIVE DOSES HAVE MARKED EFFECT HO 026
INULIN U VOLUME INC V MASSIVE DOSES PRODUCE MARKED DIURESIS P0026
IODATES S CHOLESTEROL INC N INTERFERENCE WITH ZLATKIS-ZAK REACTION P0907
IODATES S PHI DEC V INTERFERES WITH TRAPPING OF IODIDE BY THYROID R0004
IODI DES B EOSINOPHILS INC V ALLERGIC RESPONSE P062 0
IODIDES B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA P0620
IODIDES F OCCULT BLOOD P05 N INTERFERES WITH BENZIDINE TEST P0181
IODIDES F OCCULT BLOOD P05 V CHRONIC POISONING MAY CAUSE BLOODY DIARRHEA P0384
IOD IDES S CHOLESTEROL INC N INTERFERENCE WITH ZLATKIS-ZAK REACTION P0907
IODIDES S PHI INC N IODIDE SALTS IF MORE THAN IC PER DAY-LASTS 28 DAYS P0004
IODIDES S THYROXINE (T14) DEC V DEC SYNTHESIS IF DIAGNOSTIC OR THERAPEUTIC I 131 HO 907
IODIDES U URINALYSIS HEMOGLOBIN INC N INTERFERES WITH GUAIAC AND HENZIDINE TESTS HO 3 55
IOD IDES U 17 OH CORTICOSTEROIDS INC M INTERFERES WITH POPTER-SILBER REACTION P0907
IODINATED GLYCERIN S PBI INC V EFFECT LASTS UP TO 2 DAYS P0112
IODINE CONTAIN DRUG F OCCULT BLOOD P05 V NAY OCCUR WITH TOXICOLOGICAL DOSES HO 368
IODINE CONTAIN DRUG S PBI INC V IODINE CONTAMINATION P0355
IODINE CONTAIN DRUG S TOTAL IODINE INC V IODINE CONTAMINATION HO 355
IODINE CONTAIN DRUG U URINALYSIS CASTS INC V HEMORRHAGIC NEPHEITIS WITH TOXIC DOSES P036 8
IODINE CONTAIN DRUG U URINALYSIS PROTEIN INC V RESULT OF HEMORRHAGIC NEPHPITIS AT TOXIC DOSES P0368
IODINE CONTAIN DRUG U URINALYSIS RBC/HPF INC V HEMORRHAGIC NEPHRITIS WITH TOXIC DOSES P0368
IODIPANIDE S PBI INC N BUT DOES NOT AFFECT T4 EFFECT LASTS 3-4 MONTHS HO 839
IODIPA MID! S URIC ACID DEC V URICOSURIC EFFECT P0680
IODIPANIDE U URIC ACID INC V URICOSURIC EFFECT P0680
IODIPA MID! U 17 KETOCENIC STEROIDS DEC N INTERFERES WITH REACTION P06 92
IODOALPHIONIC ACID S I 131 UPTAKE DEC V ORGANIC IODINE CONTAMINATION P0355
IODOALPHIONIC ACID S PBI INC M CONTAINS IODINE (EFFECT LASTS 2-12 MONTHS) P0436
IODOALPHIONIC ACID U URINALYSIS PROTEIN INC N AFFECTS ACID PRECIPITATION METHODS P0020
IODOCASEIN S PBI INC M ORGANIC IODINE CONTAMINATION P0 355
IODOCHLORHYDROXYQU S BEI INC V CONTAINS ORGANICALLY BOUND IODINE P05 78
IODOCHLORHYDROXYQU S I 131 UPTAKE DEC V CONTAINS ORGANICALLY BOUND IODINE HO 578
IODOCHLORHYDROXYQU S PBI INC M CONTAINS IODINE (EFFECT LASTS 2-3 MONTHS) HO 94 8
IODOC HLOHHYDHOXYQU U PHENYLKETONES P05 N GREEN WITH FECL3 P0239
IODOFORM S I 131 UPTAKE DEC V ORGANICALLY BOUND IODINE, INHIBITS FURTHER UPTAKE P0596
IODOFORN S PHI INC M CONTAINS IODINE P0596
IODOPY HACET S I 131 UPTAKE DEC V DUE TO IODINE COMPONENT OF MATERIAL P0596
IODOPYR ACET S PHI INC N CONTAINS IODINE EFFECT LASTS 2 WEEKS P0907
IODOPY RACET S URIC ACID DEC V URICOSURIC ACTION P0404
IODOPYH ACET U PROTEIN TNC N IF ACID PRECIPITATION METHODS USED P0772
IOD OPT RACET U PSP EXCRETION DEC V MAY COMPETE FOR EXCRETION THROUGH RENAL TUBULES HO 287
IODOPYHACET U URIC ACID INC V URICOSURIC ACTION P04 04
IODOPY RACET U URINALYSIS PROTEIN INC N GIVES FALSE POSITIVE WITH TURBIDITY TESTS HO 233
IODOPYRINE S PHI INC N CONTAINS IODINE P06 54
IODOTHIOURACIL B WHITE CELL COUNT DEC V AGRANULOCYTOSIS HO 6 20
IODOTHI OURACIL S I 131 UPTAKE DEC V DRUG CONSISTS OF ORGANICALLY BOUND IODINE P02 55
IODOTHIOURACIL S PHI INC N CONTAINS ORGANIC IODINE (EFFECT FOR SEVERAL MONTHS) H09O7
IODOTHIOURACIL S THYROXINE (T4) INC N ORGANIC IODINE COMP. (SATIS WITH MURPHY-PATTEE) P0112
IODOTHIOUHACIL S T4 (MURPHY-PATTEE) Z M NO EFFECT ON METHOD P0596
ION EXCHANGE RESIN P AMMONIA INC V MECHANISM NOT REPORTED ?D!PENDS ON RESIN P014 17
ION EXCHANGE RESIN S CHLORIDE INC V MECHANISM NOT CITED - ?DEPENDS ON RESIN P02 04
IOPANOIC ACID B PLATELET COUNT DEC V SEVERE THROMBOCYTOPENIA IN TWO CASES R0657
IOPANOIC ACID S BILIRUBIN INC V MAY CAUSE HEPATOTOXICITY P06 20
IOPANOIC ACID S BSP RETENTION INC V COMPETES FOR HEPATO-CELLULAR PROTEIN BINDING SITES P0 833
IOPANOIC ACID S CEPHALIN FLOCCULATION INC V NAY CAUSE HEPATOTOXICITY P0620
IOPANOIC ACID S CHOLINESTEPASE DEC V POTENT INHIBITOR AT 0.06MM P0567
IOPANOIC ACID S I 131 UPTAKE DEC V DUE TO IODINE COMPONENT OF MATERIAL P0596
IOPANOIC ACID S PBI INC N ORGANIC IODINE AFFECTS TEST, EFFECT LASTS 1-4 NOS. P08 39
IOPANOIC ACID S SCOT INC V MAY CAUSE HEPATOTOXICITY H062O
IOPANOIC ACID S SCPT INC V MAY CAUSE HEPATOTOXICITY P0620
IOPANOIC ACID S THYMOL TURBIDITY INC V MAY CAUSE HEPATOTOXICITY P06 20
IOPANOIC ACID S THYROXINE (T4) INC N CONTAMINATING IODINE AFFECTS TEST P08 39
IOPANOIC ACID S URIC ACID DEC V URICOSURIC EFFECT P0680
IOPANOIC ACID U CREATININE CLEARANCE DEC V REPORTED CAUSE OF ACUTE RENAL FAILURE P0020
IOPANOIC ACID U PROTEIN INC N GIVES TURBIDITY IF ACID PRECIPITATION TESTS USED P0772
IOPANOIC ACID U URIC ACID INC V URICOSURIC EFFECT H0680
IOPANOIC ACID U URINALYSIS PROTEIN INC N CAUSES FALSE POSITIVE WITH TURBIDITY TESTS BOO 20
IOPHENDYLA TE S PHI INC N CONTAINS IODINE EFFECT LASTS UP TO 5 YEARS RO112
IOPHENOXIC ACID S I 131 UPTAKE DEC V DUE TO IODINE COMPONENT OF MATERIAL HO 596
IOPHENOXIC ACID S PHI INC M CONTAINS IODINE EFFECT LASTS UP TO 30 YEARS P0112
IOPHENOXIC ACID U URINALYSIS PROTEIN INC N AFFECTS TURBIDITY TESTS FOR UP TO 3 DAYS P00 20
IOPYDONE S I 131 UPTAKE DEC V DUE TO IODINE COMPONENT OF MATERIAL HO 596

IOPYDONE S PHI INC M CONTAINS IODINE P05 96
IOQUIN S PHI INC N CONTAINS IODINE, DURATION OF EFFECT UNCERTAIN HO 112
IOTHALAMATE S I 131 UPTAKE DEC V INTERFERES WITH UPTAKE P0026
IOTHAL AN ATE S PBI INC N CONTAINS IODINE HO 596
IOTRALAMAT! U 17 KETOGENIC STEROIDS DEC N ACTS AS REDUCING SUBST (RUTHERFORD & NELSON METHOD) P0692
IOTHALANATE U 17 KETOGENIC STEROIDS Z V NO PHYSIOLOCICAL EFFECT OBSERVED P0692
IOTHALANATE U 17 KETOSTEHOIDS Z V NO PHYSIOLOGICAL EFFECT OBSERVED P0692
IOTHALAMATE U 17 OH CORTICOSTEROIDS Z V NO PHYSIOLOGICAL EFFECT OBSERVED P0 692
IPODATE S BILIRUBIN INC V PROBABLY DUE TO COMPETITION FOR EXCRETION HO 204
IPODATE S I 131 UPTAKE DEC V INTERFERES WITH UPTAKE P0026
IPODATE S P81 INC M CONTAINS ORGANIC IODINE P0436
I PODATE S URIC ACID DEC V URICOSUPIC EFFECT R0680
IPODATE U URIC ACID INC V UHICOSURIC EFFECT RO680
IPRI NDOLF B EOSINOPHILS INC V ALLERGIC RESPONSE REPORTED R0012
IPRINDOLE S ALKALINE PHOSPHATASE INC V MILD ELEVATION WITH CHOLESTASIS R00 12
IPRINDOLE S BILIPUBIN INC V ASSOCIATED WITH LOW SERUM PHOSPHATE 90012
IPRINDOLE S DIRECT BILIRUBIN INC V ASSOCIATED WITH LOW SERUM PHOSPHATE P00 12
IPRI NDOLE S SCOT INC V HEPATIC TOXICITY P0907
IPHINDOLE S SGPT INC V HEPATIC CHOLESTASIS WITHOUT INFLAMMATION P0012
IPRINDOLF U URINALYSIS BILE INC V DUE TO HEPATIC TOXICITY 90012
IPRONIAZID B PLATELET COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) 90658
IPRONIAZID B RED CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P06 58
IPRONIAZID B WHITE CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCHASIAS) P0658
IPRONIAZID S ALKALINE PHOSPHATASE INC V MAY CAUSE CHOLESTATIC JAUNDICE HO 6 20
IPRONIAZID S BETA-GLUCUPONIDASE INC V EFFECT OF TOXIC HEPATITIS RO990
IPRONIA ZID S BILIRUBIN INC V MAY CAUSE CHOLESTATIC AND CYTOTOXIC JAUNDICE P0079
IPPONIAZID S BSP RETENTION INC V MAY CAUSE CHOLESTATIC JAUNDICE P062 0
IPRON IAZID S CEPHALIN FLOCCULATION INC V MAY CAUSE CHOLESTATIC JAUNDICE HO 6 20
IPRONIAZID S GUANASE INC V NAY CAUSE CHOLESTATIC AND CYTOTOXIC JAUNDICE ROO79
IPRONIAZID S lCD INC V MAY CAUSE CHOLESTATIC AND CYTOTOXIC JAUNDICE P0079
IPRONIAZI D S OCT INC V MAY CAUSE CHOLESTATIC AND CYTOTOXIC JAUNDICE P0079
IPRONIAZID S PYRIDOXAL DEC V OBSERVED IN PATIENT WITH TOXICITY 90224
IPRONIAZID S PYRIDOXINE DEC V OBSERVED IN PATIENT WITH TOXICITY P0224
IPRONIAZID S SCOT INC V PROLONGED USE MAY CAUSE HEPATOTOXICITY P09 90
IPRONIAZID S SGPT INC V PROLONGED USE MAY CAUSE HEPATOTOXICITY P0990
IPRONIAZID S THYMOL TURBIDITY INC V NAY CAUSE CHOLESTATIC JAUNDICE R0620
IPRONIAZID U URINALYSIS BILE INC V PROLONGED USE MAY CAUSE HEPATOTOXICITY P0620
IRON DEXTRAN B WHITE CELL COUNT INC V LEUKEMOID REACTION REPORTED P0657
IRON DEXTRAN S IRON INC V INCREASED IRON STORES P 06 20
IRON DEXTRAN S UIBC DEC V DUE TO INCREASED AVAILABILITY OF IRON P062 0
IRON SALTS F VITAMIN B12 INC V DURING TREATMENT OF IRON-DEFICIENT ANEMIA HO 425
IRON SALTS F COLOR INC N BLACK(GRAY-BLACK)DARKENS IN AIR WITH ABOUT 70MG P06 20
IRON SALTS F OCCULT BLOOD P05 N INTERFERES WITH GUAIAC TEST (?BENZIDINE) P09 27
IRON SALTS F OCCULT BLOOD Z M IF 3,3 DIMETHYLNAPHTHIDINE USED AS CHROMOGEN HO 26 2
IRON SALTS S CALCIUM INC N INTERFERE WITH DIRECT EDTA TITRATION P01436
IRON SALTS S IRON INC V EFFECT OF I.M. IRON Ho 355
IRON SALTS S SGPT INC V IN ADVANCED POISONING MAY CAUSE HEPATIC NECROSIS P0 3 68
IRON SALTS S TIBC INC V EFFECT OF I.E. IRON HO 355
IRON SALTS S UIBC DEC V EFFECT OF I.E. IRON HO 3 55
IRON SALTS U DIAGNEX BLUE EXCRETION INC V HEAVY METAL DISPLACEMENT OF DIACNEX BLUE P1001
IRON SALTS U PROTEIN INC V MAY CAUSE NEPHHOTOXICITY P014 17
IRON SALTS U SEDOHEPTULOSE DEC N FERRIC IRON INHIBITS CYSTEINE-H2S04 REACTION P06 28
IRON SALTS U URINALYSIS COLOR INC N IHON SORBITOL CAN CAUSE BROWN URINE (FE SULPHIDE) P0355
IRON SALTS U URINALYSIS HEMOGLOBIN INC V HEMATURIA REPORTED AFTER IRON SORBITOL P0657
IRON SALTS U URINALYSIS PROTEIN INC V MAY CAUSE NEPHROTOXICITY P04 17
IRON SALTS U URINALYSIS RBC/HPP INC V HEMATURIA REPORTED AFTER CHRONIC ADNIN FE SORBITOL R0467
IRON SALTS U URINALYSIS NBC/HP! INC V MAY EXACERAHATE URINARY TRACT INFECTIONS P06 57
ISOCAR HOXAZID B HEMATOCRIT DEC V MAY OCCASIONALLY PRODUCE ANEMIA P0657
ISOCARBOXAZ ID B HEMOGLOBIN DEC V MAY OCCASIONALLY PRODUCE ANEMIA P0657
ISOCARHOXAZID B RED CELL COUNT DEC V AGRANULOCYTOSIS/ANEMIA - PARR RO62O
ISOCARBOXAZID B WHITE CELL COUNT DEC V AGHANULOCYTOSIS/LEUKOPENIA - RARE P0451
ISOCARBOXAZID P AMMONIA DEC V REPORTEDLY EFFECTIVE IN REDUCING NH3 INTOXICATION RO417
ISOCARBOXAZ ID S ALKALINE PHOSPHATASE INC V CHOLESTATIC EFFECT P0 620
ISOCARBOXAZI D S BILIRUHIN INC V CHOLESTATIC EFFECT H 0620
ISOCARBOXAZID S BSP RETENTION INC V INTRAHEPATIC CHOLESTASIS REPORTED HO 171
ISOCARBOXAZID S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT P062 0
ISO CAR BOXA ZID S GLUCOSE DEC V MAO INHIBITORS HAVE SLIGHT EFFECT R014i7
ISOCARBOXAZID 5 PBI Z V NO EFFECT REPORTED WITH NORMAL DOSES P0255
ISOCAR BOXAZID S SCOT INC V CHOLESTATIC EFFECT P06 20
ISOCARBOXAZID S SGPT INC V CHOLESTATIC EFFECT P0620
ISOCARBOXAZID S TRYMOL TURBIDITY INC V CHOLESTATIC EFFECT P06 20
ISOCARBOX ARID U URINALYSIS BILE INC V CHOLESTATIC EFFECT P0620
ISOCAR BOX ARID U VMA DEC V INHIBITION OF FORMATION P01417
ISOCARBOXAZID U XYLOSE EXCRETION DEC V DECREASED G.I. TRACT ABSORPTION P0956
ISOCARBOXAZID U 5 OH INDOLEACETIC ACID DEC V DUE TO INHIBITION OF CONVERSION OF 5 HT TO S HIAA P04 17
ISOFLU HOPH ATE S CHOLINESTERASE DEC V THERAPEUTIC ACTION OF DRUG P00 26
I S ONI A Z I P B EOSINOPHILS INC V ALLERGIC PHENOMENON P0424
ISONIA RID B HEMATOCHIT DEC V HEMOLYTIC ANEMIA/RAPE MECALOBLASTIC ANEMIA P06 20
ISONIAZID B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA/RARE MEGALOBLASTIC ANEMIA R062O
ISONIAZID B LE CELL PREP P05 V MORE COMMON IN SLOW ACETYLATORS P06 22
ISONIAZID B MCV INC V IF MEGALOBLASTIC ANEMIA OCCURS P0620
ISONIAZID B METHENOGLOBIN INC V REPORTED EFFECT RO384
IS 0 NI A ZI 0 B PHDEC V LARGE DOSES MAY PRODUCE SEVERE ACIDOSIS P0384
ISONIAZID B PLATELET COUNT DEC V MAY RARELY CAUSE BONE-MARROW APLASIA P0071
ISONIAZID B RED CELL COUNT DEC V HEMOLYTIC ANEMIA (RARE COMPLICATION) P06 20
ISONIAZID B WHITE CELL COUNT DEC V AGHANULOCYTOSIS - RAPE P0071
ISONIAZID B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA P0620
ISONIAZID P AMMONIA INC V REPORTED TO OCCUR IN SOME CASES P1024
ISONIAZID S ALKALINE PHOSPHATASE INC V PROBABLE CHOLESTATIC EFFECT HO 596
I SONI A ZI D S AMYLASE INC V REPORTED CAUSE OF ACUTE PANCREATITIS, MUCH DOUBT P04 17

I S ONI A Z ID S ANTINUCLEAR ANTIBODIES P05 V UP TO 78% TUBERCULOUS PATIENTS DEVELOP ANTIBODIES Pools
ISONIAZID S BILIRUBIN INC V INTRAHEPATIC CHOLESTASIS 90299
ISONIA ZID S BSP RETENTION INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P00 29
I S ONI AZ I D S CEPHALIN FLOCCULATION INC V CYTOTOXIC HEPATOCELLULAR DAMAGE 90079
ISONI AZID S CHOLESTEROL DEC V PROBABLE HEPATOTOXIC EFFECT HO 596
ISONIAZID S COOMBS TEST P05 V IMMUNOLOGICAL RESPONSE TO DRUG P01418
ISONIAZID S FOLATE DEC V LOW INCIDENCE OF IMPAIRED ABSORPTION P0976
ISONIAZID S GLUCOSE INC V LARGE DOSES CAUSE HYPERGLYCEMIA BY GLYCOGENOLYSIS R01417
ISONIAZID S GUANASE INC V CYTOTOXIC HEPATOCELLULAR DAMAGE P0079
IS ONIA ZID S HAPTOGLOBIN DEC V HEMOLYTIC ANEMIA P06 20
ISONIAZID S I 131 UPTAKE DEC V REDUCES UPTAKE P0596
ISONIAZID S lCD INC V CYTOTOXIC HEPATOCELLULAP JAUNDICE 20079
ISONIAZID S OCT INC V CYTOTOXIC HEPATOCELLULAH DAMAGE R0079
ISONIAZID S PBI DEC V REDUCES THYROID SYNTHESIS RO596
ISONIAZID S POTASSIUM INC V REPORTED EFFECT OF OVERDOSE P0417
ISONIA ZID S SCOT INC M AT THERAPEUTIC CONC MAY AFFECT SMA 12/60 METHOD P0876
IS ONI A Z I D S SCOT INC V PROBABLE INTPAHEPATIC CHOLESTATIC JAUNDICE RO596
ISONIAZID S SGPT INC V PROBABLE INTRAHEPATIC CHOLESTATIC JAUNDICE P0596
ISONIAZID U AIC4H INC V OCCURS IF MEGALOBLASTIC ANEMIA P0976
ISONIAZID U FIGLU INC V OCCURS IF MEGALOBLASTIC ANEMIA P0976
ISONIAZID U GLUCOSE INC V GLYCOSURIA NAY FOLLOW INDUCED HYPERGLYCEMIA P014 17
ISONIAZID U PROTEIN INC V MAY HAVE NEPHROTOXIC EFFECT P0417
ISONIAZID U URINALYSIS BILE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE H 0029
I SONIAZID U URINALYSIS CASTS INC V NEPHROTOXIC EFFECT P06 20
ISONIA ZID U URINALYSIS GLUCOSE INC V DUE TO HYPERGLYCEMIA HO 596
ISONIAZID U URINALYSIS KETONES INC V MECHANISM NOT LISTED P0417
ISONIA RID U URINALYSIS PROTEIN INC V NEPHHOTOXIC EFFECT HO 299
ISONIAZID U URINALYSIS SUGAR INC M FALSE POSITIVE WITH BENEDICT’S AND CLINITEST P03 17
ISONIA ZID U VITAMIN B6 INC V DOSE RELATED EFFECT P079 1
ISONIAZID U 5 OR INDOLEACETIC ACID DEC V CAUSES DECAPHOXYLASE INHIBITION WITH REDUCED 5HT HO 2S7
ISOPPOPANIDE 5 I 131 UPTAKE DEC V CONTAINS IODINE - REDUCES FURTHER UPTAKE H01417
ISOPHOPAMIDE S PBI INC N CONTAINS IODINE P00014
ISOPPOP ANOL F OCCULT BLOOD P05 V MAY CAUSE HEMATEMESIS AND GASTROENTERITIS HO 368
ISOPROPANOL 0 BREATH ALCOHOL INC M CAN PRODUCE MEASURABLE LEVELS P03 56
ISOPROPANOL S SGPT INC V TRANSIENT AND MILD LATE TOXIC EFFECT P0368
IS OPROPANOL U BOGEN TEST P05 N PEACTS AS IF ETHANOL HO 3 68
ISOPROPANOL U URINALYSIS ACETONE INC V METABOLIZED PARTIALLY TO ACETONE P0417
ISOPPOPA NOL U URINALYSIS PROTEIN INC V TRANSIENT AND MILD LATE TOXIC EFFECT HO 368
I SOPROTERENOL B P02 DEC V BY APPROX 10 NM HG IN CHRONIC LUNG DISEASE P06 57
ISOPROTEHENOL P CATECHOLAMINE5 INC V DUE TO INHALATION - EFFECT SLIGHT HO 2 35
I SOPROTERENOL S BILIPUBIN INC M AT 1 MMOL/L AFFECTS SMA 12/60 METHOD 20876
ISOPROTERENOL S GLUCOSE INC N AT 1 MMOL/L AFFECTS SMA 12/60 METHOD P0876
ISOPROTERENOL S GLUCOSE INC V NOT AS MARKED AS WITH EPINEPHRINE R0384
I SOPHOTERENOL S NEFA INC V AS EFFECTIVE AS EPINEPHRINE HO 384
IS OPROTERE N OL S SCOT INC M AT 1 MMOL/L AFFECTS SMA 12/60 METHOD P0876
ISOPPOTERENOL U EPINEPHRINE INC V PROBABLY SMALL EFFECT WITH USUAL DOSES Ho 23S
ISOPHOTERENOL U GFR DEC V FREQUENTLY OBSERVED TO BE DIMINISHED P0835
ISOPHOTERENOL U VOLUME DEC V ANTIDIURETIC EFFECT MEDIATED THROUGH ADH RELAEASE P08 35
ISOSORBIDE S SODIUM INC V DEHYDRATION WITH OVEHDOSAGE P0871
ISOSORBIDE S UREA NITROGEN INC V DEHYDRATION WITH OVERDOSAGE 90871
ISOSORBITOL U VOLUME INC V ACTS AS OSMOTIC DIURETIC HO 3814
KA NAMYCIN B EOSINOPHILS INC V ALLERGIC REACTION R 01424
KANAMYCIN B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA P06 20
KANAMYCIN F PAT INC V MAY INDUCE MALABSORPTION WITH DIARRHEA ROLI67
KANAMYCIN P FIBRINOGEN DEC V NAY OCCUR AT BEGINNING OF THERAPY Ho 384
KA NA MY CI N P PPOTHROMBIN TIME DEC V EFFECT NOTED AT BEGINNING OF THERAPY HO657
KANANYCIN S ALKALINE PHOSPHATASE INC V MAY CAUSE HEPATOTOXICITY P06 20
KANA MYCIN S BILIPUBIN INC V MAY CAUSE HEPATOTOXICITY P06 20
KANAMYCIN S BSP RETENTION INC V MAY CAUSE HEPATOTOXICITY R0299
KA NAMYCIN S CAROTENE DEC V MAY INDUCE MALABSOPPTION WITH DIARRHEA P0467
KANAMYCIN S CEPHALIN FLOCCULATION INC V MAY CAUSE HEPATOTOXICITY P0620
KA NAMYCIN S CHOLESTEROL DEC V FORMS SALTS WITH BILE ACIDS IN GUT 90310
KANAMYCIN S CPEATININE INC V NEPHHOTOXIC EFFECT (COMMON BUT SLIGHT) POS 96
KANAMYCIN S NPN INC V NEPHPOTOXIC EFFECT RO620
KA NAMYCIN S SCOT INC V MAY CAUSE HEPATOTOXICITY P0620
KANAMYCIN S SGPT INC V MAY CAUSE HEPATOTOXICITY P0 6 20
KANAMYCIN S THYNOL TURBIDITY INC V MAY CAUSE HEPATOTOXICITY H062O
KANANYCIN S UREA NITROGEN INC V NEPHROTOXIC EFFECT (COMMON SLIGHT ELEVATION) P0021
KANAMYCIN U ALKALINE PHOSPHATASE INC V DUE TO NEPHHOTOXIC EFFECT OF DRUG HO 758
KANAMYCIN U PROTEIN INC V NEPHROTOXIC EFFECT 20299
KANAMYCIN U URINALYSIS CASTS INC V NEPHROTOXIC EFFECT (CYLINDRURIA AND GRANULAR CASTS) P0026
KANAMYCIN U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING OCCURS P02 99
KANAMYCIN U URINALYSIS PROTEIN INC V NEPHH0TOXIC EFFECT 90299
KANAE!IYCIN U URINALYSIS RBC/HPF INC V ACTUAL BLEEDING MAY OCCUR H 0299
KANAMYCIN U URINALYSIS WBC/HPF INC V NEPHPOTOXIC EFFECT P0 1467
KANAMYCIN U VOLUME DEC V NEPHPOTOXICITY MAY OCCUR WITH OLIGUPIA, AZOTEMIA P01467
KANAMYCIN U XYLOSE EXCRETION DEC V DUE TO IMPAIRED GASTROINTESTINAL ABSORPTION 90467
KAOLI N U DIAGNEX BLUE EXCRETION INC V DISPLACEMENT OF DIAGNEX BLUE FROM RESIN Ri 001
KEROSENE F OCCULT BLOOD P05 V TOXIC EFFECT IF INGESTED P0 3 814
KEROSENE S SGPT INC V HEPATIC DAMAGE WITH LARGE DOSES P03 84
KEROSENE S UREA NITROGEN INC V PENAL DAMAGE WITH LARGE DOSES HO 3 814
KEROSENE U PROTEIN INC V PENAL DAMAGE WITH LARGE DOSES 903814
KEROSENE U URINALYSIS CASTS INC V WITH SEVERE TOXICITY FOLLOWING INGESTION 90368
KFPOS ENE U URINALYSIS PROTEIN INC V PENAL DAMAGE WITH LARGE DOSES 903814
KEROSENE U URINALYSIS HBC/HPF INC V WITH SEVERE TOXICITY FOLLOWING INGESTION P03 68
KETONE BODIES U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S P0436
LACTATE B PR INC V USED IN TREAT OF METABOLIC ACIDOSIS P0026
LACTATE S CPEATININE Z N NO EFFECT ON METHOD OF POLAR AND NETCOFF HO 5146
LACTATE S URIC ACID INC V INHIBITS TUBULAR SECRETION OF UPATE R1O19
LACTATE U URIC ACID DEC V INHIBITS TUBULAR SECRETION OF UPATE P1019

LACTATION 0 HER INC V REMAINS ELEVATED FROM PREGNANCY P0291
LACTATION S ALBUMIN DEC V REMAINS ABOUT 1 G/100ML BELOW NORMAL P0291
LACTATION S CEPULOPLASNIN INC V INITIALLY HIGH FALLS TO NORMAL 90291
LACTATION S COPPER INC V INITIALLY HIGH FALLS TO NORMAL P0291
LACTATION U ESTROGENS INC V EXCRETION 5-10 UG/24H UNTIL NORMAL CYCLE RESUMES P0291
LACTATION U LACTOSE INC V QUITE COMMON, ESPECIALLY IN AFTERNOON R0291
LACTOBACILLUS P AMMONIA DEC V CAUSES REDUCTION IN HEPATIC ENCEPHALOPATHY P0605
LACTOSE U ESTRIOL DEC N INTERFERENCE WITH GLC METHOD 90830
LACTOSE U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S P0436
LACTULOSE P AMMONIA DEC V IN PATIENTS WITH HEPATIC ENCEPHALOPATHY P01410
LAXATIVES P ALDOSTERONE INC V MAY OCCUR IN RESPONSE TO HYPOKALEMIA P0657
LAXATIVES S CALCIUM DEC V EXCESSIVE USE MAY HAVE EFFECT R0620
LAXATIVES S POTASSIUM DEC V EXCESSIVE USE MAY HAVE EFFECT 90620
LAXATIVES S PROTEIN DEC V MAY OCCUR WITH CONTINUED USE P0596
LAXATIVES S SODIUM DEC V EXCESSIVE USE NAY HAVE EFFECT P0620
LEAD B ERYTHROCYTE SURVIVAL DEC V DUE TO HEMOLYSIS RO291
LEAD B HEMATOCRIT DEC V HEMOLYTIC ANEMIA P02140
LEAD B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA P0240
LEAD B LEAD INC V MAY BE INCREASED MUCH ABOVE NORMAL OF 5OUG/100ML P0291
LEAD B MCHC DEC V HEMOLYTIC ANEMIA P0240
LEAD B NCV DEC V HENOLYTIC ANEMIA P02140
LEAD B MCV INC V RARE INCREASE WITH POISONING P0291
LEAD B PLATELET COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0658
LEAD B RED CELL COUNT DEC V HEMOLYTIC ANEMIA (WITH HASOPHILIC STIPPLING) P0240
LEAD B RETICULOCYTES INC V DUE TO STIMULATION OF HEMOLYSIS P0384
LEAD B WHIT! CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0658
LEAD C PROTEIN INC V OCCURS WITH LEAD ENCEPRALOPATHY, ENCEPHALITIS P0368
LEAD E COPPER INC V OCCURS WITH POISONING P0291
LEAD E COPHOPORPHYRIN INC V OCCURS WITH POISONING 90291
LEAD E PROTOPORPHYRIN INC V OCCURS WITH POISONING R0291
LEAD F OCCULT BLOOD P05 N LEAD SULFIDE MAY SIMULATE MELENA P0368
LEAD F OCCULT BLOOD 905 V MAY BE BLOODY DIARRHEA WITH POISONING P0368
LEAD S BILIPUBIN INC V NAY CAUSE HENOLYTIC ANEMIA P0240
LEAD S IRON INC V REPORTED EFFECT P0291
LEAD S URIC ACID INC V NEPUROPATHY ASSOC WITH DEC SECRETION PER NEPURON P0069
LEAD U ALANINE INC V OCCURS WITH POISONING P0291
LEAD U ALPHA AMINO NITROGEN INC V OCCURS WITH POISONING P0291
LEAD U AMINOLEVULINIC ACID INC V OBSERVED IN POISONING P03814
LEAD U B-ISO-AMINOBUTYRIC AC INC V NEPHPOTOXIC EFFECT WITH LEAD POISONING R0291
LEAD U COPROPORPHYRIN INC V OBSERVED IN POISONING P03814
LEAD U GLUCOSE INC V NEPHROTOXIC EFFECT WITH LEAD POISONING P0291
LEAD U LEAD INC V DUE TO INCREASED BODY LOAD(IN POISONING 8OUG/100NL) P0368
LEAD U PHOSPHATE INC V OCCURS WITH POISONING P0291
LEAD U PORPHOBILINOGEN Z V NORMAL IN LEAD PORPHYRIA P0436
LEAD U PROTEIN INC V NRPHROTOXIC EFFECT WITH POISONING P03814
LEAD U URIC ACID DEC V NEPHROPATHY ASSOC WITH DEC SECRETION PER NEPHRON P0069
LEAD U URINALYSIS CASTS INC V NEPHROTOXICITY WITH POISONING (CYLINDRURIA) P03814
LEAD U URINALYSIS COLOR INC V RED BROWN (?DUE TO PORPHYRINS AND HEMOGLOBIN) P0620
LEAD U URINALYSIS GLUCOSE INC V NEPHROTOXICITY WITH POISONING P0384
LEAD U URINALYSIS HEMOGLOBIN INC V OCCURS WITH ACUTE RENOLYTIC CRISIS P0368
LEAD U URINALYSIS PROTEIN INC V NEPHPOTOXICITY WITH POISONING R0384
LEAD U URINALYSIS RBC/HPF INC V NEPHROTOXICITY WITH POISONING P0384
LEAD U UROBILINOGEN INC V DUE TO HEMOLYSIS OF POISONING P0291
LEUCINE P INSULIN INC V FACILITATES UPTAKE OF AMINO ACIDS BY TISSUES P0311
LEVARTEHENOL P ERPF DEC V BLOOD FLOW REDUCED, FILTRATION RATE UNCHANGED P03814
LEVART!RENOL P NOREPINEPHRINE INC V AFTER I.V. INFUSION R1O3O
LEVARTERENOL P VOLUME DEC V DUE TO LOSS OF PROTEIN-FREE FLUID TO TISSUES R0384
LEVARTERENOL S AMINO ACIDS INC V CATABOLIC EFFECT R0299
LEVARTEPENOL S CHOLESTEROL INC V MECHANISM NOT DISCUSSED R0245
LEVARTERENOL S URIC ACID INC V RESULT OF DECREASED URATE CLEARANCE P0324
LEVAPTERENOL U URIC ACID DEC V DECREASES URATE EXCRETION AND RENAL PLASMA FLOW P0324
LEVARTERENOL U VNA INC V NORMAL METABOLITE, EFFECT SLIGHT USUALLY RO908
LEVODOPA B HEMATOCRIT DEC V MILD NOT RELATED TO HEMOLYSIS R0O26
LEVODOPA B HEMOGLOBIN DEC V MILD NOT RELATED TO HENOLYSIS RO026
LEVODOPA B 5-ADENOSYLMETHIONINE DEC V 0-METHYLATION OF CATECROLAMINES SLOWED P0625
LEVODOPA B WHITE CELL COUNT DEC V TRANSITORY DEPRESSION IN A FEW PATIENTS P0026
LEVODOPA F OCCULT BLOOD P05 V SINGLE CASE OF GASTRITIS WITH NELENA P0780
LEV000PA P CATECHOLAMINES INC N DOSAGE DEPENDENT P00142
LEV000PA P COPTISOL DEC V PROBABLY DIMINISHED ACTH SECRETION P03914
LEV000PA P GONADOTROPINS INC V HEPORTEDNETABOLIC EFFECT P0394
LEVODOPA P GROWTH HORMONE INC V IN NORMALS SINGLE DOSE CAUSE INC IN 1-2 HOURS P0509
LEVODOPA P INSULIN INC V DUPING THERAPY OF PARKINSONISM P0509
LEVODOPA P PROLACTIN DEC V TRANSIENT EFFECT IN NONPUERPEPAL GALCTORHHEA P0611
LEVODOPA S ALKALINE PHOSPHATASE INC V PARE ELEVATION REPORTED P0026
LEVODOPA S BILIRUBIN INC N AT 1 MNOL/L AFFECTS SMA 12/60 METHOD R0876
LEV000PA S BILIHUBIN INC N THEORETICALLY REACTS WITH DIAZO REAGENT P08141
LEVODOPA S BILIRUBIN INC V RAPE ELEVATION REPORTED P0026
LEVODOPA S COOMBS TEST P05 V AUTOIMMUNE PHENOMENON (OCCURS AFTER SEVERAL MONTHS) P014 18
LEVODOPA S CREATININE INC N ACTS AS REDUCING AGENT (PROBABLE EFFECT) P0042
LEVODOPA S GLUCOSE INC N AT 10 MG/100ML AFFECTS ALKALINE FERRICYANIDE RO37O
LEVODOPA S GLUCOSE INC N AT 1 NMOL/L AFFECTS SMA 12/60 METHOD P0876
LEVODOPA S GLUCOSE Z M AT 10 MG/100NL NO EFFECT ON GLU OX OF GOCHMAN R0370
LEV000PA S GLUCOSE Z V NO EFFECT OBSERVED ALTHOUGH INC PLASMA INSULIN P0509
LEV000PA S LACTIC DEHYDROGENASE INC V HARE INSTANCE OF ELEVATION, ?ORIGIN R0026
LEVODOPA S MONOAMINE OXIDASE INC V INCREASED ACTIVITY AFTER 2-3 MONTHS THERAPY P0939
LEVODOPA S PHI INC V ?EFFECT DUE TO TETRAIODOFLUOPESCEIN IN CAPSULES P0132
LEVODOPA S SCOT INC N AT 1 MNOL/L AFFECTS SMA 12/60 METHOD P0876
LEV000PA S SGOT INC V TRANSIENT EFFECT, NORMALIZES DESPITE CONTINUATION P0026
LEVODOPA S SGPT INC V TRANSIENT EFFECT RETURNS TO NORMAL P01467
LEVODOPA S THYROXINE (T4) INC V DURING THERAPY OF PAPKINSONISN P0509

LEVODOPA S T3 UPTAKE Z V NO EFFECT OBSERVED IN CHRONIC TREATMENT P0509
LEVODOPA S UHEA NITROGEN INC V AFFECTS HEPATIC ENZYMES, PROBABLY NOT DEHYDRATION P0616
LEVODOPA S URIC ACID INC N FALSELY HIGH VALUES WITH PHOSPHOTUNGSTATE METHODS P0370
LEVODOPA S URIC ACID INC V TWO CASES REPORTED, EXAGGERATED BY FRUCTOSE 20013
LEVODOPA S URIC ACID Z M NO INCREASE REPORTED WHEN URICASE USED P0026
LEVODOPA U CREATININE CLEARANCE INC N REDUCING PROPERTIES AFFECT JAFFE METHOD 20328
LEVODOPA U CREATININE INC N PROBABLE ACTION AS REDUCING AGENT P0042
LEVODOPA U DOPAMINE INC V RESPONSE TO THERAPY IN PARKINSONISM RO718
LEVODOPA U GLUCOSE DEC N FALSE NEC, INHIBITION OF GLUCOSE OXIDASE METHOD 90317
LEV000PA U HOMOVANILLIC ACID INC V IN PARKINSONIAN PATIENTS IS RESPONSE TO THERAPY P0175
LEVODOPA U INULIN CLEARANCE INC V ?SEC. TO RENAL VASODIL. OR DIRECT ACTION ON TUBULES P0328
LEV000PA U ISO-HOMOVANILLIC ACID INC V RESPONSE TO THERAPY IN PARKINSON PATIENTS RO214
LEVODOPA U METANEPHRINES TOTAL DEC V ?DOPAMINE AS NEUROTRANSMITTER SUPPRESSES NOPMET P0475
LEVODOPA U NOPEPINEPHRINE INC V NO EFFECT ON EPINEPHRINE EXCRETION 90821
LEVODOPA U PAP CLEARANCE INC V ?SEC. TO PENAL VASODIL. OR DIRECT ACTION ON TUBULES P0328
LEVODOPA U POTASSIUM INC V ?SEC. TO RENAL VASODIL. OH DIRECT ACTION ON TUBULES P0328
LEVODOPA U PSP EXCRETION INC V INCREASED PLASMA FLOW P0328
LEVODOPA U SODIUM INC V ?SEC. TO RENAL VASODIL. OR DIRECT ACTION ON TUBULES P0328
LEVODOPA U SUGAR INC N FALSE POSITIVE WITH CLINITEST 90317
LEVODOPA U URIC ACID INC M FALSELY HICH VALUES WITH PHOSPHOTUNGSTATE METHODS P0370
LEV000PA U URINALYSIS COLOR INC N RED-TINGED ON VOIDING, BLACKENS ON STANDING 90819
LEVODOPA U URINALYSIS GLUCOSE DEC M FALSE NEC. IF CLINISTIX USED (NO EFFECT ON TESTAPE) P0317
LEVODOPA U URINALYSIS GLUCOSE Z M NO EFFECT ON TESTAPE 90317
LEVODOPA U URINALYSIS HEMOGLOBIN INC V OCCASIONAL REPORT OF HEMATURIA P0026
LEV000PA U URINALYSIS KETONES INC N INTERMITTENT FALSE P05 IF KETOSTIX OR PHENISTIX R1003
LEVODOPA U URINALYSIS PBC/HPF INC V OCCASIONAL REPORT OF HEMATURIA P0026
LEVODOPA U URINALYSIS SUGAR INC N PRODUCES TRACE POSITIVE IF CLINITEST USED P0317
LEVODOPA U VMA DEC V ?DOPAMINE AS NEUROTRANSMITT!R SUPPRESSES NORMET P01475
LEVODOPA U VMA INC V SMALL INCREASE, LARGER INCREASE HVA P0175
LEVODOPA U 5 OH INDOLEACETIC ACID DEC V IN PARKINSON’S DISEASE ?INC THYPT PYRR ACTIVITY 90158
LEVOMEPRONAZINE U FECL3 TEST P05 N P05 IF MORE THAN 100MG/DAY FOR 6 DAYS P0657
LEVOMEPROMAZINE U PHENYLKETONES P05 N PRENISTIX P05 IF MORE THAN 100MG/DAY FOP 6 DAYS 90657
LEVOTHYROXINE 0 BMR INC V METABOLIC EFFECT OF HORMONE (MAXIMUM AT ONE WEEK) P0596
LEVOTHYHOXINE P PROTHROMBIN TIME INC V MAY POTENTIATE ACTION OF ANTICOAGULANTS RO1467
LEVOTHYHOXINE S CHOLESTEROL DEC V OFTEN THERAPEUTIC INTENT P0907
LEVOTHYPOXINE S FREE THYROXINE DEC V FALLS WITH THERAPY OF HYPOTHYROID STATE P0467
LEVOTHYPOXINE S I 131 UPTAKE DEC V DUE TO METABOLIC EFFECT OF DRUG R0596
LEVOTHYPOXINE S NEFA DEC V CORRECTION OF HYPOTHYROID STATE P0907
LEVOTHYROXINE S PBI INC V IN PATIENTS ON THYROID MAINTENANCE THERAPY R0004
LEVOTHYROXINE S PHOSPHOLIPIDS DEC V CORRECTION OF HYPOTHYROID STATE P0907
LEVOTHYROXINE S THYROXINE (T4) INC V ENDOGENOUS HORMONE SUPPRESSED, EXOGENOUS MEASURED RO112
LEVOTHYROXINE S TRIGLYCERIDES INC V EFFECT OBSERVED IN HYPOTHYROID PATIENTS 90667
LICORICE B PH INC V MAY CAUSE ALKALOSIS P0596
LICORICE P ALDOSTERONE DEC V HORMONAL LIKE ACTION OF DRUG P00714
LICORICE P RENIN DEC V PS!UDOALDOSTERONISN EFFECT P0973
LICORICE S POTASSIUM DEC V ALDOSTERONE LIKE ACTION 90669
LICORICE S UREA NITROGEN INC V MAY CAUSE NEPHROPATHY P0669
LICORICE U ALDOSTERONE DEC V PSEUDOALDOSTERONISM EFFECT P0973
LICORICE U MYOGLOBIN INC V MAY FOLLOW HYPOKALENIA P0669
LICORICE U POTASSIUM INC V ALDOSTEHONE LIKE ACTION 90669
LIDOCAIN! C PROTEIN INC M REACTS WITH FOLIN-CIOCALTEU REAGENT P0355
LIGHT S BILIRUBIN DEC V BREAKDOWN OF BILIRUBIN IN VIVO AND IN VITRO 90951
LIGHT S CEPHALIN FLOCCULATION INC N FALSE P05. OCCUR AFTER SERUM EXPOSED TO LIGHT P0078
LIGHT S DIRECT BILIRUBIN DEC V BREAKDOWN OF BILl (LESS SENSITIVE THAN INDIRECT) P0355
LIGHT S TRYPTOPHAN DEC N AFFECTS FLUORONETHIC METHOD OF DENCLA S DEWEY P0575
LIGHT U CITRULLINE DEC N COLORED COMPLEX WITH DIACETYLMONOXIME UNSTABLE P0730
LIGHT U POPPHYRINS DEC N PHOTOSENSITIVE P0779
LIGHT U TRYPTOPHAN DEC M AFFECTS FLUOROMETRIC METHOD OF DENCLA & DEWEY P0575
LIGHT U UPOBILINOGEN DEC N OXIDATION BY LIGHT OCCURS 90184
LINCONYCIN B PLATELET COUNT DEC V RARE REVERSIBLE THRONBOCYTOPENIA 90384
LINCONYCIN B WHITE CELL COUNT DEC V AGRANULOCYTOSIS/LEUKOPENIA/NEUTROPENIA 90023
LINCOMYCIN F OCCULT BLOOD P05 V NAY CAUSE SEVERE ENTEPOCOLITIS RO872
LINCOMYCIN S ALKALINE PHOSPHATASE INC V HEPATOTOXIC-CHOLESTATIC EFFECT 30299
LINCOMYCIN S BILIRUBIN INC V HEPATOTOXIC-CHOLESTATIC EFFECT H0596
LINCOMYCIN S CEPHALIN FLOCCULATION INC V HEPATOTOXIC-CHOLESTATIC EFFECT RO620
LINCOMYCIN S CHOLESTEROL DEC V HEPATOTOXIC EFFECT P0596
LINCOMYCIN S FOLATE DEC N INHIBITS GROWTH OF L. CASEI P0910
LINCOMYCIN S GLUCOSE DEC V MAY OCCUR WITH HEPATOTOXICITY P0596
LINCOMYCIN S SCOT INC V HEPATOTOXIC-CHOLESTATIC EFFECT R0596
LINCOMYCIN S SGPT INC V HEPATOTOXIC-CHOLESTATIC EFFECT R0596
LINCOMYCIN S THYMOL TURBIDITY INC V HEPATOTOXIC-CHOLESTATIC EFFECT P0620
LINCOMYCIN S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS P0492
LINCOMYCIN U URINALYSIS BILE INC V OCCURS WITH HEPATOTOXICITY P0620
LINDANE S CHOLINESTERASE DEC V IN VITRO 7.1% DEC AT 1X1O-14 N 90362
LINDANE 5 LACTIC DEHYDROGENASE DEC V IN VITRO 6.1% DEC AT 1X1O-14 M P0362
LINOLEAMIDE S CHOLESTEROL DEC V INHIBITS STEPOL ABSORPTION P0280
LOTFIYRONINE 0 BMP INC V METABOLIC EFFECT OF HORMONE R0596
LIOTEIYPONINE S I 131 UPTAKE DEC V EXCEPT IN HYPERTHYHOIDISM RO596
LIOTHYPONINE S THYROXINE (T14) DEC V DEPRESSION OF ENDOGENOUS HORMONE 20596
LIOTPIX P PPOTHHOMBIN TIME INC V MAY POTENTIATE ACTION OF ORAL ANT!COAGULANTS P0467
LIOTRIX S CHOLESTEROL DEC V IN HYPOTHYROIDS FALLS TO WITHIN NORMAL RANGE P01467
LIOTRIX S PBI DEC V THERAPEUTIC RESPONSE P0026
LIOTRIX S T3 UPTAKE INC V INCREASES BUT REMAINS WITHIN NORMAL RANGE P0467
LIPENIA B HEMOGLOBIN INC N MAY CAUSE ELEVATION BY UP TO 3 G/100ML RO181
LIPEMIA B METHEMOGLOBIN INC N PRODUCES TURBIDITY P0411
LIPEMIA B SEDIMENTATION PATE INC V LARGE MOLECULAR WEIGHT COMPONENTS HAVE EFFECT P0620
LIPEMIA P HEMOGLOBIN Z V NO EFFECT OBSERVED WITH INDUCED LIPEMIA 90485
LIPENIA S ALBUMIN INC M AFFECTS MOST METHODS UNLESS BLANK CORRECTION P0998
LIPEMIA S AMYLASE INC N TURBIDITY MAY AFFECT SOME METHODS P0181
LIPEMIA S BILIRUBIN INC N INTERFERES WITH DIRECT SPECTROSCOPIC METHODS P01814

LIPEMIA S CALCIUM INC N CAUSES TURBIDITY IN FERRO-HAM PROCEDURE RC436
LIPEMIA S CEPHALIN FLOCCULATION INC N REPORTED EFFECT ADDING TO TURBIDITY R0636
LIDEMIA S CHOLESTEROL INC M TURBIDITY IF EXTRACTION NOT USED RC436
LIPENIA S ICTERIC INDEX INC !1 TURBIDITY OF SERUM R355
LIPEMIA S PROTEIN INC N TURBIDITY OF SERUM 30620
LIPENIA S SGOT INC :i TURBIOITY NAY AFFECT SOME METHODS P3181
LIPEMIA S SCOT INC V ASSOCIATED WITH ALCOHOLISM P0620
LIPEMIA S SGPT INC N TURBIDITY NAY AFFECT SOME METHODS R0181
LIPEMIA S SGPT INC V ASSOCIATED WITH ALCOHOLISM R0620
LI?EMIA S THYMOL TURBIDITY INC N DUE TO INHERENT TURBIDITY P C 620
LIPEMIA S URLA NITROGEN INC M HAY A?FCT BERTHZLOT REACTION RC51O
LI7EMIA S ZNSO4 TURBIDITY INC N EFFECT LESS 1ARXED THAN WITH PHYNOL TURBIDITY BC 436
LIPIODOL S I 131 UPTAKE DEC V INTERFERES WITH UPTAKE B C 026
LI PI000L 5 PHI INC V DOES NOT AFFECT T4 (E?FCT 1-5 YEARS) PC 83 9
LIPOCHHOME S 8ILIRUBIN INC N NAY BE MEASURED AS BILIRUBIN IN SOME METHODS 8C355
LI POCHROME S CHOLESTEROL INC 1 ABSORB STRONGLY IN BLUE REGION MAY AFFECT L-B METH P0436
LIPOMUL B HEMOGLOBIN DEC V MAY BE SEVERE HENOLYTIC ANEMIA IDb57
LIPOMUL B PLATELET COUNT DEC V THROMBOCYTOPENIA WITH FAT-OVERLOADING 20620
LIPONUL B RED CELL COUNT DEC V MAY BE PROGRESSIVE ANEMIA WITH EXCESS R 0657
LIPOMUL F OCCULT BLOOD P05 V MAY BE SEVERE G.I. TRACT BLEEDING RC657
LIPONUL S BSP RETENTION INC V PART OF FAT-OVERLOADING SYNDROME P 0 657
LIPOMUL S C02 CONTENT DEC V NEPHPOTOXIC EFFECT WITH AZOTEMIA B 299
LIPOMUL S CRLATININE INC V NEPHROTOXIC E?FECT P C 620
LIPOMUL S NPN INC V NEPHROTOXIC ?FECT P0620
LI POMUL S PHOSPHATE INC V MAY OCCUR WITH AZOTENIA RC62D
LI?OMUL S POTASSIUM INC V NEPHROTOXIC EFFECT P0620
LIPOMUL S UREA NITROGEN INC V POSSIBLE NEPHROTOXIC EFFECT 902014
LIPOMUL S URIC ACID INC V DECREASED CLEARANCE H 062)
LIPOMUL U PROTEIN INC V NEPHROTOZIC EFFECT P029 9
LIPOMUL U URINALYSIS HEMOGLOBIN INC V PRODUCES ACTUAL BLEEDING 90299
LIPOMUL U URINALYSIS PROTEIN INC V NEPHROTOXIC E?FECT 30299
LIPOMUL U URINALYSIS RBC/HPF INC V MAY CAUSE ACTUAL BLEEDING P0299
LITHIUM B LYMPHOCYTES DEC V ?DRUG ASSOCIATED ENDOCRINE EFFECT HO 869
LITHIUM B NEUTROPHILS INC V ?DHUG ASSOCIATED ENDOCRINE EFFECT P3869
LITHIUM B WHITE CELL COUNT INC V ?DRUG ASSOCIATED ENDOCRINE EFFECT (NAY DOUBLE) R0626
LITHIUM C LITHIUM INC V CONCENTRATION ABOUT HALF IN SERUM P0384
LITHIUM P CORTISOL INC V OBSERVED IN SOME PATIENTS H 07144
LITHIUM P TSP INC V MECHANISM UNCLEAR Ho 168
LITHIUM S CHOLESTEROL INC V REPORTED TO INDUCE MYXEDEMA H 0597
LITHIUM S FREE THYROXINE DEC V MECHANISM UNCLEAR, NON TOXIC GOITER MAY OCCUR HG 870
LITHIUM S GLUCOSE INC V HYPERGLYCEMIA BEEN REPORTED AFTER USE (TRANSIENT) H C 9514
LITHIUM S I 131 UPTAKE INC V MECHANISM UNCLEAR P0168
LITHIUM S LITHIUM INC V THERAPEUTIC LEVEL BETWEEN 0.5 AND 1.0 NEQ/L P03814
LITHIUM S MAGNESIUM INC V ?AFFECTS MEMBRANE TRANSPORT SYSTEMS P0937
L ITHIUM S PBI DEC V INHIBITS IODINATION OF TYHOSINE IN TBG 30026
LITHIUM S POTASSIUM DEC V SLIGHT DECREASES OBSERVED ONLY P0163
LITHIUM S POTASSIUM INC V ?BY DISPLACING FROM CELLS H3612
LITHIUM S SODIUM DEC V DUE TO INITIAL NATURIESIS AND DIURESIS R0612
LITHIUM S THYROXINE (TLI) DEC V REPORTED TO INDUCE MYXEDEMA R0597
LITHIUM S T3 UPTAKE DEC V REPORTED TO INDUCE NYXEDEMA RU 597
LITHIUM S URIC ACID DEC V REPORTED TO HAVE UPICOSUPIC EFFECT P0052
LITHIUM U ALDOSTERONE INC V OCCURS AFTER INITIAL FALL PC 685
LITHIUM U CALCIUM DEC V ?AFFECTS CA DEPENDENT CATECHOLAMINE SYSTEM HC612
LITHIUM U GLUCOSE INC V REPORTED EFFECT OF LITHIUM THERAPY IN SOME CASES P314 17
LITHIUM U MAGNESIUM INC V FOLLOWING ADMINISTRATION 0? THERAPY R0612
LITHIUM U PROTEIN INC V MAY HAVE NEPHHOTOXIC EFFECT R0417
LITHIUM U SODIUM DEC V DUE TO ACTION OF ALDOSTERONE (INITIAL INCREASE) R0685
LITHIUM U URINALYSIS GLUCOSE INC V CONSEQUENCE OF HYPERGLYCEMIA R014 17
LITHIUM U URINALYSIS PROTEIN INC V MAY HAVE SLIGHT NEPHROTOXIC EFFECT P 3 4 17
LITHIUM U VMA INC V SLIGHT INCREASE ONLY, MECHANISM NOT CLEAR P0417
LOCAL ANESTHETICS B METHEMOGLOBIN INC V REPORTED EFFECT H 0657
LOCAL ANESTHETICS B RED CELL COUNT DEC V BONE MARROW DEPRESSION REPORTED HO 657
LOCAL ANESTHETICS B WHITE CELL COUNT DEC V BM DEPRESSION AND AGRANULOCYTOSIS REPORTED HC657
LU CA NTHONE S SGPT INC V CHRONIC TOXICITY MAY CAUSE LIVER DAMAGE H 0384
LU CA NT HO NE U URINALYSIS PROTEIN INC V CHRONIC TOXICITY NAY CAUSE RENAL DAMAGE HO 3814
LUGOL’S IODINE B EOSINOPHILS INC V RARE ALLERGIC RESPONSE TO IODINES PG 02 6
LUGOL’S IODINE B PLATELET COUNT DEC V RARE POSSIBLE RESPONSE WITH PURPURA HO 026
LUGOL’S IODINE S BILIRUBIN INC V OCCASIONAL HYPERSENSITIVE REPSONSE TO IODINES P 002 5
LUGOL’S IODINE S PBI INC M NO EFFECT T4, CONTAINS IODINE,IODIDE:EFFECT TO 3WKS P3839
LUGOL’S IODINE S THYROXINE (TLL) Z ii NO EFFECT ON METHODS R0839
LYSERGIC ACID S PBI INC V STIMULATES TSP RELEASE, ?EFFECT ON I 131 UPTAKE P00014
LYSINE P INSULIN INC V SLIGHT EFFECT, AIDS METABOLISM OF AMINO ACIDS P03 11
LYSINE S UREA NITROGEN Z N NO EFFECT ON BERTHELOT REACTION H 05 10
LYSOL B HEINZ-BODY FORMATION P05 V MAY CAUSE INTRAVASCULAR HEMOLYSIS HO 197
LYSOL B HEMATOCPIT DEC V NAY CAUSE INTRAVASCULAR HEMOLYSIS HO 197
LYSOL B HEMOGLOBIN DEC V MAY CAUSE INTRAVASCULAR HENOLYSIS P0197
LYSOL B METHEMOGLOBIN INC V MAY CAUSE INTRAVASCULAR HEMOLYSIS P0197
LYSOL B RED CELL COUNT DEC V MAY CAUSE INTRAVASCULAR HENOLYSIS HO 197
LYSOL E REDUCED GLUTATHIONE DEC V MARKED EFFECT WITH HEMOLYSIS R0197
LYSOL U URINALYSIS HEMOGLOBIN INC V OCCURS WITH MASSIVE HEMOLYSIS HO 197
LYSOL U URINALYSIS SUGAR INC N EXCRETED GLUCURONIDE REACTS WITH BENEDICT’S HO 197
MAFENIDE B PCO2 DEC V INHIB OF CARBONIC ANHYDHASE WHEN APP TOPICALLY H 098
MAFENIDE B PH DEC V IF RESP IMPAIRMENT AS REDUCED RENAL BUFFERING P00148
MAFENI DE B PH INC V USUAL FINDING WITH RESP ALKALOSIS R00148
NAFENIDE B WHITE CELL COUNT DEC V PROBABLE EFFECT OBSERVED IN ONE CHILD P0048
MAFENIDE (1 AMMONIA DEC V INHIB OF CARBONIC ANHYDRASE WHEN APP TOPICALLY P0985
MAFENIDE U BICARBONATE INC V INHIB OF CARBONIC ANHYDRASE WHEN APP TOPICALLY P0985
NAFEN IDE U CHLORIDE DEC V SELECTIVE RETENTION R0048
NAFEN IDE U PH INC V INHIB OF CARBONIC ANHYDRASE WHEN APP TOPICALLY H0985
MAFENIDE U POTASSIUM INC V INHIB OF CARBONIC ANHYDRASE WHEN APP TOPICALLY P0985

MAFENI DE U URINALYSIS PH INC V INHIBITS CARBONIC ANHYDRASE IF APPLIED TOPICALLY P0985
MAGNES IUM SALTS S ALKALINE PHOSPHATASE INC N ACTIVATORS OF ENZYME IN LABORATORY PROCEDURES 20929
MAGNESIUM SALTS S CALCIUM DEC V COMPETES WITH CALCIUM FOP G.i.TRACT ABSORPTION 90554
MAGNES IUN SALTS S CALCIUM INC N MEASURED AS CA IN SON! EDTA PROCEDURES P04 36
NAG NESIU N SALTS S MAGNESIUM INC V ABSORBED FROM G.I. TRACT FROM ANTACIDS ETC 20417
MAGNESIUM SALTS U DIAGNEX BLUE EXCRETION INC V HEAVY METAL DISPLACEMENT OF DIAGNEX BLUE P1001
MALE FERN S BSP RETENTION INC V PROB INHIB OF UPTAKE BY LIVER 90657
MALE FERN S DIRECT BILIRUBIN INC V PROB INHIB OF UPTAKE OF BILIRUBIN BY LIVER HO 657
MALIC ACID S LACTATE DEC N INTERFERES WITH ENZYME METHODS P0333
MALONIC ACID U NETHYLMALONATE INC N MEASURED AS ANALYTE 20361
MALTOSE U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S P0436
NANDELIC ACID U ESTRIOL DEC N IF ACID HYDROLYSIS USED WITH HEXAMIN! MANDELATE P0657
MANDELIC ACID U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY THE DRUG P0299
NANDELIC ACID U URINALYSIS RBC/HPF INC V ACTUAL BLEEDING NAY BE CAUSED BY DRUG P02 99
MANGANESE SALTS S ALKALINE PHOSPHATASE INC M ACTIVATORS OF ENZYME IN LABORATORY PROCEDURES 90929
MANNITOL S CHLORIDE DEC V EFFECT IF MARKED DIURESIS 20026
MANNITOL S CREATININE INC V DUE TO DEHYDRATION HO 6 20
MANNITOL S OSMOLALITY INC V NAY CAUSE MARKED DEHYDRATION HO 5 96
MANNITOL S PHOSPHATE DEC N INHIBITION OF COLOR DEVELOPMENT HO 184
MA NNITOL S POTASSIUM INC V MECHANISM NOT DISCUSSED P067 2
NANNITOL S SODIUM DEC V EFFECT IF MARKED DIURESIS HO 026
NA NNITOL S SODIUM INC V NAY CAUSE MARKED DEHYDRATION P0 596
MANNITOL S URIC ACID DEC V REPORTED TO HAVE URICOSURIC ACTION 3031414
NANNITOL U SODIUM INC V SLIGHT INCREASE OCCURS ONLY P0 596
MA NNO SE S GLUCOSE INC N NON-SPECIFICITY OF FECN, 0-TOLUIDINE, NEOCUPROINE P07 50
MA NNOSE S NANNOSE INC V TWICE NORMAL LEVEL IN DIABETICS (AFTER I.V.) Polls
MANNOSE S URIC ACID INC V SIMILAR ACTION TO FRUCTOSE P 1 005
MANNOSE U ESTRIOL DEC N INTERFERENCE WITH GLC METHOD 90830
MA NNOSE U URIC ACID INC V GREAT INCREASE AFTER I.V. INFUSION Rolls
NANNOSE U URINALYSIS COLOR INC V DEEP ORANGE AFTER I.V. INFUSION HO 1 15
MA N NOSE U URINALYSIS CRYSTALS INC V MASSIVE URIC ACID CRYSTALLURIA AFTER INFUSION 90115
MAO INHIBITORS B HENATOCRIT DEC V OCCASIONAL ANEMIA MAY OCCUR P06 57
MAO INHIBITORS B HEMOGLOBIN DEC V OCCASIONAL ANEMIA MAY DEVELOP P06 57
MAO INHIBITORS B RED CELL COUNT DEC V ANEMIA NAY OCCASIONALLY OCCUR 90620
MAO INHIBITORS B WHITE CELL COUNT DEC V OCCASIONAL LEUKOPENIA/AGRANULOCYTOSIS P06 20
MAO INHIBITORS 0 HISTAMINE TEST INC V ENHANCED RESPONSIVENESS 90373
MAO INHIBITORS 0 PHENTOLANINE TEST INC V ENHANCED RESPONSIVENESS P0373
MAO INHIBITORS 0 TYRANINE TEST INC V ENHANCED RESPONSIVENESS P0373
MAO INHIBITORS P AMMONIA DEC V REPORTED EFFECT IN EXOGENOUS NH3 TOXICITY HO 53 3
MAO INHIBITORS P CATECHOLAMINES INC V PREVENT DEAMINATION HUT NOT DEGRADATION BY COMT P00142
MAO INHIBITORS P DOPAMINE INC V EFFECT OBSERVED AFTER SINGLE LARGE DOSE HO 3814
MAO INHIBITORS P EPINEPHPINE INC V EFFECT OBSERVED AFTER SINGLE LARGE DOSE 20384
MAO INHIBITORS P NOREPINEPHRINE INC V EFFECT OBSERVED AFTER SINGLE LARGE DOSE HO 3814
MAO INHIBITORS P 5 OH TRYPTAMINE INC V EFFECT OBSERVED AFTER SINGLE LARGE DOSE H03 84
MAO INHIBITORS S ALKALINE PHOSPHATASE INC V CHOLESTATIC EFFECT 90596
MAO INHIBITORS S BILIPUBIN INC V VIRAL HEPATITIS-LIKE JAUNDICE IN SOME PATIENTS 208514
MAO INHIBITORS S BSP RETENTION INC V INTRAHEPATIC CHOLESTASIS WITH POSSIBLE CELL DAMAGE P03 55
MAO INHIBITORS S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT R0620
MAO INHIBITORS S CHOLESTEROL DEC V HEPATOTOXIC EFFECT HO 596
MAO INHIBITOPS S GLUCOSE DEC V MECHANISM NOT CLEAR(POSSIBLE HEPATOTOXICITY) P0007
MAO INHIBITORS S GLUCOSE TOLERANCE INC V SEEN IN DIABETICS TREATED WITH INSULIN 20596
MAO INHIBITORS S SCOT INC V INTRAHEPATIC CHOLESTASIS P0596
MAO INHIBITORS S SGPT INC V INTRAHEPATIC CHOLESTASIS 90596
MAO INHIBITORS S THYMOL TURBIDITY INC V INTRAHEPATIC CHOLESTASIS HO 620
MAO INHIBITORS U NETANEPHPINES TOTAL INC V PREVENT DEAMINATION P 03 84
MAO INHIBITORS U NORMETANEPHRINE INC V PREVENT DEAMINATION HO 3 84
MAO INHIBITOPS U PHENYLETHYLAMINE INC V PREVENT DEAMINATION P03814
MAO INHIBITORS U TRYPTAMINE INC V DUE TO UTILIZATION OF ALTERNATIVE PATHWAYS HO 3814
MAO INHIBITORS U TYRAMINE INC V PREVENT DEAMINATION P03 814
MAO INHIBITORS U URINALYSIS BILE INC V HEPATOTOXIC EFFECT HO 620
MAO INHIBITORS U VMA DEC V INHIBITION OF NOPMETANEPHRINE CONVERSION TO VMA 901417
MAO INHIBITORS U XYLOSE EXCRETION DEC V DECREASED G.I. TRACT ABSORPTION R0355
MAO INHIBITORS U 5 OH INDOLEACETIC ACID DEC V INHIBITION OF CONVERSION OF 5HT TO 5HIAA 90531
MAO INHIBITORS U 5 OH TRYPTANINE GLUCUR INC V DUE TO INHIBITION OF CONVERSION OF 5 PT TO 5 HIAA HO 3814
MAPIHUANA P INSULIN INC V RESPONSIBLE FOR HYPOGLYCEMIA 20273
MARIHU AN A S CHLORIDE INC V REPORTED EFFECT 90596
MARIHUANA S CREATININE DEC V REPORTED EFFECT 90596
MAPIHUANA S GLUCOSE DEC V HYPOGLYCEMIC EFFECT APPROX 4 HOURS AFTER USE P0273
MAR IHUANA S POTASSIUM INC V REPORTED EFFECT P0 596
NA RIHUANA S SODIUM INC V REPORTED EFFECT P0596
MARIHUANA S UREA NITROGEN INC V REPORTED EFFECT P0596
MARIHUANA S URIC ACID DEC V REPORTED EFFECT P05 96
NAROPHEN B EOSINOPHILS INC V LOW INCIDENCE REPORTED P06S7
N DA B PCO2 INC V RESPIRATORY ACIDOSIS P0778
MDA B PH DEC V RESPIRATORY ACIDOSIS 90778
NDA S CO2 CONTENT DEC V RESPIRATORY ACIDOSIS HO 778
MDA S SCOT INC V REPORTED EFFECT ? OF MUSCLE ORIGIN P0778
MEALS B PH INC V EFFECT OF METABOLIC ALKALOSIS RO8146
MEALS P ALPHA AMINO NITROGEN INC V SMALL TRANSIENT RISE AFTER PROTEIN MEALS P0621
MEALS S ALBUMIN Z V NO EFFECT AFTER STANDARD BREAKFAST HO 181
MEALS S ALKALINE PHOSPHATASE INC V FATTY MEALS ESP IN 0 SECRETORS P0998
MEALS S BSP RETENTION INC V CAPACITY OF LIVER TO ELIMINATE BSP DECREASED P0181
MEALS S CALCIUM INC V EFFECT OF METABOLIC ALKALOSIS 90846
MEALS S CHLORIDE Z V NO EFFECT AFTER STANDARD BREAKFAST HO 181
MEALS S CHOLESTEROL ESTERS Z V NO EFFECT AFTER STANDARD BREAKFAST R0181
MEALS S CHOLESTEROL INC V REPORTED UP TO 3% INC AFTER MEALS 901436
MEALS S CHOLESTEROL Z V NO EFFECT AFTER STANDARD BREAKFAST HO, 81
MEALS S CO2 CONTENT Z V NO EFFECT AFTER STANDARD BREAKFAST ROl8l
MEALS S CREATININE Z V NO EFFECT AFTER STANDARD BREAKFAST HO 181
MEALS S GLUCOSE INC V IN EFFECT ACTS AS GLUCOSE TOLERANCE TEST P0181

NEALS S IONIZED CALCIUM DEC EFFECT MORE MARKED THAN WITH PESP ALKALOSIS HO 846
MEALS S PBI Z V NO EFFECT OF MEALS REPORTED 90255
MEALS S PHOSPHATE DEC V PHOSPHORYLATION OF GLUCOSE AND METABOLISM P03 55
MEALS S POTASSIUM Z V NO EFFECT AFTER STANDARD BREAKFAST P0181
MEALS S PROTEIN Z V NO EFFECT AFTER STANDARD BREAKFAST HO 181
MEALS S SODIUM Z V NO EFFECT AFTER STANDARD BREAKFAST P0181
MEALS S THYMOL TURBIDITY INC N CAUSE MILD LIPEMIA WHICH IS MEASURED R0l84
MEALS S UREA NI?OGEN Z V NO EFFECT REPORTED AFTER STANDARD BREAKFAST P0181
MEALS S URIC ACID Z V NO EFFECT AFTER STANDARD BREAKFAST RO181
MEALS U UREA CLEARANCE Z V NO SIGNIFICANT EFFECT OF MEALS OBSERVED P01143
MEALS U XYLOSE EXCRETION DEC V LESS ABSORBED IN NON-FASTING STATE P0766
MEASLES VACCINE B PLATELET COUNT DEC V MAY CAUSE THROMBOCYTOPENIC PU RPURA P0657
MEAT F OCCULT BLOOD P05 V MYOGLOBIN IN MEAT, NO EFFECT IF NONE FOR 3 DAYS R0262
ME3ANA ZINE S GLUCOSE DEC V APPEARS TO POTENTIATE INSULIN IN DIABETICS P0657
MECAMYLAMINE S URIC ACID INC V ? DUE TO REDUCED PENAL BLOOD FLOW 90275
MECAMY LA MINE U CATECHOLAMINES Z N NO EFFECT ON FLUORONETRIC METHOD OF CROUT HO 235
MECHLOP!THAMINE B LYMPHOCYTES DEC V OCCURS WITHIN 214 HOURS HO 3814
NE CHLOHCT HA MINE B PLATELET COUNT DEC V BONE MARROW DEPRESION P00 26
NEOPLORETH AMINE B RED CELL COUNT DEC V MILD EFFECT P0026
MECHLORETHA MINE S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT P0079
MECHLOP!THAMINE S BSP RETENTION INC V HEPATOTOXIC EFFECT P007 9
MFCHLOPETHA MINE S CEPHALIN FLOCCULATION INC V MAY CAUSE CYTOTOXIC (HEPATOCELLULAP) DAMAGE P0079
!ECHLOP!THAIIINE S CHOLINESTERASN DEC V OBSERVED ACTIVITY IN VITRO, PROBABLE IN VIVO Ri 027
NECHLORETHA MINE S GUANASE INC V MAY CAUSE CYTOTOXIC (HEPATOCELLULAR) DAMAGE HO 079
MEHLORETHANINE S lCD INC V MAY CAUSE CYTOTOXIC (HEPATOCELLULAP) DAMAGE P0079
MECHLORETHAMINE S OCT INC V MAY CAUSE CYTOTOXIC (HEPATOCELLULAR) DAMAGE P0079
MECHLORETHA MINE S SCOT INC V NAY CAUSE CYTOTOXIC (HEPATOCELLULAR) DAMAGE P0079
MECHLORETHANINE S SGPT INC V MAY CAUSE CYTOTOXIC (HEPATOCELLULAR) DAMAGE P0079
MECHLORETHA MI NE S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT P0079
MECULORETHAMINE S URIC ACID INC V LEUCOCYTE DESTRUCTION, CATABOLISM OF NUCLEIC ACIDS P09 07
?IECRLOPTTHA MINE U URINALYSIS BILE INC V HEPATOTOXIC EFFECT P0079
MEDROXY PROGESTERONE U ANDROGENS DEC V INHIBITION OF STEROID BIOSYNTHESIS IN ADRENALS 909142
MEDPOXY PROGESTERONE U PREGNANEDIOL DEC V INDUCES ANOVULATOPY STATE P0942
MEDROXYPROG ESTEPON F U 17 Op COPTICOSTEPOIDS DEC V INHIBITION OF STEROID BIOSYNTHESIS IN ADRENALS P0 942
MEFENAMIC ACID B HEMATOCRIT DEC V MAY CAUSE AUTOIMNUNE HENOLYTIC ANEMIA HO 3 13
ME?9NAMIC ACID B HEMOGLOBIN DEC V MAY CAUSE AUTOIMMUNE HEMOLYTIC ANEMIA RO313
N!FENMIC ACID B NCV INC V MEGALOBLASTIC ANEMIA REPORTED P00 26
MEFENAMIC ACID B PLATELET COUNT DEC V PA NCYTOPENI A P0240
MEFENAMIC ACID B RED CELL COUNT DEC V PANCYTOPENIA 90620
MEFENAMIC ACID B WHITE CELL COUNT DEC V PANCYTOPENIA (TEMP DEPRESSION NAY OCCUR OFTEN) P06 20
METENAMIC ACID F OCCULT BLOOD 905 V OCCURS LESS FREQUENTLY THAN WITH ASPIRIN P0026
MEFENAMIC ACID P PPOTRROMBIN TIME INC V DISPLACES COUMAPINS FROM ALBUMIN P0850
MEFENAMIC ACID S BILIRUBIN INC V MAY CAUSE AUTOIMMUNE HEMOLYTIC ANEMIA P0313
MF.FENAMIC ACID S COOMBS TEST P05 V AUTOIMMUNE PHENOMENON(OCCURS AFTER SEVERAL MONTHS) P04 18
MEFENAMIC ACID S UREA NITROGEN INC V REPORTED IN ONE STUDY WITH NORMAL VOLUNTEERS RO026
MEFENANIC ACID U PROTEIN INC V NEPHROTOXIC EFFECT P03 55
MEFENAMIC ACID U URINALYSIS BILE INC M REPORTED INTERFERENCE WITH TESTING PROCEDURE RO513
MEFENAMIC ACID U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY THE DRUG HO 299
.NETENAMIC ACID U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT P02 99
MEFENAMIC ACID U URINALYSIS RBC/HPF INC V ACTUAL BLEEDING CAUSED BY DRUG P06 20
F?RUSI OF S POTASSIUM DEC V DIURETIC ACTION LESS EFFECTIVE THAN THIAZIDES R09914
MEFRUSIDE S URIC ACID INC V INHIBITS EXCRETION OF URATE R0994
MEFRUSIDE U CHLORIDE INC V DIURETIC ACTION P0061
MEPREISIDE U POTASSIUM INC V DIURETIC ACTION, ACTS UP TO 20 HOURS P0994
MEFRUSIDE U SODIUM INC V DIURETIC ACTION, LESS EFFECTIVE THAN THIAZIDES P09914
NEFRUSIDE U VOLUME INC V DIURETIC ACTION, LESS EFFECTIVE THAN THIAZIDES P006 1
MEGESTHOL P LH DEC V SUPPRESSES LH PEAK RO847
MELANIN U AMMONIACAL AGNO3 P05 N SLOW DARKENING P0929
MELANIN U ?ECL3 TEST P05 M BROWNISH-BLACK COLOR 909 29
MELANI N U PHENYLKETONES P05 N GRAY TO BLACK WITH F!CL3 P023 9
ME LA N I N U SUGAR INC N IN LARGE QUANTITY MAY REDUCE BENEDICT’S P0929
MELANIN U THORNAPLEN TEST P05 M GREEN-BLUE TO BLUE-BLACK (NORMAL OLIVE-BROWN) HO 92 9
KELANIN U URINALYSIS COLOR INC V BROWN TO BLACK P06 63
MELANIN U UROBILINOGEN INC N MELANOGEN REACTS WITH EHRLICH’S REAGENT P014 36
MEL AR S ON YL B HEMATOCRIT DEC V MAY CAUSE HENOLYTIC ANEMIA IN G-6-PD DEFICIENCY P00 26
MELA PSONYL B HEMOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA IN G-6-PD DEFICIENCY P0026
MEL AR S ON YL B RED CELL COUNT DEC V NAY CAUSE HENOLYTIC ANEMIA IN G-6-PD DEFICIENCY P0026
MELARSONYL S SCOT INC V NAY PRODUCE HEPATOTOXICITY HO 026
MEL AR S ON YL S SCPT INC V MAY PRODUCE HEPATOTOXICITY RO026
ME LA PS ONYL U PROTEIN INC V NEPHROTOXIC EFFECT P0026
N EL AR SONYL U URINALYSIS CASTS INC V NEPHROTOXIC EFFECT R0O26
ME LA PS 0 NY L U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT 90026
MELAPSOPROL S SCOT INC V MAY PRODUCE HEPATOTOXICITY 90026
ME LA PS OPROL S SGPT INC V MAY PRODUCE HEPATOTOXICITY P00 26
MELA PSOPPOL U PROTEIN INC V N!PHROTOXIC EFFECT P0620
NE LA PS 099 OL U URINALYSIS CASTS INC V NEPHHOTOXIC EFFECT P06 20
MELA P S OPROL U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT RO620
NELPH AL AN B HEMATOCRIT DEC V ANEMIA MAY OCCUR RARELY P06 57
MELPHALA N B HEMOGLOBIN DEC V ANEMIA MAY OCCUR RARELY H 06 57
ME LP H AL AN B PLATELET COUNT DEC V NAY CAUSE BONE MARROW DEPRESSION (DOSE RELATED) HO 167
!IFLPHALA N B RED CELL COUNT DEC V NAY CAUSE BONE MARROW DEPRESSION (DOSE RELATED) P0167
ME LP H AL AN B WHITE CELL COUNT DEC V MAY CAUSE HONE MARROW DEPRESSION (DOSE RELATED) P0167
NELPHALA N F OCCULT BLOOD P05 V MAY CAUSE GASTROINTESTINAL HEMORRHAGE P0026
N ELPR AL AN S BILIHUBIN INC V MAY CAUSE HENOLYTIC ANEMIA 90636
ME LPHA LA N S COOMBS TEST P05 V IMMUNOLOGICAL RESPONSE TO DRUG (GAMMA ANTIBODY) P014 18
MEL PH AL AN S DIRECT BILIRUBIN INC V MAY CAUSE HEMOLYTIC ANEMIA R0636
N.E LP HA LA N S UREA NITROGEN INC V AZOTENIA MAY OCCUR !0026
MEL PH AL AN U 5 OH INDOLEACETIC ACID INC V PROBABLY DUE TO TISSUE DESTRUCTION IF CARCINOID P094
MENOPAUSE P GONADOTPOPINS INC V NORMAL RESPONSE HO 29 1
MENOPA USE U ESTROGENS DEC V NORMAL RESPONSE 90291

MENOPAUSE U 17 KETOSTEROIDS DEC V NORMAL RESPONSE P0291
MENSTRUATION B PLATELET COUNT DEC V BY 50 - 70 %, RISES TO NORMAL BY 14TH DAY P0291
MENSTRUATION P FIRPINOGEN INC V NORMAL RESPONSE P0291
MENSTRUATION P HEMOGLOBIN Z V NO EFFECT OBSERVED P01485
MENSTRUATION S CHOLESTEROL INC V INCREASE IMMEDIATELY BEFORE MENSTRUATION PO36
MENSTRUATION S PHI DEC V SLIGHT FALL AFTER MENSTRUATION OBSERVED P0255
MENSTRUATION U CHLORIDE INC V POST-MENSTRUAL DIUBESIS (DEC PREMENSTRUALLY) 90291
MENSTRUATION U ESTPOGENS DEC V LOWEST 2-3 DAYS AFTER ONSET P0291
MENSTRUATION U PORPHYRINS INC V MAY PRECIPITATE EPISODE OF HEPATIC PORPHYRIA P0657
MENSTRUATION U SODIUM INC V POST-MENSTRUAL DIURESIS (DEC PRENENSTPUALLY) P0291
MENSTRUATION U URINALYSIS PROTEIN INC V PRE-NENSTHUAL URINE MAY CONTAIN PROTEIN 90291
MENSTRUATION U VOLUME INC V POST-MENSTRUAL DIURESIS (DEC PPEMENSTRUALLY) R029l
MEPACRINE B RED CELL COUNT DEC V MAY PRODUCE APLASTIC ANEMIA P0620
MEPACRINE B WHITE CELL COUNT DEC V LEUKOPENIA RO620
MEPACPINE P CORTISOL INC N PRODUCES INTERFERING FLUORESCENCE P0490
NEPACRINE S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT P0620
MEPACRINE S BILIRUBIN INC V HEPATOTOXIC EFFECT 20620
NEPACPINE S BSP RETENTION INC V HEPATOTOXIC EFFECT P0620
MEPACRINE S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT 90620
NEPACPINE S SGOT INC V HEPATOTOXIC EFFECT P0620
MEPACHINE S SGPT INC V HEPATOTOXIC EFFECT P0620
MEPACRINE S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT P0620
MEPACRINE U URINALYSIS BILE INC V HEPATOTOXIC EFFECT P0620
MEPAZINE B PLATELET COUNT DEC V PANCYTOPENIA P0620
MEPAZINE B RED CELL COUNT DEC V PANCYTOPENIA/APLASTIC ANEMIA 90620
MEPAZINE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS P0329
!IEPAZINE F UPOBILINOGEN DEC V DUE TO CHOLESTASIS (PALE STOOLS RESULT) P0477
MEPAZINE P PPOTHHOMBIN TIME INC V ASSOC WITH FAILURE OF EXCRETION OF BILE SALTS R0477
MEPAZINE S ALKALINE PHOSPHATASE INC V CHOLESTATIC EFFECT P01477
MEPAZINE S BILIRUBIN INC V CHOLESTATIC EFFECT P0477
NEPAZINE S BSP RETENTION INC V CHOLESTATIC EFFECT ROL&77
MEPAZINE S CHOLESTEROL INC V CHOLESTATIC EFFECT P01477
MEPAZINE S SCOT INC V CHOLESTATIC EFFECT (UP TO 6 TIMES NORMAL) P01477
MEPAZINE S SGPT INC V CHOLESTATIC EFFECT (UP TO 6 TIMES NORMAL) P01477
MEPAZINE U UROBILINOGEN DEC V CHOLESTATIC EFFECT 901477
MEPERIDINE B PCO2 INC V DEPRESSES RESPONSIVENESS OF RESP CENTER TO CO2 P03814
NEPERIDINE B PH Z V INSIGNIFICANT EFFECT OBSERVED P0657
MEPEHIDINE B P02 DEC V SIGNIFICANT REDUCTION IN ARTERIAL OXYGEN PRESSURE P0657
NEPERIDINE S AMYLASE INC V MAY CAUSE SPASM OF SPHINCTER OF ODDI 90872
MEPERIDINE S BARBITURATE INC N FALSE POS SCREEN TEST WITH HG COMPLEX FORM 30183
MEPEPIDINE S BSP RETENTION INC V DUE TO SPASM OF SPHINCTER OF ODDI 90171
MEPEPIDINE S CPK Z V NO REPORTED EFFECT 30657
NEPEPIDINE S GLUCOSE INC V CENTRAL EFFECT ALSO INVOLVES EPINEPHRINE RELEASE P03814
NEPERIDINE S HBD INC V MAY CAUSE SPASM OF SPHINCTER O ODDI P0657
MEPEPIDINE S LACTIC DEHYDROGENASE INC V MAY CAUSE RISE IN INTHABILIARY PRESSURE R0079
NEPERIDINE S LIPASE INC V MAY CAUSE SPASM OF SPHINCTER OF ODDI 30872
MEPEPIDINE S SCOT INC V MAY CAUSE RISE IN INTRABILIARY PRESSURE P0079
MEPERIDINE S SGPT INC V MAY CAUSE RISE IN INTPABILIARY PRESSURE P0907
MEPERIDINE U MEPERIDINE P05 V MAIN EXCRETION PRODUCT IN NEONATES AND PREGNANT 90657
MEPERIDINE U NOPMEPERIDINE P05 V MAIN METABOLITE IN NORMALS 90657
MEPERIDINE U VOLUME DEC V CAUSES RELEASE OF ADH 903814
MEPERIDINE U 17 KETOSTEROIDS DEC V PROBABLE EFFECT (INHIBITS ACTH AND PGH RELEASE) P0384
MEPEPIDINE U 17 OH CORTICOSTEPOIDS DEC V PROBABLE EFFECT (INHIBITS ACTH AND PGH RELEASE) P03814
MEPHENESIN B WHITE CELL COUNT DEC V MAY CAUSE LEUKOPENIA 90620
MEPHENESIN S UREA NITROGEN INC V FATAL ANURIA WITH INTRAVASCULAR HENOLYSIS RO3814
MEPHENESIN U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG 0299
MEPHENESIN U URINALYSIS RBC/HPF INC V ACTUAL BLEEDING MAY BE CAUSED BY DRUG P0299
MEPHENESIN U VMA INC M PURPLE OR RED COLOR IN INITIAL PART OF SCREEN TEST P0178
MEPHENESIN U 5 OH INDOLEACETIC ACID INC N INTERFERES WITH NITROSONAPHTHOL REACTION P1001
MEPHENOXALONE B FOSINOPHILS INC V RARE SIDE EFFECT RO026
MEPHENOXALONE B RED CELL COUNT DEC V NAY CAUSE ANEMIA P0620
MEPHENOXALONE B WHITE CELL COUNT DEC V MILD AND TRANSITORY R0026
MEPHENYTOIN B PEMATOCRIT DEC V HEMOLYTIC/APLASTIC/MEGALOBLASTIC ANEMIA P0784
MEPHENYTOIN B HEMOGLOBIN DEC V HENOLYTIC/APLASTIC/MEGALOBLASTIC ANEMIA R0784
MEPHENYTOIN B MCV INC V MAY CAUSE MEGALOBLASTIC ANEMIA P0026
MEPHENYTOIN B PLATELET COUNT DEC V SECONDARY TO APLASTIC ANENIA/PANCYTOPENIA 207814
MEPHENYTOIN B RED CELL COUNT DEC V HEMOLYTIC ANEMIA P07814
NEPH!NYTOIN B WHITE CELL COUNT DEC V AGPANULOCYTOSIS/APLASTIC ANEMIA P07814
MEPHENYTOIN S ALKALINE PHOSPHATASE INC V HEPATOTOXICITY P0620
NEPHENYTOIN S BILIRUBIN INC V MAY CAUSE HEMOLYTIC ANEMIA P0636
MEPHENYC’OIN S BSP RETENTION INC V HEPATOTOXICITY P0620
MEPHENYTOIN S CEPHALIN FLOCCULATION INC V HEPATOTOXICITY P0620
MEPHENYTOIN S DIRECT BILIRUBIN INC V MAY CAUSE HENOLYTIC ANEMIA 30636
NEPHENYTOIN S DIRECT COOMBS TEST P05 V MECHANISM OBSCURE P0418
MEPHENYTOIN S HAPTOGLOBIN DEC V NAY CAUSE HENOLYTIC ANEMIA H0636
MEPHENYTOIN S I 131 UPTAKE Z V NO EFFECT REPORTED P0596
MEPHENYTOIN S INDIRECT COOMBS TEST P05 V MECHANISM OBSCURE P0418
MEPHENYTOIN S P91 DEC V COMPETES WITH THYROXINE FOR BINDING SITES P0596
ME?HENYTOIN S SCOT INC V HEPATOTOXICITY P0620
MEPHENYTOIN S SGPT INC V HEPATOTOXICITY P0620
MEDHENYTOIN S THYMOL TURBIDITY INC V HEPATOTOXICITY P0620
MEPHENYTOIN U URINALYSIS BILE INC V HEPATOTOXICITY 90620
MEPROBAMATE B HENATOCRIT DEC V NAY CAUSE APLASTIC ANEMIA P01 04
MFPHOBAMATE B HEMOGLOBIN INC V MAY CAUSE APLASTIC ANEMIA 901014
MEPPOBAMATE B PLATELET COUNT DEC V RARE BONE-MARROW APLASIA, THRONHOCYTOPENIA P0025
NEPPOBAMATE B RED CELL COUNT DEC V APLASTIC ANEMIA/ ERYTHROID HYPOPLASIA P0658
MEPPOBAMATE B WHITE CELL COUNT DEC V PANCYTOPENIA (MAY BE AGRANULOCYTOSIS) P0025
MEPPOBAMATE F COPROPORPHYRIN INC V NAY PRECIPITATE ACUTE PORPHYRIA P0371
MEPROBAMATE F PROTOPORPHYPIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P0371
NEPPOBAMATE P PROTHPOMBIN TIME DEC V INDUCES HEPATIC METABOLISM OF ANTICOAGULANTS P0384

NEPROBAMATE S ALKALINE PHOSPHATASE INC V MAY CAUSE CHOLESTATIC (HEPATOCANALICULAR) JAUNDICE HO 079
MEPROBAMATE S BILIRUBIN INC V MAY CAUSE CHOLESTATIC (HEPATOCANALICULAR) JAUNDICE P0079
MEPPOBAM ATE S CHOLESTEROL INC V NAY CAUSE CHOLESTATIC (HEPATOCANALICULAR) JAUNDICE R0079
N EP? OP A MA TE S P91 INC N CONTAINS IODINE P0907
NEPPOBAM ATE S PHI Z V N EFFECT WITH NORMAL DOSES HO 255
?IEPROBA MATE S SCOT INC V MAY CAUSE CHOLESTATIC (HEPATOCANALICULAR) JAUNDICE P0079
MEPPOBAM ATE S SGPT INC V NAY CAUSE CHOLESTATIC (HEPATOCANALICULAR) JAUNDICE P0079
MEPROBA MATE U AMINOLFVULINIC ACID INC V MAY PRECIPITATE ACUTE PORPHYRIA P0371
ME. P POBA ‘IA TE U COPROPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P0371
N!PROBA MATE U PORPHOBILINOGEN INC V MAY PRECIPITATE ACUTE PORPHYRIA HO 37 1
NEPPOBAMA TE U PORPHYRINS INC V MAY PRECIPITATE ATTACK OF ACUTE PORPHYRIA R0596
ME PROP A MA U 17 KETOGFNIC STEROIDS DEC M INTERFERES WITH ZIMMERMAN REACTION (HOLTOPFF-KOCH) P0816
N PROP AMA U 17 KETOGENIC STEROIDS INC M GLUCURONIDE INTERFERES WITH ZIMMERMAN REACTION R0907
N’PROBAMATE U 17 KETOSTEPOIDS DEC M INTERFERES WITH ZIMMERMAN REACTION P0816
MEPPOBA MATE U 17 KETOSTEPOIDS INC M GLUCURONIDE INTERFERES WITH ZINMERMN REACTION P08 16
ME PRO B AM A TE U 11 OH CORTICOSTEROIDS INC M GLUCUPONIDE INTERFERES WITH PORTEH-SILBEH REACTION P0596
MEPROBA MATE U 17 OH CORTICOSTEROIDS INC M SMALL EFFECT ON MODIFIED GLENN-NELSON METHOD P1001
MERALLUPIDE S CHLORIDE DEC V DIURETIC ACTION P1001
NEPALLJ9IDE S I 131 UPTAKE Z V NO EFFECT ON THYROID FUNCTION 90596
ME? ALL U S MAGNESIUM DEC V HYPOMAGNESEMIA ESP IF NH14CL ALSO GIVEN P0618
NEPALLU RIDE S PHI DEC M INTERFERES WITH DETERMINATION PROCEDURE P1021
NEPALLURI DE S POTASSIUM DEC V DIURETIC ACTION 90907
MEPALLURIDE S SODIUM DEC V DIURETIC ACTION P1001
MF.9ALLUPIDE U CALCIUM INC V REABSORPTION IMPAIRED P0723
N E P AL L U? IDE U URINALYSIS GLUCOSE DEC N INTERFERES WITH GLUCOSE OXIDASE METHOD HO 6514
MERCA PTOME PIN S PBI DEC N FORMATION OF MERCURIAL IODIDE DURING ANALYSIS H 02 33
MFRCAPTOMERIN U CALCIUM INC V REABSORPTION IMPAIRED P0723
MEPCA PTOMERIN U MAGNESIUM INC V EXCRETION INCREASED BY UP TO 30% P088 2
MEHCA PTOPUPINE B HEMATOCHIT DEC V MAY OCCUR WITH BONE-MARROW DEPRESSION P0657
MFRCAPTOPUPINF B HEMOGLOBIN DEC V MAY OCCUR WITH BONE-MARROW DEPRESSION P06 57
MERCAPTOPUPINE B PLATELET COUNT DEC V MAY CAUSE BONE-NARROW DEPRESSION P06 56
NERCAPTOPUH INE B RED CELL COUNT DEC V NAY OCCUR WITH BONE-MARROW DEPRESSION P06 57
MEPCAPTOPURINE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS P0656
NERCAPTOPUR INE P PROTHROMBIN TIME INC V DEPRESSES CLOTTING FACTOR SYNTHESIS HO 886
NERCA PTOPU PINE S ALKALINE PHOSPHATASE INC V HEPATOTOXICITY (CENTROLOHULAR NECROSIS) RO620
MERCA PTOPURINE S AMYLASE INC V ONE CASE OF HEMORRHAGIC PANCREATITIS P06 57
MERCAPTOPUTINE S BILIRUBIN INC V MAY CAUSE INCREASE, ESPECIALLY IF PRIOR DAMAGE P0862
MERCAPTOPURINE S BSP RETENTION INC V HEPATOTOXICITY (CENTROLOBULAR NECROSIS) P0620
MERCA PTOPUPINE S CEPHALIN FLOCCULATION INC V HEPATOTOXICITY (CENTPOLOBULAR NECROSIS) P0620
M.ERCA PTOPUPINE S GLUCOSF INC N AT I MMOL/L AFFECTS SMA 12/60 METHOD P0876
MERCAPTOPURINE S SGOT INC V MAY CAUSE HEPATOTOXICITY (CENTROLOBULAR NECROSIS) P00 66
MERCAPTOPUPINE S SG?T INC V MAY CAUSE HEPATOTOXICITY (CENTROLOBULAP NECROSIS) P00 66
MERCAPTOPURIN? S THYMOL TURBIDITY INC V HEPATOTOXICITY (CENTROLOBULAH NECROSIS) P06 20
NERCA PTOPU PINE S ‘IRIC ACID INC M AT I MMOL/L AFFECTS SNA 12/60 METHOD P0876
MERCAPTOPUR INE S URIC ACID INC V LEUCOCYTE DESTRUCTION, CATABOLISM OF NUCLEIC ACIDS P09 07
MERCAPTOPURINE U URIC ACID INC V INCREASED NUCLEAR PROTEIN BREAKDOWN P03 55
MERCAPTOPURINE U URINALYSIS BILE INC V HEPATOTOXIC EFFECT HO 620
MERCURIAL DIURETICS B PH INC V MAY CAUSE SYSTEMIC ALKALOSIS ESP IF HYPOCHLOREMIA HO 3814
MERCURIAL DIURETICS B PLATELET COUNT DEC V THPOMBOCYTOPFNIA REPORTED (SENSITIZATION) P03 84
MERCURIAL DI3RETICS B RED CELL COUNT DEC V ANEMIA MAY OCCUR P06 20
MERCURIAL DIURETICS B WHITE CElL COUNT DEC V NEUTROPENIA/AGRANULOCYTOSIS REPORTED P0552
MERCURIAL DIURETICS S CHLORIDE DEC V NAY CAUSE HYPOCHLOREMIC ALKALOSIS AND DIURESIS P0723
MERCURIAL DIURETICS S MAGNESIUM DEC V EFFECT MOST MARKED IF NH14CL ALSO GIVEN P06 18
MERCURIAL DI’JPETICS S PBI DEC N INTERFERE WITH ACID DISTILL, CHLORIC ACID METHODS HO 1417
MERCURIAL DIURETICS S PHI INC N INTERFERES WITH DIGESTION TECHNIQUE HO 004
MERCURIAL DIURETICS S SODIUM DEC V DIURETIC ACTION WITH SODIUM DEPLETION P06 20
MERCURIAL DIURETICS S URIC ACID INC V MAY PRECIPITATE ATTACKS OF GOUT HO 145
MEPCTJPIAL DIURETICS U CALCIUM INC V REABSORPTION IMPAIRED P0723
MERCURIAL DIURETICS U CHLORIDE INC V THERAPEUTIC INTENT (DOMINANT URINARY ANION) 90723
MERCURIAL DIURETICS U GLUCOSE DEC N MAY CAUSE FALSE NEG RESULTS WITH GLU OX METHODS P04 17
MERCURIAL DIURETICS U MAGNESIUM INC V EXCRETION INCREASED BY UP TO 30% P0882
MERCURIAL DIURETICS U SODIUM INC V THERAPEUTIC INTENT P0384
MERCURIAL DIURETICS U VOLUME INC V THERAPEUTIC INTENT P0384
MERCUPOC9RONE U URINALYSIS COLOR INC N FLUORESCENT PINK STAINING OF CELLS R0143
!IERCUPOCHROM? U UPOBILIN INC M YIELDS PINK COLOR AND MAUVE FLUORESCENCE HO 1436
MERCURY COMPOUNDS C PROTEIN INC V NAY PRODUCE GUILLAIN-BARRE LIKE SYNDROME R0911
MERCURY COMPOUNDS F COLOR INC M GREEN WITH ABOUT 130 MG OF CALOMEL HO 620
MERCURY COMPOUNDS F OCCULT BLOOD P05 V BLOODY DIARRHEA OCCURS WITH POISONING P03 814
MERCURY COMPOUNDS S CO2 CONTENT DEC V MAY BE DEPRESSED IN ESTABLISHED POISONING HO 29 1
MERCURY COMPOUNDS S PHI DEC N INTERFERE WITH CHLOPIC ACID DIGEST PROCEDURES HO 004
MERCURY COMPOUNDS S PHI Z N NO EFFECT BARKER DRY ASH PROCEDURE P0112
MERCURY COMPOUNDS S PROTEIN DEC V DUE TO ALBUMINURIA AND STARVATION P0620
MERCURY COMPOUNDS S SODIUM DEC V MAY OCCUR WITH ESTABLISHED HG POISONING P0291
MERCURY COMPOUNDS S UREA NITROGEN DEC N INHIBITS UREASE (NOTE,PRESENT IN NESSLERS REAGENT) P04 36
MERCURY COMPOUNDS U MERCURY INC V DUE TO INGESTION OF COMPOUND AND IF POISONING P0911
MERCURY COMPOUNDS U PROTEIN INC V NEPHROTOXIC EFFECT P0355
MERCURY COMPOUNDS U URINALYSIS CASTS INC V MAY CAUSE SEVERE NEPHHITIS IF ABSORBED P0026
MERCURY COMPOUNDS U URINALYSIS COLOR INC V RED BROWN DUE TO HEMATURIA P06 20
MERCURY COMPOUNDS U URINALYSIS HEMOGLOBIN INC V MAY CAUSE SEVERE NEPHRITIS IF ABSORBED P0026
MERCURY COMPOUNDS U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT P0 3 55
MERCURY COMPOUNDS U URINALYSIS RBC/HPF INC V MAY CAUSE SEVERE NEPHRITIS IF ABSORBED P0026
MERSALYL S CHLORIDE DEC V CONSEQUENCE OF DIURETIC ACTION P07 23
MERSALYL S URIC ACID DEC V URICOSURIC ACTION P04 04
MEPSALYL U CALCIUM INC V REABSORPTION IMPAIRED Ho 723
MEPSALYL U URIC ACID INC V URICOSURIC ACTION P04 014
MEHSALYL U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG HO 2 99
MERSALYL U URINALYSIS RBC/HPF INC V ACTUAL BLEEDING MAY BE CAUSED BY DRUG P02 99
MERTHIOLATE S PHI DEC M INHIBITION OF REACTION CAUSED BY CONTAMINATED SKIN P08 39
MESORIDAZINE B WHITE CELL COUNT DEC V TRANSIENT AGRANULOCYTOSIS REPORTED P 0026
MESORIDAZINE S SCOT INC V TRANSIENT EFFECT NOTED P0026

MESTRANOL P FSH DEC V HORMONAL EFFECT (INHIBITORY ACTION OF ESTROGEN) P08147
M!STPANOL P LH INC V ESTROGEN EXERTS STIMULATORY ACTION P1012
NESTRANOL S ALBUMIN DEC V METABOLIC EFFECT 90853
MFSTRANOL S ALPHA2-GLOBULIN INC V METABOLIC EFFECT 90853
MESTRANOL S ALPHA2-MACROGLOBULIN INC V MAX EFFECT ONE WEEK AFTER TREATMENT P01463
MESTRANOL S BETA-GLOBULIN INC V METABOLIC EFFECT 90853
MESTRANOL S CALCIUM DEC V INC SENS TO CALCITONIN IN POSTMENOPAUSAL WOMEN P0011
MESTPANOL S PHOSPHATE DEC V INC SENS TO CALCITONIN IN POSTMENOPAUSAL WOMEN 90011
MESTRANOL S TIBC INC V 20% RISE ON AVERAGE P0463
MESTRANOL S TRANSFEPPIN INC V MAX EFFECT ONE WEEK AFTER TREATMENT P0463
NESTRANOL S TRIGLYCERIDES INC V ?IMPAIRED TRIGLYCERIDE REMOVAL FROM CIRCULATION P0907
MESTRANOL U CALCIUM DEC V INC SENS TO CALCITONIN IN POSTM!NOPAUSAL WOMEN 90011
MESTRANOL U PHOSPHATE INC V INC RESPONSE TO CALCITONIN P0011
METAHEXAMIDE S ALKALINE PHOSPHATASE INC V HEPATOTOXICITY (VIRAL HEPATITIS TYPE) P0620
METAHEXAMIDE S BILIRUBIN INC V HEPATOTOXICITY (VIRAL HEPATITIS TYPE) 30620
METAHEXAMIDE S BSP RETENTION INC V HEPATOTOXICITY (VIRAL HEPATITIS TYPE) R062O
METAHEXAMIDE S CEPHALIN FLOCCULATION INC V HEPATOTOXICITY (VIRAL HEPATITIS TYPE) P0620
METAHEXAMIDE S SCOT INC V HEPATOTOXICITY (VIRAL-HEPATITIS TYPE) 90620
METAHEXAMIDE S SGPT INC V HEPATOTOXICITY (VIRAL-HEPATITIS TYPE) P0620
METAHEXAMIDE S THYMOL TURBIDITY INC V HEPATOTOXICITY (VIRAL-HEPATITIS TYPE) P0620
METAHEXAMIDE U PROTEIN INC N INTERFERENCE BY DRUG-METABOLITE P09614
METAHEXAMIDE U URINALYSIS BILE INC V HEPATOTOXICITY (VIRAL HEPATITIS TYPE) 90620
METAHEXAMIDE U URINALYSIS PROTEIN INC N INTERFERENCE BY DPUG-METABOLITE P0299
METALS P TESTOSTERONE INC N IN MOLAR RATIO 0! 0.7-114.0 AFFECTS C-S METHOD P0269
METANDIENONE P PPOTHRONBIN TIME INC V PROLONGS ACTION OF ANTICOAGULANTS P0620
NETANDIENONE S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT (COMMON) P0620
METANDIENONE S BILIPUBIN INC V HEPATOTOXIC EFFECT (COMMON) P0620
METANDIENONE S BSP RETENTION INC V HEPATOTOXIC EFFECT (COMMON) P0620
METANDIENONE S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT (COMMON) P0620
METANDIENONE S CHOLESTEROL INC N INTERFERES WITH ZIMMERMAN REACTION P0596
METANDIENONE S CHOLESTEROL INC V REPORTED EFFECT P0657
NETANDIENONE S GLUCOSE TOLERANCE DEC V ALTERS CURVE IN DIABETIC DIRECTION P0657
NETANDIENONE S I 131 UPTAKE DEC V ALSO MODIFIES BINDING 0’ THYROID HORMONES 90657
METANDIENONE S SCOT INC V HEPATOTOXICITY P0620
METANDIENONE S SGPT INC V HEPATOTOXICITY 90620
METANDIENONE S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT P0620
METANDIENONE U URINALYSIS BILE INC V HEPATOTOXIC EFFECT 90620
METAPPOTEPENOL U URINALYSIS SUGAR INC N INTERFERES WITH BENEDICT’S REAGENT P0299
METAXALONE S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT P0620
NETAXALONE S BILIRUBIN INC V HEPATOTOXIC EFFECT P0620
METAXALONE S BSP RETENTION INC V HEPATOTOXIC EFFECT P0299
METAXALONE S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT 90620
METAXALONE S SCOT INC V HEPATOTOXIC EFFECT P0620
METAXALONE S SGPT INC V HEPATOTOXIC EFFECT 90620
METAXALONE S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT 90620
METAXALONE U PROTEIN INC V MAY HAVE NEPPROTOXIC EFFECT P0299
METAXALONE U SUGAR INC N FALSE POSITIVE WITH COPPER REDUCTION PROCEDURES P0907
METAXALONE U URINALYSIS BILE INC V HEPATOTOXIC EFFECT P0620
METAXALONE U URINALYSIS PROTEIN INC V NEPRPOTOXIC EFFECT P0299
METAXALONE U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S, FEHLING’S REACTIONS P0907
METFORNIN B HEMATOCRIT DEC V MAY BE ASSOC WITH MEGALOBLASTIC ANEMIA P0935
M!TFOPNIN B HEMOGLOBIN DEC V ASSOCIATED WITH IMPkIRED H12 ABSORPTION RO935
METFORMIN B NCV INC V OCCURS IF MEGALOBLASTIC ANEMIA P0935
METFORNIN P INSULIN DEC V SLIGHT, ALL HYPERLIPOPROTEINEMIAS, MARKED TYPE IV R01403
METFORMIN S CAROTENE DEC V PROBABLY ASSOCIATED WITH MALABSORPTION P0935
METFORMIN S C02 CONTENT DEC V MAY CAUSE MARKED ACIDOSIS (LACTIC ACIDOSIS) P0299
METFOPMIN S FOLATE INC V HIGH IN PATIENTS IF P12 NALAHSORPTION P0935
NFTFOPMIN S GLUCOSE DEC V MODE OF ACTION UNCERTAIN (OCCURS WITH OVERDOSE) P0341
NETFORMIN S GLUCOSE TOLERANCE INC V M#{216}DEOF ACTION UNCERTAIN R03141
NETFORMIN S IRON DEC V ASSOCIATED WITH IMPAIRED Bl2 ABSORPTION P0935
METFOPMIN S LACTATE INC V POSSIBLY ALWAYS WITH PREDISPOSING CONDITION P0571
METFORMIN S TRIGLYCERIDES DEC V AVERAGE OF 26% IN TYPE IV HYPERLIPOPROTEINEMIA RO1403
METFORMIN S VITAMIN P12 DEC V DUE TO IMPAIRED Bl2 ABSORPTION P0935
NETFORMIN U AICAR INC V NAY CAUSE MEGALOBLASTIC ANEMIA P0935
METFOPMIN U FIGLU INC V MAY CAUSE NEGALOBLASTIC ANEMIA P0935
METFOPMIN U URINALYSIS KETONES INC V ASSOCIATED WITH LACTIC ACIDOSIS P0299
NETFORMIN U VITAMIN P12 DEC V MAY CAUSE MEGALOBLASTIC ANEMIA 90935
METFOPMIN U XYLOSE EXCRETION DEC V PROBABLY DOSE RELATED MALABSORPTION 30935
METHACHOLINE S AMYLASE INC V STIMULATES PANCREATIC SECRETION, CONSTRICTS AMPULLA P03814
METHACHOLINE S BILIHUBIN INC V IMPAIRS EXCRETION THROUGH BILIABY TRACT R0204
METHACHOLINE S BSP RETENTION INC V IMPAIRS EXCRETION BY SPASM OF SPHINCTER OF ODDI 90204
NETHACHOLINE S LIPASE INC V CONSTRICTS SPHtNCTER OF ODDI P02014
METHACHOLINE S SCOT INC V IMPAIRS EXCRETION B! SPASM 0! SPHINCTER OF ODDI P0204
METHACYCLINE S SCOT INC V POSSIBLE HEPATOTOXICITY R0026
METHACYCLINE S SGPT INC V POSSIBLE HEPATOTOXICITY 90026
METHACYCLINE S UREA NITROGEN INC V POSSIBLE NEPHROTOXICITY R0O26
METHADONE B PCO2 INC V MAY CAUSE DIMINSHED PULMONARY VENTILATION HO384
METHADONE S BSP RETENTION INC V HEPATOTOXIC EFFECT OP SPASM OF SPHINCTER OF ODDI P1001
METHAMPHETAMINE P COPTICOSTEROIDS INC V EFFECT MOST MARKED IN A.M. WHEN GIVEN I.V. R014l7
METHAMPHETAMINE P GROWTH HORMONE INC V SIGNIFICANT RISE 90102
METHAMPHETAMINE U 5 OH INDOLEACETIC ACID INC V SINGLE INSTANCE REPORTED P0577
METHANDPIOL S ALKALINE PHOS?HATASE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P0384
METHANDRIOL S BILIPUBIN INC V INTHAHEPATIC CHOLESTATIC JAUNDICE HO3814
NETHANDPIOL S HSP RETENTION INC V INTPAHEPATIC CHOLESTATIC JAUNDICE P0384
METHANDPIOL S SCOT INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P03814
METHANDRIOL S SGPT INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P03814
METHANDRIOL U URINALYSIS BILE INC V INTHAHEPATIC CHOLESTATIC JAUNDICE P0384
NETHANDROSTENOLONE F UROBILINOGEN DEC V LIGHT STOOLS,DUE TO CHOLESTASIS 901477
NETHANDROSTENOLONE 0 METYRAPONE TEST V ANABOLIC EFFECT R0467
METHANDROSTENOLONE P PLASNINOGEN INC V METABOLIC EFFECT P0072

METHANDPOSTENOLONE P PROTHHOMBIN TIME INC V ALSO SEEN WITH OTHER l7-ALKYL SUBSTITUTED STEROIDS P0295
METRANDROSTENOLONE S ALKALINE PHOSPHATASE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P0384
METHANDROSTENOLONE S BETA-GLUCURONIDASE INC V METABOLIC EFFECT R0O72
MFTHANDPOSTENOLONE S BILIRUBIN INC V DUE TO CHOLESTASIS P0477
METHANDROSTENOLONE S BSP RETENTION INC V CHOLESTATIC PHENOMENON P0233
METHANDROSTENOLONE S CALCIUM INC V NAY OCCUR SPONTANEOUSLY, BUT ESP IF BREAST CANCER P01467
METHANDPOSTENOLONE S CHOLESTEROL DEC V REPORTED EFFECT (MAY INCREASE AS ALTERNATIVE) P01467
NETHANDROSTENOLONE S CHOLESTEROL INC V DUE TO CHOLESTASIS P01477
METHANDROSTENOLON! S HAPTOGLOBIN INC V METABOLIC EFFECT P0072
METHAMDPOSTENOLONE S SCOT INC V UP TO 3-6 TIMES NORMAL DUE TO CHOLESTASIS P01477
METHANDROSTENOLONE S SGPT INC V UP TO 3-6 TIMES NORMAL DUE TO CHOLESTASIS P01477
METHANDROSTENOLONE S SIALIC ACID INC V METABOLIC EFFECT P0072
METHANDROSTENOLONE S TRIGLYCERIDES DEC V METABOLIC (ANABOLIC) EFFECT P0901
METHANDROSTENOLONE U URINALYSIS BILE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P03814
METHANDROSTENOLONE U UPOBILINOGEN DEC V DUE TO CHOLESTASIS P01477
METHANOL B METHANOL INC V PRESENCE OF INGESTED ALCOHOL P03814
METHANOL B PH DEC V CAUSES ACIDOSIS P0620
METHANOL C METHANOL INC V HIGHER CONCENTRATION THAN IN BLOOD P0384
METHANOL 0 BREATH ALCOHOL INC V PRESENCE OF INGESTED ALCOHOL P0356
METHANOL S AMYLASE INC V ELEVATION DUE TO PANCREATITIS P0356
METHANOL S BILIRUBIN INC N FALSE VALUE IF IMPURE METHANOL USED (EVELYN-MALLOY) ROl8l
METHANOL S BILIPUBIN INC V MANIFESTATION OF LIVER DAMAGE R0356
METHANOL S CO2 CONTENT DEC V METABOLIC ACIDOSIS DUE TO ORGANIC ACID ACCUMULATION R03814
METHANOL S DIRECT BILIRUBIN INC V MANIFESTATION OF LIVER DAMAGE 90356
METHANOL S FORMIC ACID INC V METABOLITE (WITH FORMALDEHYDE) OF OXIDATION P0384
METHANOL S KETONES INC V MOD EFFECT IN COMPARISON WITH EXTENT OF ACIDOSIS R0384
METHANOL U BOGEN TEST P05 N REACTS AS IF ETHANOL P0368
METHANOL U FORMALDEHYDE INC V METABOLITE OF OXIDATION P0384
METHANOL U PROTEIN INC V NEPHROTOXIC EFFECT WITH POISONING P0384
METHANOL U URINALYSIS ACETONE INC V SLIGHT TO MOD EFFECT IN POISONING P03814
METHANOL U URINALYSIS PROTEIN INC V OCCURS WITH POISONING P03814
METHAPYRILINE B RED CELL COUNT DEC V ANEMIA (AMA-BLOOD DYSCRASIAS) P0658
METHAQUALONE B BED CELL COUNT DEC V ONE POSSIBLE CASE OF APLASTIC ANEMIA REPORTED P0620
METHARBITAL P PPOTHPONBIN TINE DEC V THEORETICAL POSSIBILITY DUE TO ENZYME INDUCTION P01467
METHAZOLAMIDE B PLATELET COUNT DEC V PROBABLE EFFECT AS LIKE ACETAZOLANIDE HO62O
METHAZOLAMIDE B WHIT! CELL COUNT DEC V PROBABLE EFFECT AS LIKE ACETAZOLAMIDE P0620
NETHAZOLAMIDE S POTASSIUM DEC V WITH PROLONGED USE (CARBONIC ANHYDRASE INHIBITION) RO620
METHENAMINE P CATECHOLAMINES INC N INTERFERENCE WITH FLUORESCENCE P0042
METHENAMINE U ESTRIOL DEC N INTERFERES WITH HYDROLYSIS STAGE OF METHODS P03014
METHENANINE U PROTEIN INC V NEPHROTOXIC IN LARGE DOSES P0384
METHEWAMINE U PSP EXCRETION INC N PRODUCES INTERFERING COLOR IN UPINE R0233
METHENAMINE U SUGAR INC N FALSE POSITIVE WITH BENEDICT’S REAGENT P0580
METHENAMINE U URINALYSIS CRYSTALS INC V MANDELATE NAY OCCASIONALLY CAUSE CRYSTALLURIA P0384
NETHENAMINE U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING PRODUCED BY DRUG P0299
METHENAMINE U URINALYSIS PH DEC V NANDELATE IS AN ACIDIFYING AGENT P0384
MFTHENAMINE U URINALYSIS PROTEIN INC V NEPHROTOXIC IN LARGE DOSES 90299
NETHENAMINE U URINALYSIS RBC/HPF INC V MAY CAUSE ACTUAL BLEEDING R0299
METHENAMINE U UROBILINOGEN INC M PRODUCES FORMALDEHYDE WHICH INTERFERES P0081
METHENAMINE U VMA INC M INTERFERES WITH FLUOROMETRIC PROCEDURES RO596
METHENAMINE U 17 OH CORTICOSTEROIDS INC M AFFECTS POPTER-SILBER AND REDDY METHODS P0142
METHENAMINE U 5 OH INDOLEACETIC ACID DEC N SLIGHT FALSE NEC EFFECT WITH NITROSONAPHTHOL P0867
METHICILLIN B EOSINOPHILS INC V HYPERSENSITIVITY REACTION R0068
METHICILLIN B METHEMOGLOBIN INC V ONE DOUBTFUL CASE OF HEMOLYTIC ANEMIA P0026
METHICILLIN B NEUTROPHILS DEC V NEUTROPENIA WITH GRANULOCYTOPENIA MAY OCCUR P0467
METHICILLIN B PLATELET COUNT DEC V MAY RARELY CAUSE BONE NARROW DEPRESSION P0736
METHICILLIN B RED CELL COUNT DEC V MAY RARELY CAUSE BONE MARROW DEPRESSION P0736
METHICILLIN B WHITE CELL COUNT DEC V MAY CAUSE BONE MARROW DEPRESSION P0620
METHICILLIN B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA/LEUKOCYTOSIS RO62O
METHICILLIN S CALCIUM DEC V PEPORTED EFFECT (?NECHANISM) P0620
METHICILLIN S CO2 CONTENT DEC V NEPHROTOXICITY MAY CAUSE AZOTENIA P0620
METHICILLIN S CREATININE INC V NEPHPOTOXIC EFFECT R062O
METHICILLIN S HAPTOGLOBIN DEC V ONE DOUBTFUL CASE OF HENOLYTIC ANEMIA P0026
MET9ICILLIN S NPN INC V NEPRROTOXIC EFFECT P0620
METHICILLIN S PHOSPHATE INC V OCCURS WITH NEPHROTOXICITY P0620
METHICILLIN S POTASSIUM INC V POSSIBLE RESULT OF NEPHPOTOXICITY P0620
NETHICILLIN S UREA NITROGEN INC V NAY CAUSE AZOTENIA WITH NEPHROTOXICITY P0026
METHICILLIN S URIC ACID INC V NEPHROTOXIC EFFECT P0620
METHICILLIN U PROTEIN INC V NF.PHR0TOXICITY NAY OCCUR R0026
.METHICILLIN U URINALYSIS CASTS INC V WEPHPOTOXIC EFFECT (CYLINDRURIA OBSERVED) P0620
METHICILLIN U URINALYSIS HEMOGLOBIN INC V HYPERSENSITIVITY REACTION, NEPHROTOXICITY P0068
NETHICILLIN U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT P0677
METHICILLIN U URINALYSIS RBC/HPF INC V HYP3RSEN5ITIVITY REACTION, NEPHPOTOXICITY P0068
METHICILLIN U URINALYSIS WBC/HPF INC V PYURIA REPORTED AS COMPLICATION P01467
METHIMAZOLE B PLATELET COUNT DEC V THPOMBOCYTOPENIA P0656
METHIMAZOLE B RED CELL COUNT DEC V APLASTIC ANEMIA 90620
NETHIMAZDLE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS P0025
METHIMAZOLE F UROBILINOGEN DEC V CHOLESTATIC EFFECT P0477
METHINAZOLE P PROTHPOMBIN TIME INC V ASSOC WITH FAILURE OF EXCRETION OF BILE SALTS P0656
NETHIMAZOLE S ALKALINE PHOSPHATASE INC V CHOLESTATIC EFFECT P0477
METHIMAZOLE S BILIRUBIN INC V TOXIC EFFECT ASSOC. WITH BONE MARROW DEPRESSION R0086
METHIMAZOLE S BSP RETENTION INC V CROLESTATIC EFFECT H0477
METHIMAZOLE S CEPRALIN FLOCCULATION INC V HEPATOTOXIC EFFECT P0620
METHIMAZOLE S CHOLESTEROL INC V CHOLESTATIC EFFECT P01477
METRIMAZOLE S GLUCOSE INC N AT 1 NMOL/L AFFECTS SMA/60 METHOD P0876
NETHIMAZOLE S I 131 UPTAKE DEC V EFFECT MAY LAST FROM 2 TO 8 DAYS P01408
NET’IINAZOLE S PHI DEC V INHIBITS IODINATION OF TYROSINE IN TBG 90408
METHIMAZOLE S SGOT INC V CHOLESTATIC EFFECT R01477
METRIMAZOL! S SGPT INC V CHOLESTATIC EFFECT R0477
METHINAZOLE S THYMOL TURBIDITY INC V CHOLESTATIC EFFECT P0477
METHIMAZOLE S THYROXINE (T14) DEC V THERAPEUTIC INTENT(5TOPS IODINATION OF TYROSINE) P01408

METHIMAZOLE S T3 UPTAKE DEC V THERAPEUTIC RESULT 90408
METHINAZOLE U URINALYSIS BILE INC V HEPATOTOXIC EFFECT 90620
METHIMAZOLE U UHOBILINOGEN DEC V CHOLESTATIC EFFECT P0477
METHIODOL S PBI INC N BUT DOES NOT AFFECT T14 (EFFECT LASTS 1-2WEEKS) 90839
NETHIONINE B MEGALOBLASTS INC V CAN AGGRAVATE VITAMIN H12 DEFICIENCY 2O79
METHIONINE P INSULIN INC V SLIGHT EFFECT, AIDS METABOLISM OF AMINO ACIDS P0311
METHOCAPBAMOL B WHITE CELL COUNT DEC V MAY CAUSE LEUKOPENIA 20620
METHOCARBAMOL U URINALYSIS COLOR INC N BROWN, GREEN, BLUE OR BLACK ON STANDING 20122
METHOCARBANOL U URINALYSIS HEMOGLOBIN INC V MAY CAUSE INTRAVASCULAR HEMOLYSIS 90384
METHOCARBAMOL U URINALYSIS RBC/HPF INC V MAY CAUSE INTRAVASCULAR HEMOLYSIS RO3814
NETHOCARBANOL U VNA INC N FALSE P05 WITH SCREENING, NO EFFECT QUANT METH. R0299
METHOCARBAMOL U 5 OH INDOLEACETIC ACID INC N METABOLITE ALLEGEDLY REACTS WITH NITROSONAPHTHOL 901458
METHOPHENOBARBITAL B HEMATOCRIT DEC V MAY CAUSE MEGALOBLASTIC ANEMIA 30620
METHOPHENOBARBITAL B HEMOGLOBIN DEC V NAY CAUSE MEGALOBLASTIC ANEMIA 90620
METHOPHENOBARBITAL B MCV INC V NAY CAUSE MEGALOBLASTIC ANEMIA RO620
METHOPHENOBARBITAL B RED CELL COUNT DEC V MEGALOBLASTIC ANEMIA 90520
METHOTREXATE B HEMATOCRIT DEC V NAY MF.GALOBLASTIC ANEMIA (FOLIC ACID ANTAGONIST) P0976
METHOTREXATE B HEMOGLOBIN DEC V MAY NEGALOBLASTIC ANEMIA (FOLIC ACID ANTAGONIST) 90976
METHOTREXATE B MCV INC V OCCURS WITH MECALOBLASTIC ANEMIA 20976
METHOTREXATE B PLATELET COUNT DEC V MAY OCCUR WITH NEGALOBLASTIC ANEMIA 90976
METHOTREXATE B RED CELL COUNT DEC V NAY MEGALOBLASTIC ANEMIA (FOLIC ACID ANTAGONIST) R0976
METHOTHEXATE B RETICULOCYTES DEC V AFFECTS REMATOPOIESIS 903914
METHOTREXATE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS/LYNPHOCYTOPENIA 90556
METHOTREXATE F OCCULT BLOOD P05 V BLOODY DIARRHEA MAY OCCUR 20657
METHOTPEXATE S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT (SEEN IN 5% CASES PSORIASIS) P0698
NETHOTREXATE S BILIRUBIN INC V MAY CAUSE CYTOTOXIC HEPATOCELLULAP DAMAGE 90079
NETHOTREXATE S BSP RETENTION INC V HEPATOTOXICITY, MAY BE POST-NECROTIC CIRRHOSIS 904141
NETHOTREXATE S CEPHALIN FLOCCULATION INC V MAY CAUSE CYTOTOXIC HEPATOCELLULAR DAMAGE P0079
METHOTREXATE S FOLATE DEC V INHIBITS FOLATE REDUCTASE P0791
METHOTREXATE S GUANASE INC V MAY CAUSE CYTOTOXIC HEPATOCELLULAP DAMAGE 90079
METROTPEXATE S lCD INC V MAY CAUSE CYTOTOXIC HEPATOCELLULAH DAMAGE 90079
METHOTPEXATE S LACTIC DEHYDPOGENASE INC V EFFECT IN 140% CASES OF PSORIASIS (REVERSIBLE) P0698
METHOTREXATE S OCT INC V MAY CAUSE CYTOTOXIC HEPATOCELLULAP DAMAGE P0079
METHOTREXATE S PBI Z V REPORTED TO HAVE NO EFFECT E0255
NETHOTREXATE S SGOT INC V HEPATOTOXICITY (DRUG INDUCED CIRRHOSIS) 90620
METHOTREXATE S SGPT INC V MAY CAUSE CYTOTOXIC HEPATOCELLULAP DAMAGE 90079
METHOTREXATE S THYNOL TURBIDITY INC V HEPATOTOXIC EFFECT P0620
METHOTPEXATE S URIC ACID INC V SEEN IN GOUTY PATIENTS - SOME DEC IN LEUKENICS 90619
NETHOTPEXATE U AICAP INC V OCCURS WITH INDUCED FOLIC ACID DEFICIENCY P0976
METHOTREXATE U FIGLU INC V OCCURS WITH INDUCED FOLIC ACID DEFICIENCY 90976
METHOTREXATE U URINALYSIS BILE INC V HEPATOTOXICITY 90520
METHOTREXATE U URINALYSIS CRYSTALS INC N CRYSTALS OF UNKNOWN IDENTITY (PROBABLY DRUG) 90288
METHOTREXATE U URINALYSIS HEMOGLOBIN INC V NAY CAUSE HENATUHIA 91015
NETHOTRINEPRAZINE 0 PHEOCHPOMOCYTOMA TESTS V MAY CAUSE FALSE TEST AS PRODUCES HYPOTENSION 20417
NETHOTRIMEPRAZINE S BILIPUBIN INC V THREE CASES REPORTED 90a17
METHOXSALEN S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT 90620
METHOX5ALEN S BILIPUBIN INC V HEPATOTOXIC EFFECT 90520
METHOXSALEN S BSP RETENTION INC V HEPATOTOXIC EFFECT RO62O
METHOXSALEN S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT P0620
METHOXSALEN S SCOT INC V HEPATOTOXIC EFFECT 90620
NETHOXSALEN S SGPT INC V HEPATOTOXIC EFFECT 90620
METHOXSALEN S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT 90620
NETHOXSALEN U URINALYSIS BILE INC V HFPATOTOXIC EFFECT P0620
METHOXYFLURANE P ERPF DEC V DEC NOTED DUPING NORMAL ANESTHESIA 90657
NETHOXYFLURANE S ALKALINE PHOSPHATASE INC V HEPATIC TOXICITY P0861
METHOXYFLURANE S BILIRUBIN INC V HEPATIC TOXICITY RO861
METHOXYFLUPANE S BSP RETENTION INC V HEPATOTOXICITY 90620
NETHOXYFLURANE S CALCIUM DEC V SLIGHT LOWERING REPORTED IN ONE CASE 90753
METHOXYFLUPANE S CEPHALIN FLOCCULATION INC V HEPATOTOXICITY P0620
NETHOXYFLURANE S CREATININE INC V IMPAIRED RENAL TUBULAR FUNCTION 20631
NETHOXYFLURANE S FLUORIDE INC V METABOLIC DEGRADATION PRODUCT OF ANESTHETIC P0339
METHOXYFLURANE S OSNOLALITY INC V IMPAIRED RENAL TUBULAR FUNCTION RO229
METHOXYFLURANE S OXALATE INC V METABOLIC DEGRADATION PRODUCT OF DRUG P0753
NETHOXYFLURANE S SGOT INC V HEPATIC TOXICITY 90861
METHOXYFLURANE S SGPT INC V HEPATIC TOXICITY 90861
METHOXYFLURANE S SODIUM INC V IMPAIRED RENAL TUBULAR FUNCTION P0229
METHOXYFLURANE S THYNOL TURBIDITY INC V HEPATOTOXICITY RO62O
METHOXYFLURANE S UREA NITROGEN INC V IMPAIRED RENAL TUBULAR FUNCTION P0229
NETHOXYFLURANE S URIC ACID INC V DEC URATE CLEARANCE: CONTRACTION OF ECF VOLUME P0631
METHOXYFLURANE U GFP DEC V DEC NOTED DUPING NORMAL ANESTHESIA RO657
METHOXYFLURANE U OSMOLALITY DEC V NEPHHOTOXIC EFFECT OF DRUG (DOSE DEPENDENT) 90661
METHOXYFLURANE U OXALATE INC V METABOLIC DEGRADATION PRODUCT OF DRUG RO753
METHOXYFLUPANE U SPECIFIC GRAVITY DEC V IMPAIRED RENAL TUBULAR FUNCTION (DOSE DEPENDENT) P0229
METHOXYFLURANE U URINALYSIS BILE INC V HEPATOTOXIC EFFECT RO620
METHOXYFLUPANE U URINALYSIS S.C. DEC V IMPAIRED RENAL TUBULAR FUNCTION P0229
METHOXYFLURANE U VOLUME INC V IMPAIRED DISTAL RENAL TUBULAR FUNCTION 90229
METHSUXIMIDE B RED CELL COUNT DEC V RARE APLASTIC ANEMIA REPORTED P0620
METHSUXIMIDE B WHITE CELL COUNT DEC V RARE APLASTIC ANEMIA OP REVERSIBLE LEUKOPENIA 90620
NETHSUXIMIDE S BILIRUBIN INC V HEPATIC DAMAGE REPORTED 90026
METHSUXIMIDE S CEPHALIN FLOCCULATION INC V HEPATIC DAMAGE REPORTED P0620
METHSUXIMIDE S UREA NITROGEN INC V RENAL DAMAGE REPORTED 90026
METHSUXIMIDE U URINALYSIS PROTEIN INC V RENAL DAMAGE REPORTED P0355
NETHYCLOTHIAZIDE B PLATELET COUNT DEC V THROMBOCYTOPENIA WITH PURPUPA MAY OCCUR RO67
METHYCLOTHIAZIDE B RED CELL COUNT DEC V APLASTIC ANEMIA NAY OCCUR WITH THIAZDRS P0467
METHYCLOTHIAZIDE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS OH APLASTIC ANEMIA MAY OCCUR 90467
METHYCLOTHIAZIDE P ADH INC V SECRETED IN RESPONSE TO HYPONATREMIA 30325
METHYCLOTHIAZIDE P RENIN INC V STIMULATES PLASMA PENIN ACTIVITY R0386
METHYCLOTHIAZIDE S ANYLASE INC V REPORTED TOXIC EFFECT OF THIAZIDES 90467
METHYCLOTHIAZIDE S BILIPUBIN INC V REPORTED TOXIC EFFECT OF TRIAZIDES P0467
METHYCLOTHIAZIDE S CALCIUM INC V ?RELATED TO DECREASED EXCRETION 90467

NETHYCLOTHIAZIDE S CHLORIDE DEC V DIURETIC ACTION (HYPOCHLOREMIC ALKALOSIS) HO 386
NETHYCLOTHIAZIDE S C02 CONTENT INC V DIURETIC ACTION (HYPOCELOPEMIC ALKALOSIS) P0 3 86
NETHYCLOTHI AZIDE S GLUCOSE INC V DIABETOGENIC ACTION OF THIAZIDES R01467
NETHYCLOTHIAZIDE S OSMOLALITY DEC V WITH ADH SECRETION DUE TO HYPONATPEMIA 90325
NETHYCLOTHIAZIDE S POTASSIUM DEC V DIURETIC ACTION P03 86
METHYCLOTHIAZIDE S SODIUM DEC V DIUPETIC ACTION P0386
NETHYCLOTHIAZIDE S UREA NITROGEN INC V SLIGHT CHANGE ONLY P03 86
METHYCLOTHIAZIDE S URIC ACID INC V REDUCES CLEARANCE P0386
NETHYCLOTHI AZIDE U CALCIUM DEC V IMPAIRS EXCRETION HO 1467
NETHYCLOT HIAZ IDE U URINALYSIS GLUCOSE INC V NAY OCCUR AS RESULT OF HYPERGLYCEMIA P0467
METHYLBROMIDE S UREA NITROGEN INC V LATE EFFECT WITH TUBULAR NECROSIS OF POISONING P036 8
MET HYLBPOMIDE U PROTEIN INC V DUE TO TUBULAR NECROSIS HO 368
N!THYLHROMI DE U URINALYSIS CASTS INC V DUE TO TUBULAR NECROSIS P03 68
METHYLBPD MIDE U URINALYSIS PROTEIN INC V DUE TO TUBULAR NECROSIS P0368
METHYLBROMI DE U URINALYSIS PBC/HPF INC V DUE TO TUBULAR NECROSIS RO36 8
METHYLCHOLINE S AMYLASE INC V PANCREATIC STIMULATION, CONSTRICTION OF AMPULLA R0355
METHY LDOPA B EOSINOPHILS INC V ALLERGIC RESPONSE P0620
MT TH YLDO P A B HEMATOCRIT DEC V AUTOINMUNE 8EMOLYTIC ANEMIA HO 189
NET HY L DO PA H HEMOGLOBIN DEC V AUTOIMMUNE HEMOLYTIC ANEMIA P0189
METHYLDOPA B LE CELL PREP P05 V AUTOIMNUNE PHENOMENON HO 864
MET HYLDOPA B PLATELET COUNT DEC V VERY RARE OCCURS WITHIN DAYS OP MONTHS P0532
METHYL DO PA B RED CELL COUNT DEC V AUTOIMMUNE HEMOLYTIC ANEMIA/APLASTIC ANEMIA P0189
MET HYLD OPA B WHITE CELL COUNT DEC V VERY PARE, MAY CAUSE GRANULOCYTOPENIA HO 532
METHYL DO PA B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA P062 0
MET HYLDOPA F COPPOPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA ATTACK HO 37 1
METHYLDOPA 0 TYRAMINE TEST INC V ENHANCED RESPONSIVENESS REPORTED R0417
MET HYLDO PA P CATECHOLAMINES INC N REACTS LIKE CATECHOLANINES, MAY PERSIST FOR DAYS HO 384
METHYL DO PA P CATECHOLAMINES INC N INTERFERENCE WITH FLUORONETRIC METHODS H0821
METHYLDOPA P ERPE INC V SLIGHT INC OR NORMAL IN NOPMO-HYPEH-TENSIVES HO 384
METHYL DOPA P PPOTHPOMBIN TIME INC V ENHANCES ANTICOAGULANT ACTIVITY P100 1
METHYLDOP A S ALKALINE PHOSPHATASE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE 90300
METHYLDOPA S ANTINUCLEAR ANTIBODIES P05 V MOPE COMMON IN FEMALES THAN MALES P0472
MFTHYLDOPA S BILIRUBIN INC N AT 1 MMOL/L AFFECTS SMA 12/60 METHOD P0876
MET HYLDOPA S BILIRUBIN INC N THEORETICALLY REACTS WITH DIAZO REAGENT P08 141
MET HY L DO PA S BILIPUBIN INC V MILD HEPATOCELLULAP JAUNDICE IN ABOUT 1% CASES P0300
METH YL DORA S BILIRUBIN INC V INTRAHEPATIC CHOLESTATIC JAUNDICE REPORTED P02 04
NETHYLDOPA S BSP RETENTION INC V RESULT OF HEPATOCELLULAR DAMAGE (CHOLESTASIS ALSO) P1001
MET!IYLDOPA S CEPHALIN FLOCCULATION INC V RESULT OF HEPATOCELLULAR DAMAGE P1001
NETHYLDOPA S CHLORIDE INC V NAY CAUSE SALT RETENTION AND EDEMA HO 384
MET FlY L DO PA S CREATININE INC M READILY OXIDIZED AND AFFECTS ALK PICPATE METHOD P0620
METHYLDOP A S DIRECT BILIRUBIN INC V MILD HEPATOCELLULAR JAUNDICE MAY OCCUR H0355
MET HYLDOPA S DIRECT COOMBS TEST P05 V AUTOIMMUNE PHENONENON(OCCURS WITH WKS OP TREATMENT) P014 18
METHYL DOPA S GLUCOSE INC N AT 1 MMOL/L AFFECTS SMA 12/60 METHOD H0876
METHYLDOPA S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P0 620
N ETH Y L DO PA S INDIRECT COOMBS TEST P05 V AUTOIMMUNE PHENOMENOM(OCCUPS WITH WKS OF TREATMENT) P014 18
MET HYLDOPA S RHEUMATOID FACTOR P05 V REPORTED EFFECT P0 3 814
METHYLDOPA S SCOT INC M AT 1 MMOL/L AFFECTS SMA 12/60 METHOD P0876
S SCOT INC V RESULT OF HEPATOCRLLULAR DANAGE OR CHOLESTASIS P1001
METHYLDOPA S SCPT INC V RESULT OF HEPATOCELLULAR DAMAGE OR CHOLESTASIS P1001
METHYLDOPA S SODIUM INC V MAY CAUSE SALT RETENTION AND EDEMA P0620
METHYLDOPA S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT HO 189
METHYLDOPA S UREA NITROGEN INC V ?DUE TO DECREASED RENAL BLOOD FLOW P1001
MET HYLDOPA S URIC ACID INC N INTERFERES WITH PHOSPHOTUNGSTATE PROCEDURE P04 17
NTHYLDOPA U ANINOLEVULINIC ACID INC V MAY PRECIPITATE ACUTE PORPHYRIA ATTACK HO 37 1
MET HYLDOPA U BILIRUBIN INC V OCCURS AS RESULT OF HEPATOCELLULAR DAMAGE P 0946
METHYLDOPA U CATECHOLAMINES DEC V DEPLETION OF TISSUE STORES P05 96
MET HYLDOPA U COPROPOPPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA ATTACK P0371
METHYL DO PA U CREATININE INC N ACTS AS REDUCING AGENT WITH ALKALINE PICPATE P02 33
N ET HYLD OP A U GFR INC V SLIGHT INC OR NORMAL IN NOHMO-, HYPER-TENSIVES HO 384
NETHYLDOPA U METANEPHPINES TOTAL INC N QUESTIONABLE INTERFERENCE FLUOPOMETRIC METHODS P1 001
MET HYLDOPA U PORPHOBILINOGEN INC V MAY PRECIPITATE ACUTE PORPHYRIA ATTACK P0371
METHYL DOPA U SUGAR INC N FALSE P05. WITH CLINITEST, NO EFFECT GLU OX METHOD P03 17
METHYLDOPA U URIC ACID INC N INTERFERES WITH PHOSPHOTUNGSTATE PROCEDURE 30355
NETHYLDOPA U URINALYSIS PILE INC V OCCURS AS RESULT OF HEPATOCELLULAR DAMAGE P 09 46
METHYLDOPA U URINALYSIS COLOR INC N RED, PINK OR BROWN DARKENS ON STANDING P0 355
METHYLD OPA U URINALYSIS GLUCOSE Z N NO EFFECT ON GLUCOSE OXIDASE METHODS P03 17
METHYLDOP A U UROBILINOGEN INC V AUTOIMMUNE HEMOLYTIC ANEMIA HO 189
METHYLDOPA U VMA DEC V DEPLETION OF TISSUE STORES P0276
NET BY L DO PA U VMA INC N INTERFERENCE BY 5HIAA WITH NON SPEC, DIAZO REACTION HO 839
NETHYLDOPA U 5 OH INDOLEACETIC ACID DEC V INHIBITION OF AROMATIC AMINO ACID DECARBOXYLATION P0 257
NETHYLENE BLUE B HEINZ-BODY FORMATION P05 V EARLY STAGE OF HENOLYTIC ANEMIA 901 014
METHYLEN! BLUE B HEMATOCRIT DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
METHYLENE BLUE B HEMOGLOBIN DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
METHYLENE BLUE B NETHEMOGLOBIN INC V NAY CAUSE HEMOLYSIS (ALSO USED AS TREATMENT) HO 128
METHYLENE BLUE B BED CELL COUNT DEC V NAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
MFTHYLENE BLUE BILIPUBIN INC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
METHYLENE BLUE S HAPTOCLOBIN DEC V MAY CAUSE HEMOLYSIS P0620
METHYLENE BLUE U DIAGNEX BLUE EXCRETION INC N DETECTION OF METHYLENE BLUE P 1001
METHYLENE BLUE U URINALYSIS COLOR INC M BLUE COLOR HO 383
MEIHYLPHENIDATE P PROTHROMBIN TINE INC V INHIBITS METABOLISM OF COUMARINS AND PHYTONADIONE P03 58
METHYLPRDMAZINE B WHITE CELL COUNT DEC V LEUKOPENIA (AMA-BLOOD DYSCRASIAS) P0658
NETHYLTESIOSTERONE B FACTOR V DEC V SUPPRESSES ACTIVITY P0657
NETHYLTESTOSTFP.ONE B FACTOR VII DEC V SUPPRESSES ACTIVITY P06S7
MT TBY L YES TO ST EPONE B FACTOR X DEC V SUPPRESSES ACTIVITY P06 57
ME TB YLTES I OSTE HO NE UROBILINOCEN INC V PALE STOOLS, NAY CAUSE CHOLESTASIS HO 477
METHYL TESTOSTEPONE P PLASMINOGEN INC V METABOLIC EFFECT P0072
ME THYL TES lOST FRO NE p PROTHROMBIN TIME INC V ASSOC WITH FAILURE OF EXCRETION 0? BILE SALTS HO 477
METHYLTESTOSTE2ONE S ALKALINE PHOSPHATASE INC V CHOLESTATIC EFFECT P014 31
NE TB YL TES TOST 990 NE S BETA-GLUCURONIDASE INC P METABOLIC EFFECT P00 72
N ETHYLTESTOSTERONE S BILIRUBIN INC V CHOLESTATIC EFFECT P 0054

METHYL TESTOSTERONE S BSP RETENTION INC V TRANSPORT AND CONJUGATION OF PS? IMPAIRED 900514
ME TB YL YES TOST RHO NE S CALCIUM INC V MAY OCCUR ES? IN WOMEN ON THERAPY FOP BREAST CANCER P0 11 67
N ETH YL TES TO STE HONE S CEPHALIN FLOCCULATION INC V CHOLESTATIC EFFECT (MAY NOT BE AFFECTED) 90477
METHYLTESTOSTEPONE S CHOLESTEROL INC V MAY CAUSE HYPERSENSITIVE CHOLESTASIS P01405
N ET HY LT ES TOSTE HO NE S HAPTOGLOBIN INC V METABOLIC EFFECT R0072
ME THYL TES TO ST ERO NE S PBI DEC V LOWERS CONCENTRATION OF CIRCULATING TBG 90004
METHYLTESTOSTERO NE S SGOT INC V CHOLESTATIC EFFECT (MODERATE ELEVATION) 90377
ME THY L TES TO ST ERO N E S SGPT INC V CHOLESTATIC EFFECT (MODERATE ELEVATION) 90620
NET BY LTE S TOSTERO NE S TBG DEC V DIRECT EFFECT OF DRUG 20003
ME TB YL YE 510 ST ERONE S THYMOL TURBIDITY INC V CHOLESTATIC EFFECT (MAY NOT BE AFFECTED) 901477
MET HYLTE S TO STE 20 NE S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS RO92
METHYL TESTOSTERONE U CREATINE INC V METABOLIC EFFECT ? MECHANISM 90384
METHYLTES TOSTEPONE U URINALYSIS BILE INC V CHOLESTATIC EFFECT 90477
ME THY L TES TO ST ERO NE U UROBILINOGEN DEC V CHOLESTATIC EFFECT 20377
METHYLTHIOURACIL B LE CELL PREP 905 V MAY PRODUCE LE-LIKE SYNDROME 9OR07
NETHYLTHIOURACIL B WHITE CELL COUNT DEC V OCCASIONAL LEUKOPENIA OP AGPANULOCYTOSIS 90620
METHYLTHIOUPACIL P PROTHPOMBIN TINE INC V ALSO EXAGGERATED RESPONSE TO ANTICOAGULANTS HO 5145
METHYLTHIOURACIL S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT 90620
METHYLTHIOURACIL S BILIRUBIN INC V HEPATOTOXIC EFFECT 90620
METHYLTHI OUPACIL S BSP RETENTION INC V HEPATOTOXIC EFFECT 90620
MFTHYLTHIOUHACIL S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT 90620
METHYLTHI OURACIL S I 131 UPTAKE Z V NO EFFECT ON UPTAKE BY THYROID 20596
METHYLTRIOUR ACIL S PHI DEC V INHIBITS IODINATION OF TYROSINE IN TBG R000U
NETHYLTHIOU RACIL S SGOT INC V HEPATOTOXIC EFFECT P0620
METHYLTHIOUPACIL S SGPT INC V HEPATOTOXIC EFFECT 90620
METHYLTHIOU RACIL S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT P06 20
METHYLTHIOURACIL S THYROXINE (T4) DEC V INHIBITS SYSNTHESIS, STOPS IODINATION OF TYROSINE 20026
METHYLTHIOURACIL U URINALYSIS BILE INC V HEPATOTOXIC EFFECT 90620
ME TB YL TR Y PTO PH AN 1 TRYPTOPHAN INC N MEASURED AS SAME IN SPIES/CHAMBERS MITHOD 90399
MET HYPHYLON B WHITE CELL COUNT DEC V DUE TO TOXIC ACTION OF METABOLITE P06 20
METHY PRYLON U AMINOLEVULINIC ACID INC V ALA-SYNTHETASE STIMULATED IN ANIMALS 903814
ME T HYP P Y LO N U POPPHYRINS INC V MAY INDUCE PORPHYRIA IN ANIMALS, ? IN HUMANS 903814
METHYPRYLON U URINALYSIS SUGAR INC N EXCRETED AS GLUCURONIDE, ACTS AS REDUCING SUBST H 03 84
METHYPP YLON U 17 KETOGENIC STEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION P0907
ME TB Y P PYL ON U 17 KETOSTEROIDS INC N REPORTED EFFECT ON HOLTORFF-KOCH MOD OF ZIMMERMAN 90133
METHYPHYLON U 17 OH CORTICOSTEHOIDS INC N REPORTED EFFECT ON GLENN-NELSON PROCEDURE 90133
METHYSERGIDE B EOSINOPHILS DEC V STARTS TO OCCUR WITHIN ONE HOUP(UP TO 100% DEC) P06 57
METHYSERGIDE B EOSINOPHILS INC V TRANSIENT EFFECT UP TO 36 HOURS AFTER I.M. INJECT HO 3 64
NETHYSERGIDE B LYMPHOCYTES DEC V AVERAGE DEC OF 29% NOTED 90657
METHY SERGI DR B NEUTROPHILS INC V AVERAGE INC OF 23% NOTED p0657
METHY SERGI DE B WHITE CELL COUNT DEC V NEUTROPENIA REPORTED RO62O
METHYSERGIDE B WHITE CELL COUNT INC V DUE TO NEUTROPHILIA 90620
METHY SERGI DE 0 GASTRIC JUICE HCL INC V AFFECT BASAL JUICE AND AFTER HISTAMINE 90596
NETHYSEP GIDE P 5 OH TRYPTAMINE DEC V NOTED IN MIGRAINE SUBJECTS R0238
METHYS ERGIDE S UREA NITROGEN INC V POSSIBLE DEC IN ALREADY IMPAIRED PENAL FUNCTION 90029
NE TOL A ZONE S CHLORIDE DEC V DIURETIC ACTION OF DRUG ACTING ON DISTAL TUBULES RO739
METOLAZONE S CO2 CONTENT INC V DIURETIC ACTION OF DRUG ACTING ON DISTAL TUBULES 90739
METOLAZONE S GLUCOSE INC V DIABETIC-LIKE ACTION OF DIURETICS 20739
METOLAZ ONE S POTASSIUM DEC V POTASSSIUM LOSS IN URINE 90401
MET OL AZ ONE S SODIUM DEC V DIURETIC ACTION OF DRUG ACTING ON DISTAL TUBULES P07 39
METOLA ZONE S UREA NITROGEN INC V DIURETIC ACTION OF DRUG ACTING ON DISTAL TUBULES P07 39
METOLA ZONE S URIC ACID INC V DIURETIC ACTION OF DRUG ACTING ON DISTAL TUBULES 90739
MET OL A ZO NE U CALCIUM INC V DIURETIC ACTION 909014
METOLAZ ONE U CHLORIDE INC V DIURETIC ACTION OF DRUG P014 01
METOLA ZONE U FREE WATER CLEARANCE DEC V DIURETIC ACTION OF DRUG HO 9014
METOLAZ ONE U GFP DEC V DIURETIC ACTION 909014
NETOLAZONE U MAGNESIUM INC V DIURETIC ACTION RO9OL&
NET OLA ZONE U OSNOLALITY INC V DIURETIC ACTION P0904
METOLA ZONE U OSMOLAR CLEARANCE INC V DIURETIC ACTION OF DRUG P0904
METOLA ZONE U PHOSPHATE INC V DIURETIC ACTION RO9 014
NE TOL A ZO NE U POTASSIUM INC V DIURETIC ACTION P09 014
MET OLAZO NE U SODIUM INC V DIURETIC ACTION OF DRUG P040 1
ME’POLAZONE U VOLUME INC V DIURETIC ACTION P01401
MET RE CA L S PBI INC V PROBABLY DUE TO IODOCASEIN CONTAMINANT (30 DAYS) 20899
METRI FONATE S CHOLINESTERASE DEC V POWERFUL INHIBITOR OF ENZYME 90657
METRIFONATE S SGPT Z V NO EFFECT REPORTED ON HEPATIC FUNCTION 90657
NETRI FONA TE U UREA CLEARANCE Z V NO EFFECT REPORTED ON RENAL FUNCTION P0657
NETRIZOATE S GGTP INC V EFFECT OBSERVED IN SUBJECTS WITH LIVER TUMORS P00 19
METRONI DAZOLE B NEUTROPHILS DEC V TRANSIENT NEUTROPENIA NAY OCCUR 90657
METRONIDAZOLE B WHITE CELL COUNT DEC V LEUKOPENIA AND REDUCTION OF POLYMORPHS 90620
METRONIDAZOLE U URINALYSIS COLOR INC N BROWN COLOP PROBABLY DUE TO METABOLITE P0 355
METPONIDAZOLE U 17 KETOSTEPOIDS DEC V IF PREVIOUSLY ELEVATED, ? DEPRESSES ADRENAL CORTEX P03 83
NETYPAPON E P ANDROSTENEDIONE INC V INC IN 3-8 HOURS IN MEN, MARKED INC IN WOMEN Pa 596
METYR APONE P COPTICOTROPIN INC V RESPONSE TO STRESS P0563
METYRA PONE P TESTOSTERONE DEC V FALL IN 2 HOURS IN MEN, MINOR INC IN WOMEN 90696
METYRAPONE P 17 OH CORTICOSTEHOIDS INC V INDIRECTLY STIMULATES ACTH PRODUCTION P0593
NET YRA P ONE U PORPHYPINS INC V REPORTED TO PRECIPITATE ATTACK OF ACUTE PORPHYRIA P0596
NETYRA PONE U 17 KETOGENIC STEROIDS DEC N INTERFERES WITH ZIMMERMAN REACTION HO 907
METYRA PONE U 17 KETOGENIC STEROIDS INC V NORMAL RESPONSE TO INJECTION IS DOUBLING O OUTPUT PC 467
METYRA PONE U 17 KETOSTEROIDS DEC N INTERFERES WITH ZIMMERMAN REACTION 90907
MET YR A P 0 NE U 17 OH CORTICOSTEROIDS INC V NORMAL RESPONSE TO INJECTION IS 2-14 TIMES INCREASE R0593
MINERAL OIL P PROTHHONBIN TIME INC V INHIBITS ABSOPPTION OF VITAMIN K P0620
NINEPAL OIL S CAROTENE DEC V REDUCED ABSORPTION (MAY BE 50% NORMAL) P0 3814
MINOXIDIL S DIRECT COONBS TEST P05 V OCCURRED WITHOUT HEMOLYSIS IN ONE PATIENT P05 87
NITHR AMYCIN B BLEEDING TIME INC V REVERSIBLE EFFECT R0O26
MITHRA MYCIN B CLOT RETRACTION DEC V REVERSIBLE POOR RETRACTION 20026
MITHRAMYCIN B CLOTTING TIME INC V REVERSIBLE EFFECT 20026
MITHPA NYCIN B HEMOGLOBIN DEC V REVERSIBLE EFFECT 90025
NITHR AMYCIN B PLATELET COUNT DEC V THRONBOCYTOPENIA P0026
NITHRAMYCIN B WHITE CELL COUNT DEC V REVERSIBLE EFFECT P0026

NITHPA NYCIN P PROTHPONBIN TIME INC V REVERSIBLE DEC PPOTHROMBIN LEVEL P0026
MITHR AMYCIN S CALCIUM DEC V INHIBITION OF BONE RESORPTION OF CALCIUM P0879
NITBRA NYC IN S CPEATININE INC V NEPHROTOXIC EFFECT R0026
NITHR AMYCIN S LACTIC DEHYDROGENASE INC V HEPATOCELLULAR DAMAGE OBSERVED P0026
NITHRA NYC IN S PHOSPHATE DEC V INHIBITION OF BONE RESORPTION OF CALCIUM P087 9
MITHRAMYCIN S POTASSIUM DEC V DEPRESSION OF LEVEL REPORTED R0026
NITHPA MLCIN S SCOT INC V HEPATOCELLULAR DAMAGE OBSERVED P002 6
MITHPA MYCIN S SGPT INC V HEPATOCELLULAR DAMAGE OBSERVED R0026
NITHRA NYC IN S UREA NITROGEN INC V NEP8ROTOXIC EFFECT R0026
MITHPA MYCIN U CALCIUM INC V INHIBITION OF BONE RESORPTION OF CALCIUM P0879
MITHPA NYC IN U HYDROXYPROLINE DEC V INHIBITION OF BONE RESORPTION OF CALCIUM HO 879
NITHRA MYCIN U PROTEIN INC V NEPHROTOXIC EFFECT P0026
MITHP ANYCIN U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT P0026
MITOMYCIN C B PLATELET COUNT DEC V PA NCYTOPENIA P05 89
NITONYCIN C B RED CELL COUNT DEC V PANCYTOPEN IA HO 589
MITOMYCIN C B WHITE CELL COUNT DEC V PA NCYTOPENIA P05 89
MITONYCIN C S CREATININE INC V NEPHROTOXIC EFFECT P0589
MITOMYCIN C S UREA NITROGEN INC V NEPHPOTOXIC EFFECT P0589
MITOMYCIN C S URIC ACID INC V DUE TO NEPHROTOXICITY RO589
MITOMYCIN C U CREATININE CLEARANCE DEC V DUE TO NEPHROTOXICITY HO 589
MITOMYCIN C U PROTEIN INC V NEPPROTOXIC EFFECT P05 89
MITOMYCIN C U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT P0589
MITOTANE S ALKALINE PHOSPHATASE INC V POSSIBLE REPATOTOXIC EFFECT (REPORTED IN DOGS,RATS) R0467
MITOTANE S PHI DEC V RAPE REPORTED SIDE EFFECT P014 67
MITOTANE U URINALYSIS HEMOGLOBIN INC V MAY OCCASIONALLY PRODUCE HENATURIA HO 467
MITOTANE U URINALYSIS PROTEIN INC V MAY RARELY PRODUCE HENATUPIA, RENAL DAMAGE P0467
MITOTANE U URINALYSIS RBC/HPF INC V MAY OCCASIONALLY PRODUCE HEMATUHIA R0467
NITOTANE U 17 OH CORTICOSTEROIDS DEC V STIMULATES EXTRA-ADRENAL HYDROXYATION OF CORTISOL P02 17
NITOTANE U 6 HYDROXYCORTISOL INC V ALTERED CORTISOL METABOLISM INDUCED BY DRUG P067 5
MK-270 S GLUCOSE DEC V SLIGHT NON-SIGNIFICANT DECREASE IN FASTING VALUE P0809
P1K- 27 0 S GLUCOSE TOLERANCE INC V PRODUCES FLATTENING OF CURVE HO 809
NONO?LUOROSULPHON S PHI DEC V INTERFERES WITH TRAPPING OF IODIDE BY THYROID P00014
MORPHA ZINA MIDE 0 GASTRIC JUICE HCL INC V HYPERACIDITY REPORTED P0657
NORPHAZINAMIDE S BILIRUBIN INC V JAUNDICE REPORTED AS SIDE EFFECT RO657
NORPHAZINAMIDE S URIC ACID INC V DECREASED RENAL CLEARANCE HO 657
MORPHINE H PCO2 INC V DIMINISHES VENTILATION, CAUSES HYPERCAPNIA HO 026
MORPHINE 0 BMR DEC V METABOLIC EFFECT OF DRUG R0596
NOHPHI NE 0 GASTRIC JUICE HCL DEC V SLIGHT DEC IN SECRETION OF ACID P0384
MORPHINE P AMMONIA INC V IMPAIRS ABILITY OF LIVER TO METABOLIZE NH3 IN DOGS P09 31
NORPHI NE P EPINEPHRINE INC V MECHANISM OBSCURE ALSO INVOLVED IN GLUCOSE RELEASE R0496
MORPHINE P NOREPINEPHRINE DEC V MECHANISM OBSCURE HO 1496
MORPHINE P 17 KETOSTEHOIDS DEC V INHIBITS ACTH AND PIT GONADOTROPIN RELEASE R0384
MORPHINE P 17 OH CORTICOSTEROIDS DEC V INHIBITS ACTH AND PIT GONADOTROPIN RELEASE P0 384
MORPHINE S ALKALINE PHOSPHATASE INC V ASSOCIATED WITH ABNORMAL LIVER FUNCTION P0620
MOHPHI NE S AMYLASE INC V CAUSES SPASM OF SPHINCTER OF ODDI FOR 48 HOURS H 0907
MORPHINE S BARBITURATE Z N NO INTERFERENCE WITH UV ABSORPTION METHODS P0779
MOHPHI NE S BILIRUBIN INC V ASSOCIATED WITH ABNORMAL LIVER FUNCTION P062 0
MORPHINE S BSP RETENTION INC V ABNORMAL LIVER FUNCTION TESTS REPORTED P1001
MORPHINE S CPK INC V RESPONSE TO FREQUENT I.N. INJECTIONS R0080
NOPPRI NE S CPK Z V NO CHANGE, ALTHOUGH OTHER ENZYMES INC P06 57
NORPHI NE S GLUCOSE INC V MINOR, CLINICALLY INSIGNIFICANT INCREASE H 038 4
MORPHINE S HBD INC V PPOB DUE TO SPASM OF SPHINCTER OF ODDI P06 57
MORPHINE S LACTIC DEHYDP.OGENASE INC V NAY CAUSE RISE IN INTRABILIARY PRESSURE R0907
MORPHINE S LDH ISOENZNYES INC V HEPATIC FRACTION INC ? DUE TO SPASM OF SPHINCTER P06 57
MORPHINE S LEUCINE AMINOPEPTIDASE INC V POSSIBLY DUE TO SPASM OF SPHINCTER OF ODDI P0657
MORPHINE S LIPASE INC V CAUSES SPASM OF SPHINCTER OF ODDI P0907
MORPHINE S SCOT INC V MAY CAUSE RISE IN INTRABILIAPY PRESSURE P0907
MORPHI NE S SGPT INC V MAY CAUSE RISE IN INTRABILIARY PRESSURE P09 07
MORPHINE T PROTEIN INC N REACTS WITH FOLIN-CIOCALTEU OF LOWRY METHOD P02 13
NORPHI NE U SUGAR INC N INTERFERES WITH COPPER REDUCTION METHOD P0654
MORPHINE U VMA DEC V CLINICALLY SIGNIFICANT BUT SMALL EFFECT HO 632
MORPHINE U VOLUME DEC V NAY STIMULATE RELEASE OF ADH P0026
MORPHINE U 17 KETOSTEPOIDS DEC V INHIBITS ACTH AND PIT GONADOTROPIN RELEASE HO 3 814
MORPHI NE U 17 OH CORTICOSTEPOIDS DEC V INHIBITS ACTH AND PIT GONADOTROPIN RELEASE P0384
MOUTH WASHES S PHI INC N SOME MAY CONTAIN IODINE HO 355
MUSCULAR EXERCISE B HEMOGLOBIN INC V MILD EXERCISE CAUSES TRANSIENT DEC IN BLOOD VOLUME P01436
MUSCULAR EXERCISE B PLATELET COUNT INC V EFFECT OF SUDDEN EXERCISE HO 291
MUSCULAR EXERCISE B WHITE CELL COUNT INC V MAINLY DUE TO NEUTROPHILIA AFTER EXERCISE P 029 1
MUSCULAR EXERCISE P AMMONIA INC V TISSUE CATABOLISM HO 3 55
MUSCULAR EXERCISE P FIBRINOLYSIN INC V ACTIVITY INC BY EXERCISE HO 29 1
MUSCULAR EXERCISE P HEMOGLOBIN INC V LIGHT ACTIVITY CAUSES INC X 3-5, HEAVY INC X 10-30 P0779
MUSCULAR EXERCISE P HEMOGLOBIN Z V NO EFFECT NORMAL ACTIVITY HO 1485
MUSCULAR EXERCISE S ALDOLASE INC V EFFECT OF PHYSICAL TRAINING P0779
MUSCULAR EXERCISE S ALDOLASE Z V PHYSICAL ACTIVITY HAS JO EFFECT P0779
MUSCULAR EXERCISE S CHOLESTEROL INC V OCCASIONAL RESPONSE TO EXERCISE HO 184
MUSCULAR EXERCISE S CPK INC V EFFECT OF PHYSICAL TRAINING, INC WITH EXEPCISE HO 779
MUSCULAR EXERCISE S GLUCOSE INC V RISE DUE TO ADRENAL ACTIVITY P029 1
MUSCULAR EXERCISE S GLUTAMATE DEHYDROGENASE Z N PHYSICAL ACTIVITY HAS NO EFFECT P0779
MUSCULAR EXERCISE S IRON DEC V RESPONSE TO STRESS OF EXERCISE P0184
MUSCULAR EXERCISE S LACTATE INC V CONSIDERABLE EFFECT OF EXERCISE P0998
MUSCULAR EXERCISE S LACTIC DEHYDROCENASE INC V MARKED INCREASE WITH EXERCISE RO779
MUSCULAR EXERCISE S 991 Z V NO EFFECT OBSERVED HO 255
MUSCULAR EXERCISE S PYRUVATE DEC V SLIGHT FALL WITHIN 1 HOUR AND THEN STEEP DROP P0291
MUSCULAR EXERCISE S SCOT INC V MARKED AFTER EXERCISE (LESS IN TRAINED INDIVIDUALS) P0779
MUSCULAR EXERCISE S SGPT DEC V EFFECT OF PHYSICAL TRAINING P0779
MUSCULAR EXERCISE U CATECHOLAMINES INC V FOLLOWING VIGOROUS EXCERCISE (NAY BE INC 7 FOLD) P0112
MUSCULAR EXERCISE U CREATININE CLEARANCE DEC V DECREASE WITH HEAVY EXERCISE HO 505
MUSCULAR EXERCISE U CREATININE CLEARANCE INC V INCREASE WITH MILD EXERCISE RO5O5
MUSCULAR EXERCISE U OSMOLALITY DEC V EFFECT MOST MARKED WITH LIGHT EXERCISE P0505
MUSCULAR EXERCISE U PLASMIN ACTIVITY INC V ASSOC WITH PROTEINURIA P0505

MUSCULAR EXERCISE U PROTEIN INC V MOPE COMMON WITH HEAVY EXERCISE THAN MILD P 05 05
MUSCULAR EXERCISE U SPECIFIC GRAVITY DEC V APPARENT REDUCED ABILITY TO CONC AT ALL PATES 90505
MUSCULAR EXERCISE U UREA CLEARANCE DEC V RESPONSE TO STRESS OF EXERCISE 90184
MUSCULAR EXERCISE U URINALYSIS CASTS INC V HYALINE, GRANULAR BOTH INC WITH INC EXERCISE P0505
MUSCULAR EXERCISE U URINALYSIS CELLS INC V EPITHELIAL CELLS INC WITH HEAVY EXERCISE P05 05
MUSCULAR EXERCISE U URINALYSIS HEMOGLOBIN INC V MAY OCCUR AFTER SEVERE EXERCISE HO 2 91
MUSCULAR EXERCISE U URINALYSIS PH DEC V AT ALL RATES OF EXERCISE (ACID METABOLITES) 90505
MUSCULAR EXERCISE U URINALYSIS PH INC V EFFECT NOTED AFTER MILD EXERCISE 90505
MUSCULAR EXERCISE U URINALYSIS PROTEIN INC V MORE COMMON WITH HEAVY EXERCISE THAN MILD 90505
MUSCULAR EXERCISE U URINALYSIS PBC/HPF INC V INC WITH INCREASING PATES OF EXERCISE 20505
MUSCULAR EXERCISE U URINALYSIS WBC/HPF INC V NOTED AFTER HEAVY EXERCISE 90505
MUSCULAR EXERCISE U VOLUME DEC V WITH HEAVY EXERCISE 90505
MUSCULAR EXERCISE U VOLUME INC V WITH MILD EXERCISE P0505
MUSCULAR EXERCISE U 17 OH COPTICOSTEPOIDS INC V RESPONSE TO STRESS OF EXERCISE HO 1814
MUSTARD GAS B RED CELL COUNT DEC V MAY CAUSE APLASTIC ANEMIA 90658
NYOGLOBI N U URINALYSIS COLOR INC V PRODUCES RED COLOR IN URINE 90143
NAFCILLIN S BSP RETENTION INC V REPORTED EFFECT (?HEPATOTOXICITY) P00 26
NAFCILLIN S SCOT INC V POSSIBLY DUE TO TRAUMA OF INJECTION P0620
NAFENOPIN S CHOLESTEROL DEC V MORE EFFECTIVE THAN CLOFIBRATE 90280
NAPE NOPIN S TRIGLYCERIDES DEC V MORE EFFECTIVE THAN CLOFIBRATE 90280
NALIDIXIC ACID B EOSINOPHILS INC V ALLERGIC RESPONSE 904214
NALIDIXIC ACID B HENATOCHIT DEC V HENOLYTIC ANEMIA WITH G-6-PD DEFICIENCY 90093
NALIDIXIC ACID B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA WITH G-6-PD DEFICIENCY 90093
NALIDIXIC ACID B PLATELET COUNT DEC V THROMBOCYTOPENIA P0999
NALIDIXIC ACID B RED CELL COUNT DEC V HEMOLYTIC ANEMIA WITH G-6-PD DEFICIENCY P0093
NALIDIXIC ACID B WRITE CELL COUNT INC V DUE TO EOSINOPHILIA P0620
NALIDIXIC ACID F OCCULT BLOOD P05 V MAY CAUSE BLEEDING FROM G.I. TRACT P0026
NALIDIXIC ACID F UPOHILINOGEN DEC V NAY OCCUR WITH CHOLESTASIS P07 36
NALIDIXIC ACID P PROTHROMBIN TIME INC V DISPLACES COUMARINS FROM ALBUMIN P08 50
NALIDIXIC ACID S ALKALINE PHOSPHATASE INC V MAY CAUSE CHOLESTATIC JAUNDICE P07 36
NALIDIXIC ACID S BILIPUBIN INC V MAY CAUSE CHOLESTATIC JAUNDICE P0736
NALIDIXIC ACID S CEPHALIN FLOCCULATION INC V MAY CAUSE CHOLESTATIC JAUNDICE RO 736
NALIDIXIC ACID S CHEATININE INC V NAY CAUSE NITROGEN RETENTION PO36
NALIDIXIC ACID S DIRECT BILIHUBXN INC V HEMOLYTIC ANEMIA ES? IF G-6-PD DEFICIENCY 90999
NALIDIXIC ACID S GLUCOSE INC N COPPER REDUCTION METHODS AFFECTED HO 907
NALIDIXIC ACID S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA ES? IF G-6-PD DEFICIENCY P0999
NALIDIXIC ACID S NPN INC V MAY CAUSE NITROGEN RETENTION 90736
NALIDIXIC ACID S SGOT INC V MAY CAUSE CHOLESTATIC JAUNDICE H 07 36
NALIDIXIC ACID S SGPT INC V MAY CAUSE CHOLESTATIC JAUNDICE P0736
NALIDIXIC ACID S THYNOL TURBIDITY INC V MAY CAUSE CHOLESTATIC JAUNDICE P 06 54
NALIDIXIC ACID S UREA NITROGEN INC V MAY CAUSE NITROGEN RETENTION 90736
NALIDIXIC ACID S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS 9014 92
NALIDIXIC ACID U URINALYSIS GLUCOSE Z N NO EFFECT WITH CLINISTIX, TESTAPE R0999
NALIDIXIC ACID U URINALYSIS SUGAR INC N FALSE P05 WITH FEHLINGS, BENEDICT’S, CLINITEST 90999
NALIDIXIC ACID U UROBILINOGEN INC V NAY OCCUR IF CHOLESTASIS P0736
NALIDIXIC ACID U 17 KETOGENIC STEROIDS INC M INTERFERES WITH ZIMMERMAN REACTION P 0 590
NALIDIXIC ACID U 17 KETOSTEHOIDS INC M INTERFERES WITH ZIMMERMAN REACTION 90590
NALIDIXIC ACID U 17 OH CORTICOSTEROIDS Z N NO EFFECT WITH PORTER-SILBER REACTION H0999
NALORPHINE T PROTEIN INC N REACTS WITH FOLIN-CIOCALTEU OF LOWRY METHOD R0213
NA NDRO LONE H FACTOR II INC V METABOLIC EFFECT 90708
NA NDROLONE B FACTOR V INC V METABOLIC EFFECT R0708
NA NDROLONE B FACTOR VII INC V METABOLIC EFFECT 90708
NA NDROLONE B FACTOR X INC V METABOLIC EFFECT P07 08
N AN DR OLONE 0 METYRAPONE TEST V ANABOLIC EFFECT P0708
NA NDROLONE P PROTHROMBIN TIME INC V MAY INCREASE SENSITIVITY TO ANTICOAGULANTS P0708
NANDROLONE S CALCIUM INC V MAY OCCUR IN WOMEN WITH NEOPLASM OF BREAST 90708
NA NDROLONE S CHOLESTEROL DEC V DUE TO ACTION ON LIVER P0708
NANDROLONE S CHOLESTEROL INC V DUE TO ACTION ON LIVER P0708
NANDHOLONE S GLUCOSE DEC V ANABOLIC EFFECT P0708
NA NDROLONE S GLUCOSE TOLERANCE INC V ANABOLIC EFFECT H 07 08
NA NDR OLONE S I 131 UPTAKE DEC V ANABOLIC EFFECT P0708
NA NDPOLONE S PBI DEC V ANABOLIC EFFECT 90708
NA NDPO LONE S TBG DEC V ANABOLIC EFFECT P0708
NA NDROLONE S 13 UPTAKE INC V ANABOLIC EFFECT 90708
NANDPOLONE U CALCIUM INC V DUE TO HYPEPCALCEMIA P07 08
NA NDROLONE U CREATINE DEC V ANABOLIC EFFECT H 07 08
NANDR OLONE U CREATININE DEC V ANABOLIC EFFECT R07O8
NA NDHOLONE U 17 KETOSTEROIDS INC V ANABOLIC EFFECT H07O8
N A? HTHALENE B HEINZ-BODY FORMATION P05 V EARLY STAGE OF HENOLYTIC ANEMIA RO1D4
NAPHTHALE NE B HENATOCPIT DEC V NAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
N A PHTH AL EN E B HEMOGLOBIN DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
NAP HTHALE NE B NETHEMOGLOBIN INC V MAY CAUSE HENOLYSIS WITH C-6-PD DEFICIENCY P0926
NA PH TH AL ENE B RED CELL COUNT DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY HOO79
NA P HT H A LE NE B WHITE CELL COUNT INC V LEUKOCYTOSIS NAY OCCUR FOLLOWING INGESTION HO 3 68
NA PHTHALENE S BILIRUBIN INC V MAY CAUSE HENOLYSIS WITH G-6-PD DEFICIENCY HO 07 9
NAP HT HA LE NE S HAPTOGLOBIN DEC V NAY CAUSE HENOLYSIS HO 0 79
NA PH IRA LENE U ALPHA NAPHTHOL P05 V PRESENT AS METABOLITE H 036 8
NAP HT HALE NE U PROTEIN INC V NEPHHOTOXIC EFFECT HO 3 68
NA PHTHALENE U URINALYSIS CASTS INC V NEPHROTOXIC EFFECT P0368
N APHTHALENE U URINALYSIS COLOR INC V BROWN OR BLACK DUE TO BLOOD AND HEMOGLOBIN HO 368
NAPHTHA LENE U URINALYSIS HEMOGLOBIN INC V DUE TO G-6-PD RELATED HEMOLYSIS OP POISONING P0 368
N A? HTH ALE NE U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT HO 368
NAPHT HALENE U URINALYSIS PBC/HPF INC V OCCURS OCCASIONALLY FOLLOWING INHALATION OF VAPOR P03 68
NA PHTHOL U URINALYSIS COLOR INC N DARK COLOR ON STANDING P0620
NAPHTHOXYACETIC AC B PLATELET COUNT DEC V REPORTED EFFECT (AMA-BLOOD DYSCRASIAS COMMITTEE) 90658
NARCOTI CS 0 BMR DEC V METABOLIC EFFECT OF DRUGS P05 96
NARCOT ICS S AMYLASE INC V CAUSE SPASM OF SPHINCTER OF ODDI 900142
NARCOTICS S RSP RETENTION INC V IMPAIRED EXCRETION - SPASM 0? SPHINCTER OF ODDI P02 014
NARCOTICS S CPK INC V RESPONSE TO I.M. INJECTIONS HOO8O
NARCOTICS S LIPASE INC V IMPAIRED EXCRETION - SPASM OF SPHINCTER OF ODDI RO2 014

NARCOTICS S SGOT INC V IMPAIRED EXCRETION DUE TO SPASM OF SPHINCTER P0204
NF.O-LOPAX S PHI INC V CONTAINS IODINE, EFFECT LASTS FOR 1-2 WEEKS RO112
NEOMYCIN B HEMATOCHIT DEC V MEGALOBLASTIC ANEMIA (IMPAIRED P12 ABSOPP) P0976
NFOMYCD’ B HEMOGLOBIN DEC V MEGALOBLASTIC ANENIA(IMPAIRED P12 ABSOPP) R0976
NEONYCIN B MCV INC V IF MECALOBLASTIC ANEMIA DEVELOPS P0976
NEOMYCIN B PLATELET COUNT DEC V IF SEVERE MEGALOBLASTIC ANEMIA P0976
NEOMYCIN B RED CELL COUNT DEC V MEGALOBLASTIC ANEMIA (IMPAIRED B12 ABSOPP) P0976
NEOMYCIN B WHITE CELL COUNT DEC V IF SEVERE MEGALOBLASTIC ANEMIA P0976
NEOMYCIN F PAT INC V ALTERS INT VILLI,INHIBITS TRIGLYCERIDE HYDROLYSIS RO993
NEOMYCIN F NITROGEN INC V ALTERS INT VILLI,INHIBITS TRIGLYCERIDE HYDROLYSIS R0993
NEOMYCIN F UHOBILINOGEN DEC V REDUCES FLORA IN G.I. TRACT RO1417
NEOMYCIN P AMMONIA DEC V REDUCES NH3 PRODUCING BACTERIA IN G.I. TRACT R1004
NEOMYCIN P PROTHROMBIN TIME INC V REDUCES AVAILABILITY OF VITAMIN K P0947
NEOMYCIN S CHOLESTEROL DEC V FORMS SALTS WITH BILE ACIDS IN GUT P0907
NEOMYCIN S CREATINIME INC V NEPHROTOXIC EFFECT P0736
NF.OMYCIW S MAGNESIUM DEC V NAY BE LOSS IN STOOLS DUE TO STEATORPHEA H03814
NEOMYCIN S NPN INC V NEPHROTOXIC EFFECT R0620
NEOMYCIN S UREA NITROGEN INC V NEPHROTOXIC EFFECT P0299
NEOMYCIN S VITAMIN B12 DEC V IMPAIRS ABSORPTION P0976
NEOMYCIN U AICAP INC V IF NECALOBLASTIC ANEMIA DEVELOPS P0976
NEONYCIN U FIGLU INC V IF MEGALOBLASTIC ANEMIA DEVELOPS P0976
NEOMYCIN U PROTEIN INC V NEPHROTOXIC EFFECT P0299
NEOMYCIN U URINALYSIS CASTS INC V NEPHROTOXIC EFFECT P0620
NEONYCIN U URINALYSIS PROTEIN INC V NEPHHOTOXIC EFFECT P0299
NEOMYCIN U UPOBILINOGEN DEC V REDUCES FLORA IN G.I. TRACT P0417
NEOMYCIN U VITAMIN B12 DEC V WITH IMPAIRED ABSORPTION P0976
NEOMYCIN U XYLOSE EXCRETION DEC V AFFECTS INTESTINAL ABSORPTION WITH MUCOSAL DAMAGE RO486
NEOSALVARSAN B HEMOGLOBIN DEC V MAY CAUSE HEMOLYSIS P0518
NEOSTYGMINE S CHOLINESTEHASE DEC V DIRECT EFFECT OF DRUG RO913
NF.SSLER’S REAGENT S PBI DEC M CATALYTIC EFFECT OF IODINE INHIBITED BY K+, HG++ P01436
NEUROMUSCULAR B PCO2 DEC V SECONDARY TO HYPERVENTILATION POSTOPERATIVELY P03814
NEUROMUSCULAR S CHOLINESTEHASE DEC V IF ENZYME DEFICIENCY MAY CAUSE TOXICITY P0384
NEUROMUSCULAR S POTASSIUM DEC V IF K DEFICIENCY POTENTIATES EFFECT P0384
NIAGARA SKY BLUE S PBI DEC V MECHANISM OBSCURE P0004
NIALAMIDE B WHITE CELL COUNT DEC V LEUKOPENIA REPORTED P0026
NIALAMID! S ALKALINE PHOSPHATASE INC V PROBABLE HYPERSENSITIVE HEPATITIS 9.0026
NIALAMIDE S BILIRUBIN INC V PROBABLE HYPERSENSITIVE HEPATITIS P0026
NIALAMIDE S PS? RETENTION INC V HEPATOTOXIC/CHOLESTATIC SYNDROMES RO3814
NIALAMIDE S GLUCOSE DEC V MAY PROLONG ACTION OF INSULIN IN DIABETICS R0657
NIALAMIDE S PHI INC V VARIABLE EFFECT ON I 131 UPTAKE IN RATS P0004
NIALAMIDE S SCOT INC V PROBABLE HYPERSENSITIVE HEPATITIS P0026
NIALAPIIDE I UREA NITROGEN INC N BILIOUS YELLOW-GREEN WITH BERTHELOT’S REAGENT P0530
NIALAMIDE U PHENYLKETONES P05 M FADING GREEN WITH FECL3, GREEN WITH PHENISTIX R0239
NIALAMIDE U URINALYSIS BILE INC V PROBABLE HYPERSENSITIVE HEPATITIS P0026
NIALAMIDE U VMA DEC V EFFECT OBSERVED IN SCHIZOPHRENICS P0657
NICOTINAMIDE S TOTAL LIPIDS Z V NO LOWERING EFFECT OBSERVED RO384
NICOTINE P 11 OH CORTICOSTEROIDS INC V UP TO 80% INCREASE AFTER HEAVY SMOKING P0526
NICOT’NE S GLUCOSE INC V DUE TO ADRENAL PESPONSE IN POISONING P0368
NICOTINE S NEFA INC V PROBABLE STRESS RESPONSE P0657
NICOTINIC ACID P CATECHOLAMINES INC N OCCURS WITH LARGE DOSES, INTERFERING FLUORESCENCE P0417
NICO’FINIC ACID P GROWTH HORMONE INC V PRODUCED BY FALL IN FREE FATTY ACIDS P01478
NICOTINIC ACID P HEMOGLOBIN Z V NO EFFECT OBSERVED WITH INCREASED BLOOD FLOW P0485
NICOTINIC ACID P INSULIN INC V ?RESPONSE TO INCREASED GLUCOSE OUTPUT P0360
NICOTINIC ACID S ALKALINE PHOSPHATASE INC V MAY CAUSE INPARINENT OF HEPATIC FUNCTION P0719
NICOTINIC ACID S BETA-LIPOPPOTEINS DEC V CHRONIC ADMIN HAS SLIGHT EFFECT P0384
NICOTINIC ACID S BILIRUBIN INC V MAY CAUSE IMPAIRMENT OF HEPATIC FUNCTION P0719
NICOTINIC ACID S BSP RETENTION INC V LIVER FUNCTION IMPAIRMENT, ?CONPETITION FOP CONJUG P0719
NICOTINIC ACID S CEPHALIN FLOCCULATION INC V MAY IMPAIR HEPATIC FUNCTION P0620
NICOTINIC ACID S CHOLESTEROL DEC V THERAPEUTIC GOAL (REBOUND INC WHEN DISCONTINUED) P0907
NICOTINIC ACID S GLUCOSE INC V MECHANISM NOT DISCUSSED P0384
!IICOTINIC ACID S GLUCOSE TOLERANCE DEC V . REDUCED TOLERANCE OBSERVED IN DIABETICS P0596
NICOTINIC ACID S GLUCOSE TOLERANCE INC V INCREASES GLUCOSE DISAPPEARANCE AFTER I.V. GTT P0253
NICOTINIC ACID S NEFA DEC V MARKED FALL THEN PROGRESSIVE SECONDARY RISE P01478
NICOTINIC ACID S PREHETA-LIPOPROTEINS DEC V THERAPEUTIC EFFECT P0384
NICOTINIC ACID S SCOT INC V INTRAHEPATIC CHOLESTASIS OBSERVED RARELY P0360
NICOTINIC ACID S SGPT INC V INTHAHEPATIC CHOLESTASIS OBSERVED RARELY P0360
NICOTINIC ACID S THYMOL TURBIDITY INC V IMPAIRED HEPATIC FUNCTION P0620
NICOTINIC ACID S TRIGLYCERIDES DEC V THERAPEUTIC INTENT R0721
NICOTINIC ACID S URIC ACID INC V MAY RISE BY UP TO 1.5 NG/100ML IF LARGE DOSES P0721
NICOTINIC ACID U DIAGNEX BLUE EXCRETION INC V DISPLACES DIAGNEX BLUE FROM RESIN P1001
NICOTINIC ACID U GLUCOSE INC V AS RESULT OF HYPERGLYCEMIA P0384
NICOTINIC ACID U SUGAR INC N INTERFERES WITH BENEDICT’S REAGENT P0299
NICOTINIC ACID U URIC ACID CLEARANCE DEC V DECREASES BY 75%, ?DUE TO ALTERED TUBULAR HANDLING R0360
NICOTINIC ACID U URIC ACID DEC V DECREASES BY APPOXIMAT.ELY 50% P0360
NICOTINIC ACID U URINALYSIS BILE INC V MAY BE IMPAIRED HEPATIC FUNCTION P0620
NICOTINIC ACID U URINALYSIS GLUCOSE INC V DUE TO HYPERGLYCEMIA P0360
NICOTINIC ACID U URINALYSIS KETONES INC V ?DUE TO HEPATIC MOBILIZATION OF KETOGENIC AMINO AC H036O
NIFUPTIMOX S GLUCOSE DEC V MAY CAUSE DECLINE P0026
NIKETHAMIDE U PORPHYPINS INC V NAY PRECIPITATE ATTACK OF ACUTE PORPHYRIA P0596
NIRIDAZOLE B EOSINOPRILS INC V QUITE COMMON ALLERGIC RESPONSE P0657
NIRIDAZOLE B HEMATOCRIT DEC V OCCURS WITH MARKED HEMOLYSIS P0384
NIRIDAZOLE B HEMOGLOBIN DEC V OCCURS WITH MARKED HEMOLYSIS P0384
NIPIDAZOLE B METHENOGLOBIN INC V NAY CAUSE HEMOLYSIS IF G-6-PD DEFICIENCY P0384
NIRIDAZOLE B RED CELL COUNT DEC V MAY CAUSE HEMOLYSIS IF G-6-PD DEFICIENCY P0384
NIRIDAZOLE U URINALYSIS COLOR INC N URINE BECOMES DARK P0384
NITRATES B NETHEMOGLOBIN INC V MAY CAUSE HEMOLYSIS P0656
NITRATES S CHOLESTEROL DEC N INTERFERE WITH ZLATKIS-ZAK REACTION RO907
NITRATES U VOLUME INC V RENAL TUBULAR EPITHELIUM RELATIVELY IMPERMEABLE P0384
NITRAZEPAM S BARBITURATE INC N FORMS HG COMPLEX WITH DIPHENYLCARBAXONE/BAER’S METH P0095
NITRIC ACID U URINALYSIS HEMOGLOBIN INC M AFFECTS BENZIDINE TEST P0620

NITRITES B HEMATOCRIT DEC V MAY CAUSE HEMOLYTIC ANEMIA P06 20
NITRITES B HEMOGLOBIN DEC V NAY CAUSE HEMOLYTIC ANEMIA 20620
NITRITES B METHEMOGLOBIN INC V EFFECT OF ORGANIC NITRITES LESS THAN ANYL NITRITE HO 384
NITRITES H RED CELL COUNT DEC V MAY CAUSE HEMOLYTIC ANEMIA 90620
NI TRITES F OCCULT BLOOD P05 V MAY CAUSE BLOODY DIARRHEA IF INGESTED HO 36 8
NITROBENZENE B HEMATOCRIT DEC V OCCURS WITH HEMOLYSIS 90 658
NI TROB ENZENE B HEMOGLOBIN DEC V OCCURS WITH HENOLYSIS 90658
NITROBENZENE B METHEMOGLOBIN INC V MAY CAUSE HEMOLYSIS P06 58
NI TROBENZENE B RED CELL COUNT DEC V OCCURS WITH HEMOLYSIS P 065 8
NITROBENZENE U URINALYSIS COLOR INC N DARK COLOR ON STANDING 90620
NIT POFURANS B EOSIFOPHILS INC V MAY BE SERIOUS ANAPHYLACTOID REACTION P 0026
NITPOFURANS B HEINZ-BODY FORMATION P05 V OCCURS INITIALLY WITH HEPIOLYSIS 20518
NITROFUPA NS B HEMATOCRIT DEC V MAY CAUSE HEMOLYTIC ANEMIA IF G-6-PD DEFICIENCY H0O26
NITROFURANS B HEMOGLOBIN DEC V NAY CAUSE RENOLYTIC ANEMIA IF G-6-PD DEFICIENCY P00 26
NITROFURA NS B MCV INC V NAY CAUSE NEGALOBLASTIC ANEMIA P06 57
NITROFUP AN S B METHEMOGLOBIN INC V MAY CAUSE HENOLYTIC ANEMIA IF G-6-PD DEFICIENCY R0026
NITROFUHA NS B HETICULOCYTES INC V OCCURS DURING RECOVERY AFTER HEMOLYSIS 90518
NI TROFURANS B WRITE CELL COUNT DEC V MAY OCCASIONALLY CAUSE AGRANULOCYTOSIS 90657
NITPOFURA NS E REDUCED GLUTATHIONE DEC V OCCURS WITH HEMOLYSIS P05 18
NITROFURANS P HEMOGLOBIN INC V OCCURS WITH INTRAVASCULAR HEMOLYSIS P0656
NITROFURANS S ALKALINE PHOSPHATASE INC V HEPATOTOXICITY 90620
NITROFURANS S BILIRUBIN INC V HEPATOTOXICITY OP DUE TO HEMOLYTIC ANEMIA R0620
NITROFUPANS S HSP RETENTION INC V HEPATOTOXICITY HO 620
NI TROFU HANS S CEPHALIN FLOCCULATION INC V HEPATOTOXICITY P0620
NITROFURANS S FOLATE DEC V MAY INDUCE FOLATE DEF - MEGALOBLASTIC ANEMIA P0657
NITROFU HANS S SGOT INC V HEPATOTOXICITY P 06 20
NITROFURANS S SGPT INC V HEPATOTOXI CITY P0620
NITROFUPA MS S THYMOL TURBIDITY INC V HEPATOTOXICITY P.06 20
NI TROF UR ANS U CREATININE INC N REACT WITH COLOR REAGENT 90596
NITHOFURA MS U URINALYSIS BILE INC V HE PA TOT OXI CITY 90620
NITROFURANS U URINALYSIS COLOR INC N BROWN,GREEN, BLUE COLOR 20355
NITROFURA MS U URINALYSIS HEMOGLOBIN INC V MAY OCCUR WITH SEVERE HEMOLYTIC ANEMIA P0518
NITROFUHANS U URINALYSIS SUGAR INC M METABOLITES REDUCE BENEDICT’S REAGENT P05 96
NITROFUPA NTOIN B EOSINOPHILS INC V ALLERGIC RESPONSE (GREATER THAN 1%) 90542
NITROFURA NTOI N B HEINZ-BODY FORMATION P05 V NAY CAUSE HENOLYTIC ANEMIA RO1 014
NITROFURANTOIN B HFMATOCRIT DEC V MEGALOBLASTIC ANEMIA/HYPERSENSITIVITY (G-6-PD) 90633
NI TROFURA NTOIN B HEMOGLOBIN DEC V NEGALOBLASTIC ANNEI A/HYPEP SEN SITIVITY (G- 6-PD) 90633
NITROFUR ANTOIN B MCV DEC V MEGALOBLASTIC ANEMIA/HYPERSENSITIVITY (C-6-PD) P06 33
NITROFURA NTOI N B NETHEMOGLOBIN INC V MAY CAUSE HENOLYSIS WITH G-6-PD DEFICIENCY HO 926
NITROFURANTOIN H PLATELET COUNT DEC V THRO MBOCYTOPENIA 90293
NITROFURANTOIN H RED CELL COUNT DEC V HYPERSENSITIVITY (G-6-PD) /MEGALOBLASTIC ANEMIA P06 33
NITPOFUPANTOIN H WHITE CELL COUNT DEC V LEUKOPENIA/AGRANULOCYTOSIS MAY OCCUR P0293
NITROFU PA NTOIN S ALKALINE PHOSPHATASE INC V MAY CAUSE CHOLESTATIC JAUNDICE P07 36
NITROFUH ANTOIN S BILIRUBIN INC V MAY CAUSE HEMOLYTIC ANEMIA OR CHOLESTASIS P05142
NITROFURA NTOIN S BSP RETENTION INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P0305
NITPOFUPANTOIN S CEPHALIN FLOCCULATION INC V NAY BE CHOLESTATIC JAUNDICE 9 0620
NITPOFUHANTOIN S C02 CONTENT DEC V NEPHROTOXICITY MAY CAUSE AZOTEMIA P02 99
NITROFURANTOIN S CREATININE INC V NEPHROTOXIC EFFECT HO5 96
NITROFUPA NTOIN S GLUCOSE TOLERANCE DEC V SINGLE CASE REPORTED P04 13
NI TROFURANTOIN S HAPTOGLOBIN DEC V REMOLYTIC ANEMIA P0620
NITROFURANTOIN S LACTIC DERYDHOGENASE INC V NAY CAUSE RENOLYTIC ANEMIA P0542
NITROFURANTOIN S NPN INC V NEPHROTOXIC EFFECT 90620
NITROFURANTOIN S SCOT INC V MAY CAUSE CHOLESTATIC JAUNDICE P07 36
NITROFURA NTOIN S SGPT INC V NAY CAUSE CHOLESTATIC JAUNDICE P07 36
NITROFURANTOIN S THYNOL TURBIDITY INC V MAY BE CHOLESTATIC JAUNDICE P06 20
NITPOFU PA NTOI N S UREA NITROGEN INC V POSSIBLE DEC IN ALREADY IMPAIRED PENAL FUNCTION P0029
NITROFURANTOIN S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS HO1492
NITROFURA NTOIN U ALKALINE PHOSPHATASE DEC N INTERFERENCE WITH DETERMINATION METHOD P0700
NITROFURANTOIN U LACTIC D!HYDPOGENASE DEC N INTERFERENCE WITH DETERMINATION METHOD P000
NITROFURA NTOIN U SUGAR INC N METABOLITES MAY REDUCE BENEDICT’S, YIELD FALSE POS HO 596
NITROFURANTOIN U URINALYSIS BILE INC V MAY CAUSE CHOLESTATIC JAUNDICE P06 20
NITROFUPA NTOIN U URINALYSIS COLOR INC N BROWN, YELLOW COLOR 20299
NITROFURA NTOIN U UPOBILINOGEN DEC V INTRAHEPATIC CHOLESTATIC JAUNDICE 90305
NITROFURA ZONE B HEINZ-BODY FORMATION P05 V MAY OCCUR IN EARLY STAGES OF HEMOLYTIC ANEMIA PO1O
NI TROFUPAZ ONE B HEMATOCRIT DEC V MAY CAUSE HENOZYSIS WITH G-6-PD DEFICIENCY P00 79
NITROFURAZONE B HEMOGLOBIN DEC V NAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY 90079
NITROFU PAZONE B METHENOGLOBIN INC V MAY CAUSE HEMOLYTIC ANEMIA HO 1014
NITROFURA ZONE B RED CELL COUNT DEC V NAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY HO 079
NITHOFU HAZONE S BILIRUBIN INC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
NITPOFURAZONE S HAPTOGLOBIN DEC V MAY CAUSE REMOLYSIS O079
NITROPU HA ZONE U CREATININE INC N REACT WITH COLOR REAGENT P0355
NITROFURAZONE U SUGAR INC M METABOLITES MAY REDUCE BENEDICT’S REAGENT HO 3 55
NITROFURAZONE U URINALYSIS SUGAR INC N REDUCING ACTION OF METABOLITES P03 55
NITROGEN OXIDES B METHEMOGLOBIN INC V MILD ELEVATION MAY OCCUR AFTER NIT OX INHALATION P03 68
NITROGEN OXIDES B 9002 INC V RETENTION OF CO2 OCCURS HO 368
NITROGLYC EPI N B METHENOGLOBIN INC V MAY CAUSE HEMOLYSIS P0656
NITROGLYCERIN P CATECHOLANINES INC V EFFECT DOSAGE DEPENDENT P0042
NITROGLYCERIN U EPINEPHRINE INC V ?DUE TO ADRENERGIC STIMULATION OF HYPOTENSION P0 96 1
NITROGLYCER IN U NOREPINEPHRINE INC V ?DUE TO ADRENERGIC STIMULATION OF HYPOTENSION P096 1
NITROGLYCERIN U VNA INC V EFFECT GREATER THAN THAT ON CATECHOLAMINES P0961
NITRO PHENOL S ALKALINE PHOSPHATASE INC V HYPERSENSITIVE INTRAHEPATIC CHOLESTASIS P0405
NITPOPHE NOL S BILIRUBIN INC V HYPERSENSITIVE INTHAHEPATIC CHOLESTASIS P0 1405
NITROPHENOL S CHOLESTEROL INC V HYPERSENSITIVE INTRAHEPATIC CHOLESTASIS P0405
NITROPHENOL S SCOT INC V HYPERSENSITIVE INTRAREPATIC CHOLESTASIS P040 5
NI TROPH ENOL S SGPT INC V HYPERSENSITIVE INTRAHEPATIC CHOLESTASIS P01405
NITROUS OXIDE H RED CELL COUNT DEC V BONE MARROW DEPRESS (OF NO SIGNIFICANCE NORMALLY) HO 3814
NOREPI NEPH RIME P ERPF DEC V SLIGHT FALL AFTER I.V. INFUSION P0657
NOREPINEPHRINE S GLUCOSE INC N AT 10 NG/100NL AFFECTS ALKALINE FERRICYANIDE NETH R037O
NOREPI NEPH PINE S GLUCOSE Z N AT 10 MG/100ML NO EFFECT ON GLU OX OF GOCHNAN H0370
NOPEPINEP HP INE S URIC ACID INC V HEDUCES URINARY EXCRETION P06 57

NOREPINEPHPINE T UREA NITROGEN INC M BROWN WITH BEPTHELOT’S REAGENT P0530
NOREPINEPHPINE U GH DEC V SLIGHT FALL AFTER I.V. INFUSION P0657
NOREPINEPHPINE U URIC ACID CLEARANCE DEC V SHARP FALL AFTER I.V. INFUSION P0657
NOREPINEPHRINE U VOLUME DEC V SLIGHT FALL AFTER I.V. INFUSION R0657
NOPETHANDROLONE F UROBILINOGEN DEC V LIGHT STOOLS DUE TO CHOLESTASIS P01477
NORETHANDROLONE P FIBRINOGEN INC V METABOLIC EFFECT P0072
NORFTHANDPOLONE P PLASNINOGEN INC V METABOLIC EFFECT P0072
NOPETHANDHOLONE P PROTHROMBIN TINE INC V ALSO SEEN WITH OTHER 17-ALKYL SUBSTITUTED STEROIDS P0295
NOHETHANOPOLONE S ALKALINE PHOSPHATASE INC V CHOLESTASIS PRODUCED WITHOUT CHOLANGIOLITIS P01431
NORETHANDROLONE S BETA-GLUCUPONIDASE INC V METABOLIC EFFECT P0072
NO?ETHANDHOLONE S BILIRUBIN INC V INTRAHEPATIC CHOLESTASIS PRODUCED (UP TO 20%) R0366
NOPETHANDROLONE S PS? RETENTION INC V TRANSPORT AND CONJUGATION OF BSP IMPAIRED P0054
NORFTHANDPOLONE S CEPHALIN FLOCCULATION INC V CHOLESTASIS PRODUCED WITHOUT CHOLANGIOLITIS P0826
NORETHANDROLONE S CHOLESTEROL INC V DOE TO CHOLESTASIS P0477
NOHETHANDROLONE S DIRECT BILIRUBIN INC V REVERSIBLE CHOLESTASIS PRODUCED RO366
NORETHANDPOLONE S HAPTOCLOBIN INC V METABOLIC EFFECT P0072
NORETHANDROLONE S PBI DEC V CONCENTRATION OF CIRCULATING TBG LOWERED P0004
NORETHANDROLONE S SGOT INC V CHOLESTASIS PRODUCED WITHOUT CHOLANGIOLITIS P0826
NORETHANDROLONE S SGPT INC V USUALLY REVERSIBLE CHOLESTASIS P0366
NORETHANDROLONE S TBG DEC V DECREASES CONC OF TBG, INCREASES TBPA P0907
NOPETHANDROLONE S THYMOL TURBIDITY INC V CHOLESTASIS PRODUCED WITHOUT CHOLANGIOLITIS RO826
NORETHANDROLONE S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS P0492
NORETHANDROLONE U BILIPUBIN INC V CHOLESTASIS PRODUCED WITHOUT CHOLANGIOLITIS P0826
NOHETHANDHOLONE U URINALYSIS BILE INC V CHOLESTATIC EFFECT P0826
NOPETHANDHOLONE U UPOBILINOGEN DEC V MANIFESTATION OF CHOLESTASIS P0366
NOPETHANDPOSTENOL S ALKALINE PHOSPHATASE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P0834
NOPETHANDROSTENOL S BILIPUHIN INC V INTRAHEPATIC CHOLESTATIC JAUNDICE R0834
NOPETHANDROSTENOL S BSP RETENTION INC V IMPAIRED HEPATIC UPTAKE AND EXCRETION R02O4
NORETHANDROSTENOL U URINALYSIS BILE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P0834
NORETHINDRONE P CORTISOL DEC V SLIGHT EFFECT COMPARED WITH CONTROLS P0084
NOHETHINDRONE P LH DEC V APPARENT SUPPRESSION OF PRODUCTION OP RELEASE P0671
NORETHINDRONE S ALKALINE PHOSPHATASE INC V CHOLESTATIC EFFECT P0620
NORETHINDRONE S BILIRUBIN INC V CHOLESTATIC EFFECT P0620
NORETHINDPONE S 85? RETENTION INC V CHOLESTATIC PHENOMENON (OCCURS IN 20%) 9.0874
NORETHINDRONE S CEPHALIN FLOCCULATION INC V CHOLESTATIC EFFECT P0620
NORETHINDHONE S FREE THYROXINE DEC V SLIGHT EFFECT WHEN COMPARED WITH CONTROLS P0085
NORETHINDRONE S PHI DEC V WHEN TREATMENT RESULTS COMPARED WITH CONTROLS R0085
NOHF.THINDRONE S PHI INC V REPORTED EFFECT BUT MECHANISM UNKNOWN P0233
NOPETRINDPONE S SCOT INC V CHOLESTATIC EFFECT P0620
NOHETHINDRONE S SGPT INC V CHOLESTATIC EFFECT P0620
NORETHINDRONE S THYMOL TURBIDITY INC V CHOLESTATIC EFFECT P0620
NOPETRINDPONE S THYROXINE (T4) DEC V WHEN TREATMENT RESULTS COMPARED WITH CONTROLS P0085
NOHETHINDRONE S T3 UPTAKE Z V WHEN TREATMENT RESULTS COMPARED WITH CONTROLS P0085
NORETHINDRON! U CORTISOL DEC V WHEN RESULTS COMPARED WITH NORMAL MENSTRUAL CYCLE P00814
NORETRINDRONE U URINALYSIS BILE INC V CHOLESTATIC EFFECT P0620
NOFETHISTEPONE S ALKALINE PHOSPHATASE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P0384
NOPETHISTERONE S BILIRUBIN INC V INTPAHEPATIC CHOLESTATIC JAUNDICE P0384
NOPETHISTERONE S BSP RETENTION INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P03814
NOPETHISTERONE S CAROTENE DEC V HORMONAL INFLUENCE P0352
NOPETHISTERONE S CEPHALIN FLOCCULATION INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P0620
NOPETHISTEPONE S SCOT INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P0620
NOPETHISTEPONE S SGPT INC V INTRAHEPATIC CHOLESTATIC JAUNDICE R062O
NOPETHISTERONE S THYMOL TURBIDITY INC V INTPAHEPATIC CHOLESTATIC JAUNDICE P0620
NORETHISTERONE S VITAMIN A INC V DUE TO ALTERATION IN CONC OF BINDING GLOBULIN P0352
NORETHISTERONE U URINALYSIS BILE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P0384
NOHETHYNODREL S ALKALINE PHOSPHATASE INC V DUE TO CHOLESTASIS P0492
NOPETHYNODREL S BILIRUBIN INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P0384
NORETHYNODREL S BSP RETENTION INC V CHOLESTATIC PHENOMENON P0233
NOPETHYNODREL S CEPHALIN FLOCCULATION INC V CHOLESTATIC EFFECT P0620
NORETHYNODREL S GLUCOSE TOLERANCE DEC V GLUCONEOGENETIC EFFECT OF STEROIDS P0355
NOPETHYNODREL S PBI INC V INCREASES CONCENTRATION OF CIRCULATING TBG P00014
NORETHYNODREL S SCOT INC V CHOLESTATIC EFFECT R062O
NOPETHYNODREL S SGPT INC V CHOLESTATIC EFFECT P0620
NOPETHYNODREL S TBG INC V DIRECT EFFECT OF DRUG P0004
NOPETHYNODHEL S THYMOL TURBIDITY INC V CHOLESTATIC EFFECT P0620
NOHETHYNODPEL S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS P0492
NORETHYNODREL U URINALYSIS BILE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE R0384
NORTESTOSTERONE S ALKALINE PHOSPHATASE INC V REPORTED TO AFFECT LIVER FUNCTION P0596
NORTESTOSTERONE S SCOT INC V REPOPTEDT0 AFFECT LIVER FUNCTION P0596
NOPTESTOSTERONE S SGPT INC V REPORTED TO AFFECT LIVER FUNCTION H0596
NORTHIPTYLINE B WHITE CELL COUNT DEC V MAY CAUSE AGRANULOCYTOSIS R0026
NORTPIPTYLINE P PPOTMROMBIN TIME INC V PATIENTS ON COUMARINS (UNCONFIRMED CLINICALLY) P0960
NORTRIPTYLINE S ALKALINE PHOSPHATASE INC V NAY CAUSE CHOLESTATIC JAUNDICE P0026
NORTPIPTYLINE S BILIRUBIN INC V NAY CAUSE CHOLESTATIC JAUNDICE P0026
NORTRIPTYLINE S SCOT INC V NAY CAUSE CHOLESTASIS P0026
NOHTRIPTYLINE S SGPT INC V NAY CAUSE CHOLESTASIS P0026
NORTHIPTYLINE U URINALYSIS BILE INC V NAY CAUSE CHOLESTATIC JAUNDICE R0026
NOVOBIOCIN B ROSINOPHILS INC V ALLERGIC REACTION P01424
NOVOBIOCIN B HENATOCRIT DEC V HEMOLYTIC ANEMIA - MILD P0218
NOVOBIOCIN B HEMOGLOBIN DEC V HEMOLITIC ANEMIA - MILD P0218
NOVOBIOCIN B PLATELET COUNT DEC V THROMBOCYTOPENIA (IMMUNOLOGICALLY INDUCED) RO384
NOVOBIOCIN B RED CELL COUNT DEC V HEMOLYTIC ANEMIA - MILD P0218
NOVOBIOCIN B WHITE CELL COUNT DEC V MAY INDUCE BLOOD DYSCRASIAS P0620
NOVOBIOCIN B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA P0620
NOVOBIOCIN F OCCULT BLOOD P05 V INTESTINAL HEMORRHAGE MAY OCCUR P03814
NOVOBIOCIN S ALKALINE PHOSPHATASE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE CAN OCCUR P0384
NOVOBIOCIN S BILIPUBIN INC N INTERFERENCE BY METABOLITE (EVELYN-NALLOY) P0620
NOVOHIOCIN S BILIHUBIN INC V (ESP. IN NEWBORN): INHIBITS CONJUGATING MECHANISM R0109
NOVOBIOCIN S BSP RETENTION INC V COMPETITION FOP EXCRETION, NAY BE ACTUAL DAMAGE P0109
NOVOBIOCIN S CEPHALIN FLOCCULATION INC V INTRAHEPATIC CHOLESTASIS NAY OCCUR P0620

NOVOBIOCIN S DIRECT BILIRUBIN INC V COMPETES FOR CONJUGATION IN LIVER P0 1 10
NOVOBIOCI N S ICTERIC INDEX INC V COMPETITION FOR CONJUGATION MECHANISM P 06 514
NOVOBIOCIN S SGOT INC V INTRAHEPATIC CHOLESTASIS MAY OCCUR 90620
NOVOBIOCI N S SGPT INC V INTRAHEPATIC CHOLESTASIS MAY OCCUR 90620
NOVOBIOCIN S THYNOL TURBIDITY INC V INTRAHEPATIC CHOLESTASIS NAY OCCUR 90620
NOVOBIOCIN U PSP EXCRETION DEC V ? NEPHPOTOXIC EFFECT HO299
NOVOBIOCIN U URINALYSIS BILE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE CAN OCCUR 903814
NOVOBIOCIN U UROBILINOGEN INC V HEMOLYTIC ANEMIA IN C-6-PD DEFICIENCY 903814
NSD 30014 H PCO2 DEC V ARTERIAL BLOOD-LONG ACT CARBONIC ANHYDPASE INHIBIT P05 99
NSD 3004 B STANDARD BICARBONATE DEC V ART. BLOOD -LONG ACTING CARBONIC ANHYDPASE INHIBIT 90599
NSD 3004 S CO2 CONTENT DEC V LONG ACTING CARBONIC ANHYDRASE INHIBITOR HO 599
NUCLEOPHOTEINS U URINALYSIS SUGAR INC M INTERFERES WITH BENEDICT’S-?REDUCINC SUGAR P0299
NYSTATIN B EOSINOPHILS INC V MAY CAUSE ALLERGIC REACTION O736
NYSTATIN B PLATELET COUNT DEC V THROMBOCYTOPENIA (AMA-BLOOD DYSCRASIAS) P065 8
OLEANDOMYCIN B RED CELL COUNT DEC V PROBABLY DUE TO HENOLYTIC ANEMIA R 0620
OLEA NDOMYCI N S ALKALINE PHOSPHATASE INC V CHOLESTATIC JAUNDICE REPORTED P 0021
OLEANDOMYCIN S BILIRUHIN INC V MAY CAUSE INTRAHEPATIC CHOLESTATIC JAUNDICE 90355
OLEANDOMYCI N S BSP RETENTION INC V MAY CAUSE INTRAHEPATIC CHOLESTASIS P0355
OLEANDOMYCIN S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT 90620
OLEANDONYCI N S SCOT INC V MAY CAUSE HEPATOTOXICITY (CHOLESTATIC SYNDROME) 90620
OLEANDOMYCIN S SGPT INC V MAY CAUSE HEPATOTOXICITY (CHOLESTATIC SYNDROME) 90620
OLEANDONYCIN S THYMOL TURBIDITY INC V MAY CAUSE HEPATOTOXICITY R062O
OLEANDOMYCIN U URINALYSIS BILE INC V HEPATOTOXIC EFFECT HO62O
OLEANDOMYCI N U 17 KETOGENIC STEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION P 09 07
OLE ANDOMYCIN U 17 KETOSTEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION H 0703
OLEANDOMYCIN U 17 OH CORTICOSTEROIDS INC N INTERFERES WITH PORTER-SILBEH REACTION 90703
0 P1 ATE S S ANYLASE INC V IMPAIRED EXCRETION SPASM OF SPHINCTER OF ODDI H 02 014
OPIATES S BSP RETENTION INC V IMPAIRED EXCRETION SPASM OF SPHINCTER OF ODDI P02014
0 PT A TE S S SCOT INC V POSSIBLY DUE TO SPASM OF SPHINCTER OF ODDI P02 04
ORAL CONTRACEPTIVE H ANGIOTENSIN II INC V ELEVATED TO 3 TIMES NORMAL DURING ADMINISTRATION 90 174
ORAL CONTRACEPTIVE B ANTITHROMBIN III ACTIV DEC V ?PPEDISPOSING CAUSE OF THROMBOSIS Hi 028
ORAL CONTRACEPTIVE B ANTITHPONBIN III DEC V REPORTED EFFECT HO 186
ORAL CONTRACEPTIVE B CEPHALIN TINE DEC V METABOLIC EFFECT R0746
OPAL CONTRACEPTIVE B COPROPORPHYRIN INC V MAY PRECIPITATE PORPHYRIA ATTACK 90371
ORAL CONTRACEPTIVE B FACTOR I Z V USUALLY NO EFFECT OBSERVED 901 06
ORAL CONTRACEPTIVE B FACTOR II INC V REPORTED EFFECT R0639
ORAL CONTRACEPTIVE B FACTOR II INC V REPORTED EFFECT OF ESTROGENS ROl 34
ORAL CONTRACEPTIVE B FACTOR IX INC V ESTROGEN EFFECT HO 874
OPAL CONTRACEPTIVE B FACTOR V Z V USUALLY NO EFFECT OBSERVED H 0 1 06
ORAL CONTRACEPTIVE H FACTOR VII DEC V METABOLIC EFFECT P07 46
OPAL CONTRACEPTIVE B FACTOR VII INC V ESTROGEN EFFECT (HIGHER THAN IN PREGNANCY) 90874
ORAL CONTRACEPTIVE B FACTOR VIII INC V SLIGHT EFFECT OBSERVED P0412
ORAL CONTRACEPTIVE B FACTOR X DEC V METABOLIC EFFECT HO 74 6
ORAL CONTRACEPTIVE B FACTOR X INC V SLIGHT EFFECT OBSERVED P0412
ORAL CONTRACEPTIVE B FACTOR XII INC V REPORTED EFFECT 90639
OPAL CONTRACEPTIVE B HEMATOCRIT DEC V MAY CAUSE NEGALOBLASTIC ANEMIA P07 91
ORAL CONTRACEPTIVE B HENATOCHIT INC V PROBABLY PHOGESTOGEN EFFECT 90918
ORAL CONTRACEPTIVE B HEMOGLOBIN DEC V MAY CAUSE MEGALOBLASTIC ANEMIA P079 1
ORAL CONTRACEPTIVE B KAOLIN-CEPHALIN TIME DEC V METABOLIC EFFECT P07 46
ORAL CONTRACEPTIVE B LE CELL PREP P05 V MAY PRECIPITATE OP EXAGGERATE LE-LIKE SYNDPONE 90907
ORAL CONTRACEPTIVE B NCV INC V OCCURS IF NEGALOBLASTIC ANEMIA 90791
ORAL CONTRACEPTIVE B PLATELET AGGREG INC V INC RESPONSE TO ADP ROl 86
ORAL CONTRACEPTIVE B PLATELET COUNT INC V REPORTED EFFECT 90026
ORAL CONTRACEPTIVE B PROTOPORPHYRIN INC V MAY PRECIPITATE PORPHYRIA ATTACK 90371
ORAL CONTRACEPTIVE B RED CELL COUNT DEC V MAY CAUSE NEGALOBLASTIC ANEMIA 90976
ORAL CONTRACEPTIVE B RENIN SUBSTRATE INC V HORMONAL EFFECT R0026
ORAL CONTRACEPTIVE C TOTAL LIPIDS INC V ALTERED METABOLISM HO 1448
OPAL CONTRACEPTIVE E CARBONIC ANHYDPASE INC V MEASURED AS B ISOENZYME (HORMONAL EFFECT) 90829
ORAL CONTRACEPTIVE E FOLATE DEC V IMPAIRED METABOLISM DUE TO HORMONAL FACTORS R0868
ORAL CONTRACEPTIVE F COPPOPORPHYRIN INC V MAY PRECIPITATE PORPHYRIA ATTACK HO 371
ORAL CONTRACEPTIVE F PROTOPORPHYRIN INC V NAY PRECIPITATE PORPHYRIA ATTACK 90371
OPAL CONTRACEPTIVE F UROBILINOGEN DEC V PALE STOOLS, DUE TO CHOLESTASIS P01477
ORAL CONTRACEPTIVE 0 CERVICAL SECRETION INC V LEUCORRHEA DUE TO ESTROGEN IN 20% WOMEN P062 9
ORAL CONTRACEPTIVE P ALANINE DEC V HORMONAL EFFECT (SECOND PART OF CYCLE) P0226
ORAL CONTRACEPTIVE P ALDOSTERONE INC V INCREASED SYNTHESIS BY ADRENAL GLAND R0588
ORAL CONTRACEPTIVE P ALPHA AMINO NITROGEN DEC V ANABOLIC EFFECT OF SYNTHETIC STEROIDS (PROCESTOGEN) HO 225
ORAL CONTRACEPTIVE P ANGIOTENSIN INC V TWOFOLD INCREASE 90186
ORAL ONTRACEPTIVE P ASCORBIC ACID DEC V MAX EFFECT AT 2 WEEKS, GREATER EFFECT IN PLATELETS P0506
ORAL CONTRACEPTIVE P CORTISOL INC V DECREASES CORTISOL CLEARANCE (ESTROGEN EFFECT) P087a
ORAL CONTRACEPTIVE P CPYOFIBRINOGEN INC V INCIDENCE MUCH HIGHER THAN IN CONTROLS 90639
ORAL CONTRACEPTIVE P ESTRADIOL DEC V INHIBITS PHYSIOLOGICAL RISE 90535
ORAL CONTRACEPTIVE P ESTROGENS INC V OFTEN RELATED TO NAUSEA 90 186
OPAL CONTRACEPTIVE P FIBRINOGEN DEC V WHEN COMBINED ESTROGEN AND PROCESTOGEN P06 57
ORAL CONTRACEPTIVE P FIBRINOGEN INC V METABOLIC CHANGES IN LIVER SYNTHESIS (ESTROGEN) 90588
ORAL CONTRACEPTIVE P FSH DEC V OVER YEARS DEPRESSED TO 70% OF CONTROL VALUES P03 82
ORAL CONTRACEPTIVE P GLUTAMATE DEC V HORMONAL EFFECT (SECOND PART OF CYCLE) P02 26
ORAL CONTRACEPTIVE P GROWTH HORMONE INC V DUPING FIRST YEAH OF USE P00 26
OPAL CONTRACEPTIVE P INSULIN INC V IN WOMEN IN WHOM INSULIN WAS INITIALLY NORMAL P089 1
ORAL CONTRACEPTIVE P LH DEC V COMBINATION TYPE PILL LOWERED VALUE TO 20% CONTROL HO 382
ORAL CONTRACEPTIVE P LYSOLECITHIN DEC V IF ADMINISTERED FOR LONG PERIOD P06 914
ORAL CONTRACEPTIVE P NON PROT BOUND CORTISOL INC V ESTROGEN EFFECT P0 186
ORAL CONTRACEPTIVE P PLASMIN INC V ASSOC ALSO WITH INC PLASNINOGEN (COMMON EFFECT) HO 106
OPAL CONTRACEPTIVE P PLASNINOGEN INC V METABOLIC CHANGES IN LIVER SYNTHESIS (ESTROGEN) P0588
ORAL CONTRACEPTIVE P PROLINE DEC V HORMONAL EFFECT (SECOND PART OF CYCLE) 90226
ORAL CONTRACEPTIVE P PROTHROMBIN TIME DEC V DECREASES RESPONSE TO ORAL ANTICOAGULANTS P02’O
ORAL CONTRACEPTIVE P PROTHRONBIN TINE INC V ASSOC WITH FAILURE OF EXCPETION OF BILE SALTS 901477
ORAL CONTRACEPTIVE P RENIN ACTIVITY INC V ACTIVITY INCREASED ALTHOUGH CONC LOWERED 901714
ORAL CONTRACEPTIVE P PENIN DEC V METABOLIC CHANGES IN LIVER SYNTHESIS 90588
ORAL CONTRACEPTIVE P RENIN INC V ESTROGEN EFFECT
OPAL CONTRACEPTIVE P PENIN SUBSTRATE INC V METABOLIC CHANGES IN LIVER SYNTHESIS 90588

OPAL CONTRACEPTIVE P TESTOSTERONE INC V METABOLIC CHANGES IN LIVER SYNTHESIS P0 588
OPAL CONTRACEPTIVE S ALBUMIN DEC V 10% FALL IF USED FOR SEVERAL MONTHS P0459
OPAL CONTRACEPTIVE S ALKALINE PHOSPHATASE DEC V SLIGHT DECREASE REPORTED IN ONE STUDY P0657
OPAL CONTRACEPTIVE S ALKALINE PHOSPHATASE INC V NAY CAUSE CHOLESTASIS, RARE HEPATOCELLULAR DEGEN P0 477
OPAL CONTRACEPTIVE S ALPHA-LIPOPROTEINS INC V RESPONSIBLE FOR INC PHOSPHOLIPIDS HO 186
ORAL CONTRACEPTIVE S ALPHA1-ANTITRYPSIN INC V METABOLIC CHANGES IN LIVER SYNTHESIS (ESTROGEN) P05 88
OP AL ONTPACEPTIVE S ALPHA1-GLOBULIN INC V METABOLIC CHANGE WITH COMBINED CONTRACEPTIVE P062 1
ORAL CONTRACEPTIVE S ALPHA2-CLORULIN INC V MAY BE INC BY AS MUCH AS 8 TIMES HO 186
ORAL ONTHACEPTIVE S ALPHA2-MACROGLOHULIN INC V METABOLIC CHANGES IN LIVER SYNTHESIS HO 588
OR AL CONTRACEPTIVE S BEI INC V DUE TO INCREASED TBG P0026
ORAL CONTRACEPTIVE S BETA-GLOBULIN INC V METABOLIC CHANGES IN LIVER SYNTHESIS P08 53
ORAL CONTRACEPTIVE S BETA-CLUCURONIDASE INC V ALTERED METABOLISM(ESTROGEN EFFECT) H0072
ORAL CONTRACEPTIVE S BETA-LIPOPROTEINS INC V AFFECTS CHOLESTEROL(APPROX 20% INC AFTER 6 MONTHS) HO 186
OPAL CONTRACEPTIVE S BILIRUBIN INC V INTERFERES WITH CANICULAR EXCRETION Polio
OPAL CONTRACEPTIVE S BSP RETENTION INC V OCCURS IN 40%, ESTROGEN DEPRESSES SECRETORY NECH HO 566
OPAL ONTRACEPTIVE S C-REACTIVE PROTEIN DEC V PROGESTOGEN EFFECT HO 907
OPAL CONTHACEPTIVE S C-REACTIVE PROTEIN INC V ESTROGEN EFFECT P0 874
ORAL ONTRACEPTIVE S CALCIUM DEC V SEEN IN OSTEOPOROSIS, ?DUE TO FALL IN ALBUMIN Hi 016
OPAL CONTRACEPTIVE S CALCIUM INC V INC INGESTION WOULD INCREASE CONCENTRATION P 02 04
OR AL CONTRACEPTIVE S CEPHALIN FLOCCULATION INC V OBSERVED IN MANY SUBJECTS P06 57
ORAL CONTRACEPTIVE S CEHULOPLASMIN INC V ESTROGEN EFFECT ON LIVER, NO CHANGE IN ACTIVITY HO 588
OPAL CONTRACEPTIVE S CHOLESTEROL INC V IF INITIALLY LOW (NO EFFECT IF ABOUT 200 MG/100ML) P01 86
OH AL CONTRACEPTIVE S CHOLESTEROL Z V NO EFFECT OBSERVED USUALLY P06 57
ORAL CONTRACEPTIVE S CHOLINESTERASE DEC V ESTROGEN EFFECT P0907
ORAL CONTRACEPTIVE S COLOR INC V CERULOPLASMIN NAY BE SO HIGH BLUE-GREEN COLOR P0907
ORAL CONTRACEPTIVE S COPPER INC V ESTROGENS INCREASE CONC OF BINDING PROTEIN HO 918
OPAL CONTRACEPTIVE S CORTICOSTEP BIND GLOB INC V DUE TO ESEPOGENIC COMPONENT P0026
OPAL CONTRACEPTIVE S CORTISOL BINDING GLOB INC V METABOLIC CHANGES IN LIVER SYNTHESIS R0588
OPAL CONTRACEPTIVE S DIRECT BILIRUBIN INC V HYPERSENSITIVITY TO ESTHOGEN COMPONENT P04 17
OPAL CONTRACEPTIVE S ESTHADIOL BINDING GLOB INC V METABOLIC CHANGES IN LIVER SYNTHESIS P0588
OR AL CONTRACEPTIVE S ESTROGEN BINDING GLOB INC V METABOLIC EFFECT P0639
OPAL CONTRACEPTIVE S FOLATE DEC V INTERFERES WITH G.I.ABSOPPTION P0982
OPAL CONTRACEPTIVE S FREE THYROXINE DEC V WHEN TREATMENT RESULTS COMPARED WITH CONTROLS P0085
OR AL CONTRACEPTIVE S FREE THYROXINE Z V NO EFFECT OBSERVED ALTHOUGH PHI NAY BE INC P0657
OHA L CONTRACEPTIVE S FTI Z V THYROID FUNCTION UNAFFECTED P0026
OPAL CONTRACEPTIVE S GLUCOSE INC V DOES NOT AFFECT FASTING GLUCOSE HUT ALTERS GTT P0907
ORAL ONTRACEPTIVE S GLUCOSE TOLERANCE DEC V MAINLY ESTROGEN EFFECT(REVERSIHLE IN 3 OUT OF 14) P04 12
OPAL CONTRACEPTIVE S GLYCINE DEC V HORMONAL EFFECT (SECOND PART OF CYCLE) HO 226
ORAL CONTRACEPTIVE S HAPTOGLOBIN DEC V METABOLIC CHANGES IN LIVER SYNTHESIS (ESTROGEN) P05 88
ORAL CONTRACEPTIVE S I 131 UPTAKE Z V THYROID FUNCTION UNAFFECTED P00 26
ORAL CONTRACEPTIVE S INMUNOGLOBULIN IGA DEC V ESTROGEN EFFECT P0907
ORAL CONTRACEPTIVE S INMUNOGLOBULINS DEC V ESTROGEN EFFECT P0874
OPAL CONTRACEPTIVE S INMUNOCLOBULINS INC V METABOLIC CHANCES IN LIVER SYNTHESIS P0588
OPAL CONTRACEPTIVE S IRON INC V INCREASE IN AVAILABLE BINDING PROTEIN(PLUS 20% INC) P0918
OPAL CONTRACEPTIVE S ISOLEUCINE DEC V HORMONAL EFFECT (SECOND PART OF CYCLE HO 226
OPAL CONTRACEPTIVE S LACTATE INC V ALTERATION IN CARBOHYDRATE METABOLISM P0639
ORAL CONTRACEPTIVE S LEUCINE AMINOPEPTIDASE INC V POSSIBLE LIVER DAMAGE P04 12
ORAL CONTRACEPTIVE S LEUCINE DEC V HORMONAL EFFECT (SECOND PART OF CYCLE) P0226
ORAL CONTRACEPTIVE S LIPOPPOTEIN LIPASE DEC V REDUCED RESPONSE TO HEPARIN INJECTION HO 186
OPAL CONTRACEPTIVE S LIPOPROTEINS INC V 50% INC AFTER 6 MONTHS USE P0907
ORAL CONTRACEPTIVE S MAGNESIUM DEC V 0.15 NEQ/L DECREASE REPORTED (ESTROGEN EFFECT) P03 80
ORAL CONTRACEPTIVE S NEFA INC V IF GIVEN FOR 3 MONTHS P0907
ORAL CONTRACEPTIVE S OHOSONUCOID DEC V METABOLIC CHANGES IN LIVER SYNTHESIS (ESTROGEN) P05 88
OPAL CONTRACEPTIVE S PHI INC V ESTROGENS INCREASE CIRCULATING TBG P09 18
OH AL CONTRACEPTIVE S PHOSPHATE DEC V REDUCTION OF APPROXIMATELY 2 MG/100ML P0755
ORAL CONTRACEPTIVE S PHOSPHATE INC V 18% INCREASE REPORTED IN SOME PATIENTS P0657
OPAL CONTRACEPTIVE S PHOSPHOLIPIDS INC V ABOUT 20% HIGHER IN PILL-USERS AFTER 6 MONTHS P0186
OPAL CONTRACEPTIVE S PREALBUMIN INC V METABOLIC CHANGES IN LIVER SYNTHESIS P05 88
OPAL CONTRACEPTIVE S PREBETA-LIPOPROTEINS INC V PROB DUE TO INC APOPROTEIN SYNTHESIS Ho 639
OPAL CONTRACEPTIVE S PROT BINDING COHTISOL INC V WHEN RESULTS ON THERAPY COMPARED WITH NORMAL P00 84
ORAL CONTRACEPTIVE S PROTEIN DEC V ESTROGEN EFFECT R08714
ORAL ONTRACEPTIVE S PYRUVATE INC V GREATER INC THAN NORMAL DURING GTT HO 186
ORAL CONTRACEPTIVE S SCOT INC V HEPATOTOXIC EFFECT (CHOLESTASIS INDUCED) P0566
OPAL CONTPACEPTIVE S SCPT INC V CHOLESTATIC-HEPATOTOXIC EFFECT P0620
ORAL CONTRACEPTIVE S SIALIC ACID DEC V METABOLIC ALTERATION (ESTROGEN EFFECT) P0072
ORAL CONTRACEPTIVE S SODIUM INC V MAY CAUSE SODIUM RETENTION P06 20
ORAL CONT?ACEPTIVE S TBG INC V IN RESPONSE TO AMOUNT OF CIRCULATING ESTROGEN HO 186
OPAL CONTRACEPTIVE S TESTOSTERONE BIND GLOB INC V METABOLIC EFFECT HO 639
OPAL CONTRACEPTIVE S THYROXINE (T14) INC V INCREASED BINDING PROTEIN AVAILABLE P0907
ORAL CONTRACEPTIVE S TIBC INC V ESTROGEN OR PHOGESTOGEN EFFECT (USUALLY PLUS 20%) P09 18
ORAL CONTRACEPTIVE S TOTAL IODINE INC V ALTERED METABOLISM P014 12
OPAL CONTRACEPTIVE S TOTAL PHOSPHATIDES INC V ALTERED METABOLISM HO 448
OPAL CONTRACEPTIVE S TRANSFERHIN INC V METABOLIC CHANCES IN LIVER SYNTHESIS (ESTROGEN) P05 88
OPAL CONTRACEPTIVE S TRIGLYCERIDES INC V IF GIVEN FOR 3 MONTHS IMPAIRED REMOVAL (ESTROGEN) R0907
ORAL ONTRACEPTIVE S TPII000THYPONINE (T3) DEC V DUE TO INCREASE IN TBG P0827
ORAL CONTRACEPTIVE S TYPOSINE DEC V HORMONAL EFFECT (SECOND PART OF CYCLE) HO 226
ORAL CONTRACEPTIVE S T3 UPTAKE DEC V FALLS FROM 80 -100% TO 55 - 90% (RESIN TEST) HO 186
OPAL CONTRACEPTIVE S T4 (MURPHY-PATTER) INC V INCREASED BINDING PROTEIN AVAILABLE(EFFECT 2-4 WKS) P0827
OH AL CONTRACEPTIVE S VALINE DEC V HORMONAL EFFECT (SECOND PART OF CYCLE) P0226
OPAL CONTRACEPTIVE S VITAMIN B12 DEC V PROBABLE INTERFERENCE WITH G.I. ABSORPTION P0982
ORAL CONTRACEPTIVE S ZINC DEC V DURATION OF USE UNRELATED TO ZN CONCENTRATION P04 114
ORAL CONTRACEPTIVE U AICAP INC V OCCURS IF NEGALOBLASTIC ANEMIA DEVELOPS P0976
ORAL CONTRACEPTIVE U ALDOSTEPONE INC V ESTROGEN EFFECT (IN SMALL NUMBER OF PEOPLE) P0 186
ORAL CONTRACEPTIVE U AMINOLEVULINIC ACID INC V MAY PRECIPITATE PORPHYRIA ATTACK P037 1
ORAL CONTRACEPTIVE U ANDHOSTEPONE DEC V COMPARED WTIH CONTROLS - DETAILS NOT DISCUSSED P0162
OPAL CONTRACEPTIVE U CALCIUM DEC V OCCURS WITH FALL IN SERUM CONCENTRATION Hi 016
OPAL CONTRACEPTIVE U COPHOPORPHYRIN INC V NAY INDUCE PORPHYRIA CUTANEA TARDA P0792
ORAL CONTRACEPTIVE U COPTISOL DEC V WHEN RESULTS DUPING THERAPY COMPARED WITH NORMAL RO084
ORAL CONTRACEPTIVE U DEHYDROEPIANDROSTERONE DEC V COMPARED WITH CONTROLS - DETAILS NOT DISCUSSED P0 162
OPAL CONTRACEPTIVE U ESTRADIOL DEC V HORMONAL EFFECT P0593

ORAL CONTRACEPTIVE U ESTRIOL DEC V HORMONAL EFFECT P0593
ORAL CONTRACEPTIVE U ETIOCHOLANOLONE DEC V COMPARED WITH CONTROLS - DETAILS NOT DISCUSSED 20162
OPAL CONTRACEPTIVE U FIGLU INC V RESPONSE TO HISTIDINE TOLERANCE TEST P0858
ORAL CONTRACEPTIVE U FSH DEC V MARKED DEPRESSION IN NORMAL SUBJECTS 90900
ORAL CONTRACEPTIVE U GONADOTROPINS DEC V HORMONAL EFFECT ‘0593
OPAL CONTRACEPTIVE U LH DEC V MARKED DEPRESSION IN NORMAL SUBJECTS 90900
OPAL CONTRACEPTIVE U MAGNESIUM DEC V ASSOCIATED WITH FALL IN SERUM CONCENTRATION HO 3 80
ORAL CONTRACEPTIVE U POHPHOBILINOGEN INC V NAY PRECIPITATE PORPHYRIA ATTACK 90371
OPAL CONTRACEPTIVE U PORPHYPINS DEC V MAY OCCUR IN PTS WITH ESTABLISHED DISEASE PuS 57
OPAL CONTRACEPTIVE U PPEGNANEDIOL DEC V HORMONAL EFFECT (MAY BE ABSENT EXCRETION) H 05 93
ORAL CONTRACEPTIVE U UROBILINOGEN DEC V MAY INDUCE CHOLESTASIS HO 477
ORAL CONTRACEPTIVE U UROPORPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TAPDA H 0792
ORAL CONTRACEPTIVE U XANTHURENIC ACID INC V REVERSED BY PYHIDOXINE (INC TO NICOTINIC ACID) 90657
ORAL CONTRACEPTIVE U 17 KETOGENIC STEROIDS DEC V PPOB DUE TO ESTROGEN DECREASING COPTISOL SECRETION P06 95
OPAL CONTHACEPTIVE U 17 KETOSTEROIDS DEC V PROBABLE DECREASE IN CORTISOL SECRETION P0695
OPAL CONTRACEPTIVE U 17 OH CORTICOSTEHOIDS DEC V PROB DUE TO ESTROGEN DECREASING CORTISOL SECRETION 90695
ORAL CONTRACEPTIVE U 3 OH ANTHRANILIC ACID INC V REVERSED BY PYHIDOXINE (INC TO NICYTINIC ACID) HO 657
ORAL CONTRACEPTIVE U 3 OH KYNUHENINE INC V REVERSED BY PYPIDOXIWE (INC TO NICOTINIC ACID) 90657
OPAL RESINS P AMMONIA INC V EXCHANGED FOP OTHER IONS IN G.I. TRACT HO 299
OHCANOPHOSPHORUS S ALDOLASE INC V HEPATOTOXIC EFFECT 90130
ORGANOPHOSPHORUS S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT H0130
ORGANOPHOSPHOPUS S HILIHUBIN INC V HEPATOTOXIC EFFECT P0130
ORGANOPHOSPHORUS S BSP RETENTION INC V HEPATOTOXIC EFFECT 90130
ORGANOPHOSPHORUS S CEPRALIN FLOCCULATION INC V HEPATOTOXIC EFFECT 90130
ORGANOPHOSPHOPUS S CHOLINESTEHASE DEC V HEPATOTOXIC EFFECT P0130
ORGANOPHOSPHORUS S SCOT INC V HEPATOTOXIC EFFECT HO 130
OPGANOPHOSPHORUS S SGPT INC V HEPATOTOXIC EFFECT 90130
ORGANOPHOSPHORUS S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT HO 130
ORGANOPHOSPHORUS S VITAMIN A DEC V METABOLISM IMPAIRED HO 302
ORGANOPHOSPHORUS U URINALYSIS BILE INC V HEPATOTOXIC EFFECT HO 130
OROTIC ACID S BILIRUBIN DEC V ?INDUCTION EFFECT IN PREMATURE INFANTS ONLY 908141
OVULATION B PLATELET COUNT INC V INCREASES FROM 8TH TO 14TH DAY OF CYCLE 90291
OVULATION S PHI INC V SMALL INC IN OVULATORY AND LUTEAL PHASES HO 255
OVULATION U ESTROGENS INC V RISES TO PEAK AT OVULATION FALLS AFTER P029 1
OVULATION U GONADOTROPINS INC V MAY BE TEMPORARY INCREASE P0291
OVULATION U PPEGNANEDIOL INC V SLIGHT EFFECT 2 DAYS AFTER OVULATION 90291
OXACILLIN H EOSINOPHILS INC V REPORTED EFFECT (?ALLEHGIC) HO 02 6
OXACILLIN B PLATELET COUNT DEC V USUALLY ONLY ASSOC WITH LARGE PAPENTEHAL DOSES P0467
OXACILLIN B RED CELL COUNT DEC V LARGE DOSES PAHENTERAL PENICILLIN NAY HAVE EFFECT HO 1467
OXACILLIN B WHITE CELL COUNT DEC V MAY CAUSE BONE MARROW DEPRESSION 90620
OXACILLIN S ALKALINE PHOSPHATASE INC V CHOLESTATIC JAUNDICE REPORTED IN ONE CASE R0299
OXACILLIN S BILIRUHIN INC V CHOLESTATIC JAUNDICE REPORTED IN ONE CASE P07 22
OXACILLIN S BSP RETENTION INC V CHOLESTATIC JAUNDICE REPORTED IN ONE CASE P02 99
OXACILLIN S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT P06 20
OXACILLIN S CREATININE INC V TRANSIENT AZOTEMIA WITH LARGE DOSES H0026
OXACILLIN S SCOT INC V POSSIBLE HEPATOTOXIC EFFECT HO 59 6
OXACILLIN S SGPT INC V POSSIBLE HEPATOTOXIC EFFECT H 0596
OXACILLIN S THYNOL TURBIDITY INC V REVERSIBLE HEPATOCELLULAR DYSFUNCTION HO 620
OXACILLIN S UREA NITROGEN INC V TRANSIENT AZOTENIA WITH LARGE DOSES H0026
OXACILLIN S 5-NUCLEOTIDASE INC V DUE TO CH0LESTASIS P04 92
OXACILLIN U PROTEIN INC V NEPHROTOXIC EFFECT 90026
OXACILLIN U URINALYSIS BILE INC V REVERSIBLE HEPATOCELLULAR DYSFUNCTION H 06 20
OXACILLIN U URINALYSIS HEMOGLOBIN INC V NEPHROTOXICITY WITH HEMATURIA P00 26
OXACILLIN U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT P0026
OXACILLIN U URINALYSIS HBC/HPF INC V NEPHROTOXICITY WITH HENATURIA P00 26
OXALATES B HEMATOCRIT DEC N SHRINKS RBC, PLASMA VOL INC UP TO 13% P0436
OXALATES B PH DEC M SIGNIFICANT EFFECT OF NH4 OXALATE AS ANTICOAGULANT HO 181
OXALATES B PH INC N OCCURS WITH NA OP K OXALATES AS ANTICOACULANTS HO 181
OXALATES F OCCULT BLOOD P05 V OCCURS AFTER INGESTION H 0368
OXALATES P AMMONIA INC ii EFFECT IF USED AS ANTICOAGULANTS 90215
OXALATES S ACID PHOSPHATASE TOTAL DEC N INHIBITION OF ENZYME IN LABORATORY PROCEDURES 90929
OXALATES S ALKALINE PHOSPHATASE DEC N INHIBITION OF ENZYME IN LABORATORY PROCEDURES 90299
OXALATES S AMYLASE DEC N INHIBITION OF ENZYME IN LABORATORY PROCEDURES 90929
OXALATES S CALCIUM DEC M PRECIPATION OF CALCIUM OXALATE (MAY BE INCOMPLETE) P01436
OXALATES S CALCIUM INC M MAY BE COPRECIPITATION OF NA, K, MG AND PROTEIN P014 36
OXALATES S CHLORIDE DEC N IF USED AS ANTICOAGULANT NAY BE PASSAGE INTO CELLS P014 36
OXALATES S CHOLESTEROL DEC N IF USED AS ANTICOAGULANT (CAUSES WATER SHIFT) HO 4 36
OXALATES S CO2 CONTENT DEC N SIGNIFICANT ALTERATION OF PH IF USED AS ANTICOAG P0181
OXALATES S HBD DEC N ALMOST COMPLETE INACTIVATION OF ENZYME P07 79
OXALATES S LACTIC DEHYDROGENASE DEC N INHIBITION OF ENZYME ACTIVITY HO 929
OXALATES S LITHIUM INC N IF LITHIUM SALT OF OXALATES P04 36
OXALATES S NPN INC N “BALANCED” OXALATE MIXTURE CONTAINS NH14 P014 36
OXALATES S NPN INC V ACUTE RENAL FAILURE WITH CA OXALATE DEPOSITION P03 814
OXALATES S PH INC N IN VITRO ADDITION OF K SALT TO PLASMA/SERUM R0035
OXALATES S POTASSIUM INC N IF POTASSIUM SALT OF OXALATE P04 36
OXALATES S SALICYLATE INC N 250 MG/100NL GIVE EQUIV OF 0.3 MG/100ML BY TRINDEH 90606
OXALATES S SCOT Z N NO EFFECT ON ACTIVITY P0825
OXALATES S SODIUM INC N IF SODIUM SALT OF OXALATE HO 1436
OXALATES S THYMOL TURBIDITY DEC V REPORTED: NO MECHANISM CITED 90181
OXALATES S UREA NITROGEN INC N “BALANCED” OXALATE MIXTURE CONTAINS NH4 HO 1436
OXALATES U ALPHA AMINO NITROGEN INC V OXALIC ACID NAY CAUSE RENAL DAMAGE P0143
OXALATES U CALCIUM DEC N NAY BE INCOMPLETE PRECIPITATION 90436
OXALATES U CALCIUM INC N MAY BE COPRECIPITATION OF NA, K, MC R0436
OXALATES U PROTEIN INC V IF INGESTED MAY CAUSE NEPHHOTOXICITY P0368
OXALATES U URINALYSIS CRYSTALS INC V OXALATE CRYSTALS PRESENT IN URINE IN POISONING HO 358
OXALATES U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT IF INGESTED 30368
OXALATES U URINALYSIS RBC/HPF INC V NEPHROTOXIC EFFECT IF INGESTED P0 368
OXALATES U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S 90836
OXALOACETATE S SCOT DEC M INHIBITS COLOHIMETRIC METHOD 90990
OXANDPOLONE P FIBRINOGEN INC V METABOLIC EFFECT 90072

OXA NOR OLONE P PLASMINOGEN INC V METABOLIC EFFECT RO072
OXA NDPOL0N S BSP RETENTION INC V SLIGHT INC IN ONE CRILD(OTHER LFT NORMAL) P01483
OXANDROLON! S CHOLESTEROL DEC V ANABOLIC EFFECT P0369
OXA NDROL ONE S GLUCOSE DEC V ANABOLIC EFFECT P0369
OXANDROLONE S HAPTOGLOBIN INC V METABOLIC EFFECT P0072
OXA NDPOLONE S SIALIC ACID INC V METABOLIC EFFECT P0072
OXAND9OLONE S TRIGLYCERIDES DEC V INCREASES TRIGLYCERIDE HYDROLYSIS PERIPHERALLY P0369
OX AZ EPA M B ROSINOPHILS INC V RAPE ALLERGIC RESPONSE P0026
OX AZEP AM B WHITE CELL COUNT DEC V LEUKOPENIA OCCURS RARELY P0620
OXAZEPA N S ALKALINE PHOSPHATASE INC V POSSIBLE HEPATOTOXICITY P0620
OX AZEP AN S BILIRUBIN INC V POSSIBLE HEPATOTOXICITY P0620
OX AZE PA N S BSP RETENTION INC V POSSIBLE HEPATOTOXICITY P0620
OX AZ EPAM S CEPHALIN FLOCCULATION INC V POSSIBLE HEPATOTOXICITY P0620
OX AZE PA N S GLUCOSE INC M FILLER AFFECTS 0-TOLUIDINE, NEOCUPROINE METHODS R0652
OX AZE PA N S SCOT INC V POSSIBLE HEPATOTOXICITY P0620
OXAZEPAM S SCPT INC V POSSIBLE HEPATOTOXICITY P0620
OX AZ E PA N S THYMOL TURBIDITY INC V POSSIBLE HEPATOTOXICITY P0620
0 X A ZE PAM U URINALYSIS BILE INC V POSSIBLE HEPATOTOXICITY P0620
OXY NETHOLONE F UPOBILINOCEN DEC V CHOLESTATIC EFFECT P01477
OXYMETHOLOME P IBPINOGEN INC V METABOLIC EFFECT P0072
OXYMETHOLONE P PLASMINOGEN INC V METABOLIC EFFECT P0072
OXYMETHOLONE P PROTHHOMBIN TINE INC V ALSO SEEN WITH OTHER 17-ALKYL SUBSTITUTED STEROIDS P0295
OXYMETHOLONE S ALKALINE PHOSPHATASE INC V CHOLESTATIC EFFECT P0477
OXYMETHOLON S ALPHA1-ANTITRYPSIN INC V METABOLIC EFFECT P0072
OXY MET HOL ONE S BETA-GLUCURONIDASE INC V METABOLIC EFFECT P0072
OXY METHOLONE S BILIPUBIN INC V CHOLESTATIC EFFECT P0477
OXY NET H OL ONE S BSP RETENTION INC V CHOLESTATIC EFFECT P01477
OXY METH OLONE S CEPULOPLASMIN Z V NO METABOLIC EFFECT P0072
OXYMETHOLONE S CHOLESTEROL INC V CHOLESTATIC EFFECT P0477
OXY METHOLONE S HAPTOGLOBIN INC V METABOLIC EFFECT P0072
OXYMETHOLONE S OROSOMUCOID INC V ANABOLIC METABOLIC EFFECT P0072
OXY MET H OL ONE S PBI DEC V REDUCES CONCENTRATION OF CIRCULATING TBG R0004
OXYMETHOLONE S SCOT INC V CHOLESTATIC EFFECT (INC UP TO 6 TIMES NORMAL) P01477
OXY METHOLONE S SGPT INC V CHOLESTATIC EFFECT (INC UP TO 6 TIMES NORMAL) P0477
OXY MET HOLONE S SIALIC ACID INC V METABOLIC EFFECT H0072
OXY MET HOLONE S TBG DEC V DIRECT EFFECT OF DRUG R0004
OX! METHOLON E S TRIGLYCERIDES DEC V ANABOLIC EFFECT P0098
OXYMETHOLONE U UROBILINOGEN DEC V CHOLESTATIC EFFECT P01477
OX! PH E NB UTA ZONE B HEMATOCRIT DEC V DILUTIONAL EFFECT OF WATER RETENTION P0384
OXYPHENBIJTA ZONE B HEMOGLOBIN DEC V DILtJTIONAL EFFECT OF WATER RETENTI ON P0384
OXY PHE NB U TA EON E B PLATELET COUNT DEC V THPOMBOCYTOPENIA NAY OCCUR AFTER 1 WEEK THERAPY P0620
OXYPHENBUTA ZONE B RED CELL COUNT DEC V MAY CAUSE BLOOD DYSCRASIAS P0620
OXYPHENBUTAZON 9 B WHITE CELL COUNT DEC V AGPANULOCYTOSIS/LEUKOPENIA P0620
OXYPHENBUTA ZONE B WHITE CELL COUNT INC V LEUKEMIA REPORTED TO DEVELOP IN 2 SUBJECTS P0657
OX! PH E NBIJ TA Z ONE F OCCULT BLOOD P05 V MAY CAUSE GASTROINTESTINAL BLEEDING P0026
OXYPHENBUTAZONE P PHOTHROMBIN TIME INC V DISPLACES ANTICOAGULANTS FROM ALBUMIN P0620
OXYPH ENBU TA ZONE P VOLUME INC V MAY CAUSE MARKED SALT AND WATER RETENTION P0384
OXYPHENBUTZONE S ALKALINE PHOSPHATASE INC V POSSIBLE HEPATOTOXICITY P0620
OXYPHENBUTA ZONE S AMYLAS! INC V PAROTITIS IS RAPE COMPLICATION OF THERAPY P0398
OX! PHFNBUTAZONE S BILIPUBIN INC V POSSIBLE HEPATOTOXICITY R062O
OXYPHE NBUTA ZONE S BSP RETENTION INC V POSSIBLE HEPATOTOXICITY R0620
OXY PHENBUTAZONE S CEPHALIN FLOCCULATION INC V POSSIBLE HEPATOTOXICITY P0620
OXYPHE NBUTA ZONE S CHLORIDE INC V NAY CAUSE MARKED SALT HETENTION RO620
OX! PH E NB UTA ZONE S I 131 UPTAKE DEC V SANE ACTION AS OTHER DRUGS OF CLASS P0657
OXYPHENBUTA ZONE S PBI DEC V INHIBITS IODINATION OF TYPOSINE IN TBG P0004
OXYPHENBUTA ZONE S SCOT INC V POSSIBLE HEPATOTOXICITY P0620
OXYPHENBUTA ZONE S SGPT INC V POSSIBLE HEPATOTOXICITY P0620
OX! PH E NBU TA ZONE S SODIUM INC V MAY CAUSE MARKED SALT RETENTION P0620
OXYPHENBUTAZONE S THYMOL TURBIDITY INC V POSSIBLE HEPATOTOXICITY P0620
OXYPHENBUTAZONE S UREA NITROGEN INC V NAY OCCUR WITH PENAL DAMAGE P0596
OXYPHENBUTA ZONE S URIC ACID DEC V URICOSURIC EFFECT P0217
OX! P HE NBU TA Z ONE U URINALYSIS BILE INC V POSSIBLE HEPATOTOXICITY P0620
OXYP HEN BUT AZONE U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG P0299
OXYPHE NBUTA ZONE U URINALYSIS RBC/HPF INC V NAY CAUSE ACTUAL BLEEDING P0299
OX Y PHEN BU TA ZONE U VOLUME DEC V MAY CAUSE MARKED WATER RETENTION P0384
OXYPHENISATIN B LE CELL PREP P05 V MAY CAUSE LUPOID HEPATITIS P0776
OXYPHENISATIN P PHOTHPOM?IN TIME INC V MAY CAUSE HYPERSENSITIVITY REACTION P0776
OXYPHENISATIN S ALBUMIN DEC V MAY CAUSE HYPERSENSITIVITY REACTION R0776
OX! PHENI SATIN S ALKALINE PHOSPHATASE INC V HEPATIC TOXICITY IF OVER PROLONGED PERIOD P0727
OXYPHFN ISATIN S ANTINUCLEAR ANTIBODIES P05 V MAY CAUSE HYPERSENSITIVITY REACTION P0776
OXYPHENISATIN S BILIHUBIN INC V HEPATIC TOXICITY IF OVER PROLONGED PERIOD P0727
OXYPHENISATIN S BSP RETENTION INC V MAY CAUSE HYPERSENSITIVITY REACTION P0776
OXYPHENISATIN S CEPHALIN FLOCCULATION INC V NAY CAUSE HYPEPSENTIVIT! REACTION RO776
OXYPHENISATIN S COONBS TEST POS V NAY CAUSE HYPERSENSITIVITY REACTION P0776
OXYP9ENISATIN S GLOBULIN INC V MAY CAUSE HYPERSENSITIVITY REACTION P0776
OXYPHENISATIN S SGOT INC V HEPATIC TOXICITY IF OVER PROLONGED PERIOD P0727
OXYPHENISATIN S SCPT INC V MAY CAUSE HYPERSENSITIVITY REACTION R0776
OXYPHENIS AIIM S SMOOTH MUSCLE ANTIBODY P05 V ASSOCIATED WITH HYPERSENSITIVITY REACTION P0037
OXYPHENISATIN S THYMOL TURBIDITY INC V MAY CAUSE HYPERSENSITIVITY REACTION P0776
OXYPHENISATIN U URINALYSIS BILE INC V NAY CAUSE HYPERSENSITIVITY REACTION P0776
OXYTETRACYCLINE C PROTEIN INC N REACTS AS IF PHENOL WITH FOLIN-CIOCALTEU PROCEDURE P1026
OXYTETRACYCLINE P CATECHOLAMINES INC N INTERFERES WITH FLUOHONETRIC METHODS R1001
OXYTETPACYCLINF S BARBITURATE Z N NO EFFECT ON UV ABSORPTION METHODS R0779
OXYTETPACYCLINE S GLUCOSE DEC V MILD HYPOGLYCEMIC EFFECT OBSERVED IN DIABETICS P0852
OXYTETRACYCLINE S GLUCOSE TOLERANCE DEC V EFFECT OBSERVED IN ANIMALS P0070
OXYTETPAC!CLINE U FOLAT? INC V WITH DOSE OF 2.5 C/DAY P0384
OXYTET9 ACYCL IN! U METANEPHRINES TOTAL INC N INTERFERES WITH FLUORONETRIC METHODS P1001
OXYTET HACYCLINE U N-METHYLNICOTINANIDE INC V WITH DOSE OF 2.5 G/DAY P0384
OX!TETPACYCLINE U NITROGEN INC V OBSERVED IN MALNOURISHED P0384
OX YT ET PA C Y C LI NE U PORPHYRINS INC N PRODUCES INTERFERING FLUORESCENCE R0356

OXYTETRACYCLINE U RIBOFLAVIN INC V WITH DOSE OF 2.5 C/DAY P0384
0 XYTETH ACYCLINE U URINALYSIS GLUCOSE DEC N AFFECTS DIPSTICKS IF BUFFERED WITH ASCORBIC ACID P0 4 36
OXYTETHACYCLINE U URINALYSIS SUGAR INC N ACTS AS REDUCING AGENT 91001
OXYTETR ACYCLINE U VMA INC M PRODUCES INTERFERING COLOR 91001
PAIN U ADH INC V ALSO SEEN MOPE MARKEDLY WITH EMOTIONAL STRESS P05149
PAIN U EPINEPHPINE INC V ALSO SEEN MOPE MARKEDLY WITH EMOTIONAL STRESS HO 5149
PAIN U NOREPINEPHRINE INC V ALSO SEEN BUT LESS MARKEDLY WITH EMOTIONAL STRESS HO 5149
PAIN U VOLUME DEC V SLIGHT CHANGES IN RESPONSE TO STRESS SITUATIONS P054 9
PAMAQUINE B HEINZ-BODY FORMATION P05 V MAY OCCUR IN EARLY STAGES OF HENOLYSIS 901014
PA MAQUINE B HENATOCPIT DEC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS P0240
PANAQUINE B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS HO 2 40
PA NAQUINE B METHENOGLOBIN INC V MAY CAUSE HENOLYSIS IN G-6-PD DEFICIENCY P 09 26
PAMAQUINE B RED CELL COUNT DEC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS P0240
PAMAQUINE S BILIPUBIN INC V MAY CAUSE HENOLYSIS IN G-6-PD DEFICIENCY P007 9
PAMAQUINE S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA HO 2 40
PAMAQUINE U URINALYSIS COLOR INC M BROWN COLOR HO 299
PANCREOZYMIN 0 PANCREAT JUICE PROTEIN INC V INCREASE IN RESPONSE TO CHALLENGE 20151
PA NCREOZYNIN P INSULIN INC V I.V. INFUSION CAUSES INCREASE P01491
PA NCREOZYM IN S ANYLASE INC N PREPARATION CONTAINS AMYLASE HO 355
PANCHEOZYMIN S ANYLASE INC V EFFECT SEEN WHEN PANCREATIC DISORDERS,?IN NORMALS 90875
PANCREOZYNIN S GLUCOSE INC V I.V. INFUSION CAUSES INCREASE 901491
PA NCPEOZYNIN S LIPASE INC N PREPARATION CONTAINS LIPASE H 0355
PAPAVEHINE B EOSINOPHILS INC V ALLERGIC RESPONSE REPORTED TO OCCUR P0 867
PA PA VERINE S ALKALINE PHOSPHATASE INC V REVERSIBLE HEPATOTOXIC EFFECT P0793
PAPAVER INE S BILIHUBIN INC V SMALL EFFECT, REVERSIBLE HYPERSENSITIVITY REACTION HO 855
PA PA VERINE S SCOT INC V PROBABLE HYPERSENSITIVITY REACTION RO 793
PAPAVERINE S SGPT INC V PROBABLE HYPERSENSITIVITY REACTION 90793
PAHABPOMDYLANINE S I 131 UPTAKE DEC V EFFECT OBSERVED IN SOME PATIENTS P02 55
PAPABROMDYLANINE S PHI DEC V INHIBITS IODINATION OF TYROSINE IN TBG R00014
PARALDEHYDE B PHDEC V ACIDOTIC ACTION 90620
PAR ALDEHYDE B WHITE CELL COUNT INC V LEUKOCYTOSIS IN SEVERE ACUTE OR CHRONIC POISONING HO 384
PAHALDEHYDE F OCCULT BLOOD P05 V BLEEDING GASTPITIS IN ACUTE OH CHRONIC POISONING HO 3814
PAR ALDE HYDE S ALKALINE PHOSPHATASE INC V POSSIBLE HEPATOTOXICITY P0620
PAPA LDE HYDE S BILIRUBIN INC V POSSIBLE HEPATOTOXICITY H 0620
PAPALDEHY DE S BSP RETENTION INC V POSSIBLE HEPATOTOXICITY 90620
PAP A LDE HYDE S CEPHALIN FLOCCULATION INC V POSSIBLE HEPATOTOXICITY P06 20
PAHALDEHY DE S CO2 CONTENT DEC V METABOLIC ACIDOSIS IN PARALDEHYDE HABITUES H0384
PAPALDE HYDE S CREATININE INC V POSSIBLE NEPHROTOXICITY 90407
PA PALDEHY DE S GLUCOSE INC V HAS CAUSED TRANSIENT HYPERGLYCEMIA P0596
P AR ALDEHYDE S KETONES INC V TRANSIENT HYPERGLYCEMIA AND KETOSIS HO 596
PARALDEHYDE S SCOT INC V POSSIBLE HEPATOTOXICITY P06 20
PAR ALDEHYDE S SGPT INC V POSSIBLE HEPATOTOXICITY HO62O
PAHALDEHYDE S THYMOL TURBIDITY INC V POSSIBLE HEPATOTOXICITY P06 20
PAP ALDEHYDE S UREA NITROGEN INC V POSSIBLE NEPHROTOXICITY IN POISONING HO 1407
PA PA LDE HYDE U PROTEIN INC V NEPHPOTOXIC EFFECT (NEPHPOSIS WITH POISONING) R01407
PAR AL DEHY 0! U URINALYSIS BILE INC V POSSIBLE HEPATOTOXICITY H062O
PAR ALDEHYDE U URINALYSIS KETONES INC N FALSE P05 WHEN DRUG COMBINED WITH ETHANOL HO 407
PARALDEHYDE U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT (NEPHROSIS WITH POISONING) R04O7
PARALDE HYDE U 17 OH CORTICOSTEPOIDS INC N INTERFERES WITH POPTER-SILBER REACTION P0907
PAHAMETHADIONE B NEUTROPHILS DEC V MAY OCCUR WITHOUT OVERALL EFFECT ON NBC P0146 7
PAR AMETHADIONE B PLATELET COUNT DEC V APLASTIC ANEMIA MAY OCCUR RARELY 90026
PARANETHADIONE B RED CELL COUNT DEC V APLASTIC ANEMIA NAY OCCUR RARELY P06 20
PAHAMETHADIONE B WHITE CELL COUNT DEC V APLASTIC ANEMIA/NEUTROPENIA P00 26
PAPAMETHA DI ONE F OCCULT BLOOD P05 V G.I. BLEEDING MAY OCCUR (CAN AFFECT MANY ORGANS) P04 67
PAR AMETRADIONE S ALKALINE PHOSPHATASE INC V POSSIBLE HEPATOTOXICITY P06 20
PAPA METHA DIONE S BILIRUBIN INC V POSSIBLE HEPATOTOXICITY P0620
PARANETHADIONE S BSP RETENTION INC V POSSIBLE HEPATOTOXICITY P0620
PARAMETHADIONE S CEPHALIN FLOCCULATION INC V POSSIBLE HEPATOTOXICITY P06 20
PAHAMETHADIONE S CHOLESTEROL INC V POSSIBLE LIVER DAMAGE P06 20
PAHANET HADIONE S CREATININE INC V POSSIBLE NEPHPOTOXICITY HO 620
PA PAMETHADIONE S SGOT INC V POSSIBLE HEPATOTOXICITY P06 2 0
PARAMETHADIONE S SGPT INC V POSSIBLE HEPATOTOXICITY HO 620
PA RANETHA DI ONE S THYMOL TURBIDITY INC V POSSIBLE HEPATOTOXICITY P0620
PARAMETHADIONE S UREA NITROGEN INC V POSSIBLE NEPHHOTOXICITY HO 6 20
PA PA NETHA DI ONE U PROTEIN INC V MAY HAVE NEPHROTOXIC EFFECT H0677
PAR ANETHADIONE U URINALYSIS BILE INC V POSSIBLE HEPATOTOXICITY 90620
PAPANETHA DI ONE U URINALYSIS CASTS INC V MAY HAVE NEPHHOTOXIC EFFECT P 0620
PARANETHADIONE U URINALYSIS PROTEIN INC V MAY HAVE NEPHROTOXIC EFFECT P0677
PA HA NETHA SON! U SODIUM INC V NAY BE EXCRETED ALTHOUGH EDEMA MAY OCCUR P 0026
PARATHION B WHIT! CELL COUNT DEC V LEUKOPENIA (AMA-BLOOD DYSCRASIAS) HO 658
PARATHION S CHOLINESTERASE DEC V INHIBITORY ACTION OF DRUG WITH POISONING 90368
PAPATHYHOID EXTRACT S CALCIUM INC V INCREASED CALCIUM MOBILIZATION FROM BONE H02014
PARATHYROID EXTRACT S MAGNESIUM INC V DUE TO DECREASED RENAL EXCRETION HO 3814
PARATHYPOID EXTRACT S PHOSPHATE INC V DUE TO INCREASED EXCRETION IN URINE P06 20
PARATHYHOID EXTRACT U AMINO ACIDS INC V HORMONAL ACTION 90384
PARATHYROID EXTRACT U BICARBONATE INC V INHIBITS TUBULAR EXCHANGE OF NA FOR H RO699
PAPATHYROID EXTRACT U CALCIUM DEC V INCREASES TUBULAR REABSORPTION P00 26
PARATHYROID EXTRACT U CHLORIDE INC V HORMONAL ACTION a 0384
PAHATHYPOID EXTRACT U CITRATE INC V HORMONAL ACTION R0384
PARATHYROID EXTRACT U MAGNESIUM DEC V DECREASED CLEARANCE P01406
PARATHYPOID EXTRACT U PH INC V INHIBITS TUBULAR EXCHANGE OF NA FOR H HO 6 99
PAPATHYROID EXTRACT U PHOSPHATE INC V INCREASED CLEARANCE P 0406
PARATHYPOID EXTRACT U POTASSIUM INC V INCREASED CLEARANCE H0406
PARATHYROID EXTRACT U SODIUM INC V INCREASED CLEARANCE P01406
PAHATHYROID EXTRACT U SULFATE INC V HORMONAL ACTION HO 3814
PAPATHYROID EXTRACT U URINALYSIS PH INC V INHIBITS TUBULAR EXCHANGE OF NA FOR H P06 99
PAHATHYPOID EXTRACT U VOLUME INC V HORMONAL ACTION 903814
PARGYLIN! B PERIPHERAL SMEAR V POIKILOCYTOSIS AND ANISOCYTOSIS COMMON P06 57
PARGYLINE S ALKALINE PHOSPHATASE INC V POSSIBLE HEPATOTOXICITY (REVERSIBLE) R062O
PARGYLINE S BILIRUBIN INC V POSSIBLE HEPATOTOXICITY (REVERSIBLE) HO 620

PAPGYLINE S BSP RETENTION INC V POSSIBLE HEPATOTOXICITY (REVERSIBLE) HO 620
PA RGYLINE S CEPHALIN FLOCCULATION INC V POSSIBLE HEPATOTOXICIT! (REVERSIBLE) P062 0
PAHGYLIN! S GLUCOSE DEC V POSSIBLE HEPATOTOXIC EFFECT P06 20
PAPGYLINE S GLUCOSE TOLERANCE INC V FLAT CURVE MAY BE PRODUCED RO596
PARGYLIN! S SGOT INC V POSSIBLE HEPATOTOXICITY (REVERSIBLE) P06 20
PARGYLI NE S SGPT INC V POSSIBLE HEPATOTOXICITY (REVERSIBLE) P0620
PARGYLINE S THYMOL TURBIDITY INC V POSSIBLE HEPATOTOXICITY (REVERSIBLE) P0620
PARGYLI NE S UREA NITROGEN INC V POSSIBLE DEC IN ALREADY IMPAIRED RENAL FUNCTION R0O29
PARGYLINE U URINALYSIS BILE INC V POSSIBLE HEPATOTOXICITY (REVERSIBLE) P06 20
PARONOMYCIN S CHOLESTEROL DEC V REDUCTION UP TO 18%. ?MECHANISM P0818
PARONOMYCIN S UREA NITROGEN INC V POTENTIALLY NEPHROTOXIC IF GIVEN PARENTEHALLY P0026
PAROMOMYCIN U PROTEIN INC V POTENTIALLY NEPHROTOXIC IF GIVEN PARENTEPALLY HO 0 26
PAROMOMYCIN U URINALYSIS PROTEIN INC V POTENTIALLY NEPHROTOXIC IF GIVEN PAPENTEHALLY P00 26
PECAZI NE S ALKALINE PHOSPHATASE INC V MAY ALTER LIVER FUNCTION (CHOLESTASIS) P062 0
PECAZINE S BILIRUBIN INC V MAY ALTER LIVER FUNCTION (CHOLESTASIS) P06 20
PECAZI NE S BSP RETENTION INC V MAY ALTER LIVER FUNCTION (CHOLESTASIS) P062 0
PECAZINE S CEPHALIN FLOCCULATION INC V NAY ALTER LIVER FUNCTION (CHOLESTASIS) P06 20
PECAZI NE S SCOT INC V MAY ALTER LIVER FUNCTION (CHOLESTASIS) P0620
PECAZINE S SGPT INC V MAY ALTER LIVER FUNCTION (CHOLESTASIS) P0620
PECAZI NE S THYMOL TURBIDITY INC V MAY ALTER LIVER FUNCTION (CHOLESTASIS) P0620
PECAZINE U URINALYSIS BILE INC V MAY ALTER LIVER FUNCTION (CHOLESTASIS) P0620
PEMPIDINE S URIC ACID INC V ?DUE TO REDUCED PENAL BLOOD FLOW HO 275
PE NET HA N ATE S PBI INC N CONTAINS IODINE P0907
PENICILLANINE B EOSINOPHILS INC V MAY OCCUR WITH HASH P0026
PENICILLA MINE B HEMATOCHIT DEC V HYPOCHROMIC ANEMIA IN CHILD, MENSTRUATING WOMAN P0022
PENICI LLA MINE B HEMOGLOBIN DEC V H!POCHROMIC ANEMIA IN CHILD, MENSTRUATING WOMAN R0022
PE NIC ILLA MINE B MCHC DEC V HYPOCHRONIC ANEMIA IN CHILD, MENSTRUATING WOMAN P00 22
PENICILLA MI NE B PLATELET COUNT DEC V THROMBOCYTOPENIA MAY OCCUR WITH RASH P0022
PENICILLA NINE B RED CELL COUNT DEC V HYPOCHHOMIC ANEMIA IN CHILDREN & MENST. FEMALES P00 22
PENICILLA NINE B WHITE CELL COUNT DEC V LEUKOPENIA MAY OCCUR WITH RASH P0022
PENICILLA MINE S ALKALINE PHOSPHATASE INC V POSSIBLE HEPATOTOXICITY P0299
PENICI LLA MINE S CEPHALIN FLOCCULATION INC V POSSIBLE HEPATOTOXICITY P06 20
PENICILLAMINE S CHOLESTEROL INC V SINGLE CASE REPORTED P0417
PENICI LLA MINE S CREATININE INC V POSSIBLE NEPHROTOXICITY HO 355
PENICILLAMINE S SCOT INC V POSSIBLE HEPATOTOXICITY P0620
PENICILLA MINE S SGPT INC V POSSIBLE HEPATOTOXICITY H0620
PENICILLAMINE S THYMOL TURBIDITY INC V POSSIBLE HEPATOTOXICITY R0620
PENICILLA MINE S UREA NITROGEN INC V POSSIBLE NEPHROTOXICITY P0355
PENICILLAMINE U COPPER INC V IF POISONING DUE TO COPPER P0026
PENICILLA NINE U CYSTINE INC V IF CYSTINUPIA P00 26
PENICILLAMI NE U IRON INC V IF POISONING DUE TO IRON P0026
PENICILLA MINE U KYNURENINE INC V INDUCES PYPIDOXINE ANTAGONISM P0384
PENICILLA MINE U LEAD INC V IF POISONING DUE TO LEAD P0026
P!NICILLAMINE U MERCURY INC V RELATED TO DRUG DOSAGE IN TOXICITY CASES P0911
PENICI LLA MINE U PROTEIN INC V NEPHHOTOXIC EFFECT P 03 55
PENICILLAMINE U URINALYSIS PROTEIN INC V NEPHPOTOXIC EFFECT HO 355
PENICILLA MINE U XANTHURENIC ACID INC V INDUCES PYRIDOXINE ANTAGONISM HO 384
PENICILL AMINE U ZINC INC V IF POISONING DUE TO ZINC P0 384
PENICILLIN B EOSINOPHILS INC V ALLERGIC REACTION (MAY BE UP TO 20% OF ALL WBC) R0294
PENICILLIN B HEMATOCPIT DEC V HEMOLYTIC ANEMIA DUE TO BINDING TO ERYTHHOCYTES P02 94
PENICILLIN B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA DUE TO BINDING TO EHYTHROCYTES R0294
PENICILLIN B LE CELL PREP P05 V ALLERGIC RESPONSE WITH URTICARIA IN ONE CASE P03 84
PENICILLIN B NEUTROPHILS DEC V AGRANULOCYTOSIS/LEUKOPENIA P07 11
PENICILLIN H PLATELET COUNT DEC V AGRANULOCYTOSIS/THROMBOCYTOPENIA P0294
PENICILLIN B RED CELL COUNT DEC V HEMOLYTIC ANEMIA DUE TO BINDING TO EHYTHROCYTES HO 294
PENICILLI N B RETICULOCYTES INC V CONSEQUENCE OF HEMOLYTIC ANEMIA P02 94
PENICILLIN B WHITE CELL COUNT DEC V AGPANULOCYTOSIS/LEUKOPENIA P07 11
PENICILLIN C PROTEIN INC N CAUSES TURBIDITY IF SULFOSALICYLIC ACID USED P0907
PENICILLIN C PROTEIN INC M REACTS AS IF PHENOL WITH FOLIN-CIOCALTEU PROC P 1026
PENICI LLI N S BARBITURATE Z N NO EFFECT ON UV ABSORPTION METHODS RO779
PENICILLIN S BILIRUBIN DEC V COMPETES FOR ALBUMIN BINDING SITES P0907
PENICILLIN S BILIHUBIN INC V NON SPECIFIC HEPATITIS WITHOUT CHOLESTASIS P1001
PE N ICI LL I N S CPK INC V FREQUENT INJECTIONS MAY CAUSE INC UP TO 5 TIMES HO 4 43
PENICILLIN S CREATININE INC V HYPERSENSITIVITY REACTION OR NEPHROPATHY P0384
PENICILLI N S DIRECT COOMBS TEST P05 V COMBINES TO HBC, IMMUNOGLOBULINS DEVELOP TO DRUG P014 18
PENICILLIN S ELECTPOPHORESIS P05 M CAUSES BISALBUMINENIA P0 907
PENICI LLI N S FOLATE DEC N INHIBITS GROWTH OF L CASEI P0907
PENICILLIN S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA HO 620
PENICILLIN S I 131 UPTAKE DEC V IF HYDRIODIDE SALT GIVEN DECS FURTHER UPTAKE P05 96
PENICILLIN S INDIRECT COOMBS TEST P05 V COMBINES TO RBC, IMNUNOGLOBULINS DEVELOP TO DRUG P04 18
PENICILLI N S PHI INC N IF GIVEN AS HYDRIODIDE SALT P0596
PENICILLIN S POTASSIUM DEC V IF I.V. SODIUM PENICILLIN INFUSED P0907
PENICI LLI N S POTASSIUM INC V MAY OCCUR IF K SALT GIVEN I.V. ALSO ALKALOSIS P0907
PENICILLIN S SGOT INC V NONSPECIFIC HEPATITIS .WITHOUT CHOLESTASIS P1001
PENICILLIN T PROTEIN INC N MASSIVE DOSES NAY CAUSE TURBIDITY WITH ACID TESTS P0620
PENICILLIN U MERCURY INC V ACTS AS CHELATING AGENT IN ACRODYNIA AT LEAST P0568
PENICILLIN U POTASSIUM INC V IF I.V. SODIUM PENICILLIN INFUSED P0907
PENICILLIN U PROTEIN INC N CAUSES TURBIDITY IF SULFOSALICYLIC ACID USED P0907
PENICILLIN U PROTEIN INC V NEPHHOTOXICITY MAY OCCUR WITH LARGE DOSES HO 384
PENICILLIN U PSP EXCRETION DEC V INTERFERENCE WITH PSP EXCRETION R1001
PENICILLIN U SUGAR INC N FALSE POSITIVE WITH COPPER REDUCTION PROCEDURES P0907
PENICILLI N U URINALYSIS CASTS INC V RENAL CELL AND OTHER TYPES P0384
PENICILLIN U URINALYSIS GLUCOSE Z N NO EFFECT ON CLINISTIX OP TESTAPE HO 683
PENICILLIN U URINALYSIS HEMOGLOBIN INC V HYPERSENSITIVITY REACTION , NEPHROTOXICITY P0068
PENICILLIN U URINALYSIS PROTEIN INC N MASSIVE DOSES MAY PRODUCE TURBIDITY WITH ACID HO 1143
PENICILLIN U URINALYSIS PROTEIN INC V NEPHROTOXICITY NAY OCCUR WITH LARGE DOSES HO 38 14
PENICILLIN U UHINALYSIS PROTEIN Z :i NO EFFECT ON ALBUSTIX EVEN WITH MASSIVE DOSES HO143
PENICILLIN U URINALYSIS RBC/HPF INC V HYPERSENSITIVITY REACTION, NEPHROTOXICITY P0068
PENICILLIN U 17 KETOGENIC STEROIDS INC N INTERFERES WITH ZIMMERMAN (NORYMBEHSKI) REACTION HO 9 07
RE NICILLIN U 17 KETOSTEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION P0907

PENiCILLIN U 17 OH COPTICOSTEROIDS INC M ? INTERFERES WITH POPTE9-SILBER REACTION R0596
PENTAGASTHIN 0 GAS.TRIC JUICE HCL INC V IF INFUSED I.V. HO 209
PENTACASTRIN 0 GASTRIC JUICE PEPSIN INC V IF INFUSED I.V. RC2C9
PENTANIDINE B HEM.ATOCHIT DEC V NIGAL0BLAST ANEMIA-INHIBITS DIHYDROFOLATE PEDUCTASE HO 976
PENTA MIDINE B HEMOGLOBIN DEC V MEGALOBLAST ANEMIA-INHIBITS DIHYDROFOLATE R±MUCTASE PC 976
RE N T A MI D I NE B MCV INC V MEGALOBLASTIC ANEMIA P)976
PNTAMIDINE B RED CELL COUNT DEC V MEGALOBLAST ANEMIA-INHIBITS DIHYDROiOLATE REDUCTASE P0976
PENTANIDIN? S FOLATE DMC V INHIBITS DIHYDROFOLATE REDUCTASE P0976
PENTAMIDINE S GLUCOSE DEC V HYPOGLYCEMIA - POSSIBLE EFFECT H 0384
PENTAMIDINE S GLUCOSE INC V PARADOXICAL EFFECT OBSERVED H 0384
PENT AMIDINE S UREA NITROGEN INC V REVERSIBLE RENAL DYSFUNCTION REPORTED R0384
PENTAMIDINE U AICAR INC V IF MEGALOBLASTIC ANEMIA DEVELOPS P 0976
PENTAMIDINE U FIGLU INC V IF MEGALOBLASTIC ANEMIA DEVELOPS H C 976
PENTAQUINE B HEINZ-BODY FORMATION P05 V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY RC104
PENTAQUINE B HEMATOCPIT DEC V NAY CAUSE HENOLYSIS WITH G-6-PD DEFICIENCY PC 079
PENTAQUIN 9 B HEMOGLOBIN DEC V MAY CAUSE HENOLYSIS WITH G-6-PD DEFICIENCY H 0079
PFNTAQUINE B METHEMOGLOBIN INC V MAY CAUSE HENOLYSIS IN G-6-PD DEFICIENCY P0926
PENTAQUINE B RED CELL COUNT DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY R0C79
PENTAQUINE S BILIHUBIN INC V MAY CAUSE HENOL!SIS WITH G-6-PD DEFICIENCY RCC’79
PENTAQUINE S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYSIS P0079
PENTAZOCINE B PCO2 INC V HIGH DOSES PRODUCE MARKED #{149}RESPDEPRESSION P0384
PENTAZOCINE F COPROPORPHYRIN INC V NAY PRECIPITATE ACUTE PORPHYRIA ATTACK P0371
PENTAZOZ INE F PROTOPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA ATTACK P037 1
PENTAZOCINE P ERPF DEC V OBSERVED IN NORMAL INDIVIDUALS PC 384
PENTAZOCINE S ANYLASE INC V CAUSES SPASM OF SPHINCTER OF ODDI P0450
PENTAZOCINE S LIPASE INC V CAUSES SPASM 0? SPHINCTER OP ODDI HO 654
PENTAZOCINE U AMINOLEVULINIC ACID INC V MAY PRECIPITATE ACUTE PORPHYRIA ATTACK P037 1
PENTAZOCINE U AMPHETAMINES INC N INTERFERES WITH COLORINETRIC METHYL ORANGE METHOD R0346
PENTAZOCINE U COPROPORPHYRIN INC V NAY PRECIPITATE ACUTE PORPHYRIA ATTACK 90371
PENTAZOCINE U CFR Z V ALTHOUGH ERPF MAY BE CHANGED P03814
PENTA ZOC IN! U POBPHOBILINOGEN INC V MAY PRECIPITATE ACUTE PORPHYRIA ATTACK H0371
PENTAZOCINE U 11 OH CORTICOSTEROIDS DEC V ?DUL TO DEPRESSION OF ADHENOCORTICAL SECRETION P0236
PENTAZOCINE U 17 OH COPTICOSTEROIDS DEC V ?DUE TO DEPRESSION OF ADRENOCOPTICAL SECRETION PC 236
PENTOLINIUM U CATECHOLAMINES Z 11 NO EFFECT ON FLUOROMETRIC METHOD OF CHOUT RC235
PENTYLENETETRA ZOL S CHOLESTEROL DEC V MAXIMAL EFFECT SEEN AFTER TWO WEEKS P0103
RE PC HL OP ATE B PLATELET COUNT DEC V MAY CAUSE FATAL APLASTIC ANEMIA 90026
PEHCHLOHATE B RED CELL COUNT DEC V MAY CAUSE FATAL APLASTIC ANEMIA P0026
PERC HLOH ATE H WHITE CELL COUNT DEC V MAY CAUSE FATAL APLASTIC ANEMIA P0620
P FHC H LOR ATE S BILIHUBIN INC V SINGLE CASE OF ACUTE YELLOW ATROPHY OF LIVER P065 7
PERC H LOP A TE S I 131 UPTAKE Z V NO EFFECT ON UPTAKE HO 596
?EHC HLOPATE S PBI DEC V INTERFERES WITH TRAPPING OF IODINE BY THYROID 900014
PERCHLOR ATE S SGOT INC V SINGLE CASE OF ACUTE YELLOW ATROPHY OF LIVER HO 657
RE PC HL CPA TE S UREA NITROGEN INC V REPORTED CASES OF NEPHROTIC SYNDORME H 0026
PERCHLOHATE U PROTEIN INC V REPORTED CASES OP NEPHHOTIC SYNDROME 90026
RE RC H LOP ATE U URINALYSIS PROTEIN INC V REPORTED CASES OF NFPHROTIC SYNDROME P0026
PEHHEXTLENE S ALKALINE PHOSPHATASE INC V TRANSIENT ELEVATION OBSERVED PC 1453
P EPHEXILENF S SGOT INC V TRANSIENT ELEVATION OBSERVED HO 145 3
PERIODATE S PHI DEC V INTERFERES WITH TRAPPING O IODINE BY THYROID RCCC4
P ER N AN GAN A TE U URINALYSIS HEMOGLOBIN INC N INTEHFERES WITH HENZIDINL TEST 90299
PEROXIDE U URINALYSIS GLUCOSE INC N NA! PRODUCE FALSE P05 WITH CLINISTIX RC436
PERPHENA El NE B WHITE CELL COUNT DEC V SUSPECTED OF CAUSING AGPANULOCYTOSIS P0741
PFRPHENAZ IN! P CATECHOLAMINES INC V INC METABOLISM, DEC ORGAN UPTAKE OF NOREPINEPHHINE H 0355
PERPHENA ZINE S BILIRUBIN INC V LOW INCIDENCE OF JAUNDICE REPORTED R0026
PERPHENAZINE S GLUCOSE TOLERANCE DEC V ABNORMAL CURVES IN 35% SUBJECTS R0657
PERPHENAZINE S I 131 UPTAKE Z V NO EFFECT ObSERVED IN EUTHYROID SUBJECTS H 0596
PEHP HENA ZINE S PHI INC V MAY CONTAIN IODINATED CONTAMINANTS R0416
PERPHENAZI NE S TBG INC V DIRECT EFFECT OF DRUG H 00014
PERPHENAZINE S T3 UPTAKE DEC V OCCURS WITH PROLONGED USE R0620.
PERPHENAZINE U BILIRUBIN INC V LOW INCIDENCE OF JAUNDICE REPORTED HC620
PERPHENAZINE U URINALYSIS BILE INC V LOW INCIDENCE OF JAUNDICE REPORTED HC.620
PERP HENAZ IN! U 17 KETOSTROIDS Z N MINIMAL EFFECT ON ZIMMERMAN REACTION HO 133
PEHPHENA ZINE U 17 011 COPTICOSTEPOIDS DEC V ACTS ON HYPOTHALAMUS TO DEPRESS ACTH SECRETION P0133
PERPHENAZINE U 17 OH CORTICOSTEROIDS INC M ABNORMAL COLOR WITH GLENN-NELSON PROCEDURE HO 133
PHENACEM IDE B HEMATOCRIT DEC V APLASTIC ANEMIA P0026
PHENACEMIDE B HEMOGLOBIN DEC V APLASTIC ANEMIA P00 26
PHENACEMIDE B PLATELET COUNT DEC V APLASTIC ANEMIA MAY OCCUR RARELY RCC26
PHENACEMIDE B RED CELL COUNT DEC V APLASTIC ANEPIIA/AGRANULOC!TOSIS P0623
PHENACEMIDE B WHITE CELL COUNT DEC V APLASTIC ANEMIA (LEUKOPENIA REPORTED MOST OFTEN) R0C26
PHENACEMIDE S ALKALINE PHOSPHATASE INC V MA! AFFECT LIVER FUNCTION IN ABOUT 2% CASES P0620
PHENACEMIDE S BILIHUIN INC V MAY AFFECT LIVER FUNCTION IN ABOUT 2% CASES P 062 ‘3
PHENACEMIDE S BSP RETENTION INC V MAY ALTER LIVER FUNCTION IN ABOUT 2% CASES RC623
PHENACEMIDE S CEPHALIN FLOCCULATION INC V NAY AFFECT LIVER FUNCTION IN ABOUT 2% CASES RC620
PHENACEMIDE S SCOT INC V NAY AFFECT LIVER FUNCTION IN ABOUT 24 CASES R0620
PH ENAC ENI 0! S SGPT INC V NAY AFFECT LIVER FUNCTION IN ABOUT 2% CASES P0620
PHENACEMIDE S THYMOL TURBIDITY INC V MAY AFFECT LIVER FUNCTION IN ABOUT 2% CASES P0620
PHENACEMIDE S UREA NITROGEN INC V OCCASIONAL NEPHROPATHY H C02 6
PHENACEMIDE U PROTEIN INC V OCCASIONAL NEPHHOPATHY H0026
PHENACEMIDE U URINALYSIS BILE INC V MAY AFFECT LIVER FUNCTION IN ABOUT 2% CASES 20 62 0
P HENACEMIDE U URINALYSIS PROTEIN INC V OCCASIONAL NEPHROPATHY PC 299
P HE NA CL! CO DO L U 17 KTOGENIC STEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION P0907
PHENAGLYCODOL U 17 KETOSTEHOIDS INC M IiTERFEHES WITH ZIMMERMAN HEACTION R0907
PHENAZOCINE B PCO2 INC V MAY PRODUCE RESPIRATORY DEPRESSION RC384
PHENAZOPYPIDINE B HEINZ-BODY FORMATION POS V ASSOCIATED WITH HENOLYTIC ANEMIA P0657
PHENAZOPIPIDINE B HEMATOCRIT DEC V HELIOL!TIC ANEMIA (SENSITIVITY DEPENDENT) HO 240
PHENAZOPYHIDINE H HEMOGLOBIN DEC V HEMOLYTIC ANEMIA (SENSITIVITY DEPENDENT) P0240
PHENAZOPYHIDINE B METHENOGLOBIN INC V MAY CAUSE HEMOLYSIS P 0656
PHENA ZOPYRIDI NE H RED CELL COUNT DEC V HENOLYTIC ANEMIA (SENSITIVITY DEPENDENT) RC656
PHENAZOPYRIDI NE F CCLOR INC N ORANGE RED P0620
PHENAZOPYPIDINE S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT H 0620
PHENAZOPYRIDINE S BILIRUBIN DEC V ATYPICAL COLOR CAUSES INTERFERENCE R062O

PHENAZOPYRI DINE S BILIHUBIN INC N POSTULATED INC COLOR WITH DIAZOTIZATION RO204
PHENA ZOPYP IDINE S BILIRUBIN INC V SINGLE REPORT OF JAUNDICE (?DUE TO HEMOLYSIS) HO 46 1
PHENAZOPYRIDINE S BSP RETENTION INC N INC SPECTRAL ABSORBANCY IN COLOPINETRIC READING P1001
PRENAZOPYHIDINE S BSP RETENTION INC V HEPATIC DAMAGE REPORTED IN ONE CASE P046 1
PHENAZOPYRI DINE S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT P0620
PHENAZOPYRIDINE S SCOT INC V HEPATOTOXIC EFFECT P0620
PHENAZOPYHI DINE S SGPT INC V HEPATOTOXIC EFFECT P0620
PHENAZOPYRIDINE S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT RO620
PHENAZOPYRIDINE S UREA NITROGEN INC V TRANSIENT ACUTE PENAL FAILURE REPORTED P0026
PHENAZOPYRI DINE U DIAGNEX BLUE EXCRETION INC N ORANGE COLOR PRODUCES INTERFERENCE P1001
PHENAZOPYRIDINE U PORPHYRINS INC N INTERFERENCE WITH FLUORESCENCE (IN SCREENING TEST) R1001
PHENAZOPYPIDINE U PREGNANEDIOL INC N MECHANISM UNKNOWN P05 96
PHENA ZOPYPIDINE U PSP EXCRETION INC N FALSE COLOR REACTION AT ALKALINE PH H 100 1
PHENAZOPYRI DINE U URINALYSIS BILE INC N FALSE POS WITH ICTOTEST, BILI-LABSTIX P06 90
PHENAZOPYRIDINE U URINALYSIS BILE INC V HEPATOTOXIC EFFECT HO 620
PHENAZOPYBI DINE U URINALYSIS COLOR INC M ORANGE-RED, ORANGE-BROWN OP RED CQLOR P04 17
PHENA ZOPYRIDINE U URINALYSIS GLUCOSE DEC N FALSE NEGATIVE WITH GLUCOSE OXIDASE METHODS P0690
PHENAZOPYPIDINE U URINALYSIS GLUCOSE INC N FALSE POSITIVE REPORTED WITH TESTAPE P0690
PHENAZOPYRIDINE U URINALYSIS KETONES INC M FALSE P05 WITH KETOSTIX OR FECL3 P06 90
PHENAZOPYRIDINE U URINALYSIS PROTEIN INC N FALSE POSITIVE WITH LABSTIX ETC P0690
PHENAZOPYRIDINE U UROHILINOGEN INC N ORANGE-RED WITH EHPLICH’S ALDEHYDE REACTION P1001
PHENAZOPYRIDINE U VNA INC N YIELDS SIMILAR COLOR IN REACTION HO 596
PHENAZOPYRIDIN! U XYLOSE EXCRETION INC N DUE TO INTERFERING BACKGROUND COLOR P0766
PRENAZOPY RID IN! U 17 KETOGENIC STEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION P0907
PHENAZOPY RI DINE U 17 KETOSTEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION P0907
PHENA ZOPYRIDINE U 17 OH COPTICOST!ROIDS INC N INTERFERES WITH MODIFIED GLENN-NELSON METHOD HO 133
PHENELZI NE H WHITE CELL COUNT DEC V NAY CAUSE LEUKOPENIA P0026
P HE NEL Z I NE S BILIHUBIN INC N AT 1 MMOL/L AFFECTS SMA 12/60 METHOD SLIGHTLY P0876
PHENELZI NE S BILIPUBIN INC V MAY CAUSE HYPERSENSITIVE HEPATITIS P0026
PHENELZINE S BSP RETENTION INC V HEPATOTOXIC/CHOLESTATIC SYNDROMES P0384
PHENELZI NE S CHOLINESTERASE DEC V MAY CAUSE HYPERSENSITIVE HEPATITIS P0907
PHENELZINE S GLUCOSE INC V DECREASES GLUCOSE TOLERANCE P09 56
PHBNELZI NE S SCOT INC N AT 1 MMOL/L AFFECTS SMA 12/60 METHOD P0876
PHENELZINE S SCOT INC V MAY CAUSE HYPERSENSITIVE HEPATITIS P0026
PHENELZINE S SGPT INC V MAY CAUSE HYPERSENSITIVE HEPATITIS P0026
PHENELZIN E S URIC ACID INC N AT 1 MNOL/L SL AFFECTS SNA 12/60, HENRY METHODS P0876
PH!NELZI NE U URINALYSIS BILE INC V MAY CAUSE HYPERSENSITIVE HEPATITIS P0026
PHENELZINE U XYLOSE EXCRETION DEC V DECREASED ABSORPTION OF XYLOSE FROM G.I.TPACT P09 56
PHENETHICILLIN H EOSINOPHILS INC V FEW CASES REPORTED ONLY (MINOR EFFECT) HO 1467
PHENETHICILLIN B HEMOGLOBIN DEC V THEORETICAL EFFECT OF PENICILLINS P01467
PHENETHICILLIN B RED CELL COUNT DEC V THEORETICALLY MAY CAUSE HEMOLYTIC ANEMIA P01467
PHENETHICILLI N B WHITE CELL COUNT DEC V THEORETICALLY LEUKOPENIA MAY OCCUR P04 67
PHENETURIDE H WHITE CELL COUNT DEC V LEUKOPENIA REPORTED P0384
PH ENETUPI DE S ALKALINE PHOSPHATASE INC V FREQUENTLY OCCURS RO384
PHENFOPNIN B HEMATOCRIT DEC V THEORETICAL EFFECT OF FOLATE OP B12 DEFICIENCY P079 1
PHENFORMI N B HEMOGLOBIN DEC V THEORETICAL EFFECT OF FOLATE OP B12 DEFICIENCY P079 1
PHENFORNIN B NCV INC V THEORETICAL EFFECT OF FOLATE OH B12 DEFICIENCY P079 1
P,HENFOPMIN B PH DEC V ACIDOSIS CAN OCCUR R0355
PHENFORMIN B PLATELET COUNT DEC V ONE CASE OF THRONBOCYTOPENIA REPORTED RO657
PHENFORMIN P INSULIN DEC V EFFECT OBSERVED DUPING TOLERANCE TEST RO055
PHENFORMIN S BILIHUHIN Z V NO REPORTED CASES OF JAUNDICE P0026
PHENFORNIN S CHOLESTEROL DEC V INHIBITS SYNTHESIS (?ALSO G.I.TRACT ABSORPTION) P03 114
PHENFOHMIN S CO2 CONTENT DEC V MAY CAUSE MARKED ACIDOSIS P06 08
PHENPORMIN S FOLATE INC V ASSOCIATED WITH IMPAIRED ABSORPTION OF B12 P079 1
P H! NE OP NIN S GLUCOSE DEC V INHIBITS NORMAL AEROBIC METABOLISM P0603
PHENFORNIN S LACTATE INC V INHIBITS LACTATE CATABOLISM (BLOCKS TISSUE PESP) P09 07
PHENFORMIN S POTASSIUM INC V NAY OCCUR WITH LACTIC ACIDOSIS P06 52
PHENFORMI N S TRIGLYCERIDES DEC V CAUSES REDUCTION OF CARBOHYDRATE INDUCED INCREASE R0710
PH!NFORMIN S UREA NITROGEN INC V USUALLY FOUND IF LACTATE ELEVATED BY PHENFORNIN P0608
PHENFORNI N U URINALYSIS KETONES INC V OBSERVED EVEN WITH NORMAL BLOOD SUGAR P02 99
PHENFORMIN U XYLOSE EXCRETION DEC V AFFECTS INTESTINAL ABSORPTION P0903
PH ENI NDIONE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS/LEUKOPENIA P0620
PHENINDIONE B WHITE CELL COUNT INC V OCCASIONAL LEUKOCYTOSIS MAY OCCUR P0384
PHENINDIONE S ALKALINE PHOSPHATASE INC V MAY MODIFY LIVER FUNCTION (CHOLESTASIS) P0620
PHENINDIONE S BILIRUBIN INC V PROBABLE EFFECT AS BILIRUBIN CLEARANCE REDUCED ROI421
PHENINDIONE S HSP RETENTION INC V NAY MODIFY LIVER FUNCTION (CHOLESTASIS) P06 20
PHENINDIONE S CEPHALIN FLOCCULATION INC V NAY MODIFY LIVER FUNCTION (CHOLESTASIS) P0620
PHENINDIONE S DIRECT BILIRUBIN INC V PROBABLE EFFECT AS ILIRUBIN CONJUGATION AFFECTED HO 42 1
PH ENI NDI ONE S I 131 UPTAKE DEC V UNCOMMON REPORTED EFFECT R05 96
PHENINDIONE S PBI DEC V INHIBITS IODINATION OF TYROSINE IN TBG P0004
PH ENI NDI ONE S SGOT INC V NAY MODIFY LIVER FUNCTION (CHOLESTASIS) P0620
PHENINDIONE S SUPT INC V MAY MODIFY LIVER FUNCTION (CHOLESTASIS) P0620
PHENINDIONE S THYNOL TURBIDITY INC V MAY MODIFY LIVER FUNCTION (CHOLESTASIS) P0620
PHENINDION! S UREA NITROGEN INC V NEPHROTOXICITY NAY OCCUR WITH TUBULAR NECROSIS P03814
PH ENI NDI ONE U PROTEIN INC V NEPHPOTOXICITY NAY OCCUR P0677
PHENINDIONE U URINALYSIS BILE INC V NAY MODIFY LIVER FUNCTION (CHOLESTASIS) P0620
PHENINDIONE U URINALYSIS COLOR INC N RED-ORANGE COLOR PRODUCED IN ALKALINE URINE P0220
PH!NINDIONE U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG P0299
PH! NINDIONE U URINALYSIS PROTEIN INC V NEPHPOTOXICITY MAY OCCUR P0677
PHENINDIONE U URINALYSIS RBC/HPF INC V MAY CAUSE ACTUAL BLEEDING P0299
PHENIODOL S BSP RETENTION INC V EFFECT REPORTED WITHOUT ABNORMAL LIVER FUNCTION HO 596
PHENIODOL S I 131 UPTAKE DEC V DUE TO IODINE COMPONENT OF MATERIAL P 05 96
PHENIOD OL S PHI INC M CONTAINS IODINE P0596
PH ENI ODOL S UREA NITROGEN INC V REPORTED TO CAUSE PENAL FAILURE P002 0
PHENIODOL U CHEATININE CLEARANCE DEC V REPORTED TO CAUSE RENAL FAILURE P0020
PHENIPRAZINE S ALKALINE PHOSPHATASE INC V HYPERSENSITIVE HEPATITIS P06 20
PHENIPRAZINE S BILIRUBIN INC V HYPERSENSITIVE HEPATITIS R0620
PRENIPRAZINE S BSP RETENTION INC V MAY AFFECT LIVER FUNCTION P06 20
PHENIPRAZINE S CEPHALIN FLOCCULATION INC V NAY AFFECT LIVER FUNCTION P0620
PHENIPPAZINE S SCOT INC V MAY AFFECT LIVER FUNCTION P0620

PHENIPPAZINE S SGPT INC V MAY AFFECT LIVER FUNCTION P0620
PHENIPPAZINE S THYMOL TURBIDITY INC V MAY AFFECT LIVER FUNCTION R0620
PHENIPHAZINE U URINALYSIS BILE INC V MAY AFFECT LIVER FUNCTION P0620
PHENMETRAZINE U 5 OH INDOLEACETIC ACID INC V REPORTED EFFECT P0577
PHENOBAPBITAL H HENATOCRIT DEC V MEG. ANEMIA 2ND TO DISTURBANCE IN FOLIC ACID N ETA B. P077 5
PHENOBAHBITAL B HEMOGLOBIN DEC V MEG. ANEMIA 2ND TO DISTURBANCE IN FOLIC ACID N ETA B. HO 528
PHENOBARBITAL B NCV INC V MEG. ANEMIA 2ND TO DISTURBANCE IN FOLIC ACID N ET A B. P0528
PHENOBAPBITAL B PLATELET COUNT DEC V THROMBOCYTOPENIA NAY OCCUR AFTER SOME TIME P0658
PHENOBARBITAL B RED CELL COUNT DEC V MEG. ANEMIA 2ND TO DISTURBANCE IN FOLIC ACID METAB. P0528
PHENOBARBITAL H WHITE CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0658
PHENOBAHBITAL P PROTHBOMBIN TIME DEC V METABOLISM ENHANCED BY BARBITURATES P0026
PHENOBARBITAL S ALKALINE PHOSPHATASE INC V NAY CAUSE OSTEONALACIA (?ALSO LIVER EFFECT) P0396
PHENOBAPBITAL S BILIRUBIN DEC V INDUCES HEPATIC NICROSOMAL ENZ!NLS ESP IN PREGNANT P0907
PHENOBARBITAL S BSP RETENTION DEC V INC CLEARANCE BY LIVER IN NEWBORNS P 1013
PHENOBARBITAL S FOLATE DEC V MAY CAUSE MEGALOBLASTIC ANEMIA HO 79 1
PHFNOBAPBITAL S GGTP INC V VINDUCTION OP DAMAGE OF HEPATIC MICROSONES P0795
PHENOBARBITAL S PHOSPHATE DEC V INCREASES CLEARANCE (2NDRY HYPERPARATHYROIDISM) HO 396
PHENOBAPHITAL T FOLATE Z N NO EFFECT ON L. CASEI OR S. FECALIS H 06 57
PHENOBARBITAL U AICAR INC V IF NEGALOBLASTIC ANEMIA DEVELOPS P 079 1
PHENOBARBITAL U CATECHOLAMINES Z V NO EFFECT SHORT TERM INGESTION OF 120 MG/DAY P0236
PHENOBAPBITAL U EPINEPHPINE Z V NO EFFECT SHORT TERN INGESTION OF 120 MG/DAY R0236
PHENOBARHITAL U FIGLU INC V IF MEGALOBLASTIC ANEMIA DEVELOPS P079 1
PHENOBARBITAL U GLUCARIC ACID INC V DUE TO INDUCTION OF HEPATIC ENZYMES P0596
PHENOBARHITAL U NOPEPINEPHRINE Z V NO EFFECT SHORT TERM INGESTION OF 120 MG/DAY P 0236
PHENOBAPBITAL U 11 OH COPTICOSTEROIDS Z V NO EFFECT SHORT TERM INGESTION OF 120 MG/DAY P0236
PHENOBARBITAL U 17 KETOSTEHOIDS Z V NO EFFECT SHORT TERN INGESTION OF 120 MG/DAY R0236
PHENOBARBITAL U 17 OH CORTICOSTEPOIDS DEC V WITH CHRONIC INGESTION COPTISOL= 6-B-OH CORTISOL R0169
PHENOBARBITAL U 17 OH COPTICOSTEROIDS Z V NO EFFECT SHORT TERN INGESTION OF 120 MG/DAY P0 236
PHENOBAPBITAL U 6 HYDROXYCORTISOL INC V ALTERATION OF STEROID EXCRETORY PATTERN (LONG TERM) P0236
PHENOLPHTHALEIN H LE CELL PREP P05 V ASSOCIATED WITH HYPERSENSITIVITY P0657
PHENOLPHTHALEIN F COLOR INC N IMPARTS RED COLOR P 0026
PHENOLPHTHALEIN P PROTHRONBIN TIME INC V PATIENTS ON COUNAPINS H 0657
PHENOLPHTHALEIN S BSP RETENTION INC N COLOR DEVELOPMENT ON ALKALINIZATION OF SAMPLE P1001
PHENOLPHTHALEIN S GLUCOSE INC V IMPAIRED GLUCOSE TOLERANCE NAY OCCUR DUE TO K LOSS P02 16
PHENOLPHTHALEIN S GLUCOSE TOLERANCE DEC V RESULT OF HYPOKALEMIA P02 16
PHENOLPHTHALEIN S POTASSIUM DEC V I? CHRONIC LAXATIVE ABUSE AND ALDOSTERONISN H 0332
PHENOLPHTHALEIN U PSP EXCRETION INC M COLOR DEVELOPMENT ON ALKALINIZATION OF URINE P1001
PHENOLPHTHALEIN U URINALYSIS COLOR INC M PINK,RED,PURPLE (ALKALINE),OPANGE,RUST (ACID) HO 122
PHENOLPHTHALEIN U URINALYSIS HEMOGLOBIN INC V NAY CAUSE ACUTE NEPHROSIS (K DEFICIENCY) P0657
PHENOLPHTHALEIN U URINALYSIS PROTEIN INC V NAY CAUSE ACUTE NEPHROSIS (K DEFICIENCY) P0657
PHENOLPHTHALEIN U URINALYSIS RBC/HPF INC V NAY CAUSE ACUTE NEPHPOSIS (K DEFICIENCY) R0657
PHENOLS S GLUCOSE Z N AT 10 MG/100NL NO EFFECT GLU OX OF GOCHMAN P 0370
PHENOLS S GLUCOSE Z M AT 10 NG/100NL NO EFFECT ALKALINE FEPRICYANIDE P037 0
PHENOLS S SALICYLATE Z N 25 NG/100ML NO EFFECT ON TRINDER PROCEDURE R0606
PHENOLS U PHENYLKETONES P05 N VIOLET WITH FECL3, NIL WITH PHENISTIX P0239
PHENOLS U URINALYSIS CASTS INC V NEPHROTOXICITY WITH POISONING (USUSALLY RBC CASTS) P 0384
PHENOLS U URINALYSIS COLOR INC N DARK GREEN TO BROWNISH BLACK ON STANDING P0620
PHENOLS U URINALYSIS HEMOGLOBIN INC V NEPHPOTOXICITY WITH POISONING HO 384
PHENOLS U URINALYSIS PROTEIN INC V NEPHROTOXICITY WITH POISONING P0384
PHENOLS U URINALYSIS RBC/HPF INC V OCCUR WITH RENAL DAMAGE OF POISONING R0368
PHENOLS U URINALYSIS SUGAR INC N INTERFERES WITH BENEDICT’S REAGENT P029 9
PHENOTHIAZINES B EOSINOPHILS INC V ALLERGIC RESPONSE P0620
PHENOTHIAZINES B HEMATOCRIT DEC V HEMOLYTIC ANEMIA (SENSITIVITY DEPENDENT) P0240
PHENOTHIAZINES H HEMOGLOBIN DEC V HENOLYTIC ANEMIA (SENSITIVITY DEPENDENT) P 0240
PHENOT HIA Z INE S B PLATELET COUNT DEC V HENOLYT IC A NENIA (SENSITIV I TY DEPENDENT) P0240
PHENOTHIAZINES B RED CELL COUNT DEC V HEMOLYTIC ANEMIA (SENSITIVITY DEPENDENT) P0240
PHENOTHIAZINES B WHITE CELL COUNT DEC V AGRANULOCYTOSIS/LEUKOPENIA ESP IF LOW INITIALLY P0574
PHENOTHIAZINES B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA OP GENERALIZED LEUKOCYTOSIS a 0620
PHENOTHIAZINES C PROTEIN INC N FALSE POSITIVE WITH FOLIN-CIOCALTEU REAGENT P0355
PHENOTHIAZINES P CATECHOLANINES INC V INC NETABOLISM, DEC ORGAN UPTAKE OF NOREPINEPHRINE P 0042
PHENOTHIAZINES P FSH DEC V STIMULATION EFFECT OF GONADOTPOPINS INHIBITED RC596
PHENOTHIAZINES P LH DEC V STINULATION EFFECT OF GONADOTROPINS INHIBITED P0596
PHENOTHIAZINES S ALDOLASE DEC V IN SCHIZOPHPENICS WITH HIGH INITIAL VALUES P0657
PHENOTHIAZINES S ALKALINE PHOSPHATASE INC V INTRAHEPATIC CHOLESTATIC SYNDROME R0436
PHENOTHIAZINES S BILIRUBIN INC V HYPERSENSITIVITY CHOLESTATIC REACTION NAY OCCUR P0384
PHENOTHIAZINES S BSP RETENTION INC V NAY CAUSE CHOLESTATIC HEPATITIS (IN UP TO 4% PTS) P0620
PHENOTHIAZINES S CEPHALIN FLOCCULATION INC V MAY CAUSE CHOLESTATIC HEPATITIS (IN UP TO 4% PTS) P0620
PHENOTHIAZINES S CHOLESTEROL INC V FREQUENTLY REPORTED EFFECT, ?NECHANISM P0767
PHENOTHIAZINES S CPK DEC V IN SCHIZOPHRENICS WITH HIGH INITIAL VALUES P0657
PHENOTHIAZINES S CPK INC V PROBABLE EFFECT OF I.N. INJECTION P0417
PHENOTHIAZINES S DIRECT BILIRUBIN INC V RELATIVELY LARGE INC COMPARED WITH TOTAL P0384
PHENOTHIAZINES S GLUCOSE TOLERANCE DEC V MAY PRODUCE DIABETIC TYPE OF CURVE IN NORMALS P0596
PHENOTHIAZINES S I 131 UPTAKE INC V REPORTED EFFECT IN HYPERTHYROIDISN R0417
PHENOTHIAZINES S PHI DEC V ANTITHYROID EFFECT OF LARGE DOSES P0255
PHENOTHIAZINES S SGOT INC V NAY CAUSE CHOLESTATIC HEPATITIS (IN UP TO 4% PTS) HO 620
PHENOTHIAZINES S SGPT INC V NAY CAUSE CHOLESTATIC HEPATITIS (IN UP TO 4% PTS) P0620
PHENOTHIAZINES S THYNOL TURBIDITY INC V MAY CAUSE CHOLESTATIC HEPATITIS (IN UP TO 4% PTS) P0620
PHENOTHIAZINES S UREA NITROGEN DEC V DEC UREA PRODUCTION IF HEPATIC CIRRHOSIS OCCURS P 0204
PHENOTHIAZINES S URIC ACID DEC V REPORTED URICOSUPIC ACTION RO596
PHENOTHIAZINES S URIC ACID INC V REPORTED EFFECT P0726
PHENOTHIAZINES S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS P0492
PHENOTHIAZINES U ACETOACETATE INC N NETABOLITES REACT WITH PECL3 P 100 1
PHENOTHIAZINES U BILIRUBIN INC V MAY CAUSE CHOLESTATIC HEPATITIS R062O
PHENOTHIAZINES U DORA SCREEN TEST P05 N NAY PRODUCE FALSE COLOR (USUALLY BUFF/AMBER) R0802
PHENOTHIAZINES U ESTROGENS DEC V BLOCK OVULATION, INHIBIT DECIDUAL REACTION P0299
PHENOTHIAZINES U GLUCOSE INC V EFFECT SEEN ES? IN LONG TERM THERAPY OF DIABETICS P0678
PHENOTHIAZINES U GONADOTBOPINS DEC V ASSOC WITH OTHER ENDOCRINOLOGICAL CHANGES P0657
PHENOTHIAZINES U NETANEPHRINES TOTAL INC N INTERFERENCE IN PISANO PROCEDURE P0125
PHENOTHIAZINES U PHENOTHIAZINE P05 N SOME DETECTABLE UP TO 18 MONTHS AFTER THERAPY P0384
PHENOTHIAZINES U PHEN!LKETONES P05 N PINK/RED-PURPLE WITH FECL3, SAME WITH PHENISTIX P0239

PHENOTHIA ZINES U PORPHOBILINOGEN INC N MAY REACT WITH EHRLICH’S ALDEHYDE REAGENT HO 769
PHENOTHIAZI NES U PREGNANCY TESTS P05 M FALSE REACT WITH FROG, RABBIT, IMMUNOL TESTS P0717
PHENOTHIAZINES U PREGNANEDIOL DEC V REPORTED EFFECT P0596
PH ENOTHIAZI NES U PROGESTERONE DEC V ASSOC WITH OTHER ENDOCHINOLOGICAL CHANGES P0657
PHENOTHI AZI NES U URIC ACID INC V REPORTED UHICOSUPIC ACTION HO 596
PHENOTHIAZI NES U URINALYSIS BILE INC N ALLEGED INTERFERENCE WITH BILI-LABSTIX P04 17
PHENOTHIAZINES U URINALYSIS BILE INC V MAY CAUSE CHOLESTATIC HEPATITIS P0620
PHENOTHIAZI NES U URINALYSIS COLOR INC N PINK, RED, PURPLE, ORANGE, RUST COLOR P06 514
PHENOTHIAZINES U UHOBILINOGEN INC N MAY REACT WITH EHPLICH’S ALDEHYDE REAGENT P0769
PHENOTHIAZINES U VNA DEC V ALTERS BLOOD CONCENTRATION P0042
PHENOTHIAZINES U 17 KETOGENIC STEROIDS INC N YIELD SIMILAR COLOR WITH ZIMMERMAN REACTION P0596
PHENOT HIAZINES U 17 KETOSTEROIDS DEC V INHIBIT RELEASE OF STEROID HORMONES HO 596
PHENOTHI AZINES U 17 KETOSTEPOIDS INC N INC ABSOPBANCE ABNORMAL COLOR ZIMMERMAN PROCEDURE P0133
PHENOTHIA ZI NES U 17 OH CORTICOSTEROIDS DEC V INHIBIT RELEASE OF STEROID HORMONES HO 596
PHENOTHIA ZI NES U 17 OH CORTICOSTEHOIDS INC N SLIGHT INC ABSORBANCE MOD GLENN-NELSON METHOD P01 33
PHENOTHIAZI NES U 5 OH INDOLEACETIC ACID DEC M FALSE DECREASE IF NITPOSONAPHTHOL USED P100 1
PR ENOXYB?NZAMINF U CATECHOLAMINES Z M NO EFFECT ON FLUOPOMETRIC METHOD OF CROUT P0235
PHENSUXIMIDE H WHITE CELL COUNT DEC V POSSIBLE AGRANULOCYTOSIS (VERY RAPE) P0026
PHENSUXIMIDE S UREA NITROGEN INC V REVERSIBLE NEPHROPATHY (ESP IN CHILDREN) P0026
PHENSUXIMIDE U PROTEIN INC V REVERSIBLE NEPHROPATHY (ESP IN CHILDREN) P0026
PHENSUXI MIDE U URINALYSIS COLOR INC N PINK, RED, PURPLE, ORANGE AND RUST COLOR P06 514
PHENSUXINIDE U URINALYSIS PROTEIN INC V REVERSIBLE NEPHROPATHY (ESP IN CHILDREN) P0026
PHENTOLA MINE P CATECHOLAMINES INC V ?DUE TO RELEASING ACTIONOP TO ALTERED METABOLISM P0384
PHENTOLAMINE S GLUCOSE DEC V TOXIC DOSES OVER LONG PERIOD OF TIME H 038 14
PHENTOLAMINE U CATECHOLAMINES Z N NO EFFECT ON FLUOROMETPIC METHOD OF CHOUT P0235
PHENYLALA NINE P INSULIN INC V SLIGHT EFFECT, AIDS METABOLISM OF AMINO ACIDS P0311
PHENYLALANI NE S UREA NITROGEN Z N NO ETFECT ON BEHTHELOT REACTION P05 10
P HE NYLBU TA Z ONE B HENATOCRIT DEC V RN DEPRESSION/2ND TO NA AND H20 RETENTION HO 177
PHENYLBUTAZONE B HEMOGLOBIN DEC V RN DEPRESSION/2ND TO NA AND H20 RETENTION P0177
P HEN YLH UTAZ ONE B LE CELL PREP P05 V MAY PRECIPITATE OH EXAGGERATE LE-LIKE SYNDROME P0907
PH E NY LB UTAZ ONE B PLATELET COUNT DEC V MAY CAUSE APLASTIC ANEMIA OR THROMBOCYTOPENIA P02 90
PH EN YL B UT AZ ONE B RED CELL COUNT DEC V BN DEPRESSION/2ND TO NA AND H2O PETENTION HO 177
PH EN! LBUT AZ ONE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS/APLASTIC ANENIA/LEUKOPENIA P076 4
PHEN YL B UT AZO NE B WHITE CELL COUNT INC V LEUKEMIA-DRUG INDUCED P06 57
PHENYLBUTAZ ONE F OCCULT BLOOD P05 V MAY CAUSE G.I. TRACT BLEEDING P0620
PH EN YLB UT A ZONE P PROTHROMBIN TIME INC V POTENTIATES ACTION OF ANTICOAGULANTS P0008
P HE NYLBUTAZ ONE P VOLUME INC V MAY INC BY 50% DUE TO SALT AND WATER RETENTION P038 4
PHENYLBUTAZONE S ALKALINE PHOSPHATASE INC V HEPATITIS MAY OCCUR AS COMPLICATION OF THERAPY P0687
PH! NYLBUTAZON! S AMYLASE INC V PAPOTITIS NAY OCCUR AS RARE COMPLICATION HO 398
PH E NYLB U I AZ ONE S BILIPUPIN INC V GRANULONATOUS REACTION IN LIVER P0381
P HE NY LB UTAZ ONE S BSP RETENTION INC V MAY CAUSE CHOLESTASIS P06 20
PH E NY LBU TAZ ON E S CEPHALIN FLOCCULATION INC V MAY CAUSE CHOLESTASIS P0620
PH EN YLBUT A ZONE S CHLORIDE INC V MAY CAUSE SALT RETENTION (?TUHULAR DYSFUNCTION) P0957
PHENYLBUTAZ ONE S COOMBS TEST P05 V IMMUNOLOGICAL RESPONSE TO DRUG P014 18
P HE NYL BUT AZONE S CREATININE INC V MAY INC ESP IF COEXISTING RENAL DAMAGE P0657
PH P NY L BUTAZ ONE S GAMMA GLOBULIN INC V OBSERVED IN TWO CASES (?DUP TO ANTIBODIES) R0583
PHENYLBtJTAZ ONE S CUANASE INC V MAY CAUSE CHOLESTATIC AND CYTOTOXIC JAUNDICE P 0079
PHENYL BUTAZONE S I 131 UPTAKE DEC V MAY LAST UP TO TWO WEEKS P0838
PHENYLHUTAZ ONE S lCD INC V NAY CAUSE CHOLESTATIC AND CYTOTOXIC JAUNDICE P0079
PH P NY LB U TAZ ONE S OCT INC V NAY CAUSE CHOLESTATIC AND CYTOTOXIC JAUNDICE P0079
P HE NYLS UTA Z ONE S PHI DEC V COMPETES WITH THYROXINE FOR BINDING ON TBG HO 255
PH ENY LB UTA Z ONE S SCOT INC V MAY CAUSE CHOLESTATIC AND CYTOTOXIC JAUNDICE P0079
P HE N YLB UT A ZONE S SGPT INC NAY CAUSE CHOLESTATIC AND CYTOTOXIC JAUNDICE P0079
PH ENYLBUTAZ ONE S SODIUM INC V NAY CAUSE SALT RETENTION HO 957
P HEN YLB UT AZO NE S THYMOL TURBIDITY INC V MAY CAUSE CHOLESTASIS HO 620
PH ENYLHUTAZ ONE S T3 UPTAKE INC V RESIN AND RED CELL UPTAKE AFFECTED P08 38
PHENYL BUTAZONE S UREA NITROGEN INC V REPORTED NEPHROTOXIC EFFECT P06 20
PHENYLBUTAZ ONE S URIC ACID DEC V URICOSUHIC ACTION AT HIGH DOSES P0404
PHE NY L BUT AZ ONE S URIC ACID INC V ANTIURICOSUHIC ACTION AT LOW DOSES HO 404
P HE NY LHU I AZ ONE U PROTEIN INC V NEPHPOTOXICITY REPORTED P0417
PHENYL BUTAZONE U TAURINE DEC V REDUCES INCREASED OUTPUT IN RHEUNATOIDS P08 10
P H! NYLBUTAZ ONE U URIC ACID INC V URICOSURIC ACTION HO 40 4
PHE NYLB UT AZ ON E U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG P02 99
PHENYLBUTA ZONE U URINALYSIS PROTEIN INC V REPORTED NEPHHOTOXIC EFFECT P04 17
PHENYLBUTAZONE U URINALYSIS PBC/HPF INC V ACTUAL BLEEDING CAUSED BY DRUG P0299
PHENYLBUTAZONE U VOLUME DEC V CAUSES SIGNIFICANT WATER RETENTION HO 384
PH ENYLBUTAZ ONE U 17 OH CORTICOSTEROIDS DEC V CORTISOL METABOLISM DIVERTED TO 6-B-OH CORTISOL ROSS 8
PHENYLHUTAZONE U 6 HYDHOXYCORTISOL INC V LONG TERM CHANGE IN STEROID EXCRETORY PATTERN P0558
PHENYLENEDIAMINE B NETHEMOGLOHIN INC V NAY CAUSE HEMOLYSIS P0657
PHENYLBYDRAZINE B HEINZ-BODY FORMATION P05 V MAY OCCUR IN EARLY STAGES OF HEMOLYSIS HO 104
PHENYLHYORAZINE B HENATOCRIT DEC V HEMOLYTIC ANEMIA P0240
PH!NYLHYDPAZINF B HEMOGLOBIN DEC V HENOLYTIC ANEMIA RO240
PH9NYLHYDRAZINE B METHEMOGLOBIN INC V NAY CAUSE HEMOLYSIS P06 57
PHENYLHYDPAZINE B RED CELL COUNT DEC V HEMOLYTIC ANEMIA P0657
PHENYLHYDHAZINE S HILIHUBIN INC V CAUSES HENOLYSIS P0110
PH ENYLHYDFAZINE S DIRECT BILIRUBIN INC V CAUSES HEMOLYSIS P0110
PH!NYLHYDPAZINE S HAPTOCLOBIN DEC V MAY CAUSE HEMOLYSIS (HEMOLYTIC ANEMIA) P0657
PHENYLHYDRAZINF U PORPHYHINS INC V NAY OCCASIONALLY PRECIPITATE ATTACK OF PORPHYRIA Hi 001
PHENYLINDANDIONE S URIC ACID DEC V URICOSURIC ACTION HO 404
PHENYLINDANDIONE U URIC ACID INC V URICOSUPIC ACTION P01404
PHENYLISOPROPYLNYD S ALKALINE PHOSPHATASE INC V NAY CAUSE HEPATOCELLULAR JAUNDICE P06 20
PHENYLISOPROPYLHYD S BILIPUBIN INC V MAY CAUSE HEPATOCELLULAR JAUNDICE H 06 20
PHENYLISOPROPYLHYD S SCOT INC V MAY CAUSE HEPATOCELLULAH JAUNDICE P0620
PHENYLISOPBOPYLHYD S SGPT INC V MAY CAUSE HEPATOCELLULAR JAUNDICE RO620
PHENYLPROP ANOLAMINE 0 PHENTOLAMINE TEST INC V SINGLE CASE REPORTED P0 289
PHENYLPYPUVIC ACID U FECL3 TEST P05 N TRANSIENT BLUE-GREEN COLOR FORMED P0929
PHENYLSALICYLATE U URINALYSIS COLOR INC N DARK GREEN P0620
PHENYLTHIOU PEA T PROTEIN INC N REACTS WITH FOLIN-CIOCALTEU OF LOWRY METHOD P0213
PHENYPAMIDOL P PROTHRONBIN TIME INC V INHIBITS METABOLISM OF BISHYDROXYCOUMARIN P01 90
PHENYPAMIDOL S CHOLESTEROL DEC V PROBABLE INHIBIT OF HEPATIC NICROSOMAL ENZYMES HO 837

PHISOHEX U URINALYSIS RBC/HPF INC N RED GLOBULES THAT LOOK LIKE PED BLOOD CELLS P 0299
PHLOPIDZIN U GLUCOSE CLEARANCE INC V DUE TO DECREASED REABSORPTION P0878
PHLOPIDZIN U GLUCOSE INC V DECREASES GLUCOSE REABSORPTION P0878
PHLORI DEl N U INULIN CLEARANCE DEC V DECREASE OF UP TO 30 P0878
PHLORI DZIN U OSNOLALITY INC V DUE TO INCREASED EXCRETION OF GLUCOSE ETC P0878
PHLOHIDZIN U PHOSPHATE CLEARANCE DEC V DUE TO REDUCED EXCRETION HO 878
PHLOPIDZIN U PHOSPHATE DEC V PROBABLY DUE TO INCREASED REABSORPTION P0878
PHLORIDZIN U URIC ACID CLEARANCE INC V PROBABLY INHIBITS TUBULAR REABSORPTION P0878
PHLORI DZI N U URIC ACID INC V URICOSURIC ACTION IN NAN 90878
PHLOPIDZIN U URINALYSIS GLUCOSE INC V INCREASES CLEARANCE P0620
PHOSPHATES F CALCIUM INC V INC BY AVERAGE OF 32 MEQ/DAY P0147 1
PHOSPHATES F PHOSPHATE INC V DOUBLED EXCRETION COMPARED WITH BED PEST HO 147 1
PHOSPHATES P PARATHYROID HORMONE INC V UP TO 125% INC AT 1 HOUR AFTER 1G ORALLY 90770
PH OSPHATES S ACID PHOSPHATASE TOTAL DEC N INHIBITS REACTION IF HIGH CONC IN SUBSTRATE P02 99
PHOSPHATES S ALKALINE PHOSPHATASE DEC N INHIBITS REACTION IF HIGH CONC IN SUBSTRATE P0 299
PHOSPHATES S CALCIUM DEC N COMPETE WITH EDTA FOR CA (SL EFFECT SOME METHODS) P0436
P HOSP HATES S CALCIUM DEC N INHIBIT EMISSION IN SON! FLAME METHODS HO 1436
PH OSPH A TES S CALCIUM DEC V TRANSIENT EFFECT DUE TO COLLOID RETENTION IN LIVER P02 01
PHOSPHATES S IONIZED CALCIUM DEC V SLIGHT EFFECT ABOLISHED BY CA INFUSION P0770
PHOSPHATES S PHOSPHATE INC V INC OF GREATER THAN 2 MG/100 ML OBSERVED P0406
RHO SPHATES S POTASSIUM DEC V DRAWN INTO CELLS WITH GLUCONEOGENESIS P1001
PHOSPHATES U CALCIUM DEC N INHIBIT EMISSION IN SON! FLAME METHODS P0436
RHO SPHATES U CALCIUM DEC N COMPETE WITH EDTA FOR CA (MORE MARKED THAN SERUM) HO 436
PHOSPHATES U MAGNESIUM DEC V DECREASES INC EXCRETION OF BED REST P 047 1
RHO SPHATES U PHOSPHATE INC V DOUBLED EXCRETION COMPARED WITH BED REST HO 147 1
PHOSPHO SODA S PHOSPHATE INC V HIGH CONCENTRATION OF PHOSPHATE ABSORBED FROM GUT P0907
PHOS PRO HU S B COAGULATION TIME INC V DUE TO TOXICITY P03 84
PHOSPHORUS B NONOCYTES INC V REPORTED EFFECT OF POISONING P0368
PH OSPU OPUS B PLATELET COUNT INC V REPORTED EFFECT WITH POISONING P036 8
PHOSPHORUS B RED CELL COUNT DEC V OCCURS WITH CHRONIC POISONING HO 368
PHOSPHORUS B WHITE CELL COUNT DEC V REPORTED EFFECT WITH POISONING P03 68
PHOSPHORUS B WHITE CELL COUNT INC V REPORTED LEUKOCYTOSIS WITH POISONING HO 368
PHOSPHORUS F OCCULT BLOOD P05 V BLOODY DIARRHEA NAY OCCUR WITH POISONING P03 814
PHOSPHOR US P FIBRINOGEN DEC V PROBABLE HEPATOXIC EFFECT HO 368
PHOSPHORUS P PROTHRONBIN TIME INC V TOXICITY EFFECT (HYPOPROTHPONBINEMIA) P06 20
PHOSPHORUS S ALKALINE PROSPHATASE INC V HEPATOTOXIC EFFECT WITH NECROSIS P0620
PHOSPHORUS S BILIPUBIN INC V HEPATOTOXIC EFFECT WITH NECROSIS P06 20
PHOSPHORUS S BSP RETENTION INC V HEPATOTOXIC EFFECT WITH NECROSIS P0620
PHOSPHOHU S S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT WITH NECROSIS P06 20
PHOSPHORUS S CREATININE INC V NEPHPOTOXIC EFFECT WITH NECROSIS RO355
PHOS PHORUS S GLUCOSE DEC V TOXIC EFFECT P06 20
PH OSPH OPUS S ICTERIC INDEX INC V DUE TO NEPHROTOXICITY P036 8
PHOS PHORUS S NPN INC V DUE ‘TO NEPHROTOXICITY P0 368
PH 05 PU 0 RU S S SGOT INC V HEPATOTOXIC EFFECT WITH NECROSIS R0620
PHOSPHORUS S SGPT INC V HEPATOTOXIC EFFECT WITH NECROSIS P06 20
PHOSPHORUS S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT WITH NECROSIS P0620
PHOSPHORUS S UREA NITROGEN INC V NEPHPOTOXIC EFFECT P0620
PHOSPHORUS T SILICON DEC N ABOVE 60 MG/L AFFECTS JOLLES/NEURATH METHOD P0489
PHOSPHORUS T SILICON INC N UP TO 60 NG/L AFFECTS JOLLES/NEURATH METHOD P01489
PHOSPHORUS U ALPHA AMINO NITROGEN INC V DUE TO NEPHROTOXICITY HO 368
PHOSPHORUS U PROTEIN INC V RENAL TOXIC EFFECT HO 355
PHOSPHORUS U URINALYSIS BILE INC V HEPATOTOXIC EFFECT WITH NECROSIS H062O
PHOSPHORUS U URINALYSIS CASTS INC V NEPHROTOXIC EFFECT P0 368
PHOSPHORUS U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG HO 299
PHOSPHORUS U URINALYSIS PROTEIN INC V RENAL TOXIC EFFECT P03 55
PHOSPHORUS U URINALYSIS RBC/HPF INC V NEPPROTOXIC EFFECT HO 299
PHOSPHORUS U VOLUME DEC V TOXICITY EFFECT P03 84
PHYLLOER YTHPINOGEN U UROBILIN INC N PRODUCES RED FLUORESCENCE R0U36
PHYLLOEPYTHPINOGEN U UROBILINOGEN INC N PRODUCES RED COLOR WITH EHRLICH’S REAGENT P014 36
PHYSOSTIGNINE S CHOLINESTERASE DEC V DIRECT EFFECT OF DRUG P09 13
PHYTONADI ONE B HENATOCRIT DEC V HEMOLYSIS MAY OCCUR WITH G-6-PD DEFICIENCY P0620
PHYTON ADIONE B HEMOGLOBIN DEC V HENOLYSIS MAY OCCUR WITH G-6-PD DEFICIENCY P0620
PHYTONADIONE B RED CELL COUNT DEC V HENOLYSIS MAY OCCUR WITH G-6-PD DEFICIENCY P06 20
PHYTONADIONE P PROTHROMBIN TIME DEC V STIMULATES SYNTHESIS OF CLOTTING FACTORS P0886
PHYTONADIONE S BILIRUBIN INC V LARGE DOSE EFFECT, OR WITH G-6-PD DEFICIENCY HO 299
PHYTONADION E U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG P02 99
PHYTONADIONE U URINALYSIS RBC/HPF INC V ACTUAL BLEEDING CAUSED BY DRUG P0620
PICRIC ACID B RED CELL COUNT DEC V HEMOLYTIC EFFECT P03 84
PICRIC ACID S 5CR! INC V MAY CAUSE ACUTE HEPATIC CA NAG! HO 384
PICRIC ACID U URINALYSIS COLOR INC M YELLOW TO RED BROWN P0620
PICRIC ACID U URINALYSIS PROTEIN INC V NEPHROTOXICITY HO 3 84
RI DH P INSULIN DEC V REDUCES INSULIN RESPONSE TO GLUCOSE LOAD P0808
PIDH S GLUCOSE DEC V SIGNIFICANT REDUCTION AFTER GLUCOSE LOAD P0808
PILOCARPI NE B RED CELL COUNT INC V PROBABLY DUE TO CONTRACTION OF SPLEEN P0384
PILOCARPINE B WHITE CELL COUNT INC V PROBABLY DUE TO CONTRACTION OF SPLEEN HO 384
PILOCA RPINE 0 GASTRIC JUICE HCL INC V PRODUCES SECRETION LIKE THAT OF VAGAL STIMULATION P03814
PILOCAPPINE 0 GASTRIC JUICE PEPSIN INC V PRODUCES SECRETION LIKE THAT OF VAGAL STIMULATION P0384
PILOCAPPINE 0 SALIVARY POTASSIUM DEC V PRODUCES SECRETION LIKE PLASMA ULTHAFILTPATE R0384
PINEAPPLES U 5 OH INDOLEACETIC ACID INC V RICH IN SEROTONIN P0337
PINK CAPSULES S PBI INC V NAY CONTAIN IODINE IN DYE HO 355
PIPAMAZINE B PLATELET COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCPASIAS) P0658
PIPAMAZINE B RED CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P06 58
PIPANAZINE B WHITE CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0658
PIPER ACETAZINE B EOSINOPHILS INC V OCCASIONAL ALLERGIC RESPONSE P014 67
PIPERACETAZINE B HENATOCHIT DEC V MILD TRANSIENT DECREASE WITH HYPOTEN3ION P0353
PIPER ACE! AZ IN! B HEMOGLOBIN DEC V MILD TRANSIENT DECREASE WITH HYPOTENSION HO 353
PIPERACETAZ IN! B PLATELET COUNT DEC V RARE THROMBOCYTOPENIA (REVERSIBLE) P0026
PIPERACETAZINE B WHITE CELL COUNT DEC V PARE LEUKOPENIA /AGRANULOCYTOSIS (REVERSIBLE) P0026
PIPERACETAZ IN! S BILIRUBIN INC V RAPE JAUNDICE (REVERSIBLE) (LIKE INFECT HEPATITIS) P00 26
P1 PEPACETAZ IN! S SCOT INC V TRANSIENT REVERSIBLE INCREASE 90 3 53

PIPERACETAZINE S SGPT INC V TRANSIENT REVERSIBLE EFFECT R0353
PIPEHAZINES B HEMATOCRIT DEC V MAY CAUSE HEMOLYTIC ANEMIA HO 6 36
PIPEPAZINES B HEMOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P0636
PIPERA ZINES B RED CELL COUNT DEC V MAY CAUSE HEMOLYTIC ANEMIA P06 36
PIPERAZINES S BILIRUBIN INC V MAY CAUSE HEMOLYTIC ANEMIA P0636
PIPER IDINES U 17 KETOSTEROIDS INC N INTERFERENCE WITH ZIMMERMAN REACTION IN VITRO HO 133
PIPERI DI NES U 17 OH CORTICOSTEROIDS INC M INTERFERES WITH PORTER-SILBER REACTION IN VITRO P0133
PIPOBROMAN B HEMATOCHIT DEC V INTENDED EFFECT WHEN POLYCYTHEMIA PRESENT HO 467
P1 POB ROMAN B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA HAS BEEN DESCRIBED P002 1
PIPOBROMAN B PLATELET COUNT DEC V MAY CAUSE BONE MARROW DEPRESSION P0467
PIPOBROMAN B RED CELL COUNT DEC V MAY CAUSE ANEMIA (BONE MARROW DEPRESSION) P00 26
PIPORPOMAN B RETICULOCYTES INC V HEMOLYTIC ANEMIA HAS BEEN DESCRIBED P0021
PIPOBROMAN B WHITE CELL COUNT DEC V BONE NARROW DEPRESSION NAY OCCUR AFTER 4 WEEKS P0467
PIPOBROMAN S BILIRUBIN INC V MAY CAUSE HEMOLYTIC ANEMIA P0299
PIPOBROMA N U UHOBILINOGEN INC V HENOLYTIC ANEMIA HAS BEEN DESCRIBED P0021
PLANTAINS U 5 OH TRYPTAMINE INC M 5 OH TRYPTAMINE CONTAINED IN PLANTS HO 355
PLASMOQUIN B HEMATOCPIT DEC V MAY CAUSE HEMOLYTIC ANEMIA P06 20
PLASMOQUIN B HEMOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P06 20
PLASNOQUIN B METHEMOCLOBIN INC V MAY CAUSE HENOLYTIC ANEMIA P06 20
PLASMOQUI N B RED CELL COUNT DEC V NAY CAUSE HENOLYTIC ANEMIA P0620
PLUMS U 5 OH INDOLEACETIC ACID INC V RICH IN SEHOTONIN P04 17
POLIOMYELITIS VAC B PLATELET COUNT DEC V MAY RARELY CAUSE THPOMBOCYTOPENIA P06 57
POLIOMYELITIS VAC C PROTEIN INC V MAY RARELY CAUSE CUILLAIN-BAPRE SYNDROME P06 57
POLYMYXIN B S CREATININE INC V NEPHROTOXIC EFFECT H 07 36
POLYMYXIN B S NPN INC V NEPHPOTOXIC EF9ECT P06 20
POLYMYXIN B S POTASSIUM DEC V REPORTED TO OCCUR IN LEUKEMIA, MAYBE STEROID EFFECT P0285
POLYMYXIN B S UREA NITROGEN INC V NEPHPOTOXIC EFFECT RO299
POLYMYXIN B U ALKALINE PHOSPHATASE INC V DUE TO NEPHROTOXIC EFFECT OF DRUG P07 58
POLYNYXIN B U CFR DEC V NEPHHOTOXICITY INCREASES WITH CONTINUED TREATMENT HO 3814
POLYNYXIN B U LEUCINE AMINOPEPTIDASE INC V FACILITATES PERMEATION OF ENZYME INTO TUBULES P07 58
POLYMYXIN B U PROTEIN INC V NEPHROTOXIC EFFECT P0299
POLYMYXIN B U URINALYSIS CASTS INC V CYLINDRURIA MAY OCCUR WITH DAILY INJECTION HO 384
POLYMYXIN B U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG P02 99
POLYMYXIN B U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT HO 355
POLYMYXIN B U URINALYSIS RBC/HPF INC V ACTUAL BLEEDING MAY BE CAUSED BY DRUG P03 55
POLYSTYRENE SULFON F CALCIUM INC V CAUSES IMPAIRED ABSORPTION HO 299
POLYSTYRENE SULFON S CALCIUM DEC V EXCHANGED FOR POTASSIUM, INC FECAL LOSS P06 20
POLYSTYRENE SULFON S CALCIUM INC V INCREASED ADMINISTERED CALCIUM (IF IN CA FORM) P0907
POLYSTYRENE SULFON S POTASSIUM DEC V EXCHANGES POP SODIUM (IF NA FORM USED) H 06 20
POLYTHI AZIDE F CALCIUM DEC V ACCENTUATES POSITIVE CALCIUM BALANCE P06 57
POLYTHIAZIDF P ADH INC V SECRETED IN RESPONSE TO HYPONATRENIA P03 25
POLYTHIAZIDE S ALKALINE PHOSPHATASE INC V MAY AFFECT LIVER FUNCTION P0620
POLYTHIAZIDE S BILIHUBIN INC V NAY AFFECT LIVER FUNCTION P06 20
POLYTHIAZ IDE S BSP RETENTION INC V MAY AFFECT LIVER FUNCTION P0620
POLYTHIAZ IDE S CALCIUM INC V MAY BE INC BY UP TO 0.35 MEQ/L P06 57
POLYTHI AZI DE S CEPHALIN FLOCCULATION INC V MAY AFFECT LIVER FUNCTION P062 0
POLYTHIAZIDE S CHLORIDE DEC V DIURETIC EFFECT HO 325
POLYTHIAZIDE S CO2 CONTENT INC V METABOLIC ALKALOSIS WITH MARKED DIURESIS P0325
POLYTHIAZIDE S GLUCOSE INC V DIABETOGENIC ACTION HO 6 20
POLYTHIAZI DE S OSMOLALITY DEC V ADH SECRETION WITH HYPONATPENIA H0325
POLYTHIAZID! S POTASSIUM DEC V DIURETIC ACTION P0325
POLYTHIAZIDE S SCOT INC V MAY AFFECT LIVER FUNCTION P06 20
POLYTHIAZIDE S SGPT INC V MAY AFFECT LIVER FUNCTION R062O
POLYTHIAZIDE S SODIUM DEC V DIURETIC ACTION. WITH K DEFICIENCY P03 25
POLYTHIAZIDE S THYMOL TURBIDITY INC V NAY AFFECT LIVER FUNCTION P06 20
POLYTHIAZIDE U CALCIUM DEC V EXCRETION DEC BY UP TO 50% P0657
POLYTHIAZIDE U CITRATE DEC V EXCRETION DEC BY UP TO 30% P06 57
POLYTHIAZIDE U URINALYSIS BILE INC V NAY AFFECT LIVER FUNCTION P0620
POLYTHIAZIDE U URINALYSIS GLUCOSE INC V CONSEQUENCE OF HYPERGLYCEMIA P06 20
PORPHYRINS U URINALYSIS COLOR INC V BURGUNDY RED, DARKENS ON STANDING P06 20
PORPHYRINS U UROBILIN INC N PRODUCE RED FLUORESCENCE R0436
POTASSIUM P AMMONIA DEC V K REPLETION IN HEPATIC COMA NAY REDUCE NH3 P0679
POTASSIUM S CALCIUM INC N AFFECTS FLAME PHOTOMETRY IF POOP INSTRUMENT P01436
POTASS IU N S SODIUM INC N AFFECTS FLAME PHOTOMETRY IF POOR INSTRUMENT P0436
POTASSIUM ANINOBENZ S GLUCOSE DEC V REPORTED EFFECT HO 6 20
POTASSIUM CHLORATE B METHENOGLOBIN INC V MAY CAUSE HEMOLYTIC ANEMIA P06 58
POTASSIUM CHLORIDE S CHLORIDE INC V ADDED CHLORIDE P06 20
POTASSIUM CHLORIDE S GLUCOSE DEC V DRAWN INTO CELLS WITH POTASSIUM P06 20
POTASSIUM CHLORIDE S POTASSIUM INC V OVER CORRECTION OF HYPOKALEMIA P0026
POTASSIUM IODIDE B EOSINOPHILS INC V ALLERGIC RESPONSE P0 432
POTASSIUM IODIDE B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA P0620
POTASSIUM IODIDE S AMYLAS! INC V PAROTITIS REPORTED AS RESULT OF TREATMENT R0467
POTASSIUM IODIDE S PBI INC V SMALL DOSES ELEVATE IN NORMAL RANGE, OTHERS ABOVE P02 55
POTASSIUM OXALATE S CHLORIDE DEC M IF USED AS ANTICOAGULANT MAY BE SHIFT INTO CELLS HO 436
POTASSIUM OXALATE S GLUCOSE DEC N INEFFECTIVE AS ANTIGLYCOLYTIC AGENT P0620
POTASSIUM SALTS F OCCULT BLOOD P05 V MAY CAUSE ULCERATION AND HEMORRHAGE IN G.I. TRACT P0467
POTASSIUM SALTS U DIAGNEX BLUE EXCRETION INC N DISPLACEMENT OF DIAGNEX BLUE FROM RESIN H 1001
POVIDONE-IODINE S PBI INC V FOUND BY SOME INVESTIGATORS ONLY P07 57
PREDNISOLONE B WHITE CELL COUNT DEC V LEUKOPENIA P0620
PREDNI SOLONE B WHITE CELL COUNT INC V LEUCOCYTOSIS OBSERVED OCCASIONALLY P062 0
PREDNISOLONE S PHI DEC V INHIBITS IODINATION OF TYHOSINE IN TBG P0004
PREDNI SOLON! S POTASSIUM DEC V SLIGHT NINEPALOCORTICOID EFFECT 90026
PREDNISOLON! S SODIUM INC V VERY SLIGHT NINEPALOCORTICOID EFFECT 90026
PREDNI SOLONE U POTASSIUM INC V SLIGHT MINERALOCOPTICOID EFFECT P0026
PREDNISONE B PLATELET COUNT DEC V REPORTED EFFECT IN ONE INDIVIDUAL P06 57
PREDNISON! B WHITE CELL COUNT DEC N LOW COUNT BY COULTER 5, ?DUE TO FRAGILE CELLS R0598
PREDNISONE S CALCIUM DEC V IF ELEVATION DUE TO SARCOIDOSIS OR VITAMIN D H 0026
PREDNISONE S GLUCOSE INC V GLUCOCORTICOID EFFECT P06 83
PHEDNISONE 5 PHI DEC V INHIBITS IODINATION OF TYROSIN! IN TBG P0004
PREDNI SON! S POTASSIUM DEC V SLIGHT MINEPALOCOPTICOID EFFECT ONLY P0026

PREDNISONE S SODIUM INC V SLIGHT EFFECT ONLY HO 026
PPEDNISONE S TBG DEC V DECREASES CONCENTRATION OF TBG, INCREASE TBPA P0907
PPEDNI SON! S URIC ACID INC V PROMOTES NUCLEIC ACID CATABOLISM P0907
PHEDNISONE U POTASSIUM INC V SLIGHT MINERALOCOHTICOID EFFECT ONLY P00 26
PREGNA NC! B COLD AGGLUTININS P05 V OCCASIONAL RESPONSE P02 91
PREGNANCY B FACTOR II INC V NORMAL RESPONSE IN LATE PREGNANCY P0 29 1
PREGNA NC! B FACTOR IX INC V NORMAL RESPONSE IN LATE PREGNANCY H01143
PREGNANCY B FACTOR VII INC V NORMAL RESPONSE IN LATE PREGNANCY P0 291
PREGNANCY B FACTOR VIII INC V INC 100% ABOVE NORMAL IN LATE PREGNANCY P0291
PREGNANCY B FACTOR X INC V NORMAL RESPONSE IN LATE PREGNANACY P0291
PREGNANCY B FACTOR XI DEC V NORMAL RESPONSE IN LATE PREGNANCY P0291
PREGNANCY B HEMATOCRIT DEC V IN RELATION TO DECREASED HEMOGLOBIN P0291
PHEGNA NC! B HEMOGLOBIN DEC V NORMALLY SLIGHT REDUCTION (NOT BELOW 10 MG/100ML) R0291
PREGNANCY B PED CELL COUNT DEC V BY UP TO 10-15% DUE TO EXPANDED PLASMA VOLUME P02 91
PREGNA NC! B SEDIMENTATION RATE INC V NORMAL ASSOC WITH INC FIBRINOGEN AFTER 3RD MONTH R02 91
PREGNANCY B VOLUME INC V INC TO MAX OF PLUS 45% BY 32ND WEEK P029 1
PREGNA NC! B WHITE CELL COUNT INC V IN LATE PREGNANCY AND AT LABOR P02 91
PREGNANCY E CARBONIC ANHYDRASE INC V MEASURED AS B ISOENZYNE - PROGRESSIVE INCREASE P08 29
PRECNA NC! E OSMOTIC FRAGILITY INC V MAY BE OCCASIONAL INCREASE P0291
PREGNANCY E SODIUM DEC V MATERNAL INTRACELLULAR NA DECREASE TOWARDS TERM RO291
PREGNANCY 0 BMR INC V MODERATELY INC ES? IN LAST 3 MONTHS P 029 1
PREGNANCY 0 GASTRIC JUICE HCL DEC V MAY BE HYPOSECRETION P029 1
PHEGNA NC! 0 GASTRIC JUICE PEPSIN DEC V MAY BE HYPOSECRETION P0291
PREGNANCY P EPPF INC V NORMAL RESPONSE IN FIRST 8 MONTHS P0291
PREGNA NC! P FIBRINOGEN INC V MOD INC BY 16TH WEEK (PLUS 33% BY TERM) P0291
PREG NANCY P GONADOTROPINS INC V INC EARLY TO YIELD POSITIVE PREGNANCY TEST P0143
PHEGNA NC! P PENIN SUBSTRATE INC V INCREASED DUE TO HORMONAL EFFECTS 90186
PREGNANCY P VOLUME INC V INC BY PLUS 25 TO 55% BY 32ND WEEK P0291
PHEG NA NC! S ACETYL-GLUCOSAMINIDASE INC V THREE TIMES NORMAL IN LAST TRIMESTER P0291
PREGNANCY S ALBUMIN DEC V FALLS ABOUT 1G/100ML IN LAST 2 TRIMESTERS P0291
PREGNANCY S ALKALINE PHOSPHATASE INC V 2 TO 3 TIMES NORMAL ACTIVITY IN THIRD TRIMESTER P0929
PREGNANCY S ALPHA1-ANTITRYPSIN INC V IN LAST TRIMESTER COMPARED WITH CONTROLS P06 39
PREGNANCY S ALPHA1-GLOBULIN INC V MARKED INC IN LAST TWO THIMESTERS P029 1
PREGNANCY S ALPHA2-GLOBULIN INC V OCCURS IN LAST 2 TPIMESTEHS HO 291
PPECNA NC! S ANTITHROMBIN TITER DEC V OCCURS WITH PREGNANCY P0 29 1
PREGNANCY S BETA-GLOBULIN INC V SLIGHT INCREASE IN SECOND TRIMESTER HO 29 1
PREGNA NC! S BETA-GLUCUPONIDASE INC V SLIGHT DROP INITIALLY THEN LARGE INC TOWARDS TERM HO 323
PREGNANCY S BETA1A-GLOBULIN INC V IN LAST TRIMESTER COMPARED WITH CONTROLS P06 39
PHEGNA NC! S BSP RETENTION INC V MAY BE MODERATELY ABNORMAL IN LAST MONTH HO 29 1
PREGNA NC! S CERULOPLASMIN INC V IN LAST TRIMESTER COMPARED WITH CONTROLS P06 39
PREGNANCY S CHOLESTEROL INC V INCREASES FROM 8 TH WEEK (MAX BY 30TH) P0 29 1
PREGNA NC! S COPPER INC V METABOLIC EFFECT MAX IN LAST TRIMESTER P02 91
PREGNANCY S CPK DEC V SIC DEC FROM 8-20 WKS, MAX DEC 12-13 WKS P0529
PREGNA NC! S CPK INC V ACTIVITY INCREASES DURING LAST TRIMESTER P07 79
PREGNANCY S GAMMA GLOBULIN DEC V MAY FALL SLIGHTLY IN LAST 3 MONTHS P029 1
PREGNA NC! S GLUCOSE DEC V MAY BE LOW IN OCCASIONAL CASES P029 1
PREGNANCY S GLUCOSE TOLERANCE DEC V DECREASED TOLERANCE IN LAST TRIMESTER H 029 1
PREGNANCY S lCD INC V PLACENTAL ORIGIN IN LAST TRIMESTER 90291
PREGNANCY S IRON DEC V FALLS FROM MIDTERM ONWARDS 90291
PREGNA NC! S LEUCINE AMINOPEPTIDASE INC V MODERATELY INCREASED THROUGHOUT PREGNANCY P029 1
PREGNANCY S NEUTRAL FATS INC V OBSERVED THROUGHOUT PREGNANCY P0 29 1
PREGNANCY S NPN DEC V DEC 20-25% (WITH REL GREATER DEC OF UREA NITROGEN) HO 143
PREGNANCY S PBI INC V OBSERVED THROUGHOUT PREGNANCY P0291
PREGNANCY S PHOSPHOLIPIDS INC V INCREASE FROM 8 WEEK 90291
PREGNA NC! S PROT-BND POLYSACCHAHIDE INC V THROUGHOUT PREGNANCY P02 91
PREGNANCY S TIBC INC V WITH FALL OF SERUM IRON AFTER MIDTERM HO 29 1
PREGNANCY S TRANSFERRIN INC V IN LAST TRIMESTER COMPARED WITH CONTROLS P063 9
PREGNANCY S UREA NITROGEN DEC V MARKED ANABOLIC STATE ESP IN FIRST 6 MONTHS P1001
PREGNANCY U ALDOSTERONE INC V DURING LAST TRIMESTER P029 1
PREGNANCY U ALPHA AMINO NITROGEN INC V PENAL THRESHOLD OF AMINO ACIDS REDUCED HO 29 1
PREGNANCY U AMMONIA INC V OUTPUT INCREASED IN LAST TRIMESTER P0291
PREGNANCY U CREATINE INC V GENERAL EFFECT WITH PREGNANCY P029 1
PREGNA NC! U ESTROGENS INC V INC FROM 6TH MONTH UNTIL TEPM(UP TO 100UG/24H) P029 1
PREGNANCY U GFR INC V NORMAL DURING FIRST 8 MONTHS HO 291
PREGNANCY U GONADOTPOPINS INC V HCG INC FROM 2 TO 12 WEEKS, FALLS LATER P0291
PREGNANCY U LACTOSE INC V NAY OCCUR IN LAST TRIMESTER ESP IN AFTERNOON P029 1
PREGNA NC! U POPPH!RINS INC V MAY PRECIPITATE EPISODE OF HEPATIC PORPHYRIA P06 57
PREGNANCY U PROTEIN INC V MODERATE PROTEINURIA COMMON P02 91
PR! GNANCX U PROTEIN INC V MODERATE PHOTEINURIA COMNON HO 29 1
PREG NA NC! U UREA NITROGEN DEC V ESP IN FIRST 6 MONTHS Ho 291
PREGNANCY U URINALYSIS GLUCOSE INC V MAY OCCUR WITH DECREASED TOLERANCE HO 29 1
PREG NANCY U URINALYSIS PROTEIN INC V MODERATE PROTEINURIA NAY OCCUR COMMONLY P029 1
PREGNANCY U UROPEPSINOGEN INC V MODERATE INCREASE OBSERVED HO 29 1
PREGNA NC! U VOLUME INC V MAY INCREASE BY UP TO 25% IN LAST TRIMESTER P01143
PREGNANCY U 17 KETOSTEROIDS INC V UPPER LIMIT OF NORMAL AT TERM HO 291
PPEGNA NC! U 5 OH INDOLEACETIC ACID INC V MODERATE INCREASE OBSERVED P0291
PREGNANCY W ALKALINE PHOSPHATASE INC V OCCURS AFTER 3RD MONTH P029 1
PREMAPIN B FACTOR IX INC V SMALL INCREASES REPORTED 90028
PRENARIN B FACTOR V INC V SMALL INCREASES REPORTED H 0028
PH!MARIN B PLATELET AGGREG INC V SMALL INCREASES REPORTED P00 28
PREMARIN B PTT DEC V SHORTENING OF TIME IN MALES AFTER I.V. ADNIN P002 8
PREMARIN F COPROPORPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA P09 87
PREMA PIN F PPOTOPORPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA P0987
PHENARIN F UROPORPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA HO 987
PRENA PIN P FIBRINOGEN DEC V SMALL BUT SIC EFFECT AFTER I.V. IN NORMAL MALES P0028
PREMAPIN P FIBRINOGEN INC V EFFECT IN NORMAL FEMALES AFTER I.V. ADMIN P0028
PREMARIN P PROTHROMBIN TIME INC V IN NORMAL WOMEN AFTER I.V. ADMINISTRATION P 0028
PREMARIN U COPROPORPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA P0987
PREMARIN U FSH DEC V SLIGHT DECREASE ONLY EVEN WITH LARGE DOSES P0963
PREMARIN U HPG EXCRETION DEC V INHIBITS PITUITARY GONADOTROPHIC FUNCTION HO 9 34

PREMAPIN U LH INC V MARKED INITIAL EFFECT, FALLS OFF WITH LARGE DOSE P0963
PPEMARIN U UROPORPHYRIN INC V NAY INDUCE PORPHYRIA CUTANEA TARDA R0987
PRILOCAIN! P HEMATOCRIT DEC V HENOL!SIS WITH DOSES GREATER THAN 400 MG P0026
PRILOCAINE B HEMOGLOBIN DEC V HENOLYSIS WITH DOSES GREATER THAN 400 MG P0026
PRILOCAINE B METHEMOGLOBIN INC V 0-TOLUIDINE PROD AS METABOLITE CAUSES HEMOLYSIS P0230
PRILOCAINE B RED CELL COUNT DEC V HEMOL!SIS WITH DOSES GREATER THAN 400 MG P0026
PPIMAQUINE B HEINZ-BODY FORMATION P05 V NA! OCCUR IN EARLY STAGES OF HEMOLYSIS P01014
PHIMAQUIN! B HEMATOCRIT DEC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS P0240
PRIMAQUINE B HEMOGLOBIN DEC V HENOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS P0240
PRIMAQUINE B METHEMOGLOBIN INC V NAY CAUSE HENOLYSIS IN G-6-PD DEFICIENCY P0026
PRIMAQUINE B RED CELL COUNT DEC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS P0240
PRIMAQUIN! B WHITE CELL COUNT DEC V AGPANULOC!TOSIS/LEUKOPENIA P0620
PRIMAQUINE S BILIRUBIN INC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
PRIMAQUIN! S HAPTOGLOBIN DEC V NAY CAUSE HENOLYTIC ANEMIA P0620
PRIMAQUINE U URINALYSIS COLOR INC N RUST! YELLOW OR BROWN COLOR P0122
PRIMIDONE B HEMATOCRIT DEC V MEGALOBLASTIC ANEMIA 2ND DIST. IN FOLIC ACID NETAB. P0775
PRIMIDONE B HEMOGLOBIN DEC V NEGALOBLASTIC ANEMIA 2ND DIST. IN FOLIC ACID NETAB. P0775
PRIMIDONE B LE CELL PREP P05 V SINGLE DRUG RELATED CASE REPORTED P0657
PPIMIDONE B MCV INC V MEGALOBLASTIC ANEMIA 2ND DIST. IN FOLIC ACID METAB. P0775
PRIMIDONE B PLATELET COUNT DEC V PANCYTOPENIA (AMA-BLOOD D!SCRASIAS) P0658
PHIMIDONE B RED CELL COUNT DEC V NEGALOBLASTIC ANEMIA 2ND DIST. IN FOLIC ACID METAB. R0775
PRIMIDONE B WHITE CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYCRASIAS) RO658
PRIMIDON! E FOLATE DEC V IMPAIRED DECONJUGATION OF POL!GLUTAMATES IN GUT P0291
PRIMIDONE S FOLATE DEC V MA! CAUSE MEGALOBLASTIC ANEMIA(INPAIRS ABSORP) P0791
PRINIDON! T FOLAT! Z N NO EFFECT ON L. CASEI OP S. FECALIS P0657
PPIMIDONE U AICAR INC V IF MRGALOBLASTIC ANEMIA OCCURS P0791
PRIMIDONE U FICLU INC V IF MEGALOBLASTIC ANEMIA OCCURS P0791
PROBENECID B HENATOCRIT DEC V HEMOLYTIC ANEMIA (SENSITIVITY DEPENDENT) R0240
PROBENECID B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA (SENSITIVITY DEPENDENT) P0240
PROBENECID B METHEMOGLOBIN INC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0926
PROBENECID B RED CELL COUNT DEC V HEMOLYTIC ANEMIA (SENSITIVITY DEPENDENT) P02140
PROBENECID S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT (CENTROLOBULAP NECROSIS) P0620
PROBENECID S BILIPUBIN INC V HEPATOTOXIC EFFECT (CENTROLOBULAP NECROSIS) P0620
PPOBENECID S BSP RETENTION INC V HEPATOTOXIC EFFECT (CENTROLOBULAR NECROSIS) P1001
PROBENECID S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT (CENTHOLOBULAR NECROSIS) P0620
PROBENECID S SCOT INC V HEPATOTOXIC EFFECT (CENTROLOBULAR NECROSIS) P0620
PPOBENECID S SGPT INC V HEPATOTOXIC EFFECT (CENTROLOBULAP NECROSIS) P0620
PROBENECID S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT (CENTPOLOBULAR NECROSIS) R0620
PHOBENECID S UREA NITROGEN INC V POSSIBLE NEPHROTOXICIT! P01417
PROBENECID S URIC ACID DEC V URICOSUPIC ACTION P0404
PROBENECID U PAH CLEARANCE DEC V PENAL CLEARANCE IMPAIRED P0638
PROBENECID U PROTEIN INC V NEPHPOTOXIC EFFECT P1001
PHOBENECID U PSP EXCRETION DEC V INHIBITS RENAL TRANSPORT OF PSP P1001
PROBENECID U SUGAR INC N FALSE POSITIVE WITH BENEDICT’S OH CLINITEST R09O7
PROBENECID U URIC ACID DEC V SMALL DOSES DEPRESS SECRETION P0384
PHOBENECID U URIC ACID INC V URICOSURIC ACTION P01404
PHOBENECID U URINALYSIS BILE INC V POSSIBLE HEPATOTOXICIT! P0620
PPOBENECID U URINALYSIS CALCULI INC V MA! OCCUR IF LITTLE FLUID DRUNK OP EXCRETE MUCH P0046
PPOBENECID U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED B! DRUG P0299
PPOBENECID U URINALYSIS PROTEIN INC V NEPHPOTOXIC EFFECT P0417
PROBENECID U URINALYSIS RBC/HPF INC V ?DUE TO SENSITIVITY, OR TOXICITY P0129
PROBENECID U 17 KETOSTEROIDS DEC V DECREASE OF UP TO 50% REPORTED P0344
PHOBUCOL B FOSINOPHILS INC V HYPERSENSITIVITY RESPONSE (LESS THAN 10%) P0247
PHOBUCOL P GROWTH HORMONE DEC V MECHANISM OBSCURE P02147
PROBUCOL S ALDOLASE DEC V MECHANISM OBSCURE P02147
PROBUCOL S CALCIUM DEC V MECHANISM OBSCURE (EFFECT SLIGHT) P02147
PROBUCOL S CHOLESTEROL DEC V LOWERED BY NOPE THAN 20 NG/100NL IN MOST PATIENTS P0247
PPOBUCOL S CO2 CONTENT INC V MECHANISM OBSCURE (EFFECT SLIGHT) P0247
PROBUCOL S URIC ACID INC V EFFECT NOTED IN WOMEN ONLY P0247
PHOCAINAMIDE B LE CELL PREP P05 V REPORTED EFFECT P0562
PPOCAINAMIDE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS R0915
PROCAINAMIDE S ALKALINE PHOSPHATASE INC V REVERSIBLE HEPATIC TOXICITY REPORTED P0299
PROCAINANIDE S ANTINUCLEAR ANTIBODIES P05 V REPORTED TO OCCUR IN 50% PATIENTS P0907
PPOCAINAMIDE S BILIRUBIN INC V REVERSIBLE HEPATIC TOXICITY REPORTED P0417
PPOCAINAMID! 5 BSP RETENTION INC V REPORTED CASE OF HEPATIC TOXICITY P0417
PROCAINAMIDE S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT P0620
PROCAINAMIDE S COOMBS TEST P05 V MECHANISM OBSCURE P01418
PROCAINAMIDE S SCOT INC V HEPATOTOXIC EFFECT P0620
PROCAINAMIDE S SGPT INC V HEPATOTOXIC EFFECT P0620
PROCAINAMIDE S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT P0620
PROCAINANIDE U ANINOBENZOIC ACID INC V UP TO 10% EXCRETED AS THIS P03814
PROCAINAMIDE U URINALYSIS BILE INC V HEPATOTOXIC EFFECT P0620
PROCAINE C PROTEIN INC M INTERFERES WITH FOLIM-CIOCALTEU REAGENT P0355
PROCAINE S SULFA AS SULFANILAMIDE INC N METABOLIZED TO PABA WHICH INTERFERES P0384
PROCAINE U POPPHOBILINOCEN INC N INTERFERES WITH EHPLICH’S ALDEHYD! REACTION P1001
PROCAINE U UHOBILINOGEN INC N INTERFERES WITH EHRLICH’S ALDEHYDE REACTION R1001
PROCAFBAZINE B PLATELET COUNT DEC V THROMBOCYTOPENIA ND BONE MARROW DEPRESSION P0026
PROCARBAZINE B RED CELL COUNT DEC V ANEMIA AND BONE NARROW DEPRESSION P0026
PROCARBAZINE B WHITE CELL COUNT DEC V LEUKOPENIA AND BONE MARROW DEPRESSION P0026
PROCARBAZINE F OCCULT BLOOD P05 V MELENA AND G.I. TRACT BLEEDING R0O26
PROCARBAZINE S BILIRUBIN INC V REPORTED EFFECT. ?NECHANISM P01417
PROCHLORPEPAZINE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS DUE TO INTERFERENCE IN DEVELOPMENT P0025
PROCHLOPPERAZINE F UPOBILINOGEN DEC V PALE STOOLS ASSOCIATED WITH CHOLESTASIS P0026
PROCHLORPERAZIN! P PROTHROMBIN TINE INC V ASSOC WITH IMPAIRED EXCRETION OF BILE SALTS P0026
PROCHLOPPEPAZINE S ALKALINE PHOSPHATAS! INC V CHOLESTATIC EFFECT P0026
PROCHLOPPEPAZINE S BILIPUBIN INC V CHOLESTATIC EFFECT P0026
PPOCHLOHPERAZINE S BSP RETENTION INC V CHOLESTATIC EFFECT P0026
PPOCHLOPPERAZINE S CEPHALIN FLOCCULATION INC V CHOLESTATIC EFFECT P0026
PROCHLOPPEPAZINE S CHOLESTEROL INC V CHOLESTATIC EFFECT P0026
PPOCHLORPEPAZINE S SCOT INC V CHOLESTATIC EFFECT P0026

PROCHLORPERAZINE S SGPT INC V CHOLESTATIC EFFECT R0026
PPOCHLOPPERAZINE S THYMOL TURBIDITY INC V CHOLESTATIC EFFECT P0026
PROCHLOHPEHAZINE U CATECHOLAMINES INC V INC METABOLISM, DEC ORGAN UPTAKE OF NOREPINEPURINE H1001
PPOCHLORPEHAZIN U METANEPHPINES TOTAL INC V INC METABOLISM, DEC ORGAN UPTAKE OF NOREi’INEPHPINE P1001
PPOCRLOPPERAZINE U PHENYLKETONES P05 N LIGHT PURPLE WITH FECL3, ALSO WTIH PHENISTIX P0239
PROCHLORPEPAZIWE U URINALYSIS BILE INC V CHOLESTATIC EFFECT P0026
PHOCHLORPERAZINE U UPOBILINCGEN DEC V CHOLESTATIC EFFECT P0026
PPOCHLOHPERAZINE U VMA INC V INC METABOLISM, DEC ORGAN UPTAKE OF NOREPINEPHRIN! P1001
PPOCHLORPERAZIN! U 17 KETOSTEROIDS Z N NO SIGNIFICANT EFFECT WITH ZIMMERMAN REACTION P0133
PROCHLORP!RAZINE U 17 OH COBTICOSTEROIDS INC N INTERFERENCE WITH PORTER-SILBER REACTION P0133
PROCHLOPPERAZINE U 5 OH INDOLEACETIC ACID DEC N INTERFERENCE WITH NITPOSONAPHTHOL METHODS P0800
PHOCYCLIDINE S ANYLASE INC V MA! CAUSE ACUTE PAROTITIS (THEORETICAL EFFECT) P0467
PROGESTERONE P ALPHA AMINO NITROGEN DEC V CATABOLIC EFFECT P0225
PROGESTERONE S AMINO ACIDS DEC V SPECIFIC AMINO ACIDS AFFECTED IN MEN P0226
PROGESTERONE S PBI DEC V INHIBITS IODINATION OF TYROSIN! IN TBG P0004
PROGESTIN P LH DEC V SUPPRESSES LH PEAK P08147
PROGESTIN S ALBUMIN INC V NOT OBSERVED WITH COMBINED THERAPY O243
PROCESTIN S ALKALINE PHOSPHATASE INC V HEPATOTOXICITY P0620
PROGESTIN S BILIRUBIN INC V HEPATOTOXICITY ALSO TRANSIENT FAMILIAL INCREASE 90620
PROGESTIN S BSP RETENTION INC V HEPATIC TOXICITY OCCASIONAL OCCURRENCE 90679
PROGESTIN S CALCIUM INC V PROB EFFECT WITH REMISSION OF NETASTASES RO’20
PHOGESTIN S CEPHALIN FLOCCULATION INC V HEPATOTOXICIT! 90620
PPOGESTIN S CEHULOPLASNIN Z V NO EFFECT REPORTED OVER SEVERAL MONTHS 0907
PROG!STIN S COPPER Z V NO EFFECT REPORTED OVER SEVERAL MONTHS P0907
PROGESTIN S GAMMA GLOBULIN INC V NOT OBSERVED WITH COMBINED THERAPY P02143
PROCESTIN S MAGNESIUM INC V SIGNIFICANTLY HIGHER THAN IN CONTROLS P0242
PROGESTIN S PHI INC V INCREASED PRODUCTION OF TBG R1001
PROGESTIN S PROTEIN INC V METABOLIC EFFECT 90243
PROGESTIN S SCOT INC V HEPATOTOXICITY RO620
PHOGESTIN S SGPT INC V HEPATOTOXICITY P0620
PROGESTIN S SODIUM INC V MAY CAUSE SODIUM RETENTION P0596
PROGESTIN S TBG INC V INCREASED SYNTHESIS R1001
PHOCESTIN S THYMOL TURBIDITY INC V HEPATOTOXICITY P0620
PROGESTIN S TRANSFERRIN Z V NO SIGNIFICANT EFFECT AFTER 6-9 MONTHS P0907
PROGESTIN U SODIUM INC V MAY OCCUR WITH HIGH DOSES P0657
PROGESTIN U URINALYSIS BILE INC V HEPATOTOXICITY 062O
PPOCUANIL U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG P0299
PROGUANIL U URINALYSIS HBC/HPF INC V ACTUAL BLEEDING MAY BE CAUSED BY DRUG P0299
PROLACTIN S OSMOLALITY INC V EFFECT NOT MARKED 904614
PROLACTIN S SODIUM INC V PENAL RETENTION EFFECT WHEN GIVEN I.M. 904614
PROLACTIN U PH INC V INDIVIDUAL RESPONSE - MAY BE MARKED 9014614
PHOLACTIN U POTASSIUM DEC V REDUCES PENAL EXCRETION, NOT AS MARKED AS FOP NA 90464
PPOLACTIN U SODIUM DEC V REDUCES RENAL EXCRETION AT TUBULAR LEVEL P01464
PROLACTIN U URINALYSIS PH INC V INDIVIDUAL RESPONSE - NAY BE MARKED R01464
PROLACTIN U VOLUME DEC V ACTION FOP UP TO 8 HOURS WHEN GIVEN I.N. P01464
PROMAZINE B WHITE CELL COUNT DEC V AGPANULOCYTOSIS 90329
PPOMAZINE F UROBILINOGEN DEC V PALE STOOLS AS RESULT OF CHOLESTASIS 901477
PRONAZINE P PROTHEOMBIN TIME INC V ASSOC WITH FAILURE 0! EXCRETION OF BILE SALTS P0477
PROMAZINE S ALKALINE PHOSPHATASE INC V MAY CAUSE CHOLESTATIC (HEPATOCANALICULAR) JAUNDICE P0079
PROMAZINE S BILIRUBIN INC V MAY CAUSE CHOLESTATIC (HEPATOCANALICULAR) JAUNDICE P0079
PROMAZINE S BSP RETENTION INC V NAY CAUSE CHOLESTASIS RO620
PROMAZINE S CEPHALIN FLOCCULATION INC V NAY CAUSE CHOLESTASIS P0620
PROMAZINE S CHOLESTEROL INC V MA! CAUSE CHOLESTATIC (HEPATOCANALICULAR) JAUNDICE P0079
PROMAZINE S PHI Z V NO EFFECT WITH NORMAL DOSES P0255
PROMAZINE S SGOT INC V MA! CAUSE CHOLESTATIC (HEPATOCANALICULAR) JAUNDICE P0079
PPONAZINE S SGPT INC V MA! CAUSE CHOLESTATIC (HEPATOCANALICULAP) JAUNDICE P0079
PRONAZINE S THYMOL TURBIDITY INC V NAY CAUSE CHOLESTASIS P0620
PPONAZINE U PROTEIN INC V AFFECTS TURBIDITY TESTS FOR UP TO 3 DAYS 90020
PRONAZINE U URINALYSIS BILE INC V MAY CAUSE CHOLESTASIS P0620
PROMAZINE U URINALYSIS PROTEIN INC N AFFECTS TURBIDITY TESTS FOR UP TO 3 DAYS 90020
PRONAZIN! U UROBILINOGEN DEC V CHOLESTATIC EFFECT P01477
PHOMAZINE U 17 KETOSTEPOIDS DEC N IN VITRO EFFECT AT LEAST ON ZIMMERMAN REACTION H0133
PPOMAZINE U 17 OH CORTICOSTEPOIDS DEC V ACTS ON HYPOTHALAMUS TO DECREASE ACTH SECRETION P0133
PROMAZINE U 17 OH CORTICOSTEPOIDS INC N IN VITRO EFFECT AT LEAST ON GLENN-NELSON METH 90133
PPOMAZINE U 5 OH INDOLEACETIC ACID DEC N INTERFERES WITH METHOD OF GOLDENB!RG 90374
PROMETHAZINE B WHITE CELL COUNT DEC V AGRANULOC!TOSIS/LEUKOPENIA RO932
PROMETHAZINE P CATECHOLAMINES INC V INC METABOLISM, DEC ORGAN UPTAKE OF NOPEPINEPHPINE P0188
PROMETHAZINE S ALKALINE PHOSPHATASE INC V MA! CAUSE CHOLESTASIS 90620
PROMETHAZINE S BILIHUBIN INC V MAY CAUSE CHOLESTASIS HO620
PROMETHAZINE S BSP RETENTION INC V NAY CAUSE CHOLESTASIS 90620
PROMETHAZINE S CEPHALIN FLOCCULATION INC V MAY CAUSE CHOLESTASIS P0620
PPOMETHAZINE S GLUCOSE DEC V IF GIVEN I.V. OH I.M. P0263
PROMETHAZINE S SCOT INC V MAY CAUSE CHOLESTASIS P0620
PROMETHAZINE S SGPT INC V MAY CAUSE CHOLESTASIS P0620
PROMETHAZINE S THYMOL TURBIDITY INC V MA! CAUSE CHOLESTASIS P0620
PROMETHAZINE U PREGNANCY TESTS NEC M FALSE NEGATIVE WITH PREPUERIN OP OAR-TEST P0914
PRONETHAZINE U PREGNANCY TESTS P05 N FALSE POSITIVE WITH GRAVINDEX P09114
PROMETHAZINE U URINALYSIS BILE INC V MAY CAUSE CHOLESTASIS P0620
PRONETHAZINE U 17 OH COPTICOSTEROIDS DEC M INTERFERENCE WITH PORTEH-SILBER REACTION P0907
PRONETHAZINE U 5 OH INDOLEACETIC ACID DEC N INTERFERENCE WITH NITROSONAPHTHOL METHODS P0800
PHOPOXYPHENE B PCO2 INC V LARGE DOSES MAY PRODUCE RESPIRATORY DEPRESSION P03814
PROPOX!PHENE S ALKALINE PHOSPHATASE INC V HEPATIC TOXICITY (CHOLE5TATIC HEPATITIS) P0538
PROPOXYPHEN! S BILIRUBIN INC V CHOLESTATIC EFFECT R0538
PHOPOXYPHENE S BSP RETENTION INC V CHOLESTATIC EFFECT 90538
PROPOXYPHENE S CEPHALIN FLOCCULATION INC V CHOLESTATIC EFFECT 90538
PHOPOXYPHENE S GLUCOSE DEC V HYPOGLYCEMIA ALLEGEDLY OCCURRED IN ON! CASE 90986
PROPOXYPHENE S LACTIC DFHYDPOGENASE INC V CHOL!STATIC EFFECT 90538
PROPOX!PHENE S SCOT INC V CHOLESTATIC EFFECT P0538
PROPOXYPHEN! S SGPT INC V CHOLESTATIC EFFECT P0538
PPOPOX!PHENE S THYNOL TURBIDITY INC V CHOLESTATIC EFFECT P0538

PPOPOX!PHEN! S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS P0492
PROPOX!PHENE U CATECHOLAMINES Z E NO EFFECT ON FLUOROMETRIC CHOUT PROCEDURE R0236
PROPOXYP9ENE 0 URINALYSIS BILE INC V CHOLESTATIC EFFECT P0538
PHOPOXYPRENE U 11 OH COPTICOSTEROIDS DEC V SLIGHT EFFECT ONLY (PROBABLY PHYSIOLOGICAL ACTION) P0236
PPOPOXYPHENE U 17 KETOSTEPOIDS DEC V PROBABLE ACTION ON H!POTHALAMIC-PIT.ACTH SECRETION P0236
PROPOXYPEIENE U 17 KETOSTEROIDS Z N ADDED IN VITRO NO EFFECT ON ZIMMERMAN REATION P0236
PROPOXYPHENE U 17 OH CORTICOSTEROIDS DEC V PROBABLE ACTION ON HYPOTHALAMIC-PIT. ACTH SECRETION P0236
PPOPOX!PHENE U 17 OH COPTICOSTEROIDS Z N ADDED IN VITRO NO EFFECT PORTER-SILBEP PROCEDURE P0236
PROPRANOLOL B PLATELET COUNT DEC V PURPUHA PROBABLY REFLECTS ALLERGIC RESPONSE P0423
PROPRANOLOL P VOLUME DEC V DEC B! APPROX 8% USUALLY, ?MECHANISN P0917
PROPRANOLOL S ALKALINE PHOSPHATASE INC V LOW INCIDENCE DRUG INDUCED INCREASE P0657
PROPPANOLOL S GLUCOSE DEC V HAS SLIGHT EFFECT LIKE THAT OF PROLONGING INSULIN R0907
PROPRANOLOL S I 131 UPTAKE Z V NO EFFECT IN EUTHYHOID PATIENTS P0113
PROPRANOLOL S NEFA DEC V ESPECIALLY DURING AND AFTER EXERCISE ROO18
PROPRANOLOL S SCOT INC V OCCASIONALLY SEEN, PROB NOT DUE TO HEPATOTOXICITY P0683
PHOPPANOLOL S SGPT INC V LOW INCIDENCE DRUG INDUCED INCREASE P0657
PHOPHANOLOL S UREA NITROGEN INC V POSSIBLE LOW INCIDENCE DRUG RELATED EFFECTS H0657
PPOPRANOLOL #{182}3
SODIUM DEC V IMPAIRED IN NORMALS AND PATIENTS P0657
PROP!LI000NE S PBI INC N EFFECT LASTS 1-5 MONTHS P0907
PROP!LIODONE S THYROXINE (T4) INC N AT VERY HIGH CONCENTRATIONS ONLY P0112
PROP!LTHIOURACIL B LE CELL PREP P05 V MAY PRODUCE LE-LIKE SYNDROME P0907
PROP!LTHIOUPACIL B WHITE CELL COUNT DEC V AGPANULOC!TOSIS (INCIDENCE 1 IN 200) P0212
PROP!LTHIOURACIL P PROTHPOMBIN TINE INC V DEFICIENCY OF PROTHROMBIN AND PROCONVEHTIN P0026
PROP!LTHIOURACIL S ALKALINE PHOS?HATASE INC V HEPATOTOXIC EFFECT (CENTROLOBULAR NECROSIS) P0620
PPOPYLTHIOURACIL S AMYLASE DEC V REPORTED EFFECT P0079
PROPYLTHIOURACIL S BILIRUBIN INC V RARE CASE OF MEPATOTOXICIT! REPORTED R0417
PHOPYLTHIOUHACIL S BSP RETENTION INC V HEPATOTOXIC EFFECT (CENTPOLOBULAR NECROSIS) P0620
PHOP!LTHIOURACIL S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT (CENTROLOBULAR NECROSIS) P0620
PR0P!LTHIOURACIL S GLUCOSE INC N AT 1 NMOL/L AFFECTS SMA 12/60 METHOD P0876
PROP!LTHIOURACIL S I 131 UPTAKE DEC V EFFECT LASTS UP TO 8 DAYS P0417
PPOPYLTHIOUPACIL S I 131 UPTAKE Z V NO EFFECT REPORTED P0596
PPOPYLTHIOORACIL S PHI DEC V THYROXINE IN CIRCULATION DECREASED P01417
PPOP!LTHIOURACIL S PBI INC V REDUCES METABOLISM OF EXOGENOUS THYROXINE P0004
PROP!LTHIOURACIL S SCOT INC V HEPATOTOXIC EFFECT (CENTHOLOBULAR NECROSIS) P0620
PROP!LTHIOURACIL S SGPT INC V HEPATOTOXIC EFFECT (CENTHOLOBULAR NECROSIS) P0620
PPOPYLTHIOUPACIL S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT (CENTROLOBULAP NECROSIS) P0620
PROPYLTHIOtIRACIL S THYROXINE (T14) DEC V INHIBITS SYNTHESIS, STOPS IODINATION 0! TYHOSINE P01417
PPOPYLTHIOURACIL S T3 UPTAKE DEC V ACTION OF DRUG P01417
PHOP!LTHIOURACIL S UREA NITROGEN INC V ANAPHYLACTIC NEPHRITIS REPORTED P0026
PPOPYLTHIOUPACIL S URIC ACID INC N AT 1 MMOL/L AFFECTS SMA 12/60, HENRY METHODS P0876
PROPYLTRIOUPACIL U URINALYSIS BILE INC V HEPATOTOXIC EFFECT (CENTROLOBULAP NECROSIS) P0620
PHOSTATE PALPATION S ACID PHOSPHATASE TOTAL INC V RELEASE INTO BLOODSTREAM P0356
PROSTATE PALPATION S LACTIC DEHYDROGENASE INC V RELEASE INTO BLOODSTREAM P0479
PPOTANINE B THRONBOPLASTIN GE! DEC V POSSESSES ANTICOAGULANT ACTION P0384
PPOTAMINE P CATECHOLAMINES INC N CONC SOLUTIONS CAUSE STRIKING FLUORESCENCE P0188
PPOTAMINE S TOTAL LIPIDS INC V MECHANISM NOT ESTABLISHED R03814
PROTEIN F COPPOPORPHYRIN INC V RELATED TO THE MEAT CONTENT OF DIET P0291
PROTEIN P ALPHA AMINO NITROGEN INC V RISES AFTER MEALS, FALLS TO NORMAL AFTER 4 HOURS P0291
PROTEIN P ANGIOTENSIN I INC N A PHOTEIN NORMALLY PRESENT MA! INTERFERE P0714
PROTEIN P ANGIOTENSIN II INC N A PROTEIN NORMALLY PRESENT MAY INTERFERE P0714
PROTEIN P INSULIN INC V STIMULATION OF BETA CELLS BY AMINO ACIDS R0491
PROTEIN S BILIPUBIN DEC N ABSENCE OF PROTEIN AFFECTS DIAZOTIZATION P0620
PROTEIN S CAROTENE INC V RISE IN PARALLEL WITH AMINO ACIDS P0291
PROTEIN S CHLORIDE INC M FAILURE TO PRECIPITATE AFFECTS SCHALES METHOD P0436
PROTEIN S CHOLESTEROL INC N TPYPTOPHAN IN PROTEIN MA! REACT P0620
PROTEIN S CPEATINE INC V ESP IF MEAT EATEN IS RAW P0291
PROTEIN S CREATININE INC V OCCURS AFTER LARGE MEAT INTAKE P0620
PROTEIN S GASTRIN INC V OPAL FEEDING NA! PRODUCE UP TO TENFOLD INCREASE RO550
PROTEIN S POTASSIUM INC M PRESENCE RAISES TEMPERATURE INCS EMISSION P0620
PROTEIN S SODIUM INC N PRESENCE RAISES TEMPERATURE INCS EMISSION P0620
PROTEIN U AMMONIA INC V DUE TO INGESTION OF PROTEIN P0291
PROTEIN U CHEATINE INC V ESP IF MEAT EATEN IS RAW P0291
PROTEIN U GFR INC V INC IN PROPORTION TO AMOUNT OF PROTEIN P0291
PROTEIN U HISTIDINE INC V OCCURS AFTER ‘HIGH NEAT DIET P0291
PROTEIN U METHYLHISTIDINE INC V OCCURS WITH HIGH NEAT DIET P0291
PROTEIN U SULFATE INC V DERIVED FROM DIETARY PROTEIN P0283
PROTEIN U TITBATABLE ACIDITY INC V DUE TO INGESTION OF PROTEIN P0291
PROTEIN U UREA NITROGEN INC V INC IN PROPORTION TO PROTEIN INTAKE RO291
PROTEIN U URIC ACID INC V INC IN PROPORTION TO DIETARY PURINE P0291
PROTEIN U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S P0620
PROTEINURIA S BSP RETENTION DEC V FALSE LOW DUE TO LOSS OF PROTEIN BOUND BSP P0171
PROTEINURIA U ALKALINE PHOSPHATASE INC V IN RENAL DISEASE WITH NECROSIS OR ALTERED GFR P0758
PHOTEINURIA U ALPHA-CLUCOSIDASE INC V POSSIBLY CONTRIBUTED FROM WBC P0758
PROTEINURIA U BETA-GLUCURONIDASE INC V WITH ALL ACUTE OP INFLAMMATORY RENAL DISEASES P0758
PROTEINUHIA U CATALASE INC V RENAL DAMAGE IF NO BACTEHIURIA P0758
PROTEINURIA U COPPER INC V LOSS OF PROTEIN BOUND MATERIAL H0436
PROTEINURIA U GOT INC V ASSOC WITH INFECTION AND TUBULAR DAMAGE P0758
PHOTEINUPIA U GPT INC V EFFECT MUCH LESS THAN WITH GOT P0758
PROTEINURIA U LACTIC DEH!DROGENASE INC V IN LARGE NUMBER AND VARIETY PENAL DISEASES P0758
PHOTEINURIA U LEUCINE AMINOPEPTIDASE INC V WITH TOXIC RENAL DAMAGE P0758
PROTEINURIA U MUPAMIDASE INC V INCREASED IN SMALL PERCENTAGE OF CASES P0758
PPOTEINURIA U PEROXIDASE INC V INDICATIVE OF PRESENCE OF BLOOD CELLS P0758
PROTEINURIA U PREGNANCY TESTS P05 N FALSE POSITIVE TESTS IF PROTEINURIA PRESENT P0907
PHOTEINURIA U PROTEIN INC V ACTUAL EFFECT P0758
PROTEINURIA U SULFATASE INC V INC IN RENAL DISEASES P0758
PROTEINURIA U URINALYSIS PROTEIN INC V ACTUAL EFFECT P0758
PROTEINURIA U URINALYSIS PROTEIN NEC N UNABLE TO DETECT PAPAPROTEINS WITH BILI-LABSTIX P0152
PROTEINURIA U UPOBILINOGEN INC N PRODUCES TURBIDITY IN DIRECT METHODS P01436
PPOTEINUPIA U UROKINASF INC V IF PENAL INFARCTION OP HYPOXIA H0758
PROTHIONAMIDE B WHITE CELL COUNT DEC V SINGLE CASE PEPORTRD RO657

PROTHIONAMIDE S ALKALINE PHOSPHATASE INC V TEMPORARY SIDE EFFECT P0657
PROTHIONAMIDE S BILIRUBIN INC V TEMPORARY SIDE EFFECT R0657
PROTHIONAMIDE S SGPT INC V TEMPORARY SIDE EFFECT P0657
PROTOCATECHUIC ACID S URIC ACID INC N FALSELY HIGH VALUES WITH PHOSPHOTUNGSTATE METHODS P0370
PHOTOCATECHUIC ACID U URIC ACID INC N FALSELY HIGH VALUES WITH PHOSPHOTUNGSTATE METHODS R037O
PROTRIPTYLINE B WHITE CELL COUNT DEC V TRANSIENT AGRANULOCYTOSIS OR LEUKOPENIA P0026
PPOTPIPTYLINE S ALKALINE PHOSPHATASE INC V TRANSIENT REVERSIBLE CHOLESTASIS P0026
PROTRIPTYLINE S BILIRUBIN INC V TRANSIENT REVERSIBLE CHOLESTASIS P0026
PPOTRIPT!LIN! S SCOT INC V TRANSIENT REVERSIBLE CHOLESTASIS P0026
PROTRIPT!LINE S SGPT INC V TRANSIENT PEVERSILBE CHOLESTASIS P0026
PHOTRIPTYLINE U URINALYSIS BILE INC V TRANSIENT REVERSIBLE CROLESTASIS P0026
PSP S BSP RETENTION INC M MA! INCREASE COLOHIMETRIC READING P0417
PSP S CREATININE INC N CHRONOGENICIT! IN COLOR REACTION P0907
PSP S URIC ACID DEC V URICOSURIC ACTION HO404
PSP U CREATINE INC N CHROMOGENICITY IN COLOR REACTION P0620
PSP U CPEATININE INC N INTERFERNCE WITH JAFFE PROCEDURE P02014
PSP U LEUCIN! ANINOPEPTIDASE INC V FACILITATES PERMEATION OF ENZYME INTO TUBULES P0758
PSP U URIC ACID INC V UPICOSUPIC ACTION P0404
PSP U URINALYSIS ACETONE INC N CHROMOGENICIT! IN COLOR REACTION (ROTHERA TEST) P1001
PSP U URINALYSIS COLOR INC N PINK COLOR DUE TO PRESENCE OF DYE P06514
959 U VMA INC N MAY INTERFERE WITH COLORINETRIC METHOD P0030
PYPATHIAZINE B WHITE CELL COUNT DEC V MA! OCCUR WITH PROLONGED USE P0620
PYPAZINANIDE B HEMATOCRIT DEC V RAPE ANEMIA REPORTED P0657
PYPAZINANIDE B HEMOGLOBIN DEC V RARE ANEMIA REPORTED P0657
PYRAZINAMIDE P FIBRINOGEN INC V REPORTED EFFECT P0026
PYRAZINAMIDE P PROTHROMBIN TIME INC V REDUCES CONCENTRATION OF PROTHROMBIN P0026
PYRAZINANIDE S ALBUMIN DEC V HEPATOTOXICIT! (VIRAL-HEPATITIS LIKE) P0026
PYPAZINAMIDE S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT (VIRAL-HEPATITIS LIKE) P0620
PYHAZINAMIDE S BILIRUBIN INC V HEPATIC TOXICITY (APPPOX. 3%) (DOSE RELATED) P0832
PYRAZINAMIDE S BSP RETENTION INC V HEPATIC TOXICITY (APPROX. 4%) (DOSE RELATED) P0832
PYPAZINAMIDE S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT (VIRAL-HEPATITIS LIKE) P0620
PYRAZINANIDE S GLOBULIN DEC V REPORTED EFFECT (VIRAL-HEPATITIS LIKE) P0026
PYPAZINAMIDE S PHI INC V OCCURS IN FIRST WEEK AND AFTER ONE MONTH P0255
PYRAZINAMIDE S PROTEIN DEC V PART OF HEPATOTOXICIT! (VIRAL-HEPATITIS LIKE) P0384
PYRAZINANIDE S SCOT INC V HEPATIC TOXICITY REPORTED (VIRAL-HEPATITIS LIKE) P0832
PYPAZINAMIDE S SGPT INC V HEPATIC TOXICITY REPORTED (VIRAL-HEPATITIS LIKE) P0832
PYRAZINAMIDE S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT (VIRAL-HEPATITIS LIKE) P0620
PYRAZINAMIDE S URIC ACID INC V INHIBITS TUBULAR SECRETION OF URATE P0896
PYRAZINAMIDE U URIC ACID DEC V INCREASED TUBULAR REABSORPTION OF URATE P0832
PYPAZINAMIDE U URINALYSIS BILE INC V HEPATOTOXIC EFFECT (VIRAL-HEPATITIS LIKE) RO620
PYRAZINAMIDE U 17 KETOSTEROIDS DEC V TEMP DECREASED EXCRETION REPORTED P0384
PYHAZINOIC ACID B RED CELL COUNT DEC V SIDEROBLASTIC TYPE OF ANEMIA MAY OCCUR P0104
PYRAZOLONES B HEMATOCRIT DEC V APLASTIC/HENOLYTIC ANEMIA P0620
PYRAZOLONES B HEMOGLOBIN DEC V APLASTIC/HEMOLYTIC ANEMIA P0620
PYHAZOLONES B NEUTROPHILS DEC V M!ELOTOXIC EFFECT OF DRUGS P0657
PYRAZOLONES B PLATELET COUNT DEC V THROMBOCYTOPENIA P0620
PYHAZOLONES B RED CELL COUNT DEC V APLASTIC/HEMOLYTIC ANEMIA P0620
PYHAZOLONES B WHITE CELL COUNT DEC V APLASTIC/HEMOLYTIC ANEMIA (MAY BE AGRANULOC!TOSIS) P0620
PYRAZOLONES F OCCULT BLOOD P05 V MAY CAUSE G.I. TRACT BLEEDING P0620
PYRAZOLONES S UREA NITROGEN INC V MAY CAUSE NEPHPOTOXICITY P0355
PYRAZOLONES U PROTEIN INC V NEPHROTOXIC EFFECT P0355
PYRAZOLONES U SUGAR INC N INTERFERES WITH COPPER REDUCING METHODS P0299
PYRAZOLONES U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG P0299
PYRAZOLONES U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT P0299
PYRAZOLONES U URINALYSIS PBC/HPF INC V MAY CAUSE ACTUAL BLEEDING P0299
PYPIDOXINE S PYRIDOXAL PHOSPHATE INC V INC AFTER ADMINISTRATION IN NORMAL SUBJECTS P0657
PYRIDOXINE S SCOT INC V SIGNIFICANT INCREASE IN ELDERLY AFTER ADMIN P0657
PYHIDOXINE U OXALATE DEC V IN PATIENTS WITH OXALATE RENAL CALCULI P0384
PYRIDYLCARBINOL S CHOLESTEROL DEC V THERAPEUTIC GOAL P0907
PYRIMETHAMINE B HEMATOCHIT DEC V MEGALOBLASTIC ANEMIA RIOO7
PYRINETHAMINE B HEMOGLOBIN DEC V MEGALOBLASTIC ANEMIA P1007
PYPIMETHANINE B MCV INC V MEGALOBLASTIC ANEMIA P1007
PYPIMETHAMINE B PLATELET COUNT DEC V NAY OCCUR WITH SEVERE MEGALOBLASTIC ANEMIA P1007
PYPIMETHAMINE B RED CELL COUNT DEC V MECALOBLASTIC ANEMIA P1007
PYPIMETHANINE B WHITE CELL COUNT DEC V MAY OCCUR WITH SEVERE MEGALOBLASTIC ANEMIA P1007
P!RIMETHAMINE S FOLATE DEC V INHIBITS FOLATE REDUCTASE, NEGALOBLASTIC ANEMIA P0791
PYRIMETHAMINE U AICAP INC V IF NEGALOBLASTIC ANEMIA OCCURS P1007
PYPIMETHAMINE U FIGLU INC V IF MEGALOBLASTIC ANEMIA OCCURS Ri 007
PYROGALLOL U URINALYSIS COLOR INC N BROWN TO BLACK, DARKENS ON STANDING P0620
PYROGEN P CORTISOL INC V AFTER DELAY OF ONE HOUR FOLLOWING INJECTION P0082
PYROGEN P GROWTH HORMONE INC V AFTER DELAY OF ONE HOUR FOLLOWING INJECTION P0082
PYRUVATE S CREATININE INC N INTERFERES -AUTOANALYZEH METHOD(200MG% = 7.14NG%) P0546
PYRUVATE S LACTATE DEC M HIGH CONCS INTERFERE WITH ENZYMATIC METHOD P0333
PYRUVATE U PHEN!LKETONES P05 N DEEP YELLOW/GREEN WITH FECL3, NIL PHENISTIX RO239
P!RUVATE KINASE S PYRUVATE DEC N IF LDH USED IS CONTAMINATED WITH PYHUVATE KINASE P04314
PYRVINIUM PAMOATE F COLOR INC N RED P0620
PYRVINIUM PAMOATE F OCCULT BLOOD POS N COLOR OF STOOLS NAY BE MISINTERPRETED P0620
QUATERNARY U URINALYSIS PROTEIN INC M GIVES FALSE POSITIVE BY CHANGING PH P0907
QUINACRINE B HEMATOCRIT DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY R0079
QUINAC9INE B HEMOGLOBIN DEC V MA! CAUSE HEMOLYSIS WITH C-6-PD DEFICIENCY P0079
QUINACRIN! B METHEMOGLOBIN INC V MA! CAUSE HENOLYSIS WITH G-6-PD DEFICIENCY P0926
QUINACRINE B PLATELETCOUNT DEC V THROMBOCYTOPENIA OR APLASTIC ANEMIA NAY OCCUR P0620
QUINACPINE B RED CELL COUNT DEC V NA! CAUSE HEMOL!SIS WITH G-6-PD DEFICIENCY P0079
QUINACRINE B WHITE CELL COUNT DEC V LEUKOPENIA/AGPANULOCYTOSIS/APLASTIC ANEMIA P0656
QUINACRINE S BILIRUBIN INC V HEMOLYSIS MAY OCCUR WITH G-6-PD DEFICIENCY P0079
QUINACRINE S DIRECT BILIRUBIN INC V HENOLYSIS MA! OCCUR WITH G-6-PD DEFICIENCY P0355
QUINACRINE S ICTERIC INDEX INC V HEMOLYSIS NA! OCCUR WITH G-6-PD DEFICIENCY P0355
QUINACRINE S SCOT INC V HEPATITIS REPORTED (CENTROLOBULAR NECROSIS) P0026
QUINACRINE S SGPT INC V HEPATITIS REPORTED (CENTPOLOBULAH NECROSIS) P0026
QUINACRINE U DIAGNEX BLUE EXCRETION INC N RELEASE OF DYE FROM RESIN P0356

QUINACRINE U URINALYSIS COLOR INC N DEEP YELLOW COLOR ON ACIDIFICATION P0384
QUINETHAZONE B EOSINOPHILS INC V ISOLATED CASE REPORT P0657
3UINETHAZONE S ALKALINE PHOSPHATASE INC V NAY CAUSE CHOLESTATIC JAUNDICE P0620
QIJINETHAZONE S BILIRUBIN INC V MAY CAUSE CHOLESTATIC JAUNDICE R0723
QUINETHA ZONE S BSP RETENTION INC V MAY CAUSE CHOLESTATIC JAUNDICE P0620
2!JINETHAZONE S CEPHALIN FLOCCULATION INC V MAY CAUSE CHOLESTATIC JAUNDICE P0620
QUINETHAZONE S GLUCOSE INC V NAY PRECIPITATE LATENT DIABETES OR AGGRAVATE EXIST P0620
QU INETHA ZONE S POTASSIUM DEC V DIURETIC ACTION P0657
QUINITHAZONE S SGOT INC V NAY CAUSE CHOLESTATIC JAUNDICE P0620
QUINETHAZONE S SGPT INC V MAY CAUSE CHOLESTATIC JAUNDICE P0620
QUINETHAZONE S SODIUM DEC V DIURETIC ACTION WITH SODIUM DEPLETION P0620
3UINETHA ZONE S THYMOL TURBIDITY INC V MAY CAUSI CHOLESTATIC JAUNDICE P0620
QU I N ETH A Z 0 N E S UREA NITROGEN INC V OBSERVED EFFECT (?DUE TO DEHYDRATION) R0657
QUINETHAZONE S URIC ACID INC V INC UP TO 4 NG/100NL, INHIBITS TUBULAR SECRETION P0145
QUINETHAZONE U SUGAR INC N FALSE POSITIVE WITH BENEDICT’S P0620
QUINETHAZONE U URINALYSIS BILE INC V MAY CAUSE CHOLESTATIC JAUNDICE P0620
QUINETHAZONE U URINALYSIS GLUCOSE INC V OCCURS AS CONSEQUENCE OF HYPERGLYCEMIA R0620
QUINIDINE B HENATOCRIT DEC V HEMOLYTIC ANENIA(SENSITIVITY DEPENDENT)G-6-PD DEE P0953
QUINIDI NR B HEMOGLOBIN DEC V HENOLYTIC ANEMIA (SENSITIVITY DEPENDENT) G-6-PD DEE P0953
QUINIDINE B NETHENOGLOBIN INC V NAY CAUSE HEMOLYSIS IN G-6-PD DEFICIENCY P0926
2 U I N I DI N E B PLATELET COUNT DEC V ALLERGIC REACTION/PANCYTOPENIA/PURPURA P0953
QUINIDINE B RED CELL COUNT DEC V HEMOLYTIC ANEMIA (SENSITIVITY DEPENDENT)G-6-PD DEE P0953
QUINIDINE B WHITE CELL COUNT DEC V AGRA NULOCYTOSIS/LEUKOPENIA P0620
QUINIDIME P CATECHOLAMINES INC N NETABOLITE CAUSES FALSE POSITIVE P0183
QUINIDINE P PROTHROMBIN TIME INC V DEPRESSES PROTHROMBIN FORMATION IN LIVER RO544
QUINIDINE S BILIRUBIN INC V CAUSES HEMOLYTIC ANEMIA P0636
QUINIDINE S COOMBS TEST P05 V IMMUNOLOGICAL RESPONSE TO DRUG (GAMMA ANTIBODY) P04 18
QUINIDINE S DIRECT BILI}<UBIN INC V CAUSES HENOLYTIC ANEMIA P0636
QUINIDI NE S HAPTOGLOBIN DEC V CAUSES HENOLYTIC ANEMIA P0636
QUINIDINE S PBI DEC V OCCASIONAL EFFECT (USUALLY NONE) P0255
QUINIDINE U DIAGNEX BLUE EXCRETION INC N RELEASE OF DYE FROM RESIN P0356
QUINIDINE U 17 KETOSTEROIDS INC M INTERFERES WITH ZI MMERMAN REACTION HO 299
QUINIDIN? U 17 OH CORTICOSTEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION R0356
QUININE B HENATOCRIT DEC V HEMOLYTIC ANEMIA(SENSITIVIT! DEPENDENT)6-6-PD DEE P0090
QUININE B HEMOGLOBIN DEC V HEMOLYTIC ANENIA(SENSITIVITY DEPENDENT)G-6-PD DEF P0090
QUININE B METHEMOGLOBIN INC V MAY CAUSE HEMOLYSIS IN G-6-PD DEFICIENCY P 0926
QUININE B PLATELET COUNT DEC V IMMUNOLOGICAL MECHANISM P0232
QUININE B RED CELL COUNT DEC V HEMOLYTIC ANEMIA (SENSITIVITY DEPENDENT)G-6-PD DEE P0090
QUININE B SEDIMENTATION HATE DEC N AT THERAPEUTIC CONC, MAX AT 200 MIN WITH 2 NG/100ML P078 1
QUININE B WHITE CELL COUNT DEC V LEUKOPENIA (AMA-BLOOD DYSCRASIAS) R0658
QUININE B WHITE CELL COUNT INC V PRIMARY INC, ESP LYMPHOCYTES (SPLENIC CONTRACTIONS) R0384
QUININE P CATECHOLAMINES INC N INTERFERENCE BY NETABOLITE, NO EFFECT IN VITRO P018 1
QUININE P NETHEMALBUMIN INC V IF GIVEN CONCURRENTLY WITH PANAQUINE R0384
QUININF P PROTHRONBIN TIME INC V DEPRESSES PROTHROMBIN FORMATION IN LIVER P0270
QUININE S BILIPUBIN INC V MAY CAUSE HENOLYTIC ANEMIA P0636
QUININE S COOMBS TEST P05 V IMMUNOLOGICAL RESPONSE TO DRUG P04 18
QUININE S DIRECT BILIRUBIN INC V MAY CAUSE HEMOLYTIC ANEMIA P0636
QUININE S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P0636
QUININE S UREA NITROGEN INC V NAY CAUSE RENAL DAMAGE (RARE) P0384
QUININE U DIAGNEX BLUE EXCRETION INC N RELEASE OF DYE FROM RESIN P0654
QU I N I NE U PROTEIN INC V RARE PENAL DAMAGE P0384
QUININE U URINALYSIS COLOR INC N BROWN COLOR HO 299
QUININE U URINALYSIS HEMOGLOBIN INC V POSSIBLE CONTRIBUTING FACTOR P0026
QUININE U URINALYSIS HEROIN INC N FLUORESCES PRODUCING INTERFERENCE HO 996
QUININE U URINALYSIS PROTEIN INC V MAY RARELY CAUSE RENAL DAMAGE P0384
QUININE U 17 OH CORTICOSTEROIDS INC M REDDY METHOD AFFECTED, NOT POPTER-SILBER P0907
QUININE IODOBIS S PBI INC V CONTAINS 57% IODINE P0004
QUINOCIDE B HEMATOCRIT DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0518
Q U I N OC I 0! B HEMOGLOBIN DEC V NAY CAUSE HEMOLYTIC ANEMIA P05 18
QUINOIDE B RED CELL COUNT DEC V MAY CAUSE HENOLYSIS WITH G-6-PD DEFICIENCY P05 18
RADIOACTIVE B RED CELL COUNT DRC V APLASTIC ANEMIA P0620
RADIOACTIVE B WHITE CELL COUNT DEC V NAY CAUSE MARROW DEPRESSION H 0 62 0
RADIOACTIVE P PROTHROMBIN TIME INC V ALSO EXAGGERATED RESPONSE TO ANTICOAGULANTS P0384
RADIOACTIVE IODINE B WHITE CELL COUNT INC V INCIDENCE OF ACUTE LEUKEMIA HIGHER P0026
RADIOACTIVE IODINE S PBI INC V MAY CAUSE HYPOTHYRODISM (INC BY 2-3% PEP YEAR) P0026
RADIOGRAPHIC B HEMATOCRIT DEC V TRANSIENT FALL FOLLOWING RAPID I.V. INJECTION P0 194
RADIOGRAPHIC C PROTEIN INC N CAUSES TURBIDITY IF SULFOSALICYLIC ACID USED P0907
RADIOGRAPHIC P HISTAMINE INC V OBSERVED IN SOME PATIENTS IF ADMINISTERED I.V. HO 139
RADIOGRAPHIC S BILIPUBIN INC V COMPETITION FOR EXCRETION THROUGH BILE CANALICULI P0042
RADIOGRAPHIC S DSP RETENTION INC V COMPETE WITH EXCRETORY MECHANISM P017 1
P ADIOGRAPHIC S CREATININE INC V OCCASIONAL EFFECT FOLLOWING AOPTOGRAPHY P0020
RADIOGRAPHIC S ELECTROPHORESIS P05 N PRODUCES UNINTEPPRETABLE PATTERN R1001
RADIOGRAPHIC S PROTEIN INC N MAY PRODUCE INTERFERING TURBIDITY P0620
RADIOGRAPHIC S UREA NITROGEN INC V MA! PRODUCE AZOTENIA OR RENAL FAILURE R0026
RADIOGRAPHIC U GFP DEC V IF CONC SOLNS USED FOR AORTOGRAPHY P0020
RADIOGRAPHIC U LEUCINE AMINOPEPTIDASE INC V FACILITATES PERMEATION OF ENZYME INTO TUBULES P0758
RADIOGRAPHIC U PAH CLEARANCE DEC V IF CONC SOLNS USED FOR AORTOGRAPHY P0020
RADIOGRAPHIC U PROTEIN INC N TURBIDITY IF ACID PROCEDURES USED P0475
RADIOGRAPHIC U PROTEIN INC V MAY OCCUR FOLLOWING AORTOGPAPHY P0020
RADIOGRAPHIC U P59 EXCRETION INC V AFFECT RENAL EXCRETION P0355
RADIOGRAPHIC U SPECIFIC GRAVITY INC N PRESENCE OF HIGH MOLECULAR WEIGHT SUBSTANCE P0475
PADI OGFcAPHIC U URINALYSIS CASTS INC V NEPHHOTOXIC MANIFESTATION R02O4
a AOIOGRA PHIC U URINALYSIS PROTEIN INC N AFFECTS TURBIDINETRIC METHODS FOR SOME DAYS P0907
RADIOGRAPHIC U URINALYSIS PROTEIN INC V MAY OCCUR FOLLOWING AORTOGRAPHY P0020
RADIOGRAPHIC U URINALYSIS PBC/HPF INC V NEPHROTOXIC MANIFESTATION P0204
RADIOGRAPHIC U URINALYSIS S.G. INC N PRESENCE OF HIGH MOLECULAR WEIGHT SUBSTANCE P0907
RAUWOLFIA 0 GASTRIC JUICE HCL INC V STIMULATES GASTRIC SECRETION P0596
RAUWOLFIA S SODIUM INC V MAY CAUSE ELECTROLYTE RETENTION OR EDEMA P0620
RAUWOLFIA U CATECHOLANINES INC V RELEASE OF STORED NOREPINEPHRINE P0596
PAUWOLFIA U HMPG INC V RELEASE OF STORED NOREPINEPHRINE P0596

PAU WOL F I A U VMA INC V RELEASE OF STORED NOREPINEPHRINE P05 96
RAUWOLFIA U 5 OH INDOLEACETIC ACID INC V RESULT OF RELEASE OF 5 HT FROM BRAIN, TISSUES P0384
H EC U MB ENC ! B HEMOGLOBIN DEC V AVERAGE MAX DEC OF 5% OCCURS IN 20 NIN P02 97
P EC UMB ENC Y S PROTEIN DEC V AVERAGE DEC OF 1.0 G/100ML AFTER 140 MIN P02 97
RECUMBENCY U SODIUM INC V METABOLIC EFFECT P09 25
RED DYED DRUGS S PBI INC N PRESENCE OF EHYTHROCHINE DYE P00 32
RED DYED FOOD S PHI INC N PRESENCE OF EP!THROCRINE DYE P03 55
PESEPPI NE B PLATELET COUNT DEC V THROMBOCYTOPENIA WITH PURPURA MAY OCCUR P06 58
RESEPPINE 0 GASTRIC JUICE HCL INC V EXCESS SECRETION MAY ACTIVATE PEPTIC ULCERS HO 384
RESERPINE 0 T!PAMINE TEST DEC V INHIBITS RESPONSIVENESS (PRODUCES FALSE NEC.) P0373
RESERPINE P CATECHOLANINES DEC V OBSERVED NORMAL RESPONSE TO THERAPY P06 57
RESEPPINE P PROTHROMBIN TIME DEC V SHORT TERM TREATMENT BLOCKS ACTION OF ANTICOAGS 90384
RESERPINE P PPOTHROMBIN TIME INC V LONG TERM TREATMENT MARKEDLY ENHANCES ANTICOAGS P0 38 4
RESERPINE P 5 OH TR!PTAMINE DEC V OBSERVED NORMAL RESPONSE TO THERAPY HO 657
RESERPINE S GLUCOSE INC V HYPERGLYCEMIA MAY FOLLOW ADMINISTRATION P0615
RESEPPINE S PBI DEC V RARE DEPRESSION REPORTED (GIVEN ORALLY FOR 1 MONTH) HO 596
PESERPI NE S PBI INC V INCREASED METABOLISM B! HEPATIC MICROSOMES P03 55
RESEPPINE S PHI Z V NO EFFECT OBSERVED WITH ORAL, PARENTERAL ADNIN P0 255
RESERPINE S THYROXINE (T14) DEC V INCREASED METABOLISM BY HEPATIC MICHOSOMES P0907
RESEPPINE U CATECHOLAMINES DEC V DECREASED NOREPINEPHRINE SYNTHESIS 90235
PBS EPPI NE U CATECHOLAMINES INC V RELEASE OF STORED NOREPINEPHRINE P0596
HESERPINE U CATECHOLANINES Z M NO EFFECT ON FLUOROMETRIC METHOD OF CROUT P0235
HESERPINE U HMPG INC V RELEASE OF STORED NOREPINEPHRINE P0596
RESERPINE U URINALYSIS GLUCOSE INC V OCCURS AS CONSEQUENCE OF HYPERGLYCEMIA P0615
RESEPPINE U VMA DEC V DEPLETION OF CATECHOLAMINE STORES P0654
RESERPINE U VMA INC V RELEASE OF STORED NOREPINEPHRINE P0596
RESERPINE U 17 KETOSTEROIDS DEC N INTERFERENCE WITH ZIMMERMAN PROCEDURE HO 133
RESERPI NE U 17 OH CORTICOSTEROIDS DEC N INTERFERENCE WITH PORTER-SILBER REACTION P09 07
PESERPINE U 5 OH INDOLEACETIC ACID INC V RELEASE OF 5 HT FROM BRAIN AND TISSUES HO 654
RESORCIN B HEMATOCRIT DEC V HEMOLYTIC ANEMIA P0657
PESORCIN B HEMOGLOBIN DEC V NAY CAUSE HENOLYTIC ANEMIA P0657
RE SORC I N B METHEMOGLOBIN INC V OCCURS WITH HEMOLYTIC ANEMIA 90657
PESORCIN B RED CELL COUNT DEC V NAY CAUSE HEMOLYTIC ANEMIA P0657
RESOHCIN S HAPTOGLOBIN DEC V OCCURS WITH HEMOLYTIC ANEMIA P0657
HESORCINOL B HEMATOCRIT DEC V INJECT OR EXCESS ABSOHP MA! CAUSE HEMOLYSIS R0026
RESORC INOL B HEMOGLOBIN DEC V INJECT OR EXCESS ABSORB MA! CAUSE HEMOLYSIS P0026
RESORCINOL B NETHENOGLOBIN INC V INJECT OR EXCESS ABSORB MAY CAUSE HEMOLYSIS P0026
PESOHC INOL B RED CELL COUNT DEC V INJECTION OP EXCESS ABSORP MA! CAUSE HENOLYSIS P0026
P ES ORC IN OL S CREATININE INC N FALSELY HIGH VALUES IF JAFFE REACTION USED P04 36
RES OHC INOL S I 131 UPTAKE DEC V REPORTED EFFECT OF TREAT. OF VARICOSE ULCERS P03 84
RESORCI NOL S PHI DEC V REPORTED EFFECT OF TREATMENT OF VARICOSE ULCERS P03 84
RES ORCINOL U URINALYSIS COLOR INC N DARK GREEN TO GREENISH BLUE DARKENS ON STANDING P06 20
RHUBARB U PROTEIN INC V CPYSTALLURIA MAY CAUSE RENAL DAMAGE HO 053
RHUBARB U URINALYSIS COLOR INC N YELLOW-BROWN(ACID), YELLOW-PINK(ALKALINE) DARKENS P0620
RHUBARB U URINALYSIS CRYSTALS INC V CALCIUM OXALATE MAY BE DEPOSITED P0053
RHUBARB U URINALYSIS PROTEIN INC V CRYSTALLUPIA NAY CAUSE RENAL DAMAGE P005 3
RHUBARB U URINALYSIS RBC/HPF INC V CRYSTALLUPIA MAY CAUSE RENAL DAMAGE P0053
RHUBARB U URINALYSIS SUGAR INC N MAY CAUSE FALSE POSITIVE WITH BENEDICT’S R0663
RIBOFLAVIN P CATECHOLAMINES INC N INTERFERES WITH FLUOPONETRIC TECHNIQUE P06 54
RIBOFLAVIN U DIAGNEX BLUE EXCRETION INC N INTERFERING COLOR P1001
RIBOFLAVIN U URINALYSIS COLOR INC N MAY PRODUCE YELLOW COLOR WITH LARGE DOSES HO 1417
RIBOFLAVIN U UPOBILIN INC N PRODUCES YELLOW-GREEN FLUORESCENCE P04 36
RIBOSE S GLUCOSE INC N NON-SPECIFICITY OF FECN, NEOCUPPOINE METHODS P1009
RI BOSE U URINALYSIS SUGAR INC M FALSE POSITIVE WITH BENEDICT’S P014 36
HIFAMPIN B EOSINOPHILS INC V ALLERGIC REACTION P04 32
RIFAMPIN B HEMOGLOBIN DEC V REPORTED EFFECT H 0467
PIFAMPIN B PLATELET COUNT DEC V OCCURS WITH ANTIBODY PRODUCTION P0 308
RIFAMPIN B WHITE CELL COUNT DEC V TOXIC OR ALLERGIC RESPONSE (USUALLY TRANSIENT) P0714 0
RIFANPIN 0 CAPILLARY FRAGILITY INC V REPORTED IN PATIENT WITH NACHOGLOBULINEMIA HO 308
RIFAMPIN P PROTHROMBIN TIME DEC V OCCURS IN SOME PATIENTS, ESP IF ON ANTICOAGULANTS P0391
RIFANPIN S ALKALINE PHOSPHATASE INC V CAN BE SERIOUS BUT REVERSIBLE LIVER DAMAGE P07 35
RIFAMPIN S BILIRUBIN INC N DUE TO YELLOW COLORATION OF DRUG P0740
RIFAMPIN S BILIRUBIN INC V INHIBITS HEPATIC EXCRETION 90005
RIFAMPIN S BSP RETENTION INC V INHIBITS HEPATIC EXCRETION (PROBABLY) P048 1
PIFAMPIN S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT (CHOLESTASIS) P 0740
PIFA NP IN S DIRECT BILIRUBIN INC V TRANSIENT EFFECT HO 3 50
RIFAMPIN S DIRECT COOMBS TEST 905 V WEAK RESPONSE IN 8% PATIENTS 90748
BIFAMPIN S INDIRECT COOMBS TEST P05 V P05 RESPONSE IN 33% PATIENTS AFTER 3 MONTHS P074 8
RIFAMPIN S INDOCYANINE GREEN INC V DELAYED ELIMINATION FOLLOWING I.V. INJECT P0657
RIFAMPIN S PROTEIN DEC V DUE TO IMPAIRED HEPATIC METABOLISM P07 40
RIFAMPIN S SCOT INC V HEPATIC TOXICITY OCCURS IN UP TO 7% PATIENTS P0432
RIFAMPIN S SCPT INC V HEPATIC TOXICITY OCCURS IN UP TO 7% PATIENTS 90432
RIFAMPIN S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT (CHOLESTASIS) HO 74 0
RIFAMPIN S UREA NITROGEN INC V TEMPORARY RENAL FAILURE REPORTED P0281
RIFAMPIN S URIC ACID INC V TEMPORARY RENAL FAILURE REPORTED R0281
RIFAMPIN S ZNSO4 TURBIDITY INC V HEPATOTOXIC EFFECT (CHOLESTASIS) P0740
PIFAMPIN U URINALYSIS CASTS INC V RARE REPORTED SIDE EFFECT 90432
RIFAMPIN U URINALYSIS COLOR INC N RED-ORANGE DUE TO DRUG AND METABOLITES P0442
RIFANPIN U URINALYSIS PROTEIN INC V ATTRIBUTED TO DRUG IN 2 CASES P0657
RIFAMPIN U URINALYSIS PBC/HPF INC V PARE REPORTED SIDE EFFECT R0432
RISTOCETIN B EOSINOPHILS INC V ALLERGIC RESPONSE 90620
RISTOCETIN B PLATELET COUNT DEC V THROMBOCYTOPENIA MAY OCCUR (TOXIC TO PLATELETS) P06 20
RISTOCETIN B WHITE CELL COUNT DEC V LEUKOPENIA OR AGHANULOCYTOPENIA P06 20
RI STOCETIN B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA P0620
ROOM TEMPERATURE P ALPHA AMINO NITROGEN INC N PROTEOLYSIS OCCURS EVEN IN PRIG. SAT:S IF FROZEN P0436
HO TE N ON E S GLUCOSE DEC V SEVERE HYPOGLYCEMIA REPORTED WITH POISONING P036 8
SALICYLAZOSULFAPYR B HEINZ-BODY FORMATION P05 V MAY CAUSE HEMOLYTIC ANEMIA HO 104
SALICYLAZOSULFAPYR B HEMATOCPIT DEC V MA! CAUSE HEMOLYTIC ANEMIA P0620
SALICYLAZOSULFAP YR B HEMOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA HO 620
SALICYLAZOSULFAPYR B METHEMOGLOBIN INC V OCCURS WITH HEMOLYTIC ANEMIA P0620

SA LICYLAZOSULFAPYH B RED.CELL COUNT DEC V MAY CAUSE HENOLYTIC ANEMIA H C 620
SALICYLA ZOSULFAPYP S AMYLASE INC V SINGLE CASE OF PANCREATITIS REPORTED RC123
SALICYLAZOSULFAPYR S BILERUBIN INC V NAY CAUSE HEMOLYSIS IN G-6-PD DEFICIENCY PC 079
SALICYLAZOSULFAPYR S HAPTOGLOBIN DEC V OCCURS WITH HMOLYTIC ANEMIA 140620
SALICYLAZOSULFAPYR U URINALYSIS COLOR INC N PINK, RED, PURPLE, ORANGE OR RUST COLOR R’299
SALINE P ALDOSTERONE DEC V SHORT TERM RESPONSE IF GIVEN I.V. IN HYPERTENSIVES H522
SALI NI S CALCIUM DEC V EFFECT OF ISOTONIC SOLN IT HYP:RCALCEMIA 140026
SALINE S CHLORIDE INC V ADDED CHLORIDE P0620
SALINE S POTASSIUM INC V EFFECT 02 HYPERTONIC SOLUTION H 067 2
SALINE S SODIUM INC V MAY OCCUR TSP IF IMPAIRED CARDIAC/RENAL FUNCTION R0C26
SALINE S URIC ACID DEC V DIMINISHES URATE REABSORPTION 110897
SALI NE U CALCIUM INC V HYP3TONIC SOLUTION HAS CALCIURRTIC EFFECT 110026
SALINE U COPTISOL INC V REPORTED EFFECT R0296
SALINE U URIC ACID INC V HYPERTONIC SOLUTION MA! HAVE MARKED EFFECT RC 179
SALIVA S AMYLASE INC 1 SALIVA CONTAINS ANYLASE(MAY AFFECT PIPITTING) 140355
SALOL U URINALYSIS COLOR INC N DARK COLOR ON STANDING i10620
SANTONIN COLOR INC N DEEP YELLOW WITH 65 - 70MG RC62C’
SANTONIN U URINALYSIS COLOR INC N BRIGHT YELLOW (NAOH CHANGES TO PINK, SCARLET) PC 620
SA NTONIN U URINALYSIS SUGAR INC M FALSE POSITIVE WITH BENEDICT’S 110663
S A tIE RE PA UT U URINALYSIS SUGAR INC M METABOLITE MAY AFFECT GALATEST P0436
SC-161C2 B WHITE CELL COUNT INC V MECHANISM NOT EXPLAINED 110499
SC- 161C2 S POTASSIUM DEC V DURATION OF DIURETIC ACTICN SHORT H 0499
SC-161C2 U CHLORIDE INC V DURATION OF DIURETIC ACTION SHORT PC 49 9
SC- 161C2 U POTASSIUM INC V DURATION OF DIURETIC ACTION SHORT R01499
SC-16 12 U SODIUM INC V DURATION OF DIURETIC ACTION SHORT RCLI99
SC-161C2 U VOLUME INC V DURATION OF DIURETIC ACTION SHORT P01499
SF.COBARBITAL P PPOTHPOMBIN TIME DEC V INDUCES NETAOLISM OP ADMINISTERED COUNARINS 110787
SFCOBAHBITAL U 17 KETOST!FOIDS DEC M NEC INTERFERENCE ON ZINMRRMAN REACTION IN VITRO 110.133
SECO BARBITAL U 17 KETOSTEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION RC299
SECOBARBITAL U 17 OH CORTICOSTEROIDS Z N NO EFFECT GLENN-NELSON PROC WHEN ADDED IN VITRO P0 133
SECRETIN 0 GASTRIC JUICE HCL DEC V PANCREATIC SECRETION ALSO AT PEAK HO 548
SECRETIN 0 PANCREAT JUICE ANYLASE INC V NORMAL ABOVE 14.9 U/KG/803 NIN P0151
SECHETIN 0 PANCREATIC JUICE HCO3 INC V NORMAL ABOVE 90 MEQ/L HG 151
SECRETIN 0 PANCREATIC JUICE VOL INC V NORMAL RESPONSE OVER 3.2 ML/KC/8ONIN RC15i
SECRETIN P CLUCAGON Z V NO EFFECT NOTED WHEN GIVEN IN PULSES P0286
SERETIN S CALCIUM INC V INC BY .6 MEQ/L IN NORMALS, ? CAUSE PC 1147
SECRETIN S GLUCOSE INC V I.V. INFUSION CAUSES INCREASE P0491
SECRETIN S LIPASE INC V MAY CAUSE SPASM OF SPHINCTER OF ODDI R0977
SEDORMIO B PLATELET COUNT DEC V THHOMBOCYTOPENIA (IMMUNOLOGICALLY - INDUCED) 110620
SEDORMID F COPROPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA R0371
SEDORMID F PROTOPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA RC37 1
SEDOR MID U ANINOLEVULINIC ACID INC V NAY PRECIPITATE ACUTE PORPHYRIA P037 1
SEDORMIC U COPROPORPHYRIN INC V NAY PRECIPITATE ACUTE PORPHYRIA 110371
SPOORMID U PORPHOBILINOGEN INC M PRODUCES RED COLCR WITH EHELICH’S REAGENT H 0436
SEDORMID U PORPHOBILINOGEN INC V NAY PRECIPITATE ACUTE PORPHYRIA 110371
SEDORMID U UBOBILINOCEN INC :i PRODUCES RED COLOR WITH EHFLICH’S REAGENT P0436
SENNA F COLOR INC N YELLOW TO BROWN P C 620
SENNA U URINALYSIS COLOR INC N PINK, RED, PURPLE, ORANGE OR RUST 110029
SEPINE B MEGALOBLASTS INC V CAN AGGRAVATE VITAMIN B12 DEFICIENCY FtC 791
SERUM P ALPHA AMINO NITROGEN INC V RELEASE THOM RBC WITH CLOTTING (UP TO 40%HIGH) 110436
SERUM P HEMOGLOBIN INC N DURING CLOTTING NAY BE iCC FOLD INCREASE R01485
SERUM S ACID PHOSPHATASE TOTAL INC M RELEASE OF ENZYME FROM ERYTHROCYTES RiCO 1
SERUM S CHOLESTEROL Z N IF HEPAPIN USED FOR PLASMA HO 436
SERUM S LACTIC DEHYDROGENASE INC M UP TO 143% HIGHER THAN PLASMA PC 136
S ER UN S LITHIUM Z N NO DIFFERNCE OBSERVED 90756
SERUM S PH Z V CLOTTING HAS NO EFFECT R0354
SERUM S POTASSIUM INC V DUE TO RELEASE FROM ERYTHROCYTES WITH CLOTTING R1001
SILVER B PH INC V OBSERVED AFTER SILVER NITRATE ANTISEPSIS HO 657
SILVER F OCCULT BLOOD P05 V MAY CAUSE HEMORRHAGIC GASTROENTERITIS P0384
SILVER S CHLORIDE DEC V OBSERVED AFTER SILVER NITRATE ANTISEPSIS P03657
SILVER S SODIUM DEC V OBSERVED AFTER SILVER NITRATE ANTISEPSIS P0657
S ITO STE HO L S CHOLESTEROL DEC V INHIBITS ABSORP OF ENDOGENOUS 11 EXOGENOUS COMPOUND P0379
SKATOLE T TRYPTOPHAN INC M MEASURED AS SANE IN SPIES/CHAMBERS METHOD R0399
S KA T OL E U UPOBILINOGEN INC N PRODUCES A BLUE COLOR WITH EHRLICH’S REAGENT P043 6
SLEEP P GROWTH HORMONE INC V NAX RELEASE IN EARLY SLEEP B 1025
SLEEP S TYHOSINE DEC V 18 DECREASE DURING SLZP P1025
SMALLPOX VACCINE B PLATELET COUNT DEC V NAY OCCASIONALLY CAUSE THROMBOCYTOPENIC PURPURA H 0620
SMOKING B CARBOXYHEMOGLOBIN INC V SIGNIFICANTLY HIGHER IN SMOKERS R08i4
SMOKING B HEMOGLOBIN INC V SIGNIFICANTLY HIGHER IN SMOKERS PC814
SMOKING B 02-HEMOGLOBIN AFFINITY DEC V SIGNIFICANTLY LESS IN SMOKERS P0814
SMOKING B RED CELL COUNT INC V SIGNIFICANTLY HIGHER IN SMOKERS RC814
S MOE INC E ATP DEC V SIGNIFICANTLY LESS IN SMOKERS P0814
SMOKING 0 PANCREATIC JUICE HCO3 DEC V CHRONIC EFFECT HEAVY SMOKERS, LESS IN LIGHT R0172
SMOKING 0 PANCREATIC JUICE VOL DEC V CHRONIC EFFECT HEAVY SM0KBS, LESS IN LIGHT 110172
SMOKING P ASCORBIC ACID DEC V LOWER CONC OBSERVED THAN IN NON-SMOKERS P0729
SMOKING W ASCORBIC ACID DEC V LOWER CONC OBSERVED IN SMOKERS THAN NONSMOKERS PC 729
S OD IU N S POTASSIUM INC M VARIABLE CONC AFFECTS MOST FLAME METHODS R03184
SODIUM BICARBONATE B PH INC V AFFECTS ACID-BASE BALANCE IN VIVO P03623
SODIUM BICABBONAT S POTASSIUM DEC V CAUSES POTASSIUM TO SHIFT INTO CELLS P003 26
SODIUM BICARBONATE S SODIUM INC V MAY CAUSE SODIUM RETENTION P0026
SODIUM BICARBONATE U PHINC V USED TO ALKALINIZE URINE 110026
SODIUM BICARBONATE U URINALYSIS PROTEIN INC N FALSE P05 WITH LABSTIX DUF TO HIGH PH P0417
SODIUM BICARBONATE U UROBILINOGEN INC V INC CLEARANCE WHEN URINE ALKALINE 110666
SODIUM BISULFITE T PROTEIN INC N AT CONCS HIHGER THAN C..C1 AFFECTS FOLIN-CIOCALTRU P0213
SODI UN CHLORIDE S BILIRUBIN DEC N INHIBITION OF DIAZO TEST REPORTED R0436
S 00 IN I P0 DATE S CREATININT INC V NEPHHOTOXIC EFFECT H C26 0
SODI UN IPODATE S UREA NITROGEN INC V NEPHROTOXIC EFFECT R03260
S 00 I UN I PODATE U PROTEIN INC V NEPHROTOXIC EFFECT R0260
SODIUM IPODATE U URINALYSIS HEMOGLOBIN INC V NEPHROTOXIC EFFECT R032603
SODIUM I P0 DA T E U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT P0260

SODIUM IPODATE U URINALYSIS RBC/HPF INC V NEPHROTOXIC EFFECT R026C
SODIUM IPODATI U URINALYSIS WBC/HPF INC V NE?HROTOXIC EFFECT P0260
SOrIUM NITROPPUSSI S I 131 UPTAKE DEC V SINGLE CASE REPORTED (?DUE TO THIOCYANATE) Pa 702
SODIUM NITROPRUSSI S PHI DEC V SINGLE CASE REPORTED (?DUE TO THIOCYANATE) P0702
SOCIUM PHOS P32 B PLATELET COUNT DEC V THRONBOCYTOPENIA IF EXCESS USED RCC26
SODIUM PiCS 932 B RED CELL COUNT DEC V ANEMIA IF EXCESS USED P0026
SOCIUN PROS P32 B WHITE CELL COUNT DEC V LEUKOPENIA IF EXCESS USED 110026
SODIU3 ?FIYTATE S CALCIUM DEC V DECREASED G.I. TRACT ABSORPTION H 0026
SODIUM ?!YTATE U CALCIUM DEC V DECREASED G.I. TRACT ABSORBTION P0 299
SCCIU SALTS P ASMONIA DEC V REPORTED EFFECT P0620
SODIU1 S’LTS S CALCIUM INC N AFFECT FLAME PHOTOMETRY IF POOR INSTPIThENT P01436
SODIUM SALTS U DIAGNEX BLUE EXCRETION INC M DISPLACEMENT OF DIAGNEX BLUE FROM RESIN 111001
SODIUE SULEATE S CALCIUM DEC V IF GIVEN I.V. MAY CAUSE HYPOCALCENIA P0026
SC)IU SULFATE S MAGNESIUM DEC V MAY BE EXCRETED COMBINED WITH SULFATE P0026
SODIU! SOLEATE S POTASSIUM DEC V MAY BE EXCRETED COMBINED WITH SULFATE 110866
SODIUM SULFATE S SODIUM INC V IF GIVEN I.V. MAY CAUSE FLUID RETENTION AND COMA P0866
SODIUN SULFATE U CALCIUM INC V PROMOTES EXCRETION P 0384
SPECTI NONYCIN B HENATOCRIT DEC V MECHANISM NOT DISCUSSED 110045
SPCT:EOM!cIN B HEMOGLOBIN DEC V MECHANISM NOT DISCUSSED P0045
SPECTINO4YCIN S ALKALINE PHOSPHATASE INC V MECHANISM NOT DISCUSSED P0045
SPTCTINOMYCIN S SGPT INC V MECHANISM NOT DISCUSSED P00145
SPECTINONYCIN S UREA NITROGEN INC V MECHANISM NOT DISCUSSED P0045
SPECTINOMYCIN U CEFATININE CLEARANCE DEC V MECHANISM NOT DISCUSSED P00145
SPECTINOOIYCI N U VOLUME DEC V MECHANISM NOT DISCUSSED RC045
SPINAL ANESTHESIA P ERPF DEC V IN RELATION TO DEGREE OF HYPOTENSION BC 384
SPINAL ANSTH!SIA S BSP RETENTION INC V SEEN POST-OPERATIVELY, RELATED TO DEC BLOOD FLOW P03814
SPINAL ANESTHESIA U CHLORIDE DEC V OBSERVED IN NORMAL MALES, PREGNANT WOMEN P0384
SPINAL ANSTH!SIA U GEP DEC V REPORTED EFFECT, RELATED TO DEGREE OF HYPOTENSION RC384
SPINAL ANESTHESIA U SODIUM DEC V OBSERVED IN NORMAL MALES, PREGNANT WOMEN P0384
SPINAL ANESTHESIA U UROBILINOGEN DEC V RELATED TO REDUCED BEPATIC BLOOD FLOW P0384
SPINAL ANSTHLSIA U VOLUME DEC V FOUND POST-OPERATIVELY, BUT NORMAL RENAL FUNCTION R0384
SPIRONOLACTONE P COETISOL INC N FLUOROMETPIC METHODS NAY BE AFFECTED P0601
SPI FONOLACTONE S POTASSIUM DEC V DIURETIC ACTION (NOT MARKED) HO 907
S Pt RONOLACTONE S POTASSIUM INC V INHIBITS NA/K EXCHANGE IN RENAL TUBULES R038 4
SPIBONOLACTONE S SODIUM DEC V ALDOSTERONE ANTAGONISM WITH CONSEQUENT DIURESIS P062 0
SPIRONOLACTCNE S URIC ACID INC V DECREASED ORATE CLEARANCE 110620
SPIROFOLACTONF U CHLORIDE INC V DIURETIC ACTION P038 4
SPIRC’NOLAC TONE U SODIUM INC V DIURETIC ACTION RC384
SPIRONOLACTONE U 17 KETDGENIC STEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION 110907
SPIRONCLACTONE U 17 KETOSTEROIDS INC M INTERFERES WITH ZIMMERMAN REACTION P0907
S PIRONOLACTONE U 17 OH CORTICOSTEPOIDS INC N INTERFERES WITH PORTZR-SILBER REACTION R0907
STANDING OF SAMPLE U CALCIUM DEC N PRECIPITATION OF CALCIUM SALTS UNLESS ACIDIFIED P100 1
STNOZOL0L P PLASMINOGEN INC V METABOLIC EFFECT R007 2
S TA N OZOL OL S BETA-GLUCURONIDASE INC V METABOLIC EFFECT P0072
S TA N OZ CL CL S BILIRURIN INC V MAY CAUSE INTRAHEPATIC CHOLESTASIS R0384
5Th NOZCLCL S BSP RETENTION INC V DUE TO INTRAHEPATIC CHOLESTASIS P 023 3
S TA NO 2 OL CL S HAPTOGLORIN INC V METABOLIC EFFECT P00372
STANOZCLOL S SGCT INC V MAY CAUSE INTRAHEPATIC CEOLESTASIS P0233
STA NOZOLOL S SGET INC V MAY CAUSE INTRAHEPATIC CHOLESTASIS PC233
S TA N OZO LOL S SIALIC ACID INC V METABOLIC EFFECT P0072
STIR OPHEN B HEMATOCRIT DEC V MAY PRODUCE HMOLYTIC ANEMIA P063 6
STIBOPHEN B HEMOGLOBIN DEC V NAY PRODUCE H.EMOLYTIC ANEMIA PC636
S T I B 0 PH 1 N B PLATELET COUNT DEC V IMMUNOLOGICAL MECHANISM (OFTEN WITH PURPUPA) R0232
STIBOPHEN B RED CELL COUNT DEC V PRODUCES HENOLYTIC ANEMIA P0636
STIBOPHEN S BILIRUBIN INC V PRODUCES HEMOLYTIC ANEMIA P0636
STIBO PHEN S DIPECT BILIPUBIN INC V PRODUCES HEMOLYTIC ANEMIA P0636
STIBOPHT N S DIRECT COOMBS TEST P05 V PRODUCES HENOLYTIC ANEMIA 110636
STIBOPHEM S HAPTOGLOBIN DEC V PRODUCES HEMOLYTIC ANEMIA P0636
STIBOPHFN S SGOT INC V HEPATITIS REPORTED 110026
STIBOPH EN S SGPT INC V HEPATITIS REPORTED 110026
STIBOPI4EN U PROTEIN INC V RENAL IRRITATION REPORTED P0026
STIBOPHE N U URINALYSIS PROTEIN INC V RENAL IRRITATION REPORTED 110026
STIBOPHEN U VMA INC N AT NEUTRAL OR ALK PH AFFECT GITLOW PROCEDURE R0998
STILBE STROL S AMINO ACIDS DEC V SPECIFIC AMINO ACIDS AFFECTED IN MEN P0226
STILBESTROL S VITAMIN A DEC V HORMONAL EFFECT WHEN GIVEN TO LACTATING WOMEN BC 352
STORAGE CE SAMPLE 5 HFNOGLOBIN 2 N STABLE AT ROOM TEMP FOR AT LEAST 1 WEEK 110436
STORAGE O SAMPLE B PH tIC N IF ANAEROBIC STORAGE AT 37 DEG OP 2H AT ROOM TEMP P1001
STORAGE OF SAMPLE B PH INC M IF SAMPLE EXPOSED TO AIR P1031
STOHAGO 0! SAMPLE F UPOBILINOGEN DEC N DEC UP TO 46% WITHIN 24H AT 4 DEGREES P0436
STORAGE 0’ SAMPLE P AMMONIA INC N STABLE IN ICED PLASMA FOR SEVERAL HOURS P0184
STDRAGT CF SAMPLE P PPOTHHOMBIN TIME INC N OXALATED PLASMA LOSES ACTIVITY AT 4 DEGREES 110998
STORAGP OF SAMPLE P PROTHPONBIN TIME Z N STABLE AT ROOM TEMP FOP 1811 IN OXALATED PLASMA BC 998
STJRAGP OT SAMPLE S ACID PHOSPHATASE TOTAL DEC N 50% ACTIVITY LOST AFTER 5H AT ROOM TEMP R0998
STORAGE OF SAMPLE S ACID PHOSPHATASE TOTAL Z M STORAGE AT -2C DEGREES FOR OVER 14 MONTHS P 0998
STORAGE OF SAMPLE S ADLNOSINE DEAMINASE Z N NO EFFECT 1 WEEK AT 4 DEGREES, 1 MONTH AT -20 DEG R0998
STORAGE OF sAMPLE S ALOOLASE Z M NO EFFECT 1 WEEK AT 4 DEGREES, 1 MONTH AT -20 DEG 110998
STORAGE OF SAMPLE S ALKALINE PHOSPHATASE INC ,1 MAY INC 5-10% AFTER 1 DAY AT 4 DEGREES 110998
STORAGE OF SAMPLE S ALKALINE PHOSPHATASE Z N NO EFFECT 8H AT ROOM TEMP, 1 WEEK AT -20 DEGREES 110998
STORAGE OF SAMPLE S ANYLASE Z N 1 WEEK AT 4 DEGREES, 1 MONTH AT -20 AT NORMAL CONC R01436
STORAGE OF SAMPLE S BARBITURATE Z N NO EFFECT ON UV ABSORPTION METHODS 110779
STORAGE OF SAMPLE S BETA-LIPOPHOTTINS DEC N MARKED WITH 7 DAYS AT -2CDEG, MILD 28DAYS AT 0 DEG 110536
STORAGE OF SAMPLE S BSP RETENTION DEC N DEC U? TO 4% AT ROOM TEMP FOR 1611 110998
STORAGE O SAMPLE S CALCIUM Z M ROOM TEMP 811, 4 DEGREES 1 DAY, FROZEN 1 YEAR P0998
STORAGE Of SAMPLE S CEPHALIN FLOCCULATION INC N REPORTED EFFECT AFTER 2 DAYS AT 4 DEGREES P0436
STORAGE OF SAMPLE S CERULOPLASMIN DEC M OXIDASE ACTIVITY DEC AT ROOM TEMP, Z 2 DAY AT 4 DEG P0998
STORAGT OF SAMPLE S CHLORIDE Z &1 NO EFFECT AFTER 1 WEEK AT ROOM TEN?, MONTHS AT -10 R0436
STORAGE OF SAMPLE S CHOLESTEROL Z N NO EFFECT 2 DAYS AT 4 DEGREES, 5 YEARS AT -20 PO99
STORAGE OF SAMPLE S CHOLINESTERASE Z M NO EFFECT 1 WEEK AT 4 DEGREES, 1 MONTH AT -20 DEG P0998
STORAGF OP SAMPLE S ELECTROPHORESIS Z N NO EFFECT 3 DAYS AT ROOM TEMP OR 1 MONTH AT 4 DEG 1101436
STORAGE OF SAMPLE S GLUTATHION! PEDUCTASE Z N NO EFFECT 1 WEEK AT 4 DEGREES, 1 MONTH AT -20 110998
STORACT 0? SAMPLE S lCD Z M NO EFFECT 1 WEEK AT 4 DEGREES, 1 MONTH AT -20 DEG 110998

STORAGE OE SAMPLE S IRON Z N NO EFFECT 4 DAYS ROOM TEMP OR 7 DAYS AT 4 DEGREES R0436
STORAGE OF SAMPLE S LACTrC DEHYDROGENASE Z N NO EFFECT 1 WEEK AT 4 DEGREES, 1 MONTH AT -20 DEG P3 436
STORAGE OF SAMPLE S LEUCINE AMINOPEPTIDASE Z N NO EFFECT 1 WEEK AT 4 DECREES, 1 MONTH AT -20 DEG P0436
STORAGE OF SAMPLE S LIPASE Z N NO EFFECT 1 WEEK AT 4 DEGREES. 1 MONTH AT -20 DEG P01436
STORAGE )F SAMPLE S LITHIUM Z N NO EFFECT 1 WEEK AT 4 DEGREES, FROZEN FOR MONTHS PC 756
STORAGE OF SAMPLE S MAGNESIUM Z N ROOM TEMP 8H, 14 DEGREES 1 DAY, FROZEN 1 YEAR P0998
STORAGE OF SAMPLE S NEFA INC N AT ROOM TEMP DUE TO LIPOPROTEIN LIPASE P0998
STORAGE OF SAMPLE S NPNDEC N SIGNIFICANT EFEECT AT -10 DEGREES AFTER 6 MONTHS P0 998
STORAGE OF SAMPLE S NPNZ N NO EFFECT 1 DAY AT ROOM TEMP, SEVERAL AT 4 DEGREES R0L436
STORAGE OF SAMPLE S OS1OLALITY Z N NO EFFECT FOR 3H AT I100M TENP, 1CH AT 14 DEGREES P0500
STORAGE OF SAMPLE S PHI Z ii NO EFFECT 5 WEEKS AT ROOM TEMPERATURE R0L436
STORAGE OF SAMPLE S PHOSPHATE Z N ROOM TEMP 811, 4 DEGREES 1 DAY, FROZEN 1 YEAR R0998
STORAGE OF SAMPLE S PHOSPHOGLUCOMUTASE DEC Ii AFTER 8 H AT ROOM TEMP, 2 DAYS AT L4 DEGREES H C 998
STORAGE OF SAMPLE S PHOSPHOHEXOSEISOMERASE Z N NO EFFECT 1 WEEK AT 4 DEGREES, 1 MONTH AT -20 DEC PC 998
STORAGE OF SAMPLE S POTASSIUM Z M NO EFFECT FOR 2 WEEKS AT ROOM TEMP OH 4 DEGREES HO 43 6
STORAGE OF SAMPLF S PROTEIN Z N NO EFFECT FOR 1 WEEK AT ROOM TLNP, 1 MONTH AT 4 DEG P0436
STORAGE OF SAMPLE S SGOT Z N NO EFFECT 1 WEEK AT 14 DEGREES, 1 MONTH AT -20 DEG H 01436
STORAGE OF SAMPLE S SGPT Z M NO EFFECT 1 WEEK AT 4 DEGREES, 1 MONTH AT -20 DEG PC 436
STORAGE OF SAMPLE S SODIUM Z N NO EFFECT FOR 2 WEEKS AT ROOM TEMP OR 4 DEGREES P 04 36
STORAGE 3F SAMPLE S THYMOL TURBIDITY Z N USUALLY STABLE AT L4 DEGREES FOR 1 WEEK 110436
STORAGE OF SAMPLE S URIC ACID Z N NO EFFECT FOR 3 DAYS AT ROOM TEMP, 6 MONTHS FROZEN P043 6
STORAGE OF SAMPLE S ZNSOL& TURBIDITY DEC N EFFECT OBSERVED AFTER 1 DAY AT 4 DEGREES H 01436
STORAGE OF SAMPLE U ALKALINE PHOSPHATASE Z N NO EFFECT 2 DAYS AT 14 DEGREES, 1 WEEK AT -20 DEG P0998
STORAGE OF SAMPLE U ANYLASE Z N NO EFFECT 2 DAYS AT 4 DEGREES, 1 WEEK AT -20 DEG RC998
STORAGE OF SAMPLE U CALCIUM DEC N UNLESS ACIDIFIED P0998
STORAGE OF SAMPLE U CATECHOLAMINES Z N NO EFFECT AT ROOM TEMP, SEVERAL DAYS IF ACIDIFIED H 0998
STORAGE OF SAMPLE U CREATINE INC N SIGNIFICANT INC 1 DAY AT ROOM TEMPERATURE R01436
STORAGE OF SAMPLE U CREATININE Z N NO EFFECT FOP U TO 7 DAYS AT ROOM TEMP P C 1436
STORAGE OF SAMPLE U EPINEPHRINE Z N NO EFFECT AT ROOM TEMP, SEVERAL DAYS IF ACIDIFIED P0998
STORAGE OF SAMPLE U LACTIC DEHYDROGENASE DEC N LOSES ACTIVITY UNLESS ANALYZED IMMEDIATELY PC 99 8
STORAGE OF SAMPLE U LEUCINE AMINOPEPTIDASE Z N NO EFFECT 1 DAY AT 4 DEGREES, 1 WEEK AT -20 DEG P 0998
STORAGE OF SAMPLE U NOP.EPINEPHRINE F N NO EFFECT AT ROOM TENP, SEVERAL DAYS I? ACIDIFIED H 0998
STORAGE OF SAMPLE U PHOSPHATE DEC N UNLESS ACIDIFIED HO 998
STORAGE OF SAMPLE U URIC ACID DEC N AT ANY TEMPERATURE UNLESS ALKALI ADDED R077i
STORAGE OF SAMPLE U VNAZ N ACIDIFIED SEVERAL DAYS ROOM TEMP, 1 WK AT 4 DEC HO 998
STREPTOKINASE B BLEEDING TIME INC V DISSOLVES BLOOD CLOTS H 0620
STREPTOKINASE B EOSILIOPHILS INC V ALLERGIC RESPONSE R0362C
STHEPTOKINASE B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA P0620
STPEPTOKINASF S CREATININE INC V NEPHROTOXIC EFFECT (WITH TUBULAR DAMAGE) P 0620
STREPTOKINA SE S UREA NITROGEN INC V RENAL TUBULAR DAMAGE IN ONE CASE RC204
STREPTOKINASE U LEUCINE AMINOPEPTIDASE INC V ACTIVATES PEPTIDASES BY PLASMINOGEN HO 758
STREPTOKI NASE U PROTEIN INC V RENAL DAMAGE REPORTED HO 620
STREPTOKINASE U URINALYSIS PROTEIN INC V RENAL DAMAGE REPORTED P0620
STREPTOMYCIN B ZOSINOPHILS INC V HEMATOPOIETIC REACTION (OCCURS IN 50% CASES) HG 026
STPEPTOMYCIN B HEMATOCRIT DEC V HEMOLYTIC ANEMIA (SENSITIVITY DEPENDENT) P02403
STREPTOMYCIN B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA (SENSITIVITY DEPENDENT) R32L43
STREPTOMYC IN B LE CELL PREP 905 V MAY PRODUCE LE LIKE SYNDROME P 09037
STREPTOMYCIN B PLATELET COUNT DEC V PANCYTOPENIA/THROMBOCYTOPE NIA R0240
STREPTC’MYC IN B RED CELL COUNT DEC V APLASTIC/HEMOLYTIC ANEMIA (SENSITIVITY DEPENDENT) H 062 03
STREPTOMYCIN B WHITE CELL COUNT DEC V AGR ANULOCTYOSIS/LEUKOPENIA/NEUTROPENIA P36 20
STREPTOMYCIN C PROTEIN INC N REACTS AS PHENOL IF FOLIN-CIOCALTEU REACTION USED P0907
STREPTOMYCIN S BILIRURIN INC V MAY CAUSE HEMOLYTIC ANEMIA P062 0
STREPTOMYC IN S 000MBS TEST P05 V MECHANISM OBSCURE R0418
STREPTOMYCIN S CEATININE INC V NEPHROTOXICITY MAY OCCUR IN 2% P 0736
STREPTOMYCIN S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA R062O
STREPTOMYCIN S NPN INC V NEPHROTOXICITY MAY OCCUR IN 2% P 07 36
STREPTOMYCIN S UREA NITROGEN DEC N INHIBITS BEPTHELOT REACTION R09C7
STREPTOMYCIN S UREA NITROGEN INC V NEPHPOTOXICITY MAY OCCUR IN 2% P0736
STPEPTONYCIN U ALKALINE PHOSPHATASE INC V DUE TO NEPHROTOXIC EFFECT OF DRUG P0758
STREPTOMYC IN U LEUCINE AMINOPEPTIDASE INC V FACILITATES PERMEATION OF ENZYME INTO TUBULES P C 758
STREPTOMYCIN U PROTEIN INC N REACTS AS PHENOL IF FOLIN-CIOCALTEU REACTION USED P0907
STREPIONYCIN U PROTEIN INC V NEPHROTOXIC EFFECT H 038 4
STPEPTOMYC IN U SUGAR INC N FALSE POSITIVE WITH COPPER REDUCTION PROCEDURES P 09 07
STREPTOMYCIN U URINALYSIS CASTS INC V CYLINDPURIA MAY DEVELOP PC 38 4
STREPTOMYCIN U URINALYSIS PROTEIN INC V MAY CAUSE NEPHHOTOXICITY HE 384
STREPTOMYCIN U URINALYSIS SUGAR INC N ACTS AS REDUCING AGENT AFFECTS BENEDICT’S, GALATEST H 1001
STREPTOZOTOCIN P INSULIN INC V ?DUE TO RELEASE FROM DAMAGED BETA CELLS RC686
STR EPTOZOTOCI N S ACETOACETATE INC V TEMPORARY EFFECT FOLLOWING INFUSION R0686
STRE PTOZOTOC IN S C02 CONTENT DEC V ASSOCIATED WITH LOW POTASSIUM AND POLYURIA P06 86
STREPTCZOTOCIN S GASTRIN DEC V GASTRIC HYPERSECRETION REDUCED HC686
STREPTOZOTOCIN S LACTATE INC V TEMPORARY EFFECT FOLLOWING INFUSION P0686
STREPTOZOTOCIN S NEFA DEC V MECHANISM NOT ESTABLISHED YET P03686
STEEPTOZOTOC IN S POTASSIUM DEC V ASSOCIATED WITH POLYURIA P03686
STLIEPTOZ OTOCIN S PYRUVATE INC V TEMPORARY EFFECT FOLLOWING INFUSION P0 68 6
STPEPTOZOTOCIN U GLUCOSE INC V RARELY EXCEEDED 25 NG/13OML H 0686
STRE PTOZOTOC IN U POTASSIUM INC V IN SPITE OF LOW SERUM CONC RO686
STPEPTOZOTOCIN U URINALYSIS GLUCOSE INC V RARELY EXCEEDS 25 MG/100ML HO 686
STRE PTOZOTOCIN U VOLUME INC V NOTED TEN DAYS AFTER INFUSION (WITH POLYDIPSIA) P0686
STRONTIUM U MAGNESIUM INC M MEASURED BY FLUOROMETRIC METHOD OF SCHACHTER PC 923
STRYCHNI NE B WHITE CELL COUNT INC V PROBABLY DUE TO RELEASE OF EPINEPHRINE FROM ADRENAL PC 368
SUCC INIMI DES F COPROPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA RC371
SUCCINIM IDES F PROTOPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P0371
SUCC INIMIDES U AMINOLEVULINIC ACID INC V MAY PRECIPITATE ACUTE PORPhYRIA PC 37 1
S U C C IN IN I B ES U COPROPOPPHYHIN INC V MAY PRECIPITATE ACUTE PORPHYRIA R0371
SUCCINIMIDES U PORPHOBILINOGEN INC V MAY PRECIPITATE ACUTE PORPHYRIA P0 37 1
SUCC INYLCHOLI NE S CPK INC V OCCURS IF GIVEN WiTH HALOTHANE P0941
S UCCINYLCHOLINE S IONIZED CALCIUM INC V RISE NOT MARKED (I.V. ADMINISTRATION) P0306
S UCCINYLCHOLINE S NYOGLOBIN INC V OCCASIONAL RESULT OF I.V. INJECTION IN CHILDREN RC807
S UCCI NYLCHOL INE S POTASSIUM INC V IF INJECTED I.V. B 0907
SUCCINYLCHOLINE U MYOGLOBIN INC V OCCASIONAL RESULT OF I.V. INJECTION IN CHILDREN P0807

SUCCI NYLSULFATHIAZ P PROTHRONBIN TIME INC V MAY CAUSE VITAMIN K DEFICIENCY HO 026
SULFACETA N IDE B HEMATOCRIT DEC V MAY CAUSE HEMOLYSIS IF G-6-PD DEFICIENCY P00 79
SULFACETAMI DE B HEMOGLOBIN DEC V NAY CAUSE HEMOLYSIS IF G-6-PD DEFICIENCY BOO 79
SULFACETAMIDE B NETHEMOGLOBIN INC V MAY CAUSE HEMOLYSIS IF G-6-PD DEFICIENCY P09 26
SULFACETAMIDE B RED CELL COUNT DEC V MAY CAUSE HEMOLYSIS IF G-6-PD DEFICIENCY RO079
SULF ACETAMIDE S BILIRUBIN INC V NAY CAUSE HEMOLYSIS IN G-6-PD DEFICIENCY R0O79
SULFACETA MIDE S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYSIS IF G-6-PD DEFICIENCY R0O79
SULFADIAZINE B HEMATOCRIT DEC V MAY CAUSE HENOLYTIC ANEMIA P06 20
SULFADIAZINE B HEMOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P06 20
SULFADIAZINE B RED CELL COUNT DEC V MAY CAUSE HEMOLYTIC ANEMIA P06 20
SULFADIAZINE B WHITE CELL COUNT DEC V AGR ANULOCYTOS IS/LEO KOP ENI A P0 620
SULFADIAZI NE C PROTEIN INC N REACTS AS IF PHENOL WITH FOLIN-CIOCALTEU PROC Hi 026
SULFADIAZINE S ALKALINE PHOSPHATASE INC V MAY CAUSE INTRAHEPATIC CHOLESTASIS HO 405
SULFADIAZINE S BILIHUBIN INC V MAY CAUSE INTRAHEPATIC CHOLESTASIS H 04 05
SULFADIAZINE S CALCIUM DEC N DEPRESSES FLUORESCENCE OF CALCEIN METHOD P0644
SULFADIAZINE S CHOLESTEROL INC V MAY CAUSE INTRAHEPATIC CHOLESTASIS P 0405
SULFADIAZINE S HAPTOCLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA RO62O
SULFADIAZINE S UREA NITROGEN Z N NO EFFECT ON BEP.THELOT PROCEDURE P05 10
SULFADIAZINE U PROTEIN INC V DUE TO CRYSTALLUHIA AND HEMATURIA P0736
SULFADIAZINE U URINALYSIS CRYSTALS INC V LOW SOLUBILITY IN ACID URINE P07 36
SULFADIAZINE U URINALYSIS HEMOGLOBIN INC V ASSOCIATED WITH CPYSTALLURIA AND HEMATUHIA P07 36
SULFADIAZINE 0 URINALYSIS PROTEIN INC V ASSOCIATED WTTH CRYSTALLURIA AND HEMATURIA RO736
SULFADIAZINE U URINALYSIS RBC/HPF INC V ASSOCIATED WITH CRYSTALLUPIA AND OLIGURIA P07 36
SULFADIAZINE U UROBILINOGEN INC M MAY PRODUCE GREENISH COLOR WITH EHHLICH’S REAGENT P0143
SULFADIAZINE U VOLUME DEC V ASSOCIATED WITH CRYSTALLUPIA AND HEMATURIA RO736
SULFAD IMETHOXINE B PLATELET COUNT DEC V APLASTIC ANEMIA/THROMBOCYTOPENIA WITH SULFONAMIDES P0 6 20
SULFA DI METHOXINE P UROBILINOGEN DEC V PALE STOOLS WITH REVERSIBLE CHOLESTASIS R0307
SULFADIMETHOXINE S ALKALINE PHOSPHATASE INC V GRANULOMATOUS REACTION IN LIVER P0 3 07
SULFADI METHOXINE S BILIRUBIN INC V GRANULOMATOOS REACTION IN LIVER P030 7
SULFADIMETHOXINE S BSP RETENTION INC V REVERSIBLE CHOLESTASIS P03 07
SULFADIMETROXINE S CALCIUM DEC N DEPRESSES FLUORESCENCE OF CALCEIN METHOD P0644
S UL F ADIMET HO XINE S CEPHALIN FLOCCULATION INC V REVERSIBLE CHOLESTASIS HO 3 07
SULFADIMETHOXINE S DIRECT BILIRUBIN INC V GRANULOMATOUS REACTION IN LIVER P03 07
SULFADIMETHOXINE S SCOT INC V GRANULOMATOUS REACTION IN LIVER P03 07
SULFADIMETHOXINE S SGPT INC V REVERSIBLE HYPERSENSITIVE CHOLESTATIC RESPONSE P0515
SULFADIMETHOXINE S THYMOL TURBIDITY INC V REVERSIBLE CHOLESTASIS P0 307
SULFADINETHOXINE U BILIRUBIN INC V GRANULONATOUS REACTION IN LIVER P0307
SULFADI METHOXINE U URINALYSIS BILE INC V GRANULONATOUS REACTION IN LIVER P03 07
SULFADIMETHOXINE U UROBILINOGEN DEC V OCCURS WITH REVERSIBLE CHOLESTASIS P0 307
SULFADIMIDINE P CATECHOLAMINES INC M STRIKING FLUORESCENCE P0188
SULFAFUPA ZOLE F UPOBILINOGEN DEC V PALE STOOLS WITH REVERSIBLE CHOLESTASIS P0620
SULFAFUPAZOLE P PPOTHROMBIN TINE INC V FAILURE OF EXCRETION OF BILE SALTS P062 0
S ULFA FUR A ZO LE S ALKALINE PHOSPHATASE INC V REVERSIBLE CHOLESTASIS P0 6 20
SULFAFURAZOLE S BILIRUBIN INC V REVERSIBLE CHOLESTASIS P06 20
SULFAFUR AZOLE S BSP RETENTION INC V REVERSIBLE CHOLESTASIS H062O
SO LEA PU HA ZOLE S CEPHALIN FLOCCULATION INC V REVERSIBLE CHOLESTASIS P 06 20
S ULF AF UP A ZO LE S SCOT INC V REVERSIBLE CHOLESTASIS P06 20
SUL PA PU HA ZO LE S SCPT INC V REVERSIBLE CHOLESTASIS R0620
SULFAFUR AZOLE S THYMOL TURBIDITY INC V REVERSIBLE CHOLESTASIS HO 620
SUL PA PU HA ZO LE 0 URINALYSIS BILE INC V REVERSIBLE CHOLESTASIS P06 20
SULFAPURAZOLE U UPOBILINOGEN DEC V OCCURS WITH REVERSIBLE CHOLESTASIS P06 20
SO LEA CU A NIDINE C PROTEIN INC N REACTS AS IF PHENOL WITH FOLIN-CIOCALTEU PROCEDURE P1026
SULFAMERAZI NE C PROTEIN INC N REACTS AS IF PHENOL WITH FOLIN-CIOCALTEU PROCEDURE Hi 026
SULPAMEPA ZINE U URINALYSIS CRYSTALS INC V PRESENCE OF DRUG P0026
SULFA MERAZI NE U 17 OH CORTICOSTEROIDS INC N ALLEGED EFFECT ON METHOD OF H EDDY P04 17
S ULPA N ET H I ZO LE B HEMATOCHIT DEC V HEMOLYTIC ANEMIA HO 751
SULFAMETHIZOLE B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA P0751
SULFAMETHIZOLE B METHEMOGLOBIN INC V MAY CAUSE HEMOLYTIC ANEMIA HO 751
SULFA NETHIZOLE B PLATELET COUNT DEC V AGRANULOCYTOSIS/APLASTIC ANEMIA/THROMBOCYTOP ENIA P075 1
SULFANETHIZOLE B RED CELL COUNT DEC V HEMOLYTIC ANEMIA/APLASTIC ANEMIA RO751
SULFAMETHIZOLE B SULFHEMOGLOBIN INC V MAY OCCUR WITH HEMOLYTIC ANEMIA P0751
SULFAMETHIZOLE B WHITE CELL COUNT DEC V AG H A N UL OCY TO SI S HO 751
SULFA METHIZ OLE F UROBILINOGEN DEC V PALE STOOLS WITH REVERSIBLE CHOLESTASIS P0542
SULFAMETHIZOLE P PROTHRONBIN TIME INC V REACTION MAY OCCUR WITH ALL SULFONAMIDES H0467
SULFAMETHIZOLE S ALKALINE PHOSPHATASE INC V REVERSIBLE CHOLESTASIS P0 542
SULFAMETHIZOLE S AMYLASE INC V CASE OP PANCREATITIS REPORTED P0076
SULFA MET HIZOLE S BILIRUBIN INC V MAY CAUSE CHOLESTATIC JAUNDICE P0542
SULFA METHIZOLE S BSP RETENTION INC V REVERSIBLE CHOLESTASIS P0514 2
SULFAMETHIZOLE S CEPHALIN FLOCCULATION INC V REVERSIBLE CHOLESTASIS P0 542
SULFA METHIZ OLE S HAPTOGLOBIN DEC V NAY CAUSE HEMOLYTIC ANEMIA P075 1
SULPAMETHIZOLE S SCOT INC V REVERSIBLE CHOLESTASIS HO 542
SO LEA METHIZ OLE S SGPT INC V REVERSIBLE CHOLESTASIS P0542
SULFAMETHIZOLE S THYMOL TURBIDITY INC V REVERSIBLE CHOLESTASIS P0 542
SULFAMETHIZOLE U URINALYSIS BILE INC V REVERSIBLE CHOLESTASIS RO542
SULFAMETHIZOLE U UROBILINOGEN DEC V OCCURS WITH REVERSIBLE CHOLESTASIS HO 5 42
SO L PA METH OX AZ OLE B EOSINOPHILS INC V ALLERGIC RESPONSE P0542
SULPAMETHOXAZOLE B HEMATOCRIT DEC V MAY CAUSE HEMOLYTIC ANEMIA HO 542
SO LFA N ETH OX AZ 0 LE B HEMOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P0542
SULPAMETHOX AZOLE B PLATELET COUNT DEC V THROMBOCYTOPENI A RO5 42
S ULFA NET H OXA ZO LE B RED CELL COUNT DEC V MAY CAUSE HEMOLYTIC ANEMIA P0 542
SULFA METH OXAZOLE B WHITE CELL COUNT DEC V TOXIC REACTION TO DRUG H 054 2
SULF AM ET HO X A ZOLE F UROBILINOGEN DEC V PALE STOOLS WITH REVERSIBLE CHOLESTASIS P0 6 20
SULFA METH OXAZOLE P ALPHA AMINO NITROGEN INC M MEASURED IN NAPHTHOQUINONE METHOD OF FRAME R0779
S U LPAM ETH OX AZOLE P PROTHHOMBIN TIME INC V POSSIBLY DUE TO DRUG-INDUCED VITAMIN K DEFICIENCY HO 542
SO LPA N ETH OX AZ OLE S ALKALINE PHOSPHATASE INC V CHOLESTATIC JAUNDICE MAY OCCUR P05142
S OLE AM ET HO X A ZOLE S BILIHUBIN INC V REVERSIBLE CHOLESTASIS OR HEMOLYTIC ANEMIA RO620
SULFA METHOXAZOLE S BSP RETENTION INC V REVERSIBLE CHOLESTASIS P0620
SULPANETHOX AZOLE S CEPHALIN FLOCCULATION INC V REVERSIBLE CHOLESTASIS P0 620
SULFAMETHOXAZOLE S HAPTOGLOBIN DEC V NAY CAUSE HENOLYTIC ANEMIA P0542
SULPAMETHOXAZOLE S LACTIC DEHYDROGENASE INC V MAY CAUSE HENOLYTIC ANEMIA H 0542

SULFAMETHOX AZOLE S PHI DEC V SMALL EFFECT WITH THERAPEUTIC DOSES P0417
SU LEA METH OX A Z OLE S SCOT INC V CHOLESTATIC JAUNDICE MAY OCCUR P0542
SUL FAN ET POX A ZO LE S SGPT INC V CHOLESTATIC JAUNDICE MAY OCCUR P0542
SU LFA MET H OX A Z OLE S THYMOL TURBIDITY INC V REVERSIBLE CHOLESTASIS RO620
SOL’AMETHOX AZOLE S THYROXINE (TA) INC N ERRATIC ELUTION FROM COLUMN = FALSE RESULT 110183
SULFA NETHOXAZOLE U POPPHYRINS INC N MAY CAUSE FALSE POSITIVE WITH FLUORESCENT METHODS HO 299
SULFA METH OXAZOLE U PROTEIN INC V NAY CAUSE HEMATURIA WITH CHYSTALLURIA P0736
SULFAMETHOXA ROLE U PSP EXCRETION DEC V MORE COMMON EFFECT RO 299
SULFA NETHOXAZOLE U PSP EXCRETION INC V POSSIBLE LARGE DOSE EFFECT P02 99
SULFAMETHOXAZOLE U URINALYSIS BILE INC V REVERSIBLE CHOLESTASIS HO 620
SULFA METH OXAZOLE U URINALYSIS COLOR INC N BROWN COLOR OBSERVED P0299
SULFANETHOX AZOLE U URINALYSIS CRYSTALS INC V LOW SOLUBILITY IN ACID URINE P0736
SULFA METHOX AZOLE U URINALYSIS HEMOGLOBIN INC V NAY CAUSE HEMATUPIA WITH OLIGURIA 110736
SOLE AM FT POX AZ OLE U URINALYSIS PROTEIN INC N MAY INTERFERE WITH SULFOSALICYLIC ACID METHODS P0 299
SULFA NETHOXAZOLE U URINALYSIS PROTEIN INC V MAY CAUSE HEMATURIA WITH CRYSTALLURIA P07 36
SULFA METHOX PIZOLE U URINALYSIS RBC/HPF INC V MAY CAUSE HEMATURIA WITH CRYSTALLURIA P0736
SO LEA METH OX AZ OLE U URINALYSIS SUGAR INC N NA! CAUSE POSITIVE WITH FLUORESCENT METHODS HO 299
SULFAMET9 OXAZOLE U UROBILINOGEN DEC V OCCURS WITH REVERSIBLE CHOLESTASIS P0620
SULPAMETHOXA ZOLE U UROBILINOGEN INC N MAY REACT WITH EHRLICH’S TO PRODUCE FALSE COLOR 110029
SULFA METHOXYPYRI D B HEMATOCRIT DEC V HEMOLYTIC/APLASTIC ANEMIA P0620
SULFANETHOXYPYRID B HEMOGLOBIN DEC V HENOLYTIC/APLASTIC ANEMIA HO 620
SULFAMETHOXYPYPID B METHENOGLOBIN INC V MAY CAUSE HEMOLYTIC ANEMIA 110658
SULFANETROXYPYRID B PLATELET COUNT DEC V THROMBOCYTOPENIA MAY OCCUR AFTER DAYS TO WEEKS P0658
SOLFAMETHOXYPYFID B RED CELL COUNT DEC V ANEMIA (AMA-BLOOD DYSCRASIAS) RO658
SULFAMETHOXYPYRID B WHITE CELL COUNT DEC V LEUKOPENIA (AMA-BLOOD DYSCRASIAS) P0658
SULFA METHOXYPY RID F UPOBILINOGEN DEC V NAY CAUSE REVERSIBLE CHOrESTASIS R062O
SULFAMETROXYPYRID S ALKALINE PHOSPHATASE INC V REVERSIBLE CHOLESTASIS P0620
SULFAMETHOXYPYRID S BILIPUBIN INC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
SULFANETHOXYPYRID S BSP RETENTION INC V REVERSIBLE CHOLESTASIS P0620
SULFAMETROXYPYRID S CEPHALIN FLOCCULATION INC V REVERSIBLE CHOLESTASIS HO 620
SULFAMETH OXYPYRID S HAPTOGLOBIN DEC V NAY CAUSE HENOLYTIC ANEMIA P 0658
SULFA METROXYPY RID S SCOT INC V REVERSIBLE CHOLESTASIS P0620
SULPAMETROXYPYHI D S SGPT INC V REVERSIBLE CHOLESTASIS P0620
SULFPIN!THOXYPYRID S THYMOL TURBIDITY INC V REVERSIBLE CHOLESTASIS HO 620
SOLFANETHOXYPYRID U URINALYSIS BILE INC V REVERSIBLE CROLESTASIS P0620
SULFANETHOXYPYRID U UPOBILINOGEN DEC V OCCURS WITH REVERSIBLE CHOLESTASIS P0620
SULFANILPIMI DE B HEINZ-BODY FORMATION POS V MAY OCCUR IN EARLY STAGES OF HEMOLYSIS P0104
SULFANILAMIDE B HENATOCPIT DEC V MAY CAUSE HEMOLYTIC ANEMIA P0079
SULFANILA NIDE B HPMOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA 110079
SULAN ILAMIDE B ,METHEMOGLOBIN INC V MAY CAUSE HENOLYTIC ANEMIA R0658
SULPANILA NIDE B RED CELL COUNT DEC V NAY CAUSE HEMOLYTIC ANEMIA RO079
SULFANILAMIDE C PROTEIN INC N REACTS AS IF PHENOL WITH FOLIN-CIOCALTEU METHOD Hi 026
SULFANILA MIDE S ALKALINE PHOSPHATASE INC V MAY CAUSE REVERSIBLE CHOLESTASIS RO596
SOLFANILAMI DE S BILIRUBIN INC V NAY CAUSE HENOLYSIS WITH G-6-PD DEFICIENCY P0079
SULFANILA MIDE S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P0079
SULFANILAMI DE S SGOT INC V MAY CAUSE REVERSIBLE CHOLESTASIS RO596
SULFAN ILA MIDE S SGPT INC V MAY CAUSE REVEPS IBLE CHOLESTA SIS HO 596
SULFANILA MIDE U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S RO436
SULPANILAMIDE U UROBILINOGEN INC N YIELDS GREENISH COLOR WITH EHRLICHS RO1143
SULFA PR ENAZ OLE S GLUCOSE DEC V REPORTED EFFECT P0620
SOL’APYRIDINE B HEMATOCRIT DEC V MAY CAUSE HENOLYTIC ANEMIA R0O79
SULFAPYRI DI NE B HEMOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P0079
SULFAPYRIDINE B METHENOGLOBIN INC V MAY CAUSE HEMOLYTIC ANEMIA R0658
SULFAPYRIDI NE B RED CELL COUNT DEC V MAY CAUSE HENOLYTIC ANEMIA 110079
SULFAPYPIDINE S ALKALINE PHOSPHATASE INC V MAY CAUSE REVERSIBLE CHOLESTASIS P0596
SULFAPYRIDINE S BILIRUBIN INC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
SULFAPYRI DINE S HPIPTOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P0079
SULFAPYRIDINE S SCOT INC V MAY CAUSE REVERSIBLE CHOLESTASIS P0596
SULFAPYRI DI NE S SGPT INC V MAY CUASE REVERSIBLE CHOLESTASIS P0596
SULFAPYH IDINE U UROBILINOGEN INC N YIELDS GREENISH COLOR WITH EHRLICHS 110143
SULFA RTRPOL B PLATELET COUNT INC V MECHANISM OF ACTION UNKNOWN 110315
SULFATES E G-6-PD DEC V SENSITIVE TO SULFATE ION AT CONC OF 5MM IN VITRO P0135
SULFATES S CALCIUM DEC N THEORETICAL INHIBITION OF EMISSION IN FLAME METHODS R0436
SULFATES S CALCIUM DEC V BRIEF HYPOCALCENIC EFFECT IF INFUSED I.V. P0620
SULFATES S POTASSIUM DEC V MAY BE EXCRETED COMBINED WITH SULFATE P0620
SULFATES S SODIUM DEC V MAY BE EXCRETED COMBINED WITH SULFATE R062O
SULFATES U CALCIUM DEC N INHIBIT EMISSION IN SOME FLAME METHODS P0436
SULFATES U CALCIUM INC V DUE TO DIURESIS AND CASO4 FORMATION P0026
SULFATES U POTASSIUM INC V INC EXCRETION COMBINES WITH SULFATE P0026
SULFATES U SODIUM INC V INC EXCRETION COMBINES WITH SULFATE P0026
SULFATHIAZOLE S SCOT INC N AT 1 MMOL/L AFFECTS SMA 12/60 METHOD HO 876
SULFATHI A ROLE U UPOBILINOGEN INC M YIELDS GREENISH COLOR WITH EHRLICHS P01 43
SULEHYDRYL COMPS S ALKALINE PHOSPHATASE DEC N INHIBIT ENZYME ACTIVITY IN LABORATORY METHODS P09 29
SULFI N?YHAZONE B PLATELET AGGREG DEC V REPORTED EFFECT RO326
SULFINPYPA ZONE B RED CELL COUNT DEC V PARE BLOOD DYSCRASIA R0O26
SULFI NPYRAZONE S URIC ACID DEC V URICOSURIC ACTION P04014
SULFINPYR AZONE U PAP CLEARANCE DEC V INHIBITS TUBULAR TRANSPORT P0026
SOLFI NPYPAZONE 0 PSP EXCRETION DEC V COMPETITION FOR EXCRETION P0287
SULFINP YR AZONE U URIC ACID INC V URICOSURIC ACTION P04014
SULFISOXAZOLE B EOSINOPRILS INC V ALLERGIC RESPONSE HO 542
SULFISOXAZOLE B HEMATOCRIT DEC V AGRANULOCYTOSIS/APLASTIC ANEMIA P075 1
SULFISOXAZOLE B HEMOGLOBIN DEC V AGRANULOCYTOSIS/APLASTIC ANEMIA 110751
SULFISOXAZOLE B NETHEMOGLOBIN INC V MAY CAUSE HEMOLYTIC ANEMIA P0790
SULFISOXAZOLE B PLATELET COUNT DEC V AGRANULOCYTOSIS/APLASTIC ANEMIA (AFTER DAYS) RO751
SULFI SOXAZOLE B RED CELL COUNT DEC V AGRANULOCYTOSIS/APLASTIC ANEMIA P075 1
SULFISOXAZOLE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS/APLASTIC ANEMIA P075 1
SULFI SOXAZOLE C PROTEIN INC N CAUSES TURBIDITY IF SULFOSALICYLIC ACID USED 110907
SULFISOXTt ROLE F UROBILINOCEN DEC V PALE STOOLS WITH REVERSIBLE CHOLESTASIS HO 542
SULFI SOXAZOLE P PROTHRONBIN TIME INC V OCCURS WITH FAILURE 0? EXCRETION OF BILE SALTS P02 70
SULFISOXAZOLE S ALKALINE PHOSPHATASE INC V MAY CAUSE CHOLESTASIS P0542

SULFISOXA ZO LE S BILIRUBIN DEC V DISPLACEMENT FROM ALBUMIN BINDING SITES R0907
SULFI SOXAZOLE S BILIRUBIN INC V MAY CAUSE CHOLESTATIC JAUNDICE OR HEMOLYSIS P05142
SULFISOXAZOLE S BSP RETENTION INC V MAY CAUSE CROLESTASIS R05L12
SULFISOXAZOLE S CALCIUM DEC N DEPRESSES FLUORESCENCE OF CALCEIN METHOD P0644
SULFISOXAZOLE S CEPHALIN FLOCCULATION INC V NAY CAUSE CHOLESTASIS HO 542
SULFISOXAZOLE S RAPTOGLOBIN DEC V MAY CAUSE HENOLYTIC ANEMIA 30542
SULFISOXAZOLE S LACTIC DEHYDROGENASE INC V MAY CAUSE HEMOLYTIC ANEMIA 90 542
SU LFIS OXA ZOLE S LIPASE INC V PARE EFFECT ON PANCREAS, SALIVARY GLANDS R0657
SULFISOXAZOLE S SCOT INC V MAY CAUSE CHOLESTATIC JAUNDICE RO542
SULFISOXAZOLE S SGPT INC V NAY CAUSE CHOLESTASIS P 0542
SULFI SOXAZOLE S THYMOL TURBIDITY INC V NAY CAUSE CHOLESTASIS H 05 42
SULFIS OXA ZOLE U DIAGNEX BLUE EXCRETION INC V DISPLACEMENT OF DIAGNEX BLUE FROM RESIN P100 1
SULFI SOXAZOLE U PROTEIN INC N CAUSES TURBIDITY IF SULPHOSALICYLIC ACID USED H 0907
SULFISOXAZOLE U URINALYSIS BILE INC V NAY CAUSE CHOLESTASIS P0542
SULFI SOXAZ OLE U URINALYSIS PROTEIN INC N MAY PRODUCE TURBIDITY WITH ACID METHODS P0143
SULFISOXA ZOLE U URINALYSIS PROTEIN Z N NO EFFECT ON ALBUSTIX HO 143
SULFIS OXAZOLE U UHOBILINOGEN DEC V WITH REVERSIBLE CHOLESTASIS 90542
SULFONAMIDES B EOSINOPHILS INC V HYPERSENSITIVITY RESPONSE Do U24
SULFONAMIDES B HEINZ-BODY FORMATION POS V OCCURS WITH MARKED HENOLYTIC ANEMIA P05 18
SULFONAMIDES B HEMATOCRIT DEC V MAY CAUSE HEINZ-BODY HEMOLYTIC ANEMIA P0736
SULFONAMIDES B HEMOGLOBIN DEC V AGRANULOCYTOSIS/9EMOLYTIC ANEMIA/SEN. DEP. (G-6-PD) P06 57
SULFONAMIDES B LE CELL PREP P05 V MAY PRODUCE LE-LIKE SYNDROME P0907
SULFONAMIDES B NETHEMOGLOBIN INC V AGRANULOCYTOSIS/APLASTIC OH HEMOLYTIC ANEMIA 90657
SULFONAMI DES B PLATELET COUNT DEC V AGRANULOCYTOSIS/APLASTIC ANEMIA P065 7
SULFONAMIDES B RED CELL COUNT DEC V NAY CAUSE HEINZ-BODY HENOLYTIC ANEMIA HO 6 20
SULFONA MI DES B HETICULOCYTES DEC V AGHANULOCYTOSIS WITH APLASTIC OR HEMOLYTIC ANEMIA P04 94
SULFONAMIDES B RETICULOCYTES INC V IN RESPONSE TO HEMOLYSIS OCCURS WITH RECOVERY HO 3814
SULFONA MI DES B WHITE CELL COUNT DEC V AGRANULOCYTOSIS/APLASTIC ANEMIA R0657
SULFONAMIDES B WHITE CELL COUNT INC V ASSOC WITH HENOLYSIS (ESP WITH LONG-ACTING DRUGS) P06 20
SULFONA NI DES C PROTEIN INC N REACTS AS PHENOL WITH FOLIN-CIOCALTEU REAGENT P09 07
SULFONAMIDES E REDUCED GLUTATHIONE DEC V OCCURS EARLY BEFORE OVERT REMOLYSIS P05 18
SULFONA NI DES F COPROPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P037 1
SULFONAMIDES F OCCULT BLOOD P05 V HENATEMESIS AND NELENA MAY OCCUR P06 57
SULFONPI NIDES F PROTOPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P0371
SULFONAMIDES F UROBILINOGEN DEC V PALE STOOLS WITH REVERSIBLE CHOLESTASIS HO 1377
SULFONAMIDES P ALPHA AMINO NITROGEN INC N REACTS WITH NAPHTHOQUINONE (METHOD OF FRAME) R0436
SULFONAMIDES P HEMOGLOBIN INC V MAY OCCUR WITH INTRAVASCULAR HEMOLYSIS P06 56
SULFONAMIDES P PROTHRONBIN TIME INC V POTENTIATE ACTION OF ADMINISTERED COUNPIRINS P0 545
SULFONANI DES S ALKALINE PHOSPHATASE INC V HYPERSENSITIVITY REACTION WITH CHOLESTASIS P03 45
SULFONAMIDES S BARBITURATE INC N NAY INTERFERE WITH UV ABSORPTION METHOD H079
SULFONAMIDES S BILIHUBIN DEC V DISPLACEMENT FROM ALBUMIN BINDING SITES POP 07
SULFONAMIDES S BILIRUBIN INC V HEPATIC/ CHOLESTATIC EFFECT, ALSO AFFECTS ALB BIND P0 1 10
SULFONAMIDES S BSP RETENTION INC V NAY CAUSE CHOLESTASIS P 07 36
SULFONAMIDES S CALCIUM DEC N DEPRESS FLUORESCENCE OF CALCFIN METHOD R0644
SULFONAMIDES S CEPHALIN FLOCCULATION INC V MAY CAUSE CHOLESTASIS RO736
SULFONAMIDES S CHOLESTEROL INC V CHOLESTATIC EFFECT R0L177
SULFONAMIDES S COOMBS TEST P05 V IMMUNOLOGICAL RESPONSE TO DRUG R0418
SULFONAMIDES S HAPTOGLOBIN DEC V NAY CAUSE HEMOLYTIC ANEMIA IF G-6-PD DEFICIENCY P00 26
SULFONAMIDES S I 131 UPTAKE DEC V EFFECT LASTS ABOUT 7 DAYS POLl 08
SULFONAMIDES S NPN INC V OCCASIONAL UREMIA WITH/WITHOUT CRYSTALLURIA H062O
SULFONAMIDES S PHI DEC V INHIBITS IODINATION OF TYROSINE IN TBG HO 004
SULFONAMIDES S SGOT INC V MAY CAUSE CHOLESTASIS P06 20
SULFONAMIDES S SGPT INC V NAY CAUSE CHOLESTASIS P0620
SULFONANI DES S THYNOL TURBIDITY INC V NAY CAUSE CHOLESTASIS H 0736
SULFONAMIDES S THYROXINE (T4) DEC V ACTS LIKE THIOUREA ON THYROID GLAND HO 112
SULFONA MI DES S UREA NITROGEN INC N REACTS LIKE UREA WITH DMABA & BERTHELOT REACTIONS RO907
SULFONAMIDES S UREA NITROGEN INC V RARE UREMIA MAY OCCUR WITH/WITHOUT CHYSTALLURIA P0 384
StILFONA MI DES S 5-NUCLEOTIDASE INC V MAY CAUSE CHOLESTASIS P04 92
SULFONAMIDES U ALKALINE PHOSPHATASE INC V DUE TO NEPHROTOXIC EFFECT OF DRUG R0758
SULFONA MI DES U ALPHA AMINO NITROGEN INC N REACTS WITH NAPHTHOQUINONE (METHOD OF FRAME) 9 04 36
S ULFO N A N IDES U ANINOLEVULINIC ACID INC V MAY PRECIPITATE ACUTE PORPHYRIA RO371
SULFONAMIDES U COPROPORPHYRIN INC V NAY PRECIPITATE ACUTE PORPHYRIA 90371
SULFONAMIDES U LEUCINE ANINOPEPTIDASE INC V FACILITATES PERMEATION OF ENZYME INTO TUBULES RO758
SULFONAMIDES U PAR CLEARANCE INC N REACT AS IF PAH WITH BRATTON-NARSHALL METHOD P0 779
SULFONANI DES U PORPHOBILINOGEN INC V MAY PRECIPITATE ACUTE PORPHYRIA HO 37 1
SULFONAMIDES U PORPHYHINS INC V NAY PRECIPITATE ACUTE PORPHYRIA HO 59 6
SULFONA MI DES U PROTEIN INC N REACTS AS PHENOL WITH FOLIN-CIOCALTEU REAGENT RO90
SULFONAMIDES U PROTEIN INC N NAY CAUSE FALSE POS WITH SULFOSALICYLIC ACID P0417
SULFONAMIDES U PROTEIN INC V MAY CAUSE NEPHPOTOXICITY P0417
SULFONAMIDES U PSP EXCRETION DEC V REDUCES RENAL EXCRETION OF PSP R1001
SULFONA NI DES U SUGAR INC N AFFECTS BENEDICT’S AND CLINITEST HO LI 17
SULFONAMIDES U URIC ACID INC V URICOSURIC EFFECT R0355
SULFONA NI DES U URINALYSIS BILE INC V NAY CAUSE CHOLESTASIS P06 20
SULFONAMIDES U URINALYSIS CASTS INC V HEMOGLOBIN CASTS NAY CAUSE RENAL FAILURE HO 3 84
SULFONA MI DES U URINALYSIS COLOR INC M BROWN COLOR WITH SOME SULFONAMIDES P0299
SULFONAMIDES U URINALYSIS CRYSTALS INC V PRESENCE OF DRUG P0 6 20
SULFONAMIDES U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG (DUE TO HEMOLYSIS) HO 2 99
SULFONAMIDES U URINALYSIS PROTEIN INC V MAY CAUSE NEPHROTOXICITY HO 620
SU LFONA NIDE S U URINALYSIS HBC/HPF INC V NAY CAUSE ACTUAL BLEEDING 90299
SULFONAMI DES U URINALYSIS TURBIDITY INC V ESP IF GIVEN WITH METHENAMINE-DUE TO ORATES 90467
SULFONAMIDES U UROBILINOGEN DEC V CHOLESTATIC EFFECT HO 477
SOLFONANI DES U UROBILINOGEN INC N REACT WITH EHRLICH’S REAGENT ROLl 36
SULFONAMIDES U UROBILINOGEN INC V HEMOLYTIC ANEMIA WITH G-6-PD DEFICIENCY HO 3 84
SO LFONEMETH ANE B COPPOPOPPHYRIN INC V MAY PROVOKE ATTACK OF PORPHYRIA RO371
SULFONEMETHANE B METHENOGLOBIN INC V NAY CAUSE HEMOLYTIC ANEMIA P0658
SO LF ONE N ETH A NE B PROTOPORPHYRIN INC V MAY PROVOKE ATTACK OF PORPHYRIA 30371
SULFONEMETHANE F COPPOPORPHYRIN INC V NAY PROVOKE ATTACK OF PORPHYRIA P0371
SULFONENETH A NE P PROTOPORPHYRIN INC V MAY PROVOKE ATTACK OF PORPHYRIA P0371
SO LFO N EM PT H ANE U ANINOLEVULINIC ACID INC V NAY PROVOKE ATTACK OF PORPHYRIA HO 3 71
SU L P0 NE NETHA NE U COPROPORPHYRIN INC V MAY PROVOKE ATTACK OF PORPHYRIA P0371

SUL FONEP! 9TRAN E U PORPHOBILINOGEN INC V NAY PROVOKE ATTACK OF PORPHYRIA P0371
SULFONEMEIHA NE U POPPEYRINS INC V STIMULATES FORMATION OF ALA-SYNTHETASE PC 384
SO L F C N L N T H A NE U UFINALYSIS COLOR INC V RED-BROWN (MAY PROVOKE PORPHYRIA) 110620
SULFONENETHA NE U OROPORPHYPIN INC V MAY PROVOKE ATTACK OF PORPHYRIA H 037 1
SCLF3LS B HEINZ-BODY FORMATION P05 V REPORTED EFFECT IN FIRST FEW DAYS R0384
SOLE ONES B HEMATOCRIT DEC V MAY CAUSE HEMOLYSIS P0026
S U LE ON? S B HEMOGLOBIN DEC V MAY CAUSE HEMOLYSIS R0026
S UL F 0 NES a METHEMOGLOBIN INC V HEMOLYSIS NAY OCCUR WITH G-6-PD DEFICIENCY 110026
SOLE ONLS B BED CELL COUNT DEC V HEMOLYSIS MAY OCCUR WITH G-6-PD DEFICIENCY P0620
SULFONES B RETICULOCYTES INC V OCCURS DURING RECOVERY PHASE P0518
SUIFONES B WHITE CELL COUNT DEC V AGEANULOCYTOSIS/LEUKOPENIA 110026
SOLE OWLS H RFDUCED GLOTATHIONE DEC V FALLS SHARPLY PRECEDING HEMOLYSIS R0518
SULFCNES P HEMOGLOBIN INC V NAY OCCUR WITH HENOLYSIS R0656
3IJLFONLS S ALKALINE PHOSPHATASE INC V MAY AFFECT LIVER FUNCTION R0620
S Ut F ONES S BILIPUBIN INC V MAY CAUSE HEMOL!SIS WITH G-6-PD DEFICIENCY 110079
SULFONS S 551 RETENTION INC V MAY AFFECT LIVER FUNCTION P0620
SULFONES S CEPHALIN FLOCCULATION INC V MAY AFFECT LIVER FUNCTION R0620
SULFONrS S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA R0079
SOt FONTS S SCOT INC V MAY AFFECT LIVER FUNCTION P 0620
S U LF ONES S SGPT INC V MAY AFFECT LIVER FUNCTION P0620
SU LF 0 N‘ S S IHYMOL TURBIDITY INC V PlAY AFFECT LIVER FUNCTION P0620
S UL F ONES U PROTEIN INC V NAY HAVE NEPUROTOXIC EFFECT P0299
S ULFONIS U URINALYSIS BILE INC V MAY AFFECT LIVER FUNCTION R0620
SULFON S 0 URINALYSIS HEMOGLOBIN INC V NAY HAVE NEPHROTOXIC EFFECT PC 299
SULFONE S U URINALYSIS PROTEIN INC V MAY HAVE NEPHROTOXIC EFFECT RC299
S UL F ONES U URINALYSIS BBC/HPF INC V NAY HAVE NEPHPOTOXIC EFFECT P0620
SULFONFTHYLMETHANE B METHEMOGLOBIN INC V MAY CAUSE HEMOLYTIC ANEMIA R0658
SULFO}LETHYLMETHANE F COPROPOHPHYRIN INC V NAY PRECIPITATE ACUTE PORPHYRIA R0371
SULFONETHYLMETHA NE F PROTOPORPHYHIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P0371
SOLFONETHYL METHANE U AMINOLEVULINIC ACID INC V MAY PRECIPITATE ACUTE PORPHYRIA R0371
S OLFONETHYLMETHANE U COPROPORPHYRIN INC V NAY PRECIPITATE ACUTE PORPHYRIA P037 1
SULFON1THYLMETHA NE U PORPHOBILINOGEN INC V MAY PRECIPITATE ACUTE PORPHYRIA 110371
SULFONFTHYLMETHANE U URINALYSIS COLOR INC V RED (MAY PROVOKE PORPHYRIA) P0620
SULFONYLUREA S B ACETALDEHYDE INC V MECHANISM NOT YET ELUCIDATED 110384
S ULF ONYL U Pr AS B PLATELET COUNT DEC V PANCYTOPENIA P0620
SULF ONYLOREAS B RED CELL COUNT DEC V PANCYTOPENIA 110620
SULFONYLUPEA S B WHITE CELL COUNT DEC V PANCYTOPENIA/AGRANULOCYTOSIS P0620
SULFONYI UREA S S BILIRUBIN INC V IN SOME CASES PROB ATTRIBUTABLE TO DRUG P0657
SULEONYLUPEAS S GLUCOSE DEC V MAY CAUSE SEVERE HYPOGLYCEMIA R0657
SULFOWYLUREAS S SODIUM DEC V POTENTIATES VASOPRESSIN, CAUSES WATER RETENTION 110327
S UL FOX ONE B HEMATOCHIT DEC V MAY CAUSE HEMOLYTIC ANEMIA P0079
SULFOXONE B HEMOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P0079
SOLFOXONE B METHENOGLOBIN INC V MAY CAUSE HENOLYSIS IN G-6-PD DEFICIENCY 110926
SULFOXCN? B PEE CELL COUNT DEC V NAY CAUSE HEMOLYTIC ANEMIA P0079
S ULP OX ONE S BILIPUBIN INC V MAY CAUSE HENOLYSIS IN G-6-PD DEFICIENCY 110079
SULF OXCNI S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA 110079
SULTRIAME B WHITE CELL COUNT DEC V LEUKOPENIA/ALSO INCS HALF LIFE 0? DIPHENYLNYDANTOIN RC384
SULTHIAME F OCCULT BLOOD P05 V ONE CASE REPORTED WITH POISONING R0657
SULTHIAME U URINALYSIS CRYSTALS INC V IN POISONING IDENTIFIED AS PURE DRUG P0657
SUNTAN OIL S PHI INC N MANY PREPARATIONS CONTAIN IODINE P0620
SURFININ B HEMATOCRIT DEC V HEMOLYTIC ANEMIA REPORTED 110026
SUFANIN B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA REPORTED P0026
SURA MEN B HD CELL COUNT DEC V HEMOLYTIC ANEMIA REPORTED P 0026
SURA MIN B WHITE CELL COUNT DEC V AGRANULOCYTOSIS REPORTED R0026
SUPA NIN J PROTEIN INC V USUAL EFFECT DURING TREAT OF ACUTE STAGE P 0026
SUHAMIN U URINALYSIS CASTS INC V CYLINDRURIA REPORTED P0026
S U? A NI N U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG 110355
SURANIN U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT P0299
SUPAMIN U URINALYSIS RBC/HPF INC V MAY CAUSE ACTUAL BLEEDING 110299
SWEET POTATOES S ICTEPIC INDEX INC N DUE TO COLOR R0356
SYROSINGOPINE 0 GASTRIC JUICE HCL INC V EXCESSIVE AMOUNTS NAY BE RELEASED RC596
SYPOSINGOPINE U CATECHOLAMINES INC V RELEASE OF STORED NOREPINEPHRINE 110596
SYROSINGOPINE U HNPG INC V RELEASE OF STORED NOREPINEPHRINE R0596
SYPOSINGOPIN E U YNA INC V RELEASE OF STORED NOREPINEPHRINE RC596
TAP TRA?S S ACID tHOSPHATASE TOTAL DEC N STRONG INHIBITORS OF PROSTATIC ENZYME R0929
TAPTPATF S S UREA NITROGEN INC V IF ABSORBED MAT CAUSE RENAL DAMAGE RC384
TAPTRATF S U PROTEIN INC V IF ABSORBED MAY CAUSE RENAL DAMAGE P0384
TAPT?ATE S U URINALYSIS PROTEIN INC V IF ABSORBED MAY CAUSE RENAL DAMAGE 110384
TEA P CATECHOLAMINES INC N CONC SOLUTIONS CAUSE STRIKING FLUORESCENCE PC 188
TEA 0 VNA INC N METABOLITES INTERFERE WITH ANALYSIS P0909
TESTOLACTONE S CALCIUM INC V PROB EFFECT DURING REMISSION OF NETASTASES 110026
TEST OLACT ONE U 17 KETOSTEROIDS INC V REPORTED EFFECT R0417
T ES TO STE 30 N F B VOLUME DEC V PRODUCES POLYCYTHENIC-LIKE STATE P0657
I ES T OS T E RON F P FIRRINOGEN DEC V METABOLIC EFFECT P0072
TE STOSTE RONZ S ALKALINE PHOSPHATASE INC V MAY CAUSE CHOLESTASIS P0620
TESTOSTERONE S BILIRUBIN INC V MAY CAUSE CHOLESTATIC AND CYTOTOXIC LIVER DAMAGE R0079
I ES T OS T r H ONE S BSP RETENTION INC V MAY CAUSE CHOLESTASIS 110620
TESTOSTERONE S CALCIUM INC V MAY OCCUR WITH TREATMENT OF BREAST CANCER R0657
TE STOSTE HONE S COPHALIN FLOCCULATION INC V MAY CAUSE CHOLESTASIS 110620
TESTOSTERONE S CHCLESTEHOL INC V HOLESTATIC EFFECT 110417
T ES T OS T FR 0 NE S CHOLINESTEBASE DEC V METABOLIC EFFECT P0072
T ESTOSTERONE. S COPTICOSTFP BIND GLOB DEC V METABOLIC EFFECT 110072
TES T OS I F HO !JF S UANASE INC V MAY CAUSE CHOLESTATIC AND CYTOTOXIC LIVER DAMAGE 110079
TLSTOSTHONE 5 HAPTDGLOBIN INC V METABOLIC EFFECT(IF AQUEOUS SOLN I.N.) P0072
TESTOSTERONF S ICC INC V MAY CAUSE CHOLESTATIC AND CYTOTOXIC LIVER DAMAGE 110079
TESTOSTERONE S OCT INC V NAY CAUSE CHOLESTATIC AND CYTOTOXIC LIVER DAMAGE 110079
TESTOST ER ONE S PHI DEC V DECREASED TEG SYNTHESIS, AND AFFECTS BINDING P1001
TESTOSTE HONE S PHI Z V NO EFFECT SHORT TERM ADMINISTRATION IN MEN R025,
TESTOSTERONE S SGOT INC V MAY CAUSE CHOLESTATIC AND CYTOTOXIC LIVER DAMAGE 110079
TESTOSTERONE S SGPT INC V NAY CAUSE CHOLESTATIC AND CYTOTOXIC LIVER DAMAGE R0079

TESTOST EHON P S SIALIC ACID INC V METABOLIC EFFECT (IF AQUEOUS SOLN I.!.) P0072
TESTOSTERONE S TBG DEC V DIRECT EFFECT OF DRUG P0004
TESTOSTERONE S THYNOL TURBIDITY INC V MAY CAUSE CHOLESTASIS P06 20
TESTOSTERONE S THANSFERRIN DEC V METABOLIC EFFECT P00 72
TESTOSTERONE U ESTROGENS INC V PROBABLY DUE TO CONVERSION TO ESTROGEN H 098 3
TESTOSTERONE U URINALYSIS BILE INC V NAY CAUSE CHOLESTASIS P06 20
TESTOS T ERONE U UROBILINOGEN DEC V MAY CAUSE CHOLESTASIS R0620
TESTOSTERONE U 17 OR CORTICOSTEROIDS INC N COMMON KETO GROUP INVOLVED IN COLOR REACTION HO 2 33
TETRACAINE C PROTEIN INC N INTERFERES WITH FOLIN-CIOCALTEU REAGENT P03 55
TETRACHL OROTHYRON S THYROXINE (T4) DEC V DISPLACES THYROXINE FROM TBG HO 907
TETRACOSACT PIN P CORTICOSTEROIDS INC V THERAPEUTIC INTENT HAS PROLONGED ACTION R0517
TETRACYCLINE B COAGULATION TIME INC V DELAYED COAGULATION REPORTED EFFECT P0620
TETRACYCLINE B EOSINOPHILS INC V ALLERGIC RESPONSE RO142LI
TETRACYCLINE B HENATOCRIT DEC V NAY CAUSE HENOLYTIC ANEMIA 90620
TETRACYCLINE B HEMOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P06 20
TETRACYCLI NE B LE CELL PREP P05 V NAY PRODUCE LE-LIKE SYNDROME P09 07
TETRACYCLINE B NEUTROPHILS DEC V NEUTROPENIA MAY OCCUR OCCASIONALLY R0467
TETRACYCLINE B PH DEC V NAY CAUSE ACIDOSIS WITH RENAL IMPAIRMENT P0596
TETRACYCLINE B PLATELET COUNT DEC V THRONBOCYTOPENIA/PANCYTOPENIA P06 20
TETRACYCLINE B RED CELL COUNT DEC V MAY CAUSE HEMOLYTIC ANEMIA H 06 20
TETRACYCLINE B THRONBOPLASTIN GEN DEC V IMPAIRED RATE OF REGENERATION OBSERVED P0384
TETRACYCLINE B WHITE CELL COUNT DEC V LEUKOPENIA (AMA -BLOOD DYSCRASIAS) HO 658
TETRACYCLINE B WHITE CELL COUNT INC V LEUKOCYTOSIS WITH ATYPICAL LYMPHOCYTES P03 84
TETRACYCLINE C PROTEIN INC N REACTS AS IF PHENOL WITH FOLIN-CIOCALTEU PROCEDURE P 10 26
TETRACYCLINE F COLOR INC N RED IF GLUCOSANINE POTENTIATED SYRUP FORM P06 20
TETRACYCLINE F OCCULT BLOOD P05 V MAY OCCUR WITH HEMATENESIS AND MELENA HO 282
TETRACYCLINE F UROBILINOGEN DEC V REDUCES FLORA IN G.I. TRACT P0417
TETRACYCLINE P AMMONIA INC V IF GIVEN I.V. IN LARGE DOSES H0417
TETRACYCLINE P CATECHOLANINES INC N INTERFERES WITH FLUORONETRIC TECHNIQUES P0042
TETRACYCLINE P PROTRROMBIN TIME INC V ASSOC WITH CHOLESTASIS, AND REDUCED ACTIVITY HO 2 82
TETRACYCLINE S ALKALINE PHOSPHATASE INC V NAY OCCUR WITH CHOLESTASIS P0417
TETRACYCLINE S ANYLASE INC V TOXIC EFFECT ESP IN PREGNANT WOMEN P014 17
TETRACYCLINE S BILIPUBIN INC V HEPATIC INJURY NAY OCCUR ESP IF GIVEN I.V. 110
TETRACYCLINE S BSP RETENTION INC V CHOLESTATIC ESPECIALLY IN PREGNANT WOMEN P0736
TETRACYCLINE S CALCIUM DEC V OBSERVED IN PREGNANT WOMEN HO 657
TETRACYCLINE S CEPRALIN FLOCCULATION INC V NAY CAUSE CHOLESTASIS P0620
TETRACYCL INE S CHOLESTEROL DEC V HEPATOTOXICITY MAY OCCUR P07 36
TETRACYCLINE S COOMBS TEST 205 V MECHANISM OBSCURE P04 18
TETRACYCLINE S CO2 CONTENT DEC V NAY CAUSE ACIDOSIS WITH NEPHEOTOXICITY P00 26
TETRACYCLINE S CREATININE INC V NEPHPOTOXICITY NAY CAUSE FANCONI LIKE SYNDROME HO 736
TETH ACYCLINE S DIRECT BILIRUBIN INC V CHOLESTATIC EFFECT HO 282
TETRACYCLINE S FOLATE DEC N INHIBITS GROWTH OF L CASPI P09 07
TETRACYCLINE S NPN INC V DUE TO NEPHROTOXICITY OH ANTIANABOLIC EFFECT 90620
T ETH A C Y C LINE S PHOSPHATE DEC V NAY OCCUR WITH FANCONI SYNDROME P00 26
TETRACYCLINE S PHOSPHATE INC V MAY OCCUR WITH NEPHPOTOXICITY P06 20
TETRACYCLINE S POTASSIUM DEC V FANCONI LIKE SYNDROME MAY OCCUR WITH DEGRADED P0417
TETRACYCLINE S POTASSIUM INC V OCCURS WITH AZOTEMIA P0026
TETRACYCL INE S SCOT INC V HEPATOTOXIC ESPECIALLY IN PREGNANT WOMEN P07 36
TETRACYCLINE S SGPT INC V HEPATOTOXIC EXPECIALLY IN PREGNANT WOMEN P0736
TETRACYCLINE S SODIUM INC V MAY CAUSE HYPERNATRENIA WITH RENAL IMPAIRMENT HO 596
TETRACYCLINE S TRYMOL TURBIDITY INC V MAY CAUSE CHOLESTASIS H06 20
TETRACYCLINE S UREA NITROGEN INC V ANTI-ANABOLIC ACTION, AMINO ACIDS DEGRADED TO UREA HO 153
TETRACYCLINE U AMINO ACIDS INC V NEPHROTOXIC EFFECT WITH DEGRADED TETRACYCLINE P03 55
TETRACYCLINE U HENCE-JONES PROTEIN INC V NEPHROTOXIC EFFECT WITH DEGRADED TETRACYCLINE HO 299
TETRACYCLINE U GLUCOSE DEC N PREVENTS OXIDATION OF CHROMAGEN GLU OX METHODS P06 54
TETR ACYCL INE 0 GLUCOSE INC V DEGRADED NAY CAUSE FANCONI LIKE SYNDROME P07 36
TETRACYCLINE U HISTIDINE INC V UNEXPLAINED MECHANISM 903814
TETRACYCLINE U NITROGEN INC V WITH IMPAIRMENT OF PROTEIN SYNTHESIS HO 596
TETRACYCLINE U NITROGEN INC V DUE TO ANTIANABOLIC EFFECT BOO 26
TETRACYCLINE U PHOSPHATE INC V DEGRADED MATERIAL MAY CAUSE FANCONI SYNDROME P06 57
TETRACYCLINE U PORPHYRINS INC N INTERFERING FLUORESCENCE R0356
TETRACYCLINE U PROTEIN INC V NEPHROTOXIC EFFECT WITH DEGRADED TETRACYCLINE R0355
TETRACYCLINE U SODIUM INC V NATURIESIS AND DIURESIS EFFECTS OF DRUG HO 153
TETRACYCLINE U SUGAR INC N FALSE POSITIVE COPPER REDUCTION PROCEDURE P09 07
TETRAC YCL INE U THREONINE INC V UNEXPLAINED MECHANISM HO 384
TETRACYCLI NE U TRYPTOPHAN INC V UNEXPLAINED MECHANISM 90384
TETR ACYCL INE U URINALYSIS GLUCOSE DEC N FALSE NEC. DIPSTICK RESULTS IF BUFF. WITH ASCORBIC P03 18
TETRACYCLINE U URINALYSIS GLUCOSE INC V DEGRADED MATERIAL MAY CAUSE FANCONI SYNDROME P06 57
TETRACYCLINE U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT WITH DEGRADED TETRACYCLINE HO 355
TETRACYCLINE U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S AND CLINITEST P0417
TETRACYCLINE U UROBILINOGEN DEC V REDUCES FLORA IN G.I. TRACT P0417
TETRACYCL INE U VOLUME INC V NAY HAVE DIURETIC OR NEPHROTOXIC ACTION P0153
TETPAIODOFLUOHES CE S PHI INC V RED DYE USED TO COLOR MANY PHARMACEUTICALS P0004
TETRA IODOFLUORESCE U UROBILIN INC N PINK COLOR WITH MAUVE FLUORESCENCE 901436
TETRAI ODOPHTHAL PIN S BSP RETENTION INC V COMPETITIVE UPTAKE AND EXCRETION OF DYE POLl 81
TETHAIODOPHT HALEIN S PRECIPITABLE IODINE INC N IODINE CONTAMINATION P03 55
TETRALIN U URINALYSIS COLOR INC N GREENISH BLUE P0620
TETPIDA Z-B S PBI INC N IODINE CONTAMINATION P03 55
THALLIUM F OCCULT BLOOD P05 V DUE TO INGESTION OF TOXIC DOSE P0 36 8
THALLIUM S SGPT INC V DUE TO HEPATIC NECROSIS HO 368
THALLIUM U URINALYSIS CASTS INC V DAMAGE TO RENAL TUBULAR EPITHELIUM P0368
THALLIUM U URINALYSIS CELLS INC V DAMAGE TO RENAL TUBULAR EPITHELIUM HO 368
THALLIUM U URINALYS]S PROTEIN INC V DAMAGE TO RENAL TUBULAR EPITHELIUN P03 68
THENAL IDINE B WHITE CELL COUNT DEC V LEUKOPENIA (AMA-BLOOD DYSCRASIAS) P0658
THEOPHYLLINE F OCCULT BLOOD P05 V IN LARGE DOSES NAY CAUSE GASTRIC HEMORRHAGE HO 1467
TH EOPHYLLINE S BARBITURATE INC N IDENTICAL ULTRAVIOLET SPECTRA P09 36
THEOPHYLLINE S BILIRUBIW INC M CAUSES DEPRESSION OF COLOR FORMATION P0620
TH EOPR YLLI NE S URIC ACID INC N REDUCTION OF PHOSPHOTUNGSTATE BY METABOLITES P0596
THEOPHYLLINE U CATECHOLANINES INC V NORMAL RESPONSE EVEN WHEN GIVEN ORALLY RO059
THEOPHYLLINE U URIC ACID INC N REDUCTION OF PHOSPHOTUNGSTATE BY METABOLITES 90182

THEOPHYLLINE U URINALYSIS PROTEIN INC V WHEN HIGH DOSES SODIUM GLYCINATE SALT GIVEN P0620
THIABENDAZOLE B PLATELET COUNT DEC V THRONBOCYTOPENIA HO 647
THIABENDAZOLE B WHITE CELL COUNT DEC V AGRA NO LOCYTOSIS/LEUKOPENIA R0647
THIABENDAZOLE F UPOBILINOGEN DEC V PALE STOOLS, CHOLESTATIC EFFECT HO 6147
THIABENDAZOLE S ALDOLASE INC V PPOB OF MUSCLE ORIGIN ALTHOUGH TAKEN ORALLY P06 57
THIABENDAZOLE S ALKALINE PHOSPRATASE INC V PAR! CHOLE STASIS P0149 2
EHIABENDAZOLE S BILIPUBIN INC V RARE CHOLESTASIS P0647
THIABENDAZOLE S BSP RETENTION INC V HARE CHOLESTASIS HO 647
THIABENDAZOLE S CEPHALIN FLOCCULATION INC V HARE CHOLESTASIS AND PARENCHYMAL LIVER DAMAGE 90647
TRIABENDAZOLE S CHOLESTEROL INC V CHOLESTATIC EFFECT P0614 7
THIABENDAZOLE S GLUCOSE DEC V ASYMPTOMATIC LOWERING OBSERVED 900 26
THIABENDAZOLE S GLUCOSE INC V PARE CASE OF HYPERGLYCEMIA REPORTED P01417
THIABENDAZOLE S SCOT INC V RAPE CHOLESTASIS AND PARENCHYNAL LIVER DAMAGE P0647
THIABENDAZOLE S SGPT INC V RAPE CHOLESTASIS P0647
THIABENDAZOLE S THYMOL TURBIDITY INC V RARE CHOLESTASIS HO 6147
TRIABENDAZOLE S 5-NUCLEOTIDASE INC V RARE CHOLESTASIS P04 92
THIABENDAZOLE U MYOGLOBIN Z V NOT OBSERVED ALTHOUGH SERUM ALDOLASE INC HO 657
THIABENDAZOLE U ODOR INC N ODOR SIMILAR TO THAT AFTER INGEST OF ASPAPAGINE P0647
THIABFNDAZOLE U PROTEIN INC V NAY CAUSE NEPHROXICITY P014 17
THIABENDAZOLE U URINALYSIS CRYSTALS INC N LOW SOLUBILITY OF DRUG, TSP. AT NEUTRAL PH P0647
THIABENDAZOL! U URINALYSIS PROTEIN INC V MAY CAUSE NEPHROTOXICITY RO1417
THIABENDAZOLE U OROBILINOGEN DEC V CHOLESTATIC EFFECT P06 147
THIACETAZONE B RED CELL COUNT DEC V RARE STEVENS-JOHNSON SYNDROME INDUCED P0657
THIACETAZONE B WHITE CELL COUNT DEC V DRUG RELATED ACRANULOCYTOSIS (PARE) HO 6 57
THIACETAZON! F UROBILINOGEN DEC V PALE STOOLS, OCCURS WITH CHOLESTASIS P0079
THIACETAZONE S ALKALINE PHOSPHATASE INC V NAY CAUSE CHOLESTATIC (HEPATOCANALICULAP) JAUNDICE HO 0 79
THIACETAZONE S BILIRUBIN INC V NAY CAUSE CHOLESTATIC(HEPATOCANALICULAR) JAUNDICE P0079
THIACETAZONE S 352 RETENTION INC V MAY CAUSE CHOLESTA 515 P0079
THIACETAZONE S CEPHALIN FLOCCULATION INC V NAY CAUSE CHOLESTA SIS P00 79
THIACETAZONE S CHOLESTEROL INC V MAY CAUSE CHOLESTATIC (HEPATOCANALICULAR) JAUNDICE H0O79
THIACETAZONF S SCOT INC V NAY CAUSE CHOLESTATIC (HEPATOCANALICUL AR) JAUNDICE P0079
THIACETAZONE S SGPT INC V MAY CAUSE CHOLESTATIC (HEPATOCANALICULAP) JAUNDICE P0079
THIAETAZONE S THYMOL TURBIDITY INC V MAY CAUSE CHOLESTA SI S P0079
THIACETAZONE U URINALYSIS BILE INC V NAY CAUSE CHOLE STASIS P0079
THIACETAZONE U UHOBILINOGEN DEC V MAY CAUSE CHOLESTASI S P0079
THIAMAZOLE B WHITE CELL COUNT DEC V RARE AGHANULOCYTOSIS OR PANCYTOPENIA P0657
THIANAZOLE S ALKALINE PHOSPHATASE INC V MAY AFFECT LIVER FUNCTION (CHOLESTASIS) HO 6 20
THIAMAZOLE S BILIRUBIN INC V MAY AFFECT LIVER FUNCTION (CHOLESTASIS) P06 20
THIAMAZOLE S HSP RETENTION INC V MAY AFFECT LIVER FUNCTION (CHOLESTASIS) HO 620
THIANAZOLE S CEPHALIN FLOCCULATION INC V NAY AFFECT LIVER FUNCTION P0620
THIANAZOLE S I 131 UPTAKE Z V NO EFFECT ON UPTAKE BY THYROID HO 596
THIAMAZOLE S PBI DEC V ANTITHYROID ACTION OF DRUG 90596
THIAMAZOLE S SCOT INC V MAY AFFECT LIVER FUNCTION (CHOLESTASIS) P06 20
THIAMAZOLE S SGPT INC V NAY AFFECT LIVER FUNCTION (CHOLESTASIS) HO 6 20
THIAMAZOLE S THYMOL TURBIDITY INC V MAY AFFECT LIVER FUNCTION P06 20
THIAMAZOLE U URINALYSIS BILE INC V MAY AFFECT LIVER FUNCTION P0620
THIAMYL SODIUM T PROTEIN INC N REACTS WITH FOLIN-CIOCALTRU OF LOWRY METHOD P02 13
THIAZIDES B PLATELET COUNT DEC V REPORTED TO CAUSE THPONBOCYTOPENIA P0723
THIAZIDES B RED CELL COUNT DEC V RARE HYPERSENSITIVE DEPRESSION OF BONE MARROW P06 20
THIAZIDES B WHITE CELL COUNT DEC V REPORTED TO CAUSE AGRANULOCYTOPENIA P07 23
THIAZIDES F UROBILINOGFN DEC V MAY CAUSE CHOLESTASIS WITH PALE STOOLS HO 1477
THIAZIDES 0 HISTAMINE TEST DEC V FALSE NEG. DUE TO HYPOTENSIVE EFFECT OF DRUG R0417
THIAZIDES 0 PHENTOLAMINE TEST DEC V FALSE NEG. DUE TO HYPOTENSIVE EFFECT OF DRUG ROLl 17
THIAZIDES 0 TYRANINE TEST DEC V MAY ATTENUATE RESPONSE TO TYRANINE HO 303
THIAZIDES P AMMONIA INC V ASSOC WITH K DEPLETION AND ALKALOSIS P0356
THIAZIDES P PROTHPONBIN TIME INC V ASSOC WITH FAILURE OF EXCRETION OF BILE SALTS HO 477
THIAZIDES P VOLUME DEC V DUE TO DIURETIC ACTION P0384
THIAZIDES S ALKALINE PHOSPHATASE INC V CHOLESTATIC HEPATITIS REPORTED HO 3814
THIAZIDES S ANYLASE INC V MAY INCREASE UP TO 200% IN A WEEK P 0223
THIAZIDES S BILIHUBIN INC V CHOLESTATIC HEPATITIS REPORTED TO OCCUR P03814
THIAZIDES S 952 RETENTION INC V REDUCED PLASMA VOLUME AND HEPATIC BLOOD FLOW P04 17
THIAZIDES S CALCIUM INC V MAY INCREASE UP TO 0.25 MEQ/L RO723
THIAZIDES S CEPHALIN FLOCCULATION INC V NAY CAUSE CHOLESTASIS P0620
THEAZIDES S CHLORIDE DEC V DIURETIC ACTION (IMPAIRED TUBULAR REABSORPTION) P0620
THIAZIDES S CHOLESTEROL INC V INFREQUENT CHOLESTATIC EFFECT 90 1477
THIAZIDES S C02 CONTENT INC V OVER 60% HAVE VALUE OVER 3ONEQ/L IN LONG TERM P0089
THIAZIDES S CREATININE INC V NEPHROTOXIC EFFECT WITH LARGE DOSES P05 96
THIAZIDES S GLUCOSE INC V DECREASED GLUCOSE TOLERANCE P002 1
THIAZIDES S GLUCOSE TOLERANCE DEC V DIABETOGENIC-LIKE ACTION OF DRUG HO 723
THIAZIDES S MAGNESIUM DEC V CONSEQUENCE OF DIURESIS R0482
THIAZIDES S P91 DEC V INC EXCRETION WITH PROLONGED THERAPY NAY OCCUR P03 84
THIAZIDES S PHI Z V REPORTED TO HAVE NO EFFECT RO255
THIAZIDES S POTASSIUM DEC V CONSEQUENCE OF DIURESIS RO3814
THIAZIDES S SCOT INC V NAY CAUSE CHOLESTASIS P06 20
THIAZIDES S SGPT INC V MAY CAUSE CHOLESTASIS P06 20
THIAZIDES S SODIUM DEC V DIURETIC ACTION WITH SODIUM DEPLETION P0021
THIAZIDES S THYMOL TURBIDITY INC V MAY CAUSE CHOLESTASIS P06 20
THIAZIDES S T3 UPTAKE DEC V SLIGHT EFFECT OBSERVED ONLY P064 2
THIAZIDES S UREA NITROGEN INC V NEPHROTOXIC EFFECT IN LARGE DOSES HO 299
THIAZIDES S URIC ACID INC V DECREASED RENAL EXCRETION 90355
THIAZIDES S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS HO 492
THIAZIDES U BROMIDE INC V IN CASES OF BROMIDE INTOXICATION HO 384
THIAZIDES U CALCIUM DEC V BY OP TO 50% (APPEAR TO HAVE EXTRA-RENAL EFFECT) P0723
THIAZIDES U CHLORIDE INC V DIURETIC ACTION P03 84
THIAZIDES U CITRATE DEC V BY UP TO 30% P07 23
THIAZIDES 0 COPTISOL DEC V ? CHANGED SECRETION OH RENAL HANDLING P02 96
THIAZIDES U CREATINE 04 V CLEARANCE TESTS DECREASED BY 10/20% P06 56
THIAZIDES U CREATININE CLEARANCE DEC V MAY CAUSE DECREASE BY UP TO 20% P0656
THIAZIDES U CREATININE DEC V CLEARANCE TESTS DECREASED BY 10/20% H 0656
THIAZIDES U GFR DEC V ESPECIALLY IF ADNINSTEPED I.V. P03 84

THIAZIDES U GLUCOSE INC V NAY OCCUR IN PPEDIABETICS ESPECIALLY R011414
THIAZIDES U MAGNESIUM INC V INCREASE OF 33% REPORTED P0882
THIAZIDES U POTASSIUM INC V DIURETIC ACTION R038L&
THIAZIDES U PSP EXCRETION DEC V COMPETITION FOR EXCRETION BY TUBULES R0287
THIAZIDES U SODIUM INC V DIURETIC ACTION P0384
THIAZIDES U SUGAR INC N INTERFERES WITH BENEDICT’S REAGENT P0299
THIAZIDES U URIC ACID CLEARANCE DEC V DECREASED PENAL CLEARANCE R0657
THIAZIDES U UHIC ACID DEC V DECREASED RENAL EXCPFTION(18% IN LONG TERM) 90089
TRIAZIDES U URINALYSIS GLUCOSE INC V NAY OCCUR ESPECIALLY IN PREDIABETICS P01144
THIAZIDES U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY THE DRUG R0299
THIAZIDES U URINALYSIS PBC/HPF INC V NAY CAUSE ACTUAL BLEEDING RO299
THIAZIDES U UROBILINOGEN DEC V CHOLESTATIC EFFECT R0477
TRIAZOLSULFONE B HEMATOCRIT DEC V MAY CAUSE HENOLYTIC ANEMIA RO62O
TRIAZOLSULFONE B HEMOGLOBIN DEC V NAY CAUSE HEMOLYTIC ANEMIA P0620
THIAZOLSULFONE P METHEMOGLOBIN INC V HEMOLYTIC ANEMIA R0620
TRIAZOLSULFONE B RED CELL COUNT DEC V MAY CAUSE HEMOLYTIC ANEMIA P0620
THIAZOLSULFONE S BILIRUBIN INC V HEMOLYTIC ANEMIA 90620
THIAZOLSULFONE S HAPTOGLOBIN DEC V HENOLYTIC ANEMIA P06 20
THIAZOLSULFONE U URINALYSIS COLOR INC N RED, PINK, PURPLE, ORANGE AND PUST COLOR 90355
THIOCYANATES B RED CELL COUNT DEC V MAY CAUSE ANEMIA R0620
THIOCYANATES S I 131 UPTAKE Z V DOES NOT AFFECT UPTAKE BY THYROID RO596
TRIOCYANATES S PHI DEC V BLOCKAGE OF THYROXINE BIOSYNTHESIS RO356
THIOCYANATES S SGOT INC V NAY CAUSE HEPATIC NECROSIS P0384
THIOCYANATES S SGPT INC V MAY CAUSE HEPATIC NECROSIS P0384
THIOCYANATES S UREA NITROGEN INC V MAY CAUSE NEPHROSIS HO384
THIOCYANATES U PROTEIN INC V MAY CAUSE NEPHROSIS P0384
THIOCYANATES U URINALYSIS PROTEIN INC V MAY CAUSE NEPHROSIS RO38LI
THIOGLYCOLATE B WHITE CELL COUNT DEC V REPORTED EFFECT P0658
THIOGUANINE B PLATELET COUNT DEC V IMMUNOLOGICALLY INDUCED THRONBOCYTOPENIA 90167
THIOGUANINE B WHITE CELL COUNT DEC V MAY CAUSE NARROW DEPRESSION P0167
THIOGUANINE S ALKALINE PHOSPHATASE INC V MAY CAUSE CHOLESTASIS P0620
THIOGUANINE S BILIPUBIN INC V MAY CAUSE CHOLESTASIS P0620
THIOGUANINE S BSP RETENTION INC V NAY CAUSE CHOLESTASIS P0620
THIOGUANINE S CEPHALIN FLOCCULATION INC V NAY CAUSE CHOLESTASIS P0620
THIOGUANINE S SGOT INC V MAY CAUSE CHOLESTASIS P0620
THIOGUANINE S SGPT INC V MAY CAUSE CHOLESTASIS P0620
THIOGUANINE S THYMOL TURBIDITY INC V MAY CAUSE CHOLESTASIS 90620
THIOGUANINE S URIC ACID INC V RAPID DESTRUCT OF TISSUES - NUCLEIC AC CATABOLISM RO3814
THIOGUANINE U URIC ACID INC V DUE TO AUGMENTED TISSUE CATABOLISM 90384
THIOGUANIN? U URINALYSIS BILE INC V NAY CAUSE CIIOLESTASIS P0620
THIOLS S CPK INC N THREE TO TENFOLD ENHANCEMENT P0080
THIOLS U PORPHOBILINOGEN DEC N UNLESS PRIOR SEPAPATION IS EMPLOYED k10322
THIOPENTAL S PHI DEC V INHIBITS IODINATION OF TYROSINE IN TBG 90004
THIOPENTAL U GLUCAPIC ACID INC V ENHANCED EXCRETION WITH ANESTHESIA P0001
THIOPROPAZATE B WHITE CELL COUNT DEC V RARE LEUKOPENIA P0026
THIORIDAZINE B HEMATOCRIT DEC V SIGNIFICANT DECREASE REPORTED P0456
THIORIDAZINE B HEMOGLOBIN DEC V SIGNIFICANT EFFECT REPORTED RO456
THIORIDAZINE B WHITE CELL COUNT DEC V AGHANULOCYTOSIS DUE TO INHIBITION OF DEVELOPMENT RO741
THIOPIDAZINE S ALKALINE PHOSPHATASE INC V HYPERSENSITIVITY REACTION 90508
THIORIDAZINE S BILIHUBIN DEC V ? DUE TO EFFECT ON BILIPUBIN METABOLISM P0456
THIORIDAZINE S BILIPUBIN INC V HEPATOTOXICITY (QUESTIONABLE) P0508
THIORIDAZINE S BSP RETENTION INC V HEPATOTOXICITY P0508
THIORIDAZINE S CEPHALIN FLOCCULATION INC V HEPATOTOXICITY P0508
THIORIDAZINE S SCOT INC V HEPATOTOXICITY P0508
THIOPIDAZINE S SGPT INC V HEPATOTOXICITY P0508
THIOPIDAZINE S THYMOL TURBIDITY INC V HEPATOTOXICITY 90508
THIORIDAZINE U HPG EXCRETION DEC V TOTAL GONADOTROPHIC ACTIVITY REDUCED 90919
THIORIDAZINE U URINALYSIS BILE INC V HEPATOTOXICITY R05O8
THIOSENICARBAZONES B HENATOCRIT DEC V LARGE DOSE EFFECT P0384
THIOSEMICARBAZONES B HEMOGLOBIN DEC V LARGE DOSE EFFECT P0384
THIOSENICARBAZONES B RED CELL COUNT DEC V HYDHAZONE COMPLEX FORMED WITH PYRIDOXAL P04 P0791
THIOSENICARBAZONES B WHITE CELL COUNT DEC V LEUKOPENIA/AGRANULOCYTOSIS IN 0.5% R0384
THIOSEMICARBAZONES S ALKALINE PHOSPHATASE INC V NAY AFFECT LIVER UNCTION 90620
THIOSENICARBAZONES S BILIRUBIN INC V MAY AFFECT LIVER FUNCTION P0620
THIOSENICARBAZONES S BSP RETENTION INC V NAY AFFECT LIVER FUNCTION P0620
THIOSENICARBAZONES S CEPHALIN FLOCCULATION INC V NAY AFFECT LIVER FUNCTION P0620
THIOSEMICAHBAZONES S SGOT INC V MAY AFFECT LIVER FUNCTION P0620
THIOSENICARBAZONES S SGPT INC V NAY AFFECT LIVER FUNCTION 90620
THIOSEMICARBAZONES S THYMOL TURBIDITY INC V MAY AFFECT LIVER FUNCTION P0620
THIOSENICARBAZONES U PROTEIN INC V NEPHPOTOXIC EFFECT P0355
THIOSEMICARBAZONES U URINALYSIS BILE INC V NAY AFFECT LIVER FUNCTION P0620
THIOSENICARBAZONES U URINALYSIS PROTEIN INC V NEPHHOTOXIC EFFECT P0299
THIOTEPA B HEMATOCHIT DEC V NAY BE RAPID DECREASE P0657
THIOTEPA B HEMOGLOBIN DEC V MAY BE RAPID DECREASE H0657
THIOTEPA B PLATELET COUNT DEC V NAY CAUSE BONE MARROW DEPRESSION P0026
THIOTEPA B RED CELL COUNT DEC V MAY CAUSE BONE MARROW DEPRESSION R0026
THIOTEPA B WHITE CELL COUNT DEC V MAY CAUSE BONE NARROW DEPRESSION 90026
THIOTEPA F OCCULT BLOOD P05 V MAY B! ULCERATION OF G.I. TRACT P0657
THIOTHIXENE B WHITE CELL COUNT DEC V TRANSITORY LEUKOPENIA P0620
TRIOTHIXENE P PROTHROMBIN TINE DEC V RARELY REPORTED SIDE EFFECT P0026
THIOTHIXENE S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT (REVERSIBLE CHOLESTASIS) 90299
THIOTHIXENE S BILIRUBIN INC V HEPATOTOXIC EFFECT (REVERSIBLE CHOLESTASIS) 90620
THIOTHIXENE S BSP RETENTION INC V HEPATOTOXIC EFFECT (REVERSIBLE CHOLESTASIS) P0620
THIOTHIXENE S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT (REVERSIBLE CHOLESTASIS) P0620
THIOTHIXENE S SGOT INC V HEPATOTOXIC EFFECT (REVERSIBLE CHOLESTASIS) P0620
THIOTHIXENE S SGPT INC V HEPATOTOXIC EFFECT (REVERSIBLE CHOLESTASIS) 90620
THIOTHIXENE S THYNOL TURBIDITY INC V HEPATOTOXIC EFFECT (REVERSIBLE CHOLESTASIS) P0620
THIOTHIXENE U URINALYSIS BILE INC V HEPATOTOXIC EFFECT (REVERSIBLE CHOLESTASIS) P0620
THIOURACIL B PLATELET COUNT DEC V THRONBOCYTOPENIA P0697
THIOURACIL B WHITE CELL COUNT DEC V AGRANULOCYTOSIS (IN ABOUT 1% CASES) P0937

THIOURACIL S ALKALINE PHOSPHATASE INC V MAY CAUSE INTRAHEPATIC CHOLESTASIS P0405
THIOUHACIL S BILIRUBIN INC V NAY CAUSE INTEAHEPATIC CHOLESTASIS RC4O5
THIOURACIL S CiOLESTEPOL INC M INTERFERES WITH ZLATKIS-ZAK REACTION RC97
THIOUBACIL S CHOLESTEROL INC V MAY CAUSE INTRAHEPATIC CHOLESTASIS 110405
T}IOUFCIL S PBI’ DEC V INHIBITS IOOINATION OF TYROSINE RESIDUES IN TBG RCCC4
THIOUH9A S UREA NITROGEN INC N REACTS WITH LANTHYDROL Ii METHOD OF POSSE 110436
THICURA T PROTEIN INC M REACTS WITH ?OLIN-CIOCALTEU OF LOWRY METHOD P0213
rHYNOL S GLUCOSE DEC N 1NG/NL INHIBITS COLOR 10 MG/1CML BY O-TOLUIDINE P0221
THYMOL S PHI INC V AFFECTS PHI IF GIVEN AS THYMOL IODIDE RCOO4
VHYMCL S UREA NITROGEN DEC N INHIBITS UREASE AFFECTING RESULTS P0355
THYMOL U ACETOACETATE Z N NO EFFECT ON GERHARDT PROCEDURE C779
THYMOL U ACETONE Z N NO EFFECT ON ROTHEBA PROCDUHE 11C779
THYMOL U AMINO ACIDS Z N NO EFFECT ON NINHYDRIN P0779
THYMOL U AMMONIA Z N NO EFFECT ON NESSLER, BERTHELOT METHODS 110779
IHYIIOL U AMYLASE Z N NO EFFECT ON STARCH HYDROLYSIS 110779
THYMOL U BICARBONATE Z ?i NO EFFECT ON VAN SLYKE, NATELSON METHODS R0779
THYNOL U BILIROBIN Z M NO iFFECT ON FOUCHET PROCEDURE P0779
THYMOL U CALCIUM Z N NO EFFECT ON FLAME PHOTOMETRIC LiETHODS R779
THYNOL U CHLORIDE Z N NO EFFECT ON SCHALES AND SCHALES METHOD 110779
THYMOL U CREATINE Z M NO EFFECT ON JAFFE, VAN PILSUM METHODS 30779
THYNOL U CREATININE Z N NO EFFECT ON JAFFE, VAN PILSUN METHODS C779
THYNOL U GLUCOSE Z N NO EFFECT O GLUCOSE-OXIDASE METHODS RC779
THYMOL U INDICAN Z N NO EFFECT ON ODERMAYER AND JAFFL METHODS RC779
THYNOL U P10SPHATE Z N NO EFFECT ON FISKE AND SUBBAROW METHOD P0779
THYMOL U PORPHOBILINOGEN Z N NO EFFECT ON WALDENSTPOII METHOD P0779
THYMOL U POTASSIUM Z N NO EFFECT ON FLAME PHOTOMETRIC METHODS P0779
THYMOL U PROTEIN Z N NO EFFECT ON BIURET, BOILING TESTS P0779
THYMOL U SODIUM Z N NO EFFECT ON FLAME PHOTOMETRIC METHODS P0779
THYMOL U SUGAR Z N NO EFFECT ON REDUCING METHODS R779
THYMOL U UPEA NITROGEN Z N NO EFFECT ON BERTHELOT METHOD R0779
THYNOL U URINALYSIS BILE INC N AFFECTS DETERMINATION OF BILE ACIDS (HAY’S TEST) P0779
THYNOL U URINALYSIS COLOR INC N GREENISH BLUE R0623
THYMOL U URINALYSIS PROTEIN INC N EXCESS NAY GIVE FALSE 205 WITH TURBIDITY PROCS RC143
THYMOL U UROBILINOGEN Z N NO EFFECT ON WALDENSTROM PROCEDURE P0779
THYMOL U XYLOSE EXCRETION Z N NO EFFECT ON ANALYTICAL METHOD P0779
THYROID 0 BMR INC V METABOLIC EFFECT OF HORMONE P0596
THYROID P PPOTHPOMBIN TIME INC V PROLONGS ACTION OF ANTICOAGULANTS R0620
THYROID S CHOLESTEROL DEC V PHYSIOLOGICAL EFFECT P0417
THYROID S GLUCOSE INC V METABOLIC ACTION OF HORMONE P0204
THYROID S I 131 UPTAKE DEC V CONSEQUENCE OF TREATMENT RCLI17
THYROID S PRI INC V INCLEASES BY 1-2 UG/100ML/DAY/1 GRAIN GIVEN P0417
THYROID S PROTEIN INC V PHYSIOLOGICAL EFFECT EXERTS ANABOLIC EFFECT 110211
THYROID S THYNOL TURBIDITY INC V INCREASE PROTEIN METABOLISM R02C4
THYROID S THYROXINE (T4) INC V INC AVAILABLE THYROXINE R0596
THYROID S T3 UPTAKE INC V CONSEQUENCE OF TREATMENT P0417
THYROTROPIN S I 131 UPTAKE INC V RESULTS VARY WITH THYROID STATUS 110596
THYROTHOPIN S PHI iNC V STARTS WITHIN 15i1, MAY INC BY UP TO 5.5 UG/100ML H0255
THYROTHOPIN S THYROXINE (TU) INC V SEVERAL HOURS AFTER I.M. INJECTION RC457
THYROTRCPIN-PELEAS P CORTISOL Z V NO EFFECT IN NOiMAL SUBJECTS RDC34
THYPOTROPIN-PELEAS P FSH Z V NO EFFECT IN NORMAL SUBJECTS 110034
THYROTHOPIN-RELEAS P GROWTH HORMONE Z V NO EFFECT IN NORMAL SUBJECTS RC034
THYHOTHOPIN-RELEAS P LH Z V NO EFFECT IN NORMAL SUBJECTS R0034
THYROTROPIN-RELEAS P PROLACTIN INC V RESPONSE WITHIN 5 MINUTES TO I.V, INJECTION P0484
THYPOTPOPIN-RELEAS P TSH INC V THREEFOLD INCREASE IN 30 NIN RC034
rHYR0TR0PIN-PELEAs S THYROXINE (T4) INC V BUT NO CHANGE IN PERCENT FREE T4 P0457
THYROTROPIN-RELEAS S TRIIODOTHYHONINE (T3) INC V BUT NO CHANGE IN PXRCFNT FREE T3 R0457
TIN MAGNESIUM INC N MEASURED BY FLUOROMETRIC METHOD OF SCHACHTER P0923
TIOCARLIDE B WHITE CELL COUNT DEC V ASSOC WITH REL LMPH0CYTOSIS AND NONOCYTOSIS P0657
TIOCARLIDE S BILIRUBIN INC V HARE OBSERVATION RC657
TIOCAPIIDE S GLUCOSE DEC V HYPOGLYCEMIC REACTIONS OBSERVED R0657
TIOCARLIDE S PBI DEC N MYXEDEMA REPORTED IN ONE CASE P0657
TIOCAPLIDE S SGPT INC V REPORTED EFFECT IN 4% SUBJECTS 110657
TOBACCO SMOKE S POTASSIUM INC N INTERFERES WITH FLAME PHOTOMETRY P0356
TOLAZAMIDE B PLATELET COUNT DEC V THROMBOCYTOPENIA/PANCYTOPENIA 110384
TOLAZAMIDE B RED CELL COUNT DEC V MAY CAUSE HEMOLYTIC ANEMIA P0384
POLAZAMIDE B WHITE CELL COUNT DEC V LEUKOPENIA/AGRANULOCYTOSIS P0384
TOLAZAMIDE F UROBILINOGEN DEC V PALE STOOLS WITH CHOLESTASIS P0620
TOLAZAMIDE P PHOTHROMBIN TIME INC V OCCURS WITH FAILURE TO EXCRETE BILE SALTS 110620
TOLAZAMIDE S ALKALINE PHOSPHATASE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P0029
TOLAZAMIDE S BILIPOBIN INC V CHOLESTATIC JAUNDICE R062C
TOLAZAMIDE S BSP RETENTION INC V CHOLESTASIS R0620
TOLAZAMIDE S CEPHALIN FLOCCULATION INC V CHOLESTASIS P0620
TOLAZANIDE S GAMMA GLOBULIN INC V TRANSIENT INCREASES REPORTED 110657
TOLAZAMIDE S GLUCOSE DEC N SULFONYLUREA DERIVATIVE STIMULATES INSULIN SECRET R0856
TOLAZAMIDE S SCOT INC V CHOLESTASIS P0620
TOLAZANIDE S SGPT INC V CHOLESTATIC EFFECT HC620
TOLAZAMIDE S THYMOL TURBIDITY INC V CHOLESTASIS P0620
TOLAZAPIIDE S 5-NUCLEOTIDASE INC V DUE TO HOLESTASIS P0492
TOLAZANIDE U URINALYSIS BILE INO V CHOLESTATIC EFFECT P0620
POLAZAMIDE U UPOBILINOGEN DEC V CHOLESTATIC EFFECT 110620
TOLAZOLINE B PLATELET COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCHASIAS) P0658
TOLAZOLINE B RED CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCHASIAS) P0658
TOLAZOLINE B WHITE CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0658
TOLAZOLINE 0 GASTRIC JUICE HCL INC V ALSO ENHANCES HISTAMINE STIMULATION P0384
TOLAZOLINE 0 GASTRIC JUICE PEPSIN INC V ALSO ENHANCES HISTAMINE STIMULATION R0384
TOLBUTAMIDE B COPROPOHPHYRIN INC V MAY PRECIPITATE CUTANEOUS PORPHYRIA R0371
TOLBUTANIDE B HENATOCRIT DEC V AGRANULOCYTOSIS/APLASTIC ANEMIA ROC24
TOLBUTAMIDE B HEMOGLOBIN DEC V AGRANULOCYTOSIS/APLASTIC ANEMIA R0024
TOLBUTAMIDE B NEUTROPHILS DEC V OCCASIONALLY OBSERVED 110657
TOLBUTAMIDE B PLATELET COUNT DEC V AGRANULOCYTOSIS/APLASTIC ANEMIA 110199

TOLBUTA MIDE B PROTOPORPHYRIN INC V MAY PRECIPITATE CUTANEOUS PORPHYRIA RO371
TOLBUTAMIDE B RED CELL COUNT DEC V AGRANULOCYTOSIS/APLASTIC ANEMIA BOO 24
TOLBUTAMIDE B WHITE CELL COUNT DEC V AGPANULOCYTOSIS/APLASTIC ANEMIA HO 199
TOLBUTAMIDE C PROTEIN INC N CAUSES TURBIDITY IF SULFOSALICYLIC ACID USED P09 07
TOLBUTANIDE F COPROPOHPHYRIN INC V NAY PRECIPITATE CUTANEOUS PROPHYPIA 90371
TOLBUTANIDE F PROTOPORPHYRIN INC V NAY PRECIPITATE CUTANEOUS PORPHYRIA 90371
TOLBUTA NIDE F UROBILINOGEN DEC V PALE STOOLS WITH CHOLESTASIS MAY OCCUR 90477
TOLBUTAMIDE P INSULIN INC V MARKED RISE ASSOCIATED WITH HYPOGLYCEMIA P03 34
TOLBUTA NIDE P PROTHHONBIN TIME INC V OCCURS WITH FAILURE TO EXCRETE BILE SALTS 90 270
TOLBUTA MI DE S ALKALINE PHOSPHATASE INC V MAY CAUSE INTPAHEPATIC CHOLESTATIC SYNDROME 30079
TOLBUTAMIDE S BILIPUBIN INC V CHOLESTATIC JAUNDICE REPORTED H0417
TOLBUTA MI DE S BSP RETENTION INC V MAY CAUSE CYTOTOXIC LIVER DAMAGE OR CHOLESTASIS P0079
TO LB UT A N I OP S CEPHALIN FLOCCULATION INC V CHOLESTATIC PHENOMENON P06 20
TOLBUTAMIDE S GLUCOSE DEC V THERAPEUTIC INTENT (PROMOTES INSULIN SECRETION) HO 334
TOLB UT AN IDE S GLUCOSE INC N FALSE INC(LITTLE EFFECT AT NORMAL CONC)WITH GLU OX P08 56
TOLBUTAMIDE S I 131 UPTAKE DEC V UNCOMMON REPORTED EFFECT HO 596
TOLBUT AN IDE S NEFA INC V EFFECT OBSERVED IN NORMAL SUBJECTS 907147
TOLBUTAMIDE S PBI DEC V INHIBITS IODINATION OF TYROSINE RESIDUES IN TBG 90004
TOLBUTAMIDE S SGOT INC N AT 1 MMOL/L AFFECTS SMA 12/60 METHOD 90876
TOLBU TA MIDE S SGOT INC V NAY CAUSE CYTOTOXIC LIVER DAMAGE OH CHOLESTASIS R0O79
TOLBOTANI DE S SGPT INC V MAY CAUSE CYTOTOXIC LIVER DAMAGE OR CHOLESTASIS H 0079
TOLBUTAMIDE S THYMOL TURBIDITY INC V NAY CAUSE CYTOTOXIC LIVER DAMAGE OH CHOLESTASIS P06 20
TOLBUTA NI DE S THYROXINE (T14) DEC V DISPLACES FROM TBG 90907
TOLBUTAMIDE S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS HOLI92
TOLBOTA NI DR U ANINOLEVULINIC ACID INC V MAY PRECIPITATE PORPHYRIA ATTACK H0371
TOLBUTAM IDE U COPROPORPHYHIN INC V MAY PRECIPITATE PORPHYRIA ATTACK RO371
TOLBUTAMIDE U PORPHOBILINOGEN INC V MAY PRECIPITATE PORPHYRIA ATTACK 90371
TOLBUTANIDE U PROTEIN INC N CAUSES TURBIDITY IF SULFOSALICYLIC ACID USED 90843
TOLBUTA MI DE U URINALYSIS BILE INC V CHOLESTATIC JAUNDICE REPORTED ROLl 17
TOLBOTANIDE U UHINALYSIS PROTEIN INC N INTERFERES WITH SULPHOSALICYLIC ACID METHOD HO 843
TOLBUTA NIDE U URINALYSIS PROTEIN Z M NO EFFECT ON ALBUSTIX RO143
TOLBUTAMI DR U UROBILINOGEN DEC V POSSIBLE CHOLESTATIC EFFECT ROLl 77
TOLBUTA MIDE U UROPORPHYRIN INC V MAY PRECIPITATE PORPHYRIA ATTACK 90371
TOLONI UN U URINALYSIS COLOR INC M GREEN AND BLUE COLOR P02 99
TOLUIDINE BLUE B HEINZ-BODY FORMATION P05 V MAY CAUSE HENOLYSIS WITH G-6-PD DEFICIENCY HO 104
TOLUIDINF BLUE B HEMATOCRIT DEC V MAY CAUSE HENOLYSIS WITH 6-6-PD DEFICIENCY P01 014
TOLUIDINE BLUE B HEMOGLOBIN DEC V NAY CAUSE HEMOLYSIS WITH C-6-PD DEFICIENCY HO 104
TOLUIDINE BLUE B RED CELL COUNT DEC V MAY CAUSE HENOLYSIS WITH C-6-PD DEFICIENCY 90104
TOOTHPASTE S PHI INC V SOME MAY CONTAIN ENOUGH 12 TO CAUSE EFFECT 30255
TOUP.NI QUET B HEMOGLOBIN INC V VENOUS STASIS NAY CAUSE SIGNIFICANT INCREASE 91001
TOURNIQUET B SEDIMENTATION RATE INC V HEMOCONCENTRATION INCREASES RATE 90143
TOURNI QUET P HEMOGLOBIN Z V NO EFFECT OBSERVED WITH LOCAL CIRCULATORY STASIS 90485
TOURNIQUET S ALBUMIN INC V AFFECTS ALL PROTEIN BOUND CONSTITUENTS ALSO HO 1436
TOURNIQUET S CALCIUM INC V DUE TO RELATIVE INC OF PLASMA PROTEINS HO 2 67
TOURNIQUET S PHI INC V OCCLUSION FOR 5 NIN MAY CAUSE INC UP TO 2 UG/100ML P02 55
TOURNIQUET S POTASSIUM INC V ESPECIALLY IF FOREARM MUSCLES EXERCISED ALSO P0436
TOURNI QUET S PROTEIN INC V AFFECTS ALL PROTEIN BOUND CONSTITUENTS ALSO HO L436
THANYLCYPROMINE B WHITE CELL COUNT DEC V THEORETICAL EFFECT OF THIS TYPE OF DRUG HO026
TRA NYLCYPROMINE S ALKALINE PHOSPHATASE INC V MAY AFFECT LIVER FUNCTION (?HYPEPSENSITIVITY) HO620
TRANYLCYPROMINE S BILIRUBIN INC V MAY AFFECT LIVER FUNCTION (?HYPERSENSITIVITY) .0620
TRANYLCYPRONINE S BSP RETENTION INC V HEPATOTOXIC/CHOLESTATIC SYNDROMES 90384
TRA NYL CY PROM IN P S CEPHALIN FLOCCULATION INC V NAY AFFECT LIVER FUNCTION (?HYPERSENSITIVITY) H0620
TPA NYLCYPRONINE S SCOT INC V MAY AFFECT LIVER FUNCTION (?HYPERSENSITIVITY) P06 20
TRANYLCYPROMINE S SGPT INC V NAY AFFECT LIVER FUNCTION (?HYPERSENSITIVITY) 90620
TRANYLCYPROMINE S THYMOL TURBIDITY INC V MAY AFFECT LIVER FUNCTION (?HYPERSENSITIVITY) 90620
TRANYLCYPROMINE U URINALYSIS BILE INC V NAY AFFECT LIVER FUNCTION (?HYPERSENSITIVITY) 90620
TRASYLOL S AMYLASE INC V ONE CASE ALLERGIC PANCREATITIS REPORTED 30657
TRI AMCI NOLONE S GLUCOSE INC V GLUCOCOPTICOID EFFECT H0683
TRIA NCINOLONE U POTASSIUM INC V ONLY IN EXCEEDINGLY LARGE DOSES P00 26
TRIANCI NOLONE U SODIUM INC V MILD DIURESIS WITH NA LOSS IN FIRST FEW DAYS HO 026
TP IANCINO LONE U URINALYSIS GLUCOSE INC V CONSEQUENCE OF HYPERGLYCEMIA 90683
TRIA MTERENE B EOSINOPHILS INC V ALLERGIC RESPONSE H 014214
TPIANTEHENE B HENATOCRIT DEC V NAY CAUSE NEGALOBLASTIC ANEMIA(FOLIC AC ANTAGONIST) P0976
TRIA MTERENE B HEMOGLOBIN DEC V NAY CAUSE MEGALOBLASTIC ANEMIA(FOLIC AC ANTAGONIST) HO 976
TRIAMTERENE B NCV INC V MEGALOBLASTIC ANEMIA P0976
TRIA MTERENE B RED CELL COUNT DEC V NAY CAUSE MEGALOBLASTIC ANEMIA(FOLIC AC ANTAGONIST) 90976
TPIAMTERENE B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA P06 20
THIA MT ERENE S CHLORIDE DEC V DIURETIC ACTION WITH IMPAIRED TUBULAR REABSORPTION HO204
TRIAMTERENE S CHLORIDE INC V NEPHHOTOXIC AND AZOTENIC EFFECT P06 20
THIANTERENE S C02 CONTENT DEC V NEPEPOTOXIC EFFECT 90299
TRI ANT ERENE S CHEATININE INC V NEPHROTOXIC EFFECT (CAUSES REDUCED GFR) R062O
TRIANTERENE S FOLATE DEC V INHIBITS DIHYDHOFOLATE REDUCTASE H 09 76
THIANTERENE S GLUCOSE INC V EFFECTLESS COMMON THAN WITH THIAZIDES P0556
TRIANTEHENE S POTASSIUM DEC V DIURETIC ACTION HO 9 07
TRIANTERENE S POTASSIUM INC V POTASSIUM SPARING ACTION (AFFECTS NA/K EXCHANGE) P0620
TPIAMTERENE S QUINIDINE INC N INTERFERING FLUOPESENCE P03 55
TRIANTERENE S SODIUM DEC V DIURETIC ACTION P0620
TPIAMTERENE S UREA NITROGEN INC V NEPHROTOXIC EFFECT (WITH EXCESSIVE DIUPESIS) HO 367
T RI A NT ER ENE S URIC ACID INC V SIGNIFICANT EFFECT IN ABOUT 17% CASES 901417
TRIA NTEHENE U AICAB INC V IF MEGALOBLASTIC ANEMIA OCCURS 90976
TRIANTERENE U CALCIUM INC V IMPAIRS REABSORPTION HO 72 3
TRIA NTEPENE U CHLORIDE INC V DIURETIC ACTION 90384
TRIAMTEPENE U DIAGNEX BLUE EXCRETION INC N INCREASED DYE RELEASE FROM RESIN P0355
TRIAMTERENE U FIGLU INC V IF MEGALOBLASTIC ANEMIA OCCURS P0976
TPIANTEHENE U GFR DEC V CAUSES REDUCED GLONERU4H FILTRATION HATE 90204
TRIAMTERENE U SODIUM INC V DIURETIC ACTION (INCHEAED CLEAPANCE) H 0384
TRI ANT ERENE U URIC ACID INC V SLIGHT URICOSURIC ACTION R0355
THIANTERENE U URINALYSIS COLOR INC N GREEN, BLUE WITH BLUE FLUORESCENCE 90299
TPIA MTERENE U URINALYSIS PH INC V SLIGHT ALKALINIZATION (MECHANISM NOT KNOWN) 90384
TR IC HLOHMETHIAZI DR S CALCIUM INC V IMPAIRED EXCRETION 90907

PP ICHLOHNETHIAZIDE S GLUCOSE INC V DIABETOGENIC LIKE ACTION OF DRUG: AFFECTS GTT P0907
TRICHLOHNETHI AZI DR S POTASSIUM DEC V DIURETIC ACTION P0907
TPICHLORMETHIAZIDE S URIC ACID INC V INHIBITION OF TUBULAR SECRETION OF ORATE R04O4
TRIF!LOPMETHIAZI DE U CALCIUM DEC V IMPAIRED EXCRETION P09 07
TPICHLORMET HIAZIDE U GLUCOSE INC V DIABETOGENIC LIKE ACTION OF DRUG P09 07
TPICHLORMETHIAZIDE U URINALYSIS GLUCOSE INC V DIABETOGENIC-LIKE ACTION OF DRUG 90907
TRICHLOROETHYLENE S BILIRUBIN INC V POTENTIALLY HEPATOTOXIC ROO26
TRICFILOROETHYLENF S SCOT INC V POTENTIALLY HEPATOTOXIC P0026
TPICHLOPOETHYLENE S SGPT INC V POTENTIALLY HEPATOTOXIC P0026
TH ICHLOROETHY LPH OS P PROTHRONBIN TIME INC V POTENTIATES ACTION OF COUNARINS (REDUCES BINDING) P085 1
TPIETHYLENEMPLAMINE B PLATELET COUNT DEC V MAY CAUSE BONE NARROW DEPRESSION P0026
TRIETHYLENEMELANINE B RED CELL COUNT DEC V MAY CAUSE BONE MARROW DEPRESSION P0026
TRIETHYLENEMELANINE B WHITE CELL COUNT DEC V MAY CAUSE BONE NARROW DEPRESSION P0026
TRIETHYLENEMELA MINE S CHOLINESTEPASE DEC V OBSERVED IN VITRO, PROBABLE EFFECT IN VIVO H 1027
TRI ETHYLENENELAMINE S SGOT INC V HEPATOTOXICITY (PROLONGED TREAT, LARGE DOSE) P002 6
THIETHYLENEMELA NINE S SGPT INC V HEPATOTOXICITY (PROLONGED TREAT, LARGE DOSE) P00 26
THI FLOCI N U AMMONIA INC V INHIBITS CARBONIC ANHYDRASE P0009
TRIFLOCIN U POTASSIUM INC V DIURETIC ACTION P0009
THI FLOCI N U SODIUM INC V DIURETIC ACTION P0009
TPIFLOCIN U TITHATABLE ACIDITY INC V INHIBITS CARBONIC ANHYDRASE 110009
TRIFLUOPERAZINE B PLATELET COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0658
TPIFLUOPEP A ZINE B RED CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCPASIAS) P06 58
TRIFLUOPEHAZINE B WHITE CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0657
TPIFLOOPERA ZINE F UROBILINOGEN DEC V PALE STOOLS WITH CHOLESTASIS HO 477
TRIFLUOPERAZINE P PROTHROMHIN TINE INC V ASSOC WITH FAILURE OF EXCRETION OF BILE SALTS P0477
TRIFLUOPEPAZINE S ALKALINE PHOSPHATASE INC V CHOLESTATIC EFFECT P01477
TRIFLUOPEPAZINE S BILIRURIN INC V CHOLESTATIC EFFECT HO 1477
TRIFLUOPEHAZINE S BSP RETENTION INC V CHOLESTATIC EFFECT P0477
TPIFLtJOPEHAZINE S CHOLESTEROL INC V INC OF UP TO 35 MG/100ML REPORTED P0767
TPIFLUOPFRAZIWE S PBI Z V NO EFFECT WITH NORMAL DOSES P0255
TR IFLUOPE PA El NE S SGOT INC V CHOLESTATIC EFFECT HO 477
TPI FLUOPERAZINE S SGPT INC V CHOLESTATIC EFFECT P0477
TRIFLUOPERA ZINE U UROBILINOGEN DEC V CHOLESTATIC EFFECT P0477
TRIFLU PEPIDOL B ROSINOPHILS INC V ALLERGIC RESPONSE P0620
TRIFLUPER IDOL B WHITE CELL COUNT DEC V RARE LEUKOPENIA/AGPANULOCYTOSIS P0384
THY FLU PEHIDOL B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA P0620
TPIFLUPERIDOL S BILIRUBIN INC V ELEVATED IN CHRONIC AND ACUTE HEPATITIS P0299
TRIFLU PEPIDOL S CHOLESTEROL DEC V INHIBITS BIOSYNTHESIS IN LIVER P0384
TPIFLOPERIDOL S DESMOSTEROL INC V FURTHER METABOLISM INHIBITED SO ACCUMULATES P0384
TRIFLUPERIDOL S SGPT INC V HEPATOCELLULAR CHANGES OBSERVED P0384
TPIFLUPRONAZINE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS DUE TO INHIBITION OF DEVELOPMENT P074 1
TRIFLUPROMAZINE S BILIPUBIN INC V LIVER DYSFUNCTION EXCEPTIONALLY RARE P00 26
TRIIODOTHYPONINE P TSH DEC V EFFECT MARKED IN EUTHYROID, HYPOTHYROID SUBJECTS P095 0
TRIIODOTHYR ONINE S CHOLESTEROL DEC V PHYSIOLOGICAL CONSEQUENCE OF HORMONE P0907
TRIIODOTHYPONINE S PHI DEC V PITUITARY SUPPRESSION OF TSH P0004
TRIIODOTHYPONINE S THYROXINE (T4) DEC V DIMINISHED SYNTHESIS R09O7
TRI !IEPRAZINE B WHITE CELL COUNT DEC V MAY CAUSE LEUKOPENIA OR AGRANULOCYTOSIS P0026
TRIMEPPAZINE S BILIRUBIN INC V NAY CAUSE CHOLESTASIS P0026
TRIMEPPAZINE S SCOT INC V NAY CAUSE CHOLESTASIS P0026
TPIMEPPAZINE S SGPT INC V MAY CAUSE CHOLESTASIS P0026
TPIMEPHAZINE U URINALYSIS BILE INC V NAY CAUSE CHOLESTASIS P0026
TRIMETHADIONE B HENATOC?IT DEC V APLASTIC ANEMIA P0784
TRIMETHADIONE B HEMOGLOBIN DEC V APLASTIC ANEMIA 90784
THI METHADIONE B LE CELL PREP P05 V MAY PRODUCE LE-LIKE SYNDROME P0907
TRIMETHADIONE B NEUTHOPHILS DEC V MODERATE NEUTROPENIA QUITE COMMON HO 384
TRI NETHADIONE B PLATELET COUNT DEC V APLASTIC ANEMIA NAY OCCUR RARELY P0784
TR IMETHADIONE B RED CELL COUNT DEC V APLASTIC ANEMIA P0658
TRIMETHADIONE B WHITE CELL COUNT DEC V APLASTIC ANEMIA P0784
TRI METHADIONE F OCCULT BLOOD P05 V G.I. BLEEDING REPORTED (NAY AFFECT MANY ORGANS) P0 299
TRI METHADIONE S ALKALINE PHOSPHATASE INC V HEPATOTOXICITY WITH CENTROLOBULAR NECROSIS P06 20
TPINETHADIONE S BILIROBIN INC V HEPATOTOXICITY WITH CENTROLOBULAR NECROSIS P06 20
TRI METHADIONE S BSP RETENTION INC V HEPATOTOXICITY WITH CENTROLOBULAR NECROSIS P0620
TRINETHADIONE S CEPHALIN FLOCCULATION INC V NAY CAUSE HEPATOTOXICITY WITH NECROSIS P0620
TPIMETHADIONE S CHOLESTEROL INC V MAY AFFECT LIVER FUNCTION (HEPATITIS) P0620
TRINFTHADIONE S PROTEIN DEC V REVERSIBLE EFFECT DUE TO URINARY LOSS P0596
TR INETHADIONE S SCOT INC V MAY CAUSE HEPATOTOXICITY WITH NECROSIS 90620
TRI METHADIONE S SGPT INC V MAY CAUSE HEPATOTOXICITY WITH NECROSIS P0620
TPIMETHADIONE S THYMOL TURBIDITY INC V NAY CAUSE HEPATOTOXICITY WITH NECROSIS P0620
TRY MFTHADIONE S UREA NITROGEN INC V NEPHPOPA.THY REPORTED R0026
TPIMET HADIONE T FOLATE Z N NO EFFECT ON L. CASEI OP S. FECALIS HO 657
CR1 METHA DIONE U PROTEIN INC V NAY HAVE NEPHROTOXIC EFFECT P04 17
THINETHADIONE U URINALYSIS BILE INC V NAY CAUSE HEPATOTOXICITY WITH NECROSIS P0620
TRI METHADI ONE U URINALYSIS CASTS INC V NAY HAVE NEPPROTOXIC EFFECT P062 0
THIMETHADIONE U URINALYSIS HEMOGLOBIN INC V HENATUHIA MAY OCCUR ESPECIALLY IN CHILDREN P0596
THI NETHADI ONE 0 URINALYSIS PROTEIN INC V MAY HAVE NEPHPOTOXIC EFFECT P0444
TRIMETHADIONE U URINALYSIS PBC/HPF INC V HEMATURIA MAY OCCUR ESPECIALLY IN CHITDREN HO 596
TRINETHOPPI N B HEMATOCRIT DEC V FOLIC ACID ANTAGONIST ?NEGALOBLASTIC ANEMIA R0976
TRIMET HOPRIN B HEMOGLOBIN DEC V FOLIC ACID ANTAGONIST ?NEGALOBLASTIC ANEMIA P0976
TRIMETHOPRI N B NCV INC V OCCURS WITH MEGALOBLASTIC ANEMIA 90976
TRI MET HOPRIN B PLATELET COUNT DEC V MOST COMMON SERIOUS TOXIC EFFECT HO 765
THINET HOPRIN B RED CELL COUNT DEC V FOLIC ACID ANTAGONIST ?NEGALOBLASTIC ANEMIA P0976
TRINETHOPHIN B SEDIMENTATION RATE DEC V WITH SULFA CAUSED MARKED DEC IN RHEUMATOIDS 90507
TPI NETHOPPIM S FOLATE DEC V USUALLY WITH SULFA - NO HENATOLOGICAL ABNORMALITY P0736
TPIMETHYLENENELA N B HEMOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P0620
TRY METHYL EN ENELAN B RED CELL COUNT DEC V MAY CAUSE HENOLYTIC ANEMIA P0620
TRINETHYLENENELA N S BILIRUBIN INC V MAY CAUSE HEMOLYTIC ANEMIA P06 36
TRI METHYLENENFLAN S DIRECT COOMBS TEST P05 V MAY CAUSE HENOLYTIC ANEMIA P0636
TRIMETOZINE 0 URINALYSIS GLUCOSE INC N FALSE P05 WITH GLUC OX (COMBISTIX) REPORTED HO 205
TRI NI TROTOLUENE B HENATOCRIT DEC V MAY CAUSE HEMOLYSIS RO658
TRINITROTOLUENE H HEMOGLOBIN DEC V NAY CAUSE HEMOLYSIS HO 658

THINITROTOLUENE B NETHEMOGLOBIN INC V ASSOCIATED WITH HENOLYSIS P0658
TPINITROTOLUENE B RED CELL COUNT DEC V MAY CAUSE HENOLYSIS H0658
THINITROTOLUENE B SULFHENOGLOBIN INC V ASSOC WITH NETHEMOGLOBINEMIA AND HENOLYSIS 30658
TRINITROTOLUENE U URINALYSIS COLOR INC V RED BROWN DUE TO HEMOGLOBIN R0620
THINITROTOLUENE 0 URINALYSIS HEMOGLOBIN INC V NAY CAUSE HENOLYSIS P0620
TRINITHOTOLUENE U URINALYSIS PBC/HPF INC V NAY CAUSE HEMOLYSIS 30520
TRIOXAZINE U SUGAR INC N INTERFERES WITH BENEDICT’S REAGENT P0299
TRIOXSALEN S ALKALINE PHOSPHATASE INC V NAY AFFECT LIVER FUNCTION P0620
TRIOXSALEN S BILIHUBIN INC V NAY AFFECT LIVER FUNCTION 90620
THIOXSALEN S ESP RETENTION INC V MAY AFFECT LIVER FUNCTION 90620
THIOXSALEN S CEPHALIN FLOCCULATION INC V MAY AFFECT LIVER FUNCTION P0620
TRIOXSALEN S SCOT INC V MAY AFFECT LIVEP FUNCTION P0620
TPIOXSALEN S SGPT INC V NAY AFFECT LIVER FUNCTION P0620
TRIOXSALEN S THYNOL TURBIDITY INC V NAY AFFECT LIVER FUNCTION 30620
TRIOXSALEN U URINALYSIS BILE INC V MAY AFFECT LIVER FUNCTION 90620
THIPELENNANINE B HEMATOCHIT DEC V HENOLYTIC ANEMIA 90240
TRIPELENNAMINE B HEMOGLOBIN DEC V HENOLYTIC ANEMIA RO240
TRIPELENNANINE B RED CELL COUNT DEC V HEMOLYTIC ANEMIA P0657
TRIPELENNANINE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS/ LEUKOPENIA (RARE) P0932
THIPELENNAMINE S HAPTOGLOBIN DEC V HENOLYTIC ANEMIA H0240
THOMETHANINE B PCO2 DEC V CORRECTION OF RESPIRATORY ACIDOSIS 90782
TPOMETHANINE B PH INC V CAN CORRECT METABOLIC OH HYPERCAPNIC ACIDOSIS P0782
TRONETHANINE S CO2 CONTENT INC V CORRECTION OF RESPIRATORY ACIDOSIS RO782
THONETHAMINE S GLUCOSE DEC V HYPOGLYCEMIA ESP IF I.V., ALSO TRANSIENT IF ORAL H0782
THOMETHANINE S POTASSIUM INC V REPORTED EFFECT 90782
TRYPAN BLUE S PHI DEC V MECHANISM OBSCURE P0004
THYPAPSANIDE S SCOT INC V MAY CAUSE LIVER DAMAGE P0026
TPYPAHSAMIDE S SGPT INC V MAY CAUSE LIVER DAMAGE 30026
TRYPSIN U URINALYSIS HEMOGLOBIN INC V OCCASIONAL REPORTED OCCURRENCE P0299
THYPSIN U URINALYSIS PBC/HPF INC V OCCASIONAL REPORTED OCCURRENCE 90299
TPYPTANINE T TRYPTOPHAN INC N MEASURED AS SAME IN SPIES/CHAMBERS METHOD P0399
TPYPTOPHAN C PROTEIN INC N INTERFERES WITH FOLIN-CIOCALTEU REAGENT P1026
TPYPTOPHAN S CHOLESTEROL INC N AFFECTS DIRECT REACTIONS USING ACETIC ACID P01436
TRYPTOPHAN U PHOSPHATE INC V INHIBITS TUBULAR REABSORPTION P0284
TRYPTOPHAN U UROBILINOGEN INC N PRODUCES AN ORANGE COLOR WITH EHRLICH’S REAGENT P01436
THYPTOPHAN-THIOL T THYPTOPHAN INC N MEASURED AS SAME IN SPIES/CHAMBERS METHOD R0399
TOBOCUHARINE B PH DEC V LARGE DOSE EFFECT WITH PROLONGED RECOVERY P0596
TUBOCURAHINE B PH INC V RESPIRATORY ALKALOSIS WITH LOW DOSES P0596
TUBOCURARINE S CPK INC V DUE TO I.M. INJECTIONS OR HISTAMINE RELEASE R0208
TURPENTINE U GLUCOSE INC V MANIFESTATION OF NEPHROTOXICITY OF POISONING P0368
TURPENTINE U ODOR INC V ODOR RESEMBLES THAT OF VIOLETS P0368
TURPENTINE U PROTEIN INC V MAY HAVE NEPHROTOXIC EFFECT 90299
TURPENTINE U URINALYSIS GLUCOSE INC V DUE TO INGESTION - NEPHROTOXIC EFFECT P0368
TURPENTINE 0 URINALYSIS HEMOGLOBIN INC V NEPHROTOXIC EFFECT FOLLOWING INGESTION RO368
TURPENTINE U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT 90355
TYROSINE C PROTEIN INC N REACTS AS IF PHENOL WITH FOLIN-CIOCALTRU PROC P1026
TYROSINE S BILIHUBIN INC N REACTS WITH DIAZO REAGENT RO436
TYROTHRICIN B HENATOCRIT DEC V NAY CAUSE HENOLYSIS EVEN IF APPLIED TOPICALLY P0026
TYROTHRICIN B HEMOGLOBIN DEC V NAY CAUSE HEMOLYSIS EVEN IF APPLIED TOPICALLY P0026
TYHOTHRICIN B RED CELL COUNT DEC V HEMOLYSIS EVEN WHEN APPLIED TOPICALLY P0026
TYHOTHRICIN S BILIHUBIW INC V HEMOLYSIS EVEN WHEN APPLIED TOPICALLY 30026
URACIL MUSTARD B PLATELET COUNT DEC V MAY CAUSE BONE NARROW DEPRESSION P0026
UPACIL MUSTARD B RED CELL COUNT DEC V MAY CAUSE BONE MARROW DEPRESSION P0026
URACIL MUSTARD B WHITE CELL COUNT DEC V MAY CAUSE BONE MARROW DEPRESSION P0026
UPACIL MUSTARD S ALKALINE PHOSPHATASE INC V NAY AFFECT LIVER FUNCTION P0620
OPACIL MUSTARD S BILIPUBIN INC V MAY AFFECT LIVER FUNCTION P0620
UPACIL MUSTARD S BSP RETENTION INC V NAY AFFECT LIVER FUNCTION P0620
URACIL MUSTARD S CEPHALIN FLOCCULATION INC V NAY AFFECT LIVER FUNCTION 90620
URACIL MUSTARD S SCOT INC V NAY AFFECT LIVER FUNCTION 90620
UPACIL MUSTARD S SGPT INC V NAY AFFECT LIVER FUNCTION P0620
UPACIL MUSTARD S THYMOL TURBIDITY INC V NAY AFFECT LIVER FUNCTION P0620
URACIL MUSTARD U URINALYSIS BILE INC V MAY AFFECT LIVER FUNCTION P0620
UREA B HEMOGLOBIN DEC V RAPID INFUSION OF CONC SOLN MAY CAUSE HEMOLYSIS P0299
UREA P AMMONIA INC N BREAKDOWN OF UREA TO AMMONIA P0299
UREA P HEMOGLOBIN INC V RAPID INFUSION OF CONC SOLN MAY CAUSE HENOLYSIS P0299
UREA S BILIRUBIN DEC N BROWN COLOR IN DIAZO REACTION OF UREMICS P0436
UREA S GENTAMICIN INC N AFFECTS MEASUREMENT BY PH METHOD P0348
UREA S OSMOLALITY INC N OSMOTICALLY ACTIVE CONSTITUENT IN SAMPLES H0500
UREA S POTASSIUM DEC V NAY CAUSE SEVERE DEPLETION WITH DIURESIS P0299
UREA S SALICYLATE Z N UP TO 1000 MG/100NL NO EFFECT ON TRINDER METHOD P0606
UREA S SODIUM DEC V MAY CAUSE SEVERE DEPLETION WITH DIURESIS P0299
UREA S UREA NITROGEN INC V WHEN MASSIVE INFUSION FOP SICKLE-CELL DISEASE P0630
UREA U ALPHA AMINO NITROGEN Z N NO EFFECT IF DINITROFLUOROBENZENE METHOD USED P0385
UREA U OSMOLALITY INC N OSMOTICALLY ACTIVE CONSTITUENT IN SAMPLES P0500
UREA U PORPHOBILINOGEN DEC N INHIBITS COLOR DEVELOPMENT UNLESS PRIOR SEPARATION RO322
UREA U URINALYSIS HEMOGLOBIN INC V HENOGLOBINURIA MAY OCCUR ESP IF HYPOTHERMIA R0299
UREA U UROBILINOGEN DEC N PRODUCES YELLOW COLOR WITH EHPLICH’S REAGENT P01436
UREA U VOLUME INC V ACTS AS OSMOTIC DIURETIC P0630
UHETHAN B HEMATOCPIT DEC V MAY OCCUR WITH BONE NARROW DEPRESSION P0657
UHETHAN B HEMOGLOBIN DEC V MAY OCCUR WITH BONE NARROW DEPRESSION R0657
UHETHAN B PLATELET COUNT DEC V BONE MARROW APLASIA/PANCYTOPENIA P0026
URETHAN B RED CELL COUNT DEC V BONE MARROW APLASIA/PANCYTOPENIA P0620
URETHAN B WHITE CELL COUNT DEC V BONE MARROW APLASIA/PANCYTOPENIA P0026
URETHAN S BILIRUBIN INC V HEPATOTOXICITY WITH CENTROLOBULAR NECROSIS P0026
UHETHAN S SCOT INC V MAY CAUSE LIVER DAMAGE AND NECROSIS P0026
URETHAN S SGPT INC V NAY CAUSE LIVER DAMAGE AND NECROSIS P0026
URIC ACID P ALPHA AMINO NITROGEN INC M REACTS IN NAPHTHOQUINONE NEHOD OF FRAME P0436
URIC ACID S CREATININE Z N NO EFFECT ON METHOD OF POLAR AND NETCOFF R0546
URIC ACID S GLUCOSE DEC N IF MEASURED BY 0-TOLUIDINE 90750
URIC ACID S GLUCOSE INC N IF MEASURED BY ALE FEPRICYANIDE REDUCTION P0750

URIC ACID S GLUCOSE Z N NO EFFECT AT 100 MG/100NL GLU OX OF GOCHNAN P0370
URIC ACID S UREA NITROGEN INC N MAY REACT WITH BERTHELOT IF UREASE NOT USED P0779
URIC ACID T PROTEIN INC N REACTS WITH FOLIN-CIOCALTEU OF LOWRY METHOD HO 440
URIC ACID U URINALYSIS SUGAR INC N ACTS AS REDUCING AGENT WITH BENEDICT’S P062 0
UROBILIN U URINALYSIS COLOR INC N EXCESS MAY CAUSE YELLOW TO AMBER COLOR HO 66 3
VAGINAL POWDER U GLUCOSE INC N POWDERS OFTEN CONTAIN GLUCOSE P0596
VAGINAL POWDER U URINALYSIS GLUCOSE INC N POWDERS NAY CONTAIN GLUCOSE P014 17
VALINE P INSULIN INC V SLIGHT EFECT, AIDS METABOLISM OF AMINO ACIDS P0311
VALINE U PHOSPHATE INC V INHIBITS TUBULAR REABSORPTION HO 284
VANCONYCIN B POSINOPHILS INC V ALLERGIC RESPONSE P04214
VANCOMYCIN B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA R062O
VANCOMYCIN S UREA NITROGEN INC V NEPHROTOXIC EFFECT (MAY EVEN BE FATAL) P03 55
V A N CO N YC IN U PROTEIN INC V NEPHHOTOXICITY NAY OCCUR HO 355
VANCONYCIN U URINALYSIS PROTEIN INC V NEPHHOTOXICITY NAY OCCUR P03 55
VANILLA U VMA INC N NAY BE MEASURED BY COLORINETRIC METHOD P0355
VANILLIC ACID U PHENYLKETONES P05 N RED-VIOLET/BROWN WITH FECL3, BROWN PHENISTIX P0239
VANILLIN S GLUCOSE Z N AT 10 MG/100ML NO EFFECT GLU OX OF GOCHMAN P03 70
VAN ILL IN S GLUCOSE Z N AT 10 MC/100ML NO EFFECT ALKALINE FERRICYANIDE HO 370
VA SOPHES SIN P CORTISOL INC V MAY BE RISE OF UP TO 6 UG/100ML OP MORE P0914 0
VASOPPESSIN S PBI INC V STIMULATES THYROIDAL I 131 RELEASE P0004
VA SOPRESSIN S SODIUM DEC V MAY OCCUR WITH WATER RETENTION P0026
VASOPRESSIN U LEUCINE AMINOPEPTIDASE INC V ACTIVATES PEPTIDASES BY RELEASE OF PLASMINOGEN P0758
U VOLUME DEC V THERAPEUTIC INTENT P0026
VINBLASTINE B PLATELET COUNT DEC V MAY CAUSE BONE MARROW DEPRESSION P002 6
VINBLASTINE B RED CELL COUNT DEC V ANEMIA (SECONDARY TO LEUKOPENIA) P0026
VINBLASTINE B RETICULOCYTES DEC V ABSENCE FROM PERIPHERAL BLOOD OBSERVED P03 84
VINBLASTINE B WHITE CELL COUNT DEC V LEUKOPENIA P0026
VI NBLASTINE S URIC ACID DEC V OF THEORETICAL VALUE IN ACUTE GOUT P0378
VINCRISTINE B PLATELET COUNT DEC V NAY CAUSE BONE NARROW DEPRESSION HO 3 84
VI NCRI STI NE B WHITE CELL COUNT DEC V USUALLY REVERSIBLE LEUKOPENIA R0O26
VINCRISTINE S PBI Z V REPORTED TO HAVE NO EFFECT HO 255
VINCRI STINE S URIC ACID INC V INCREASED NUCLEIC ACID CATABOLISM P0907
VINYL ETHER S BILIHUBIN INC V POTENTIALLY HEPATOTOXIC R0026
VINYL ETHER S GLUCOSE INC V TRANSIENT EFFECT (LESS THAN WITH ETHER) 90026
VINYL ETHER S SGOT INC V POTENTIALLY HEPATOTOXIC P00 26
VINYL ETHER S SGPT INC V POTENTIALLY HEPATOTOXIC P0026
VINYL ETHER S UREA NITROGEN INC V POTENTIALLY NEPHROTOXIC P0026
VIONYCIN B EOSINOPHILS INC V ALLERGIC RESPONSE P0424
VIONYCIN B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA P0620
VIONYCIN S CALCIUM DEC V MAY CAUSE TETANY WITH ELECTROLYTE IMBALANCE HO 026
VIOMYCIN S CHOLESTEROL INC N INTERFERES WITH ZLATKIS-ZAK REACTION P0907
VIOMYCIN 002 CONTENT INC V ALTERED ELECTROLYTE BALANCE HO 355
VIOMYCIN S CREATININE INC V NEPHROTOXIC MAY CAUSE NITROGEN RETENTION P0620
VIOMYCIN S POTASSIUM DEC V NAY OCCUR WITH NEPHROTOXICITY HO 620
VIOMYIN S UREA NITROGEN INC V FREQUENT COMPLICATION P03 814
VIOMYCIN U CALCIUM INC V PROMOTES URINARY LOSS P0355
VI OMYCI N U CHLORIDE INC V PHOMOTES URINARY LOSS HO 02 6
VIONYCIN U POTASSIUM INC V PROMOTES URINARY LOSS P0026
VIOMYCIN U PROTEIN INC V MAY HAVE NEPHROTOXIC EFFECT P03 55
VIOMYCIN U URINALYSIS CASTS INC V NEPHROTOXICITY WITH CYLINDRURIA P0026
VIOMYCIN U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG HO 355
VIONYCIN U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT 110355
VIONYCIN TJ URINALYSIS RBC/HPF INC V MAY CAUSE ACTUAL BLEEDING P03 55
VITAMIN A B HENATOCRIT DEC V ANEMIA OBSERVED RO657
VITAMIN A B HEMOGLOBIN DEC V ANEMIA OBSERVED P0657
VITAMIN A B METHEMOCLOBIN INC V NAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0926
VITAMIN A B NEUTROPHILS DEC V LEUKOPENIA WITH HYPOPLASTIC ANEMIA REPORTED P0149 5
VITAMIN A B RED CELL COUNT DEC V WITH EXCESSIVE DOSES AND USE P06 20
VITAMIN A B SEDIMENTATION RATE INC V OBSERVED EFFECT BUT EXPLANATION UNKNOWN P0657
VITAMIN A B WHITE CELL COUNT DEC V LEUKOPENIA WITH HYPOPLASTIC ANEMIA REPORTED H 1010
VITAMIN A P PROTHROMBIN TINE INC V HEMORRHAGIC TREND EXP IF VITAMIN K RESTRICTED P06 20
VITAMIN A S BILIRUBIN INC N INTERFERES WITH ANALYSIS P0356
VITAMIN A S CHOLESTEROL INC M INTERFERES WITH ZLATKIS-ZAK REACTION P0907
VITAMIN A S DIRECT BILIHUBIN INC N INTERFERES WITH ANALYSIS P0356
VITAMIN A S I 131 UPTAKE DEC V SIG EFFECT WHEN ADMINISTERED FOR 3 WEEKS P0255
VITAMIN A S PSI DEC V INHIBITS IODINATION OF TYROSINE RESIDUES IN TBG P000 14
VITAMIN A S PBI INC V WHEN GIVEN IN COD LIVER OIL P06 20
VITAMIN A S PBI Z V NO EFFECT OBSERVED WHEN GIVEN FOR 3 WEEKS P0255
VITAMIN A S VITAMIN A INC V INGESTED COMPOUND IN SERUM P03 814
VITAMIN B P CATECHOLANINES INC N NAY BE INTERFERENCE WITH FLUORESCENCE HO 4 17
VITAMIN B U DIAGNEX BLUE EXCRETION INC N RELEASE OF DYE FROM RESIN P03 56
VITAMIN 912 B HEMATOCRIT INC V SUCCESSFUL TREAT MAY CAUSE MILD POLYCYTHENIA HO 657
VITAMIN B12 B RED CELL COUNT INC V SUCCESSFUL TREAT MAY CAUSE MILD POLYCYTHEMIA P0657
VITAMIN 912 P VITAMIN 912 INC V DURING TREATMENT OF VITAMIN B12 DEFICIENCY R0425
VITAMIN D F CALCIUM DEC V DUE TO EXCESSIVE ABSORPTION P029 1
VITA!’!IN 0 PHOSPHATE DEC V DUE TO EXCESSIVE ABSORPTION HO 29 1
VITAMIN D S ALKALINE PHOSPHATASE INC V MAY BE AFFECTED IN SOME CASES P0292
VITAMIN D S CALCIUM INC V EFFECT OF INCREASED G.I. TRACT ABSORPTION H 1001
VITAMIN 0 S CHOLESTEROL INC N INTERFERES WITH ZLATKIS-ZAK REACTION HO 907
VITAMIN D S CREATININE INC V MANIFESTATION OF HYPERVITAMINOSIS D P0026
VITAMIN 0 S NPN INC V MANIFESTATION OF HYPERVITAMINOSIS D HO 6 20
VITAMIN 0 S PHI INC V WHEN GIVEN IN COD LIVER OIL P0620
VITAMIN 0 S PHOSPHATE INC V EFFECT OF INC G.I. TRACT AND PENAL ABSORPTION R1001
VITAMIN D S UREA NITROGEN INC V MANIFESTATION OF HYPERVITAMINOSIS D P0026
VITAMIN D U CALCIUM INC V ASSOCIATED WITH HYPERCALCEMIA HO 299
VITAMIN D U PHOSPHATE INC V MAY BE NORMAL IN MANY CASES P0973
VITAMIN 0 U PROTEIN INC V NEPHPOTOXIC EFFECT WITH HYPERCALCEMIA RO299
VITAMIN D U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT AND RYPERCALCENIA R0299
VITAMIN P U ANINOLEVULINIC ACID DEC V POSSIBLE REDUCTION TO NORMAL LEVELS IN PORPHYRIA HO 688
VITAMIN P U PORPHOBILINOGEN DEC V POSSIBLE REDUCTION TO NORMAL LEVELS IN PORPHYRIA P0688

VITAMIN P U UROPORPHYRIN DEC V REDUCE TO NORMAL LEVELS IN PORPHYRIA 90688
VITAMIN K B HEMATOCRIT DEC V K3 AND K4 ONLY, ESP WITH G-6-PD DEFICIENCY 30570
VITAMIN K B HEMOGLOBIN DEC V K3 AND KU ONLY, ESP WITH G-6-PD DEFICIENCY HO 570
VITAMIN K B PLATELET COUNT DEC V PANCYTOPENIA REPORTED AFTER K3 AND K4 H 0657
VITAMIN K B RED CELL COUNT DEC V K3 AND K4 ONLY, ESP WITH G-6-PD DEFICIENCY 90570
VITAMIN K B WHITE CELL COUNT DEC V PANCYTOPENIA REPORTED AFTER K3 AND KLI 90657
VITAMIN K P CATECROLAMINES INC N MAY REACT LIKE EPINEPHRINE IN SHAW TEST 30160
VITAMIN K P PROTHROMBIN TIME DEC V THERAPEUTIC INTENT, AFFECTS ACTION OF WARFAPIN 90620
VITAMIN K S BILIRUBIN INC V LARGE DOSES IN NEONATES OH G-6-PD DEFICIENCY ROO79
VITAMIN K U PORPHYRINS INC V REPORTED SIDE EFFECT HO 6 57
VITAMIN K U URINALYSIS HEMOGLOBIN INC V EFFECT OF TREAT OF HEMORRHAGIC STATES IN CHILDREN 90026
VITAMIN K U URINALYSIS PROTEIN INC V REPORTED SIDE EFFECT 90657
VITAMIN K U UROBILINOGEN INC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENCY P0384
VITAMIN K U 17 OH CORTICOSTEROIDS INC N ALLEGED IN VITRO INTERFERENCE WITH HEDDY METHOD P04 17
VITAMIN PREPS S I 131 UPTAKE DEC V IF PREPARATIONS CONTAIN IODINE HO 596
VITAMIN PREPS S PHI INC N IODINE CONTAMINATION P03 55
VNA S GLUCOSE Z N AT 10 MG/100NL NO EFFECT GLU OX OF GOCHMAN 30370
VMA S GLUCOSE Z M AT 10 NG/100ML NO EFFECT ALKALINE FERHICYANIDE P0 370
N- 2 354 S URIC ACID DEC V MARKED ANTI-GOUT RESPONSE 30488
W- 2354 U URIC ACID INC V URICOSUPIC ACTION HO Li88
WALNUTS U 5 OH INDOLEACETIC ACID INC V RICH IN SEPOTONIN .01417
WAPFAHIN B BLEEDING TINE INC V MAY BE PROLONGED HO 368
WARFARIN B CLOTTING TIME INC V MAY BE PROLONGED HO 368
WARFAPIN B FACTOR II DEC V THERAPEUTIC ACTION H067
WARFARIN B FACTOR IX DEC V THERAPEUTIC ACTION 90Li67
WAPEAPIN B FACTOR VII DEC V THERAPEUTIC ACTION 30467
WARFAHIN B FACTOR X DEC V THERAPEUTIC ACTION P OP 67
WAHFAHIN B MCV DEC V MAY BE SECONDARY MICROCYTIC HYPOCHROMIC ANEMIA P03 68
WAPFARIN F OCCULT BLOOD P05 V NAY CAUSE CASTRO-INTESTINAL BLEEDING R0368
WAHFAPIN P PPOTHROMBIN TIME INC V THERAPEUTIC INTENT (INHIBITS PROTHROMBIN FORMATION) 90384
WARFARIN U URINALYSIS HEMOGLOBIN INC V DUE TO OVERDOSAGE IN SOME CASES HO 368
WARFAHIN U URINALYSIS RBC/HPF INC V EXCESSIVE DOSES MAY CAUSE HENATURIA P02 83
X-RAY THERAPY B LYMPHOCYTES DEC V DUE TO CELL DESTRUCTION 30291
X-RAY THERAPY B NEUTROPHILS DEC V ALSO TOXIC GRANULATION IN CELLS P02 91
X-RAY THERAPY B PLATELET COUNT DEC V THPOMBOCYTOPENIA P029 1
X-RAY THERAPY B RED CELL COUNT DEC V OCCURS WITH ONSET OF APLASTIC ANEMIA RO29
X-RAY THERAPY B WHITE CELL COUNT DEC V CELL DESTRUCTION IN LEUKEMICS H0930
X-RAY THERAPY P FIBRINOGEN INC V INDICATIVE OF TISSUE DAMAGE P0291
X-RAY THERAPY P PROTHROMBIN TINE INC V ALSO EXAGGERATED RESPONSE TO ANTICOAGULANTS HO 3814
X-RAY THERAPY S ALPHA1-GLOBULIN INC V INC DUE TO TISSUE DAMAGE 90291
X-RAY THERAPY S ALPHA2-GLOBULIN INC V INC RAPIDLY DUE TO TISSUE DAMAGE P029 1
X-RAY THERAPY S FERRITIN.INC V OCCURS WITHIN 2H OF DEEP X-RAY THERAPY 90291
X-RAY THERAPY S GAMMA GLOBULIN INC V MAY FALL IN SOME CASES (TISSUE DAMAGE) P 02 91
X-RAY THERAPY S PROPERIDIN DEC V DUE TO TISSUE DESTRUCTION R0291
X-RAY THERAPY S SGOT INC V OCCURS WITH LOCAL IRRADIATION INJURY P0291
X-RAY THERAPY U CREATINE INC V OCCURS WITH TISSUE DESTRUCTION HO 29 1
X-RAY THERAPY U LEUCINE AMINOPEPTIDASE INC V TOXIC DAMAGE DUE TO RELEASED METABOLITES P07 58
X-RAY THERAPY U MURAMIDASE INC V ASSOC WITH CELL DESTRUCTION IN LEUKENICS H0930
XA NTHI NES B FACTOR V INC V EFFECT OF NETHYLXANTHINES H038L1
X ANTHI NES P FIBRINOGEN INC V REPORTED EFFECT P0384
XA NTHINES P PROTHROMBIN TIME DEC V ANTAGONIZES EFFECTS OF COUMARINS P0620
XANTHINES S NEFA INC V REPORTED EFFECT P0384
XANTHINES T PROTEIN INC M REACTS WITH FOLIN-CIOCALTEU OF LOWRY METHOD 901440
X A NTR I N ES U CHLORIDE INC V DIURETIC ACTION 90384
XANTHINES U POTASSIUM INC V SLIGHT DIURETIC EFFECT ONLY 90384
XA NTHINES U SODIUM INC V DIURETIC ACTION H 03 84
XANTHINES U VOLUME INC V DIURETIC ACTION HO 384
XANTHOPHYLL S BILIRUBIN INC M NAY DEEPEN COLOR OF SERUM (?SIGNIFICANCE) P02 99
XY LITOL B PH DEC V PRONOUNCED METABOLIC ACIDOSIS IN MANY PATIENTS 909214
XYLITOL P INSULIN INC V ? SAME MECHANISM AS GLUCOSE TO RELEASE IN DOGS P056 1
KYLITOL S BILIHUBIN INC V MAINLY INDIRECT - BY 2 TO 3 TIMES NORMAL IN SOME P0277
XYLITOL S URIC ACID INC V INCREASES BY 1.5 TO 2 TIMES NORMAL P0277
XYLITOL U URIC ACID INC V AS RESULT OF INCREASED SERUM CONC (MAY BE DOUBLED) 90277
XYLOSE S GLUCOSE INC N NON-SPECIFICITY OF O-TOLUIDINE,FECN,NEOCUPROINE H 1009
X I LOSE U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S HO 436
XY LULOSE U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S P04 36
ZINC U MAGNESIUM INC N MEASURED BY FLUOROMETRIC METHOD OF SCHACHTER P09 23
ZINC SALTS S ALKALINE PHOSPHATASE DEC N INHIBITORS OF ENZYME IN LABORATORY PROCEDURES P092 9
ZOXAZOLANINE U PROTEIN INC V HAS NEPHROTOXIC EFFECT HO417
ZOXAZOLANI NE U URINALYSIS PROTEIN INC V MAY HAVE N!PHROTOXIC EFFECT P04 17
1 1-OXYSTEROIDS P ALPHA ANINO NITROGEN INC V PROMOTE TISSUE CATABOLISM R0299
1 1 -OXYSTEROIDS U ALPHA AMINO NITROGEN INC V PROMOTE TISSUE CATABOLISM P06 20
5- HYDR 0 XYIN DOLEA CET U UROBILINOGEN INC N REACTS WITH ERPLICH’S REAGENT R036
5-HYDPOXYTRY PTA MINE T UREA NITROGEN INC M GREEN COLOR WITH BERTHELOT’S REAGENT 90530
5-HYDROXYTHYPT AN INE U CHLORIDE DEC V SLIGHT EFFECT WITH INTRADEPNAL INJECTION R0384
5-HYDHOXYTRYPTA NINE U GFR DEC V VASCULAR EFFECT IN KIDNEY P0384
5-fl YDROXYTRYPTAM INE U SODIUM DEC V SLIGHT EFFECT WITH INTRADERMAL INJECTION P03814
5-HYDHOXYTRYPTA NINE U VOLUME DEC V WITH DOSES LARGE ENOUGH TO AFFECT CVS H 0384
5-HYDROXYTRYPTAMINE U 5 OH INDOLEACETIC ACID INC V MAY BE INGESTED VIA FOOD IN LARGE AMOUNTS P01417

DISULFIRAM B ACETALDFHYDE INC V ETHANOL METABOLISM DIVERTED (10 TINES NORMAL CONC) P0384
SO LFO NY LU PEAS B ACETALDEHYDE INC V MECHANISM NOT YET ELUCIDATED P03 84
ACETYLSALICYLIC AC S ACETOACETATE INC V DUE TO LATE METABOLIC ACIDOSIS AND RENAL IMPAIR HO 384
STREPTOZOTOC IN S ACETOACETATE INC V TEMPORARY EFFECT FOLLOWING INFUSION P06 86
AC ETA TES U ACETOACETATE INC N NAY INTERFERE WITH GERHARDT FECL3 PROCEDURE HO 143
ACETYLSALICYLIC AC U ACETOACETATE INC V ACIDOTIC RESPONSE ESP IN CHILDREN HO 36 8
ACETYLSALICYLIC AC U ACETOACETATE INC N REACTS WITH GEPHAHDT FECL3 PROCEDURE P100 1
ANTIPYPINE U ACETOACETATE INC N INTERFERES WITH FERRIC CHLORIDE TEST H06 514
CY AN ATE U ACETOACETATE INC N MAY PRODUCE INTERFERING COLOR WITH GERHARDT FECL3 HO 299
PHENOTHI AZINES U ACETOACETATE INC N METABOLITES REACT WITH FECL3 P1001
TEIYMOL U ACETOACETATE Z N NO EFFECT ON GERHARDT PROCEDURE 90779
T9YMOL U ACETONE Z N NO EFFECT ON ROTHERA PROCEDURE P0779
?PPGN ANCY S ACETYL-GLUCOSAMINIDASE INC V THREE TINES NORMAL IN LAST TRIMESTER H 0291
CONTACT WITH CLOT S ACID PHOSPHTASE TOTAL DEC N LABILE AT ROOM TEMPERATURE P1001
CO??E9 S ACID PHOSPHATASE TOTAL DEC N CUPRIC IONS INHIBIT RED CELL ENZYME P0929
FLUORIDES S ACID PHOSPHATASE TOTAL DEC N ENZYME ACTIVITY INHIBITED BY FLUORIDE 90003
FLUOI DES S ACID PHOSPHATASE TOTAL DEC V IN VIVO INHIBITION OBSERVED P033 8
903 MALDEHYDE S ACID PHOSPHATASE TOTAL DEC N STRONG INHIBITOR OF HED CELL ENZYME P09 29
OXALATES S ACID PHOSPHATASE TOTAL DEC N INHIBITION OF ENZYME IN LABORATORY PROCEDURES P092 9
PHD SPHATPS S ACID PHOSPHATASE TOTAL DEC N INHIBITS REACTION IF HIGH CONC IN SUBSTRATE P0299
STORAGE OF SAMPLE S ACID PHOS?HATASE TOTAL DEC N 50% ACTIVITY LOST AFTER 5H AT ROOM TEMP P0998
TARTRATES S ACID PHOSPHATASE TOTAL DEC N STRONG INHIBITORS OF PROSTATIC ENZYME P09 29
A NDHO3 ENS S ACID PHOSPHATASE TOTAL I NC V EFFECT OF HORMONE IN FEMALES 90299
CLDWIBHATE S ACID PHOSPHATASE TOTAL I NC V REPORTED EFFECT (?MECHANISM) P02 99
URMOLYSIS S ACID PHOSPHATASE TOTAL IN C N ERYTHHOCYTES CONTAIN CONSIDERABLE ACTIVITY P077 9
PPOSTATE PALPATION S ACID PHOSPHATASE TOTAL I NC V RELEASE INTO BLOODSTREAM P03 56
SERUM S ACID PHOSPHATASE TOTAL INC N RELEASE OF ENZYME FROM ERYTHROCYTES P1001
STORAGE OF SAMPLE S ACID PHOSPHATASE TOTAL Z N STORAGE AT -20 DEGREES FOR OVER 14 MONTHS P0998
STORAGE 0? SAMPLE S ADENOSINE DEAMINASE Z N NO EFFECT 1 WEEK AT 4 DEGREES, 1 MONTH AT -20 DEC P0998
CHLORTHALI DONE P ADH INC V SECRETED IN RESPONSE TO HYPONATRENIA P0325
ETHER P ADH INC V EFFECT IN MODERATE TO DEEP ANESTHESIA HO 3814
HYDPOCHLOHOTHIAZIDE P ADH INC V SECRETED IN RESPONSE TO HYPONATPEMIA HO 325
METHYCLOTHIAZIDE P ADH INC V SECRETED IN RESPONSE TO HYPONATPENIA P0325
POLYTHIAZIDE P ADH INC V SECRETED IN RESPONSE TO HYPONATPEMIA H 0325
CHLOHPROP AM IDE U ADH INC V STIMULATES RELEASE FROM NEUHOHYPOPHYSIS HO 357
PAIN U ADH INC V ALSO SEEN MOPE MARKEDLY WITH EMOTIONAL STRESS P0549
AMINOSALICYLIC AC U AICAR INC V OCCURS WITH VITAMIN B12 DEFICIENCY P0976
ANTICONVULSANTS U AICAH INC V OCCURS WITH NEGALOBLASTIC ANEMIA RO976
BARBITURATES U AICAR INC V OCCURS IF MEGALOBLASTIC ANEMIA R0976
COLC HIC INE U AICAR INC V MEGALOBLASTIC ANEMIA WITH B12 DEFICIENCY P0976
CYCLOSF.BINE U AICAR INC V OCCURS WITH FOLIC ACID DEFICIENCY P0976
DIPHPNYLHYDA NTOIN U AICAR INC V OCCURS WITH IMPAIRED ABSORPTION OF FOLIC ACID P0976
PS T HOG EN S U AICAP INC V OCCURS WITH MEGALOBLASTIC ANEMIA P0976
ETHANOL U AICAR INC V NAY OCCUR WITH FOLIC ACID OH B12 DEFICIENCY P0976
ISONIAZI 0 U AICAR INC V OCCURS IF MEGALOBLASTIC ANEMIA RO976
METFORIIN U AICAR INC V MAY CAUSE MEGALOBLASTIC ANEMIA P09 35
NETHOTPEXATE U AICAR INC V OCCURS WITH INDUCED FOLIC ACID DEFICIENCY P0976
NEOMYCIN U AICAP INC V IF MEGALOBLASTIC ANEMIA DEVELOPS R0976
ORAL CONTRACEPTIVE U AlTAR INC V OCCURS IF MEGALOBLASTIC ANEMIA DEVELOPS P0976
PENTAMIDINE U AICAR INC V IF MEGALOBLASTIC ANEMIA DEVELOPS R0976
PHENOBABRITAL U AICAH INC V IF NEGALOBLASTIC ANEMIA DEVELOPS P079 1
PRIMIDONE U AICAR INC V IF MEGALOBLASTIC ANEMIA OCCURS HO 791
PYRIMETHA MINE U AICAP INC V IF NEGALOBLASTIC ANEMIA OCCURS P1007
TRIANTEPENE U AICAH INC V IF NEGALOBLASTIC ANEMIA OCCURS P0976
OPAL CONTRACEPTIVE P ALANINE DEC V HORMONAL EFFECT (SECOND PART OF CYCLE) P0226
GLUCOSE S ALANINE INC V RISE RELATED TO GLUCONEOGENESIS AFTER LOAD P03 97
LEAD U ALANINE INC V OCCURS WITH POISONING HO 29 1
ACETYLSALICYLIC AC S ALBUMIN DEC M DECREASED DYE BINDING CAPACITIY P0907
ASPAHAGINASE S ALBUMIN DEC V HEPATOTOXICITY (OBSERVED IN 80% PATIENTS) P070 5
AZATHIOPPINE S ALBUMIN DEC V MAY CAUSE HEPATOTOXICITY P0893
BILIRUBIN S ALBUMIN DEC N IF HABA, METHYL ORANGE, OR BIUHET METHODS USED P0576
CARBON DISULFIDE S ALBUMIN DEC V EFFECT GREATER THAN ON TOTAL PROTEIN P0254
CATHARTICS S ALBUMIN DEC V RARE PROTEIN-LOSING GASTPOENTEROPATHY R0384
CYCLOPHOS PHI NIDE S ALBUMIN DEC V MAY CAUSE HEPATOTOXICITY RO893
FSTROGFNS S ALBUMIN DEC V METABOLIC CHANGES IN LIVER SYNTHESIS P0588
ETHINYLESTBADIOL S ALBUMIN DEC V METABOLIC EFFECT H0149
HFMOLYSIS S ALBUMIN DEC N AFFECTS MEASUREMENT BY HABA, BIURET, METHYL ORANGE R0998
LACTAT ION S ALBUMIN DEC V REMAINS ABOUT 1 C/100ML BELOW NORMAL HO 291
MESTRANOL S ALBUMIN DEC V METABOLIC EFFECT H 0853
OPAL CONIPACEPTIVE S ALBUMIN DEC V 10% FALL IF USED FOR SEVERAL MONTHS HO 459
OXYPUENI SATIN S ALBUMIN DEC V NAY CAUSE HYPERSENSITIVITY REACTION HO776
PREGNANCY S ALBUMIN DEC V FALLS ABOUT 1G/100NL IN LAST 2 TPIMESTERS HO 29 1
PYRAZINIMIDE S ALBUMIN DEC V HEPATOTOXICITY (VIRAL-NEPATITIS LIKE) P0026
HEMOGLOBIN S ALBUMIN INC N IF NO BLANK WITH HABA DYE, SLIGHT EFFECT BCG P0670
HEPARI N S ALBUMIN INC M PROMOTES BINDING OF HABA DYE TO GLOBULINS P0907
LIPEMIA S ALBUMIN INC N AFFECTS MOST METHODS UNLESS BLANK CORRECTION P0998
PROGESTIN S ALBUMIN INC V NOT OBSERVED WITH COMBINED THERAPY P0243
TOURNIQUET S ALBUMIN INC V AFFECTS ALL PROTEIN BOUND CONSTITUENTS ALSO P014 36
BILIRUBIN S ALBUMIN Z N NO EFFECT IF BRONOCP.ESOL GREEN USED IN METHOD P0576
MEALS S ALBUMIN Z V NO EFFECT AFTER STANDARD BREAKFAST H0181
PHENOT HIAZ INES S ALDOLASE DEC V IN SCHIZOPHRENICS WITH HIGH INITIAL VALUES HO 657
PPO8UCOL S ALDOLASE DEC V MECHANISM OBSCURE R02147
ACETYLSALICYLIC AC S ALDOLASE INC V EXPTL EFFECT SEEN IN RABBITS WITH PROLONGED USE HO 806
CA BENOXOLONE S ALDOLASE INC V DOE TO HYPOKALEMIC NYOPATHY P00714
CHLOPINATED INSECT S ALDOLASE INC V PRESUMED DAMAGE OF LIVER CELLS HO 130
CORTI SONE S ALDOLASE INC V IN EXPTL ANIMALS ? OF MUSCLE ORIGIN P0990
HEMOLYS IS S ALDOLASE INC M HIGH CONTENT IN EHYTHPOCYTES AND PLATELETS P02 44
MUSCULAR EXERCISE S ALDOLASE INC V EFFECT OF PHYSICAL TRAINING P0779
OP GA NOPHOS PHORU S S ALDOLASE INC V HEPATOTOXIC EFFECT P01 30
THIABENDZOLP S ALDOLASE INC V PROB OF MUSCLE ORIGIN ALTHOUGH TAKEN ORALLY P06 57

MUSCULAR EXERCISE S ALDOLASE Z V PHYSICAL ACTIVITY HAS NO EFFECT P0779
STORAGE OF SAMPLE S ALDOLASE Z N NO EFFECT 1 WEEK AT 4 DEGREES, 1 MONTH AT -20 DEG P 0998
LICORICE P ALDOSTERONE DEC V HORMONAL LIKE ACTION OF DRUG R00714
SALINE P ALDOSTERONE DEC V SHORT TERN RESPONSE IF GIVEN I.V. IN HYPERTENSIVES HO 522
CLONI DINE U ALDOSTERONE DEC V SECONDARY TO EFFECT ON PENIN P0455
HEPARIN U ALDOSTERONE DEC V SUPPRESSED SECRETION WITH PROTRACTED TREATMENT P01467
LICORICE U ALDOSTEHONE DEC V PSEUDOALDOSTERONISN EFFECT H 097 3
ANGIOTENS IN P ALDOSTERONE INC V INC OF 14 TIMES NORMAL AFTER I.V. FOR 1 HOUR P0331
ERECT POSTURE P ALDOSTEPONE INC V INCREASES APPROX 6 TIMES IF NORMAL DIET 90026
LAXATIVES P ALDOSTEHONE INC V MAY OCCUR IN RESPONSE TO HYPOKALEMIA H0657
ORAL CONTRACEPTIVE P ALDOSTERONS INC V INCREASED SYNTHESIS BY ADRENAL GLAND RO588
LITHIUM U ALDOSTER0NE INC V OCCURS AFTER INITIAL FALL P0685
OPAL CONTRACEPTIVE U ALDOSTERONE INC V ESTROGEN EFFECT (IN SMALL NUMBER OF PEOPLE) 90186
PREGNANCY U ALDOSTERONE INC V DURING LAST TRIMESTER HO 29 1
ARSENICALS S ALKALINE PHOSPHATASE DEC N ARSENATES ARE INHIBITORS OF ENZYME IN LAB PROCS P0929
AZATRIOPRINE S ALKALINE PHOSPRATASE DEC V IMPROVES BILIARY EXCRETION IN BILIAHY CIRRHOSIS P0799
BERYLLIUM SALTS S ALKALINE PHOSPHATASE DEC N INHIBITORS OF ENZYME IN LABORATORY PROCEDURES RO929
CONTACT WITH CLOT S ALKALINE PHOSPHATAS! DEC N REPORTED EFFECT ?TEMPERATURF OR STABILITY RI 001
CYANIDES S ALKALINE PHOSPRATASE DEC N INHIBITORS OF ENZYME IN LABORATORY METHODS HO 929
FLUORIDES S ALKALINE PHOSPHATASE DEC M INHIBITORY ACTION ON ENZYME P0436
FLUORIDES S ALKALINE PHOSPHATASE DEC V IN VIVO INHIBITION WITH DOSES FOR FLUORIDATION P03 21
GLYCI N! S ALKALINE PHOSPHATASE DEC N IF USED AS BUFFER IN LAB PROC AS COMPLEXES MG P092 9
ORAL CONTRACEPTIVE S ALKALINE PHOSPHATASE DEC V SLIGHT DECREASE REPORTED IN ONE STUDY HO 657
OXALATES S ALKALINE PHOSPHATASE DEC N INHIBITION OF ENZYME IN LABORATORY PROCEDURES R0299
PHOSPHATES S ALKALINE PHOSPHATASE DEC N INHIBITS REACTION IF HIGH CONC IN SUBSTRATE HO 299
SULFHYDRYL COMPS S ALKALINE PHOSPHATASE DEC N INHIBIT ENZYME ACTIVITY IN LABORATORY METHODS H0929
ZINC SALTS S ALKALINE PHOSPHATASE DEC N INHIBITORS OF ENZYME IN LABORATORY PROCEDURES 90929
ETHI 0 NA MI DE U ALKALINE PHOSPHATASE DEC N INTERFERENCE WITH DETERMINATION PROCEDURE 90758
NITROFURANTOIN U ALKALINE PHOSPHATASE DEC N INTERFERENCE WITH DETERMINATION METHOD R0700
ACETOHEXA MIDE S ALKALINE PHOSPHATASE INC V MAY CAUSE INTRAHEPATIC CHOLESTATIC JAUNDICE 90204
ACETOP HEN AZINE S ALKALINE PHOSPHATASE INC V CHOLESTATIC HEPATITIS WITH OBSTRUCTION P06 20
ACETOPHENETIDIN S ALKALINE PHOSPHATASE INC V MAY CAUSE HEPATIC TOXICITY P0620
ACETYLSALICYLIC AC S ALKALINE PHOSPHATASE INC V PROLONGED USE MAY CAUSE HEPATIC TOXICITY HO 573
AJMALIN! S ALKALINE PHOSPHATASE INC V INTRAHEPATIC CHOLESTASIS P0 088
ALBUMI N, HUMAN S ALKALINE PHOSPHATASE INC V PLACENTAL A.P. IF FROM PITNAN-NOOHE OR PARKE-DAVIS P04 17
ALLOPU RINOL S ALKALINE PHOSPHATASE INC V REVERSIBLE CLINICAL HEPATOTOX!CITY NOTED 90204
AMBULATION S ALKALINE PHOSPHATASE INC V FOLLOWING PROLONGED BED REST(?INC BONE FORMATION) 90471
AMINOSALICYLIC AC S ALKALINE PHOSPHATASE INC V REVERSIBLE CHOLESTASIS MAY OCCUR H 0477
ANITRI PTYLINE S ALKALINE PHOSPHATASE INC V RARE CASES OF CHOLESTASIS (TRANSIENT) P06 73
ANODIA QUINE S ALKALINE PHOSPHATASE INC V REPORTED HEPATOTOXICITY 90620
AMPHOTERICIN B S ALKALINE PHOSPHATAS! INC V DUE TO HEPATOCELLULAP DYSFUNCTION P062 0
ANABOLIC STEROIDS S ALKALINE PHOSPHATASE INC V CHOLESTATIC SYNDROME HO 3814
A N DROG EN S S ALKALINE PHOSPHATASE INC V MAY CAUSE CHOLESTATIC SYNDROME P02 99
ANTICONVULSANTS S ALKALINE PHOSPHATASE INC V OCCURS IN 214% CHILDREN (90% BONY OPIGIN) P04 73
ANTIFUNGAL AGENTS S ALKALINE PHOSPHATASE INC V HEPATOTOXICITY NAY OCCUR RO355
ANTIMONY COMPOUNDS S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT HO 596
ARSENICALS S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT (CHOLESTASIS/CHOLANGIOLITIS) HO 596
ASPAR AGIN ASP S ALKALINE PHOSPHATASE INC V NAY CAUSE HEPATOTOXICITY (FREQUENT) P0427
ASPIDIUM S ALKALINE PHOSPHATASE INC V NAY CAUSE HEPATIC TOXICITY P06 20
AZATHIOPRINE S ALKALINE PHOSPHATASE INC V NAY BE VERY HIGH, LIVER DAMAGE OR BILIAHY STASIS P01467
BARBITU RATES S ALKALINE PHOSPHATASE INC V RAPE CASE OF HEPATOTOXICITY P0114
BENZIODARONE S ALKALINE PHOSPHATASE INC V MAY CAUSE HEPATIC TOXICITY R0620
BISNUTH S ALKALINE PHOSPHATASE INC V HEPATOTOXICITY P0620
BLOOD GROUP S ALKALINE PHOSPHATA5E INC V 0 SECRETOR SUBJECTS - HIGHEST INTESTINAL COMPONENT 110969
BROMSULFALEIN S ALKALINE PHOSPHATASE INC N INTERFERES WITH BESSEY PROCEDURE P0 192
CARBAMAZEPINE S ALKALINE PHOSPRATAS! INC V CHOLESTATIC AND HEPATOCELLULAP DAMAGE P076 2
CAHBENICILLIN S ALKALINE PHOSPHATASE INC V TRANSIENT ELEVATIONS REPORTED HO 3814
CARBUTANIDE S ALKALINE PHOSPHATASE INC V HEPATOTOXICITY P0620
CEPHALORIDINE S ALKALINE PHOSPHATASE INC V MECHANISM NOT LISTED P014 17
CR ENODEOXYCHOLIC S ALKALINE PHOSPHATASE INC V MILD TRANSIENT ELEVATION OBSERVED 902148
CHLOR AMPHEN ICOL S ALKALINE PHOSPHATASE INC V ?HEPATOTOXIC-CHOLESTATIC EFFECT RO596
CHLORDIAZEPOXIDE S ALKALINE PHOSPHATASE INC V INFREQUENT CHOLESTATIC EFFECT P0596
CHLORINATED INSECT S ALKALINE PHOSPHATASE INC V PRESUMED DAMAGE OF LIVER CELLS P0130
CHLOR NEZA NONE S ALKALINE PHOSPHATASE INC V HEPATOTOXICITY H 0620
CHLOPOFO RN S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT WITH NECROSIS H062O
CHLOP OT HIAZ IDE S ALKALINE PHOSPHATASE INC V NAY CAUSE CHOLESTATIC JAUNDICE R0620
CULORPRONAZINE S ALKALINE PHOSPHATASE INC V HEPATIC SENSITIVITY TO DRUG (IN UP TO 2% PATIENTS) P085 9
CULORPROPAMIDE S ALKALINE PHOSPHATASE INC V INFREQUENT INTRAHEPATIC CHOLESTASIS P04 77
CHLORPROTHI XENE S ALKALINE PHOSPHATASE INC V HEPATOTOXICITY (REVERSIBLE) 306 20
CII LORTETRACYCLI NE S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT WITH CENTROLOBULAR NECROSIS 90355
CHLOR ZOXA ZONE S ALKALINE PHOSPHATAS! INC V MAY CAUSE HEPATOTOXICITY HO 620
CINCHOPHEN S ALKALINE PHOSPHATAS! INC V NAY CAUSE INTRAHEPATIC CHOLESTASIS P 0620
CLINDANYCIN S ALKALINE PHOSPHATASE INC V TRANSIENT ABNORMALITY NOTED 90949
CLOFIBPATE S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT R062O
CLONI DINE S ALKALINE PHOSPHATASE INC V SINGLE PROBABLE CASE OF TOXIC HEPATITIS P0365
COLCHIC IN! S ALKALINE PHOSPHATASE INC V POSSIBLE HEPATOTOXIC EFFECT 90596
COUMARIN S ALKALINE ?HOSPHATASE INC V NAY CAUSE HEPATOTOXICITY H 0990
CYCLOPHOSPHAMIDE S ALKALINE PHOSPHATASE INC V MAY CAUSE HEPATOTOXICITY P06 20
CYCLOPPOPANE S ALKALINE PHOSPHATASE INC V MAY CAUSE HEPATOTOXICITY (LASTS SEVERAL DAYS) P06 20
CYCLOSERINE S ALKALINE PHOSPHATASE INC V NAY CAUSE HEPATOTOXICITY P0620
DESI P PA MI N! S ALKALINE PHOSPHATAS? INC V TRANSIENT CHOLESTASIS (RARE) 30620
DIPHENYLHYDANTOIN S ALKALINE P9OSPHATASE INC V HEPATOTOXICITY WITH CENTROLOBULAR NECROSIS P06 20
DISULFIRAN S ALKALINE PHOSPHATASE INC V ONE POSSIBLE CASE OF CHOLESTASIS REPORTED P01467
ECTYL UREA S ALKALINE PHOSPHATASE INC V MAY CAUSE CROLESTASIS WITH CHOLANGIOLITIS P0620
ERYTHHOMYCIN S ALKALINE PHOSPRATASE INC V MAY CAUSE INTRAHEPATIC CHOLESTASIS (REVERSIBLE) P03 30
ESTRADIOL S ALKALINE PHOSPHATASE INC V OCCURS IN UP TO 50% CASES R0681
ESTPOG ENS S ALKALINE PHOSPHATASE INC V TRANSIENT INCREASES 2 TO 50% REPORTED 90566
ES TR ONE S ALKALINE PHOSPHATASE INC V OCCURS IN UP TO 50% CASES 90681
ETHER S ALKALINE PHOSPHATASE INC V HEPATIC DISTURBANCE (TRANSIENT) P0839
ETHIONAMIDE S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT P06 20

FTHOTOIN S ALKALINE PHOSPHATASE INC V PROBABLE IDIOSYNCRATIC HEPATITIS HO 6 20
ETH OX A Z SHE S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT P0620
FATTY FOODS S ALKALINE PHOSPHATASE INC V EFFECT MOST MARKED 14H AFTER MEAL IN 0 SECRETORS P0969
FENOXY PROPAZNE S ALKALINE PHOSPHATASE INC V PRODUCED FATAL HEPATOTOXICITY R0657
FLOP ANT YRONE S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT P06 20
FLUOROCYTOSINE S ALKALINE PHOSPHATASE INC V REVERSIBLE HEPATOTOXICITY IN 10% P0898
FLtIOXY MESTEPONF S ALKALINE PHOSPHATASE INC V INTHAHEPATIC CHOLE5TATIC JAUNDICE H 03 84
FLUPHENAZINE S ALKALINE PHOSPHATASE INC V HYPERSENSITIVITY RESPONSE P0620
FLU PAZ E PA N S ALKALINE P9OSPHATASE INC V NAY CAUSE HEPATIC TOXICITY H 0788
GENTANICIN S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT RO384
GLYCOPYRROL AT? S ALKALINE PHOSPHATASE INC V HEPATOTOXICITY P06 20
GOLD S ALKALINE PHOSPHATASE INC V RAPE SIDE EFFECT WITH LIVER DAMAGE (REVERSIBLE) P0029
GRISEOFULVIN S ALKALINE PHOSPHATASE INC V MAY BE HEPATOTOXIC P0596
CU ANOXAN S ALKALINE PHOSPRATASE INC V MAY CAUSE HEPATIC TOXICITY P0620
HALOPEPIDOL S ALKALINE PHOSPHATASE INC V NAY CAUSE HEPATOCELLULAR CHANGES H 0620
H ALOTH ANE S ALKALINE PHOSPHATASE INC V REVERSIBLE DEPRESSION OF LIVER FUNCTION P086 1
HENOLYSIS S ALKALINE PHOSPHATASE INC N PBC CONC 6X SERUM SO EFFECT MININAL HO 1436
HYDANTOINS S ALKALINE PHOSPRATASE INC V SEVERE DELAYED HYPERSENSITIVITY REPORTED P0657
HYDRA ElMS S ALKALINE PHOSPHATASE INC V MAY CAUSE HEPATOTOXICITY P06 20
HYDHOFLUMETHIAZIDE S ALKALINE PHOSPHATASE INC V MAY CAUSE INTHAHEPATIC CROLESTASIS P04 67
HYDROXYACETAMIDE S ALKALINE PHOSPHATASE INC V HEPATOTOXICITY P02 99
IBUFENAC S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT P 06 20
ICTEPOGENIN S ALKALINE PHOSPHATASE INC V CAUSES INTPAHEPATIC CHOLESTASIS P00 514
IDOXU PIDINE S ALKALINE PHOSPHATASE INC V CHOLESTATIC JAUNDICE REPORTED IN ONE CASE HO 259
1 N I P P A NINE S ALKALINE PHOSPHATASE INC V NAY CAUSE CHOLESTATIC JAUNDICE P05 12
INDOMETHACIN S ALKALINE PHOSPHATASE INC V CYTOTOXIC AND CHOLESTATIC LIVER DAMAGE P 052 1
IPRINDOLE S ALKALINE PHOSPHATASE INC V MILD ELEVATION WITH CHOLESTASIS P00 12
IPRONIAZ ID S ALKALINE PHOSPHATASE INC V MAY CAUSE CHOLESTATIC JAUNDICE HO 620
ISOCAPBOXAZID S ALKALINE PHOSPHATASE INC V CHOLESTATIC EFFECT RO62O
IS ONIA ZID S ALKALINE PHOSPHATASE INC V PROBABLE CHOLESTATIC EFFECT HO 596
KANANYCIN S ALKALINE PROSPHATASE INC V MAY CAUSE HEPATOTOXICITY P0620
LEVODOPA S ALKALINE PHOSPHATASE INC V RARE ELEVATION REPORTED P00 26
LINCOMYCIN S ALKALINE PHOSPHATASE INC V HEPATOTOXIC-CHOLESTATIC EFFECT P02 99
MAGNESIUM SALTS S ALKALINE PHOSPHATASE INC N ACTIVATORS OF ENZYME IN LABORATORY PROCEDURES P09 29
MANGANESE SALTS S ALKALINE PHOSPHATASE INC N ACTIVATORS OF ENZYME IN LABORATORY PROCEDURES P09 29
MAO INHIBITORS S ALKALINE PHOSPHATASE INC V CHOLESTATIC EFFECT HO 596
MEALS S ALKALINE PHOSPHATAS! INC V PATTY MEALS ESP IN 0 SECRETOPS R0998
NECHLORETHAMINE S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT R0O79
NEPACRINE S ALKALINE PHOSPHATAS! INC V HEPATOTOXIC EFFECT P06 20
MEPAZINE S ALKALINE PHOSPHATASE INC V CHOLESTATIC EFFECT P01477
MEPHENYTOIN S ALKALINE PHOSPHATASE INC V HEPATOTOXICITY P06 20
MEPHOBA MATE S ALKALINE PHOSPHATASE INC V NAY CAUSE CHOLESTATIC (REPATOCANALICULAR) JAUNDICE P0079
NEHCA PTOPU PINE S ALKALINE PHOSPHATASE INC V HEPATOTOXICITY (CENTROLOBULAR NECROSIS) HO 6 20
METAHEXA MIDE S ALKALINE PHOSPHATASE INC V HEPATOTOXTCITY (VIRAL HEPATITIS TYPE) RO620
NETA NOTE NONE S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT (COMMON) P06 20
NETAXALONE S AL’ALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT P0620
METHANDR IOL S ALKALINE PROSPHATASE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE HO 384
NETH A NDPOSTENOLONE S ALKALINE PHOSPHATASE INC V INTRAHEPATIC CHOLESTATIC JA UN DICE HO 384
NETHIN AZOLE S ALKALINE PHOSPHATASE INC V CHOLESTATIC EFFECT P0477
N ETH OT H EX ATE S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT (SEEN IN 5% CASES PSOPIASIS) P0698
NETHOX SALEM S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT P06 20
NET HOXY FLU BA NE S ALKALINE PHOSPHATASE INC V HEPATIC TOXICITY P086 1
METHYL DOPA S ALKALINE PHOSPRATASE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE HO 3 00
NETHYLTESTOSTE HONE S ALKALINE PHOSPHATAS! INC V CHOLESTATIC EFFECT H 0431
NETHYLTHIOURACIL S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT P06 20
NITOTA NE S ALKALINE PHOSPHATASE INC V POSSIBLE HEPATOTOXIC EFFECT (REPORTED IN DOGS,RATS) HO 4 67
NORPHI NE S ALKALINE PHOSPHATASE INC V ASSOCIATED WITH ABNORMAL LIVER FUNCTION P0620
NALIDIXIC ACID S ALKALINE PHOSPRATASE INC V MAY CAUSE CHOLESTATIC JAUNDICE P07 36
NIALANIDE S ALKALINE PHOSPHATASE INC V PROBABLE HYPERSENSITIVE HEPATITIS P0026
NICOTINIC ACID S ALKALINE PHOSPHATASE INC V NAY CAUSE INPARIMENT OF HEPATIC FUNCTION P07 19
NITHOFUPANS S ALKALINE PHOSPHATASE INC V HEPATOTOXICITY P0620
NITROFURANTOIN S ALKALINE PHOSPRATASE INC V MAY CAUSE CHOLESTATIC JAUNDICE P0736
NITROPHENOL S ALKALINE PHOSPHATASE INC V HYPERSENSITIVE INTRAHEPATIC CHOLESTASIS P0405
NOR ETH A NDR 0 LO NE S ALKALINE PHOSPHATASE INC V CHOLESTASIS PRODUCED WITHOUT CHOLANGIOLITIS P043 1
NOHETHA NDROSTENOL S ALKALINE PHOSPHATASE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE 90834
NOHETHINDRONE S ALKALINE PHOSPHATAS! INC V CHOLESTATIC EFFECT P0620
NORETHISTEPONE S ALKALINE PHOSPHATASE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P038 4
NO RETHYNODP EL S ALKALINE PHOSPHATASE INC V DUE TO CHOLESTASIS P0492
NO? TES T OS SE RONE S ALKALINE PHOSPHATASE INC V REPORTED TO AFFECT LIVER FUNCTION HO 596
NORTRI PTY LINE S ALKALINE PHOSPHATASE INC V NAY CAUSE CHOLESTATIC JAUNDICE P0026
NOVOBIOCIN S ALKALINE PHOSPHATASE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE CAN OCCUR P 0384
OLEANDOMYCI N S ALKALINE PHOSPHATASE INC V C}IOL!STATIC JAUNDICE REPORTED P002 1
OPAL CONTRACEPTIVE S ALKALINE PUOSPHATASF INC V MAY CAUSE CHOLESTASIS, PARE HEPATOCELLULAP DEGEN 110 4 77
ORGANOPHOSPHORUS S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT RO13O
OXACILLIN S ALKALINE PHOSPHATASE INC V CHOLESTATIC JAUNDICE REPORTED IN ONE CASE HO 299
OXAZFPAM S ALKALINE PHOSPHATASE INC V POSSIBLE REPATOTOXICITY P0620
OXYMF.THOLONE S ALKALINE PHOSPHATASE INC V CHOLESTATIC EFFECT P0477
OXYPHENBUTAZONE S ALKALINE PHOSPHATASE INC V POSSIBLE REPATOTOXICITY P06 20
OXYPHENISATIN S ALKALINE PROSPHATASE INC V HEPATIC TOXICITY IF OVER PROLONGED PERIOD P0727
PAPAVERINE S ALKALINE PROSPHATASE INC V REVERSIBLE HEPATOTOXIC EFFECT P07 93
PARALDEHYDE S ALKALINE PHOSPHATASE INC V POSSIBLE HEPATOTOXICITY P0620
PARANETHADIONE S ALKALINE PHOSPHATASE INC V POSSIBLE HEPATOTOXICITY P 0620
PAHCYLINE S ALKALINE PHOSPHATASE INC V POSSIBLE HEPATOTOXICITY (REVERSIBLE) HO 620
PECAZINE S ALKALINE PHOSPHATASE INC V NAY ALTER LIVER FUNCTION (CHOLESTASIS) HO 620
PENICI LLANI NE S ALKALINE PHOSPHATASE INC V POSSIBLE HEPATOTOXICITY R0299
PER HEX IL! NE S ALKALINE PHOSPHATASE INC V TRANSIENT ELEVATION OBSERVED HO 1453
PHENACEMI DE S ALKALINE PHOSPHATASE INC V MAY AFFECT LIVER FUNCTION IN ABOUT 2% CASES P0620
PHENAZOPYRI DINE S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT P0620
PHENETURIDE S ALKALINE PHOSPHATASE INC V FREQUENTLY OCCURS P0384
PH ENI NDIOWE S ALKALINE PHOSPHATASE INC V NAY MODIFY LIVER FUNCTION (CHOLESTASIS) P06 20

PHENIPPAZINE S ALKALINE ?HOSPHATASE INC V HYPERSENSITIVE HEPATITIS RO62O
PHENOBAPBITAL S ALKALINE PHOSPHATASE INC V MAY CAUSE OSTEOMALACIA (?ALSO LIVER EFFECT) P0396
PHENOTHIAZINES S ALKALINE PHOSPHATASE INC V IN’TRAHEPATIC CHOLESTATIC SYNDROME R0436
PHENYLBUTAZONE S ALKALINE PHOSPHATASE INC V HEPATITIS MAY OCCUR AS COMPLICATION O THERAPY P0687
PHENYLISOPROPYLHYD S ALKALINE PHOSPHATASE INC V NAY CAUSE HEPATOCELLULAR JAUNDICE 90620
PHOSPHORUS S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT WITH NECROSIS RO62O
POLYTHIAZIDE S ALKALINE PHOSPHATASE INC V MAY AFFECT LIVER FUNCTION 90620
PREGNANCY S ALKALINE PHOSPHATASE INC V 2 TO 3 TIMES NORMAL ACTIVITY IN THIRD TRIMESTER P0929
PROBENECID S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT (CENT?0LOBULAH NECROSIS) P0620
PROCAINAMIDE S ALKALINE PHOSPHATASE INC V REVERSIBLE HEPATIC TOXICITY REPORTED P0299
PHOCHLOHPEHAZINE S ALKALINE PHOSPHATASE INC V CHOLESTATIC EFFECT 90026
PROGESTIN S ALKALINE PHOSPHATASE INC V HEPATOTOXICITY 90620
PPOMAZINE S ALKALINE PHOSPHATASE INC V NAY CAUSE CHOLESTATIC (HEPATOCANALICULAR) JAUNDICE 30079
PHOMETHAZINE S ALKALINE PHOSPHATASE INC V MAY CAUSE CHOLESTASIS H0620
PROPOXYPHENE S ALKALINE PHOSPHATASE INC V HEPATIC TOXICITY (CHOLESTATIC HEPATITIS) 30538
PROPHANOLOL S ALKALINE PHOSPHATASE INC V LOW INCIDENCE DRUG INDUCED INCPEASE P0657
PROPYLTRIOURACIL S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT (CENTROLOBULAR NECROSIS) P0620
PROTHIONAMIDE S ALKALINE PHOSPHATASE INC V TEMPORARY SIDE EFFECT 90657
PROTRIPTYLINE S ALKALINE PHOSPHATASE INC V TRANSIENT REVERSIBLE CHOLESTASIS 90026
PYRAZINAMIDE S ALKALINE PHOSPHATAS! INC V HEPATOTOXIC EFFECT (VIRAL-HEPATITIS LIKE) R0620
QUINETHAZONE S ALKALINE PHOSPHATASE INC V NAY CAUSE CHOLESTATIC JAUNDICE 30620
RIFAMPIN S ALKALINE PHOSPHATASE INC V CAN BE SERIOUS BUT REVERSIBLE LIVEP DAMAGE HO735
SPECTINONYCIN S ALKALINE PHOSPHATASE INC V MECHANISM NOT DISCUSSED P00145
STORAGE OF SAMPLE S ALKALINE PHOSPHATASE INC N MAY INC 5-10% AFTER 1 DAY AT 4 DEGREES P0998
SULFADIAZINE S ALKALINE PHOSPHATASE INC V MAY CAUSE INTHAHEPATIC CHOLESTASIS R0405
SULFADINETHOXINE S ALKALINE PHOSPHATASE INC V GRANULONATOUS REACTION IN LIVER HO3O7
SULFAFURAZOLE S ALKALINE PHOSPHATASE INC V REVERSIBLE CHOLESTASIS R0620
SULFAMETHIZOLE S ALKALINE PHOSPHATASE INC V REVERSIBLE CHOLESTASIS R0542
SULFANETHOXAZOLE S ALKALINE PROSPHATASE INC V CHOLESTATIC JAUNDICE NAY OCCUR 90542
SULFAMETHOXYPYRID S ALKALINE PHOSPHATASE INC V REVERSIBLE CHOLESTASIS P0620
SULFANILAMIDE S ALKALINE PHOSPHATASE INC V MAY CAUSE REVERSIBLE CHOLESTASIS H0596
SULFAPYRIDINE S ALKALINE PHOSPHATASE INC V MAY CAUSE REVERSIBLE CHOLESTASIS 90596
SULFISOXAZOLE S ALKALINE PHOSPHATASE INC V NAY CAUSE CHOLESTASIS P0542
SULFONAMIDES S ALKALINE PHOSPHATASE INC V HYPERSENSITIVITY REACTION WITH CHOLESTASIS P0345
SULFONES S ALKALINE PHOSPHATASE INC V NAY AFFECT LIVER FUNCTION R0620
TESTOSTERONE S ALKALINE PHOSPHATASE INC V MAY CAUSE CHOLESTASIS HO620
TETRACYCLINE S ALKALINE PHOSPHATASE INC V NAY OCCUR WITH CHOLESTASIS 901417
THIABENDAZOLE S ALKALINE PHOSPHATASE INC V RARE CHOLESTASIS P0492
THIACETAZONE S ALKALINE PHOSPHATASE INC V MAY CAUSE CHOLESTATICQIEPATOCANALICULAH) JAUNDICE P0079
THIANAZOLE S ALKALINE PHOSPHATAS! INC V NAY AFFECT LIVER FUNCTION (CHOLESTASIS) P0620
THIAZIDES S ALKALINE PHOSPHATASE INC V CHOLESTATIC HEPATITIS REPORTED R0384
THIOGUANINE S ALKALINE PHOSPHATASE INC V NAY CAUSE CHOLESTASIS P0620
THIORIDAZINE S ALKALINE PHOSPHATASE INC V HYPERSENSITIVITY REACTION 90508
THIOSEMICAPBAZONES S ALKALINE PHOSPHATASE INC V NAY AFFECT LIVER FUNCTION 90620
THIOTHIXENE S ALKALINE PHOSPHATAS! INC V HEPATOTOXIC EFFECT (REVERSIBLE CHOLESTASIS) 90299
THIOURACIL S ALKALINE PHOSPHATASE INC V NAY CAUSE INTHAHEPATIC CHOLESTASIS 901405
T0LAZANID! S ALKALINE PHOSPHATASE INC V INTRAREPATIC CHOLESTATIC JAUNDICE R0029
TOLBUTAMIDE S ALKALINE PHOSPHATASE INC V NAY CAUSE INTRAHEPATIC CHOLESTATIC SYNDROME 90079
THANYLCYPHOMINE S ALKALINE PHOSPHATASE INC V MAY AFFECT LIVER FUNCTION (?HYPERSENSITIVITY) 90620
TRIFLUOPERAZINE S ALKALINE PHOSPHATASE INC V CHOLESTATIC EFFECT p0477
TPINETHADIONE S ALKALINE PHOSPHATASE INC V HEPATOTOXICITY WITH CENTROLOBULAP NECROSIS P0620
TPIOXSALEN S ALKALINE PHOSPHATASE INC V MAY AFFECT LIVE? FUNCTION P0620
UHACIL MUSTARD S ALKALINE PHOSPHATASE INC V NAY AFFECT LIVER FUNCTION P0620
VITANIN D S ALKALINE PHOSPHATASE INC V NAY BE AFFECTED IN SOME CASES P0292
ACETYLSALICYLIC AC U ALKALINE PHOSPHATASE INC V DUE TO NEPHROTOXIC EFFECT OF DRUG P0758
KANANYCIN U ALKALINE PHOSPHATASE INC V DUE TO NEPHROTOXIC EFFECT OF DRUG R0758
POLYNYXIN B U ALKALINE PHOSPHATASE INC V DUE TO NEPHPOTOXIC EFFECT OF DRUG RO758
PPOTEINUPIA U ALKALINE PHOSPHATASE INC V IN RENAL DISEASE WITH NECROSIS OR ALTERED GFH 0758
STREPTONYCIN U ALKALINE PHOSPHATASE INC V DUE TO NEPHROTOXIC EFFECT 0? DRUG P0758
SULFONAMIDES U ALKALINE PHOSPHATASE INC V DUE TO NEPHROTOXIC EFFECT OF DRUG P0758
PREGNANCY W ALKALINE PHOSPHATASE INC V OCCURS AFTER 3RD MONTH P0291
STORAGE OF SAMPLE S ALKALINE PHOSPHATASE Z M NO EFFECT 811 AT ROOM TEMP, 1 WEEK AT -20 DEGREES 90998
STORAGE OF SAMPLE U ALKALINE PHOSPHATASE Z N NO EFFECT 2 DAYS AT 14 DEGREES, 1 WEEK AT -20 DEC 90998
ALLOPURINOL S ALLOXANTHINE INC V ACCUMULATES WITH CHRONIC ADMINISTRATION P0384
GROWTH HORMONE P ALPHA AMINO NITROGEN DEC V INCREASED PERIPHERAL REMOVAL 90621
INSULIN P ALPHA AMINO NITROGEN DEC V INCREASED UPTAKE BY TISSUES 30355
OPAL CONTRACEPTIVE P ALPHA AMINO NITROGEN DEC V ANABOLIC EFFECT OF SYNTHETIC STEROIDS (PROGESTOGEN) P0225
PROGESTERONE P ALPHA AMINO NITROGEN DEC V CATABOLIC EFFECT 90225
AMMONIA P ALPHA AMINO NITROGEN INC N UNLESS REMOVED DURING ANALYTIC PPOCEDURE 301136
CONTACT WITH CLOT P ALPHA AMINO NITROGEN INC N PROTEOLYSIS OCCURS EVEN IN REFRIGERATOP P0436
CORTICOTHOPIN P ALPHA AMINO NITROGEN INC V TISSUE AND PROTEIN CATABOLISM 90355
EPINEPHHINE P ALPHA AMINO NITROGEN INC V METABOLIC EFF!CT-GLUCONEOGEN!SIS 30111
HEMOLYSIS P ALPHA AMINO NITROGEN INC N RELEASE OF GLUTATHIONE FROM EHYTHROCYTES 30436
MEALS P ALPHA AMINO NITROGEN INC V SMALL TRANSIENT RISE AFTER PROTEIN MEALS 90621
PROTEIN P ALPHA AMINO NITROGEN INC V RISES AFTER MEALS, FALLS TO NORMAL AFTER 14 HOURS P0291
ROOM TEMPERATURE P ALPHA AMINO NITROGEN INC N PROTEOLYSIS OCCURS EVEN IN ERIC. SATIS IF FPOZEN 901436
SERUM P ALPHA AMINO NITROGEN INC V RELEASE FROM RBC WITH CLOTTING(UP TO 40%HIGH) R036
SULFAMETHOXAZOLE P ALPHA AMINO NITROGEN INC N MEASURED IN NAPHTHOQUINONE METHOD OF FRAME P0779
SULFONANIDES P ALPHA AMINO NITROGEN INC N REACTS WITH NAPHTHOQUINONE (METHOD OF FRAME) H036
URIC ACID P ALPHA AMINO NITROGEN INC N REACTS IN NAPHTHOQUINONE NEHOD OF EPAME H0436
li-OXYSTEROIDS P ALPHA AMINO NITROGEN INC V PROMOTE TISSUE CATABOLISM 90299
ACETYLSALICYLIC AC U ALPHA AMINO NITROGEN INC V INHIBTION OF REABSORPTION, INC PROTEIN CATABOLISM P0384
AMMONIA U ALPHA AMINO NITROGEN INC N UNLESS REMOVED DURING ANALYTIC PROCEDURE P01136
CORTICOTROPIN U ALPHA AMINO NITROGEN INC V CATABOLISM OF BODY TISSUES 91001
CORTISONE U ALPHA AMINO NITROGEN INC V INCREASED TISSUE CATABOLISM P1001
LEAD U ALPHA AMINO NITROGEN INC V OCCURS WITH POISONING 90291
OXALATES U ALPHA AMINO NITROGEN INC V OXALIC ACID MAY CAUSE RENAL DAMAGE R0143
PHOSPHORUS U ALPHA AMINO NITROGEN INC V DUE TO NEPHROTOXICITY P0368
PP!GNANCY U ALPHA AMINO NITROGEN INC V PENAL THRESHOLD OF AMINO ACIDS REDUCED 90291
SULFONAMIDES U ALPHA AMINO NITROGEN INC N REACTS WITH NAPHTHOQUINONE (METHOD 0? FRAME) 90436

1 1-OXYSTEROIDS U ALPHA AMINO NITROGEN INC V PROMOTE TISSUE CATABOLISM P0620
CREATININE U ALPHA AMINO NITROGEN Z M NO EFFECT IF DINITPOFLUOROBENZENE METHOD USED P0385
UREA U ALPHA AMINO NITROGEN Z N NO EFFECT IF DINITROFLUOROBENZENE METHOD USED R0385
NA PHTHALENE U ALPHA NAPHTHOL P05 V PRESENT AS METABOLITE H 0368
PROTE INU RI A U ALPHA-GLLJCOSIDASE INC V POSSIBLY CONTRIBUTED FROM WBC P 0758
FRUCTOSE S ALPHA-KETOGLUTAHATE INC V RISES MORE RAPIDLY THAN AFTER GLUCOSE P01476
ESTR OGENS S ALPHA-LIPOPROTEINS INC V METABOLIC EFFECT (ALMOST DOUBLED IN SOME STUDIES) R0072
ETHINYLESTRADIOL S ALPHA-LIPOPROTEINS INC V MAY ALMOST DOUBLE IN SOME STUDIES 1103814
ORAL CONTRACEPTIVE S ALPHA-LIPOPROTEINS INC V RESPONSIBLE FOR INC PHOSPHOLIPIDS R0186
C HOLESTY PANT NE S ALPHA-TOCOPHEPOL DEC V ?INHIBITS SYNTHESIS OF CARRIER LIPOPROTEIN 110978
CLOFI BRAT! S ALPHA-TOCOPHEROL DEC V ?INHIBITS SYNTHESIS OF CARRIER LIPOPROTEIN RO978
ESTROGENS S ALPHA1-ANTITRYPSIN INC V METABOLIC EFFECT P0072
ORAL CONTRACEPTIVE S ALPHA1-ANTITRYPSIN INC V METABOLIC CHANGES IN LIVER SYNTHESIS (ESTROGEN) R0588
OXYMETHOLONE S ALPHA1-ANTITRYPSIN INC V METABOLIC EFFECT P0072
PREGNANCY S ALPHA1-ANTITRYPSIN INC V IN LAST TRIMESTER COMPARED WITH CONTROLS 110639
ORAL CONTRACEPTIVE S ALPHA1-GLOBULIN INC V METABOLIC CHANGE WITH COMBINED CONTRACEPTIVE P062 1
PREGNANCY S ALPHA1-GLOBULIN INC V MARKED INC IN LAST TWO TRIMESTERS P029 1
X-RAY THERAPY S ALPHA1-GLOBULIN INC V INC DUE TO TISSUE DAMAGE R0291
ASPARAGINASE S ALPHA2-GLOBULIN DEC V DEC TO 70% OF CONTROL AT 2 WEEKS P0705
DIPHENYLHYDA NTOIN S ALPHA2-GLOBULIN INC V RELATED TO DURATION OF THERAPY P0657
NESTRANOL S ALPHA2-GLOBULIN INC V METABOLIC EFFECT R0853
ORAL CONTRACEPTIVE S ALPHA2-GLOBULIN INC V MAYBEINCBYASNUCHAS8TINES Ho i 86
PREG NANCY S ALPHA2-GLOBULIN INC V OCCURS IN LAST 2 TRIMESTERS P0291
X-RAY THERAPY S ALPHA2-GLOBULIN INC V INC RAPIDLY DUE TO TISSUE DAMAGE H 029 1
ESTROGENS S ALPHA2-MACPOGLOBULIN INC V METABOLIC EFFECT P0072
MESTRANOL S ALPHA2-MACROGLOBULIN INC V NAY EFFECT ONE WEEK AFTER TREATMENT P01463
ORAL CONTRACEPTIVE S ALPHA2-MACROGLOBULIN INC V METABOLIC CHANGES IN LIVER SYNTHESIS R0588
GLU COSE S AMINO ACIDS DEC V (SOME AFFECTED ONLY)-DEPOSITED IN MUSCLE R0397
PROGESTERONE S AMINO ACIDS DEC V SPECIFIC AMINO ACIDS AFFECTED IN MEN 110226
STILBESTROL S AMINO ACIDS DEC V SPECIFIC AMINO ACIDS AFFECTED IN MEN 110226
EPIN EPHEINE U AMINO ACIDS DEC V METABOLIC EFFECT ASSOCIATED WITH GLUCONEOGENESIS P0620
I NS U LI N U AMINO ACIDS DEC V METABOLIC EFFECTS P0355
BISMUTH SALTS S AMINO ACIDS INC V TOXICITY EFFECT R0299
GLUCOCORTICO IDS S AMINO ACIDS INC V DUE TO BREAKDOWN OF TISSUE PROTEINS P0026
LEVA RTER ENOL S AMINO ACIDS INC V CATABOLIC EFFECT P 0299
ACETYLSALICYLIC AC U AMINO ACIDS INC V TWO FOLD INCREASE AFTER 1.6G IN NORMALS 110301
ANINOCAPROIC ACID U AMINO ACIDS INC N REACTS WITH NINHYDRIN MEASURED AS AMINO ACID 111015
AMPICILLIN U AMINO ACIDS INC N PRESENCE OF DRUG AS ADDITIONAL SPOT 110749
B- HYDEOX TA MINOBU TY R U AMINO ACIDS INC N FALSE POSITIVE NINHYDHIN REACTING SPOT 110811
BISMUTH SALTS U AMINO ACIDS INC V MAY PRODUCE FANCONI SYNDROME WITH POISONING 110657
CORT ICOTPOPI N U AMINO ACIDS INC V CATABOLISM OF BODY TISSUES P 1001
IIYDROXYAMINOBUTYRIC U AMINO ACIDS INC N ADDITIONAL SPOT BY NV! (?ALSO TLC) 110811
INSULIN U AMINO ACIDS INC V METABOLIC EFFECTS P 0299
PARATHYROID EXTRACT U AMINO ACIDS INC V HORMONAL ACTION P03814
TETRACYCLINE U AMINO ACIDS INC V NEPHROTOXIC EFFECT WITH DEGRADED TETRACYCLINE R0355
THYPIOL U AMINO ACIDS Z N NO EFFECT ON NINHYDRIN P 0779
PROCAINAMIDE U AMINOBENZOIC ACID INC V UP TO 10% EXCRETED AS THIS P0384
HENATIN S AMINOLEVULINIC ACID DEC V IN A PATIENT WITH ACUTE INTERMITTENT PORPHYRIA P0131
HEMATIN U AMINOLEVULINIC ACID DEC V IN A PATIENT WITH ELEVATION DUE TO PORPHYRIA P0131
VITAMIN E U ANINOLEVULINIC ACID DEC V POSSIBLE REDUCTION TO NORMAL LEVELS IN PORPHYRIA R0688
AMMONIA U ANINOLEVULINIC ACID INC N IF NO PRELIMINARY SEPARATION P0779
ANTICONVULSA NTS U AMINOLEVULINIC ACID INC V REPORTED IN ONE CHILD R0657
BARBI TURATES U AMINOLEVULINIC ACID INC V NAY PRECIPITATE ACUTE PORPHYRIA P037 1
CHLOPDIAZEPOXIDE U AMINOLEVULINIC ACID INC V MAY PRECIPITATE ACUTE PORPHYRIA P037 1
CHLORPROPAMI DE U AMINOLEVULINIC ACID INC V MAY PRECIPITATE CUTANEOUS PORPHYRIA H 037 1
DICHLOHALPHENAZONE U ANINOLEVULINIC ACID INC V MAY PRECIPITATE ACUTE PORPHYRIA P0 37 1
DIPHENYLHYDA NTOIN U AMINOLEVULINIC ACID INC V MAY PRECIPITATE ACUTE PORPHYRIA P037 1
ESTROGENS U AMINOLEVULINIC ACID INC V NAY PRECIPITATE PORPHYRIA ATTACK P0371
ETHANOL U AMINOLEVULINIC ACID INC V MAY PRECIPITATE ATTACK OF PORPHYRIA P037 1
GLUCOS AMINE U ANINOLEVULINIC ACID INC N IF NO PRELIMINARY SEPARATION PROCEDURE P0779
GLUTETHIMIDE U AMINOLEVULINIC ACID INC V MAY PRECIPITATE ACUTE PORPHYRIA P037 1
GLYCIWE U AMINOLEVULINIC ACID INC N IF NO PRELIMINARY SEPARATION 110779
GOLD U ANINOLEVULINIC ACID INC V OCCURS WITH PANMYELOPATHY RO384
GRISEOFULVI N U AMINOLEVULINIC ACID INC V MAY PRECIPITATE ACUTE PORPHYRIA ATTACK 110371
LEAD U AMINOLEVULINIC ACID INC V OBSERVED IN POISONING PC 384
MEPROBAM ATE U ANINOLEVULINIC ACID INC V MAY PRECIPITATE ACUTE PORPHYRIA P037 1
METHYLDOPA U AMINOLEVULINIC ACID INC V MAY PRECIPITATE ACUTE PORPHYRIA ATTACK P037 1
MUM YPRYLON U AMINOLEVULINIC ACID INC V ALA-SYNTHETASE STIMULATED IN ANIMALS 110384
ORAL CONTRACEPTIVE U AMINOLEVULINIC ACID INC V NAY PRECIPITATE PORPHYRIA ATTACK P037 1
PENTAZOC IN! U AMINOLEVULINIC ACID INC V MAY PRECIPITATE ACUTE PORPHYRIA ATTACK R037 1
SEDO PM ID U AMINOLEVULINIC ACID INC V NAY PRECIPITATE ACUTE PORPHYRIA P037 1
SUCC INIMIDES U AMINOLEVULINIC ACID INC V NAY PRECIPITATE ACUTE PORPHYRIA R0371
SULFONAMIDES U AMINOLEVULINIC ACID INC V MAY PRECIPITATE ACUTE PORPHYRIA P0371
SULFONENETHA NE U AMINOLEVULINIC ACID INC V MAY PROVOKE ATTACK OF PORPHYRIA 110371
S ULFO N ETH YL N ETH ANE U AMINOLEVULINIC ACID INC V MAY PRECIPITATE ACUTE PORPHYRIA P0371
TOLBUTAM IDE U ANINOLEVULINIC ACID INC V MAY PRECIPITATE PORPHYRIA ATTACK HO 37 1
ARGININE P AMMONIA DEC V CAPABLE OF REACTING WITH AMMONIA P0534
DIPHENHYDRANINE P AMMONIA DEC V REPORTED EFFECT IN EXOGENOUS NH3 TOXICITY HO 533
GLUTANIC ACID P AMMONIA DEC V CAPABLE OF REACTING WITH AMMONIA 110534
ISOCARBO XAZID P AMMONIA DEC V REPORTEDLY EFFECTIVE IN REDUCING NH3 INTOXICATION P0417
LACTOBACILLU S P AMMONIA DEC V CAUSES REDUCTION IN HEPATIC ENCEPHALOPATHY 110605
LACTULOS! P AMMONIA DEC V IN PATIENTS WITH HEPATIC ENCEPHALOPATHY R0410
MAO INHIBITORS P AMMONIA DEC V REPORTED EFFECT IN EXOGENOUS NH3 TOXICITY RO533
NEOMYCIN P AMMONIA DEC V REDUCES NH3 PRODUCING BACTERIA IN G.I. TRACT 111004
POTASSIUM P AMMONIA DEC V K REPLETION IN HEPATIC COMA MAY REDUCE NH3 P067 9
SODIUM SALTS P AMMONIA DEC V REPORTED EFFECT R0620
ACE? AZOL AMIDE U AMMONIA DEC V INCREASED ALKALINITY P0384
NAFENIDE U AMMONIA DEC V INHIB OF CARBONIC ANHYDRASE WHEN APP TOPICALLY 110985
ACETAZOLA N IDE P AMMONIA INC V ?DIVERTS NH3 FROM KIDNEY TO GENERAL CIRCULATION 110356
ANNONIUM SALTS P AMMONIA INC N INCREASED BLOOD LEVELS P0356

ASPARACINASE P AMMONIA INC V NAY RE NARKED,?ASSOC WITH ABNORMAL LIVER FUNCTION P C 14147
ASL’ARAGINE P AMMONIA INC V POTENTIAL SCURCE OF AMMONIA RC534
BARBITtYP ATES P AMMONIA INC V IMPAIRED METABOLISM IN DOGS P0931
CHLOROTHIAZID P AMMONIA INC V DECREASED POTASSIUM AND ALKALOSIS H C 356
CBLORTHALIDONP P AMMONIA INC V PARTIALLY DUE TO DECRLSLD POTASSIUM AND ALKALOSIS RC336
CONTACT WITH CLOT P AMMONIA INC M BREAKDOWN OF UREA IF DELAY IN ANALYSIS P.O 355
ETHACPYNIC ACID P AMMONIA INC V ?DUE TO HYPOKALEMIA AND ALKALOSIS P3417
FIBBIN HYDPOLYSATE P AMMONIA INC V DUE TO HIGH AMMONIA CONTENT OF SOLUTION RC968
EILTER PAPER P AMMONIA INC N ISP IF ACID-WASHED PAPER (ABSORBS NH3 PROM AIR) PC 181
FLUORIDES P AMMONIA INC N CAUSE INCREASE IF USED AS ANTICOAGULANTS PC 215
FURAPROMIDIUN P AMMONIA INC V OCCASIONAL INCREASE O3SERVD RC657
FUPOSFNIDF P AMMONIA INC V ACTS LIKE THIAZIDES CAUSES HYPOKALEMIA & ALKALOSIS B0417
LUC0SL P AMMONIA INC V NAY INCREASE AS GLUCOSE INCS IN CIRPHOTICS P3417
GLUTANINE P AMMONIA INC V POTENTIAL SOURCE OF ADDITIONAL AMMONIA P0534
HEMOGLOBIN P AMMONIA INC M SLIGHT INTERFZP.NCE WITH COLOR DEVELOPMENT H 353 3
HEMOLYSI S P AMMONIA INC N SOME INTERFERENCE WITH COLON DEVELOPMENT RC355
HEPA HIN P AMMONIA INC N CONTAINS VARIABLE AMOUNTS OF AMMONIUM SALTS P018 1
HY DROFLUNETHIAZIDE P AMMONIA INC V MAY OCCUR ESP IF PREEXISTING HEPATIC IMPAIRMENT P3467
ION EXCHANGE RESIN P AMMONIA INC V MECHANISM NOT REPORTED TDEPENDS ON RESIN P. 17
ISON IAZ ID P AMMONIA INC V REPORTED TO OCCUR IN SOME CASES R 1024
MORPHINE P AMMONIA INC V IMPAIRS ABILITY OF LIVER TO METABOLIZE NH3 IN DOGS P093 1
MUSCULAR EXERCISE P AMMONIA INC V TISSUE CATABOLISM P0355
ORAL RESINS P AMMONIA INC V EXCHANGED FOR OTHER IONS IN G.I. TRACT P3299
OXALATES P AMMONIA INC N EFFECT IFUSED AS ANTICOAGULANTS PC 215
STORAGE OF SAMPLE P AMMONIA INC N STABLE INICED PLASMA FOR SEVERAL HOURS P C 184
TETRACYCLINE P AMMONIA INC V IF GIVEN I.V. IN LARGE DOSES P04 17
THIAZIDES P AMMONIA INC V ASSOC WITH K DEPLETION AND ALKALOSIS P0356
UREA P AMMONIA INC N BREAKDOWN OF UREA TO AMMONIA PC 299
GLYC INE U AMMONIA INC V SAME EXTENT IN GOUTY AND NORMAL SUBJECTS P 1020
PREGNANCY U AMMONIA INC V OUTPUT INCREASED IN LAST TRIMESTER P029 1
PROTEIN U AMMONIA INC V DUE TO INGESTION OF PROTEIN R0291
TPIFLOCIN U AMMONIA INC V INHIBITS CARBONIC ANHYDPASE P3CC9
BILIRUBIN P AMMONIA Z N NO EFFECT ON MEASUREMENT PROCEDURE HO 530
EDTA P AMMONIA Z N SATISFACTORY AS ANTICOAGULANT R0215
TB! NOL U AMMONIA Z N NO EFFECT ON NESSLER, BEHTHELOT METHODS R0779
HONOGENTISIC ACID U ANNONIACAL AGNO3 P05 N RAPID DARKENING OF SOLUTION RC929
MELANIN U AMNONIACAL AGNO3 P05 N SLOW DARKENING P3929
PENTAZOC IMP U AMPHETAMINES INC N INTERFERES WITH COLORIMETRIC METHYL ORANGE METHOD RD 346
CITRATES S AMYLASS DEC N INHIBITION OP ENZYME ACTIVITY P0635
OXALATES S AMYLASE DEC N INHIBITION OF ENZYME IN LABORATORY PROCEDURES R0929
PPOPYLTHIOUHACIL S ANYLASE DEC V REPORTED EFFECT HOC 79
ACE1YLSALICYLIC AC S AMYLASE INC V SINGLE CASE REPORTED RiCO 1
ANINOSALICYLIC AC S AMYLASE INC V MAY CAUSE ACUTE PANCREATITIS P0384
ASPAPAGINASE S AMYLASE INC V MAY CAUSE PANCREATIC TOXICITY P0427
AZATHIOPRINE S AMYLASE INC V UNUSUAL SIDE EFFECT BUT NAY CAUSE PANCREATITIS P0467
BET HANECHOL S AMYLASE INC V NAY CAUSE INC SECRETION, SPASM OF SPHINCTER OF ODDI P0250
CARBON TETRACHLOR S AMYLASE INC V PANCREATITIS OCCURS RARELY HO 384
CHLORIDE SALTS S ANYLASE INC N CHLORIDE ENHANCES ENZYME ACTIVITY P0863
CHLOHOTHIAZIDE S AMYLASE INC V INFREQUENT CONSEQUENCE OP THERAPY BC 117
C HLOHTHALIDONE S ANYLASE INC V MAY PRECIPITATE ACUTE PANCREATITIS R0503
C HOLINERGICS S AMYLASE INC V CAUSE SPASM OF SPHINCTER OF ODDI P0042
CODEINE S AMYLASE INC V MAY CAUSE SPASM OF SPHINCTER OF ODDI H 0384
CORTICOTROPIN S AMYLASE INC V INCREASE MAY BE MARKED (BOTH SHORT AND LONG TERM) P0 196
CYPHOHEPTIDI NE S ANYLASE INC V MECHANISM NOT LISTED P0417
DEXA METHASON E S AMYLASE INC V MAY CAUSE PANCPEATITIS AS SIDE EFFECT P CII 67
DIATRIZOATE S AMYLASE INC V BLOCKAGE OF PANCREATIC DUCT FOR 6-18 HOURS R0029
ETHACRYNIC ACID S AMYLAS! INC V ISOLATED CASE OP ACUTE PANCPEATITIS P0417
ETHANOL S ANYLASE INC V DUE TO STIMULATION OF PANCREATIC SECRETION P 0356
FENTANYL S AMYLASE INC V NAY CAUSE SPASM OF SPHINCTER OF ODDI RC026
FLUORIDES S ANYLASE INC N EFFECT OP FLUORIDE, ACTIVATES AMYLASE P0929
EU ROSEMIDE S ANYLASE INC V MAY INDUCE MILD PANCREATITIS P0907
GLUCOCOPTICO lOS S AMYLASE INC V WELL DOCUMENTED EARLY AND LATE PANCHEATITIS P0657
HEMOLYSIS S AMYLASE INC N REPORTED EFFECT P0079
HISTAMINE S ANYLASE INC V SUBCUTANEOUS INJECT MAY CAUSE ACUTE PANCREATITIS P 0836
HYDROC HLOROTHIAZIDE S AMYLASE INC V ACUTE PANCREATITIS MAY OCCUR P0922
HYDROFLUMETHIAZIDE S AMYLASE INC V ACUTE PANCREATITIS MAY OCCCUR WITH THIAZIDES P0467
IIYDPOFLUMETHIAZIDE S ANYLASE INC V OCCASIONAL COMPLICATION 0? THERAPY RC467
I NDONETHACIN S AMYLASE INC V SINGLE CASE REPORTED (?CORRECT IMPLICATION) P0400
ISONIAZ ID S AMYLASE INC V REPORTED CAUSE OF ACUTE PANCREATITIS, MUCH DOUBT P0417
LIPEMIA S AMYLASE INC M TURBIDITY NAY AFFECT SOME METHODS P0181
MEPFRIDI NE S ANYLASE INC V MAY CAUSE SPASM OF SPHINCTER OF ODDI P087 2
MERCA PTOPUPINE S ANYLASE INC V ONE CASE OP HEMORRHAGIC PANCREATITIS RC657
METHACHOLINE S AMYLASE INC V STIMULATES PANCREATIC SECRETION, CONSTRICTS AMPULLA P0384
METHANOL S ANYLASE INC V ELEVATION DUE TO PANCREATITIS P0356
MFTHYCLDTHIAZIDE S AMYLASE INC V REPORTED TOXIC EFFECT OF THIAZIDES P 0467
MET BY LCHOLINE S ANYLASE INC V PANCREATIC STIMULATION, CONSTRICTION OF ANPULLA RC355
MORPHINE S ANYLASE INC V CAUSES SPASM OF SPHINCTER OF ODDI FOR 48 HOURS H 0907
NA RCOTIC S S AMYLASE INC V CAUSE SPASM OF SPHINCTER OP ODDI R0C42
OPIATES S ANYLASE INC V IMPAIRED EXCRETION SPASM OF SPHINCTER OF ODDI P0204
OXY PH EN BUTAZ ONE S AMYLASE INC V PAROTITIS IS RARE COMPLICATION OF THERAPY P0398
PANCREOZYNIN S AMYLASE INC N PREPARATION CONTAINS AMYLASE P0355
PA NCPEOZYMIN S ANYLASE INC V EFFECT SEEN WHEN PANCREATIC DISORDERS,?IN NORMALS P0875
PFNTAZOCI NE S ANYLASE INC V CAUSES SPASM OF SPHINCTER OF ODDI PC450
PH EN YL RU TA ZO NE S ANYLASE INC V PAROTITIS MAY OCCUR AS RAPE COMPLICATION RC398
POTASSIUM IODIDE S AMYLASE INC V PAROTITIS REPORTED AS RESuLT OF TREATMENT P0467
P HOC Y CL I DINE S AMYTASE INC V MAY CAUSE ACUTE PAROTITIS (THEORETICAL EFFECT) P01467
SALICYLA ZOSULFAPYR S AMYLASE INC V SINGLE CASE OF PANCREATITIS REPORTED PC 123
SALIVA S ANYLASE INC N SALIVA CONTAINS AMYLASE(NA! AFFECT PIPETTING) RC355
SULFA NET HIZOLE S ANYLASE INC V CASE OF PANCREATITIS REPORTED P 0076
TETRACYCLINE S AMYLASE INC V TOXIC EFFECT ESP IN PREGNANT WOMEN P3417

THIAZ IDES S AMYLASE INC V NAY INCREASE UP TO 200% IN A WEEK HO 223
TRASYLOL S ANYLASE INC V ONE CASE ALLERGIC PANCREATITIS REPORTED P0657
HEPAPIN S AMYLASE Z N NO EFFECT ON AMYLASE ACTIVITY P0998
STORAGE OF SAMPLE S AMYLASE Z .M 1 WEEK AT 4 DEGREES, 1 MONTH AT -20 AT NORMAL CONC P04 36
STORAGE OF SAMPLE U AMYLASE Z N NO EFFECT 2 DAYS AT 14 DEGREES, 1 WEEK AT -20 DEG P09 98
THY MOL U AMYLASE Z N NO EFFECT ON STARCH HYDROLYSIS R0779
NEDROXYPPOCESTE9ONE U ANDROGENS DEC V INHIBITION OF STEROID BIOSYNTHESIS IN ADRENALS P09 142
CLOMIPHENE P ANDROSTENEDIONE INC V LIBERATES LH,ANTI-STEBOID HORMONE EFFECT OF DRUG P0193
CY PR OT ER ON? P ANDPOSTENEDIONE INC V BY UP TO 1450% I? ACETATE DERIVATIVE USED P0887
METYPAPONE P ANDROSTENEDIONE INC V INC IN 3-8 HOURS IN MEN, MARKED INC IN WOMEN P06 96
DE IA MET HASO NE U ANDROSTEPONE DEC V SUPPRESSION OF ACTH P06 53
OPAL CONTRACEPTIVE U PLNDROSTFPONE DEC V COMPARED WTIH CONTROLS - DETAILS NOT DISCUSSED HO 162
CORTICOTROP IN P ANDROSTERONE INC V HORMONAL EFFECT P06 60
GONADOTROPIN U ANDROSTEPONE INC V 150% INCREASE WHEN GIVEN TO NORMAL MEN P08145
PROTEIN P ANGIOTENSIN I INC N A PROTEIN NORMALLY PRESENT NAY INTERFERE P0714
ESTROGENS B ANGIOTENSIN II INC V OCCURS WITHIN 5 DAYS, INC NAY BE 3 TIMES NORMAL P0174
ORAL CONTRACEPTIVE B ANGIOTENSIN II INC V ELEVATED TO 3 TINES NORMAL DUPING ADMINISTRATION HO 174
PROTEIN P ANGIOTENSIN II INC M A PROTEIN NORMALLY PRESENT NAY INTERFERE P07 14
OPAL CONTRACEPTIVE P ANGIOTENSIN INC V TWOFOLD INCREASE P0186
HYDRALAZINE S ANTINUCLEAR ANTIBODIES P05 V MORE COMMON IN SLOW ACETYLATORS 90731
ISONIAZID S ANTINUCLEAR ANTIBODIES POS V UP TO 78% TUBERCULOUS PATIENTS DEVELOP ANTIBODIES P00 15
NETHY LOOPA S ANTINUCLEAR ANTIBODIES P05 V MOPE COMMON IN FEMALES THAN MALES P04 72
OXYPHFNISATIN S ANTINUCLEAR ANTIBODIES P05 V MAY CAUSE HYPERSENSITIVITY REACTION P0776
PROCAI NA MID! S ANTINUCLEAR ANTIBODIES P05 V REPORTED TO OCCUR IN 50% PATIENTS HO 907
ORAL CONTRACEPTIVE B ANTITHONBIN III ACTIV DEC V ?PPEDISPOSING CAUSE OF THROMBOSIS Ri 028
FSTPOGENS S ANTITHRONBIN III ACTIV DEC V ?PREDISPOSING CAUSE OF THROMBOSIS P1028
ORAL CONTRACEPTIVE B ANTITHPONBIN III DEC V REPORTED EFFECT P0186
PREGNANCY S ANTITRPONBIN TITER DEC V OCCURS WITH PREGNANCY HO 291
COPPER S ARGINASE INC V INCREASED WHEN HEMOLYTIC CRISIS OCCURS P0 124
HENOLYSIS S APGINASE INC M RATIO OF 1000 TO 1 BETWEEN CELLS AND SERUM P0181
GLUCOSE S ARGININ! DEC V PROBABLE MUSCLE UPTAKE P0 397
CYCLOLEUINE U ARGININE INC V REVERSIBLE MARKED AMINOACIDUHIA P0154
DIN!PCAPROL U ARSENIC INC V IF POISONING DUE TO ARSENIC P00 26
ESTPOG ENS P ASCORBIC ACID DEC V EFFECT MARKED AT 2 WKS, < EFFECT IN PLATELETS P0506
OPAL CONTRACEPTIVE P ASCORBIC ACID DEC V MAX EFFECT AT 2 WEEKS, GREATER EFFECT IN PLATELETS HO 506
SMOKI NC P ASCOPBIC ACID DEC V LOWER CONC OBSERVED THAN IN NON-SMOKERS HO 72 9
ACE’YLSALICYLIC AC N ASCORBIC ACID DEC V PROLONGED ADMIN DECREASES CONC IN HUFFY COAT P03 26
SMOKING W ASCORBIC ACID DEC V LOWER CONC OBSERVED IN SMOKERS THAN NONSMOKERS P0729
ACETYLSALICYLIC AC U ASCORBIC ACID INC V REPORTED EFFECT P0246
AMINO ACIDS E ATP DEC V ASSOCIATED WITH LOW SERUM PHOSPHATE P0938
SMOKING F ATP DEC V SIGNIFICANTLY LESS IN SMOKERS P08 114
LE AD U B-ISO-AMINOBUTYPIC AC INC V NEPPROTOXIC EFFECT WITH LEAD POISONING RO291
DI PH !NYLHYDANTOIN S BARBITURATE DEC N NEGATIVE INTERFERENCE WITH DIPHENYLCAPBAZONE NETH. P00 96
GLUTETHIMIDE S BARBITURATE DEC N NEGATIVE INTERFERENCE WITH COLOPINETHIC METHOD P0096
ACETYLSALICYLIC AC S BARBITURATE INC N MAY INTERFERE WITH UV SPECTROPHOTOMETRY P01 814
ANTIPYRINE S BARBITURATE INC N EXTRACTION PROPERTIES OF FREE FORM SIMILAR P09 36
ATROPINE S BARBITURATE INC N FALSE P05 SCREEN TEST WITH HG COMPLEX FORM RO1 83
MEPFRIDINE S BARBITURATE INC N FALSE P05 SCREEN TEST WITH HG COMPLEX FORM P0 183
NI TRAZEPA N S BARBITURATE INC N FORMS HG COMPLEX WITH DIPRENYLCARBAXONE/BAER’S METH P0095
SULFONAMIDES S BARBITURATE INC N MAY INTERFERE WITH UV ABSORPTION METHOD P0779
T H FOPH YLL IN! S BARBITURATE INC M IDENTICAL ULTRAVIOLET SPECTRA P0936
DIGITALIS S BARBITURATE Z M NO INTERFERENCE WITH UV ABSORPTION METHODS P0779
GLUTARINIDE S BARBITURATE Z N NO EFFECT ON UV ABSORPTION METHODS P0779
MORPHINE S BARBITURATE Z M NO INTERFERENCE WITH UV ABSORPTION METHODS P0779
OXYTETRACYC LINE S BARBITURATE Z N NO EFFECT ON U? ABSORPTION METHODS P0779
PENICILLIN S BARBITURATE Z N NO EFFECT ON UV ABSORPTION METHODS P07 79
STORAGE OF SAMPLE S BARBITURATE Z N NO EFFECT ON UV ABSORPTION METHODS P0779
D!SIPRANINE B BASOPHILS INC V MILD EFFECT NOTED IN SOME PATIENTS P0657
I000C HLORHYDPOXYQU S BEI INC V CONTAINS ORGANICALLY BOUND IODINE HO 578
OPAL CONTRACEPTIVE S BRI INC V DUE TO INCREASED TBG P0026
DIATP IZOAT! S B!I Z N NO EFFECT REPORTED WITH HYPAQUE HO 255
TETPACYCLIWE U HENCE-JONES PROTEIN INC V NEPHROTOXIC EFFECT WITH DEGRADED TETRACYCLINE P02 99
ASPAR AGIN ASE S BETA-GLOBULIN DEC V DEC TO 70% OF CONTROL AT 2 WEEKS P0705
MESTRA NOL S BETA-GLOBULIN INC V METABOLIC EFFECT P0853
OPAL CONTRACEPTIVE S BETA-GLOBULIN INC V METABOLIC CHANGES IN LIVER SYNTHESIS HO 853
PREGNANCY S BETA-GLOBULIN INC V SLIGHT INCREASE IN SECOND TRIMESTER R0291
ANABOLIC STEROIDS S B!TA-GLUCURONIDASE INC V METABOLIC EFFECT P0072
CR LOP PROMAZINE S BETA-CLUCURONIDASE INC V RESULT OF TOXIC HEPATITIS P0990
ESTROGENS S BETA-GLUCURONIDASE INC V METABOLIC EFFECT P0072
ELUOXY MESTEPONE S BETA-GLUCURONIDASE INC V METABOLIC EFFECT P0072
IPPONIAZID S BETA-GLUCUPONIDASE INC V EFFECT OF TOXIC HEPATITIS HO 990
METHA NDPOSTE NOLONE S BETA-GLUCUPONIDASE INC V METABOLIC EFFECT P0072
METHYL T ES TO ST EPO NE S BETA-GLUCURONIDASE INC P METABOLIC EFFECT P0072
NORET HA ND ROLON! S BETA-GLUCUPONIDASE INC V METABOLIC EFFECT P0072
OPAL CONTRACEPTIVE S BETA-CLUCURONIDASE INC V ALTERED METABOLISN(ESTROGEN EFFECT) P0072
OXY MET HOL ONE S BETA-GLUCURONIDASE INC V METABOLIC EFFECT P0072
PREGNANCY S BETA-GLUCURONIDASE INC V SLIGHT DROP INITIALLY THEN LARGE INC TOWARDS TERM P0323
STANOZOLOL S BETA-GLUCURONIDASE INC V METABOLIC EFFECT RO072
BACTERIUPIA U BETA-GLUCUPONIDASE INC V HIGH ACTIVITY POSSIBLE WITH BACTERIAL CONTAMINATION P0758
PROTEINURIA U BETA-GLUCUHONIDASE INC V WITH ALL ACUTE OR INFLAMMATORY RENAL DISEASES P0758
ASPARAGINASE S BETA-LIPOPPOTEINS DEC V OBSERVED IN UNUSUAL HYPERLIPIDENIC RESPONSE R07O5
CHOLESTYHAMINE S BETA-LIPOPPOTEINS DEC V BUT DOES NOT AFFECT VERY LOW-DENSITY LIPOPROTEINS HO 384
CLOFIBRATE S BETA-LIPOPROTEINS DEC V THERAPEUTIC EFFECT (MECHANISM DISPUTED) P00 26
DEXTROTHYPOXINE S BETA-LIPOPROTEINS DEC V THERAPEUTIC EFFECT P0026
ESTROGENS S BETA-LIPOPROTEINS DEC V METABOLIC EFFECT (DECREASE OF 30%) P0072
ETHINYLESTR ADIOL S BETA-LIPOPPOTEINS DEC V DECREASES BY UP TO 30% P03814
NICOTINIC ACID S BETA-LIPOPPOTEINS DEC V CHRONIC ADNIN HAS SLIGHT EFFECT P 03 84
STORAGE OF SAMPLE S BETA-LIPOPROTEINS DEC N MARKED WITH 7 DAYS AT -2ODEG, MILD 28DAYS AT 0 DEG HO 536
OPAL CONTRACEPTIVE S BETA-LIPOPROTEINS INC V AFFECTS CHOL!STEROL(APPROX 20% INC AFTER 6 MONTHS) P0 186
CR ENODEOXYCHOLIC S BETA-LIPOPPOTEINS Z V NO EFFECT OBSERVED DURING TREAT OF GALLSTONES R0248

ASPARAGI NA SE S BETA1A-GLOBULIN DEC V DIMINISHED HEPATIC SYNTHESIS P0705
PREGNANCY S BETA1A-GLOBULIN INC V IN LAST TRIMESTER COMPARED WITH CONTROLS P0639
ASPARAGINA SE S BETA2-GLYCOPHOTEIN DEC V DIMINISHED HEPATIC SYNTHESIS P0705
DIAZOXIDE U BICARBONATE DEC V EFFECT NOT AS MARKED AS WITH SODIUM P004 9
ACETAZOLA MIDE U BICARBONATE INC V INHIBITION OF CARBONIC ANHYDRASE P0384
ACETYLSALICYLIC AC U BICARBONATE INC V RESPONSE TO RESP ALKALOSIS OF EARLY TOXICITY P0384
MAFENIDE U BICARBONATE INC V INHIB OF CARBONIC ANHYDRASE WHEN APP TOPICALLY P0985
PARATHYROID EXTRACT U BICARBONATE INC V INHIBITS TUBULAR EXCHANGE OF NA FOR H P0699
THY MOL U BICARBONATE Z N NO EFFECT ON VAN SLYKE, NATELSON METHODS P0779
CLOFI BRAT! F BILE ACIDS DEC V AFTER TWO WEEKS TREATMENT SIGNIFICANT PALL P0668
BARBITURATES S BILIRUBIN DEC V INDUCES GLUCURONYL TRANSFEPASE IN NEWBORN INFANTS P0417
CAFFEINE S BILIRUBIN DEC N ALLEGED LOWER VALUES WHEN USED AS COUPLING AGENT P0299
CHLOPOPHENOTHA NE S BILIHUBIN DEC V EFFECT ON CONGENITAL NON-HEN. HYPERBILIBUBINENIA P0907
CORTICOSTEROIDS S BILIRUBIN DEC V WHEN ELEVATED AS INCREASES BILE FLOW P0604
ETHANOL S BILIRUBIN DEC V DECREASES BILl. IN INFANT IF GIVEN TO PREG. WOMAN 80582
H EMOLY S IS S BILIRUBIN DEC M METH EMOG LOBI N FORMATION AFFEC TS DIAZOTI ZATION 80634
LIGHT S BILIPUBIN DEC V BREAKDOWN OF BILIRUBIN IN VIVO AND IN VITRO 80951
OROTIC ACID S BILIRUBIN DEC V ?INDUCTION EFFECT IN PREMATURE INFANTS ONLY 80841
PENICILLIN S BILIRUBIN DEC V COMPETES FOP ALBUMIN BINDING SITES 80907
PHENA ZOPYRIDINE S BILIRUBIN DEC V ATYPICAL COLOR CAUSES INTERFERENCE 80620
PHENOBARBITA L S BILIRUBIN DEC V INDUCES HEPATIC NICROSONAL ENZYMES ESP IN PREGNANT 80907
PROTEIN S BILIRUBIN DEC N ABSENCE OF PROTEIN AFFECTS DIAZOTIZATION 80620
SODIUM CHLORIDE S BILIHUBIN DEC N INHIBITION OF DIAZO TEST REPORTED 80436
SULFI SOXAZOLE S BILIRUBIN DEC V DISPLACEMENT FROM ALBUMIN BINDING SITES 80907
SULFONAMIDES S BILIRUBIN DEC V DISPLACEMENT FROM ALBUMIN BINDING SITES 80907
THIORIDAZI NE S BILIRUBIN DEC V ? DUE TO EFFECT ON BILIRUBIN METABOLISM 80456
UREA S BILIRUBIN DEC M BROWN COLOR IN DIAZO REACTION OF URENICS 80436
ACETANINOPHEN S BILIRUBIN INC V HEPATIC DAMAGE REPORTED WITH OVERDOSE 80797
ACETANILID S BILIPUBIN INC V HEMOLYSIS WITH G-6-PD DEFICIENCY 80620
ACETAZOLA tIlDE S BILIPUBIN INC V SINGLE CASE OF CHOLESTATIC JAUNDICE REPORTED 80555
ACETOHEXAMIDE S BILIRUBIN INC V NAY CAUSE INTRAHEPATIC CHOLESTATIC JAUNDICE 80204
ACETOPHENAZINE S BILIRUBIN INC V CHOLESTASIS WITH INTPAHEPATIC OBSTRUCTION P 0355
ACETOPHENETI DI N S BILIPUBIN INC V RAPE CASE OF HEPATIC TOXICITY REPORTED P038 4
A CETY LPH HWY LHY DR AZ S BILIPUBIN INC V NAY CAUSE HEMOLYTIC ANEMIA 80620
ACETYLSALICYLIC AC S BILIRUBIN INC V COMPETITION FOR ALBUMIN BINDING 80426
AJMALINE S BILIRUBIN INC V INTRAHEPATIC CHOLESTASIS 80088
ALLOPUHINOL S BILIPUBIN INC V REPORTED IN RENAL FAILURE ALSO IN OTHER PATIENTS 80585
AMINOPHENOL S BILIRUBIN INC N AT 1 MNOL/L AFFECTS SNA 12/60 METHOD P0876
AMINOPYRINE S BILIRUBIN INC V HEMOLYSIS IN G-6-PD DEFICIENCY 80079
AMINOSALICYLIC AC S BILIRUBIN INC V REVERSIBLE CHOLESTASIS CAUSED BY DRUG 80091
ANINOTHIAZOLE S BILIRUBIN INC V JAUNDICE WITH FBBPILE REACTIONS 80384
AMITRIPTYLINE S BILIRUBIN INC V RARE CASES OF TRANSIENT CHOLESTASIS 80673
ANODIAQUINE S BILIRUBIN INC V REPORTED EFFECT P0620
AMPHOTERICIN B S BILIPUBIN INC V PlAY CAUSE HEPATOCELLULAR DYSFUNCTION P0384
ANYL NITRITE S BILIRUBIN INC V WITH INCREASED HENOLYSIS 80656
ANABOLIC STEROIDS S BILIPUBIN INC V CHOLESTATIC SYNDROME 80299
A ND HO GE N S S BILIRUBIN INC V NAY CAUSE CHOLESTATIC SYNDROME 80299
ANTIFUNGAL AGENTS S BILIRUBIN INC V HEPATOTOXIC EFFECT R0355
ANTIMALAPIALS S BILIRUBIN INC V MAY CAUSE HEMOLYTIC ANEMIA 80518
ANTIMONY COMPOUNDS S BILIRUBIN INC V HEPATOTOXIC EFFECT 80596
PINTIPYHETICS S BILIRUBIN INC V OCCURS WITH HEMOLYTIC ANEMIA R0518
ANTIPYRINE S BILIRUBIN INC V HEMOLYSIS IN G-6-PD DEFICIENCY 80079
ARSENICALS S BILIRUBIN INC V HEPATOTOXIC EFFECT (CHOLESTASIS/CHOLANGIOLITIS) 80596
ASCORBIC ACID S BILIRUBIN INC N AT THERAPEUTIC CONC MAY AFFECT SMA 12/60 METHOD 80876
ASPARAGINA SE S BILIRUBIN INC V UP TO 4MG/1CONL (DOSE RELATED EFFECT) 80705
ASPIDION S BILIHUBIN INC V MAY CAUSE HEPATIC TOXICITY 80299
AZATHIOPRINE S BILIRUBIN INC V MAY CAUSE HEPATOTOZICITY (NOT USUALLY VERY HIGH) 80893
BARBITUR ATES S BILIRUBIN INC V RARE CASES OF JAUNDICE FOLLOWING USE 80114
BENZIODA RONE S BILIRUBIN INC V MAY CAUSE HEPATIC TOXICITY 80620
BETHA NECHOL S BILIPUBIN INC V IMPAIRED EXCRETION DUE TO SPASM OF SPHINCTER 80204
BISMUTH S BILIRUBIN INC V HE PATOTOXIC ITY 80620
BORIC ACID S BILIRUBIN INC V TOXICITY EFFECT WITH HEPATOMEGALY 80368
BUNAMIODYL S BILIRUBIN INC V COMPETITION FOR HEPATIC UPTAKE OF UNCONJUGATED 80108
B U SULF AN S BILIRUBIN INC V OCCURS WITH HEMOLYTIC ANEMIA 80467
BUTAPEHA ZINE S BILIRUBIN INC V CHOLESTATIC HEPATITIS WITH OBSTRUCTION P0026
CADMIUM S BILIRUBIN INC V MAY OCCUR EVEN FOLLOWING RESPIRATORY EXPOSURE P0368
CARBAMAZEPINE S BILIRUBIN INC V CHOLESTATIC AND HEPATOCELLULAR DAMAGE 80762
CARBENOXOLONE S BILIRUBIN INC V POSSIBLE HEPATOTOXIC EFFECT OF DRUG 80669
CARBON TETRACHLOP S BILIHUBIN INC V HEPATOTOXIC EFFECT 80620
CARBUTAMIDE S BILIRUBIN INC V HEPATOTOXICITY 80620
CAROTENE S BILIRUBIN INC N COLOR MAY INTERFERE WITH DIRECT METHODS 80299
CARP HENAZINE S BILIRUBIN INC V PROBABLE CHOLESTATIC EFFEC T (REVERSIBLE) 80620
CARROTS S BILIRUBIN INC N COLOR MAY BE MISINTERPRETED 80356
CEPHALOT BIN S BILIRUBIN INC V MAY CAUSE HEMOLYTIC ANEMIA 80393
CHLORAL S BILIRUBIN INC V PROBABLY NON-SPECIFIC EFFECT ON CELLS 80420
CHLORAMPHENICOL S BILIRUBIN INC V HEPATOTOXIC-CHOLESTATIC EFFECT 80596
CHLORDANE S BILIRUBIN INC V DUE TO HEPATOTOXICITY 80368
CHLOP DIAZEPOXIDE S BILIRUBIN INC V INFREQUENT CHOLESTATIC EFFECT 80299
C HL OR NEZ A NONE S BILIPUBIN INC V HEPATOTOXICITY 80620
CHLOROFORM S BILIRUBIN INC V HEPATOTOXIC EFFECT WITH NECROSIS 80620
C HLOROQUI NE S BILIRUBIN INC V HENOLYTIC ANEMIA IN G-6-PD DEFICIENCY 80467
CULOHOTHIAZIDE S BILIRUBIN INC V REPORTED TO CAUSE CHOLESTATIC JAUNDICE 80723
CHLORPROMAZINE S BILIRUBIN INC V SENSITIVITY REACTION (MAY CAUSE JAUNDICE IN INFANT) 80859
CHLORPROPAMI DE S BILIRUBIN INC V CHOLESTATIC JAUNDICE OF ALLERGIC NATURE MAY OCCUR 80417
CHLORPROTHIX EN! S BILIRUBIN INC V HEPATOTOXICITY (REVERSIBLE) 80620
CHLOPTETRACYCLINE S BILIRUBIN INC V HEPATOTOXIC EFFECT WITH CENTROLOBULAR NECROSIS 80355
CHLOR ZOXAZONE S BILIRUBIN INC V NAY CAUSE HEPATOTOXICITY 80620
CHOLINERGICS S BILIRUBIN INC V IMPAIRED EXCRETION DUE TO SPASM OF SPHINCTER 80204
CINCHOPHEN S BILIRUBIN INC V NAY CAUSE HYPERSENSITIVE CHOLESTASIS 80620
CLI NDANYCI N S BILIRUBIN INC V OCCURS ESPECIALLY IF PREEXISTING LIVER DISEASE 80735

CLOFIBRATE S BILIRUBIN INC V HEPATOTOXIC EFFECT P0620
CLONIDINE S 3ILIRUBIN INC V TOXIC HEPATITIS REPORTED HO 365
COLCRICI NE S BILIPUBIN INC V MAY CAUSE HEPATIC TOXICITY P 06 20
COPPER S BILIRUBIN INC V MARKED INCREASE WITH HEMOLYSIS OF TOXICITY P0 124
COUMAPIN S BILIP!JBIN INC V NAY CAUSE HEPATOTOXICITY R0990
CYCLOPHOSPRAMIDE S BILIRUBIN INC V MAY CAUSE HEPATOTOXICITY 90620
CYCL OP P OPA NE S BILIHUBIN INC V MAY CAUSE HEPATOTOXICITY (LASTS SEVERAL DAYS) P0620
CYCLOSERINE S BILIPUPIN INC V NAY CAUSE HEPATO’IOXICITY P06 20
DESIPPAMINE S BILIRtJBIN INC V RARE TRANSIENT CHOLESTASIS P01417
DEX TB A N S BILIRUBIN INC N CAUSES TURBIDITY WITH METHANOL IN EVELYN-MALLOY P0907
DIAZEPAM S BILIPUBIN INC V PRESUMED HEPATIC TOXIC EFFECT 31001
DI MPPCAPPOL S BILIPUBIN INC V NAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
DINITROPHENOL S BILIPUBIN INC V DUE TO TOXIC HEPATITIS 90368
DIPRENHYDRA MINE S BILIRUPIN INC V MAY OCCUR WITH HEMOLYTIC ANEMIA P0 932
DIPHENYLHYD ANTOIN S BILIRUBIN INC V RARE HYPERSENSITIVITY REACTION P01417
DI PYFONE S BILIPUBIN INC V MAY CAUSE HEMOLYTIC ANEMIA P06 36
DISULFIRAM S BILIRUBIN INC V ONE POSSIBLE CASE OF CHOLESTASIS REPORTED HO 467
DOXEPI N S BILIPUBIN INC V THEORETICAL POSSIRILITY DUE TO CLASS OF COMPOUND 90026
ECTYL UREA S RILIPUBIN INC V MAY CAUSE CHOLESTASIS WITH CHOLANGIOLITIS P0620
!PINEPHB IN! S BILIRUBIN INC M AT 1 MMOL/L AFFECTS SNA 12/60 METHOD RO876
FPYTHROMYCIN S BILIPUBIN INC V CAUSES CHOLESTASIS IN APPROX 15% PATIENTS P03 30
ESTA DI OL S BILIBUBIN INC V CHOLESTASIS NAY OCCUR P0620
ESTROGENS S BILIRUBIN INC V MAY CAUSE CHOLESTASIS (MAY BE HEPATOCELLULAH DEGEN) 30620
EST PC NE S BILIRUBIN INC V MAY CAUSE CHOLESTASIS 90620
ETHACPYNIC ACID S BILIRUBIN INC V CHOLESTASIS OR HEPATOCELLULAR DAMAGE P0 840
ETHER S BILIPUBIN INC V HEPATIC DISTURBANCE (TRANSIENT) P08 39
ETHIONAMID! S BILIRUBIN INC V HEPATOTOXICITY IN ABOUT 2% CASES P0417
ETHOSUXI MID! S BILIPUBIN INC V BABE IDIOSYNCRATIC HEPATITIS REPORTED R0026
ETHOTOIN S BILIBUBIN INC V PROBABLE IDIOSYNCRATIC HEPATITIS R0620
ETHOXAZEN! S BILIRUBIN INC V HEPATOTOXIC EFFECT 30299
ETHOXAZENE S BILIRUBIN INC N POSTULATED PRODUCTION OF COLOR WITH EHRLICH’S DIAZO P0029
ETHYL CHLORIDE S BILIPUBIN INC V NAY CAUSE LIVER DAMAGE 90026
FAVA BEANS S BILIPtJBIN INC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P00 79
FENOXY PROPAZINE S BILIRUBIN INC V PRODUCED FATAL HEPATOTOXICITY P06 57
FLAVASPIDIC ACID S RILIRUBIN INC V INHIBITS UDP-GLUCUPONYL THANSFEHASE 90701
FLUOROCYTOS IN! S BILIPUBIN INC V REVERSIBLE HEPATOTOXICITY IN 10% 90898
FLUOROURACIL S BILIRUBIN INC V SINGLE CASE REPORTED 90417
FLUOXY MESTE RON? S BILIRUBIN INC V INTPAHEPATIC CHOLESTATIC JAUNDICE 90384
FLUPHENAZI NE S BILIPUBIN INC V HYPERSENSITIVITY RESPONSE H0620
FLURAZEPA N S BILIRUBIN INC V MAY CAUSE HEPATIC TOXICITY P0788
FLUPOX EN! S BILIRUPIN INC V POTENTIALLY HEPATOTOXIC P0026
FURALTADO N! S BILIRUBIN INC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
FURAZOLIDONE S BILIRUBIN INC V MAY CAUSE HENOLYSIS WITH G-6-PD DEFICIENCY P0079
GENTANICIN S BILIRUBIN INC V AFFECTS LIVER FUNCTION P0026
GLYCOPYRROL ATE S BILIPUBIN INC V HEPATOTOXICITY 90620
GOLD S BILIRUBIN INC V RARE SIDE EFFECT WITH LIVER DAMAGE P06 57
GU A NOX A N S BILIRUBIN INC V NAY CAUSE HEPATIC TOXICITY 90620
HALOPERIDOL S BILIRUBIN INC V NAY CAUSE HEPATOCELLULAP CHANGES P0620
HAL OT HA NE S BILIRUBIN INC V REVERSIBLE DEPRESSION OF LIVER FUNCTION 90861
HEMOGLORIN S BILIRUBIN INC N PERCENTAGE OF UNCONJUGATED DECREASES WITH INC HGB R0620
HISTIDINE S BILIRUBIN INC N REACTS WITH DIAZO REAGENT P0 1436
HYDANTOINS S BILIRUBIN INC V SEVERE DELAYED HYPERSENSITIVITY REPORTED 90657
HYDRAZIN! S BILIRUBIN INC V MAY CAUSE HEPATOTOXICITY RO 620
HYDROCHLOBOTHIAZIDE S BILIPUBIN INC V CHOLESTATIC JAUNDICE REPORTED EFFECT OF THIAZIDES P 0723
HYDROFLUMETHIAZIDE S BILIBUBIN INC V MAY CAUSE INTRAHEPATIC CHOLESTATIC JAUNDICE HO 1467
HYDROXYACETANIDE S BILIRUBIN INC V HEPATOTOXICITY P0620
IBUFENAC S BILIRUBIN INC V PROBABLE EFFECT AS BILIPUBIN CLEARANCE REDUCED P0421
ICT EPOGENI N S HILIPUBIN INC V CAUSES INTRAHEPATIC CHOLESTASIS P00514
IDOXURIDINE S BILIRUBIN INC V CHOLESTATIC JAUNDICE REPORTED IN ONE CASE RO259
INIPPAMINE S BILIRUBIN INC V MAY CAUSE CHOLESTATIC JAUNDICE P05 12
INDANDIONES S BILIRUBIN INC V AS RESULT OF HYPERSENSITIVITY HO 657
INDICAN S BILIRUBIN INC N NAY PRODUCE BROWN DIAZO COLOR IN UREMIC SERUM P04 36
INDOMETHACIN S BILIRUBIN INC V CYTOTOXIC AND CHOLESTATIC TYPES OF LIVER DAMAGE Ho 521
INSECTICIDES S BILIPUBIN INC V MAY CAUSE HEMOLYTIC ANEMIA P0636
IOPANOIC ACID S BILIPUBIN INC V MAY CAUSE HEPATOTOXICITY P06 20
IPODATE S BILIRUBIN INC V PROBABLY DUE TO COMPETITION FOR EXCRETION 90204
IPRINDOLE S PILIPUBIN INC V ASSOCIATED WITH LOW SERUM PHOSPHATE P0012
IPRONIAZID S BILIRUBIN INC V NAY CAUSE CHOLESTATIC AND CYTOTOXIC JAUNDICE P0079
ISOCA RBOXAZID S BILIRUBIN INC V CHOLESTATIC EFFECT R 0620
ISONIA ZID S BILIRUBIN INC V INTRAHEPATIC CHOLESTASIS HO 299
ISOPPOTERENOL S BILIPUBIN INC M AT 1 NMOL/L AFFECTS SMA 12/60 METHOD 90876
K ANAM Y(CIN S BILIRUBIN INC V MAY CAUSE HEPATOTOXICITY P06 20
LEAD S BILIPUBIN INC V MAY CAUSE HEMOLYTIC ANEMIA P 02 40
LEVODOPA S BILIRUBIN INC V RARE ELEVATION REPORTED R0026
LEV000PA S PILIRUBIN INC N AT 1 MNOL/L AFFECTS SMA 12/60 METHOD HO 876
LEVODOPA S BILIPOBIN INC N THEORETICALLY REACTS WITH DIAZO REAGENT P08141
LI NCOMYCIN S BILIRUBIN INC V HEPATOTOXIC-CHOLESTATIC EFFECT P0596
LIPENIA S BILIRUBI! INC N INTERFERES WITH DIRECT SPECTROSCOPIC METHODS P01814
L I P OC HROM F S BILIRUBIN INC N MAY BE MEASURED AS BILIPUBIN IN SOME METHODS 90355
LUGOL’S IODINE S 3ILIRUBIN INC V OCCASIONAL HYPERSENSITIVE REPSONSE TO IODINF.S P0026
MAO INHIBITORS S BILIRUBIN INC V VIRAL HEPATITIS-LIKE JAUNDICE IN SOME PATIENTS HO 8 514
NEFENAMIC ACID S BILIRUBIN INC V NAY CAUSE AUTOIMMUNE HEMOLYTIC ANEMIA 30313
M?LPHALAN S BILIPUBIN INC V MAY CAUSE HFMOLYTIC ANEMIA P06 36
MEPAC PINE S BILIPUBIN INC V HEPATOTOXIC EFFECT P06 20
MEPAZINE S BILIRUBIN INC V CHOLESTATIC EFFECT P0477
MEPHNYTOIN S BILIBUBIN INC V NAY CAUSE HENOLYTIC ANEMIA P 06 36
MEPROBAM ATE S BILIRUBIN INC V MAY CAUSE CHOLESTATIC (HEPATOCANALICULAR) JAUNDICE R0079
?IERCkPTOPURI N?. S BILIRUBIN INC V NAY CAUSE INCREASE, ESPECIALLY IF PRIOR DAMAGE R0862
NETAHEXAMIDE S BILIHUBIN INC V HEPATOTOXICITY (VIRAL HEPATITIS TYPE) P06 20
META ND I! N ONE S BILIRUBIN INC V HEPATOTOXIC EFFECT (COMMON) P06 20

N ET A X A LONE S BILIRUBIN INC V HEPATOTOXIC EFFECT P 06 20
METHACHOL IN! S BILIRUBIN INC V IMPAIRS EXCRETION THROUGH BILIARY TRACT R0204
METHA NDRIOL S BILIRUBIN INC V INTRAHEPATIC CHOLESTATIC JAUNDICE 903 8LL
N ETH AN DR 057 ENOLO NE S BILIRUBIN INC V DUE TO CHOLESTASIS 90i477
METHANOL S BILIRUBIN INC N ALSE VALUE IF IMPURE METHANOL USED (EVELYN-NALLOY) R0181
METHANOL S BILIRUBIN INC V MANIFESTATION OF LIVER DAMAGE 30356
METRINAZOLE S BILIRUBIN INC V TOXIC EFFECT ASSOC. WITH BONE MARROW DEPRESSION P0086
NETH OTREX ATE S BILIPUBIN INC V NAY CAUSE CYTOTOXIC HEPATOCELLULAR DANAE 90079
NET HOTPIMEPRA ZINE S BILIRUPIN INC V THREE CASES REPORTED RO 1417
N ETH OX SAL EN S BILIRUBIN INC V HEPATOTOXIC EFFECT P0620
METHOXYFLURANE S BILIRUBIN INC V HEPATIC TOXICITY P086 1
METHSUXI MIDE S BILIRUBIN INC V HEPATIC DAMAGE REPORTED P0026
METHYCLOT HIAZIDE S BILIRUBIN INC V REPORTED TOXIC EFFECT OF THIAZIDES RO 1467
NETHYLDOPA S BILIPUBIN INC V INTRAHEPATIC CHOLESTATIC JAUNDICE REPORTED 90204
METHYLDOPA S BILIRUBIN INC N THEORETICALLY REACTS WITH DIAZO REAGENT P084 1
NET HYLDOPA S BILIBUBIN INC V MILD HEPATOCELLULAR JAUNDICE IN AROUT 1% CASES P0 3 00
N ETHYL DOP A S BILIHUBIN INC N AT 1 NMOL/L AFFECTS SMA 12/60 METHOD P0876
NETHYLENE BLUE S BILIRUBIN INC V MAY CAUSE HENOLYSIS WITH G-6-PD DEFICIENCY HO 079
METHYL TES TO ST ERO NE S BILIRUBIN INC V CHOLESTATIC EFFECT P00 54
NETHYLTHIOURACIL S BILIRUBIN INC V HEPATOTOXIC EFFECT HO 620
NOR PH A Z I N AM I DE S BILIRUBIN INC V JAUNDICE REPORTED AS SIDE EFFECT 30657
MORPHINE S BILIRUPIN INC V ASSOCIATED WITH ABNORMAL LIVER FUNCTION HO 620
NALIDIXIC ACID S BILIRUBIN INC V MAY CAUSE CHOLESTATIC JAUNDICE 30736
N APHTHALENE S BILIHUBIN INC V NAY CAUSE HENOLYSIS WITH G-6-PD DEFICIENCY 90079
NIALAMIDE S BILIRUBIN INC V PROBABLE HYPERSENSITIVE HEPATITIS 90026
NICOTINIC ACID S BILIRUBIN INC V MAY CAUSE IMPAIRMENT OF HEPATIC FUNCTION RO719
NITROFURANS S BILIRUBIN INC V HEPATOTOXICITY OP DUE TO HEMOLYTIC ANEMIA 90620
NI TROFUHANTOIN S BILIRUBIN INC V MAY CAUSE HEMOLYTIC ANEMIA OR CHOLESTASIS P0514 2
NITROFURAZON! S BILIRUBIN TNC V NAY CAUSE HENOLYSIS WITH G-6-RD DEFICIENCY H 0079
NITPOPHENOL S BILIRUBIN INC V HYPERSENSITIVE INTPAHEPATIC CHOLESTASIS P0405
NORETHA ND POLONE S BILIRUBIN INC V INTRAHEPATIC CHOLESTASIS PRODUCED (UP TO 20%) P0 366
NORETHANDRO STENOL S BILIRUBIN INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P08 314
NOPETHIND RON! S BILIRUBIN INC V CHOLESTATIC EFFECT P0620
NOPETHI STERONE S BILIRUBIN INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P03 84
NOHET HYNODRE L S BILIPUBIN INC V INTRAHEPATIC CHOLESTATIC JAUNDICE 90384
NOHTRI PTYLI NE S BILIRUBIN INC V MAY CAUSE CHOLESTATIC JAUNDICE P0026
NOVOBIOCIN S BILIPUBIN INC V (!SP. IN NEWBORN): INHIBITS CONJUGATING MECHANISM HO 109
NOV OBIOCIN S BILIRUBIN INC N INTERFERENCE BY METABOLITE (EVELYN-NALLOY) HO 620
OLEANDOMYCIN S BILIRUBIN INC V MAY CAUSE INTRAHEPATIC CHOLESTATIC JAUNDICE 90355
OPAL CONTRACEPTIVE S BILIRUBIN INC V INTERFERES WITH CANICULAR EXCRETION Polio
OPGANOPHOSPHORUS S BILIRUBIN INC V HEPATOTOXIC EFFECT 30130
OXACILLIN S BILIRUBIN INC V CHOLESTATIC JAUNDICE REPORTED IN ONE CASE 90722
OX AZEP AN S BILIRUBIN INC V POSSIBLE HEPATOTOXICITY 30620
OXY MET HOLONE S BILIPUBIN INC V CHOLESTATIC EFFECT 90477
OXY PHENBUTAZONE S BILIHUBIN INC V POSSIBLE HEPATOTOXICITY P06 20
OXYPHENISATIN S BILIRUBIN INC V HEPATIC TOXICITY IF OVER PROLONGED PERIOD RO727
PA MAQUINE S BILIRUBIN INC V NAY CAUSE HEMOLYSIS IN G-6-PD DEFICIENCY P0079
PAPA VEHINE S BILIRUBIN INC V SMALL EFFECT, REVERSIBLE HYPERSENSITIVITY REACTION R0855
PA RALDEHYDE S BILIRUBIN INC V POSSIBLE HEPATOTOXICITY P062 0
PAR AMET HADIONE S BILIRUBIN INC V POSSIBLE HEPATOTOXICITY 90620
PA RGYLI NE S BILIRUBIN INC V POSSIBLE HEPATOTOXICITY (REVERSIBLE) 90620
PECAZIN! S BILIHUBIN INC V MAY ALTER LIVER FUNCTION (CHOLESTASIS) P06 20
PENICILLI N S BILIRUBIN INC V NON SPECIFIC HEPATITIS WITHOUT CHOLESTASIS P1001
PENTAQUINE S BILIRUBIN INC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY 90079
PERCH LORATE S BILIRUBIN INC V SINGLE CASE OF ACUTE YELLOW ATROPHY OF LIVER 90657
PERPHENAZINE S BILIRUBIN INC V LOW INCIDENCE OF JAUNDICE REPORTED 900 26
PHENACENIDE S BILIRUBIN INC V NAY AFFECT LIVER FUNCTION IN ABOUT 2% CASES P 06 20
PHENAZOPYRIDINE S BILIRUBIN INC N POSTULATED INC COLOR WITH DIAZOTIZATION P02 04
PHENAZOPY RIDINE S BILIRUBIN INC V SINGLE REPORT OF JAUNDICE (?DUE TO HEMOLYSIS) P0461
PHENELZINE S BILIRUBIN INC V NAY CAUSE HYPERSENSITIVE HEPATITIS R0026
PH ENELZINE S BILIRUBIN INC N AT 1 ZINOL/L AFFECTS SNA 12/60 METHOD SLIGHTLY P0876
PHENINDIONE S BILIHUBIN INC V PROBABLE EFFECT AS BILIRUBIN CLEARANCE REDUCED 90421
PHENI PRAZIN! S BILIPUBIN INC V HYPERSENSITIVE HEPATITIS P062 0
PHENOTHIAZINES S BILIRUBIN INC V HYPERSENSITIVITY CHOLESTATIC REACTION NAY OCCUR HO 384
PH! NY LB UTAZ ONE S BILIRUBIN INC V GRANtJLOMATOUS REACTION IN LIVER 90381
PHENYL HYDRA ZINE S BILIRUBIN INC V CAUSES HEMOLYSIS P0 110
PHENYLI SOPROPYLHYD S BILIPUBIN INC V NAY CAUSE HEPATOCELLULAR JAUNDICE 90620
PHOSPHORUS S BILIRUBIN INC V HEPATOTOXIC EFFECT WITH NECROSIS 90620
PHYTONADI ONE S BILIBUBIN INC V LARGE DOSE EFFECT, OR WITH G-6-PD DEFICIENCY P0299
PIPERACFTAZINE S BILIPUBIN INC V RARE JAUNDICE (REVERSIBLE) (LIKE INFECT HEPATITIS) 90026
PIPEPAZINES S BILIRUBIN INC V MAY CAUSE HEMOLYTIC ANEMIA P 06 36
PIPOBROMAN S BILIRUBIN INC V NAY CAUSE HEMOLYTIC ANEMIA P0 299
POLYTHIAZ IDE S BILIRUBIN INC V MAY AFFECT LIVER FUNCTION P0620
PRINAQUINE S BILIRUBIN INC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
PPOBENECID S BILIRUBIN INC V HEPATOTOXIC EFFECT (CENTROLOBULAP NECROSIS) P0620
PROCAI NA MID! S BILIRUBIN INC V REVERSIBLE HEPATIC TOXICITY REPORTED H 01417
PROCARBAZINE S BILIRUBIN INC V REPORTED EFFECT. ?MECHANISN P0417
PR OC BLOB PE RAZ IN! S BILIRUBIN INC V CHOLESTATIC EFFECT RO026
PROGESTIN S BILIPUBIN INC V HEPATOTOXICITY ALSO TRANSIENT FAMILIAL INCREASE 90620
PROMAZINE S BILIRUBIN INC V MAY CAUSE CHOLESTATIC (HEPATOCANALICULAR) JAUNDICE P0079
PHOMETHAZINE S BILIRUBIN INC V MAY CAUSE CHOLE STASIS P062 0
PPOPOXYP9ENE S BILIRUBIN INC V CHOLESTATIC EFFECT P0538
PROPYLTHI OUBACIL S BILIPUBN INC V RARE CASE OF HEPATOTOXICITY REPORTED P04 17
PROTHIONAMIDE S BILIRUBIN INC V TEMPORARY SIDE EFFECT P0657
PROTRI PTYLI NE S BILIPUBIN INC V TRANSIENT REVERSIBLE CHOLESTASIS 90026
PYRAZINANIDE S BILIRUBIN INC V HEPATIC TOXICITY (APPHOX. 3%) (DOSE BELATED) R0832
QUINACPINE S BILIRUBIN INC V HENOLYSIS MAY OCCUR WITH G-6-PD DEFICIENCY 90079
QUINETHAZONE S BILIRUBIN INC V MAY CAUSE CHOLESTATIC JAUNDICE 90723
QUINIDINE S BILIRUHIN INC V CAUSES HEMOLYTIC ANEMIA 90636
QUININE S BILIRUBIN INC V MAY CAUSE HENOLYTIC ANEMIA 90636

RADIOGRAPHIC S BILIRUBIN INC V COMPETITION FOR EXCRETION THROUGH BILE CANALICULI RCCL$2
RIFAMPIN S BIL1RUBIN INC Fl DUE TO YELLOW COLORATION OF DRUG 9.0743
RIFAMPIN S BILIPUBIN INC V INHIBITS HPATIC EXCRETION HZ C 35
SALICYLAZOSULFAPYR S BILIPUBIN INC V MAY CAUSE HEMOLYSIS IN G-6-PD DEFICIENCY RCC.79
STANOZOLOL S BILIRU&IN INC V NAY CAUSE INTRAHEPATIC CHOLESTASIS P0384
STIHOP!iN S BILIRUBIN INC V PRODUCES HENOLYTIC ANEMIA RC636
STREPTOMYCIN S BILIBUBIN INC V NAY CAUSE HEMOLYTIC ANEMIA RC620
SULF ACETAM IDE S BILIRUBIN INC V NAY CAUSE HENOLYSIS IN G-6-PD DEFICIENCY RC79
SULFADIAZINE S BILIPUBIN INC V NAY CAUSE INIRAHEPATIC CHOLESTASIS Pct&C5
SULFA DINETHOXINE S BILIFUBIN INC V GRANULONATOUS REACTION IN LIVER P0307
S UL F AF UP A ZOLE S BILIRUBIN INC V REVERSIBLE CHOLESTASIS PC 62 C
S ULFANFT HIZOLE S BILIRUBIN INC V NAY CAUSE CHOLESTATIC JAUNDICE HG 54 2
S ULF A MET F!OXA ZO LE S BILIPUBIN INC V REVERSIBLE CHOLESTASIS OP HENOLYTIC ANEMIA RC623
SULFAMETHOXYPYRID S BILIRUBIN INC V NAY CAUSE HENOLYSIS WITH G-6-PD DEFICIENCY P0079
SULFANILAMIDE S BILIRUBIN INC V NAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY RCC79
SULF APYRIDI NF S BILIBUBIN INC V NAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
SULFISOXAZOLE S BILIRUSIN INC V NPY CAUSE CHOLESIATIC JAUNDICE OR HEMOLYSIS R0542
SULFONAMIDES S BILIRUEIN INC V HPATIC/ CHOLESTATIC EFFECT, ALSO AFFECTS ALB BIND PC 110
S TYLF ON ES S BILIFUBIN INC V MAY CAUSE HkMOLYSIS WITH G-6-PD DEFICIENCY PC 079
S ULF ONYL UREA S S BILIRI1BIN INC V IN SOME CASES PROS ATTRIBUTABLE TO DRUG H 0657
S ULFOX ONE S BILIRUBIN INC V MAY CAUSE HENOLYSIS IN G-6-PD DEFICIENCY PC 079
TESTOSTERONE S BILIRUBIN INC V NAY CAUSE CHOLESTATIC AND CYTOTOXIC LIVER DAMAGE RCC79
TETRACYCLINE S BILIRUBIN INC V HEPATIC INJURY MAY OCCUR LSP IF GIVEN I.V. PC 110
7 H EO P flY LL I NE S BILIRUBIN INC M CAUSES DEPRESSION OF COLOR FORMATION PC 62 3
I BlAB! ND AZOLE S BILIROBIN INC V RARL CHOLESTASIS P0647
THIACETAZONE S BILIRUBIN INC V NAY CAJSE CHOLESTATIC (HEPATOCANALICULAR) JAUNDICE RC079
THIAMAZOLE S BILILUBIN INC V NAY AFFECT LIVER FUNCTION (CHOLESTASIS) RC620
THIA ZI DES S BILIRUBIN INC V CHOLESTATIC HEPATITIS REPORTED TO OCCUR H C 3 814
THIAZOLSULFONE S BILIPUBIN INC V HEMOLYTIC ANEMIA RC620
IHIOGUANINE S BILIPUBIN INC V MAY CAUSE CHOLESTASIS 9C620
IHIOPIDAZINE S BILIRUBIN INC V HEPATOTOXICITY (QUESTIONABLE) P C 508
I BIOS EMICARBAZ ONES S BILIRUBIN INC V MAY AFFECT LIVER FUNCTION B 0620
THIOTHI XEN E S BILIRUBIN INC V HEPATOTOXIC EFFECT (REVERSIBLE CHOLESTASIS) P062 0
THIOUPACIL S BILIRUBIN INC V MAY CAUSE INTRAHEPATIC CHOLESTASIS P040 5
TIOCARLIDE S BILIRUBIN INC V RAPE OBSERVATION RC657
lOLA ZAN IDE S BILIRUBIN INC V CHOLESTATIC JAUNDICE PC 620
TOLBUTANIDE S ILIPUBIN INC V CHOLESTATIC JAUNDICE REPORTED P0417
IPANYLCYPPOMINE S BILIRUBIN INC V MAY AFFECT LIVER FUNCTION (?HYPERSENSITIVITY) RC620
TRICHLOFOETHYLENE S BILIRUBIN INC V POTENTIALLY HEPATOTOXIC PC’C26
FRIFLUOPEP AZI NE S BILIRUBIN INC V CHOLESTATIC EFFECT P0477
TRIFLOPERI DOL S BILIPUBIN INC V ELEVATED IN CHRONIC AND ACUTE HEPATITIS P0299
TRIFLUPROMAZINE S BILIPUBIN INC V LIVER DYSFUNCTION EXCEPTIONALLY PARE R0026
IFINEPPAZINE S BILIRUIN INC V NAY CAUSE CHOLESTASIS P 0026
TEIMETHA DIONE S BILIRUBIN INC V HEPATOTOXICITY WITH CENTPOLOBULAR NECROSIS P 0520
IRINETHYLENENELAN S BILIRUBIN INC V MAY CAUSE HEMOLYTIC ANEMIA P0636
TPIOXS&LEN S BILIRUBIN INC V FlAY AFFECT LIVER FUNCTION P3620
TYROSIN! S BILIRUBIN INC N REACTS WITH DIAZO PEALNT P0436
TYROTHRICIN S BILIRUBIN INC V HEMOLYSIS EVEN WHEN APPLIED TOPICALLY P0026
URACIL MUSTARD S BILIRUBIN INC V MAY AFFECT LIVER FUNCTION 90620
U RETHAN S BILIRUBIN INC V HEPATOTOXICITY WITH CENTPOLOBULAP NECROSIS PC 026
VINYL ETHER S BILIHUBIN INC V POTENTIALLY HEPATOTOXIC PC 326
VITAMIN A S BILIRUBIN INC M INTERFERES WITH ANALYSIS P0356
VITAMIN K S BILIRUBIN INC V LARGE DOSES IN NEONATES OR G-6-PD DEFICIENCY B 0079
XANT HOPHYLL S BILIRUBIN INC N MAY DEEPEN COLOR OF SERUM (?SIGNIFICANCE) PC 299
KY LIT OL S BILIRUBIN INC V MAINLY INDIRECT - BY 2 13 3 TINES NORMAL IN SOME P0277
ACETOHEX AM IDE U BILIRUBIN INC V MAY CAUSE INTRAHEPATIC CHOLESTATIC JAUNDICE RC620
ACET OPHENAZINE U BILIRUBIN INC V ChOLESTASIS WITH INTRAHEPAIIC OBSTRUCTION P. 0 62C
HLOPPROTHIXENE U BILIRUBIN INC V MAY CAUSE HEPATOTOXICITY (REVERSIBLE) PC 620
!THOXAZENE U BILIRUBIN INC V HEPATOTOXIC EFFECT B 0299
FL UPHENA ZINE U BILIRUBIN INC V HYPERSENSITIVITY RESPONSE H C 620
INIPHAMI NE U BILIPUBIN INC V MAY CAUSE CHOLESTATIC JAUNDICE PC 512
!I!THYLDOPA U BILIRUBIN INC V OCCURS AS RESULT OF HEPATOCELLULAR DAMAGE P0946
NOR ET HA ND P OLONE U BILIPUBIN INC V CHOLESTASIS PRODUCED WITHOUT CHOLANGIOLITIS R0826
PERPHENAZINE U BILIRUBIN INC V LOW INCIDENCE OF JAUNDICE REPORTED P062 3
PHENOTHIAZINES U BILIRUBIN INC V MAY CAUSE CHOLESTATIC HEPATITIS P0620
SULFADIMETHOXINE U BILIRUBIN INC V GRANULONATOUS REACTION IN LIVER R0307
PHENFORNIN S BILIRUBIN Z V NO REPORTED CASES OF JAUNDICE BOO 26
THY MOL U BILIHUBIN Z N NO EFFECT ON FOUCHET PROCEDURE P0779
‘3ISNUTH SALTS S BISMUTH INC V MEASURABLE IN POISONING H0657
BISMUTH SALTS U BISMUTH INC V MEASURABLE WITH POISONING P0657
ACETYLSALICYLIC AC B BLEEDING TIME INC V ALSO INHIBITS PLATELET GLYCOLYSIS P 0326
DEXT PAN a BLEEDING TIME INC V OBSERVED EFFECT BUT EXPLANATION UNCERTAIN R0620
FLUR OXENE B BLEEDING TINE INC V PROLONGED DURING ANESTHESIA, NORMAL IN 24H HO 026
MITHRANYCIN B BLEZOING TINE INC V REVERSIBLE EFFECT P0026
STREPTOKINASE B BLEEDING TIME INC V DISSOLVES BLOOD CLOTS P0620
WARFAPIN B BLEEDING TIME INC V NAY BE PROLONGED P0368
CYCLOPROPANE B BLEEDING TIN! Z V ANESTHESIA HAS NO EFFECT P0384
ETHER B BLEEDING TIME Z V ANESTHESIA HAS NO EFFECT 903814
COHTICOTROPIN 0 BNR DEC V METABOLIC ACTION OF HORMONE P0596
GLtJCOCORTICO IDS 0 8MB DEC V METABOLIC ACTION OF HORMONES RC596
MORPHINE 0 BMP DEC V METABOLIC EFFECT OF DRUG B C 596
NARCOTICS 0 BMP DEC V METABOLIC EFFECT OF DRUGS R0596
ACETYLSALICYLIC AC 0 BMR INC V REPORTED METABOLIC EFFECT P 0596
AMPHETAN INES 0 BMR INC V METABOLIC EFFECT OF JEUGS E596
CAFFEINE 0 BNR INC V METABOLIC EFFECT OF DRUG (TEMPORARY EFFECT) PC 596
LACTATION 0 BNR INC V REMAINS ELEVATED FROM PREGNANCY P329 1
LEVOTHYROXINE 0 BlIP INC V METABOLIC EFFECT OF HORMONE (MAXIMUM AT ONE WEEK) P0596
LIOTHYRONI NE 0 BE? INC V METABOLIC EFFECT OF HORMONE HO 596
PREGNANCY 0 BMP INC V MODERATELY INC ESP IN LAST 3 MONTHS P0291
THYROID 0 BMR INC V METABOLIC EFFECT OF HORMONE HO 596

ACETONE U BOGEN TEST P05 N REACTS AS IF ETHANOL 90368
ETHER U BOGEN TEST P05 N REACTS AS IF ETHANOL HO 368
FORMALDEHYDE U BOGEN TEST P05 M REACTS AS IF ETHANOL P 0368
ISOPROPANOL U BOGEN TEST 905 N REACTS AS IF ETHANOL 90368
METHANOL U BOGEN TEST P05 N REACTS AS IF ETHANOL 90368
ETHANOL 0 BREATH ALCOHOL INC V PRESENCE OF INGESTED ALCOHOL P0 3 84
ISOPROPA NOL 0 BREATH ALCOHOL INC M CAN PRODUCE MEASURABLE LEVELS 30356
METHANOL 0 BREATH ALCOHOL INC V PRESENCE OF INGESTED ALCOHOL P03 56
BROMIDES S BROMIDE INC V CONC MEASURABLE WITH THERAPEUTIC DOSES 0657
BRONI SOVALUN S BROMIDE INC V METABOLITE (CONC MAY EXCEED 25 NEQ/L) P03 84
CAR RHO NA L S BROMIDE INC V NETABOLITE CONC NAY EXCEED 25 MEQ/L 90384
HEMOLYSI S S BROMIDE INC N MAY CAUSE COLOP IN PROTEIN-FREE FILTRATE 901 81
THIAZ IDES U BROMIDE INC V IN CASES OF BROMIDE INTOXICATION 90384
BARBI TUPA TES S BSP RETENTION DEC V INC CONJUGATION WITH GLUTATHION! P03 84
PHENOBARBITAL S BSP RETENTION DEC V INC CLEARANCE BY LIVER IN NEWBORNS P1013
PROTFI NURIA S BSP RETENTION DEC V FALSE LOW DUE TO LOSS OF PROTEIN BOUND BSP 90171
STORAGE OF SAMPLE S BSP RETENTION DEC N DEC UP TO 4% AT ROOM TEMP FOR 16H 30998
ACETOH EXA MID! S BSP RETENTION INC V MAY CAUSE INTRAHEPATIC CHOLESTATIC JAUNDICE P02 04
ACETOP HENA ZINE S BSP RETENTION INC V CHOLESTASIS WITH INTHAHEPATIC OBSTRUCTION 90620
ACETOPHENETIDIN S BSP RETENTION INC V MAY CAUSE HEPATIC TOXICITY 90620
ADIPIODONE S BSP RETENTION INC V REPORTED WITHOUT EVIDENCE OF LIVER DAMAGE 90 596
ALLOPURINOL S BSP RETENTION INC V ASSOCIATED WITH REVEBSIBLE HEPATOTOXICITY P08143
AMINOSALICYLIC AC S BSP RETENTION INC V REVERSIBLE CHOLESTASIS CAUSED HY DRUG P07 15
AMITRIPTYLI NE S BSP RETENTION INC V DUE TO TRANSIENT CHOLESTASIS P0620
AND BAR BIT AL S BSP RETENTION INC V PROBABLY NON-SPECIFIC EFFECT ON CELLS 90958
AMODIAQFJINE S BSP RETENTION INC V REPORTED HEPATOTOXICITY P0620
ANPHOTERICIN B S BSP RETENTION INC V DUE TO HEPATOCELLULAR DYSFUNCTION 90620
ANABOLIC STEROIDS S BSP RETENTION INC V CHOLESTATIC SYNDROME 90299
A N DR OG ENS S BSP RETENTION INC V NAY CAUSE CHOLESTATIC SYNDROME P02 99
ANTIFUNGAL AGENTS S BSP RETENTION INC V HEPATOTOXIC EFFECT NAY IMPEDE CLEARANCE 90355
ANTI MONY CONPOUN DS S BSP RETENTION INC V HEPATOTOXIC EFFECT P 05 96
A? SENICALS S BSP RETENTION INC V HEPATOTOXIC EFFECT (CHOLESTASIS/CHOLANGIOLITI 5) P0 596
ASPARAGINASE S BSP RETENTION INC V HEPATOTOXICITY (USUALLY MILD) 30427
ASPIDIUM S BSP RETENTION INC V NAY CAUSE HEPATIC TOXICITY P02 99
AZA DRUGS S BSP RETENTION INC V MAY CAUSE HEPATOTOXICITY BO355
BARBITURATES S BSP RETENTION INC V MAY INCREASE RETENTION IF GIVEN WITHIN 2(4!! P0 38 3
BENZIODARONE S BSP RETENTION INC V MAY CAUSE HEPATIC TOXICITY 90620
BET HA NEC HOL S 959 RETENTION INC V IMPAIRED EXCRETION DUE TO SPASM OF SPHINCTER 302014
BISMUTH S BSP RETENTION INC V HEPATOTOXICITY 90620
BUNAMIODYL S BSP RETENTION INC V CONPET. FOR HEPATO-CELLULAP PROTEIN BINDING SITES ROlOl
CAPREOMYCIN S BSP RETENTION INC V TRANSIENT INCREASE IN 5% SUBJECTS P06 57
CARBANAZEPINE S BSP RETENTION INC V CHOLESTATIC AND HEPATOCELLULAP DAMAGE RO417
CARBE NOXOLONE S BSP RETENTION INC V REVERSIBLE HEPATOTOXIC EFFECT 90669
CARBON TETRACHLOR S BSP RETENTION INC V REDUCED HEPATIC BLOOD FLOW AND LIVER DAMAGE BO376
CARBUTA HIDE S BSP RETENTION INC V HEPATOTOXICITY 90620
CARPHENAZINE S BSP RETENTION INC V PROBABLE CHOLESTATIC EFFECT (REVERSIBLE) P062 0
C HLOR AL S BSP RETENTION INC V PROBABLY NON-SPECIFIC EFFECT ON CELLS HO 1420
CHLOPA MPH ENICOL S BSP RETENTION INC V HEPATOTOXICITY P05 96
CHLORDIA ZEPOXIDE S BSP RETENTION INC V INFREQUENT CHOLESTATIC EFFECT 90(477
CHLOROFORM S BSP RETENTION INC V HEPATOTOXIC EFFECT WITH NECROSIS P05 20
CHLOPOTHIAZIDE S BSP RETENTION INC V NAY CAUSE CHOLESTATIC JAUNDICE P0620
CR LOP PROMAZINE S BSP RETENTION INC V INDUCES TRANSIENT CHOLESTATIC HEPATITIS (1 CASE) P0271
CHLOR PROPANIDE S BSP RETENTION INC V INFREQUENT CHOLESTATIC EFFECT P0477
C HLOR PR OT HIX EN! S BSP RETENTION INC V MAY CAUSE HEPATOTOXICITY (REVERSIBLE) 90620
CHLORT!TRACYCLIN E S BSP RETENTION INC V HEPATOTOXIC EFFECT WITH CENTPOLOBULAR NECROSIS RO65
CHLOP ZOXA Z ONE S BSP RETENTION INC V MAY CAUSE HEPATOTOXICITY 90620
CHOLERETICS S BSP RETENTION INC V REPORTED EFFECT (?COMPETITION FOR EXCRETION) P 0299
CHOLESTYPANINE S BSP RETENTION INC V FEW CASES REPORTED P9OB NOT HEPATOTOXICITY P0 1467
CHOLINERGICS S BSP RETENTION INC V IMPAIRED EXCRETION DUE TO SPASM OF SPHINCTER P02 04
CINCHOPHEN S BSP RETENTION INC V MAY CAUSE HEPATOTOXICITY (VIRAL-HEPATITIS LIKE) P0 620
CLOFIBPATE S BSP RETENTION INC V INTRAHEPATIC CHOLESTASIS REPORTED 90299
CLONIPHE NE S BSP RETENTION INC V MAY CAUSE HEPATOTOXICITY RO355
CLONIDI NE S BSP RETENTION INC V SINGLE PROBABLE CASE OF TOXIC HEPATITIS P03 65
COLCHIC IN! S BSP RETENTION INC V MAY CAUSE HEPATIC TOXICITY R0620
COPPER S BSP RETENTION INC V INCREASED WITH HEMOLYTIC CRISIS 90124
COUMARIN S BSP RETENTION INC V NAY CAUSE HEPATOTOXICITY P09 90
CYCLOPHOS PHAMIDE S BSP RETENTION INC V MAY CAUSE HEPATOTOXICITY B 06 20
CY CLO P P OP AN! S BSP RETENTION INC V NAY CAUSE HEPATOTOXICITY (LASTS SEVERAL DAYS) P06 20
CYCLOS ERINE S BSP RETENTION INC V MAY CAUSE HEPATOTOXICITY RO62O
DEHYDPOCHOLIC ACID S BSP RETENTION INC V HEPATIC UPTAKE OP BILIAPY EXCRETION IMPAIRED HO 1417
DESIPRANINE S BSP RETENTION INC V RARE TRANSIENT CHOLESTASIS P 06 20
DIPHENYLBYDANTOIN S BSP RETENTION INC V DUE TO HYPERSENSITIVITY OP INTRAHEPATIC CHOLESTASIS RO L( 17
FCTYLUREA S BSP RETENTION INC V MAY CAUSE CHOLESTASIS WITH CHOLANGIOLITIS HO 620
EPYTHROMYCIN S BSP RETENTION INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P0029
ESTPAD IOL S BSP RETENTION INC V CHOLESTATIC EFFECT IN ALMOST ALL SUBJECTS RO681
E S TP OG ENS S BSP RETENTION INC V CHOLESTATIC EFFECT IN MOST CASES (DOSE RELATED) P 06 81
ES 79 ONE S BSP RETENTION INC V OCCURS IN ALMOST ALL CASES P068 1
ETHA NB UTOL S BSP RETENTION INC V FEW CASES REPORTED 90657
ETHER S BSP RETENTION INC V HEPATIC DISTURBANCE (TRANSIENT) P06 20
ETHIONANI DE S BSP RETENTION INC V !!EPATOTOXIC EFFECT P0620
ETROTOIN S BSP RETENTION INC V PROBABLE IDIOSYNCRATIC HEPATITIS P06 20
ETHOXAZENE S BSP RETENTION INC V HEPATOTOXIC EFFECT P0654
ET BOX AZ EWE S BSP RETENTION INC N INCREASES ABSOPPANCY IN TEST, FALSELY HIGH RESULT RO1417
FLAVASPIDIC ACID S P59 RETENTION INC V COMPETITION FOR HEPATO-C!LLULAP BINDING SITES P0701
FL OR A NTY RON E S BSP RETENTION INC V HEPATOTOXIC EFFECT 90299
FLUOXY NESTERONE S BSP RETENTION INC V ? HEPATOTOXIC, CHOLESTATIC EFFECT RO355
FLUPHE NAZ IN! S BSP RETENTION INC V HYPERSENSITIVITY RESPONSE 90620
FL UP AZ EPA N S BSP RETENTION INC V MAY CAUSE HEPATOTOXICITY P0788
FLU P OXE NE S BSP PETENTION INC V POTENTIALLY HEPATOTOXIC 90026
G LY CO PY P ROL A TE S BSP RETENTION INC V HEPATOTOXICITY P06 20

GOLD S BSP PETENTION INC V H!?ATOTOXICITY WITH CENTROLOBULAR NECROSIS P06 20
GUA POX A N S BSP RETENTION INC V MAY CAUSE HEPATIC TOXICITY P03 47
HALO?EPI DOL S 35? RETENTION INC V NAY CAUSE HEPATOCELLULAR CHANGES P0620
HA LOT HA NE S 35? RETENTION INC V REVERSIBLE DEPRESSION OF LIVER FUNCTION P08 61
HENOLYSI S S BSP RETENTION INC N ABSORB OF HGB VARIES WITH PH (AFFECTS SOME PROCS) P03 55
HEPAP IN S 95? RETENTION INC N COLOR INTENSITY INC IN SERUM, WAVELENGTH SHIFTED P02 19
HYDP.AZINE S 95? RETENTION INC V MAY CAUSE HEPATOTOXICITY P0620
HYDROFL UNET HIA ZIDE S BSP RETENTION INC V NAY CAUSE INTPAHE?ATIC CHOLESTASIS P04 67
HYDPOXYACETANIDE S 95? RETENTION INC V H!?ATOTOXICITY P 06 20
IBUFENAC S BSP RETENTION INC V HEPATOTOXIC EFFECT P06 20
ICTEROGENI N S BSP RETENTION INC V CAUSES INTRAHEPATIC CHOLESTASIS P0054
INIPRANINE S BSP RETENTION INC V NAY CAUSE CHOLESTATIC JAUNDICE P06 64
INDANDIONES S BSP RETENTION INC V MAY CAUSE HEPATOTOXICITY 90620
INDOMETHACIN S BSP RETENTION INC V CYTOTOXIC AND CHOLESTATIC LIVER DAMAGE P0 521
IOPANOIC ACID S 95? RETENTION INC V COMPETES FOR HEPATO-CELLULAR PROTEIN BINDING SITES P0833
IPHONIAZID S BSP RETENTION INC V MAY CAUSE CHOLESTATIC JAUNDICE P06 20
ISOCAP.BOXAZ ID S BSP RETENTION INC V INTPAHEPATIC CHOLESTASIS REPORTED HO 17 1
I S 0 NI A El 0 S BSP RETENTION INC V INTRAHEPATIC CHOLESTATIC JAUNDICE HO 02 9
KANA NYC IN S 3SP PETENTION INC V NAY CAUSE REPATOTOXICITY R0299
LI PONUL S BSP RETENTION INC V PART OF FAT-OVERLOADING SYNDROME 90657
MALE FERN S BSP RETENTION INC V PROB INHIB OF UPTAKE BY LIVER P0657
MAO INHIPITORS S BSP RETENTION INC V INTRAHEPATIC CHOLESTASIS WITH POSSIBLE CELL DAMAGE P03 55
MEALS S BSP PETE4TION INC V CAPACITY 0! LIVER TO ELIMINATE 95? DECREASED HO 181
NECHLORETHA MINE S BSP RETENTION INC V HE.PATOTOXIC EFFECT 90079
NE?ACRIN! S BSP RETENTION INC V HEPATOTOXIC EFFECT P0620
NEPAZINE S FSP RETENTION INC V CHOLESTATIC EFFECT P0(477
MEPEPIDINE S 35? RETENTION INC V DUE TO SPASM OF SPHINCTER OF ODDI P0171
MEPHENYTOIN S ESP RETENTION INC V HEPATOTOXICITY HO 620
MERCAPTO?UPINE S BSP 9ETENTION INC V HEPATOTOXICITY (CENTROLOBULAR NECROSIS) R0620
NETAHEXA HIDE S BSP RETENTION INC V HEPATOTOXICITY (VIRAL HEPATITIS TYPE) R0620
META NDI ENON F S BSP RETENTION INC V HEPATOTOXIC EFFECT (COMMON) 90620
H FT A XAL ONE S 95? RETENTION INC V HEPATOTOXIC EFFECT HO 299
METHACHOLINE S 95? RETENTION INC V IMPAIRS EXCRETION BY SPASM OF SPHINCTER OF ODDI P02 04
METHADONE S PS? RETENTION INC V H!PATOTOXIC EFFECT OR SPASM OF SPHINCTER OF ODDI P1001
METHA NDPI OL S BSP RETENTION INC V INTRAHE?ATIC CHOLESTATIC JAUNDICE P0384
METHANDROSTENOLONE S BSP RETENTION INC V CHOLESTATIC PHENOMENON H0233
METHINAZOLE S 35? RETENTION INC V CHOLESTATIC EFFECT R0477
METHOTREXATE S BSP RETENTION INC V HEPATOTOXICITY, NAY BE POST-NECROTIC CIRRHOSIS HO 4 41
NETHOXSALEN S BSP RETENTION INC V HEPATOTOXIC EFFECT RO620
N ETHOXYFL UR A NE S PS? RETENTION INC V HEPATOTOXICITY R0620
MET HYLDOPA S PS? RETENTION INC V RESULT OF HEPATOCELLULAR DAMAGE (CHOLESTASIS ALSO) P1001
N ETHY L T ES TO ST EPONE S 35? PF.TENTION INC V TRANSPORT AND CONJUGATION OF BSP IMPAIRED P00 54
NETHYLTHIOOPACI L S 35? RETENTION INC V HEPATOTOXIC EFFECT 90620
MORPHI NE S BSP RETENTION INC V ABNORMAL LIVER FUNCTION TESTS REPORTED Ri 001
NAFCILLIN S BSP RETENTION INC V REPORTED EFFECT (?HEPATOTOXICITY) BOO 26
NARCOT ICS S BSP RETEETION INC V IMPAIRED EXCRETION - SPASM OF SPHINCTER OF ODDI P 02 04
NIALAMIDE S BSP RETENTION INC V HEPATOTOXIC/CHOLESTATIC SYNDROMES HO 38 4
NICOTINIC ACID S BSP RETENTION INC V LIVER FUNCTION IMPAIRMENT, ?CONPETITION FOR CONJUG P0719
NITHOFURA NS S 95? RETENTION INC V HEPATOTOXICITY P0620
NI TPOFURANTOIN S 95? RETENTION INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P0305
NORETHA NDROLONE S 35? RETENTION INC V TRANSPORT AND CONJUGATION OF BSP IMPAIRED 90054
NORETHA NDROSTENOL S BSP RETENTION INC V IMPAIRED HEPATIC UPTAKE AND EXCRETION P02 014
NORET HIND P ON! S 35? RETENTION INC V CHOLESTATIC PHENOMENON (OCCURS IN 20%) BO8 714
NORE’TF!I STEPONE S BSP RETENTION INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P 03 814
NORETHYNODR!L S 95? RETENTION INC V CHOLESTATIC PHENOMENON R0233
NOVOBIOCIN S BSP RETENTION INC V COMPETITION FOR EXCRETION, MAY BE ACTUAL DAMAGE HO 109
OLEANDOMYCIN S 35? RETENTION INC V MAY CAUSE INTRAHEPATIC CHOLESTASIS P03 55
OPIATES S BSP RETENTION INC V IMPAIRED EXCRETION SPASM OF SPHINCTER OF ODDI 902014
ORAL CONTRACEPTIVE S 95? RETENTION INC V OCCURS IN 40%, ESTROGEN DEPRESSES SECRETORY NEC!! P 0566
ORGA NOPHOS?HOPUS S BSP RETENTION INC V H!?ATOTOXIC EFFECT 90130
OXACILLIN S BSP RETENTION INC V CBOLESTATIC JAUNDICE REPORTED IN ONE CASE HO 299
OXA NDROLONE S 35? RETENTION INC V SLIGHT INC IN ONE CRILD(OTHEB LFT NOPAL) P01483
OX AZP AN S 95? RETENTION INC V POSSIBLE H!PATOTOXICITY P0620
OXY MET HOLONE S 95? RETENTION INC V CHOLESTATIC EFFECT P0477
0 XYPHE N B UT A ZONE S BSP RETENTION INC V POSSIBLE HEPATOTOXICITY P0 620
OXYPHENISATIN S RSP RET!NTON INC V MAY CAUSE HYPERSENSITIVITY REACTION 90776
PAR ALDEHYDE S 35? RETENTION INC V POSSIBLE HE?ATOTOXICITY 90620
PARANETHADIONE S 95? RETENTION INC V POSSIBLE HEPATOTOXICITY P0620
PARGYLIN! S 35? RETENTION INC V ?OSSIBLE HEPATOTOXICITY (REVERSIBLE) R0620
?ECAZINE S 35? 9ETENTION INC V MAY ALTER LIVER FUNCTION (CHOLESTASIS) P0620
PHENACEMI DE S ES? BETENTION INC V MAY ALTER LIVER FUNCTION IN ABOUT 2% CASES 90620
PHENAZOPYPI DINE S BS? RETENTION INC H INC SPECTRAL ABSORBANCY IN COLOPIMETRIC READING P1001
P9!NAZ0?YRIDIN S 35? RETENTION INC V HEPATIC DAMAGE REPORTED IN ONE CASE HO 146 1
?REN!!LZI NE S 35? RETENTION INC V HEPATOTOXIC/CHOLESTATIC SYNDROMES RO384
PHENINDIONE S BSP RETENTION INC V NAY MODIFY LIVER FUNCTION (CHOLESTASIS) P06 20
PHENIODOL S 95? P!TENTIO1 INC V EFFECT REPORTED WITHOUT ABNORMAL LIVER FUNCTION P0596
PHENIPRAZIN! S BSP RETENTION INC V MAY AFFECT LIVER FUNCTION HO 620
?HENOLPHT HA LEIN S PS? RETENTION INC N COLOR DEVELOPMENT ON ALKALINIZATION OF SAMPLE P1001
PHENOTHIAZINES S BS? 9ETENTION INC V NAY CAUSE CHOLESTATIC HEPATITIS (IN U? TO (4% PTS) P0620
PRENYLBUTAZONE S BSP RETENTION INC V MAY CAUSE CHOLESTASIS H 0620
PHOSPHORUS S BSP RETENTION INC V HEPATOTOXIC EFFECT WITH NECROSIS P06 20
POLYTHIAZIDE S 95? RETENTION INC V NAY AFFECT LIVER FUNCTION P06 20
PREGNANCY S BSP RETENTION INC V MAY BE MODERATELY ABNORMAL IN LAST MONTH HO 29 1
?P.OBENECID S 35? HETE1TION INC V HEPATOTOXIC EFFECT (CENTROLOBULAR NECROSIS) P1001
PROCAINAN IDE S 95? RETENTION INC V REPORTED CASE OF HEPATIC TOXICITY R0417
?ROCHLOPP!PAZINE S BSP RETENTION INC V CHOLESTATIC EFFECT P0026
?POGESTIN S 35? RETENTION INC V HE?ATIC TOXICITY OCCASIONAL OCCURRENCE P06 79
PRONAZINE S 95? RETENTION INC V MAY CAUSE CHOLESTASIS 90620
PROMETHAZINE S 95? RETENTION INC V NAY CAUSE CHOLESTASIS P0620
PRO POX YP 9 P N E S BS? RETENTION INC V CHOLESTATIC EFFECT HO 5 38

PROPYLTRIOD HA OIL S PS? RETENTION INC V HEPATOTOXIC EFFECT (ENTROLOBULAP NECROSIS) 90620
PS? S BSP RETENTION INC M MAY INCREASE COLOPIMETPIC READING 901417
PYRAZINA HIDE S BSP RETENTION INC V HEPATIC TOXICITY (APPROX. 14%) (DOSE RELATED) P0832
QUINETHAZONE S BS? RETENTION INC V HAY CAUSE CHOL!STA’T!C JAUNDICE P0620
RADIOGRAPHIC S 95? RETENTION INC V COMPETE WITH EXCRETORY MECHANISM P0 171
RIFANPIN S BSP RETENTION INC V INHIBITS HEPATIC EXCRETION (PROBABLY) 901481
SPINAL ANESTHESIA S BSP RETENTION INC V SEEN POST-OPERATIVELY, RELATED TO DEC BLOOD FLOW P03 84
STA NOZOLOL S BSP RETENTION INC V DUE TO INTPAHEPATIC CHOLESTASIS 90233
SULFADINETHOXINE S BSP RETENTION INC V REVERSIBLE CHOLESTASIS HO 307
SU LEA EU HA ZOLE S BSP RETENTION INC V REVERSIBLE CHOLESTASIS 90620
SULFAMFTHIZOLE S BSP RETENTION INC V REVERSIBLE CHOLESTASIS P05142
SU L FA MET H OX AZ 0 LE S BSP RETENTION INC V REVERSIBLE CHOLESTASTS 90620
SULFAMETHOXYPYPID S ES? RETENTION INC V REVERSIBLE CHOLESTASIS 90620
SULEISOXAZOLE S BSP RETENTION INC V NAY CAUSE CHOLESTASIS 90542
SULFONAMI DES S BS? RETENTION INC V MAY CAUSE CHOLESTASIS P0736
SULFONES S BSP RETENTION INC V NAY AFFECT LIVER FUNCTION P06 20
TESTOSTERONE S BSP RETENTION INC V MAY CAUSE CROLESTASIS P06 2 0
TETRACYCLINE S BSP RETENTION INC V CHOLESTATIC ESPECIALLY IN PREGNANT WOMEN P0 7 36
TETRAI ODOPHTHALEIN S BSP RETENTION INC V COMPETITIVE UPTAKE AND EXCRETION OF DYE P01(8 1
THIABENDAZOLE S BSP RETENTION INC V PARE CHOLESTASIS 90647
THIAC E1’AZ ONE S PS? RETENTION INC V MAY CAUSE CHOLESTASIS 90079
THIAMAZOLE S BSP RETENTION INC V MAY AFFECT LIVER FUNCTION (CHOLESTASIS) R0620
THIAZIDES S BSP RETENTION INC V REDUCED PLASMA VOLUME AND HEPATIC BLOOD FLOW 90417
THIOGUANINE S BSP RETENTION INC V MAY CAUSE CHOLESTASIS 90620
THIOP IDAZ IN! S BSP RETENTION INC V HEPATOTOXICITY PC 508
THIOSEMICARBAZONES S BSP RETENTION INC V MAY AFFECT LIVER FUNCTION P06 20
THIOTHIXENE S BSP RETENTION INC V HEPATOTOXIC EFFECT (REVERSIBLE CHOLESTASIS) P0 6 20
TOLAZA MID! S BSP RETENTION INC V CHOLESTASIS P06 20
TOLBUTA HIDE S BSP RETENTION INC V MAY CAUSE CYTOTOXIC LIVER DAMAGE OH CHOLESTASIS 90079
TRA NYLCYPPONIN! S PS? RETENTION INC V HEPATOTOXIC/CHOLESTATIC SYNDROMES 90384
TB. IFLUOPERA ZINE S BSP RETENTION INC V CHOLESTATIC EFFECT 30 477
TRI METHADIONE S BSP RETENTION INC V HEPATOTOXICITY WITH CENTHOLOBULAR NECROSIS 30620
TPIOXSALEN S BSP RETENTION INC V MAY AFFECT LIVER FUNCTION P06 20
UPACIL MUSTARD S BSP RETENTION INC V MAY AFFECT LIVER TUNCTION 90620
OPAL CONTRACEPTIVE S C-REACTIVE PROTEIN DEC V PROGESTOGEN EFFECT 90907
ESTROGENS S C-REACTIVE PROTEIN INC V ALTERED LIVER METABOLISM 90 874
ORAL CONTRACEPTIVE S C-REACTIVE PROTEIN INC V ESTROGEN EFFECT HO 8714
EDTA U CADMIUM INC V IF POISONING DO! TO CADMIUM 90026
A MB UL A TION F CALCIUM DEC V AFTER SEVERAL WEEKS BED R!ST(GRADUAL EFFECT) 90471
CHLOROTRIAZ IDE F CALCIUM DEC V ACCENTUATES POSITIVE CALCIUM BALANCE 657
ETHINYLESTPADIOL P CALCIUM DEC V DECREASE LESS MARKED THAN IN URINE P1 016
FLUORIDES F CALCIUM DEC V REDUCES LOSS IN BONE DISORDERS 90384
HYDROCHLOHOTHIAZIDE F CALCIUM DEC V ACCENTUATES POSITIVE CALCIUM BALANCE H 0657
POLYTHIAZIDE F CALCIUM DEC V ACCENTUATES POSITIVE CALCIUM BALANCE P0657
VITAMIN D F CALCIUM DEC V DUE TO EXCESSIVE ABSORPTION P0291
ACETAZOL ANI DE S CALCIUM DEC V DEFECTIVE CA AND P04 REABSORPTION CAN BE INDUCED P0204
ACETYLSALICYLIC AC S CALCIUM DEC N DEPRESSES FLUORESCENCE OF CALCEIN METHOD 906144
ALKALINE ANTACIDS S CALCIUM DEC V INHIBITION OF ABSORPTION P06 20
AMBULATION S CALCIUM DEC V FOLLOWING SEVERAL WEEKS OF BED REST 90471
ANTICONVULSANTS S CALCIUM DEC V FOUND IN 30% CHILDREN ON PROLONGED THERAPY HO 473
ASPARAGINASE S CALCIUM DEC V OBSERVED IN 60% (?DUE TO HYPOALBUNINENIA) P07 05
BILIPUBIN S CALCIUM DEC N IF CALCEIN TITRATION USED P0017
CALCITONIN S CALCIUM DEC V DEC OF GREATER THAN 0.5 MEQ/L OBSERVED HO 406
CA RB EN OX OLO N! S CALCIUM DEC V ALDOSTERONE LIKE EFFECT OF DRUG 90669
CI TB A TE S S CALCIUM DEC V COMPLEXES CALCIUM 90620
CONTACT WITH CLOT S CALCIUM DEC N ABSORPTION BY CONTAINER 30355
CONTACT WITH CLOT S CALCIUM DEC H IF PROLONGED FACILITATES PASSAGE OF 920 FROM CELLS ROLl 36
COPTICOST EPOIDS S CALCIUM DEC V ANTAGONIZES ACTION OF VITAMIN 0 AND PARATHYROID P0026
CORTISONE S CALCIUM DEC V IF ELEVATED DUE SARCOIDOSIS OR VITAMIN D P002 6
DIATH IZOATE S CALCIUM DEC V ?DUE TO SMALL AMOUNT OF EDTA IN MEDIUM 90560
DRONOSTA NOLONE S CALCIUM DEC V NAY OCCUR WITH RRESSION P0026
EDT A S CALCIUM DEC V COMPLEXES CALCIUM BY CHELATION 30554
EDTA S CALCIUM DEC N IF DETERMINED BY OXALATE OP OTHER PRECIP. TECH. 90907
ETHINYLESTRADIOL S CALCIUM DEC V SIGNIFICANT FALL, ASSOCIATED WITH DEC ALBUMIN P1016
FLUORIDES S CALCIUM DEC M MAY PRECIPITATE CALCIUM (FORMS INSOLUBLE SALT) 30436
FUPOSENIDE S CALCIUM DEC V DIURETIC ACTION (DIFF EFFECT HYDROCHLORTHIAZIDE) 901146
GLUCAGON S CALCIUM DEC V OCCURS 10 TO 20 MIN AFTER ADMIN IF HYPOGLYCEMIA P0 592
GLUCOCORTICOI 05 S CALCIUM DEC V EFFECTIVE IF HYPERCALCENIA DUE TO SAPCOID,VITANIN D P0026
GLUCOSE S CALCIUM DEC V MAY FALL BY 0.5 MEQ/L DURING GTT HO 592
HEMOGLOBIN S CALCIUM DEC N INTERFERENCE WITH CALCEIN TITRATION R0O 17
HEMOLYSIS S CALCIUM DEC N INTERFERES WITH CALCEIN FLUORESCENCE METHODS 30644
HEPAPIN S CALCIUM DEC N INTERFERES WITH !DTA AND ELUOPOMETRIC METHODS 91001
LAXATIVES S CALCIUM DEC V EXCESSIVE USE MAY HAVE EFFECT R062O
MAGNESIUM SALTS S CALCIUM DEC V COMPETES WITH CALCIUM FOP G.I.TRACT ABSORPTION 90554
NESTRANOL S CALCIUM DEC V INC SENS TO CALCITONIN IN POSTMENOPAUSAL WOMEN P00 11
M!THICILLIN S CALCIUM DEC V REPORTED EFFECT (?MFCHANISM) RO620
NETHOXY FLU PANE S CALCIUM DEC V SLIGHT LOWERING REPORTED IN ONE CASE R0753
NITHRAMYCIN S CALCIUM DEC V INHIBITION OF BONE RESORPTION OF CALCIUM P0879
ORAL CONTRACEPTIVE S CALCIUM DEC V SEEN IN OSTEOPOROSIS, ?DUE TO FALL IN ALBUMIN 91016
OXALATES S CALCIUM DEC Ii PHECIPATION OF CALCIUM OXALATE (NAY BE INCOMPLETE) P 04 36
PH OSPHATES S CALCIUM DEC N INHIBIT EMISSION IN SOME FLAME METHODS ROLL 36
PHOSPHATES S CALCIUM DEC V TRANSIENT EFFECT DUE TO COLLOID RETENTION IN LIVER RO2O1
PHOSPHATES S CALCIUM DEC N COMPETE WITH EDTA FOR CA (SL EFFECT SOME METHODS) 30436
POLYSTYRENE SULFON S CALCIUM DEC V EXCHANGED FOR POTASSIUM, INC FECAL LOSS 30620
?REDNI SON! S CALCIUM DEC V IF ELEVATION DUE TO SARCOIDOSIS OR VITAMIN D P0026
PROBUCOL S CALCIUM DEC V MECHANISM OBSCURE (EFFECT SLIGHT) P0 2147
SALINE S CALCIUM DEC V EFFECT OF ISOTONIC SOLN IF HYPERCALCEMIA R0026
SODIUM PHYTAT? S CALCIUM DEC V DECREASED G.I. TRACT ABSORPTION P00 26
SODIUM SULFATE S CALCIUM DEC V I! GIVEN I.V. MAY CAUSE HYPOCALCEMIA 90026
SULFADIAZINE S CALCIUM DEC N DEPRESSES FLUORESCENCE OF CALCEIN METHOD R064L$

S ULFADIMETHOXINE S CALCIUM DEC M DEPRESSES FLUORESCENCE OF CALCEIN METHOD P0644
SULFATES S CALCIUM DEC V BRIEF HYPOCALCEMIC EFFECT IF INFUSED I.V. P0620
SULFATES S CALCIUM DEC N THEORETICAL INHIBITION OF EMISSION IN FLAME METHODS P01436
SULFISOXAZOLE S CALCIUM DEC N DEPRESSES FLUORESCENCE OF CALCE1N METHOD P0644
SULFONAMIDES S CALCIUM DEC N DEPRESS FLUORESCENCE OF CALCEIN METHOD HO 644
TETRACYCLINE S CALCIUM DEC V OBSERVED IN PREGNANT WOMEN P0657
VIOMYCIN S CALCIUM DEC V MAY CAUSE TETANY WITH ELECTROLYTE IMBALANCE P0026
AMBULATION U CALCIUM DEC V FOLLOWING SEVERAL WEEKS OF BED REST P047 1
BENDROFL UMET HIAZ IDE U CALCIUM DEC V IMPAIRED EXCRETION MAY OCCUR WITH THIAZIDES P0720
BICARBONATES U CALCIUM DEC V PROTECTS SKELETON FROM REABSORPTION OF P04 P0077
CHLOROTHIAZI DE U CALCIUM DEC V IMPAIRED EXCRETION WITH CHRONIC ADMINISTRATION P0907
ETHINYLESTRADIOL U CALCIUM DEC V ASSOCIATED WITH DECREASED SERUM CONCENTRATION P1016
LITHI UN U CALCIUM DEC V ?AFFECTS CA DEPENDENT CATECHOLANINE SYSTEM R0612
MESTRA NOL U CALCIUM DEC V INC SENS TO CALCITONIN IN POSTNENOPAUSAL WOMEN P00 11
METHYCLOTHIAZIDE U CALCIUM DEC V IMPAIRS EXCRETION P0467
ORAL CONTRACEPTIVE U CALCIUM DEC V OCCURS WITH FALL IN SERUM CONCENTRATION H 1016
OXALA TES U CALCIUM DEC N MAY BE INCOMPLETE PRECIPITATION P0436
PARATHYROID EXTRACT U CALCIUM DEC V INCREASES TUBULAR REABSORPTION R0026
PHOSPHATES U CALCIUM DEC N COMPETE WITH EDTA FOR CA (MORE MARKED THAN SERUM) P0436
PHOSPHATES U CALCIUM DEC N INHIBIT EMISSION IN SOME FLAME METHODS P0 436
POLYTHIAZI DE U CALCIUM DEC V EXCRETION DEC BY UP TO 50% R0657
SODIUM PHYTATE U CALCIUM DEC V DECREASED G.I. TRACT ABSORPTION P0299
STANDING OF SAMPLE U CALCIUM DEC N PRECIPITATION OF CALCIUM SALTS UNLESS ACIDIFIED P100 1
STORAGE OF SAMPLE U CALCIUM DEC N UNLESS ACIDIFIED P0998
SULFATES U CALCIUM DEC N INHIBIT EMISSION IN SOME FLAME METHODS HO 436
THIAZIDES U CALCIUM DEC V BY UP TO 50% (APPEAR TO HAVE EXTRA-RENAL EFFECT) P0723
TRIC HLOP METHIAZI DE U CALCIUM DEC V IMPAIRED EXCRETION P0907
BED REST F CALCIUM INC V UP TO 70 MEQ/DAY IN HEALTHY MALES R0471
PHOSPHATES F CALCIUM INC V INC BY AVERAGE OF 32 NEQ/DAY R0471
POLYSTYRENE SULFON F CALCIUM INC V CAUSES IMPAIRED ABSORPTION P0299
ALKALINE ANTACIDS S CALCIUM INC V THEORETICAL POSSIBILITY WITH ABSORP OF CA SALTS R0883
AMINOPHENOL S CALCIUM INC M AT 0.1 MMOL/L AFFECTS SMA 12/60 METHOD P0876
ANABOLIC STEROIDS S CALCIUM INC V POSITIVE EFFECT ON CALCIUM RETENTION P002 1
A NDROGENS S CALCIUM INC V POSITIVE EFFECT ON CALCIUM RETENTION P002 1
ANTACIDS S CALCIUM INC V MAY OCCUR IF CA CONTAINING PREPARATIONS P0657
BED REST S CALCIUM INC V INCREASE OF APPPOX 0.1 MEQ/L P047 1
BENDROFLUMETHIA ZIDE S CALCIUM INC V DUE TO INC CONC OF PROTEIN DUE TO TEMP NA DEPLETION P0720
BILIPUBIN S CALCIUM INC N IF HIGH MAY CONFUSE EDTA TITRATION END-POINT P0436
BROMSULFALEIN S CALCIUM INC N MAY INTERFERE WITH COLORIMETRIC PROCEDURES P0654
CALCIFEPOL S CALCIUM INC V ENHANCES ABSORPTION FROM G.I. TRACT RO2OLI
CALCIUM SALTS S CALCIUM INC N POSSIBLE CONTAMINATION OF DISTILLED WATER P1001
CALCIUM SALTS S CALCIUM INC V DIRECT EFFECT OF INCREASED GUT ABSORPTION BOO 26
CHLOROTHIAZIDE S CALCIUM INC V IMPAIRED EXCRETION WITH CHRONIC ADMINISTRATION P 0907
OPPER S CALCIUM INC N INTERFERES WITH EDTA TITRATION PROCEDURES P0436
DIHYDROTACHY STEROL S CALCIUM INC V WEAK ANTIPACHITIC ACTIVITY P0620
DR ON OST A NOL 0 NE S CALCIUM INC V USUALLY IF OSTEOLYTIC METASTASES P0026
ESTROG ENS S CALCIUM INC V POSITIVE EFFECT ON CALCIUM RETENTION P0384
FILTER PAPER S CALCIUM INC M ORDINARY PAPER CONTAINS HIGH CONCENTRATION P018 1
HEPARIN S CALCIUM INC N IF CA SALT USED MAY AFFECT RESULT P0998
HYDRALAZINE S CALCIUM INC N AT 1 MMOL/L HAS SLIGHT EFFECT ON SMA 12/60 METHOD P0876
HYDROCHLOROTHIAZIDE S CALCIUM INC V IMPAIRED EXCRETION (PHOB ALSO RELEASED FROM BONE) P090 7
IRON SALTS S CALCIUM INC H INTERFERE WITH DIRECT EDTA TITRATION P0436
LIPEMIA S CALCIUM INC N CAUSES TURBIDITY IN FERPO-HAN PROCEDURE R0436
MAGNESIUM SALTS S CALCIUM INC N MEASURED AS CA IN SOME EDTA PROCEDURES P0436
MEALS S CALCIUM INC V EFFECT OF METABOLIC ALKALOSIS P0846
NETHANDROSTENOLONE S CALCIUM INC V NAY OCCUR SPONTANEOUSLY, BUT ESP IF BREAST CANCER P0467
NETHYCLOTHIAZIDE S CALCIUM INC V ?PELATED TO DECREASED EXCRETION P0467
METHYLTESTOSTERONE S CALCIUM INC V MAY OCCUR ESP IN WOMEN ON THERAPY FOR BREAST CANCER P0467
NANDROLONE S CALCIUM INC V MAY OCCUR IN WOMEN WITH NEOPLASM OF BREAST P 0708
ORAL CONTRACEPTIVE S CALCIUM INC V INC INGESTION WOULD INCREASE CONCENTRATION HO 20 4
OXALATES S CALCIUM INC N MAY BE COPRECIPITATION OF NA, K, MG AND PROTEIN P0436
PARATHYROID EXTRACT S CALCIUM INC V INCREASED CALCIUM MOBILIZATION FROM BONE P02014
POLYSTYRENE SULFON S CALCIUM INC V INCREASED ADMINISTERED CALCIUM (IF IN CA FORM) HO 907
POLYTHIAZIDE S CALCIUM INC V MAY BE INC BY UP TO 0.35 MEQ/L P0 657
POTASSIUM S CALCIUM INC N AFFECTS FLAME PHOTOMETRY IF POOR INSTRUMENT P0436
PROGESTIN S CALCIUM INC V PROB EFFECT WITH REMISSION OF METASTASES P0620
SECRETIN S CALCIUM INC V INC BY 0.6 MEQ/L IN NORMALS, ? CAUSE P0147
SODIUM SALTS 5 CALCIUM INC N AFFECT FLAME PHOTOMETRY IF POOR INSTRUMENT HO 436
T ES TOLA CT ONE S CALCIUM INC V PROB EFFECT DURING REMISSION OF METASTASES P0026
TESTOSTERONE S CALCIUM INC V MAY OCCUR WITH TREATMENT OF BREAST CANCER P0657
THIAZIDES S CALCIUM INC V MAY INCREASE UP TO 0.25 MEQ/L P0723
TOURNIQUET S CALCIUM INC V DUE TO RELATIVE INC OF PLASMA PROTEINS P0267
TR IC HLOPMETHIAZIDE S CALCIUM INC V IMPAIRED EXCRETION P0907
VITAMIN D S CALCIUM INC V EFFECT OF INCREASED G.I. TRACT ABSORPTION P 1001
ACETAZOLA MID! U CALCIUM INC V INHIBITS TUBULAR REABSORPTION P0723
ASPARAGINASE U CALCIUM INC V ATYPICAL RESPONSE BUT OBSERVED IN SOME P0705
BED REST U CALCIUM INC V UP TO 50 MEQ/DAY IN HEALTHY MALES P01471
CALCIFER OL U CALCIUM INC V AS RESULT OF INC ABSORPTION P0204
CALCITONIN U CALCIUM INC V ACTS INDEPENDENTLY OF PARATHYPOID P0406
CALCIUM SALTS U CALCIUM INC N POSSIBLE CONTAMINATION OF DISTILLED WATER P1001
CALCIUM SALTS U CALCIUM INC V INC EXCRETION WITH LARGE OPAL DOSES P0 384
CROLESTY RAMI NE U CALCIUM INC V BINDS HEAVY METALS P0299
COPTICOSTEPOIDS U CALCIUM INC V METABOLIC EFFECT P0596
CORTICOTROPIN U CALCIUM INC V AVERAGE OR LARGE DOSES PROMOTE EXCRETION P0467
DEXA METH AS ONE U CALCIUM INC V METABOLIC EFFECT P0467
DIHYDROTACHY STEPOL U CALCIUM INC V HYPERCALCIURIC EFFECT P0299
DI MEPCAPROL U CALCIUM INC V EFFECTIVE BUT LESS GOOD THAN EDTA P0026
EDTA U CALCIUM INC V EXCRETION OF CHELATE P0026
ETHACPYNIC ACID U CALCIUM INC V IMPAIRED REABSORPTION P0723
FUROSEMIDE U CALCIUM INC V IMPAIRED REABSORPTION (INITIAL EFFECT ONLY) P0723

GLUCOCORTICOIDS U CALCIUM INC V PROMOTE RENAL EXCRETION HO 026
GROWTH HORMONE U CALCIUM INC V NORMAL METABOLIC RESPONSE P06 49
HERA LLU HIDE U CALCIUM INC V REABSORPTION IMPAIRED P07 23
MERCAPTONEP IN U CALCIUM INC V REABSORPTION IMPAIRED 307 23
MERCURIAL DIURETICS U CALCIUM INC V REABSORPTION IMPAIRED R0723
U CALCIUM INC V REABSORPTION IMPAIRED P0 72 3
U CALCIUM INC V DIURETIC ACTION R09O
MITHRAMYCIN U CALCIUM INC V INHIBITION OF BONE RESORPTION OF CALCIUM R0879
NA NDPOLONE U CALCIUM INC V DUE TO HYPERCALCEMIA O708
OX AL AT ES U CALCIUM INC H MAY B! COPRECIPITATION OF NA, K, MG P0436
SALINE U CALCIUM INC V HYPERTONIC SOLUTION HAS CALCIURETIC EFFECT R0026
SODIUM SULFATE U CALCIUM INC V PROMOTES EXCRETION 90384
SULFATES U CALCIUM INC V DUE TO DIUPESIS AND CASO14 FORMATION P00 26
TRIANTEPENE U CALCIUM INC V IMPAIRS REABSORPTION P 0723
VIONYCIN U CALCIUM INC V PROMOTES URINARY LOSS R0355
VITAMIN D U CALCIUM INC V ASSOCIATED WITH HYPEPCALCENIA 30299
ANTIBIOT ICS S CALCIUM Z H NO EFFECT ON FLUORESCENCE OF CALCEIN P06 44
BARBITURATES S CALCIUM Z N NO EFFECT ON FLUORESCENCE OF CALCEIN 906414
EDTA S CALCIUM Z N NO EFFECT ON FLAME PHOTOMETRIC METHODS 90596
HYDROCORTISONE S CALCIUM Z H NO EFFECT ON FLUORESCENCE OF CALCEIN 905414
STORAGE OF SAMPLE S CALCIUM Z N ROOM TEMP 8H, 4 DEGREES 1 DAY, FROZEN 1 YEAR P0998
THY MOL U CALCIUM Z N NO EFFECT ON FLAME PHOTOMETRIC METHODS 90779
RIFAMPIN 0 CAPILLARY FRAGILITY INC V REPORTED IN PATIENT WITH MACROGLOBULIN!MIA P03 08
CYCLOPRO?A NE 0 CAPILLARY FRAGILITY Z V ANESTHESIA HAS NO EFFECT 303814
ETHER 0 CAPILLARY FRAGILITY Z V ANESTHESIA HAS NO EFFECT P03 84
ORAL CONTRACEPTIVE E CARBONIC ANHYDPASE INC V MEASURED AS B ISOENZYME (HORMONAL EFFECT) HO 829
PPEGNA NCY F CARBONIC ANHYDRASE INC V MEASURED AS B ISO!NZYNB - PROGRESSIVE INCREASE 90829
CARBON MONOXIDE B CARBOXYHEMOGLOBIN INC V DUE TO PRESENCE OF CARBON MONOXIDE 90368
SMOKING B CARBOXYHEMOGLOBIN INC V SIGNIFICANTLY HIGHER IN SMOKERS R0814
!THINYLESTP ADIOL S CAROTENE DEC V HORMONAL INFLUENCE 30352
KANAMYCIN S CAROTENE DEC V MAY INDUCE MALABSOPPTION WITH DIARRHEA P0467
METFOR MIN S CAROTENE DEC V PROBABLY ASSOCIATED WITH MALABSORPTION P0935
MINERAL OIL S CAROTENE DEC V REDUCED ABSORPTION (NAY B! 50% NORMAL) P0384
NOPETHI STERON E S CAROTENE DEC V HORMONAL INFLUENCE 90352
PROTEIN S CAROTENE INC V RISE IN PARALLEL WITH AMINO ACIDS 90291
BACTERIUPIA U CATALAS! INC V INFECTED OPINES HAVE ACTIVITY 90758
PHOTE INU RIA U CATALASE INC V PENAL DAMAGE IF NO BACTEPIURIA 90758
RES!PPINE P CATECHOLAMINES DEC V OBSERVED NORMAL RESPONSE TO THERAPY P065 7
CLONIDINE U CATECHOLANINES DEC V DOSE RELATED EFFECT (PRIMARY ACTION OF DRUG) 90455
METHYL DOPA U CATECHOLAMINES DEC V DEPLETION OF TISSUE STORES 30596
RESERPINE U CATECHOLAMINES DEC V DECREASED NOREPINEPURINE SYNTHESIS HO 235
AJMALINE P CATECHOLAMINES INC V RELEASE OF STORED NOR!PINEPHRINE P0596
AMINOPHYLLIN! P CAT!CHOLAMINES INC V RESPONSE TO I.V. THERAPEUTIC DOSE R0059
AMPICILLIN P CATECHOLAMINES INC N CONC SOLUTIONS CAUSE STRIKING FLUORESCENCE P0188
ASCORBIC ACID P CATECHOLAMINES INC N CONC SOLUTIONS CAUSE STRIKING FLUORESCENCR HO 188
CHLOPPPONAZ IN! P CATECHOLANINES INC V INC METABOLISM, DEC ORGAN UPTAKE OF NOPEPINEPHPINE P0355
COCOA P CATECHOLAMINES INC V CATECHOLS PRESENT IN COCOA HO 198
C YCLO P P 0 PA N! P CATECHOLAMINES INC V SIGNIFICANT INC, MAY REDUCE BLOOD TO KIDNFYS ETC BOO 26
!PI NEPH PINE P CATECHOLAMINES INC V PRESENCE OF EPINEPHPINE R0235
ETHANOL P CATECHOLAMINES INC V SLIGHT INCREASE FOLLOWING MODERATE DOSES BOO 51
ETHER P CATECHOLAMINES INC V PESPONSE TO STRESS P0752
I SOPROTERENOL P CATECHOLAMINES INC V DUE TO INHALATION - EFFECT SLIGHT P0235
LEVODOPA P CATECHOLAMINES INC N DOSAGE DEPENDENT 90042
MAO INHIBITORS P CATECHOLANINES INC V PREVENT DEAMINATION BUT NOT DEGRADATION BY CONT P00 142
MET RENA MI NE P CATECHOLAMINES INC M INTERFERENCE WITH FLUORESCENCE P0042
METHYLDO?A P CAT!CHOLAMINES INC N INTERFERENCE WITH FLUOROMETRIC METHODS HO 82 1
MET HYLDOPA P CATECHOLAMINES INC M REACTS LIKE CATECHOLAMINES, MAY PERSIST FOR DAYS P03 814
NICOTINIC ACID P CATECHOLAMINES INC M OCCURS WITH LARGE DOSES, INTERFERING FLUORESCENCE P0417
NITROGLYCERIN P CATECHOLANINES INC V EFFECT DOSAGE DEPENDENT 90042
P CATECHOLANINES INC M INTERFERES WITH FLUORONETRIC METHODS P1 001
PERPHENAZINE P CATECHOLANINES INC V INC METABOLISM, DEC ORGAN UPTAKE OF NOPEPINEPHRINE P0 355
PHENOTHIAZI NES P CATECHOLAMINES INC V INC METABOLISM, DEC ORGAN UPTAKE OF NOPEPINEPHRINE P0042
P HE NTOLA NINE P CATECHOLAMINES INC V ?DUE TO RELEASING ACTION OR TO ALTERED METABOLISM HO 384
PROMETHAZINE P CATECHOLAMINES INC V INC METABOLISM, DEC ORGAN UPTAKE OP NOR!PINEPHRINE P01 88
PROTA MINE P CATECHOLAMINES INC N CONC SOLUTIONS CAUSE STRIKING FLUORESCENCE HO 188
QUINIDINE P CATECHOLAMINES INC N METABOLITE CAUSES FALSE POSITIVE 90193
QUININE P CATECHOLAMINES INC N INTERFERENCE BY NETABOLITE, NO EFFECT IN VITRO 30181
PIBOFLAVI N P CATECHOLANINES INC N INTERFERES WITH FLUORON!TPIC TECHNIQUE R0654
S ULF AD I M ID IN! P CATECHOLAMINES INC N STRIKING FLUORESCENCE P0 188
TEA P CATECHOLAMINES INC N CONC SOLUTIONS CAUSE STRIKING FLUORESCENCE P0 188
TETRACYCLINE P CATECHOLAMINES INC H INTERFERES WITH FLUOROMETRIC TECHNIQUES R0042
VITAMIN B P CATECHOLAMINES INC N MAY B! INTERFERENCE WITH FLUORESCENCE P014 17
VITAMIN K P CATECHOLAMINES INC M MAY REACT LIKE EPINEPHRINE IN SHAW TEST P0160
ACETYLSALICYLIC AC U CATECHOLAMINES INC M INTERFERING FLUORESCENCE IN MANY PROCEDURES P0 596
BANANAS U CATECHOLANINES INC N CATECHOLS IN BANANAS R0234
CARBON TETRACHLOH U CATECHOLANINES INC N SPURIOUS RESULTS HO 112
CHLORAL HYDRATE U CATECHOLAMINES INC N INTERFERES WITH FLUOROMETRIC PROCEDURES P04 17
CHLOPTETRACYCLINE U CATECHOLAHINES INC N INTERFERENCE WITH FLUOROMETRIC METHODS HO 69 1
DENECLOCYCLINE U CATECHOLANINES INC N PRODUCES INTERFERING FLUORESCENCE WITH ANALYSIS P05 39
U CATECHOLAMINES INC N INTERFERES WITH FLUOPOMETPIC METHODS P0 233
EPYTHROMYCIN U CATECHOLAMINES INC N INTERFERES WITH FLUOROMETRIC METHODS P0233
FORMALDEHYDE U CATECHOLAMINES INC N INTERFERES WITH PROCEDURES FOR ANALYSIS P02 33
FORMALDEHYDE U CATECHOLANINES INC N INTERFERES WITH FLUOROMETRIC METHOD P0299
HYDRALAZI NE U CATECHOLAMINES INC N INTERFERES WITH SOME FLUORONFTRIC METHODS HO 596
HYDHOQU INONE U CATECHOLANINES INC N REACTS LIKE EPINEPHPINE WITH NELSON-SHAW TEST 90160
MUSCULAR EXERCISE U CATECHOLAMINES INC V FOLLOWING VIGOROUS EXCERCISE (MAY BE INC 7 FOLD) HO 112
PROCRLORPEPAZINE U CATECHOLAHINES INC V INC METABOLISM, DEC ORGAN UPTAKE OF NOPEPINEPHPINE P1001
PAUWOLFIA U CATECHOLAMINES INC V RELEASE OF STORED NOREPINEPHRINE HO 596
R!SERPINE U CATECHOLAMINES INC V RELEASE OF STORED NOREPINEPHRINE 30596
SYROSI NGOPINE U CATECHOLAMINES INC V RELEASE OF STORED N09!PINEPHRINE P05 96

THEOPHYLLINE U CATECHOLAMINES INC V NORMAL RESPONSE EVEN WHEN GIVEN ORALLY R0O59
ACETAMINOPHEN U CATECHOLAMINES Z V NO EFFECT WITH SHORT TERM INGESTION 2.6 G/DAY P0 236
ACETYLSALICYLIC AC U CATECHOLAMINES Z M NO EFFECT ON FLUOROMETRIC CROUT PROCEDURE P0236
ACETYLSALICYLIC AC U CATECHOLAMINES Z V NO EFFECT WITH SHORT TERN INGESTION 2.6 G/DAY P0 236
CHLOPDIAZEPOXIDE U CATECHOLAMINES Z V NO EFFECT SHORT TERN INGESTION OF 30 MG/DAY P0236
CHLOPOTHIAZIDF U CATECHOLANINES Z N NO EFFECT ON FLUOROMETRIC METHOD OF CPOUT P0235
DIAZEPAM U CATECHOLANINES Z V NO EFFECT SHORT TERM INGESTION OF 15 MG/DAY P0236
DIGITOXIN U CATECHOLAMINES Z N NO EFFECT ON FLUOROMETRIC METHOD OF CPOUT HO 235
DIPRENRYDRANIWE U CATECHOLAMINES Z V NO EFFECT SHORT TERM INGESTION OF 150 MG/DAY P02 36
HYDRALAZINE U CATECHOLANINES Z N NO EFFECT ON FLUOROMETRIC METHOD OF CROUT P0235
NECANYLAMINE U CATECHOLAMINES Z N NO EFFECT ON FLUOPOMETRIC METHOD OF CROUT P0235
P EN TOL I N I UN U CATECHOLANINES Z N NO EFFECT ON FLUOPOMETRIC METHOD OF CROUT P0235
PHENOBARB ITAL U CATECHOLAMINES Z V NO EFFECT SHORT TERM INGESTION OF 120 MG/DAY P0236
PHENOXYBENZ AMINE U CATECHOLAMINES Z N NO EFFECT ON FLUOPOMETRIC METHOD OF CROUT P0235
PHENTOLA MINE U CATECHOLAMINES Z N NO EFFECT ON FLUOROMETRIC METHOD OF CROUT P0235
PROPOXYPH EN! U CATECHOLAMINES Z N NO EFFECT ON FLUOHONETRIC CROUT PROCEDURE P0236
RESER PINE U CATECHOLANINES Z N NO EFFECT ON FLUOROMETRIC METHOD OF CPOUT P0 2 35
STORAGE OF SAMPLE U CATECHOLAMINES Z N NO EFFECT AT ROOM TEMP, SEVERAL DAYS IF ACIDIFIED P0998
ACETO HEXA HIDE S CEPHALIN FLOCCULATION INC V MAY CAUSE INTPAHEPATIC CHOLESTATIC JAUNDICE P06 20
AC ETOPRENAZINE S CEPHALIN FLOCCULATION INC V CHOLESTASIS WITH INTRAHEPATIC OBSTRUCTION HO 620
AMINOSALICYLIC AC S CEPHALIN FLOCCULATION INC V REVERSIBLE CHOLESTASIS CAUSED BY DRUG P0715
A MITPI PTYLI NE S CEPHALIN FLOCCULATION INC V RARE CASES OF TRANSIENT CHOLESTASIS P06 20
ANODIAQUINE S CEPHALIN FLOCCULATION INC V REPORTED HEPATOTOXICITY H0620
. AMPROTERICIN B S CEPHALIN FLOCCULATION INC V DUE TO HEPATOCELLULAR DYSFUNCTION P06 20
AMPICILLIN S CEPHALIN FLOCCULATION INC N ALTERS TIME OF FLOCCULATION P0 54 1
ANABOLIC STEROIDS S CEPHALIN FLOCCULATION INC V DUE TO CHOLESTATIC SYNDROME P0596
ANDROGEN S S CEPHALIN FLOCCULATION INC V CHOLESTATIC PHENOMENON P0620
ANTIMONY COMPOUNDS S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT P0596
ARSENICALS S CEPHALIN FLOCCULATION INC V REPATOTOXIC EFFECT (CHOLESTASIS/CHOLANGIOLITIS) P0596
ASPARAGINASE S CEPHALIN FLOCCULATION INC V HEPATOTOXICITY HO 4 27
ASPIDIUM S CEPHALIN FLOCCULATION INC V MAY CAUSE HEPATIC TOXICITY P062 0
BACTERIAL CONTAM S CEPHALIN FLOCCULATION INC N IF REAGENT CONTAMINATED TURBIDITY MEASURED P100 1
B ENZI ODA PONE S CEPRALIN FLOCCULATION INC V MAY CAUSE HEPATIC TOXICITY P0620
BISMUTH S CEPHALIN FLOCCULATION INC V HEPATOTOXICITY P0620
CARBON TETRACHLOP S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT P0620
CARPHENAZINE S CEPHALIN FLOCCULATION INC V PROBABLE CHOLESTATIC EFFECT (REVERSIBLE) P0620
CHLOPA MPH ENICOL S CEPHALIN FLOCCULATION INC V HEPATOTOXICITY 90596
CHLORDIAZEPOXIDE S CEPHALIN FLOCCULATION INC V INFREQUENT CHOLESTATIC EFFECT P0620
CHLORMEZANONE S CEPHALIN FLOCCULATION INC V HEPATOTOXICITY P0620
CHLOROFORM S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT WITH NECROSIS P0620
CHLOPOTHIAZIDE S CEPHALIN FLOCCULATION INC V NAY CAUSE CHOLESTATIC JAUNDICE P0620
CHLOP PROPAM IDE S CEPHALIN FLOCCULATION INC V HEPATOCELLULAR DAMAGE, AFFECTS PROTEIN SYNTHESIS P0620
CHLORPROTRIXENE S CEPHALIN FLOCCULATION INC V MAY CAUSE HEPATOTOXICITY (REVERSIBLE) RO62O
CHLOPTETRACYCLINE S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT WITH CENTROLOBULAR NECROSIS P03 55
CHLORZOXA ZONE S CEPHALIN FLOCCULATION INC V MAY CAUSE HEPATOTOXICITY P06 20
CINCHOPHEN S CEPHALIN FLOCCULATION INC V NAY CAUSE HEPATOTOXICITY (VIRAL-HEPATITIS LIKE) R062O
CLO FIBR ATE S CEPRALIN FLOCCULATION INC V HEPATOTOXIC EFFECT P06 20
COLCHICINE S CEPHALIN FLOCCULATION INC V NAY HAVE HEPATOTOXIC EFFECT P0620
COPPER S CEPHALIN FLOCCULATION INC V TRANSIENT EFFECT IN POISONING P0 657
COU MARl N S CEPHALIN FLOCCULATION INC V MAY CAUSE HEPATOTOXICITY P0990
CYCLOPHOSPHANIDE S CEPHALIN FLOCCULATION INC V NAY CAUSE HEPATOTOXICITY P06 20
CYCLOPROPA NE S CEPHALIN FLOCCULATION INC V MAY CAUSE HEPATOTOXICITY (LASTS SEVERAL DAYS) P06 20
CYCLOSERINE S CEPHALIN FLOCCULATION INC V NAY CAUSE HEPATOTOXICITY P0620
DESIPPANINE S CEPHALIN FLOCCULATION INC V RARE TRANSIENT CHOLESTASIS P0620
DICLOXACILLIN S CEPHALIN FLOCCULATION INC V MILD HEPATIC DYSFUNCTION NOTED P0043
DIPHENYLHYDANTCIN S CEPHALIN FLOCCULATION INC V HEPATOTOXICITY WITH CENTROLOBULAR NECROSIS P06 20
ECTYLUREA S CEPHALIN FLOCCULATION INC V MAY CAUSE CHOLESTASIS WITH CHOLANGIOLITIS P06 2 0
EPYTHR OMYCIN S CEPHALIN FLOCCULATION INC V WEAK EFFECT DUE TO CHOLESTASIS HO 1477
ESTRADIOL S CEPHALIN FLOCCULATION INC V CHOL!STATIC EFFECT P0620
ESTROGENS S CEPHALIN FLOCCULATION INC V MAY OCCUR WITH CHOLESTASIS HO 596
EST HONE S CEPHALIN FLOCCULATION INC V MAY CAUSE CHOLESTASIS P0620
ETHER S CEPHALIN FLOCCULATION INC V REPATIC DISTURBANCE (TRANSIENT) HO 620
ETHIONA MI DE S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT P06 20
ETHOSUXIM IDE S CEPHALIN FLOCCULATION INC V PARE HEPATITIS REPORTED P0620
ETHOTOIN S CEPHALIN FLOCCULATION INC V HEPATOTOXICITY P0620
ETH OX AZ EN F S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT HO 6 20
FLORA NTY P ONE S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT P0620
FLUOR OCYTOS IN! S CEPHALIN FLOCCULATION INC V REVERSIBLE HEPATOTOXICITY IN 10% P0898
FLUPHENAZINE S CEPHALIN FLOCCULATION INC V HYPEPSENSITIVITY(MAYBE NORMAL WHEN OTHER TESTS NOT) P062 0
FL UP AZEPAM S CEPHALIN FLOCCULATION INC V NAY CAUSE HEPATOTOXICITY P0788
GLASSWARE S CEPHALIN FLOCCULATION INC N IF HEAVY METALS. STRONG ACIDS PRESENT P1001
GL YCOP YR P OL ATE S CEPHALIN FLOCCULATION INC V H!PATOTOXICITY P0620
GOLD S CEPRALIN FLOCCULATION INC V HEPATOTOXICITY WITH CENTROLOBULAR NECROSIS P06 20
GUANOXAN S CEPHALIN FLOCCULATION INC V NAY CAUSE HEPATIC TOXICITY P0620
HALOP!RIDOL S CEPHALIN FLOCCULATION INC V MAY CAUSE HEPATOCELLULAR CHANGES P0620
HALOTHANE S CEPHALIN FLOCCULATION INC V REVERSIBLE DEPRESSION OF LIVER FUNCTION P06 20
HEAT S CEPHALIN FLOCCULATION INC N AS ROOM TEMPERATURE IS INCREASED 90355
HYDRAZINE S CEPHALIN FLOCCULATION INC V MAY CAUSE HEPATOTOXICITY P06 20
HYDPOXYACFTA MIDE S CEPHALIN FLOCCULATION INC V HEPATOTOXICITY 90620
IBUFENAC S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT P0620
ICTEROGENIN S C!PHALIN FLOCCULATION INC V CAUSES INTRAHEPATIC CHOLESTASIS R00 54
I NDA NDI ONES S CEPRALIN FLOCCULATION INC V MAY CAUSE HEPATOTOXICITY P0620
INDONETH ACIN S CEPHALIN FLOCCULATION INC V CYTOTOXIC AND CHOLESTATIC LIVER DAMAGE P052 1
IOPANOIC ACID S CEPHALIN FLOCCULATION INC V NAY CAUSE HEPATOTOXICITY P06 20
IPPONIAZID S CEPHALIN FLOCCULATION INC V NAY CAUSE CHOLESTATIC JAUNDICE P06 20
ISOCARBOXAZID S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT P06 20
ISONIAZID S CEPHALIN FLOCCULATION INC V CYTOTOXIC HEPATOCELLULAR DAMAGE P00 79
KANAMYCIN S CEPHALIN FLOCCULATION INC V NAY CAUSE HEPATOTOXICITY 90620
LIGHT S CEPHALIN FLOCCULATION INC N FALSE P05. OCCUR AFTER SERUM EXPOSED TO LIGHT P0078
LINCOMYCIN S CEPHALIN FLOCCULATION INC V HEPATOTOXIC-CHOLESTATIC EFFECT HO 620

LIPEMIA S CEPHALIN FLOCCULATION INC N REPORTED EFFECT ADDING TO TURBIDITY R0436
MAO INHIBITORS S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT P0620
MECHLOPETHAMINE S CEPHALIN 9LOCCULATION INC V MAY CAUSE CYTOTOXIC (REPATOCELLULAP) DAMAGE p0079
MEPACRIN! S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT P0620
MEPHENYTOIN S CEPHALIN FLOCCULATION INC V HEPATOTOXICITY 90620
NERCAPTOPURINE S CEPHALIN FLOCCULATION INC V HEPATOTOXICITY (CENTPOLOBULAR NECROSIS) 90620
NETAHEXANIDE S CEPHALIN FLOCCULATION INC V HEPATOTOXICITY (VIRAL HEPATITIS TYPE) P0620
METANDIENONE S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT (COMMON) P0620
METAXALONE S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT 90620
N!THINAZOLE S CEPHALIN FLOCCULATION INC V RFPATOTOXIC EFFECT P0620
NETHOTREXATE S CEPHALIN FLOCCULATION INC V MAY CAUSE CYTOTOXIC H!PATOCELLULAR DAMAGE P0079
METHOXSALEN S C!PHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT 90620
NETHOXYFLUPANE S CEPHALIN FLOCCULATION INC V HEPATOTOXICITY 90620
NETHSUXINIDE S CEPHALIN FLOCCULATION INC V HEPATIC DAMAGE REPORTED 90620
NETHYLDOPA S CEPHALIN FLOCCULATION INC V RESULT OF HEPATOCELLULAR DAMAGE R1001
N!THYLTESTOSTEBONE S CEPHALIN FLOCCULATION INC V CHOLESTATIC EFFECT (MAY NOT BE AFFECTED) 90477
M!THYLTHIOURACIL S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT P0620
NALIDIXIC ACID S CEPHALIN FLOCCULATION INC V NAY CAUSE CHOLESTATIC JAUNDICE 90736
NICOTINIC ACID S CEPHALIN FLOCCULATION INC V NAY IMPAIR HEPATIC FUNCTION 30620
NITPOFURANS S CEPHALIN FLOCCULATION INC V HEPATOTOXICITY P0620
NITROFURANTOIN S CEPHALIN FLOCCULATION INC V MAY BE CHOLESTATIC JAUNDICE 30620
NORETHANDPOLONE S CEPHALIN FLOCCULATION INC V CHOLESTASIS PRODUCED WITHOUT CHOLANGIOLITIS P0826
NORETHINDRONE S CEPHALIN FLOCCULATION INC V CHOL!STATIC EFFECT 0620
NORETHISTEPONE S CEPHALIN FLOCCULATION INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P0620
NOPETHYNODHEL S CEPHALIN FLOCCULATION INC V CHOLESTATIC EFFECT RO620
NOVOBIOCIN S C!PHALIN FLOCCULATION INC V INTRAHEPATIC CHOL!STASIS NAY OCCUR P0620
OLEANDOMYCIN S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT 90620
OPAL CONTRACEPTIVE S C!PRALIN FLOCCULATION INC V OBSERVED IN MANY SUBJECTS P0657
ORGANOPHOSPHOPUS S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT 90130
OXACILLIN S CEPHALIN FLOCCULATION INC V REPATOTOXIC EFFECT P0620
OXAZEPAM S CEPHALIN FLOCCULATION INC V POSSIBLE HEPATOTOXICITY 90620
OXYPRENBUTAZONE S CEPHALIN FLOCCULATION INC V POSSIBLE HEPATOTOXICITY P0620
OXYPHENISATIN S CEPHALIN FLOCCULATION INC V MAY CAUSE HYPERSENSITIVITY REACTION 90776
PARALDEHYDE S CEPHALIN FLOCCULATION INC V POSSIBLE HEPATOTOXICITY P0620
PARAMETHADIONE S CEPHALIN FLOCCULATION INC V POSSIBLE HEPATOTOXICITY R0620
PARGYLINE S CEPHALIN FLOCCULATION INC V POSSIBLE HEPATOTOXICITY (REVERSIBLE) P0620
PECAZIN! S CEPHALIN FLOCCULATION INC V NAY ALTER LIVER FUNCTION (CHOLESTASIS) P0620
PENICILLANINE S CEPHALIN FLOCCULATION INC V POSSIBLE HEPATOTOXICITY P0620
PHENACEMID! S CEPHALIN FLOCCULATION INC V MAY AFFECT LIVER FUNCTION IN ABOUT 2% CASES P0620
PHENAZOPYRIDINE S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT P0620
PHENINDIONE S CEPHALIN FLOCCULATION INC V MAY MODIFY LIVER FUNCTION (CHOLESTASIS) R0620
PHENIPRAZINE S CEPHALIN FLOCCULATION INC V NAY AFFECT LIVER FUNCTION O62O
PH!NOTHIAZINES S CEPHALIN FLOCCULATION INC V NAY CAUSE CHOLESTATIC HEPATITIS (IN UP TO 4% PTS) P0620
PH!NYLBUTAZONE S CEPHALIN FLOCCULATION INC V NAY CAUSE CHOLESTASIS P0620
PHOSPHORUS S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT WITH NECROSIS P0620
POLYTHIAZIDE S CEPHALIN FLOCCULATION INC V MAY AFFECT LIVER FUNCTION P0620
PPOBENECID S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT (CENTROLOBULAR NECROSIS) 90620
PROCAINAMIDE S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT 30620
PROCHLOPPEPAZINE S CEPHALIN FLOCCULATION INC V CHOLESTATIC EFFECT 90026
PROGESTIN S CEPHALIN FLOCCULATION INC V REPATOTOXICITY P0620
PRONAZINE S CEPHALIN FLOCCULATION INC V MAY CAUSE CHOLESTASIS 30620
PPONETHAZINE S CEPHALIN FLOCCULATION INC V MAY CAUSE CHOLESTASIS 90620
PROPOXYPHENE S CEPHALIN FLOCCULATION INC V CHOLESTATIC EFFECT P0538
PPOPYLTHIOURACIL S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT (CENTROLOBULAR NECROSIS) RO620
PYRAZINAMIDE S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT (VIRAL-HEPATITIS LIKE) P0620
QUINETHAZONE S CEPHALIN FLOCCULATION INC V NAY CAUSE CHOLESTATIC JAUNDICE RO620
RIFAMPIN S CEPHALIN FLOCCULATION INC V HEPATOTOXIC EFFECT (CHOLESTASIS) P0740
STORAGE OF SAMPLE S CEPHALIN FLOCCULATION INC N REPORTED EFFECT AFTER 2 DAYS AT 4 DEGREES R0436
SULFADINETHOXINE S CEPHALIN FLOCCULATION INC V REVERSIBLE CHOLESTASIS P0307
SULFAFURAZOLE S CEPHALIN FLOCCULATION INC V REVERSIBLE CHOLESTASIS P0620
SULFAMETHIZOLE S CEPRALIN FLOCCULATION INC V REVERSIBLE CHOLESTASIS 90542
SULFAM!THOXAZOLE S CEPHALIN FLOCCULATION INC V REVERSIBLE CHOLESTASIS P0620
SULFANETHOXYPYHID S CEPHALIN FLOCCULATION INC V REVERSIBLE CHOLESTASIS P0620
SULFISOXAZOLE S CEPHALIN FLOCCULATION INC V NAY CAUSE CHOLESTASIS P05142
SULFONAMIDES S CEPHALIN FLOCCULATION INC V NAY CAUSE CHOLESTASIS 90736
SULFONES S CEPHALIN FLOCCULATION INC V MAY AFFECT LIVER FUNCTION P0620
TESTOSTERONE S CEPHALIN FLOCCULATION INC V NAY CAUSE CHOLESTASIS RO620
TETRACYCLINE S CEPHALIN FLOCCULATION INC V MAY CAUSE CHOLESTASIS R0620
THIABENDAZOLE S CEPHALIN FLOCCULATION INC V PARE CHOLESTASIS AND PARENCHYNAL LIVER DAMAGE P0647
TEIIACETAZONE S CEPHALIN FLOCCULATION INC V MAY CAUSE CHOLESTASIS RO079
THIANAZOLE S CEPHALIN FLOCCULATION INC V MAY AFFECT LIVER FUNCTION P0620
THIAZIDES S CEPHALIN FLOCCULATION INC V MAY CAUSE CHOLESTASIS P0620
THIOGUANINE S CEPHALIN FLOCCULATION INC V MAY CAUSE CHOLESTASIS P0620
TRIORIDAZINE S CEPHALIN FLOCCULATION INC V HEPATOTOXICITY P0508
THIOSENICARBAZONES S CEPHALIN FLOCCULATION INC V NAY AFFECT LIVER FUNCTION P0620
THIOTHIXENE S CEPRALIN FLOCCULATION INC V HEPATOTOXIC EFFECT (REVERSIBLE CHOLESTASIS) 90620
TOLAZANIDE S CEPHALIN FLOCCULATION INC V CHOLESTASIS P0620
TOLBUTANIDE S CEPHALIN FLOCCULATION INC V CHOLESTATIC PHENOMENON 90620
TRANYLCYPROMINE S CEPHALIN FLOCCULATION INC V MAY AFFECT LIVER FUNCTION (?HYPERSENSITIVITY) P0620
TRINETHADIONE S CEPHALIN FLOCCULATION INC V NAY CAUSE HEPATOTOXICITY WITH NECROSIS P0620
TRIOXSALEN S CEPHALIN FLOCCULATION INC V NAY AFFECT LIVER FUNCTION P0620
UPACIL MUSTARD S CEPHALIN FLOCCULATION INC V NAY AFFECT LIVER FUNCTION P0620
OPAL CONTRACEPTIVE B CEPHALINTIN! DEC V METABOLIC EFFECT 90746
ASPARAGINASE S CERULOPLASMIN DEC V DIMINISHED HEPATIC SYNTHESIS R07O5
HENOLYSIS S CEPULOPLASNIN DEC N MAY AFFECT LINEARITY OF REACTION CURVE P0779
STORAGE OF SAMPLE S CEPULOPLASMIN DEC N OXIDASE ACTIVITY DEC AT ROOM TEMP, Z 2 DAY AT 14 D!G P0998
ANDROGENS S CEPULOPLASMIN INC V HORMONAL EFFECT P0079
COPPER S CEPULOPLASMIN INC V OBSERVED WITH COPPER POISONING P0657
DIPHENYLRYDANTOIN S C!PULOPLASHIN INC V EFFECT ON SYNTHESIS OF PROTEIN IN LIVER P0907
ESTPOGENS S CERULOPLASMIN INC V BUT NO CHANGE IN CERULOPLASMIN ACTIVITY P06140

LACTATION S CEPULOPLASNIN INC V INITIALLY HIGH FALLS TO NORMAL P02 91
OPAL CONTRACEPTIVE S C!PULOPLASMIN INC V ESTROGEN EFFECT ON LIVER, NO CHANGE IN ACTIVITY P0588
PREGNANCY S CERULOPLASMIN INC V IN LAST TRIMESTER COMPARED WITH CONTROLS P0 639
OXYMETROLONE S CERULOPLASMIN Z V NO METABOLIC EFFECT P0072
PROGESTIN S CEPULOPLASMIN Z V NO EFFECT PEPOHTED OVER SEVERAL MONTHS P0907
ESTROGENS 0 CERVICAL SECRETION INC V LEUCORPHEA IN 20% WOMEN ON ORAL CONTRACEPTION P06 29
ORAL CONTRACEPTIVE 0 CERVICAL SECRETION INC V LEUCORPHEA DUE TO ESTROGEN IN 20% WOMEN P0629
AL DOST ER ONE S CHLORIDE DEC V RYPOKALEMIC HYPOCHLOREMIC ALKALOSIS MAY OCCUR RO3 814
BICARBONATES S CHLORIDE DEC V INDUCES METABOLIC ALKALOSIS P0 2014
BROMIDES S CHLORIDE DEC V REVERSIBLE HALIDE DYSEQUILIBRATION P0204
CONTACT WITH CLOT S CHLORIDE DEC N IF EXPOSED TO AIR WATER SHIFT FROM ERYTHPOCYTES HO 1436
CORTICOSTEPOIDS S CHLORIDE DEC V METABOLIC ALKALOSIS WITH REDUCED CL REABSOPPTION P0663
COPTICOTROP IN S CHLORIDE DEC V MAY CAUSE HYPOCHLOPEMIC ALKALOSIS HO 62 1
CORTISONE S CHLORIDE DEC V MAY CAUSE HYPOCHLOPEMIC ALKALOSIS P1028
DI UPETICS S CHLORIDE DEC V DIURETIC ACTION IF EXCESSIVE P0620
ETHACRYNIC ACID S CHLORIDE DEC V DIURETIC ACTION (INHIBITS TUBULAR PEABSORPTION) HO 723
FUROSEMIDE S CHLORIDE DEC V DIURETIC ACTION (INHIBITS TUBULAR REABSORPTION) P0021
GLUCOSE S CHLORIDE DEC V DILUTIONAL EFFECT WHEN INFUSED P0 204
HEMOLY SIS S CHLORIDE DEC N DILUTIONAL EFFECT P0620
HYDPOCHLOROTHIAZIDE S CHLOPIDE DEC V MAY CAUSE MARKED REDUCTION P0 325
HY DROC ORTI SON! S CHLORIDE DEC V MAY CAUSE HYPOCHLOREMIC HYPOKALEMIC ALKALOSIS P03 84
RYDROFLUMET hA ZIDE S CHLORIDE DEC V DIURETIC ACTION P01467
MA NNITOL S CHLORIDE DEC V EFFECT IF MARKED DIURESIS 90026
MERALLURID! S CHLORIDE DEC V DIURETIC ACTION P1001
MERCURIAL DIURETICS S CHLORIDE DEC V NAY CAUSE HYPOCHLOREMIC ALKALOSIS AND DIUPESIS P07 23
MER SALYL S CHLORIDE DEC V CONSEQUENCE OF DIURETIC ACTION P0 723
HETHYCLOTHIAZIDE S CHLORIDE DEC V DIURETIC ACTION (HYPOCHLORENIC ALKALOSIS) P03 86
METOLAZONE S CHLORIDE DEC V DIURETIC ACTION OF DRUG ACTING ON DISTAL TUBULES P0739
OXALATES S CHLORIDE DEC N IF USED AS ANTICOAGULANT NAY BE PASSAGE INTO CELLS HO 436
POLYTHI AZ IDE S CHLORIDE DEC V DIURETIC EFFECT P0325
POTASSIUM OXALATE S CHLORIDE DEC N IF USED AS ANTICOAGULANT MAY B! SHIFT INTO CELLS HO 436
SILVER S CHLORIDE DEC V OBSERVED AFTER SILVER NITRATE ANTISEPSIS P0657
THIAZ IDES S CHLORIDE DEC V DIURETIC ACTION (IMPAIRED TUBULAR REABSORPTION) P0 620
TPIAMTERENE S CHLORIDE DEC V DIURETIC ACTION WITH IMPAIRED TUBULAR REABSORPTION P02 04
COPTICOSTEROIDS U CHLORIDE DEC V PROMOTES RETENTION (MINERALOCORTICOID EFFECT) P00 26
CORTI SONE U CHLORIDE DEC V CAUSES RETENTION BOO 26
DIAZOXIDE U CHLORIDE DEC V EFFECT OVER 2H OF 4MG/KG GIVEN I.V. OR ORALLY HO 50 1
EPI NEPHPI NE U CHLORIDE DEC V WITH INC FILTRATION FRACTION 90384
MAFENIDE U CHLORIDE DEC V SELECTIVE RETENTION P00148
SPINAL ANESTHESIA U CHLORIDE DEC V OBSERVED IN NORMAL MALES, PREGNANT WOMEN R0384
5-HYDPOXYTRYPTANINE U CHLORIDE DEC V SLIGHT EFFECT WITH INTRADERMAL INJECTION R0384
ACETAZOLA MID! S CHLORIDE INC V LOSS OF HC03 BY CARBONIC ANHYDRASE INHIBITION P0299
AMNONIUM CHLORIDE S CHLORIDE INC V ADDED CHLORIDE AND METABOLIC ACIDOSIS P06 20
A NDROGENS S CHLORIDE INC V NAY CAUSE SALT AND WATER RETENTION R0384
BORIC ACID S CHLORIDE INC V TOXICITY EFFECT (WITH ACUTE TUBULAR NECROSIS) P0620
BROMIDES S CHLORIDE INC M MEASURED AS CL NERCUPIMETRIC, ELECTROMETPIC METHODS P0436
BPOMI SOVALUN S CHLORIDE INC N NETABOLITE MAY BE MEASURED AS CHLORIDE P03 84
CAP BRO N A L S CHLORIDE INC N BROMIDE AS METABOLITE MAY BE MEASURED AS CL HO 384
CHLORIDE SALTS S CHLORIDE INC V INCREASED ABSORPTION WITH INCREASED SERUM LEVELS R0204
CHLOROTHI AZIDE S CHLORIDE INC V WITH PROLONGED THERAPY HYPERCHLOREMIC ALKALOSIS P0 596
CHOLESTYPAMINE S CHLORIDE INC V IS CHLORIDE SALT OF BASIC ANION EXCHANGE RESIN P1001
CORTICOSTEROIDS S CHLORIDE INC V MAY CAUSE RETENTION P06 20
DIAZOXID! S CHLORIDE INC V NAY CAUSE SALT RETENTION P0 384
ESTROGENS S CHLORIDE INC V NAY CAUSE SALT AND WATER RETENTION P03 84
GLASSWARE S CHLORIDE INC N IF CHLORIDE PRESENT P1001
GUANETHIDINE S CHLORIDE INC V SALT RETENTION ? DUE TO TUBULAR EFFECT P0384
HYDPOC HLOROTHIAZ IDE S CHLORIDE INC V HYPERCHLOREMIC ALKALOSIS WITH PROLONGED THERAPY P0596
HYDPOCORTISONE S CHLORIDE INC V MAY CAUSE RETENTION AND EDEMA P0026
ION EXCHANGE RESIN S CHLORIDE INC V MECHANISM NOT CITED - ?DEPENDS ON RESIN P0204
MARIHUANA S CHLORIDE INC V REPORTED EFFECT P05 96
METHYL DOPA S CHLORIDE INC V MAY CAUSE SALT RETENTION AND EDEMA P03 84
0 X YR H! NB UTA ZO NE S CHLORIDE INC V MAY CAUSE MARKED SALT RETENTION P06 20
PH ENYLBUTAZONE S CHLORIDE INC V MAY CAUSE SALT RETENTION (?TUBULAR DYSFUNCTION) P0957
POTASSIUM CHLORIDE S CHLORIDE INC V ADDED CHLORIDE P0620
PROTRI N S CHLORIDE INC N FAILURE TO PRECIPITATE AFFECTS SCHALES METHOD P0436
SALINE S CHLORIDE INC V ADDED CHLORIDE P06 20
TRIANTERENE S CHLORIDE INC V NEPHROTOXIC AND AZOTEMIC EFFECT P06 2 0
AMILOR IDE U CHLORIDE INC V DIURETIC ACTION HO 384
AMMONIUM CHLORIDE U CHLORIDE INC V DIURETIC ACTION RO3 814
BROMIDES U CHLORIDE INC N BROMIDE MEASURED AS CHLORIDE P0 355
CHLORTH ALl DONE U CHLORIDE INC V MAY PRODUCE MARKED DIURESIS P0657
CLOPAMIDE U CHLORIDE INC V DIURETIC ACTION P076 1
DIAPA HIDE U CHLORIDE INC V DIURETIC ACTION P06 09
DIGITALIS U CHLORIDE INC V DIURETIC ACTION IN CARDIAC FAILURE HO 3814
ETHACPYNIC ACID U CHLORIDE INC V PRESENT AS MAJOR ANION P0384
FUPOSEMIDE U CHLORIDE INC V DIURETIC ACTION P01452
GLASSWARE U CHLORIDE INC N IF CHLORIDE PRESENT P1001
HYDPOFLUMETHIAZIDE U CHLORIDE INC V DIURETIC ACTION P04 67
NEFRUS IDE U CHLORIDE INC V DIURETIC ACTION P0061
MENSTRUATION U CHLORIDE INC V POST-MENSTPUAL DIURESIS (DEC PPEMENSTRUALLY) P02 91
MERCURIAL DIURETICS U CHLORIDE INC V THERAPEUTIC INTENT (DOMINANT URINARY ANION) P07 23
NETOLA ZONE U CHLORIDE INC V DIURETIC ACTION OF DRUG P0140 1
PARATHYROID EXTRACT U CHLORIDE INC V HORMONAL ACTION HO 384
SC-161 02 U CHLORIDE INC V DURATION OF DIURETIC ACTION SHORT 901499
SPIPONOLACTONE U CHLORIDE INC V DIURETIC ACTION P0 384
THIAZIDES U CHLORIDE INC V DIURETIC ACTION P03814
TPIAMTEPENE U CHLORIDE INC V DIURETIC ACTION P03 84
VIOHY IN U CHLORIDE INC V PROMOTES URINARY LOSS P0026
XA NT!1I NFS U CHLORIDE INC V DIURETIC ACTION P0384
MEALS S CHLORIDE Z V NO EFFECT AFTER STANDARD BREAKFAST P0 181

STORAGE OF SAMPLE S CHLORIDE Z N NO EFFECT AFTEP 1 WEEK AT ROOM TEMP, MONTHS AT -10 90436
THYMOL U CHLORIDE Z N NO EFFECT 0! SCHALES AND SCHALES METHOD P0779
ACETYLSALICYLIC AC S CHOLESTEROL DEC V DOSES OVER 5G REPORTED TO HAVE EFFECT 90384
ALLOPUPINOL S CHOLESTEROL DEC #{149} V HEPATOTOXIC EFFECT P0596
ALUMINUM NICOTINATE S CHOLESTEROL DEC V THERAPEUTIC INTENT THROUGH NICOTINIC ACID RELEASE P0040
AMINOSALICYLIC AC S CHOLESTEROL DEC V AS EFFECTIVE AS N!OMYCIN, MECHANISM OBSCURE 90579
ANDROGENS S CHOLESTEROL DEC V DECREASED SYNTHESIS P1OC1
ANDROSTEPONE S CHOLESTEROL DEC V THERAPEUTIC EFFECT 90355
ANTIMONY COMPOUNDS S CHOLESTEROL DEC V HEPATOTOXIC EFFECT P0596
ASCORBIC ACID S CHOLESTEROL DEC V TENDS TO FALL IN PEOPLE UNDER 25 WREN 1G/DAY GIVEN 90892
ASPAPAGINASE S CHOLESTEROL DEC V HEPATOTOXICITY (EFFECT MARKED) 90427
AZATHIOPRINE S CHOLESTEROL DEC V IMPROVES BILIABY EXCRETION IN BILIARY CIRRHOSIS 9099
BOXIDINE S CHOLESTEROL DEC V INHIBITS TRANSFORM OF 7-DEHYDROCHOLESTEPOL P0351
CARBON DISULFIDE S CHOLESTEROL DEC V IN PEOPLE WITH EXPOSURE TO 37 PPM FOP 5.7 YEARS R0254
CARBUTAMID! S CHOLESTEROL DEC V HEPATOTOXICITY P06 20
CHLOROFORM S CHOLESTEROL DEC V HEPATOTOXIC EFFECT WITH NECROSIS P0620
CHLORPROPAMIDE S CHOLESTEROL DEC V MAY INHIBIT HEPATIC SYNTHESIS (?ALSO ABSORPTION) P0596
CHLORTETHACYCLINE S CHOLESTEROL DEC V HEPATOTOXIC EFFECT WITH CENTHOLOBULAH NECROSIS 90356
CHOLESTYRANINE S CHOLESTEROL DEC V THERAPEUTIC GOAL (?INC BIND OF BILE SALTS IN GUT) 30465
CLOFIBRATE S CHOLESTEROL DEC V THERAPEUTIC GOAL (PROBABLY DIMINISHED SYNTHESIS) 901141
CLOMIPHENE S CHOLESTEROL DEC V POSSIBLE INTERFERENCE WITH SYNTHESIS 9OC26
COLCHICINE S CHOLESTEROL DEC V MAY HAVE HEPATOTOXIC EFFECT 90904
COLESTIPOL S CHOLESTEROL DEC V THERAPEUTIC INTENT P0280
COPTICOTROPIN S CHOLESTEROL DEC V ESTER CONCENTRATION REDUCED BY STIM OF ADRENAL 90204
DEXTROTHYPOXINE S CHOLESTEROL DEC V THERAPEUTIC INTENT (ENHANCES EXCRETION) 90417
EDTA S CHOLESTEROL DEC V REPORTED TO OCCUR IF GIVEN I.V. P0417
ERYTHPONYCIN S CHOLESTEROL DEC V HEPATOTOXIC EFFECT P0596
ESTROGENS S CHOLESTEROL DEC V REDUCES BY UP TO 18%:USED THERAPEUTICALLY 90681
ETHINYLESTRADIOL S CHOLESTEROL DEC V DECREASES BY UP TO 50% 903814
GLUCAGON S CHOLESTEROL DEC V REPORTED EFFECT. MECHANISM NOT LISTED P0245
HALOPERIDOL S CHOLESTEROL DEC V INHIBITS CHOLESTEROL BIOSYNTHESIS P0620
HEPAPIN S CHOLESTEROL DEC V MECHANISM NOT DISCUSSED 90379
INSULIN S CHOLESTEROL DEC V THERAPEUTIC GOAL P0907
ISONIAZID S CHOLESTEROL DEC V PROBABLE HEPATOTOXIC EFFECT P0596
KANAMYCIN S CHOLESTEROL DEC V FORMS SALTS WITH BILE ACIDS IN GUT 90310
LEVOTHYPOXINE S CHOLESTEROL DEC V OFTEN THERAPEUTIC INTENT 90907
LINCOMYCIN S CHOLESTEROL DEC V HEPATOTOXIC EFFECT R0596
LINOLEANIDE S CHOLESTEROL DEC V INHIBITS STEROL ABSORPTION 90280
LIOTPIX S CHOLESTEROL DEC V IN HYPOTHYROIDS FALLS TO WITHIN NORMAL RANGE 90467
MAO INHIBITORS S CHOLESTEROL DEC V HEPATOTOXIC EFFECT 90596
METHANDROSTENOLONE S CHOLESTEROL DEC V REPORTED EFFECT (MAY INCREASE AS ALT!RNA’IVE) P0467
NAFENOPIN S CHOLESTEROL DEC V NOPE EFFECTIVE THAN CLOFIBRATE P0280
NANDROLONE S CHOLESTEROL DEC V DUE TO ACTION ON LIVER P0708
NEOMYCIN S CHOLESTEROL DEC V FORMS SALTS WITH BILE ACIDS IN GUT 90907
NICOTINIC ACID S CHOLESTEROL DEC V THERAPEUTIC GOAL (REBOUND INC WHEN DISCONTINUED) P0907
NITRATES S CHOLESTEROL DEC N INTERFERE WITH ZLATKIS-ZAK REACTION 30907
OXALATES S CHOLESTEROL DEC N IF USED AS ANTICOAGULANT (CAUSES WATER SHIFT) 90436
OXANDPOLONE S CHOLESTEROL DEC V ANABOLIC EFFECT .0369
PAROMOMYCIN S CHOLESTEROL DEC V REDUCTION UP TO 18%. ?MECHI&NISM P0818
PENTYLENET!TRAZOL S CHOLESTEROL DEC V MAXIMAL EFFECT SEEN AFTER TWO WEEKS 90103
PHENFORNIN S CHOLESTEROL DEC V INHIBITS SYNTHESIS (?ALSO G.I.TRACT ABSORPTION) R0314
PHENYPAMIDOL S CHOLESTEROL DEC V PROBABLE INHIBIT OF HEPATIC NICROSONAL ENZYMES 90837
PROBUCOL S CHOLESTEROL DEC V LOWERED BY MORE THAN 20 NG/100ML IN MOST PATIENTS P02147
PYRIDYLCARBINOL S CHOLESTEROL DEC V THERAPEUTIC GOAL 90907
SITOST!POL S CHOLESTEROL DEC V INHIBITS ABSOPP OF ENDOGENOUS & EXOGENOUS COMPOUND P0379
TETRACYCLINE S CHOLESTEROL DEC V HEPATOTOXICITY MAY OCCUR R0736
THYROID S CHOLESTEROL DEC V PHYSIOLOGICAL EFFECT P0417
TRIFLUPERIDOL S CHOLESTEROL DEC V INHIBITS BIOSYNTHESIS IN LIVER 90384
TRIIODOTRYRONIN! S CHOLESTEROL DEC V PHYSIOLOGICAL CONSEQUENCE OF HORMONE P0907
CARBON DISULFIDE S CHOLESTEROL ESTERS DEC V WHILE CHOLESTEROL WAS INCREASED P0083
CONTACT WITH CLOT S CHOLESTEROL ESTERS INC N FREE DECS AT SAME TINE DUE TO ESTERASE ACTION 90436
CORTICOTPOPIN S CHOLESTEROL ESTERS INC V INITIAL FALL THEN RISE ABOUT 10% P0621
CORTISONE S CHOLESTEROL ESTERS INC V INCREASE ABOUT 20% WITH VIGOROUS TREATMENT 91028
MEALS S CHOLESTEROL ESTERS Z V NO EFFECT AFTER STANDARD BREAKFAST P0181
AC!TOHEXAMIDE S CHOLESTEROL INC V MAY CAUSE INTPAHEPATIC CHOLESTATIC JAUNDICE P0596
ACETOPHENAZINE S CHOLESTEROL INC V CHOLESTASIS WITH INTRAHEPATIC OBSTRUCTION P0767
ACETYLSALICYLIC AC S CHOLESTEROL INC M ALLEGED EFFECT (BUT ALSO NO EFFECT AT 3OMG/100NL) P0436
AMINOPYBINE S CHOLESTEROL INC N INTERFERES WITH MEASUREMENT PROCEDURE P0436
ANABOLIC STEROIDS S CHOLESTEROL INC V CHOLESTATIC PHENOMENON 90596
ANDROGENS S CHOLESTEROL INC V CHOLESTATIC PHENOMENON P0596
APSENICALS S CHOLESTEROL INC V HEPATOTOXIC EFFECT (MAY BE VERY HIGH) P0596
ASCORBIC ACID S CHOLESTEROL INC V WHEN ATHEROSCLEROTIC, ?MOBILIZATION FROM ARTERIES P0892
ASPARAGINASE S CHOLESTEROL INC V UNUSUAL REPONSE IN SOME PATIENTS P0705
BILE SALTS S CHOLESTEROL INC V AUGMENT CHOLESTEROL POOL P0204
BILIRUBIN S CHOLESTEROL INC M INTERFERES WITH DIRECT PROCEDURES P0355
BROMIDES S CHOLESTEROL INC N INTERFERES WITH ZLATKIS-ZAK METHOD (UP TO 10%) P0777
CARBON DISULFIDE S CHOLESTEROL INC V WITH OTHER LET NORMAL ON CHRONIC EXPOSURE RO083
CHLORPHONAZINE S CHOLESTEROL INC V ASSOC WITH HEPATOCANALICULAR CHOLESTATIC JAUNDICE P0079
CRLORPPOPAMIDE S CHOLESTEROL INC V INFREQUENT CHOLESTATIC EFFECT P0477
CHOLESTANOL S CHOLESTEROL INC N YIELDS YELLOW COLOR WITH ZLATKIS-ZAK METHOD R01436
CINCHOPHEN S CHOLESTEROL INC V MAY CAUSE INTRAHEPATIC CHOLESTASIS P01405
CLOFIBRATE S CHOLESTEROL INC V PARADOX EFFECT IN PATIENTS WITH BILIAHY CIRRHOSIS P0750
CORTICOSTEROIDS S CHOLESTEROL INC V EFFECT OF PROLONGED HORMONE ACTION P0211
COPTICOSTEROIDS S CHOLESTEROL INC N MANY STEROIDS REACT WITH FECL3 REAGENT P0436
CORTICOTPOPIN S CHOLESTEROL INC V EFFECT OF HORMONE ACTION AFTER INITIAL FALL P0596
CORTISONE S CHOLESTEROL INC V INCREASE ABOUT 20% WITH VIGOROUS TREATMENT P1028
CYCLOPHOSPHANIDE S CHOLESTEROL INC V SINGLE CASE OF DRUG INDUCED MYXEDENA 90207
DIGITONIN S CHOLESTEROL INC M IF P-TOLUENESULFONIC ACID REACTION USED 901436
DIPHENYLHYDANTOIN S CHOLESTEROL INC V HEPATOTOXICITY WITH CENTROLOBULAR NECROSIS 90955
EPINEPHBINF S CHOLESTEROL INC V METABOLIC EFFECT (INDIRECTLY THROUGH ACTH STIM) P0417

GOLD S CHOLESTEROL INC V NAY CAUSE HYPERSENSITIVE CHOLESTASIS P01405
HEMOGLOBIN S CHOLESTEROL INC M INTERFERENCE WITH ZLATKIS-ZAK AND DIRECT METHODS P03 55
HEHOLYSIS S CHOLESTEPOL INC N VALUES HIGH BY 10% IF EXTRACTION NOT USED P04 36
HEPARIN S CHOLESTEROL INC V REBOUND EFFECT OF CESSATION OF TREATMENT P014 67
INIPRANINE S CHOLESTEROL INC V POSSIBLE CHOLESTATIC EFFECT R0767
TODATES S CHOLESTEROL INC N INTERFERENCE WITH ZLATKIS-ZAK REACTION R0907
IDDIDES S CHOLESTEROL INC N INTERFERENCE WITH ZLATKIS-ZAK REACTION P0907
LEVARTERENOL S CHOLESTEROL INC V MECHANISM NOT DISCUSSED P0245
LIPENIA S CHOLESTEROL INC N TURBIDITY IF EXTRACTION NOT USED P0436
LIPOCHROME S CHOLESTEROL INC N ABSORB STRONGLY IN BLUE REGION MAY AFFECT L-B METH P04 36
LITHIUM S CHOLESTEROL INC V REPORTED TO INDUCE MYXEDEMA P0597
MEALS S CHOLESTEROL INC V REPORTED UP TO 3% INC AFTER MEALS P0436
MENSTRUATION S CHOLESTEPOL INC V INCREASE IMMEDIATELY BEFORE MENSTRUATION P014 36
MEPAZIWE S CHOLESTEROL INC V CHOLESTATIC EFFECT P0477
NEPROBAMATE S CHOLESTEROL INC V NAY CAUSE CHOLESTATIC (HEPATOCANALICULAR) JAUNDICE P0079
NETANDIENONE S CHOLESTEROL INC N INTERFERES WITH ZIMMERMAN REACTION P0 596
NETANDIENONE S CHOLESTEROL INC V REPORTED EFFECT R0657
METHANDROSTENOLONE S CHOLESTEROL INC V DUE TO CHOLESTASIS P0477
METHIMAZOLE S CHOLESTEROL INC V CHOLESTATIC EFFECT P0477
NETHYLTESTOST!RON! S CHOLESTEROL INC V MAY CAUSE HYPERSENSITIVE CHOLESTASIS P0405
MUSCULAR EXERCISE S CHOLESTEROL INC V OCCASIONAL RESPONSE TO EXERCISE P0184
NANDROLONE S CHOLESTEROL INC V DUE TO ACTION ON LIVER P0708
NITROPHENOL S CHOLESTEROL INC V HYPERSENSITIVE INTRAHEPATIC CHOLESTASIS P0405
NORETMANDROLONE S CHOLESTEROL INC V DUE TO CHOLESTASIS P0477
ORAL CONTRACEPTIVE S CHOLESTEROL INC V IF INITIALLY LOW (NO EFFECT IF ABOUT 200 MG/100NL) P0 186
OXYMETHOLONE S CHOLESTEROL INC V CHOLESTATIC EFFECT P0477
PAPANETHADIONE S CHOLESTEROL INC V POSSIBLE LIVER DAMAGE R0620
PENICILLANINE S CHOLESTEROL INC V SINGLE CASE REPORTED P04 17
PHFN0THItZINES S CHOLESTEROL INC V FREQUENTLY REPORTED EFFECT, ?M!CHANISM P0767
PREGNANCY S CHOLESTEROL INC V INCREASES FROM 8 TH WEEK (MAX BY 3 0TH) P0 29 1
PROCHLORPEPAZINE S CHOLESTEROL INC V CHOLESTATIC EFFECT P00 26
PRONAZINE S CHOLESTEROL INC V NAY CAUSE CHOLESTATIC (HEPATOCANALICULAR) JAUNDICE P0079
PROTEIN S CHOLESTEROL INC N TRYPTOPRAN IN PROTEIN MAY REACT P0620
SULFADIAZINE S CHOLESTEROL INC V NAY CAUSE INTRAHEPATIC CHOLESTASIS P0405
SULFONAMIDES S CHOLESTEROL INC V CHOLESTATIC EFFECT P0477
TESTOSTERONE S CHOLESTEROL INC V CHOLESTATIC EFFECT P0417
THIABFNDAZOL! S CHOLESTEROL INC V CHOL!STATIC EFFECT P0647
THIACETAZONE S CHOLESTEROL INC V MAY CAUSE CHOLBSTATIC(HEPATOCANALICULAR) JAUNDICE P0079
THIAZID!S S CHOLESTEROL INC V INFREQUENT CHOLESTATIC EFFECT P01477
THIOURACIL S CHOLESTEROL INC V MAY CAUSE INTRAHEPATIC CHOLESTASIS P0405
THIOURACIL S CHOLESTEROL INC N INTERFERES WITH ZLATKIS-ZAK REACTION P0907
TPIFLUOPEPAZINE S CHOLESTEROL INC V INC OF UP TO 35 MG/100ML REPORTED P0767
TRIMETHADION! S CHOLESTEROL INC V NAY AFFECT LIVER FUNCTION (HEPATITIS) P06 20
TRYPTOPHAN S CHOLESTEROL INC N AFFECTS DIRECT REACTIONS USING ACETIC ACID P01436
VIONYCIN S CHOLESTEROL INC N INTERFERES WITH ZLATKIS-ZAK REACTION P0907
VITAMIN A S CHOLESTEROL INC N INTERFERES WITH ZLATKIS-ZAK HEACTION P0907
VITAMIN 0 5 CHOLESTEROL INC N INTERFERES WITH ZLATKIS-ZAK REACTION P0907
CHENODEOXYCHOLIC S CHOLESTEROL Z V NO EFFECT OBSERVED DUPING TREAT OF GALLSTONES P0248
MEALS S CHOLESTEROL Z V NO EFFECT AFTEP STANDARD BREAKFAST R0181
ORAL CONTRACEPTIVE S CHOLESTEROL Z V NO EFFECT OBSERVED USUALLY P0657
SERUM S CHOLESTEROL Z N IF HEPAPIN USED FOP PLASMA P0 143 6
STORAGE OF SAMPLE S CHOLESTEROL Z N NO EFFECT 2 DAYS AT 14 DEGREES, 5 YEARS AT -20 P0998
ECHOTHIOPHATE N CHOLINESTEPASE DEC V DIRECT EFFECT OF DRUG P09 13
ADIPI000NE S CHOLINESTERAS! DEC V FAIRLY POWERFUL INHIBITOR P0567
ALDRIN S CROLINESTEPASE DEC V IN VITRO 6.0% DEC AT 1110-14 M P0 3 62
CARBON DISULFIDE S CHOLINESTERASE DEC V NOT USUALLY SEVERE ENOUGH TO PRODUCE SYMPTOMS P036 8
CYCLOPHOSPHAMIDE S CHOLINESTERASE DEC V CAUSES INHIBITION OF ACTIVITY P 10 27
DEMECAPIUN S CHOLINESTERASE DEC V THERAPEUTIC INTENT P0026
DIAZINON S CHOLINESTERASE DEC V IN VITRO 8.2% DEC AT 1X1O-14 M P0 362
DIELDPIN S CHOLINESTEPASE DEC V IN VITRO 7.2% DEC AT 1X1O-14 M P0362
ESTROGENS S CHOLINESTEPASE DEC V ALTERED LIVER METABOLISM P08 74
INSECTICIDES S CHOLINEST!RASE DEC V DIRECT EFFECT OF DRUG P0913
IOPANOIC ACID S CHOLINEST!PASE DEC V POTENT INHIBITOR AT 0.06MM P0567
ISOFLUROPHATE S CHOLINESTEPASE DEC V THERAPEUTIC ACTION OF DRUG P00 26
LINDANE S CHOLINESTERASE DEC V IN VITRO 7.1% DEC AT 1110-14 N P0 362
MECHLORETHAMINE S CHOLINESTEPASE DEC V OBSERVED ACTIVITY IN VITRO, PROBABLE IN VIVO P1027
METRIFONAT! S CHOLINESTERASE DEC V POWERFUL INHIBITOR OF ENZYME P0657
NEOSTYGMINE S CHOLINESTERASE DEC V DIRECT EFFECT OF DRUG P09 13
NEUROMUSCULAR S CHOLINESTEPASE DEC V IF ENZYME DEFICIENCY MAY CAUSE TOXICITY P0384
ORAL CONTRACEPTIVE S CHOLINESTERASE DEC V ESTROGEN EFFECT P0907
OPGANOPHOSPHOPUS S CHOLINESTERASE DEC V HEPATOTOXIC EFFECT P0 130
PARATHION S CHOLINESTERAS! DEC V INHIBITORY ACTION OF DRUG WITH POISONING P0 368
PH!NELZINE S CHOLINESTERASE DEC V MAY CAUSE HYPERSENSITIVE HEPATITIS P0907
PHYSOSTIGMINE S CHOLINESTERASE DEC V DIRECT EFFECT OF DRUG P0913
TESTOSTERONE S CHOLIN!STERASE DEC V METABOLIC EFFECT - P0072
TPIETHYLEN!MELANINE S CHOLINESTERASE DEC V OBSERVED IN VITRO, PHOBABLE EFFECT IN VIVO P1 027
CHLORINATED INSECT F C9OLINESTERASE INC V POWERFUL INHIBITOR OF ENZYME P0 130
STORAGE O SAMPLE S CHOLINESTERASE Z N NO EFFECT 1 WEEK AT 4 DEGREES, 1 MONTH AT -20 DEG P0998
EDTA U CHROMIUM INC V IF POISONING DUE TO CHROMIUM P0026
ASPAPAGINASE S CHYLONTCBONS INC V OBSERVED I N UNUSUAL HYPEPLIPI DEMIC RESPONSE P0705
ACETAZOLAMIDE U CITRATE DEC V ALTERATION OF ACID BASE STATUS, DIURESIS HO 723
BENDROFLUMETHIAZIDE U CITRATE DEC V UP TO 30% DECREASE OBSERVED P0657
CRLOROTHIAZIDE U CITRATE DEC V UP TO 30% DECREASE OBSERVED P0657
HYDROCHLOPOTHIAZIDE U CITRATE DEC V BY tIP TO 30% REPORTED P0814 9
POLYTRIAZID? U CITRATE DEC V EXCRETION DEC BY UP TO 30% P0657
THIAZIDES U CITRATE DEC V BY UP TO 30% P0723
BLOOD TRANSFUSIONS S CITRATE INC V IF CITRATED BLOOD USED P05 96
FRUCTOSE S CITRATE INC V RISES MOPE RAPIDLY THAN AFTER GLUCOSE P0 476
PARATHYROID EXTRACT U CITRATE INC V HORMONAL ACTION R0384
LIGHT U CITRULLINE DEC N COLORED COMPLEX WITH DIACETYLMONOXIME UNSTABLE RO730
1186 CLIN1CAL CHEMISTRY, Vol. 18, No. 10, 1972

MITHRAMYCIN B CLOT RETRACTION DEC V REVERSIBLE POOR RETRACTION P0026
RI SHYDROXYCOUMA PIN B CLOTTING TINE INC V SLIGHT EFFECT N GLASS, GREATER IN SILICONE 90384
CAP BENICILLIN B CLOTTING TIME INC V REPORTED EFFECT 90966
HEPAPIN B CLOTTING TIME INC V CONCENTPATION RELATED EFFECT P0704
MITHR AMYCIN B CLOTTING TIME INC V REVERSIBLE EFFECT RO026
WARFARIN B CLOTTING TIME INC V MAY BE PROLONGED 90368
CY CLOP P OP ANN B CLOTTING TIME Z V ANESTHESIA HAS NO EFFECT 30384
ETHER B CLOTTING TINE Z V NO EFFECT OF ANESTHESIA 90384
ANINOPHYLLIN! B COAGULATION TIME DEC V REPORTED EFFECT R0384
EPINEPHPINE B COAGULATION TIME DEC V PROBABLY DUE TO INCREASED ACTIVITY OF FACTOR V 90520
A NTICOAGULANTS B COAGULATION TIN! INC V THERAPEUTIC INTENT P0620
PHOSPHORUS B COAGULATION TIME INC V DUE TO TOXICITY 90384
TETPACYCLI NE B COAGULATION TINE INC V DELAYED COAGULATION REPORTED EFFECT 30620
PREGNANCY B COLD AGGLUTININS POS V OCCASIONAL RESPONSE 90291
ALKALINE ANTACIDS F COLOR DEC N WHIT! DISOLORATION OP SPECKLING 90620
ALUMINUM SALTS F COLOR DEC N WHITE DISCOLORATION OP SPECKLING 90620
ACETYLSALICYLIC AC F COLOR INC V RED OR BLACK DUE TO GASTROINTESTINAL BLEEDING 90620
ANTHPAQUINONE F COLOR INC N BROWNISH STAINING 90620
ANTICOAGULANTS F COLOR INC V RED TO BLACK DUE TO INTERNAL BLEEDING #{176}0620
BISMUTH SALTS F COLOR INC N BLACKENS OH DISCOLORS STOOL WITH 5G ORALLY 90620
DIT HIAZINE F COLOR INC N GREEN TO BLUE 90620
IRON SALTS F COLOR INC N BLACK(GRAY-BLACK)DARKENS IN AIR WITH ABOUT 70MG 90620
MERCURY COMPOUNDS F COLOR INC N GREEN WITH ABOUT 130 MG OF CALOMEL 90620
PHENAZOPYRI DINE F COLOR INC N ORANGE RED P0620
PHENOLPHTHA LEIN F COLOR INC N IMPARTS RED COLOR 90026
PYRVINIUM PANOATE F COLOR INC N RED 90620
SANTONIN F COLOR INC N DEEP YELLOW WITH 65 - 70MG 90620
SE N NA F COLOR INC N YELLOW TO BROWN P06 20
TETRACYCLINE F COLOP INC N RED IF GLUCOSAMINE POTENTIATED SYRUP FORM 30620
OPAL CONTRACEPTIVE S COLOR INC V CEPULOPLASMIN NAY BE SO HIGH BLUE-GREEN COLOR P090
ACETOP HENET IDIN S COOMBS TEST P05 V IMMUNOLOGICAL RESPONSE TO DRUG 90 104
CHLOPPROMAZINE S COOMBS TEST P05 V IMMUNOLOGICAL RESPONSE TO DRUG 901418
CHLOP PROP AN ID! S COOMBS TEST P05 V IMMUNOLOGICAL RESPONSE TO DRUG 90418
DIPHENYLHYDANTOI N S COOMBS TEST P05 V IMMUNOLOGICAL RESPONSE TO DRUG 90418
DI PYPONE S COOMBS TEST POS V IMMUNOLOGICAL RESPONSE TO DRUG 90104
ET}IOSUXIMIDE S COOMBS TEST P05 V MECHANISM OBSCURE P0418
HYDPALAZI NE S COOMBS TEST P05 V MECHANISM OBSCURE RO41 8
ISONIA ZID S COOMBS TEST POS V IMMUNOLOGICAL RESPONSE TO DRUG 30418
LEVODOPA S COOMBS TEST P05 V AUTOIMMUN! PHENOMENON (OCCURS AFTER SEVERAL MONTHS) 90418
MEFENAMIC ACID S COOMBS TEST P05 V AUTOIMNUNE PH!NOMEWON(OCCURS AFTER SEVERAL MONTHS) P04 18
N ELPH A L A N S COONBS TEST P05 V IMMUNOLOGICAL PESPONSE TO DRUG (GAMMA ANTIBODY) 9041 8
OXYPHENISATIN S COONBS TEST P05 V NAY CAUSE HYPERSENSITIVITY REACTION P0776
PH E NY LBUT AZ ONE S COOMBS TEST 205 V IMMUNOLOGICAL RESPONSE TO DRUG 90418
PROCAINAMIDE S COONBS TEST P05 V MECHANISM OBSCURE 90418
QUINIDIN! S COOMBS TEST P05 V IMMUNOLOGICAL RESPONSE TO DRUG (GAMMA ANTIBODY) 90418
QUININE S COOMBS TEST P05 V IMMUNOLOGICAL RESPONSE TO DRUG P0418
STPEPTOMYC IN S COOMBS TEST P05 V MECHANISM OBSCURE 90418
SULFONAMIDES S COOMBS TEST P05 V IMMUNOLOGICAL RESPONSE TO DRUG ‘0418
TETRACYCLINE S COOMBS TEST P05 V MECHANISM OBSCURE 90418
ACETYLPENICILLAMINE S COPPER DEC V ELIMINATION O HEAVY METALS IN CASES OF HG POISON P0511
LEAD N COPPER INC V OCCURS WITH POISONING HO 29 1
COPPER S COPPER INC V MAY BE NORMAL IN TOXIC CASES WITH HEMOLYSIS 90124
ESTROGENS S COPPER INC V ASSOCIATED WITH INCREASED CERULOPLASMIN P0506
LACTATION S COPPER INC V INITIALLY HIGH FALLS TO NORMAL P0 29 1
ORAL CONTRACEPTIVE S COPPER INC V ESTROGENS INCREASE CONC OF BINDING PROTEIN 90918
PREGNANCY S COPPER INC V METABOLIC EFFECT MAX IN LAST TRIMESTER 90291
COPPER U COPPER INC V OBSERVED WITH POISONING P06 57
DIMERCA PROL U COPPER INC V IF CAUSE OF POISONING (PENICILLAMINE BETTER) P 0026
EDTA U COPPER INC V IF POISONING DUE TO COPPER 90026
PENICILLA MINE U COPPER INC V IF POISONING DUE TO COPPER 90026
PROTEI NURIA U COPPER INC V LOSS OF PROTEIN BOUND MATERIAL P0” 36
PP OGE S T IN S COPPER Z V NO EFFECT REPORTED OVER SEVERAL MONTHS P 0907
BARBITUPA TES B COPROPORPHYRIN INC V MAY PRECIPITATE ACUTE CUTANEOUS PORPHYRIA P0371
CHLOPPROPA MID! B COPPOPOPPHYPIN INC V NAY PRECIPITATE CUTANEOUS PORPHYRIA 90371
ESTROGENS B COPPOPORPHYRIN INC V MAY PRECIPITATE PORPHYRIA ATTACK P0371
ETHANOL B COPPOPORPHYRIN INC V NAY PRECIPITATE ATTACK OF PORPHYRIA P0371
OPAL CONTRACEPTIVE B COPROPORPHYRIN INC V NAY PRECIPITATE PORPHYRIA ATTACK HO 371
S ULFO N EM ETH ANN B COPPOPORPHYRIN INC V MAY PROVOKE ATTACK OF PORPHYRIA 90371
TOLBUTA MID! B COPPOPORPHYPIN INC V NAY PRECIPITATE CUTANEOUS PORPHYRIA P0 37 1
LEAD E COPROPOPPRYRIN INC V OCCURS WITH POISONING 90291
BARBITURATES F COPROPORPHYRIN INC V NAY PRECIPITATE ACUTE PORPHYRIA P037 1
CHLOPDIAZEPOXIDE F COPROPOPPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA HO 371
CHLORPROPA NIDE F COPROPORPHYRIN INC V MAY PRECIPITATE CUTANEOUS PORPHYRIA 90371
DICHLORALPHENAZONE F COPROPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P 1005
DIETHYLSTILBESTPOL F COPROPORPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA P0975
DI PHENYLHYDANTOI N F COPPOPORPHYRIN INC V NAY PRECIPITATE ACUTE PORPHYRIA P03 71
ESTROGENS F COPROPOPPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA 90975
ETHANOL F COPROPORPHYRIN INC V NAY PRECIPITATE ATTACK OF PORPHYRIA 90371
ETHINYLESTPADIOL F COPPOPORPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA R0975
GLUTETHI NI DE F COPROPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA 90371
GPISEOFULVIN F COPPOPORPHYPIN INC V MAY PRECIPITATE ACUTE PORPHYRIA ATTACK P0 371
NEPPOBA MAT! F COPROPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P0 37 1
METHYLDOPA F COPROPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA ATTACK P037 1
ORAL CONTRACEPTIVE F COPROPORPHYPIN INC V MAY PRECIPITATE PORPHYRIA ATTACK P037 1
PENTAZOCINE F COPPOPORPHYPIN INC V MAY PRECIPITATE ACUTE PORPHYRIA ATTACK HO 371
PPEMA PIN F COPPOPOHPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA P 09 87
PROTEIN F COPROPOPPHYRIN INC V RELATED TO THE MEAT CONTENT OF DIET 90291
SEDORNID F COPROPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA HO 37 1
SUCCINIMIDES F COPPOPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P03 71
SULFONAMIDES F COPROPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA 90371

SULFONEM!THANF F COPROPORPHYRIN INC V MAY PROVOKE ATTACK OF PORPHYRIA P0371
SULFONETRYLMETHAN! F COPROPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P0371
TOLBUTAMIDE F COPROPORPHYRIN INC V MAY PRECIPITATE CUTANEOUS PROPHYRIA P0371
BARBITURATES U COPBOPOPPMYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P0371
CHLORDIPLZEPOXIDF U COPROPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P0371
DICHLO9ALPHENAZONE U COPPOPOPPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P0371
DIETHYLSTILBESTPOL U COPPOPORPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA P0975
DIPHENYL9YDANTOIN U COPROPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P0371
ESTROGENS U COPROPORPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA P0975
ETHANOL U COPROPORPHYRIN INC V MAY PRECIPITATE ATTACK OF PORPHYRIA R0371
GLJTETHIMIDE U COPROPORPHYPIN INC V NAY PRECIPITATE ACUTE PORPHYRIA P0371
GOLD U COPROPORPHYRIN INC V OCCURS WITH PANMYELOPATHY P0384
GPISEOFULVIN U COPROPOHPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA ATTACK P0371
LEAD U COPROPOPPHYRIN INC V OBSERVED IN POISONING P0384
MEPPOBAMATE U COPROPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P0371
METHYLDOPA U COPROPORPHYPIN INC V NAY PRECIPITATE ACUTE PORPHYRIA ATTACK P0371
ORAL CONTRACEPTIVE U COPPOPORPRYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA P0792
PENTAZOCINE U COPPOPORPHYPIN INC V NAY PRECIPITATE ACUTE PORPHYRIA ATTACK P0371
PRENAPIN U COPROPORPRYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA P0987
SEDORMID U COPROPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P0371
SUCCINIMIDES U COPHOPO9PHYPIN INC V NAY PRECIPITATE ACUTE PORPHYRIA P0371
SULFONAMIDES U COPROPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P0371
SULFONENETHANE U COPROPORPHYRIN INC V MAY PROVOKE ATTACK OP PORPHYRIA P0371
SULFONETHYLNETHANE U COPRO?OPPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P0371
TOLBUTAMIDE U COPHOPORPHYRIN INC V MAY PRECIPITATE PORPHYRIA ATTACK P0371
TESTOSTERONE S CORTICOSTER BIND GLOB DEC V METABOLIC EFFECT P0072
ESTROGENS S CORTICOSTEP BIND GLOB INC V METABOLIC EFFECT P0072
ORAL CONTRACEPTIVE S COBTICOST!R BIND GLOB INC V DUE TO ESTROGENIC COMPONENT P0026
ANDROGENS P COPTICOSTEROIDS DEC V MAY CAUSE CHOLESTATIC SYNDROME P0355
DEXANETHASONE P COPTICOSTEPOIDS DEC V EFFECT SEEN FOLLOWING MORNING IF GIVEN IN EVENING P0824
COPTICOTPOPIN P CORTICOSTEPOIDS INC V MAXIMUM RESPONSE SEEN AFTER 14 HOUPS P0058
DEXTPOAMPHNTAMINF P CORTICOSTEROIDS INC V EFFECT MOST MARKED IN EVENINGS P0102
DIPHENYLHYDANTOIN P CORTICOSTEPOIDS INC V ALTERS STEROID METABOLISM P0959
HEPAPIN P CORTICOSTEROIDS INC N IF CONTAMINATED BY IMPURITIES P05214
INSULIN P CORTICOSTEROIDS INC V SIGNIFICANT EFFECT AT 4OMIN, MAXIMAL AT 6OMIN P0058
NETHANPHETAN!NE P CORTICOSTEROIDS INC V EFFECT MOST MARKED IN A.M. WHEN GIVEN I.V. P0417
TETRACOSACT?IN P CORTICOSTEROIDS INC V THERAPEUTIC INTENT HAS PROLONGED ACTION P0517
DEXAMETHASONE P CORTICOTROPIN DEC V EFFECT MEASURED AFTER 9 HOURS P0058
INSULIN P COPTICOTROPIN INC V RESPONSE TO STRESS P0662
METYPAPONE P COPTICOTROPIN INC V RESPONSE TO STRESS P0563
ANABOLIC STEROIDS S CORTISOL BINDING GLOB INC V METABOLIC EFFECT P0072
ORAL CONTRACEPTIVE S COPTISOL BINDING GLOB INC V METABOLIC CHANGES IN LIVER SYNTHESIS P0588
DIPHENYLMYDANTOIN P COPTISOL DEC V CHRONIC ADMINISTRATION EFFECT IN CUSHINGS SYNDROME P0596
LEVODOPA P CORTISOL DEC V PROBABLY DIMINISHED ACTH SECRETION P0394
NORETHINDPONF P CORTISOL DEC V SLIGHT EFFECT COMPARED WITH CONTROLS P0084
ETHACHYNIC ACID U COPTISOL DEC V ?DUE TO CHANGED SECRETION OR PENAL HANDLING P0417
NORETHINDRONE U CORTISOL DEC V WHEN RESULTS COMPARED WITH NORMAL MENSTRUAL CYCLE P00814
ORAL CONTRACEPTIVE U COPTISOL DEC V WHEN RESULTS DURING THERAPY COMPARED WITH NORMAL P0084
THIAZIDES U COPTISOL DEC V ? CHANGED SECRETION OP RENAL HANDLING P0296
CORTICOTROPIN P COBTISOL INC V THERAPEUTIC INTENT P0467
CORTISONE P CORTISOL INC V EFFECT LASTS FOP 24 HOURS AT LEAST P0490
CYCLIC AMP P CORTISCL INC V HORMONAL ACTION P0319
ESTROGENS P CORTISOL INC V INCREASES CONC OF BINDING GLOBULIN P0417
ETHANOL P COPTISOL INC V EFFECT SEEN IF HIGH DOSES GIVEN I.V. P01493
ETHER P COPTISOL INC V EFFECT OBSERVED IN MODERATE TO DEEP ANESTHESIA P0384
FUSIDIC ACID P CORTISOL INC N INTERFERING FLUORESCENCE P0490
HEMOLYSIS P COPTISOL INC M PRODUCES INTERFERENCE WITH FLUOPOMETRIC METHOD P01490
HYDPOCORTISONE P CORTISOL INC V EFFECT LASTS FOP AT LEAST 214 HOURS P01490
LITHIUM P C0PTISOL INC V OBSERVED IN SOME PATIENTS P0744
MEPACRINE P CORTISOL INC N PRODUCES INTERFERING FLUORESCENCE P01490
ORAL CONTRACEPTIVE P COPTISOL INC V DECREASES CORTISOL CLEARANCE (ESTROGEN EFFECT) P0874
PYROGEN P CORTISOL INC V AFTER DELAY OF ONE HOUR FOLLOWING INJECTION P0082
SPIRONOLACTONE P CORTISOL INC N FLUOBOMETRIC METHODS MAY BE AFFECTED P0601
VASOPRESSIN P CORTISOL INC V MAY BE RISE OF UP TO 6 UG/IOOML OP MORE P0940
SALINE U CORTISOL INC V REPORTED EFFECT P0296
CHLOROPHENOTHANE P CORTISOL Z V OCCUPATIONAL EXPOSURE NO EFFECT P0206
ETHACPYNIC ACID P COPTISOL Z V NO EFFECT OBSERVED WITH THERAPY P0657
THYROTROPIN-PELEAS P CORTISOL Z V NO EFFECT IN NORMAL SUBJECTS P00314
ACETAZOLANIDE S C02 CONTENT DEC V CARBONIC ANHYDRASE INHIBITION IN RENAL TUBULES P0204
ACETYLSALICYLIC AC S C02 CONTENT DEC V INITIAL ACIDOSIS WITH EXCESSIVE DOSES P0299
ANILORIDE S C02 CONTENT DEC V REDUCES ALKALOSIS INDUCED BY OTHER DIURETICS P0050
CONTACT WITH CLOT S CO2 CONTENT DEC N PH SHIFT IN DRAWN BLOOD ALLOWS AT LEAST 5% DROP P0436
DIMEPCAP?OL S C02 CONTENT DEC V ASSOCIATED WITH METABOLIC ACIDOSIS P0299
EDTA S C02 CONTENT DEC V NEPHHOTOXIC EFFECT (ESP CA EDTA) P0355
EDEA S CO2 CONTENT DEC M SIGNIFICANT ALTERATION OF PH IN DRAWN SAMPLE P01436
ETHANOL S CO2 CONTENT DEC V CAUSES LACTIC ACOSIS P0706
FLUORIDES S CO2 CONTENT DEC N ALTERATION OF PH WITH LOSS OF CO2 P1001
FRUCTOSE S C02 CONTENT DEC V METABOLIC RESPONSE TO LARGE DOSE FRUCTOSE P0815
LIPOMUL S C02 CONTENT DEC V NEPPROTOXIC EFFECT WITH AZOTEMIA P0299
MDA S C02 CONTENT DEC V RESPIRATORY ACIDOSIS P0778
MERCURY COMPOUNDS S CO2 CONTENT DEC V MAY BE DEPRESSED IN ESTABLISHED POISONING P0291
NETFORMIN S C02 CONTENT DEC V NAY CAUSE MARKED ACIDOSIS (LACTIC ACIDOSIS) P0299
METHANOL S C02 CONTENT DEC V METABOLIC ACIDOSIS DUE TO ORGANIC ACID ACCUMULATION P03814
HETHICILLIN S CO2 CONTENT DEC V NFPHROTOXICITY MAY CAUSE AZOTEMIA P0620
NITPOFUPANTOIN S C02 CONTENT DEC V NEPHROTOXICITY MAY CAUSE AZOTENIA P0299
NSD 3004 S C02 CONTENT DEC V LONG ACTING CARBONIC ANHYDRASE INHIBITOR P0599
OXALATES S C02 CONTENT DEC M SIGNIFICANT ALTERATION OF PH IF USED AS ANTICOAG P0181
PARALDEHYDE S CO2 CONTENT DEC V METABOLIC ACIDOSIS IN PAPALDEHYDE HABITUES P0384
PHENFOPMIN S CO2 CONTENT DEC V MAY CAUSE MARKED ACIDOSIS P0608
STR!PTOZOTOCIN S C02 CONTENT DEC V ASSOCIATED WITH LOW POTASSIUM AND POLYURIA P0686

TETRACYCLINE S CO2 CONTENT DEC V PAY CAUSE ACIDOSIS WITH NEPHROTOXICITY RC26
TRIAMTER LEE S CO2 CONTENT DEC V NEPHPOTOXIC #{163}FFECT R C 299
ACF.TYLSALICYLIC AC S C02 CONTENT INC V LATER ALTERATION OF ACID BASE BALANCE
A LDOSTER ONE S CO2 CONTENT INC V METABOLIC ALKALOSIS P C 299
BLNDROFLUMETHIAZIDE S CO2 CONTENT INC V METABOLIC ALKALOSIS BC 325
BICAPRONATES S CO2 CONTENT INC V INDUCES METABOLIC ALKALOSIS P C 2C 4
CARB ENOXOL ONE S C02 CONTENT INC V HYPOKALEMIC ALKALOSIS RC669
CHLORTHA LI DONE S C02 CONTENT INC V METABOLIC ALKALOSIS IN SEVERE CASES F C 325
ETHACEINIC ACID S CO2 CONTENT INC V ASSOC WITH HYPOCHLOPEMIC ALKLOSIS B C 840
HY DROCHLOROTHIAZIDE S CO2 CONTENT INC V MAY CAUSE METABOLIC ALKALOSIS RC325
HYDPOCORTISONL S CO2 CONTENT INC V MAY CAUSE HYPOCHLOREMIC HYPOKALEMIC ALKALOSIS P0384
HYDROFLU METHIAZ IDE S CO2 CONTENT INC V MAY CAUSE HYPOCHLOPENIC ALKALOSIS P0467
METHYCLOTHIAZIDE S C02 CONTENT INC V DIURETIC ACTION (HYPOCHLORZMIC ALKALOSIS) 3C386
NETOLAZONE S CO2 CONTENT INC V DIURETIC ACTION 01 DRUG ACTING ON DISTAL TUBULES hO 7 39
POLYTHIA ZIDE S CO2 CONTENT INC V METABOLIC ALKALOSIS WITH MARKED DIURESIS RC325
PR OBU CCL S CO2 CONTENT INC V MECHANISM OBSCURE (EFFECT SLIGHT) F 0247
THIAZIDES S C02 CONTENT INC V OVER 60% HAVE VALUE OVER 3CMEQ/L IN LONG TERM P C 089
TROMETHAMINE S CO2 CONTENT INC V CORRECTION OF RESPIRATORY ACIDOSIS R0782
VIOMYCIN S C02 CONTENT INC V ALTERED ELECTROLYTE BALANCE 90355
MEALS S CO2 CONTENT Z V NO LFFECT AFTER STANDARD BREAKFAST PC 181
HEPARIN S CPK DEC P1 REPORTED EFFCT 9CC79
PHENOTHIAZI NES S CPK DEC V IN SCHIZ0PHRNICS WITH HIGH INITIAL VALUES PC 657
PREGNANCY S CPK DEC V SIC DEC FPOM a-2C WKS, MAX DEC 12-13 WKS RC529
AMPHOTFRICIN B S CPK INC V RHABDOMYOLYSIS CAUSED BY SEVERL HYPOKALENIA PC 285
AMPICILLIN S CPK INC V PROBABLE EFFECT OF I.N. INJECTION hO 541
ANAL GSICS S CPK INC V MAY CAUSL EFFECT IF INJECTED I.M 90080
BARBITURATES S CPK INC V OCCURS WITH POISONING, PROBABLE MUSCLE ORIGIN P1OC8
CAPBENICILLIN S CPK INC V PROBABLY DUE 10 TRAUMA OF I.N. INJECTION R0541
CARBPOMAL S CPK INC V OCCURS WITH POISONING, PROBABLE MUSCLE ORIGIN P1008
CHLORPROMAZINE S CPK INC V MAY BE DUE TO INJECTION ONLY (OCCURS IN 20%) P C. 645
CLOFIBPATE S CPK INC V ORIGINATES FROM SRELETAL MUSCLE (IN UP TO 15%) R0907
CLONIDINE S CPK INC V TEMPORARY EFFECT OF UNKNOWN SIGNIFICANCE P0365
DIURETICS S CPK INC V NAY OCCUR AS RESULT OF I.M. INJECTIONS P0080
ELECTEOCAUTERY S CPK INC V EFFECT OF MUSCLE DAMAGE P0355
ETHANOL S CPK INC V EFFECT NOTICED IN ALCOHOLICS AFTER ALCOHOL PC 46
El HCHLORVY NOL S CPK INC V OCCURS WITH POISONING. PROBABLE MUSCLE ORIGIN P1008
1. N. INJECTIONS S CPK INC V MUSCLE DAMAGE R0839
INSULIN S CPK INC V IS AN ACTIVATOR OF ENZYME PC 2 8
MORPHINE S CPK INC V RESPONSE TO FREQUENT IM INJECTIONS RCC80
MUSCULAR EXERCISE S CPK INC V EFFECT OF PHYSICAL TRAINING, INC WITH EXERCISE P0779
NARCOTICS S CPK INC V RESPONSE TO I.M. INJECTIONS P0080
PENICILLIN S CPK INC V FREQUENT INJECTIONS MAY CAUSE INC UP TO 5 TIMES
PHENOTHIAZ INES S CPK INC V PROBABLE EFFECT OF I.M. INJECTION P0417
PREGNANCY S CPK INC V ACTIVITY INCREASES DURING LAST TRIMESTER HO 779
S UCC INYLCHOLINE S CPK INC V OCCURS IF GIVEN WITH HALOTHANE b0941
THIOLS S CPK INC N THREE TO TENFOLD ENHANCEMENT P C C8 0
TUBOCURARINE S CPK INC V DUE TO I.E. INJECTIONS OR HISTAMINE RELEASE PC 20 8
HEMOLYSIS S CPK Z N SLIGHT HEMOLYSIS HAS NO EFFECT P077 9
MEPERIDI NE S CPK Z V NO REPORTED EFFECT P0657
MORPHINE S CPK Z V NO CHANGE, ALTHOUGH OTHER ENZYMES INC RC657
ANABOLIC STEROIDS U CREATINE DEC V ANABOLIC EFFECT P 0355
ANDPOGENS CREATINE DEC V ANABOLIC EFFECT PC 355
NA NDPOL ONE U CPEATINE DEC V ANABOLIC EFFECT P0708
THIAZIDES U CREATINE DEC V CLEARANCE TESTS DECREASED BY 10/20% R0656
ARGININE S CREATINE INC V INCORPORATED INTO UREA CYCLE R)C26
BPOMSULFALEI N S CREATINE INC N PRESENCE OF INTERFERING COLOR PC 620
PROTEIN S CREATXNE INC V ESP IF MEAT EATEN IS PAW 90291
AMINOPHENA ZONE U CREATINE INC V REPORTED EFFECT P0596
CAFFEINE U CREATIN! INC V ACTS ON INTERMEDIARY METABOLISM P0384
NETHYLTESTOSTERONE U CREATINE INC V METABOLIC EFFECT ? MECHANISM P0384
PP!GNA NCY U CREATINE INC V GENERAL EFFECT WITH PREGNANCY P029 1
PROTEIN U CREATIN! INC V ESP IF MEAT EATEN IS PAW P0291
PS P U CREATIN! INC M CHROMOGENICITY IN COLOR REACTION R0620
STORAGE OF SAMPLE U CREATINE INC N SIGNIFICANT INC 1 DAY AT ROOM TEMPERATURE B 0436
X-RAY THERAPY U CREATINE INC V OCCURS WITH TISSUE DESTRUCTION P 0. 29 1
THY MOL U CREATINE Z N NO EFFECT ON JAFFE, VAN PILSUM METHODS P077 9
ANPHOTERICIN B U CPEATININE CLEARANCE DEC V NEPHROTOXICITY EFFECT (DECREASE UP TO 36%) P0170
BUNAMIODYL U CREATININE CLEARANCE DEC V AT DOSE OF 4.5G; OCCURRED WITHOUT LIVER EFFECT P 0980
C AR B E NOX OL ONE U CREATININE CLEARANCE DEC V DUE TO NEPHROPATHY P 0669
CHLOPOTHIAZI DE U CPEATININE CLEARANCE DEC V REPORTED EFFECT P 0596
DIAZOXIDE U CREATININE CLEARANCE DEC V EFFECT OVER 2H OF 4MG/KG GIVEN I.V. PC501
HYOROCH LOPOTHI AZIOE U CREATININE CLEARANCE DEC V REPORTED EFFECT P0596
IOPANOIC ACID U CR EAT ININE CLEARANCE DEC V REPORTED CAUSE OF ACUTE RENAL FAILURE P0020
MITOMYCIN C U CREATININE CLEARANCE DEC V DUE TO NEPHROTOXICITY P0589
MUSCULAR EXERCISE U CREATININ E CLEARANCE DEC V DECREASE WITH HEAVY EXERCISE PC 50 5
PHENIODOL U CREATININE CLEARANCE DEC V REPORTED TO CAUSE RENAL FAILURE P0020
SPECTINOMYCIN U CPEATININE CLEARANCE DEC V MECHANISM NOT DISCUSSED P0045
THIA ZIDES U CREATININE CLEARANCE DEC V MAY CAUSE DECREASE BY UP TO 20% PC 656
LEV000PA U CR EATININE CLEARANCE INC N REDUCING PROPERTIES AFFECT JAFFE METHOD PC 328
MUSCULAR EXERCISE U CPEATININE CLEARANCE INC V INCREASE WITH MILD EXERCISE P0505
ALKALINE ANTACIDS S C PEA TININE DEC V MAY CAUSE MILK-ALKALI SYNDROME P05 96
MARIHUANA S CREATININE DEC V REPORTED EFFECT P 0596
ANABOLIC STEROIDS U CREATININE DEC V ANABOLIC EFFECT P0355
A NOR OGEN S U CREATININE DEC V ANABOLIC EFFECT P 02 99
N AN DR OLONE U CREATININE DEC V ANABOLIC EFFECT P0708
THIAZIDES U C REATI NINE DEC V CLEARANCE TESTS DECREASED BY 10/20% P 0656
ACETAMINOPHEN S CREATININE INC V REVERSIBLE TUBULAR NECROSIS REPORTED P0137
ACETOACETATE S CREATININE I NC N INTERFERES - GRAFNETTER AND AUTOANALYZER METHODS P0546
ACETONE S CREATININE INC M INTERFERES WITH JAFFE METHOD P0546
ACETOPHENETIDIN S CREATININE I NC V NAY CAUSE AZOTENIA P 0620

AMINOHIPPUPIC ACID S CREATININE INC N CHROMOGENICITY IN COLOR REACTION 90907
AMPHOTERICIN B S CREATININE INC V NEPHPOTOXIC EFFECT 90620
A? IN!NE S CREATININE INC M I METHOD OF VOG!S-PPOSKAUER USED P014 36
ARGININE S CREATININE INC V INCORPORATED INTO UREA CYCLE P0026
AP’ZNICALS S CREATININE INC V NEPHROTOXICITY (COMMON WITH THERAPEUTIC DOSES) 90355
ASCORBIC ACID S CREATININE INC N CHROMOGENICITY IN COLOR REACTION(ACTS AS RED.AGENT) 90299
BARBITURATES S CREXTININE INC V SHOCK AND RENAL FAILURE IN INTOXICATION 90654
BETHANIDINE S CPEATININE INC V EFFECT REPORTED IN ONE PATIENT 90902
BROMSULFALEIN S CREATININE INC N PRESENCE OF INTERFERING COLOR P06 20
CAP9EOMYC IN S CREATININE INC V NEPPROTOXIC EFFECT P06 20
CA RB UTA MID! S CPEATININE INC V NEPHROTOXIC EFFECT P06 20
CEPHALOPIDINE S CREATININE INC V NEPHROTOXIC ESP IF COMBINED WITH DIURETIC HO 7 36
CHLOPTHALIDONE S CREATININ INC V NEPHPOTOXIC EFFECT P0596
CLOFIBPPITE S CHEATININ INC V POSSIBLY DERIVED FROM MUSCLE DAMAGE (IN 15%) HO 596
C L 0 NI DI NE S CPEATININE INC V APPROXIMATELY O.1MG/100NL P1016
COLISTIMETHATE S CREATININE INC V N!PHROTOXIC EFFECT (USUALLY REVERSIBLE) P07 36
COLISTIN S CREATININE INC V NEPHPOTOXIC EFFECT (REVERSIBLE RENAL DAMAGE) P0620
DEMECLOCYCLINE S CP!ATININE INC V DOSE RELATED NEPHROTOXICITY HO 572
DEXT PA N S CREATININE INC V BLOCKS TUBULES CAUSING RENAL FAILURE R0203
DOXYCYCLINE S CREATININE INC V WEPHROTOXIC EFFECT P07 34
FRUCTOSE S CPEATININE INC M INTERFERENCE WITH JAFFE-REACTION P1001
GENTAMICIN S CREATININE INC V NEPHPOTOXIC EFFECT 90596
GLUCOSE S CREATININE INC N INTERFERES WITH JAFFE REACTION P0620
GLYCOCYAMIDINE S CREATININE INC N REACTS TO GIVE FALSE INC WITH JAFFE REAGENT P09 07
GLYCOCYA N IN! S CREATININE INC N I? REACTION OF VOGES-PPOSKAUER USED 901436
GUA NI DINE S CREATININE INC N IF REACTION OF VOGES-PROSKAUER USED P04 36
KANAMYCIN S CREATININE INC V NEPHROTOXIC EFFECT (COMMON BUT SLIGHT) HO 596
LEVODOPA S CREATININE INC N ACTS AS REDUCING AGENT (PROBABLE EFFECT) P004 2
LIPOMUL S CREATININE INC V NEPHROTOXIC EFFECT P06 20
NA NNITOL S CREATININE INC V DUE TO DEHYDRATION P0620
MFTHICILLIN S CHEATININE INC V NEPHROTOXIC EFFECT P06 20
N ET HOXY F LU BA NE S CREATININE INC V IMPAIRED PENAL TUBULAR FUNCTION P0631
NETHYLDOP A S CREATININE INC N HEADILY OXIDIZED AND AFFECTS ALK PICRATE METHOD P0620
MITHRA MYCIN S CPEATININE INC V NEPHHOTOXIC EFFECT 90026
MITOMYCIN C S CPEATININ! INC V NEPHROTOXIC EFFECT 90589
NALIDIXIC ACID S CREATININE INC V MAY CAUSE NITROGEN RETENTION P0736
NEOMYCIN S C9EATININ! INC V NEPHROTOXIC EFFECT P 0736
NITROFURANTOIN S CREATININE INC V NEPHROTOXIC EFFECT HO 596
OXACILLIN S C9FATININE INC V TRANSIENT AZOTEMIA WITH LARGE DOSES P0026
P AR AL DE HYDE S CREATININE INC V POSSIBLE NEPHPOTOXICITY HO 407
PA RAMETHADI ONE S CREATNINE INC V POSSIBLE NEPHROTOXICITY P06 20
PENICILLAMINE S CREATININE INC V POSSIBLE NEPHROTOXICITY P0355
PENICILLI N S CREATININE INC V HYPERSENSITIVITY REACTION OP NEPHROPATHY P0384
PH! N YL BUT A ZO NE S CPEATININ! INC V MAY INC ESP IF COEXISTING RENAL DAMAGE P0657
PHOSPHORUS S CREATININE INC V NEPHROTOXIC EFFECT WITH NECROSIS 90355
POLYMYXIN B S CREATININE INC V NEPHROTOXIC EFFECT P07 36
PROTEIN S CREATININE INC V OCCURS AFTER LARGE NEAT INTAKE P06 20
. PSP S CREATININ! INC N CHROMOGENICITY IN COLOR REACTION P0907
PYRUVATE S CREATININE INC N INTERFERES -AUTOANALYZER NETHOD(200MG% 7.4MG%) HO 5146
?ADIOG9APUIC S CREATININE INC V OCCASIONAL EFFECT FOLLOWING AORTOGRAPHY P0020
RESORCINOL S CREATININE INC N FALSELY HIGH VALUES IF JAFFE REACTION USED HO 1436
SODIUM IPODATE S CREATININE INC V NEPHROTOXIC EFFECT P0260
STREPTOKINAS! S CRFATININE INC V NSPHPOTOXIC EFFECT (WITH TUBULAR DAMAGE) P06 20
STRETOMYCI N S CREATININ! INC V NEPHROTOXICITY MAY OCCUR IN 2% HO 736
TETRACYCLINE S CPEATININ! INC V NEPHROTOXICITY MAY CAUSE FANCONI LIKE SYNDROME P0736
THIAZIDES S CREATININE INC V NEPHROTOXIC EFFECT WITH LARGE DOSES P0 596
TRIA NT?9ENE S CPEATININE INC V NEPHROTOXIC EFFECT (CAUSES REDUCED GFR) P0620
VIOMYCIN S CPEATININE INC V NEPHPOTOXIC MAY CAUSE NITROGEN RETENTION P06 20
VITAMIN D S CREATININ! INC V MANIFESTATION OF HYPERVITAMINOSIS D P0026
ASCORBIC ACID U CPEATININE INC N ACTS AS REDUCING AGENT P00 42
COPTICOSTEROIDS U CREATININE INC V ASSOC WITH NEGATIVE NITROGEN BALANCE P 0620
LEVODOPA U CREATININE INC N PROBABLE ACTION AS REDUCING AGENT R0O42
MET HYLDOPA U CREATININE INC N ACTS AS REDUCING AGENT WITH ALKALINE PICRATE P0 2 33
NITROFURANS U CPEATININ! INC N REACT WITH COLOR REAGENT P0596
NITROFURA ZONE U CREPITININE INC N REACT WITH COLOR REAGENT P0355
PS? U CREATININE INC N INTERFERNCE WITH JAFFE PROCEDURE P02 04
ACETOACET ATE S CREATININ! Z N NO EFFECT ON METHOD OF POLAR AND METCOFF HO 5146
ASCORBIC ACID S CREATININE Z N NO EFFECT ON METHOD OF POLAR AND NETCOFF P05146
EDTA S CREATININE Z N NO EFFECT ON ANALYTICAL METHODS REPORTED P01436
GLUTATHIONE S CREATININE Z N NO EFFECT ON METHOD OF POLAR AND METCOFF P0546
HENOLYSIS S CHEATININE Z N MODERATE HEMOLYSIS HAS NO EFFECT P09 07
LACTATE S CREATININE Z N NO EFFECT ON METHOD OF POLAR AND METCOFF P0546
MEALS S CREATININE Z V NO EFFECT AFTER STANDARD BREAKFAST R0181
URIC ACID S CREATININE Z N NO EFFECT ON METHOD OF POLAR AND METCOFF 90546
STORAGE OF SAMPLE U CREATININE Z M NO EFFECT FOR 4 TO 7 DAYS AT ROOM TEMP P0436
THYMOL U CREATININE Z N NO EFFECT ON JAFFE, VAN PILSUN METHODS P0 779
OPAL CONTPACEPTIVE P C9YOFIBRINOGEN INC V INCIDENCE MUCH HIGHER THAN IN CONTROLS P06 39
HYD9OCYANIC ACID B CYANMETHEMOGLOBIN INC V REACTS WITH METHEMOGLOBIN HO 384
CYCLOLEUCINE U CYSTINE INC V REVERSIBLE MARKED AMINOACIDURIA P0154
PENICILLA MINE U CYSTIN? INC V IF CYSTINURIA P00 26
CLONI PHENE P DEHYDROEPIANDROST 5014 INC V LIBERATES LH,ANTI-STEBOID HORMONE EFFECT OF DRUG HO 193
DEXAMETHASONE U DEHYDROEPIANDPOSTERONE DEC V SUPPRESSION OF AcTH HO 653
ORAL CONTRACEPTIVE U DEHYDPOEPIANDPOSTEBONE DEC V COMPARED WITH CONTROLS - DETAILS NOT DISCUSSED HO 162
CLOMIPHENE P DEHYDROEPIANDROSTERONE INC V LIBERATES LH,ANTI-ST!POID HORMONE EFFECT OF DRUG HO 193
COPTICOTROPIN P DEHYDPOEPIANDPOSTEBONE INC V HORMONAL EFFECT P06 60
H ALOPER IDOL S DESNOSTEPOL INC V FURTHER METABOLISM INHIBITED SO ACCUMULATES HO 384
TRIFLU PERIDOL S DESMOSTEPOL INC V FURTHER METABOLISM INHIBITED SO ACCUMULATES P0 384
DI ?HNYLHYDANTOIN 0 DEXANETHASONE SUPPRESS V ALTERS STEROID METABOLISM P04 17
CHLOPOPHENOTHANE 0 DEXAMETHASONE SUPPRESS Z V NORMAL IN SUBJECTS WITH OCCUPATIONAL EXPOSURE P 020 6
H ALOFE NATE S DTT4 INC V LOWERS BINDING TO TBG AND ALBUMIN P02 56

CAFFEINE U DIAGNEX BLUE EXCRETION DEC V AS NA BENZOATE SALT; LOW GASTRIC ACIDITY 90299
ALUMINUM SALTS U DIAGNEX BLUE EXCRETION INC V HEAVY METAL DISPLACEMENT 0’ DIAGNEX BLUE 91001
BARIUM SALTS U DIAGNEX BLUE EXCRETION INC V HEAVY METAL DISPLACEMENT OF DIAGNEX BLUE 001
CALCIUM SALTS U DIAGNEX BLUE EXCRETION INC V HEAVY METAL DISPLACEMENT CM RESIN 90620
IRON SALTS U DIAGNEX BLUE EXCRETION INC V HEAVY METAL DISPLACEMENT OF DIAGNEX BLUE R 001
KAOLIN U DIAGNEX BLUE EXCRETION INC V DISPLACEMENT OF DIAGNEX BLUE FROM RESIN 91001
MAGNESIUM SALTS U DIAGNEX BLUE EXCRETION INC V HEAVY METAL DISPLACEMENT OF DIAGNEX BLUE Ri 001
METHYLENE BLUE U DIAGNEX BLUE EXCRETION INC M DETECTION OF METHYLEN BLUE 91001
NICOTINIC ACID U DIAGNEX BLUE EXCRETION INC V DISPLACES DIAGNEX BLUE FROM RESIN 91001
PHENAZOPYRIDINE U DIAGNEX BLUE EXCRETION INC N ORANGE COLOR PRODUCES INTERFERENCE 91001
POTASSIUM SALTS U DIAGNEX BLUE EXCRETION INC N DISPLACEMENT OF DIAGNEX BLUE FROM RESIN 91001
QUINACPINE U DIAGNEX BLUE EXCRETION INC N RELEASE OF DY! FROM RESIN P0356
QUINIDINE U DIAGNEX BLUE EXCRETION INC N RELEASE OF DYE FROM RESIN 90356
QUININE U DIAGNEX BLUE EXCRETION INC M RELEASE OF DYE FROM RFSIN 90654
RIBOFLAVIN U DIAGNEX BLUE EXCRETION INC N INTERFERING COLOR P1001
SODIUM SALTS U DIAGNEX BLUE EXCRETION INC N DISPLACEMENT OF DIAGNEX BLUE FROM RESIN 91001
SULFISOXAZOLE U DIAGNEX BLUE EXCRETION INC V DISPLACEMENT OF DtAGNEX BLUE FROM RESIN 10O1
TRIAMTERENE U DIAGNEX BLUE EXCRETION INC N INCREASED DYE RELEASE FROM RESIN 90355
VITAMIN B U DIAGNEX BLUE EXCRETION INC N RELEASE OF DYE FROM RESIN H0356
CAFFEINE S DIRECT BILIPUBIN DEC ALLEGED LOWER VALUES IF USED AS COUPLING AGENT 90356
HEMOLYSIS S DIRECT BILIRUBIN DEC N INTERFERENCE WITH DIRECT SPECTROPHOTONETRY 901436
LIGHT S DIRECT BILIPUBIN DEC V BREAKDOWN OF BILl (LESS SENSITIVE THAN INDIRECT) P0355
ACETANINOPHEN S DIRECT BILIPUBIN INC V HEPATIC NECROSIS WITH DOSE OF lOG REPORTED P0137
ACETANILID S DIRECT BILIPUBIN INC V HEMOLYSIS WITH G-6-PD DEFICIENCY P0620
ACETOHEXAMIDE S DIRECT BILIRUBIN INC V MAY CAUSE HEMOLYTIC ANEMIA 90298
ACETOPHENETIDIN S DIRECT BILIRUBIN INC V MAY CAUSE HEMOLYTIC ANEMIA 90636
ACETYLPHENYLHYDHAZ S DIRECT BILIRUBIN INC V MAY CAUSE HEMOLYTIC ANEMIA 90620
ACETYLSALICYLIC AC S DIRECT BILIRUBIN INC V OCCURS WITH HEMOLYTIC ANEMIA 90907
AMINOPYRINE S DIRECT BILIRUBIN INC V MAY CAUSE HEMOLYTIC ANEMIA 0620
ANINOSALICYLIC AC S DIRECT BILIPUBIN INC V REVERSIBLE CHOLESTASIS CAUSED BY DRUG OO91
ANABOLIC STEROIDS S DIRECT BILIRUBIN INC V CHOLESTATIC SYNDROME 90620
ANDPOGENS S DIRECT BILIPUBIN INC V MAY CAUSE CHOLESTATIC SYNDROME 90620
ANTIMALAFIALS S DIRECT BThIPUBIN INC V MAY CAUSE HEMOLYTIC ANEMIA R0518
ANTIPYRETICS S DIRECT BILIRUBIN INC V OCCURS WITH HEMOLYTIC ANENIA ROS18
CARROTS S DIRECT BILIRUBIN INC N COLOR MAY BE MISINTERPRETED 90356
CEPHALOTHIN S DIRECT BILIPUBIN INC V MAY CAUSE HEMOLYTIC ANEMIA 90393
CELOPPRONAZINE S DIRECT BILIRUBIN INC V SENSITIVITY REACTION TO DRUG (IN UP TO 2% PATIENTS) 90859
DEXTPAN S DIRECT BILIRUBIN INC N TURBIDITY DEVELOPS WITH EVELYN-MALLOY METHOD 902014
DIPYPONE S DIRECT BILIRUBIN INC V MAY CAUSE HENOLYTIC ANEMIA 90636
ERYTHROMYCIN S DIRECT BILIBUBIN INC V REPORTED EFFECT 90620
FAVA BEANS S DIRECT BILIRUBIN INC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY RO079
FLAVASPIDIC ACID S DIRECT BILIPUBIN INC V INHIBITS UPTAKE OF BILIPUBIN BY LIVER CELLS 90110
FLUPH!NAZINE S DIRECT BILIRUBIN INC V RELATIVELY HIGH COMPARED WITH TOTAL 903814
FLUPAZEPAM S DIRECT BILIRUBIN INC V NAY CAUSE HEPAIC TOXICITY 90788
HEMOGLOBIN S DIRECT BILIPUBIN INC M OCCURS WITH DIRECT SPECTPOPHOTOMETRIC METHOD 90140
INDONETHACIN S DIRECT BILIRUBIN INC V CYTOTOXIC AND CHOLESTATIC LIVER DAMAGE 90521
IPPINDOLE S DIRECT BILIRUBIN INC V ASSOCIATED WITH LOW SERUM PHOSPHATE P0012
MALE FERN S DIRECT BILIPUBIN INC V PROP INHIB OF UPTAKE OF BILIRUBIN BY LIVER 90657
NELPHALAN S DIRECT BILIPUBIN INC V MAY CAUSE HENOLYTIC ANEMIA P0636
MEPHENYTOIN S DIRECT BILIRUBIN INC V NAY CAUSE HEMOLYTIC ANEMIA 90636
METHANOL S DIRECT BILIRUBIN INC V MANIFESTATION OF LIVER DAMAGE P0356
METHYLDOPA S DIRECT BILIPUBIN INC V MILD HEPATOCELLULAR JAUNDICE MAY OCCUR 90355
NALIDIXIC ACID S DIRECT BILIPUBIN INC V HEMOLYTIC ANEMIA !SP IF G-6-PD DEFICIENCY 90999
NORETHANDPOLONE S DIRECT BILIPUBIN INC V REVERSIBLE CHOLESTASIS PRODUCED 90366
NOVOBIOCIN S DIRECT BILIRUBIN INC V COMPETES FOR CONJUGATION IN LIVER POlIO
ORAL CONTRACEPTIVE S DIRECT BILIRUBIN INC V HYPERSENSITIVITY TO ESTROGEN COMPONENT 9.0417
PHENINDIONE S DIRECT BILIPUBIN INC V PROBABLE EFFECT AS BILIPUBIN CONJUGATION AFFECTED 90421
PHENOTHIAZINES S DIRECT BILIRUBIN INC V RELATIVELY LARGE INC COMPARED WITH TOTAL P0384
PHENYLHYDRAZINE S DIRECT BILIRUBIN INC V CAUSES HEMOLYSIS 90110
QUINACRINE S DIRECT BILIRUBIN INC V HENOLYSIS MAY OCCUR WITH G-6-PD DEFICIENCY 90355
QUINIDINE S DIRECT BILIPUBIN INC V CAUSES HEMOLYTIC ANEMIA 90636
QUININE S DIRECT BILIRUBIN INC V MAY CAUSE HENOLYTIC ANEMIA 90636
RIFAMPIN S DIRECT BILIRUBIN INC V TRANSIENT EFFECT 90350
STIBOPHEN S DIRECT BILIRUBIN INC V PRODUCES HEMOLYTIC ANEMIA 90636
SULFADIMETHOXINE S DIRECT BILIRUBIN INC V GRANULOMATOUS REACTION IN LIVER 90307
TETRACYCLINE S DIRECT BILIRUBIN INC V CHOLESTATIC EFFECT 90282
VITAMIN A S DIRECT BILIRUBIN INC N INTERFERES WITH ANALYSIS P0356
ACETOPHENETIDIN S DIRECT COONBS TEST 905 V AUTOIMMUNE PHENOM!NON(OCCUPS AFTER SEVERAL MONTHS) P0418
AMINOSALICYLIC AC S DIRECT COOMBS TEST P05 V IMMUNOLOGICAL RESPONSE TO DRUG P0418
CARBROMAL S DIRECT COONBS TEST P05 V UNUSUAL CAUSE OF HENOLYTIC ANEMIA 90636
CEPHALEXIN S DIRECT COOMPS TEST P05 V INCIDENCE LOW 90309
CEPHALOPIDINE S DIRECT COOMBS TEST P05 V NO INMUNOL RESPONSE(CO!PLEX BINDS TO CELL-8% CASES) 90418
CEPHALOTHIN S DIRECT COONBS TEST P05 V NONIMtIUNOLOGIC PHENOMENON, COMPLEX BINDS TO CELL R01418
CYCLOPHOSPHANIDE S DIRECT COONBS TEST P05 V MAY CAUSE HEMOLYTIC ANEMIA 90636
INSECTICIDES S DIRECT COOMBS TEST P05 V MAY CAUSE H!MOLYTIC ANNIA 90636
MEPHENYTOIN S DIRECT CCOMBS TEST 905 V MECHANISM OBSCURE P0418
METHYLDOPA S DIRECT COOMBS TEST P05 V AUTOIMMUN! PHENOMENON(OCCU9S WITH WKS OF TREATMENT) P01418
NINOXIDIL S DIRECT COOMBS TEST POS V OCCURRED WITHOUT HENOLYSIS IN ONE PATIENT 90587
PENICILLIN S DIRECT CCOMBS TEST P03 V COMBINES TO RBC, INNUNOGLOBULINS DVEL0P TO DRUG 90418
RIFANPIN S DIRECT COOMBS TEST P05 V WEAK RESPONSE IN 8% PATIENTS RO7148
STIBOPHEN S DIRECT COONBS TEST P05 V PRODUCES HEMOLYTIC ANEMIA RO636
TRINETHYLENEMELAN S DIRECT COOMBS TEST P05 V NAY CAUSE HEMOLYTIC ANEMIA 90636
ACETYLSALICYLIC AC U DO?A SCREEN TEST P05 N LIGHT AMBER COLOR PRODUCED 08O2
DIAZEPAM U DOPA SCREEN TEST P05 N VERY SLIGHT PURPLE COLOR PRODUCED 90902
PHENOTHIAZINES U DOPA SCREEN TEST POS N MAY PRODUCE FALSE COLOR (USUALLY BUFF/AMBER) 90802
MAO INHIBITORS P DOPANIN! INC V EFFECT OBSERVED AFTER SINGLE LARGE DOSE 90384
LEVODOPA U DOPAMINE INC V RESPONSE TO THERAPY IN PARKINSONISM 90718
ANTICONVULSANTS E EGOT DEC V IN TREATED PATIENTS COMPARED WITH CONTROLS 90768
HEMOLYSIS S ELECTROPHORESIS P05 N NAY AUGMENT BETA, BETWEEN ALPHA2 AND BETA 901436
PENICILLIN S ELECTROPHORESIS POS N CAUSES BISALBUMINE?IIA 90907

RADIOGRAPHIC S ELECTROPH0RESIS P05 N PRODUCES UNINTEPPRETARL! PATTERN P1001
STORAGE 0? S!PLE S ELECTROPHORESIS I M NO EFFECT 3 DAYS AT ROOM TEMP OR 1 MONTH AT 4 DEG P04 36
ESTROGENS S ELECTPOPHCRETIC INDEX INC V INCREASES BINDING CAPACITY OF TBG P0997
ACETYLSALICYLIC AC B EOSINOPHILS DEC V MAY CAUSE APLASTIC ANEMIA OR PANCYTOPENIA P0928
C 0 P TI CO I P 0 P I N 9 EOSINOPHILS DEC V STRIKING RESPONSE IN NORMALS P03 84
DES IPRA FIN! B HOSINOPHILS DEC V AGPANULOCYTOSIS HO 228
EPINE?H RI NE B FOSINOPHILS DEC V MAY CAUSE EOSINOPENIA (DIRECT ACTION) P0142 4
GL000CO7TICOIDS B EOSINOPHILS DEC V REDUCED INFLAMMATORY RESPONSE P00 26
HYDR000RTI SONE B ZOSINOPHILS DEC V STRIKING EFFECT IN NORMALS H 03 84
INDOMFTHACIN B EOSINOPHILS DEC V OCCASIONAL EFFECT 90126
METHY SEPG IDE B HOSINOPHILS DEC V STARTS TO OCCUR WITHIN ONE HOUR(UP TO 100% DEC) 90657
AILOPUPI NOL B EOSIN0PHILS INC V MAY CAUSE SEVERE SENSITIVITY REACTION 90665
AMINDSALICYLIC AC 9 EOSINOPHILS INC V HYPERSENSITIVITY REACTION P0424
AMPICILLN B NOSINOPHILS INC V ALLERGIC REACTION P014 24
AR SENICALS B EOSINOPHILS INC V UP TO 50% OBSERVED IN ONE CASE, OTHERS 10-20% P04 15
CAPP?ONYIN B FOSINOPHILS INC V ALLERGIC REACTION (MAY BE UP TO 35%) P0156
CARBON DISULFIDF B EOSINOPHILS INC V OCCASIONAL RESPONSE P0368
CFPHALEXN B EOSINOPHILS INC V ALLERGIC RESPONSE P0736
CEPHALOBIDI NE B EOSINOPHILS INC V MAY BE UP TO 10% IN 1% PEOPLE 90298
CEPHALOTiIIN B EOSINOPHILS INC V ALLERGIC RESPONSE P 06 51
CHLOPANPH!NICOL B EOSINOPHILS INC V ALLERGIC REACTION P0 1424
CHLOP PROMAZI NE B EOSINOPHILS INC V OFTEN PRECURSOR OF JAUNDICE P0657
CHLORPROPAMIDE B EOSINOPHILS INC V ALLERGIC RESPONSE P0424
CLI NDA MYCI N B EOSINOPHILS INC V OCCASIONAL ALLERGIC RESPONSE P0735
. CLOXACILLIN B EOSINOPHILS INC V HYPERSENSITIVITY RESPONSE 9014214
PESPRA NINE B EOSINOPHILS INC V ALLERGIC REACTION P0992
DI CLOX ACILL IN B TOSINOPHILS INC V MILD ALLERGIC RESPONSE P0043
DIETHYLCARBANAZI NE B EOSINOPHILS INC V NAY INTENSIFY EOSINOPHILIA OF FILARIAL INFECTION P0 384
DIGITALIS B EOSINOPHILS INC V ALLERGIC RESPONSE NAY BE LARGE WITH TOXICITY P042 4
DIPHENYLHYDANTOIN B EOSINOPHILS INC V PARE HYPERSENSITIVITY REACTION 901411
DOXYCYCLI NE B !OSINOPHILS INC V ALLERGIC RESPONSE REPORTED P 07 34
ERYTEROMYCIN B EOSINOPHILS INC V ASSOC WITH HYPERSENSITIVITY REACTION P06 23
ETHOSUXI MIDE B EOSINOPHILS INC V PARE EOSINOPHILIA REPORTED P0 02 6
FLOP ANTY RON! B EOSINOPHILS INC V IN PATIENTS WITH PREEXISTING LIVER DISEASE HO 6 20
FLUORI DES B EOSINOPHILS INC EOSINOPHILIA REPORTED AS ALLERGIC REACTION R0657
GOLD B EOSINOPHILS INC V TRANSIENT ALLERGIC RESPONSE P0933
HETACILLIN B EOSINOPHILS INC V PROBABLY ALLERGIC RESPONSE P04 67
INIPRAMINE B EOSINOPHILS INC V ALLERGIC RESPONSE (MAY PRODUCE LOEFFLER’S SYNDROME) P0 857
INDANDIONES B EOSINOPHILS INC V WITH OTHER SIGNS OF HYPERSENSITIVITY P0657
IODIDES B ROSINOPHILS INC V ALLERGIC RESPONSE P0620
IPRINDOLE B ROSINOPHILS INC V ALLERGIC RESPONSE REPORTED P00 12
I S 0 NI A ZI D B EOSINOPHILS INC V ALLERGIC PHENOMENON P0424
KANAMYCIN B FOSINOPHILS INC V ALLERGIC REACTION HO 4 24
LUGOL’S IODINE B ZOSINOPHILS INC V PARE ALLERGIC RESPONSE TO IODINES P0026
MAR09EN B EOSINOPHILS INC V LOW INCIDENCE REPORTED P06 57
NE PH EN OX A LO NE B EOSINOPHILS INC V PARE SIDE EFFECT P0026
NETHICILLIN B EOSINOPHILS INC V HYPERSENSITIVITY REACTION 90068
NETRYLDOPA 9 POSINOPHILS INC V ALLERGIC RESPONSE 90620
METHYSERGIDE B EOSINOPHILS INC V TRANSIENT EFFECT UP TO 36 HOURS AFTER I.M. INJECT P03 64
NALIDIXIC ACID B EOSINOPHILS INC V ALLERGIC RESPONSE HO 1424
NIRIDAZOLE B EOSINOPHILS INC V QUITE COMMON ALLERGIC RESPONSE P0657
NITROFUPA NS B EOSINOPHILS INC V MAY BE SERIOUS ANAPHYLACTOID REACTION P0 026
NI TROFURANTOIN B EOSINOPHILS INC V ALLERGIC RESPONSE (GREATER THAN 1%) P0542
NOVOBIOCIN B EOSINOPHILS INC V ALLERGIC REACTION P0 424
NYSTATIN B EOSINOPHILS INC V NAY CAUSE ALLERGIC REACTION P07 36
OXACI LLI N B EOSINOPHILS INC V REPORTED EFFECT (?ALLEPGIC) P0026
OX AZ! PA N B EOSINOPHILS INC V RARE ALLERGIC RESPONSE P0026
PAPA VEBINE B EOSINOPHILS INC V ALLERGIC RESPONSE REPORTED TO OCCUR HO 467
PENICILLA NINE B EOSINOPHILS INC V MAY OCCUR WITH RASH P00 26
PENICILLIN B !OSINOPHILS INC V ALLERGIC REACTION (MAY B! UP TO 20% OF ALL WBC) P02 94
PH ENETHICILLI N B EOSINOPHILS INC V FEW CASES REPORTED ONLY (MINOR EFFECT) P01467
PHENOTHIAZINES B EOSINOPHILS INC V ALLERGIC RESPONSE P06 20
PIPEPACETAZINE B EOSINOPHILS INC V OCCASIONAL ALLERGIC RESPONSE 90467
POTASSIUM IODIDE B EOSINOPHILS INC V ALLERGIC RESPONSE P0 1432
PPOBUCOL B EOSINOPHILS INC V HYPERSENSITIVITY RESPONSE (LESS THAN 10%) P02 147
QUINFTHAZON E B EOSINOPHILS INC V ISOLATED CASE REPORT P06 57
PIFANPIN B MOSINOPHILS INC V ALLERGIC REACTION P0432
PISTCCETIN B EOSINOPHILS INC V ALLERGIC RESPONSE P06 20
STREPTOKINASE B EOSINOPHILS INC V ALLERGIC RESPONSE P06 20
STRIPTOMYCI N B EOSINOPHILS INC V HEMATOPOIETIC REACTION (OCCURS IN 50% CASES) P0 02 6
SULFA NETHOXAZOLF B EOSINOPHILS INC V ALLERGIC RESPONSE P0542
SULFISOXAZOLE B EOSINOPHILS INC V ALLERGIC RESPONSE P0 542
SU LFONA MI DES B ROSINOPHILS INC V HYPERSENSITIVITY RESPONSE P01424
TETRACYCLINE B !OSINOPHILS INC V ALLERGIC RESPONSE P04214
T9 IA MT EREN! B KOSINOPHILS INC V ALLERGIC RESPONSE P0 424
TPIFLUPERIDOL B EOSINOPHILS INC V ALLERGIC RESPONSE P0620
VANCONYCIN B EOSINOPHILS INC V ALLERGIC RESPONSE 90424
VIOMYCIN P EOSINOPHILS INC V ALLERGIC RESPONSE P0424
ANGIOTENSIN P EPINEPHPINE DEC V DEC SLIGHTLY LESS THAN NOPEPINEPHRINE INC 91030
DEXT9OMOPAMIDE P EPINEPHRINE DEC V MECHANISM OBSCURE P014 96
CLONIDINE U EPINEPHRINE DEC V PRIMARY ACTION OF DRUG P01455
ETHER P EPINE?HRINE INC V RESPONSE TO STRESS P0752
FENTANYL P EPINEPHPINE INC V MECHANISM OBSCURE HO 1496
INSULIN P EPINEPHRINE INC V STIMULATION OF ADRENAL MEDULLA, ?BY HYPOGLYCEMIA P06 62
MAO INHIBITORS P EPINEPHRINE INC V EFFECT OBSERVED AFTER SINGLE LARGE DOSE R03814
MORPHI NE P EPINEPHRINE INC V MECHANISM OBSCURE ALSO INVOLVED IN GLUCOSE RELEASE P04 96
ANINOPHYLLINE U EPINEPHRINE INC V THREEFOLD INCREASE IN RESPONSE TO I.V. DOSE HO 059
ETHANOL U EPINEPHRINE INC V SLIGHT INCREASE FOLLOWING INGESTION P 0051
GUANETHIDINE U EPINEPHRINE INC V SLIGHT INCREASED OUTPUT REPORTED 90805
I SOPPOTERENOL U EPINEPHRIN! INC V PROBABLY SMALL EFFECT WITH USUAL DOSES P0235

NITROGLYCERIN U EPINEPHRINE INC V ?DUE TO ADPENERGIC STIMULATION OF HYPOTENSION 90961
PAIN U EPINEPHPINE INC V ALSO SEEN MORE MARKEDLY WITH EMOTIONAL STRESS R05149
ACETAMINOPHEN U EPINEPHPINE Z V NO EFFECT WITH SHORT TERM INGESTION 2, G/DAY P0236
ACETYLSALICYLIC AC U EPINEPHRINE Z V NO EFFECT WITH SHORT TERM INGESTION 2.6 G/DAY 90235
CHLORDIAZEPOXIDE U EPINEPHRIN! Z V NO EFFECT SHORT TERM INGESTION OF 30 MG/DAY 90236
DIAZEPAM U EPINEPHPINE I V NO EFFECT SHORT TERM INGESTION OF 15 MG/DAY P0236
DI PHENH YDRA MINE U EPINEPHPINE Z V NO EFFECT SHOP? TERM INGESTION OF 150 MG/DAY 90236
PHENOBAHBITAL U EPINEPHRINE Z V NO EFFECT SHOPT TERM INGESTION OF 120 MG/DAY P0236
STORAGE OF SAMPLE U EPINEPHRIN! I N NO EFFECT AT ROOM TEMP, SEVERAL DAYS I’ ACIDIFIED 90998
AMPHOTEHICIN B P ERPF DEC V OCCURS IN HIGH PERCENTAGE OF PATIENTS 90026
ANGIOTENSI N P ERPF DEC V MARKED DEC FOLLOWING ADMINISTRATION 90557
DI AZOXIDE P ERPF DEC V AFTER I.V. INJECT IMMEDIATE REDUCTION NOTED 90049
EPI NEPHPINE P ERPF DEC V NAY DEC UP TO 40% BUT NO EFFECT ON BLOOD PRESSURE 90384
ETHER P ERPF DEC V PROBABLY DUE TO RENAL VASOCONSTRICTION P0394
GANGLIONIC BLOCKING P EPPF DEC V RETURNS TO NORMAL USUALLY WITHIN 2 HOURS 90384
H ALOT H A NE P ERPF DEC V UP TO 38% DEC REPORTED IN NORMALS 90657
LEVAPTEPENOL P EPPF DEC V BLOOD FLOW REDUCED, FILTRATION PATE UNCHANGED P0384
MET HO X YFL URA NE P EPPF DEC V DEC NOTED DUPING NORMAL ANESTHESIA HO 657
NOREPI NEPHRINE P ERPF DEC V SLIGHT FALL AFTER I.V. INFUSION 90657
PENTAZOCINE P ERPF DEC V OBSERVED IN NORMAL INDIVIDUALS P03 34
SPINAL ANESTHESIA P ERPF DEC V IN RELATION TO DEGREE OF HYPOTENSION ?0384
CHLOPPROM AZINE P ERPF INC V SLIGHT INC IN RENAL BLOOD FLOW P0384
METHYLDOPA P EPPF INC V SLIGHT INC OP NORMAL IN NORMO-HYPER-TENSI VHS 90384
PREGNANCY P ERPF INC V NORMAL RESPONSE IN FIRST 8 MONTHS 90291
ACETANILID B ERYTHROCYTE SURVIVAL DEC V DUE TO HEMOLYSIS RO3 814
ACETOPHENETIDIN B EPYTHHOCYTE SURVIVAL DEC V ASSOCIATED WITH DRUG INDUCED HEMOLYSIS P0384
ACETYLSALICYLIC AC B EHYTHROCYTE SURVIVAL DEC V LARGE DOSES INCREASE DESTRUCTION 9.0384
LEAD B EPYTHPOCYTE SUPVIVAL DEC V DUE TO HEMOLYSIS RO291
ANABOLIC STEROIDS S ERYTHROPOIETIN INC V METABOLIC EFFECT 90072
ORAL CONTRACEPTIVE S ESTRADIOL BINDING GLOB INC V METABOLIC CHANGES IN LIVER SYNTHESIS 90588
OPAL CONTRACEPTIVE P ESTRADIOL DEC V INHIBITS PHYSIOLOGICAL RISE HO 535
ORAL CONTRACEPTIVE U ESTRADIOL DEC V HORMONAL EFFECT 90593
CLOMIPHENE P ESTRADIOL INC V INC IN BOTH FOLLICULAR AND LUTEAL PHASES OVER NORM 90783
GA LACTOSE U ESTRIOL DEC N INTERFERES WITH GLC METHOD 90830
GLUCOSE U ESTRIOL DEC N INTERFERENCE WITH GLC METHOD HO 830
LACTOSE U ESTRIOL DEC N INTERFERENCE WITH GLC METHOD P08 30
NANDELIC ACID U ESTRIOL DEC N IF ACID HYDROLYSIS USED WITH HEXAMIN! MANDELAT! 90657
NA NNOSE U ESTHIOL DEC N INTERFERENCE WITH GLC METHOD RO830
METHENAMINE U ESTHIOL DEC N INTERFERES WITH HYDROLYSIS STAGE OF METHODS 90304
ORAL CONTRACEPTIVE U ESTPIOL DEC V HORMONAL EFFECT 90593
ESTHOG ENS S ESTROGEN BINDING GLOB INC V ALTERED LIVER METABOLISM HO87LI
OPAL CONTRACEPTIVE S ESTROGEN BINDING GLOB INC V METABOLIC EFFECT 90639
MENOPAUSE U ESTROGENS DEC V NORMAL RESPONSE 90291
MENSTRUATION U ESTROGENS DEC V LOWEST 2-3 DAYS AFTER ONSET 90291
PHENOTHIAZI NES U ESTROGENS DEC V BLOCK OVULATION, INHIBIT DECIDUAL REACTION P0299
ORAL CONTRACEPTIVE P ESTROGENS INC V OFTEN RELATED TO NAUSEA P0 186
CHLORPROMAZI NE U ESTROGENS INC V BLOCKS OVULATION, MAINTAINS DECIDUAL REACTION 90384
CLOMIPHENE U ESTROGENS INC V DUE TO ACTION ON HYPOTHALAMIC-PITUITARY AXIS HO 693
CORTICOTROPIN U ESTROGENS INC V HORMONAL EFFECT 90593
GONADOTROPIN U ESTROGENS INC V HORMONAL ACTION 90593
LACTAT ION U ESTROGENS INC V EXCRETION 5-10 UG/211H UNTIL NORMAL CYCLE RESUMES 90291
OVULATI ON U ESTROGENS INC V RISES TO PEAK AT OVULATION FALLS AFTER 90291
PREGNANCY U ESTROGENS INC V INC FROM 6TH MONTH UNTIL TEPN(UP TO 100UG/24H) 90291
TESTOSTERONE U ESTROGENS INC V PROBABLY DUE TO CONVERSION TO ESTROGEN 90983
ETHANOL B ETHANOL INC V PRESENCE OF ALCOHOL (HIGHER IN PLASMA THAN RBC) 9.0 384
ETHANOL C ETHANOL INC V USUALLY AT LOW!R CONCENTRATION THAN IN BLOOD 90384
ETHANOL U ETHANOL INC V AT EQUILIBRIUM APPROX 130% BLOOD CONCENTRATION P0384
DEXA METH A SON! U ETIOCHOLANOLONE DEC V SUPPRESSION OF ACTH P06 53
ORAL CONTRACEPTIVE U ETIOCHOLANOLON! DEC V COMPARED WITH CONTROLS - DETAILS NOT DISCUSSED P0162
GONADOTHOPIN U ETIOCHOLANOLONE INC V 150% INCREASE WHEN GIVEN TO NORMAL MEN ?O8L15
CLOFI BR ATE B EUGLOBULIN LYSIS TIME DEC V REPORTED OBSERVATION 90657
ORAL CONTRACEPTIVE B FACTOR I I V USUALLY NO EFFECT OBSERVED 106
WARFARIN B FACTOR II DEC V THERAPEUTIC ACTION 90467
ESTROGENS B FACTOR II INC V REPORTED EFFECT RO13LL
N AN DROLO N B B FACTOR II INC V METABOLIC EFFECT .0708
ORAL CONTRACEPTIVE B FACTOR II INC V REPORTED EFFECT P0639
ORAL CONTRACEPTIVE B FACTOR II INC V REPORTED EFFECT OF ESTROGENS 90134
PREGNANCY B FACTOR II INC V NORMAL RESPONSE IN LATE PREGNANCY 0291
BI SHYDROXYCOUMAPIN B FACTOR IX DEC V DOSE RELATED EFFECT P03 84
DEXTRAN B FACTOR IX DEC V SLIGHT EFFECT (MORE THAN HENODILUTION) 90657
HEPARIN B FACTOR IX DEC V REPORTED EFFECT 90384
WARFAR IN B FACTOR IX DEC V THERAPEUTIC ACTION HO 1467
ESTROGENS B FACTOR IX INC V ALTERED PROTEIN METABOLISM 908714
ORAL CONTRACEPTIVE B FACTOR IX INC V ESTROGEN EFFECT 908714
PREGNANCY B FACTOR IX INC V NORMAL RESPONSE IN LATE PREGNANCY 90143
PPENAHIN B FACTOR IX INC V SMALL INCREASES REPORTED 30028
ASPARAGINASE B FACTOR V DEC V DIMINISHED HEPATIC SYNTHESIS P0 180
DEXTRAN B FACTOR V DEC V SLIGHT EFFECT (MORE THAN H?MODILUTION) RO657
H! PA P I N B FACTOR V DEC V CONCENTRATION RELATED EFFECT 90384
ME TM Y L TES TOST EPO NE B FACTOR V DEC V SUPPRESSES ACTIVITY P0657
ANABOLIC STEROIDS B FACTOR V INC V METABOLIC EFFECT P007 2
EPINEPHPIN! B FACTOR V INC V TRANSIENT EFFECT P 05 96
NANDROLONE B FACTOR V INC V METABOLIC EFFECT 90708
PREMARIN B FACTOR V INC V SMALL INCREASES REPORTED P 0028
XANTHINES B FACTOR V INC V EFFECT OF NETHYLXANTHINES 90384
OPAL CONTRACEPTIVE B FACTOR V Z V USUALLY NO EFFECT OBSERVED 90106
ACETYLSALICYLIC AC B FACTOR VII DEC V ACTS LIKE BISHYDROXYCOUMARIN R0384
ASPARAGINASE B FACTOR VII DEC V DIMINISHED HEPATIC SYNTHESIS 90180
BISHYDROXYCOUNAP IN B FACTOR VII DEC V DOSE RELATED EFFECT 903814
DEXTRAN B FACTOR VII DEC V DEC BY 50% IN NORMALS 90657

METHYLTISTOSTERONE B FACTOR VII DEC V SUPPRESSES ACTIVITY P0 657
OPAL CONTRACEPTIVE B FACTOR VII DEC V METABOLIC EFFECT P0746
WAPFA PIN B FACTOR VII DEC V THERAPEUTIC ACTION HO 46 7
ANABOLIC STEROIDS B FACTOP VII INC V METABOLIC EFFECT P0072
ESTROGENS B FACTOR VII INC V ALTERED PROTEIN METABOLISM P0874
NA ND? OLONE B FACTOR VII INC V METABOLIC EFFECT 90708
ORAL CONTRACEPTIVE B FACTOR VII INC V ESTROGEN EFFECT (HIGHER THAN IN PREGNANCY) P0874
PEGNA NCY B FACTO? VII INC V NORMAL RESPONSE IN LATE PP!GNANCY 90291
ASP.9AGINASE B FACTOR VIII DEC V DIMINISHED HEPATIC SYNTHESIS HO 180
OPAL CONTRACEPTIVE B FACTO? VIII INC V SLIGHT EFFECT OBSERVED P04 12
PBEGN ANCY B FACTOR VIII INC V INC 100% ABOVE NORMAL IN LATE PREGNANCY 90291
RI SHY DROXYCOUMA PIN B FACTO? X DEC V DOSE RELATED EFFECT P03 84
METHYLTESTOSTERONE B FACTOR X DEC V SUPPRESSES ACTIVITY H0657
OPAL CONTRACEPTIVE B FACTOR X DEC V METABOLIC EFFECT P07146
WARFABIN B FACTOR X DEC V THERAPEUTIC ACTION HO 467
ANAPOLI STEROIDS 9 FACTOR X INC V METABOLIC EFFECT P0072
ESTROGENS B FACTOR X INC V SLIGHT EFFECT OBSERVED 90186
NA N DR C LONE B FACTOR X INC V METABOLIC EFFECT P07 08
OPAL CONTRACEPTIVE B FACTOR X INC V SLIGHT EFFECT OBSERVED 90412
PEGNA NCY B FACTOR X INC V NORMAL RESPONSE IN LATE PPEGNANACY RO291
HTPAPIN B FACTOR XI DEC V CONCENTRATION RELATED EFFECT 90384
PP!GNA NCY B FACTOR XI DEC V NORMAL RESPONSE IN LATE PREGNANCY P0291
ORAL CONTRACEPTIVE B FACTOR XII INC V REPORTED EFFECT P0639
AZATHIOPRINE P FAT INC V NAY OCCASIONALLY CAUSE STEATORPHEA HO 4 67
BI SAC ODYL F FAT INC V MAY CAUSE STEATORRMEA IF PROTRACTED INGESTION HO993
KANAMYCIN F FAT INC V MAY INDUCE NALABSORPTION WITH DIARRHEA HO 1467
NEOMYCI N F FAT INC V ALTERS INT VILLI,INHIBITS TRIGLYCERIDE HYDROLYSIS HO 993
HOMOGENTISIC ACID U FECL3 TEST P05 M TRANSIENT BLUE COLOR P0 929
LEV ONEPROMA ZI NE U ?ECL3 TEST P05 N P05 IF MORE THAN 100MG/DAY FOR 6 DAYS P06 57
MELANIN U FECL3 TEST P05 N BROWNISH-BLACK COLOR 90929
PHENYLPYPUVIC ACID U FECL3 TEST POS N TRANSIENT BLUE-GREEN COLOR FORMED P0929
X-RAY THERAPY S FERPITIN INC V OCCURS WITHIN 2H OF DEEP X-RAY THERAPY HO 29 1
ANABOLIC STEROIDS P FIBRINOGEN DEC V METABOLIC EFFECT P 0072
ANCPOO P FIBRINOGEN DEC V CONVERTS TO FIBRIN SHREDS P0 742
ASPARAGINASE P FIBRINOGEN DEC V MARKED EFFECT IN ALMOST ALL PATIENTS 90705
CLOFI BRATE P FIBRINOGEN DEC V REPORTED OBSERVATION IN SOME CASES HO 195
DIX TR A N P FIBPINOGEN DEC V SLIGHT EFFECT (MOPE THAN HEMODILUTION) P06 57
KA NANYCIN P FIBRINOGEN DEC V MAY OCCUR AT BEGINNING OF THERAPY 903814
OPAL CONTRACEPTIVE P FIBHINOGEN DEC V WHEN COMBINED ESTROGEN AND PHOGESTOGEN P06 57
PHOSPHORUS P FIBRINOGEN DEC V PROBABLE HEPATOXIC EFFECT P036 8
PPENAR IN P FIBRINOGEN DEC V SMALL BUT SIG EFFECT AFTER I.V. IN NORMAL MALES 900 28
TESTOSTERONE P FIBRINOGEN DEC V METABOLIC EFFECT P0072
ACETYLSALICYLIC AC P FIBRINOGEN INC V ASSOC WITH INC SEDIMENTATION RATE P03 84
ESTPOG ENS ? FIBRINOGEN INC V ALTERED LIVER METABOLISM P0874
MENSTRUATION P FIBRINOGEN INC V NORMAL RESPONSE P0 29 1
NORETHA NDROLONE P FIBRINOGEN INC V METABOLIC EFFECT P 007 2
OPAL CONTRACEPTIVE P FIBRINOGEN INC V METABOLIC CHANGES IN LIVER SYNTHESIS (ESTROGEN) HO 588
OXA NDPOLONE P FIBPINOGEN INC V METABOLIC EFFECT R0O72
OXY NET HOL ONE P FIBRINOGEN INC V METABOLIC EFFECT P007 2
PREGNANCY P FIBRINOGEN INC V MOD INC BY 16TH WEEK (PLUS 33% BY TERM) HO 291
PR! MA R N P FIBPINOGEN INC V EFFECT IN NORMAL FEMALES AFTER I.V. ADMIN P0028
PYBAZINA MID! P FIBRINOGEN INC V REPORTED EFFECT P00 26
X-RAY THERAPY P FIBPINOGEN INC V INDICATIVE OF TISSUE DAMAGE P02 91
XANTHINES P FIBRINOGEN INC V HEPORTEP EFFECT HO 384
CYCLOPROPANE P FIBRINOGEN Z V ANESTHESIA HAS NO EFFECT P0384
MUSCULAR EXERCISE P FIBRINOLYSIN INC V ACTIVITY INC BY EXERCISE 90291
ANINOSALICYLIC AC U FIGLU INC V OCCURS WITH VITAMIN B12 DEFICIENCY P0976
ANTICONVULS ANTS U FIGLU INC V OCCURS WITH MEGALOBLASTIC ANEMIA P0976
BARBITURATES U FIGLU INC V OCCURS IF NEGALOBLASTIC ANEMIA P0976
COLCHICIN E U FIGLU INC V MEGALOBLASTIC ANEMIA WITH P12 DEFICIENCY P0976
CYCLOSERINE U FIGLU INC V OCCURS WITH FOLIC ACID DEFICIENCY P0976
DI P9!NYLHYDANTOIN U FIGLU INC V OCCURS WITH IMPAIRED ABSORPTION OF FOLIC ACID P0976
ESTROGENS U FIGLU INC V OCCURS WITH MEGALOBLASTIC ANEMIA P0976
ETHANOL U FIGLU INC V MAY OCCUR WITH FOLIO ACID OP B12 DEFICIENCY P0976
ISONIA ZID U FIGLU INC V OCCURS IF MEGALOBLASTIC ANEMIA P0976
METEOR NI N U FIGLU INC V MAY CAUSE MEGALOBLASTIC ANEMIA P0935
METHOTPEXATE U FIGLU INC V OCCURS WITH INDUCED FOLIC ACID DEFICIENCY H0976
NEONYCIN Ti FIGLU INC V IF MEGALOBLASTIC ANEMIA DEVELOPS P0976
OPAL CONTRACEPTIVE U FIGLU INC V RESPONSE TO HISTIDINE TOLERANCE TEST 90868
PENTA MI DI NE U FIGLU INC V IF NEGALOBLASTIC ANEMIA DEVELOPS P 0976
PHENOBARBITAL U FIGLU INC V IF MEGALOBLASTIC ANEMIA DEVELOPS 90791
PRIMIDONE U FIGLU INC V IF MEGALOBLASTIC ANEMIA OCCURS P 079 1
PYRIMETHANINE U FIGLU INC V IF MEGALOBLASTIC ANEMIA OCCURS P1007
TRIANTERENE U FIGLU INC V IF MEGALOBLASTIC ANEMIA OCCURS 90976
N! THOX Y FL UP ANE S FLUORIDE INC V METABOLIC DEGRADATIONPHODUCT OF ANESTHETIC P0 339
DIPHENYLHYDANTOIN I FOLATE DEC V IMPAIRED DECONJUGATION OF POLYGLUTAMATES IN GUT P09 10
ORAL CONTRACEPTIVE F FOLATE DEC V IMPAIRED METABOLISM DUE TO HORMONAL FACTORS 90868
P9INIDONE F FOLATE DEC V IMPAIRED DECONJtJGATION OF POLYGLUTANATES IN GUT P0 29 1
ANINOSAL!CYLIC AC S OLATE DEC V NAY OCCUR WITH PROTRACTED THERAPY P065 7
AMPICILLIN S OLATE DEC N INHIBITS GROWTH OF L. CASEI P09 10
ANTICONVULSANTS S FOLATE DEC V MAY CAUSE MEGALOBLASTIC ANEMIA H 0791
ARSENICALS S FOLATE DEC V MEGALOBLASTIC ANEMIA AFTER EOWLER’S SOLN HO 657
BARBITURATES S FOLATE DEC V NAY CAUSE MEGALOBLASTIC ANEMIA (IMPAIRS ABSOPP) P0976
CHLORAMPHEN ICOL S FOLATE DEC N INHIBITS GROWTH OF L. CASEI 909 10
CHLOROGTJANIDE S TOLATE DEC V ANTAGONISES FOLIO ACID P0026
CYCLOSEHINE S FOLATE DEC V MAY CAUSE MEGALOBLASTIC ANEMIA P0976
DIPHENYLHYDANTOIN S FOLATE DEC V MAY CAUSE MEGALOBLASTIC ANEMIA (IMPAIRS ABSOPP) P 0976
EPYTHROMYCIN S FOLATE DEC M INHIBITS GROWTH OF L. CASEI 90910
ESTROGENS S R’OLATE DEC V NAY IMPAIR ABSORPTION 90976
ETH ANOL S FOLATE DEC V AFFECTS ABSORPTION IF SEVERE ALCOHOLISM P0976

ISONIAZID S FOLATE DEC V LOW INCIDENCE OF IMPAIRED ABSORPTION H 0976
LINCONYCIN S OLATE DEC N INHIBITS GROWTH OF L. CASEI 90910
METHOTREX ATE S FOLATE DEC V INHIBITS FOLATE PEDUCTASE R091
NITROFUHA NS S FOLATE DEC V MAY INDUCE FOLATE DEE - MEGALOBLASTIC ANEMIA HO657
OPAL CONTRACEPTIVE S FOLAT! DEC V INTERFERES WITH G.I.ABSOPPTION HO 982
PENICILLIN S FOLATE DEC N INHIBITS GROWTH 0? L CASEI 90907
PENTAMIDINE S FOLATE DEC V INHIBITS DIHYDROFOLATE REDUCTASE 90976
PHENOBAPBITAL S FOLATE DEC V MAY CAUSE MEGALOBLASTIC ANEMIA P079 1
PPIMIDONE S FOLATE DEC V NAY CAUSE M!GALOBLASTIC AN!NIA(INPAIPS ABSOHP) P079 1
PYHINETHANINE S FOLAT! DEC V INHIBITS FOLATE REDUCTASE, MEGALOBLASTIC ANEMIA 90791
TETRACYCLINE S FOLATE DEC N INHIBITS GROWTH OF L CASEI 90907
TPI AMTERENE S FOLATE DEC V INHIBITS DIRYDROFOLATE REDUCTASE O976
TR INETHOPRI N S FOLATE DEC V USUALLY WITH SULFA - NO HEMATOLOGICAL ABNORMALITY 90736
DIPHENYLHYDANTOIN T FOLATE DEC N MILD DEPRESSANT EFFECT ON L, CASEI 90657
METFOPNIN S FOLATE INC V HIGH IN PATIENTS IF 312 MALABSORPTION 90935
PHENFORNIN S FOLATE INC V ASSOCIATED WITH IMPAIRED ABSORPTION OF 312 P07 91
CHLORT!TRACYC LINE U FOLATE INC V WITH DOSE OF 3G/DAY p0384
OXYTETHACYCLI NE U FOLATE INC V WITH DOSE OF 2.5 G/DAY 903814
PH!NOBA?B ITAL 1’ FOLATE Z N NO EFFECT ON L. CASh OR S. FECALIS P0657
PRIMIDONE I FOLATE Z N NO EFFECT ON L. CASEI OP S. FECALIS 90657
TPIMETHADIONE T FOLATE Z N NO EFFECT ON L. CASEI OR S. FECALIS 90657
METHANOL U FORMALDEHYDE INC V METABOLITE OF OXIDATION 90384
METHANOL S FORMIC ACID INC V METABOLIT! (WITH FORMALDEHYDE) OF OXIDATION P03 84
ACETYLSALICYLIC AC U FOUCHET TEST 905 N PRODUCES PURPLE COLOR 90143
DIPHENYLHYDANTOIN S FREE THYROXINE DEC V COMPETES WITH T4 FOR TBG, INC LIVER DEGRADATION 90004
LEVOTHYROXI NE S FREE THYROXINE DEC V FALLS WITH THERAPY OF HYPOTHYROID STAT! 901467
LITHIUM S FREE THYROXINE DEC V MECHANISM UNCLEAR, NON TOXIC GOITER MAY OCCUR 90870
NORETHINDPONE S FREE THYROXINE DEC V SLIGHT EFFECT WHEN COMPARED WITH CONTROLS 90085
ORAL CONTRACEPTIVE S FREE THYROXINE DEC V WHEN TREATMENT RESULTS COMPARED WITH CONTROLS P0085
ACETYLSALICYLIC AC S FREE THYROXINE INC V INTERFERES WITH BINDING TO TBG AND TBPA P0 565
ESTROGENS S FREE THYROXINE INC V INCREASES BINDING CAPACITY OF TBG 90997
H A L OF E NATE S FREE THYROXINE INC V INTERFERES WITH BINDING OF T14 TO TBG 90674
HEPAPIN S FREE THYROXINE INC V PROBABLE MODIFICATION OF THYROXINE BINDING P06 55
OPAL CONTRACEPTIVE S FREE THYROXINE I V NO EFFECT OBSERVED ALTHOUGH PB! MAY BE INC 90657
ACETYLSALICYLIC AC S FREE TRIIODOTHYBONINE INC V INTERFERES WITH BINDING TO TBG P0565
METOLA ZONE U FREE WATER CLEARANCE DEC V DIURETIC ACTION OF DRUG HO 904
HEMOLYSIS S FRUCTOSE P04 ALDOLASE I N SLIGHT HEMOLYSIS HAS NO EFFECT HO 779
AMINO ACIDS I FRUCTOSE-6-P DEC V ASSOCIATED WITH LOW SERUM PHOSPHATE Ho 938
DIETHYLSTILB!STROL P FSH DEC V AT DOSES AFFECTING PIT-GONADAL AXIS 90525
ESTRADIOL P ESH DEC V RELATIVELY SLOWER THAN LB IN RESPONSE TO I.V. R1012
ES T P OG ENS P FSH DEC V HORMONAL EFFECT PO8L&7
MESTPANOL P P511 DEC V HORMONAL EFFECT (INHIBITORY ACTION 0’ ESTROGEN) P08 47
OPAL CONTRACEPTIVE P FSH DEC V OVER YEARS DEPRESSED TO 70% 0? CONTROL VALUES P0 38 2
PHENOTHIAZINES P FSH DEC V STIMULATION EFFECT 0? GONADOTPOPINS INHIBITED P0 596
OPAL CONTRACEPTIVE U FSH DEC V MARKED DEPRESSION IN NORMAL SUBJECTS 90900
PRENAPIN U FSH DEC V SLIGHT DECREASE ONLY EVEN WITH LARGE DOSES R0963
CLONIPHENE P ESH INC V MAXIMUM INC OF 350% OF CONTROL IN MALES P08 20
CLOMI PH EN! U FSH INC V DUE TO ACTION ON HYPOTHALAMIC-PITUITARY AXIS RO693
CYP P0 T ER 0 NE P FSH Z V NO CHANGE FOLLOWING ORAL ADMINISTRATION 90887
THYROTPOPIN-RELEAS P FSH I V NO EFFECT IN NORMAL SUBJECTS 900314
ESTROGENS S FTI INC V INCREASES BINDING CAPACITY OF ERG 90997
ORAL CONTRACEPTIVE S FTI I V THYROID FUNCTION UNAFFECTED 90026
ESTROGENS S G-C COMPONENT INC V ALTERED METABOLISM P0072
COPPER E G-6-PD DEC V STRONGLY INHIBITED(N0 ACTIVITY AT 100UM) IN VITRO 90135
SULFATES E G-6-PD DEC V SENSITIVE TO SULFATE ION AT CONC OF 5MM IN VITRO P0 135
BCG VACCINE S GAMMA GLOBULIN DEC V ASSOC WITH SEVERE REACTION 90657
G OLD S GAMMA GLOBULIN DEC V SINGLE CASE REPORTED P0657
PPEGNA NCY S GAMMA GLOBULIN DEC V MAY FALL SLIGHTLY IN LAST 3 MONTHS 90291
ANINOPYRINE S GAMMA GLOBULIN INC V SPECIFIC ANTI300IES TO DRUG MAY DEVELOP P 05 83
ASPARAGINASE S GAMMA GLOBULIN INC V INC CONTINUOUSLY TO 170% OF MEAN AT 4 WEEKS P0705
HYDANTOINS S GAMMA GLOBULIN INC V OBSERVED IN CASES OF HYPERSENSITIVITY 90657
HYDRALA ZINE S GAMMA GLOBULIN INC V REPORTED FINDING P06 57
PH ENYLBIJTAZONE S GAMMA GLOBULIN INC V OBSERVED IN TWO CASES (?DUE TO ANTIBODIES) 90583
PR OGESTIN S GAMMA GLOBULIN INC V NOT OBSERVED WITH COMBINED THERAPY 90243
TOLAZAMIDE S GAMMA GLOBULIN INC V TRANSIENT INCREASES REPORTED P065 7
X-RAY THERAPY S GAMMA GLOBULIN INC V NAY FALL IN SOME CASES (TISSUE DAMAGE) 90291
ATPOPI NE 0 GASTRIC JUICE HCL DEC V VOLUME ALSO REDUCED 90384
BARBITURATES 0 GASTRIC JUICE HCL DEC V SECRETION SLIGHTLY DEPHESSED P0 384
CARBON DISULFIDE 0 GASTRIC JUICE HCL DEC V FREQU!NT;ALSO HIGH INCIDENCE CHRONIC GASTRITIS P02 54
DIAZEPAM 0 GASTRIC JUICE HCL DEC V PRESUMED CENTRAL ACTION LASTS FOP SR AFTER 10MG P0118
GPANGLIONIC BLOCKING 0 GASTRIC JUICE HCL DEC V VOLUME AND ACIDITY GENERALLY REDUCED 90384
MORPHINE 0 GASTRIC JUICE HCL DEC V SLIGHT DEC IN SECRETION OF ACID Ho 384
PR !G NANCY 0 GASTRIC JUICE HCL DEC V NAY BE HYPOSECRETION 90291
SECHETIN 0 GASTRIC JUICE HCL DEC V PANCREATIC SECRETION ALSO AT PEAK 905148
AJMALINE 0 GASTRIC JUICE HCL INC V STRONG STIMULANT ACTION 90596
B!TAZOLE 0 GASTRIC JUICE HCL INC V USED TO STIMULATE SECRETION 90026
CAFFEINE 0 GASTRIC JUICE HCL INC V EFFECT OF I.V. INFUSION, ALSO IF GIVEN ORALLY 90209
COPTI COTROPIN 0 GASTRIC JUICE HCL INC V EFFECT 0? PROTRACTED THERAPY 901467
ETHANOL 0 GASTRIC JUICE HCL INC V PSYCHICALLY, REFLEXLY AND THPU HISTAMINE/GASTPIN P0 384
HISTAMINE 0 GASTRIC JUICE HCL INC V USED DIAGNOSTICALLY P0026
NETHYSERGIDE 0 GASTRIC JUICE HCL INC V AFFECT BASAL JUICE AND AFTER HISTAMINE HO 596
MORPHAZINAMIDE 0 GASTRIC JUICE HCL INC V HYPERACIDITY REPORTED RO657
PENTAGASTRIN 0 GASTRIC JUICE HCL INC V IF INFUSED I.V. 90 209
PILOCAPPINE 0 GASTRIC JUICE HCL INC V PRODUCES SECRETION LIKE THAT OF VAGAL STIMULATION HO 3 814
PAUWOLFIA 0 GASTRIC JUICE HCL INC V STIMULATES GASTRIC SECRETION 90596
RESERPI NE 0 GASTRIC JUICE HCL INC V EXCESS SECRETION NAY ACTIVATE PEPTIC ULCERS 90384
SYPOSINGOPIN! 0 GASTRIC JUICE HCL INC V EXCESSIVE AMOUNTS NAY BE RELEASED 90596
TO LA Z OL I NE 0 GASTRIC JUICE HCL INC V ALSO ENHANCES HISTAMINE STIMULATION P03 84
BARBITURATES 0 GASTRIC JUICE PEPSIN DEC V SECRETION SLIGHTLY DEPRESSED 90384
FT HANOL 0 G A ST RI C JUICE PEPSIN DEC V UNLESS MAJOR PSYCHIC COMPONENT 90384

PREGNANCY 0 GASTRIC JUICE PEPSIN DEC V MAY BE HYPOSECRETION P029 1
CAFFEINE 0 GASTRIC JUICE PEPSIN INC V EFFECT OF I.V. INFUSION, ALSO IF GIVEN ORALLY P0209
HISTAMINE 0 GASTRIC JUICE PEPSIN INC V EFFECT OCCURS WITH SECRETION OF ACID P03814
PENTAGASTRIN 0 GASTRIC JUICE PEPSIN INC V IF INFUSED I.V. P0209
PILOCAPPINE 0 GASTRIC JUICE PEPSIN INC V PRODUCES SECRETION LIKE THAT OF VAGAL STIMULATION P03 814
TOLAZOLINE 0 GASTRIC JUICE PEPSIN INC V ALSO ENHANCES HISTAMINE STIMULATION P0 3814
DIAZEPAN 0 GASTRIC JUICE VOLUME DEC V PRESUMED CENTRAL ACTION LASTS FOR SB AFTER 10MG P0 118
STR EPTOZOTOCI N S GASTRIN DEC V GASTRIC HYPERSECRETION REDUCED P06 86
AMINO ACIDS S GASTRIN INC V OPAL FEEDING PRODUCES UP TO TENFOLD INCREASE HO 550
P90Th N S GASTRIN INC V OPAL FEEDING MAY PRODUCE UP TO TENFOLD INCREASE P0550
UP F A S GENTAMICIN INC N AFFECTS MEASUREMENT BY PH METHOD P0348
ACETPI ZOATE U GYP DEC V WHEN 70% INJECTED FOP AORTOGBAPHY P0020
ACETYLSALICYLIC AC U GFR DEC V N!PHPOTOXICITY OF DRUG OCCURRING ACUTELY 90087
AMPHOT!PICIN B U GFP DEC V OCCURS IN HIGH PERCENTAGE OF PATIENTS P00 26
A NGIOTENSIN U GFP DEC V VASOCONSTRICTIVE EFFECT IN KIDNEY P0 3 814
DIAZOXIDE U GFP DEC V EFFECT OVER 2H OF 4MG/KG GIVEN I.V. P050 1
DI U P ITT CS U GFP DEC V EFFECT ON CLEARANCES P07 23
EPINEPHRINE U GFR DEC V SLIGHT FALL AFTER I.N. INJECTION P06 57
ETHER U GER DEC V DUE TO RENAL VASOCONSTRICTION P03814
FUROSEMIDE U G!P DEC V EXCESSIVE DIURESIS NAY CAUSE EFFECT P0657
GANGLIONIC BLOCKING U GFP DEC V RETURNS TO NORMAL USUALLY WITHIN 2 HOURS P03 84
HALOTHANE U GFP DEC V UP TO 19% DEC HEPORTED IN NORMALS P0657
ISOPROTEPENOL U GFR DEC V FREQUENTLY OBSERVED TO BE DIMINISHED P0835
N ET HO X YEL DR A NE U GFR DEC V DEC NOTED DURING NORMAL ANESTHESIA P0657
NETOLA Z ONE U GFR DEC V DIURETIC ACTION P0 904
NOP!PINEPHRINE U GFP DEC V SLIGHT FALL AFTER I.V. INFUSION P0657
POLYMYXIN B U GFR DEC V NEPHROTOXICITY INCREASES WITH CONTINUED TREATMENT 90384
RADIOGRAPHIC U GFR DEC V IF CONC SOLNS USED FOR AOPTOGRAPHY P0020
SPINAL ANESTHESIA U GFR DEC V REPORTED EFFECT, RELATED TO DEGREE OF HYPOTENSION R0384
THIAZIDES U GER DEC V ESPECIALLY IF ADNINSTERED I.V. P0 384
TRIANTER! NE U GFR DEC V CAUSES REDUCED GLOMERULAR FILTRATION RAT! 90204
5-HYDPOXYTRYPTAMINE U GFR DEC V VASCULAR EFFECT IN KIDNEY P0384
DIGITALIS U GFR INC V IMPROVEMENT WITH RELIEF OF EDEMA P03814
METHYL DOPA U GFR INC V SLIGHT INC OR NORMAL IN NOPMO-, HYPEP-TENSIVES P0384
PREGNANCY U GYP INC V NORMAL DURING FIRST 8 MONTHS HO 29 1
PPOTEI N U GFR INC V INC IN PROPORTION TO AMOUNT OF PROTEIN P02 91
PE NTAZOC IN! U GFR Z V ALTHOUGH REP? MAY BE CHANGED P0 3814
ETHANOL S GGTP INC V SEEN WITH OTHER LFTS NORMAL IN CHRONIC ALCOHOLISM R0794
M!TPIZOATE S GGTP INC V EFFECT OBSEPVED IN SUBJECTS WITH LIVER TUMORS P00 19
PHENOPARBI TAL S GGTP INC V ?INDUCTION OR DAMAGE OF HEPATIC MICROSOMES P0795
ESTROGENS S GGTP I V NO METABOLIC EFFECT 90072
PYRAZINANIDE S GLOBULIN DEC V REPORTED EFFECT (VIRAL-HEPATITIS LIKE) P0026
INDOLEACETIC ACID S GLOBULIN INC N REACTS AS TPYPTOPHAN IN METHOD OF GOLDENBERG 90375
OXYPHENISATIN S GLOBULIN INC V MAY CAUSE HYPERSENSITIVITY REACTION P0776
CA!PULIN P GLUCAGON INC V AFTER I.V. INFUSION IN NORMALS P0312
SECPETIN P GLUCAGON I V NO EFFECT NOTED WHEN GIVEN IN PULSES P0286
ANINOPYRINE U GLUCARIC ACID INC V AS RESULT OF HEPATIC ENZYME INDUCTION P0 596
ANTICONVULSANTS U GLUCAPIC ACID INC V OCCURS IN 914 A CHILDREN (HEPATIC ENZYME INDUCTION) 901473
BA RBITURA TES U GLUCAPIC ACID INC V AS RESULT OF HEPATIC ENZYME INDUCTION P0596
PHENOBARBITAL U GLUCAPIC ACID INC V DUE TO INDUCTION OF HEPATIC ENZYMES P0 596
Till OPENTAL U GLUCARIC ACID INC V ENHANCED EXCRETION WITH ANESTHESIA 90001
PHLOBIDZIN U GLUCOSE CLEARANCE INC V DUE TO DECREASED REABSORPTION P0878
AC ETA MI NOPH EN S GLUCOSE DEC V REPORTED EFFECT OF METABOLITE P025 1
ACETOHEXANIDE S GLUCOSE DEC V SULFONYLUREA DERIVATIVE PROMOTES INSULIN SECRETION P0204
ACETYLSALICYLIC AC S GLUCOSE DEC V IN DIABETICS AND IF TOXIC DOSES INGESTED P0299
ALLOPURINOL S GLUCOSE DEC V HEPATOTOXIC EFFECT P0596
AMINOSALICYLIC AC S GLUCOSE DEC V MAY CAUSE LOWERING IN DIABETICS 90596
ANABOLIC STEROIDS S GLUCOSE DEC V ANABOLIC EFFECT IN FASTING STATE P05 96
A NDROG! NS S GLUCOSE DEC V ANABOLIC EFFECT IN FASTING STATE P0596
ANTIMONY COMPOUNDS S GLUCOSE DEC V HEPATOTOXIC EFFECT 90596
AR SENICALS S GLUCOSE DEC V HEPATOTOXIC EFFECT P0596
ASCORBIC ACID S GLUCOSE DEC N SLIGHT EFFECT WITH COUPLED GLUCOSE OXIDASE METHOD P037 0
ATROPINE S GLUCOSE DEC V POSSIBLE SLIGHT FALL IF GIVEN AS PREMEDICATION P0643
B ENZENE S GLUCOSE DEC V TOXIC EFFECT P0620
BILIP UBIN S GLUCOSE DEC N EFFECT CAN BE AVOIDED BY USING SONOGYI FILTRATE P014 36
BUFORNIN S GLUCOSE DEC V THERAPEUTIC INTENT P0657
CARBON TETRACHLOR S GLUCOSE DEC V HEPATOTOXIC EFFECT P0620
CARBUTAMIDE S GLUCOSE DEC V HEPATOTOXICITY P0620
CAT IC H OL S S GLUCOSE DEC N MAY INHIBIT GLU OX PROCEDURES P0436
CHLOPOFOR N S GLUCOSE DEC V HEPATOTOXIC EFFECT WITH NECROSIS P0 620
CHLORPROPAMI DI S GLUCOSE DEC V SULFONYLUREA DERIVATIVE PROMOTES INSULIN SECRETION 90733
CONTACT WITH CLOT S GLUCOSE DEC N AT 4 DEGREES CHANGES 1-3 MG/100ML/HOUP RO 1436
CONTACT WITH CLOT S GLUCOSE DEC N GLUCOSE METABOLISM BY CELLS P01 81
CYPRO HEPT ID IN! S GLUCOSE DEC V SMALL DECREASE (10%), OFTEN NO CHANGE P0 1417
CYSTEIN? S GLUCOSE DEC M MAY AFFECT SOME GLU 0 PROCEDURES R0436
DIMERCAPROL S GLUCOSE DEC V AFTER INITIAL INCREASE P06 20
EPYTHPOMYCI N S GLUCOSE DEC V HEPATOTOXIC EFFECT P0596
ETHACRYNIC ACID S GLUCOSE DEC V SYMPTOMATIC HYPOGLYCEMIA REPORTED P08140
ETHANOL S GLUCOSE DEC V REDUCED TO BELOW 50 MG/100ML: EFFECT FOR UP TO 24H P0 187
FENELUR AMINE S GLUCOSE DEC V DIRECT EFFECT, INCREASED GLUCOSE UPTAKE BY MUSCLE 9091414
FRUCTOSE S GLUCOSE DEC V MARKED FALL NAY OCCUR 1 HOUR AFTER I.V. FRUCTOSE 90815
GLUTATHION! S GLUCOSE DEC N MAY AFFECT SOME GLU OX METHODS P01436
GLYBURIDE S GLUCOSE DEC V LONG ACTING SULFONYLUREA = INSULIN SECRETION P0595
GLYMIDINE S GLUCOSE DEC V PLASMA HALF-LIFE APPOXINATELY 4 HOURS P06 89
GUAN!THIOINE S GLUCOSE DEC V ANTIDIABETIC ACTIVITY (RISE ONCE STOP THERAPY) P0402
HA LOPERI DOL S GLUCOSE DEC V INSULIN LIKE ACTION OF DRUG REPORTED IN ONE CASE P04 17
HEMOLYS IS S GLUCOSE DEC N AFFECTS GLU OX AVOIDABLE BY SOMOGYI FILTRATE P01436
HYDRAZINE S GLUCOSE DEC V MAY POTENTIATE ACTION OF INSULIN IN DIABETICS 90596
HYDPOXYH!XANIDE S GLUCOSE DEC V MILD EFFECT (STIMULATES RELEASE OP INSULIN) 91018
INSULIN S GLUCOSE DEC V NATURAL ACTION OF HORMONE P0620

I SOCARBOXAZID S GLUCOSE DEC V MAO INHIBITORS HAVE SLIGHT EFFECT 90417
LINCOMYCIN S GLUCOSE DEC V MAY OCCUR WITH HEPATOTOXICITY 30 596
MAO INHIBITORS S GLUCOSE DEC V MECHANISM NOT CLEAR(POSSIBLE HEPATOTOXICITY) 90007
NARIHUANA S GLUCOSE DEC V HYPOGLYCEMIC EFFECT APPROX 4 HOURS AFTER US! P0273
MEBANAZINE S GLUCOSE DEC V APPEARS TO POTENTIATE INSULIN IN DIABETICS 90657
METEOR MIN S GLUCOSE DEC V MODE OF ACTION UNCERTAIN (OCCURS WITH OVERDOSE) HO 341
NK-270 S GLUCOSE DEC V SLIGHT NON-SIGNIFICANT DECREASE IN FASTING VALUE P 0809
N ANDROLONE S GLUCOSE DEC V ANABOLIC EFFECT H 07 08
NIALA MID! S GLUCOSE DEC V MAY PROLONG ACTION OF INSULIN IN DIABETICS P0657
NIFUPTIMOX S GLUCOSE DEC V MAY CAUSE DECLINE 90026
OXA NDROLONE S GLUCOSE DEC V ANABOLIC EFFECT 90369
OXYTETRACYCLINE S GLUCOSE DEC V MILD HYPOGLYCEMIC EFFECT OBSERVED IN DIABETICS P0 852
PAP GYLINE S GLUCOSE DEC V POSSIBLE HEPATOTOXIC EFFECT P0620
PENTAMIDINE S GLUCOSE DEC V HYPOGLYCEMIA - SSIBLE EFFECT P0384
PHENFOPEIN S GLUCOSE DEC V INHIBITS NORMAL AEROBIC METABOLISM P0603
PHENTOLANI NE S GLUCOSE DEC V TOXIC DOSES OVER LONG PERIOD OF TIME P03 84
PHOSPHORUS S GLUCOSE DEC V TOXIC EFFECT 90620
PIDH S GLUCOSE DEC V SIGNIFICANT REDUCTION AFTER GLUCOSE LOAD 90808
POTASSIUM AMINOB!NZ S GLUCOSE DEC V REPORTED EFFECT 90620
POTASSIUM CHLORIDE S GLUCOSE DEC V DRAWN INTO CELLS WITH POTASSIUM P 0620
POTASSIUM OXALATE S GLUCOSE DEC N INEFFECTIVE AS ANTIGLYCOLYTIC AGENT P06 20
PPEGNA NCY S GLUCOSE DEC V NAY BE LOW IN OCCASIONAL CASES 90291
PROMETH AZIN I S GLUCOSE DEC V IF GIVEN I.V. OP I.M. P 0263
PRO POXY P HE NE S GLUCOSE DEC V HYPOGLYCEMIA ALLEGEDLY OCCURRED IN ONE CASE P0 986
PPOPRA NOLOL S GLUCOSE DEC V HAS SLIGHT EFFECT LIKE THAT OF PROLONGING INSULIN P0907
P0 TEN ONE S GLUCOSE DEC V SEVERE HYPOGLYCEMIA REPORTED WITH POISONING HO 3 68
SUL PA PH ENA Z OLE S GLUCOSE DEC V REPORTED EFFECT 90620
S ULFON YL U RE AS S GLUCOSE DEC V MAY CAUSE SEVERE HYPOGLYCEMIA 90657
THIABENDAZOLE S GLUCOSE DEC V ASYMPTOMATIC LOWERING OBSERVED P 00 26
THYMOL S GLUCOSE DEC N 1MG/ML INHIBITS COLOR = 10 NG/100ML BY 0-TOLUIDINE P022 1
TIOCARLIDE S GLUCOSE DEC V HYPOGLYCEMIC REACTIONS OBSERVED P06 57
TOLAZAMIDE S GLUCOSE DEC N SULFONYLUREA DERIVATIVE STIMULATES INSULIN SECRET HO 856
TOLBUTAMIDE S GLUCOSE DEC V THERAPEUTIC INTENT (PROMOTES INSULIN SECRETION) P0334
TRONETHAMINE S GLUCOSE DEC V HYPOGLYCEMIA ISP IF I.V., ALSO TRANSIENT IF ORAL P07 82
URIC ACID S GLUCOSE DEC N IF MEASURED BY 0-TOLUIDINE 90750
ACETYLSALICYLIC AC U GLUCOSE DEC N GLUCOSE OXIDASE METHODS INHIBITED BY GENTISIC ACID P03 17
ASCORBIC ACID U GLUCOSE DEC M IMPAIRED COLOR DEVIL OF CHRONOGEN IN GLU OX NETH P0 299
L!VODOPA U GLUCOSE DEC N FALSE NEG, INHIBITION OF GLUCOSE OXIDASE METHOD P03 17
MERCURIAL DIURETICS U GLUCOSE DEC N MAY CAUSE FALSE WIG RESULTS WITH GLU OX METHODS P0 4 17
TETRACYCLINE U GLUCOSE DEC M PREVENTS OXIDATION OP CHRONAGEN GLU OX METHODS P06 514
ACETAZOLANID! S GLUCOSE INC V SEEN IN PREDIABETICS AND IF HYPOGLYCEMIC AGENTS P0559
ACETYLAMINOPHENOL S GLUCOSE INC N AT 1 MNOL/L AFFECTS SMA 12/60 METHOD 90876
ACETYLSALICYLIC AC S GLUCOSE INC V INC ABSORP. AND STEROID RELEASE INHIBITS TCA CYCLE P09 07
ALUMINUM NICOTINAT! S GLUCOSE INC V PRODUCES CARBOHYDRATE INTOLERANCE OVER LONG TERM 90547
AMINO ACIDS S GLUCOSE INC V AS RESULT OP I.V. INFUSION P03 49
AMINOPHENOL S GLUCOSE INC N AT 1 NMOL/L AFFECTS SMA 12/60 METHOD 90876
AMINOSALICYLIC AC S GLUCOSE INC N AT 1 MMOL/L AFFECTS SNA 12/60 METHOD P0 876
ANINOSALICYLIC AC S GLUCOSE INC V HYPERGLYCEMIA REPORTED WITH PROTRACTED THERAPY P06 76
ANTIPYRINE S GLUCOSE INC V SEVERE HYPERGLYCEMIA UNRESPONSIVE TO INSULIN P06 57
APGININE S GLUCOSE INC V SLIGHT INC IN NORMALS , MORE IN DIABETICS 90890
ASCORBIC ACID S GLUCOSE INC N AFFECTS ALKLAINE FERPICYANIDE METHODS P0370
ASCORBIC ACID S GLUCOSE INC N AT 1 MMOL/L AFFECTS SMA 12/60 METHOD P0 876
ASPAPAGINASE S GLUCOSE INC V MAY BE HYPEROSMOTIC NONKETOTIC HYPERGLYCEMIA P0180
BENZYL ALCOHOL S GLUCOSE INC V USED AS SALINE PRESERVATIVE, EFFECT IN NICE?HUNANS P0067
BETA-ADRENERGIC S GLUCOSE INC V MASKS SPURIOUS HYPOGLYCEMIA FROM INSULIN OVERDOSE P03 55
BILIRUBIN S GLUCOSE INC M MAY HAVE MARKED EFFECT ON 0-TOLUIDINE METHOD H 1009
CAERULIN S GLUCOSE INC V SLIGHT EFFECT AFTER I.V. INFUSION 90312
CAFFEINE S GLUCOSE INC V EFFECT IN ORDER OF 10 MG/100ML ONLY P0 202
CHLOROTHIAZIDE S GLUCOSE INC V DIABETOGENIC PROPERTIES OF DRUG AFFECT GET 90907
CHLORPRON AZ IN! S GLUCOSE INC V ABNORMALLY HIGH WITH REPEATED DOSES 904146
CHLORT HALID ONE S GLUCOSE INC V DIABETOGENIC-LIKE ACTION AFFECTS PRE- OP DIABETIC 90033
CLOPENTHI XOL S GLUCOSE INC V GLYCOSENIC EFFECT REPORTED 90657
CLOPE XOLON! S GLUCOSE INC V DIABETOGENIC ACTION p0620
CORTI C OST!ROI DS S GLUCOSE INC V TENDS TO BE HIGH (AS IN CUSHING’S SYNDROME) 90384
CORTICOTR OPIN S GLUCOSE INC V GLUCONEOGENESIS, INSULIN ANTAGONISM P100 1
COPTI SONE S GLUCOSE INC V GLUCONEOGENESIS P0596
CREATININE S GLUCOSE INC N IF MEASURED BY ALK FERRICYANIDE REDUCTION 90750
CYCLIC AMP S GLUCOSE INC V HORMONAL ACTION P03 19
CYCLOPROPANE S GLUCOSE INC V MODERATE WITH DEPLETION OF LIVER GLYCOGEN 90026
CYSTEINE S GLUCOSE INC N AT 1OMG/100ML AFFECTS ALKALINE FERPICYANIDE P03 70
DIX AM ET HASO NE S GLUCOSE INC V HORMONAL ACTION P0683
DEXTRAN S GLUCOSE INC N AFFECTS 0-TOLUIDINE PPOCEDUPE:TUHBIDITY AT ACID PH P09 07
DEXTROAMPHETANIN! S GLUCOSE INC V METABOLIC EFFECT 90620
DEXTPOT HYROXINE S GLUCOSE INC V EFFECT SEEN IN DIABETICS 90417
DIAPAMIDE S GLUCOSE INC V ALTERS GLUCOSE TOLERANCE 90609
DIAZOXIDE S GLUCOSE INC V INHIBITS INSULIN RELEASE, PERIPH GLUC UTILIZATION P0200
DI MERCAPPOL S GLUCOSE INC V INITIAL RESPONSE TO TOXIC DOSES 90620
DIPHENYLHYDANTOI N S GLUCOSE INC V INHIBITORY EFFECT ON INSULIN SECRETION RD 241
EDTA S GLUCOSE INC N IF GREATER THAN 1 MG/ML AFFECT 0-TOLUIDINE 90221
EPHEDRINE S GLUCOSE INC V LESS EFFECTIVE THAN EPINEPHRINE P0384
EPI NEPH RI NE S GLUCOSE INC N AT 1 MMOL/L AFFECTS SMA 12/60 METHOD 90876
EPINEPHPINE S GLUCOSE INC N AT 10 MG/100ML AFFECTS ALKALINE FERRICYANIDE 90370
EPIN!PHRI NE S GLUCOSE INC V CHARACTERISTIC ACTION OF HORMONE P04 17
ERGOTHIONINE S GLUCOSE INC N AT 10 NG/100ML AFFECTS ALKALINE FERRICYANIDE P03 70
ESTROGENS S GLUCOSE INC V METABOLIC EFFECT 901467
ITHACRYNIC ACID S GLUCOSE INC V DIABETOGENIC PROPERTIES 90907
IT HA NOL S GLUCOSE INC V TRANSIENT HYPERGLYCEMIA IN DEVELOPING INTOXICATION 90384
ETHER S GLUCOSE INC V METABOLIC EFFECT (TRANSIENT EFFECT) 91014
IT HIONA N IDE S GLUCOSE INC V HTPERGLYCEMIA REPORTED HO 596
ETHYL EN! S GLUCOSE INC V AFTER PROLONGED USE MAY B! MODERATE INC HOC 26

FLUORIDES S GLUCOSE INC N IF GREATER THAN 5 NG/ML AFFECTS 0-TOLUIDINE P0 221
FRUCTOSE S GLUCOSE INC N NON SPECIFICITY OF 0-TOLUIDINE, NEOCUPPOINE, FECN 90750
FUPOSEMIDE S GLUCOSE INC V DIAB!TOGENIC-LIKE ACTION OF DRUG: AFFECTS GTE 90907
GA LA CT OS I S GLUCOSE INC N MARKED EFFECT ON FECN, 0-TOLUIDINE METHODS Hi 009
GENTISIC ACID S GLUCOSE INC N FALSELY HIGH WITH ALKALINE FEPRICYANIDE HO 3 70
GLUCAGON S GLUCOSE INC V COUNTERACTS HYPOGLYCEMIA BY GLYCOGENOLYSIS P02 98
GL UCOCORTICO IDS S GLUCOSE INC V DIABETOGENIC ACTION (INC GLUCONEOGENESIS) 30620
GLtJCURONIC ACID S GLUCOSE INC N INTERFERES WITH SOME METHODS 90620
GLUTATHION! S GLUCOSE INC N INTERFERES WITH NEOCUPROINE, ALK FECN METHODS P1009
HALOT HAN! S GLUCOSE INC V RESPONSE TO STRESS OF SURGERY P07 12
HENOGLOBI N S GLUCOSE INC N NAY HAVE MARKED EFFECT WITH 0-TOLUIDINE Hi 009
HE P A P I N S GLUCOSE INC V SINGLE REPORT OF RISE OF 30 MG/100 ML P02 19
HYDRALAZI NE S GLUCOSE INC N AT 1 MMOL/L AFFECTS SMA 12/60 METHOD P0876
HYDROCHLOPOTHIAZIDE S GLUCOSE INC V DIABETOGENIC-LIKE ACTION OF DRUG P09 07
HYDROFLUNETHIAZIDE S GLUCOSE INC V MAY OCCUR (SIMILAR ACTION TO OTHER THIAZIDES) P0 1467
INDONETHACIN S GLUCOSE INC V RARE SIDE EFFECT ROU17
ISONIAZID S GLUCOSE INC V LARGE DOSES CAUSE HYPERGLYCEMIA BY GLYCOGENOLYSIS P01417
ISOPPOTERENOL S GLUCOSE INC N AT 1 NNOL/L AFFECTS SMA 12/60 METHOD 90876
ISOPPOTEPENOL S GLUCOSE INC V NOT AS MARKED AS WITH EPINEPHPINE 90394
LEV000PA S GLUCOSE INC N AT 10 MG/100ML AFFECTS ALKALINE FERRICYANIDE P0370
LEVODOPA S GLUCOSE INC N AT 1 MMOL/L AFFECTS SNA 12/60 METHOD 90876
LITHIUM S GLUCOSE INC V HYPERGLYCEMIA BEEN REPORTED AFTER USE (TRANSIENT) P 09514
MANNOSE S GLUCOSE INC N NON-SPECIFICITY OF PECN, 0-TOLUIDINE, NEOCUPROINE HO7SO
MEALS S GLUCOSE INC V IN EFFECT ACTS AS GLUCOSE TOLERANCE TEST P01 81
NEPEPIDINE S GLUCOSE INC V CENTRAL EFFECT ALSO INVOLVES EPINEPHPINE RELEASE P0 384
MERCAPTOPURINE S GLUCOSE INC N AT 1 MMOL/L AFFECTS SMA 12/60 METHOD 30876
METHIMAZOL! S GLUCOSE INC N AT 1 MMOL/L AFFECTS SMA/60 METHOD P0876
METHYCLOTHIAZIDE S GLUCOSE INC V DIABETOGENIC ACTION OF THIAZIDES R01467
METHYLDOPA S GLUCOSE INC N AT 1 MNOL/L AFFECTS SMA 12/60 METHOD P0876
METOLAZONE S GLUCOSE INC V DIABETIC-LIKE ACTION OF DIURETICS P07 39
MORPHINE S GLUCOSE INC V MINOR, CLINICALLY INSIGNIFICANT INCREASE HO 3814
MUSCULAR EXERCISE S GLUCOSE INC V RISE DUE TO ADRENAL ACTIVITY P029 1
NALIDIXIC ACID S GLUCOSE INC N COPPER REDUCTION METHODS AFFECTED P 09 07
NICOTINE S GLUCOSE INC V DUE TO ADRENAL RESPONSE IN POISONING P03 68
NICOTINIC ACID S GLUCOSE INC V MECHANISM NOT DISCUSSED P 03 84
NOREPINZPHRIN! S GLUCOSE INC N AT 10 MG/100ML AFFECTS ALKALINE FERPICYANIDE METH HO 370
OPAL CONTRACEPTIVE S GLUCOSE INC V DOES NOT AFFECT FASTING GLUCOSE BUT ALTERS GTT P0907
OXAZEPAM S GLUCOSE INC M FILLER AFFECTS 0-TOLUIDINE, NEOCUPROINE METHODS HO 6 52
PANCPEOZYMIN S GLUCOSE INC V I.V. INFUSION CAUSES INCREASE P 04 91
PAPALDEHYDE S GLUCOSE INC V HAS CAUSED TRANSIENT HYPERGLYCEMIA 90596
PENTAMIDINE S GLUCOSE INC V PARADOXICAL EFFECT OBSERVED 90384
PHENELZIN! S GLUCOSE INC V DECREASES GLUCOSE TOLERANCE P0956
PHENOLPHTHALEIN S GLUCOSE INC V IMPAIRED GLUCOSE TOLERANCE MAY OCCUR DUE TO K LOS’S P0216
POLYTHIAZIDE S GLUCOSE INC V DIABETOGENIC ACTION P0620
PREDNISONE S GLUCOSE INC V GLUCOCORTICOID EFFECT P0683
PROPYLTHIOUPACIL S GLUCOSE INC N AT 1 NMOL/L AFFECTS SMA 12/60 METHOD P0876
QUINETHAZONE S GLUCOSE INC V MAY PRECIPITATE LATENT DIABETES OP AGGRAVATE EXIST P06 20
RESERPINE S GLUCOSE INC V HYPERGLYCEMIA MAY FOLLOW ADMINISTRATION P06 15
PIBOSE S GLUCOSE INC N NON-SPECIFICITY OF PECN, NEOCUPROINE METHODS 91009
SECPETIN S GLUCOSE INC V I.V. INFUSION CAUSES INCREASE P04 91
THIABENDAZOLE S GLUCOSE INC V RAPE CASE OF HYPERGLYCEMIA REPORTED P0 4 17
THIAZIDES S GLUCOSE INC V DECREASED GLUCOSE TOLERANCE P 002 1
THYROID S GLUCOSE INC V METABOLIC ACTION OF HORMONE P0 204
TOLBUTANIDE S GLUCOSE INC N FALSE INC(LITTLE EFFECT AT NORMAL CONC)WITH GLU OX P08 56
TPIANCINOLONE S GLUCOSE INC V GLUCOCORTICOID EFFECT P06 83
TRIANTERENE S GLUCOSE INC V EFFECT LESS COMMON THAN WITH THIAZIDES HO 556
TRICHLORMETHIAZIDE S GLUCOSE INC V DIABETOGENIC LIKE ACTION OF DRUG: AFFECTS GTT P09 07
URIC ACID S GLUCOSE INC N IF MEASURED BY ALK FERRICYANIDE REDUCTION P 07 50
VINYL ETHER S GLUCOSE INC V TRANSIENT EFFECT (LESS THAN WITH ETHER) P00 26
XYLOSE S GLUCOSE INC N NON-SPECIFICITY OP O-TOLUIDINE,FECN,NEOCUPROINE P1009
ACETYLSALICYLIC AC U GLUCOSE INC V INHIBITS LIVER AND MUSCLE GLYCOGEN SYNTHESIS 90384
AMINOSALICYLIC AC U GLUCOSE INC V GLYCOSUPIA REPORTED WITH PROTRACTED THERAPY P0676
CARBANAZEPINE U GLUCOSE INC V SINGLE CASE 0? GLYOSURIA REPORTED P0417
CHLOROTHIAZIDE U GLUCOSE INC V DIABETOGENIC-LIKE ACTION OF DRUG AFFECTS GTE P09 07
CHLORTHALIDONE U GLUCOSE INC V DIABETOGENIC-LIKE ACTION OF DRUG AFFECTS GET P09 07
COPTICOSTEROIDS U GLUCOSE INC V AS RESULT OF HYPERGLYCEMIA P06 20
COPTICOTROPIN U GLUCOSE INC V INCREASED BLOOD GLUCOSE, REDUCED TMG P1 001
DEXTROTHYROXINE U GLUCOSE INC V OCCURS DUE TO ELEVATION OP BLOOD SUGAR P04 17
DIPH!NYLHYDANTOIN U GLUCOSE INC V OCCURS WTIH INHIBITION OF INSULIN SECRETION P0241
IDEA U GLUCOSE INC V REPORTED EFFECT. ?MECHANISM 90384
EPHEDHINE U GLUCOSE INC V MAY CAUSE GLYCOSURIA 90299
!THACPYNIC ACID U GLUCOSE INC V DIABETOGENIC PROPERTIES P09 07
ETHER U GLUCOSE INC V DUE TO HYPERGLYCEMIA 90620
FURAZOLIDONE U GLUCOSE INC N IF GIVEN IN VAGINAL POWDER ,GLUCOSE MAY BE PRESENT P0355
FUPOSENIDE U GLUCOSE INC V DIABETOGENIC-LIKE ACTION OF DRUG P0907
GLUCAGON U GLUCOSE INC V MOBILIZES HEPATIC GLYCOGEN, CAUSES GLYCOSURIA P0620
GROWTH HORMONE U GLUCOSE INC V MAY CAUSE HYPERGLYCEMIA AND GLYCOSURIA P06 20
HYDPOCHLOPOTHIAZID! U GLUCOSE INC V DIABETOGENIC-LIKE ACTION OF DRUG P09 07
HYDROGEN PEROXIDE U GLUCOSE INC N OXIDISES CHROMOGEN IN GLUCOSE OXIDASE TEST 90299
HY POCHLORITES U GLUCOSE INC M OXIDATION OF CHROMOGEN (0-TOLIDINE) P02 99
INDOMETHACIN U GLUCOSE INC V RAPE SIDE EFFECT P014 17
ISONIAZID U GLUCOSE INC V GLYCOSURIA MAY FOLLOW INDUCED HYPERGLYCEMIA P04 17
LEAD U GLUCOSE INC V NEPHPOTOXIC EFFECT WITH LEAD POISONING HO 291
LITHIUM U GLUCOSE INC V REPORTED EFFECT OF LITHIUM THERAPY IN SOME CASES P04 17
NICOTINIC ACID U GLUCOSE INC V AS RESULT OF HYPERGLYCEMIA 903814
PHENOTHIAZINES U GLUCOSE INC V EFFECT SEEN ESP IN LONG TERN THERAPY OF DIABETICS P0678
PHLOPIDZIN U GLUCOSE INC V DECREASES GLUCOSE REABSORPTION HO 878
STPEPTOZOTOCI N U GLUCOSE INC V RARELY EXCEEDED 25 MG/100NL 90686
TETRACYCLINE U GLUCOSE INC V DEGRADED MAY CAUSE FANCONI LIKE SYNDROME P0736
THIAZIDES U GLUCOSE INC V NAY OCCUR IN PREDIABETICS ESPECIALLY R01144

TPICHLORMETHIAZIDE U GLUCOSE INC V DIABETOGENIC LIKE ACTION OF DRUG P0907
TURPENTINE U GLUCOSE INC V MANIFESTATION OF NEPHROTOXICITY OF POISONING P036 8
VAGINAL POWDER U GLUCOSE INC N POWDIPS OFTEN CONTAIN GLUCOSE 90596
CHLOHOTHIAZI DE S GLUCOSE TOLERANCE DEC V DIABETOGENIC-LIKE ACTION OF DRUG P0723
CHLOPPPONAZINE S GLUCOSE TOLERANCE DEC V ABNORMAL CURVES IN 40% PATIENTS P0 657
CHLOPTHALI DONE S GLUCOSE TOLERANCE DEC V DIABETOGENIC-LIKE ACTION OF DRUG 90723
CLOPAMIDE S GLUCOSE TOLERANCE DEC V POSSIBLE EFFECT OF HYPOKALEMIA 91002
COPTICOTROPIN S GLUCOSE TOLERANCE DEC V CORTICOSTEROID IMPAIRMENT OF INSULIN SECRETION P0065
CORTISONE S GLUCOSE TOLERANCE DEC V GLUCONEOGINESIS AND ANTI-INSULIN EFFECTS 90596
DEX A METH A SON! S GLUCOSE TOLERANCE DEC V MAY IMPAIR CARBOHYDRATE TOLERANCE P0467
DIAPAMIDE S GLUCOSE TOLERANCE DEC V MODIFICATION OF GLUCOSE TOLERANCE 90609
DIPHENYLHYDANTOI N S GLUCOSE TOLERANCE DEC V DECREASES INSULIN EXCRETION 90596
FS TROG I N S S GLUCOSE TOLERANCE DEC V EFFECT VARIABLE DEPENDING ON STRENGTH P01417
ETHACRYNIC ACID S GLUCOSE TOLERANCE DEC V DIABETOGENIC-LIKE ACTION OF DRUG P0723
ETHANOL S GLUCOSE TOLERANCE DEC V POSSIBLE DIMINISHED TISSUE UPTAKE P0279
ETHINYLESTRADIOL S GLUCOSE TOLERANCE DEC V HORMONAL EFFECT 90683
FERROUS ASCOHBINATE S GLUCOSE TOLERANCE DEC V MECHANISM NOT REPORTED 901417
UR OSEMIDE S GLUCOSE TOLERANCE DEC V DIABETOGENIC-LIKE ACTION OF DRUG P07 23
GLUCAGON S GLUCOSE TOLERANCE DEC V DECREASED INSULIN SENSITIVITY 90363
GROWTH HORMONE S GLUCOSE TOLERANCE DEC V REDUCES DISAPPEARANCE RATE AFTER I.V. GTE P02S3
HYDROCHLOROTHIAZIDE S GLUCOSE TOLERANCE DEC V DIABETOGENIC-LIKE ACTION OF DRUG P0723
HYDROPLUNETHIAZIDE S GLUCOSE TOLERANCE DEC V DIABETOGENIC LIKE ACTION OF DRUG P014 67
INIPPANINE S GLUCOSE TOLERANCE DEC V PRELIMINARY OBSERVATIONS ONLY REPORTED 90056
METANDIENONE S GLUCOSE TOLERANCE DEC V ALTERS CURVE IN DIABETIC DIRECTION 90657
NICOTINIC ACID S GLUCOSE TOLERANCE DEC V REDUCED TOLERANCE OBSERVED IN DIABETICS P0 596
NITROFURANTOIN S GLUCOSE TOLERANCE DEC V SINGLE CASE REPORTED P0413
NORET BY NOD RE L S GLUCOSE TOLERANCE DEC V GLUCONEOGENETIC EFFECT OF STEROIDS 903 55
ORAL CONTRACEPTIVE S GLUCOSE TOLERANCE DEC V MAINLY ESTROGEN EFFECT(REVERSIBLE IN 3 OUT 0? 4) 90412
OXYTETRACYCLINE S GLUCOSE TOLERANCE DEC V EFFECT OBSERVED IN ANIMALS 90070
PEHPHENAZI NE S GLUCOSE TOLERANCE DEC V ABNORMAL CURVES IN 35% SUBJECTS RO657
PH ENOLPBTHALEIN S GLUCOSE TOLERANCE DEC V RESULT OF HYPOKALEMIA 90216
PHENOTHIA lINES S GLUCOSE TOLERANCE DEC V NAY PRODUCE DIABETIC TYPE OF CURVE IN NORMALS 90596
PRIG NANCY S GLUCOSE TOLERANCE DEC V DECREASED TOLERANCE IN LAST TRIMESTER 90291
THIAZIDES S GLUCOSE TOLERANCE DEC V DIABETOGENIC-LIKE ACTION OF DRUG R0723
CAFFEINE S GLUCOSE TOLERANCE INC V DEC OF GLUCOSE AT 30 AND 60 MINUTES 90316
CLOFIBRATE S GLUCOSE TOLERANCE INC V IMPROVEMENT HEL TO DEG OF ABNORMAL TRIGLYCERIDES P0099
GLYBUPIDE S GLUCOSE TOLERANCE INC V MARKED IMPROVEMENT NOTED R0595
GUANETHIDINE S GLUCOSE TOLERANCE INC V ANTIDIABETIC ACTIVITY (CHANGE AT END OF TREATMENT) P0402
MAO INHIBITORS S GLUCOSE TOLERANCE INC V SEEN IN DIABETICS TREATED WITH INSULIN P0 596
NETFORM IN S GLUCOSE TOLERANCE INC V NODE OF ACTION UNCERTAIN 903141
MK-270 S GLUCOSE TOLERANCE INC V PRODUCES FLATTENING OF CURVE 90809
NA NDROLON! S GLUCOSE TOLERANCE INC V ANABOLIC EFFECT P0708
NICOTINIC ACID S GLUCOSE TOLERANCE INC V INCREASES GLUCOSE DISAPPEARANCE AFTER I.V. GTE RO253
PA RGYLI NE S GLUCOSE TOLERANCE INC V FLAT CURVE MAY B! PRODUCED P05 96
ACETYLSALICYLIC AC S GLUCOSE Z N AT 10 MG/100NL NO EFFECT ALKALINE FERPICYANIDE RO37O
ACETYLSALICYLIC AC S GLUCOSE Z N AT 10 MG/100ML NO EFFECT ON GLU OX OF GOCHNAN P03 70
CREATININ! S GLUCOSE Z M NO EFFECT AT 100MG/100ML GLU OX OF GOCHNAN P0 370
CYSTEINE S GLUCOSE I N AT I0NG/100ML NO EFFECT ON GLU OX OF GOCHMAN P0 370
EPINEPHRINE S GLUCOSE Z N AT 10 MG/100ML NO EFFECT GLU OX OF GOCHNAN P0370
ER GOT HIONINE S GLUCOSE I N AT 10 MG/100ML NO EFFECT GLU OX OF GOCHNAN RO370
GENTISIC ACID S GLUCOSE Z N HAS NO EFFECT ON GLU OX METHOD OF GOCHMAN P03 70
GLUTAT HION! S GLUCOSE Z N AT 10 MG/100NL NO EFFECT GLU OX OF GOCHMAN P 03 70
LEVODO PA S GLUCOSE Z V NO EFFECT OBSERVED ALTHOUGH INC PLASMA INSULIN P0509
LEVODOPA S GLUCOSE Z N AT 10 NG/100NL NO EFFECT ON GLU OX O GOCHNAN P03 70
NOPEPINEPHPINE S GLUCOSE Z N AT 10 MG/100ML NO EFFECT ON GLU OX OF GOCHNAN P0370
PHENOLS S GLUCOSE I N AT 10 MG/100NL NO EFFECT ALKALINE FERPICYANIDE HO 370
PHENOLS S GLUCOSE Z N AT 10 NG/100ML NO EFFECT GLU OX OF GOCHMAN P03 70
URIC ACID S GLUCOSE Z N NO EFFECT AT 100 NG/100ML GLU OX OF GOCHMAN HO 370
VANILLIN S GLUCOSE Z N AT 10 MG/100ML NO EFFECT GLU OX OF GOCHMAN P0370
VANILLIN S GLUCOSE I N AT 10 NG/100NL NO EFFECT ALKALINE FERRICYANIDE P0370
VMA S GLUCOSE Z N AT 10 MG/100ML NO EFFECT GLU OX OF GOCHMAN HO 370
VMA S GLUCOSE Z N AT 10 MG/100ML NO EFFECT ALKALINE FERRICYANIDE HO 370
THY NOL U GLUCOSE Z N NO EFFECT ON GLUCOSE-OXIDASE METHODS P0779
AMINO ACIDS I GLUCOSE-6-PO4 DEC V ASSOCIATED WITH LOW SERUM PHOSPHATE P0938
ORAL CONTRACEPTIVE P GLUTAMATE DEC V HORMONAL EFFECT (SECOND PART OF CYCL!) P0226
HEMOLYSIS S GLUTAMATE DEHYDROGENASE I N SLIGHT HEMOLYSIS HAS NO EFFECT P0779
MUSCULAR EXERCISE S GLUTAMATE DEHYDROGENASE Z N PHYSICAL ACTIVITY HAS NO EFFECT P0779
STORAGE OF SAMPLE S GLUTATHIONE REDUCTASE Z N NO EFFECT 1 WEEK AT 4 DEGREES, 1 MONTH AT -20 P0998
OPAL CONTRACEPTIVE S GLYCINE DEC V HORMONAL EFFECT (SECOND PART OF CYCLE) P0226
GLYCI NE S GLYCIN! INC V SIMILAR MARKED INC IN GOUTY AND NORMALS P1 020
GLYCIIJE U GLYCINE INC V SIMILAR MARKED INC IN GOUT! AND NORMALS R1020
DI MERCAPROL U GOLD INC V IF POISONING DUE TO GOLD 90026
ESTROGENS S GONADAL BINDING GLOB INC V METABOLIC EFFECT P0072
CHLOPPROMAZINE U GONADOTROPINS DEC V BLOCKS OVULATION, MAINTAINS DECIDUAL REACTION 90384
ORAL CONTRACEPTIVE U GONADOTROPINS DEC V HORMONAL EFFECT P0 593
PHINOTHIAZI NES U GONADOTROPINS DEC V ASSOC WITH OTHER ENDOCRINOLOGICAL CHANGES P06 57
LEVODOPA P GONADOTPOPINS INC V REPORTED METABOLIC EFFECT P03 94
MENOPAUSE P GONADOTHOPINS INC V NORMAL RESPONSE P029 1
PREGNANCY P G0NADOTOPINS INC V INC EARLY TO YIELD POSITIVE PREGNANCY TEST HO 143
OVULATION U GONADOTROPINS INC V NAY BE TEMPORARY INCREASE 90291
PREGNANCY U GONADOTROPINS INC V HCG INC FROM 2 TO 12 WEEKS, FALLS LATER 90291
PHOTEINURIA U GOT INC V ASSOC WITH INFECTION AND TUBULAR DAMAGE P07 58
PPOTEINURIA U GPT INC V EFFECT MUCH LESS THAN WITH GOT 90758
ASPAPAGINASE B GRANULOCYTES DEC V SLIGHT REDUCTION (NOT DOSE DEPENDENT) 9070 5
CHLORPROMAZINE P GROWTH HORMONE DEC V PROB INHIBITS SECRETION OF PIT. GROWTH HORMONE HO 86 5
COPTICOSTEPOIDS P GROWTH HORMONE DEC V SUPPRESSES SECRETION OF HORMONE P0657
PROBUCOL P GROWTH HORMONE DEC V MECHANISM OBSCURE P02147
ARGININE P GROWTH HORMONE INC V EFFECT ALSO SHOWN BY PROTEIN MEALS P0759
CYCLIC AMP P GROWTH HORMONE INC V HORMONAL ACTION 90319
ESTROGENS P GROWTH HORMONE INC V MODULATORS OF HIGH SECRETION IN NORMALS 90649

FENFLURAMINE P GROWTH HORMONE INC V ACTION ON BRAIN STIMULATING RELEASE P0582
3LUCAGON P G P 0 WE H HORMONE INC V HORMONAL ACTION (POTENT STIMULANT) P0363
GLUCOSE P GROWTH HORMONE INC V DELAYED RISE AFTER INITIAL SLIGHT FALL P0474
HA LOTHA NE P GROWTH HORMONE INC V ?METABOLIC RESPONSE TO SURGICAL STRESS P0712
LEV000PA P GROWTH HORMONE INC V IN NORMALS SINGLE DOSE CAUSE INC IN 1-2 HOURS R0509
METHAMPHETANINE P GROWTH HORMONE INC V SIGNIFICANT RISE R0102
NICOTINIC ACID P GROWTH HORMONE INC V PRODUCED BY FALL IN FREE FATTY ACIDS P0478
OPAL CONTRACEPTIVE P GROWTH HORMONE INC V DUPING FIRST YEAR OF USE P0026
PYROGEN P GROWTH HORMONE INC V AFTER DELAY OF ONE HOUR FOLLOWING INJECTION P008 2
SLEEP P GR 0 WT H HORMONE INC V MAX RELEASE IN EARLY SLEEP B 1025
THYROTROPI N-PELEAS P GROWTH HORMONE Z V NO EFFECT IN NORMAL SUBJECTS P0034
AMINOSALICYLIC AC S GUANASE INC V MAY CAUSE CYTOTOXIC HEPATOCELLULAP DAMAGE P0079
ANABOLIC STEROIDS S GUANASE INC V DUE TO CHOLESTATIC SYNDROME P0596
ANDROGENS S GUANASE INC V CHOLESTATIC PHENOMENON P0620
ANTIMONY COMPOUNDS S GUANASE INC V HEPATOTOXIC EFFECT P 0596
APSEN ICA LS S GUANASE INC V HEPATOTOXIC EFFECT P0596
CHLOPPPOPAMI DE S GUANASE INC V MAY CAUSE CYTOTOXIC LIVER DAMAGE P0079
IPPONIAZID S GUANASE INC V MAY CAUSE CHOLESTATIC AND CYTOTOXIC JAUNDICE P0079
ISONIAZID S GUANASE INC V CYTOTOXIC HEPATOCELLULAR DAMAGE P0079
MECHLOPETHANI NE S GUANASE INC V NAY CAUSE CYTOTOXIC (HEPATOCELLULAR) DAMAGE P0079
N ETH OT REX A TE S GUANASE INC V MAY CAUSE CYTOTOXIC HEPATOCELLULAR DAMAGE P007 9
PHENYLBUTA ZONE S GUANASE INC V MAY CAUSE CHOLESTATIC AND CYTOTOXIC JAUNDICE P0079
TESTOSTERONE S GUANASE INC V MAY CAUSE CHOLESTATIC AND CYTOTOXIC LIVER DAMAGE P007 9
DI PY ROWE S HAPTOBLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P0636
INDOMETHAC IN S HAPTOBLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P0026
ETHY LESTRENOL S HAPTOBLOBIN INC V METABOLIC EFFECT P0072
FL 00 X Y NEST ER ONE S HAPTOBLOBIN INC V METABOLIC EFFECT P007 2
ACETANILID S HAPTOGLOBIN DEC V HEMOLYSIS WITH G-6-PD DEFICIENCY P0620
ACETOHEXANIDE S HAPTOGLOBIN DEC V NAY CAUSE HEMOLYTIC ANEMIA P0298
ACETYLPHENYLHYDRAZ S HAPTOGLOBIN DEC V MAY CAUSE HENOLYTIC ANEMIA P0620
AMINOPYRINE S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P0620
AMINOSALICYLIC AC S HAPTOGLOBIN DEC V EFFECT OF HENOLYTIC ANEMIA P0240
CHLOPPPONAZINE S HAPTOGLOBIN DEC V HEMOLYTIC ANEMIA P 0620
COPPER S HAPTOGLOBIN DEC V MAY BE HEMOLYSIS WITH POISONING P0657
DI NERCAPROL S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYSIS P0079
DIPHENHYDRAMINE S HAPTOGLOBIN DEC V CONSEQUENCE OF HEMOLYTIC ANEMIA P0932
ESTROGENS S HAPTOGLOBIN DEC V ALTERED LIVER METABOLISM P0874
ETHINYLESTRA DIOL S HAPTOGLOBIN DEC V METABOLIC EFFECT P0 149
PUPA LEA DONE S HAPTOGLOBIN DEC V DUE TO HEMOLYSIS P0079
FUPAZOLIDONE S HAPTOGLOBIN DEC V DUE TO HEMOLYSIS P0079
ISONIAZID S HAPTOGLOBIN DEC V HENOLYTIC ANEMIA P0620
ME PHENYTOI N S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P 0636
MET HICILLIN S HAPTOGLOBIN DEC V ONE DOUBTFUL CASE OF HENOLYTIC ANEMIA P0026
METHYLDOPA S HAPTOGLOBIN DEC V NAY CAUSE HENOLYTIC ANEMIA P0620
METHYLENE BLUE S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYSIS P0620
NALIDIXIC ACID S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA ISP IF G-6-PD DEFICIENCY P0999
N A PHT HAL EWE S HAPTOGLOBIN DEC V MAY CAUSE HENOLYSIS P0079
NIT ROFURA NTOI N S HAPTOGLOBIN DEC V HEMOLYTIC ANEMIA P0620
NITHOFURAZONE S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYSIS P0079
ORAL CONTRACEPTIVE S HAPTOGLOBIN DEC V METABOLIC CHANGES IN LIVER SYNTHESIS (ESTROGEN) P0588
PANAQUIN E S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P0240
PENICILLIN S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P0620
PENTAQUI NE S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYSIS P0079
PHENYLHYDRAZINE S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYSIS (HEMOLYTIC ANEMIA) P0657
PRIMAQUINE S HAPTOGLOBIN DEC V NAY CAUSE HEMOLYTIC ANEMIA P0620
QUINIDI NE S HAPTOGLOBIN DEC V CAUSES HEMOLYTIC ANEMIA P0636
JUININE S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P0636
RESORCIN S HAPTOGLOBIN DEC V OCCURS WITH HEMOLYTIC ANEMIA P0657
SALICYLAZOSULFA PYR S HAPTOGLOBIN DEC V OCCURS WITH HEMOLYTIC ANEMIA P0620
STIBOPHEN S HAPTOGLOBIN DEC V PRODUCES HENOLYTIC ANEMIA P0636
STPEPTOMYCIN S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P0620
SULFACETAMIDE S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYSIS IF G-6-PD DEFICIENCY P0079
SULFADIAZINE S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P0620
SULFAMETHIZOLE S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P075 1
S ULF A MET HOXA ZOLE S HAPTOGLOBIN DEC V NAY CAUSE HEMOLYTIC ANEMIA P0542
SULFAMETHOXYPYPID S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P0658
SULFANILAMIDE S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P0079
SULFAPYPIDINE S HAPTOGLOBIN DEC V MAY CAUSE HENOLYTIC ANEMIA P0079
SULFI SOXAZOL E S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P05142
SULFONAMIDES S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA IF G-6-PD DEFICIENCY P0026
S U LF ON ES S HAPTOGLOBIN DEC V NAY CAUSE HEMOLYTIC ANEMIA P0079
SULFOXONE S HAPTOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P0079
THIAZOLSULFONE S HAPTOGLOBIN DEC V HENOLYTIC ANEMIA P0620
FPIPELENNAMI NE S HAPTOGLOBIN DEC V HEMOLYTIC ANEMIA B 0240
ANABOLIC STEROIDS S HAPTOGLOBIN INC V METABOLIC EFFECT P 007 2
METHA N DR OS TE NOLON I S HAPTOGLOBIN INC V METABOLIC EFFECT P0072
N ETH Y LTE ST OS TE HONE S HAPTOGLOBIN INC V METABOLIC EFFECT P0072
NORETHANDROLONE S HAPTOGLOBIN INC V METABOLIC EFFECT P0072
OXANDROLONE S HAPTOGLOBIN INC V METABOLIC EFFECT P0072
OXY METUOLONE S HAPTOGLOBIN INC V METABOLIC EFFECT P0072
S TA N OZO LOL S HAPTOGLOBIN INC V METABOLIC EFFECT P0072
TESTOSTERONE S HAPTOGLOBIN INC V METABOLIC EFFECT(IP AQUEOUS SOLN I.M.) P0072
HEPARI N S HBD DEC N SIGNIFICANT INACTIVATION P0779
OXA LATE S S HBD DEC N ALMOST COMPLETE INACTIVATION OF ENZYME P0779
HEMOLYSIS S HBD INC N EPYTHPOCYTES CONTAIN LARGE AMOUNTS P0779
MEPEPIDI NE S HBD INC V MAY CAUSE SPASM OF SPHINCTER OF ODDI P0657
MORPHINE S HBD INC V PROB DUE TO SPASM OF SPHINCTER OF ODDI P0657
CITRATES S HBD Z M NO EFFECT ON ACTIVITY P0779
EDT A S HBD Z N NO EFFECT ON ACTIVITY P0779
ACETANILID B HEINZ-BODY FORMATION P05 V OCCURS INITIALLY PRIOR TO OVERT HENOLYSIS P0518

ACETOPHENETIDIN B HEINZ-BODY FORMATION P05 V OCCURS INITIALLY PRIOR TO OVERT H!NOLYSS 90518
ACETYLSALICYLIC AC B HEINZ-BODY FORMATION P05 V OCCUR INTIALLY BUT DISAPPEAR WITH HEMOLYSIS 90518
ANINOPYPINE B HEINZ-BODY FORMATION POS V OCCURS INITIALLY BEFORE OVERT HEMOLYSIS 90518
ANTINALARIALS B HEINZ-BODY FORMATION P05 V OCCURS PRIOR TO OVERT HEMOLYSIS 90518
ANTIPYRETICS B HEINZ-BODY FORMATION P05 V OCCURS PRIOR TO OVERT HENOLYSIS P0518
ANTIPYRINE B HEINZ-BODY FORMATION P05 V OCCURS INITIALLY PRIOR TO HENOLYSIS 30518
ARSENICALS B HEINZ-BODY FORMATION 205 V SOME NAY CAUSE HENOLYTIC ANEMIA 90104
DIANINODIPHENYLSUL? B HEINZ-BODY FORMATION P05 V EARLY STAGE OF HEMOLYTIC ANEMIA RO1OL&
FUPALTADONE B HEINZ-BODY FORMATION P05 V EARLY STAGE OF HENOLYTIC AN9MIA 90104
FUHAZOLIDONE B HEINZ-BODY FORMATION P05 V EARLY STAG! OF HEMOLYTIC ANEMIA 901014
LYSOL B HEINZ-BODY FORMATION P05 V MAY CAUSE INTRAVASCULAR HEMOLYSIS 90197
NETRYLENE BLUE B HEINZ-BODY FORMATION POS V EARLY STAGE OF HENOLYTIC ANEMIA P01 04
NAPHTHALEN! B HEINZ-BODY FORMATION P05 V EARLY STAGE OF HENOLYTIC ANEMIA 90104
NITROFURANS B HEINZ-BODY FORMATION P05 V OCCURS INITIALLY WITH HIMOLYSIS P0518
NITPOFURANTOIN B HEINZ-BODY FORMATION P05 V MAY CAUSE HEMOLYTIC ANEMIA P01014
NITROFUHAZONE B HEINZ-BODY FORMATION P05 V MAY OCCUR IN EARLY STAGES OF HEMOLYTIC ANEMIA P01014
PAMAQUINE B HEINZ-BODY FORMATION P05 V MAY OCCUR IN EARLY STAGES OF HENOLYSIS P01014
PENTAQUINE B HEINZ-BODY FORMATION P05 V NAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY 90104
PHENAZOPYRIDINE B HEINZ-BODY FORMATION P05 V ASSOCIATED WITH HEMOLYTIC ANEMIA R0657
PHENYLHYDRAZIN B HEINZ-BODY FORMATION P05 V MAY OCCUR IN EARLY STAGES OF HEMOLYSIS 901014
PRIMAQUINE B HEINZ-BODY FORMATION P05 V MAY OCCUR IN EARLY STAGES OF HENOLYSIS 90104
SALICYLAZOSULFAPYR B HEINZ-BODY FORMATION P05 V MAY CAUSE HEMOLYTIC ANEMIA P0104
SULFANILAMIDE B HEINZ-BODY FORMATION P05 V MAY OCCUR IN EARLY STAGES OF HENOLYSIS P01014
SULFONAMIDES B HEINZ-BODY FORMATION P05 V OCCURS WITH MARKED HEMOLYTIC ANEMIA 90518
SULFONES B HEINZ-BODY FORMATION P05 V REPORTED EFFECT IN FIRST FEW DAYS 903814
TOLUIDINE BLUE B HEINZ-BODY FORMATION P05 V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY R0i04
ACETANILID B HEMATOCRIT DEC V HEMOLYTIC ANEMIA P0656
ACETOHEXAMIDE B HEMATOCRIT DEC V NAY CAUSE ANEMIA AND HEMOLYSIS IF G-6-PD DEFICIENCY R0298
ACETOPHENETIDIN B HENATOCRIT DEC V HEMOLYTIC ANEMIA 90240
ACETYLPHENYLHYDRAZ B !IENATOCRIT DEC V MAY CAUSE HEMOLYTIC ANEMIA R0620
ACETYLSALICYLIC AC B HENATOCRIT DEC V DEPRESSES BONE MARROW, G.I. BLEEDING, HEM ANEMIA 90240
ALLOPUHINOL B HENATOCRIT DEC V PARE CASE OF ANEMIA REPORTED 90026
AMINOBENZOIC ACID B HENATOCPIT DEC V INDUCES MALABSORPTION AND NEGALOBLASTIC ANEMIA P0716
AMINOPYPINE B HEMATOCRIT DEC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS 90240
AMINOSALICYLIC AC B HEMATOCRIT DEC V HENOLYTIC ANEMIA/MEGALOBLASTIC ANEMIA 90240
AMPHETAMINES B HEMATOCRIT DEC V HENOLYTIC ANEMIA (DEPENDS ON PRIOR SENSITIVITY) P02140
AMPHOTEHICIN B B HEMATOCRIT DEC V BONE NARROW DEPRESSION WITH HEMOLYTIC ANEMIA P0945
ANTICONVULSANTS B HEMATOCRIT DEC V NAY CAUSE MEGALOBLASTIC/APLASTIC ANEMIA P0791
ANTIMALARIALS B HEMATOCRIT DEC V NAY CAUSE HEMOLYTIC ANEMIA P0518
ANTIPYRETICS B HEMATOCPIT DEC V MAY CAUSE HEMOLYTIC ANEMIA P0518
ANTIPYRINE B HENATOCRIT DEC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS P0240
APSENICALS B HEMATOCRIT DEC V PANCYTOP!NIA 90240
ASPARAGINASF B HEMATOCRIT DEC V NAY CAUSE ANEMIA P0427
BARBITURATES B HEMATOCRIT DEC V NAY CAUSE NEGALOBLASTIC ANEMIA P0976
BENZOCAINE B HEMATOCRIT DEC V MAY CAUSE HEMOLYSIS 90121
BUSULFAN B HEMATOCRIT DEC V PANCYTOPENIA/HINOLYTIC ANEMIA P0467
BUTAPEPAZINE B HENATOCRIT DEC V TRANSITORY ANEMIA P0026
CAPBAMAZEPINE B HENATOCRIT DEC V PANCYTOPENIA P0278
CARBON DISULFIDE B H!MATOCHIT DEC V HYPOCHROMIC ANEMIA COMMON 90254
CEPHALORIDIN! B HENATOCHIT DEC V MAY CAUSE ANEMIA R0026
CEPHALOTHIN B HEMATOCRIT DEC V HENOLYTIC ANEMIA 90392
CHLORAMPHENICOL B HEMATOCRIT DEC V NORMALLY SLIGHT RESPONSE/NAY BE PANCYTO?ENIA 90272
CHLOROQUINE B HEMATOCRIT DEC V G-6-PD HEMOLYTIC ANEMIA/PANCYTOPENIA 90912
CHLOROTHIAZIDE B HEMATOCRIT DEC V PANCYTOPENIA RO024
CHLOPPPOMAZINE B HEMATOCRIT DEC V HENOLYTIC ANEMIA 90222
CHLOHPPOPAMIDE B HENATOCRIT DEC V MILD ANEMIA, RAPE APLASTIC ANEMIA P0733
COLCHICIN! B HEMATOCRIT DEC V MEGALOBLASTIC ANENIA(IMPAIPED ABSORP B12) P0976
COLD AGGLUTININS B HEMATOCPIT DEC N SPURIOUS NACROCYTOSIS DUE TO AGGLUTINATION P0732
COPPER B HEMATOCRIT DEC V WITH HEMOLYSIS OF COPPER TOXICITY P01214
CORTICOSTEROIDS B HENATOCRIT DEC V NAY CAUSE G.I. BLEEDING WITH LOW FE STORES 90104
CYCLOSERINI B HENATOCRIT DEC V NAY CAUSE MEGALOBLASTIC ANEMIA RO976
DIANINODIPHENYLSULF B HENATOCRIT DEC V HEMOLYSIS (HEMOLYTIC ANEMIA) 90451
DIMEPCAPROL B PEMATOCPIT DEC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS 902140
DIPHENHYDRAMINE B HEMATOCRIT DEC V HEMOLYTIC ANEMIA P0932
DIPHFNYLHYDANTOIN B HEMATOCRIT DEC V MEGALOBLASTIC/HEMOLYTIC/APLASTIC ANEMIA,PANCYTOP!N 90873
DIPYPONE B HEMATOCRIT DEC V HEMOLYTIC ANEMIA P0569
DOXAPHAN B HENATOCPIT DEC V NOTED POSTOPERATIVELY IN A FEW PATIENTS 90010
EDTA B HENATOCRIT DEC V NAY OCCUR WITH PROLONGED THERAPY 90026
ESTROGENS B HEMATOCRIT DEC V NAY IMPAIR ABSORPTION OF FOLATE 90976
ETHANOL B HEMATOCHIT DEC V MAY AFFECT FOLIC ACID ABSORPTION AND USAGE P0976
ETHOSUXINIDE B HEMATOCPIT DEC V APLASTIC ANEMIA 90026
FAVA BEANS P HEMATOCRIT DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY 90079
FURALTADONE B HENATOCRIT DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY R0O79
FUPAZOLIDONE B HENATOCRIT DEC V NAY CAUSE HEMOLYSIS WITH G-6--PD DZ?ICIENCY 90079
FUROSENIDE B HENATOCHIT DEC V MAY CAUSE ANEMIA 90452
GLtJCOSULFONE B HENATOCRIT DEC V HENOLYTIC ANEMIA 90240
GOLD B HENATOCRIT DEC V APLASTIC ANEMIA 90933
HYDPALAZINE B HENATOCRIT DEC V MAY CAUSE HEMOLYTIC ANEMIA 90014
HYDROFLUNETHIAZIDE B HENATOCRIT DEC V PANCYTOPENIA P0991
INDONETHACIN B HENATOCRIT DEC V 2NDARY TO G. I . BLEED/AGRA NULOCYTOSI S/PA NCYTOPENI A HO 120
ISOCAPBOXAZID B HEMATOCRIT DEC V NAY OCCASIONALLY PRODUCE ANEMIA 90657
ISONIAZID B HEMATOC9IT DEC V HEMOLYTIC ANEMIA/PARE MEGALOBLASTIC ANEMIA 90620
LEAD B H!NATOCRIT DEC V HEMOLYTIC ANEMIA P02140
LEVODOPA B HEMATOCHIT DEC V MILD NOT RELATED TO HEMOLYSIS 90026
LYSOL B H!!ATOCRIT DEC V NAY CAUSE INTRAVASCULAR HENOLYSIS 90197
MAO INHIBITORS B HEMATOCRIT DEC V OCCASIONAL ANEMIA MAY OCCUR P0557
MEFENAMIC ACID B HENATOCRIT DEC V MAY CAUSE AUTOIMNUNE HEMOLYTIC ANEMIA 90313
MELAPSONYL B HEMATOCHIT DEC V MAY CAUSE HEMOLYTIC ANEMIA IN G-6-PD DEFICIENCY 90026
MELPHALAN B HEMATOCRIT DEC V ANEMIA MAY OCCUR RARELY P0657
MEPHENYTOIN B HENATOCRIT DEC V HENOLYTIC/APLASTIC/MEGALOBLASTIC ANEMIA 3O84

N EPP 0 B AN ATE B HEMATOCHIT DEC V MAY CAUSE APLASTIC ANEMIA HO 104
NERCAPTOPURINE B HEMATOCRIT DEC V NAY OCCUR WITH BONE-NARROW DEPRESSION P0 657
NETFORMIN B HENATOCRIT DEC V NAY B! ASSOC WITH MEGALOBLASTIC ANEMIA P0935
!!THOPHENOBARBITAL B HINATOCRIT DEC V NAY CAUSE MEGALOBLASTIC ANEMIA P0620
METHOTPEXATE B HEMATOCPIT DEC V NAY MEGALOBLASTIC ANEMIA (FOLIC ACID ANTAGONIST) R0976
NET HYLDOPA B HENATOCRIT DEC V AUTOIMMUNE HEMOLYTIC ANEMIA HO 189
N!THYLENE BLUE B HEMATOCPIT DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
NALIDIXIC ACID B HENATOCRIT DEC V HENOLYTIC ANEMIA WITH G-6-PD DEFICIENCY HO 093
NA PH TB A LEN E B HENATOCHIT DEC V NAY CAUSE HENOLYSIS WITH G-6-PD DEFICIENCY P00 79
NEONYCIN B H!MATOCPIT DEC V NEGALOBLASTIC ANEMIA (IMPAIRED B12 ABSORP) HO 976
NIRIDAZOLE B HEMATOCRIT DEC V OCCURS WITH MARKED HENOLYSIS P0384
NITRITES B HENATOCRIT DEC V NAY CAUSE HENOLYTIC ANEMIA P06 20
NITPOBENZEN! B HENATOCRIT DEC V OCCURS WITH HEMOLYSIS P 06 58
NITROFUPANS B HEMATOCRIT DEC V NAY CAUSE HEMOLYTIC ANEMIA IF G-6-PD DEFICIENCY P0026
NITROFURA NTOIN B HEMITOCRIT DEC V NEGALOBLASTIC ANEMIA/HYPERSENSITIVITY (G-6-PD) P 06 33
NITROFUPAZONE B HEMATOCRIT DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
NOVOBIOCIN B HENATOCPIT DEC V HENOLYTIC ANEMIA - MILD P0218
ORAL CONTRACEPTIVE B H!NATOCPIT DEC V NAY CAUSE MEGALOBLASTIC ANEMIA P 07 91
OXALATES B HEMATOCPIT DEC N SHRINKS PBC, PLASMA VOL INC UP TO 13% P0 436
OXY PH 1 NB UTA ZON I B HENATOCHIT DEC V DILUTIONAL EFFECT OF WATER RETENTION P03 84
PAMAQUINE B HEMATOCRIT DEC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS P0240
PFNICILLA MINE B HEMATOCRIT DEC V HYPOCHRONIC ANEMIA IN CHILD, MENSTRUATING WOMAN 90022
PENICILLIN B HEMATOCRIT DEC V HEMOLYTIC ANEMIA DUE TO BINDING TO ERYTHROCYTES HO 2 94
PENTA MI DI N! B HENATOCRIT DEC V MEGALOBLAST ANEMIA-INHIBITS DIHYDROFOLATE REDUCTASE HO 976
PE N TAQ UI NE B HENATOCRIT DEC V NAY CAUSE HENOLYSIS WITH G-6-PD DEFICIENCY 90079
PHENACEMIDE B HEMATOCPIT DEC V APLASTIC ANEMIA P0026
PHENAZOPYRIDINE B HEMATOCPIT DEC V HFNOLYTIC ANEMIA (SENSITIVITY DEPENDENT) HO 240
PH!NFOPMIN B HEMATOCRIT DEC V THEORETICAL EFFECT OP FOLATE OR 912 DEFICIENCY P079 1
PHENOBARBITAL B HEMATOCRIT DEC V MEG. ANEMIA 2ND TO DISTURBANCE IN FOLIC ACID METAB. P0775
PHENOT HIAZINES B HENATOCRIT DEC V HENOLYTIC ANEMIA (SENSITIVITY DEPENDENT) RO24O
PH ENYLBUTAZ ONE B HEMATOCRIT DEC V RN DEPR!SSION/2ND TO NA AND H20 RETENTION HO 177
PHENYLHYDRAZINE B HEMATOCRIT DEC V HEMOLYTIC ANEMIA P0240
PHYTONADI ONE B HENATOCRIT DEC V HEMOLYSIS MAY OCCUR WITH G-6-PD DEFICIENCY P0620
PIPERACETAZINE B HEMATOCRIT DEC V MILD TRANSIENT DECREASE WITH HYPOTENSION P0 353
PIPEPAZINES B HENATOCHIT DEC V NAY CAUSE HEMOLYTIC ANEMIA P06 36
PIPOBROM AN B HEMATOCRIT DEC V INTENDED EFFECT WHEN POLYCYTHEMIA PRESENT RO1467
PLASNOQUI N B HEMATOCRIT DEC V NAY CAUSE HENOLYTIC ANEMIA H 06 20
PREGNANCY B HEMATOCPIT DEC V IN RELATION TO DECREASED HEMOGLOBIN HO 29 1
PRILOCAINE B HENATOCRIT DEC V HEMOLYSIS WITH DOSES GREATER THAN 400 MG P 0026
PHINAQUINE B HENATOCHIT DEC V HENOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS P0240
PRINIDONE B HEMATOCRIT DEC V MEGALOBLASTIC ANEMIA 2ND DIST. IN FOLIC ACID METAB. P077 5
PROBENECID B HEMATOCRIT DEC V HEMOLYTIC ANEMIA (SENSITIVITY DEPENDENT) P0 240
PYRAZINAMIDE B HEMATOCRIT DEC V RAPE ANEMIA REPORTED P06 57
PY P AZ OL ON ES B HEMATOCRIT DEC V APLASTIC/HENOLYTIC ANEMIA P06 20
PYRINETHAMI NE B HENATOCRIT DEC V MEGALOBLASTIC ANEMIA P 1007
QUI NACRIN! B HENATOCPIT DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
QUINIDINE B HENATOCPIT DEC V HEMOLYTIC ANEMIA (SENSITIVITY DEPENDENT) G-6-PD DIP P0 9 53
QUININE B HEMATOCRIT DEC V HENOLYTIC ANEMIA (SENSITIVITY DEPENDENT) 6-6-PD DIP P0090
QUINOCIDE B HENATOCRIT DEC V MAY CAUSE HENOLYSIS WITH G-6-PD DEFICIENCY 90518
RADIOGRAPHIC B HEMATOCRIT DEC V TRANSIENT FALL FOLLOWING RAPID I.V. INJECTION P0194
RESORCIN B HENATOCRIT DEC V HENOLYTIC ANEMIA P06 57
RESORCI NOL B HEMATOCRIT DEC V INJECT OR EXCESS ABSORP NAY CAUSE HEMOLYSIS 90026
SALICYLAZOS ULFAPYR B HENATOCRIT DEC V MAY CAUSE HEMOLYTIC ANEMIA HO 620
SPECTINONYCIN B HEMATOCRIT DEC V MECHANISM NOT DISCUSSED P00 145
STI BOP HEN B NEMATOCRIT DEC V MAY PRODUCE HEMOLYTIC ANEMIA RO636
STREPTONYCIN B HEMATOCRIT DEC V HEMOLYTIC ANEMIA (SENSITIVITY DEPENDENT) P02140
SULFACETAMI DI B H!NATOCRIT DEC V NAY CAUSE HEMOLYSIS IF G-6-PD DEFICIENCY P0079
SULFADIAZINE B HEMATOCRIT DEC V MAY CAUSE HEMOLYTIC ANEMIA H 0620
SULFA METHI ZOL! B H!MATOCRIT DEC V HENOLYTIC ANEMIA RO751
SULFAMETHOXAZOLE B HIMATOCRIT DEC V MAY CAUSE HENOLYTIC ANEMIA HO 542
SULFAMETHOXYPYRI D B HEMATOCRIT DEC V HEMOLYTIC/APLASTIC ANEMIA P0620
SULFANILANIDE B HENATOCRIT DEC V NAY CAUSE HEMOLYTIC ANEMIA P0079
SULFA PYRI DINE B HEMATOCRIT DEC V MAY CAUSE HENOLYTIC ANEMIA P00 79
SULFISOXAZOLE B H!MATOCRIT DEC V AGRANULOCYTOSIS/APLASTIC ANEMIA 90751
SULFONAMIDES B HENATOCRIT DEC V MAY CAUSE HEINZ-BODY HENOLYTIC ANEMIA R0736
SULFONES B HEMATOCRIT DEC V MAY CAUSE HENOLYSIS P0026
SULFOX ONE B HEMATOCRIT DEC V MAY CAUSE HEMOLYTIC ANEMIA 90079
SURAMIN B HEMATOCRIT DEC V HEMOLYTIC ANEMIA REPORTED P0026
TETRACYCLINE B HENATOCRIT DEC V MAY CAUSE HEMOLYTIC ANEMIA R0620
THIAZOLSULFONE B HEMATOCRIT DEC V NAY CAUSE HENOLYTIC ANEMIA P0620
THIOPIDAZINE B HEMATOCRIT DEC V SIGNIFICANT DECREASE REPOTED R01456
THIOSEMICAPSAZONES B HENATOCRIT DEC V LARGE DOSE EFFECT P03 84
THIOTEPA B HIMATOCRIT DEC V MAY BE RAPID DECREASE HO 6 57
TOLBUTAMIDE B HENATOCRIT DEC V AGRANULOCYTOSIS/APLASTIC ANEMIA P0024
TOLUIDINE BLUE B HEMATOCRIT DEC V MAY CAUSE HEMOLYSIS WITH 6-6-PD DEFICIENCY HO 1014
TRIAMTERENE B HENATOCRIT DEC V MAY CAUSE NEGALOBLASTIC ANEMIA(FOLIC AC ANTAGONIST) P0976
ER IMET HAD 10 NE B HENATOCRIT DEC V APLASTIC ANEMIA P0784
TRIMETHOPPI N B HEMATOCRIT DEC V FOLIC ACID ANTAGONIST ?MEGALOBLASTIC ANEMIA P0976
TRINITROTOLUENE B HEMATOCRIT DEC V MAY CAUSE HEMOLYSIS P06 58
TRY PELENNAN IN! B HINATOCRIT DEC V HEMOLYTIC ANEMIA P0 24 0
TYROTHRICIN B HENATOCRIT DEC V NAY CAUSE HEMOLYSIS EVEN IF APPLIED TOPICALLY P00 26
UP ETH A N B HEMATOCRIT DEC V NAY OCCUR WITH BONE NARROW DEPRESSION P0657
VITAMIN A B HEMATOCRIT DEC V ANEMIA OBSERVED P06 57
VITAMIN K B HENATOCRIT DEC V K3 AND K4 ONLY, ESP WITH G-6-PD DEFICIENCY P05 70
AN DR 0 GE N S B HEMATOCRIT INC V ASSOCIATED WITH INCREASED WELL BEING P0026
C YCL OPRO PA NE B HEMATOCPIT INC V POSSIBLE EFFECT DUE TO DEC PLASMA VOLUME P0384
DR OMO ST AN OL ONE B HEMATOCRIT INC V RESPONSE TO ANDPOGENS P0026
ORAL CONTRACEPTIVE B HEMATOCRIT INC V PROBABLY PROGESTOGEN EFFECT P09 18
VITAMIN B12 B HEMATOCRIT INC V SUCCESSFUL TREAT MAY CAUSE MILD POLYCYTHEMIA P0657
ACETA NINOPH!N B HEMOGLOBIN DEC V ANEMIA/PANCYTOPENIA P0026

ACETANILID B HEMOGLOBIN DEC V !IEMOLYTIC ANEMIA P0656
ACETAZOLANIDE B HEMOGLOBIN DEC V ANEMIA DUE TO PANCYTOPENIA/AGPANULOCYTOSIS 90620
ACETOHEXAMIDE B HEMOGLOBIN DEC V MAY CAUSE ANEMIA AND HEMOLYSIS IF G-6-PD DEFICIENCY P0298
ACETOPHENETIDIN B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA P02 40
ACETYLPHENYLHYDPAZ B HEMOGLOBIN DEC V NAY CAUSE HENOLYTIC ANEMIA P0620
ACETYLSALICYLIC AC B HEMOGLOBIN DEC V DEPRESSES BONE MARROW, G.I. BLEEDING, HEN ANEMIA R024O
ACETYLSULPANILANIDE B HEMOGLOBIN DEC V MAY CAUSE HENOLYTIC ANEMIA 90518
ALLOPURINOL B HEMOGLOBIN DEC V RAPE CASE OF ANEMIA REPORTED 90026
ANINOBENZOIC ACID B HEMOGLOBIN DEC V INDUCES MALABSORPTION AND MEGALOBLASTIC ANEMIA P07 16
AMINOPYRINE B HEMOGLOBIN DEC V HENOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS P0240
AMINOSALICYLIC AC B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA/MEGALOBLASTIC ANEMIA HO 2 140
AMPHETAMINES B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA (DEPENDS ON PRIOR SENSITIVITY) P02 40
AMPHOTEPICIN B B HEMOGLOBIN DEC V BONE MARROW DEPRESSION WITH HEMOLYTIC ANEMIA R0945
ANTICONVULSANTS B HEMOGLOBIN DEC V NAY CAUSE MEGALOBLASTIC/APLASTIC ANEMIA HO791
ANTIMALAHIALS B HEMOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA 90518
ANTIPYRETICS B HEMOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA 90518
ANTIPYRINE B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS R0240
ARSENICALS P HEMOGLOBIN DEC V MEGALOBLASTIC A NEMIA/PANCYTOPENIA 90240
ASPAPAGINASE B HEMOGLOBIN DEC V MAY CAUSE ANEMIA 90427
BARBITURATES B HEMOGLOBIN DEC V NAY CAUSE MEGALOBLASTIC ANEMIA 90976
BENZ!NE B HEMOGLOBIN DEC V DUE TO APLASTIC ANEMIA P 03 814
BENZOCAINE B HEMOGLOBIN DEC V MAY CAUSE HEMOLYSIS P0 121
BRONATE B HEMOGLOBIN DEC V NAY CAUSE HEMOLYSIS P 03 84
BUSULFAN B HEMOGLOBIN DEC V PANCYTOPENIA/HEMOLYTIC ANEMIA R0467
BUTAPEPAZINE B HEMOGLOBIN DEC V TRANSITORY ANEMIA REPORTED P00 26
CARBAMAZEPINE B HEMOGLOBIN DEC V PANCYTOPENIA P0 278
CARBENICILLIN B HEMOGLOBIN DEC V HENOLYTIC ANEMIA REPORTED 901467
CARBON DISULFIDE B HEMOGLOBIN DEC V HYPOCHPOMIC ANEMIA COMMON HO 2 514
CEPHALOPIDINE B HEMOGLOBIN DEC V MAY CAUSE ANEMIA 90026
CEPHALOTHIN B HEMOGLOBIN DEC V COOMBS POSITIVE HEMOLYTIC ANEMIA P0 392
CHLOPAMPHENICOL B HEMOGLOBIN DEC V NORMALLY SLIGHT RESPONSE/MAY BE PANCYTOPENIA P0272
CHLORATE B HEMOGLOBIN DEC V CAUSES HEMOLYSIS P0384
CHLOROQUINE B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS R0912
CHLOROTHIAZIDE B HEMOGLOBIN DEC V PANCYTOP!NIA 90024
CHLORPPONAZINE B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA 90 222
CHLOPPROPANIDE B HEMOGLOBIN DEC V MILD ANEMIA, RAPE APLASTIC ANEMIA P0733
CHOLESTYRAMINE B HEMOGLOBIN DEC V IMPAIRS ABSORPTION OF IRON 905140
COLCHICINE B HEMOGLOBIN DEC V MEGALOBLASTIC ANENIA(IMPAIRED ABSORP B12) 90976
COPPER B HEMOGLOBIN DEC V MAY BE MARKED DECREASE P0 657
COPTICOSTEPOIDS B HEMOGLOBIN DEC V MAY CAUSE G.I. BLEEDING WITH LOW FE STORES 90104
CYCLOSFPINE B HEMOGLOBIN DEC V MAY CAUSE MEGALOBLASTIC ANEMIA P0976
CYTARABINE B HEMOGLOBIN DEC V MAY CAUSE ANEMIA O620
DACTINONYCIN B HEMOGLOBIN DEC V NAY CAUSE ANEMIA P0 02 6
DEHYDROCHOLIC ACID B HEMOGLOBIN DEC V MILD HEMOLYTIC ACTION IF INJECTED P002 6
DIAMINODI PHENYLSIYLF B HEMOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P04 51
DIMERCAPROL B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS R02140
DINITROPHENOL B HEMOGLOBIN DEC V MAY CAUSE ANEMIA/APLASTIC ANEMIA P03 84
DIPHFNHYDRAMINE B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA P09 32
DIPHENYLBYDANTOIN B HEMOGLOBIN DEC V MEGALOBLASTIC/HE MOLYTIC/APLASTIC ANEMIA, PANCYTOPEN P0 873
DIPYRONE B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA P0 569
DOXAPRAM B HEMOGLOBIN DEC V NOTED POSTOPERATIVELY IN A FEW PATIENTS P00 10
EDTA B HEMOGLOBIN DEC V MAY OCCUR WITH PROLONGED THERAPY P00 26
ESTROGENS B HEMOGLOBIN DEC V IMPAIRS ABSORPTION OF FOLATE HO 976
ETHANOL B HEMOGLOBIN DEC V MAY AFFECT FOLIC ACID ABSORPTION AND USAGE P0 976
ETHOSUXIMIDE B HEMOGLOBIN DEC V APLASTIC ANEMIA R0026
AVA BEANS B HEMOGLOBIN DEC V MAY CAUSE HENOLYSIS WITH G-6-PD DEFICIENCY 90079
FIBRIN HYDPOLYSAT! B HEMOGLOBIN DEC V ?DUE TO SEPTICEMIA OP HYPOPHOSPHATEMIA P09 68
FURALTADONE B HEMOGLOBIN DEC V MAY CAUSE HENOLYSIS WITH G-6-PD DEFICIENCY P0079
PURAZOLIDONE B HEMOGLOBIN DEC V NAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY 90079
FUPOSEMIDE B HEMOGLOBIN DEC V NAY CAUSE ANEMIA P0452
GLUCOSULFONE B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA P024 0
GOLD B HEMOGLOBIN DEC V APLASTIC ANEMIA 90933
HYDRALAZINE B HEMOGLOBIN DEC V NAY CAUSE HEMOLYTIC ANEMIA R0O14
HYDROFLUMETHIAZIDE B HEMOGLOBIN DEC V PANCYTOPENIA 90991
INDONETHACIN B HEMOGLOBIN DEC V 2NDARY TO G.I.BLEED/AGRANUL0CYTOSIS/PANCYTOPENIA R0120
ISOCARBOXAZID B HEMOGLOBIN DEC V NAY OCCASIONALLY PRODUCE ANEMIA RO657
ISONIAZID B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA/RARE MEGALOBLASTIC ANEMIA 90620
LEAD B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA P0240
LEVODOPA B HEMOGLOBIN DEC V MILD NOT RELATED TO HEMOLYSIS P0026
LIPONUL B HEMOGLOBIN DEC V MAY B! SEVERE H!NOLYTIC ANEMIA 90657
LYSOL B HEMOGLOBIN DEC V NAY CAUSE INTRAVASCULAR HENOLYSIS 90197
MAO INHIBITORS B HEMOGLOBIN DEC V OCCASIONAL ANEMIA NAY DEVELOP RO657
NEFENAMIC ACID B HEMOGLOBIN DEC V NAY CAUSE AUTOIMMUNE HEMOLYTIC ANEMIA P0313
NELAPSONYL B HEMOGLOBIN DEC V NAY CAUSE HEMOLYTIC ANEMIA IN G-6-PD DFFICIENCY 90026
MELPHALAN B HEMOGLOBIN DEC V ANEMIA NAY OCCUR RARELY P06 57
MEPHENYTOIN B HEMOGLOBIN DEC V HENOLYTIC/APLASTIC/MEGALOBLASTIC ANEMIA P0784
NERCAPTOPURINE B HEMOGLOBIN DEC V NAY OCCUR WITH BONE-NARROW DEPRESSION P0657
NETFOPMIN B HEMOGLOBIN DEC V ASSOCIATED WITH IMPAIRED 912 ABSORPTION 90935
METHOPHENOBARBITAL B HEMOGLOBIN DEC V MAY CAUSE MEGALOBLASTIC ANEMIA 90620
NETHOTREXATE B HEMOGLOBIN DEC V MAY = MEGALOBLASTIC ANEMIA (FOLIC ACID ANTAGONIST) P0976
METHYLDOPA B HEMOGLOBIN DEC V AUTOINMUNE HEMOLYTIC ANEMIA P0 189
METHYLENE BLUE B HEMOGLOBIN DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY 90079
NITHPANYCIN B HEMOGLOBIN DEC V REVERSIBLE EFFECT 90026
NALIDIXIC ACID B HEMOGLOBIN DEC V HENOLYTIC ANEMIA WITH G-6-PD DEFICIENCY 90093
NAPHTHALENE B HEMOGLOBIN DEC V NAY CAUSE HEMOLYSIS WITH G-6-PD DEFICI1NCY 90079
NEONYCIN P HEMOGLOBIN DEC V NEGALOBLASTIC ANEMIA(IMPAIRED B12 AB3OFP) P0976
NEOSALVARSAN B HEMOGLOBIN DEC V NAY CAUSE HEMOLYSIS 90518
NIPIDAZOLE B HEMOGLOBIN DEC V OCCURS WITH MARKED HEMOLYSIS 90384
NITRITES B HEMOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA RO62O
NITPOBENZENE B HEMOGLOBIN DEC V OCCURS WITH HEMOLYSIS P0658

NITROPURANS B HEMOGLOBIN DEC V MAY CAUSE HENOLYTIC ANEMIA IF G-6-PD DEFICIENCY P00 26
NI TPOFU PA NTOI N B HEMOGLOBIN DEC V MEGALOBLASTIC ANEMIA/HYPERSENSITIVITY (G-6-PD) R06 33
NITROFUPA ZONE B HEMOGLOBIN DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
NOVOBIOCIN B HEMOGLOBIN DEC V HENOLYTIC ANEMIA - MILD P02 18
ORAL CONTRACEPTIVE B HEMOGLOBIN DEC V MAY CAUSE MEGALOBLASTIC ANEMIA P0 79 1
OXY PH 1 NB U TA ZONE B HEMOGLOBIN DEC V DILUTIONAL EFFECT OF WATER RETENTION P03 84
PANAQUINE B HEMOGLOBIN DEC V HENOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS P0240
PENICILLA MINE B HEMOGLOBIN DEC V HYPOCHROMIC ANEMIA IN CHILD, MENSTRUATING WOMAN P0022
PENICILLIN B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA DUE TO BINDING TO ERYTHROCYTES P0294
PENTA NIDINE B HEMOGLOBIN DEC V MEGALOBLAST ANEMIA-INHIBITS DIHYDROFOLATE PEDUCTASE P0976
PENTAQUINE B HEMOGLOBIN DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
PHENACENIDE B HEMOGLOBIN DEC V APLASTIC ANEMIA P0026
PHENAZO PYPI DINE B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA (SENSITIVITY DEPENDENT) P0240
PHENETHICILLIN B HEMOGLOBIN DEC V THEORETICAL EFFECT OF PENICILLINS P0 467
PHENFORMIN B HEMOGLOBIN DEC V THEORETICAL EFFECT OF FOLATE OP B12 DEFICIENCY P0791
PHENOBARBITA L B HEMOGLOBIN DEC V MEG. ANEMIA 2ND TO DISTURBANCE IN FOLIC ACID NETAB. R0528
PHENOTHIAZI MIS B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA (SENSITIVITY DEPENDENT) P024 0
P HE NYLB UTA Z ONE B HEMOGLOBIN DEC V BM DEPRESSION/2ND TO NA AND H20 RETENTION P0 177
PHENYLHYDRAZIN? B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA P024 0
PHYTONADIONE B HEMOGLOBIN DEC V HEMOLYSIS MAY OCCUR WITH G-6-PD DEFICIENCY P0620
P1 PERACETAZINE B HEMOGLOBIN DEC V MILD TRANSIENT DECREASE WITH HYPOTENSION R0353
PIPERAZINES B HEMOGLOBIN DEC V NAY CAUSE HENOLYTIC ANEMIA R0636
P1 POB P ON A N B HEMOGLOBIN DEC V HENOLYTIC ANEMIA HAS BEEN DESCRIBED P0021
PL ASMOQUIN B HEMOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA R0620
PREGNANCY B HEMOGLOBIN DEC V NORMALLY SLIGHT REDUCTION (NOT BELOW 10 MG/100ML) P0291
PRILOCAINE B HEMOGLOBIN DEC V HEMOLYSIS WITH DOSES GREATER THAN 400 MG P0026
PRIMAQUINE B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS P0240
PRI NIDONE B HEMOGLOBIN DEC V MEGALOBLASTIC ANEMIA 2ND DIST. IN FOLIC ACID METAB. P0775
PROBENECID B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA (SENSITIVITY DEPENDENT) P02140
PYRAZI NANI DI B HEMOGLOBIN DEC V RARE ANEMIA REPORTED P0657
p YR AZOLONES B HEMOGLOBIN DEC V APLASTIC/HENOLYTIC ANEMIA P0 6 20
PY RI METHA NINE B HEMOGLOBIN DEC V NEGALOBLASTIC ANEMIA P1 007
QUINACRINE B HEMOGLOBIN DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
QUINIDINE B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA (SENSITIVITY DEPENDENT) G-6-PD DEF P0953
QUININE B HEMOGLOBIN DEC V HENOLYTIC ANEMIA(SENSITIVITY DEPENDENT)G-6-PD DIP P0090
QUINOCIDE B HEMOGLOBIN DEC V MAY CAUSE HENOLYTIC ANEMIA P05 18
RECUMBENCY B HEMOGLOBIN DEC V AVERAGE MAX DEC OF 5% OCCURS IN 20 NIN P02 97
RESOPCI N B HEMOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P0657
RESORCINOL B HEMOGLOBIN DEC V INJECT OP EXCESS ABSORB NAY CAUSE HEMOLYSIS P0026
RIFAMPIN B HEMOGLOBIN DEC V REPORTED EFFECT P01467
SALICYLAZOSULFAPYR B HEMOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA R0620
SPECTI NOMYCI N B HEMOGLOBIN DEC V MECHANISM NOT DISCUSSED R0045
STIBOPHEN B HEMOGLOBIN DEC V MAY PRODUCE HEMOLYTIC ANEMIA P06 36
STREPTONYCIN B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA (SENSITIVITY DEPENDENT) P0240
SULFACETAMI DE B HEMOGLOBIN DEC V MAY CAUSE HEMOLYSIS IF G-6-PD DEFICIENCY P0079
SULFAD IAZ IN! B HEMOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P0620
SULFAMETHIZOL! B HEMOGLOBIN DEC V HEMOLYTIC ANEMIA P075 1
S ULF A MET H OXA ZOL! B HEMOGLOBIN DEC V NAY CAUSE HEMOLYTIC ANEMIA P05142
SULFA METHOXYPYRI D B HEMOGLOBIN DEC V HEMOLYTIC/APLASTIC ANEMIA P06 2 0
SULFANILA MIDE B HEMOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA R0079
SULFA PYRI DINE B HEMOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P0079
SULFISOXAZOLE B HEMOGLOBIN DEC V AGRANULOCYTOSIS/APLASTIC ANEMIA P075 1
SULFONAMIDES B HEMOGLOBIN DEC V AGFANULOCYTOSIS/HEMOLYTIC ANEMIA/SEN. DEP. (G-6-PD) P0657
SULFONES B HEMOGLOBIN DEC V NAY CAUSE HEMOLYSIS P0026
SU LFOX ONE B HEMOGLOBIN DEC V MAY CAUSE HENOLYTIC ANEMIA P0079
SURAMIN B HEMOGLOBIN DEC V HENOLYTIC ANEMIA REPORTED P0026
TETRACYCLINE B HEMOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA R0620
THIAZOLSULFON! B HEMOGLOBIN DEC V NAY CAUSE HEMOLYTIC ANEMIA R0620
THIORIDAZINE B HEMOGLOBIN DEC V SIGNIFICANT EFFECT REPORTED P0456
THIOSEMICABBAZON ES B HEMOGLOBIN DEC V LARGE DOSE EFFECT R0384
THIOTEPA B HEMOGLOBIN DEC V NAY BE RAPID DECREASE R0657
TOLBUTA MID! B HEMOGLOBIN DEC V AGPANULOCYTOSIS/APLASTIC ANEMIA P0024
TOLUIDINE BLUE B HEMOGLOBIN DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0 104
TRIA NT IRENE B HEMOGLOBIN DEC V MAY CAUSE MEGALOBLASTIC ANEMIA(FOLIC AC ANTAGONIST) P0976
TRINETHADIONE B HEMOGLOBIN DEC V APLASTIC ANEMIA P0784
TRINETHOPPI N B HEMOGLOBIN DEC V FOLIC ACID ANTAGONIST ?MEGALOBLASTIC ANEMIA P0976
TRIMETHYLENEMELA N B HEMOGLOBIN DEC V MAY CAUSE HEMOLYTIC ANEMIA P0620
TRY NITROTOL UENE B HEMOGLOBIN DEC V MAY CAUSE HEMOLYSIS P065 8
TRIPELENNAMINE B HEMOGLOBIN DEC V HENOLYTIC ANEMIA P0 240
TYROTHRICIN B HEMOGLOBIN DEC V NAY CAUSE HENOLYSIS EVEN IF APPLIED TOPICALLY P0026
UREA B HEMOGLOBIN DEC V RAPID INFUSION OF CONC SOLN MAY CAUSE HENOLYSIS RO 299
UP ETH A N B HEMOGLOBIN DEC V MAY OCCUR WITH BONE NARROW DEPRESSION P06 57
VITAMIN A B HEMOGLOBIN DEC V ANEMIA OBSERVED P0657
VITAMIN K B HEMOGLOBIN DEC V K3 AND K4 ONLY, ISP WITH G-6-PD DEFICIENCY P0570
BILIRUBIN B HEMOGLOBIN INC N IN HIGH CONCS AFFECTS. OXY-HENOGLOBIN METHODS 90779
DPOMOSTANOLONE B HEMOGLOBIN INC V RESPONSE TO ANDPOGENS P0026
ERECT POSTURE B HEMOGLOBIN INC V DUE TO REDISTRIBUTION OF BODY WATER P1001
LIPEMIA B HEMOGLOBIN INC N MAY CAUSE ELEVATION BY UP TO 3 G/100ML P0181
MEPROBAM ATE B HEMOGLOBIN INC V MAY CAUSE APLASTIC ANEMIA P0 104
MUSCULAR EXERCISE B HEMOGLOBIN INC V MILD EXERCISE CAUSES TRANSIENT DEC IN BLOOD VOLUME R0436
SMOKING B HEMOGLOBIN INC V SIGNIFICANTLY HIGHER IN SMOKERS P08 14
TOURNIQUET B HEMOGLOBIN INC V VENOUS STASIS MAY CAUSE SIGNIFICANT INCREASE P 100 1
AC ETA NILID P HEMOGLOBIN INC V OCCURS WITH MARKED HEMOLYSIS P05 18
ACETO PHI NET ID IN P HEMOGLOBIN INC V MAY OCCUR WITH HEMOLYSIS P0 5 18
ACETYLSALICYLIC AC P HEMOGLOBIN INC V OCCURS WITH HEMOLYTIC ANEMIA P05 18
AMINOPYR IN! P HEMOGLOBIN INC V NAY OCCUR WITH MARKED HEMOLYSIS P0518
AMYL NITRITE P HEMOGLOBIN INC V IF INTRAVASCULAR HENOLYSIS OCCURS P0656
ANTINALAPIALS P HEMOGLOBIN INC V OCCURS WITH MARKED HENOLYSIS 90518
ANTIPY RETICS P HEMOGLOBIN INC V MAY OCCUR WITH MARKED HENOLYSIS P05 18
COPPER P HEMOGLOBIN INC V NAY OCCUR WITH HEMOLYSIS OF TOXICITY P0124
1.204 CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

DIMERCAPROL P HEMOGLOBIN INC V OCCURS WITH INTRAVASCULAR HEMOLYSIS P0240
MUSCULAR EXERCISE P HEMOGLOBIN INC V LIGHT ACTIVITY CAUSES INC X 3-5, HEAVY INC X 10-30 R0779
NITROFURANS P HEMOGLOBIN INC V OCCURS WITH INTRAVASCULAR HEMOLYSIS P0656
SERUM P HEMOGLOBIN INC N DURING CLOTTING NAY BE 100 FOLD INCREASE P0485
SULFONAMIDES P HEMOGLOBIN INC V MAY OCCUR WITH INTRAVASCULAR HEMOLYSIS HO 656
SULFONES P HEMOGLOBIN INC V MAY OCCUR WITH HEMOLYSIS P0 656
UREA P HEMOGLOBIN INC V RAPID INFUSION OF CONC SOLN NAY CAUSE HEMOLYSIS R0299
STORAGE OF SAMPLE B HEMOGLOBIN Z M STABLE AT ROOM TEMP FOR AT LEAST 1 WEEK P04 36
RPINEPHPI NE P HEMOGLOBIN Z V NO EFFECT OBSERVED WITH INCREASED BLOOD PLOW P04 85
LIPE MIA P HEMOGLOBIN Z V NO EFFECT OBSERVED WITH INDUCED LIPEMIA 90485
MENSTRUATI ON P HEMOGLOBIN Z V NO EFFECT OBSERVED P04 85
MUSCULAR EXERCISE P HEMOGLOBIN Z V NO EFFECT NORMAL ACTIVITY 901485
NICOTINIC ACID P HEMOGLOBIN Z V NO EFFECT OBSERVED WITH INCREASED BLOOD FLOW P04 85
TOURNIQUET P HEMOGLOBIN Z V NO EFFECT OBSERVED WITH LOCAL CIRCULATORY STASIS 90485
GENTA NICI N U HEPARIN SULFATE INC V REACTS WITH HEPARIN TO FORM PRECIPITATE P0268
COPPER E HEXOKINASE DEC V VERY SENSITIVE TO INHIBITION BY COPPER IN VITRO HO 135
RADIOGRAPHIC P HISTAMINE INC V OBSERVED IN SOME PATIENTS IF ADMINISTERED I.V. P0139
THIAZIDES 0 HISTAMINE TEST DEC V FALSE MEG. DUE TO HYPOTENSIVE EFFECT OF DRUG P0 1417
MAO INHIBITORS 0 HISTAMINE TEST INC V ENHANCED RESPONSIVENESS P0373
PROTEIN U HISTIDINE INC V OCCURS AFTER HIGH MEAT DIET 90291
TETRACYCLINE U HISTIDINE INC V UNEXPLAINED MECHANISM P0 3814
AJMALI NE U HMPG INC V RELEASE OF STORED NOREPINEPHRINE 90596
DISULFIRA N U HNPG INC V INHIBTION OF ALDEHYDE DEHYDROGENASE 90596
PA UWOLFI A U HMPG INC V RELEASE OF STORED NOREPINEPHRINE P0596
RESERPINE U HMPG INC V RELEASE OF STORED NOPEPINIPHRINE P0 596
SYROSI NGOPI NE U HMPG INC V RELEASE OF STORED NOREPINEPHRINE 90596
ACETYLSALICYLIC AC U HONOGENTISIC ACID INC N INTERFERES WITH MEASUREMENT PROCEDURE P0356
LIV ODOPA U HONOVANILLIC ACID INC V IN PARKINSONIAN PATIENTS IS RESPONSE TO THERAPY P0 175
ESTRADIOL U HPG EXCRETION DEC V IN OOPHORECTOMIZED OH POSTMENOPAUSAL WOMEN P09 314
ES T RONE U RPG EXCRETION DEC V IN OOPHOPECTONIZED OR POSTMENOPAUSAL WOMEN 90934
PREMARIN U HPG EXCRETION DEC V INHIBITS PITUITARY GONADOTROPHIC FUNCTION P0934
THIOPIDAZINE U HPG EXCRETION DEC V TOTAL GONADOTROPHIC ACTIVITY REDUCED P09 19
AMBULATION U HYDROXYPROLINE DEC V FOLLOWING SEVERAL WEEKS OF BED REST 90471
MITHRA MYCIN U HYDROXYPROLINE DEC V INHIBITION OF BONE RESORPTION OF CALCIUM P0 879
BED PEST U HYDROXYPPOLINE INC V MAXIMAL DURING SECOND MONTH BED PEST P047 1
CORTICOSTEROIDS U HYDROXYPROLINE INC V STIMULATE GROWTH IN CHILDREN 90657
GROWTH HORMONE U HYDROXYPPOLINE INC V METABOLIC EFFECT P03 84
ALLOPURINOL S HYPOXANTHINE INC V INHIBITS XANTHINE OXIDASE (SLIGHT INC ONLY) P00 26
ALLOPURI NOL U HYPOXANTHINE INC V INHIBITS XANTHINE OXIDASE R0026
ACETRI ZOATE S I 131 UPTAKE DEC V DUE TO IODINE COMPONENT OF MATERIAL P0 5 96
ACETYLSALICYLIC AC S I 131 UPTAKE DEC V WITH LARGE DOSES AND CHRONIC ADMINISTRATION R0408
ADIPIODONE S I 131 UPTAKE DEC V DUE TO IODINE COMPONENT OF MATERIAL P05 96
ANINOB!NZOIC ACID S I 131 UPTAKE DEC V NAY IMPAIR UPTAKE 90596
ANINOGLUTETHINIDE S I 131 UPTAKE DEC V REPORTED EFFECT P0 596
AMINOSALICYLIC AC S I 131 UPTAKE DEC V MAY CAUSE GOITPOUS HYPOTHYPOIDISM P07 36
AM PHENON I S I 131 UPTAKE DEC V REPORTED EFFECT P0255
ANTIHISTAMINES S I 131 UPTAKE DEC V UNCOMMON REPORTED EFFECT P0 596
BENZI ODARONE S I 131 UPTAKE DEC V DUE TO IODINE COMPONENT OF DRUG P0596
CAPBUTAMIDE S I 131 UPTAKE DEC V SUBSTANTIAL EFFECT OBSERVED IN ELDERLY P0 255
CHLORDIAZ!POXIDE S I 131 UPTAKE DEC V ?ANTITHYROID EFFECT P0075
COBALT SALTS S I 131 UPTAKE DEC V REPORTED EFFECT P0596
CORTI COTROPIN S I 131 UPTAKE DEC V ?EPFECT ON TSR - LASTS UP TO 8 DAYS P0408
CORTISONE S I 131 UPTAKE DEC V PROBABLY DIMINISHES TSH SECRETION P0657
CYCLOPHOSPHANIDE S I 131 UPTAKE DEC V SINGLE CASE OF DRUG INDUCED MYXEDEMA R02O7
DIATRIZOATE S I 131 UPTAKE DEC V DUE TO IODINE OMPONENT OF MATERIAL 90596
DI AZEPAN S I 131 UPTAKE DEC V CONFLICTING REPORTS ? NO EFFECT P0355
DIIODOHYD ROXY QUI N S I 131 UPTAKE DEC V EFFECT LASTS FOR SEVERAL WEEKS P01417
DI NERCAPROL S I 131 UPTAKE DEC V ELEMENTAL IODINE TRAPPED IN THYROID P0620
DIPROTIZOATE S I 131 UPTAKE DEC V DUE TO IODINE COMPONENT OF DRUG P0 596
DISULFIRAN S I 131 UPTAKE DEC V UNCOMMON REPORTED EFFECT P05 96
DITHIAZINE S I 131 UPTAKE DEC V DUE TO IODINE COMPONENT OF DRUG HO 596
GALLAMI NE S I 131 UPTAKE DEC V DUE TO IODINE COMPONENT OF DRUG P05 96
GL UCOCORT ICO IDS S I 131 UPTAKE DEC V ASSOCIATED WITH REDUCED BMR HO 596
INDOCYANINE GREEN S I 131 UPTAKE DEC V CONTAINS IODINE, INHIBITS FURTHER UPTAKE 90596
IODOALPHIONIC ACID S I 131 UPTAKE DEC V ORGANIC IODINE CONTAMINATION P0 355
IODOCHLORHYDROXYQU S I 131 UPTAKE DEC V CONTAINS ORGANICALLY BOUND IODINE 90578
I000FORM S I 131 UPTAKE DEC V ORGANICALLY BOUND IODINE, INHIBITS FURTHER UPTAKE 90596
IODOPYPACET S I 131 UPTAKE DEC V DUE TO IODINE COMPONENT OF MATERIAL 90596
IODOTHIOU PA CIL S I 131 UPTAKE DEC V DRUG CONSISTS OF ORGANICALLY BOUND IODINE P02 55
IOPANOIC ACID S I 131 UPTAKE DEC V DUE TO IODINE COMPONENT OF MATERIAL 90596
IOPHENOXIC ACID S I 131 UPTAKE DEC V DUE TO IODINE COMPONENT OF MATERIAL P05 96
IOPYDONE S I 131 UPTAKE DEC V DUE TO IODINE COMPONENT OF MATERIAL P0 596
IOTHALAMATE S I 131 UPTAKE DEC V INTERFERES WITH UPTAKE P0026
IPODATE S I 131 UPTAKE DEC V INTERFERES WITH UPTAKE P00 26
ISONIAZID S I 131 UPTAKE DEC V REDUCES UPTAKE R0596
ISOPROPAMIDE S I 131 UPTAKE DEC V CONTAINS IODINE - REDUCES FURTHER UPTAKE P014 17
LEVOTHYROXI NE S I 131 UPTAKE DEC V DUE TO METABOLIC EFFECT OF DRUG 90596
LIOTH YRONINE S I 131 UPTAKE DEC V EXCEPT IN HYPERTHYROIDISM P0 596
LIPIODOL S I 131 UPTAKE DEC V INTERFERES WITH UPTAKE R0026
METANDIENONE S I 131 UPTAKE DEC V ALSO MODIFIES BINDING OP THYROID HORMONES 90657
METHI MAZOLE S I 131 UPTAKE DEC V EFFECT MAY LAST FROM 2 TO 8 DAYS P01408
NANDROLON I S I 131 UPTAKE DEC V ANABOLIC EFFECT R07O8
OX YPHE NBIJ TA ZONE S I 131 UPTAKE DEC V SAME ACTION AS OTHER DRUGS OF CLASS 90657
PARABRONDYLANIN! S I 131 UPTAKE DEC V EFFECT OBSERVED IN SOME PATIENTS P02 55
PENICILLIN S I 131 UPTAKE DEC V IF HYDRIODIDE SALT GIVEN DECS FURTHER UPTAKE P0596
PHENINDIONE S I 131 UPTAKE DEC V UNCOMMON REPORTED EFFECT P0596
PHENIODOL S I 131 UPTAKE DEC V DUE TO IODINE COMPONENT OF MATERIAL P0 596
PH ENYLBUTAZONE S I 131 UPTAKE DEC V MAY LAST UP TO TWO WEEKS 90838
PROPYLTHIOUP ACIL S I 131 UPTAKE DEC V EFFECT LASTS UP TO 8 DAYS P04 17
RESOP.CINOL S I 131 UPTAKE DEC V REPORTED EFFECT OF TREAT. OF VARICOSE ULCERS P0 3814

SODIUM NITROPRUSSI S I 131 UPTAKE DEC V SINGLE CASE REPORTED (?DUE TO THIOCYANATE) P0702
SULFONAMIDES S I 131 UPTAKE DEC V EFFECT LASTS ABOUT 7 DAYS P014 08
THYROID S I 131 UPTAKE DEC V CONSEQUENCE OF TREATMENT P04 17
TOLBUTA MID! S I 131 UPTAKE DEC V UNCOMMON REPORTED EFFECT 90596
VITAMIN A S I 131 UPTAKE DEC V SIG EFFECT WHEN ADMINISTERED FOR 3 WEEKS P02 55
VITAMIN PREPS S I 131 UPTAKE DEC V IF PREPARATIONS CONTAIN IODINE 90596
BARBI TUBA TES S I 131 UPTAKE INC V ? DUE TO ENZYME INDUCTION HO 596
ESTROGENS S I 131 UPTAKE INC V INCREASED UPTAKE REPORTED P0 596
LITHIUM S I 131 UPTAKE INC V MECHANISM UNCLEAR P0 168
PHENOTHIAZINES S I 131 UPTAKE INC V REPORTED EFFECT IN HYPERTHYROIDISM P04 17
THY POTBOPI N S I 131 UPTAKE INC V RESULTS VARY WITH THYROID STATUS 90596
ANDROGINS S I 131 UPTAKE Z V NO EFFECT ON UPTAKE REPORTED HO 596
BPOMSULFALEIN S I 131 UPTAKE Z V NO EFFECT ON UPTAKE REPORTED P05 96
CAPBIMAZOLE S I 131 UPTAKE Z V NO EFFECT ON UPTAKE BY THYROID P0 596
DEXTPOTHYBOXINE S I 131 UPTAKE Z V NO EFFECT REPORTED 90596
NEPHEN YTOIN S I 131 UPTAKE Z V NO EFFECT REPORTED 90596
MEP A LL U RIDE S I 131 UPTAKE Z V NO EFFECT ON THYROID FUNCTION 90596
NETHYLTRIOUHACIL S I 131 UPTAKE Z V NO EFFECT ON UPTAKE BY THYROID HO 596
ORAL CONTRACEPTIVE S I 131 UPTAKE Z V THYROID FUNCTION UNAFFECTED P0026
P!RCHLORAT! S I 131 UPTAKE Z V NO EFFECT ON UPTAKE HO 596
PERPHE NAZ IN! S I 131 UPTAKE Z V NO EFFECT OBSERVED IN EUTHYPOID SUBJECTS P0596
PROPRA NOLOL S I 131 UPTAKF Z V NO EFFECT IN EUTHYROID PATIENTS P0113
PPOPYLTHIOURACIL S I 131 UPTAKE Z V NO EFFECT REPORTED 90596
THIANAZOLE S I 131 UPTAKE Z V NO EFFECT ON UPTAKE BY THYROID P05 96
#{149}TRIOCYANATE S S I 131 UPTAKE Z V DOES NOT AFFECT UPTAKE BY THYROID HO 596
ALLOPU RI NOL S lCD INC V REVERSIBLE CLINICAL HEPATOTOXICITY REPORTED P05 96
AMINDSALICYLIC AC S lCD INC V NAY CAUSE CYTOTOXIC HEPATOCELLULAR DAMAG P0079
AMODIAQUI NE S lCD INC V REPORTED HEPATOTOXICITY P06 20
AMPHOTEPICIN B S lCD INC V DUE TO HEPATOCELLULAR DYSFUNCTION P0620
ANABOLIC STEROIDS S lCD INC V DUE TO CHOLESTATIC SYNDROME P0596
ANDROGENS S lCD INC V CHOLESTATIC PHENOMENON P06 20
ANTIMONY COMPOUNDS S lCD INC V HEPATOTOXIC EFFECT 90596
ARSENICALS S lCD INC V HEPATOTOXIC EFFECT P0990
CARBON TETRACHLOP S lCD INC V NAY BE EXTENSIVE HEPATIC NECROSIS P0990
CHLOPDIAZ!POXID! S lCD INC V INFREQUENT CHOLESTATIC EFFECT RO620
CHLORPRONAZ IN! S lCD INC V MAY BE HYPERSENSITIVE REACTION P0990
ETHANOL S lCD INC V OCCURS WITHIN 14 HOURS IN NORMAL SUBJECTS P0372
IPRONIAZID S lCD INC V NAY CAUSE CHOLESTATIC AND CYTOTOXIC JAUNDICE P0079
ISONIAZID S lCD INC V CYTOTOXIC HEPATOCELLULAP JAUNDICE P0079
NECHLOPETHAMINE S lCD INC V MAY CAUSE CYTOTOXIC (HEPATOCELLULAR) DAMAGE HO 0 79
METHOTHEXATE S lCD INC V MAY CAUSE CYTOTOXIC HEPATOCELLULAR DAMAGE P0079
PHENYLBUTA ZONE S lCD INC V MAY CAUSE CHOLESTATIC AND CYTOTOXIC JAUNDICE P0079
PREGNANCY S lCD INC V PLACENTAL ORIGIN IN LAST TRIMESTER P0291
TESTOSTERONE S lCD INC V MAY CAUSE CHOLESTATIC AND CYTOTOXIC LIVER DAMAGE P0079
STORAGE OF SAMPLE S lCD Z N NO EFFECT 1 WEEK AT 14 DEGREES, 1 MONTH AT -20 DIG R0998
ACETAM INO PHEN S ICTERIC INDEX INC V NAY CAUSE HEPATIC TOXICITY P0620
CAROTENE S ICTERIC INDEX INC N INTERFERING BACKGROUND COLOR P03 55
CARROTS S ICTEHIC INDEX INC :i COLOR MAY BE MISINTERPRETED HO 355
H!MOGLOB IN S ICTEPIC INDEX INC N CONTRIBUTES BACKGROUND COLOR P0184
HEMOLY 515 S ICTEPIC INDEX INC N PRESENCE OF HEMOGLOBIN PRODUCES RED COLOR P0 438
LIPENIA S ICTEPIC INDEX INC N TURBIDITY OF SERUM P0 355
NOVOBI OCI N S ICTERIC INDEX INC V COMPETITION FOR CONJUGATION MECHANISM P06514
PHOSPHORUS S ICTERIC INDEX INC V DUE TO NEPHPOTOXICITY HO 368
QUINACRINE S ICTEPIC INDEX INC V HEMOLYSIS NAY OCCUR WITH G-6-PD DEFICIENCY P03 55
SWEET POTATOES S ICTERIC INDEX INC N DUE TO COLOR R0356
DIPHENYLHYDANTOI N S IMMUNOGLOBULIN IGA DEC V OBSERVED IN 21% (MECHANISM NOT ELUCIDATED) P0889
ORAL CONTRACEPTIVE S IMNUNOGLOBULIN IGA DEC V ESTROGEN EFFECT 90907
ASPAPAGINAS! S IMMUNOGLOBULIN IGA INC V INCREASED HEPATIC SYNTHESIS P0705
DIAZOXIDE S INMUNOGLOBULIN IGG DEC V EFFECT MAY BE PERSISTENT ? MECHANISM P004 9
ASPARAGINAS! S IMNUNOGLOBULIN IGG INC V INCREASED HEPATIC SYNTHESIS 90705
AZATHIOPIN E S IMNUNOGLOBULIN 1GM DEC V REDUCED WHEN BILIAPY CIRRHOSIS TREATED P0799
ASPARAGINASE S IMMUNOGLOBULIN 1GM INC V INCREASED HEPATIC SYNTHESIS 90705
ESTROG ENS S INMUNOGLOBULINS DEC V ALTERED LIVER METABOLISM P0874
ORAL CONTRACEPTIVE S IMMUNOGLOBULINS DEC V ESTROGEN EFFECT P0 874
ORAL CONTRACEPTIVE S INMUNOGLOBULINS INC V METABOLIC CHANGES IN LIVER SYNTHESIS P05 88
ESTROGENS S INNUNOGLOBULINS Z V NO METABOLIC EFFECT P0072
FORMALIN U INDICAN DEC N PREVENTS OB!RMEYER TEST REACTION P01143
THYNOL U INDICAN Z N NO EFFECT ON OBERNAYER AND JAFFE METHODS P0779
CAR BR ONAL S INDIRECT COONBS TEST P05 V UNUSUAL CAUSE OF HEMOLYTIC ANEMIA P0636
CLONIDINE S INDIRECT COOMBS TEST P05 V MECHANISM NOT DISCUSSED P 1016
MEP HE NYT OIN S INDIRECT COOMBS TEST P05 V MECHANISM OBSCURE P04 18
METHYLDOPA S INDIRECT COONBS TEST P05 V AUTOIMMUNE PHENOMENOM(OCCURS WITH WKS OF TREATMENT) P04 18
PENICILLIN S INDIRECT COOMBS TEST P05 V COMBINES TO RBC, IMMUNOGLOBULINS DEVELOP TO DRUG P0418
RIFAMPIN S INDIRECT COONBS TEST P05 V P05 RESPONSE IN 33% PATIENTS AFTER 3 MONTHS 90748
BY SULFITES S INDOCYANINE GREEN DFC N AS CONTAMINANT OF HEPARIN NAY REDUCE PEAK P0026
CYCLO PR OP AN I S INDOCYANINE GREEN INC V HEPATIC EXTRACTION IMPAIRED AFTER INJECTION P0 384
RIPAMPIN S INDOCYANINE GREEN INC V DELAYED ELIMINATION FOLLOWING I.V. INJECT P0657
ASPAPAGINASE P INSULIN DEC V ?DUE TO DEC PRODUCTION WITH DEC PROTEIN SYNTHESIS HO 180
DIPHENYLHYDANTOIN P INSULIN DEC V REDUCES INSULIN RESPONSE TO GLUCOSE CHALLENGE 90613
ETHACPYNIC ACID P INSULIN DEC V REDUCTION IN FASTING STATE NOTED P0657
ETHER P INSULIN DEC V DUE TO RELEASE OF EPINEPHPINE CAUSING INHIBITION P1014
FUPOSENID! P INSULIN DEC V I.V. INJECTION EFFECT, LITTLE ON BLOOD SUGAR HO 657
HENOLYSIS P INSULIN DEC M CAUSES DESTRUCTION OF HORMONE FOR RADIOIMMUNOASSAY P0150
HE?APIN P INSULIN DEC M EFFECT IN HEPAPINIZED PLASMA AND SERUM P0709
HYDPOCHLOROTHIAZ IDE P INSULIN DEC V I.V. INJECTION HAS EFFECT WITH LITTLE ON SUGAR HO 657
METORMI N p INSULIN DEC V SLIGHT, ALL HYPEPLIPOPROTEINEMIAS, MARKED TYPE IV P0403
PHENFORMIN P INSULIN DEC V EFFECT OBSERVED DURING TOLERANCE TEST P0055
PIDH P INSULIN DEC V REDUCES INSULIN RESPONSE TO GLUCOSE LOAD 90808
AMINO ACIDS P INSULIN INC V ? DUE TO ACTION ON BETA CELLS HO 49 1
ARGININE P INSULIN INC V SLIGHT EFFECT AND METABOLISM BY TISSUES P03 11

CHLOPPROPANI DI P INSULIN INC V EFFECT OBSERVED DUPING TOLERANCE TEST 90600
CYCLIC AMP P I NSU LI N INC V HORMONAL ACTION 90319
GLUCAGON P INSULIN INC V STIMULATES BETA CELLS OF PANCREAS 90817
GLUCOSE P INSU LI N I NC V MARKED RISE IMMEDIATELY AFTER ORAL OP I.V. ADNIN. P1011
GLYBU HIDE P INSULIN INC V SIGNIFICANT INCREASE REPORTED P0595
HEPARIN P INSULIN INC N SPURIOUSLY HIGH VALUES REPORTED FOP IMNUNOASSAY P0064
LEUCINE P INSULIN INC V FACILITATES UPTAKE OF AMINO ACIDS BY TISSUES 90311
LEVODOP A P INSULIN INC V DURING THERAPY OF PARKINSONISM 90509
LYSINE P INSULIN INC V SLIGHT EFFECT, AIDS METABOLISM OF AMINO ACIDS 90311
NAPIHUANA P INSULIN INC V RESPONSIBLE FOP HYPOGLYCEMIA P0273
NET HIONINE P I NSULIN I NC V SLIGHT EFFECT, AIDS METABOLISM OF AMINO ACIDS 90311
NICOTINIC ACID P INSULIN IN C V ?RESPONSE TO INCREASED GLUCOSE OUTPUT R0360
ORAL CONTRACEPTIVE P INSULIN INC V IN WOMEN IN WHOM INSULIN WAS INITIALLY NORMAL 90891
PANCREOZYN IN P INSULIN INC V I.V. INFUSION CAUSES INCREASE P049 1
PHENYLALA NINE P INSULIN INC V SLIGHT EFFECT, AIDS METABOLISM OF AMINO ACIDS P0311
PROTEI N P INSULIN INC V STIMULATION OF BETA CELLS BY AMINO ACIDS P04 91
STPEPTOZOTOCIN P INSULIN INC V ?DUE TO RELEASE FROM DAMAGED BETA CELLS 90686
ROLBUTA MID! P INSULIN INC V MARKED RISE ASSOCIATED WITH HYPOGLYCEMIA P0334
VALINE P INSULIN INC V SLIGHT EFFECT, AIDS NETABOLISZI OF AMINO ACIDS HO 311
XYLITOL P INSULIN INC V ? SANE MECHANISM AS GLUCOSE TO RELEASE IN DOGS 90561
GLUCOSE U INSULIN INC V OCCURS THREE HOURS AFTER GLUCOSE LOAD P0803
DIAZOXIDE U INULIN CLEARANCE DEC V EFFECT OVER 2H OF 14MG/KG GIVEN I.V. ROSOl
PHLORIDZIN U INULIN CLEARANCE DEC V DECREASE OF UP TO 30% 90878
DEX TR A N U INULIN CLEARANCE INC M INTERFERES WITH ANALYTICAL PROCEDURE O657
LEVODOPA U INULIN CLEARANCE INC V ?SEC. TO PENAL VASODIL. OR DIRECT ACTION ON TUBULES HO 328
CITRATES S IONIZED CALCIUM DEC V COMPLEXES CALCIUM (EFFECT OF TRANSFUSIONS) P0743
EDTA S IONIZED CALCITIM DEC V CHELATE5 CALCIUM 90026
HYPERVENTILATION S IONIZED CALCIUM DEC V EFFECT OF RESPIRATORY ALKALOSIS a 08146
MEALS S IONIZED CALCIUM DEC V EFFECT MORE MARKED THAN WITH RESP ALKALOSIS R08146
PH OS PH ATES S IONIZED CALCIUM DEC V SLIGHT EFFECT ABOLISHED BY CA INFUSION H 0770
SUCCINYLCHOLINE S IONIZED CALCIUM INC V RISE NOT MARKED (I.V. ADMINISTRATION) HO 306
ACETYLSALICYLIC AC S IRON DEC V NAY BE MARKEDLY REDUCED WITH LARGE DOSES 903814
ALLOPUR INOL S IRON DEC V 140% REDUCTION IN ONE WEEK (ACCUMULATES IN LIVEP) 90466
CHOLESTYRAMINE S IRON DEC V IMPAIRS ABSORPTION OF IRON 90540
CORTICOTROP IN S IRON DEC V DECREASE IN IRON BINDING GLOBULIN H 100 1
CORTI SONE S IRON DEC V REDUCED SYNTHESIS OF TRANSFERRIN 91001
DIURNAL VARIATION S IRON DEC V TOWARDS LATE AFTERNOON OP EVENING HO 9 98
EDT A S IRON DEC M INTERFERES WITH METHOD OF YOUNG-HICKS P0779
EPINEPHRINE S IRON DEC V 1 ML 1% SOLN I.M. EFFECT FOR 6 HOUR 105
NETFORMI N S IRON DEC V ASSOCIATED WITH IMPAIRED B12 ABSORPTION 90935
MUSCULAR EXERCISE S IRON DEC V RESPONSE TO STRESS OP EXERCISE 901814
PREGNANCY S IRON DEC V FALLS FROM MIDTERM ONWARDS P02 91
ACETOP HENET IDIN S IRON INC V MAY OCCUR WITH CHRONIC HEMOLYSIS 90657
BLOOD TRANSFUSIONS S IRON INC V I FREQUENT MAY CAUSE HEMOCHROMATOSIS HO 596
CHLOPAMPHENICOL S IRON INC V REVERSIBLE TOXIC REACTION 90736
DEXTRAN S IRON INC N CAUSES TURBIDITY WITH METHOD OF YOUNG-HICKS P0779
HEMOLYSIS S IRON INC N INTERFERES WITH COLOPIMETRIC PROCEDURE P04 39
IRON DEXTRAN S IRON INC V INCREASED IRON STORES p0620
IRON SALTS S IRON INC V EFFECT OF I.N. IRON P0355
LI AD S IRON INC V REPORTED EFFECT HO 29 1
ORAL CONTRACEPTIVE S IRON INC V INCREASE IN AVAILABLE BINDING PROTEIN (PLUS 20% INC) P0918
DEFEROXAMINE U IRON INC V PRIMARY AFFINITY FOR TRIVALENT IRON R0026
PENICILLAMINE U IRON INC V I? POISONING DUE TO IRON P0026
BILIRUBIN S IRON Z N NO EFFECT ON IRON MEASUREMENT P0779
HEMOGLOBIN S IRON Z N NO EFFECT UNLESS CONC GREATER THAN 500 MG/100ML P0779
STORAGE OF SAMPLE S IRON Z N NO EFFECT 4 DAYS ROOM TEMP OR 7 DAYS AT 14 DEGREES P 04 36
LEVODOPA U ISO-HOMOVANILLIC ACID INC V RESPONSE TO THERAPY IN PARKINSON PATIENTS P0214
GLUCOSE S ISOLEUCINE DEC V PROBABLE MUSCLE UPTAKE P03 97
OPAL CONTRACEPTIVE S ISOLEUCINE DEC V HORMONAL EFFECT (SECOND PART OF CYCLE P0226
ORAL CONTRACEPTIVE B KAOLIN-CEPHALIN TIME DEC V METABOLIC EFFECT P07146
ACETYLSALICYLIC AC S KETONES DEC V INC OXIDATION OF KETON! BODIES IN DIABETICS P03 84
ACETYLSALICYLIC AC U KETONES DEC V INC OXIDATION OF KETON! BODIES IN DIABETICS 90384
ACETYLSALICYLIC AC S KETONES INC V DUE TO INDUCED ACIDOSIS P036 8
FENFLURA MINE S KETONES INC V (AVERAGE INCREASE OF 57%) 90725
METHANOL S KETON!S INC V MOD EFFECT IN COMPARISON WITH EXTENT OF ACIDOSIS R03 814
P AR AL DEH YDE S KETONES INC V TRANSIENT HYPERGLYCEMIA AND KETOSIS 90596
ACETYLSALICYLIC AC U KETONES INC N REDDISH COLOR WITH GERHARDT’S TEST 90299
PENICILLANINE U KYNURENINE INC V INDUCES PYRIDOXINE ANTAGONISM 90384
GLYCEHIC ACID S LACTATE DEC N HIGH CONCS INTERFERE WIThH ENZYMATIC METHOD 90333
MALIC ACID S LACTATE DEC N INTERFERES WITN ENZYME METHODS 90333
PYRU VA TI S LACTATE DEC N HIGH CONCS INTERFERE WITH ENZYMATIC METHOD R0333
ACETYLSALICYLIC AC S LACTATE INC V DUE TO LATE METABOLIC ACIDOSIS AND RENAL IMPAIR 90384
BUFORMIN S LACTATE INC V RISES BUT NOT USUALLY TO LEVEL OF ACIDOSS P0657
DINERCAPROL S LACTATE INC V ASSOC WITH METABOLIC ACIDOSIS P0026
EPINEPHPINE S LACTATE INC V MARKED EFFECT LIKE BETA-ADPENERGIC COMPS 90384
ETHANOL S LACTATE INC V CAUSES LACTIC ACOSIS P01 87
ETHER S LACTATE INC V METABOLIC EFFECT 91014
FRUCTOSE S LACTATE INC V METABOLIC RESPONSE TO I.V. OP ORAL FRUCTOSE P08 15
HEMOLYSIS S LACTATE INC N DUE TO METABOLIC ACTIVITY OF CELLS P0998
METFORMIN S LACTATE INC V POSSIBLY ALWAYS WITH PREDISPOSING CONDITION P0571
MUSCULAR EXERCISE S LACTATE INC V CONSIDERABLE EFFECT O EXEBCIS! R0998
OPAL CONTRACEPTIVE S LACTATE INC V ALTERATION IN CARBOHYDRATE METABOLISM 90639
PHENFORNIN S LACTATE INC V INHIBITS LACTATE CATABOLISM (BLOCKS TISSUE RESP) P0907
STR!PTOZOTOCI N S LACTATE INC V TEMPORARY EFFEZT FOLLOWING INFUSION 90686
ALDPIN S LACTIC DEHYDROGENASE DEC V IN VITRO 4.5% DEC AT 1X1O-4 N P0 362
ASCORBIC ACID S LACTIC DEHYDROGENASE DEC N AT THERAPEUTIC CONC MAY DEPRESS SMA 12/60 VALUE R0876
CLO F lB PATE S LACTIC DEHYDROGENASE DEC V POSSIBLY DERIVED FROM MUSCLE DAMAGE HO 596
DIELDPIN S LACTIC D!HYDROGENASE DEC V IN VITRO 9.0% DEC AT 1X1O-14 N 90362
FLUORI DES S LACTIC DEHYDROGENASE DEC V IN VIVO INHIBITION WITR LOW DOSES 90338
LINDANE S LACTIC DEHYDROGENASE DEC V IN VITRO 6.1% DEC AT 1X1O-4 N 90362

OX ALA TES S LACTIC DEHYDROGENASE DEC N INHIBITION OF ENZYME ACTIVITY 90929
ETHI ONAMI DE U LACTIC DEHYDROGENASE DEC N INTERFERENCE WITH DETERMINATION PROCEDURE 90758
NITPOFURA NTOIN U LACTIC D!HYDROG!NASE DEC N INTERFERENCE WITH DETERMINATION METHOD 90700
STORAGE O’ SAMPLE U LACTIC DEHYDROGENASE DEC N LOSES ACTIVITY UNLESS ANALYZED IMMEDIATELY RO998
ACTTYLSALICYLIC AC S LACTIC 0EHYD?OGENASE INC V EXPTL EFFECT SEEN IN RABBITS WITH PROLONGED USE HO 806
BI SHYDROYCOUMA PIN S LACTIC DEHYDROGENASE INC V NAY BE HIGH ENOUGH TO SIMULATE NYOCARDIAL INFARCT P00 79
CAR BEN ICILLIN S LACTIC DEHYDOGENAS! INC V TRANSIENT ELEVATIONS REPORTED RO3 814
CODEY NE S LACTIC DEH!DROGENASE INC V MAY CAUSE RISE IN INTRABILIARY PRESSURE P0907
CONTACT WITH CLOT S LACTIC DTHYDR3GENASE INC N HIGH INTRACELLULAR CONC OF LDH ACTIVITY 901436
COPPER S LACTIC DEHYDPOGFNASE INC V TOXIC EFFECT, SHAH? INCREASE WITH HEMOLYCIC CRISIS 90124
HALOT9 AN! S LACTIC DEHYDROGENAS! INC V !1!PATOTOXIC IN RARE CASES, ?IDIOSYNCRACY P0861
H!MOLYSIS S LACTIC DEHYDROGENASE INC N RELEASED FROM RBC’S AND PLATELETS 90355
IMI PRAMINE S LACTIC DE9YDROGENASE INC V MAY CAUSE CHOLESTATIC JAUNDICE RO512
LFVODOPA S LACTIC DEFIYDROGENASE INC V RAPE INSTANCE OF ELEVATION, ?ORIGIN P002 6
MEPEPIDIN! S LACTIC DEHYDROGENASE INC V MAY CAUSE RISE IN INTRABILIARY PRESSURE P0079
ME 19 OTR EX ATE S LACTIC O!HYDROGENASE INC V EFFECT IN 140% CASES OF PSORIASIS (REVERSIBLE) P06 98
NIT9PAMYCIN S LACTIC DE9YDROGENASE INC V HEPATOCELLULAR DAMAGE OBSERVED 90026
MORPHINE S LACTIC DF9YDROGENASE INC V MAY CAUSE RISE IN INTRABILIARY PRESSURE P0 907
MUSCULAR EXERCISE S LACTC OTHYDROGENASE INC V MARKED INCREASE WITH EXERCISE 90779
NI TPOTU? ANOIN S LACTC DEHYROGENASE INC V MAY CAUSE HENOLYTIC ANEMIA 90542
PROPOXY?9ENE S LACTIC DEHYDROGENAS! INC V CHOLESTATIC EFFECT P0538
PROSTATE PALPATION S LACTIC DE9YD?OG!NAS INC V RELEASE INTD BLOODSTREAM P0 1479
SERUM S LACT:C DEHYDHOGENASE INC N U? TO 140% HIGHER THAN PLASMA P0136
SULFAMITHOXAZOLE S LACTIC DEHYDPOGENASE INC V NAY CAUSE HEMOLYTIC ANEMIA 90542
SULFISOXAZOLE S LACTIC DEHYDROGENAS! INC V MAY CAUSE HEMOLYTIC ANEMIA 905142
ACTTYLSALICYLIC AC U LACTIC DEHYDHOGENAS! INC V RENAL IRRITATION & DESQUAMATION OF EPITHELIAL CELLS P0758
PROTEINU PIA U LACTIC HYDROGENAS! INC V IN LARGE NUMBER AND VARIETY RENAL DISEASES 90758
STORAGE OF SAMPLE S LACTIC DEHYDHOGENAS? Z N NO EFFECT 1 WEEK AT 14 DEGREES, 1 MONTH AT -20 DIG R0436
LACTATION TI LACTOSE INC V QUITE COMMON, ESPECIALLY IN AFTERNOON 90291
?STGNANCY U LACTOSE INC V NAY OCCUR IN LAST TRIMESTER ISP IN AFTERNOON 90291
MO 9 P H I NE S LDH ISOENZMYES INC V HIPATIC FRACTION INC ? DUE TO SPASM OF SPHINCTER P0657
AC ETAZOLA MID! 9 LE CELL PR!? ?OS V MAY PRODUCE LI-LIKE SYNDROME 90907
AMINOSALICYLIC AC B LE CELL PHEP 905 V MAY PRODUCE LI-LIKE SYNDROME 90622
CHLOROTHAZIDE B LI CELL PR!? 905 V MAY PRODUCE LI-LIKE SYNDROME HO 910
CHLORPROTHIXENE B LE CELL PREP 905 V NAY PRODUCE LI-LIKE SYNDROME 90910
DIPHENYLHYOANTOI N B LE CELL PR!? POS V REPORTED APPEARANCE OF LI CELLS 90596
ETHOSUXIM IDE B LI CELL PREP 905 V SEVERAL CASES OF LUPUS ERYTHEMATOSUS REPORTED 903814
GRISEOFULVIN B LE CELL PREP P05 V NAY PRODUCE LE-LIKE SYNDROME P09 10
HY DANTOIN S B LE CELL PP!P P05 V MAY CAUSE APPEARANCE OF LI CELLS HO 596
H YD P A LA Z I NE B LE CELL PREP 905 V NOPE COMMON IN SLOW ACETYLATORS 90731
15091 AZI D B LI CFLL PREP P05 V MORE COMMON IN SLOW ACETYLATOPS 90622
MET HYLDODA B LI CELL PREP 905 V AUTOIMMUN! PHENOMENON 90864
METHYLTHIOUPACIL B LE CELL PREP P05 V MAY PRODUCE LI-LIKE SYNDROME P0 907
ORAL CONTRACEPTIVE B LI CELL PREP 905 V MAY PRECIPITATE OR EXAGGERATE LI-LIKE SYNDROME R09O7
OXYPHENI SATIN B LE CELL PREP 905 V MAY CAUSE LUPOID HEPATITIS P0776
PENICILLIN B LI CELL PREP P05 V ALLERGIC RESPONSE WITH JPTICARIA IN ON! CASE P0384
PH ENOLPHTHALEIN B LB CELL PREP 905 V ASSOCIATED WITH HYPERSENSITIVITY P06 57
PH! N YL B UT AZ ONE B LE CELL PR!? P05 V NAY PRECIPITATE OR EXAGGERATE LI-LIKE SYNDROME P0 907
PRINI DONE B LE CELL 9919 POS V SINGLE DRUG RELATED CASE REPORTED 90657
PROCAINAMIDE B LI CELL PREP P05 V REPORTED EFFECT 90562
PROPYLTHIOUHACIL B LE CELL PREP P05 V MA! PRODUCE LE-LIKE SYNDROME 90907
STPEPTOMYCIN B LI CELL PRF P05 V MAY PRODUCE LI LIKE SYNDROME P0 907
SULFONA MID! S B LI CELL PREP P05 V MAY PRODUCE LI-LIKE SYNDROME 90907
TETFACYCLI NE B LI CELL PREP ?OS V MAY PRODUCE LE-LIKE SYNDROME P0907
TRIMETHADIONE B LE CELL PREP P05 V MAY PRODUCE LE-LIKE SYNDROME P0 907
LEAD B LEAD INC V MAY BE INCREASED MUCH ABOVE NORMAL OF 5OUG/100ML 9029 1
DIMEPCAPROL U LEAD INC V IF POISONING DUE TO LEAD P00 26
EDTA U LEAD INC V IF POISONING DUE TO LEAD H 0 026
LEAD U LEAD INC V DUE TO INCREASED BODY LOAD(IN POISONING 8OUG/100ML) P0368
PENICILLANI NE U LEAD INC V IF POISONING DUE TO LEAD 90026
ACETYLSALICYLIC AC U LEUCINE ANINOPEPTIDASE DEC V DUE TO ANTIFIBRINOLYTIC ACTION P0 758
AMINOCAPPOIC ACID U LEUCINE ANINOP!#{176}TIDASE DEC V DUE TO ANTIFIBRINOLYTIC ACTION P0758
ANINONETHYLCYCLOHEX U LEUCINE ANINOPEPTIDASE DEC V DUE TO ANTIFIBPINOLYTIC ACTION P0758
ESTROGENS S LEUCINE AMINOPEPTIDASE INC V ALTERED METABOLISM P0072
MORPHINE S LEUCINE .AMINOPEPTIDAS! INC V POSSIBLY DUE TO SPASM OF SPHINCTER OF ODDI R0657
ORAL CONTRACEPTIVE S LEUCINE AMINOPEPTIDASE INC V POSSIBLE LIVER DAMAGE P0 1412
PREGNANCY S LEUCINE AMINOPEPTIDASI INC V MODERATELY INCREASED THROUGHOUT PREGNANCY HO 29 1
POLYNYXIN B U LEUCINE ANINOPEPTIDASE INC V FACILITATES PERMEATION OF ENZYME INTO TUBULES P0758
PROTFI NURIA U LEUCINE ANINOPEPTIDASE INC V WITH TOXIC RENAL DAMAGE P0758
P59 U LEUCI NE AMINOPEPTIDASE INC V FACILITATES PERMEATION OF ENZYME INTO TU3ULES P0758
RADIOGRAPHIC U L PUC IN! ANINOPEPTIDASE INC V FACILITATES PERMEATION OF ENZYME INTO TUBULES P0758
STREPTOKINASE U LEUCIN! AMINOPEPTIDASE INC V ACTIVATES PEPTIDASES BY PLASMINOGEN R0758
STHEPTOMYCIN U LEUCINE AMINOPEPTIDASE INC V FACILITATES PERMEATION OP ENZYME INTO TUBULES P0758
SULFONAMIDES U LEUCINE AMINOPEPTIDASE INC V FACILITATES PERMEATION OF ENZYME INTO TUBULES P0758
VASOPRESSIN U LEUCINE ANINOPEPTIDASE INC V ACTIVATES PEPTIDASES BY RELEASE OF PLASMINOGEN P0758
X-RAY THERAPY U LEUCINE AMINOPEPTIDASE INC V TOXIC DAMAGE DUE TO RELEASED MITABOLITES P0758
STORAGE OF SAMPLE S LEUCINE AMINOPEPTIDASE Z N NO EFFECT 1 WEEK AT 4 DEGREES, 1 MONTH AT -20 DIG P04 36
STORAGE O SAMPLE U LEUCINE ANINOPEPTIDASE Z N NO EFFECT 1 DAY AT 14 DEGREES, 1 WEEK AT -20 DEG P0 998
GLUCOSE S LEUCINE DE C V PROBABLE MUSCLE UPTAKE HO 397
OPAL CONTRACEPTIVE S LEUCINE DEC V HORMONAL EFFECT (SECOND PART OP CYCLE) R0226
DIETHYLSTILBESTPOL P LH DEC V AT DOSES AFFECTING PIT-GONADAL AXIS P0 525
ESTRADI OL P LU DEC V IN RESPONSE TO I.V. INFUSION FOR SHORT DURATION Ri 012
MEGESTROL P LH DEC V SUPPRESSES LH PEAK R08L17
NOPETHI NDONE P LH DEC V APPARENT SUPPRESSION OF PRODUCTION OR RELEASE R0671
OPAL CONTRACEPTIVE P LH DEC V COMBINATION TYPE PILL LOWERED VALUE TO 20% CONTROL RO 382
PH!NOTHIAZIN!S P LH DEC V STIMULATION EFFECT 0! GONADOTROPINS INHIBITED P0596
PROGESTIN P LH DEC V SUPPRESSES LH PEAK P0847
CHLORMADI NONE U LB DEC V USUAL EFFECT IN NORMAL WOMEN P0900
OPAL CONTRACEPTIVE U LH DEC V MARKED DEPPESSION IN NORMAL SUBJECTS P0900
CLOMIPHENE P LH INC V UP TO 700% IN NORMAL MALES FOR FIRST 21 DAYS P0820

N ES T PA NOL P LB INC V ESTROGEN EXERTS STIMULATOR! ACTION B 1C12
CLOMIPHENE U LH NC V DUE TO ACTION ON HYPOTHALAMIC-PITUITARY AXIS RC693
PREMAPIN U LII INC V MAPKED INITIAL EFFECT, FALLS OFF WITH LARGE DOSE P096 3
CYPHOTEFONE P LB 2 V NO CHANGE FOLLOWING ORAL ADMINSTRATION RC887
TH YR OTROPI N-RELEAS P LH’Z V NO EFFECT IN NORMAL SUBJECTS P0034
HEMOGLOBI N S LIPASE DEC N INHIBITS LIPASE ACTIVITY P0530
HEMOLYSIS S LIPASE DEC N INHIBITION OF LIPASE ACTIVITY 90437
BET HANECHOL S LIPASE INC V MAY CAUSE INC SECR!TIOt, SASN OF SPHINCTER OF ODDI 90 2 SC
CHOLIN!RGICS S LIPASL INC V IMPAIRED XCPETION-SPASM OF SPHINCTER OF ODDI P0384
CODEINE S LIPASE INC V CAUSES SPASM OF SPHINCTR OF 0001 PC 977
ETTIA NOL S LIPASE INC V CHEMICAL OR PHYSICAL PANCREATITIS P0355
I NDONETHACIN S LIPASE INC V ASSOC WITH CHOLESTATIC LIVER DAMAGI PC 355
NEPERIDINE S LIPAS? INC V NAY CAUSE SPASM OF SPHINCTER OF 0001 P 872
METHACHOLINE S LIPASE INC V CONSTRICTS S?HINCTER OF ODDI P0204
NORPHINT S LIPASE INC V CAUSES SPASM OF SPHINCTER OF 0001 RC9C7
NARCOTICS S LIPASE INC V IMPAIRED EXCRETION - SPASM OF SPHINCTER OF ODDI P02014
PA NCREOZYMIN S LIPASE INC N PREPARATION CONTAINS LIPASE P0355
PENTAZOCIN I S LIPASE INC V CAUSES SPASM OF SPHINCTEL OF ODDI P0654
SECRETIN S LIPASE INC V MAY CAUSE SPASM OF SPHINCTER OF ODDI PC 977
SULFIS OXAZOLE S LIPASE INC V RARE EFFECT ON PANCREAS, SALIVARY GLANDS P0657
STORAGI OF SAMPLE S LIPASE Z N NO EFFECT 1 WEEK AT 4 DEGREES, 1 MONTH AT -20 DIG P0436
HEPARIN S LIPOPPOTEIN ELECTROPHOR 90 S N ALTERS ILECTROPHORETIC PATTERN P0536
ASP AR AGINASE S LIPOPROTEIN LIPASE DEC V OBSERVED IN UNUSUAL HYPERLIPIDEMIC RESPONSE P0705
ESTROGENS S LIPOPPOTEIN LIPASE DEC V METABOLIC EFFECT E0C72
ORAL CONTRACEPTIVE S LIPOPPOTEIN LIPASE DEC V REDUCED RESPONSE TO HEPARIN INJECTION P0186
HEPARIN S LIPOPROTEIN LIPASE INC V RELEASE OF TISSUE LIPASE INTO PLASMA RC384
ASPAPAGINASE S LIPOPROTEINS DEC V POSSIBLE DEPRLSSED SYNTHESIS P C42 7
EPINEPHPINE S LIPOPPOTEINS INC V EFFECT ON LOW DENSITY COMPONENTS P0384
ESTROGENS S LIPOPROTEINS INC V IF VERY LOW DENSITY P0874
OPAL CONTRACEPTIVE S LIPOPROTEINS INC V 50% INC AFTER 6 MONTHS US 90907
LITHIU! C LITHIUM INC V CONCENTRAIION ABOUT HALF IN SERUM P0384
LITHIUM S LITHIUM INC V THERAPEUTIC LEVEL BETWEEN .5 AND 1.0 MEQ/L 90384
OX A LAT ES S LITHIUM INC N IF LITHIUM SALT OF OXALATES PC 436
CONTACT WITH CLOT S LITHIUM Z N NO EFFECT OBSERVED OVER 24 HOURS RC’756
SERUM S LITHIUM Z M NO DIFFERNCE OBSENVED 9 0 756
STORAGE OF SAMPLE S LITHIUM Z N NO EFFECT 1 WEEK AT 4 DEGREES, FROZEN FOR MONTHS R0756
ASPARAGINASE B LYMPHOCYTES DEC V SLIGHT REDUCTION (NOT DOSE DEPENDENT) PC 70 5
CHLORANBUCIL B LYMPHOCYTES DEC V MARKED DECREASE MAY OCCUR PC 467
OPTICOTROPIN B LYMPHOCYTES DEC V MARKED DROP OCCURS WITHIN 2 HOURS PC 3814
GLUCOCORTICOIDS B LYMPHOCYTES DEC V ALSO DECREASE IN LYNPHOI TISSUF P C’26
LITHIUM B LYMPHOCYTES DEC V ?DRUG ASSOCIATED ENDOCPINE EFFECT BC 869
MECHLOPETHA MI NE B LYMPHOCYTES DEC V OCCURS WITHIN 24 HOURS BC 3814
METHYSERGIDE B LYMPHOCYTES DEC V AVERAGE DEC OF 29% NOTED P0657
X-RAY THERAPY B LYMPHOCYTES DEC V DUE TO CELL DESTRUCTION P0291
AMINOSALICYLIC AC B LYMPHOCYTES INC V MAY PRODUCE SYNDROME LIKE INFECTIOUS MONONUCLEOSIS P0 3814
CARBON DISULFIDE B LYMPHOCYTES INC V EFFECT USUALLY SLIGHT IN POISONING PC 368
GRISEOFULVIN B LYMPHOCYTES INC V (RELATIVE LYNPHOCYTOSIS) PC 657
C! C LCLFU CI NE U LYSINE INC V REVERSIBLE MARKED AMINOACIDURIA RC154
ORAL CONTPACPTIVE P LYSOLECITHIN DEC V IF ADMINISTERED FOP LONG PERIOD P0694
ANPHOTFRICIN B S MAGNESIUM DEC V (OCCASIONAL) ASSOCIATED WITH TOXIC EFFECT OF DRUG 90C38
CALCIUM GLUCONATE S MAGNESIUM DEC N FALSE DECREASE IF MEASURED BY TITAN-YELLOW P003 1
CALCIUM SALTS S MAGNESIUM DEC V COMPETES FOP ABSORPTION FROM GUT AND TUBULES 90031
CITPATES S MAGNESIUM DEC V COMPLEXES MG (NAY OCCUR WITH BLOOD TRANSFUSIONS) 900914
DIATRIZOATE S MAGNESIUM DEC V ?DUE TO SMALL AMOUNT OP FOTA IN MEDIUM P056C
ETHANOL S MAGNESIUM DEC V FOLLOWING ETHANOL INDUCED URINARY EXCRETION P0905
INSULIN S MAGNESIUM DEC V EFFECT SEEN IN TREATMENT OF DIABETIC COMA PC 965
MEPALLURIDE S MAGNESIUM DEC V HYPONAGNESEMIA ESP IF NH4CL ALSO GIVEN P06 18
MERCURIAL DIURETICS S MAGNESIUM DEC V EFFECT MOST MARKED IF NH6CL ALSO GIVEN P0618
NEOMYCIN S MAGNESIUM DEC V MAY BE LOSS IN STOOLS DUE TO STEATORRHEA P 0384
ORAL CONTRACEPTIVE S MAGNESIUM DEC V C.15 NEQ/L DECREASE REPORTED (ESTROGEN EFFECT) RC380
SODIUM SULFATE S MAGNESIUM DEC V MAY BE EXCRETED COMBINED WITH SULFATE 90026
THIA ZIDES S MAGNESIUM DEC V CONSEQUENCE OF DIURESIS P0482
CALCIUM GLUCONATE U MAGNESIUM DEC N FALSE DECREASE IF MEASURED BY TITAN-YELLOW P0031
ORAL CONTRACEPTIVE U MAGNESIUM DEC V ASSOCIATED WITH FALL IN SERUM CONCENTRATION B 0380
PAPATHYROID EXTRACT U MAGNESIUM DEC V DECREASED CLEARANCE P0406
PHOSPHATES U MAGNESIUM DEC V DECREASES INC EXCRETION OF BED PEST P047 1
ALKALINE ANTACIDS S MAGNESIUM INC V THEORETICAL POSSIRILITY P0883
LITHIUM S MAGNESIUM INC V ?AFFECTS MEMBRANE TRANSPORT SYSTEMS P C 9C 7
MAGNESIUM SAtTS S MAGNESIUM INC V ABSORBED FROM G.I. TRACT FROM ANTACIDS ETC P C 1417
PARATHYROID EXTRACT S MAGNESIUM INC V DUE TO DECPEASLD RENAL EXCRETION P0384
PROGESTIN S MAGNESIUM INC V SIGNIFICANTLY HIGHER THAN IN CONTBOLS P0 2142
A LDOSTER ONE U MAGNESIUM INC V MAGNESIUM EXCRETION INCREASED TO SAME EXTENT AS K P0 965
AMNONIUN SALTS U MAGNESIUM INC V DIURETIC ACTION OBSERVED WITH ACICOSIS P06 17
AMPHOTERICIN E U MAGNESIUM INC V FOLLOWING I.V. INFUSION FOR 2 HOURS P 0657
BARIUM U MAGNESIUM INC N MEASURED BY FLUOPOMETRIC METHOD OF SCHACHTER RC923
BED PEST U MAGNESIUM INC V SLIGHT EFFECT ONLY P 0147 1
CADM IU U MAGNESIUM INC N MEASURED IN FLUOPONETRIC METHOD OF SCHACHTER P0923
CALCITONIN U MAGNESIUM INC V ACTS INDEPENDENTLY OF PARATHYBOID P0406
ETHACRYNIC ACID U MAGNESIUM INC V INCREASE UP TO SEVEN TINES REPORTED RC417
ETHANOL U MAGNESIUM INC V INCREASED EXCRETION SEEN IN CHRONIC ALCOHOLICS PC 905
LITHIUM U MAGNESIUM INC V FOLLOWING ADMINISTRATION OF THERAPY P0612
NERCA PTOMERIN U MAGNESIUM INC V EXCRETION INCREASED BY UP TO 30% RC882
MERCURIAL DIURETICS U MAGNESIUM INC V EXCRETION INCREASED BY UP TO 3C% P088 2
METOLAZONE U MAGNESIUM INC V DIURETIC ACTION P C 904
STRONTIUM U MAGNESIUM INC M MEASURED BY FLUOPONETRIC METHOD OF SCHACHTEP P09 23
I HIAZ IDES U MAGNESIUM INC V INCREASE OP 33% REPORTED P 088 2
TIN U MAGNESIUM INC N MEASURED BY FLUOROMETRIC METHOD OF SCHACHTEP R0923
ZINC U MAGNESIUM INC N MEASURED BY FLUOROMETRIC MFTHOD OF SCHACHTER PC 923
AMMONIUM SALTS S MAGNESIUM Z V NO EFFECT OBSERVED IN SPITE OF URINARY CHANGE R0617
STOPAGZ OF SAMPLE S MAGNESIUM Z N ROOM TEMP 8H, 4 DEGREES I DAY, FROZEN 1 YEAR P0998

EDTA U MANGANESE INC V IF POISONING DUE TO MANGANESE P0026
MA NNOSE S NANNOSE INC V TWICE NORMAL LEVEL IN DIABETICS (AFTER I.V.) P0115
LEAD B NCHC DEC V HENOLYTIC ANEMIA P02140
P!NICI LLA MINE B MCHC DEC V HYPOCRROMIC ANEMIA IN CHILD, MENSTRUATING WOMAN 90022
COLD AGGLUTININS B MCHC INC N SPURIOUS MACROCYTOSIS DUE TO AGGLUTINATION P0732
LEAD B MCV DEC V HENOLYTIC ANEMIA P02140
N I I 90 F U P AN TO IN B MCV DEC V MEGALOBLASTIC ANEMIA/HYPERSENSITIVITY (G-6-PD) 90633
WARFAPIN B NCV DEC V EAY BE SECONDARY MICPOCYTIC HYPOCHROMIC PNENIA R0368
ACETOPHENETIDIN B MCV INC V MACROCYTIC ANEMIA (MAY OCCUR OCCASIONALLY) P06 07
AMINOBENZOIC ACID B NCV INC V INDUCES L1&LABSORPTION AND MEGALOBLASTIC ANEMIA 90716
AMINOSALICYLIC AC B MCV INC V IF MEGALOBLASTIC ANEMIA OCCURS R0976
A ETICONVULS A NTS B MCV INC V MAY CAUSE MEGALOBLASTIC/APLASTIC ANEMIA 90976
BARBITURATES B MCV INC V MAY CAUSE MEGALOBLASTIC ANEMIA P0976
COLCHICINE B MCV INC V MEGALOBLASTIC ANEMIA WITH 912 DEFICIENCY P0976
COLD AGGLUTININS B NCV INC N SPURIOUS MACPOCYTOSIS DUE TO AGGLUTINATION 90732
CYCLOSEPINE B MCV INC V MAY CAUSE MEGALOBLASTIC ANEMIA P0 976
DI?HENYLHYDANTOIN B MCV INC V NAY OCCUR WITH NEGALOBLASTIC ANEMIA P087 3
ESTROGENS B MCV INC V MEGALOBLASTIC ANEMIA R0976
ETHOTOIN B MCV INC V THEORETICAL EFFECT ON FOLIC ACID METABOLISM P0467
GLUTET RIM IDE B ECV INC V NAY CAUSE MEGALOBLASTIC ANEMIA 903814
ISONIAZID B MCV INC V IF NEGALOBLASTIC ANEMIA OCCURS 90620
LEAD B MCV INC V PARE INCREASE WITH POISONING P0 29 1
NEFENANIC ACID B MCV INC V NEGALOBLASTIC ANEMIA REPORTED 90026
NE?HENYTOI N B NCV INC V MAY CAUSE MEGALOBLASTIC ANEMIA P0026
METFOP.MIN B MCV INC V OCCURS IF MEGALOBLASTIC ANEMIA P09 35
NETHOPHENOBA PBITAL B NCV INC V MAY CAUSE MEGALOBLASTIC ANEMIA P0620
NETHOTREXATE B NCV INC V OCCURS WITH MEGALOBLASTIC ANEMIA P0976
NEONYI N B MCV INC V I” NEGALOBLASTIC ANEMIA DEVELOPS HO 976
NITROFURANS B M.CV INC V MAY CAUSE MEGALOBLASTIC ANEMIA P0 657
OPAL CONTRACEPTIVE B MCV INC V OCCURS IF MEGALOBLASTIC ANEMIA P079 1
PENTANIDINE B NCV INC V MEGALOBLASTIC ANEMIA P0976
PHENFORNIN B MCV INC V THEORETICAL EFFECT OF FOLATE OR B12 DEFICIENCY P079 1
PRENOBARBITAL B NCV INC V MEG. ANEMIA 2ND TO DISTURBANCE IN FOLIC ACID METAB. HO 528
PRIMIDONE B MCV INC V MEGALOBLASTIC ANEMIA 2ND DIST. IN FOLIC ACID METAB. P0775
PYRIMETHANINE B NCV INC V MFGALOBLASTIC ANEMIA Ri 007
TPIAMTERENE B MCV INC V MEGALOBLASTIC ANEMIA 90976
TBI MEIROPRI M B NCV INC V OCCURS WITH MESALOBLASTIC ANEMIA P0976
GLYCINE B MEGALORLASTS INC V NAY PROVOKE OR ACCENTUATE MEGALOBLASTOSIS P079 1
METHIONINE B MEGALOBLASTS INC V CAN AGGRAVATE VITAMIN B12 DEFICIENCY R0791
SEPIN? B NEGALOELASTS INC V CAN AGGRAVATE VITAMIN B12 DEFICIENCY P079 1
MEPEPI DI NE U MEPEPIDINE 905 V MAIN EXCRETION PRODUCT IN NEONATES AND PREGNANT P0657
ACETYLPENICILLANINE S MERCURY INC V MOBILIZATION OF HG IN CASE OF POISONING P0511
ACETYLPENICILLAMINE C MERCURY INC V ELIMINATION OF HEAVY METALS IN CASES OF HG POISON P05 11
DIMEP.CAPROL U MERCURY INC V IF POISONING DUE TO MERCURY P0026
MERCURY COMPOUNDS U MERCURY INC V DUE TO INGESTION OF COMPOUND AND IF POISONING P09 11
PENICILLAMINE U MERCURY INC V RELATED TO DRUG DOSAGE IN TOXICITY CASES P09 11
PENICILLIN U MERCURY INC V ACTS AS CHELATING AGENT IN ACRODYNIA AT LEAST P0568
LEVODO PA U NETANEPHPINES TOTAL DEC V ?DOPAMINE AS NEUROTRANSMITTER SU?PRISSES NORNET P047 5
CHLORPROMAZ I NE U METANEPHEINES TOTAL INC N INTERFERENCE IN LISANO PROCEDURE 90125
HYDRAZINE U METANEPHRINES TOTAL INC V NAY POTENTIATE ACTION OF DRUGS ON CNS 90596
INIPPA MINE U METANEPHRINES TOTAL INC N INTERFERENCE WITH PISANO METHOD HO 125
MAO INHIBITORS U MBTANEPHPINES TOTAL INC V PREVENT DEAMINATION 90384
MET HYLDOPA U METANEPHRINES TOTAL INC M QUESTIONABLE INTERFERENCE FLUORONETRIC METHODS 91001
OXYTETHACYCLI NE U METANEPHRINES TOTAL INC N INTERFERES WITH FLUOROMETRIC METHODS 91001
PHENOTHIAZINES U METANEPHEINES TOTAL INC N INTERFERENCE IN PISANO PROCEDURE P0 125
PROCHLOPPEPAZINE U METANEPHRINES TOTAL INC V INC METABOLISM, DEC ORGAN UPTAKE OF NOREPINEPHHINE P1 001
ETHANOL B METHANOL INC V COMPETITIVE INHIBITION OF ALCOHOL DEHYDROGENASE P06 10
NETHA NOL B METHANOL INC V PRESENCE OF INGESTED ALCOHOL P03 84
METHANOL C METHANOL INC V HIGHER CONCENTRATION THAN IN BLOOD P0384
ANTIPYPINE P NETHEMALBUMIN INC V OCCURS WITH INTRAVASCULAR HENOLYSIS P02140
COPPER p METHFMALBUMIN INC V OCCURS WITH ACUTE INTRAVASCULAR HEMOLYSIS 90124
DIMERCAPROL P NETHEMALBUMIN INC V OCCURS WITH INTRAVASCULAR REMOLYSIS 902140
DIPYPONE P NETHENALBUMIN INC V OCCURS WITH HEMOLYTIC ANEMIA R0569
FUR ALTADONP P NETHENALBUMIN INC V NAY OCCUR WITH HEMOLYSIS P0079
FUPAZOLIDONE P MRTHEMALBUMIN INC V MAY OCCUR WITH HENOLYSIS P007 9
QUININE P METHENALBUMIN INC V ? GIVEN CONCURRENTLY WITH PAMAQUINE P03 84
ACETAMI NOPHEN B NETHEMOGLOBIN INC V MAY RARELY CAUSE HEMOLYSIS P03 84
ACETANILID B METHENOGLOBIN INC V INTRAVASCULAR HEMOLYSIS HO 656
ACETOPHENETI DIN B METHENOGLOBIN INC V HEMOLYTIC ANEMIA P0128
ACETYLSALICYLIC AC B METHENOGLOBIN INC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY 90926
ANINOSALICYLIC AC B NETHENOGLOBIN INC V MAY CAUSE HEMOLYTIC ANEMIA P0026
AMMOKIUM NITRATE B METHENOGLOBIN INC V NAY CAUSE HEMOLYTIC ANEMIA P0658
AMYL ALCOHOL B NETHEMOGLOBIN INC V MAY CAUSE HENOLYSIS FOLLOWING INGESTION P0368
ANYL NITRITE B NETHENOGLOBIN INC V HEMOLYTIC ANEMIA 90656
ANALGESICS B NETHENOGLOBIN INC V MAY CAUSE INTRAVASCULAR HEMOLYSIS 90910
ANILINE B METHENOGLOBIN INC V OCCURS AS RESULT OF INTRAVASCULAR HEMOLYSIS P0368
ANTIMALAPIALS B METHEMOGLOBIN INC V MAY CAUSE HENOLYTIC ANEMIA P0518
ANTI?! PINE B METHEMOGLOBIN INC V INCREASE SELDOM OCCURS P03 814
BENZOCA INE B METHENOGLOBIN INC V HEMOLYSIS 90121
BISMUTH SUBNITPATE B METHEMOGLOBIN INC V NAY CAUSE HEMOLYTIC ANEMIA 90658
BROMATE B METHEMOGLOBIN INC V NAY CAUSE HEMOLYSIS 90384
CHLOPA MPH ENICOL B NETHEMOGLOBIN INC V MAY CAUSE HEMOLYSIS IN G-6-PD DEFICIENCY R0926
CHLORATE B NETHENOGLOBIN INC V MAY CAUSE HEMOLYSIS 903814
COPPER B METHENOGLOBIN INC V MAY OCCUR WITH COPPER TOXICITY RO124
DIANINODIPHENYLSULF B METHEMOGLOBIN INC V MAY CAUSE HEMOLYTIC ANEMIA 901451
DI MERCA PROL B METHFMOGLOBIN INC V NAY CAUSE HEMOLYSIS IN G-6-PD DEVICIENCY H 0926
DINITROPHENOL B METHENOGLOBIN INC V NAY CAUSE HEMOLYSIS/APLASTIC ANEMIA P0658
DIPRENYLHYDANTOIN B TIETHEMOGLOBIN INC V OCCURS WITH HEMOLYTIC ANEMIA HO 596
FURAZOLIDONE B MITHENOGLOBIN INC V MAY CAUSE HEHOLYSIS WITH G-6-PD DEFICIENCY P0926
GLUCOSULFONE B NETHEMOGLOBIN INC V REMOLYTIC ANEMIA P02 140
1210 CLINICAL bHEMISTRY, Vol. 18, No. 10, 1972

GLUTETHIMIDE B METHEMDGLOBIN INC V BLEEDING ASSOCIATED WITH OV!9DOSAE ?0657
RYDANTOINS B METENOG10BIN INC V REPORTED EFFECT P0596
ISONIAZID P NETHEMOGLOBIN INC V REPORTED EFFECT 90394
LIPENIA B MECHENOGLOBIN INC N PRODUCES TURBIDITY 90411
LOCAL ANESTHETICS B METHEMOGLOBIN INC V REPORTED EFFECT 90657
LYSOL B NETHENOGLOBIN INC V MAY CAUSE INTRAVASCULAR HEMOLYSIS P0197
METHICILLIN B METHEMOGLOBIN INC V ONE DOUBTFUL CASE OF HEMOLYTIC ANEMIA 90026
METHYLENE BLUE B METHEMOGLOBIN INC V MAY CAUSE HENOLYSIS (ALSO USED AS TREATMENT) 90128
NAPHTHALENE B NETHEMOGLOBIN INC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY 90926
NIRIDAZOLE B METHEMOGLOBIN INC V MAY CAUSE HEMOLYSIS IF G-6-PD DETICENCY 90384
NITRATES B METHENOGLOBIN INC V MAY CAUSE HEMOLYSIS 90556
NITRITES B NETHEMOGLOBIN INC V EFFECT OF ORGANIC NITRITES LESS THAN AMYL NITRITE 90384
NIT9OBENZENE B METHEMOGLOBIN INC V MAY CAUSE HENOLYSIS 30658
NITROFtIPANS B METHEMOGLOBIN INC V NAY CAUSE HEMOLYTIC ANEMIA IF G-6-PD DEFICIENCY P0026
NITROFUPANTOIN B METHENOGLOBIN INC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY 90926
NITROFURAZONE B METHEMOGLOBIN INC V MAY CAUSE HENOLYTIC ANEMIA P0104
NITROGEN OXIDES B METHEMOGLOBIN INC V MILD ELEVATION MAY OCCUR AFTER NIT OX INHALATION 90369
NITROGLYCERIN B METHEMOGLOBIN INC V MAY CAUSE HENOLYSIS RO656
PAMAQUINE B METHEMOGLOBIN INC V NAY CAUSE HENOLYSIS IN G-5-PD DE’ICIENCY R0#{176}26
PENTAQUINE B METHEMOGLOBIN INC V MAY CAUSE HEMOLYSTS IN G-6-PD DEFICIENCY 90926
PHENAZOPYPIDINE B NETHEMOGLOBIN INC V MAY CAUSE REMOLYSIS P0656
PHENYLENEDIAMINE B METHEMOGLOBIN INC V NAY CAUSE HEMOLYSIS R0657
PHENYLHYD9AZINE B METHENOGLOBIN INC V MAY CAUSE HEMOLYSIS ROGS7
PLASMOQUIN B METHEMOGLOBIN INC V MAY CAUSE RENOLYTIC ANEMIA 90620
POTASSIUM CHLORATE B METHEMOGLOBIN INC V MAY CAUSE HENOLYTIC ANEMIA P0658
PPILOCAINE B METHEMOGLOBIN INC V 0-TOLUIDINE PROD AS NETABOLITE CAUSES HEMOLYSIS 90230
PRINAQUINE B METHEMOGLOBIN INC V MAY CAUSE REMOLYSIS IN G-6-PD DEFICIENCY P0026
PROBENECID B METHEMOGLOBIN INC V NAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY 90926
QUINACRINE B METHEMOGLOBIN INC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY 9C926
QUINIDINE B NETHENOGLOBIN INC V MAY CAUSE HENOLYSIS IN G-6-PD DEFICIENCY P0926
QUININE B METHEMOGLOBIN INC V NAY CAUSE HEMOLYSIS IN G-6-PD DEFICIENCY R026
R!SOPCIN B NETHEMOGLOBIN INC V OCCURS WITH HEMOLYTIC ANEMIA P0657
RESORCINOL B METHENOGLOBIN INC #{149} V INJECT OR EXCESS ABSORB NAY CAUSE HEMOLYSIS R0026
SALICYLAZOSULFAPYP B METHEMOGLOBIN INC V OCCURS WITH HEMOLYTIC ANEMIA 90620
SULFACETAMIDE B METHENOGLOBIN INC V MAY CAUSE HEMOLYSIS I? G-6-P!) DEFICIENCY 90926
SULFANETHIZOLE B METREMOGLOBIN INC V MAY CAUSE HEMOLYTIC ANEMIA 90751
SULFAMETHOXYPYPID B METHEMOGLOBIN INC V MAY CAUSE HEMOLYTIC ANEMIA 90658
SULFANILANIDE B METREMOGLOBIN INC V MAY CAUSE HENOLYTIC ANEMIA 90558
SULFAPYRIDINE B METHENOGLOBIN INC V NAY CAUSE HEMOLYTIC ANEMIA P0658
SULFISOXAZOLE P NETHENOGLOBIN INC V MAY CAUSE HEMOLYTIC ANEMIA 90790
SULFONAMIDES B METHEMOGLOBIN INC V AGRANULOCYTOSIS/APLASTIC OR HEMOLYTIC ANEMIA R0657
SULFONEMETHANE B METHENOGLOBIN INC V MAY CAUSE HENOLYTIC ANEMIA P0658
SULFONES B METHEMOGLOBIN INC V BEMOLYSIS MAY OCCUR WITH G-6-PD DEFICIENCY P0026
SULFONETHYLMETHANE B METHEMOGLOBIN INC V MAY CAUSE HEMOLYTIC ANEMIA 90658
SULFOXONE B NETHEMOGLOBIN INC V NAY CAUSE HEMOLYSIS IN G-6-PD DEFICIENCY P0926
THIAZOLSULFONE B METHENOGLOBIN INC V HEMOLYTIC ANEMIA P0620
TRINITROTOLUENE B METREMOGLOBIN INC V ASSOCIATED WITH HENOLYSIS R0658
VITAMIN A B NETHEMOGLOBIN INC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0926
PROTEIN U NETHYLHISTIDINF INC V OCCURS WITH HIGH MEAT DIET P0291
ANINOSALICYLIC AC U METHYLMALONATE INC V OCCURS WITH VITAMIN B12 DEFICIENCY P0976
COLCHICINE U METHYLMALONATE INC V OCCURS WITH IMPAIRED ABSORPTION OF B12 P0976
ETHANOL U NETHYLNALONATE INC V MAY OCCUR I? B12 DEFICIENCY 90976
NALONIC ACID U METHYLMALONATE INC N MEASURED AS ANALYT! R0361
METHANDPOST?NOLONE 0 NETYPAPONE TEST V ANABOLIC EFFECT p0467
NANDROLONE 0 METYRAPONE TEST V ANABOLIC EFFECT 90708
LEVODOPA S MONOAMINE OXIDASE INC V INCREASED ACTIVITY AFTER 2-3 MONTHS THERAPY P0939
ANPICILLIN B MONOCYTES INC V ASSOCIATED WITH AGRANULOCYTOSIS P0390
CARBON DISULFIDE B MONOCYTES INC V OCCURS IN 25% CASES REGARDLESS OF DURATION 90254
CHLOPPROMAZIN! B MONOCYTES INC V OCCASIONALLY BEFORE AGRANULOCYTOSIS 90602
GRISEOFULVIN B MONOCYTES INC V (RELATIVE MONOCYTOSIS) P0657
PHOSPHORUS B MONOCYTES INC V REPORTED EFFECT OF POISONING R0368
PROTEINUPIA U NUPAMIDASE INC V INCREASED IN SMALL PERCENTAGE OF CASES P0758
X-RAY THERAPY U MURAMIDASE INC V ASSOC WITH CELL DESTRUCTION IN LEUKEMICS P0930
AMPHETAMINES B MYELOBLASTS INC V MYELOBLASTIC LEUKEMIA 90100
CHLOPOGUANIDE B MYELOCYTES INC V UP TO 10% IN PATIENTS WITH OVERT MALARIA 903814
AMBULATION S MYOGLOBIN INC V FOLLOWS PHYSICAL EXERTION 90462
SUCCINYLCHOLIN! S NYOGLOBIN INC V OCCASIONAL RESULT OF I.V. INJECTION IN CHILDREN 90807
AMBULATION U MYOGLOBIN INC V FOLLOWS PHYSICAL EXERTION P01462
AMPHOTEPICIN B U MYOGLOBIN INC V CAUSED BY RHABDOMYOLYSIS p0285
CAPBENOXOLONE U MYOGLOBIN INC V MYOPATHY FOLLOWING HYPOKALEMIA P0669
LICORICE U MYOGLOBIN INC V MAY FOLLOW HYPOKALEMIA P0669
SUCCINYLCHOLINE U NYOGLOBIN INC V OCCASIONAL RESULT OF I.V. INJECTION IN C9ILDREN R0807
THIABENDAZOLE U MYOGLOBIN Z V NOT OBSERVED ALTHOUGH SERUM ALDOLAS! INC P0657
CHLOPTETPACYCLINE U N-METHYLNICOTINAMIDE INC V WITH DOSE OF 3G/DAY 903814
OXYTETRACYCLINE U N-METHYLNICOTINAMIDE INC V WITH DOSE OF 2.5 G/DAY P0384
ESTROGENS S NA9HTHYLAMIDASE ISOENE INC V METABOLIC EFFECT P0072
ACETYLSALICYLIC AC S NEFA DEC V INC FATTY ACID OXIDATION, DECREASED LIPOGENESIS P0384
CLOIBRATE S NEFA DEC V DISPLACEMENT FROM ALBUMIN 90384
GLUCOSE S NEFA DEC V EFFECT GREATER IN NORMALS THAN IN DIABETICS 907147
INSULIN S NEFA DEC V EFFECT SIMILAR IN NORMALS AND DIABETICS P0747
LEVOTHYROXINE S NEFA DEC V CORRECTION OF HYPOTHYROID STATE R09C7
NICOTINIC ACID S NEFA DEC V MAPKED FALL THEN PROGRESSIVE SECONDARY RISE P0478
P9OP9ANOLOL S NEFA DEC V ESPECIALLY DURING AND AFTER EXERCISE P0018
STREPTOZOTOCIN S NEFA DEC V MECHANISM NOT ESTABLISHED YET 9068#{128}
AMPHETAMINES S NEFA INC V BUT DOES NOT MODIFY CARBOHYDRATE UTILIZATION 903814
CAFEPINE S NEFA INC V 220 MG RAISED NEFA BY APPROX 3O 90516
CARBUTAMIDE S NEFA INC V REPORTED TO CAUSE HYPE?LIPEMIA 90595
COFFEE S NEFA INC V POSSIBLY DUE TO STRESS EFFECT R0657
DIAZOXIDE S NEFA INC V SIGNIFICANT RISE OBSERVED AFTER ORAL OR I.V. ADNIN P0O9
EPINEPHRINE S NEFA INC V TRANSIENT METABOLIC EFFECT 90384

ETHANOL S NEFA INC V ALTERED METABOLISM WITH DEC FATTY ACID OXIDATION R0384
GLUCOSE S NEFA INC V DELAYED RISE 3 HOURS AFTER ADMINISTRATION P01474
GROWTH HORMONE S NEFA INC V INDUCES LIPOLYSIS (?AT ADENYL CYCLASE STEP) P02 53
HE? ARIN S NEFA INC V ALSO OCCURS WITH SITUATIONAL STRESSES P0998
ISOPROTERENOL S NEFA INC V AS EFFECTIVE AS EPINEPHRINE P03814
NICOTINE S NEFA INC V PROBABLE STRESS RESPONSE 90657
OPAL CONTRACEPTIVE S NEPA INC V IF GIVEN FOR 3 MONTHS P0907
STORAGE OF SAMPLE S NEA INC N AT ROOM TEMP DUE TO LIPOPPOTEIN LIPASE P0998
TOLBUTANID? S NEFA INC V EFFECT OBSERVED IN NORMAL SUBJECTS 907147
XANTHINES S NEFA INC V REPORTED EFFECT 903814
PREGNANCY S NEUTRAL FATS INC V OBSERVED THROUGHOUT PREGNANCY P 02 91
CLOFIBRATE F NEUTRAL STEROIDS DEC V AFTER TWO WEEKS TREATMENT FALL OBSERVED HO 668
ACETANINOPHEN B NEUTROPHILS DEC V MAY CAUSE NEUTROPENIA/PANCYTOPENIA P03 84
AMINDSALICYLIC AC B NEUTROPHILS DEC V IF SEVERE MEGALOBLASTIC ANEMIA OCCURS P0976
ANTICONVU LSANTS B NEUTROPHILS DEC V MAY OCCUR WITHOUT EFFECT ON WRITE CELL COUNT P01467
ANTIPYPINE B NEUTFOPHILS DEC V MYRLOTOXIC ACTION OF DRUGS P0657
AZATHIOPRINE N NEUTROPHILS DEC V DRUG RELATED LEUKOPENIA (CURED BY CESSATION) P01422
CAP BENICILLIN P NEUTROPHILS DEC V NEUTPOPENIA REPORTED OCCASIONALLY 90467
CEPHALOT HIM B NEUTROPHILS DEC V NEUTROPENIA OP LEtJKOPENIA HARE P002 1
CHLOR AMBUCIL B NEUTROPHILS DEC V SEVERE NEUTPOPENIA MAY BE PRODUCED P0 467
CHLORA MPHENICOL B NEUTOPHILS DEC V COMMON TOXIC REACTION/APLASTIC ANEMIA P06 57
CHLOROTHI AZ IDE B NEUTPOPHILS DEC V OCCASIONALLY OBSERVED P06 57
CHLORT HA LIDONE B NEUTROPHILS DEC V FEW CASE REPORTED P0657
DIAZEPAM B NEUTROPHILS DEC V TRANSITORY NEUTROPENIA REPORTED P0026
DTPHENYLHYDA NTCI N B NEtJTPOPHILS DEC V MEGALOBLPASTIC/HEMOLYTIC/APLASTIC ANEMIA,PANCYTOPEN ROO25
ETHACRYNIC ACID 9 NEUTBOPRILS DEC V OCCASIONAL NEUTROPENIA OR AGRANULOCYTOSIS P0657
HYDROCHLOROTHIAZIDE B NEUTROPHILS DEC V OCCASIONALLY OBSERVED P0657
INDOMETUPLCI N B NEUTROPHILS DEC V PARE NEUTROPENIA/MAY ALSO CAUSE APLASTIC ANEMIA P03 84
METHICILLIN B NEUTFOPHILS DEC V NEUTROPENIA WITH GPANULOCYTOPENIA MAY OCCUR 90467
METPONI DAZ OLE B NEUTROPHILS DEC V TRANSIENT NEUTROPENIA MAY OCCUR P0657
PARAMETHADIONE B NEUrPOPHILS DEC V MAY OCCUR WITHOUT OVERALL EFFECT ON NBC P04 67
PENICILLIN P NEURPOPHILS DEC V AGRANULOCYTOSIS/LEUKOPENIA 90711
PYR AZOLONES B NEUTROPNILS DEC V MYFLOTOXIC EFFECT OF DRUGS P0657
TETRACYCLINE B NEUTROPHILS DEC V NEUTROPENIA MAY OCCUR OCCASIONALLY P0 467
TOLBUTAMIDE B NEUTROPHILS DEC V OCCASIONALLY OBSERVED P0657
TRIMETHADIONE B NEIJTROPHILS DEC V MODERATE NEUTROPENIA QUITE COMMON 90384
VITAMIN A B NEUTROPHILS DEC V LEUKOPENIA WITH HYPOPLASTIC ANEMIA REPORTED P01495
X-RAY THERAPY B NEUTROPHILS DEC V ALSO TOXIC GRANULATION IN CELLS P0 29 1
CLIOQUI NOL B NEU’CROPHILS INC V TOXIC EFFECT REPORTED P092 1
CORTISONE B NEUTROPHILS INC V SIGNIFICANT GRANULOCYTOSIS OBSERVED P0384
LITHIUM 3 NEUTOPHILS INC V ?DRUG ASSOCIATED ENDOCRINE EFFECT P0869
MET BY S E R G IDE B NEUTROPHILS INC V AVERAGE INC OF 23% NOTED P0 657
EDTA U NICKEL INC V IF POISONING DUE TO NICKEL P0026
NEONYCIN F NITROGEN INC V ALTERS INT VILLI.INHIBITS TRIGLYCERIDE HYDROLYSIS 90993
ACETYLSALICYLIC AC U NITROGEN INC V EFFECT OBSERVED IN ADULTS 90881
ANINOPHENAZONE U NITROGEN INC V REPORTED EFFECT P0 596
AS?APAGI NA SE U NITROGEN INC V EFFECT GREATEST IN RESPONDERS TO THERAPY P0705
BED REST U NITROGEN INC V NEGATIVE NITROGEN BALANCE (OVER 1 G/DAY) 90471
CHLO!’TETPICYCLINE U NITROGEN INC V EFFECT OBSERVED IN MALNOURISHED P 0384
OXYTF.TRACYCLINE U NITROGEN INC V OBSERVED IN MALNOURISHED P03 84
TETRACYCLINE U NITROGEN INC V WITH IMPAIRMENT OF PROTEIN SYNTHESIS P0596
TETP ACYCLINE Ti NITROGEN INC V DUE TO ANTIANABOLIC EFFECT P0026
ESTROGENS P NON PROT BOUND CORTISOL INC V HORMONAL ACTION P0417
ORAL CONTRACEPTIVE P NON PROT BOUND COPTISOL INC V ESTROGEN EFFECT P0 186
DEXTRONORAN IDE P NOPEPINEPHRINE DEC V MECHANISM OBSCURE P0496
FENTANYL P NOREPINEPHRINE DEC V MECHANISM OBSCURE P0496
MORPHINE P NOREPINEPHRINE DEC V MECHANISM OBSCURE P0 496
BETHA NI DINE U NOPEPINE?HRINE DEC V REPORTED EFFECT RO417
CLONIDINE U NOREPINEPHRINE DEC V DOSE RELATED EFFECT (PRIMARY ACTION OF DRUG) P0455
GUANETHIDINE U NO?EPINEPHPINE DEC V NON SIGNIFICANT DECREASE PEPOPTED 90805
GUANOXAN U NOPEPINEPHRINE DEC V DECREASED OUTPUT REPORTED P0 805
ANGIOTENSIN P NOPEPINEPHFINE INC V OF SANE MAGNITUDE AS IF NOREPINEPHPINE GIVEN P1 030
CHLORPPON AZINE P NOREPINEPHRINE INC V INCREASES METABOLISM, DECREASES ORGAN UPTAKE P03 84
ETH ER P NOREPINEPHRINE INC V RESPONSE TO STRESS P0752
LEVARTERENOL P NOPEPINEPHPINE INC V AFTER I.V. INFUSION R1030
MAO INHIBITORS P NOREPINEPHPINE INC V EFFECT OBSERVED AFTER SINGLE LARGE DOSE P0384
AMINOPHYLLINE U NOREPINEPHPINE INC V TWOFOLD INCREASE IN RESPONSE TO I.V. DOSE P0059
ETHANOL U NOREPINEPHRINE INC V SLIGHT INC (BUT LESS THAN EPINEPHPINE) R0051
LEVODOPA U NOREPINFPHPINE INC V NO EFFECT ON EPINEPHRINE EXCRETION P 082 1
NITROGLYCERIN U NOREPINEPHRINE INC V ?DUE TO ADRENERGIC STIMULATION OF HYPOTENSION P0 96 1
PAIN U NOREPINEPHRINE INC V ALSO SEEN BUT LESS MARKEDLY WITH EMOTIONAL STRESS P05149
ACETAMINOPHEN U NOREPINEPHRINE Z V NO EFFECT WITH SHORT TERM INGESTION 2.6 S/DAY P0 236
ACETYLSALICYLIC AC U NOREPINEPHRINE Z V NO EFFECT WITH SHORT TERM INGESTION 2.6 3/DAY P02 36
CHLORDI AZEPOXIDE U NOREPIN!PHPINF Z V NO EFFECT SHORT TERM INGESTION OF 30 MG/DAY 90236
DIAZEPAM U NOREPINEPURINE Z V NO EFFECT SHORT TERM INGESTION OF 15 MG/DAY P0236
DI PHENHYDRAMI NE U NOREPINFPHPINE Z V NO EFFECT SHORT TERN INGESTION OF 150 MG/DAY P0236
PHENOBAPBITAL U NOREPINEPHPINE Z V NO EFFECT SHORT TERM INGESTION OF 120 MG/DAY P0236
STORAGE OF SAMPLE U NOPEPINEPHRIN! Z N NO EFFECT AT ROOM TEMP, SEVERAL DAYS I’ ACIDIFIED P0998
MEPERIDINE U NORMEPERIDINE P05 V MAIN METABOLITE IN NORMALS P06 57
HYDRAZI NE U NORMETANEPHPINE INC V MAY POTENTIATE ACTION 0! DRUGS ON CNS P0596
MAO INHIBITORS U NORMETANEPHRINE INC V PREVENT DEAMINATION P0384
PREGNANCY S NPN DEC V DEC 20-25% (WITH PEL GREATER DEC 0? UREA NITROGEN) P01 43
STORAGE OF SAMPLE S NPN DEC M SIGNIFICANT EFFECT AT -10 DEGREES AFTER 6 MONTHS P0998
ACETOPHENET IDIN S NPN INC V MAY CAUSE AZOTEMIA P0620
ANPHOTERICIN B S NPN INC V NEPHPOTOXIC EFFECT P0620
APSENICALS S NPN INC V NEPHROTOXICITY (COMMON WITH THERAPEUTIC DOSES) P0 355
CA PPEOMYCIN S NPN INC V NEPHROTOXIC EFFECT P0620
CARBUTANIDE S NPN INC V NEPHPOTOXIC EFFECT P06 20
CEPHALOPIDI NE S NPN INC V NEPHROTOXIC ESP IF COMBINED WITH DIURETIC R0736
CHLORTETRACYCLINE S NPN INC V EFFECT OBSERVED IN MALNOURISHED P0 384

COLISTIMETHATE S NPN INC V NEPHROTOXIC EFFECT (USUALLY REVERSIBLE) RO’36
COLISTIN S NPN INC V N!PHPOTOXIC EFFECT (REVERSIBLE PENAL DAMAGE) 90620
EDTA S NPN INC V NEPHPOTOXIC EFFECT (ESP CA EDTA) P06 20
EDTA S NPN INC N THEORETICAL INC OF 7 MG/100ML AS ANTICOAGULANT 90436
FILTER PAPER S NPN INC N IF CONTAINS AMMONIA AFFECTS SOME METHODS RO36
KANAMYCIN S NPN INC V NEPHROTOXIC EFFECT P06 20
LIPOMUL S NPN INC V NEPHPOTOXIC EFFECT 90620
METHICILLIN S NPN INC V NEPHBOTOX!C EFFECT P06 20
NALIDIXIC ACID S NPN INC V MAY CAUSE NITROGEN PETENTION 90736
NEONYCIN S NPN INC V NEPPROTOXIC EFFECT 062O
NITPOFUPANTOIN S NPN INC V NEPHROTOXIC EFFECT 90620
OXALATES S NPN INC V ACUTE PENAL FAILURE WITH CA OXALATE DEPOSITION RO 38 44
OXALATES S NPN INC N “BALANCED” OXALATE MIXTURE CONTAINS NHLI 40436
PHOSPHORUS S NPN INC V DUE TO NEPHROTOXICITY 368
POLYMYXIN B S NPN INC V NEPHPOTOXIC EFFECT P06 20
STREPTOMYCIN S NPN INC V NEPHROTOXICITY NAY OCCUR IN 2% 90736
SULFONAMIDES S NPN INC V OCCASIONAL UREMIA WITH/WITHOUT CRYSTALLURIA P0620
TETRACYCLINE S RPM INC V DUE TO NEPHROTOXICITY OR ANTIANABOLIC EFECT P06 20
VITAMIN D S N?N INC V MANIFESTATION OF HYPEPVITAMINOSIS D 90620
STORAGE OF SAMPLE S rPM Z N NO EFFECT 1 DAY AT ROOM TENP, SEVERAL AT (1 DEGREES P014 36
INDICAN U OBEPMAYER TEST P05 M PRODUCES BLUE COLOR(INDIGO BLUP)N CRLOROFOPM 90929
ASCOPBIC ACID F OCCULT BLOOD NEG N INTERFERES WITH ANALYTIC METHODS HO 6 20
ACETYLSALICYLIC AC F OCCULT BLOOD P05 V IN OVER 70% PATIENTS WHEN MOPE THAN 3G/OAY GIVEN P0974
AMINOPHYLLINE F OCCULT BLOOD 905 V HEMATEMESIS MAY OCCUR EARLY WITH POISONING R065
AMINOSALICYLIC AC F OCCULT BLOOD P05 V REVERSIBLE GASTRITIS CAUSED BY DRUG P0384
AMPHOTERICIN B F OCCULT BLOOD 905 V MELENA AND HEMOPRHAGIC GASTROENTEPITIS P0026
AMYL ALCOHOL F OCCULT BLOOD P05 V NAY CAUSE GASTROINTESTINAL HEMORRHAGE HO 368
APSENICALS F OCCULT BLOOD P05 V OBSERVED IN SEVERAL CASES WITH POISONING P014 15
BARIUM SALTS F OCCULT BLOOD P05 V MAY CAUSE SEVERE G.I. TRACT HEMORRHAGE 90384
BORIC ACID F OCCULT BLOOD P05 V TOXICITY EFFECT 90620
BROMIDES F OCCULT BLOOD 905 N INTERFERES WITH BENZIDINE TEST P0355
CARBON TETRACHLOP F OCCULT BLOOD 905 V HEMATENESIS IF INGESTED 90384
CHLORAMPHENICOL F OCCULT BLOOD P05 V MAY BE G.I. HEMORRHAGE, WITH LOW PROTHPCNBIN P0 026
CHLOPPROPANIDE F OCCULT BLOOD P05 V ASSOCIATED WITH SEVERE DIARRHEA AND BLEEDING P0733
COLCHICINE F OCCULT BLOOD POS V TOXICITY EFFECT P06 20
COPTIOSTEROIDS F OCCULT BLOOD P05 V NAY INCREASE INCIDENCE OF GASTRIC ULCFPS P0104
CYCLOPHOSPHANIDE F OCCULT BLOOD 905 V HEMORRHAGIC COLITIS REPORTED P06 57
DEXANETHASONE F OCCULT BLOOD P05 V MAY AGGRAVATE PEPTIC ULCER AND CAUSE BLEEDING RO467
DIPYRONE F OCCULT BLOOD P05 V MAY CAUSE GASTROINTESTINAL BLEEDING P 00 2 6
ETHACRYNIC ACID F OCCULT BLOOD P05 V ONE CASE PEPORTED(26% IF GIVEN I.V. POSSIBLY) P0117
FISH F OCCULT BLOOD P05 N AFFECT MOST METHODS IF NOT WITHHELD FOR 3 DAYS 90262
FLUORIDES F OCCULT BLOOD P05 V IF LARGE ANT INGTED MAY = HEMORRHAGIC GASTRITIS P0368
FORMALDEHYDE F OCCULT BLOOD P05 V INGESTION MAY CAUSE HENATEMESIS R0368
GOLD F OCCULT BLOOD P05 V ASSOC WITH THROMBOCYTOPENIA P06 57
RETACILLIN F OCCULT BLOOD P05 V CAUSED BLEEDING WITH DOSE OF (IG P02 64
HYDRALAZINE F OCCULT BLOOD P05 V P ARE GASTROINTESTI NAL HEMORRHAGE 903814
HYPOCRLORITES F OCCULT BLOOD P05 V CORROSIVE ACTION ON G.I. TRACT IF SWALLOWED 90368
IBUFENAC F OCCULT BLOOD 905 V MAY CAUSE G.I. TRACT BLEEDING 90620
INDOMETHACIN F OCCULT BLOOD 905 V NAY CAUSE ULCERATION OF STOMACH,DUODENUM, GUT 90648
IODIDES F OCCULT BLOOD P05 V CHRONIC POISONING MAY CAUSE BLOODY DIARRHEA P0384
IODIDES F OCCULT BLOOD POS N INTERFERES WITH BENZIDINE TEST P0181
IODINE CONTAIN DRUG F OCCULT BLOOD POS V MAY OCCUR WITH TOXICOLOGICAL DOSES P0368
IRON SALTS F OCCULT BLOOD P05 N INTERFERES WITH GUAIAC TEST (?BENZIDINE) 90927
ISOPROPANOL F OCCULT BLOOD P05 V MAY CAUSE REMATEMESIS AND GASTPOENTEPITIS 90368
KEROSENE F OCCULT BLOOD P05 V TOXIC EFFECT IF INGESTED 903 84
LEAD F OCCULT BLOOD P05 N LEAD SULFIDE MAY SIMULATE MELENA P0 368
LEAD F OCCULT BLOOD 905 V MAY BE BLOODY DIARRHEA WITH POISONING P0368
LEVODOPA F OCCULT BLOOD P05 V SINGLE CASE OF GASTRITIS WITH MELENA P0 780
LINCOMYCIN F OCCULT BLOOD P05 V NAY CAUSE SEVERE ENTEROCOLITIS P0872
LIPOMUL F OCCULT BLOOD P05 V NAY BE SEVERE G.I. TRACT BLEEDING P0657
MEAT P OCCULT BLOOD 205 V MYOGLOBIN IN MEAT, NO EFFECT IF NONE POP 3 DAYS P02 62
MEFENANIC ACID F OCCULT BLOOD POS V OCCURS LESS FREQUENTLY THAN WITH ASPIRIN P0026
MELPHALAN F OCCULT BLOOD P05 V NAY CAUSE GASTROINTESTINAL HEMORRHAGE P0026
MERCURY COMPOUNDS F OCCULT BLOOD P05 V BLOODY DIARRHEA OCCURS WITH POISONING P0 384
METHOTPEXATE F OCCULT BLOOD 905 V BLOODY DIARRHEA MAY OCCUR 90657
NALIDIXIC ACID F OCCULT BLOOD 905 V MAY CAUSE BLEEDING FROM G.I. TRACT P0026
NITRITES F OCCULT BLOOD P05 V MAY CAUSE BLOODY DIARRHEA IF INGESTED P03 68
NOVOBIOCIN F OCCULT BLOOD P05 V INTESTINAL HEMORRHAGE MAY OCCUR P03 84
OXALATES F OCCULT BLOOD P05 V OCCURS AFTER INGESTION P03 68
OXYPHENBUTAZONE F OCCULT BLOOD 905 V MAY CAUSE GASTROINTESTINAL BLEEDING P0026
PARALDEHYDE F OCCULT BLOOD P05 V BLEEDING GASTRITIS IN ACUTE OR CHRONIC POISONING 90384
PARAMETHADIONE F OCCULT BLOOD P05 V G.I. BLEEDING MAY OCCUR (CAN AFFECT MANY ORGANS) P0467
PHENYLBUTAZONE F OCCULT BLOOD P05 V MAY CAUSE G.I. TRACT BLEEDING P06 20
PHOSPHORUS P OCCULT BLOOD POS V BLOODY DIARRHEA NAY OCCUR WITH POISONING 903814
POTASSIUM SALTS F OCCULT BLOOD P05 V NAY CAUSE ULCERATION AND HEMORRHAGE IN G.I. TRACT PO(I6
PROCAPBAZINE F OCCULT BLOOD 205 V MELENA AND G.I. TRACT BLEEDING P 0026
PYPAZOLONES F OCCULT BLOOD 905 V MAY CAUSE G.I. TRACT BLEEDING P0620
PYPVINIUM PAMOATE F OCCULT BLOOD P05 N COLOR OF STOOLS MAY BE MISINTERPRETED P06 20
SILVER F OCCULT BLOOD P05 V MAY CAUSE HEMORRHAGIC GASTPO!NTERITIS 90384
SULFONAMIDES F OCCULT BLOOD P05 V HENATEMESIS AND MELENA MAY OCCUR 90657
SULTHIAME . F OCCULT BLOOD POS V #{149} ONE CASE REPORTED WITH POISONING 90657
TETRACYCLINE P OCCULT BLOOD P05 V MAY OCCUR WITH HEMATENESIS AND MELENA P0 282
THALLIUM F OCCULT BLOOD P05 V DUE TO INGESTION OP TOXIC DOSE P03 68
THEOPHYLLINE F OCCULT BLOOD P05 V IN LARGE DOSES MAY CAUSE GASTRIC HEMORRHAGE P0 1467
THIOTEPA P OCCULT BLOOD 205 V MAY BE ULCERATION OF G.I. TRACT 90657
TRIMETHADIONE F OCCULT BLOOD 905 V G.I. BLEEDING REPORTED (NAY AFFECT MANY ORGANS) 90299
WARPAPIN F OCCULT BLOOD P05 V NAY CAUSE GASTPO-INTESTINAL BLEEDING 90368
IRON SALTS F OCCULT BLOOD Z N IF 3,3 DINETHYLNAPHTHIDINE USED AS CHROMOGEN P0252
AMINOSALICYLIC AC S OCT INC V MAY CAUSE CYTOTOXIC HEPATOCELLULA? DAMAGE 90079
CHLOROFORM S OCT INC V HEPATOTOXIC EFFECT WITH NECROSIS 90990

CHLOPPPOPAMIDE S OCT INC V MAY CAUSE CYTOTOXIC LIVER DAMAGE 90079
ETHANOL S OCT INC V OCCURS AT 15 HOURS IN NORMAL SUBJECTS P0372
IPRONIAZID S OCT INC V MAY CAUSE CHOLES’TATIC AND CYTOTOXIC JAUNDICE R0079
ISONIAZID S OCT INC V CYTOTOXIC HEPATOCELLULAR DAMAGE P0079
MECHLORETHAMINE S OCT INC V MAY CAUSE CYTOTOXIC (HEPATOCELLULAR) DAHAG! P0079
METHOTP EXATE S OCT INC V MAY CAUSE CYTOTOXIC HEPATOCELLULAR DAMAGE P007 9
PRENYLBtYT AZONE S OCT INC V MAY CAUSE CROLESTATIC AND CYTOTOXIC JAUNDICE P00 79
TESTOS TERONE S OCT INC V MAY CAUSE CHOLESTATIC AND CYTOTOXIC LIVER DAMAGE 90079
THI ABENDAZOLE U ODOR INC N ODOR SIMILAR TO THAT AFTFR INGEST OF ASPAPAGINE P06147
TURPENTINE U ODOR INC V ODOR RESEMBLES THAT OF VIOLETS P03 68
951903 ENS S OPOSOMUCOID DEC V ALTERED METABOLISM P0149
ETRINYLESTRADIOL S OROSOMUCOID DEC V METABOLIC EFFECT 901149
OPAL CONTRACEPTIVE S OROSOMUCOD DEC V METABOLIC CHANGES IN LIVER SYNTHESIS (ESTROGEN) P0598
OXYM!THOLONE S OPOSOMUCOID INC V ANABOLIC METABOLIC EFFECT P0072
AZAUBI DINE U OROTIC ACID INC V METABOLIC EFFECT MAY CAUSE CRYSTALLUP!A P0092
BENDROFLUMETHIAZIDE S OSMOLALITY DEC V DUE TO RYPONATREMIA HO 325
CHLORTRALIDONE S OSMOLALITY DEC V WITH ADR SECRETION IN RESPONSE TO DIUP!SIS 90325
RYDPOCHLOROT HIAZ IDE S OSMOLALITY DEC V DUE TO HYPONATPENIA OF DIURETIC ACTION P03 25
NETHYCLOTHIAZIDE S OSMOLALITY DEC V WITH ADR SECRETION DUE TO HYPONATREMIA P03 25
POLYTHI AZ IDE S OSMOLALITY DEC V ADH SECRETION WITH HYPONATRENIA p0325
MET HOX Y FLU PA NE U OSMOLALITY DEC V NEPHROTOXIC EFFECT OF DRUG (DOSE DEPENDENT) HO 66 1
MUSCULAR ExERCISE U OSMOLALITY DEC V EFFECT MOST MARKED WITH LIGHT EXERCISE 90505
CORTICOSTEPOID S S OSMOLALITY INC V ASSOCIATED WITH NA AND CL RETENTION 90384
ETHANOL S OSMOLALITY INC V OSMOTIC ACTIVITY OF ALCOHOL-MIN FROM OTHER SOURCES P0785
GLUCOSE S OSMOLALITY INC N OSMOTICALLY ACTIVE CONSTITUENT IN SAMPLES P0 500
INULIN S OSNOLALITY IN V MASSIVE DOSES HAVE MARKED EFFECT 90026
MANNITOL S OSNOLALITY INC V MAY CAUSE MARKED DEHYDRATION HO 596
METH OXY FLU PA NE S OSMOLALITY INC V IMPAIRED RENAL TUBULAR FUNCTION P022 9
PROLACTIN S OSPIOLALITY INC V EFFECT NOT MARKED 90464
UREA S OSMOLALEY INC N OSMOTICALLY ACTIVE CONSTITUENT IN SAMPLES P 0 500
CHLORPPOPAN IDE U OSMOLALITY INC V IN PATIENTS WITH DIABETES INSIPIDUS 90840
GLUCOSE U OSNOLALITY INC M OSMOTICALLY ACTIVE CONSTITUENT IN SAMPLES 90500
N ETOL A Z ON U OSMOLALITY INC V DIURETIC ACTION P0904
PHLOPIDZIN U OSMOLALITY INC V DUE TO INCREASED EXCRETION OF GLUCOSE ETC P0878
UP P A U OSNOLALITY INC N OSMOTICALLY ACTIVE CONSTITUENT IN SAMPLES P05 00
STORAGE OF SAMPLE S OSNOLALITY Z M NO EFFECT FOR 3H AT ROOM TEMP, lOB AT (I DEGREES P0 500
DIAZOXI DI U OSMOLAP CLEARANCE DEC V EFFECT OVER 2H OF 14 MG/KG GIVEN I.V. P05 01
NETOLA ZONE U OSMOLAR CLEARANCE INC V DIURETIC ACTION OF DRUG RO9OU
PREGNANCY F OSMOTIC FRAGILITY INC V MAY BE OCCASIONAL INCREASE P02 91
CALCIUM CARBIMIDE U OXALATE DEC N INHIBITS ENZYMATIC PROCEDURE FOP MEASUREMENT P1022
PYRIDOXINE U OXALATE DEC V IN PATIENTS WITH OXALATE PENAL CALCULI 90384
METHOX YFL UP A N! S OXALATE INC V METABOLIC DEGRADATION PRODUCT OF DRUG P0753
METH OX Y FLORA NE U OXALAT! INC V METABOLIC DEGRADATION PRODUCT OF DRUG P07 53
SMOKING B 02-HEMOGLOBIN AFFINITY DEC V SIGNIFICANTLY LESS IN SMOKERS P08 14
ACETR IZOATE U PAN CLEARANCE DEC V WHEN 70% INJECTED FOR AOPTOGRAPHY P0020
CHLOPOTHI AZ IDE U PAH CLEARANCE DEC V COMPETITIVE INHIBITION OF SECRETION P0 404
DIAZOX IDE U PAR CLEARANCE DEC V EFFECT OVER 2R OF 4MG/KG GIVEN I.V. 90501
PR 0 BE NEC ID U PAR CLEARANCE DEC V PENAL CLEARANCE IMPAIRED RO638
PAD 10 GP A P HIC U PAR CLEARANCE DEC V IF CONC SOLNS USED FOR AORTOGRAPRY P00 20
SUL’I NPYPAZONE U PAN CLEARANCE DEC V INHIBITS TUBULAR TRANSPORT P0026
AMINOBENZOIC ACID U PAR CLEARANCE INC N MEASURED AS IF PAR HO 779
ANINOSALICYLIC AC U PAR CLEARANCE INC N VERY SLIGHT EFFECT, MEASURED AS IF PAR P0779
AZOSULFAM IDE U PAR CLEAHANCE INC N SLIGHT EFFECT ONLY, MEASURED AS IF PAR 90779
CLONIDINE U PAR CLEARANCE INC V NONSIGNIFICANT EFFECT IN HYPEPTENSIVES HO 127
HYDROCORTISONE U PAR CLEARANCE INC V INCREASES GFR R0384
LEV000PA U PAH CLEARANCE INC V ?SEC. TO PENAL VASODIL. OP DIRECT ACTION ON TUBULES 90328
SULFONAMIDES U PAR CLEARANCE INC N REACT AS IF PAR WITH BRATTON-MARSHALL METHOD P0779
SECRETIN 0 PANCREAT JUICE AMYLASE INC V NORMAL ABOVE 14.9 U/KG/80 MIN P0 151
PA NCR! 0EV MIN 0 PANCREAT JUICE PROTEIN INC V INCREASE IN RESPONSE TO CHALLENGE P0151
SMOKING 0 PANCREATIC JUICE HCO3 DEC V CHRONIC EFFECT HEAVY SMOKERS, LESS IN LIGHT P0 172
SECRET IN 0 PANCREATIC JUICE HCO3 INC V NORMAL ABOVE 90 NEQ/L P0 151
SMOKING 0 PANCREATIC JUICE VOL DEC V CHRONIC EFFECT HEAVY SMOKERS, LESS IN LIGHT P0172
SECRETIN 0 PANCREATIC JUICE VOL INC V NORMAL RESPONSE OVER. 3.2 ML/KG/8OMTN P0151
PHOSPHATES P PARATHYROID HORMONE INC V UP TO 125% INC AT 1 HOUR AFTER 1G ORALLY P0770
AC!TAZOLANI DE S PBI DEC V INHIBITS IODINATION OF TYROSINE IN TBG 90004
ACETYLSALICYLIC AC S PBI DEC V COMPETES FOR TBPA ALSO UNCOUPLES PROSPRORYLATION P0 299
AMINOBEEZOIC ACID S PBI DEC V INHIBITS IODINATION OF TYROSINE IN TBG 900014
AMINOGLUTETHIMIDE S PBI DEC V INHIBITS IODINATION OF TYROSINE IN TBG P0004
AMINOSALICYLIC AC S P81 DC V INHIBITS IODINATION OF TYPOSINE IN TBG 90848
AMINOTHIAZOLE S PBI DEC V INHIBITS JODINATION OF TYROSINE IN TBG P0004
A NP HE N ONE S PBI DEC V INHIBITS IODINATION OF TYPOSINE IN TBG P0004
ANABOLIC STEROIDS S 991 DEC V REDUCES CONCENTRATION OF CIRCULATING TBG P0 0 0 Li
ANDOGENS S PBI DEC V REDUCED SYNTHESIS OF TBG 90596
CARBIMAZOLE S PBI DEC V INHIBITS IODINATION OF TYPOSINE IN TBG P0004
CARBUTANIDE S PHI DEC V INHIBITS IODINATION OFTYROSINE IN TBG 90004
CHLORATE S PBI DEC V INTERFERES WITH TRAPPING OF IODIDE BY THYROID 90004
CHLORMERODIN S PBI DEC N FORMATION OF MERCURIAL IODIDE DURING ANALYSIS 30233
CHLOPPPOMAZINE S PBI DEC V MECHANISM OBSCURE (OBSERVED IF OVER 600MG GIVEN) PO00L
CHLOPPROPANIDE S P81 DEC V QUESTIONABLE EFFECT (MAY BE SLIGHT IN DIABETICS) 90004
COBALT SALTS S P31 DEC V CAUSE DECREASE, POSSIBLY TO EXTENT OF GOITER R03 814
COPPER S ?BI DEC N AS CONTAMINANT OF WATER MAY AFFECT ANALYSIS P0641
COPTICOSTEROIDS S PHI DEC V IF CHRONIC ADMIN IN SMALL OR LARGE DOSES P0255
CORTICOTROPIN S PBI DEC V REDUCED THYROBINDING GLOBULIN 91001
CORTISONE S PBI DEC V INHIBITS IODINATION OP TYPOSINE, ALSO HEMODILUTION 90004
CV A N I DF S S PHI DEC V INHIBIT IODINATION OF TYROSINE IN TBG R000L4
DESSICATED THYROID S PHI DEC V OBSERVED WITH SOME BATCHES (T4 CONVERTED TO T3) P02 33
DIFLUOPOPHO SPH ATE S PHI DEC V INTERFERES WITH TRAPPING OF IODIDE BY THYROID P000 14
DINITROPHENOL S PHI DEC V COMPETES WITH THYROXINE FOR TBG P0004
DIPHENYLHYDANTOIN S 231 DEC V COMPETES WITH THYROXINE FOR BINDING SITES RO417
DISULFIPA N S PHI DEC V UNCOMMON REPORTED EFFECT 90596

DOCA S PHI DEC V INHIBITS IODINATION 0? TYROSINE IN TBG ‘0O0LL
EPI NEPHRINE S P31 DEC V CAUSES RELEASE OF PRI FROM THYROID ROO0
ETHIONA MID! S PBI DEC V ANTITHYROID EFFECT AFTER SEVERAL WEEKS 40 LI 17
EVANS BLUE S PHI DEC V MECHANISM OBSCURE 9030L1
FLUORIDES S PHI DEC V LARGE DOSES INTERFEPE WITH 12 TRAPPING 3! THYROID P0 004
FLU CR09 ORATE S PHI DEC V INTERFERES WITH TRAPPING 0’ IODIDE BY THYROID 90004
GENTISIC ACID S PHI DEC V COMPETES FOP BINDING WITH TBPA 900044
GLJCOC0RTICOIDS S PHI DEC V REDUCED AMOUNT OF TBG 90355
GOLD S PHI DEC M INTERFERES WITH CHLOPIC ACID, BARKER M!7HODS 30112
HA LOFE NATE S PHI DEC V INHIBITS BINDING OF T14 TO TBG P0674
HEMOLYSIS S PBI DEC V IF MARKED, RBC’S CONTAIN NO 12 (DILUTIOi EFEECT) 90112
HYDROC HLOROTHIAZIDE S PHI DEC V MECHANISM OBSCURE 90004
HYDPOCOPTISONE S PHI DEC V INHIBITS IODINATION OF TYROSIN! IN TBG HO 004
HYPOC HLORITES S PHI DFC V INTERFERES WITH TRAPPING OF IODIDE BY THYROID O0O44
IODATES S PBI DEC V INTERFERES WITH TRAPPING OF IODIDE BY I’IYROID ROO0
ISONIA ZID S PHI DEC V REDUCES THYROID SYNTHESIS 30596
LIOTPIX S PHI DEC V THERAPEUTIC RESPONSE 90026
LITRI UN S PHI DEC V INHIBITS IODINACION OF TYROSINE IN TBG 90025
MENSTRUATION S PHI DE C V SLIGHT FALL AFTER MENSTPUATION OBSERVED 30255
MEPHENYTOIN S PHI DEC V COMPETES WITH THYROXINE FOR BINDING SIT3S 90596
MEPALLU RIDE S PHI DEC N INTERFERES WITH DETERMINATION PROCEDURE R1C2I
MERCAPTOMEPIN S PHI DEC M FORMATION OF MERCURIAL IODIDE DURING ANALYSIS 90233
MERCURIAL DIURETICS S PHI DEC M INTERFERE WITH ACID DISTILL, CHLOPIC ACID METHODS ROLI17
MERCURY COMPOUNDS S PBI DEC N INTERFERE WITH CHLORIC ACID DIGEST PROCEDURES 90004
MERTHIOLATE S PBI DEC N INHIBITION 0! REACTION CAUSED BY CONTAMINATED SKIN P0 83 9
METHINAZOLE S PHI DEC V INHIBITS IODINATION OF TYROSINE IN TBG R01408
NE T HYLTE S TOST E P0 NE S PBI DEC V LOWERS CONCENTRATION 0’ CIRCULATING TBG 90004
METHYLTHI OUPACIL S PHI DEC V INHIBITS IODINATION OF TYROSINE IN TBG 900044
N ITOTANE S PHI DEC V PARE REPORTED SIDE EFFECT 90467
MONOFLUOPOSUL PHON S PBI DEC V INTERFERES WITH TRAPPING 0? IODIDE BY THYROID 90004
N AN DR OLONE S PHI DEC V ANABOLIC EFFECT RO708
NESSLER’S REAGENT S PHI DEC N CATALYTIC EFFECT 0? IODINE INHIBITED BY K+, RG++ RO Ii 36
NIAGARA SKY BLUE S PHI DEC V MECHANISM OBSCURE 900014
NOPETH A NDROLONE S PHI DEC V CONCENTRATION OF CIRCULATING TBG LOWERED 90004
NORETHINDRONE S PHI DEC V WHEN TREATMENT RESULTS COMPARED WITH CONTROLS 90095
OX! MET HOLONE S PHI DE C V REDUCES CONCENTRATION OF CIRCULATING TBG 90004
OXY PREN BUTA ZONE S PHI DEC V INHIBITS IODINATION OF TYROSINE IN TBG 90004
PAP ABRONDYLA MINE S PHI DEC V INHIBITS IODINATION OF TYPOSINE IN THG 900044
PERCH L ORATE S PHI DEC V INTERFERES WITH TRAPPING OF IODINE B! THYROID HO 0 04
PERIODATE S PHI DE C V INTERFERES WITH TRAPPING OF IODINE BY TNYROID 90004
PHENI NDIONE S PHI DEC V INHIRITS IODINATION OF TYROSIWE IN TBG P0004
PHENDTHIAZINES S PHI DEC V ANTITHYROID EFFECT 0’ LARGE DOSES 90255
PH E NYLB U TAZ ONE S PHI DEC V COMPETES WITH THYROXINE FOR BINDING ON THG 90255
PREDNISOLONE S PHI DEC V INHIBITS IODINATION OF TYROSINE IN THG P00 04
PREDNISONE S PB! DEC V INHIBITS IODINATION OF TYROSINE IN THG P 0004
PROGESTERONE S PHI DEC V INHIBITS IODINATION OF TYROSINE IN TBG 90004
PROPYLTHIOU RACIL S PHI DEC V THYROXINE IN CIRCULATION DECREASED 301417
QUINIDINE S PHI DEC V OCCASIONAL EFFECT (USUALLY NONE) 90255
RESERPINE S PBI DEC V RAPE DEPRESSION REPORTED (GIVEN ORALLY FOP 1 MONTH) HO 596
RESORCINOL S PHI DEC V REPORTED EFFECT OF TREATMENT OF VAPICOS ULCERS
SODIUM NITROPPUSSI S PHI DEC V SINGLE CASE REPORTED (?DUE TO THIOCYANAT!) P0702
SU LEA METH OX AZ OLE S PHI DEC V SMALL EFFECT WITH THERAPEUTIC DOSES 901417
SULFONAMIDES S PHI DEC V INHIBITS IODIN&TION OF TYROSIN! IN THG P0004
TESTOS TEPONE S PHI DEC V DECREASED THG SYNTHESIS. AND AFFECTS BINDING 9 1001
THIAMAZOLE S PBI DEC V ANTITHYROID ACTION OF DRUG P05 96
THIA ZIDES S PHI DEC V INC EXCRETION WITH PROLONGED THERAPY MAT OCCUR 90384
THI OCYANATES S PBI DEC V BLOCKAGE OF THYROXINE BIOSYNTHESIS P03 56
THIOPENTAL S P91 DEC V INHIBITS IODINATION OF TYROSINE IN TRG p0004
TRIOURACIL S PBI DEC V INHIBITS IODINATION OF TYROSIN! RESIDUES IN TBG 90004
TIOCAPLIDE S P91 DEC N MYXEDEMA REPORTED IN ON! CASE P06 57
TOLBUTA MID! S PHI DEC V INHIBITS IODINATION OP TYROSINE RESIDUES IN TBG 90004
TRIIODOTHYHONIN! S PBI DEC V PITUITARY SUPPRESSION OF TSR 300014
TRYPAN BLUE S PBI DEC V MECHANISM OBSCURE P 0004
VITAMIN A a PBI DEC V INHIBITS IODINATION OF TYROSINE RESIDUE:3 IN TBG R00O
ACETPIZOATE S PHI INC N BUT DOES NOT AFFECT T4 (EFFECT LASTS 2 TO 4 WEEKS) P0839
ADI P1 ODONE S PHI INC N CONTAINS IODINE R0596
ALBUMIN, HUMAN S PHI INC V CAUSES EFFECT IF IODINATED 90907
ANT’SEPTICS S PHI INC N IF CONTAIN IODINE AND USED TO CLEAN SKIN P02 55
BARIUM SALTS S PBI INC N OCCASIONALLY CONTAMINATED WITH INORGANIC IODINE 90255
BENZI ODA BONE S PHI INC M CONTAINS 46% IODINE 90004
BISMUTH SALTS S PHI INC V MANY BISMUTH SALTS CONTAIN IODINE P0004
BROMIDES S PHI INC N MAY BE CONTAMINATED WITH IODINE ‘0355
BPONSULFALEI N S PBI INC N ORGANIC IODIDE CONTAMINATION OF SOME BS? SOLNS P0738
BUNAMIODYL S PBI INC V EFFECT UP TO 2 MONTHS (AFFECTS T14 AT HIGH CONCS) 90191
CHINIOFON S PHI INC N CONTAINS 27.5% IODINE R0004
CHLORIDE SALTS S PHI INC M LABORATORY CONTAMINATION MAY CAUSE SIG HEFECT 90255
CHLOPMADINON! S PHI INC V DUE TO INCREASED BINDING GLOBULIN P0620
CLIOQUINOL S PHI INC N IS AN ORGANIC IODINE COMPOUND P0 596
COUGH MEDICINES S PHI INC V SOME MAY CONTAIN IODIDES 90355
DANDRUFF MEDICATION S PHI INC N IODINE CONTAMINATION (IN SOME PREPARATIONS) P03 55
DECAMETHONIUM S PHI INC V CONTAINS (19.5% IODINE 90004
DESSICATED THYPOID S PHI INC V INCREASES BY 1-2 UG/100ML/DAY PER GRAIN GIVEN P0 112
DEXTROTHYPOXINE S PHI INC V CONTAINS 65% IODIN!(MAY CAUSE INC TO 1O-25UG/IO0NL) 90004
DIATRIZOATE S PBI INC N HUT DOES NOT AFFECT T4, EFFECT LASTS 2-5 DAYS P0 83 9
DI!THYLSTILBESTROL S PHI INC V INCREASES CONCENTRATION 0’ CIRCULATING HG 90004
DII000CA!F!INE S PSI INC V CONTAINS 66.5% IODINE P00014
DIIODOHYDPOXYQUIN S PHI INC M CONTAINS 65% IODINE, EFFECT LASTS FOP SOME WEEKS 90004
DIIODOQUINOLINE S PHI INC N CONTAINS 67% IODINE P0004
DIMETHYLTUBOCURAR S PHI INC V CONTAINS 35 IODINE P0004
DIPROTIZOATE S PHI INC N BUT DOES NOT AFFECT T4 (EFFECT FOR 1-2 4!EKS) 90839

DITHIAZINE S PHI INC N CONTAINS 24.5% IODINE P00 04
DIURNAL VARIATION S PHI INC V SMALL STATISTICALLY SIGNIFICANT EFFECT P0255
ESTRADIOL S PHI INC V INCREASES CONCENTRATION OF CIRCULATING TBG P000
ESTPOENS S PHI INC V INCREASES BINDING CAPACITY OF TBG P09 97
ESTRON! S P31 INC 7 INCREASES CONCENTRATION OF CIRCULATING THG P000 4
ETHER S PHI INC V CAUSES MOBILIZATION 0? PHI STORES P0004
ETHINYLESTR ADIOL S PHI INC V INCREASES CONCENTRATION OF CIRCULATING TBG P000 4
FT HIODOL S PHI INC N CONTAINS IODINE P0026
ELOPAQUIN S P91 INC N CONTAINS IODINE, EFFECT LASTS 2-14 WEEKS P0112
!LtJOROPYPINIDI NE S PHI I NC V MECHANISM OBSCURE P0004
G ALLA MI N! S ?BI INC N ORGANIC IODINE CONTAMINATION P05 96
GARGLES S PHI I NC N SOME MAY CONTAIN ORGANIC AND INORGANIC IODINE P0 3 55
!IIPPUPAN S PHI INC N BUT DOES NOT AFFECT T4 P083 9
HYDROXYQUINOLINE S PHI I NC N IN VAGINAL SUPPOSITORIES (OFTEN IODINATED) 90907
INDOCYANINE GREEN S PHI INC N ORGANIC IODINE CONTAMINATION P03 55
INSULIN S PHI I NC V MECHANISM OBSCURE P0004
IODIDES S PB INC N IODIDE SALTS IF MORE THAN 1G PEP DAY-LASTS 28 DAYS 90004
IODINATED GLYCERIN S PBI I NC V EFFECT LASTS UP TO 2 DAYS 90112
IODINE CONTAIN DRUG S PHI INC V IODINE CONTAMINATION P0 355
IODIPANIDE S PHI INC N HUT DOES NOT AFFECT T4 EFFECT LASTS 3-Li MONTHS P08 39
IODOALPHIONIC ACID S PHI INC N CONTAINS IODINE (EFFECT LASTS 2-12 MONTIS) P 04 36
IODOCA SEIN S PHI I NC N ORGANIC IODINE CONTAMINATION 90355
IODOCHLORHYDROXYQU S PHI I NC N CONTAINS IODINE (EFFECT LASTS 2-3 MONTHS) R09148
IODOFORM S PBI IN C N CONTAINS IODINE 90596
S PHI I NC N CONTAINS IODINE EFFECT LASTS 2 WEEKS P0907
IODOPYRI N! S PHI INC N CONTAINS IODINE 90654
IODOTHIOURACIL S PBI INC M CONTAINS ORGANIC IODINE (EFFECT FOR SEVERAL MONTHS) P0907
IOPANOIC ACID S PHI INC N ORGANIC IODINE AFFECTS TEST, EFFECT LASTS 1-14 NOS. 90839
IOPHENDYLATE S PHI INC M CONTAINS IODINE EFFECT LASTS UP TO 5 YEARS 90112
IOPHENOXIC ACID S PHI INC M CONTAINS IODINE EFFECT LASTS UP TO 30 YEARS P0112
lOP YDO NE S PHI INC M CONTAINS IODINE HO 596
IOQUIN S PHI INC N CONTAINS IODINE, DURATION OP EFFECT UNCERTAIN P0112
IOTHALAMATE S PHI I NC N CONTAINS IODINE P0596
IPODATE S PHI INC N CONTAINS OPGANIC IODINE RO436
ISOPPOPAMIDE S PBI INC N CONTAINS IODINE P00 04
LEVODOPA S PHI I NC V ?E’FECT DUE TO TETRAIODOFLUORESCEIN IN APSULES 90132
LEVOTH YROXI NE S PHI INC V IN PATIENTS ON THYROID NAINTENANC THERAPY P0004
LIPIODOL S PHI INC V DOES NOT AFFECT T4 (EFFECT 1-5 YEARS) P08 39
LUGOL’S IODINE S PHI INC N NO EFFECT T4, CONTAINS IODINE,I0DIDE:E?ECT TO 3WKS P083 9
LYSERGIC ACID S PHI INC V STIMULATES TSR RELEASE, ?EFFECT ON I 131 UPTAKE P0004
MEPROHA MATE S PHI INC M CONTAINS IODINE P0 907
MERCURIAL DIURETICS S PHI I NC M INTERFERES WITH DIGESTION TECHNIQUE R0004
METHIODOL S PHI INC N HUT DOES NOT AFFECT T4(EFFECT LASTS 1-2WEBKS) P08 39
N ETR CC AL S PHI INC V PROBABLY DUE TO IODOCASEIN CONTAMINANT (30 DAYS) P0 899
MOUTH WASHES S PHI INC M SOME NAY CONTAIN IODINE P 0355
N CO-LOP AX S PHI INC V CONTAINS IoDINE, EFFECT LASTS FOP 1-2 WEEKS HO 112
NIALAMIDE S PHI INC V VARIABLE EFFECT ON I 131 UPTAKE IN PATS H0004
NORETHINDRONZ S PHI INC V REPORTED EFFECT BUT MECHANISM UNKNOWN P0233
#{149}NORETHYNODPEL S PHI INC V INCREASES CONCENTRATION OF CIRCULATING TBG P 00 04
ORAL CON7BAC!PTIVC S PHI IN C V ESTROGENS INCREASE CIRCULATING TBG P0918
OVULATION S PHI I NC V SMALL INC IN OVULATORY AND LUTEAL PHASES P0 255
PENETHA MATE S PB! INC M CONTAINS IODINE P09 07
PENICILLIN S PHI INC N IF GIVEN AS HYDRIODIDE SALT HO 596
PERPHENAZINE S PHI INC V MAY CONTAIN IODINATED CONTAMINANTS P04 16
PHENIODOL S PHI INC N CONTAINS IODINE P0596
PINK CAPSULES S PHI INC V MAY CONTAIN IODINE IN DY! 90355
POTASSIUM IODIDE S P31 INC V SMALL DOSES ELEVATE IN NORMAL RANGE, OT9ERS ABOVE P02 55
POVIDONE-IODINE S PHI INC V FOUND BY SOME INVESTIGATORS ONLY P07 57
PREGNANCY S PHI INC V OBSERVED THROUGHOUT PREGNANCY P0 291
PR OGEST IN S PHI INC V INCREASED PRODUCTION OF THG R1001
PROPYLIODON E S PBI INC N EFFECT LASTS 1-5 MONTHS P0907
PPOPYLTHIOURACIL S PHI INC V REDUCES METABOLISM OF EXOGENOUS THYROXINE P 0004
PYPAZINAMIDE S PHI INC V OCCURS IN FIRST WEEK AND AFTER ONE MONTH HO 255
QUININE IODOHIS S PHI I NC V CONTAINS 57% IODINE P0004
RADIOACTIVE IODINE S PHI INC V MAY CAUSE RYPOTHYRODISM (INC BY 2-3% PEE YEAR) P0026
RED DYED DRUGS S PHI INC N PRESENCE OF ERYTHROCBINE DYE P0032
RED DYED FOOD S PHI I NC N PRESENCE OF EPYTHPOCRINE DYE P0 3 55
RESEPPI NE S PHI INC V INCREASED METABOLISM BY HEPATIC NICROSONES P0355
SUNTAN OIL S PHI INC N MANY PREPARATIONS CONTAIN IODINE P0620
TETPAI ODOFLUORESCE S PHI INC V RED DYE USED TO COLOR MANY PHARMACEUTICALS R0004
TETRIDAZ-H S PHI INC M IODINE CONTAMINATION P03 55
THY MOL S PHI INC V AFFECTS PHI IF GIVEN AS THYNOL IODIDE P00014
THYROID S PHI INC V INCREASES BY 1-2 UG/100NL/DAY/1 GRAIN GIVEN P0417
THYROTPOPIN S PSI INC V STARTS WITHIN 15H, MAY INC BY UP TO 5.5 UG/100ML P0255
TOOTHPASTE S PHI INC V SOME MAY CONTAIN ENOUGH 12 TO CAUSE EFFECT 80255
TOURNIQUET S PHI NC V OCCLUSION FOP 5 MIN NAY CAUSE INC UP TO 2 UG/100NL P0255
VASOPRESSIN S PHI INC V STIMULATES THYROIDAL I 131 RELEASE 90004
VITAMIN A S PHI INC V WREN GIVEN IN COD LIVER OIL P0620
VITAMIN D S PHI INC V WHEN GIVEN IN COD LIVER OIL P0620
VITAMIN PREPS S PHI INC N IODINE CONTAMINATION P03 55
ACETAZOLAMI DE S PHI Z V REPORTED TO HAVE NO CLINICAL EFFECT P0255
ANTIBIOTICS S PHI Z V NO EFFECT OBSERVED P02 55
ANTICOAGULANTS S PHI Z V NO EFFECT OBSERVED P0255
ANTIHISTAMINES S PHI Z V PROBABLY EXERT NO CLINICALLY SIGNIFICANT EFFECT HO 255
CHLOPPROMAZINE S PHI Z V NO EFFECT OBSERVED WITH NORMAL DOSES P0 255
DEXTROAMPHETANINE S PHI Z V APPEARS TO HAVE NO EFFECT P0255
D I A ZE P A N S PHI Z V CONFLICTING REPORTS ? NO EFFECT 90417
DIGITALIS S PHI Z V NO EFFECT OBSERVED P0255
FLUORIDES S PHI Z V AT CONCS USED TO CAUSE FLUORIDATION OF WATER P02 55
FLUOPOUPACIL S PHI V NO EFFECT OBSERVED RO255

HYDPOXYZINE S PHI Z V NO EFFECT WITH NORMAL DOSES 30255
IMIPRAMINE S PHI Z V NO EFFECT REPORTED WITH NORMAL DOSES 30255
ISOCAPBOXAZID S PHI Z V NO EFFECT REPORTED WITH NORMAL DOSES 90255
MEALS S PHI Z V NO EFFECT OF MEALS REPORTED P0255
NEPROBA NATE S PSI Z V NO EFFECT WITH NORMAL DOSES P0255
MERCURY COMPOUNDS S PHI Z N NO EFFECT BARKER DRY ASH PROCEDURE 30112
METHOTREXATE S PHI Z V REPORTED TO HAVE NO EFFECT 90255
MUSCULAR EXERCISE S PHI Z V NO EFFECT OBSERVED 90255
PPOMAZINE S PHt Z V NO EFFECT WITH NORMAL DOSES 90255
RESERPINE S PHI Z V NO EFFECT OBSERVED WITH OPAL, PAPENTEBAL ADMIN 90255
STORAGE OF SAMPLE S PHI Z N NO EFFECT 5 WEEKS AT ROOM TEMPERATURE PO36
TESTOSTERONE S PHI Z V NO EFFECT SHORT TERM ADMINISTRATION IN HEN RO255
THIAZIDES S PHI Z V REPORTED TO RAVE NO EFFECT 90255
TRIFLU OPERA ZINC S PHI Z V NO EFFECT WITH NORMAL DOSES P0255
VI NCR! STI NE S PHI Z V REPORTED TO HAVE NO EFFECT 90255
VITAMIN A S PHI Z V NO EFFECT OBSERVED WHEN GIVEN FOR 3 WEFKS 90255
ACETYLSALICYLIC AC B PCO2 DEC V IN TOXICITY WITH INC RESP RATE AND PULM VENT RO384
ETHAMIVA N B PCO2 DEC V INC DEPTH OF R!SP AND IMPROVED PULM VENTILATION P0026
ETHER B PCO2 DEC V MAY BE SLIGHT EFFECT DURING ANESTHESIA 90384
MAFENIDE H PCO2 DEC V INRIH OF CARBONIC ANRYDPASF WHEN APP TOPICALLY 90985
NEUROMU SCULAP B PCO2 DEC V SECONDARY TO HYPERVENTILATION POSTOPERA’IVELY RO38LI
NSD 3004 H PCO2 DEC V ARTERIAL BLOOD-LONG ACT CARBONIC ANHYDRASE INHIBIT RO599
TROMETHANINE B PCO2 DEC V CORRECTION OF RESPIRATORY ACIDOSIS P0782
APOMOPPHINE B PCO2 INC V MAY DEPRESS RESPIRATION P0384
BARBITURATES H PCO2 INC V RESPIRATORY DEPRESSANT 303844
CODEINE B PCO2 INC V MAY CAUSE RESPIRATORY DEPRESSION 30384
CT 134 1 B PCO2 INC V POST-INDUCTION MEASUREMENT IN ARTERIAL BLOOD 90823
DEX TROM ET ROB PH AN H PCO2 INC V HIGH DOSES NAY PRODUCE PESP DEPRESSION RO38Li
MDA H 9002 INC V RESPIRATORY ACIDOSIS 90778
MEPERI DINE P PCO2 INC V DEPRESSES RESPONSIVENESS OF P!SP CENTER TO C02 90384
METHADONE H PCO2 INC V MAY CAUSE DIMINSHED PULMONARY VENTILATION 90384
MORPH! NC B PCO2 INC V DIMINISHES VENTILATION, CAUSES HYPERCAPHIA P0026
NITROGEN OXIDES B PCO2 INC V RETENTION OF CO2 OCCURS 90368
PENTAZOCI NE B PCO2 INC V HIGH DOSES PRODUCE MARKED RESP DEPRESSION P0384
PHENAZOCINE H PCO2 INC V MAY PRODUCE RESPIRATORY DEPRESSION 90384
PPOPOXYPHENE B PCO2 INC V LARGE DOSES MAY PRODUCE RESPIRATORY DEPRESSION 90384
AMINO ACIDS E PEP DEC V ASSOCIATED WITH LOW SERUM PHOSPHATE 90938
AC!TOPRENETIDIN H PERIPHERAL SMEAR V PYKNO-SCHISTO-,SPHEPOCYTES, HEINZ BODIES ETC P0252
ANINOSALICYLIC AC B PERIPHERAL SMEAR V ATYPICAL LYMPHOCYTES WITH EOSINOPHILIA 30657
PARGYLINE H PERIPHERAL SMEAR V POIKILOCYTOSIS AND ANISOCYTOSIS COMMON P0657
PROTEINUPIA U PEROXIDASE I NC V INDICATIVE OF PRESENCE OF BLOOD CELLS P0758
ACETAZOLA MIDE H PH DEC V DUE TO INHIBITION OF CARBONIC ANHYDRASE 90620
ACETYLSALICYLIC AC B PH DEC V NAY CAUSE ACIDOSIS LATER (RESP AND METABOLIC) 90620
AMINOHENZOIC ACID H PH DEC V ACIDOSIS FROM USE OF FREE ACID REPORTED R038’4
ANINOSALICYLIC AC B PR DEC V MOD STRONG ACID, LOSS OF FIXED CATION ACIDOSIS RO384
AMMONIUM CHLORIDE H PH DEC V FOLLOWING ADMINISTRATIONS (METABOLIC ACIDOSIS) 30620
AMMONIUN OXALATE H PH DEC M ALTERS ACID-BASE BALANCE IF USED AS ANTICOAGULANT P0620
ARGININE B PH DEC V CHLORIDE SALT TENDS TO CAUSE ACIDOSIS 90026
BLOOD TRANSFUSIONS H PH DEC V IF MASSIVE TRANSFUSIONS GIVEN 90596
CALCIUM CHLORIDE B PH DEC V IS AN ACIDIFYING SALT R062O
CITPATES B PR DEC V SIGNIFICANT ACID SHIFT PRODUCED P0354
CITRATES H PH DEC N SIGNIFICANT EFFECT OF NA CITRATE AS ANTICOAGULANT P0181
CYCLOPROPANE H PH DEC V MAY CAUSE METABOLIC ACIDOSIS 90394
DIMERCAPPOL H PR DEC V MAY INDUCE METABOLIC ACIDOSIS P0026
EDTA H PR DEC N AFFECTS ACID-BASE BALANCE IF USED AS ANTICOAGULANT P0520
ETHANOL H PH DEC V CAUSES LACTIC ACIDOSIS 90176
8
ETHER H PR DEC V METABOLIC ACIDOSIS ESP IN CHILDREN 90026
ETHOXAZOLANIDE B PH DEC V NAY CAUSE METABOLIC ACIDOSIS 90596
FRUCTOSE B PH DEC
PH DEC VV ASSOCIATED WITH LACTIC ACIDOSIS 90227
ISONIAZID LARGE DOSES MAY PRODUCE SEVER! ACIDOSIS 30384
MAFENIDE H PH DEC V IF RESP IMPAIRMENT AS REDUCED RENAL BUFEERING P0048
MDA B PR DEC V RESPIRATORY ACIDOSIS R0778
METHANOL H PH DEC V CAUSES ACIDOSIS P0620
OXALATES B PH DEC N SIGNIFICANT EFFECT OF NH4 OXALATE AS ANTICOAGULANT 90181
PAR ALDEHYDE H PH DEC V ACIDOTIC ACTION P0620
PHENFOPMIN H PH DEC V ACIDOSIS CAN OCCUR P0355
STORAGE OF SAMPLE B PH DEC N IF ANAEROBIC STORAGE AT 37 DEG OR 2H AT ROOM TEMP P1001
TETRA CYCL INC B PH DEC V MAY CAUSE ACIDOSIS WITH RENAL IMPAIRMENT P0596
TUBOCURARINE B PH DEC V LARGE DOSE EFFECT WITH PROLONGED RECOVERY 90596
XYLITOL H PH DEC V PRONOUNCED METABOLIC ACIDOSIS IN MANY PATIENTS R0924
CITRATES S PH DEC N IN VITRO ADDITION OF NA SALT TO PLASMA/SERUM P0035
EDTA S PH DEC N IN VITRO ADDITION OF NA SALT TO PLASMA/SERUM P0035
AC ETA TES H PH INC V ALKALINIZING ACTION DUE TO RAPID METABOLISM 903814
ACETYLSALICYLIC AC B PR INC V INITIAL RESPIRATORY ALKALOSIS P0957
ANTACIDS B PR INC V MAY CAUSE OCCASIONAL METABOLIC ALKALOSIS P0026
CITPATES B PH INC V RESTORES BICAPH RESERVE, MAY CAUSE ALKALOSIS P0026
ETHACRYNIC ACID H PH INC V HYPOCHLOREMIC ALKALOSIS MAY OCCUR P09140
GLUTAMIC ACID H PH INC V NA SALT MAY CAUSE ALKALOSIS P0026
HE AT H PH INC M INC 0.015 PEP DEGREE (MAY ALSO AFFECT BUFFERS) P0181
HYPERVENTILATION B PH INC V DUE TO RESPIRATORY ALKALOSIS 90836
LACTATE H PH INC V USED IN TREAT OF METABOLIC ACIDOSIS 30026
LICORICE H PH INC V MAY CADS! ALKALOSIS 90596
MAFENIDE H PH INC V USUAL FINDING WITH R!SP ALKALOSIS 30048
MEALS H PR INC V EFFECT OF METABOLIC ALKALOSIS 30846
MERCURIAL DIURETICS B PH INC V MAY CAUSE SYSTEMIC ALKALOSIS ESP IF HYP3CHLOPEMIA P0384
OXALATES H PH INC N OCCURS WITH NA OR K OXALATES AS ANTICOAGULANTS 90181
SILVER H PH INC V OBSERVED AFTER SILVER NITRATE ANTISEPSIS 90657
SODIUM BICARBONATE H PH INC V AFFECTS ACID-BASE BALANCE IN VIVO R0620
STORAGE OF SAMPLE B PR INC N IF SAMPLE EXPOSED TO AIR 91001
TROMETHAMINE B PH INC V CAN CORRECT METABOLIC OP HYPEPCAPNIC ACIDOSIS 90782

TUBOCURARINE B PH INC V RESPIRATORY ALKALOSIS WITH LOW DOSES P0596
OX AL ATES S PH INC N IN VITRO ADDITION OF K SALT TO PLASMA/SERUM P0035
ALD OS T F R ONE U PH INC V EXCHANGED WITH K ION FOR NA ION P0384
MAFENIDE U PH INC V IHIB OF CARBONIC ANHYDRASE WREN APP TOPICALLY P0985
PARATHYROID EXTRACT U PH INC V INHIBITS TUBULAR EXCHANGE OF NA FOR H P0699
PROLACTIN U PH INC V INDIVIDUAL RESPONSE - MAY HE MARKED R01464
SODIUM BICARBONATE U PH INC V USED TO ALKALINIZE URINE P00 26
MEPERI DINE B PR Z V INSIGNIFICANT EFFECT OBSERVED P0657
SERUM S PH Z V CLOTTING HAS NO EFFECT P03514
HEAT S PHENOL TURBIDITY INC N INCS GREATLY WITH CHANGE OF TEMPERATURE P0181
PHENOTHIA ZI NES U PHENOTHIAZINE P05 V SOME DETECTABLE UP TO 18 MONTHS AFTER THERAPY HO 384
THIAZIDES 0 PHENTOLAMINE TEST DEC V FALSE MEG. DUE TO HYPOTENSIVE EFFECT OF DRUG P014 17
MAO INHIBITORS 0 PHENTOLAMINE TEST INC V ENHANCED RESPONSIVENESS P0373
PH ENYLPROPA NOLA MINE 0 PHENTOLANINE TEST INC V SINGLE CASE REPORTED P0289
ASCORBIC ACID S PHENYLALANINE DEC V REDUCES ELEVATED LEVEL OF PREMATURE INFANTS P0 384
GLUCOSE S PHENYLALANINE DEC V PROBABLE MUSCLE UPTAKE R0397
MAO INHIBITORS U PHENYLETHYLAMINE INC V PREVENT DEANINATION P 03 84
DETERGENTS U PRENYLKETONES NEG M FALSE NEG RESULTS (BROWN COLOR) WITH FECL3 TEST P0831
ACETOACETAT E U PHENYLKETONES P05 M RED/RED-BROWN WITH FECL3. NO EFFECT PHENISTIX P0239
ACETOPHENETIDIN U PHENYLKETONES P05 M RED FADING WITH FECL3, PINK/RED PHENISTIX P0 2 39
ACETYLSALICYLIC AC U PHENYLKETONES P05 N PURPLE WITH FECL3, PURPLE WITH PHENISTIX P02 99
AMINOBENZOIC ACID U PHENYLKETONES P05 N GREEN WITH FECL3 P0 239
AMINOSALICYLIC AC U PHENYLKETONES P05 N RED-BROWN WITH FECL3, PINK TO PURPLE PHENISTIX P023 9
ANTIPYPINE U PHENYLKETONES P05 N RED FADING WITH FECL3, PINK TO RED PHENISTIX P02 39
BILIPUBI N U PHENYLKETONES P05 N BLUE-GREEN WITH FECL3 P023 9
CHLOPPROMAZINE U PHENYLKETONES P05 M LIGHT PURPLE WITH FECL3, SAME WITH PHENISTIX P0239
CR1 NEPHRINE U PHENYLKETONES P05 N GREEN IN HIGH CONENTRATIONS WITH FECL3 P0239
HOMOGENTISIC ACID U PHENYLKETONES P05 M BLUE/GREEN FADING WITH FECL3, NIL WITH PHENISTIX P0239
IODOCHLORHYDROXY QU U PHENYLKETONES P05 M GREEN WITH FECL3 90239
LEVOMEPROMAZINE U PHENYLKETONES P05 M PHENISTIX P05 IF MORE THAN 100MG/DAY FOP 6 DAYS 90657
MELANIN U PHENYLKETONES P05 M GRAY TO BLACK WITH FECL3 P02 39
NIALAMIDE U PHENYLKETONES P05 N FADING GREEN WITH FECL3, GREEN WITH PRENISTIX P0239
PHENOLS U PHENYLKETONES P05 N VIOLET WITH FECL3, NIL WITH PHENISTIX P0239
PHENOTHI AZI NES U PHENYLKETONES P05 M PINK/RED-PURPLE WITH FECL3, SAME WITH PHENISTIX R023 9
PROCHLORPEPA ZINC U PHENYLKETONES POS N LIGHT PURPLE WITH FECL3, ALSO WTIH PHENISTIX P0 2 39
PYPUVATE U PHENYLKETONES P05 M DEEP YELLOW/GREEN WITH FECL3, NIL PHENISTIX P023 9
VANILLIC ACID U PHENYLKETONES P05 M RED-VIOLET/BROWN WITH FECL3, BROWN PHENISTIX P0239
HOMOGENTISIC ACID U PHENYLKETONES Z N NO EFFECT WITH PHENISTIX P023 9
METHOTPINEPRAZINE 0 PHEOCHPOMOCYTONA TESTS V MAY CAUSE FALSE TEST AS PRODUCES HYPOTENSION P0417
PHLOPIDZI N U PHOSPHATE CLEARANCE DEC V DUE TO REDUCED EXCRETION RO878
VITAMIN 0 F PHOSPHATE DEC V DUE TO EXCESSIVE ABSORPTION P0291
ACETAZOLA NI DC S PHOSPHATE DEC V DEFECTIVE CA AND P014 REABSORPTION CAN B! INDUCED P02014
ALKALINE ANTACIDS S PHOSPHATE DEC V THEORETICAL POSSIBILITY RO883
ALUMINUM SALTS S PHOSPHATE DEC V BINDING OF PHOSPHATE IN G.I.TRACT P 1001
AMINO ACIDS S PHOSPHATE DEC V IF GIVEN I.V. HYPERALIMETATION P0 938
ANESTHETIC AGENTS S PHOSPHATE DEC V OBSERVED AFTER ANESTHESIA P0355
CALCITONI N S PHOSPHATE DEC V DUE TO URINARY LOSS P0384
El’ I NE P HR INC S PHOSPHATE DEC V INCREASED GLUCONEOGENESIS 90029
ETHER S PHOSPHATE DEC V REPORTED; NO MECHANISM CITED P03 84
ETHINYLESTPADIOL S PHOSPHATE DEC V DECREASE OF APPROXIMATELY 2 MG/100ML P0 755
FIBPIN HYDPOLYSATE S PHOSPHATE DEC V INTRACELLULAR TRANSFER P0968
FR UCTOSE S PHOSPHATE DEC V PHOSPHORYLATION OCCURS AFTER I.V. INJECTION P0476
GLUCOSE S PHOSPHATE DEC V DUPING GTE, LESS MARKED AND LONGER THAN CA P0592
HYPER VENTILATION S PHOSPHATE DEC V EFFECT OF RESPIRATORY ALKALOSIS P0846
INSULT N S PHOSPHATE DEC V INCREASED PHOSPHOPYLATION OF GLUCOSE P1001
MANNITOL S PHOSPHATE DEC M INHIBITION OF COLOR DEVELOPMENT P0 184
MEALS S PHOSPHATE DEC V PHOSPHORYLATION OF GLUCOSE AND METABOLISM P03 55
MESTRANOL S PHOSPHATE DEC V INC SENS TO CALCITONIN IN POSTMENOPAUSAL WOMEN P0011
MITHRA MYCIN S PHOSPHATE DEC V INHIBITION OF BONE RESORPTION OF CALCIUM P0879
OPAL CONTRACEPTIVE S PHOSPHATE DEC V REDUCTION OF APPROXIMATELY 2 MG/100ML P0755
PHENOBARHITAL S PHOSPHATE DEC V INCREASES CLEARA NCE (2NDRY HYPERPARATHYROIDISP() P0 39 6
TETRACYCLINE S PHOSPHATE DEC V MAY OCCUR WITH FANCONI SYNDROME P0026
ALUMINUM SALTS U PHOSPHATE DEC V DEC ABSORPTION AND EXCRETION P00 26
PHLORI DZI N U PHOSPHATE DEC V PROBABLY DUE TO INCREASED REABSORPTION P0878
STORAGE OF SAMPLE U PHOSPHATE DEC N UNLESS ACIDIFIED HO 998
BED REST F PHOSPHATE INC V SLIGHT EFFECT ONLY P0471
PHOSPHATES F PHOSPHATE INC V DOUBLED EXCRETION COMPARED WITH BED PEST P0 147 1
ANABOLIC STEROIDS S PHOSPHATE INC V AUGMENTS PHOSPHATE RETENTION P0 204
ANDROGENS S PHOSPHATE INC V AUGMENTS PHOSPHATE BALANCE P02014
BED REST S PHOSPHATE INC V INC UP TO 0.5 MG/100 ML P 0147 1
CALCIFEROL S PHOSPHATE INC V BETTER ABSORPTION AND UTILIZATION P0 2014
CONTACT WITH CLOT S PHOSPHATE INC N RELEASE FROM EPYTHROCYTES AND PLATELETS P0355
DETERGENTS S PHOSPHATE INC N CONTAMINATED GLASSWARE ETC P0620
GROWTH HORMONE S PHOSPHATE INC V GRADUAL SLIGHT RISE - METABOLIC EFFECT P0649
HEMOLY SIS S PHOSPHATE INC V RELEASED FROM PBC’S AND PLATELETS P0624
HEPAPIN S PHOSPHATE INC M PHOSPHATE CONTAMINATION OF HEPARIN REPORTED P0 119
HYDROCHLOPOTHIAZIDE S PHOSPHATE INC V ALTERED PAPATHYROID METABOLISM P0146
LIPOMUL S PHOSPHATE INC V MAY OCCUR WITH AZOTEMIA P06 20
METHICILLI N S PHOSPHATE INC V OCCURS WITH NEPHROTOXICITY P0620
ORAL CONTRACEPTIVE S PHOSPHATE INC V 18% INCREASE REPORTED IN SOME PATIENTS P0657
PARATHYROID EXTRACT S PHOSPHATE INC V DUE TO INCREASED EXCRETION IN URINE P0620
PRO SP HATES S PHOSPHATE INC V INC OF GREATER THAN 2 MG/100 ML OBSERVED P0 406
PHOSPHO SODA S PHOSPHATE INC V HIGH CONCENTRATION OF PHOSPHATE ABSORBED FROM GUT R0907
TETRACYCLINE S PHOSPHATE INC V MAY OCCUR WITH NEPHROTOXICITY P0620
VITAMIN D S PHOSPHATE INC V EFFECT OF INC G.I. TRACT AND RENAL ABSORPTION P1001
ACETAZOL AMIDE U PHOSPHATE INC V INHIBITS TUBULAR REABSORPTION R0204
AC ET OA C ET ATE U PHOSPHATE INC V INHIBITS TUBULAR REABSORPTION P0284
ACETYLSALICYLIC AC U PHOSPHATE INC V INHIBITS TUBULAR REABSORPTION P0 3 84
ALANINE U PHOSPHATE INC V INHIBITS TUBULAR REABSORPTION P0284
AMINO PHEN AEON C U PHOSPHATE INC V REPORTED EFFECT P0596

ASPARAGIN AS! U PHOSPHAT! INC V RESPONSE IN ALL TRFATED PATIENTS P0705
BED REST U PHOSPHATE INC V INC OF APPPOX 200 MG/DAY R071
BICAPHONATES U PHOSPHATE INC V POSSIBLE COMPETITION FOR SAME EXCRETORY ECHANISM 90284
BISMUTH SALTS U PHOSPHATE INC V FANCONI SYNDROME WITH POISONING 30657
CALCITONIN U PHOSPHATE INC V ACTS INDEPENDENTLY OF PARATHYROID 30406
CORTICOSTE POID S U PHOSPHATE INC V METABOLIC EFFECT 70596
DIRYDROTACHYSTEROL U PHOSPHATE INC V DIURESIS ALMOST AS GREAT AS WITH VITAMIr D3 30026
GLYCINE U PHOSPHATE INC V INHIBITS TUBULAR REABSORPTION 90284
HYDROCHLOROTHIAZIDE U PHOSPHATE INC V ALTERED PAPATHYROID METABOLISM 90146
LEAD 13 PHOSPHATE INC V OCCURS WITH POISONING 90291
NESTRANOL 13 PHOSPHATE INC V INC RESPONSE TO CALCITONIN 90011
NETOLAZONE U PHOSPHATE INC V DIURETIC ACTION 30904
PARATHYROID EXTRACT U PHOSPHATE INC V INCREASED CLEARANCE 9040#{128}
PHOSPHATES U PHOSPHATE INC V DOUBLED EXCRETION COMPARED WITH BED REST 90471
TETRACYCLINE U PHOSPHATE INC V DEGRADED MATERIAL MAY CAUSE FANCONI SYNDPOME 90657
TPYPTOPHAN U PHOSPHATE INC V INHIBITS TUBULAR REABSORPTION 3028
VALINE U PHOSPHATE INC V INHIBITS TUBULAR REABSORPTION 30284
VITAMIN D U PHOSPHATE INC V NAY BE NORMAL IN MANY CASES 093
STORAGE OF SAMPLE S PHOSPHATE Z N ROOM TEMP 8H, 4 DEGREES 1 DAY, FROZEN 1 YEAR 0998
THYMOL U PHOSPHATE Z N NO EFFECT ON FISKE AND SUBBAROW METHOD 90779
COPPER C PHOSPHOFFUCTOKINASE DEC V SF.VERLY AFFECTED IN VITRO 130 135
STORAGE OF SAMPLE S PHOSPHOGLUCOMUTASE DEC N AFTER 8 H AT ROOM TEMP, 2 DAYS AT #{163}4DFGB!!S r0998
COPPER C PHOSPHOGLYCEPIC KINASE DEC V LESS MARKED INHIBITION IN VITRO ?0135
HENOLYSIS S PHOSPHOHEXOSEISONERASE Z N SMALL DEGREE HAS NO EFFECT 90998
STORAGE OF SAMPLE S PHOSPHOHEXOSEISOMEPASE Z M NO EFFECT 1 WEEK AT 4 DEGREES, I MONTH A’ -20 ORG 90998
ACETYLSALICYLIC AC S PHOSPHOLIPIDS DEC V INC FATTY ACID OXIDATION, DEC LIPOGENESIS 30384
ASPAPAGINASE S PROSPHOLIPIDS DEC V PARALLEL DECREASE IN CHOLESTEROL ?07C5
CHOLESTYRANINE S PHOSPROLIPIDS DEC V THERAPEUTIC EFFECT 90596
CLOFIBRATE S PHOSPHOLIPIDS DEC V EFFECT LESS MARKED THAN WITH TRIGLYCEPIDES 90141
DEXTPOTHYROXINE S PROSPHOLIPIDS DEC V THERAPEUTIC EFFECT 30026
HEMOLYSIS S PHOSPHOLIPIDS DEC N ORGANIC PHOSPHATE HYDROLYSES TO INORGANIC 90998
LEVOTHYROXINE S PHOSPHOLIPIDS DEC V CORRECTION OF HYPOTHYROID STATE 90907
ASPAPAGINASE S PHOSPHOLIPIDS INC V RARE RESPONSE AFTER INITIAL HYPOLIPIDEMIA RO705
CHLORPRONAZINE S PHOSPHOLIPIDS INC V MAY CAUSE XANTHOMATOUS HILIAPY CIRRHOSIS 90405
EPINEPHRINE S PHOSPHOLIPIDS INC V METABOLIC EFFECT 90384
ESTROGENS S PHOSPHOLIPIDS INC V ALTERED METABOLISM 90874
ORAL CONTRACEPTIVE S PHOSPROLIPIDS INC V ABOUT 20% HIGHER IN PILL-USERS AFTER 6 MONTHS 90186
PREGNANCY S PHOSPHOLIPIDS INC V INCREASE FROM 8 WEEK R0291
BLOOD TRANSFUSIONS P PHTHALAT!S P05 V WHEN BLOOD STORED FOR FEW DAYS IN PLASTIC PACK 906114
MUSCULAR EXERCISE U PLASMIN ACTIVITY INC V ASSOC WITH PPOTEINURIA 90505
OPAL CONTRACEPTIVE P PLASMIN INC V ASSOC ALSO WITH INC PLASMINOGEN (COMMON EFFECT) 70106
ANABOLIC STEROIDS P PLASMINOGEN INC V METABOLIC EFFECT 70072
ESTROGENS P PLASMIWOGEN INC V ALTERED METABOLISM p0 874
ETHYLESTRENOL P PLASMINOGEN INC V METABOLIC EFFECT 90072
FLUOXYNESTERONE P PLASMINOGEN INC V METABOLIC EFFECT 0072
METHANDROSTENOLONE P PLASMINOGEN INC V METABOLIC EFFECT 90072
METRYLTESTOSTERONE P PLASMINOGEN INC V METABOLIC EFFECT 90072
NORETHANDPOLONE P PLASMINOGEN INC V METABOLIC EFFECT 0072
ORAL CONTRACEPTIVE P PLASMINOGEN INC V METABOLIC CHANGES IN LIVER SYNTHESIS (ESTROGEN) 90588
OXANDHOLONE P PLASNINOGEN INC V METABOLIC EFFECT 0072
OXYMETHOLONE P PLASMINOGEN INC V METABOLIC EFFECT ROO2
STANOZOLOL P PLASMINOGFN INC V METABOLIC EFFECT 90072
HISHYDROXYCOUMARIN H PLATELET ADHESIVENESS DEC V RELATED TO DOSE 90384
ACETYLSALICYLIC AC H PLATELET AGGREG DEC V INHIBITS RELEASE OF ADP FROM PLATELETS 90394
DIPYPIDAMOLE B PLATELET AGGREG DEC V WEAK INHIBITION OF ADENOSINE DEAMINASE 90326
SULFINPYPAZONE H PLATELET AGGREG DEC V REPORTED EFFECT 90326
HISHYDROXYCOUMAPIN B PLATELET AGGREG INC V IN RESPONSE TO ADP RO384
ORAL CONTRACEPTIVE H PLATELET AGGREG INC V INC RESPONSE TO ADP 90186
PREMARIN B PLATELET AGGREG INC V SMALL INCREASES REPORTED P002 8
ACETAZOLAMIDE H PLATELET COUNT DEC V MAY CAUSE PANCYTOPENIA WITH APLASTIC ANEMIA 30564
ACETOHEXAMIDE B PLATELET COUNT DEC V THRONBOCYTOPENIA AND APLASTIC ANEMIA REPORTED P062 0
ACETOPHENAZINE H PLATELET COUNT DEC V AGRANULOCYTOSIS OR APLASTIC ANEMIA 90026
ACETOPHENETIDIN B PLATELET COUNT DEC V HEMOLYTIC OP APLASTIC ANEMIA 30435
ACETYLSALICYLIC AC H PLATELET COUNT DEC V DECREASED PLATELET SURVIVAL TIME, NAY HE PURPUPA P09 20
ALLOPURINOL H PLATELET COUNT DEC V RAPE POTENTIALLY DANGEROUS COMPLICATION 90378
AMINOBENZOIC ACID H PLATELET COUNT DEC V INDUCES NALABSOPPTION AND MEGALOHLASTIC ANEMIA 90932
AMINOPYRINE H PLATELET COUNT DEC V NAY CAUSE HEMOLYTIC OP APLASTIC ANEMIA 31023
ANINOSALICYLIC AC H PLATELET COUNT DEC V NAY OCCUR WITH SEVERE MEGALOBLASTIC ANEMIA 90976
AMPHOTEPICIN B H PLATELET COUNT DEC V BONE MARROW DEPRESSION WITH HEMOLYTIC AN:MIA 709445
ANTAZOLINE B PLATELET COUNT DEC V THROMBOCYFOPENIA (IMMUNOLOGICALLY INDUCEE)) 90932
ANTICONVULSANTS H PLATELET COUNT DEC V MAY OCCUR WITH SEVERE MEGALOBLASTIC ANEMIA P 0976
ANTILYMPHOCYTE H PLATELET COUNT DEC V OBSERVED LESS COMMONLY WITH OTHER IMMUNOSUPRESSANTS P0893
ANTIMONY COMPOUNDS B PLATELET COUNT DEC V THROMBOCYTOPENIA 90620
ANTINEOPLASTIC H PLATELET COUNT DEC V NAY CAUSE APLASTIC ANEMIA 90620
ANTIPYRIN! H PLATELET COUNT DEC V ASSOCIATED WITH HENOLYTIC ANEMIA 30557
APPONAL H PLATELET COUNT DEC V IMMUNOLOGICAL MECHANISM RC65
ARSENICAL5 H PLATELET COUNT DEC V PANCYTOPENIA 90240
ARSENOBENZENES B PLATELET COUNT DEC V THPONBOCYTOPENIA 90620
ASPARAGINASE H PLATELET COUNT DEC V NAY CAUSE HONE MARROW DEPRESSION 1O7O5
AZATRIOPRINE B PLATELET COUNT DEC V MAY CAUSE BONE MARROW DEPRESSION 90860
BARBITURATES B PLATELET COUNT DEC V THROMBOCYTOPENIA 90620
BENZENE H PLATELET COUNT DEC V PROBABLE MYELOTOXIC EFFECT (COMMON) 90658
BUSULFAN B PLATELET COUNT DEC V PANCYTOPENIA/THRONBOCYTOPENIA 30467
CARBAMAZEPINE H PLATELET COUNT DEC V T9ROMHOCYTOPFNIA MAY OCCUR AFTER 1 Y9(IMFUNOLOGIC) 90278
CAPHANID! H PLATELET COUNT DEC V REPORTED EFFECT (AMA-BLOOD DYSCRASIAS CO?IMITTEF) P065 8
CAPHENICILLIN H PLATELET COUNT DEC V OCCASIONALLY THRONHOCYTOPENIA MAY OCCUR DO 44 57
CARBON TETPACHLOR H PLATELET COUNT DEC V ANCYT0PENIA (AMA-BLOOD DYSCPASIAS) 90658
CARBUTAMIDE B PLATELET COUNT DEC V NAY CAUSE APLASTIC ANEMIA OR THROMHOCYTOPFNIA 91000
CEPHALOTHIN H PLATELET COUNT DEC V INC RESISTANCE TO OSMOTIC FRAGILITY 9.0656
CHLOPAMHUCIL B PLATELET COUNT DEC V DOSE DEPENDENT HONE NARROW DEPRESSION 9002#{128}

CHLORAMPHENICOL H PLATELET COUNT DEC V PANCYTOPENIA/APLASTIC ANEMIA P0272
CHLORDANE H PLATELET COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCPASIAS) P0658
CHLOPO?HENOTHANE B PLATELET COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0658
CHLOROQUINE H PLATELET COUNT DEC V PANCYTOPENIA P0912
CHLOROTHIAZIDE B PLATELET COUNT DEC V PANCYTOPENIA DUE TO APLASTIC ANEMIA MAY OCCUR P0060
CHLORPROMAZINE H PLATELET COUNT DEC V ASSOC WITH PUPPURA AND PANCYTOPENIA #{149} P0026
CHLORPROPAMIDE B PLATELET COUNT DEC V THROMBOCYTOPENIA OR APLASTIC ANEMIA MAY OCCUR R0024
CHLDPTETRACYCLINE H PLATELET COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0658
CHLORTHALIDONE B PLATELET COUNT DEC V ASSOCIATED WITH RARE AGRANULOCYTOSIS P0657
COLCHICINE B PLATELET COUNT DEC V SELECTIVE THRONHOCYTOPENIA OP APLASTIC ANEMIA P0656
CYCLOPHOSPHAMIDE B PLATELET COUNT DEC V NAY CAUSE HONE MARROW DEPRESSION P0025
CYCLOSEPINE B PLATELET COUNT DEC V MAY OCCUR WITH MEGALOBLASTIC ANEMIA P0976
CYTAPABINE B PLATELET COUNT DEC V DUE TO HONE MARROW DEPRESSION P0620
DACTINONYCIN B PLATELET COUNT DEC V THRONHOCYTOPENIA/PANCYTOPENIA P0026
DESERPIDINE H PLATELET COUNT DEC V POSSIBLE EFFECT AS RELATED COMPOUNDS CAUSE THIS P0467
DEXTRONETHORPHAN B PLATELET COUNT DEC V THPOMHOCYTOPENIA(AMA-HL000 DYSCRASIAS) P0658
DIAZOXIDE B PLATELET COUNT DEC V IMMUNOLOGIC RESPONSE OCCURS FROM DAYS TO MONTHS P0967
DICEILOPPUENAMIDE H PLATELET COUNT DEC V PROBABLE EFFECT (LIKE ACETAZOLAMIDE) P0026
DIETHYLSTILBESTROL B PLATELET COUNT DEC V THROMBOCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0658
DIGITALIS B PLATELET COUNT DEC V (RARE) PANCYTOPENIA/THROMBOCYTOPENIA P1017
DIGITOXIN H PLATELET COUNT DEC V RARE TRROMBOCYTOPENIA (DUE TO IMMUNE MECHANISM) P1017
DIPHENYLHYDANTOIN H PLATELET COUNT DEC V MEGALOBLASTIC/REMOLYTIC/APLASTIC ANEMIA/PANCYTOPEN P0025
DOXYCYCLINE H PLATELET COUNT DEC V THROMBOCYTOPENIA REPORTED P0734
EDTA B PLATELET COUNT DEC V TRANSIENT BONE MARROW DEPRESSION P0026
ETHACPYNIC ACID H PLATELET COUNT DEC V THROMBOCYTOPENIA REPORTED P0723
ETHANOL B PLATELET COUNT DEC V TOXIC NARROW SUPPRESSION, DUE TO CHPON ALCOHOLISM P0176
ETHINAMATE B PLATELET COUNT DEC V THROMBOCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0658
ETHOSUXIMIDE B PLATELET COUNT DEC V APLASTIC ANEMIA/THROHOCYTOPENIA/PANCYTOPENIA RO026
ETHOXAZOLANIDE H PLATELET COUNT DEC V THROMBOCYTOPENIA P0656
FLUOR3URACIL H PLATELET COUNT DEC V MAY CAUSE BONE MARROW DEPRESSION P0026
FUPOSENIDE H PLATELET COUNT DEC V MAY BE ASSOCIATED WITH PURPURA P0452
GLUTETHIMIDE H PLATELET COUNT DEC V THPOMHOCYTOPENIA OR APLASTIC ANEMIA P0026
GOLD B PLATELET COUNT DEC V APLASTIC ANEMIA (THPOMBOCYTOPENIA) P0933
HEPARIN B PLATELET COUNT DEC V REPORTED EFFECT FOLLOWING I.V. INFUSIONS P0656
HETACILLIN H PLATELET COUNT DEC V THROMHOCYTOPENIA MAY OCCUR OCCASIONALLY P0467
HEXACHLOROBENZENE B PLATELET COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0658
HEXANETHYLNELANINE H PLATELET COUNT DEC V MODERATE EFFECT IN A THIRD OF PATIENTS P0995
HYDANTOINS H PLATELET COUNT DEC V TRPOMBOCYTOPENIA (IMMUNOLOGICALLY INDUCED) P0620
HYDRALAZINE H PLATELET COUNT DEC V PANCYTOPENIA MAY OCCUR WITH PURPURA P0014
HYDPOCHLOPOTHIAZIDE H PLATELET COUNT DEC V THROMBOCYTOPENIA REPORTED P0723
HYDROFLUNETHIAZIDE B PLATELET COUNT DEC V PANCYTOPENIA OH THROMBOCYTOPENIA WITH PUPPUPA 90991
HYDROXYCHLOROQUINE H PLATELET COUNT DEC V THROMBOCYTOPENIA P07514
HYDROXYUREA B PLATELET COUNT DEC V THPOMHOCYTOPENIA P0026
IMMUNE SEPA H PLATELET COUNT DEC V FALL OBSERVED SEVERAL DAYS AFTER INJECT P0657
INDOMETHACIN H PLATELET COUNT DEC V RARE AGRANULOCYTOSIS/PANCYTOPENIA/APLASTIC ANEMIA P0786
IOPANOIC ACID H PLATELET COUNT DEC V SEVERE THROMHOCYTOPENIA IN TWO CASES P0657
IPRONIAZID H PLATELET COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0658
ISONIAZID B PLATELET COUNT DEC V NAY RARELY CAUSE HONE-NARROW APLASIA P0071
LEAD H PLATELET COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0658
LINCOMYCIN B PLATELET COUNT DEC V PARE REVERSIBLE THROMBOCYTOPENIA P03814
LIPOMUL B PLATELET COUNT DEC V THRONBOCYTOPENIA WITH FAT-OVERLOADING P0620
LUGOL’S IODINE B PLATELET COUNT DEC V RAPE POSSIBLE RESPONSE WITH PURPUPA P0026
MEASLES VACCINE H PLATELET COUNT DEC V NAY CAUSE THROMBOCYTOPENIC PURPUPA P0657
NECHLORETHANINE B PLATELET COUNT DEC V HONE MARROW DEPRESION 30026
NEFENAMI ACID H PLATELET COUNT DEC V PANCYTOPENIA P02140
MELPHALAN H PLATELET COUNT DEC V MAY CAUSE BONE MARROW DEPRESSION (DOSE RELATED) P0167
MENSTRUATION H PLATELET COUNT DEC V BY 50 - 70 %, RISES TO NORMAL BY 4TH DAY P0291
NEPAZINE H PLATELET COUNT DEC V PANCYTOPENIA P0620
MEPHENYTOIN H PLATELET COUNT DEC V SECONDARY TO APLASTIC ANEMIA/PANCYTOPENIA P0784
NEPHOBAMATE H PLATELET COUNT DEC V RAPE BONE-NARROW APLASIA, THROMBOCYTOPENIA P0025
NERCAPTOPUPINE B PLATELET COUNT DEC V MAY CAUSE BONE-MARROW DEPRESSION P0656
MERCURIAL DIURETICS H PLATELET COUNT DEC V THROMBOCYTOPENIA REPORTED (SENSITIZATION) P0384
NETHAZOLANIDE H PLATELET COUNT DEC V PROBABLE EFFECT AS LIKE ACETAZOLAMIDE P0620
NETHICILLIN H PLATELET COUNT DEC V MAY RARELY CAUSE HONE MARROW DEPRESSION P0736
METHIMAZOLE H PLATELET COUNT DEC V THROMBOCYTOPENIA RO656
METHOTREXATE H PLATELET COUNT DEC V MAY OCCUR WITH MEGALOBLASTIC ANEMIA P0976
NETHYCLOTHIAZIDE H PLATELET COUNT DEC V THROMHOCYTOPENIA WITH PURPUPA MAY OCCUR P0467
NETHYLDOPA B PLATELET COUNT DEC V VERY RAPE OCCURS WITHIN DAYS OP MONTHS P0532
NITHRANYCIN H PLATELET COUNT DEC V THROMBOCYTOPENIA P0026
NITOMYCIN C H PLATELET COUNT DEC V PANCYTOPENIA P0589
NALIDIXI ACID H PLATELET COUNT DEC V THROMBOCYTOPENIA P0999
NAPHTHOXYACETIC AC H PLATELET COUNT DEC V REPORTED EFFECT (AMA-BLOOD DYSCRASIAS COMMITTEE) P0658
NEOMYCIN B PLATELET COUNT DEC V IF SEVERE NEGALOBLASTIC ANEMIA P0976
NITROFURANTOIN H PLATELET COUNT DEC V THPOMHOCYTOPENIA P0293
NOVOBIOCIN H PLATELET COUNT DEC V THROMBOCYTOPENIA (IMMUNOLOGICALLY INDUCED) P0384
NYSTATIN B PLATELET COUNT DEC V THROMBOCYTOPENIA (AMA-BLOOD DYSCPASIAS) P0658
OXACILLIN B PLATELET COUNT DEC V USUALLY ONLY ASSOC WITH LARGE PARENTEPAL DOSES P0467
OXYPHENHUTAZONE B PLATELET COUNT DEC V THRONHOCYTOPENIA MAY OCCUR AFTER 1 WEEK THERAPY 90620
PARAMETHADIONE H PLATELET COUNT DEC V APLASTIC ANEMIA MAY OCCUR RARELY P0026
PENICILLAMINE B PLATELET COUNT DEC V THRONBOCYTOPENIA MAY OCCUR WITH RASH P0022
PENICILLIN H PLATELET COUNT DEC V AGPANULOCYTOSIS/THPOMHOCYTOPENIA P0294
PERCULORATE B PLATELET COUNT DEC V NAY CAUSE FATAL APLASTIC ANEMIA P0026
PHENACEMIDE H PLATELET COUNT DEC V APLASTIC ANEMIA MAY OCCUR RARELY P0026
PHENFORMIN H PLATELET COUNT DEC V ONE CASE OF THROMBOCYTOPENIA REPORTED P0657
PHENOBARHITAL H PLATELET COUNT DEC V THPONBOCYTOPENIA MAY OCCUR AFTER SOME TIME P0658
PHENOTHIAZINES B PLATELET COUNT DEC V HEMOLYTIC ANEMIA (SENSITIVITY DEPENDENT) P0240
PMENYLBUTAZONE H PLATELET COUNT DEC V NAY CAUSE APLASTIC ANEMIA OR THPOMHOCYTOPENIA P0290
PIPAMAZINE H PLATELET COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0658
PIPERACETAZINE B PLATELET COUNT DEC V PARE THROMBOCYTOPENIA (REVERSIBLE) P0026
PIPOBRONAN B PLATELET COUNT DEC V MAY CAUSE HONE NARROW DEPRESSION P0467

POLIONYELITIS VAC B PLATELET COUNT DEC V MAY RARELY CAUSE THPOMBOCYTOPENIA P06 57
PPEDNISONE B PLATELET COUNT DEC V REPORTED EFFECT IN ONE INDIVIDUAL 906 57
PRINIDONE B PLATELET COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0658
PPOCAR HAZINE B PLATELET COUNT DEC V THROMHOCYTOPENIA
#{149} AND BONE NARROW DEPRESSION P0026
PROPRA NOLOL B PLATELET COUNT DEC V PURPUPA PROBABLY REFLECTS ALLERGIC RESPONSE 90423
PYRAZOLONES B PLATELET COUNT DEC V THPOMBOCYTOPENIA P06 20
PYRIMETRA MINE H PLATELET COUNT DEC V MAY OCCUR WITH SEVERE MEGALOBLASTIC ANEMIA 91007
QUI NAC PINE H PLATELET COUNT DEC V THPOMBOCYTOPENIA OR APLASTIC ANEMIA NAY OCCUR R0620
QUINIDINE B PLATELET COUNT DEC V ALLERGIC REACTION/PANCYTOPENIA/PUPPIJRA 90953
QUININE H PLATELET COUNT DEC V IMMUNOLOGICAL MECHANISM 30232
PESEPPINE H PLATELET COUNT DEC V TRPOMBOCYTOPENIA WITH PUPPUPA MAY OCCUR P0658
PIFAMPIN H PLATELET COUNT DEC V OCCURS WITH ANTIBODY PRODUCTION 90308
PISTOCETIN B PLATELET COUNT DEC V THROMBOCYTOPENIA MAY OCCUR (TOXIC TO PLATELETS) 90620
SEDORMID H PLATELET COUNT DEC V THROMBOCYTOPENIA (IMMUNOLOGICALLY - INDUCED) R062O
SMALLPOX VACCINE H PLATELET COUNT DEC V NAY OCCASIONALLY CAUSE THROMBOCYTOPENIC PUPPUPA RO620
SODIUM PROS P32 B PLATELET COUNT DEC V THROMBOCYTOPENIA IF EXCESS USED 90026
STI BOP HEN B PLATELET COUNT DEC V IMMUNOLOGICAL MECHANISM (OFTEN WITH PURPURA) 9.0232
STREPTONYCIN B PLATELET COUNT DEC V PANCYTOPENIA/THROMHOCYTOPENIA 30240
SULFADIMETROXINE H PLATELET COUNT DEC V APLASTIC ANEMIA/THROMBOCYTOPENIA WITH SULFONAMIDES P 06 20
SULFAMETHIZOLE H PLATELET COUNT DEC V AGRANULOCYTOSIS/APLASTIC ANEMIA/THRONHOCYTOPENIA 90751
SD LE A NETH OX AZO LE H PLATELET COUNT DEC V THRONHOCYTOPENI A 90542
S 13LEA MET POX Y PY RID B PLATELET COUNT DEC V TRROMHOCYTOPENIA MAY OCCUR AFTER DAYS TO WEEKS 90658
SULFI SOXA ZOLE B PLATELET COUNT DEC V AGRANULOCYTOSIS/APLASTIC ANEMIA (AFTER DAYS) 30751
SULFONAMIDES B PLATELET COUNT DEC V AGRANULOCYTOSIS/APLASTIC ANEMIA P0657
SULFONYL UREA S H PLATELET COUNT DEC V PANCYTOPENIA 90620
TETP ACYCLINE H PLATELET COUNT DEC V THPOMBOCYTOPENIA/PANCYTOPENIA 90620
THIAH ENDAZOLE H PLATELET COUNT DEC V THROMHOCYTOPENIA 90647
THIAZIDES H PLATELET COUNT DEC V REPORTED TO CAUSE THRONBOCYTOPENIA 30723
THIOGEJANINE H PLATELET COUNT DEC V IMMUNOLOGICALLY INDUCED THROMBOCYTOPENIA 90167
THIOTEPA B PLATELET COUNT DEC V NAY CAUSE BONE MARROW DEPRESSION P0026
THIOUPACIL H PLATELET COUNT DEC V THROMBOCYTOPENIA 90697
TOLAZAMIDE B PLATELET COUNT DEC V THRONBOCYTOPENIA/PANCYTOPENIA 90384
TO LA Z OL INC H PLATELET COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCPASIAS) 90658
TOLHUTAMI DE H PLATELET COUNT DEC V AGRANULOCYTOSIS/APLASTIC ANEMIA 901 99
TPIETRYLENEMELAMINE H PLATELET COUNT DEC V MAY CAUSE BONE MARROW DEPRESSION 70026
TPIFLUOPERA ZINC H PLATELET COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCPASIAS) P0658
TR IMET HAD ION! H PLATELET COUNT DEC V APLASTIC ANEMIA NAY OCCUR RARELY 90784
TRI METHOPPIM B PLATELET COUNT DEC V MOST COMMON SERIOUS TOXIC EFFECT 90765
URACIL MUSTARD H PLATELET COUNT DEC V MAY CAUSE BONE MARROW DEPRESSION 90026
U P ETH A N B PLATELET COUNT DEC V HONE MARROW APLA5IA/PANCYTOPENIA 90026
VINBLASTINE B PLATELET COUNT DEC V MAY CAUSE BONE MARROW DEPRESSION 90026
VINCRISTINE B PLATELET COUNT DEC V MAY CAUSE BONE MARROW DEPRESSION P03 84
VITAMIN K B PLATELET COUNT DEC V PANCYTOPENIA PEPORTED AFTER K3 AND K4 P0657
X-RAY THERAPY B PLATELET COUNT DEC V THRONHOCYTOPENIA P029 1
DIPYP I DAMOLE H PLATELET COUNT INC V POSSIBLY DUE TO ALTERATION OF TURNOVER P03 26
GLUCOCORT ICOIDS H PLATELET COUNT INC V STIMULATE PRODUCTION OF PLATELETS RO026
MUSCULAR EXERCISE B PLATELET COUNT INC V EFFECT OF SUDDEN EXERCISE 90291
ORAL CONTRACEPTIVE B PLATELET COUNT INC V REPORTED EFFECT P0026
OVULATION H PLATELET COUNT INC V INCREASES FROM 8TH TO 14TH DAY 0? CYCLE 110291
PHOSPHORUS B PLATELET COUNT INC V REPORTED EFFECT WITH POISONING R0368
SULFAPTHPOL H PLATELET COUNT INC V MECHANISM OF ACTION UNKNOWN 110315
CYCLOPR OP A NE H PLATELET COUNT Z V ANESTHESIA HAS NO EFFECT R0384
ETHER H PLATELET COUNT Z V ANESTHESIA HAS NO EFFECT 903814
REMATIN S PORPHOHILINOGEN DEC V IN A PATIENT WITH ACUTE INTERMITTENT PORPHYRIA R0131
ASCORBIC ACID U PORPHOBILINOGEN DEC N INHIBITION OF COLOR DEVELOP IF NO PRIOR SEPAPATION 90322
HEMATIN U PORPHOBILINOGEN DEC V IN A PATIENT WITH ELEVATION DUE TO PORPHYRIA P0131
THIOLS U POPPHOBILINOGEN DEC N UNLESS PRIOR SEPARATION IS EMPLOYED O322
UREA U PORPHOBILINOGEN DEC N INHIBITS COLOR DEVELOPMENT UNLESS PRIOR SEPARATION P0 3 22
VITAMIN E U POPPHOBILINOGEN DEC V POSSIBLE REDUCTION TO NORMAL LEVELS IN PORPHYRIA 90688
AMINOSALICYLIC AC U POPPHOHILINOGEN INC N REACTS WITH EHRLICH’S REAGENT 90554
ANTICONVU LSANTS U PORPHOHILINOGEN INC V DRUG RELATED EFFECT REPORTED IN ONE CHILD P0657
BARBITURATES U PORPHOHILINOGEN INC V MAY PRECIPITATE ACUTE PORPHYRIA 90371
CASCARA U PORPHOBILINOGEN INC N COLOR EXTRACTABLE INTO CHLOROFORM 90436
CHLOPDIAZEPOXIDE U PORPHOBILINOGEN INC V NAY PRECIPITATE ACUTE PORPHYRIA 90371
CR LOP PP OMAZINE U PORPHOBILINOGEN INC N REACTS WITH EHRLICH’S ALDEHYDE REAGENT 111 001
CHLORPROPAMIDE U PORPHOHILINOGEN INC V MAY AGGRAVATE CUTANEOUS PORPHYRIA P0 371
DICHLOPALPHENAZONE U PORPHOBILINOGEN INC V NAY PRECIPITATE ACUTE PORPHYRIA P0371
DIPHENYLRYDANTOIN U PORPHOHILINOGEN INC V NAY PRECIPITATE ACUTE PORPHYRIA HO 371
ESTROG ENS U PORPHOBILINOGEN INC V MAY PRECIPITATE PORPHYRIA ATTACK P0371
ETHANOL U PORPHOHILINOGEN INC V NAY PRECIPITATE ATTACK OF PORPHYRIA 90371
GLUTET HI MID! U PORPHOBILINOGEN INC V MAY PRECIPITATE ACUTE PORPHYRIA 90371
GRISEOFULVIN U PORPHOBILINOGEN INC V MAY PRECIPITATE ACUTE PORPHYRIA ATTACK 90 371
MEPPOHA MATE U PORPHOBILINOGEN INC V MAY PRECIPITATE ACUTE PORPHYRIA P0 37 1
METHYL DOPA U PORPHOBILINOGEN INC V NAY PRECIPITATE ACUTE PORPHYRIA ATTACK P0 37 1
OPAL CONTRACEPTIVE U PORPHOHILINOGEN INC V MAY PRECIPITATE PORPHYRIA ATTACK P0371
PENTAZOCI NE U PORPHOHILINOGEN INC V MAY PRECIPITATE ACUTE PORPHYRIA ATTACK R03 71
PHENOTHIAZINES U PORPHOHILINOGEN INC N MAY REACT WITH EHRLICH’S ALDEHYDE REAGENT 90769
PROCAI NE U POPPHOBILINOGEN INC N INTERFERES WITH EHRLICH’S ALDEHYDE REACTION 91 001
SEDORMID U PORPHOBILINOGEN INC V MAY PRECIPITATE ACUTE PORPHYRIA 30371
SEDORMID U PORPHOBILINOGEN INC N PRODUCES RED COLOR WITH EHRLICH’S REAGENT P04 36
SUCCININIDES U PORPHOBILINOGEN INC V MAY PRECIPITATE ACUTE PORPHYRIA 90371
SULFONAMIDES U PORPHOBILINOGEN INC V MAY PRECIPITATE ACUTE PORPHYRIA 90371
S ULFO NEMET HA NE U POPPROBILINOGEN INC V MAY PROVOKE ATTACK OF PORPHYRIA 30371
SD L EON CT H YL METHA NE U PORPROBILINOGEN INC V NAY PRECIPITATE ACUTE PORPHYRIA P037 1
TOLHUTAMIDE U POPPHOBILINOGEN INC V MAY PRECIPITATE PORPHYRIA ATTACK 90371
LEAD U PORPHOBILINOGEN Z V NORMAL IN LEAD PORPHYRIA 90436
THY MDL U POPPHOBILINOGEN Z N NO EFFECT ON WALDENSTPOM METHOD 90779
LIGHT U PORPHYRINS DEC N PHOTOSENSITIVE 90779
OPAL CONTRACEPTIVE U PORPRYRINS DEC V MAY OCCUR IN PTS WITH ESTABLISHED DISEASE P0657
GRISEOFULVIN H PORPHYRINS INC V MAY PRECIPITATE ACUTE PORPHYRIA ATTACK P07 36

ACPIFLAV INC U PORPHYPINS INC N PRODUCE FLUORESCENCE P1001
AMINOPYBINE U PORPHYRINS INC V STIMULATES FORMATION OF ALA-SYNTHETASE P03 84
ANTIPYRETICS U PORPHYPINS INC V REPORTED EFFECT P0 355
A P HO NA L U POPPHYRINS INC V MAY PRECIPITATE ATTACK OF ACUTE PORPHYRIA P0657
CAP BR 0 HAL U POHPHYRINS INC V NAY PRECIPITATE ATTACK OF ACUTE PORPHYRIA P0596
CHLORAL HYDRATE U PORPHYRINS INC V MAY PRECIPITATE ATTACK OF ACUTE PORPHYRIA P0596
CHLORDIAZEPOXIDE U PORPHYRINS INC V NAY PRECIPITATE ATTACK OF ACUTE PORPHYRIA P0596
ETHA NOL U PORPHYRINS INC V INCREASED SYNTHESIS OF PORPHYRINS P1001
ETHOXAZENE U PORPHYPINS INC N FALSE POSITIVE WITH FLUORESCENT METHODS 91001
CT H OX A Z EWE U PORPHYRINS INC V HEPATOTOXIC EFFECT 90299
GLUTETRINIDE U PORPHYPINS INC V MAY PRECIPITATE ATTACK OF ACUTE PORPHYRIA HO 596
GRISEOFULVIN U PORPHYRINS INC V STIMULATES FORMATION OF ALA-SYNTHETASE P 038 4
HEMOGLOBIN U PORPHYRINS INC M AFFECTS DV ABSORPTION SCPEEENING METHODS R0779
HEXACHLOROBENZENE U PORPHYRINS INC V STIMULATES FORMATION OF ALA-SYNTHETASE P0384
MENSTRUATION U PORPHYPINS INC V NAY PRECIPITATE EPISODE OF HEPATIC PORPHYRIA P0657
ME PP OH A MA TE U POPPHYRINS INC V NAY PRECIPITATE ATTACK OF ACUTE PORPHYRIA P 0596
NETHYPRYLON U PORPHYRINS INC V NAY INDUCE PORPHYRIA IN ANIMALS, ? IN HUMANS P03 84
METYRA PONE U PORPHYRINS INC V REPORTED TO PRECIPITATE ATTACK OF ACUTE PORPHYRIA P0 596
NI KETHAMI DC U PORPHYPINS INC V MAY PRECIPITATE ATTACK OF ACUTE PORPHYRIA P05 96
OXYTETRACYCLINE U POPPHYRINS INC N PRODUCES INTERFERING FLUORESCENCE P0 356
PHENAZOPYRI DINE U POPPHYPINS INC N INTERFERENCE WITH FLUORESCENCE (IN SCREENING TEST) P1001
PHENYLHYDRAZINE U PORPHYPINS INC V MAY OCCASIONALLY PRECIPITATE ATTACK OF PORPHYRIA P100 1
PREGNANCY U PORPHYPINS INC V MAY PRECIPITATE EPISODE OF HEPATIC PORPHYRIA P0657
S ULF AM El HO X A ZOL C U POPPRYPINS INC N MAY CAUSE FALSE POSITIVE WITH FLUORESCENT METHODS P0 299
SULFONAMIDES U PORPHYPINS INC V MAY PRECIPITATE ACUTE PORPHYRIA P0596
S ULFO N EM ET H A NE 11 POPPHYPINS INC V STIMULATES FORMATION OF ALA-SYNTHETASE P0384
TETPACYCL INE U PORPHYRINS INC N INTERFERING FLUORESCENCE P0356
VITAMIN K U PORPHYPINS INC V REPORTED SIDE EFFECT P0657
DIGOXIN C POTASSIUM DEC V 6% DROP WITHIN 2 DAYS, AFFECTS MEMBRANE ATP-AS! P0 527
ACETAZOLAMIDE S POTASSIUM DEC V DIURETIC ACTION,CARHONIC ANHYDRASE INHIBITION P0204
ACETYLSALICYLIC AC S POTASSIUM DEC V DIURETIC ACTION, PESPIRATORY ALKALOSIS P0 204
ALDOSTEPONE S POTASSIUM DEC V HYPOKALEMIC HYPOCHLOREMIC ALKALOSIS MAY OCCUR P03 84
AMINOSALICYLIC AC S POTASSIUM DEC V DUE TO ACTION ON PENAL TUBULES OR VOMITING HO 637
AMMONIUM CHLORIDE S POTASSIUM DEC V PERPETUATES POTSSIUM DEFICIENCY, CATION LESS P0620
AMPHOTERICIN H S POTASSIUM DEC V (FREQUENT) ASSOCIATED WITH RENAL DAMAGE P00 38
B ENDRO FL U HEIR IAZIDE S POTASSIUM DEC V MARKED DIURETIC RESPONSE P0325
BETAMETHASONE S POTASSIUM DEC V OCCURS INFREQUENTLY P00 26
BICARHONATES S POTASSIUM DEC V INDUCES METABOLIC ALKALOSIS 90204
BISACODYL S POTASSIUM DEC V ASSOC WITH STEATORRHEA IF USED IN EXCESS P0993
CA P H EN OX OLON E S POTASSIUM DEC V ALDOSTERONE LIKE EFFECT P0336
CATHAPTICS S POTASSIUM DEC V EXCESSIVE USE MAY CAUSE HYPOKALEMIA P03 814
CRLOROTHIAZ IDE S POTASSIUM DEC V DIURETIC ACTION P0907
CHLOPTHALIDONE S POTASSIUM DEC V DIURETIC INDUCED DEPLETION P0355
CLOPA MID! S POTASSIUM DEC V RESULT OF DIURETIC ACTION P 1002
C LOP EX OL ONE S POTASSIUM DEC V DIURETIC ACTION P06 57
CORTICOSTEPOIDS S POTASSIUM DEC V MINERALOCORTICOID EFFECT WITH INC PENAL EXCRETION P002 1
COPTICOTROPIN S POTASSIUM DEC V INC URINARY EXCRETION (MINERALOCORTICOID EFFECT) P1001
CORTISONE S POTASSIUM DEC V MINEPALOCORTICOID EFFECT P100 1
DI A PA N IDE S POTASSIUM DEC V DIURETIC ACTION P06 09
DICHLOPPHENAMIDE S POTASSIUM DEC V DIURETIC ACTION (INHIBITS CARBONIC ANHYDRASE) P0620
DID RETICS S POTASSIUM DEC V LOSS IN URINE P06 20
DOCA S POTASSIUM DEC V OCCURS AS RESULT OF INCREASED EXCRETION P0026
EDTA S POTASSIUM DEC N REACTS WITH POTASSIUM P06 20
EPINEPHPINE S POTASSIUM DEC V AFTER INITIAL RISE, DUE TO HORMONAL ACTION P0620
ETHACRYNIC ACID S POTASSIUM DEC V DIURETIC ACTION P0907
ETHANOL S POTASSIUM DEC V INAPPROPRIATE SECRETION OF ADH IN BEEP DRINKERS P0265
ETHOXAZOLANIDE S POTASSIUM DEC V PROBABLE EFFECT (LIKE ACETAZOLAMIDE) P0026
FLUDROCORTI SON! S POTASSIUM DEC V MAY CAUSE INCREASED URINARY EXCRETION P0026
FUPOSEMIDE S POTASSIUM DEC V DIURETIC ACTION P0907
GLUCOCOPTICOI DS S POTASSIUM DEC V MAY CAUSE POTASSIUM LOSS P0026
GLUCOSE S POTASSIUM DEC V SHIFT INTRACELLULARLY WHEN INFUSION GIVEN P0880
HYDPOCHLOROTHIAZIDE S POTASSIUM DEC V DIURETIC ACTION P0 907
HYDROCOPTISONE S POTASSIUM DEC V PROMOTES URINARY ELIMINATION P00 26
HYDROFLUMETHIAZIDE S POTASSIUM DEC V DIURETIC ACTION P01467
I N S DL I N S POTASSIUM DEC V THERAPEUTIC EFFECT, CAUSES INTRACELLULAR SHIFT P0383
LAXATIVES S POTASSIUM DEC V EXCESSIVE USE MAY RAVE EFFECT P06 20
LICORICE S POTASSIUM DEC V ALDOSTERONE LIKE ACTION P0669
LITHIUM S POTASSIUM DEC V SLIGHT DECREASES OBSERVED ONLY P0 163
NEFPUS IDE S POTASSIUM DEC V DIURETIC ACTION LESS EFFECTIVE THAN THIAZIDES P0994
NERALLUPIDE S POTASSIUM DEC V DIURETIC ACTION P0907
METHAZOLANI DE S POTASSIUM DEC V WITH PROLONGED USE (CARBONIC ANHYDRASE INHIBITION) P062 0
METHYCLOTHIAZIDE S POTASSIUM DEC V DIURETIC ACTION P0386
METOLAZONE S POTASSIUM DEC V POTASSSIUM LOSS IN URINE P 04 01
MITHRAMYCIN S POTASSIUM DEC V DEPRESSION OF LEVEL REPORTED P00 26
NEUROMUSCULAR S POTASSIUM DEC V IF K DEFICIENCY POTENTIATES EFFECT P03 84
PENICILLIN S POTASSIUM DEC V IF I.V. SODIUM PENICILLIN INFUSED P0907
PHENOLPHTHALEI N S POTASSIUM DEC V IF CHRONIC LAXATIVE ABUSE AND ALDOSTERONISM P0332
PHOSPHATES S POTASSIUM DEC V DRAWN INTO CELLS WITH GLUCONEOGENESIS P1001
POLYNYXIN B S POTASSIUM DEC V REPORTED TO OCCUR IN LEUKEMIA, MAYBE STEROID EFFECT P0285
POLYSTYRENE SULFON S POTASSIUM DEC V EXCHANGES FOP SODIUM (IF NA FORM USED) P0620
POLYTHIAZIDE S POTASSIUM DEC V DIURETIC ACTION P0325
PPEDNISOLONE S POTASSIUM DEC V SLIGHT MINERALOCORTICOID EFFECT P0026
PPEDNISONE S POTASSIUM DEC V SLIGHT MINERALOCOPTICOID EFFECT ONLY P0026
QU I N ET H AZ ON C S POTASSIUM DEC V DIURETIC ACTION P06 57
SC- 16 102 S POTASSIUM DEC V DURATION OF DIURETIC ACTION SHORT P014 99
SODIUM BICARBONATE S POTASSIUM DEC V CAUSES POTASSIUM TO SHIFT INTO CELLS P002 6
SODIUM SULFATE S POTASSIUM DEC V NAY BE EXCRETED COMBINED WITH SULFATE P08 66
SPI PONOLACTONE S POTASSIUM DEC V DIURETIC ACTION (NOT MARKED) P0907
STREPTOZOTOCIN S POTASSIUM DEC V ASSOCIATED WITH POLYURIA P0686
SULFATES S POTASSIUM DEC V MAY BE EXCRETED COMBINED WITH SULFATE P0620

TETRACYCLINE S POTASSIUM DEC V FANCONI LIKE SYNDROME MAY OCCUR WITH DEGRADLD HC417
THIA ZIDES S 20TSSIUM DEC V CONSEQUENCE OF DIUPESIS P.38U
TRIAMTER #{163}NE S POTASSIUM DEC V DIURETIC ACTION i9C7
TRI HLOR NETHIAZ IDE S POTASSIUM DEC V DIURETIC ACTION R0937
UREA S POTASSIUM DEC V MAY CAUSE SVER DEPLETION WITH DIUBESIS h299
VIONYCI N S POTASSIUM DEC V MAY OCCU3 WITH NEPHROTOXICIIY RC620
ANILOPIDE U POTASSIUM DEC V MAY OCCUR EVEN IF MARKED SODIUM LOSS 90384
DIAZOXItE U P0TASSIU DEC V EFFECT OVER 2H OF 4MG/KG GIVEN I.V. 90501
EPINEPHRI NE U POTASSIUM DC V WITH INC !IL2RATION FFACTION RC384
GLUCOSF U POTASSIUM DEC V AFTER ORAL GLUCOSE AND FALL IN SERUM CONC
PPOLACTIN U POTASSIUM DEC V REDUCES RENAL EXCRETION, NOT AS MARKED AS FOB NA 90464
ANILORIDE S POTASSIUM INC V ALSO INHIBITS KALURESIS CAUSED BY IHIAZIDES p .
774
AMINOCAPROIC ACID S POTASSIUM INC V REPORTED EFFECT ZSP IF R3NAL FUNCTION IMPAIRED RO’L41
AMPHOTERICIN B S POTASSIUM INC V MAY OCCUR WITH RENAL TOXICITY P 0 17C
BLOOD TRANSFUSIONS S POTASSIUM INC V MAY OCCUR WITH RELEASE FRO?1 RBC 90596
BORIC ACID S POTASSIUM INC V TOXICITY EFFECT WITH ACUTE TUBULAR NECROSIS 30204
CALCIUM S POTASSIUM INC H EMISSION SPECTRUM MAY INTEBFLRE 90620
CARBACRYLAMIN! RES S POTASSIUM INC V PART OF RESIN IS IN FORM 01 POTASSIUZI SALT 30620
CEPHALORIDINE S POTASSIUM INC V NAY OCCUR WITH NEPHR0TOXICILY R62C
CONTACT WITH CLOT S POTASSIUM INC N RELEASE FROM ERYTHROCYTES AND PLATELETS 91001
EPINEPHRI NE S POTASSIUM INC V INITIAL PISE ACCOMPANIES GLUCOSE MOBILIZATION 30384
FLUORIDES S POTASSIUM INC N WITH INHIBITION OF PHOSPHORYLATION P 04 36
GLUCPtGON S POTASSIUM INC V INMED. INC IN DOGS THAN FALL TO NORMAL OR LESS R.210
HE1OLYSIS S POTASSIUM INC V RELEASED FROM BBC’S AND PLATELETS 90181
HEPAPIN S POTASSIUM INC V DECREASED RENAL EXCRETION P0384
HISTAMINE S POTASSIUM INC V MARKED EFFECT OF I.V. INJECT (?INVOLVES G.I. TRACT) 30384
ISONIAZID S POTASSIUM INC V REPORTED EFFECT OF OVERDOSE P0417
LI PONUL S POTASSIUM INC V NEPHROTOXIC EFFECT 90620
LITHIUM S POTASSIUM INC V ?BY DISPLACING FROM CELLS RC612
MANNITOL S POTASSIUM INC V MECHANISM NOT DISCUSSED P 0672
MARIRUANA S POTASSIUM INC V REPORTED EFFECT RC596
MERHICILLIN S POTASSIUM INC V POSSIBLE RESULT OF NEPHROTOXICITY 90620
OXALATES S POTASSIUM INC N IF POTASSIUM SALT OF OXALATE BC 435
PENICILLIN S POTASSIUM INC V NAY OCCUR IF K SALT GIVEN I.V. ALSO ALKALOSIS 30907
PHENFORMIN S POTASSIUM INC V MAY OCCUR WITH LACTIC ACIDOSIS PC 652
POTASSIUM CHLORIDE S POTASSIUM INC V OVER CORRECTION OF HYPOKALEMIA 90026
PROTEIN S POTASSIUM INC N PRESENCE RAISES TEMPERATURE INCS EMISSION 30620
SALINE S POTASSIUM INC V EFFECT OF HYPERTONIC SOLUTION 30672
SERUM S POTASSIUM INC V DUE TO RELEASE FROM ERYTHROCYTES WITH CLOTTING RiCO 1
SODIUM S POTASSIUM INC H VARIABLE CONC AFFECTS MOST FLAME METHODS R01814
S PIP ONOLACTONE S POTASSIUM INC V INHIBITS NA/K EXCHANGE IN PENAL TUBULES 30384
SUCCINYLCHOLINE S POTASSIUM INC V IF INJECTED I.V. B C 907
TETRACYCLINE S POTASSIUM INC V OCCURS WITH AZOTEMIA 5CC 26
TOBACCO SMOKE S POTASSIUM INC N INTERFERES WITH FLAME PHOTOMFTRY R0356
rOURNIQUET S POTASSIUM INC V ESPECIALLY IF FOREARM MUSCLES EXERCISED ALSO 90436
TPIAMTERENE S POTASSIUM INC V POTASSIUM SPARING ACTION (AFFECTS NA/K EXCHANGE) R0620
TRONETHAMINE S POTASSIUM INC V REPORTED EFFECT P0782
ACETAZOLANIDE U POTASSIUM INC V DIURETIC ACTION 90384
ACETYLSALICYLIC AC U POTASSIUM INC V DIRECT EFFECT ON RENAL TUBULES P0384
AL DOS T ER ONE U POTASSIUM INC V CONSERVATION OF NA WITH INCPEASED K LOSS 30965
AMNONIUM CHLORIDE U POTASSIUM INC V DIURETIC ACTION AND HYPEBCHLOBEMIC ACIDOSIS R0334
B ETA NET HA SONE U POTASSIUM INC V OCCURS INFREQUENTLY 3CC62
CALCITONIN U POTASSIUM INC V ACTS INDEPENDENTLY OF PARATHYROID 30406
C AR H E N OX OL ONE U POTASSIUM INC V ALDOSTERONE LIKE EFFECT R0669
CATHAPTICS U POTASSIUM INC V SECONDARY ALDOSTERONISK IF BLOOD VOLUME REDUCED 903814
C HL OPT HA LIDO NE U POTASSIUM INC V MAY PRODUCE MARKED DIURESIS 90657
LOPAMIDE U POTASSIUM INC V DIURETIC ACTION P 376 1
CORTICOSTEPOIDS U POTASSIUM INC V PROMOTES EXCRETION (NINERALOCORTICOID EFFECT) 30026
CORTICOTROPIN U POTASSIUM INC V MOBILIZATION OF K FROM TISSUES P0384
CORTISONi U POTASSIUM INC V PROMOTES EXCRETION P0026
DEXANET HASONE U POTASSIUM INC V METABOLIC EFFECT 33467
DIAPAMIDE U POTASSIUM INC V DIURETIC ACTION 90609
DI U PET IC S U POTASSIUM INC V DIURETIC ACTION P0620
DOCA U POTASSIUM INC V PRO?IOTES INCREASED URINARY ELIMINATION P 0026
EDIA U POTASSIUM INC V OCCURS PARTICULARLY I? GIVEN I.V. RC417
THACRYNIC ACID U POTASSIUM INC V MARKED DIURETIC RESPONSE MAY OCCUR RC417
F LUD ROCO RTISONE U POTASSIUM INC V INCREASES URINARY ELIMINATION 90025
FUROSEMIDE U POTASSIUM INC V DIURETIC ACTION 30452
HYDROCOR TIS ONE U POTASSIUM INC V INCREASES ELIMINATION IN URINE P0026
L F V OD 0 PA U POTASSIUM INC V ?SEC. TO RENAL VASODIL. OP DIRECT ACTION ON TUBULES 90328
LICORICE U POTASSIUM INC V ALD0ST3R0N LIKE ACTION RC66 9
NAFENID! U POTASSIUM INC V INHIB OF CARBONIC ANHYDRASE WHEN APP TOPICALLY P0985
?IEFRUSIDE U POTASSIUM INC V DIURETIC ACTION. ACTS UP TO 20 HOURS 90994
MET OLA2ONE U POTASSIUM INC V DIURETIC ACTION 90934
PAPATHYROID EXTRACT U POTASSIUM INC V INCREASED CLEARANCE R 0 406
PENICILLIN U POTASSIUM INC V IF I.V. SODIUM PENICILLIN INFUSED 90907
PREDNISOLONE U POTASSIUM INC V SLIGHT MINERALOCORTICOID EFFECT 90 326
PREDNISONT U POTASSIUM INC V SLIGHT MINERALOCORTICOID EFFECT ONLY P C 026
SC-1612 U POTASSIUM INC V DURATION OF DIURETIC ACTION SHORT 33499
STPEPTOZOTOCIN U POTASSIUM INC V IN SPITE OF LOW SERUM CONC 30686
SULFATES U POTASSIUM INC V INC EXCRETION COMBINES WITH SULFATE P0026
IHIAZIDES U POTASSIUM INC V DIURETIC ACTION 30384
TRIA MCI NOL ONE U POTASSIUM INC V ONLY IN EXCEEDINGLY LARGE DOSES P0026
TRIFLOCIN U POTASSIUM INC V DIURETIC ACTION PC 009
VIONYCIN U POTASSIUM INC V PROMOTES URINARY LOSS 90026
XANTHINES U POTASSIUM INC V SLIGHT DIURETIC EFFECT ONLY P0384
MEALS S POTASSIUM Z V NO EFFECT AFTER STANDARD BREAKFAST 90181
STORAGE OF SAMPLE S POTASSIUM Z L’l NO EFFECT FOR 2 WEEKS AT 9003 TEMP OP 4 DEGREES P0436
THY MOL U POTASSIUM Z N NO EFFECT ON FLAME PHOTOMETRIC METHODS 90779
HARBITU? ATES B P02 DEC V SLIGHT DEC DUPING SLEEP WITH HYPNOTIC DOSE B

CT1341 H P02 DEC V POST-INDUCTION MEASUREMENT IN ARTERIAL BLOOD P0823
ISOPROTERENOL B P02 DEC V BY APPROX 10 MM HG IN CHRONIC LUNG DISEASE P0657
MEPER IDINE B P02 DEC V SIGNIFICANT REDUCTION IN ARTERIAL OXYGEN PRESSURE R0657
ORAL CONTRACEPTIVE S PR!ALHUMIN INC V METABOLIC CHANGES IN LIVER SYNTHESIS P0588
CLOFIRPATE S PREHETA-LIPOPPOTEINS DEC V THERAPEUTIC INTENT P0057
HEPAPI N S PPEHETA-LIPOPPOTEINS DEC V NON-SUSTAINED RESPONSE TO SMALL I.V. INJECTION P03 814
NICOTINIC ACID S PPEBETA-LIPOPROTEINS DEC V THERAPEUTIC EFFECT HO 384
AS PA RAGINA SE S PHEH!TA-LIPOPBOTEINS INC V OBSERVED IN UNUSUAL HYPERLIPIDEMIC RESPONSE P0705
ESTROGENS S PREHETA-LIPOPROTEINS INC V REPORTED EFFECT P0384
ORAL CONTRACEPTIVE S PREBETA-LIPOPROTEINS INC V PROB DUE TO INC APOPROTEIN SYNTHESIS P063 9
TETRAIODDPHTHALEIN S PRECIPITABLE IODINE INC H IODINE CONTAMINATION P03 55
ESTPO ENS S PREGNANCY PROTEIN INC V METABOLIC EFFECT P0072
PROMETHAZINE U PREGNANCY TESTS NEG N FALSE NEGATIVE WITH PREPUERIN OP DAP-TEST P09 14
CHLORPROMAZINE U PREGNANCY TESTS P05 N GIVES FALSE P05 WITH FROG, RABBIT AND IMMUNOL TEST P09 07
PHENOTHIAZINES U PREGNANCY TESTS P05 N FALSE REACT WITH FROG, RABBIT, IMMUNOL TESTS R0717
PPOMETHAZINE U PREGNANCY TESTS POS H FALSE POSITIVE WITH GRAVINDEX P0914
PROTEINUPIA U PREGNANCY TESTS P05 N FALSE POSITIVE TESTS IF PROTEINURIA PRESENT P0907
NEDROXYPPOGESTERONE U PREGNANEDIOL DEC V INDUCES ANOVULATORY STATE P09 42
ORAL CONTRACEPTIVE U PREGNANEDIOL DEC V HORMONAL EFFECT (NAY HE ABSENT EXCRETION) P0593
PHENOTHIAZINES U PREGNANEDIOL DEC V REPORTED EFFECT 90596
COPTICOTROPIN U PREGNANEDIOL INC V HORMONAL EFFECT P05 93
GONADOTROPIN U PPEGNANEDIOL INC V HORMONAL ACTION P059 3
OVULATION U PREGNANEDIOL INC V SLIGHT EFFECT 2 DAYS AFTER OVULATION P02 91
PHENAZOPYRIDINE U PPEGNANEDIOL INC N MECHANISM UNKNOWN P0596
GONADOTPOPIN U PREGNANETPIOL INC V VARIABLE CHANGE WHEN GIVEN TO NORMAL MEN P0845
ETHINYLESTRADIOL P PROGESTERONE DEC V LUTEAL PHASE ALSO SHORTENED HO 497
PH ENOTHIAZI NES U PROGESTERONE DEC V ASSOC WITH OTHER ENDOCRINOLOGICAL CHANGES P06 57
CLOMIP HEN! P PROGESTERONE INC V INC OVER NORMAL IN LUTEAL PHASE P0783
CRLOP PPONAZ IRE U PROGESTINS DEC V BLOCKS OVULATION, MAINTAINS DECIDUAL REACTION P03814
LEVODOPA P PROLACTIN DEC V TRANSIENT EFFECT IN NONPUERPEPAL GALCTOPPHEA P0611
CHLORPROMAZINE P PPOLACTIN INC V MARKED INC IN NORMALS IN 2 HOURS P0943
THYPOTROPIN-PELEAS P PROLACTIN INC V RESPONSE WITHIN 5 MINUTES TO I.V. INJECTION P0484
ORAL CONTRACEPTIVE P PROLINE DEC V HORMONAL EFFECT (SECOND PART OF CYCLE) P0226
AMPHETAMINES B PPONYELOBLASTS INC V MYELOBLASTIC LEUKEMIA P01 00
X-RAY THERAPY S PROPERIDIN DEC V DUE TO TISSUE DESTRUCTION P0 29 1
DI ETHYLSTILHESTROL 0 PPOSTAT FLUID ACID PHOS DEC V MARKEDLY LOWER IN BENIGN HYPEPTPOPHY P0525
ORAL CONTRACEPTIVE S PROT BINDING CORTISOL INC V WHEN RESULTS ON THERAPY COMPARED WITH NORMAL P0084
PREGNANCY S PROT-HND POLYSACCHAPIDE INC V THROUGHOUT PREGNANCY P029 1
ALBUMIN C PROTEIN DEC N TURBIDITY < GLOBULINS WITH SULFOSALICYLIC ACID P0620
AMNONIUM IONS S PROTEIN DEC M CUPRIC AMMONIUM COMPLEX FORMED(CU AVAILABILITY DEC) P04 36
CARBON DISULFIDE S PROTEIN DEC V EFFECT SLIGHT P0 254
CATHARTICS S PROTEIN DEC V RARE PROTEIN LOSING GASTROENTEPOPATRY R 0384
DEXTR AN S PROTEIN DEC V DUE TO HEMODILUTION 90596
ESTROGENS S PROTEIN DEC V ALTERED METABOLISM P0874
LAXATIVES S PROTEIN DEC V MAY OCCUR WITH CONTINUED USE P0596
MERCURY COMPOUNDS S PROTEIN DEC V DUE TO ALHUNINUPIA AND STARVATION P0 620
OPAL CONTRACEPTIVE S PROTEIN DEC V ESTROGEN EFFECT P0874
PYPAZINANIDE S PROTEIN DEC V PART OF HEPATOTOXICITY (VIRAL-HEPATITIS LIKE) P0 384
RECUMBENCY S PROTEIN DEC V AVERAGE DEC OF 1.0 G/100NL AFTER 40 NIN P02 97
PIFAMPIN S PROTEIN DEC V DUE TO IMPAIRED REPATIC METABOLISM P0740
TRI METHADIONE S PROTEIN DEC V REVERSIBLE EFFECT DUE TO URINARY LOSS P0596
AC!TOPHENETIDIN C PROTEIN INC N REACTS AS IF PHENOL WITH FOLIN-CIOCALTEU REAGENT P09 07
ACETYLSALICYLIC AC C PROTEIN INC N FALSE POSITIVE WITH FOLIN-CIOCALTEU REAGENT P 1026
AMINOSALICYLIC AC C PROTEIN INC N REACTS AS PHENOL IF FOLIN-CIOCALTEU REACTION USED P0907
CHLORA MPH ENICOL C PROTEIN INC N SLIGHT EFFECT ON FOLIN-CIOCALTEU PROCEDURE P 1026
CHLORPROM AZINE C PROTEIN INC N REACTS AS IF PHENOL WITH FOLIN-CIOCALTEU REAGENT P0907
GLOBULIN C PROTEIN INC N COLOR EQUIV > ALBUMIN WITH FOLIN-CIOCALTEU P0343
L E AD C PROTEIN INC V OCCURS WITH LEAD ENCEPHALOPATHY, ENCEPHALITIS P0368
L I DOC A IN! C PROTEIN INC N REACTS WITH FOLIN-CIOCALTEU REAGENT P03 55
MERCURY COMPOUNDS C PROTEIN INC V MAY PRODUCE GttILLAIN-BAPPE LIKE SYNDROME P09 11
OXYTETRACYCLINE C PROTEIN INC N REACTS AS IF PHENOL WITH FOLIN-CIOCALTEU PROCEDURE R1026
PENICILLIN C PROTEIN INC N REACTS AS IF PHENOL WITH FOLIN-CIOCALTEU PROC P1026
PENICILLIN C PROTEIN INC N CAUSES TURBIDITY IF SULFOSALICYLIC ACID USED P0907
PHENOTHIAZINES C PROTEIN INC M FALSE POSITIVE WITH FOLIN-CIOCALTEU REAGENT R0355
POLIOMY!LITIS VAC C PROTEIN INC V MAY RARELY CAUSE GUILLAIN-BARPE SYNDROME P0657
PHOCAI NE C PROTEIN INC N INTERFERES WITH FOLIN-CIOCALTEU REAGENT P0355
RADIOGRAPHIC C PROTEIN INC N CAUSES TURBIDITY IF SULFOSALICYLIC ACID USED P0907
STREPTONYCI N C PROTEIN INC N REACTS AS PHENOL IF FOLIN-CIOCALTEU REACTION USED P0907
SULFADIAZINE C PROTEIN INC M REACTS AS IF PHENOL WITH FOLIN-CIOCALT!U PROC P1026
SULFAGUANIDINE C PROTEIN INC N REACTS AS IF PHENOL WITH FOLIN-CIOCALTEU PROCEDURE P1026
SULFAMEPAZINE C PROTEIN INC N REACTS AS IF PHE!L WITH FOLIN-CIOCALTEU PROCEDURE P1026
SULFANILAMIDE C PROTEIN INC N REACTS AS IF PHENOL WITH FOLIN-CIOCALTEU METHOD P1026
SULFISOXAZOLE C PROTEIN INC H CAUSES TURBIDITY IF SULFOSALICYLIC ACID USED P0907
SULFONA MID! S C PROTEIN INC N REACTS AS PHENOL WITH .F0LIN-CIOCALTEU REAGENT P0907
TETRACAINE C PROTEIN INC N INTERFERES WITH FOLIN-CIOCALTEU REAGENT P0355
TETRACYCLINE C PROTEIN INC N REACTS AS IF PHENOL WITH FOLIN-CIOCALTEU PROCEDURE P 1026
TOLHUTAMIDE C PROTEIN INC N CAUSES TURBIDITY IF SULFOSALICYLIC ACID USED P0907
TRYPTOPHAN C PROTEIN INC N INTERFERES WITH FOLIN-CIOCALTEU REAGENT P 1026
TYROSI NE C PROTEIN INC N REACTS AS IF PHENOL WITH FOLIN-CIOCALTEU PROC P1 026
ANABOLIC STEROIDS S PROTEIN INC V ASSOCIATED WITH INCREASED PROTEIN SYNTHESIS 90211
ANDROGENS S PROTEIN INC V ASSOCIATED WITH INCREASED PROTEIN SYNTHESIS P02 11
ANGIOTENSIN S PROTEIN INC V HENOCONCENTPATION EFFECT P0384
HILIRUBI N S PROTEIN INC N NO EFFECT UP TO 29 M/10OML P01436
BROMSULFALEIN S PROTEIN INC N COLOR AUGMENTATION WITH ALKALINE BIUPET P0 181
CLOFIBPATE S PROTEIN INC V REPORTED EFFECT, MECHANISM NOT DISCUSSED P0683
CORTICOSTEPOIDS S PROTEIN INC V PHYSIOLOGICAL DOSES PROMOTE PROTEIN SYNTHESIS P0211
COPTICOTPOPIN S PROTEIN INC V PHYSIOLOGICAL DOSES PROMOTE PROTEIN SYNTHESIS 90211
DEXTRAN S PROTEIN INC N TURBIDITY EFFECT WITH BIURET REACTION P09 07
DIGITALIS S PROTEIN INC V IMPROVED HEPATIC FUNCTION AND DEC HYPOVOLEMIA P03 84
EPIN!PH RI NE S PROTEIN INC V DUE TO HEMOCONCENTRATION P03 84

ERECT POSTURE S PROTEIN INC V BY 0.75 G/100ML COMPARED WITH REST AND RECUMBENCY 90998
GROWTH HORMONE S PROTEIN INC V ASSOCIATED WITH INCREASED PROTEIN SYNTHESIS P0211
HEMOGLOBIN S PROTEIN INC M 1 MG MEASURED AS EQUIVALENT TO 1.9 MG PROTEIN R0436
HEMOLYS IS S PROTEIN INC N ADDED PROTEIN MEASURED R0620
INSULI N S PROTEIN INC V ASSOCIATED WITH INCREASED PROTEIN SYNTHESIS P02 11
LIPENIA S PROTEIN INC N TURBIDITY OF SERUM 30620
PROGESTIN S PROTEIN INC V METABOLIC EFFECT RO23
PADIOGR APHIC S PROTEIN INC N MAY PRODUCE INTERFERING TURBIDITY 30620
THYPOI D S PROTEIN INC V PHYSIOLOGICAL EFFECT EXERTS ANABOLIC EFFECT P0211
TO URN I Q UET S PROTEIN INC V AFFECTS ALL PROTEIN BOUND CONSTITUENTS ALSO P04 36
ACETYLGLUCOSA MINE T PROTEIN INC M SLIGHT REACTION WTIH FOLIN-CIOCALTEU REAGENT 90440
ASCORBIC ACID T PROTEIN INC N REACTS WITH FOLIN-CIOCALTEU OF LOWRY PROCEDURE 90213
CYSTEINE T PROTEIN INC H REACTS WITH FOLIN-CIOCALTEU OF LOWRY PROCEDURE 90213
DITHIOERYTHRITOL T PROTEIN INC N REACTS WITH FOLIN-CIOCALTRU OF LOWRY PROCEDURE 30213
EPINEPHRINE T PROTEIN INC N REACTS WITH FOLIN-CIOCALTEU OF LOWRY PROCEDURE 90213
GALACTOSANINE T PROTEIN INC N REACTS WITH FOLIN-CIOCALT!U OF LOWRY METHOD ROL$40
GLUCOSAMINE T PROTEIN INC N REACTS WITH FOLIN-CIOCALTEU OF LOWRY METHOD 90440
GUANINE T PROTEIN INC N REACTS WITH FOLIN-CIOCALTEU OF LOWRY METHOD R014O
HE XOS A MINE T PROTEIN INC M HEXOSAMINES, N-ACETYL-DEPIVS AFFECT LOWPY METHOD 90097
INDOLE T PROTEIN INC N REACTS WITH FOLIN-CIOCALTEU OF LOWRY METHOD P0414 0
MORPHINE T PROTEIN INC M REACTS WITH FOLIN-CIOCALT!U OF LOWRY METHOD 90213
NALORPHINE T PROTEIN INC H REACTS WITH FOLIN-CIOCALTEU OF LOWRY METHOD 90213
PENICILLIN T PROTEIN INC N MASSIVE DOSES MAY CAUSE TURBIDITY WITH ACID TESTS P06 20
PH ENYLTHI OU HEA T PROTEIN INC M REACTS WITH FOLIN-CIOCALTEU OF LOWRY METHOD 90213
SODIUM BISULFITE T PROTEIN INC N AT CONCS HIHGER THAN 0.01 S AFFECTS FOLIN-CIOCALTEU P0213
THIANYL SODIUM T PROTEIN INC N REACTS WITH FOLIN-CIOCALTEU OF LOWRY METHOD P02 13
THIOUREA T PROTEIN INC N REACTS WITH FOLIN-CIOCALTRU OF LOWRY METHOD P02 13
URIC ACID T PROTEIN INC N REACTS WITH FOLIN-CIOCALTEU OF LOWRY METHOD P04 40
XANTHINES T PROTEIN INC N REACTS WITH FOLIN-CIOCALTEU OF LOWRY METHOD P014 40
ACETA MINOPHEN U PROTEIN INC V PENAL DAMAGE MAY OCCUR P0 137
ACETANILID U PROTEIN INC V HEMOLYSIS MAY CAUSE PENAL DAMAGE P0384
ACETOPHENETIDIN U PROTEIN INC V HEMOLYSIS MAY CAUSE PENAL DAMAGE 30384
ACETYLSALICYLIC AC U PROTEIN INC M INTERFERENCE WITH FOLIN-CIOCALTEU REACTION P 1001
ACETYLSALICYLIC AC U PROTEIN INC V MAY CAUSE NEPHROTOXICITY 30417
ACIDS U PROTEIN INC V INGESTION NAY CAUSE SEVERE RENAL DAMAGE P036 8
ANINOSALICYLIC AC U PROTEIN INC V MAY OCCUR AS RESULT OF NEPHROTOXICITY R0677
AMPHOTERICIN B U PROTEIN INC V N!PHROTOXIC EFFECT P02 99
AMP ICILLIN U PROTEIN INC V NECROSIS OF TUBULES DUE TO N!PHPOTOXICITY P09 16
ANTIMONY COMPOUNDS U PROTEIN INC V NEPHROTOXIC EFFECT RO299
ARSENICALS U PROTEIN INC V NEPUROTOXIC EFFECT P0299
ASPARAGINASE U PROTEIN INC V TRANSIENT EFFECT FOR FEW DAYS RO705
BACITP ACIN U PROTEIN INC V MAY CAUSE NEPHROTOXICITY P03 55
BISMUTH SALTS U PROTEIN INC V NEPHPOTOXIC EFFECT 90299
CADMIUM U PROTEIN INC V GENERALIZED IMPAIRMENT OF PROX TUBULAR FUNCTION P0006
CAPPEOMYC IN U PROTEIN INC V NEPHROTOXIC EFFECT (TRANSIENT) 30299
CAPBARSONE U PROTEIN INC V NEPHPOTOXIC EFFECT 30299
CAR BE N OX 0 LONE U PROTEIN INC V DUE TO MYOGLOBINURIA AND NEPHROPATHY P0 669
CARBON DISULFIDE U PROTEIN INC V MANIFESTATION OF PENAL DAMAGE P02 514
CARBON TETRACHLOR U PROTEIN INC V NEPHROTOXIC EFFECT 90299
CARBUTANI DE U PROTEIN INC V NEPHROTOXIC EFFECT P0964
CEPHALOPIDINE U PROTEIN INC V NAY BE RESULT OF NEPHROTOXICITY 30449
CHLORAL U PROTEIN INC V PENAL DAMAGE WITH HIGH CONCENTRATION P03 84
CHLORPROPAM IDE U PROTEIN INC V NEPHROTOXIC EFFECT P0964
CHLORTHALI DONE U PROTEIN INC V NEPHPOTOXIC EFFECT P0355
COLISTIMETHATE U PROTEIN INC V COMMON NEPHROTOXIC EFFECT P0736
COLISTIN U PROTEIN INC V NEPHROTOXIC EFFECT (REVERSIBLE PENAL DAMAGE) P0676
COHTICOTPOPIN U PROTEIN INC V NAY BE N!PHROTOXIC IN CHRONIC DISHSE P014145
DENECL OCYCL IRE U PROTEIN INC V NEPHROTOXIC EFFECT P0572
DIATRIZOATE U PROTEIN INC N INTERFERES WITH SULFOSALICYLIC,NITRIC ACID TESTS 30 1475
DIHYDPOTAC HYSTEPOL U PROTEIN INC V NAY INDUCE INCREASED GLOMERULAR PERMEABILITY P0 299
DI NI TPO PHENOL U PROTEIN INC V DUE TO NEP9ROTOXICITY P0 36 8
DOXAPRA N U PROTEIN INC V MAY HAVE NEPHROTOXIC EFFECT 90299
DOXYCYCLI NE U PROTEIN INC V NEPHROTOXIC EFFECT 90734
EDTA U PROTEIN INC V NEPHROTOXIC EFFECT (ESP CA EDTA) 90026
ETHOSUXINIDE U PROTEIN INC V POSSIBLE REVERSIBLE NEPHROPATHY P02 99
GENTAMICIN U PROTEIN INC V NEPHROTOXIC EFFECT R0299
GOLD U PROTEIN INC V MAY CAUSE NEPHROTOXICITY P06 57
GPISEOFULVIN U PROTEIN INC V MAY CAUSE NEPHROTOXICITY HO 198
INDOMETHACI N U PROTEIN INC V REPORTED IN ONE PATIENT P0 157
IODOPYR ACET U PROTEIN INC M IF ACID PRECIPITATION METHODS USED P0772
IOPANOIC ACID U PROTEIN INC N GIVES TURBIDITY IF ACID PRECIPITATION TESTS USED 30772
IRON SALTS U PROTEIN INC V MAY CAUSE NEPHROTDXICITY 30417
ISONIAZID U PROTEIN INC V MAY HAVE NEPHROTOXIC EFFECT P01417
KANAMYCIN U PROTEIN INC V NEPHROTOXIC EFFECT P 02 99
KEROSENE U PROTEIN INC V PENAL DAMAGE WITH LARGE DOSES 903814
LEA D U PROTEIN INC V N!PHROTOXIC EFFECT WITH POISONING P03 84
LIPOMUL U PROTEIN INC V N!PHROTOXIC EFFECT HO 299
LITHIUM U PROTEIN INC V MAY HAVE NEPHROTOXIC EFFECT P04 17
MEFENAMIC ACID U PROTEIN INC V NEPHROTOXIC EFFECT P0355
NELARSONYL U PROTEIN INC V NEPHROTOXIC EFFECT 90026
MELAP SOPROL U PROTEIN INC V NEPHROTOXIC EFFECT P0620
MERCURY COMPOUNDS U PROTEIN INC V NEPHROTOXIC EFFECT P0355
METAHEXAMIDE U PROTEIN INC M INTERFERENCE BY DRUG-METABOLITE P0964
MET AX AL ONE U PROTEIN INC V MAY HAVE NEPHROTOXIC EFFECT 30299
METHANOL U PROTEIN INC V NEPHROTOXIC EFFECT WITH POISONING P0384
METHENAMIN! U PROTEIN INC V NEPHROTOXIC IN LARGE DOSES P03 84
METHICILLI N U PROTEIN INC V NEPHROTOXICITY MAY OCCUR P0026
METHYLBHOMIDE U PROTEIN INC V DUE TO TUBULAR NECROSIS RO368
MITHRA NYCIN U PROTEIN INC V NEPPROTOXIC EFFECT P 0026
NITONYCIN C U PROTEIN INC V NEPHROTOXIC EFFECT P0589

MUSCULAR EXERCISE U PROTEIN INC V MORE COMMON WITH HEAVY EXERCISE THAN MILD 90505
NAPHTHALENE U PROTEIN INC V NEPHROTOXIC EFFECT 90368
WEOMYCIN U PROTEIN INC V NEPHPOTOXIC EFFECT P0299
OXACILLIN U PROTEIN INC V NEPHROTOXIC EFFECT P0026
OXALATES U PROTEIN INC V IF INGESTED MAY CAUSE NEPHROTOXICITY P0368
PARALDEHYDE U PROTEIN INC V NEPHPOTOXIC EFFECT (NEPHPOSIS WITH POISONING) 90407
PAPAMETHADION! U PROTEIN INC V MAY HAVE NEPHROTOXIC EFFECT 30677
PAROMONYCIN U PROTEIN INC V POTENTIALLY NEPHROTOXIC IF GIVEN PARENTEPALLY P0026
PENICILLAMINE U PROTEIN INC V NEPHROTOXIC EFFECT R0355
PENICILLIN U PROTEIN INC N CAUSES TURBIDITY IF SULFOSALICYLIC ACID USED 30907
PENICILLIN U PROTEIN INC V NEPHROTOXICITY MAY OCCUR WITH LARGE DOSES 30384
PERCHLOPATE U PROTEIN INC V REPOBTEDOASES OF NEPHROTIC SYNDROME 30026
PHENACEMIDE U PROTEIN INC V OCCASIONAL NEPHROPATHY 30026
PHENINDION! U PROTEIN INC V NEPHROTOXICITY MAY OCCUR P0677
PHENSUXIMIDE U PROTEIN INC V REVERSIBLE NEPHROPATHY (ESP IN CHILDREN) P0026
PHENYLBUTAZONE U PROTEIN INC V NEPHPOTOXICITY REPORTED P0417
PHOSPHORUS U PROTEIN INC V RENAL TOXIC EFFECT RO355
POLYMYXIN B U PROTEIN INC V NPHROT0XIC EFFECT P0299
PREGNANCY U PROTEIN INC V MODERATE PROTEINURIA COMMON 30291
PREGNANCY U PROTEIN INC V MODERATE PROTEINURIA COMMON RO291
PPOBENECID U PROTEIN INC V NEPHROTOXIC EFFECT 91001
PROMAZINE U PROTEIN INC V AFFECTS TURBIDITY TESTS FOP UP TO 3 DAYS 90020
PPOTEINURIA U PROTEIN INC V ACTUAL EFFECT P0758
PYRAZOLONES U PROTEIN INC V NEPHROTOXIC EFFECT 90355
QUININE U PROTEIN INC V PARE PENAL DAMAGE 30384
RADIOGRAPHIC U PROTEIN INC N TURBIDITY IF ACID PROCEDURES USED P0475
RADIOGRAPHIC U PROTEIN INC V MAY OCCUR FOLLOWING AOPTOGRAPHY 90020
RHUBARB U PROTEIN INC V CRYSTALLURIA MAY CAUSE PENAL DAMAGE P0053
SODIUM IPODATE U PROTEIN INC V NEPHROTOXIC EFFECT P0260
STIBOPHEN U PROTEIN INC V RENAL IRRITATION REPORTED P0026
STREPTOKINASE U PROTEIN INC V PENAL DAMAGE REPORTED P0620
STPEPTOMYCIN U PROTEIN INC N REACTS AS PHENOL IF FOLIN-CIOCALTRU REACTION USED P0907
STREPTOMYCIN U PROTEIN INC V NEPHROTOXIC EFFECT 90384
SULFADIAZINE U PROTEIN INC V DUE TO CRYSTALLURIA AND HEMATURIA P0736
SULFAMETHOXAZOLE U PROTEIN INC V MAY CAUSE HEMATURIA WITH CRYSTALLURIA 90736
SULFISOXAZOLE U PROTEIN INC N CAUSES TURBIDITY IF SULPHOSALICYLIC ACID USED 30907
SULFONAMIDES U PROTEIN INC N MAY CAUSE FALSE 305 WITH SULFOSALICYLIC ACID 30417
SULFONAMIDES U PROTEIN INC N REACTS AS PHENOL WITH FOLIN-CIOCALTEU REAGENT P0907
SULFONAMIDES U PROTEIN INC V MAY CAUSE NEPHROTOIICITY 90417
SULFONES U PROTEIN INC V MAY HAVE NEPHPOTOXIC EFFECT 30299
SURAMIN U PROTEIN INC V USUAL EFFECT DURING TREAT OF ACUTE STAG! P0026
TARTRATES U PROTEIN INC V IF ABSORBED NAY CAUSE RENAL DAMAGE 903814
TETRACYCLINE U PROTEIN INC V NEPHROTOXIC EFFECT WITH DEGRADED TETRACYCLINE P0355
THIABENDAZOL! U PROTEIN INC V NAY CAUSE NEPHROTOXICITY P01417
THIOCYANATES U PROTEIN INC V NAY CAUSE NEPHROSIS R0384
THIOSEMICARBAZONES U PROTEIN INC V NEPHROTOXIC EFFECT 90355
TOLBUTAMID! U PROTEIN INC N CAUSES TURBIDITY IF SULFOSALICYLIC ACID USED P0843
TRIMETHADIONE U PROTEIN INC V MAY HAVE NEPHEOTOXIC EFFECT H0417
TURPENTINE U PROTEIN INC V NAY HAVE NEPHROTOXIC EFFECT P0299
VANCOMYCIN U PROTEIN INC V NEPHROTOXICITY MAY OCCUR 90355
VIOMYCIN U PROTEIN INC V MAY HAVE NEPHROTOXIC EFFECT P0355
VITAMIN D U PROTEIN INC V N!PHROTOXIC EFFECT WITH HYPERCALCEMIA P0299
ZOXAZOLAMINE U PROTEIN INC V HAS NEPHROTOXIC EFFECT R01417
ASCORBIC ACID C PHOTEIN Z N NO EFFECT ON FOLIN-CIOCALTEU PROCEDURE P1026
ERYTHROMYCIN C PROTEIN Z N NO EFFECT ON FOLIN-CIOCALTEU PROCEDURE P1026
MEALS S PROTEIN Z V NO EFFECT AFTER STANDARD BREAKFAST P0181
STORAGE OF SAMPLE S PROTEIN Z N NO EFFECT FOR 1 WEEK AT ROOM TEMP, 1 MONTH AT 4 DEG 301436
THYMOL U PROTEIN Z N NO EFFECT ON BIURET, BOILING TESTS P0779
ACETYLSALICYLIC AC P PROTHPOMBIN TIME DEC V SMALL DOSE EFFECT P0620
AMOBARBITAL P PROTHROMBIN TIME DEC V ANTAGONIZES ACTION OF COUMARINS (ENZ INDUCTION) R0787
ANABOLIC STEROIDS P PROTHHOMBIN TIME DEC V INC PROTHROMBIN AS METABOLIC EFFECT 906814
ANTIHISTANINES P PROTHPOMBIN TIME DEC V ACCELERATE METABOLISM OF ANTICOAGULANTS P0620
ANTIPYRINE P PROTHRONBIN TIME DEC V OBSERVED IN MAN AND EXPTL ANIMALS P0657
AZATHIOPRINE P PROTHRONBIN TIME DEC V MAY CAUSE HEPATOTOXICITY 90893
BARBITURATES P PROTHRONBIN TINE DEC V METAB OF COUMAPINS ENHANCED (ENZ INDUCT IN LIVER) P0387
BUTABARBITAL P PROTHROMBIN TIM! DEC V DEC RESPONSE TO ANTICOAGULANTS (ENZ INDUCTION) P0886
CAFFEINE P PROTHROMBIN TIME DEC V OBSERVED IN PATIENTS RECEIVING ANTICOAGULANTS P0620
CHLORAL BETAINE P PPOTHPOMBIN TINE DEC V MAY DECREASE POTENCY OF COUMAPIN ANTICOAGULANTS P0026
CHLOPAL HYDRATE P PROTHROMBIN TIME DEC V ACCELERATES RATE OF INACTIVATION OF COUMARINS P0620
CHLORDAN! P PPOTHHOMBIN TIME DEC V INDUCES HEPATIC METABOLISM OF ANTICOAGULANTS P0384
COLCHICINE P PROTHPOMBIN TIME DEC V PATIENTS ON COUMARINS P0656
CORTICOSTEROIDS P PROTHRONBIN TINE DEC V ACCELERATE METABOLISM OF ANTICOAGULANTS P0620
CORTICOTROPIN P PPOTHPOMBIN TIME DEC V PATIENTS ON COUMARINS (MAY INDUCE ENZYMES) P0656
CORTISONE P PROTHPONBIN TINE DEC V PATIENTS ON COUMARINS P06146
DICHLOPALPHENAZONE P PPOTHRONBIN TIME DEC V ANTAGONIZES ACTION OF ADMINISTERED COUMARINS P0787
DIGITALIS P PROTHROMBIN TIME DEC V ANIMAL EXPERIMENTS SUGGEST INC COAGULABILITY P0620
DIURETICS P PROTHROMBIN TIME DEC V IN PATIENTS RECEIVING ANTICOAGULANTS P0620
EDTA P PROTHPONBIN TIME DEC V TRANSIENT FALL DUPING ADMINISTRATION (WITHIN 12 H) P0620
ETHCHLOPVYNOL P PROTHROMBIN TIME DEC V DEC POTENCY OF COUMARIN ANTICOAGS (ENZ INDUCTION) 901498
GLUTETHIMIDE P PROTHROMBIN TIME DEC V INCS PATE OP DEGRADATION OF ADMINISTERED COUMAPINS P0787
GRISEOFULVIN P PPOTHROMBIN TIME DEC V INDUCES HEPATIC METABOLISM OF ANTICOAGULANTS P0237
HEPTABAPBITAL P PROTHP0MBIN TINE DEC V INDUCES HEPATIC METABOLISM OF ANTICOAGULANTS P0596
KANAMYCIN P PROTHRONBIN TIME DEC V EFFECT NOTED AT BEGINNING OF THERAPY R0657
MEPROBANAT! P PROTHPOMBIN TIME DEC V INDUCES HEPATIC METABOLISM OF ANTICOAGULANTS P0384
METHARBITAL P PROTHROMBIN TIME DEC V THEORETICAL POSSIBILITY DUE TO ENZYME INDUCTION P0467
OPAL CONTRACEPTIVE P PROTHROMBIN TIME DEC V DECREASES RESPONSE TO ORAL ANTICOAGULANTS P0270
PHENOBARBITAL P PPOTHRONBIN TIME DEC V METABOLISM ENHANCED BY BARBITURATES P0026
PHYTONADIONE P PROTHROMBIN TIME DEC V STIMULATES SYNTHESIS OF CLOTTING FACTORS P0886
RESEPPINE P PROTHPOMBIN TINE DEC V SHORT TERM TREATMENT BLOCKS ACTION OF ANTICOAGS P03814
PIFANPIN P PROTHROMBIN TIME DEC V OCCURS IN SOME PATIENTS, ESP IF ON ANTICOAGULANTS R0391

SECOBAPBITAL P PROTUROMBIN TIME DEC V INDUCES METABOLISM OF ADMINISTERED COUMARINS P0787
THIOTHIXENE P PHOTHROMBIN TINE DEC V RARELY REPORTED SIDE EFFECT 30026
VITAMIN K P PROTHHOMBIN TINE DEC V THERAPEUTIC INTENT, AFFECTS ACTION OF WAPFARIN P0620
XANTHINES P PROTHROMBIN TIME DEC V ANTAGONIZES EFFECTS OF COUNAPINS P0620
ACETAMINOPHEN P PPOTHPOMBIN TINE INC V DEPRESSES CLOTTING FACTOR SYNTHESIS P0137
ACETOHEXAMIDE P PROTH?OMBIN TIME INC V OCCURS IF FAILURE TO EXCRETE BILE SALTS P0026
AC!TOPHEN!TIDIN P PPOTHROMBIN TIME INC V TRANSIENT INCREASES REPORTED R0657
ACETYLSALICYLIC AC P PROTHRONBIN TIME INC V LARGE DOSE EFFECT (DEC SYNTHESIS OF CLOT FACTORS) P0270
ALLOPURINOL P PROTHRONBIN TIME INC V PATIENTS ON COUNARINS (UNCONFIRMED CLINICALLY) P0960
ANINOPYRINE P PPOTHRONBIN TIME INC V OBSERVED IN MAN AND EXPTL ANIMALS P0620
AMINDSALICYLIC AC P PPOTHROMBIN TIME INC V DRUG SUPPRESSES FORMATION OF PROTHPOMBIN 90763
ANABOLIC STEROIDS P PROTHPONBIN TIN! INC V EXAGGERATED RESPONSE TO ANTICOAGULANTS REPORTED P0467
ANESTHETIC AGTNTS P PROTHPOEBIN TIME INC V OBSERVED EFFECT R01467
ANTIBIOTICS P PROTHPONBIN TIME INC V DECREASED SYNTHESIS OF VIT K BY G.I. TRACT P1001
ANTICOAGULANTS P PROTHROMBIN TIME INC V THERAPEUTIC INTENT P0620
ANTIPYRINE P PROTHPOMBIN TINE INC V PATIENTS ON COUNARINS 90657
ASPAPAGINAS! P PROTHROMBIN TIME INC V DIMINISHED SYNTHESIS OF PPOTHROMBIN BY LIVER P0180
BARBITURATES P PPOTHROMBIN TIME INC V THEORETICALLY IF CHOLESTASIS OCCURS P0620
BISHYDPOXYCOUMAPIN P PROTHROMBIN TIME INC V DOSE RELATED EFFECT P03814
BP!TYLIUM P PPOTHRONBIN TIME INC V ENHANCES ANTICOAGULANT ACTIVITY P0384
BROMELAINS P PROTHRONBIN TIME INC V EFFECT OBSERVED OVER 14H PERIOD IN ANIMALS P0026
CARBFNICILLIN P PPOTHROMBIN TIME INC V EFFECT OBSERVED ESPECIALLY IN UREMICS P0467
CEPHALOPIDINE P PPOTHPOMBIN TIME INC V REPORTED EFFECT P0026
CHLORAL HYDRATE P PPOTHRONBIN TIME INC V DISPLACES ANTICOAGULANTS FROM ALBUMIN P0886
CHLORAMPHENICOL P PROTHROMBIN TIME INC V MAY CAUSE LOWERED PPOTHPONBIN AND HEMORRHAGE 90270
CHLOBDIAZEPOXIDE P PPOTHRONBIN TINE INC V ASSOC WITH FAILURE OF EXCRETION OF BILE SALTS P01477
CHLO9PROMAZINE P PPOTHPOMBIN TIN! INC V ASSOC WITH FAILURE OF EXCRETION OF BILE SALTS 901477
CHLOPPPOPAMIDE P PROTHROMBIN TIM! INC V ASSOC WITH FAILURE OF EXCRETION OF BILE SALTS P0477
CHLORTHALIDONE P PROTHPOMBIN TIME INC V PATIENTS ON COUMARINS P0656
CHOLESTYRANIN! P PPOTHPOMBIN TIME INC V COMBINES WITH BILE ACIDS (VIT K NOT ABSORBED) P0270
CLOTIBPAT! P PROTHPOMBIN TIME INC V DISPLACES ANTICOAGtJLANTS FROM BINDING PROTEIN P0707
CORTICOSTEROIDS P PROTHROMBIN TIME INC V ALLEGED POTENTIATION OF EFFECT OF ANTICOAGULANTS P01467
CORTICOTROPIN P PROTHROMBIN TIME INC V PROLONGS ACTION OF ANTICOAGULANTS P0620
CPEMONYCIN P PROTHPOMBIN TINE INC V NAY CAUSE HYPOPROTHROMBINEMIA P0026
CYCLOPHOSPHAMIDE P PROTHROMBIN TIME INC V MAY CAUSE HYPOPROTHROMBINEMIA P0893
DEXTROTHYROXINE P PPOTHROMBIN TIME INC V INCS RECEPTOR SITE AFFINITY FOP ANTICOAGULANTS P0885
DIAZOXIDE P PROTHROMBIN TIME INC V DISPLACES ANTICOAGULANTS FROM ALBUMIN P0850
DIPHENYLEIYDANTOIN P PPOTHROMBIN TIME INC V PATIENTS ON COUMARINS WHICH INHIBIT ITS METABOLISM 90596
DISULFIRAN P PROTHPOMBIN TIME INC V INHIBITS METABOLISM OF COUMAPINS P0801
EDTA P PROTHROMBIN TINE INC N WHEN USED AS ANTICOAGULANT P1029
ERYTHPONYCIN P PROTHROMBIN TINE INC V ASSOC WITH IMPAIRED AVAILABILITY OF BILE SALTS P0596
ETHACRYNIC ACID P PPOTHROMBIN TIME INC V DISPLACES COUMARINS FROM ALBUMIN P0850
ETHANOL P PROTHPOMBIN TIME INC V WITH LARGE QUANTITIES AND ALCOHOLISM P0620
GLUCAGON P PHOTHPONBIN TIME INC V PATIENTS ON COUMARINS 90543
GLtJTETHINIDE P PROTHROMBIN TIME INC V EFFECT OBSERVED WITH OVERDOSAGE P0657
GUANETHIDINE P PHOTHRONBIN TIME INC V ENHANCES ANTICOAGULANT ACTIVITY RO384
HEPARIN P PROTHPOMBIN TIME INC V CONCENTRATION RELATED EFFECT P0704
HYDROXYZINE P PPOTHROMBIN TIME INC V PROLONGS ACTION OF ANTICOAGULANTS 91001
INDONETHACIN P PROTHRONBIN TIME INC V DISPLACES ANTICOAGULANTS FROM BINDING PROTEIN P0682
LEVOTHYROXINE P PROTHROMBIN TIME INC V MAY POTENTIATE ACTION OF ANTICOAGULANTS P01467
LIOTRIX P PROTHROMBIN TIME INC V MAY POTENTIATE ACTION OF OPAL ANTICOAGULANTS P0467
MEFENAMIC ACID P PROTHPOMBIN TIME INC V DISPLACES COUNARINS FROM ALBUMIN P0850
MEPAZINE P PPOTHPOMBIN TIME INC V ASSOC WITH FAILURE OF EXCRETION OF BILE SALTS P0477
NERCAPTOPURIN! P PROTHROMBIN TIME INC V DEPRESSES CLOTTING FACTOR SYNTHESIS P0886
METANDIENONE P PROTHROMBIN TIME INC V PROLONGS ACTION OF ANTICOAGULANTS P0620
METHANDROSTENOLONE P PHOTHROMBIN TIME INC V ALSO SEEN WITH OTHER 17-ALKYL SUBSTITUTED STEROIDS P0295
METHIMAZOLE P PROTHROMBIN TINE INC V ASSOC WITH FAILURE OF EXCRETION OF BILE SALTS P0656
METHYLDOPA P PROTHRONBIN TIME INC V ENHANCES ANTICOAGULANT ACTIVITY P1001
M!THYLPHENIDAT! P PPOTHROMBIN TIME INC V INHIBITS METABOLISM OF COUNARINS AND PHYTONADIONE P0358
NETHYLTESTOSTERONE P PROTHRONBIN TIME INC V ASSOC WITH FAILURE OF EXCRETION OF BILE SALTS P01477
METHYLTHIOUPACIL P PROTHROMBIN TIME INC V ALSO EXAGGERATED RESPONSE TO ANTICOAGULANTS P0545
MINERAL OIL P PPOTHPOMBIN TIME INC V INHIBITS ABSORPTION OF VITAMIN K P0620
NITHRANYCIN P PROTHRONBIN TIME INC V REVERSIBLE DEC PROTHRONBIN LEVEL P0026
NALIDIXIC ACID P PROTHRONBIN TIME INC V DISPLACES COUMAPINS FROM ALBUMIN P0850
NANDROLON! P PROTHPOMBIN TIME INC V NAY INCREASE SENSITIVITY TO ANTICOAGULANTS P0708
NEOMYCIN P PHOTHROMBIN TIME INC V REDUCES AVAILABILITY OF VITAMIN K P0947
NORETHANDROLONE P PROTHROMBIN TINE INC V ALSO SEEN WITH OTHER 17-ALKYL SUBSTITUTED STEROIDS P0295
NORTEIPTYLINE P PROTHROMBIN TIME INC V PATIENTS ON COUMARINS (UNCONFIRMED CLINICALLY) P0960
ORAL CONTRACEPTIVE P PPOTHROMBIN TIME INC V ASSOC WITH FAILURE OF EXCRETION OF BILE SALTS P0477
OXYMETHOLONE P PROTHROMBIN TIME INC V ALSO SEEN WITH OTHER 17-ALKYL SUBSTITUTED STEROIDS P0295
OXYPHENBUTAZONE P PROTHROMBIN TIME INC V DISPLACES ANTICOAGULANTS FROM ALBUMIN P0620
OXYPHENISATIN P PROTHRONBIN TIME INC V MAY CAUSE HYPERSENSITIVITY REACTION 90776
PHENOLPHTHALEIN P PROTHPOMBIN TIME INC V PATIENTS ON COUMARINS P0657
PHENYLBUTAZONE P PROTHROMBIN TIME INC V POTENTIATES ACTION OF ANTICOAGULANTS P0008
PHENYPAMIDOL P PHOTHPOMBIN TIME INC V INHIBITS METABOLISM OF ISHYDR0XYCOUMARIN P0190
PHOSPHORUS P PROTHROMBIN TIME INC V TOXICITY EFFECT (HYPOPPOTHROMBINEMIA) P0620
PRENARIN P PROTHROMBIN TIME INC V IN NORMAL WOMEN AFTER I.V. ADMINISTRATION P0028
PPOCHLORPERAZINE P PPOTHPOMBIN TINE INC V ASSOC WITH IMPAIRED EXCRETION OF BILE SALTS P0026
PROMAZINE P PPOTHPOMBIN TIME INC V ASSOC WITH FAILURE OF EXCRETION OF BILE SALTS P01477
PPOPYLTHIOURACIL P PPOTHROMBIN TINE INC V DEFICIENCY OF PROTUROMBIN AND PROCONV!PTIN P0026
PYRAZINAMIDE P PPOTHPOMBIN TIME INC V REDUCES CONCENTRATION OF PROTHROMBIN P0026
QUINIDINE P PROTHROMBIN TIME INC V DEPRESSES PROTHROMBIN FORMATION IN LIVER P0544
QUININE P PPOTHROMBIN TIME INC V DEPRESSES PROTHPOMBIN FORMATION IN LIVER P0270
RADIOACTIVE P PROTHPONBIN TIME INC V ALSO EXAGGERATED RESPONSE TO ANTICOAGULANTS 90384
RES!RPINE P PROTHROMBIN TIME INC V LONG TERM TREATMENT MARKEDLY ENHANCES ANTICOAGS P0384
STORAGE OF SAMPLE P PROTHRONBIN TIME INC M OXALATED PLASMA LOSES ACTIVITY AT 14 DEGREES P0998
SUCCINYLSULFATHIAZ P PROTHROMBIN TINE INC V MAY CAUSE VITAMIN K DEFICIENCY P0026
SULFAFURAZOLE P PPOTHROMBIN TIM! INC V FAILURE OF EXCRETION OF BILE SALTS P0620
SULFAMETHIZOLE P PROTHROMBIN TIME INC V REACTION MAY OCCUR WITH ALL SULFONAMIDES P01467
SULFAMETHOXAZOLE P PPOTHROMBIN TIME INC V POSSIBLY DUE TO DRUG-INDUCED VITAMIN K DEFICIENCY P0542

SULFI SOXAZOL! P PROTHROMBIN TIM! INC V OCCURS WITH FAILURE OF EXCRETION OF BILE SALTS P02 70
SULFONAMIDES P PROTHRONBIN TIME INC V POTENTIATE ACTION OF ADMINISTERED COUMARINS P0545
TETPACYLI NE P PROTHPONBIN TIME INC V ASSOC WITH CHOLESTASIS, AND REDUCED ACTIVITY P02 82
THIAZIDES P PROTHROMBIN TIME INC V ASSOC WITH FAILURE OF EXCRETION OF BILE SALTS P0477
THYROID P PROTHPOMBIN TIME INC V PROLONGS ACTION OF ANTICOAGULANTS P06 20
TOLAZAMIDE P PPOTHPOMBIN TINE INC V OCCURS WITH FAILURE TO EXCRETE BILE SALTS P0620
TOLBUTA NI DE P PPOTHROMBIN TIME INC V OCCURS WITH FAILURE TO EXCRETE BILE SALTS P0270
TRICHLDPO!THYLPHOS P PROTHROMBIN TIME INC V POTENTIATES ACTION OF COUMARINS (REDUCES BINDING) P0 85 1
TRIFLUOPERAZINE P PROTHROMBIN TIME INC V ASSOC WITH FAILURE OF EXCRETION OF BILE SALTS P01477
VITAMIN A P PROTHPOMBIN TIN! INC V HEMORRHAGIC TREND EXP IF VITAMIN K RESTRICTED P0620
WARFAPIN P PROTHRONBIN TIME INC V THERAPEUTIC INTENT (INHIBITS PROTHRONBIN FORMATION) P0384
X-RAY THERAPY P PPOTHRONBIN TIME INC V ALSO EXAGGERATED RESPONSE TO ANTICOAGULANTS P0384
CHLORDIAZEPOXIDE P PPOTHPONBIN TIME Z V DOES NOT AFFECT ACTION OF ADMINISTERED COUMARINS P0787
CHLOROTHIAZID! P PPOTHRONBIN TIME Z V DOES NOT AFFECT ACTION OF ADMINISTERED COUMAPINS P0787
C YC LOP P OPA NE P PPOTHROMBIN TIME Z V ANESTHESIA HAS NO EFFECT P03814
ETHER P PROTHRONBIN TIME Z V ANESTHESIA HAS NO EFFECT P03 84
HEMOLYSIS P PPOTHPONBIN TINE Z N HAS NEGLIGIBLE EFFECT P0998
STOPAGE OF SAMPLE P PPOTHROMBIN TIME Z N STABLE AT ROOM TEMP FOR 18H IN OXALATED PLASMA P0998
BARBITURATES B PROTOPORPHYRIN INC V MAY PRECIPITATE ACUTE CUTANEOUS PORPHYRIA P037 1
CHLOPPPOPA MID! B PROTOPOPPHYRIN INC V MAY PRECIPITATE CUTANEOUS PORPHYRIA P0 37 1
ESTROGENS B PROTOPORPHYRIN INC V MAY PRECIPITATE PORPHYRIA ATTACK P0 37 1
ETHANOL B PROTOPORPHYPIN INC V MAY PRECIPITATE ATTACK OF PORPHYRIA P037 1
ORAL CONTRACEPTIVE B PROTOPORPHYPIN INC V NAY PRECIPITATE PORPHYRIA ATTACK P037 1
SU LEO NE METHA NE B PROTOPORPHYPIN INC V MAY PROVOKE ATTACK OF PORPHYRIA P0 37 1
TOLBUTANIDE B PROTOPORPHYPIN INC V MAY PRECIPITATE CUTANEOUS PORPHYRIA P037 1
LEAD E PROTOPORPHYRIN INC V OCCURS WITH POISONING P0 29 1
BARBITURATES F PROTOPORPHYPIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P0371
CHLOPDIAZ!POXIDE F PROTOPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P0 37 1
CHLORPPOPAMI DE F PROTOPORPHYPIN INC V NAY PRECIPITATE CUTANEOUS PORPHYRIA P03 71
D IC BLOR A LP HEN A ZONE F PROTOPORPHYPIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P0 37 1
DIETHYLSTILBESTROL F PROTOPORPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TAPDA P0 975
DIPHENYLBYDANTOIN F PROTOPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P037 1
FSTRO3 ENS F PPOTOPORPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA P0975
ETHANOL F PROTOPORPHYPIN INC V MAY PRECIPITATE ATTACK OF PORPHYRIA P037 1
ETHINYLESTPADIOL F PROTOPORPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA P0975
GLUTETHIMIDE F PROTOPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P0 37 1
GRISEOFULVIN F PROTOPORPHYRIN INC V NAY PRECIPITATE ACUTE PORPHYRIA ATTACK HO 37 1
MEPROBANA TE F PHOTOPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P037 1
OPAL CONTRACEPTIVE F PROTOPORPHYPIN INC V MAY PRECIPITATE PORPHYRIA ATTACK P0 37 1
PENTAZOCINE F PROTOPOPPHYRIN INC V NAY PRECIPITATE ACUTE PORPHYRIA ATTACK P037 1
PPE MAR IN F PROTOPORPHYRIN INC V NAY INDUCE PORPHYRIA CUTANEA TARDA P0987
SEDORNID F PROTOPORPHYRIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P03 71
SUCCINIMIDES F PROTOPORPHYPIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P0371
SULFONAMIDES F PROTOPOPPHYPIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P0371
SULFON!M!TH AN! F PROTOPORPHYRIN INC V MAY PROVOKE ATTACK OF PORPHYRIA P037 1
SULPONETHYLNETHANE F PROTOPORPHYPIN INC V MAY PRECIPITATE ACUTE PORPHYRIA P0 37 1
TOLBUTAM ID! F PP0T0POPHYPIN INC V MAY PRECIPITATE CUTANEOUS PORPHYRIA 90371
CHLORPROPANIDE U PPOTOPORPHYRIN INC V MAY PRECIPITATE CUTANEOUS PORPHYRIA P0 37 1
ACETAZOLAMIDE U PSP EXCRETION DEC V INC URINE FLOW P0299
ACETYLSALICYLIC AC U PSP EXCRETION DEC V COMPETES WITH PSP FOP EXCRETION P1001
ATROPI N! U PSP EXCRETION DEC V INTERFERES WITH SECRETION BY TUBULES P0779
CAPINA MIDE U PSP EXCRETION DEC V INHIBITS SECRETION P0 299
DIURETICS U PSP EXCRETION DEC V BLOCKING OF SECRETORY MECHANISM P02 99
I000PYRACET U PSP EXCRETION DEC V MAY COMPETE FOR EXCRETION THROUGH RENAL TUBULES P0 287
NOVOBIOCI N U PSP EXCRETION DEC V ? NEPHROTOXIC EFFECT P0299
PENICILLIN U PSP EXCRETION DEC V INTERFERENCE WITH PSP EXCRETION P1001
PRO BE N E CI D U PSP EXCRETION DEC V INHIBITS RENAL TRANSPORT OF PSP P1001
SULFAM!THOXAZOL! U PSP EXCRETION DEC V MORE COMMON EFFECT P0299
SULFI NPYPAZONE U PSP EXCRETION DEC V COMPETITION FOP EXCRETION P02 87
SULFONAMIDES U PSP EXCRETION DEC V REDUCES PENAL EXCRETION OF PSP P100 1
THIAZI DES U PSP EXCRETION DEC V COMPETITION FOR EXCRETION BY TUBULES P02 87
ANTHPAQUINONE U PSP EXCRETION INC N INTERFERENCE BY COLOR OF COMPOUND P0551
BILE U PSP EXCRETION INC N INTERFERING COLOR P062 0
BROMSULFALEIN U PSP EXCRETION INC N DEVELOPMENT OF COLOR AT ALKALINE PH P100 1
CASCARA U PSP EXCRETION INC H CONVERTED TO ANTHRAQUINONE-G.I. TRACT (RED COLOR) P0233
DANTHRON U PSP EXCRETION INC N RED COLOR INTERFERES WITH PSP DETERMINATION P0355
ET BOX A Z EN U PSP EXCRETION INC N PRODUCES INTERFERING BACKGROUND COLOR R0299
FORMALDEHYDE U PSP EXCRETION INC N PRODUCES INTERFERING COLOR REACTION P0233
HEMOGLOB IN U PSP EXCRETION INC N INTERFERING COLOR P0620
LEVODOPA U PSP EXCRETION INC V INCREASED PLASMA FLOW P0328
METHENAMINE U PSP EXCRETION INC N PRODUCES INTERFERING COLOR IN URINE P0 233
PHENAZOPYRI DINE U PSP EXCRETION INC N FALSE COLOR REACTION AT ALKALINE PH Ri 001
PH!NOLPHTHA LEIN U PSP EXCRETION INC N COLOR DEVELOPMENT ON ALKALINIZATION OF URINE P1001
RADIOGRAPHIC U PSP EXCRETION INC V AFFECT PENAL EXCRETION R0355
SULFAMETHOXA ZOLE U PSP EXCRETION INC V POSSIBLE LARGE DOSE EFFECT P0299
PPEMARI N B PTT DEC V SHORTENING OF TIME IN MALES AFTER I.V. ADMIN P0 02 8
HEPARIN B PTT INC V CONCENTRATION RELATED EFFECT P0704
IPRONIAZID S PYRIDOXAL DEC V OBSERVED IN PATIENT WITH TOXICITY P0224
PYRIDOXINE S PYRIDOXAL PHOSPHATE INC V INC AFTER ADMINISTRATION IN NORMAL SUBJECTS P0657
IPRONIAZI 0 S PYPIDOXINE DEC V OBSERVED IN PATIENT WITH TOXICITY P0224
MUSCULAR EXERCISE S PYRUVATE DEC V SLIGHT FALL WITHIN 1 HOUR AND THEN STEEP DROP P0 29 1
PYRUVATE KINASE S PYPUVATE DEC N IF LDH USED IS CONTAMINATED WITH PYRUVATE KINASE R.0t$34
ACETYLSALICYLIC AC S PYPUVATE INC V DUE TO LATE METABOLIC ACIDOSIS AND PENAL IMPAIR P0384
ETHER S PYRUVAT! INC V METABOLIC EFFECT R1014
FRUCTOSE S PYRUVAT! INC V RISES MOPE RAPIDLY THAN AFTER GLUCOSE P01476
HEMOLYSIS S PYPUVATE INC H DUE TO METABOLIC ACTIVITY OF CELLS P0998
OPAL CONTRACEPTIVE S PYPUVATE INC V GREATER INC THAN NORMAL DUPING GTT P0186
STR!PTOZOTOCIN S PYRUVATE INC V TEMPORARY EFFECT FOLLOWING INFUSION P0686
COPPER E PYRUVATE KINASE DEC V SEVEPLY AFFECTED IN VITRO P0 135
TPIAMTERENE S QUINIDINE INC N INTERFERING FLtJORESENCE P0355

BISHYDROXYCOUMARIN B PECALCIFICATION TINE INC V EFFECT ON CITRATED PLASMA RO384
ACETA MI NOPH EN B RED CELL COURT DEC V MAY CAUSE HEMOLYTIC ANEMIA RO62O
ACETAN IL ID B RED CELL COUNT DEC V HEMOLYTIC ANEMIA/AGRANULOCYTOSIS 90658
ACETAZOLAMI DE B RED CELL COUNT DEC V MAY CAUSE PANCYTOPENIA/AGRANULOCYTOSIS R0620
ACETOHEXANIDE B RED CELL COUNT DEC V MAY CAUSE HENOLYTIC ANEMIA RO298
ACETOP HENAZ IN! B RED CELL COUNT DEC V POSSIBLE APLASTIC ANEMIA P 06 20
AC!TOP R!N!T IDIN B RED CELL COUNT DEC V HEMOLYTIC ANEMIA P02 140
ACETYLPHE NY LHYDRAZ B RED CELL COUNT DEC V MAY CAUSE HEMOLYTIC ANEMIA P0620
ACETYLSALICYLIC AC B RED CELL COUNT DEC V HEMOLYSIS/G-6-PD D!F./GI HEMORRHAGE/DIR SM DEPRESS ROR4L4
ACETYLSULFA NILANIDE B RED CELL COURT DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY R0518
ALLOPURI NOL B RED CELL COUNT DEC V RAPE CASE OF ANEMIA MAY OCCUR 90026
AMINOBENZOIC ACID B RED CELL COUNT DEC V INDUCES MALABSORPTION AND MEGALOBLASTIC ANEMIA R0716
AMINOPYRINE B RED CELL COUNT DEC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS 902140
AMINOSALICYLIC AC B RED CELL COUNT DEC V HEMOLYTIC ANEMIA/MEGALOBLASTIC ANEMIA 90240
A NI TRI PTYLI NE B RED CELL COUNT DEC V PARE TRANSIENT AGRANULOCYTOSIS P0026
AMPHETAMINES B RED CELL COUNT DEC V HEMOLYTIC ANEMIA (DEPENDS ON PRIOR SENSITIVITY) 90240
ANPHOTEPICIN B B RED CELL COUNT DEC V BONE MARROW DEPRESSION WITH HEMOLYTIC ANEMIA 90945
AMYL NITRITE B RED CELL COUNT DEC V HENOLYTIC ANEMIA (SLIGHT OR MARKED EFFECT) RO656
ANTIMALARIALS B RED CELL COUNT DEC V MAY CAUSE HEMOLYTIC ANEMIA P05 18
ANTIMONY COMPOUNDS B RED CELL COUNT DEC V PANCYTOPENIA/NAY CAUSE HEMOLYTIC ANEMIA 90620
ANTINEOPLASTIC B RED CELL COUNT DEC V MAY CAUSE APLASTIC ANEMIA P0620
ANTIPYPETICS B RED CELL COUNT DEC V MAY CAUSE HEMOLYTIC ANEMIA 90518
A NT IPYR IN! B RED CELL COUNT DEC V HEMOLYTIC ANEMIA IN -6-PD DEFICIENT PERSONS P0240
APSENICALS B RED CELL COUNT DEC V MEGALOBLASTIC ANENIA/PANCYTOPENIA P024 0
AZATHIOPRINE B RED CELL COUNT DEC V BONE MARROW DEPRESSION WITH ANEMIA R0026
BARBITURA TES B RED CELL COURT DEC V APLASTIC OR MEGALOBLASTIC ANEMIA P0620
BEN ZEN! B RED CELL COUNT DEC V MILD MACROCYTIC ANEMIA /APLASTIC ANEMIA 30658
BENZ OCAINE B RED CELL COUNT DEC V NAY CAUSE HEMOLYSIS P0 121
BISHYDROXYCOUMAR IN B RED CELL COUNT DEC V MAY CAUSE ANEMIA (AMA-BLOOD DYSCPASIAS COMMITTEE) P06 58
BPOMATE B RED CELL COUNT DEC V MAY CAUSE HEMOLYSIS 30384
B US UL FAN B RED CELL COUNT DEC V PANCYTOPENIA/HEMOLYTIC ANEMIA 90467
BUTAPERAZINE B RED CELL COUNT DEC V TRANSITORY ANEMIA 90026
CAR BAN AZEPINE B RED CELL COUNT DEC V PANCYTOPENIA 30278
CARBENICILLIN B RED CELL COUNT DEC V HEMOLYTIC ANEMIA REPORTED 90467
CARBON TETPACHLOP B RED CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) 90658
CEPHALORIDINE B RED CELL COUNT DEC V MAY CAUSE ANEMIA R0026
CEPHALOTHI N B RED CELL COUNT DEC V HENOLYTIC ANEMIA RO392
CHLORA MBUCIL B RED CELL COUNT DEC V DOSE DEPENDENT BONE MARROW DEPRESSION P00 26
CHLORA MPH ENICOL B RED CELL COUNT DEC V DOSE RELATED RESPONSE USUAL/APLASTIC ANEMIA 90272
CHLOR ATE B RED CELL COUNT DEC V DESTROYS CELLS ON ABSORPTION 90384
CHLORDA NE B RED CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P06 58
C HLOR OP HE ROTH AN! B RED CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P06 58
CHLOPOQUINE B RED CELL COUNT DEC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS 90912
CHLOROTHIAZIDE B RED CELL COUNT DEC V PANCYTOPENIA/APLASTIC ANEMIA 30024
CHLORPR OMAZ IN! B RED CELL COUNT DEC V HEMOLYTIC ANEMIA P0 222
CHLOPPROPAMIDE B RED CELL COUNT DEC V MILD ANEMIA, PARE APLASTIC ANEMIA R0733
CHLORTETRACYC LINE B RED CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) 30658
COLCHICINE B RED CELL COUNT DEC V MEGALOBLASTIC ANEMIA (IMPAIRED ABSORP B12) RO976
COLD AGGLUTININS B RED CELL COUNT DEC M SPURIOUS MACPOCYTOSIS DUE TO AGGLUTINATION 907 32
CORTICOSTEPOI DS B RED CELL COUNT DEC V MAY CAUSE G.I. BLEEDING WITH LOW IRON STORES ROl 04
CYCLOSER IN! B RED CELL COUNT DEC V MAY CAUSE MEGALOBLASTIC ANEMIA P0 976
CYTARABINE B RED CELL COUNT DEC V MEGALOBLASTIC ANEMIA (RELATIVELY INFREQUENT) R0620
DACTINOMYCIN B RED CELL COUNT DEC V ANEMIA/PANCYTOPENIA 90026
DESIPPAMINE B RED CELL COUNT DEC V TRANSIENT AGRANULOCYTOSIS (UP TO 25% REPORTED) 90026
DIAMINODIPHENYLSULF B RED CELL COUNT DEC V MAY CAUSE HENOLYTIC ANEMIA P045 1
DIETHYLPPOPION B RED CELL COUNT DEC V MAY CAUSE BONE MARROW DEPRESSION P0047
DIGITALIS B RED CELL COUNT DEC V APLASTIC ANENIA/PANCYTOPENIA RO620
DIIODO HYDRO XYQUIN B RED CELL COUNT DEC V MAY CAUSE ANEMIA 90620
DIMEPCAPROL B RED CELL COUNT DEC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS 902140
DI NITPOPHENOL B RED CELL COUNT DEC V MAY CAUSE ANEMIA/APLASTIC ANEMIA RO384
DIPHENHYDPA MINE B RED CELL COUNT DEC V HENOLYTIC ANEMIA P09 32
DI PHENYLHYDANTOIN B RED CELL COUNT DEC V MEGALOBLASTIC/HEMOLYTIC/APLASTIC ANEMIA/PANCYTOPEN P0 873
DIPYRONE B RED CELL COUNT DEC V HENOLYTIC ANEMIA 90569
DOXAPPAN B RED CELL COURT DEC V NOTED POSTOPERATIVELY IN A FEW PATIENTS R0620
!DTA B RED CELL COUNT DEC V TRANSIENT BONE NARROW DEPRESSION P0026
ESTROGENS B RED CELL COUNT DEC V NEGALOBLASTIC ANEMIA (IMPAIRS ABSORP OF FOLATE) P0976
ETHANOL B RED CELL COUNT DEC V MAY AFFECT FOLIC ACID ABSORPTION AND USAGE R0976
ETHOSUXIMIDE B RED CELL COURT DEC V APLASTIC ANENIA/PANCYTOPENIA 30620
ETHOTOIN B RED CELL COUNT DEC V NAY CAUSE MARROW DEPRESS OP MEGALOBLASTIC ANEMIA P0026
FAVA BEANS B RED CELL COUNT DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY 30079
FLUOROUPACIL B RED CELL COUNT DEC V MAY CAUSE BONE MARPOW DEPRESSION 90026
FUR A LTA DO NE B RED CELL COUNT DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P 0079
FUPAZOLIDONE B RED CELL COUNT DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY 90079
EU P OS! N IDE B RED CELL COUNT DEC V NAY CAUSE ANEMIA P04 52
GENTA MXCI N B RED CELL COUNT DEC V MAY CAUSE ANEMIA 90026
GL UCOS U L F ONE B RED CELL COUNT DEC V HEMOLYTIC ANEMIA P06 58
GLUTETHI MIDE B RED CELL COUNT DEC V MAY CAUSE APLASTIC/MEGALOBLASTIC ANEMIA P0026
GOLD B RED CELL COUNT DEC V APLASTIC ANEMIA P0933
HA LOPERIDOL B RED CELL COUNT DEC V MAY CAUSE ANEMIA P062 0
HETACILL IN B RED CELL COUNT DEC V OCCASIONAL ANEMIA REPORTED WITH PENICILLINS P0 467
H EX ACH L OP OR ENZ EN E B RED CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIA 5) 30658
HYDRALAZINE B RED CELI COUNT DEC V PANCYTOPENIA NAY OCCUR 90014
HYDROC H LOROTHI AZ IDE B RED CELL COUNT DEC V APLASTIC ANEMIA MAY OCCUR 90467
HYDROFLUMET HIAZIDE B RED CELL COUNT DEC V PANCYTOPENIA, APLASTIC ANEMIA R0991
HYDPOXYCHLOPOQUINE B RED CELL COUNT DEC V ANEMIA 90620
HYDRDXYUREA B RED CELL COUNT DEC V ANEMIA (MAY BE TRANSIENT MEGALOBLASTIC) 30026
INDOMETHACIN B RED CELL COUNT DEC V 2NDAPY TO G.I.BLEED/AGRANULOCYTOSIS/PANCYTDPENIA P0 120
IPPONI AZID B RED CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) 30658
ISOCARBOXAZID B RED CELL COUNT DEC V AGRANULOCYTOSIS/ANEMIA - PARE 30620
ISONIAZID B RED CELL COUNT DEC V HEMOLYTIC ANEMIA (PARE COMPLICATION) 30620

LEAD B RED CELL COUNT DEC V HEMOLYTIC ANEMIA (WITH BASOPHILIC STIPPLING) P024 0
LIPOMUL B RED CELL COUNT DEC V MAY BE PROGRESSIVE ANEMIA WITH EXCESS R0657
LOCAL ANESTHETICS B RED CELL COUNT DEC V BONE MARROW DEPRESSION REPORTED P0657
LYSOL B RED CELL COUNT DEC V NAY CAUSE INTRAVASCULAR HEMOLYSIS P0 197
MAO INHIBITORS B RED CELL COUNT DEC V ANEMIA MAY OCCASIONALLY OCCUR P062 0
MECHLORETHAMINE B RED CELL COUNT DEC V MILD EFFECT 30026
!EF!NANIC ACID B RED CELL COUNT DEC V PANCYTOPENIA P06 20
MEL AR SON YL B RED CELL COUNT DEC V MAY CAUSE HEMOLYTIC ANEMIA IN G-6-PD DEFICIENCY P0026
MELPHA LA N B RED CELL COUNT DEC V MAY CAUSE BONE NARROW DEPRESSION (DOSE RELATED) P0 167
MEPACRINE B RED CELL COUNT DEC V NAY PRODUCE APLASTIC ANEMIA P06 20
NEPAZ IRE B RED CELL COUNT DEC V PANCYTOPENIA/APLASTIC ANEMIA P0620
NEPHENOX ALONE B RED CELL COUNT DEC V NAY CAUSE ANEMIA P0620
NEPHE NYTOIN B RED CELL COUNT DEC V HEMOLYTIC ANEMIA P07 814
NE PP OBA MA TE B RED CELL COUNT DEC V APLASTIC ANEMIA/ ERYTHROID HYPOPLASIA P06 58
MEPCAPTOPURINE B RED CELL COUNT DEC V MAY OCCUR WITH BONE-MAPPOW DEPRESSION P0 657
MERCURIAL DIURETICS B RED CELL COUNT DEC V ANEMIA MAY OCCUR P0620
METHAPYHILINE B RED CELL COUNT DEC V ANEMIA (AMA-BLOOD DYSCRASIAS) P06 58
NETHA QUAL ONE B RED CELL COUNT DEC V ONE POSSIBLE CASE OF APLASTIC ANEMIA REPORTED P0620
METHICILL IN B RED CELL COUNT DEC V MAY RARELY CAUSE BONE MARROW DEPRESSION P07 36
METHI MAZ OLE B FED CELL COUNT DEC V APLASTIC ANEMIA P06 20
METHOPH!NOBAPBIT AL B RED CELL COUNT DEC V NEGALOBLASTIC ANEMIA P0620
N El HOTR ElATE B RED CELL COUNT DEC V MAY = MEGALOBLASTIC ANEMIA (FOLIC ACID ANTAGONIST) P0976
METHSUXIMIDE B RED CELL COUNT DEC V PARE APLASTIC ANEMIA REPORTED P0620
M!THYCLOT HIAZ IDE B RED CELL COUNT DEC V APLASTIC ANEMIA MAY OCCUR WITH THIAZIDES P01467
M!THYLDOPA B RED CELL COUNT DEC V AUTOIMMUNE HEMOLYTIC ANEMIA/APLASTIC ANEMIA P0189
METHYLEN! BLUE B RED CELL COUNT DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
MITOMYCIN C B RED CELL COUNT DEC V PANCYTOPENIA P05 89
MUSTARD GAS B RED CELL COUNT DEC V MAY CAUSE APLASTIC ANEMIA P0658
NALIDIXIC ACID B RED CELL COUNT DEC V HEMOLYTIC ANEMIA WITH G-6-PD DEFICIENCY P0093
N AP HT HA LE N! B RED CELL COUNT DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
NEOMYCIN B RED CELL COUNT DEC V MEGALOBLASTIC ANEMIA (IMPAIRED B12 ABSOPP) P0976
NIRIDAZOL! B RED CELL COUNT DEC V MAY CAUSE HEMOLYSIS IF G-6-PD DEFICIENCY P038 14
NITRI TES B RED CELL COUNT DEC V MAY CAUSE HEMOLYTIC ANEMIA P0620
NITPOBENZ!NE B RED CELL COUNT DEC V OCCURS WITH HEMOLYSIS P0658
NITROFURA NTOIN B RED CELL COUNT DEC V HYPERSENSITIVITY (G-6-PD)/MEGALOBLASTIC ANEMIA 30633
NITROFURAZONE B RED CELL COUNT DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
NITROUS OXIDE B RED CELL COUNT DEC V BONE MARROW DEPRESS (OF NO SIGNIFICANCE NORMALLY) P0384
NOVOBIOCIN B RED CELL COUNT DEC V HEMOLYTIC ANEMIA - MILD P0218
OLEANDONYCIN B RED CELL COUNT DEC V PROBABLY DUE TO HENOLYTIC ANEMIA R0620
OPAL CONTRACEPTIVE B RED CELL COUNT DEC V NAY CAUSE MEGALOBLASTIC ANEMIA HO 976
OXACILLIN B RED CELL COUNT DEC V LARGE DOSES PARENTERAL PENICILLIN MAY HAVE EFFECT P0 467
OXYPH ENBUTAZONE B RED CELL COUNT DEC V MAY CAUSE BLOOD DYSCRASIAS P062 0
PAMAQUINE B RED CELL COUNT DEC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS P0 2140
PARAM!THADIONE B RED CELL COUNT DEC V APLASTIC ANEMIA MAY OCCUR RARELY R0620
PENICILLAMIN! B RED CELL COUNT DEC V HYPOCHROMIC ANEMIA IN CHILDREN & MENST. FEMALES P00 22
PENICILLI N B RED CELL COUNT DEC V HEMOLYTIC ANEMIA DUE TO BINDING TO EPYTHROCYTES P02 94
PENTAMIDINE B RED CELL COUNT DEC V MEGALOBLAST ANEMIA-INHIBITS DIHYDROFOLATE REDUCTASE P0 976
PENTAQUINE B RED CELL COUNT DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0079
P!PCHLOP ATE B RED CELL COUNT DEC V MAY CAUSE FATAL APLASTIC ANEMIA P0026
PHENACEMID! B RED CELL COUNT DEC V APLASTIC ANEMIA/AGRANULOCYTOSIS P0620
PHENAZOPYPIDINE B RED CELL COUNT DEC V HEMOLYTIC ANEMIA (SENSITIVITY DEPENDENT) P0656
PHENETHICILLIN B 9ED CELL COUNT DEC V THEORETICALLY MAY CAUSE HEMOLYTIC ANEMIA P0467
PHENOBARBITAL B RED CELL COUNT DEC V MEG. ANEMIA 2ND TO DISTURBANCE IN FOLIC ACID NETAB. P05 28
PHENOTHIA ZINES B RED CELL COUNT DEC V HEMOLYTIC ANEMIA (SENSITIVITY DEPENDENT) P02140
PH!NYLBUTAZONE B RED CELL COUNT DEC V BM DEPPESSION/2ND TO NA AND H2O RETENTION 30177
PH!NYLHYDRAZINE B RED CELL COUNT DEC V HEMOLYTIC ANEMIA P0657
PHOSPH OPUS B RED CELL COUNT DEC V OCCURS WITH CHRONIC POISONING P036 8
PHYTONADIONE B RED CELL COUNT DEC V H!NOLYSIS MAY OCCUR WITH G-6-PD DEFICIENCY P0620
PICRIC ACID B RED CELL COUNT DEC V HEMOLYTIC EFFECT P0384
PIPAMAZINE B RED CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0 658
PIPE9AZINES B RED CELL COUNT DEC V MAY CAUSE HEMOLYTIC ANEMIA P0636
PIPOBROMAN B RED CELL COUNT DEC V MAY CAUSE ANEMIA (BONE MARROW DEPRESSION) P0026
PLASNOQUIN B RED CELL COUNT DEC V NAY CAUSE HEMOLYTIC ANEMIA P0620
PREGNANCY B RED CELL COUNT DEC V BY UP TO 10-iSA DUE TO EXPANDED PLASMA VOLUME P029 1
PRILOCAINE B RED CELL COUNT DEC V H!MOLYSIS WITH DOSES GREATER THAN 1400 MG P0026
PRIMAQUIN! B RED CELL COUNT DEC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS 90240
P91 MI DONE B RED CELL COUNT DEC V MEGALOBLASTIC ANEMIA 2ND DIST. IN FOLIC ACID METAB. P0775
PPOB!NECID B RED CELL COUNT DEC V HENOLYTIC ANEMIA (SENSITIVITY DEPENDENT) P02140
PROCAPBAZINE B RED CELL COUNT DEC V ANEMIA AND BONE MARROW DEPRESSION 30026
PYRAZINOIC ACID B RED CELL COUNT DEC V SIDEROBLASTIC TYPE OF ANEMIA NAY OCCUR P0 104
PYRAZOLONES B RED CELL COUNT DEC V APLASTIC/HEMOLYTIC ANEMIA P06 20
PYRIMETHAMINE B RED CELL COUNT DEC V MEGALOBLASTIC ANEMIA P1007
QU IRA CR IRE B RED CELL COUNT DEC V MAY CAUSE HENOLYSIS WITH G-6-PD DEFICIENCY P0079
QUINIDINE B RED CELL COUNT DEC V HEMOLYTIC ANEMIA (SENSITIVITY DEPENDENT)G-6-PD DEE P0953
QUININE B RED CELL COUNT DEC V HEMOLYTIC ANEMIA (SENSITIVITY DEPENDENT)G-6-PD DEE P0090
QUINOCIDE B RED CELL COUNT DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY P0518
RADIOACTIVE B RED CELL COUNT DEC V APLASTIC ANEMIA P0620
PESOTCI N B RED CELL COUNT DEC V MAY CAUSE HEMOLYTIC ANEMIA P0657
RESOPCINOL B RED CELL COUNT DEC V INJECTION OP EXCESS ABSORP MAY CAUSE H!MOLYSIS P00 26
SALICYLAZOSULFAPYR B RED CELL COUNT DEC V MAY CAUSE HENOLYTIC ANEMIA P062 0
SODIUM P1105 P32 B RED CELL COUNT DEC V ANEMIA IF EXCESS USED P0026
STIBOPHEN B RED CELL COUNT DEC V PRODUCES H!MOLYTIC ANEMIA P0636
STREPTOMYCIN B RED CELL COUNT DEC V APLASTIC/HEMOLYTIC AN! MIA (SE NSITI VITY DEPENDENT) P0620
SULFACETA MID! B RED CELL COUNT DEC V MAY CAUSE HEMOLYSIS IF G-6-PD DEFICIENCY P0079
SULTADIAZINE B RED CELL COUNT DEC V MAY CAUSE HEMOLYTIC ANEMIA P0 620
SULFA METHIZOLF B RED CELL COUNT DEC V HENOLYTIC ANEMIA/APLASTIC ANEMIA P07 51
S UL F AM FT 1101 AZO LE B RED CELL COUNT DEC V MAY CAUSE HEMOLYTIC ANEMIA P0542
SULFAMETHOXYPYRID B RED CELL COUNT DEC V ANEMIA (AMA-BLOOD DYSCRASIAS) P0658
SULTANILAMIDE B RED CELL COUNT DEC V MAY CAUSE HENOLYTIC ANEMIA P0079
SULFAPYRIDINE B RED CELL COUNT DEC V MAY CAUSE HEMOLYTIC ANEMIA P0079

SULFINPYRAZONE B RED CELL COUNT DEC V PARE BLOOD DYSCRASIA 90026
SULFISOXAZOL! B RED CELL COUNT DEC V AGPANULOCYTOSIS/APLASTIC ANEMIA 90751
SULFONAMIDES B RED CELL COUNT DEC V MAY CAUSE HEINZ-BODY HEMOLYTIC ANEMIA 30620
SULFONES B RED CELL COUNT DEC V HEMOLYSIS MAY OCCUR WITH G-6-PD DEFICIENCY 90620
SULFONYLUPEAS B RED CELL COUNT DEC V PANCYTOPENIA 20620
SULFOXONE B RED CELL COUNT DEC V MAY CAUSE HENOLYTIC ANEMIA 90079
SURANIN B RED CELL COUNT DEC V HEMOLYTIC ANEMIA REPORTED 30026
TETRACYCLINE B RED CELL COUNT DEC V MAY CAUSE HEMOLYTIC ANEMIA 30620
THIACETAZONE B RED CELL COUNT DEC V PARE STEVENS-JOHNSON SYNDROME INDUCED 30657
THIAZIDES B RED CELL COUNT DEC V RAPE HYPERSENSITIVE DEPRESSION OF BONE MARROW 90620
THIAZOLSULFONE B RED CELL COUNT DEC V MAY CAUSE HEMOLYTIC ANEMIA 90620
THIOCYANATES B RED CELL COUNT DEC V MAY CAUSE ANEMIA O620
THIOSEMICARBAZONES B RED CELL COUNT DEC V HYDRAZONE COMPLEX FORMED WITH PYPIDOXAL P04 P0791
THIOTEPA B RED CELL COUNT DEC V MAY CAUSE BONE MARROW DEPRESSION 0026
TOLAZAMIDE B RED CELL COUNT DEC V MAY CAUSE HEMOLYTIC ANEMIA 30384
TOLAZOLINE B RED CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0658
TOLBUTANIDE B RED CELL COUNT DEC V AGPANULOCYTOSIS/APLASTIC ANEMIA 300214
TOLUIDINE BLUE B RED CELL COUNT DEC V MAY CAUSE HEMOLYSIS WITH G-6-PD DEFICIENCY RO’04
TRIANTEREN! B RED CELL COUNT DEC V MAY CAUSE MEGALOBLASTIC AN!MIA(FOLIC AC ANTAGONIST) 90976
TRIETHYLENEMELAMINE B RED CELL COUNT DEC V MAY CAUSE BONE MARROW DEPRESSION RO026
TRIFLLJOPERAZINE B RED CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) 20658
TPIMETHADIONE B RED CELL COUNT DEC V APLASTIC ANEMIA 90658
TRIMETHOPPIM B RED CELL COUNT DEC V FOLIC ACID ANTAGONIST ?MEGALOBLASTIC ANEMIA 90976
TPIMETHYLENEMELAM B RED CELL COUNT DEC V MAY CAUSE HEMOLYTIC ANEMIA 90620
TRINITHOTOLUENE B RED CELL COUNT DEC V MAY CAUSE HEMOLYSIS 20658
TPIPELENNAMINE B RED CELL COUNT DEC V HEMOLYTIC ANEMIA 90657
TYROTHPICIN B RED CELL COUNT DEC V HEMOLYSIS EVEN WHEN APPLIED TOPICALLY 90026
URACIL MUSTARD B RED CELL COUNT DEC V MAY CAUSE BONE MARROW DEPRESSION 30026
URETHAN B RED CELL COUNT DEC V BONE NARROW APLASIA/PANCYTOPENIA 90620
VINBLASTINE B RED CELL COUNT DEC V ANEMIA (SECONDARY TO L!UKOPENIA) 20026
VITAMIN A B RED CELL COUNT DEC V WITH EXCESSIVE DOSES AND US! ?052O
VITAMIN K B RED CELL COUNT DEC V K3 AND K4 ONLY, ESP WITH G-6-PD DEFICIENCY 90570
X-RAY THERAPY B RED CELL COUNT DEC V OCCURS WITH ONSET OF APLASTIC ANEMIA 90291
ANDROGENS B RED CELL COUNT INC V MAY PRODUCE ERYTHROCYTEMIA (INCS WELL-BEING) 90026
COPTICOTROPIN B RED CELL COUNT INC V ESP MARKED IF GIVEN TO ANEMICS RO384
DROMOSTANOLONE B RED CELL COUNT INC V RESPONSE TO ANDROGENS 90026
EPIN!PHPINE B RED CELL COUNT INC V DUE TO HEMOCONC!NTRATION 90384
GLUCOCOPTICOIDS B RED CELL COUNT INC V STIMULATE ERYTHPOPOIESIS R0026
PILOCAPPINE B RED CELL COUNT INC V PROBABLY DUE TO CONTRACTION OF SPLEEN 90384
SMOKING B RED CELL COUNT INC V SIGNIFICANTLY HIGHER IN SMOKERS 30814
VITAMIN B12 B RED CELL COUNT INC V SUCCESSFUL TREAT NAY CAUSE MILD POLYCYTHEMIA 90657
ACETANILID E REDUCED GLUTATHIONE DEC V SHARP FALL BEFORE OVERT HENOLYSIS 90518
ACETOPHENETIDIN E REDUCED GLUTATHIONE DEC V SHARP FALL PRIOR TO OVERT HEMOLYSIS 90518
ACETYLSALICYLIC AC E REDUCED GLUTATHIONE DEC V OCCURS INITIALLY BEFORE OVERT HEMOLYSIS 90518
AMINOPYRINE E REDUCED GLUTATHION! DEC V SHARP FALL BEFORE OVERT HEMOLYSIS 90518
ANTIMALARIALS E REDUCED GLUTATHIONE DEC V OCCURS PRIOR TO OVERT HEMOLYSIS P0518
ANTIPYPETICS E REDUCED GLUTATHIONE DEC V SHARP FALL BEFORE OVERT HEMOLYSIS P0518
COPPER E REDUCED GLUTATHIONE DEC V MARKED DECREASE WITH HEMOLYSIS OF TOXICITY P0124
LYSOL E REDUCED GLUTATHIONE DEC V MARKED EFFECT WITH HEMOLYSIS 90197
NITROFUPANS E REDUCED GLUTATHIONE DEC V OCCURS WITH HEMOLYSIS 90518
SULFONAMIDES E REDUCED GLUTATHIONE DEC V OCCURS EARLY BEFORE OVERT HEMOLYSIS 90518
SULFONES E REDUCED GLUTATHIONE DEC V FALLS SHARPLY PRECEDING HEMOLYSIS R0518
ESTROGENS P RENIN ACTIVITY INC V DUE TO INCREASED SUBSTRATE P0174
ETHINYLESTRADIOL P RENIN ACTIVITY INC V MEN AND WOMEN, INDEPENDENT OF DIET AND POSTURE RO657
ORAL CONTRACEPTIVE P RENIN ACTIVITY INC V ACTIVITY INCREASED ALTHOUGH CONC LOWERED P0174
ANGIOTENSIN P RENIN DEC V CAUSES DEC IN NORMALS WHEN GIVEN I.V. 90331
CLONIDINE P PENIN DEC V DOSE RELATED EFFECT(2NDRY TO ACT OF CATECHOLANINES) 90455
ESTROGENS P RENIN DEC V INHIBITION OF CIRC LEVEL BY ANGIOTENSIN P01714
LICORICE P RENIN DEC V PSEUDOALDOSTERONISM EFFECT P0973
OPAL CONTRACEPTIVE P RENIN DEC V METABOLIC CHANGES IN LIVER SYNTHESIS 30588
AMBULATION P PENIN INC V ACTIVITY INCREASED BY MOD TO SEVERE EXERCISE 90062
DIAZOXIDE P PENIN INC V EFFECT OBSERVED IN SOME HYPEPTENSIVES P03814
ERECT POSTURE P RENIN INC V INCREASES APPHOX 2 TIMES IF NORMAL DIET 30026
METHYCLOTHIAZIDE P RENIN INC V STIMULATES PLASMA PENIN ACTIVITY 30386
ORAL CONTRACEPTIVE P RENIN INC V ESTROGEN EFFECT 90874
ORAL CONTRACEPTIVE B RENIN SUBSTRATE INC V HORMONAL EFFECT 90026
ESTROGENS P RENIN SUBSTRATE INC V HORMONAL ACTION RO17O
OPAL CONTRACEPTIVE P PENIN SUBSTRATE INC V METABOLIC CHANGES IN LIVER SYNTHESIS 90588
PREGNANCY P RENIN SUBSTRATE INC V INCREASED DUE TO HORMONAL EFFECTS 90186
AZATHIOPPINE B RETICULOCYTES DEC V GRADUAL REDUCTION OBSERVED 90519
CHLORAMPHENICOL B PETICULOCYTES DEC V REVERSIBLE TOXIC REACTION OP PANCYTOPENIA P0656
DACTINOMYCIN B PETICULOCYTES DEC V PETICULOCYTOPENIA/PANCYTOPENIA 90026
METHOTREXATE B RETICULOCYTES DEC V AFFECTS HEMATOPOIESIS 30384
SULFONAMIDES B RETICULOCYTES DEC V AGRANULOCYTOSIS WITH APLASTIC OR HEMOLYTIC ANEMIA 904914
VINBLASTINE B PETICULOCYTES DEC V ABSENCE FROM PERIPHERAL BLOOD OBSERVED 90384
ACETANILID B RETICULOCYTES INC V OCCURS DUPING RECOVERY FROM HEMOLYSIS 90518
ACETOPHENETIDIN B PETICULOCYTES INC V RESPONSE TO HEMOLYSIS DURING RECOVERY RO252
ACETYLSALICYLIC AC B PETICULOCYTES INC V RESPONSE DURING RECOVERY FROM HEMOLYSIS 30518
ALLOPURINOL B RETICULOCYTES INC V MILD(NAY BE ASSOCIATED WITH OTHER DRUGS) P0166
AMINOPYRINE B RETICULOCYTES INC V MAY OCCUR DUPING RECOVERY FROM HEMOLYSIS 90518
AMYL NITRITE B PETICULOCYTES INC V HEMOLYTIC ANEMIA (UP TO 15%) 90656
ANTIMALARIALS B PETICULOCYTES INC V OCCURS DURING RECOVERY FROM HEMOLYSIS R0518
ANTIPYRETICS B RETICULOCYTES INC V OCCURS DUPING RECOVERY FROM HEMOLYSIS 90518
ANTIPYRINE B PETICULOCYTES INC V OCCURS WITH HEMOLYTIC ANEMIA (RECOVERY) RO240
APSENICALS B RETICULOCYTES INC V VALUES OBSERVED RANGING UP TO 18% 901415
CORTICOTPOPIN B RETICULOCYTES INC V ESP IF GIVEN TO ANEMICS P0384
DIMERCAPROL B RETICULOCYTES INC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENT PERSONS 90240
FURALTADONE B RETICULOCYTES INC V OCCURS WITH HEMOLYSIS P0079
FUPAZOLIDONE B RETICULOCYTES INC V OCCURS WITH HEMOLYSIS 20079
LEAD B RETICULOCYTES INC V DUE TO STIMULATION OF HEMOLYSIS 90384

NITPOFURA NS B RETICULOCYTES INC V OCCURS DUPING RECOVERY AFTER HEMOLYSIS P05 18
PENICILLIN B PETICULOCYTES INC V CONSEQUENCE OF HEMOLYTIC ANEMIA P0294
PIPOBROMA N B RETICULOCYTES INC V HEMOLYTIC ANEMIA HAS BEEN DESCRIBED P002 1
SULFONAMIDES B RETICULOCYTES INC V IN RESPONSE TO HEMOLYSIS OCCURS WITH RECOVERY P0 384
SULFONES B RETICULOCYTES INC V OCCURS DURING RECOVERY PHASE R05 18
MET HYL DO PA S RHEUMATOID FACTOR P05 V REPORTED EFFECT P0384
CHLORTETRACYCLINE U RIBOFLAVIN INC V WITH DOSE OF 3C/DAY P03 84
OXYTETPACYCLINE U RIBOFLAVIN INC V WITH DOSE OF 2.5 G/DAY P03 814
LEVOD OPA B 5-ADENOSYLMETHIONINE DEC V 0-METHYLATION OF CATECHOLAMINES SLOWED P0625
ACETOACETATE S SALICYLATE INC N 50 NG/100ML GIVE EQUIV OF 1 MG/100ML BY TRINDER P06 06
ACETYLSALICYLIC AC S SALICYLATE INC V DUE TO INGESTION OF COMPOUND P0 368
AMINOBENZOIC ACID S SALICYLATE INC V BY COMPETING FOP GLYCINE FOP CONJUGATION P03 814
OX AL AlES S SALIC!LATE INC N 250 MG/100NL GIVE EQUIV OF 0.3 MG/100ML BY TPINDER P0606
BILIRUBIN S SALICYLATE Z N UP TO 20 MG/100ML NO EFFECT ON TPINDEP PROCEDURE R0606
GLUCOSE S SALICYLATE Z N UP TO 1000 MG/100ML NO EFFECT ON TRINDER METHOD P0606
HEPAPI N S SALICYLATE Z M NO EFFECT ON TRINDER PROCEDURE P0606
PHENOLS S SALICYLATE Z M 25 MG/100NL NO EFFECT ON TRINDER PROCEDURE P0606
UREA S SALICYLATE Z N UP TO 1000 MG/100ML NO EFFECT ON TPINDER METHOD P0606
PILOCAP PINE 0 SALIVARY POTASSIUM DEC V PRODUCES SECRETION LIKE PLASMA ULTRAFILTRATE P0384
CLONID IN! 0 SALIVARY POTASSIUM INC V MECHANISM NOT DISCUSSED P0127
CLONIDIN! 0 SALIVARY VOLUME DEC V MECHANISM NOT DISCUSSED R0127
ACETYLSALICYLIC AC B SEDI MENTATION PATE DEC V IF ELEVATED REDUCES TOWARD NORMAL VALUE R0384
FLUORI DES B SEDI M EN I ATIO N PATE DEC M RETARDS RATE WHEN COMPARED WITH HEPAPIN P01 143
GLUCOSE B SEDI MENTATION RATE DEC N HIGH BLOOD SUGAR LOWERS SED RATE P0 620
QUININE B SEDIMENTATION RATE DEC N AT THERAPEUTIC CONC, MAX AT 200 MIN WITH 2 MG/100NL P0781
TP IN! F HOPR IN B SEDI MENTATION RATE DEC V WITH SULFA CAUSED MARKED DEC IN RHEUMATOIDS P0507
AETYLSALICYLIC AC B SEDIMENTATION PATE INC V OCCURS IN SOME PATIENTS (REVERSIBLE) P03814
CHOLESTEROL B SEDIMENTATION RATE INC M PROBABLY BY INCREASING VISCOSITY P0 1143
DEXTRA N B SEDI MEN F ATION PATE INC V DUE TO CELL AGGREGATING PROPERTIES P06 20
GLOBULIN B SEDIMENTATION RATE INC V HIGH MOLECULAR WEIGHT PROTEINS CONTRIBUTE P0620
GLYMIDINE B SEDIMENTATION RATE INC V SLIGHT RISE IN MEAN RATE REPORTED P0657
LIPEMIA B SEDIMENTATION PATE INC V LARGE MOLECULAR WEIGHT COMPONENTS HAVE EFFECT P0620
PREGNANCY B SEDI MENTATION PATE INC V NORMAL ASSOC WITH INC FIBRINOGEN AFTER 3RD MONTH P029 1
TOURNIQUET B SEDIMENTATION RATE INC V HENOCONCENTRATION INCREASES PATE P01143
VITAMIN A B SEDI MENTATION PATE INC V OBSERVED EFFECT BUT EXPLANATION UNKNOWN P0657
RI SH Y DROXYCOUMA PIN B SEDIMENTATION PATE Z V UNALTERED BY COUMARINS P03 814
IRON SALTS U SEDOHEPTULOSE DEC N FEPPIC IRON INHIBITS CYSTEINE-H2SO14 REACTION P06 28
GLYCI NE S SERINE INC V SIMILAR MARKED INC IN GOUT! AND NORMALS Ri 020
GLYCINE U SEPINE INC V SIMILAR MARKED INC IN GOUT! AND NORMALS P 1020
FLUOPI DES S SGOT DEC V IN VIVO INHIBITION WITH LOW DOSES P0338
OXALO ACETATE S 5501 DEC N INHIBITS COLORIMETRIC METHOD P0990
ACETAMINOPHEN S SGOT INC V HEPATIC NECROSIS WITH DOSE OF 10 C REPORTED P0137
ACETO ACETATE S SGOT INC N INTERFERENCE IN DIAZONIUM END POINT REACTIONS P0027
ACETOHEXAMIDE S SGOT INC V MAY CAUSE INTRAHEPATIC CHOLESTATIC JAUNDICE P0596
ACETOPHENAZINE S SGOT INC V CHOLESTASIS WITH INTRAHEPATIC OBSTRUCTION P0620
ACETOPHENET IDIN S SGOT INC V MAY CAUSE HEPATIC TOXICITY P0620
AC!TYLANINOPH!NOL S SGOT INC M AT THERAPEUTIC CONC NAY AFFECT SNA 12/60 METHOD P0876
ACETYLSALICYLIC AC S SGOT INC V PROLONGED ADNIN. MAY CAUSE HEPATIC TOXICITY P0573
AJMALINE S SGOT INC V INTRAHEPATIC CHOLESTASIS P0088
ALLOPUP INOL S SGOT INC V REVERSIBLE CLINICAL HEPATOTOXICITY REPORTED P0 596
A MA NTA DINE S SGOT INC V REPORTED EFFECT NO MECHANISM DISCUSSED P06 20
ANINOB!NZOIC ACID S SGOT INC V TOXIC HEPATITIS REPORTED P03814
AMI NOPHENOL S SGOT INC N AT 1 MMOL/L AFFECTS SMA 12/60 METHOD P0 876
AMINOPYRINE S SGOT INC V LIVER DAMAGE UP TO HEPATIC NECROSIS SEEN P0657
AMINOSALICYLIC AC S SGOT INC V MAY CAUSE CYTOTOXIC REPATOCELLULAR DAMAGE P0079
AMINOSALICYLIC AC S SGOT INC N AT 1 NNOL/L AFFECTS SEA 12/60 METHOD P0876
A MITRIPTY LINE S SGOT INC V PARE CASES OF TRANSIENT CHOLESTASIS P0673
AMODIAQUINE S SGOT INC V REPORTED HEPATOTOXICITY P0620
AMPHOTEPICIN B S SGOT INC V HEPATOTOXICITY REPORTED P0620
AM PICILLIN S SGOT INC V PROBABLE EFFECT OF I.E. INJECTION R0541
ANABOLIC STEROIDS S SGOT INC V CHOLESTATIC SYNDROME (INTPAHEPATIC CHOLESTASIS) P0 596
ANDPOG ENS S SCOT INC V NAY CAUSE CHOLESTATIC SYNDROME P05 96
ANTIFUNGAL AGENTS S SGOT INC V HEPATOTOXICITY MAY OCCUR P0 355
ANTIMONY COMPOUNDS S SGOT INC V HEPATOTOXIC EFFECT P05 96
AR SEN ICALS S SGOT INC V HEPATOTOXIC EFFECT (CHOLESTASIS/CHOLANGIOLITIS) P0596
ASCORBIC ACID S SGOT INC N AT 1 MMOL/L AFFECTS SNA 12/60 METHOD P0876
ASPARAGINASE S SGOT INC V HEPATOTOXICITY P0427
ASPIDIUM S SCOT INC V MAY CAUSE HEPATIC TOXICITY P0620
AZASERINE S SGOT INC V NAY CAUSE HEPATOTOXICITY P0990
AZATHIOPRINE S SGOT INC V MAY CAUSE HEPATOTOXICITY P0893
BARBITURATES S SCOT INC V OCCURS WITH POISONING, PROBABLE MUSCLE ORIGIN P1008
BARIUM SALTS S SCOT INC V SEVERE LIVER DAMAGE IF TANNIC ACID IN ENEMA P0026
BENZIODARONE S SCOT INC V MAY CAUSE HEPATIC TOXICITY P0620
B!THA NECHOL S SGOT INC V IMPAIRED EXCRETION DUE TO SPASM OF SPINCTER P0204
BILIRUBIN S SCOT INC M INTERFERENCE IN DIAZONIUM END POINT REACTIONS P0027
BISHYDROXYCOUMARIN S SCOT INC V MAY SIMULATE MYOCARDIAL INFARCT (GREATER THAN GPT) P0079
BI SMUTH S SCOT INC V HEPATOTOXICITY P0620
BUTAPEPA ZIN! S SCOT INC V CHOLESTATIC HEPATITIS WITH OBSTRUCTION P0026
CA RBAMAZ!PI NE S SCOT INC V CHOLESTATIC AND HEPATOCELLULAP DAMAGE P0762
CAR BAR SO RE S SCOT INC V MAY CAUSE HEPATITIS/LIVER NECROSIS P00 26
CARBENICILLIN S SCOT INC V EFFECT OF DRUG? HEPATOTOXIC P0355
CAR BE NOXO LO NE S SCOT INC V ASSOC WITH MYOPATHY R0669
CARBON MONOXIDE S SCOT INC V ASSOC WITH HEPATOMEGALY P0368
CARBON T!TRACHLOP S SGOT INC V MAY BE EXTENSIVE HEPATIC NECROSIS P0990
CARB9OMAL S SCOT INC V OCCURS WITH POISONING, PROBABLE MUSCLE ORIGIN Ri 008
CAP HUlA ?IIDE S SCOT INC V HEPATOTOXICITY P06 20
CAR PH ENAZINE S SCOT INC V PROBABLE CHOLESTATIC EFFECT (REVERSIBLE) P0620
CE P HAL OP I DINE S SCOT INC V TRANSIENT SLIGHT RISE ?HEPATOTOXICITY P0298
CH ENODEOXYCHOLIC S SCOT INC V MILD TRANSIENT ELEVATION OBSERVED P0248
CHLOR ANPH!NICOL S SCOT INC V HEPATOTOXIC-CHOLESTATIC EFFECT P0596

CHLORDIAZEPOXIDE S SCOT INC V NAY PRODUCE HEPATOTOXIC EFFECT R0002
CHLORMEZA NONE S SCOT INC V HEPATOTOXICITY RO620
CHLOROFORM S SCOT INC V HEPATOTOXIC EFFECT WITH NECROSIS P0 620
CHLOPOQUIN! S SCOT INC V REPORTED EFFECT NO MECHANISM CITED 30620
CHLOPOTHIAZIDE S SCOT INC V MAY CAUSE CHOLESTATIC JAUNDICE P0620
CHLOR PRO MAE IN! S SGOT INC V HEPATIC SENSITIVITY TO DRUG (IN UP TO 2% PATIENTS) P0 8 59
CHLOPPROPAMIDE S SCOT INC V NAY CAUSE CYTOTOXIC LIVER DAMAGE 90079
C HL OP PR OF HI X EN! S SGOT INC V MAY CAUSE HEPATOTOXICITY (REVERSIBLE) 90620
CH LOPTETPACYCLIN E S SCOT INC V HEPATOTOXIC EFFECT WITH CENTROLOBULAP NECROSIS R0355
CHLORZOXAZONE S SCOT INC V MAY CAUSE HEPATOTOXICITY 90620
CHOLESTYRANINE S SCOT INC V FEW CASES REPORTED PROB NOT HEPATOTOXICITY P0467
CHOLINERGICS S SGOT INC V IMPAIRED EXCRETION DUE TO SPASM OF SPHINCTER 90204
CINCHO PHEN S SCOT INC V NAY CAUSE HEPATOTOXICITY (VIRAL-HEPATITIS LIKE) P0620
CLINDAMYCIN S SGOT INC V TRANSIENT ABNORMALITY NOTED P0 9 49
CLOFIBRATE S SCOT INC V TRANSIENTLY ELEVATED DURING EARLY THERAPY 90099
CLONIDINE S SCOT INC V SINGLE PROBABLE CASE OF TOXIC HEPATITIS P0 3 65
CLOXACILLI N S SCOT INC V FEW CASES REPORTED ?DUE TO I.M. INJECTION 90026
CODEINE S SCOT INC V MAY CAUSE RISE IN INTRABILIAPY PRESSURE P0907
COLCHICINE S SGOT INC V POSSIBLE HEPATOTOXIC EFFECT 90596
COPPER S SCOT INC V TOXIC EFFECT, SHARP RISE WITH HEMOLYTIC CRISIS P0 124
COPTI SON! S SCOT INC V MAY CONTRIBUTE TO LONG DURATION OF HEPATITIS P0596
COUMARIN S SCOT INC V MAY CAUSE HEPATIC TOXICITY RO990
CYCLOPHOSPHAMIDE S SCOT INC V MAY CAUSE HEPATOTOXICITY 90893
CYCLOPROPANE S SCOT INC V MAY CAUSE HEPATOTOXICITY (LASTS SEVERAL DAYS) R0620
CYCLOSERI NE S SGOT INC V MAY CAUSE HEPATOTOXICITY P 06 20
D!HYDRO!METINE S SCOT INC V POSSIBLY DUE TO GENERALIZED MYOSITIS 90657
DESIPPAMINE S SCOT INC V RARE TRANSIENT CHOLESTASIS a 06 20
DIATRI ZOATE S SCOT INC V HAS CAUSED SEVERE MUSCLE SPASM AND PENAL FAILURE P0621
DICLOXAC ILLIN S SCOT INC V MILD HEPATIC DYSFUNCTION OBSERVED ROOL$3
DINITROP9ENOL S SCOT INC V HEPATOTOXICITY WITH CENTPOLOBULAR NECROSIS 90384
DIPRENYLHYDANTOIN S SCOT INC V INTRAHEPATIC CHOLESTATIC JAUNDICE 90620
DOXYCYCLINE S SCOT INC V REPORTED EFFECT (?HEPATIC ORIGIN) P0026
ECTYLU PEA S SGOT INC V MAY CAUSE CHOLESTASIS WITH CHOLANCIOLITIS P 0620
EPINEPHRINE S SCOT INC N AT 1 MMOL/L AFFECTS SMA 12/60 METHOD P0876
ERYTHROMYCIN S SCOT INC V CAUSES HEPATIC TOXICITY IN SOME CASES P0 3 30
ERYTHROMYCIN S SCOT INC N COLORIMETRIC ASSAY IF DNPH OR DIAZONIUM SALT USED 30907
ESTRADIOL S SCOT INC V CHOLESTATIC EFFECT P06 20
ESTROG ENS S SGOT INC V NAY CAUSE CHOLESTASIS, PARE HEPATOCELLULAP DEGEN 90596
ESTRONE S SCOT INC V MAY CAUSE CHOLESTASIS P06 20
ETHACPYNIC ACID S SCOT INC V CHOLESTASIS WITH HEPATOCELLULAR DAMAGE 90249
ETHANBUTOL S SCOT INC V DECREASED LIVER FUNCTION REPORTED P0026
ETHCHLORVYNOL S SCOT INC V OCCURS WITH POISONING, PROBABLE MUSCLE ORICIN 91008
ETHER S SCOT INC V HEPATIC DISTURBANCE (TRANSIENT) 90839
ETHIONANIDE S SCOT INC V INTPAHEPATIC CHOLESTATIC JAUNDICE 90384
ETHOSUXIM IDE S SCOT INC V INC IN ON! THIRD CASES 90657
ETHOTOIN S SCOT INC V HEPATOTOXICITY 90620
ET 901 AZ EWE S SCOT INC V HEPATOTOXIC EFFECT 90620
ETHYL CHLORIDE S SCOT INC V NAY CAUSE LIVER DAMAGE R0O26
FENOXYPPOPAZINE S SCOT INC V PRODUCED FATAL HEPATOTOXICITY 30657
FIBRINOLYSIN S SCOT INC V SERUM HEPATITIS AS LATE COMPLICATION 90026
FLORA NTYPONE S SCOT INC V H!PATOTOXIC EFFECT P0620
FLUF!NAMIC ACID S SCOT INC V TRANSIENT ELEVATION REPORTED P06 57
FLUORI DES S SCOT INC N INC ACTIVITY OBSERVED WITH COLOPIMETRIC METHOD P0825
FLUOROCYTOS IN! S SCOT INC V REVERSIBLE HEPATOTOXICITY IN 10% P0 898
FLUOXY MESTERONE S SCOT INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P03 84
FLUPHENAZINE S SCOT INC V HYPERSENSITIVITY RESPONSE P0620
FLU PAZ E PAM S SCOT INC V MAY CAUSE HEPATIC TOXICITY 90788
FL UPOXEN! S SCOT INC V POTENTIALLY HEPATOTOXIC P00 26
CENTAMICI N S SCOT INC V MAY CAUSE HEPATOTOXICITY (OP DUE TO I.!. INJECTION) P0596
CL! CO P YR P OL ATE S SCOT INC V HEPATOTOXICITY 90620
GOLD S SCOT INC V HEPATOTOXICITY WITH CENTROLOBULAR NECROSIS P06 20
GRISEOFULVIN S SCOT INC V NAY BE HEPATOTOXIC P0 596
GUANETHIDINE S SCOT INC V POSSIBLE MYOPATHIC COMPLICATION 30596
CUANOCHLOR S SCOT INC V POSSIBLE EFFECT ON LIVER P 05 96
GUANOXAN S SCOT INC V NAY CAUSE HEPATIC TOXICITY 30620
HALOPERI DOL S SCOT INC V MAY CAUSE HEPATOCELLULAR CHANCES P0620
HALOT HAN! S SCOT INC V ALLERGIC HEPATIC HYPERSENSITIVITY 90861
HEMOGLOBIN S SCOT INC M IF GREATER THAN 25 MC/100ML P0825
HEMOLYSIS S SCOT INC V RELEASED FROM PBC’S AND PLATELETS P06 20
HEPTACH LOP S SCOT INC V LIVER DAMAGE OCCURS AS LATE EFFECT OF POISONING P0368
H!TACILLIN S SCOT INC V OBSERVED WITH OTHER PENICILLINS (CAUSE?) P0 467
HYCANTHONE S SCOT INC V TRANSIENT CHANGE IN LIVER FUNCTION P0026
HYDRALAZIN! S SGOT INC N AT 1 MMOL/L AFFECTS SNA 12/60 METHOD P0876
HYDRAZIN! S SCOT INC V MAY CAUSE HEPATOTOXICITY 30620
HYDROFLUMETHIAZI DE S SCOT INC V MAY CAUSE INTRAHEPATIC CHOLESTASIS P04 67
HYDROXYACETA MID! S SCOT INC V TOXICITY EFFECT P06 20
I. M.INJ!CTIONS S SCOT INC V MUSCLE DAMAGE P083 9
IBUFENAC S SCOT INC V HEPATOTOXIC EFFECT P0620
ITT EROG ENIN S SCOT INC V CAUSES INTRAHEPATIC CHOLESTASIS 30054
IDOXUR IDINE S SCOT INC V CHOLESTATIC JAUNDICE REPORTED IN ON! CASE P0 2 59
IMIPPAMINE S SCOT INC V MAY CAUSE CHOL!STATIC JAUNDICE 90512
INDANDIONES S SCOT INC V HEPATOCELLULAR DAMAGE WITH CHOLESTASIS 90620
INDOMETHACI N S SCOT INC V CYTOTOXIC AND CHOLESTATIC LIVER DAMAGE P05 21
IOPANOIC ACID S SCOT INC V MAY CAUSE HEPATOTOXICITY HO 620
IPRINDOLE S SCOT INC V HEPATIC TOXICITY P0907
IPPONIAZID S SCOT INC V PROLONGED USE MAY CAUSE HEPATOTOXICITY P0990
ISOCARBOXAZID S SCOT INC V CHOLESTATIC EFFECT 90620
ISONIAZID S SCOT INC N AT THERAPEUTIC CONC MAY AFFECT SMA 12/60 METHOD 90876
ISONIAZID S SCOT INC V PROBABLE INTRAHEPATIC CHOLESTATIC JAUNDICE P0596
I SOPROTERENOL S SCOT INC N AT 1 MMOL/L AFFECTS SMA 12/60 METHOD 90876

KANAMYCIN S SCOT INC V MAY CAUSE H!PATOTOXICITY P0620
LEVODOPA S SCOT INC M AT 1 MMOL/L AFFECTS SMA 12/60 METHOD P0 876
LEVODOPA S SCOT INC V TRANSIENT EFFECT, NORMALIZES DESPITE CONTINUATION P0026
LINCOMYCIN S SCOT INC V HEPATOTOXIC-CHOLESTATIC EFFECT 30596
LIPEMIA S SCOT INC N TURBIDITY MAY AFFECT SOME METHODS 90181
LIPENIA S SCOT INC V ASSOCIATED WTIH ALCOHOLISM P0620
MAO INHIBITOPS S SCOT INC V INTRAHEPATIC CHOLESTASIS P 0596
MD A S SCOT INC V REPORTED EFFECT ? OF MUSCLE ORIGIN P0778
MECHLORETHA NI NE S SCOT INC V MAY CAUSE CYTOTOXIC (HEPATOCELLULAR) DAMAGE P0079
MEL AR SON YL S SCOT INC V NAY PRODUCE HEPATOTOXICITY 90026
MELA PSOPROL S SCOT INC V MAY PRODUCE HEPATOTOXICITY 90026
MEPACPINE S SCOT INC V HEPATOTOXIC EFFECT 30620
MEPAZINE S SCOT INC V CHOLESTATIC EFFECT (UP TO 6 TIMES NORMAL) RO477
MEP!PIDIN! S SCOT INC V NAY CAUSE RISE IN INTRABILIARY PRESSURE 90079
ME P H.! NYT 01 N S SCOT INC V HEPATOTOXICITY 90620
ME PPOB A MA TE S SCOT INC V NAY CAUSE CHOLESTATIC (HEPATOCANALICULAR) JAUNDICE P0079
MERCAPTOPURINE S SCOT INC V MAY CAUSE HEPATOTOXICITY (CENTROLOBULAR NECROSIS) 90066
MESOPIDAZINE S SCOT INC V TRANSIENT EFFECT NOTED 90026
NETAHEXAMIDE S SCOT INC V HEPATOTOXICITY (VIRAL-HEPATITIS TYPE) 90620
META NDI ENONE S SCOT INC V HEPATOTOXICITY R0620
METAXALONE S SCOT INC V HEPATOTOXIC EFFECT 90620
METHACHOLINE S SCOT INC V IMPAIRS EXCRETION BY SPASM OF SPHINCTER OF ODDI 90 2014
METHACYCLINE S SCOT INC V POSSIBLE HEPATOTOXICITY P0026
METHA NDPIOL S SCOT INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P0384
METHAN DR OS F EN OLO NE S SCOT INC V UP TO 3-6 TIMES NORMAL DUE TO CHOLESTASIS 90477
NET HIM AZ OLE S SCOT INC V CHOLESTATIC EFFECT P01477
METHOTPEX ATE S SCOT INC V HEPATOTOXICITY (DRUG INDUCED CIRRHOSIS) P0620
MET BOX SA LE N S SCOT INC V HEPATOTOXIC EFFECT P06 20
METHOXYFLUPANE S SCOT INC V HEPATIC TOXICITY P086 1
MET HYLDOPA S SCOT INC V RESULT OF HEPATOCELLULAP DAMAGE OR CHOLESTASIS P1001
METHYL DO PA S SCOT INC N AT 1 MNOL/L AFFECTS SMA 12/60 METHOD 90876
ME THYLTESTOSTERONE S SCOT INC V CHOLESTATIC EFFECT (MODERATE ELEVATION) 30477
METHYLTHIOUPACIL S SCOT INC V HEPATOTOXIC EFFECT 90620
MITHP AMYCIN S SCOT INC V HEPATOCELLULAP DAMAGE OBSERVED 90026
NORPHI NE S SCOT INC V MAY CAUSE RISE IN INTRABILIARY PRESSURE 90907
MUSCULAR EXERCISE S SCOT INC V MARKED AFTER EXERCISE (LESS IN TRAINED INDIVIDUALS) P0779
NAFCILLIN S SCOT INC V POSSIBLY DUE TO TRAUMA OF INJECTION 90620
NALIDIXIC ACID S SCOT INC V NAY CAUSE CHOLESTATIC JAUNDICE P07 36
NAPCOT ITS S SCOT INC V IMPAIRED EXCRETION DUE TO SPASM OF SPHINCTER 902014
NIALAMIDE S SCOT INC V PROBABLE HYPERSENSITIVE HEPATITIS 90026
NICOTINIC ACID S SGOT INC V INTRAHEPATIC CHOLESTASIS OBSERVED RARELY 90360
NITROFURANS S SCOT INC V HEPATOTOXICITY 90620
NITPOFURA NT 01W S SCOT INC V MAY CAUSE CHOLESTATIC JAUNDICE P0736
NITROPHENOL S SCOT INC V HYPERSENSITIVE INTPAHEPATIC CHOLESTASIS 90405
NORETHA ND P0 LONE S SCOT INC V CHOLESTASIS PRODUCED WITHOUT CHOLANCIOLITIS HO 826
WOPETHI NDPONE S SCOT INC V CHOLESTATIC EFFECT P062 0
NORETHISTERONE S SCOT INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P06 20
NORETH YNODREL S SCOT INC V CHOLESTATIC EFFECT P0620
NOR TE S TOS TEPO NE S SGOT INC V REPORTED TO AFFECT LIVER FUNCTION P0596
NOPEPI PTYLI NE S SCOT INC V MAY CAUSE CHOLESTASIS 90026
NOVOBIOCIN S SCOT INC V INTRAHEPATIC CHOLESTASIS MAY OCCUR 90620
OLEANDOMYCI N S SCOT INC V MAY CAUSE HEPATOTOXICITY (CHOLESTATIC SYNDROME) 90620
OPIATES S SCOT INC V POSSIBLY DUE TO SPASM OF SPHINCTER OF ODDI P0204
ORAL CONTRACEPTIVE S SCOT INC V H!PATOTOXIC EFFECT (CHOLESTASIS INDUCED) 90566
OR C AN 0 PRO S P HO P US S SCOT INC V HEPATOTOXIC EFFECT P0130
OXACILLIN S SCOT INC V POSSIBLE HEPATOTOXIC EFFECT HO 596
OX AZ! PAM S SCOT INC V POSSIBLE HEPATOTOXICITY 90620
OX! MET HOLONE S SCOT INC V CHOLESTATIC EFFECT (INC UP TO 6 TIMES NORMAL) P0 477
OX! PHENBUTA ZONE S SCOT INC V POSSIBLE HEPATOTOXICITY P0620
OXYPHENISATIN S SCOT INC V HEPATIC TOXICITY IF OVER PROLONGED PERIOD R0727
PA PA V ! RI NE S SCOT INC V PROBABLE HYPERSENSITIVITY REACTION 30793
P AR AL D EH YDE S SCOT INC V POSSIBLE HEPATOTOXICITY R0620
PARAMETHADIONE S SCOT INC V POSSIBLE HEPATOTOXICITY 90620
PARCYLINE S SCOT INC V POSSIBLE HEPATOTOXICITY (REVERSIBLE) P0620
PECAZI NE S SCOT INC V MAY ALTER LIVER FUNCTION (CHOLESTASIS) P06 20
P!NICILLAMINE S SCOT INC V POSSIBLE HEPATOTOXICITY P0620
PENICILLIN S SCOT INC V NONSPECIFIC HEPATITIS WITHOUT CHOLESTASIS 91001
PERCHLOR AT! S SCOT INC V SINGLE CASE OF ACUTE YELLOW ATROPHY OF LIVER 90657
PERHEXILENE S SCOT INC V TRANSIENT ELEVATION OBSERVED P0453
PHENACEMID! S SCOT INC V MAY AFFECT LIVER FUNCTION IN ABOUT 2% CASES P0620
PHENAZOPYRI DINE S SCOT INC V HEPATOTOXIC EFFECT 90620
PHENELZINE S SCOT INC V MAY CAUSE HYPERSENSITIVE HEPATITIS 30026
PHENELZINE S SCOT INC N AT 1 MMOL/L AFFECTS SMA 12/60 METHOD P 0876
PHENINDIONE S SCOT INC V NAY MODIFY LIVER FUNCTION (CHOLESTASIS) P0620
PHENIPRAZINE S SCOT INC V MAY AFFECT LIVER FUNCTION P06 20
PHENOTHIAZINES S SGOT INC V MAY CAUSE CHOLESTATIC HEPATITIS (IN UP TO 14% PTS) 30620
PH E NY LBUT AZ ONE S SCOT INC V MAY CAUSE CHOLESTATIC AND CYTOTOXIC JAUNDICE P0079
PHENYLISOPROPYLHYD S SCOT INC V MAY CAUSE HEPATOCELLULAP JAUNDICE R0620
PHOSPHORUS S SCOT INC V HEPATOTOXIC EFFECT WITH NECROSIS 30620
PIPEPACETAZINE S SCOT INC V TRANSIENT REVERSIBLE INCREASE 30353
POLYTHIAZI DE S SCOT INC V MAY AFFECT LIVER FUNCTION 0620
PROBENECID S SCOT INC V HEPATOTOXIC EFFECT (CENTROLOBULAR NECROSIS) 90620
PROCAINAMIDE S SGOT INC V HEPATOTOXIC EFFECT P0620
PPOCHLOPPEPAZINE S SCOT INC V CHOLESTATIC EFFECT 90026
PPOGESTIN S SCOT INC V HEPATOTOXICITY P0620
PROMAZI NE S SCOT INC V MAY CAUSE CHOLESTATIC (HEPATOCANALICULAP) JAUNDICE 90079
PROMETHAZINE S SCOT INC V MAY CAUSE CHOLESTASIS P06 20
PROPOXY PH ENE S SCOT INC V CHOL9STATIC EFFECT 90538
PROPPA NOLOL S SCOT INC V OCCASIONALLY SEEN, POB NOT DUE TO HEPATOTOXICITY 90683
PROPYLTHIOURACIL S SCOT INC V HE?ATOTOXIC EFFECT (CENT9OLOBULAR NECROSIS) 90620

PPOTPI PTYLI NE S SCOT INC V TRANSIENT REVERSIBLE CHOLESTASIS P0026
PYRAZINAMIDE S SCOT INC V HEPATIC TOXICITY REPORTED (VIRAL-HEPATITIS LIKE) 90832
PYRIDOXINE S SCOT INC V SIGNIFICANT INCREASE IN ELDERLY AFTER ADNIN P0657
QUINACRINE S SGOT INC V HEPATITIS REPORTED (CENTPOLOBULAR NECROSIS) P00 26
QUINETHAZONE S SCOT INC V MAY CAUSE CHOL!STATIC JAUNDICE HO 620
PIFAMPIN S SCOT INC V HEPATIC TOXICITY OCCURS IN UP TO 7% PATIENTS P04 32
STA NOZOLOL S SCOT INC V MAY CAUSE INTRAHEPATIC CHOLESTASIS P0 233
STI BOPHEN S SCOT INC V HEPATITIS REPORTED P0026
SULFADIMETHOXINE S SCOT INC V GRANULOMATOUS REACTION IN LIVER P0307
SULFAFUR AZOLE S SCOT INC V REVERSIBLE CHOLESTASIS P06 20
SULFA METEIIZOLE S SCOT INC V REVERSIBLE CHOLESTASIS P0 54 2
SULFAMETHOX AZOLE S SCOT INC V CHOLESTATIC JAUNDICE MAY OCCUR P0 542
SULFANETHOXYPYRID S SCOT INC V REVERSIBLE CHOLESTASIS P06 20
SULFANILANIDE S SCOT INC V MAY CAUSE REVERSIBLE CHOLESTASIS P0596
SULFAPYRIDINE S SCOT INC V NAY CAUSE REVERSIBLE CHOLESTASIS P0 596
SULFATHI AZOLE S SCOT INC N AT 1 MMOL/L AFFECTS SMA 12/60 METHOD P0876
SULFISOXA ZOLE S SCOT INC V NAY CAUSE CHOLESTATIC JAUNDICE P0 542
SULFONAMI DES S SCOT INC V MAY CAUSE CHOLESTASIS P062 0
SULFONES S SCOT INC V NAY AFFECT LIVER FUNCTION HO 620
TESTOSTERONE S SCOT INC V MAY CAUSE CHOLESTATIC AND CYTOTOXIC LIVER DAMAGE P0079
TETRACYCLINE S SCOT INC V HEPATOTOXIC ESPECIALLY IN PREGNANT WOMEN P0736
THIABENDAZOLE S SCOT INC V PARE CHOLESTASIS AND PARENCHYMAL LIVER DAMAGE P0647
THI ACET AZONE S SCOT INC V NAY CAUSE CHOLESTATIC(HEPATOCANALICULAR) JAUNDICE P0079
TH IAMAZOLE S SCOT INC V MAY AFFECT LIVER FUNCTION (CHOLESTASIS) P06 20
THIAZIDES S SCOT INC V MAY CAUSE CHOLESTASIS P0620
THIOCYANATES S SCOT INC V MAY CAUSE HEPATIC NECROSIS P0384
THIOCUANINE S SGOT INC V MAY CAUSE CHOLESTASIS P0620
THIOPIDAZINE S SCOT INC V HEPATOTOXICITY P0 508
THIOSEMICARBAZON ES S SCOT INC V MAY AFFECT LIVER FUNCTION 90620
THIOTHIX!NE S SCOT INC V HEPATOTOXIC EFFECT (REVERSIBLE CHOLESTASIS) HO 620
TOLAZAMI 0! S SCOT INC V CHOLESTASIS P062 0
TOLBUTA MID! S SCOT INC N AT 1 MMOL/L AFFECTS SMA 12/60 METHOD HO 876
TOLBUTA NI DE S SCOT INC V NAY CAUSE CYTOTOXIC LIVER DAMAGE OR CHOLESTASIS P0079
TPANYLCYPROMINE S SCOT INC V NAY AFFECT LIVER FUNCTION (?HYPEPS!NSITIVITY) P0620
TRICHLOROETHYLENE S SCOT INC V POTENTIALLY HEPATOTOXIC P00 26
TRIETHYLENE MELANIN! S SCOT INC V HEPATOTOXICITY (PROLONGED TREAT, LARGE DOSE) P0026
TRIFLUOPERAZI NE S SCOT INC V CHOLESTATIC EFFECT P014 77
TRIMEPPAZINE S SCOT INC V MAY CAUSE CHOLESTASIS 90026
TRINETHADIONE S SCOT INC V MAY CAUSE HEPATOTOXICITY WITH NECROSIS P0620
TRIOXSALEN S SCOT INC V NAY AFFECT LIVER FUNCTION P06 20
TPYPAPSAMIDE S SCOT INC V MAY CAUSE LIVER DAMAGE P0026
UPACIL MUSTARD S SCOT INC V MAY AFFECT LIVER FUNCTION P06 2 0
UP ETHA N S SCOT INC V MAY CAUSE LIVER DAMAGE AND NECROSIS P 00 26
VINYL ETHER S SCOT INC V POTENTIALLY HEPATOTOXIC P0026
X-RAY THERAPY S SCOT INC V OCCURS WITH LOCAL IRRADIATION INJURY P0 29 1
EDTA S SGOT Z N NO EFFECT ON ACTIVITY P0 825
HEPARIN S SCOT Z N NO EFFECT ON ACTIVITY P0825
S SCOT Z N NO EFFECT ON ACTIVITY P08 25
STORAGE OF SAMPLE S SCOT Z M NO EFFECT 1 WEEK AT 14 DEGREES, 1 MONTH AT -20 DEC R0436
MUSCULAR EXERCISE S SGPT DEC V EFFECT OF PHYSICAL TRAINING P0779
ACETAMINOPHEN S SGPT INC V HEPATIC NECROSIS WITH DOS! OF 10 C REPORTED P0 137
ACETOHEXA MID! S SGPT INC V NAY CAUSE INTRAHEPATIC CROLESTATIC JAUNDICE P0596
ACETOPHENAZINE S SGPT INC V CHOLESTASIS WITH INTRAHEPATIC OBSTRUCTION P0620
ACETOPHE NET IDIN S SCPT INC V NAY CAUSE HEPATIC TOXICITY P0620
ACETYLSALICYLIC AC S SCPT INC V PROLONGED USE MAY CAUSE HEPATIC TOXICITY P0299
AJMALINE S SGPT INC V INTRAHEPATIC CHOLESTASIS P0088
ALLOPUPINOL S SCPT INC V REVERSIBLE CLINICAL HEPATOTOXICITY REPORTED P05 96
ANINOPYRINE S SGPT INC V LIVER DAMAGE UP TO HEPATIC NECROSIS SEEN HO 657
AMINOSALICYLIC AC S SCPT INC V MAY CAUSE CYTOTOXIC REPATOCELLULAR DAMAGE P 0079
ANITRIPTYLINE S SGPT INC V PARE CASES OF TRANSIENT CHOLESTASIS P0 673
AMODIAQUINE S SGPT INC V REPORTED HEPATOTOXICITY P0620
AMPHOTERICIN B S SGPT INC V HEPATOTOXICITY REPORTED P0620
AMPICILLIN S SCPT INC V PROBABLE EFFECT OF I.M. INJECTION P0514 1
AMYL ALCOHOL S SGPT INC V MAY CAUSE LIVER DAMAGE IF INGESTED P03 68
ANABOLIC STEROIDS S SCPT INC V CHOLESTATIC SYNDROME (INTRAHEPATIC CHOLESTASIS) P0 596
ANDROGENS S SCPT INC V MAY CAUSE CHOLESTATIC SYNDROME P05 96
ANTIFUNGAL AGENTS S SGPT INC V HEPATOTOXICITY MAY OCCUR P0 355
ANTIMONY COMPOUNDS S SCPT INC V HEPATOTOXIC EFFECT P0596
AR SENICALS S SGPT INC V HEPATOTOXIC EFFECT (CHOLESTASIS/CHOLANCIOLITIS) P0 596
ASPAPAGINASE S SGPT INC V HEPATOTOXICITY P 014 27
ASPIDIUM S SGPT INC V MAY CAUSE HEPATIC TOXICITY P06 20
AZASERIN! S SGPT INC V NAY CAUSE HEPATOTOXICITY P0990
AZATHIOPRINE S SCPT INC V MAY CAUSE HEPATOTOXICITY P0893
BARBITURATES S SCPT INC V OCCURS WITH POISONING, PROBABLE MUSCLE ORIGIN P1008
BARIUM SALTS S SGPT INC V SEVERE LIVER DAMAGE IF TANNIC ACID IN ENEMA P0026
BENZIODARONE S SCPT INC V NAY CAUSE HEPATIC TOXICITY P0620
RI SHY DROXYCOUMAR IN S SCPT INC V MAY BE HIGH ENOUGH TO SIMULATE MYOCARDIAL INFARCT P0079
BISMUTH S SGPT INC V HEPATOTOXICITY P0620
BUTAPERAZINE S SCPT INC V CHOLESTATIC HEPATITIS WITH OBSTRUCTION P0026
CARBAMAZEPINE S SCPT INC V CHOLESTATIC AND HEPATOCELLULAR DAMAGE P0762
CA RBAP SON! S SGPT INC V MAY CAUSE HEPATITIS/LIVER NECROSIS P0026
CARBENICILLIN S SCPT INC V ELEVATION REPORTED ? DUE TO HEPATOTOXICITY P01467
CA RB ENOXOLONE S SCPT INC V ASSOC WITH MYOPATH! P066 9
CARBON TETRACHLOR S SGPT INC V MAY BE EXTENSIVE HEPATIC NECROSIS P0990
CARBPOMAL S SCPT INC V OCCURS WITH POISONING, PROBABLE MUSCLE ORIGIN P100 8
CAP BUT AMID! S SCPT INC V HEPATOTOXICITY P0620
CARPHENAZINE S SCPT INC V PROBABLE CHOLESTATIC EFFECT (REVERSIBLE) P06 20
CEPHALORIDINE S SCPT INC V TRANSIENT SLIGHT RISE ?HEPATOTOXICITY P0298
CEPHALOTHIN S SCPT INC V SINGLE CASE REPORTED P06 57
CHINIO5’ON S SCPT INC V LARGE DOSES MAY OCCASIONALLY CAUSE HEPATIC DAMAGE P03 84

CHLORAMBUCIL S SCPT INC V OCCASIONAL HEPATOTOXICITY REPORTED HO 384
CHLORA MPH ENICOL S SGPT INC V HEPATOTOXIC-CHOLESTATIC EFFECT P0596
CHLOPD AN! S SGPT INC V DUE TO HEPATOTOXICITY HO 368
CHLORDIAZEPOXID! S SGPT INC V MAY PRODUCE HEPATOTOXIC EFFECT P0002
CHL OP N EZ A NO NE S SGPT INC V HEPATOTOXICITY P06 20
CHLOROFORM S SGPT INC V HEPATOTOXIC EFFECT WITH NECROSIS HO 620
CHLOPOTHI AZI DE S SGPT INC V MAY CAUSE CHOLESTATIC JAUNDICE P062 0
CHLOPPPOMAZINE S SGPT INC V MAY BE DAMACE OF BILIARY CANALICULI P0990
CHLOR?ROPAMI 0! S SGPT INC V NAY CAUSE CYTOTOXIC LIVER DAMAGE P0079
CHLOPPROTHIXENE S SGPT INC V MAY CAUSE HEPATOTOXICITY (REVERSIBLE) HO 620
CHLOPTETPACYCLIN E S SCPT INC V HEPATOTOXIC EFFECT WITH CENTROLOBULAP NECROSIS 30355
CHLOR ZOXAZONE S SGPT INC V MAY CAUSE HEPATOTOXICITY P0620
CHOLESTY PA MINE S SGPT INC V FEW CASES REPORTED PROB NOT HEPATOTOXICITY P04 67
CINCHOPHEN S SGPT INC V MAY CAUSE HEPATOTOXICITY (VIRAL-HEPATITIS LIKE) P0620
CLINDA MYCIN S SCPT INC V MILD TRANSIENT RISES SEEN P07 35
CLOFI BRAT! S SGPT INC V HEPATOTOXIC EFFECT P06 20
CLONIDINE S SCPT INC V SINGLE PROBABLE CASE OF TOXIC HEPATITIS R0365
CODEINE S SGPT INC V MAY CAUSE RISE IN INTRABILIARY PRESSURE P0907
COLCHICINE S SGPT INC V POSSIBLE HEPATOTOXIC EFFECT P0596
COPPER S SGPT INC V TOXIC EFFECT, SHARP RISE WITH HENOLYTIC CRISIS P01 24
CORTISONE S SGPT INC V MAY CONTRIBUTE TO LONG DURATION OF HEPATITIS P0596
COUMARIN S SCPT INC V MAY CAUSE HEPATIC TOXICITY P099 0
CYCLOPHOS PHA MID! S SGPT INC V MAY CAUSE HEPATOTOXICITY P08 93
CYCLOPPOPANE S SGPT INC V MAY CAUSE HEPATOTOXICITY (LASTS SEVERAL DAYS) P06 2 0
CYCLOSEP IN! S SGPT INC V MAY CAUSE HEPATOTOXICITY P06 20
CYTARABINE S SGPT INC V HEPATOTOXIC EFFECT P0384
DESIPRAMIN! S SGPT INC V PARE TRANSIENT CHOLESTASIS P06 20
DIIODOHTD POX! QUI N S SGPT INC V HEPATIC DAMAGE REPORTED IN ANIMALS P0384
DINITPOPHENOL S SGPT INC V HEPATOTOXICITY WITH CENTPOLOBULAP NECROSIS P0384
DIPHENYLBYDA NTCI N S SGPT INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P06 20
DISULFIP AN S SGPT INC V ONE CASE OF QUESTIONABLE CHOLESTASIS REPORTED R0467
ECTYLU REA S SGPT INC V MAY CAUSE CHOLESTASIS WITH CHOLANCIOLITIS P062 0
ERYTHRONYCIN S SGPT INC V MAY CAUSE HEPATIC TOXICITY P0330
EPYTHRONYCIN S SCPT INC M INTERFERES WITH COLOPIMETRIC PROCEDURES P0 596
ESTRADIOL S SGPT INC V CHOLESTATIC EFFECT P06 2 0
ESTROGENS S SGPT INC V MAY CAUSE CHOLESTASIS, PARE HEPATOCELLLJLAR DEGEN HO 596
ESTRONE S SGPT INC V MAY CAUSE CHOLESTASIS P0620
ET’dACRYNIC ACID S SGPT INC V CHOLESTASIS WITH HEPATOCELLULAR DAMAGE HO 2149
ETHAMBUTOL S SCPT INC V DECREASED LIVER FUNCTION REPORTED H0026
ETHCHLORVYNOL S SCPT INC V OCCURS WITH POISONING, PROBABLE MUSCLE ORIGIN P 1008
ET H ER S SGPT INC V HEPATIC DISTURBANCE (TRANSIENT) P0620
ETHIONANIDE S SCPT INC V INTRAHEPATIC BILE DUCT DAMAGE, TOXIC HEPATITIS P0557
ETHOTOIN S SCPT INC V HEPATOTOXICITY P06 20
ETHOXAZENE S SGPT INC V HEPATOTOXIC EFFECT R0620
ETHYL CHLORIDE S SCPT INC V MAY CAUSE LIVER DAMAGE P0026
FENOXY PRO PAZINE S SCPT INC V PRODUCED FATAL HEPATOTOXICITY P0657
FLORA NTY ROWE S SCPT INC V HEPATOTOXIC EFFECT P06 20
FLUFENANIC ACID S SGPT INC V TRANSIENT ELEVATION REPORTED P0657
FLUOROCYTOSINE S SGPT INC V REVERSIBLE HEPATOTOXICITY IN 10% P0898
FLUOXY NESTEPONE S SCPT INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P03 84
FLUP HENA ZIN! S SCPT INC V HYPERSENSITIVITY RESPONSE P06 20
FLU PAZ EPA M S SCPT INC V MAY CAUSE HEPATIC TOXICITY P0 788
FL UPO XE NE S SGPT INC V POTENTIALLY HEPATOTOXIC P0026
GENTAMICIN S SGPT INC V NAY CAUSE HEPATOTOXICITY P0596
CL YCOP YR P DL AT! S SGPT INC V HEPATOTOXICITY P0620
COLD S SCPT INC V HEPATOTOXICITY WITH CENTROLOBULAP NECROSIS P06 20
GRISEOFULVIN S SGPT INC V MAY BE HEPATOTOXIC P0596
CUANETHIDINE S SCPT INC V POSSIBLE MYOPATHIC COMPLICATION P0596
CUANOCHLOR S SGPT INC V POSSIBLE EFFECT ON LIVER P0596
GUANOXAN S SCPT INC V MAY CAUSE HEPATIC TOXICITY P0620
H ALOPERI DOL S SGPT INC V NAY CAUSE HEPATOCELLULAP CHANCES P06 20
HAL OT HA NE S SGPT INC V ALLERGIC HEPATIC HYPERSENSITIVITY P0 86 1
HEMOLYSI S S SGPT INC V RELEASED FROM PBS’S AND PLATELETS P 0620
HE P T A C H LOP S SGPT INC V LIVER DAMAGE OCCURS AS LATE EFFECT OF POISONING P0 368
HYCA NTH ONE S SCPT INC V TRANSIENT CHANGE IN LIVER FUNCTION P0026
HYD ANTO INS S SCPT INC V SEVERE DELAYED HYPERSENSITIVITY REPORTED P06 57
HYDRAZI NE S SCPT INC V MAY CAUSE HEPATOTOXICITY P 06 20
HYDROFLUMET HIAZIDE S SGPT INC V NAY CAUSE INTRAHEPATIC CHOLESTASIS P04 67
HYDROXY AC ETA MID! S SGPT INC V TOXICITY EFFECT P06 20
IBUFENAC S SCPT INC V HEPATOTOXIC EFFECT P0620
ICTEROGENIN S SGPT INC V CAUSES INTPAHEPATIC CHOLESTASIS P00514
IMIPRANINE S SGPT INC V MAY CAUSE CHOLESTATIC JAUNDICE P0512
INDANDION!S S SCPT INC V HEPATOCELLULAP DAMAGE WITH CHOLESTASIS P0620
INDONETHACIN S SCPT INC V CYTOTOXIC AND CHOLESTATIC LIVER DAMAGE P052 1
IOPANOIC ACID S SGPT INC V MAY CAUSE HEPATOTOXICITY P0 620
IPRINDOLE S SCPT INC V HEPATIC CHOLESTASIS WITHOUT INFLAMMATION P0012
IPRONIAZID S SCPT INC V PROLONGED USE MAY CAUSE HEPATOTOXICITY P0990
IRON SALTS S SCPT INC V IN ADVANCED POISONING MAY CAUSE HEPATIC NECROSIS R0368
ISOCARBOXAZID S SGPT INC V CHOLESTATIC EFFECT P0620
ISONIAZID S SCPT INC V PROBABLE INTRAHEPATIC CHOLESTATIC JAUNDICE P0596
ISOPROPANOL S SGPT INC V TRANSIENT AND MILD LATE TOXIC EFFECT P0368
KANANYCIN S SCPT INC V MAY CAUSE HEPATOTOXICITY P06 20
KEROSENE S SGPT INC V HEPATIC DAMAGE WITH LARGE DOSES P0384
LEVODOPA S SGPT INC V TRANSIENT EFFECT RETURNS TO NORMAL P0467
LINCOMYCIN S SGPT INC V HEPATOTOXIC-CHOLESTATIC EFFECT P0596
LIPEMIA S SGPT INC V ASSOCIATED WITH ALCOHOLISM P0620
LIPENIA S SGPT INC N TURBIDITY MAY AFFECT SOME METHODS P01 81
LUCANT HONE S SCPT INC V CHRONIC TOXICITY MAY CAUSE LIVER DAMAGE P0 384
MAO INHIBITORS S SCPT INC V INTRAHEPATIC CHOL!STASIS P0596
M!CHLORETHA MINE S SCPT INC V NAY CAUSE CYTOTOXIC (HEPATOC!LLULAP) DAMAGE P0079

MELARSONYL S SCPT INC V NA! PRODUCE HEPATOTOXICITY P00 26
MELA PSOPPOL S SGPT INC V MAY PRODUCE HEPATOTOXICITY 90026
MEPACP IN! S SGPT INC V HEPATOTOXIC EFFECT P06 20
MEPAZINE S SGPT INC V CHOLESTATIC EFFECT (UP TO 6 TINES NORMAL) B 01477
MEPEP IDIN! S SCPT INC V MAY CAUSE RISE IN INTRABILIARY PRESSURE 90907
NEPHENYTOIN S SGPT INC V HEPATOTOXICITY 20620
NEPROBAM ATE S SCPT INC V MAY CAUSE CHOLESTATIC (HEPATOCANALICULAR) JAUNDICE P0 079
MEPCA PTOPU RI N! S SCPT INC V NAY CAUSE HEPATOTOXICITY (CENTROLOBULAP NECROSIS) 90066
METAHEXAN ID! S SGPT INC V REPATOTOXICITY (VIRAL-HEPATITIS TYPE) P0620
METANDIENONE S SCPT INC V HEPATOTOXICITY P0620
METAXALONE S SGPT INC V HEPATOTOXIC EFFECT O62O
MET HA CYC LINE S SCPT INC V POSSIBLE HEPATOTOXICITY 90026
METHANDRIOL S SCPT INC V INTRAH!PATIC CHOLESTATIC JAUNDICE 903814
METHANDPOSTENOLONE S SCPT INC V UP TO 3-6 TIMES NORMAL DUE TO CHOLESTASIS R0477
METHIMAZOLE S SCPT INC V CHOLESTATIC EFFECT RO477
METHOTREXAT! S SCPT INC V MAY CAUSE CYTOTOXIC HEPATOCELLULAB DAMAGE 90079
METHOXSAL!N S SCPT INC V HEPATOTOXIC EFFECT P0620
M!THOXYFLUPANE S SCPT INC V HEPATIC TOXICITY 90861
METHYLDOPA S SGPT INC V RESULT OF HEPATOCELLULAP DAMAGE OP CHOLESTASIS 91001
N!TH!LTESTOST!RONE S SGPT INC V CHOLESTATIC EFFECT (MODERATE ELEVATION) 90620
METHYLTHIOURACIL S SCPT INC V HEPATOTOXIC EFFECT 90620
MITHRAM!CIN S SCPT INC V HEPATOCELLULAP DAMAGE OBSERVED 90026
MORPHINE S SGPT INC V MAY CAUSE RISE IN INTRABILIARY PRESSURE P0907
NALIDIXIC ACID S SCPT INC V MAY CAUSE CHOL!STATIC JAUNDICE P0736
NICOTINIC ACID S SGPT INC V INTRAHEPATIC CHOLESTASIS OBSERVED RARELY 90360
NITROFURANS S SCPT INC V HEPATOTOXICITY R062O
NITROFURANTOIN S SGPT INC V MAY CAUSE CHOLESTATIC JAUNDICE P07 36
NITROPRENOL S SCPT INC V HYPERSENSITIVE INTRAHEPATIC CHOLESTASIS P014 05
NOPETHANDROLON! S SGPT INC V USUALLY REVERSIBLE CHOLESTASIS P0 366
NOPETHINDRONE S SCPT INC V CHOLESTATIC EFFECT 90620
NORETHISTEPONE S SGPT INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P06 20
NORETHYNODREL S SGPT INC V CHOLESTATIC EFFECT 90620
NOPTESTOSTERONE S SGPT INC V REPORTED TO AFFECT LIVER FUNCTION HO 596
NOPTPIPTYLINE S SGPT INC V MAY CAUSE CHOLESTASIS P0026
NOVOBIOCIN S SGPT INC V INTRAHEPATIC CHOLESTASIS MAY OCCUR 90620
OLEANDOMYCIN S SGPT INC V NAY CAUSE HEPATOTOXICITY (CHOLESTATIC SYNDROME) P0620
ORAL CONTRACEPTIVE S SGPT INC V CHOLESTATIC-HEPATOTOXIC EFFECT P06 20
OP CANOPHOS PHOPU S S SGPT INC V HEPATOTOXIC EFFECT 30130
OXACILLI N S SGPT INC V POSSIBLE HEPATOTOXIC EFFECT 90596
OXAZEPAM S SGPT INC V POSSIBLE HEPATOTOXICITY 90620
OX! METHOLONE S SCPT INC V CHOLESTATIC EFFECT (INC UP TO 6 TIMES NORMAL) P04 77
OXYPHENBUTA ZONE S SGPT INC V POSSIBLE HEPATOTOXICITY 90620
OXYPHENISATIN S SGPT INC V MA! CAUSE HYPERSENSITIVITY REACTION P0776
PAPAVERINE S SGPT INC V PROBABLE HYPERSENSITIVITY REACTION P0793
PARALDEHYDE S SCPT INC V POSSIBLE HEPATOTOXICITY P06 20
PARAMETHADIONE S SGPT INC V POSSIBLE HEPATOTOXICITY P0 6 20
PARG!LIN! S SGPT INC V POSSIBLE HEPATOTOXICITY (REVERSIBLE) 90620
PECAZIN! S SCPT INC V MAY ALTER LIVER FUNCTION (CHOLESTASIS) P06 20
PENICILLA MINE S SGPT INC V POSSIBLE HEPATOTOXICITY 90620
PH ENACENIDE S SGPT INC V MAY AFFECT LIVER TUNCTION IN ABOUT 2% CASES 90620
PHENAZOPYRI DINE S SGPT INC V HEPATOTOXIC EFFECT P0620
PHEN!LZINE S SGPT INC V MAY CAUSE HYPERSENSITIVE HEPATITIS 90026
PHENI NDION! S SGPT INC V NAY MODIFY LIVER FUNCTION (CHOLESTASIS) P0620
PHENIPPAZIN! S SCPT INC V MAY AFFECT LIVER FUNCTION P0620
PHENOT HIAZIN!S S SCPT INC V MAY CAUSE CHOLESTATIC HEPATITIS (IN UP TO 4% PTS) P0 620
PHENYLBUT AZONE S SCPT INC V MA! CAUSE CHOLESTATIC AND CYTOTOXIC JAUNDICE P0079
PHENYLISOPROPYLH!D S SGPT INC V MAY CAUSE HEPATOCELLULAR JAUNDICE R0620
PHOSPHO PUS S SCPT INC V HEPATOTOXIC EFFECT WITH NECROSIS P0620
PICRIC ACID S SCPT INC V NAY CAUSE ACUTE HEPATIC CAMACE P0384
P1 PERACETAZIN! S SGPT INC V TRANSIENT REVERSIBLE EFFECT P0353
POLYTHIAZIDE S SGPT INC V MAY AFFECT LIVER FUNCTION P06 20
PROBENECI D S SCPT INC V HEPATOTOXIC EFFECT (CENTROLOBULAP NECROSIS) P06 20
PROCAINAM IDE S SGPT INC V HEPATOTOXIC EFFECT P06 20
PPOCH LORPEPAZI NE S SGPT INC V CHOLESTATIC EFFECT P0026
PROGE STIN S SCPT INC V HEPATOTOXICITY 90620
PROMAZINE S SCPT INC V MAY CAUSE CHOLESTATIC (HEPATOCANALICULAR) JAUNDICE P0079
PROMETHAZINE S SGPT INC V MAY CAUSE CHOLESTASIS P0620
PP 0 POX Y PH EN! S SCPT INC V CHOLESTATIC EFFECT P05 38
PRO PRANOLOL S SCPT INC V LOW INCIDENCE DRUG INDUCED INCREASE P06 57
PROP!LTHIOU RACIL S SGPT INC V HEPATOTOXIC EFFECT (CENTROLOBULAP NECROSIS) 90620
PROTHIONAMIDE S SGPT INC V TEMPORARY SIDE EFFECT P0657
PPOTR IPTYLI N! S SGPT INC V TRANSIENT PEVEPSILBE CHOLESTASIS P00 26
PYPAZINAMIDE S SCPT INC V HEPATIC TOXICITY REPORTED (VIRAL-HEPATITIS LIKE) P0832
QUINACRINE S SCPT INC V HEPATITIS REPORTED (CENTROLOBULAP NECROSIS) 90026
QUINETHAZONE S SGPT INC V MAY CAUSE CHOLESTATIC JAUNDICE P062 0
PIFAMPIN S SGPT INC V HEPATIC TOXICITY OCCURS IN UP TO 7% PATIENTS P0 1432
SPECTI NOMYCIN S SCPT INC V MECHANISM NOT DISCUSSED P0 0145
STANOZOLOL S SGPT INC V MAY CAUSE INTRAHEPATIC CHOLESTASIS HO 233
STIBOPHEN S SCPT INC V HEPATITIS REPORTED P 00 26
SULFADIMETHOXIN! S SCPT INC V REVERSIBLE HYPERSENSITIVE CHOLESTATIC RESPONSE P0515
SULFAFURAZOLE S SCPT INC V REVERSIBLE CHOLESTASIS P06 20
SULFAMETHIZOL! S SGPT INC V REVERSIBLE CHOLESTASIS P0542
SU L FA METH OX AZ OLE S SCPT INC V CHOLESTATIC JAUNDICE MA! OCCUR P0 5142
SULFANETHOXYPYRID S SGPT INC V REVERSIBLE CHOLESTASIS P0620
SULFANILA MIDE S SCPT INC V MAY CAUSE REVERSIBLE CHOLESTASIS P0596
SULFAPYRI DINE S SGPT INC V MA! CUASE REVERSIBLE CHOLESTASIS P05 96
SULFISOXAZOLE S SCPT INC V MAY CAUSE CHOLESTASIS 905142
SULFONA MI DES S SCPT INC V NA! CAUSE CHOLESTASIS P062 0
SULFONES S SCPT INC V MA! AFFECT LIVER FUNCTION P0620
TESTOSTERONE S SCPT INC V MAY CAUSE CHOLESTATIC AND CYTOTOXIC LIVER DAMAGE P0079

TETRACYCLINE S SGPT INC V HEPATOTOXIC EXP!CIALLY IN PREGNANT WOMEN P0736
THALLIUM S SCPT INC V DUE TO HEPATIC NECROSIS P0 368
THIABENDAZOLE S SGPT INC V RAPE CHOLESTASIS P0647
THI ACETAZONE S SGPT INC V MAY CAUSE CHOLESTATIC(HEPATOCANALICULAR) JAUNDICE P0079
THIANAZOLE S SCPT INC V MAY AFFECT LIVER FUNCTION (CHOLESTASIS) P0620
THIAZIDES S SCPT INC V NAY CAUSE CHOLESTASIS P0620
THIOCYA NATES S SCPT INC V MAY CAUSE HEPATIC NECROSIS P03814
THIOGUANINE S SCPT INC V MAY CAUSE CHOLESTASIS P06 20
THIORIDAZINE S SGPT INC V HEPATOTOXICITY P0508
THIOSENICARBAZON ES S SGPT INC V MAY AFFECT LIVER FUNCTION P 062 0
THIOTHIXENE S SGPT INC V HEPATOTOXIC EFFECT (REVERSIBLE CHOLESTASIS) P0 620
TIOCARLI 0! S SGPT INC V REPORTED EFFECT IN 14% SUBJECTS P0657
TOLAZAMIDE S SCPT INC V CHOLESTATIC EFFECT P0620
TOLBUTAMIDE S SCPT INC V MA! CAUSE CYTOTOXIC LIVER DAMAGE OP CHOLESTASIS P0079
TRANYLCY PPONINE S SCPT INC V MAY AFFECT LIVER FUNCTION (?HYPERSENSITIVIT!) P0620
TR ICHLORO!THY LEN! S SCPT INC V POTENTIALLY HEPATOTOXIC P0026
TRI ETHYLENEMELAM IN! S SCPT INC V H!PATOTOXICITY (PROLONGED TREAT, LARGE DOSE) BOO 26
TRIFLUOPEPA ZINE S SGPT INC V CHOLESTATIC EFFECT P01477
TRIFLUPEPI DOL S SCPT INC V HEPATOCELLULAP CHANGES OBSERVED P03 84
TPINEPRAZINE S SGPT INC V MAY CAUSE CHOLESTASIS P0026
TRI METHADIONE S SGPT INC V MAY CAUSE H!PATOTOXICITY WITH NECROSIS P062 0
TRIOXSAL!N S SGPT INC V MA! AFFECT LIVER FUNCTION P06 20
TRYPAPSANI 0! S SCPT INC V MAY CAUSE LIVER DAMAGE P0026
URACIL MUSTARD S SCPT INC V MAY AFFECT LIVER FUNCTION R0620
UP ETH A N S SGPT INC V MAY CAUSE LIVER DAMAGE AND NECROSIS P0026
VINYL ETHER S SGPT INC V POTENTIALLY HEPATOTOXIC P0026
METPIFONATE S SCPT Z V NO EFFECT REPORTED ON HEPATIC FUNCTION P06 57
STORAGE OF SAMPLE S SGPT Z N NO EFFECT 1 WEEK AT 14 DECREES, 1 MONTH AT -20 DEC P014 36
ESTROGENS S SIALIC ACID DEC V ALTERED METABOLISM P0072
OPAL CONTRACEPTIVE S SIALIC ACID DEC V METABOLIC ALTERATION (ESTROGEN EFFECT) P0072
ETHYLESTR!NOL S SIALIC ACID INC V METABOLIC EFFECT P0072
METHA NDROSTENOLONE S SIALIC ACID INC V METABOLIC EFFECT P0072
OXANDPOLONE S SIALIC ACID INC V METABOLIC EFFECT P0072
OXY METHOLONE S SIALIC ACID INC V METABOLIC EFFECT P0072
STANOZOLOL S SIALIC ACID INC V METABOLIC EFFECT P0072
TESTOSTERONE S SIALIC ACID INC V METABOLIC EFFECT (IF AQUEOUS SOLN I.M.) P0072
PHOSPHORUS T SILICON DEC N ABOVE 60 MC/L AFFECTS JOLLES/NEUPATH METHOD P0489
PHOSPHORUS T SILICON INC N UP TO 60 MG/L AFFECTS JOLLES/NEURATH METHOD P0489
OXYPHENISATIN S SMOOTH MUSCLE ANTIBODY P05 V ASSOCIATED WITH HYPERSENSITIVITY REACTION P00 37
PREGNANCY E SODIUM DEC V MATERNAL INTRACELLULAR NA DECREASE TOWARDS TERM P029 1
AMMONIUM CHLORIDE S SODIUM DEC V CATION LOSS AS EXCESS CHLORIDE EXCRETED P0204
AMPHOTEPICIN B S SODIUM DEC V SIGNIFICANT EFFECT EVEN IN NORMAL SUBJECTS P0170
BENDROFLU METHIAZ IDE S SODIUM DEC V MAY CAUSE HYPONATPENIA DUE TO K DEPLETION P03 25
CARBACRYLAMINE RES S SODIUM DEC V CATION-EXCHANGE WITH REDUCED C.I.TRACT ABSORPTION P0620
CATHAPTICS S SODIUM DEC V EXCESSIVE USE NAY CAUSE NA DEPLETION R0384
CHLOPOTHIAZIDE S SODIUM DEC V MAY CAUSE HYPONATREMIA P0 596
CHLORPPOPAMIDE S SODIUM DEC V INDUCES INAPPROPRIATE ADH SECRETION P0979
CHLORTHALIDONE S SODIUM DEC V SEVERE HYPONATREMIA WITH K DEPLETION P0325
DICHLORPH ENA MID! S SODIUM DEC V CATION LOSS AS EXCESS CHLORIDE IS EXCRETED P0204
DI URETICS S SODIUM DEC V DIURETIC ACTION P07 23
!THACPYNIC ACID S SODIUM DEC V DIURETIC ACTION R0620
ETHANOL S SODIUM DEC V INAPPROPRIATE SECRETION OF ADH IN BEEP DRINKERS P0265
FUROSENIDE S SODIUM DEC V DIURETIC ACTION WITH SODIUM DEPLETION P 002 1
HENOLYSIS S SODIUM DEC V DILUTION EFFECT P06 20
HEPARIN S SODIUM DEC V INC EXCRETION DUE TO ALDOSTERONE SUPPRESSION P0620
HYDPOCHLOPOTRIAZ IDE S SODIUM DEC V MAY CAUSE HYPONATREMIA R0325
HYDROFLU MET HIAZ IDE S SODIUM DEC V DIURETIC ACTION P01467
LAXATI YES S SODIUM DEC V EXCESSIVE USE MAY HAVE EFFECT P0620
LITHIUM S SODIUM DEC V DUE TO INITIAL NATURIESIS AND DIURESIS P06 12
MA NNITOL S SODIUM DEC V EFFECT IF MARKED DIUPESIS R0026
MEPALLURIDE S SODIUM DEC V DIURETIC ACTION P1001
MERCURIAL DIURETICS S SODIUM DEC V DIURETIC ACTION WITH SODIUM DEPLETION P 0620
MERCURY COMPOUNDS S SODIUM DEC V MAY OCCUR WITH ESTABLISHED HG POISONING P029 1
NETHYCLOTHIAZIDE S SODIUM DEC V DIURETIC ACTION P0386
NETOL A ZONE S SODIUM DEC V DIURETIC ACTION OF DRUG ACTING ON DISTAL TUBULES P0739
POLYTHIAZIDE S SODIUM DEC V DIURETIC ACTION, WITH K DEFICIENCY P0325
QUINETHAZON! S SODIUM DEC V DIURETIC ACTION WITH SODIUM DEPLETION P06 20
SILVER S SODIUM DEC V OBSERVED AFTER SILVER NITRATE ANTISEPSIS P0657
SPI RONOLACTONE S SODIUM DEC V ALDOSTERONE ANTAGONISM WITH CONSEQUENT DIURESIS P0620
SULFATES S SODIUM DEC V NA! BE EXCRETED COMBINED WITH SULFATE P0620
SULFONYL UREA S S SODIUM DEC V POTENTIATES VASOPPESSIN, CAUSES WATER RETENTION P03 2 7
THIAZIDES S SODIUM DEC V DIURETIC ACTION WITH SODIUM DEPLETION P00 21
TRIAMTEPEN! S SODIUM DEC V DIURETIC ACTION P06 20
UP E A S SODIUM DEC V MAY CAUSE SEVERE DEPLETION WITH DIURESIS P0299
VASOPP!SSIN S SODIUM DEC V MAY OCCUR WITH WATER RETENTION P0026
AL DOS TERO NF U SODIUM DEC V DUE TO HORMONAL ACTION P0965
ANCIOTENSIN U SODIUM DEC V DUE TO EFFECT ON RENAL TUBULES P0384
CORTICOSTEROIDS U SODIUM DEC V PROMOTES RETENTION (NINEPALOCORTICOID EFFECT) P002 6
CORTISONE U SODIUM DEC V CAUSES RETENTION P0026
DIAZOXIDE. U SODIUM DEC V EFFECT OVER 2H OF 4MG/KG GIVEN I.V. R0501
DOCA U SODIUM DEC V EXCHANGED WITH K ION P03 814
EPIN!PHRI NE U SODIUM DEC V WITH INC FILTRATION FRACTION P03 84
CUANCYDINE U SODIUM DEC V PROBABLE ACTION ON RENAL TUBULES P0962
LITHIUM U SODIUM DEC V DUE TO ACTION OF ALDOSTEPONE (INITIAL INCREASE) P06 85
PROLACTIN U SODIUM DEC V REDUCES PENAL EXCRETION AT TUBULAR LEVEL P0464
PROPRA NOLOL U SODIUM DEC V IMPAIRED IN NORMALS AND PATIENTS P0657
SPINAL ANESTHESIA U SODIUM DEC V OBSERVED IN NORMAL MALES, PREGNANT WOMEN P03 84
5-RYDROXYTRYPTAMINE U SODIUM DEC V SLIGHT EFFECT WITH INTRADEPNAL INJECTION P0384
DIGOXIN ! SODIUM INC V 16% INC, DUE TO EFFECT ON MEMBRANE ATP-ASE P0527
ANABOLIC STEROIDS S SODIUM INC V MINEPALOCORTICOID EFFECT WITH RETENTION P0620

ANDPOGENS S SODIUM INC V MINERALOCORTICOID EFFECT WITH INC RETENTION R002 1
ANGIOTENSIN S SODIUM INC V DUE TO SALT RETAINING ACTION OF ALDOSTEPONE 20384
B ETA M ETHA SON! S SODIUM INC V OCCURS INFREQUENTLY WITH EDEMA 90026
BICAPBONATES S SODIUM INC V INDUCES METABOLIC ALKALOSIS 90204
BORIC ACID S SODIUM INC V TOXICITY EFFECT H 0620
CALCIUM S SODIUM INC N EMISSION SPECTRUM MAY INTERFERE 90620
CLONI DINE S SODIUM INC V PROBABLE DIRECT ACTION ON RENAL TUBULES P03 84
COPPER S SODIUM INC N MAY INTERFERE WITH FLAME PHOTOMETRY 90620
CORTI C OSTEROI DS S SODIUM INC V MAY CAUSE RETENTION P0620
CORTICOTROPIN S SODIUM INC V CAUSES RETENTION WITH EDEMA 90026
CORTISONE S SODIUM INC V MINERALOCORTICOID EFFECT 91001
DETERGENTS S SODIUM INC N CONTAMINATED GLASSWARE ETC 90620
DIAZOX IDE S SODIUM INC V MAY CAUSE SALT RETENTION P0384
DOCA S SODIUM INC V MAY CAUSE RETENTION AND EDEMA 90026
ESTROGENS S SODIUM INC V MAY CAUSE SALT AND WATER RETENTION P03 84
ETHANOL S SODIUM INC V SLIGHTLY HIGHER AFTER HEAVY BEEP DRINKING P02 714
FLUDROCOPTISONE S SODIUM INC V MAY CAUSE SODIUM RETENTION AND EDEMA 30026
FLUOPI DES S SODIUM INC N IF SALT OF FLUORIDE 20436
CL UCOCORT ICOIDS S SODIUM INC V MAY CAUSE SODIUM RETENTION ?0026
GUANETHIDINE S SODIUM INC V SALT RETENTION ? DUE TO TUBULAR EFFECT 20384
HEPAPIN S SODIUM INC N IF NA SALT USED MAY AFFECT RESULT 90998
HYDROCOPTISONE S SODIUM INC V MAY CAUSE RETENTION AND EDEMA 90026
ISOSOPBIDE S SODIUM INC V DEHYDRATION WITH OVEPDOSACE 90871
MA NNITOL S SODIUM INC V MAY CAUSE MARKED DEHYDRATION 90596
NAP IHUA NA S SODIUM INC V REPORTED EFFECT 90596
NETH OX Y FLU PA NE S SODIUM INC V IMPAIRED PENAL TUBULAR FUNCTION P022 9
MET HYLDO PA S SODIUM INC V NAY CAUSE SALT RETENTION AND EDEMA 30620
ORAL CONTRACEPTIVE S SODIUM INC V MAY CAUSE SODIUM R!TENTION p0620
OXALATES S SODIUM INC M IF SODIUM SALT OF OXALATE R0U36
OXYPH !NBtTTAZONE S SODIUM INC V MAY CAUSE MARKED SALT RETENTION 90620
P HEN YL BUT A ZONE S SODIUM INC V MAY CAUSE SALT RETENTION 90957
POTASS IUM S SODIUM INC M AFFECTS PLAN? PHOTOMETRY IF POOP INSTRUMENT P0436
PREDNISOLONE S SODIUM INC V VERY SLIGHT MIN!PALOCOPTICOID EFFECT P0026
PREDNISONE S SODIUM INC V SLIGHT EFFECT ONLY 90026
PROC!STIN S SODIUM INC V MAY CAUSE SODIUM RETENTION 90596
PROLACTIN S SODIUM INC V RENAL RETENTION EFFECT WHEN GIVEN I.M. P0 1464
PROTEI N S SODIUM INC N PRESENCE RAISES TEMPERATURE INCS EMISSION P0620
RAUWOLFIA S SODIUM INC V MAY CAUSE ELECTROLYTE RETENTION OP EDEMA RO620
SALINE S SODIUM INC V MAY OCCUR !SP IF IMPAIRED CARDIAC/PENAL FUNCTION P0026
SODIUM BICARBONATE S SODIUM INC V MA! CAUSE SODIUM RETENTION 30026
SODIUM SULFATE S SODIUM INC V IF GIVEN I.V. MAY CAUSE FLUID RETENTION AND COMA P0 866
TETP ACYCLINE S SODIUM INC V MAY CAUSE HYPEPNATRENIA WITH PENAL IMPAIRMENT P0 596
ACETAZ OLA MID! U SODIUM INC V DIURETIC ACTION P0384
AC!TYLSALICYLIC AC U SODIUM INC V RESPONSE TO PESP ALKALOSIS OF EARLY TOXICITY 30384
AMILORIDE U SODIUM INC V DIURETIC ACTION 90173
AMMONIUM CHLORIDE U SODIUM INC V DIURETIC ACTION 90384
CALCITONIN U SODIUM INC V ACTS INDEPENDENTLY OF PARATHYROID R0107
CHLOROTHIAZIDE U SODIUM INC V DIURETIC ACTION R 0596
CHLORTHALIDON! U SODIUM INC V NAY PRODUCE MARKED DIUPESIS P0657
CLOPAMI DR U SODIUM INC V DIURETIC ACTION (RAPID EFFECT) 90761
0! XA MET HA SO N! U SODIUM INC V MILD DIURESIS WITH NA LOSS MAY OCCUR INITIALLY 90026
DIAPA MID! U SODIUM INC V DIURETIC ACTION P 06 09
DIGITALIS U SODIUM INC V DIURETIC ACTION IN CARDIAC FAILURE 90384
DOPAMINE U SODIUM INC V DIURETIC EFFECT 90596
ETHACRYNIC ACID U SODIUM INC V THERAPEUTIC INTENT P0 840
FUROSEMID! U SODIUM INC V DIURETIC ACTION P0452
HEPAPIN U SODIUM INC V DUE TO ALDOSTEPONE SUPPRESSION 90204
HYDROC HLOROTHI AZ IDE U SODIUM INC V DIUETIC ACTION OF DRUG 90596
HYDROCORTISON! U SODIUM INC V ENHANCES EXCRETION ESP IF PRIOR LOADING 903814
HYDROFLUMETHIAZIDE U SODIUM INC V DIURETIC ACTION P0467
LEVODO PA U SODIUM INC V ?SEC. TO RENAL VASODIL. OP DIRECT ACTION ON TUBULES 90328
NANNITOL U SODIUM INC V SLIGHT INCREASE OCCURS ONLY P0 596
M!FRUSID! U SODIUM INC V DIURETIC ACTION, LESS EFFECTIVE THAN THIAZIDES P0 9 94
MENSTRUATION U SODIUM INC V POST-MENSTRUAL DIURESIS (DEC PRENENSTRUALLY) 90291
MERCURIAL DIURETICS U SODIUM INC V THERAPEUTIC INTENT P0 384
NET OL A ZO NE U SODIUM INC V DIURETIC ACTION OF DRUG 90401
PA PA N ETHA SON E U SODIUM INC V MAY BE EXCRETED ALTHOUGH EDEMA NA! OCCUR 90026
PARATHYROID EXTRACT U SODIUM INC V INCREASED CLEARANCE P0406
PPOGESTI N U SODIUM INC V MAY OCCUR WITH HIGH DOSES 90657
RECUMBENCY U SODIUM INC V METABOLIC EFFECT P09 25
SC-161 02 U SODIUM INC V DURATION OF DIURETIC ACTION SHORT P0499
SPIRONOL ACTON! U SODIUM INC V DIURETIC ACTION 903814
SULFATES U SODIUM INC V INC EXCRETION COMBINES WITH SULFATE 90026
TETRACYCLINE U SODIUM INC V NATURIESIS AND DIURESIS EFFECTS OF DRUG P0153
THIAZIDES U SODIUM INC V DIURETIC ACTION 90384
TPIAMCINOLONE U SODIUM INC V MILD DIUPESIS WITH NA LOSS IN FIRST FEW DAYS 90026
TPIAMTEPEN! U SODIUM INC V DIURETIC ACTION (INCREASED CLEARANCE) RO384
TPIFLOCIN U SODIUM INC V DIURETIC ACTION 30009
XANTHINES U SODIUM INC V DIURETIC ACTION 903814
MEALS S SODIUM Z V NO EFFECT AFTER STANDARD BREAKFAST 90181
STORAGE OF SAMPLE S SODIUM Z N NO EFFECT FOR 2 WEEKS AT ROOM TEMP OP U DEGREES 901436
THY MOL U SODIUM Z N NO EFFECT ON FLAME PHOTOMETRIC METHODS P 0779
EDTA S SORBITOL DEHYDPOCENASE DEC N INHIBITORY EFFECT P0779
HENOLYSIS S SORBITOL DEHYDPOGENASE Z M SLIGHT H!MOLYSIS HAS NO EFFECT PO’79
CARBENOXOLON! U SPECIFIC GRAVITY DEC V IMPAIRED CONCENTRATION WITH HYPOKALEMIA 90669
METH OX Y FLU PA NE U SPECIFIC GRAVITY DEC V IMPAIRED PENAL TUBULAR FUNCTION (DOSE DEPENDENT) P0 229
MUSCULAR EXERCISE U SPECIFIC GRAVITY DEC V APPARENT REDUCED ABILITY TO CONC AT ALL PATES 90505
DEXTRAN U SPECIFIC GRAVITY INC N HIGH MOLECULAR WEIGHT 90299
DIATRIZOATE U SPECIFIC GRAVITY INC M PRESENCE OF HIGH MOLECULAR WEIGHT COMPOUND P0475
RADIOGRAPHIC U SPECIFIC GRAVITY INC N PRESENCE OF HIGH MOLECULAR WEIGHT SUBSTANCE 90475
CLINICAL CHEM1STRY, Vol. 18, No. 10, 1972 1239

NSD 304 B STANDARD BICARBONATE DEC V ART. BLOOD -LONG ACTING CARBONIC ANHYDRASE INHIBIT P0599
AC I A N I L ID U SUGAR INC N ACTS AS REDUCING SUBSTANCE WITH BENEDICT’S REAGENT P0654
ACETOPHENETIDI N U SUGAR INC N FALSE POSITIVE WITH BENEDICT’S TEST P0383
ACETYLSALICYLIC AC U SUGAR INC N FALSE POSITIVE WiTH CLINITEST OR BENEDICT’S P0299
AMINOSALICYLIC AC U SUGAR INC N ACTS AS REDUCING AGENT WITH BENEDICT’S REAGENT P0044
ASCORBIC ACID U SUGAR INC N FALSE POSITIVE WITH BENEDICT’S AND CLINITEST R0299
CARBON TTRACHLOR U SUGAR INC V DUE TO HEPATIC AND PENAL DAMAGE P0620
CEPHALOTHIN U SUGAR INC N FALSE POSITIVE WITH COPPER REDUCTION PROCEDURES P0907
FURAZOLI DONE U SUGAR INC N METABOLITES NAY GIVE FALSE POSITIVE WITH BENEDICT’S P0417
LEV000PA U SUGAR INC N FALSE POSITIVE WITH CLINITEST P03 17
MELA NI N U SUGAR INC M IN LARGE QUANTITY NAY REDUCE BENEDICT’S P0929
ME I A X A LO NE U SUGAR INC N FALSE POSITIVE WITH COPPER REDUCTION PROCEDURES P0907
METHENAMINE U SUGAR INC M FALSE POSITIVE WITH BENEDICT’S REAGENT P 0580
METHYLDOPA U SUGAR INC N FALSE P05. WITH CLINITEST, NO EFFECT GLU OX METHOD P03 17
IIORPHINE U SUGAR INC M INTERFERES WITH COPPER REDUCTION METHOD P0 654
NICOTINIC ACID U SUGAR INC N INTERFERES WITH BENEDICT’S REAGENT P 0299
NITPOFUPA NTOIN U SUGAR INC N METAbOLITES NAY REDUCE BENEDICT’S, YIELD FALSE P05 P0596
NITROFURAZONE U SUGAR INC M METABOLITES MAY REDUCE BENEDICT’S REAGENT R0355
PENICILLIN U SUGAR INC N FALSE POSITIVE WITH COPPER REDUCTION PROCEDURES P0907
PROBENECID U SUGAk( INC N FALSE POSITIVE WITH BEN0ICT’S OR CLINITEST R0907
PYRA ZOL ONES U SUGAR INC N INTERFERES WITH COPPER REDUCING METHODS P029 9
QUINETHAZONE U SUGAR INC N FALSE POSITIVE WITH BENEDICT’S R0620
STREPTOMYCIN U SUGAR iNC N FALSE POSITIVE WITH COPPER REDUCTION PROCEDURES P0907
SULFONAMIDES U SUGAR INC N AFFECTS BENEDICT’S AND CLINITEST P0417
TETRACYCLINE U SUGAR INC N FALSE POSITIVE COPPER REDUCTION PROCEDURE P 0907
THIA ZIDES U SUGAR INC N INTERFERES WITH BENEDICT’S REAGENT P0299
TRIOXAZI NE U SUGAR INC N INTERFERES WITH BENEDICT’S REAGENT P0299
THYMOL U SUGAR Z N NO EFFECT ON REDUCING METHODS P0779
ACETOPHENETIDIN S SULFA AS SULFANILAMIDE INC N INTERFERES WITH ANALYTICAL PROCEDURE P0356
AMINOBENZOIC ACID S SULFA AS SULFANILAMIDE INC N MEASURED AS IF SULFONAMIDE P 0384
AMINOHIPPUPIC ACID S SULFA AS SULFANILAMIDE INC M MEASURED AS IF SULFONAMIDE P0779
AMINOSALICYLIC AC S SULFA AS SULFANILAMIDE INC N VERY SLIGHT EFFECT, MEASURED AS IF SULFA P0779
AZOSULFAMIDE S SULFA AS SULFANILAMIDE INC N SLIGHT EFFECT, MEASURED AS IF SULFONAMIDE R0779
PROCAINE S SULFA AS SULFANILAMIDE INC M METABOLIZED TO PABA WHICH INTERFERES P0384
PROTEINUPIA U SULFATASE INC V INC IN RENAL DISEASES P0758
ACLTAMIN0PHEN U SULFATE DEC V REDUCES INCREASED OUTPUT OF PHEUMATOIDS P0810
PAPATHYROTD EXTRACT U SUlFATE INC V HORMONAL ACTION P0384
PROTEIN U SULFATE INC V DERIVED FROM DIETARY PROTEIN P0283
A C El A N I I. I D B SULFHENOGLOBIN INC V HEMOLYTIC ANEMIA IN ACUTE POISONING P0384
ACETOPHENETIDIN B SULPHENOGLOBIN INC V HEMOLYSIS MAY OCCUR FREQUENTLY P0342
C LUC OS U LE ONE B SULFHEMOGLOBIN INC V HEMOLYTIC ANEMiA P0658
SULFA MITHIZOLE B SULFHEMOGLOBIN INC V MAY OCCUR WITH HEMOLYTIC ANEMIA P075 1
TRI NIT ROTOLUENE B SULFHEMOGLOBIN INC V ASSOC WITH NETHEMOGLOBINENIA AND HEMOLYSIS P0658
ACETYLSALICYLIC AC U TAUPINE DEC V REDUCES ELEVATED CONC IN RHEUMATOID PATIENTS P0810
PH EN YLBU TAZ ONE U TAURINE DEC V REDUCES INCREASED OUTPUT IN PHEUMATOIDS P0810
ANABOLIC STEROIDS S TBG DEC V DIRECT EFFECT OF DRUG R0004
A NDPOGFNS S TBG DEC V DIRECT EFFECT OF DRUG P00014
COPTICOTROPIN S TBG DEC V REDUCED SYNTHESIS P1001
CORTI SONE S TBG DEC V REDUCED SYNTHESIS P 100 1
ME TH Y LT EST OS TE RON! S TBG DEC V DIRECT EFFECT OF DRUG P0004
NANDROLONE S TBG DEC V ANABOLIC EFFECT P0708
NOR ET HA N 0 ROLONE S TBG DEC V DECREASES CONC OF TBG, INCREASES TBPA P 0907
OX YNET H OL ONE S TBG DEC V DIRECT EFFECT OF DRUG P 0004
PREDNI SONS S TBG DEC V DECREASES CONCENTRATION OF TBG, INCREASE TBPA P0907
TESTOSTERONE S TBG DEC V DIRECT EFFECT OF DRUG P0004
CHLOR MADI NONE S TBG INC V THERAPEUTIC EFFECT P0620
CLOFIBPATF S TISG INC V INCREASES CONCENTRATION P0907
DIETHYLSTILPFSTROL S TBG INC V DIRECT EFFECT OF DRUG P0004
EPI NEPHRI NE S TBG INC V BINDING CAPACITY INC AFTER INFUSION P0509
ESTR ADIOL S TBG INC V DIRECT EFFECT OF DRUG R0004
ESTROGENS S TBG INC V INCREASES BINDING CAPACITY OF TBG P0997
ESTR ONE S TBG INC V DIRECT EFFECT OF DRUG P0004
ETHI NYLESTRADIOL S TBG INC V DIRECT EFFECT OF DRUG P0004
NORETHYNODREL S TBG INC V DIRECT EFFECT OF DRUG P0004
OPAL CONTRACEPTIVE S TBG INC V IN RESPONSE TO AMOUNT OF CIRCULATING ESTROGEN RO 186
PEPPHENAZI NE S TUG INC V DIRECT EFFECT OF DRUG P0004
PROGE STI N S TBG INC V INCREASED SYNTHESIS a 1001
HALOFENATE S TBG Z V NO EFFECT OBSERVED AFTER 3 WEEKS P0674
ESTROGENS S TBPA DEC V METABOLIC EFFECT P007 2
ANABOLIC STEROIDS S TBPA INC V METABOLIC EFFECT P0072
HALOFENATE S TBPA Z V NO EFFECT OBSERVED AFTER 3 WEEKS P0 674
OPAL CONTRACEPTIVE S TESTOSTERONE BIND GLOB INC V METABOLIC EFFECT R0639
CYPPOTER ONE P TESTOSTERONE DEC V BY 20-140% (ANTIANDROGENIC EFFECT) R0887
DIETHYLSTILBESTROL P TESTOSTERONE DEC V AT DOSES AFFECTING PITUITARY-GONADAL AXIS P0525
MEl’ YRA P0 NE P TESTOSTERONE DEC V FALL IN 2 HOURS IN MEN, MINOR INC IN WOMEN P0696
DEXANETHASON E U TESTOSTERONE DEC V SLIGHT EFFECT IN MEN P0798
CHOLESTEROL P TESTOSTERONE INC N AT 1-20 UG AFFECTS COMPETITIVE BINDING METHOD P026 9
CLOMI PilE NE P TESTOSTERONE INC V LIBERATES LH,ANTI-STEPOID HORMONE EFFECT OF DRUG P0193
ESTROGENS P TESTOSTERONE INC V ALTERED METABOLISM P0874
HEMOLYSIS P TESTOSTERONE INC N IF GREATER THAN 5 NG/100ML AFFECTS C-S METHOD P0269
METALS P TESTOSTERONE INC N IN MOLAR PATIO OF 0.7-14.0 AFFECTS C-S METHOD P0269
ORAL CONTRACEPTIVE P TESTOSTERONE INC V METABOLIC CHANCES IN LIVER SYNTHESIS P0588
CLOMI PilE NE U TESTOSTERONE INC V LIBERATES LH,ANTI-STEROID HORMONE EFFECT OF DRUG P 007 3
CORTICOTROPIN U TESTOSTERONE INC V MODERATE EFFECT IN MEN P0798
GONA DOT ROPIN U TESTOSTERONE INC V MARKED EFFECT IN NORMAL MEN P0798
CREATININE U THORMAHLEN TEST P05 N LARGE AMOUNTS GIVE BROWN COLOR P092 9
MFLANIN U THORMAFILEN TEST P05 N GREEN-BLUE TO BLUE-BLACK (NORMAL = OLIVE-BROWN) P092 9
C LUC OS F S THREON1NE DEC V PROBABLE MUSCLE UPTAKE P0397
TETRACYCLINE U THEZONINE INC V UNEXPLAINED MECHANISM P0384
ASPARAGINASE B THLOMBIN TIME INC V OCCURS WITH DECREASED FIBRINOGEN CONCENTRATION P0705
1240 CLINICALCHEMISTRY, Vol. 18, No. 10, 1972

HEPARIN B THROMBIN TIME INC V RELATED TO CONC OF CIRCULATING HEPARIN P0704
C YC LOP POPA NE B THROMBIN TIME Z V ANESTHESIA HAS NO EFFECT 90384
HEPARIN B THRONBOPLASTIN CEN DEC V ABNORMAL RESPONSE (INHIBITION) P0384
PROTA MINE B THRONBOPLASTIN GEN DEC V POSSESSES ANTICOAGULANT ACTION P0384
TETRACYCLINE B THROMBOPLASTIN CEN DEC V IMPAIRED RATE OF REGENERATION OBSERVED P0 384
HEAT S THYMOL TURBIDITY DEC N AS ROOM TEMPERATURE IS INCREASED P0 181
OX AL AT!S S THYMOL TURBIDITY DEC V REPORTED: NO MECHANISM CITED P0 181
ACETOHEXA MID! S THYMOL TURBIDITY INC V NAY CAUSE INTPAHEPATIC CHOLESTATIC JAUNDICE 90620
ACETOPHENAZINE S THYMOL TURBIDITY INC V CHOL!STASIS WITH INTRAHEPATIC OBSTRUCTION P0620
AJMALINE S THYMOL TURBIDITY INC V INTRAHEPATIC CHOL!STASIS 90088
ALBUMI N S THYMOL TURBIDITY INC N IF HIGH 90620
AMINOSALICYLIC AC S THYMOL TURBIDITY INC V LIVER DAMAGE MAY OCCUR WITH 10% MORTALITY 90736
A NI TRI PTYLI N! S THYMOL TURBIDITY INC V RAPE CASES OF TRANSIENT CHOLESTASIS P06 2 0
AMODI AQUINE S THYMOL TURBIDITY INC V REPORTED HEPATOTOXICITY 90620
AMPHOTERICIN B S THYMOL TURBIDITY INC V DUE TO HEPATOCELLULAR DYSFUNCTION 90620
ANABOLIC STEROIDS S THYMOL TURBIDITY INC V DUE TO CHOLESTATIC SYNDROME 90596
A N DR OG ENS S THYMOL TURBIDITY INC V CHOLESTATIC PHENOMENON 90620
ANTIMONY COMPOUNDS S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT 90 596
APSENICALS S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT P0596
ASPARAGINASE S THYMOL TURBIDITY INC V HEPATOTOXICITY 901427
ASPIDIUM S THYMOL TURBIDITY INC V NAY CAUSE HEPATIC TOXICITY 90620
BENZI ODARONE S THYMOL TURBIDITY INC V MAY CAUSE HEPATIC TOXICITY P0620
BISMUTH S TRYMOL TURBIDITY INC V HEPATOTOXICITY 90620
CARBON TETRACHLOP S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT RO620
CAPPH!NAZ IN! S THYMOL TURBIDITY INC V PROBABLE CHOLESTATIC EFFECT (REVERSIBLE) 90620
CEPHALOTHIN S THYMOL TURBIDITY INC V REPORTED IN ALCOHOLIC PATIENT WITH CIRRHOSIS P 062 0
CHLORAMPHEN ICOL S THYMOL TURBIDITY INC V HEPATOTOXICITY R0596
CHLOPDIAZEPOXIDE S THYMOL TURBIDITY INC V INFREQUENT CHOL!STATIC EFFECT 90620
CHLOPMEZANONE S THYNOL TURBIDITY INC V HEPATOTOXICITY R062O
CHLOROFORM S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT WITH NECROSIS 90620
CHLOROTHI AZ IDE S THYMOL TURBIDITY INC V MAY CAUSE CHOLESTATIC JAUNDICE P06 20
CHLORPROPA MID! S THYMOL TURBIDITY INC V MAY CAUSE CYTOTOXIC LIVER DAMAGE 30620
CHLORPPOT HIXENE S THYNOL TURBIDITY INC V NAY CAUSE HEPATOTOXICITY (REVERSIBLE) 90620
CHLORTETRACYCLINE S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT WITH CENTROLOBULAP NECROSIS P0 355
CHLORZOXAZONE S THYNOL TURBIDITY INC V NAY CAUSE HEPATOTOXICITY P0620
CINC HO PH! N S THYNOL TURBIDITY INC V MAY CAUSE HEPATOTOXICITY (VIPAL-HEPATITIS LIKE) 90620
CLOFIBRATE S THYMOL TURBIDITY INC V H!PATOTOXIC EFFECT P0620
COLCHICINE S THYMOL TURBIDITY INC V MAY HAVE HEPATOTOXIC EFFECT P0 6 20
CORTI COSTEPOI DS S THYMOL TURBIDITY INC V PHYSIOLOGICAL DOSES INCREASE PROTEIN SYNTHESIS P0211
CORTICOTROP IN S THYMOL TURBIDITY INC V PHYSIOLOGICAL DOSE INCREASE PROTEIN SYNTHESIS P0211
COUMARIN S THYMOL TURBIDITY INC V MAY CAUSE HEPATOTOXICITY R0990
CYCLOPHOSPHAMIDE S THYMOL TURBIDITY INC V MAY CAUSE HEPATOTOXICITY 90620
C YC LOPR 0 PA N! S THYMOL TURBIDITY INC V MAY CAUSE HEPATOTOXICITY (LASTS SEVERAL DAYS) P06 20
CYCLOSERINE S THYMOL TURBIDITY INC V MAY CAUSE HEPATOTOXICITY 90620
DESIPRAMI NE 5 THYMOL TURBIDITY INC V PARE TRANSIENT CHOLESTASIS RO62O
DIPHENYLHYDANTOIN S THYMOL TURBIDITY INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P0620
ECTYLU PEA S THYMOL TURBIDITY INC V MAY CAUSE CHOLESTASIS WITH CHOLANCIOLITIS 90620
ERYTHROMYCIN S THYMOL TURBIDITY INC V WEAK EFFECT DUE TO CHOLESTASIS 90477
ESTRADIOL S THYMOL TURBIDITY INC V CHOLESTATIC EFFECT 90620
ESTROG ENS S THYMOL TURBIDITY INC V OCCURS WITH CHOLESTASIS P 0596
ESTP ONE S THYMOL TURBIDITY INC V MAY CAUSE CHOLESTASIS 90620
ETHER S THYMOL TURBIDITY INC V HEPATIC DISTURBANCE (TRANSIENT) P0620
ETHIONAMIDE S THYMOL TURBIDITY INC V INTRAHEPATIC CHOLESTASIS 90620
ETHOTOI N S THYNOL TURBIDITY INC V HEPATOTOXICITY P0620
ETHOXAZEN! S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT 90620
FATTY FOODS S THYMOL TURBIDITY INC M LIPEMIA CAUSES FALSE HIGH VALUES DUE TO TURBIDITY P0356
FLOPANT YRONE S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT P0620
FLUOROCYTOSINE S THYMOL TURBIDITY INC V REVERSIBLE HEPATOTOXICITY IN 10% P0898
FLUPHENAZIN! S THYMOL TURBIDITY INC V HYPERSENSITIVITY RESPONSE R062O
FLUPAZEPA N S THYNOL TURBIDITY INC V MAY CAUSE HEPATOTOXICITY 90788
CLY CO PY PP OL A T! S THYNOL TURBIDITY INC V HEPATOTOXICITY 90620
GOLD S THYMOL TURBIDITY INC V HEPATOTOXICITY WITH CENTROLOBULAR NECROSIS P06 20
GROWTH HORMONE S THYMOL TURBIDITY INC V INC PROTEIN SYNTHESIS P02 11
GUANOXAN S THYMOL TURBIDITY INC V MAY CAUSE HEPATIC TOXICITY R06 20
HALOP!RIDOL S THYMOL TURBIDITY INC V MAY CAUSE H!PATOCELLULAR CHANCES P062 0
HA LOT H AN! S THYMOL TURBIDITY INC V ALLERGIC HEPATIC HYPERSENSITIVITY P06 20
HEPARIN S THYMOL TURBIDITY INC N AFFECTS PHYSICO-CHEM PROPERTIES ALTERING TURBIDITY 901436
HYDR AZINE S THYMOL TURBIDITY INC V MAY CAUSE HEPATOTOXICITY 90620
HYDROXYACETANID! S THYNOL TURBIDITY INC V HEPATOTOXICITY 90620
IBUFENAC S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT R0620
ICTEPOG ENIN S THYNOL TURBIDITY INC V CAUSES INTRAHEPATIC CHOL!STASIS 900514
INDANDIONES S THYMOL TURBIDITY INC V MAY CAUSE HEPATOTOXICITY 90620
INDOMETHACIN S THYMOL TURBIDITY INC V CYTOTOXIC AND CHOL!STATIC LIVER DAMAGE P 05 2 1
INSULIN S THYMOL TURBIDITY INC V ASSOCIATED WITH INCREASED PROTEIN SYNTHESIS 90211
IOPANOIC ACID S THYMOL TURBIDITY INC V MAY CAUSE HEPATOTOXICITY P0620
I PRONIAZID S THYMOL TURBIDITY INC V MAY CAUSE CHOLESTATIC JAUNDICE 90620
ISOCARBOXAZID S THYMOL TURBIDITY INC V CHOLESTATIC EFFECT 90620
KANAMYCIN S THYMOL TURBIDITY INC V MAY CAUSE HEPATOTOXICITY P062 0
LINCOMYCIN S THYMOL TURBIDITY INC V HEPATOTOXIC-CHOLESTATIC EFFECT P06 20
LIPEMIA S THYMOL TURBIDITY INC M DUE TO INHERENT TURBIDITY P062 0
MAO INHIBITORS S THYMOL TURBIDITY INC V INTRAHEPATIC CHOLESTASIS R062O
MEALS S THYMOL TURBIDITY INC N CAUSE MILD LIPENIA WHICH IS MEASURED 90184
MECHLOPETHANINE S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT P0079
NEPACRI N! S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT P06 20
NEPH!N YTOIN S THYNOL TURBIDITY INC V HEPATOTOXICITY R0620
MEPCA PTOPURIN! S THYMOL TURBIDITY INC V BEPATOTOXICITY (CENTROLOBULAR NECPOSI 5) P06 20
METAHEXAMIDE S THYMOL TURBIDITY INC V HEPATOTOXYCITY (VIRAL-HEPATITIS TYPE) 90620
NETANDI!NONE S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT 90620
METAX ALONE S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT P06 20
NET HIMAZOL! S THYMOL TURBIDITY INC V CHOLESTATIC EFFECT 90U77

METHOTREXATE S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT P0620
METHDXSAL!N S THYNOL TURBIDITY INC V HEPATOTOXIC EFFECT P0620
METHOXYFLUPANE S THYMOL TURBIDITY INC V HEPATOTOXICITY P0620
NETHYLDOPA S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT P01 89
METHYLTESTOSTERONE S THYNOL TURBIDITY INC V CHOLESTATIC EFFECT (NAY NOT BE AFFECTED) P01477
M!THYLTHIOURACIL S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT P0620
NALIDIXIC ACID S THYMOL TURBIDITY INC V MAY CAUSE CHOLESTATIC JAUNDICE P0654
NICOTINIC ACID S THYMOL TURBIDITY INC V IMPAIRED HEPATIC FUNCTION P0620
NITROFURANS S THYMOL TURBIDITY INC V HEPATOTOXICITY P0620
NITPOFUPANTOIN S THYMOL TURBIDITY INC V MAY B! CHOLESTATIC JAUNDICE R062O
NOPETHANDROLONE S THYNOL TURBIDITY INC V CHOLESTASIS PRODUCED WITHOUT CHOLANCIOLITIS P0826
NORETHINDPONE S THYMOL TURBIDITY INC V CHOLESTATIC EFFECT P0620
NORETHISTEPONE S THYMOL TURBIDITY INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P0620
NOP!THYNODPEL S THYMOL TURBIDITY INC V CHOLESTATIC EFFECT P0620
NOVOBIOCIN S THYMOL TURBIDITY INC V INTEAHEPATIC CHOLESTASIS MAY OCCUR P0620
OLEANDOMYCIN S THYMOL TURBIDITY INC V MAY CAUSE HEPATOTOXICITY 30620
ORGANOPHOSPHOPUS S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT P0130
OXACILLIN S THYMOL TURBIDITY INC V REVERSIBLE HEPATOCELLULAR DYSFUNCTION P0620
OXAZEPAM S THYMOL TURBIDITY INC V POSSIBLE HEPATOTOXICITY P0620
OXYPHENBUTAZON! S THYMOL TURBIDITY INC V POSSIBLE HEPATOTOXICITY R062O
OXYPRENISATIN S THYMOL TURBIDITY INC V MAY CAUSE HYPERSENSITIVITY REACTION P0776
PAPALDEHYDE S THYNOL TURBIDITY INC V POSSIBLE HEPATOTOXICITY P0620
PARAMETHADIONE S THYMOL TURBIDITY INC V POSSIBLE HEPATOTOXICITY 90620
PAPGYLINE S THYMOL TURBIDITY INC V POSSIBLE HEPATOTOXICITY (REVERSIBLE) P0620
PECAZINE S THYMOL TURBIDITY INC V NAY ALTER LIVER FUNCTION (CHOLESTASIS) P0620
PENICILLAMINE S THYMOL TURBIDITY INC V POSSIBLE HEPATOTOXICITY P0620
PHENACEMIDE S THYNOL TURBIDITY INC V MAY AFFECT LIVER FUNCTION IN ABOUT 2% CASES P0620
PHENAZOPYRIDIN! S THYNOL TURBIDITY INC V HEPATOTOXIC EFFECT P0620
PHENINDIONE S THYMOL TURBIDITY INC V MAY MODIFY LIVER FUNCTION (CHOLESTASIS) 30620
PHENIPPAZINE S THYMOL TURBIDITY INC V MAY AFFECT LIVER FUNCTION P0620
PHENOTHIAZINES S THYNOL TURBIDITY INC V MAY CAUSE CHOLESTATIC HEPATITIS (IN UP TO 14% PTS) P0620
PHENYLBUTAZONE S THYMOL TURBIDITY INC V MAY CAUSE CHOLESTASIS P0620
PHOSPHORUS S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT WITH NECROSIS P0620
POLYTHIAZIDE S THYMOL TURBIDITY INC V MAY AFFECT LIVER FUNCTION P0620
PROBENECID S THYNOL TURBIDITY INC V HEPATOTOXIC EFFECT (CENTROLOBULAR NECROSIS) P0620
PROCAINAMIDE S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT P0620
PPOCHLORPEPAZIN! S THYMOL TURBIDITY INC V CHOLESTATIC EFFECT P0026
PROGESTIN S THYMOL TURBIDITY INC V HEPATOTOXICITY P0620
PROMAZINE S THYNOL TURBIDITY INC V MAY CAUSE CHOLESTASIS P0620
PROMETHAZIN! S TRYMOL TURBIDITY INC V MAY CAUSE CHOLESTASIS P0620
PROPOXYPHENE S THYMOL TURBIDITY INC V CHOLESTATIC EFFECT P0538
PPOPYLTHIOUPACIL S THYNOL TURBIDITY INC V HEPATOTOXIC EFFECT (CENTPOLOBULAR NECROSIS) P0620
PYRAZINAMIDE S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT (VIRAL-HEPATITIS LIKE) P0620
QUINETHAZONE S THYMOL TURBIDITY INC V MAY CAUSE CHOLESTATIC JAUNDICE P0620
PIFAMPIN S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT (CHOLESTASIS) P0740
SULFADINETHOXINE S THYMOL TURBIDITY INC V REVERSIBLE CHOLESTASIS P0307
SULFAFURAZOLE S THYMOL TURBIDITY INC V REVERSIBLE CHOLESTASIS P0620
SULFAMFTHIZOLE S THYMOL TURBIDITY INC V REVERSIBLE CHOLESTASIS P05142
SULFAMETHOXAZOLE S THYMOL TURBIDITY INC V REVERSIBLE CHOLESTASIS P0620
SULFAMETHOXYPYPID S THYMOL TURBIDITY INC V REVERSIBLE CHOLESTASIS P0620
SULVISOXAZOLE S THYMOL TURBIDITY INC V NAY CAUSE CHOLESTASIS P05142
SULFONAMIDES S THYMOL TURBIDITY INC V MAY CAUSE CHOLESTASIS P0736
SULFONES S THYMOL TURBIDITY INC V MAY AFFECT LIVER FUNCTION P0620
TESTOSTERONE S THYMOL TURBIDITY INC V MAY CAUSE CHOLESTASIS P0620
TETRACYCLINE S THYMOL TURBIDITY INC V NAY CAUSE CHOLESTASIS P0620
THIABENDAZOLE S THYMOL TURBIDITY INC V PARE CHOLESTASIS P0647
THIACETAZONE S THYMOL TURBIDITY INC V MAY CAUSE CHOLESTASIS P0079
THIAMAZOLE S THYMOL TURBIDITY INC V MAY AFFECT LIVER FUNCTION P0620
THIAZIDES S THYMOL TURBIDITY INC V MAY CAUSE CHOLESTASIS P0620
THIOGUANINE S THYMOL TURBIDITY INC V MAY CAUSE CHOLESTASIS P0620
THIOPIDAZINE S THYMOL TURBIDITY INC V HEPATOTOXICITY P0508
THIOSEMICAPBAZONES S THYMOL TURBIDITY INC V MAY AFFECT LIVER FUNCTION P0620
THIOTHIXENE S THYMOL TURBIDITY INC V HEPATOTOXIC EFFECT (REVERSIBLE CHOLESTASIS) P0620
THYROID S THYMOL TURBIDITY INC V INCREASE PROTEIN METABOLISM P0204
TOLAZAMIDE S THYMOL TURBIDITY INC V CHOLESTASIS P0620
TOLBUTAMIDE S THYMOL TURBIDITY INC V MAY CAUSE CYTOTOXIC LIVER DAMAGE OR CHOLESTASIS P0620
TPANYLCYPROMINE S THYMOL TURBIDITY INC V MAY AFFECT LIVER FUNCTION (?HYPERSENSITIVITY) P0620
TRIMETHADION! S THYMOL TURBIDITY INC V MAY CAUSE HEPATOTOXICITY WITH NECROSIS P0620
TPIOXSALEN S THYMOL TURBIDITY INC V MAY AFFECT LIVER FUNCTION P0620
URACIL MUSTARD S THYMOL TURBIDITY INC V MAY AFFECT LIVER FUNCTION P0620
BILIRUBIN S THYMOL TURBIDITY Z N NO EFFECT UP TO 14 NC/100NL P01436
HEMOGLOBIN S THYNOL TURBIDITY Z N NO EFFECT UP TO CONC OF 114 MC/100ML P01436
STORAGE OF SAMPLE S THYMOL TURBIDITY Z N USUALLY STABLE AT 4 DEGREES FOR 1 WEEK P0436
ESTROGENS S THYROID BINDING PATIO DEC V INCREASES BINDING CAPKCITY OF TBG P0997
AC!TYLSALICYLIC AC S THYROXINE (T14) DEC V DISPLACES THYROXINE FROM BINDING SITES (TBPA) P0907
AMBULATION S THYROXINE (T4) DEC V TRANSIENT? DUE TO INC CELLULAR UTILIZATION P0266
AMINOSALICYLIC AC S THYROXINE (T4) DEC V MAY CAUSE GOITROUS HYPOTHYROIDISM P0736
CHLORPROMAZINE S THYROXINE (T4) DEC V INCREASED METABOLISM BY HEPATIC NICROSOMES P0907
CHLORPROPAMIDE S THYROXINE (T4) DEC V DISPLACES THYROXINE FROM TBG P0907
CHOLESTYRANIN! S THYROXINE (T4) DEC V DECREASED INTESTINAL ABSORPTION OF THYROXINE P0907
COPTICOTROPIN S THYROXINE (T4) DEC V REDUCED THYPOBINDINC GLOBULIN P1001
CORTISONE S THYROXINE (T4) DEC V DECREASED SYNTHESIS P0907
DINITPOPHENOL S THYROXINE (T4) DEC V DISPLACED FROM BINDING SITES ON TBG P0907
DIPHENYLHYDANTOIN S THYROXINE (T14) DEC V DISPLACES THYROXINE FROM BINDING SITES P0907
ETHIONAMIDE S THYROXINE (T4) DEC V ANTITHYROID EFFECT AFTER SEVERAL WEEKS R01417
HALOF!NAT! S THYROXINE (T4) DEC V INTERFERES WITH BINDING OF T14 TO TBC P0674
HEPAPIN S THYROXINE (T4) DEC V PROBABLE MODIFICATION OF THYROXINE BINDING P0813
IODIDES S THYROXINE (T4) DEC V DEC SYNTHESIS IF DIAGNOSTIC OR THERAPEUTIC I 131 P0907
LIOTHYRONIN! S THYROXINE (T14) DEC V DEPRESSION OF ENDOGENOUS HORMONE P0596
LITHIUM S THYROXINE (T4) DEC V REPORTED TO INDUCE MYXEDEMA P0597

METHI MAZ OLE S THYROXINE (T4) DEC V THERAPEUTIC INTENT(STOPS IODINATION OF TYPOSIN!) 30408
METHYLTHIOURACIL S THYROXINE (T4) DEC V INHIBITS SYSNTHESIS, STOPS IODINATION OF TYPOSIN! 30026
NOPETHI NDPONE S THYROXINE (T4) DEC V WHEN TREATMENT RESULTS COMPARED WITH CONTROLS P0085
PROPYLTHIOUPACIL S THYROXINE (T4) DEC V INHIBITS SYNTHESIS, STOPS IODINATION OF TYPOSINE P04 17
RESERPINE S THYROXINE (T14) DEC V INCREASED METABOLISM BY HEPATIC MICROSOM!S P0907
SULFONAMIDES S THYROXINE (T4) DEC V ACTS LIKE THIOUREA ON THYROID GLAND P0112
T ETP AC HLO POT BY RON S THYROXINE (T14) DEC V DISPLACES THYROXINE FROM TBG 90907
TOLBUTAMI DE S THYROXINE (T4) DEC V DISPLACES FROM TBC P0907
TR IIODOTHYRONINE S THYROXINE (T4) DEC V DIMINISHED SYNTHESIS P0907
CELLULOSE ACETATE S THYROXINE (TL4) INC M DUE TO PHTHALATES AS PLASTICIZER IN CONTAINERS 90822
DESSICATED THYROID S THYROXINE (T4) INC V INCREASES BY 1-2 UG/100ML/DAY PER GRAIN GIVEN P0 112
DEXTROTHY ROXI NE S THYROXINE (T4) INC V MECHANISM NOT DISCUSSED P014 17
ESTPOC!NS S THYROXINE (T4) INC V INCREASES BINDING CAPACITY OF TBG 90112
ETHER S THYROXINE (T14) INC V EFFECT OBSERVED IN NOD TO DEEP ANESTHESIA P03 84
IODOTHIOURACIL S THYROXINE (T4) INC N ORGANIC IODINE COMP. (SATIS WITH MURPHY-PATTEE) P0112
IOPANOIC ACID S THYROXINE (T14) INC N CONTAMINATING IODINE AFFECTS TEST 90839
LEVODOPA S THYROXINE (T4) INC V DURINC THERAPY OF PARKINSONISM 90509
LEVOTHYPOXI N! S THYROXINE (T4) INC V ENDOGENOUS HORMONE SUPPRESSED, EXOGENOUS MEASURED 90112
OPAL CONTRACEPTIVE S THYROXINE (T4) INC V INCREASED BINDING PROTEIN AVAILABLE P0907
PROPYLIODONE S THYROXINE (T4) INC N AT VERY HIGH CONCENTRATIONS ONLY 90112
SULFAM!THOXAZOL! S THYROXINE (T14) INC M ERRATIC ELUTION FROM COLUMN = FALSE RESULT P0183
THYROID S THYROXINE (T14) INC V INC AVAILABLE THYROXINE 90596
THYROTROPI N S THYROXINE (T4) INC V SEVERAL HOURS AFTER I.M. INJECTION P04 57
THYPOTROPIN-PELEAS S THYROXINE (T4) INC V BUT NO CHANCE IN PERCENT FREE T4 90457
DIAZEPAM S THYROXINE (T14) Z V CONFLICTING REPORTS ? NO EFFECT 90417
LUGOL’S IODINE S THYROXINE (T14) Z N NO EFFECT ON METHODS P08 39
CHLOPAMPHEN ICOL S TIBC DEC V DECREASED UPTAKE BY ERYTHPOID TISSUE P0596
COPTICOTROPIN S TIBC DEC V DECREASE IN IRON BINDING GLOBULIN P1001
CORTI SON! S TIBC DEC V REDUCED SYNTHESIS OF TRANSFERRIN 91 001
IRON SALTS S TIBC INC V EFFECT OF I.M. IRON P0 355
MESTRA NOL S TIBC INC V 20% RISE ON AVERAGE P046 3
OPAL CONTRACEPTIVE S TIBC INC V ESTROGEN OP PROGESTOGEN EFFECT (USUALLY PLUS 20%) P0918
PREGNANCY S TIBC INC V WITH FALL OF SERUM IRON AFTER MIDTERM 90291
BILIRUBIN S TIBC Z N NO EFFECT ON MEASUREMENT P0779
HENOGLOBI N S TIBC Z N NO EFFECT ON MEASUREMENT P0779
ACETAZOLAMIDE U TITRATABLE ACIDITY DEC V INCREASED ALKALINITY 90384
PROTEIN U TITRATABLE ACIDITY INC V DUE TO INGESTION OF PROTEIN P029 1
TRIFLOCI N U TITRATABLE ACIDITY INC V INHIBITS CARBONIC ANHYDRASE P0009
IODINE CONTAIN DRUG S TOTAL IODINE INC V IODINE CONTAMINATION P03 55
ORAL CONTRACEPTIVE S TOTAL IODINE INC V ALTERED METABOLISM P0412
ASPARAGINASE S TOTAL LIPIDS DEC V PARALLEL DECREASE IN CHOLESTEROL P0705
CHOLESTYRAMI NE S TOTAL LIPIDS DEC V LOWERS BILE ACIDS BY IONIC BINDING 90620
CLOFIBRATE S TOTAL LIPIDS DEC V NORMAL RESPONSE (MAY INCREASE IN DIABETICS) P0 6 57
EDTA S TOTAL LIPIDS DEC V OCCURS IF ELEVATED LIPIDS AND GIVEN I.V. P014 17
GLUCA CON S TOTAL LIPIDS DEC V TRANSFER OF LIPIDS TO PLATELETS 90185
ORAL CONTRACEPTIVE C TOTAL LIPIDS INC V ALTERED METABOLISM P01448
ASPAPACINASE S TOTAL LIPIDS INC V RAPE RESPONSE AFTER INITIAL HYPOLIPIDEMIA 90705
FILTER PAPER S TOTAL LIPIDS INC N IF LOW-FAT PAPER NOT USED IN SOME METHODS P0181
PROTAMINE S TOTAL LIPIDS INC V MECHANISM NOT ESTABLISHED P0 384
NICOTINAMIDE S TOTAL LIPIDS Z V NO LOWERING EFFECT OBSERVED P0 3814
OPAL CONTRACEPTIVE S TOTAL PHOSPHATIDES INC V ALTERED METABOLISM 90448
ASPARACINASE S TPANSFERRIN DEC V REPORTED EFFECT P0 705
CORTI SON! S TRANSFERRIN DEC V REDUCED SYNTHESIS Ri 001
TESTOS TEP ONE S TRANSFERRIN DEC V METABOLIC EFFECT R0072
ESTROG ENS S TRANSFERRIN INC V ALTERED LIVER SYNTHESIS R0640
ME STR A N OL S TPANSFEPRIN INC V MAX EFFECT ONE WEEK AFTER TREATMENT P0 4 63
ORAL CONTRACEPTIVE S TRANSFEPPIN INC V METABOLIC CHANCES IN LIVER SYNTHESIS (ESTROGEN) 90588
PREGNANCY S TRANSFERPIN INC V IN LAST TRIMESTER COMPARED WITH CONTROLS P0639
PROGESTIN S TRANSFERPIN Z V NO SIGNIFICANT EFFECT AFTER 6-9 MONTHS 90907
ASCORBIC ACID S TRIGLYCERIDES DEC V EFFECT OBSERVED IN ATHEROSCLEROTIC PATIENTS P0 884
ASPAPA CINASE S TRIGLYCERIDES DEC V NOTED AFTER FIRST WEEK IN SOME PATIENTS P0705
CHOLESTYRAMINE S TRIGLYCERIDES DEC V THERAPEUTIC EFFECT P0 596
CLOFIBRATE S TRIGLYCERIDES DEC V INHIBITS TRANSFER FROM LIVER TO PLASMA P0 141
COLESTIPOL S TRIGLYCERIDES DEC V THERAPEUTIC INTENT P02 80
DEXTROTHYROXIN! S TRIGLYCERIDES DEC V THERAPEUTIC EFFECT BOO 26
FENFLURANINE S TRIGLYCERIDES DEC V (NOT CONSTANT FINDING) 90907
GLUCA CON S TRIGLYCERIDES DEC V TRANSFER OF LIPIDS TO PLATELETS 90185
HA LOFE NATE S TRIGLYCERIDES DEC V REDUCED BY UP TO 50% P06 74
REPARI N S TRIGLYCERIDES DEC V PROMPT DEC WHEN SMALL DOSE GIVEN I.V. P03 84
METFORMIN S TRIGLYCERIDES DEC V AVERAGE OF 26% IN TYPE IV HYPERLIPOPPOTEINEMIA P0 140 3
METHA NDROSTENOLONE S TRIGLYCERIDES DEC V METABOLIC (ANABOLIC) EFFECT P0 901
NAFENOPIN S TRIGLYCERIDES DEC V MORE EFFECTIVE THAN CLOFIBRATE P0280
NICOTINIC ACID S TRIGLYCERIDES DEC V THERAPEUTIC INTENT P0 72 1
OXANDROLONE S TRIGLYCERIDES DEC V INCREASES TRIGLYCERIDE HYDROLYSIS PERIPHERALLY P03 69
OXY MET H OL ON E S TRIGLYCERIDES DEC V ANABOLIC EFFECT P0098
PHENFORMIN S TRIGLYCERIDES DEC V CAUSES REDUCTION OF CARBOHYDRATE INDUCED INCREASE P0710
ASPAPAGINASE S TRIGLYCERIDES INC V RARE RESPONSE AFTER INITIAL HYPOLIPIDEMIA P0705
CHOLESTYP AMINE S TRIGLYCERIDES INC V MECHANISM OBSCURE (MAY OCCUR IN DIABETICS) 90504
DIHYDROXYACETONE S TRIGLYCERIDES INC N MEASURED AS GLYCEROL WITH ENZYMATIC METHODS P0779
ESTROGENS S TRIGLYCERIDES INC V ASSOC WITH INC VERY LOW DENSITY LIPOPPOTEINS P06 27
ET HANOL S TRIGLYCERIDES INC V INFUSION CAUSES INCREASED HEPATIC SYNTHESIS P0 1487
ETHYNODIOL S TRIGLYCERIDES INC V DECREASED REMOVAL FROM CIRCULATION P0907
FR UCTOSE S TRIGLYCERIDES INC V OCCURS IN EXPTL ANIMALS, CONTRADICTORY IN HUMANS P0 476
CLYCERAL DEll YDE S TRIGLYCERIDES INC N MEASURED AS GLYCEROL WITH ENZYMATIC PROCEDURES P0779
LEVOTHYROXINE S TRIGLYCERIDES INC V EFFECT OBSERVED IN HYPOTHYROID PATIETS P0 667
MESTPA NOL S TRIGLYCERIDES INC V ?IMPAIRED TRIGLYCERIDE REMOVAL FROM CIRCULATION P0 907
OPAL CONTRACEPTIVE S TRIGLYCERIDES INC V IF GIVEN FOR 3 MONTHS IMPAIRED REMOVAL (ESTROGEN) R0907
OPAL CONTRACEPTIVE S TRIIODOTHYRONINE (T3) DEC V DUE TO INCREASE IN TBG P0827
CELLULOSE ACETATE S TRIIODOTHYRONINE (T3) INC N INHIBITS BINDING OF T14 TO TBG R0822
HEPARIN S TRIIODOTHYRONINE (T3) INC V INTERFEPES WITH THYROXINE BINDING TO PROTEIN P05 02

THYPOTROPIN-PELEAS S TPIIODOTHYRONINE (T3) INC V BUT NO CHANCE IN PERCENT FREE T3 P0457
ANABOLIC STEROIDS S TRYPSIN INHIBITOR INC V METABOLIC EFFECT P0072
ESTROGENS S TRYPSIN INHIBITOR INC V METABOLIC EFFECT P0072
MAO INHIRITORS U TPYPTAMINE INC V DUE TO UTILIZATION OF ALTERNATIVE PATHWAYS 90384
LI’HT S ‘9YPTOPHAN DEC N AFFECTS FLUOPONETRIC METHOD OF DENCLA & DEWEY P0575
LIGHT U TRYPTOPHAN DEC N AFFECTS FLUOP.OM!TPIC METHOD OF DENCLA & DEWEY 90575
ACETYLTRYPTOPHAN T TRYPTOPHAN INC N MEASURED AS SAME BY SPIES/CHAMBERS METHOD 90399
INDOLEACETIC ACID T TPYPTOPHAN INC N MEASURED AS SAME AS SPIES/CHAMBERS METHOD R0399
INDOLEPROPIONIC AC T TRYPTOPHAN INC M MEASURED AS SAME AS SPIES/CHAMBERS METHOD P0399
METHYLTRYPTOPHAN T TPYPTOPHAN INC N MEASURED AS SAME IN SPIES/CHAMBERS METHOD P0399
SKATOLE T TRYPTOPHAN INC M MEASURED AS SAME IN SPIES/CHAMBERS METHOD P0399
TRYPTANINE T TRYPTOPHAN INC M MEASURED AS SAME IN SPIES/CHAMBERS METHOD P0399
TPYPTOPHAN-THIOL T TRYPTOPHAN INC N MEASURED AS SANE IN SPIES/CHAMBERS METHOD P0399
TETPACYCLINE U TRYPTOPHAN INC V UNEXPLAINED MECHANISM P0384
ACETYLSALICYLIC AC P TSH DEC V DEC RELEASE AFTER ADMINISTRATION P0657
COPTICOSTEROIDS P TSH DEC V USUAL RESPONSE IN PATIENTS ON STEROIDS 90596
HEPARIN P TSH DEC V INTERFERES WITH THYROXINE BINDING TO PROTEIN P0502
TPIIODOTHYPONINE P TSR DEC V EFFECT MARKED IN EUTHYPOID, HYPOTHYROID SUBJECTS P0950
LITHIUM P TSH INC V MECHANISM UNCLEAR P0168
THYROTBOPIN-RELEAS P TSH INC V THREEFOLD INCREASE IN 30 MIN P0034
MAO INHIBITORS U TYRAMINE INC V PREVENT DEAMINATION P03814
PESERPINE 0 TYRANINE TEST DEC V INHIBITS RESPONSIVENESS (PRODUCES FALSE NEC.) P0373
THIAZIDES 0 TYRANIN! TEST DEC V MAY ATTENUATE RESPONSE TO TYRANIN! P0303
CUANETHIDINE 0 TYRAMINE TEST INC V INC RESPONSE TO TYRAMINE DUE TO MAO INHIBITION P0373
HYDRALAZINE 0 TYRANINE TEST INC V INC RESPONSIVENESS P0417
MAO INHIBITORS 0 TYPAMINE TEST INC V ENHANCED RESPONSIVENESS 90373
METHYLDOPA 0 TYRANINE TEST INC V ENHANCED RESPONSIVENESS REPORTED P0417
ASCORBIC ACID S TYROSIN! DEC V REDUCES ELEVATED LEVEL IN PREMATURE INFANTS P0384
ETHINYLESTRADIOL S TYROSINE DEC V INDUCTION OF TYPOSINF-TPANSAMINASE BY STEROID P0796
OPAL CONTRACEPTIVE S TYPOSINE DEC V HORMONAL EFFECT (SECOND PART OF CYCLE) P0226
SLEEP S TYPOSINE DEC V 18% DECREASE DURING SLEEP . P1025
CHLORDIAZEPOXIDE S T3 UPTAKE DEC V ?ANTITHYRDID EFFECT (RESIN TEST AFFECTED) P0075
DIAZEPAM S T3 UPTAKE DEC V RESIN TEST AFFECTED P0596
ESTROGENS S T3 UPTAKF DEC V INCREASES BINDING CAPACITY OF TBG P0997
LITHIUM S T3 UPTAKE DEC V REPORTED TO INDUCE MYXEDEMA P0597
METHINAZOLE S T3 UPTAKE DEC V THERAPEUTIC RESULT P01408
ORAL CONTRACEPTIVE S T3 UPTAKE DEC V FALLS FROM 80 -100% TO 55 - 90% (RESIN TEST) P0186
PERPHENAZINE S T3 UPTAKE DEC V OCCURS WITH PROLONGED USE P0620
PROPYLTHIOURACIL S T3 UPTAKE DEC V ACTION OF DRUG P0417
THIAZIDES S T3 UPTAKE DEC V SLIGHT EFFECT OBSERVED ONLY P0642
ACETYLSALICYLIC AC S T3 UPTAKE INC V RED CELL UPTAKE AFFECTED ALSO AFFECTS RESIN TEST P0299
BISHYDPOXYCOUNARIN S T3 UPTAKE INC V P!D CELL UPTAKE AFFECTED P01814
DEXTROTHYROXINE S T3 UPTAKE INC V MECHANISM NOT DISCUSSED P0417
DIPHENYLNYDANTOIN S T3 UPTAKR INC V AFFECTS BOTH RESIN AND RED CELL UPTAKE P0417
HALOFENATE S T3 UPTAKE INC V RESIN UPTAKE INC BY 20% AFTER 3 WEEKS P0674
HEPARIN S T3 UPTAKE INC V RED CELL UPTAKE INC, RESIN UNAFFECTED P0828
LIOTRIX S T3 UPTAKE INC V INCREASES BUT REMAINS WITHIN NORMAL RANGE P0467
NANDROLONE S T3 UPTAKE INC V ANABOLIC EFFECT 90708
PHENYLBUTAZONE S T3 UPTAKE INC V RESIN AND RED CELL UPTAKE AFFECTED P0838
THYROID S T3 UPTAKE INC V CONSEQUENCE OF TREATMENT P0417
LEVODOPA S T3 UPTAKE Z V NO EFFECT OBSERVED IN CHRONIC TREATMENT P0509
NOR!THINDRONE S T3 UPTAKE Z V WHEN TREATMENT RESULTS COMPARED WITH CONTROLS P0085
ESTROGENS S T14 (MURPHY-PATTEE) INC V INCREASES BINDING CAPACITY OF TBG P0997
HALOFENATE S T4 (NURPHY-PATTEE) INC V SIGNIFICANT INCREASE OBSERVED P0674
OPAL CONTRACEPTIVE S T14 (NUPPHY-PATT!E) INC V INCREASED BINDING PROTEIN AVAILABLE(!FFECT 2-14 WKS) P0827
IODOTHIOURACIL S T4 (MURPHY-PATTEE) Z N NO EFFECT ON METHOD P0596
CORTICOTROPIN S UIBC DEC V DECREASE IN IRON BINDING GLOBULIN P1001
I9ON D!XTRAN S UIBC DEC V DUE TO INCREASED AVAILABILITY OF IRON P0620
IRON SALTS S UIBC DEC V EFFECT OF I.M. IRON P0355
DIURNAL VAPIATION U UREA CLEARANCE DEC V CLEARANCE LEAST IN MORNING P0143
ERECT POSTURE U UREA CLEARANCE DEC V DECREASE OBSERVED AFTER RISING P0143
MUSCULAR EXERCISE U UREA CLEARANCE DEC V RESPONSE TO STRESS OF EXERCISE R0184
DIURETICS U UREA CLEARANCE INC V NAY BE OBSERVED AFTER USE OF DIURETICS 90143
MEALS U UREA CLEARANCE Z V NO SIGNIFICANT EFFECT OF MEALS OBSERVED P0143
M!TPIFONATE U UREA CLEARANCE Z V NO EFFECT REPORTED ON RENAL FUNCTION P0657
ACETOHYDPOXAMIC AC S UREA NITROGEN DEC V INHIBITION OF UREASE (LIMITED IN VIVO EFFECT) P0906
CHLORANPHENICOL S UREA NITROGEN DEC M INHIBITS BERTHELOT REACTION P0907
FLUORIDES S UREA NITROGEN DEC N UPEASE ACTIVITY INHIBITED BY FLUORIDE P0181
GLASSWARE S UREA NITROGEN DEC N IF MERCURY PRESENT AFFECTS NESSLERIZATION R1001
GLUCOSE S UREA NITROGEN DEC V PROTEIN SPARING !FFECT OF GLUCOSE AND HEMODILUTION P1001
GROWTH HORMONE S UREA NITROGEN DEC V METABOLIC EFFECT 90649
HEMOLYSIS S UREA NITROGEN DEC N RED CELL CONC LESS THAN SERUM P0181
MERCURY COMPOUNDS S UREA NITROGEN DEC N INHIBITS UPEASE (NOTE PRESENT IN NESSLEPS REAGENT) P0436
PHENOTHIAZINES S UREA NITROGEN DEC V DEC UREA PRODUCTION IF HEPATIC CIRRHOSIS OCCURS P0204
PREGNANCY S UREA NITROGEN DEC V MARKED ANABOLIC STATE ESP IN FIRST 6 MONTHS P1001
STREPTOMYCIN S UREA NITROGEN DEC N INHIBITS BERTHELOT REACTION P0907
THYMOL S UREA NITROGEN DEC N INHIBITS UR.EASE AFFECTING RESULTS P0355
BACTERIAL CONTAN U UREA NITROGEN DEC N RAPID EVOLUTION OF NH3 CHANGES PH, LOSS OF NH3 P01436
FORMALDEHYDE U UREA NITROGEN DEC N INHIBITS UREASE (CAN NOT BE USED AS PRESERVATIVE) P01436
GLASSWARE U UREA NITROGEN DEC N IF MERCURY PRESENT AFFECTS NESSLERIZATION 91001
PREGNANCY U UREA NITROGEN DEC V ESP IN FIRST 6 MONTHS RO291
ACETAMINOPHEN S UREA NITROGEN INC V PEVERSIBLE TUBULAR NECROSIS REPORTED P0137
ACETAZOLANIDE S UREA NITROGEN INC V MAY OCCUR WITH PROLONGED TREATMENT P0596
ACETOHEXAMIDE S UREA NITROGEN INC N CHEM. STRUCT. AUSES TO BE MEAS. BY DIACETYL REACT. P0204
ACETONE S UREA NITROGEN INC N TURBIDITY IN N!SSLEPIZATION PROCEDURES P0436
ACETOPHENETIDIN S UREA NITROGEN INC V MAY CAUSE AZOTEMIA P0620
ACETYLSALICYLIC AC S UREA NITROGEN INC V MAY HAVE NEPHPOTOXIC EFFECT P0955
ALKALINE ANTACIDS S UREA NITPOCEN INC V PROLONGED USE NAY CAUSE NEPHROTOXICITY 90596
ALLANTOIN S UREA NITROGEN INC N REACTS WITH XANTHYDPOL IN METHOD OF FOSS! 901436
ALLOPUPINOL S UREA NITROGEN INC V AZOTEMIA AS SENSITIVITY REACTION IN 2 CASES P0665

AMILORIDE S UREA NITROGEN INC V MAY OCCUR WITH EXCESSIVE SALURESIS 90657
AMINO ACIDS S UREA NITROGEN INC N MAY REACT WITH BERTHELOT IF UREASE NOT USED R0779
AMINO ACIDS S UREA NITROGEN INC V AS RESULT OF I.V. INFUSION R03149
AMINOPHENOL S UREA NITROGEN INC N MAY REACT IN BERTHELOT PROCEDURE 90510
ANINOPYRINE S UREA NITROGEN INC V RARE SUGGESTION OF NEPHPOTOXIC ACTION 90657
AMINOSALICYLIC AC S UREA NITROGEN INC M REACTS AS UREA WITH DINETHYLAMINOBENZALDEHYDE 90907
AMMONIUM SALTS S UREA NITROGEN INC M IF UREASE USED AND AMMONIA MEASURED 90436
AMPHOTERICIN B S UREA NITROGEN INC V NEPHROTOXIC EFFECT P0620
ANABOLIC STEROIDS S UREA NITROGEN INC V IMPROVES NITROGEN BALANCE 90204
ANDPOG!NS S UREA NITROGEN INC V AUGMENTS NITROGEN BALANCE 90204
ANTIMONY COMPOUNDS S UREA NITROGEN INC V NEPHROTOXIC EFFECT (COMMON AT THERAPEUTIC DOSES) 90299
ARCININE S UREA NITROGEN INC V INCORPORATED INTO UREA CYCLE 90026
ARSENICALS S UREA NITROGEN INC V NEPHROTOXIC EFFECT (COMMON WITH THERAPEUTIC DOSES) 903814
ASPARACINASE S UREA NITROGEN INC V OCCURS IN 50% SUBJECTS (PRERENAL ORIGIN) R027
ASPABACINE S UREA NITROGEN INC N BLUE COLOR WITH BERTHELOT’S REAGENT 90530
BACITRACIN S UREA NITROGEN INC V PENAL TOXICITY (ESPECIALLY IF GIVEN I.V.) 30384
BISMUTH SALTS S UREA NITROGEN INC MAY CAUSE RENAL FAILURE 90657
BLOOD TRANSFUSIONS S UREA NITROGEN INC V CATABOLISM OF INFUSED PROTEIN 90299
BORIC ACID S UREA NITROGEN INC V TOXICITY EFFECT WITH ACUTE TUBULAR NECROSIS 90204
BOXIDINE S UREA NITROGEN INC V POSSIBLE RELATIONSHIP TO TUMOR DESTRUCTION 90351
BRONAT! S UREA NITROGEN INC V ANURIA AND AZOTEMIA MAY OCCUR WITHIN HOURS P0368
BUSULFAN S UREA NITROGEN INC V RENAL DAMAGE MAY OCCUR FROM UPATE DEPOSITION P0384
CALCIUM SALTS S UREA NITROGEN INC V AZOTEMIA WITH MILK-ALKALI SYNDROME 90384
CAPPEONYCIN S UREA NITROGEN INC V NEPHPOTOXIC EFFECT (IN 6% SUBJECTS) P0384
CAPBAMAZEPINE S UREA NITROGEN INC V MAY CAUSE KIDNEY DYSFUNCTION P0026
CARBENOXOLONE S UREA NITROGEN INC V DUE TO NEPHROPATHY WITH HYPOKALEMIA R007
CARBON DISULFIDE S UREA NITROGEN INC V PENAL IMPAIRMENT OBSERVED 90254
CARBUTAMID! S UREA NITROGEN INC V NEPHROTOXIC EFFECT 90620
CEPHALORIDINE S UREA NITROGEN INC V HIGH DOSES, NEPHROTOXICITY REPORTED P0029
CEPHALOTHIN S UREA NITROGEN INC V RARE ELEVATION NOTED (POSSIBLE NEPHROTOXICITY) P0298
CHLOPAL HYDRATE S UREA NITROGEN INC N REACTS WITH NESSLER REACTION 90907
CHLORAMPHENICOL S UREA NITROGEN INC N REACTS WITH NESSLER REAGENT 90907
CHLOROBUTANOL S UREA NITROGEN INC M FALSE INCREASE WITH DIRECT NESSLEPIZATION 901436
CRLOPTHALIDON! S UREA NITROGEN INC V NEPHPOTOXIC EFFECT 90021
CLONIDINE S UREA NITROGEN INC V ASSOCIATED WITH DECREASED GFR AT START OP THERAPY 90773
COLISTIMETHATE S UREA NITROGEN INC V NEPHROTOXIC EFFECT (USUALLY REVERSIBLE) 90620
COLISTIN S UREA NITROGEN INC V NEPHPOTOXIC EFFECT/MAY OCCUR AFTER LARGE DOSES 90620
CREATINE S UREA NITROGEN INC M MAY REACT WITH BEPTHELOT IF UREASE NOT USED P0779
CREATININ! S UREA NITROGEN INC M INC CONCS AFFECT NESSLERIZATION METHODS SLIGHTLY 901436
CREMOMYCIN S UREA NITROGEN INC V DEHYDRATION NAY SIMULATE PENAL DISEASE 90026
DEMECLOCYCLINE S UREA NITROGEN INC V DOSE RELATED NEPHROTOXICITY 90572
DEXTRAN S UREA NITROGEN INC V BLOCKS TUBULES CAUSING PENAL FAILURE 90203
DEXTRAN S UREA NITROGEN INC N REACTS AS IF UREA WITH DIMETHYLAMINOBENZALD!HYDE P0907
DIATRIZOATE S UREA NITROGEN INC V HAS CAUSED ACUTE RENAL FAILURE WITH MYELOGRAPHY 90621
DINITROPHENOL S UPEA NITROGEN INC V REPORTED TO CAUSE PENAL DAMAGE 90384
DIPYRONE S UREA NITROGEN INC V REPORTED TO CAUSE ANURIA 90026
DIURETICS S UREA NITROGEN INC V REDUCED CLEARANCE 90723
DOXAPRAM S UREA NITROGEN INC V ? NEPHROTOXIC EFFECT 90299
DOXYCYCLINE S UREA NITROGEN INC V NEPHROTOXIC EFFECT 90734
EDTA S UREA NITROGEN INC V NEPHROTOXICITY (ESP CA EDTA) 30355
ETHACRYNIC ACID S UREA NITROGEN INC V MAY CAUSE DETERIORATION IF PENAL FUNCTION IMPAIRED 90029
ETHOSUXIMIDE S UREA NITROGEN INC V POSSIBLE REVERSIBLE NEPHPOPATHT P0026
FIBRINOLYSIN S UREA NITROGEN INC V PENAL FAILURE REPORTED (PARE COMPLICATION) R0026
FUROSEMIDE S UPEA NITROGEN INC V ?NEPHPOTOXIC EFFECT(PEVERSIBLE) USUALLY DEHYDRATION P0029
GENTAMICIN S UREA NITROGEN INC V N!PHPOTOXIC EFFECT WITH LARGE DOSES 90596
GUANETHIDINE S UREA NITROGEN INC V ASSOC WITH BLOOD PRESSURE PEDUCTION, DEC BLOOD FLOW P0467
GUANETHIDINE S UREA NITROGEN INC M DUE TO CHEM SIMILARITY TO UREA R0029
GUANOCHLOP S UREA NITROGEN INC V MAY DECREASE RENAL BLOOD FLOW P0299
CUANOXAN S UREA NITROGEN INC V DUE TO DECREASED BLOOD FLOW 90596
HEMOGLOBIN S UREA NITROGEN INC M NAY AFFECT COLOR OF UPEASE/BERTHELOT PROCEDURE 90779
HEMOLYSIS S UREA NITROGEN INC N COLOR PRODUCED IN PROTEIN-FREE FILTRATES 90181
HYDPOCHLOPOTHIAZIDE S UREA NITROGEN INC V MAY OCCUR WITH PROLONGED THERAPY R0596
HYDROFLUNETHIAZIDE S UREA NITROGEN INC V MAY OCCUR ESP IF PREEXISTING PENAL DISEASE 90467
IMMUNE SERA S UREA NITROGEN INC V NEPHRITIS MAY OCCUR WITH SERUM SICKNESS 90657
INDOMETHACIN S UREA NITROGEN INC V OCCASIONAL INC USUALLY TO UPPER NORMAL LIMIT 90659
ISOSORBIDE S UREA NITROGEN INC V DEHYDRATION WITH OVERDOSAGE 90871
KANANYCIN S UREA NITROGEN INC V NEPHROTOXIC EFFECT (COMMON SLIGHT ELEVATION) 90021
KEROSENE S UREA NITROGEN INC V PENAL DAMAGE WITH LARGE DOSES p03814
LEVODOPA S UREA NITROGEN INC V AFFECTS HEPATIC ENZYMES, PROBABLY NOT DEHYDRATION P0616
LICORICE S UREA NITROGEN INC V MAY CAUSE NEPHROPATHY 90669
LIPEMIA S UREA NITROGEN INC N MAY AFFECT BERTHELOT REACTION P0510
LIPOMUL S UREA NITROGEN INC V POSSIBLE NEPHPOTOXIC EFFECT 902014
NAPIHUANA S UREA NITROGEN INC V REPORTED EFFECT R0596
NEF!NAMIC ACID S UREA NITROGEN INC V REPORTED IN ONE STUDY WITH NORMAL VOLUNTEERS 90026
M!LPHALAN S UREA NITROGEN INC V AZOT!MIA MAY OCCUR 90026
MEPHENESIN S UREA NITROGEN INC V FATAL ANUPIA WITH INTRAVASCULAR HENOLYSIS R03814
METHACYCLINE S UREA NITROGEN INC V POSSIBLE NEPHROTOXICITY P0026
METHICILLIN S UPEA NITROGEN INC V MAY CAUSE AZOTENIA WITH NEPHPOTOXICITY 90026
METHOXYFLURANE S UREA NITROGEN INC V IMPAIRED PENAL TUBULAR FUNCTION 90229
NETHSUXIMIDE S UREA NITROGEN INC V PENAL DAMAGE REPORTED 90026
NETHYCLOTHIAZIDE S UREA NITROGEN INC V SLIGHT CHANGE ONLY 90386
METHYLBRONIDE S UREA NITROGEN INC V LATE EFFECT WITH TUBULAR NECROSIS OF POISONING P0368
METHYLDOPA S UREA NITROGEN INC V ?DUE TO DECREASED RENAL BLOOD FLOW R100I
METHYSEPGIDE S UREA NITROGEN INC V POSSIBLE DEC IN ALREADY IMPAIRED RENAL FUNCTION 90029
NETOLAZONE S UREA NITROGEN INC V DIURETIC ACTION OF DRUG ACTING ON DICTAL TUBULES P0739
MITHRAMYCIN S UREA NITROGEN INC V NEPHPOTOXIC EFFECT 90026
P!ITOMYCIN C S UREA NITROGEN INC V NEPHROTOXIC EFFECT 90589
NALIDIXIC ACID S UREA NITROGEN INC V MAY CAUSE NITROGEN RETENTION 90736
NEONYCIN S UREA NITROGEN INC V NEPHROTOXIC EFFECT 90299
NITROFUPA NTOIN S UPEA NITROGEN INC V POSSIBLE DEC IN ALREADY IMPAIRED PENAL FUNCTION 90029

OXACILLIN S UREA NITROGEN INC V TRANSIENT AZOT!MIA WITH LARGE DOSES P00 26
OXALATES S UREA NITROGEN INC N “BALANCED” OXALATE MIXTURE CONTAINS NH4 P0436
OXYPHENBUTAZONE S UREA NITROGEN INC V MAY OCCUR WITH PENAL DAMAGE P0596
PAPALDEHYDE S UREA NITROGEN INC V POSSIBLE NEPHROTOXICITY IN POISONING P01407
ARANETHADION! S UREA NITROGEN INC V POSSIBLE NEPHPOTOXICITY P06 20
PARGYLINE S UREA NITROGEN INC V POSSIBLE DEC IN ALREADY IMPAIRED PENAL FUNCTION P0029
PAROMONYCIN S UREA NITROGEN INC V POTENTIALLY NEPHPOTOXIC IF GIVEN PARENTERALLY P0026
PENICILLAMIN! S UREA NITROGEN INC V POSSIBLE NEPHROTOXICITY P0355
PENTAMIDINE S UREA NITROGEN INC V REVERSIBLE RENAL DYSFUNCTION REPORTED P0 384
PERCHLORATE S UREA NITROGEN INC V REPORTED CASES OF NEPHROTIC SYNDORME P00 26
PHENACEMIDE S UREA NITROGEN INC V OCCASIONAL NEPHROPATHY R0026
PHENAZOPYPIDINE S UREA NITROGEN INC V TRANSIENT ACUTE RENAL FAILURE REPORTED R0026
PHENFORMIN S UREA NITROGEN INC V USUALLY FOUND IF LACTATE ELEVATED BY PHENFORNIN P06 08
PHENINDIONE S UREA NITROGEN INC V NEPHROTOXICITY MAY OCCUR WITH TUBULAR NECROSIS P0 384
PHENIODOL S UREA NITROGEN INC V REPORTED TO CAUSE PENAL FAILURE P002 0
PHENSUXIMIDE S UREA NITROGEN INC V REVERSIBLE NEPHROPATHY (ESP IN CHILDREN) P00 26
PHENYLBUTAZONE S UREA NITPOGEN INC V REPORTED NEPHROTOXIC EFFECT P0 62 0
PHOSPHORUS S UREA NITROGEN INC V N!PHROTOXIC EFFECT P06 20
POLYNYXIN B S UREA NITROGEN INC V NEPHROTOXIC EFFECT P02 99
PROBENECID S UREA NITROGEN INC V POSSIBLE NEPHROTOXICITY P04 17
PROPRANOLOL S UREA NITROGEN INC V POSSIBLE LOW INCIDENCE DRUG RELATED EFFECTS P06 57
PROPYLTHIOURACIL S UREA NITROGEN INC V ANAPHYLACTIC NEPHEITIS REPORTED P0026
PYRAZOLONES S UREA NITROGEN INC V MAY CAUSE NEPHPOTOXICITY R0355
QUINETHAZONE S UREA NITROGEN INC V OBSERVED EFFECT (?DUE TO DEHYDRATION) P0657
QUININE S UPEA NITROGEN INC V MAY CAUSE RENAL DAMAGE (RARE) P03814
RADIOGRAPHIC S UREA NITROGEN INC V MAY PRODUCE AZOTEMIA OP RENAL FAILURE P0026
RIFAMPIN S UREA NITROGEN INC V TEMPORARY PENAL FAILURE REPORTED P0281
SODIUM IPODATE S UREA NITROGEN INC V NEPHROTOXIC EFFECT P026 0
SPECTINOMYCIN S UREA NITROGEN INC V MECHANISM NOT DISCUSSED P00145
STREPTOKINAS! S UREA NITROGEN INC V RENAL TUBULAR DAMAGE IN ON! CASE P02 014
STREPTOMYCIN S UREA NITROGEN INC V NEPHPOTOXICITY MAY OCCUR IN 2% 90736
SULFONAMIDES S UREA NITROGEN INC V RAPE UREMIA NAY OCCUR WITH/WITHOUT CRYSTALLURIA P03 814
SULFONAMIDES S UREA NITROGEN INC N REACTS LIKE UREA WITH DMABA & BEPTHELOT REACTIONS P0907
TAPTPAT!S S UREA NITROGEN INC V IF ABSORBED NAY CAUSE RENAL DAMAGE 90384
TETRACYCLINE S UREA NITROGEN INC V ANTI-ANABOLIC ACTION, AMINO ACIDS DEGRADED TO UREA P0 153
THIAZIDES S UREA NITROGEN INC V NEPHROTOXIC EFFECT IN LARGE DOSES P0299
THIOCYANATES S UREA NITROGEN INC V MAY CAUSE NEPHROSIS 90384
THIOUREA S UREA NITROGEN INC N REACTS WITH XANTHYDPOL IN METHOD OF FOSS! P01436
TRIANTEPENE S UREA NITROGEN INC V NEPHROTOXIC EFFECT (WITH EXCESSIVE DIUPESIS) P0367
TPIMETHADIONE S UREA NITROGEN INC V NEPHPOPATHY REPORTED P0026
UREA S UREA NITROGEN INC V WHEN MASSIVE INFUSION FOP SICKLE-CELL DISEASE P06 30
URIC ACID S UREA NITROGEN INC N NAY REACT WITH BERTHELOT IF UPEASE NOT USED 90779
VANCOMYCIN S UREA NITROGEN INC V NEPHROTOXIC EFFECT (MAY EVEN BE FATAL) P0355
VINYL ETHER S UREA NITROGEN INC V POTENTIALLY NEPHROTOXIC 90026
VIOMYCIN S UPEA NITROGEN INC V FREQUENT COMPLICATION P03 84
VITAMIN 0 5 UREA NITROGEN INC V MANIFESTATION OF HYPERVITAMINOSIS D 90026
CHLORPPOMAZINE T UREA NITROGEN INC N PRODUCES TURBIDITY WITH BERTHELOT’S REAGENT P0530
LUTAMIN! T UREA NITROGEN INC N BLUE COLOR WITH BEPTHELOTS REAGENT 90530
IMIPRAMINE T UREA NITROGEN INC N PRODUCES TURBIDITY WITH BERTHELOT’S REAGENT P0530
NIALANID! T UREA NITROGEN INC N BILIOUS YELLOW-GREEN WITH BERTHELOT’S REAGENT P0530
WORZPINEPHPINE T UREA NITROGEN INC M BROWN WITH BERTH!LOT’S REAGENT P0530
5-HYDROXYTRYPTAMINE T UREA NITROGEN INC N GREEN COLOR WITH BERTHELOT’S REAGENT P0530
PROTEIN U UREA NITROGEN INC V INC IN PROPORTION TO PROTEIN INTAKE 90291
ACETYLSALICYLIC AC S UREA NITROGEN Z N NO EFFECT ON BERTHELOT PROCEDURE P05 10
ALANINE S UREA NITROGEN Z M NO EFFECT ON BERTHELOT REACTION P05 10
ARGININ! S UREA NITROGEN Z M NO EFFECT ON B!RTHELOT REACTION 9051 0
BILIPUBIN S UREA NITROGEN Z N NO EFFECT ON BEPTHELOT REACTION P05 10
CREATININE S UREA NITROGEN Z N NO EFFECT ON BERTHELOT PROCEDURE P05 10
EDTA S UREA NITROGEN Z M NO EFFECT ON ANALYTICAL METHODS REPORTED P0436
GLUCOSAMINE S UREA NITROGEN Z M NO EFFECT ON BEPTHELOT REACTION P05 10
GUANIDINE S UREA NITROGEN Z N NO EFFECT ON BERTHELOT REACTION P0510
HISTIDINE S UREA NITROGEN Z N NO EFFECT ON BERTHELOT REACTION P0510
LYSINE S UREA NITROGEN Z N NO EFFECT ON BEPTHELOT REACTION P0510
MEALS S UREA NITROGEN Z V NO EFFECT REPORTED AFTER STANDARD BREAKFAST P0 18 1
PHENYLALANINE S UREA NITROGEN Z N NO EFFECT ON BEPTHELOT REACTION P05 10
SULFADIAZINE S UREA NITROGEN Z N NO EFFECT ON BERTHELOT PROCEDURE R0510
THYMOL U UREA NITROGEN Z N NO EFFECT ON BERTHELOT METHOD 90779
ANGIOTENSIN U URIC ACID CLEARANCE DEC V LARGE DECREASE FOLLOWING ADMINISTRATION 90657
DIAZOXIDE U URIC ACID CLEARANCE DEC V EFFECT OVER 2H OF 4MG/KG GIVEN I.?. P05 01
EPIN!PHPINE U URIC ACID CLEARANCE DEC V SHARP FALL FOLLOWING I.M. INJECTION P0 657
NICOTINIC ACID U URIC ACID CLEARANCE DEC V DECREASES BY 75%, ?DUE TO ALTERED TUBULAR HANDLING P03 60
NOREPINEPHRINE U URIC ACID CLEARANCE DEC V SHARP FALL AFTER I.V. INFUSION P0657
THIAZIDES U URIC ACID CLEARANCE DEC V DECREASED RENAL CLEARANCE P0 657
FRUCTOSE U URIC ACID CLEARANCE INC V DOSE RELATED EFFECT P0815
PHLORIDZIN U URIC ACID CLEARANCE INC V PROBABLY INHIBITS TUBULAR REABSORPTION 90878
ACETOHEXAMID! S URIC ACID DEC V MILD URICOSURIC ACTION P1018
ACETYLSALICYLIC AC S URIC ACID DEC V MILD UPICOSURIC ACTION (LARGE DOSE EFFECT) P02014
ALLOPITRINOL S URIC ACID DEC V INHIBITION OF XANTHINE OXIDASE P0299
AZATHIOPRINE S URIC ACID DEC V IN PATIENTS WITH GOUT DECREASES CONCENTRATION 90888
BENZIODARON! S URIC ACID DEC V STIMULATES SECRETION OF URATE 90388
BISCOUMACETATE S URIC ACID DEC V URICOSUPIC ACTION 901404
BISHYDROXYCOUNARIN S UPIC ACID DEC V UPICOSURIC ACTION P0039
CADMIUM S URIC ACID DEC V GENERALIZED IMPAIRMENT OF PROX TUBULAR FUNCTION P0006
CHLOROTHIAZIDE S URIC ACID DEC V IF GIVEN I.V. IN LARGE DOSES HAS URICOSURIC EFFECT P0404
CHLORPPONAZINE S URIC ACID DEC V URICOSURIC ACTION WITHIN 2-3 DAYS P0907
CHLOPPPOTHIXENE S URIC ACID DEC V UPICOSURIC EFFECT WITHIN 2-3 DAYS OF START OF DRUG P0907
CINCHOPHEN S URIC ACID DEC V URICOSUPIC ACTION P062 0
CLOFIBRATE S URIC ACID DEC V OCCURS IN ABOUT 10% (MAY OCCASIONALLY CAUSE GOUT) P00 16
CORTICOST!POIDS S URIC ACID DEC V PRODUCES NEGATIVE NITROGEN BALANCE P062 0
CORTICOTROPIN S URIC ACID DEC V URICOSUPIC ACTION R0404

COUMARIN S URIC ACID DEC V URICOSURIC EFFECT 90355
CYANIDES S URIC ACID DEC M URICASE IS SENSITIVE TO CYANIDE P0436
DIATRIZOATE S URIC ACID DEC V URICOSURIC EFFECT 90680
ETHACRYNIC ACID S URIC ACID DEC V IF GIVEN I.V. IN LARGE DOSES HAS URICOSUPIC EFFECT P0895
GLUCOSE S URIC ACID DEC V INCREASED URATE CLEARANCE ALSO SEEN IN DIABETICS P0877
GRISEOFULVIN S URIC ACID DEC V EFFECTIVE IN TREATMENT OF GOUT ?NECHANISM 90972
HALOFENATE S URIC ACID DEC V UPICOSURIC ACTION 90674
HYDROXYHEXAMIDE S URIC ACID DEC V MILD URICOSUPIC ACTION P1018
INDOMETHACIN S URIC ACID DEC V OF SOME VALUE IN TREAT OF GOUTY ARTHRITIS P0378
IODIPANIDE S URIC ACID DEC V URICOSURIC EFFECT 90680
IODOPYRACET S URIC ACID DEC V URICOSUPIC ACTION 90404
IOPANOIC ACID S URIC ACID DEC V UBICOSURIC EFFECT P0680
IPODATE S URIC ACID DEC V URICOSURIC EFFECT P0680
LITHIUM S URIC ACID DEC V REPORTED TO HAVE URICOSURIC EFFECT P0052
NANNITOL S URIC ACID DEC V REPORTED TO HAVE URICOSURIC ACTION 903144
MAPIHUANA S URIC ACID DEC V REPORTED EFFECT 90596
MERSALYL S URIC ACID DEC V URICOSURIC ACTION 90404
OXYPHENBUTAZONE S URIC ACID DEC V URICOSUPIC EFFECT 90217
PHENOTHIAZINES S URIC ACID DEC V REPORTED URICOSURIC ACTION 30596
PHENYLBUTAZONE S URIC ACID DEC V URICOSURIC ACTION AT HIGH DOSES 904014
PH!NYLINDANDIONE S URIC ACID DEC V URICOSURIC ACTION P04014
PROBENECID S URIC ACID DEC V URICOSURIC ACTION P01404
PSP S URIC ACID DEC V URICOSURIC ACTION 90404
SALINE S URIC ACID DEC V DIMINISHES URATE REABSORPTION 90897
SULFINPYRAZONE S URIC ACID DEC V URICOSURIC ACTION 90404
VINBLASTINE S URIC ACID DEC V OF THEORETICAL VALUE IN ACUTE GOUT 90378
W-23514 S UPIC ACID DEC V MARKED ANTI-GOUT RESPONSE 901488
ACETAZOLANIDE U URIC ACID DEC V INHIBITION OF TUBULAR SECRETION OF UPATE RO299
ACETOACETAT! U URIC ACID DEC V INHIBITS TUBULAR SECRETION OF URATE P0377
ACETYLSALICYLIC AC U URIC ACID DEC V LOW DOSES EFFECT P1001
ALLOPUPINOL U URIC ACID DEC V INHIBITION OF XANTHINE OXIDASE 90299
ANGIOTENSIN U URIC ACID DEC V DECREASES URATE EXCRETION AND PENAL PLASMA FLOW P0324
AZATHIOPRINE U URIC ACID DEC V IN PATIENTS WITH GOUT REDUCES EXCRETION P0888
B-HYDROXYBUTYRATE U URIC ACID DEC V INHIBITS TUBULAR SECRETION OF URATE 90377
BERYLLIUM SALTS U URIC ACID DEC V NEPHROPATHY ASSOC WITH DEC EXCRETION PER NEPHRON 90520
CHLOROTHIAZIDE U URIC ACID DEC V IMPAIRED CLEARANCE 90596
CHLORTHALIDONE U URIC ACID DEC V DECREASED CLEARANCE 90596
CITRATES U URIC ACID DEC V ANTAGONISM OF UPICOSURIC EFFECT P0355
DIAZOXIDE U URIC ACID DEC V EFFECT OVER 2H OF 14MG/KG GIVEN I.V. P0501
ETHACPYNIC ACID U URIC ACID DEC V DECREASED ORATE CLEARANCE RO299
ETHANOL U URIC ACID DEC V MECHANISM OBSCURE 903814
ETHOXAZOLAMIDE U URIC ACID DEC V DECREASES URATE CLEARANCE P05%
HYDROCHLOROTHIAZIDE U URIC ACID DEC V DECREASED UPATE CLEARANCE P0596
LACTATE U URIC ACID DEC V INHIBITS TUBULAR SECRETION OF URATE 91019
LEAD U URIC ACID DEC V NEPHROPATHY ASSOC WITH DEC SECRETION PER NEPHRON P0069
L!VAPTEPENOL U URIC ACID DEC V DECREASES URATE EXCRETION AND RENAL PLASMA FLOW P03214
NICOTINIC ACID U URIC ACID DEC V DECREASES BY APPOXIMATELY 50% 90360
PPOBENECID U URIC ACID DEC V SMALL DOSES DEPRESS SECRETION P0384
PYRAZINAMIDE U URIC ACID DEC V INCREASED TUBULAR REABSORPTION OF UPATE RO832
STORAGE OF SAMPLE U URIC ACID DEC N AT ANY TEMPERATURE UNLESS ALKALI ADDED P0771
THIAZID!S U URIC ACID DEC V DECREASED PENAL EXCP!TION(18% IN LONG TERM) P0089
ACETAMINOPHEN S URIC ACID INC N FALSELY HIGH VALUES WITH PHOSPHOTUNGSTATE METHODS P0370
ACETAZOLAMID! S URIC ACID INC V DECREASED UPATE CLEARANCE 90299
ACETOACETATE S URIC ACID INC V INHIBITS TUBULAR SECRETION OF URATE P0377
ACETOPH!NETIDIN S URIC ACID INC N MEASURED AS URIC ACID BY SMA 12/60 METHOD P0876
ACETYLAMINOPHENOL S URIC ACID INC N REACTS AS IF URIC ACID WITH SMA 12/60 METHOD P0876
ACETYLSALICYLIC AC S URIC ACID INC V SMALL DOS! EFFECT P0596
ACETYLSALICYLIC AC S URIC ACID INC V LOW DOSES REDUCE PENAL EXCRETION OF URIC ACID 91001
AC!TYLSALICYLIC AC S URIC ACID INC N ACTS AS REDUCING SUBST WITH NON-SPECIFIC METHODS P01417
ALUMINUM NICOTINATE S URIC ACID INC V MAY INCREASE URIC ACID TO PRODUCE GOUT 90040
ANINOPHENOL S URIC ACID INC N AT 1 MMOL/L AFFECTS SMA 12/60 AND HENRY METHODS 90876
AMINOPHYLLINE S URIC ACID INC M REACTS AS IF URIC ACID IN METHOD OF BITTNER 90724
ANABOLIC STEROIDS S URIC ACID INC V IMPROVES NITROGEN BALANCE P0620
ANDPOC!NS S URIC ACID INC V AUGMENTS NITROGEN BALANCE P0620
ANGIOTENSIN S URIC ACID INC V REDUCED UPATE CLEARANCE IF GIVEN I.V. 90324
ANTINEOPLASTIC S URIC ACID INC V DESTRUCTION OF NtJCLEOPPOTEIN P0042
ASCORBIC ACID S URIC ACID INC M MEASURED AS REDUCING SUBSTANCE 902014
AZATHIOPRINE S URIC ACID INC V RAPID DESTRUCT OF TISSUES AND NUCLEIC AC CATABOLISM P0384
AZATHYMINE S URIC ACID INC V DUE TO TISSUE DESTRUCTION P0620
AZAURIDIN! S URIC ACID INC V DUE TO TISSUE DESTRUCTION P0620
B-HTDPOXYBUTYRATE S URIC ACID INC V INHIBITS TUBULAR SECRETION OF UBATE P0377
BENDROFLUNETHIAZIDE S URIC ACID INC V INHIBITION OF TUBULAR SECRETION OF URAT! P0404
BERYLLIUM SALTS S URIC ACID INC V NEPHROPATHY ASSOC WITH DEC EXCRETION PEP NEPHRON 90520
BLOOD TRANSFUSIONS S URIC ACID INC V CATABOLISM OF INFUSED BLOOD CELLS P0355
BUSULFAN S URIC ACID INC V AS A RESULT OF TISSUE DESTRUCTION 90620
CAPREOMYCIN S URIC ACID INC V NEPHROTOXIC EFFECT ASSOCIATED WITH HYPERURICEMIA P0433
CHLORAL S URIC ACID INC M AFFECTS PHOSPHOTUNGSTATE REDUCTION METHODS R0596
CHLORINE S URIC ACID INC N IF STANDARDS MADE IN CONTAMINATED WATER P0183
CHLOROTHIAZIDE S URIC ACID INC V DECREASED URATE CLEARANCE P0907
CHLOPTHALIDONE S URIC ACID INC V DECREASES URATE CLEARANCE P0159
CITPATES S URIC ACID INC V ANTAGONISM OF URICOSUPIC EFFECT 90355
CLOPEXOLONE S URIC ACID INC V OCCURS AS WITH THIAZIDE DRUGS 90657
COFFEE S URIC ACID INC N COMPONENT OF COFFEE MEASURED (METHOD OF BITTN!R) P0724
CYCLOTHIAZIDE S URIC ACID INC V INHIBITION OF TUBULAR SECRETION OF URATE P01404
DEXTRAN S URIC ACID INC N REDUCES PHOSPHOTUNGSTATE P0596
DIAPAMID! S URIC ACID INC V IMPAIRED EXCRETION P0609
DIAZOXIDE S URIC ACID INC V INHIBITION OF TUBULAR URIC ACID EXCRETION 30501
DIURETICS S URIC ACID INC V REDUCED CLEARANCE 900142
EPINEPHPINE S URIC ACID INC N AT 1 NMOL/L AFFECTS SMA 12/60, HENRY METHODS P0876
EPIN!PHRINE S URIC ACID INC V RESULT OF VASOCONSTRICTION IN KIDNEY P0417

ERGOTHIONINE S URIC ACID INC N FALSELY HIGH VALUES WITH PHOSPHOTUNCSTATE METHODS P0370
ETHACRYNIC ACID S URIC ACID INC V DECREASED UPATE CLEARANCE WITH LOW DOSES P0907
ETHAMBUTOL S URIC ACID INC V REPORTED EFFECT, NO DETAILS GIVEN P0417
ETHANOL S URIC ACID INC V SEEN IN ACUTELY INTOXICATED AND IN RESPONSE TO DIET P0586
ETHOXAZOLAMIDE S URIC ACID INC V DECREASES URATE CLEARANCE P0596
YLUMETHIAZIDE S URIC ACID INC V INHIBITION OF TUBULAR SECRETION OF URATE R01404
FORMALDEHYDE S URIC ACID INC N IF ADDED TO STANDARDS INHIBITS URICASE P0184
FRUCT3SE S URIC ACID INC V FOLLOWING I.V. INFUSION: DOSE RELATED EFFECT P0907
FUPOSEMID! S UPIC ACID INC V DECREASED UPATE CLEARANCE P0907
CENTAMICIN S URIC ACID INC V REPORTED EFFECT OF I.M. INJECTION P07145
GENTISIC ACID S URIC ACID INC N FALSELY HIGH VALUES WITH PHOSPHOTUNGSTATE METHODS P0370
GLUCOSE S URIC ACID INC M REDUCING SUBSTANCE REACTS WITH PHOSPHOTUNGSTATE R0204
GLtJTATHIONE S URIC ACID INC N ACTS AS REDUCING AGENT WITH PHOSPHOTUNGSTATE P0184
HEMOLYSIS S UPIC ACID INC N FALSE POSITIVE WITH GLUTATHIONE AND ERCOTHIONINE P0182
HYDRALAZIN’ S URIC ACID INC N AT 1 MNOL/L AFFECTS SMA 12/60 AND HENRY METHODS 90876
HYDROCHLOROTHIAZIDE S URIC ACID INC V DECREASED UPATE CLEARANCE P0907
HYDROFLUMETHIAZIDE S URIC ACID INC V PROBABLY DUE TO IMPAIRED CLEARANCE 90467
HYOPOXYOPEA S URIC ACID INC V PROBABLE EFFECT OF CELL CATABOLISM P0417
IBUTENAC S URIC ACID INC V SIDE EFFECT SIMILAR TO THAT OF ASPIRIN P0620
LACTATE S URIC ACID INC V INHIBITS TUBULAR SECRETION OF UPATE R1019
LEAD S URIC ACID INC V NEPHROPATHY ASSOC WITH DEC SECRETION PER NEPHPON 90069
LEVAPTERENOL S URIC ACID INC V RESULT OF DECREASED URATE CLEARANCE P0324
LEVODOPA S URIC ACID INC V TWO CASES REPORTED, EXAGGERATED BY FRUCTOSE P0013
LEVODOPA S URIC ACID INC N FALSELY HIGH VALUES WITH PHOSPHOTUNCSTAT! METHODS R0370
LIPOMUL S URIC ACID INC V DECREASED CLEARANCE P0620
NANNOSE S URIC ACID INC V SIMILAR ACTION TO FRUCTOSE P1005
MECAMYLAMINE S URIC ACID INC V ? DUE TO REDUCED PENAL BLOOD FLOW P0275
MECHLOPETHANINE S URIC ACID INC V LEUCOCYTE DESTRUCTION, CATABOLISM OF NUCLEIC ACIDS 90907
MEFRUSIDE S URIC ACID INC V INHIBITS EXCRETION OF URATE 90994
NERCAPTOPURINE S URIC ACID INC V LEUCOCYTE DESTRUCTION, CATABOLISM OF NUCLEIC ACIDS P0907
NEPCAPTOPUPINE S URIC ACID INC N AT 1 MNOL/L AFFECTS SMA 12/60 METHOD P0876
MERCURIAL DIURETICS S URIC ACID INC V NAY PRECIPITATE ATTACKS OF GOUT P0145
NETHICILLIN S URIC ACID INC V NEPHPOTOXIC EFFECT P0620
METHOTREXATE S URIC ACID INC V SEEN IN GOUTY PATIENTS - SOME DEC IN LEUKEMICS 30619
METHOXYFLURANE S URIC ACID INC V DEC URATE CLEARANCE: CONTRACTION OF ECF VOLUME 90631
METHYCLOTHIAZIDE S URIC ACID INC V REDUCES CLEARANCE P0386
METHYLDOPA S URIC ACID INC N INTERFERES WITH PHOSPHOTUNGSTATE PROCEDURE P01417
NETOLAZONE S URIC ACID INC V DIURETIC ACTION OF DRUG ACTING ON DISTAL TUBULES P0739
MITOMYCIN C S URIC ACID INC V DUE TO NEPHROTOXICITY P0589
MORPHAZINAMIDE S URIC ACID INC V DECREASED RENAL CLEARANCE P0657
NICOTINIC ACID S URIC ACID INC V MAY RISE BY UP TO 1.5 NC/100ML IF LARGE DOSES P0721
NOPRPINEPHRINE S URIC ACID INC V REDUCES URINARY EXCRETION P0657
P!MPIDINE S URIC ACID INC V ?DUE TO REDUCED PENAL BLOOD FLOW 90275
PHENELZINE S URIC ACID INC N AT 1 MMOL/L SL AFFECTS SMA 12/60, HENRY METHODS 90876
PHENOTHIAZINES S URIC ACID INC V REPORTED EFFECT P0726
PHENYLBUTAZONE S URIC ACID INC V ANTIURICOSURIC ACTION AT LOW DOSES P014014
PREDNISONE S URIC ACID INC V PROMOTES NUCLEIC ACID CATABOLISM P0907
PPOBUCOL S URIC ACID INC V EFFECT NOTED IN WOMEN ONLY R0247
PROPYLTRIOURACIL S URIC ACID INC N AT 1 MMOL/L AFFECTS SMA 12/60, HENRY METHODS P0876
PROTOCATECHUIC ACID S URIC ACID INC N 9ALSELY HIGH VALUES WITH PHOSPHOTUNGSTATE METHODS R0370
PYRAZINAMIDE S URIC ACID INC V INHIBITS TUBULAR SECRETION OF UPATE P0896
QUINETHAZONE S URIC ACID INC V INC UP TO 4 MC/100NL, INHIBITS TUBULAR SECRETION P0145
RIFAMPIN S URIC ACID INC V TEMPORARY RENAL FAILURE REPORTED P0281
SPIRONOLACTONE S URIC ACID INC V DECREASED UPAT! CLEARANCE R0620
THEOPHYLLINE S URIC ACID INC N REDUCTION OF PHOSPHOTUNGSTATE BY METABOLITES P0596
THIAZIDES S URIC ACID INC V DECREASED RENAL EXCRETION P0355
THIOGUANINE S URIC ACID INC V RAPID DESTRUCT OF TISSUES - NUCLEIC AC CATABOLISM P0384
TRIAMTER!NE S URIC ACID INC V SIGNIFICANT EFFECT IN ABOUT 17% CASES P0417
TRICHLOPMETHIAZIDE S URIC ACID INC V INHIBITION OF TUBULAR SECRETION OF UPATE P0404
VINCPISTINE S URIC ACID INC V INCREASED NUCLEIC ACID CATABOLISM P0907
XYLITOL S URIC ACID INC V INCREASES BY 1.5 TO 2 TINES NORMAL P0277
ACETAMINOPHEN U URIC ACID INC N FALSELY HIGH VALUES WITH PHOSPHOTUNCSTATE METHODS P0370
ACETOHEXAMIDE U URIC ACID INC V URICOSURIC ACTION P01404
ACETOPHEN!TIDIN U URIC ACID INC N MEASURED AS URIC ACID BY SNA 12/60 METHOD P0876
ACETYLAMINOPHENOL U URIC ACID INC N REACTS AS IF URIC ACID WITH SMA 12/60 METHOD P0876
ACETYLSALICYLIC AC U URIC ACID INC N ACTS AS REDUCING SUBST WITH NON-SPECIFIC METHODS P0417
ACETYLSALICYLIC AC U URIC ACID INC V HIGH DOSE EFFECT (GREATER THAN 3 C DAILY) P0299
ASCORBIC ACID U UPIC ACID INC N MEASURED AS REDUCING SUBSTANCE 30436
ASPAPAGINASE U URIC ACID INC V MARKED RESPONSE IF LYSIS OF TISSUES P0705
BENZIODARONE U URIC ACID INC V STIMULATES SECRETION OF UPATE P0388
BISCOUNACETATE U URIC ACID INC V URICOSURIC ACTION P0404
BISHYDPOXYCOUMAPIN U URIC ACID INC V UPICOSUPIC ACTION P014014
CADMIUM U URIC ACID INC V GENERALIZED IMPAIRMENT OF PPOX TUBULAR FUNCTION P0006
CAFFEINE U URIC ACID INC M REDUCTION OF PHOSPHOTUNGSTATE BY METABOLITES P0182
CHLOROTHIAZIDE U URIC ACID INC V IF GIVEN I.V. IN LARGE DOSES HAS URICOSURIC EFFECT P0404
CHLORPPOMAZINE U URIC ACID INC V URICOSURIC ACTION REPORTED P0596
CHLORPPOTHIXENE U URIC ACID INC V URICOSURIC ACTION P01430
CLOFIBRATE U URIC ACID INC V WEAK TRANSIENT URICOSURIC EFFECT P0026
CORTICOTROPIN U URIC ACID INC V URICOSURIC ACTION P0404
COUMAPIN U URIC ACID INC V URICOSURIC EFFECT P0355
DIATRIZOATE U URIC ACID INC V URICOSURIC EFFECT P0680
ERCOTHIONINE U URIC ACID INC N FALSELY HIGH VALUES WITH PHOSPHOTUNGSTATE METHODS R0370
ETHACRYNIC ACID U URIC ACID INC V IF GIVEN I.V. IN LARGE DOSES HAS URICOSURIC EFFECT P0895
FRUCTOSE U URIC ACID INC V DOSE RELATED EFFECT P0815
CENTISIC ACID U URIC ACID INC N FALSELY HIGH VALUES WITH PHOSPHOTUNCSTATE METHODS P0370
GLUCOSE U URIC ACID INC V INFUSIONS HAVE URICOSURIC ACTION P0877
GLYCINE U URIC ACID INC V INC TUBULAR SECRETION ESP IN GOUTY SUBJECTS 91020
HALOFENATE U URIC ACID INC V EFFECT INDEPENDENT OF CFR 90674
HYDROXYHEXAMIDE U URIC ACID INC V MILD URICOSURIC ACTION P1018
IODIPAMIDE U URIC ACID INC V UPICOStJRIC EFFECT P0680

IODOPYR ACET U URIC ACID INC V URICOSUPIC ACTION P0404
IOPANOIC ACID U URIC ACID INC V URICOSURIC EFFECT R0680
IPODATE U URIC ACID INC V URICOSUPIC EFFECT P 0680
LEVODOPA U URIC ACID INC N FALSELY HIGH VALUES WITH PHOSPHOTUNCSTATE METHODS P0370
MANNOSE U URIC ACID INC V GREAT INCREASE AFTER I.V. INFUSION P0115
MEPCAPTOPURINE U URIC ACID INC V INCREASED NUCLEAR PROTEIN BREAKDOWN P03 55
MEPSALYL U URIC ACID INC V URICOSURIC ACTION P0 404
MET HYLDOPA U URIC ACID INC N INTERFERES WITH PHOSPHOTUNGSTATE PROCEDURE P0 355
PHENOTHIAZI NES U URIC ACID INC V REPORTED URICOSURIC ACTION P05 96
P HE NYLB UTA Z ONE U URIC ACID INC V tIRICOSURIC ACTION 90404
PHENYLI NDANDIONE U URIC ACID INC V URICOSURIC ACTION P 014 04
PHLOPIDZIN U URIC ACID INC V URICOSUPIC ACTION IN MAN 90878
PROBENECID U URIC ACID INC V URICOSUPIC ACTION R04014
P P 0 T! IN U URIC ACID INC V INC IN PROPORTION TO DIETARY PURINE P0 29 1
PROTOCATECHUIC ACID U URIC ACID INC N FALSELY HIGH VALUES WITH PHOSPHOTUNGSTATE METHODS P0370
p59 U URIC ACID INC V URICOSURIC ACTION P0 404
SALINE U URIC ACID INC V HYPERTONIC SOLUTION MAY HAVE MARKED EFFECT P0 179
SULFINPYR AEON! U URIC ACID INC V UPICOSURIC ACTION R04O4
SULFONAMIDES U URIC ACID INC V URICOSURIC EFFECT R0355
THEOPHYLLINE U URIC ACID INC N REDUCTION OF PHOSPHOTUNCSTATE BY NETABOLITES P01 82
THIOCUANINE U URIC ACID INC V DUE TO AUGMENTED TISSUE CATABOLISM P0 3814
TRIAMTERENE U URIC ACID INC V SLIGHT UPICOSUPIC ACTION P03 55
W- 2354 U URIC ACID INC V UPICOSURIC ACTION P0 1488
XYLITOL U URIC ACID INC V AS RESULT OF INCREASED SERUM CONC (MAY BE DOUBLED) P02 77
ACETYLSALICYLIC AC S URIC ACID Z N NO EFFECT ON METHODS USING URICAS! 90771
CONTACT WITH CLOT S URIC ACID Z M NO EFFECT 8H AT ROOM TEMP IF URICASE USED 90771
HEMOLYSIS S URIC ACID Z N NO EFFECT IF MEASURED BY UPICASE AND IS MODERATE P077 1
LEVODOPA S URIC ACID Z N NO INCREASE REPORTED WHEN URICASE USED P0026
MEALS S URIC ACID Z V NO EFFECT AFTER STANDARD BPEAKFAST 90181
STORAGE OF SAMPLE S URIC ACID Z N NO EFFECT FOP 3 DAYS AT ROOM TEMP, 6 MONTHS FROZEN P0436
BROMSUL? ALE IN U URINALYSIS ACETONE INC N DEVELOPMENT OP COLOR AT ALKALINE PH (ROTHERA TEST) R1001
ISOPPOPANOL U URINALYSIS ACETONE INC V METABOLIZED PARTIALLY TO ACETONE 90417
METHA NOL U URINALYSIS ACETONE INC V SLIGHT TO MOD EFFECT IN POISONING P0384
PS P U URINALYSIS ACETONE INC N CHRONOGENICITY IN COLOR REACTION (ROTHERA TEST) P 100 1
AC ETA MI NOPH EN U URINALYSIS BILE INC V HEPATIC NECROSIS MAY OCCUR WITH DOSE OF 10 C P0137
ACETO HEXA MID! U URINALYSIS BILE INC V MAY CAUSE INTRAHEPATIC CHOLESTATIC JAUNDICE 90620
ACETOPHENAZINE U URINALYSIS BILE INC V CHOLESTASIS WITH INTRAHEPATIC OBSTRUCTION 90620
ACETOPHENET IDIN U URINALYSIS BILE INC V MAY CAUSE HEPATIC TOXICITY 90620
ACRIFLAVI NE U URINALYSIS BILE INC N PRODUCES YELLOW COLOR WHEN URINE SHAKEN P0 143
AJMALINE U URINALYSIS BILE INC V INTRAHEPATIC CHOLESTASIS P0088
A LL OPU RI NOL U URINALYSIS BILE INC V HEPATOTOXIC EFFECT P0 596
AMINOSALICYLIC AC U URINALYSIS BILE INC V H!PATOTOXICITY P0 620
APIITRIPTYLINE U URINALYSIS BILE INC V DUE TO TRANSIENT CHOLESTASIS 90620
AMODIAQUIN! U URINALYSIS BILE INC V REPORTED HEPATOTOXICITY P0620
AMPHOTEPICIN B U URINALYSIS BILE INC V REPORTED HEPATOTOXICITY 90620
ANABOLIC STEROIDS U URINALYSIS BILE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P0384
A NDROGE NS U URINALYSIS BILE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P0384
ANTIFUNGAL AGENTS U URINALYSIS BILE INC V HEPATOTOXICITY MAY OCCUR P0355
ANTIMONY COMPOUNDS U URINALYSIS BILE INC V HEPATOTOXICITY 90620
ARSENICALS U URINALYSIS BILE INC V HEPATOTOXICITY (CHOLESTASIS/CHOLANGIOLITIS) 90620
ASPIDIUN U URINALYSIS BILE INC V MAY CUASE HEPATIC TOXICITY P06 20
BENZIODARONE U URINALYSIS BILE INC V MAY CAUSE HEPATIC TOXICITY P0620
BISMUTH U URINALYSIS BILE INC V HEPATOTOXICITY P06 20
CARBON TETRACHLOP U URINALYSIS BILE INC V HEPATOTOXIC EFFECT 90620
CARBUTANIDE U UPINALYSIS BILE INC V HEPATOTOXI CITY P0620
CARPHENAZINE U URINALYSIS BILE INC V PROBABLE HOLESTATIC EFFECT (REVERSIBLE) P06 20
CHLOP AMPHEN ICOL U URINALYSIS BILE INC V HEPATOTOXICITY 90620
CHLORDIAZ!POXIDE U URINALYSIS BILE INC V HEPATOTOXIC EFFECT P06 20
CHLOP NEZ ANON! U URINALYSIS BILE INC V HEPATOTOXICITY R06 20
CHLOROTHIAZIDE U URINALYSIS BILE INC V MAY CAUSE CHOLESTATIC JAUNDICE P06 20
C H L OR PP OMA ZI N E U URINALYSIS BILE INC N ALLEGED INTERFERENCE WITH BILI-LABSTIX P014 17
CHLOR PROPA MID! U URINALYSIS BILE INC V CHOLESTATIC JAUNDICE P00 29
CHLOPPROTHI XENE U URINALYSIS BILE INC V MAY CAUSE HEPATOTOXICITY (REVERSIBLE) 90355
CHLORTETP AC YCLINE U URINALYSIS BILE INC V HEPATOTOXIC EFFECT WITH CENTROLOBULAR NECROSIS P03 55
CH LORE OX AZ ONE U URINALYSIS RILE INC V MAY CAUSE HEPATOTOXICITY P02 99
CINCHOPHEN U URINALYSIS BILE INC V MAY CAUSE HEPATOTOXICITY (VIRAL-HEPATITIS LIKE) P0620
CLOFI BRAT! U URINALYSIS BILE INC V HEPATOTOXIC EFFECT P0620
COLCHICINE U URINALYSIS BILE INC V MAY CAUSE HEPATOTOXICITY P0620
COUNAPIN U URINALYSIS BILE INC V MAY CAUSE HEPATOTOXICITY P0990
CYCLOPHOSPHAMIDE U URINALYSIS BILE INC V MAY CAUSE HEPATOTOXICITY P0620
CYC LOP P OPA NE U URINALYSIS BILE INC V MAY CAUSE HEPATOTOXICITY (LASTS SEVERAL DAYS) P06 20
CYCLOSEPINE U URINALYSIS BILE INC V MAY CAUSE HEPATOTOXICITY P0620
DES IPRA MINE U URINALYSIS BILE INC V RAPE TRANSIENT CHOLESTASIS R0620
DI NI TROPH ENOL U URINALYSIS BILE INC V DUF TO HEPATOTOXICITY P036 8
DIPHENYLHYDANTOI N U URINALYSIS BILE INC V HEPATOTOXICITY P06 20
DOXEPI N U URINALYSIS BILE INC V THEORETICAL POSSIBILITY DUE TO CLASS OF COMPOUND 90026
!CTYLUREA U URINALYSIS BILE INC V MAY CAUSE CHOLESTASIS WITH CHOLANGIOLITIS P06 20
ERYTHPOMYCI N U URINALYSIS BILE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P0 029
ESTRADIOL U URINALYSIS BILE INC V CHOLESTATIC EFFECT 90620
ESTROGENS U URINALYSIS BILE INC V DUE TO CHOLESTA SIS P0620
ES TR ON F U URINALYSIS BILE INC V MAY CAUSE CHOLESTASIS 90620
ET HEP U URINALYSIS BILE INC V HEPATIC DISTURBANCE (TRANSIENT) P06 20
ETHIONAMIDE U URINALYS]S BILE INC V HEPATOTOXIC EFFECT 90620
ETHOTOIN U URINALYSIS BILE INC V HEPATOTOXICITY 90620
ETH OX AZ EN! U URINALYSIS BILE INC N ATYPICAL RED COLOR WITH BILI-LABSTIX AND ICTOTEST R01417
ETHOXA ZEN! U URINALYSIS BILE INC V HEPATOTOXIC EFFECT 90620
FLORA NTYPONE U URINALYSIS BILE INC V HEPATOTOXIC EFFECT P062 0
FLUFENAMIC ACID U URINALYSIS BILE INC M PROBABLY DUE TO INTERFERING METABOLITE P0417
FLUOXY MESTERONE U URINALYSIS BILE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P03 84
FLUPHENAZINE U URINALYSIS BILE INC V HYPERSENSITIVITY RESPONSE 90620

FLUPAZEPA N U URINALYSIS BILE INC V MAY CAUSE HEPATOTOXICITY 90788
FORMALI N U URINALYSIS BILE INC N MAY GIVE YELLOW RING WITH CNELIN TEST 90143
GLYCOPYP P0 LATE U URINALYSIS BILE INC V HEPATOTOXICITY 90620
COLD U URINALYSIS BILE INC V HEPATOTOXICITY WITH CENTROLOBULAP NECROSIS P0620
GUANOXAN U URINALYSIS BILE INC V MAY CAUSE HEPATIC TOXICITY P06 20
HALOPEBI DOL U URINALYSIS BILE INC V MAY CAUSE HEPATOCELLULAP CHANGES P06 20
H ALOTH A NE U URINALYSIS BILE INC V ALLERGIC HEPATIC HYPERSENSITIVITY 90620
HYDRAZI NE U URINALYSIS BILE INC V MAY CAUSE HEPATOTOXICITY RO62O
HYDROXYACETAMIDE U URINALYSIS BILE INC V HEPATOTOXICITY P06 20
IBUFENAC U URINALYSIS BILE INC V HEPATOTOXIC EFFECT 90620
ICT ER OC EN I N U URINALYSIS BILE INC V CAUSES INTRAHEPATIC CHOLESTASIS P00 54
IMIPPAMINE U URINALYSIS BILE INC V MAY CAUSE CHOLESTATIC JAUNDICE 90620
I NDANDI ONES U URINALYSIS BILE INC V NAY CAUSE HEPATOTOXICITY 90620
INDOMETHACIN U URINALYSIS BILE INC V CYTOTOXIC AND CHOLESTATIC LIVER DAMAGE 90029
IPRI NDOLE U URINALYSIS BILE INC V DUE TO HEPATIC TOXICITY 90012
IPPONIA ZID U URINALYSIS BILE INC V PROLONGED USE MAY CAUSE HEPATOTOXICITY 90620
ISOCAPBOXAZID U URINALYSIS BILE INC V CHOLESTATIC EFFECT 90620
ISONIAZID U URINALYSIS BILE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE 90029
LI NCONYCI N U URINALYSIS BILE INC V OCCURS WITH HEPATOTOXICITY P06 20
MAO INHIBITORS U URINALYSIS BILE INC V HEPATOTOXIC EFFECT 90620
MECHLORETHA MINE U URINALYSIS BILE INC V HEPATOTOXIC EFFECT 90079
MEFENAMIC ACID U URINALYSIS BILE INC N REPORTED INTERFERENCE WITH TESTING PROCEDURE 90513
NEPACR IN! U URINALYSIS BILE INC V HEPATOTOXIC EFFECT 90620
ME PHENYTOIN U URINALYSIS BILE INC V HEPATOTOXICITY P06 20
NERCA PTOPURIN! U URINALYSIS BILE INC V HEPATOTOXIC EFFECT P0620
METAH EXAMIDE U URINALYSIS BILE INC V HEPATOTOXICITY (VIRAL HEPATITIS TYPE) P062 0
NETA NDIENONE U URINALYSIS BILE INC V HEPATOTOXIC EFFECT 90620
ME TA I A L ON! U URINALYSIS BILE INC V HEPATOTOXIC EFFECT 90620
M!THANDRIOL U URINALYSIS BILE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE 90384
METRA NDPOSTENOLONE U URINALYSIS BILE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE 90384
METHIM AZOLE U URINALYSIS BILE INC V HEPATOTOXIC EFFECT P0620
PIETROTREXATE U URINALYSIS BILE INC V HEPATOTOXICITY 90620
METRO IS ALEN U URINALYSIS BILE INC V HEPATOTOXIC EFFECT 9.0620
N FT H OXY F LU PA NE U URINALYSIS BILE INC V HEPATOTOXIC EFFECT P06 20
METHYLDOPA U URINALYSIS BILE INC V OCCURS AS RESULT OF HEPATOCELLULAR DAMAGE R0946
METHYLTESTOSTE RONE U URINALYSIS BILE INC V CHOLESTATIC EFFECT 90477
METHYLTHIOUP ACIL U URINALYSIS BILE INC V HEPATOTOXIC EFFECT P 0620
NIALANIDE U URINALYSIS BILE INC V PROBABLE HYPERSENSITIVE HEPATITIS 90026
NICOTINIC ACID U URINALYSIS BILE INC V NAY B! IMPAIRED HEPATIC FUNCTION 90620
NITROFU PANS U URINALYSIS BILE INC V HEPATOTOXICITY R0620
NITROFUPA NTOIN U URINALYSIS BILE INC V MAY CAUSE CHOLESTATIC JAUNDICE 90620
NOR!THA NDROLONE U URINALYSIS BILE INC V CHOL!STATIC EFFECT 90826
NOR!THA NDROSTENOL U URINALYSIS BILE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P0 834
NOPETHINDRONE U URINALYSIS BILE INC V CHOLESTATIC EFFECT P0620
NORETHI STEPONE U URINALYSIS BILE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE P03 84
NO R ETH YNO DR EL U URINALYSIS BILE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE 90384
NORTRI PTYLI NE U URINALYSIS BILE INC V MAY CAUSE CHOLESTATIC JAUNDICE P00 26
NOVOBIOCIN U URINALYSIS BILE INC V INTRAHEPATIC CHOLESTATIC JAUNDICE CAN OCCUR 90384
OLEANDOMYCIN U URINALYSIS BILE INC V HEPATOTOXIC EFFECT 90620
OP C ANOP HOS P HO PUS U URINALYSIS BILE INC V HEPATOTOXIC EFFECT P0 130
OXACILLIN U URINALYSIS BILE INC V REVERSIBLE HEPATOCELLULAP DYSFUNCTION 90620
OX AZ! PAM U URINALYSIS BILE INC V POSSIBLE HEPATOTOXICITY 90620
OX! PH! NBU TA Z ONE U URINALYSIS BILE INC V POSSIBLE HEPATOTOXICITY 90620
OXYPHENI SATIN U URINALYSIS BILE INC V NAY CAUSE HYPERSENSITIVITY REACTION P0776
PAR A LDE HYDE U URINALYSIS BILE INC V POSSIBLE HEPATOTOXICITY P06 20
PAPANETHA DI ONE U URINALYSIS BILE INC V POSSIBLE HEPATOTOXICITY 90620
PARCYLIN! U UPINALYSIS BILE INC V POSSIBLE HEPATOTOXICITY (REVERSIBLE) P0 6 20
PECAZIN! U URINALYSIS BILE INC V MAY ALTER LIVER FUNCTION (CHOLESTASIS) P0620
PEPPHENAZINE U URINALYSIS BILE INC V LOW INCIDENCE OF JAUNDICE REPORTED 90620
PH ENACEMIDE U URINALYSIS BILE INC V NAY AFFECT LIVER FUNCTION IN ABOUT 2% CASES P06 20
PH ENAZOPYPI DINE U URINALYSIS BILE INC N FALSE P05 WITH ICTOTEST, BILI-LABSTIX P06 90
PHENA ZOPYRIDIN! U URINALYSIS BILE INC V HEPATOTOXIC EFFECT R0620
PHENELZINE U URINALYSIS BILE INC V MAY CAUSE HYPERSENSITIVE HEPATITIS P0026
PHENINDIONE U UPINALYSIS BILE INC V MAY MODIFY LIVER FUNCTION (CHOLESTASIS) P06 20
PHENIPRAZINE U URINALYSIS BILE INC V NAY AFFECT LIVER FUNCTION P0620
PHENOTHIAZINES U URINALYSIS BILE INC N ALLEGED INTERFERENCE WITH BILI-LABSTIX P04 17
PHENOT HIAZINES U URINALYSIS BILE INC V NAY CAUSE CHOLESTATIC HEPATITIS 90620
PHOSPHORUS U URINALYSIS BILE INC V HEPATOTOXIC EFFECT WITH NECROSIS 90620
POLYTHIAZIDE U URINALYSIS BILE INC V NAY AFFECT LIVER FUNCTION 90620
PROBENECI D U URINALYSIS BILE INC V POSSIBLE HEPATOTOXICITY P06 20
PPOCAINAMIDE U URINALYSIS BILE INC V HEPATOTOXIC EFFECT 90620
PROCHLORPERAZINE U URINALYSIS BILE INC V CHOLESTATIC EFFECT P0026
PROGE STIN U UPINALYSIS BILE INC V HEPATOTOXICITY 90620
PROMAZI NE U URINALYSIS BILE INC V NAY CAUSE CHOLESTASIS 90620
PPOMETHAZINE U URINALYSIS BILE INC V MAY CAUSE CHOLESTASIS P0 620
PPOPOX!PU EN! U URINALYSIS BILE INC V CHOLESTATIC EFFECT 90538
PPOPYLTHIOUPACIL U URINALYSIS BILE INC V HEPATOTOXIC EFFECT (CENTPOLOBULAR NECROSIS) P06 20
PROTRIPTYLINE U URINALYSIS BILE INC V TRANSIENT REVERSIBLE CHOLESTASIS 90026
PYRAZINAMIDE U URINALYSIS BILE INC V HEPATOTOXIC EFFECT (VIRAL-HEPATITIS LIKE) P0 620
QUINETHAZONE U URINALYSIS BILE INC V MAY CAUSE CHOLESTATIC JAUNDICE 90620
SULFADIM!THOXINE U URINALYSIS BILE INC V GRANULOMATOUS REACTION IN LIVER 30307
SULFAFU PA ZOLE U URINALYSIS BILE INC V REVERSIBLE CHOLESTASIS P0 620
SULFANETHIZOLE U URINALYSIS BILE INC V REVERSIBLE CHOLESTASIS 905142
SULFAMETHOXA ZOLE U URINALYSIS BILE INC V REVERSIBLE CHOLESTASIS 30620
SULFA NETHOXYPYRID U URINALYSIS BILE INC V REVERSIBLE CHOLESTASIS P062 0
SULFISOXAZOLE U URINALYSIS BILE INC V MAY CAUSE CHOLESTASIS 90542
SULFONA MI DES U URINALYSIS BILE INC V MAY CAUSE CHOLESTASIS 90620
S ULFO N ES U URINALYSIS BILE INC V MAY AFFECT LIVER FUNCTION P0 620
TESTOSTERONE U URINALYSIS BILE INC V MAY CAUSE CHOLESTASIS 90620
THIACETAZONE U URINALYSIS BILE INC V MAY CAUSE CHOL!STASIS 90079

THIAMAZOL! U URINALYSIS BILE INC V MAY AFFECT LIVER FUNCTION 90620
THIOGUANINE U URINALYSIS BILE INC V MAY CAUSE CHOLESTASIS P0620
THIORIDAZINE U URINALYSIS BILE INC V HEPATOTOXICITY R0508
TRIOSEMICARBAZONES U URINALYSIS BILE INC V MAY AFFECT LIVER FUNCTION 90620
THIOTHIXENE U URINALYSIS BILE INC V HEPATOTOXIC EFFECT (REVERSIBLE CHOLESTASIS) P0620
THYMOL U URINALYSIS BILE INC N AFFECTS DETERMINATION OF BILE ACIDS (HAY’S TEST) P0779
TOLAZAMIDE U UPINALYSIS BILE INC V CHOLESTATIC EFFECT P0620
TOLBUTAMIDE U URINALYSIS BILE INC V CHOLESTATIC JAUNDICE REPORTED P0417
TRANYLCYPROMINE U URINALYSIS BILE INC V MAY AFFECT LIVER FUNCTION (?HYPERSENSITIVITY) 90620
TPINEPRAZINE U URINALYSIS BILE INC V MAY CAUSE CHOLESTASIS 90026
TRIMETHADION! U URINALYSIS BILE INC V MA! CAUSE HEPATOTOXICITY WITH NECROSIS P0620
TPIOXSALEN U URINALYSIS BILE INC V NAY AFFECT LIVER FUNCTION P0620
URACIL MUSTARD U URINALYSIS BILE INC V MAY AFFECT LIVER FUNCTION P0620
PR0BENECID U URINALYSIS CALCULI INC V MAY OCCUR IF LITTLE FLUID DRUNK OP EXCRETE MUCH P00146
ACETANINOPH!N U URINALYSIS CASTS INC V RENAL DAMAGE DUE TO HEMOLYSIS/ANURIA P0384
ACETANILID U URINALYSIS CASTS INC V DUE TO HEMOLYSIS AND RENAL DAMAGE P03814
AC!TOPHENETIDIN U URINALYSIS CASTS INC V MAY OCCUR IF INTRAVASCULAR HEMOLYSIS R03814
AC!TYLSALICYLIC AC U URINALYSIS CASTS INC V OCCURS WITH POISONING P0368
ACIDS U URINALYSIS CASTS INC V PENAL DAMAGE FOLLOWING INGESTION P0368
AMPROTERICIN B U URINALYSIS CASTS INC V GRANULAR AND HYALIN! CASTS WITH TOXICITY P0026
AMPICILLIN U URINALYSIS CASTS INC V OCCURS AS RESULT OF NEPHROTOXICITY P0916
ANTIMONY COMPOUNDS U URINALYSIS CASTS INC V NEPHPOTOXIC EFFECT P0620
APSENICALS U URINALYSIS CASTS INC V NEPHROTOXIC EFFECT P0620
BACITRACIN U URINALYSIS CASTS INC V NEPHROTOXIC EFFECT (CYLINDRURIA MAY OCCUR) P0620
BPOMATE U URINALYSIS CASTS INC V DUE TO PENAL DAMAGE P0368
CALCITONIN U URINALYSIS CASTS IN V POSSIBLE NEPHPOTOXIC EFFECT (INC GRANULAR CASTS) 901419
CAPREOMYCIN U URINALYSIS CASTS INC V NEPRROTOXIC EFFECT (USUALLY GRANULAR CASTS) P0620
CEPHALOPIDINE U URINALYSIS CASTS INC V NEPHROTOXICITY (HYALINE AND GRANULAR) P0298
CHLOROCUANIDE U URINALYSIS CASTS INC V NEPHROTOXIC EFFECT P0620
COLISTIMETHATE U URINALYSIS CASTS INC V NEPHROTOXIC EFFECT P0620
DINITPOPHENOL U URINALYSIS CASTS INC V DUE TO TOXIC NEPHRITIS P0368
EDTA U URINALYSIS CASTS INC V NEPHROTOXIC EFFECT (ESP CA EDTA) P0620
GRISEOFULVIN U URINALYSIS CASTS INC V CYLINDPURIA MAY OCCUR WITHOUT RENAL INSUFFICIENCY P0384
HYDROGEN SULFIDE U URINALYSIS CASTS INC V OCCURS DUE TO NEPHROTOXOCITY P0368
INDOMETHACIN U URINALYSIS CASTS INC V GRANULAR CASTS IN ONE PATIENT P0157
IODINE CONTAIN DRUG U URINALYSIS CASTS INC V HEMORRHAGIC NEPHRITIS WITH TOXIC DOSES 90368
ISONIAZID U URINALYSIS CASTS INC V NEPHROTOXIC EFFECT P0620
KANAMYCIN U URINALYSIS CASTS INC V NEPHROTOXIC EFFECT (CYLINDRURIA AND GRANULAR CASTS) 90026
EFROSEN! U URINALYSIS CASTS INC V WITH SEVERE TOXICITY FOLLOWING INGESTION P0368
LEAD U URINALYSIS CASTS INC V NEPHROTOXICITY WITH POISONING (CYLINDRURIA) P0384
MELARSONYL U URINALYSIS CASTS INC V NEPHROTOXIC EFFECT P0026
MELARSOPROL U URINALYSIS CASTS INC V NEPHPOTOXIC EFFECT P0620
MERCURY COMPOUNDS U URINALYSIS CASTS INC V MAY CAUSE SEVERE NEPHRITIS IF ABSORBED P0026
METHICILLIN U URINALYSIS CASTS INC V NEPHPOTOXIC EFFECT (CYLINDRURIA OBSERVED) 90620
METHYLBROMIDE U URINALYSIS CASTS INC V DUE TO TUBULAR NECROSIS P0368
MUSCULAR EXERCISE U URINALYSIS CASTS INC V HYALINE, GRANULAR BOTH INC WITH INC EXERCISE P0505
NAPHTHALENE U URINALYSIS CASTS INC V NEPHPOTOXIC EFFECT P0368
N!ONYCIN U URINALYSIS CASTS INC V NEPHROTOXIC EFFECT P0620
PAPANETHADIONE U URINALYSIS CASTS INC V MAY HAVE NEPHROTOXIC EFFECT 90620
PENICILLIN U URINALYSIS CASTS INC V PENAL CELL AND OTHER TYPES P0384
PHENOLS U URINALYSIS CASTS INC V NEPHROTOXICITY WITH POISONING (USUSALLY PBC CASTS) P03814
PHOSPHORUS U URINALYSIS CASTS INC V NEPHROTOXIC EFFECT P0368
POLYMYXIN B U URINALYSIS CASTS INC V CYLINDRUPIA NAY OCCUR WITH DAILY INJECTION P0384
RADIOGRAPHIC U URINALYSIS CASTS INC V NEPHPOTOXIC MANIFESTATION P0204
PIFAMPIN U URINALYSIS CASTS INC V PARE REPORTED SIDE EFFECT R01432
STREPTOMYCIN U URINALYSIS CASTS INC V CYLINDRURIA MAY DEVELOP P0384
SULFONAMIDES U URINALYSIS CASTS INC V HEMOGLOBIN CASTS MAY CAUSE RENAL FAILURE P03814
SURAMIN U URINALYSIS CASTS INC V CYLINDRURIA REPORTED P0026
THALLIUM U URINALYSIS CASTS INC V DAMAGE TO RENAL TUBULAR EPITHELIUN P0368
TRIMETHADIONE U URINALYSIS CASTS INC V MAY HAVE NEPHPOTOXIC EFFECT 90620
VIOMYCIN U URINALYSIS CASTS INC V NEPHROTOXICITY WITH CYLINDRUPIA 90026
ACETAMINOPHEN U URINALYSIS CELLS INC V MAY BE MARKED INC IN PENAL TUBULAR CELLS 903814
ACETOPHENETIDIN U URINALYSIS CELLS INC V MAY BE MARKED INC IN RENAL TUBULAR CELLS P03814
ACETYLSALICYLIC AC U URINALYSIS CELLS INC V TUBULAR EPITHELIAL CELLS INC INITALLY, MAY PERSIST P0384
ANTIPYRINE U URINALYSIS CELLS INC V RENAL ACTION OF DRUG P0988
CAFFEINE U URINALYSIS CELLS INC V MAY CAUSE MARKED INC IN PENAL TUBULAR CELLS 90384
CALCITONIN U URINALYSIS CELLS INC V POSSIBLE NEPHPOTOXIC EFFECT (INC EPITHELIAL CELLS) P0419
CASTOR OIL U URINALYSIS CELLS INC V MULTINUCLEATED GIANT CELLS IN 50% PATIENTS P0657
CHLOROGUANIDE U URINALYSIS CELLS INC V MAY CAUSE TRANSIENT APPEARANCE OF EPITHELIAL CELLS P0384
CORTISONE U URINALYSIS CELLS INC V INC NUMBER OBSERVED WITH LONG-TERN TREATMENT P0657
MUSCULAR EXERCISE U URINALYSIS CELLS INC V EPITHELIAL CELLS INC WITH HEAVY EXERCISE P0505
THALLIUM U URINALYSIS CELLS INC V DAMAGE TO PENAL TUBULAR EPITHELIUM 90368
ETHANOL U URINALYSIS COLOR DEC N DIUPESIS INDUCED REDUCES COLOR P0417
ACETOPHENETIDIN U URINALYSIS COLOR INC M PINK-RED COLORATION DUE TO NETABOLITE 90299
ACETOPHENETIDN U URINALYSIS COLOR INC V MAY CAUSE HENATURIA (RED-BROWN COLOR) P0657
ACPIFLAVINE U URINALYSIS COLOR INC N GREENISH FLUORESCENCE P0663
ALOIN U URINALYSIS COLOR INC M RED-BROWN/YELLOW PINK(ALKALINE),YELLOW BROWN(ACID) P0620
AMINOPYRINE U URINALYSIS COLOR INC N RED BROWN P0620
AMINOSALICYLIC AC U URINALYSIS COLOR INC N ABNORMAL COLOR (NOT DISTINCTIVE) 90122
AMITRIPTYLINE U URINALYSIS COLOR INC N GREENISH-BLUE COLOR P0299
ANILINE U URINALYSIS COLOR INC V BROWN COLOR DUE TO INTRAVASCULAR HEMOLYSIS 90368
ANISINDION! U URINALYSIS COLOR INC M ORANGE (ALKALINE), PINK-RED-BROWN (ACID) P0620
ANTHRAQUINON! U URINALYSIS COLOR INC N PINK, RED, PURPLE, ORANGE 6 RUST P06514
ANTIPYRINE U URINALYSIS COLOR INC M RED BROWN (GREEN IN REFLECTED LIGHT) P0620
AZUPESIN U URINALYSIS COLOR INC N BLUE OR GREEN FOR A FEW DAYS AFTER TEST P01417
BEETS U URINALYSIS COLOR INC M RED DUE TO ANTHOCYANINS AND OTHER PIGMENTS 90620
BENZ!NE U URINALYSIS COLOR INC N RED BROWN P0620
BILE U URINALYSIS COLOR INC M GREEN COLOR WITH OXIDIZED BILE ON STANDING P01143
BILIRUBIN U URINALYSIS COLOR INC N YELLOWISH FOAM P0663
BILIVERDIN U URINALYSIS COLOR INC M GREENISH FOAM 90663

BLOOD U URINALYSIS COLOR INC V SMOKY bED TO BROWN DUE TO HEiATUF.IA 90663
BROMSU LFALEI N U URINALYSIS COLOR INC N RYt) IN ALKALINE URINE RC8BC
CARBON TETRACHLOR U URINALYSIS COLOR INC V R1D BROWN DUE TO HENATURIA P C 62 C
CARROTS U UPINALYSIS COLOR INC N YELLOi COLOR SOLUbLE IN P!TROLEUN ETHER RCb2
CASCARA U URINALYSIS COLOR INC t BROWN (ACIL),YEL-PINK(ALKALINE)BLACK ON STANDING RC299
CHLOROQU IN! U URINALYSIS COLOR INC 1 BROWN COLOR R C 299
CHLOR ZOXA ZONE U URINALYSIS COLOR INC N PINK, FED, PURPLE OP RUST RC299
CHRYSAPOBIN U URINALYSIS COLOR INC N OXIDATION PRODUCT COLORS ALKALINE URINE RED R 384
CINHOPHEN U URINALYSIS COLOR INC N PED BROWN P C 62
CONGO RED U UPINALYSIS COLOR INC V DYE NOT TAKEN UP B ANYLOID RC026
COPPER U URINALYSIS COLOR INC t BLUE DIAPES (ALKALINE U9IE ON COPPER FASTLNINGS) PC 161
CREOSOTE U URINAlYSIS COLOR INC N DARK GREEN P C 62 C
CRESOL U URINALYSIS COLOR INC : DARK BROWN ON STANDING PC 62 C
DA NT H RON U URINALYSIS COLOR INC N RED COLORATION IN URINE P355
DEFEROXAMINE U URINALYSIS COLOR INC N FORMS IRON CHLLATE WITH REDDISH COLOR PC417
DI NITROPHENOL U URINALYSIS COLOR INC V RED BROWN DUE TO HEMATURIA P0623
DIPHENYLBYDA NTOI N U URINALYSIS COLOR INC N PINK,RED OP RED-BROWN COLOR MAY OCCUR iC1417
DITHIAZINE U URINALYSIS COLOR INC M BLUE RC62O
DOAN’S PILLS U URINALYSIS COLOR INC M GRENISH BLUE 90620
ENODIN U URINALYSIS COLOR INC N PINK, RED, PURILL & RUST COLOR PC 355
ETHOX ZEN! U URINALYSIS COLOR INC N RLD,PINK, ORANGE & RUST COLORS RC654
EVANS BLUE U URINALYSIS COLOR INC N BLUE COLOR DUE TO PRESENCE OF DYE PC 143
FLUORESCEIN U URIUALYSIS COLOR INC N I.V. ADMINISTRATION MAY CAUSE YELLOW-ORANGE COLOR P0417
FURA ZOLIDONE U URINALYSIS COLOR INC K NETABOLITES NAY PPODUCE BPO1N COLOR RC417
FURAZOLI UN U URINALYSIS COLOR INC N RED, PINK, PURPLE, ORANGE & RUST COLORS R355
HEMOGLOB IN U URINALYSIS COLOR INC N CLEAR RED TO REDDISH BROWN RC663
HOMOGENTISIC ACID U URINALYSIS COLOR INC N BLACK (OCCURS WITH ALKAPTONURIA) BC 663
I NDA NDIONES U URINALYSIS COLOR INC V NAY BE ORANGE TO RED IN COLOR PC 654
INDICAN U URINALYSIS COLOR INC N OCCURS IF INCREASED AND OXIDIZED ON STANDING RC143
INDIGOTINDIS ULFON U URINALYSIS COLOR INC N COLOR USED TO MEASURE KIDNEY FUNCTION PC026
INDOMETHACIN U URINALYSIS COLOR INC V INDIRECT RESULT OF HrPATIC TOXICITY, GREEN URINE R)32C
IRON SALTS U URINALYSIS COLOR INC N IRON SORBITOL CAN CAUSE BROWN URINE (FE SULPHIDE) P C 355
LEAD U URINALYSIS COLOR INC V RED BROWN (?DUL TO PORPHYPINS AND HEMOGLOBIN) 90620
LEVODOPA U URINALYSIS COLOR INC E RED-TINGED ON VOIDING, BLACKENS ON STANDING RC819
NANNOSE U URINALYSIS COLOR INC V DEEP ORANGE AFTER I.V. INFUSION 93115
MELANIN U URINALYSIS COLOR INC V BROWN TO BLACK P0663
MER CUR OC HP ONE U URINALYSIS COLOR INC N FLUOPiESCENT PINK STAINING OF CELLS R:143
MERCURY COMPOUNDS U URINALYSIS COLOR INC V PRO EROWN DU TO HEMATURIA PC 620
NETHOCARBAMOL U URINALYSIS COLOR INC N BROWN, GRE..N, ELUE OR BLACK ON STANDING P0122
MET RYLDOPA U URINALYSIS COLOR INC N RED, PINK OP BPOWN DARKENS ON STANDING 9C355
METHYLENE BLUE U UFINALYSIS COLOR INC N BLUE COLOR P0383
NETRONIDAZOLE U URINALYSIS COLOR INC N BROWN COLOR PROBABLY DUE TO METABOLIT P.O 355
MYOGLOBI N U URINALYSIS COLOR INC V PRODUCES RED COLOR IN UIIN 9C143
NAP HTHALENE U URINALYSIS COLOR INC V BROWN OR BLACK DUE TO BL000 AND HEMOGLOBIN i(0368
NA PH THOL U URINALYSIS COLCP INC M DARK COLOR ON STANDING P 06 26
NIPIDAZOLE U URINALYSIS COLOR INC N URINE BECOMES DARK 96384
NITPOBENZENE U URINALYSIS COLOR INC N DAPK COLOR ON STANDING 90620
NITROFURANS U URINALYSIS COLOR INC 4 BROWN,GREEN, BLUE COLOR R355
NITROFURA NTOIN U URINALYSIS COLOR INC N BROWN, YELLOW COLOR PC 299
PAMAQUIN! U URINALYSIS COLOR INC N BROWN COLOR 96299
PHENA ZOPYRID IN! U URINALYSIS COLOR INC N ORANGE-RED, ORANGE-BROWN OR RED COLOR PC417
PHENINDI ONE U URINALYSIS COLOR INC N RED-ORANGE COLOR PRODUCED IN ALKALINE URINE P6220
PHENOLPHTHALEIN U URINALYSIS COLOR INC N PINK.PED,PURPLE (ALKALINE) ,ORANGE,RUST (ACID) R6122
PHENOLS U URINALYSIS COLOR INC N DARK GREEN TO BROWNISH BLACK ON STANDING BC 620
PH!NOTHIAZINES U URINALYSIS COLOR INC N PINK, RED, PURPLE, ORANGE, RUST COLOR BC 654
PHENSUXI MI DE U URINALYSIS COLOR INC N PINK, RED, PURPLE, ORANGE AND RUST COLOR R0654
PHENYLSALICYLATE U URINALYSIS COLOR INC M DARK GREEN R0620
PICRIC ACID U URINALYSIS COLOR INC YELLOW TO RED BROWN P0620
PORPHYRINS U URINALYSIS COLOR INC V BURGUNDY RED, DARKENS ON STANDING P0620
PPI MAQU IN! U URINALYSIS COLOR INC N RUSTY YELLOW OR BOWN COLOR P0122
PSP U URINALYSIS COLOR INC M PINK COLOR DUE TO PRESENCE OF DYE P06514
PYROGALLOL U URINALYSIS COLOR INC N BROWN TO BLACK, DARKENS ON STANDING PC 620
QUI NACRINE U URINALYSIS COLOR INC N DEEP YELLOW COLOR ON ACIDIFICATION 93384
QUININE U URINALYSIS COLOR INC N BROWN COLOR PC299
RESORCINOL U URINALYSIS COLOR INC N DARK GREEN TO GREENISH BLUE DARKENS ON STANDING P0620
RHUBARB U URINALYSIS COLOR INC N YELLOW-BROWN (ACID) , YLL0W-PINK(ALKALINL) DARKENS R3620
RIBOFLAVIN U URINALYSIS COLOR INC N MAY PRODUCE YELLOW COLOR WITH LARGE DOSES P0417
RIFAMPIN U URINALYSIS COLOR INC M RED-ORANGE DUE TO DRUG AND METABOLITES 90442
SALICYLAZOSEILFA PYP U URINALYSIS COLOR INC N PINK, RED, PURPLE, ORANGE OR RUST COLOR R0299
SALOL U URINALYSIS COLOR INC N DARK COLOR ON STANDING 90620
SANTONIN U URINALYSIS COLOR INC N BRIGHT YELLOW (NACH CHANGES TO PINK, SCARLET) P6620
SF NH A U URINALYSIS COLOR INC N PINK, RED, PUPPL, ORANGE OP RUST P0029
S ULF A NET H OXA ZOLE U URINALYSIS COLOR INC N BROWN COLOR OBSERVED PC 299
SULFONA MID! S U URINALYSIS COLOR INC N BROWN COLOR WITH SOME SULFONAMIDES PC 299
S UL F ONE N ET BA NE U URINALYSIS COLOR INC V RED-BROWN (NAY PROVOKE PORPHYRIA) P0620
S UL? OMT HYLNET HA NE U URINALYSIS COLOR INC V RED (NAY PROVOKE PORPHYRIA) B 0620
TETRALIN U URINALYSIS COLOR INC N GREENISH BLUE P 620
THIA ZOLSULFONE U URINALYSIS COLOR INC N RED, PINK, i’URPLE, ORANGE AND RUST COLOR hO 355
THLMOL U URINALYSIS COLOR INC N GREENISH BLUL RC620
TOLONI UN U URINALYSIS COLOR INC N GREEN AND BLUE COLOR P0299
TPIA MTRENE U URINALYSIS COLOR INC N GREEN, BLUE WITH BLUE FLUORESCENCE 93 299
TRI NITROTOLUENE U URINALYSIS COLOR INC V RED BROWN DUE TO HEMOGLOBIN BC 620
UROBIL’N U URINALYSIS COLOR INC N EXCESS NAY CAUSE YELLOW TO AMBER COLOR RC663
ACET AZOLAM IDE U URINALYSIS CRYSTALS INC N PRESENCE OF DRUG P0299
AMPICILLIN U URINALYSIS CRYSTALS INC M PRESENCE OF DRUG MAXIMAL AT PH 5 BC 714 9
AZAURIDINE U URINALYSIS CRYSTALS INC V AY OCCUR DU TO RESPONSE TO TISSUE DESTRUCTION R 3092
FOMALIN U URINALYSIS CRYSTALS INC N UREA PRECIPITATION P0520
MA NH OS E U URINALYSIS CRYSTALS INC V MASSIVE URIC ACID CRYSTALLURIA AFTER INFUSION Rolls
METHE NAN IN! U URINALYSIS CRYSTALS INC V NANDELATE MAY OCCASIONALLY CAUSE CPYSTALLURIA BC 384
METHOTREXATF U URINALYSIS CRYSTALS INC M CRYSTALS OF UNKNOWN IDENTITY (PROBABLY DRUG) R3288

OXALATES U URINALYSIS CRYSTALS INC V OXALATE CRYSTALS PRESENT IN URINE IN POISONING P0368
RHUBARB U URINALYSIS CRYSTALS INC V CALCIUM OXALATE MAY BE DEPOSITED P0053
SULFADIAZINE U URINALYSIS CRYSTALS INC V LOW SOLUBILITY IN ACID URINE 90736
SULFANERAZINE U URINALYSIS CRYSTALS INC V PRESENCE OF DRUG P0026
SULFANETHOXAZOLE U URINALYSIS CRYSTALS INC V LOW SOLUBILITY IN ACID URINE 90736
SULFONAMIDES U URINALYSIS CRYSTALS INC V PRESENCE OF DRUG 90620
SULTHIAME U URINALYSIS CRYSTALS INC V IN POISONING IDENTIFIED AS PURE DRUG P0657
THIABENDAZOLE U URINALYSIS CRYSTALS INC N LOW SOLUBILITY OF DRUG, ESP. AT NEUTRAL PH P06147
ACETYLSALICYLIC AC U URINALYSIS GLUCOSE DEC V MAY REDUCE HYPERGLYCEMIA, GLYCOSURIA IN DIABETES R03814
ASCORBIC ACID U URINALYSIS GLUCOSE DEC N MAY INHIBIT TESTAP! AND CLINISTIX P0907
DIPYRONE U URINALYSIS GLUCOSE DEC N MAY CAUSE FALSE NEGATIVE WITH ENZYME TESTS P01436
LEVODOPA U URINALYSIS GLUCOSE DEC N FALSE NEC. IF CLINISTIX USED (NO EFFECT ON TESTAPE) 90317
M!RALLUPIDE U URINALYSIS GLUCOSE DEC N INTERFERES WITH GLUCOSE OXIDASE METHOD 90654
OXYTETRACYCLINE U URINALYSIS GLUCOSE DEC M AFFECTS DIPSTICKS IF BUFFERED WITH ASCORBIC ACID P0436
PHENAZOPYRIDINE U URINALYSIS GLUCOSE DEC N FALSE NEGATIVE WITH GLUCOSE OXIDASE METHODS 90690
TETRACYCLINE U URINALYSIS GLUCOSE DEC N FALSE NEC. DIPSTICK RESULTS IF BUFF. WITH ASCORBIC 90318
ACETYLSALICYLIC AC U URINALYSIS GLUCOSE INC V DUE TO HYPERGLYCEMIA P03814
ANYL ALCOHOL U URINALYSIS GLUCOSE INC V ASSOCIATED WITH RENAL DAMAGE P0368
ANTIPYRINE U URINALYSIS GLUCOSE INC V PENAL ACTION OF DRUG 90988
BISMUTH SALTS U URINALYSIS GLUCOSE INC V MAY PRODUCE FANCONI SYNDROME WITH POISONING P0657
CARBAMAZEPINE U URINALYSIS GLUCOSE INC V SINGLE CASE OF GLYCOSUPIA REPORTED P01417
CARBON T!TPACHLOP U URINALYSIS GLUCOSE INC V DUE TO HEPATIC AND RENAL DAMAGE 90620
CHLORTHALIDONE U URINALYSIS GLUCOSE INC V DIABETOGENIC-LIKE ACTION OF DRUG AFFECTS GTE P0910
CORTICOSTEPOIDS U URINALYSIS GLUCOSE INC V AS RESULT OF HYPERGLYCEMIA 90620
CORTICOTROPIN U URINALYSIS GLUCOSE INC V INCREASED BLOOD GLUCOSE, REDUCED TMG P1001
DEXAM!THASONE U URINALYSIS GLUCOSE INC V ASSOCIATED WITH HYPERGLYCEMIA 90467
DEXTROAMPHETANINE U URINALYSIS GLUCOSE INC V WILL OCCUR IF HYPERGLYCEMIA P0620
DEXTROTHYROXINE U URINALYSIS GLUCOSE INC V OCCURS DUE TO HYPERGLYCEMIA 90417
DIAPAMIDE U URINALYSIS GLUCOSE INC V RESULT OF MARKED HYPERGLYCEMIA P0609
DIAZOXID! U URINALYSIS GLUCOSE INC V IF HYPERGLYCEMIA OCCURS 90200
DIPHENYLPYDANTOIN U URINALYSIS GLUCOSE INC V OCCURS WITH HYPERGLYCEMIA 90241
EDTA U URINALYSIS GLUCOSE INC V MAY CAUSE TUBULAR DAMAGE P0384
EPHEDRINE U URINALYSIS GLUCOSE INC V INCREASED EXCRETION OF GLUCOSE P0299
ETHACRYNIC ACID U URINALYSIS GLUCOSE INC V DIABETOGENIC PROPERTIES 90907
ETHER U URINALYSIS GLUCOSE INC V FOLLOWS HYPERGLYCEMIA P0620
ETHIONAMIDE U URINALYSIS GLUCOSE INC V DUE TO HYPERGLYCEMIA P0596
FUPAZOLIDONE U URINALYSIS GLUCOSE INC N DUE TO PRESENCE OF GLUCOSE IN VAGINAL POWDER 90355
FUROSEMIDE U URINALYSIS GLUCOSE INC V DUE TO HYPERGLYCEMIA P0907
GLUCAGON U URINALYSIS GLUCOSE INC V MOBILIZES ENOUGH GLYCOGEN TO CAUSE GLYCOSUPIA P0026
GLUCOCORTICOIDS U URINALYSIS GLUCOSE INC V DUE TO HYPERGLYCEMIA P0620
GROWTH HORMONE U URINALYSIS GLUCOSE INC V OCCURS IF PRONOUNCED HYPERGLYCEMIA P0620
HYOROCHLOROTHIAZIDE U URINALYSIS GLUCOSE INC V DUE TO HYPERGLYCEMIA IF PRODUCED P0907
HYDROFLUNETHIAZIDE U URINALYSIS GLUCOSE INC V NAY OCCUR AS CONSEQUENCE OF HYPERGLYCEMIA P0467
HYDROGEN PEROXIDE U URINALYSIS GLUCOSE INC N OXIDIS!S CHPOMOGEN IN GLUCOSE OXIDAS! TESTS P0299
IBUFENAC U URINALYSIS GLUCOSE INC V AUGMENTATION OF DIABETIC GLYCOSURIA SEEN P0657
INDOMETHACIN U URINALYSIS GLUCOSE INC V AS RESULT OF RARE HYPERGLYCEMIA P0417
ISONIAZID U URINALYSIS GLUCOSE INC V DUE TO HYPERGLYCEMIA P0596
LEAD U URINALYSIS GLUCOSE INC V NEPHPOTOXICITY WITH POISONING 90384
LITHIUM U URINALYSIS GLUCOSE INC V CONSEQUENCE OF HYPERGLYCEMIA P0417
M!THYCLOTHIAZIDE U URINALYSIS GLUCOSE INC V MAY OCCUR AS RESULT OF HYPERGLYCEMIA P0467
NICOTINIC ACID U URINALYSIS GLUCOSE INC V DUE TO HYPERGLYCEMIA P0360
PEROXIDE U URINALYSIS GLUCOSE INC N MAY PRODUCE FALSE P05 WITH CLINISTIX R01436
PHENAZOPYPIDINE U URINALYSIS GLUCOSE INC N FALSE POSITIVE REPORTED WITH TESTAPE P0690
PHLORIDZIN U URINALYSIS GLUCOSE INC V INCREASES CLEARANCE P0620
POLYTHIAZIDE U URINALYSIS GLUCOSE INC V CONSEQUENCE OF HYPERGLYCEMIA P0620
PREGNANCY U URINALYSIS GLUCOSE INC V MAY OCCUR WITH DECREASED TOLERANCE P0291
QUINETHAZONE U URINALYSIS GLUCOSE INC V OCCURS AS CONSEQUENCE OF HYPERGLYCEMIA P0620
RESERPINE U URINALYSIS GLUCOSE INC V OCCURS AS CONSEQUENCE OF HYPERGLYCEMIA P0615
STREPTOZOTOCIN U URINALYSIS GLUCOSE INC V RARELY EXCEEDS 25 MC/100ML P0686
TETRACYCLINE U URINALYSIS GLUCOSE INC V DEGRADED MATERIAL MAY CAUSE FANCONI SYNDROME P0657
THIAZIDES U URINALYSIS GLUCOSE INC V MAY OCCUR ESPECIALLY IN PREDIABETICS P01414
TRIAMCINOLONE U URINALYSIS GLUCOSE INC V CONSEQUENCE OF HYPERGLYCEMIA P0683
TRICHLORNETHIAZIDE U URINALYSIS GLUCOSE INC V DIABETOGENIC-LIKE ACTION OF DRUG P0907
TRIMETOZINE U URINALYSIS GLUCOSE INC N FALSE P05 WITH GLUC OX (COMBISTIX) REPORTED P0205
TURPENTINE U URINALYSIS GLUCOSE INC V DUE TO INGESTION - NEPHROTOXIC EFFECT P0368
VAGINAL POWDER U URINALYSIS GLUCOSE INC N POWDERS MAY CONTAIN GLUCOSE P01417
C!PRALORIDINE U URINALYSIS GLUCOSE Z N WITH TESTAPE P0298
GLUCUPONIC ACID U URINALYSIS GLUCOSE Z M NO EFFECT ON CLINISTIX, LABSTIX METHODS 90999
GLUCURONIC ACID U URINALYSIS GLUCOSE Z N NO EFFECT ON TESTAPE 90999
LEVODOPA U URINALYSIS GLUCOSE Z N NO EFFECT ON TESTAPE P0317
METHYLDOPA U URINALYSIS GLUCOSE Z N NO EFFECT ON GLUCOSE OXIDASE METHODS P0317
NALIDIXIC ACID U URINALYSIS GLUCOSE Z N NO EFFECT WITH CLINISTIX, TESTAPE 90999
PENICILLIN U URINALYSIS GLUCOSE Z N NO EFFECT ON CLINISTIX OR TESTAPE P0683
ASCORBIC ACID U URINALYSIS HEMOGLOBIN DEC N IN LARGE AMOUNTS INHIBYTS GUAIAC TEST P0299
ACETANILID U URINALYSIS HEMOGLOBIN INC V OCCURS WITH HEMOLYSIS P0518
ACETOPHENETIDIN U URINALYSIS HEMOGLOBIN INC V OCCURS WITH MARKED HEMOLYSIS P0518
ACETYLSALICYLIC AC U URINALYSIS HEMOGLOBIN INC V OCCURS WITH SEVERE HEMOLYTIC ANEMIA P0518
ACIDS U URINALYSIS HEMOGLOBIN INC V RENAL DAMAGE FOLLOWING INGESTION P0368
ANINOPYPINE U URINALYSIS HEMOGLOBIN INC V MAY OCCUR WITH MARKED HEMOLYSIS P0518
AMINOSALICYLIC AC U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG R0299
AMPHOT!RICIN B U URINALYSIS HEMOGLOBIN INC V NEPHROTOXICITY, BLEEDING ACTUALLY CAUSED BY DRUG P0299
AMPICILLIN U URINALYSIS HEMOGLOBIN INC V OCCURS AS RESULT OF NEPHPOTOXICITY 90916
ANTIMALARIALS U URINALYSIS HEMOGLOBIN INC V MAY OCCUR WITH MARKED HEMOLYSIS P0518
ANTIPYRETICS U URINALYSIS HEMOGLOBIN INC V OCCURS WITH MARKED HEMOLYSIS P0518
ANTIPYRINE U URINALYSIS HEMOGLOBIN INC V OCCURS WITH MARKED HEMOLYSIS 90518
ARSENICALS U URINALYSIS HEMOGLOBIN INC V MAY BE MARKED HEMATURIA P0368
BACITRACIN U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG 90299
BACTERIURIA U URINALYSIS HEMOGLOBIN INC N FALSE POSITIVE WITH HEMATEST R1001
BISMUTH SALTS U URINALYSIS HEMOGLOBIN INC V MAY CAUSE SEVER! PENAL DAMAGE P0657
BLOOD TRANSFUSIONS U URINALYSIS HEMOGLOBIN INC V MAY OCCUR ESP WITH FROZEN GLYCEROLIZED BLOOD P0596

BR 3 N I D F S U URINALYSIS HEMOGLOBIN INC N INTERFERES WITH GUAIAC AND BENZIDINE TESTS R1001
CARBON DISULFIDE U URINALYSIS HEMOGLOBIN INC V MANIFESTATION OF PENAL DAMAGE 90254
CHLOROGUANIDE U URINALYSIS HEMOGLOBIN INC V DRUG PRODUCES ACTUAL BLEEDING 90299
COLCHICINE U URINALYSIS HEMOGLOBIN INC V MAY CAUSE BLEEDING 90620
COLISTIMETHATE U URINALYSIS HEMOGLOBIN INC V COMMON NEPHROTOXIC EFFECT R0736
COPPER U URINALYSIS HEMOGLOBIN INC V MAY OCCUR WITH COPPER TOXICITY 90124
COPPER U URINALYSIS HEMOGLOBIN INC N FALSE POSITIVE WITH GUAIAC AND BENZIDINE TESTS 90620
COUMARIN U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING NAY OCCUR WITH HIGH DOSES P0355
CYLOPHOSPHANIDE U URINALYSIS BEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG P0299
ETHYLENE CLYCOL U URINALYSIS HEMOGLOBIN INC V DUE TO NEPHROTOXICITY P0368
FEPPICYANIDE U URINALYSIS HEMOGLOBIN INC N INTERFERES WITH BENZIDINE TEST P0299
FILTER PAPER U URINALYSIS HEMOGLOBIN INC N INTERFERES WITH BENZIDINE TEST P01143
FORMALDEHYDE U URINALYSIS HEMOGLOBIN INC N INTERFERES WITH BENZIDINE TEST P0299
FORMALIN U URINALYSIS HEMOGLOBIN INC N REACTION WITH BENZIDINE P0620
GOLD U URINALYSIS HEMOGLOBIN INC V PRODUCES ACTUAL BLEEDING P0299
HTDPALAZINE U URINALYSIS HEMOGLOBIN INC V REPORTED FINDING R0657
HYDROGEN SULFIDE U URINALYSIS HEMOGLOBIN INC V OCCURS DUE TO NEPUPOTOXOCITY P0368
INDANDIONES U URINALYSIS HEMOGLOBIN INC V MAY CAUSE HEMATURIA - MANIFESTATION OF OVERDOSE P0355
INDOMETHACIN U URINALYSIS HEMOGLOBIN INC V PRODUCES ACTUAL BLEEDING P0299
IODIDES U URINALYSIS HEMOGLOBIN INC N INTERFERES WITH GUAIAC AND BENZIDINE TESTS P0355
IRON SALTS U URINALYSIS HEMOGLOBIN INC V HENATURIA REPORTED AFTER IRON SOPBITOL P0657
KANAMYCIN U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING OCCURS P0299
LEAD U URINALYSIS HEMOGLOBIN INC V OCCURS WITH ACUTE H!MOLYTIC CRISIS P0368
LEVODOPA U URINALYSIS HEMOGLOBIN INC V OCCASIONAL REPORT OF HEMATUPIA P0026
LIPOMUL U URINALYSIS HEMOGLOBIN INC V PRODUCES ACTUAL BLEEDING 90299
LYSOL U URINALYSIS HEMOGLOBIN INC V OCCURS WITH MASSIVE HEMOLYSIS 90197
MANDELIC ACID U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY THE DRUG P0299
NEFENANIC ACID U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY THE DRUG P0299
MEPHENESIN U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG 90299
MERCURY COMPOUNDS U URINALYSIS HEMOGLOBIN INC V NAY CAUSE SEVERE NEPHRITIS IF ABSORBED 90026
NEPSALYL U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG P0299
NETHENAMINE U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING PRODUCED BY DRUG 90299
NETHICILLIN U URINALYSIS HEMOGLOBIN INC V HYPERSENSITIVITY REACTION, NEPHROTOXICITY P0068
METHOCARBAMOL U URINALYSIS HEMOGLOBIN INC V MAY CAUSE INTRAVASCULAR HEMOLYSIS P0384
METHOTREXATE U URINALYSIS HEMOGLOBIN INC V NAY CAUSE HEMATURIA 91015
NITOTANE U URINALYSIS HEMOGLOBIN INC V NAY OCCASIONALLY PRODUCE HENATUPIA P0467
MUSCULAR EXERCISE U URINALYSIS HEMOGLOBIN INC V MAY OCCUR AFTER SEVERE EXERCISE P0291
NAPHTHALENE U URINALYSIS HEMOGLOBIN INC V DUE TO C-6-PD RELATED HEMOLYSIS OR POISONING P0368
NITRIC ACID U URINALYSIS HEMOGLOBIN INC N AFFECTS BENZIDIN! TEST 90620
NITROFURANS U URINALYSIS HEMOGLOBIN INC V NAY OCCUR WITH SEVERE HEMOLYTIC ANEMIA P0518
OXACILLIN U URINALYSIS HEMOGLOBIN INC V NEPHPOTOXICITY WITH HEMATURIA P0026
OXYPHENBUTAZONE U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG P0299
PENICILLIN U URINALYSIS HEMOGLOBIN INC V HYPERSENSITIVITY REACTION, NE?HROTOXICITY P0068
PERMANGANPtTE U URINALYSIS HEMOGLOBIN INC N INTERFERES WITH BEEZIDINE TEST P0299
PHENINDIONE U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG P0299
PHENOLPHTHAL!IN U URINALYSIS HEMOGLOBIN INC V MAY CAUSE ACUTE NEPHROSIS (K DEFICIENCY) P0657
PHENOLS U URINALYSIS HEMOGLOBIN INC V NEPHPOTOXICITY WITH POISONING 903814
PHENYLBUTAZONE U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG P0299
PHOSPHORUS U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG R0299
PHYTONADIONE U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG P0299
POLYMYXIN B U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG 90299
PPOBENECID U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG P0299
PROGUANIL U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG P0299
PYRAZOLONES U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG P0299
QUININE U URINALYSIS HEMOGLOBIN INC V POSSIBLE CONTRIBUTING FACTOR P0026
SODIUM IPODATE U URINALYSIS HEMOGLOBIN INC V NEPHPOTOXIC EFFECT P0260
SULFADIAZINE U URINALYSIS HEMOGLOBIN INC V ASSOCIATED WITH CRYSTALLURIA AND HEMATURIA P0736
SULFAM!THOXAZOLE U URINALYSIS HEMOGLOBIN INC V NAY CAUSE HENATUPIA WITH OLIGURIA P0736
SULFONAMIDES U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG (DUE TO HENOLYSIS) P0299
SULFONES U URINALYSIS HEMOGLOBIN INC V MAY HAVE NEPHROTOXIC EFFECT P0299
SURANIN U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG P0355
THIAZIDES U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY THE DRUG P0299
TRIMETHA1)IONE U URINALYSIS HEMOGLOBIN INC V HENATURIA MAY OCCUR ESPECIALLY IN CHILDREN P0596
TRINITROTOLUENE U URINALYSIS HEMOGLOBIN INC V MAY CAUSE HEMOLYSIS P0620
TRYPSIN U URINALYSIS HEMOGLOBIN INC V OCCASIONAL REPORTED OCCURRENCE P0299
TURPENTINE U URINALYSIS HEMOGLOBIN INC V NEPHROTOXIC EFFECT FOLLOWING INGESTION P0368
UREA U URINALYSIS HEMOGLOBIN INC V H!MOGLOBINUPIA NAY OCCUR ESP IF HYPOTHERMIA 90299
VIOMYCIN U URINALYSIS HEMOGLOBIN INC V ACTUAL BLEEDING CAUSED BY DRUG P0355
VITAMIN K U URINALYSIS HEMOGLOBIN INC V EFFECT OF TREAT OF HEMORRHAGIC STATES IN CHILDREN P0026
WARFARIN U URINALYSIS HEMOGLOBIN INC V DUE TO OVERDOSAGE IN SOME CASES P0368
QUININE U URINALYSIS HEROIN INC N FLUORESCES PRODUCING INTERFERENCE P0996
ACETYLSALICYLIC AC U URINALYSIS KETONES DEC V BY INC OXIDATION OF KETONE BODIES IN DIABETICS P0384
AC!TYLSALICYLIC AC U URINALYSIS KETONES INC V ACIDOTIC RESPONSE ESP IN CHILDREN P0368
INSULIN U URINALYSIS KETONES INC V OCCURS ESP IF LOW LIVE.R GLYCOCEN STORES P0383
ISONIAZID U URINALYSIS KETONES INC V MECHANISM NOT LISTED P0417
LEVODOPA U URINALYSIS KETONES INC N INTERMITTENT FALSE 905 IF KETOSTIX OP PHENISTIX P1003
NETFORMIN U URINALYSIS KETONES INC V ASSOCIATED WITH LACTIC ACIDOSIS P0299
NICOTINIC ACID U URINALYSIS KETONES INC V ?DUE TO HEPATIC MOBILIZATION OF KETOGENIC AMINO AC P0360
PAPALDEHYDE U URINALYSIS KETONES INC N FALSE 905 WHEN DRUG COMBINED WITH ETHANOL 901407
PHENAZOPYRIDINE U URINALYSIS KETONES INC N FALSE P05 WITH KETOSTIX OP FECL3 R0690
PHENFORNIN U URINALYSIS KETONES INC V OBSERVED EVEN WITH NORMAL BLOOD SUGAR P0299
ACETAMINOPHEN U URINALYSIS METH!MOGLOB INC V RENAL DAMAGE DUE TO HEMOLYSIS P0384
ACETANILID U URINALYSIS NETHEMOGLOB INC V DUE TO HENOLYSIS AND PENAL DAMAGE 90384
ACETOPHENETIDIN U URINALYSIS METHEMOGLOB INC V FREE METHENOGLOBIN MAY OCCUR WITH HEMOLYSIS P0384
ANILINE U URINALYSIS METHENOGLOB INC V DUE TO INTRAVASCULAR HENOLYSIS P0368
DIAZOXIDE U URINALYSIS PH DEC V DUE TO DEC BICARBONATE EXCRETION P0049
METHENAMINE U URINALYSIS PH DEC V MANDELATE IS AN ACIDIFYING AGENT P0384
MUSCULAR EXERCISE U URINALYSIS PH DEC V AT ALL PATES 0? EXERCISE (ACID NETABOLITES) P0505
ACETAZOLAMIDE U URINALYSIS PH INC V INHIBITION OF CARBONIC ANHYDRASE P0384
ALDOSTERONE U URINALYSIS PH INC V H AND K IONS EXCHANGED FOR NA ION 90384
1254 CLINICAL CHEMiSTRY, Vol. 18, No. 10, 1972

A MILOPIDE U URINALYSIS PH INC V MODERATE INCREASE SOMETIMES OBSERVED R0384
C AR BENO XOLO NE U URINALYSIS PH INC V IMPAIRED ACIDIFICATION WITH HYPOKALEMIA P0669
MAFENIDE U URINALYSIS PH INC V INHIBITS CARBONIC ANHYDRASE IF APPLIED TOPICALLY RO985
MUSCULAR EXERCISE U URINALYSIS PH INC V EFFECT NOTED AFTER MILD EXERCISE P0 505
PARATHYROID EXTRACT U URINALYSIS PH INC V INHIBITS TUBULAR EXCHANGE OF NA FOP H P0699
PROL ACTIN U URINALYSIS PH INC V INDIVIDUAL RESPONSE - NAY BE MARKED R0464
TRIAMTERENE U URINALYSIS PH INC V SLIGHT ALKALINIZATION (MECHANISM NOT KNOWN) P03 84
ACETAMINOPHEN U URINALYSIS PROTEIN I NC V NEPHROTOXIC EFFECT OF DRUG P0137
ACETANILID U URINALYSIS PROTEIN INC V DUE TO RENAL DAMAGE WITH HEMOLYSIS 90384
ACETAZ OLA MI DR U URINALYSIS PROTEIN INC N MAKES URINE HIGHLY ALKALINE, CAUSES FALSE POSITIVE ROO39
ACETOP HENET IDIN U URINALYSIS PROTEIN INC V MAY OCCUR IF INTRAVASCULAR HENOLYSIS 903814
ACETYLSALICYLIC AC U URINALYSIS PROTEIN INC V MAY CAUSE NEPHROTOXICITY P0417
ACIDS U URINALYSIS PROTEIN INC V RENAL DAMAGE FOLLOWING INGESTION P0 368
ALKALINE URINE U URINALYSIS PROTEIN INC N HIGHLY BUFFERED URINE MAY AFFECT CONBISTIX P06 20
ANINOPHYLLINE U URINALYSIS PROTEIN INC V INC IN RENAL DISEASE (OCCURS EARLY WITH POISONING) P0 2 99
AMINOPYRI NE U URINALYSIS PROTEIN INC V NEPHPOTOXICITY REPORTED 906S7
ANINOSALICYLIC AC U UPINALYS IS P P OT El N I NC N REACTS WITH FOLIN-CIOCALTEU OF LOWRY PROCEDURE P0 3 55
AMINOSALICYLIC AC U URINALYSIS PROTEIN IN C V NAY CAUSE NEPHROTOXICITY RO355
AMPHOTERICIN B U UPINALYS IS PROTEIN I NC V NEPHROTOXICITY HO 299
AMPICILLIN U URINALYSIS PROTEIN INC V NECROSIS OF TUBULES DUE TO NEPHROTOXICITY P0916
ANTIMONY COMPOUNDS U UPIN ALYS IS PROTEIN I NC V NEPUROTOXIC EFFECT P02 99
ANTIPYRINE U URINALYSIS PROTEIN INC V PENAL ACTION OF DRUG P0988
ARSENICALS U UPINALYS IS PROTEIN INC V NEPHROTOXIC EFFECT R0299
ASPARAGINASE U 091 NALY SIS PROTEIN INC V TRANSIENT SLIGHT EFFECT FOP FEW DAYS P070 5
BACITRACIN U URINALYSIS PROTEIN INC V N!PHROTOXIC EFFECT P02 99
BISMUTH SALTS U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT P0 299
BORIC ACID U URINALYSIS PROTEIN INC V DUE TO RENAL DAMAGE P0 36 8
BRO NATE U URINALYSIS PROTEIN INC V DUE TO PENAL DAMAGE P03 68
BUNANIODYL U URINALYSIS PROTEIN INC N AFFECTS TURBIDITY TESTS FOP UP TO 3 DAYS H 0020
CADMIUM U URINALYSIS PPOTEI N I NC V GENERALIZED IMPAIRMENT OF PROX TUBULAR FUNCTION P0006
CAPREO NYC IN U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT (TRANSIENT) P0299
CAP BAR SON! U UPINALYS IS PROTEIN I NC V NEPHROTOXIC EFFECT P0 299
CAP BE NOX OLO NE U URINALYSIS PROTEIN INC V DUE TO MYOGLOBIN AND NEPHROPATHY P0669
CARBON DISULFID! U URINALYSIS PROTEIN I NC V MANIFESTATION OF PENAL DAMAGE P0 254
CARBON MONOXIDE U URINALYSIS PROTEIN INC V ASSOC WITH OLIGUPIA AND RENAL DAMAGE P0368
CARBON TETPACHLOR U URINALYSIS P P OTE I N I NC V NEPHROTOXIC EFFECT 90299
CARBUTAMID! U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT 90964
CARINAMIDE U URINALYSIS PROTEIN I NC N PRODUCES PRECIPITATE WITH ACID TESTS 90143
CEPHALORIDINE U URINALYSIS PROTEIN INC V MAY BE RESULT OF NEPHPOTOXICITY 90449
CEPHALORIDINE U URINALYSIS PROTEIN INC M PRECIPITATE OCCURS WITH SULFOSALICYLIC ACID P05 81
CEPHALORIDINE U URINALYSIS PROTEIN INC N WEAK P05 WITH ALBUSTIX AT HIGH CONCS P058 1
CEPHALOTHI N U URINALYSIS PROTEIN INC V RARE EFFECT FOLLOWING I.V. INFUSION P0657
CEPHALOTHIN U URINALYSIS PROTEIN INC N PRECIPITATE OCCURS WITH SULFOSALICYLIC ACID 90581
CEPHALOTHIN U URINALYSIS PROTE IN INC N WEAK POSITIVE WITH ALBUSTIX AT HIGH CONCS 90581
CHLOR AL U URINALYSIS PROTEIN I NC V PARENCHYMATOUS RENAL INJURY IN CHRONIC INTOXICATION P0 3 84
CHLORPROMAZINE U URINALYSIS PROTEIN INC N AFFECTS TURBIDITY TESTS FOR UP TO 3 DAYS P0020
CHLORPROPAMIDE U UPINALYS IS PROTEIN I NC V NEPHROTOXIC EFFECT P0964
CHLOPTHALIDONE U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT 90355
CHRYSAROBIN U URINALYSIS PROTEIN I NC V KIDNEY IRRITATION BY METABOLITE P00 26
COLISTIMETHATE U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT 906 20
COLISTIN U URINALYSIS PROTEIN INC V N!PHPOTOXIC EFFECT (REVERSIBLE RENAL DAMAGE) P06 76
CORTICOTROPIN U URINALYSIS PROTEI N INC V NAY BE NEPHROTOXIC IN CHRONIC DISEASE P0 445
DENECLOCYCLINE U URINALYSIS PROTEIN INC V N!PHROTOXICITY R0572
DIHYDROTACHYSTEROL U URINALYSIS PROTEIN INC N INCREASED GLONERULAR PERMEABILITY P0 299
DI NITROPHENOL U URINALYSIS PROTEIN INC V DUE TO NEPHROTOXICITY P03 68
DITHIAZINE U URINALYSIS PPOTE IN I NC V TRANSIENT PROTEINUPIA MAY OCCUR P0 657
DITHIAZI NE U URINALYSIS PROTEIN INC N REACTS WITH FOLIN-CIOCALTEU OF LOWRY PROCEDURE 90654
DOX APR AM U URINALYSIS PROTEIN I NC V ? NEPHROTOXIC EFFECT R0299
DOXYCYCLINE U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT P0734
EDTA U UPINALYS IS PROTEIN I NC V NEPHROTOXIC EFFECT (ESP CA EDTA) 90355
ETHOSUXIMID! U URINALYSIS PROTEIN INC V POSSIBLE REVERSIBLE NEPHROPATHY 90299
ETHYLENE GLYCOL U URINALYSIS PROTEIN I NC V DUE TO NEPHROTOXICITY 90368
GENTA MICIN U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT R0299
GOLD U URINALYSIS PROTEIN I NC V NEPHROTOXIC EFFECT (AT LEAST IN 50% CASES) 90299
CR1 SEOFULVIN U URINALYSIS PROTEIN INC V ? N!PHPOTOXIC EFFECT (TRANSIENT AND REVERSIBLE) P02 99
HYDRALAZ I NE U URINALYSIS PROTEIN INC V REPORTED FINDING P0657
HYDROGEN SULFIDE U URINALYSIS PROTEIN I NC V OCCURS DUE TO NEPHPOTOXICITY P0 368
INDOMETHACIN U URINALYSIS PROTEIN I NC V REPORTED IN ONE PATIENT P0 157
IODINE CONTAIN DRUG U URINALYSIS P P OTE I N I NC V RESULT OF HEMORRHAGIC NEPHRITIS AT TOXIC DOSES P036 8
I000ALPHIONIC ACID U URINALYSIS PROTEIN INC N AFFECTS ACID PRECIPITATION METHODS 90020
IODOPYRACET U URINALYSIS PROTEIN I NC N GIVES FALSE POSITIVE WITH TURBIDITY TESTS 90233
IOPANOIC ACID U URINALYSIS PROTEIN INC N CAUSES FALSE POSITIVE WITH TURBIDITY TESTS 90020
IOPH!NOXIC ACID U URINALYSIS PROTEIN INC N AFFECTS TURBIDITY TESTS FOP UP TO 3 DAYS 90020
IRON SALTS U URINALYSIS PROTEIN I NC V MAY CAUSE NEPHPOTOXICITY 90417
ISONIAZID U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT R0299
ISOPROPANOL U URINALYSIS PROTEIN I NC V TRANSIENT AND MILD LATE TOXIC EFFECT 90368
KANAMYCIN U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT R0299
KEROSENE U URINALYSIS PROTEIN I NC V RENAL DAMAGE WITH LARGE DOSES 90384
LEAD U URINALYSIS P RO TE IN INC V NEPHROTOXICITY WITH POISONING R0384
LIPOMUL U UPINALYS IS PROTEIN I NC V NEPHROTOXIC EFFECT P0299
LITHIUM U URINALYSIS PROTEIN INC V MAY HAVE SLIGHT NEPHPOTOXIC EFFECT 90417
LU CA NTH ONE U URINALYSIS PROTEIN INC V CHRONIC TOXICITY MAY CAUSE RENAL DAMAGE P03 84
MEFENANIC ACID U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT 90299
NELA R SONYL U URINALYSIS PROTEIN INC V NEPHPOTOXIC EFFECT P0 026
NELAR SOPR OL U URINALYSIS PROTEIN INC V NEPPROTOXIC EFFECT RO62O
MENSTRUATION U URINALYSIS PROTEIN INC V PRE-NENSTRUAL URINE MAY CONTAIN PROTEIN P0291
MERCURY COMPOUNDS U URINALYSIS PROTEIN INC V NEPHPOTOXIC EFFECT P0 355
NETAHEXANIDE U URINALYSIS PROTEIN INC N INTERFERENCE BY DRUG-METABOLITE 90299
MET AX AL ONE U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT P0 2 99
METHA NOL U URINALYSIS PROTEIN INC V OCCURS WITH POISONING 90384

METHENAMINE U URINALYSIS PROTEIN INC V NEPHROTOXIC IN LARGE DOSES P0299
METHICILLIN U URINALYSIS PROTEIN INC V NEPHPOTOXIC EFFECT P0677
METHSUXIMIDE U URINALYSIS PROTEIN INC V RENAL DAMAGE REPORTED P0355
METHYLBROMIDE U URINALYSIS PROTEIN INC V DUE TO TUBULAR NECROSIS 90368
MITHPAMYCIN U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT RO026
MITOMYCIN C U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT 90589
NITOTANE U URINALYSIS PROTEIN INC V MAY RARELY PRODUCE HEMATURIA. RENAL DAMAGE R0467
MUSCULAR EXERCISE U URINALYSIS PROTEIN INC V MOPE COMMON WITH HEAVY EXERCISE THAN MILD P0505
NAPHTHALENE U URINALYSIS PROTEIN INC V NEPHPOTOXIC EFFECT 90368
NEOMYCIN U URINALYSIS PROTEIN INC V NEPHPOTOXIC EFFECT 90299
OXACILLIN U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT P0026
OXALATES U URINALYSIS PROTEIN INC V N!PHROTOXIC EFFECT IF INGESTED P0368
PARALDEHYDE U URINALYSIS PROTEIN INC V NEPHPOTOXIC EFFECT (NEPHROSIS WITH POISONING) 90407
PAPAMETHADIONE U URINALYSIS PROTEIN INC V MAY HAVE NEPHPOTOXIC EFFECT P0677
PAROMONYCIN U URINALYSIS PROTEIN INC V POTENTIALLY NEPHROTOXIC IF GIVEN PAPENTERALLY 90026
PENICILLAMINE U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT 90355
PENICILLIN U URINALYSIS PROTEIN INC M MASSIVE DOSES MAY PRODUCE TURBIDITY WITH ACID P0143
PENICILLIN U URINALYSIS PROTEIN INC V NEPHROTOXICITY MAY OCCUR WITH LARGE DOSES P03814
PEPCHLORATE U URINALYSIS PROTEIN INC V REPORTED CASES OF NEPHROTIC SYNDROME 90026
PHENACENIDE U URINALYSIS PROTEIN INC V OCCASIONAL NEPHROPATHY 90299
PHENAZOPYPIDINE U URINALYSIS PROTEIN INC N FALSE POSITIVE WITH LABSTIX ETC RO690
PHENINDIONE U URINALYSIS PROTEIN INC V NEPHROTOXICITY MAY OCCUR P0677
PHENOLPHTHALEIN U URINALYSIS PROTEIN INC V NAY CAUSE ACUTE NEPHROSIS (K DEFICIENCY) R0657
PHENOLS U URINALYSIS PROTEIN INC V NEPHROTOXICITY WITH POISONING P0384
PHENSUXIMIDE U URINALYSIS PROTEIN INC V REVERSIBLE NEPHROPATHY (ESP IN CHILDREN) P0026
PHENYLBUTAZONE U URINALYSIS PROTEIN INC V REPORTED NEPHROTOXIC EFFECT R0417
PHOSPHORUS U URINALYSIS PROTEIN INC V PENAL TOXIC EFFECT P0355
PICRIC ACID U URINALYSIS PROTEIN INC V NEPHPOTOXICITY 90384
POLYMYXIN B U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT P0355
PREGNANCY U URINALYSIS PROTEIN INC V MODERATE PPOTEINURIA MAY OCCUR COMMONLY 90291
PROBENECID U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT P0417
PROMAZINE U URINALYSIS PROTEIN INC N AFFECTS TURBIDITY TESTS FOR UP TO 3 DAYS P0020
PROTEINURIA U URINALYSIS PROTEIN INC V ACTUAL EFFECT 90758
PYRAZOLONES U URINALYSIS PROTEIN INC V NEPHPOTOXIC EFFECT P0299
QUATERNARY U URINALYSIS PROTEIN INC N GIVES FALSE POSITIVE BY CHANGING PH R0907
QUININE U URINALYSIS PROTEIN INC V NAY RARELY CAUSE PENAL DAMAGE P0384
RADIOGRAPHIC U URINALYSIS PROTEIN INC V NAY OCCUR FOLLOWING AORTOCPAPHY P0020
RADIOGRAPHIC U URINALYSIS PROTEIN INC N AFFECTS TURBIDIMETRIC METHODS FOP SOME DAYS P0907
RHUBARB U URINALYSIS PROTEIN INC V CRYSTALLURIA MAY CAUSE PENAL DAMAGE P0053
RIFAMPIN U URINALYSIS PROTEIN INC V ATTRIBUTED TO DRUG IN 2 CASES 90657
SODIUM BICARBONATE U URINALYSIS PROTEIN INC N FALSE P05 WITH LABSTIX DUE TO HIGH PH P0417
SODIUM IPODATE U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT P0260
STIBOPHEN U URINALYSIS PROTEIN INC V PENAL IRRITATION REPORTED 90026
STREPTOKINASE U URINALYSIS PROTEIN INC V RENAL DAMAGE REPORTED P0620
STPEPTOMYCIN U URINALYSIS PROTEIN INC V MAY CAUSE NEPHROTOXICITY P0384
SULFADIAZIN! U URINALYSIS PROTEIN INC V ASSOCIATED WTTH CRYSTALLURIA AND HEMATURIA P0736
SULFAMETHOXAZOLE U URINALYSIS PROTEIN INC N NAY INTERFERE WITH SULFOSALICYLIC ACID METHODS 90299
SULFAMETHOXAZOLE U URINALYSIS PROTEIN INC V MAY CAUSE HEMATURIA WITH CRYSTALLUPIA RO736
SULFISOXAZOLE U URINALYSIS PROTEIN INC N MAY PRODUCE TURBIDITY WITH ACID METHODS 90143
SULFONAMIDES U URINALYSIS PROTEIN INC V MAY CAUSE NEPHROTOXICITY P0620
SULFONES U URINALYSIS PROTEIN INC V MAY HAVE N!PHPOTOXIC EFFECT R0299
SURAMIN U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT P0299
TARTPATES U URINALYSIS PROTEIN INC V IF ABSORBED NAY CAUSE PENAL DAMAGE P03814
TETRACYCLINE U URINALYSIS PROTEIN INC V NEPHPOTOXIC EFFECT WITH DEGRADED TETRACYCLINE P0355
THALLIUM U URINALYSIS PROTEIN INC V DAMAGE TO RENAL TUBULAR EPITHELIUM 90368
THEOPHYLLINE U URINALYSIS PROTEIN INC V WHEN HIGH DOSES SODIUM CLYCINATE SALT GIVEN P0620
THIABENDAZOLE U URINALYSIS PROTEIN INC V MAY CAUSE NEPHROTOXICITY P0417
THIOCYANATES U URINALYSIS PROTEIN INC V MAY CAUSE NEPHROSIS P03814
THIOSEMICARBAZONES U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT 90299
THYMOL U URINALYSIS PROTEIN INC N EXCESS MAY GIVE FALSE P05 WITH TURBIDITY PROCS P01143
TOLBUTAMIDE U URINALYSIS PROTEIN INC N INTERFERES WITH SULPHOSALICYLIC ACID METHOD 908143
TRIMETHADIONE U URINALYSIS PROTEIN INC V MAY HAVE NEPHPOTOXIC EFFECT P01444
TURPENTINE U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT P0355
VANCONYCIN U URINALYSIS PROTEIN INC V NEPHROTOXICITY MAY OCCUR P0355
VIOMYCIN U URINALYSIS PROTEIN INC V NEPHPOTOXIC EFFECT P0355
VITAMIN D U URINALYSIS PROTEIN INC V NEPHROTOXIC EFFECT AND HYPERCALCEMIA P0299
VITAMIN K U URINALYSIS PROTEIN INC V REPORTED SIDE EFFECT P0657
ZOXAZOLAMINE U URINALYSIS PROTEIN INC V NAY HAVE NEPHROTOXIC EFFECT RO417
PPOT!INURIA U URINALYSIS PROTEIN NEG N UNABLE TO DETECT PARAPROTEINS WITH BILI-LABSTIX P0152
PENICILLIN U URINALYSIS PROTEIN Z N NO EFFECT ON ALBUSTIX EVEN WITH MASSIVE DOSES 90143
SULFISOXAZOLE U URINALYSIS PROTEIN Z N NO EFFECT ON ALBUSTIX 90143
TOLBUTANIDE U URINALYSIS PROTEIN Z N NO EFFECT ON ALBUSTIX 90143
FORMALDEHYDE U URINALYSIS PBC/HBF INC V INGESTION MAY CAUSE HEMATURIA AND RENAL DAMAGE P0368
ACETAMINOPHEN U URINALYSIS RBC/HPF INC V RENAL DAMAGE DUE TO HENOLYSIS 90384
ACETANILID U URINALYSIS RBC/HPF INC V DUE TO HEMOLYSIS AND PENAL DAMAGE P0384
ACETOPHENETIDIN U URINALYSIS RBC/HPF INC V HEMOLYSIS MAY CAUSE OLIGURIA OR ANURIA P03814
ACETYLSALICYLIC AC U URINALYSIS PBC/HPF INC V INITIAL EFFECT ALWAYS, MAY PERSIST P0384
ALLOPU8INOL U URINALYSIS RBC/HPF INC V ASSOCIATED WITH SEVERE SENSITIVITY REACTION P0665
AMINOPYRINE U URINALYSIS RBC/HPF INC V RARE NEPHPOTOXICITY REPORTED 90657
ANINOSALICYLIC AC U URINALYSIS RBC/HPF INC V BLEEDING CAUSED BY DRUG P0355
AMPHOTERICIN B U URINALYSIS RBC/HPF INC V NEPHROTOXICITY 90299
ANPICILLIN U URINALYSIS RBC/HPF INC V NECROSIS OF TUBULES DUE TO NEPHROTOXICITY 90916
ARSENICALS U URINALYSIS PBC/HPF INC V NEPHROTOXICITY WITH TUBULAR NECROSIS 90384
BACITRACIN U URINALYSIS RBC/HPF INC V ACTUAL BLEEDING CAUSED BY DRUG P0299
BISMUTH SALTS U URINALYSIS RBC/HPF INC V NAY CAUSE SEVERE PENAL DAMAGE P0657
BPOMATE U URINALYSIS RBC/HPF INC V DUE TO RENAL DAMAGE 90368
CAFFEINE U URINALYSIS PBC/HPF INC V DAILY ADMIN CAUSES MODERATE INCREASE P0657
CARBON DISULFIDE U URINALYSIS RBC/HPF INC V MANIFESTATION OF PENAL DAMAGE 902514
CHLOROGUANIDE U URINALYSIS RBC/HPF INC V DRUG PRODUCES ACTUAL BLEEDING 90299
COLCHICINE U URINALYSIS RBC/HPF INC V MAY CAUSE BLEEDING P0620

COLISTIN!THAT! U URINALYSIS RBC/HPF INC V COMMON NEPHPOTOXIC EFFECT P0736
COUNARIN U URINALYSIS RBC/HPF INC V ACTUAL BLEEDING NAY OCCUR WITH HIGH DOSES P0299
CYCLOPHOSPHANIDE U URINALYSIS RBC/HPF INC V ACTUAL BLEEDING MAY BE CAUSED BY DRUG P0299
DIATRIZOATE U URINALYSIS RBC/HPF INC V HAS CAUSED ACUTE RENAL FAILURE WITH MYELOCRAPHY 90621
DINITROPHENOL U URINALYSIS RBC/HPF INC V DUE TO TOXIC NEPHRITIS P0368
ETHYLENE GLYCOL U URINALYSIS RBC/HPF INC V DUE TO NEPHROTOXICITY 90368
GOLD U URINALYSIS RBC/HPF INC V PRODUCES ACTUAL BLEEDING P0299
HYDRALAZINE U URINALYSIS RBC/HPF INC V REPORTED FINDING P0657
HYDROGEN SULFIDE U URINALYSIS RBC/HPF INC V OCCURS WITH NEPHROTOXICITY(USUALLY MARKED) 90368
INDANDIONES U URINALYSIS RBC/HPF INC V NAY CAUSE HEMATUPIA - MANIFESTATION OF OVERDOSE P0355
INDONETHACIN U URINALYSIS RBC/HPF INC V MAY CAUSE ACTUAL BLEEDING 90299
IODINE CONTAIN DRUG U URINALYSIS RBC/HPF INC V HEMORRHAGIC NEPHRITIS WITH TOXIC DOSES P0368
IRON SALTS U URINALYSIS RBC/HPF INC V HEMATURIA REPORTED AFTER CHRONIC ADMIN FE SORBITOL 90467
KANAMYCIN U URINALYSIS RBC/HPF INC V ACTUAL BLEEDING MAY OCCUR P0299
KEROSENE U URINALYSIS PBC/HPF INC V WITH SEVERE TOXICITY FOLLOWING INGESTION P0368
LEAD U URINALYSIS RBC/HPF INC V NEPHROTOXICITY WITH POISONING 90384
LEVODOPA U URINALYSIS RBC/HPF INC V OCCASIONAL REPORT OF HEMATURIA P0026
LIPOMUL U URINALYSIS RBC/HPF INC V MAY CAUSE ACTUAL BLEEDING P0299
NANDELIC ACID U URINALYSIS RBC/HPF INC V ACTUAL BLEEDING MAY BE CAUSED BY DRUG P0299
NEFENAMIC ACID U URINALYSIS RBC/HPF INC V ACTUAL BLEEDING CAUSED BY DRUG P0620
MEPRENESIN U URINALYSIS RBC/HPF INC V ACTUAL BLEEDING NAY BE CAUSED BY DRUG P0299
MERCURY COMPOUNDS U URINALYSIS RBC/HPF INC V MAY CAUSE SEVERE NEPHRITIS IF ABSORBED P0026
MERSALYL U URINALYSIS RBC/HPF INC V ACTUAL BLEEDING MAY BE CAUSED BY DRUG P0299
METHENAMINE U URINALYSIS RBC/HPF INC V MAY CAUSE ACTUAL BLEEDING 90299
METHICILLIN U URINALYSIS PBC/HPF INC V HYPERSENSITIVITY REACTION, NEPHPOTOXICITY P0068
NETHOCARBAMOL U URINALYSIS RBC/HPF INC V MAY CAUSE INTRAVASCULAR HEMOLYSIS P03814
NETHYLBRONIDE U URINALYSIS RBC/HPF INC V DUE TO TUBULAR NECROSIS P0368
MITOTANE U URINALYSIS RBC/HPF INC V MAY OCCASIONALLY PRODUCE HEMATURIA P01467
MUSCULAR EXERCISE U URINALYSIS RBC/HPF INC V INC WITH INCREASING RATES OF EXERCISE P0505
NAPHTHALENE U URINALYSIS RBC/HPF INC V OCCURS OCCASIONALLY FOLLOWING INHALATION OF VAPOR 90368
OXACILLIN U URINALYSIS RBC/HPF INC V NEPHROTOXICITY WITH HEMATUPIA P0026
OXALATES U URINALYSIS PBC/HPF INC V NEPHROTOXIC EFFECT IF INGESTED 90368
OXYPHENBUTAZONE U URINALYSIS RBC/HPF INC V NAY CAUSE ACTUAL BLEEDING P0299
PENICILLIN U URINALYSIS RBC/HPF INC V HYPERSENEITIVITY REACTION, NEPHROTOXICITY P0068
PHENINDIONE U URINALYSIS RBC/HPF INC V MAY CAUSE ACTUAL BLEEDING P0299
PHENOLPHTHALEIN U URINALYSIS PBC/HPF INC V NAY CAUSE ACUTE NEPHROSIS (K DEFICIENCY) P0657
PHENOLS U URINALYSIS PBC/HPF INC V OCCUR WITH RENAL DAMAGE OF POISONING P0368
PHENYLBUTAZONE U URINALYSIS RBC/HPF INC V ACTUAL BLEEDING CAUSED BY DRUG P0299
PHISOHEX U URINALYSIS RBC/HPF INC N RED GLOBULES THAT LOOK LIKE RED BLOOD CELLS 90299
PHOSPHORUS U URINALYSIS RBC/HPF INC V NEPHPOTOXIC EFFECT P0299
PHYTONADIONE U URINALYSIS RBC/HPF INC V ACTUAL BLEEDING CAUSED B! DRUG P0620
POLYNYXIN B U URINALYSIS RBC/HPF INC V ACTUAL BLEEDING NAY BE CAUSED BY DRUG P0355
PPOBENECID U URINALYSIS PBC/HPF INC V ?DUE TO SENSITIVITY, OR TOXICITY 90129
PPOGITANIL U URINALYSIS RBC/HPF INC V ACTUAL BLEEDING NAY BE CAUSED BY DRUG P0299
PYRAZOLONES U URINALYSIS RBC/HPF INC V MAY CAUSE ACTUAL BLEEDING P0299
RADIOGRAPHIC U URINALYSIS RBC/HPF INC V NEPHROTOXIC MANIFESTATION 902014
RHUBARB U URINALYSIS RBC/HPF INC V CRYSTALLURIA MAY CAUSE RENAL DAMAGE P0053
RIFAMPIN U URINALYSIS RBC/HPF INC V RAPE REPORTED SIDE EFFECT 90432
SODIUM IPODATE U URINALYSIS RBC/HPF INC V NEPHROTOXIC EFFECT P0260
SULFADIAZINE U URINALYSIS PBC/HPF INC V ASSOCIATED WITH CRYSTALLUPIA AND OLIGUPIA P0736
SULFAMETHOXAZOLE U URINALYSIS RBC/HPF INC V MAY CAUSE HEMATURIA WITH CRYSTALLURIA P0736
SULFONAMIDES U URINALYSIS RBC/HPF INC V MAY CAUSE ACTUAL BLEEDING P0299
SULFONES U URINALYSIS RBC/HPF INC V MAY HAVE NEPHROTOXIC EFFECT P0620
SURAMIN U URINALYSIS PBC/HPF INC V NAY CAUSE ACTUAL BLEEDING P0299
THIAZIDES U URINALYSIS RBC/HPF INC V MAY CAUSE ACTUAL BLEEDING P0299
TRINETHADIONE U URINALYSIS RBC/HPF INC V HEMATURIA NAY OCCUR ESPECIALLY IN CHILDREN P0596
TRINITROTOLUENE U URINALYSIS RBC/HPF INC V MAY CAUSE HEMOLYSIS 90620
TRYPSIN U URINALYSIS RBC/HPF INC V OCCASIONAL REPORTED OCCURRENCE P0299
VIOMYCIN U URINALYSIS RBC/HPF INC V NAY CAUSE ACTUAL BLEEDING P0355
WARFARIN U URINALYSIS RBC/HPF INC V EXCESSIVE DOSES MAY CAUSE HENATUPIA P0283
CARBENOXOLONE U URINALYSIS S.C. DEC V IMPAIRED ABILITY TO CONCENTRATE WITH LOW K 90669
METHOXYFLUPANE U URINALYSIS S.G. DEC V IMPAIRED RENAL TUBULAR FUNCTION P0229
DEXTRAN U URINALYSIS S.G. INC N HIGH MOLECULAR WEIGHT P0299
DIATPIZOATE U URINALYSIS S.C. INC N PRESENCE OF HIGH MOLECULAR WEIGHT COMPOUND P01475
RADIOGRAPHIC U URINALYSIS S.G. INC N PRESENCE OF HIGH MOLECULAR WEIGHT SUBSTANCE P0907
ACETANILID U URINALYSIS SUGAR INC N ACTS AS REDUCING AGENT WITH NON-SPECIFIC TESTS P0355
ACETYLSALICYLIC AC U URINALYSIS SUGAR INC N CONJUGATE MAY REACT WITH BENEDICT’S P0436
AMINO ACIDS U URINALYSIS SUGAR INC N FALSE POSITIVE CAUSED BY SOME WITH BENEDICT’S R0299
AMINDSALICYLIC AC U URINALYSIS SUGAR INC N ACTS AS REDUCING AGENT WITH NON-SPECIFIC METHODS P0355
AMYGDALINS U URINALYSIS SUGAR INC N MEASURED AS REDUCING AGENTS WITH BENEDICT’S P0620
ANTIPYPINE U URINALYSIS SUGAR INC M ACTS AS REDUCING AGENT P0654
APABINOSE U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S 901436
ASPIDIUM U URINALYSIS SUGAR INC N ACTS AS REDUCING AGENT P0299
BISMUTH SALTS U URINALYSIS SUGAR INC N INTERFERES WITH BENEDICT’S REACTION P0299
CARINAMIDE U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S 901436
CEPHALORIDINE U URINALYSIS SUGAR INC N ABNORMAL DARK COLOR WITH BENEDICT’S B CLINITEST P0317
CEPHALOTHIN U URINALYSIS SUGAR INC N BROWN-BLACK COLOR WITH CLINITEST (FALSE POSITIVE) 90044
CHLORAL U URINALYSIS SUGAR INC N EXCRETED AS GLUCURONIDE FALSE P05 WITH BENEDICT’S P0299
CHLORAL BETAINE U URINALYSIS SUGAR INC N EXCRETED AS GLUCUPONIDE, ACTS AS REDUCING SUBST P0356
CHLORAL HYDRATE U URINALYSIS SUGAR INC N EXCRETED AS GLUCURONIDE, REDUCES BENEDICT’S P0596
CHLORAMPHENICOL U URINALYSIS SUGAR INC N FALSE POSITIVE WITH COPPER REDUCTION PROCEDURES P0907
CHLOROFORM U URINALYSIS SUGAR INC V POSITIVE WITH BENEDICT’S, FEHLING’S SOLNS P1001
CHLOPTETRACYCLINE U URINALYSIS SUGAR INC N ACTS AS REDUCING SUBSTANCE P0356
CINCHOPHEN U URINALYSIS SUGAR INC N ACTS AS A REDUCING SUBSTANCE 90654
CREATININE U URINALYSIS SUGAR INC N ACTS LIKE REDUCING SUBSTANCE WITH BENEDICT’S 90620
CRESOL U URINALYSIS SUGAR INC N EXCRETED AS GLUCUPONID! REACTS WITH BENEDICT’S P0197
DIATRIZOATE U URINALYSIS SUGAR INC M AFFECTS COPPER REDUCTION TECHNIQUES DUE TO 12 90654
EDTA U URINALYSIS SUGAR INC N REDUCES BENEDICT’S REAGENT 90355
ETHINAMATE U URINALYSIS SUGAR INC N THEORETICAL EFFECT AS EXCRETED AS GLUCUPONIDE 903814
FORMALDEHYDE U URINALYSIS SUGAR INC N INTERFERES WITH BENEDICT’S REAGENT P0299

FORMALIN U URINALYSIS SUGAR INC N MAY REDUCE FEHLINGS AND CLINITEST P0436
FRUCTOSE U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S R0436
GALACTOSE U URINALYSIS SUGAR INC N GIVES POSITIVE WITH BENEDICT’S P0436
GLtJCURONIC ACID U URINALYSIS SUGAR INC N INTERFERES WITH BENEDICT’S, FEHLINGS, CLINITEST P0999
HIPPURIC ACID U URINALYSIS SUGAR INC N REDUCES BENEDICT’S SOLUTION P0299
HONOGENTISIC ACID U URINALYSIS SUGAR INC M REDUCES BENEDICT’S SOLUTION P0299
HYPOCHLOBITES U URINALYSIS SUGAR INC N NAY CAUSE FALSE P05 WITH CLINISTIX 90436
INDICAN U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S 90663
ISONIAZID U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S AND CLINITEST P0317
KETONE BODIES U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S P01436
LACTOSE U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S P0436
LEVODOPA U URINALYSIS SUGAR INC N PRODUCES TRACE POSITIVE IF CLINITEST USED P0317
LYSOL U URINALYSIS SUGAR INC M EXCRETED GLUCURONIDE REACTS WITH BENEDICT’S P0197
MALTOSE U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S 90436
METAPROTERENOL U URINALYSIS SUGAR INC N INTERFERES WITH BENEDICT’S REAGENT P0299
METAXALONE U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S, FEHLING’S REACTIONS P0907
METHYPRYLON U URINALYSIS SUGAR INC N EXCRETED AS GLUCUPONIDE, ACTS AS REDUCING SUBST P0384
NALIDIXIC ACID U URINALYSIS SUGAR INC N FALSE P05 WITH FEHLINGS, BENEDICT’S, CLINITEST P0999
NITROFURANS U URINALYSIS SUGAR INC N METABOLITES REDUCE BENEDICT’S REAGENT R0596
NITROFUPAZONE U URINALYSIS SUGAR INC N REDUCING ACTION OF NETABOLITES P0355
NUCLEOPROTEINS U URINALYSIS SUGAR INC N INTERFERES WITH BENEDICT’S-?REDUCING SUGAR 90299
OXALATES U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S P0436
OXYTETRACYCLINE U URINALYSIS SUGAR INC N ACTS AS REDUCING AGENT P1001
PHENOLS U URINALYSIS SUGAR INC N INTERFERES WITH BENEDICT’S REAGENT P0299
PROTEIN U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S P0620
RHUBARB U URINALYSIS SUGAR INC N MAY CAUSE FALSE POSITIVE WITH BENEDICT’S RO663
RIBOSE U URINALYSIS SUGAR INC M FALSE POSITIVE WITH BENEDICT’S 901436
SANTONIN U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S 90663
SAUERKRAUT U URINALYSIS SUGAR INC N NETABOLITE MAY AFFECT GALATEST P01436
STREPTONYCIN U URINALYSIS SUGAR INC N ACTS AS REDUCING AGENT AFFECTS BENEDICT’S, GALATEST P1001
SULFAMETHOXAZOLE U URINALYSIS SUGAR INC N NAY CAUSE POSITIVE WITH FLUORESCENT METHODS P0299
SULFANILANIDE U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S P0436
TETRACYCLINE U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S AND CLINITEST P0417
URIC ACID U URINALYSIS SUGAR INC N ACTS AS REDUCING AGENT WITH BENEDICT’S P0620
XYLOSE U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S R0436
XYLULOS! U URINALYSIS SUGAR INC N FALSE POSITIVE WITH BENEDICT’S P01436
SULFONAMIDES U URINALYSIS TURBIDITY INC V ESP IF GIVEN WITH NETHENAMINE-DUE TO URATES P0467
ACETYLSALICYLIC AC U URINALYSIS WBC/HPF INC V OCCURS WITH POISONING 90368
ALLOPURINOL U URINALYSIS WBC/HPF INC V ASSOCIATED WITH SEVERE SENSITIVITY REACTION P0665
AMPICILLIN U URINALYSIS WBC/HPF INC V NECROSIS OF TUBULES DUE TO NEPHROTOXICITY P0916
IRON SALTS U URINALYSIS WBC/HPF INC V MAY EXACERABATE URINARY TRACT INFECTIONS 90657
KANANYCIN U URINALYSIS WBC/HPF INC V NEPHROTOXIC EFFECT P0467
NETHICILLIN U URINALYSIS WBC/HPF INC V PYURIA REPORTED AS COMPLICATION 90467
MUSCULAR EXERCISE U URINALYSIS WBC/HPF INC V NOTED AFTER HEAVY EXERCISE P0505
SODIUM IPODATE U URINALYSIS WBC/HP? INC V NEPHROTOXIC EFFECT P0260
ACRIFLAVINE U UROBILIN INC N PRODUCES YELLOW-GREEN FLUORESCENCE P0436
ALLOPURINOL 1! UROBILIN INC V TRANSIENT INCREASES REPORTED P0657
FLUORESCEIN U UROBILIN INC N PRODUCES YELLOW-GREEN FLUORESCENCE P0436
M!RCUPOCHROME U UROBILIN INC N YIELDS PINK COLOR AND MAUVE FLUORESCENCE 90436
PHYLLOEPYTHRINOGEN U UROBILIN INC N PRODUCES RED FLUORESCENCE 901436
PORPHYRINS U UROBILIN INC N PRODUCE RED FLUORESCENCE 90436
RIBOFLAVIN U UPOBILIN INC N PRODUCES YELLOW-GREEN FLUORESCENCE P0436
TETRAIODOFLUOPESCE U UROBILIN INC M PINK COLOR WITH MAUVE FLUORESCENCE P0436
ACETOHEXANIDE F UPOBILINOGEN DEC V THEORETICALLY IF CHOLESTASIS OCCURS 90026
AJMALINE F UROBILINOGEN DEC V INTRAHEPATIC CHOLESTASIS P0088
ANINOSALICYLIC AC F UROBILINOGEN DEC V PALE STOOLS MAY OCCUR IF CHOLESTASIS P0477
ANTIBIOTICS F URORILINOGEN DEC V INHIBIT G.I.TRACT FLORA 90355
CHLOPAMPHENICOL F UROBILINOGEN DEC V REDUCTION OF FLORA IN G.I. TRACT P0417
CHLORDIAZEPOXIDE F UROBILINOGEN DEC V INFREQUENT CHOLESTATIC EFFECT P0477
CHLORPRONAZINE P UPOBILINOGEN DEC V PALE STOOLS, DUE TO CHOLESTASIS P0477
CHLORPPOPANIDE P UPOBILINOGEN DEC V PALE STOOLS DUE TO CHOLESTASIS(INFREQUENT) R01477
ERYTHRONYCIN F UROBILINOGEN DEC V MAY CAUSE CHOLESTASIS (REVERSIBLE) P0477
MEPAZINE F UROBILINOGEN DEC V DUE TO CHOLESTASIS (PALE STOOLS RESULT) P0477
METHANDROSTENOLONE F UROBILINOGEN DEC V LIGHT STOOLS,DUE TO CHOLESTASIS P0477
NETHIMAZOLE F UROBILINOGEN DEC V CHOLESTATIC EFFECT P0477
NALIDIXIC ACID F UPOBILINOGEN DEC V MA! OCCUR WITH CHOLESTASIS P0736
NEOMYCIN F UROBILINOGEN DEC V REDUCES FLORA IN G.I. TRACT P01417
NOPETHANDROLONE F UROBILINOGEN DEC V LIGHT STOOLS DUE TO CHOLESTASIS P0477
ORAL CONTRACEPTIVE F UPOBILINOGEN DEC V PALE STOOLS, DUE TO CHOLESTASIS 901477
OXYNETHOLONE F UPOBILINOGEN DEC V CHOLESTATIC EFFECT P0477
PROCHLORPERAZINE F UPOBILINOGEN DEC V PALE STOOLS ASSOCIATED WITH CHOLESTASIS P0026
PROMAZINE F UPOBILINOGEN DEC V PAL! STOOLS AS RESULT OF CHOLESTASIS P01477
STORAGE OF SAMPLE F UROBILINOGEN DEC N DEC UP TO 46% WITHIN 24H AT 4 DEGREES P0436
SULFADINETHOXINE F UROBILINOGEN DEC V PALE STOOLS WITH PEVER-SIBLE CHOLESTASIS P0307
SULFAFURAZOLE F ITROBILINOGEN DEC V PALE STOOLS WITH REVERSIBLE CHOLESTASIS P0620
SULFANETHIZOLE F UROBILINOGEN DEC V PALE STOOLS WITH REVERSIBLE CHOLESTASIS P0542
SULFAMETHOXAZOLE F UPOBILINOGEN DEC V PALE STOOLS WITH REVERSIBLE CHOLESTASIS P0620
SULFAMETHOXYPYPID F UROBILINOGEN DEC V NAY CAUSE REVERSIBLE CHOLESTASIS P0620
SULFISOXAZOLE F UROBILINOGEN DEC V PALE STOOLS WITH REVERSIBLE CHOLESTASIS P0542
SULFONAMIDES F UROBILINOGEN DEC V PALE STOOLS WITH REVERSIBLE CHOL!STASIS P01477
TETRACYCLINE F UROBILINOGEN DEC V REDUCES FLORA IN G.I. TRACT P0417
THIABENDAZOLE F UROBILINOGEN DEC V PALE STOOLS, CHOLESTATIC EFFECT P0647
THIACETAZONE F UROBILINOGEN DEC V PALE STOOLS, OCCURS WITH CHOLESTASIS P0079
THIAZIDES F UROBILINOGEN DEC V MAY CAUSE CHOLESTASIS WITH PALE STOOLS P0477
TOLAZANIDE F UPOBILINOGEN DEC V PALE STOOLS WITH CHOLESTASIS P0620
TOLBUTANIDE F UROBILINOGEN DEC V PALE STOOLS WITH CHOLESTASIS MAY OCCUR P0477
TPIFLUOPERAZINE F UPOBILINOGEN DEC V PALE STOOLS WITH CHOLESTASIS P0477
ACETOHEXAMIDE U UROBILINOGEN DEC V THEORETICAL EFFECT IF CHOL!STASIS RO026
AJMALINE U UROBILINOGEN DEC V INTRAHEPATIC CHOLESTASIS P0088
ANNONIUM SALTS U UROBILINOGEN DEC V ACIDIFICATION OF URINE DECREASES EXCRETION R0666

ANTIBIOTICS U UROBILINOGEN DEC V INHIBIT G.I.TPACT FLORA P0356
ASCORBIC ACID U UPOBILINOGEN DEC V LOWERED PH REDUCES EXCRETION 90666
CHLOR ANPRENICOL U UROBILINOGEN DEC V REDUCTION OF FLORA IN G.I. TRACT 90417
CHLORDIAZEPOXIDE U UROBILINOCEN DEC V INFREQUENT CHOLESTATIC EFFECT P0477
CHLORPROMAZINE U UROBILINOGEN DEC V MAY BE CHOLESTASIS P0 477
CHLORPROPAMIDE U UPOBILINOGEN DEC V CHOLESTASIS MAY OCCUR INFREQUENTLY P0 477
ERYTHROMYCIN U UROBILINOGEN DEC V MAY OCCUR WITH CHOLESTASIS 90477
LIGHT U UROBILINOGEN DEC N OXIDATION BY LIGHT OCCURS P0184
MEPAZINE U UROBILINOGEN DEC V CHOLESTATIC EFFECT P01477
MET HA ND P0 STE N OLO NE U UROBILINOGEN DEC V DUE TO CHOLESTA SIS 90477
NETHI MAZOLE U UROBILINOGEN DEC V CHOLESTATIC EFFECT P01477
MET HYLTESTOSTF RON! U UROBILINOGEN DEC V CHOLESTATIC EFFECT R0477
NEOMYCI N U UROBILINOCEN DEC V REDUCES FLORA IN G.I. TRACT P0417
NITROFURA NTOIN U UROBILINOGEN DEC V INTRAHEPATIC CHOLESTATIC JAUNDICE 90305
NORETHA NDROLONE U UROBILINOGEN DEC V MANIFESTATION OF CHOLESTASIS P0366
ORAL CONTRACEPTIVE U UROBILINOGEN DEC V MAY INDUCE CHOLESTASIS R0477
OXY N ET H OL ON E U UROBILINOGEN DEC V CHOLESTATIC EFFECT P0 4 77
PROCHLORPER AZINE U UROBILINOGEN DEC V CHOLESTATIC EFFECT 90026
PRONAZINE U UROBILINOGEN DEC V CHOLESTATIC EFFECT P0 1477
SPINAL ANESTHESIA U UROBILINOGEN DEC V RELATED TO REDUCED HEPATIC BLOOD FLOW 90384
SULFADINETHOXINE U UROBILINOGEN DEC V OCCURS WITH REVERSIBLE CHOLESTASIS 90 3 07
SULFAFURAZOLE U UROBILINOGEN DEC V OCCURS WITH REVERSIBLE CHOLESTASIS 90620
SULFA METHIZ OLE U UROBILINOGEN DEC V OCCURS WITH REVERSIBLE CHOLESTASIS R05142
SULFA METHOXAZOLE U UROBILINOGEN DEC V OCCURS WITH REVERSIBLE CHOLESTASIS 90620
SULFAMETHOXYPYRID U UPOBILINOGEN DEC V OCCURS WITH REVERSIBLE CHOLESTASIS P0620
SULFI SOXAZOLE U UROBILINOGEN DEC V WITH REVERSIBLE CHOLESTASIS P054 2
SULFONAMIDES U UROBILINOGEN DEC V CHOLESTATIC EFFECT P0477
TESTOSTERONE U UROBILINOGEN DEC V MAY CAUSE CHOLESTASIS R0620
TETPACYCL INE U UROBILINOGEN DEC V REDUCES FLORA IN G.I. TRACT P01417
THI AB ENDAZOLE U UROBILINOGEN DEC V CHOLESTATIC EFFECT P06 47
THI ACETA ZONE U UPOBILINOGEN DEC V MAY CAUSE CHOLESTASIS 90079
THIAZIDES U UROBILINOCEN DEC V CHOLESTATIC EFFECT RO477
TOLAZANIDE U UROBILINOGEN DEC V CHOLESTATIC EFFECT 90620
TOLBUTA MID! U UPOBILINOGEN DEC V POSSIBLE CHOLESTATIC EFFECT P01477
TRIFLUOPERAZINE U UROBILINOGEN DEC V CHOLESTATIC EFFECT P04 77
URE A U UPOBILINOGEN DEC N PRODUCES YELLOW COLOR WITH EHRLICH’S REAGENT 90436
AMYL NITRITE F UPOBILINOGEN INC V IF HEMOLYTIC ANEMIA OCCURS R0656
ANTIPYRINE F UROBILINOGEN INC V OCCURS WITH HEMOLYTIC ANEMIA P0 240
NETHYLTESTOSTERONE F UROBILINOGEN INC V PALE STOOLS, MAY CAUSE CHOLESTASIS P0477
ACETAZOLAMIDE U UROBILINOGEN INC V EXCRETION INCREASED BY ALKALINIZATION OF URINE P0666
AC ETONE U UROBILINOGEN INC M MAY PRODUCE SIMILAR COLOR IN REACTION 90620
AMINOSALICYLIC AC U UROBILINOGEN INC N REACTS WITH EHPLICH’S REAGENT (YELLOW COLOR) ROO8I
AMYL NITRITE U UROBILINOGEN INC V LESS RELIABLE INDEX THAN FECAL IF H!MOLYSIS OCCURS P0656
ANTIPYRINE U UPOBILINOGEN INC V OCCURS WITH HEMOLYTIC ANEMIA P0240
ANTIPYRINE U UPOBILINOGEN INC N PRODUCES SIMILAR COLOR WITH EHRLICHS P1001
BANANAS U UROBILINOGEN INC N SHIAA PRODUCED REACTS WITH EHRLICH’S REAGENT P014 36
BILE SALTS U UROBILINOGEN INC N CONVERTED TO ACIDS, PRODUCE TURBIDITY P0436
BILIRU BIN U UROBILINOGEN INC N PRODUCES GREEN COLOR DUE TO BILIVERDIN P0436
BI L IV E PD IN U UPOBILINOGEN INC N NAY PRODUCE GREEN COLOR 901436
BPOMSULFALEIN U UROBILINOGEN INC V PRESENCE OF BSP IN URINE AND LIVER DISEASE P02 99
BROMSULFALEIN U UROBILINOGEN INC N COLOR DEVELOPMENT WITH EHRLICH’S ALDEHYDE P1001
CASCARA U UROBILINOCEN INC N REACTS WITH EHRLICH’S REAGENT P014 36
CHLOROQUINE U UROBILINOGEN INC V HENOLYTIC ANEMIA IN G-6-PD DEFICIENCY P0 467
CHLORPROMAZINE U UPOBILINOGEN INC N REACTS WITH ERHLICH’S ALDEHYDE REAGENT P100 1
COFFEE U UROBILINOGEN INC N ACETYLTPYPTOPHAN PRODUCED REACTS WITH EHRLICH’S P014 36
DIURNAL VARIATION U UROBILINOGEN INC V MAXIMUM EXCRETION IN AFTERNOON 90143
FORMALDEHYDE U UROBILINOGEN INC N INTERFERES WITH COLOR REACTION P02 33
FORMALIN U UROBILINOGEN INC N INTERFERES WITH EHRLICHS REACTION P0143
HENOLYSIS U UROBILINOGEN INC V FURTHER METABOLISM OF HEMOGLOBIN P06 20
INIPRANINE U UROBILINOGEN INC V MAY CAUSE CHOLESTATIC JAUNDICE 90512
INDICAN U UROBILINOGEN INC N PRODUCES YELLOW COLOR WITH EHRLICH’S REAGENT P0 43 6
INDOLE U UROBILINOGEN INC N PRODUCES RED COLOR WITH EHRLICH’S REAGENT P0 1436
INDOLEACETIC ACID U UPOBILINOGEN INC N PRODUCES RED COLOR WTIH ERPLICH’S REAGENT P014 36
LEAD U UROBILINOGEN INC V DUE TO HEMOLYSIS OF POISONING 90291
MELANI N U UROBILINOGEN INC N MELANOGEN REACTS WITH EHPLICH’S REAGENT ROLl 36
METHENAMINE U UROBILINOGEN INC N PRODUCES FORMALDEHYDE WHICH INTERFERES 90081
METHYLDOPA U UROBILINOGEN INC V AUTOIMMUNE HEMOLYTIC ANEMIA P01 89
NALIDIXIC ACID U UROBILINOGEN INC V MAY OCCUR IF CHOLESTASIS 90736
NOVOBI OCIN U UROBILINOGEN INC V HENOLYTIC ANEMIA IN G-6-PD DEFICIENCY 90384
PHENAZOPYPIDINE U UROBILINOGEN INC N ORANGE-RED WITH EHRLICH’S ALDEHYD! REACTION 91001
PHENOTHIAZINES U UROBILINOCEN INC M MAY REACT WITH EHRLICH’S ALDEHYDE REAGENT P0769
PHYLLOERYTHRINOGEN U UPOBILINOGEN INC N PRODUCES RED COLOR WITH EHRLICH’S REAGENT P0436
PIPOBBOMA N U UROBILINOGEN INC V HEMOLYTIC ANEMIA HAS BEEN DESCRIBED P 0021
PROCAINE U UROBILINOGEN INC N INTERFERES WITH EHRLICH’S ALDEHYDE REACTION P1001
PROTE INU RIA U UROBILINOGEN INC N PRODUCES TURBIDITY IN DIRECT METHODS P0436
SEDORMI D U UROBILINOGEN INC N PRODUCES RED COLOR WITH EHRLICH’S REAGENT 901436
SKATOL! U UROBILINOGEN INC N PRODUCES A BLUE COLOR WITH EHRLICH’S REAGENT 90436
SODIUM BICARBONATE U UPOBILINOCEN INC V INC CLEARANCE WHEN URINE ALKALINE P 0666
SULFADIA ZINE U UPOBILINOGEN INC N MAY PRODUCE GREENISH COLOR WITH EHRLICH’S REAGENT P0 143
SULFAMETH OXAZOLE U UROBILINOGEN INC N MAY REACT WITH EHPLICH’S TO PRODUCE FALSE COLOR 90029
SULFAN ILA MID! U UROBILINOGEN INC M YIELDS GREENISH COLOR WITH EHRLICHS P0 143
SULFA PY RI DI NE U UPOBILINOGEN INC M YIELDS GREENISH COLOR WITH EHRLICHS P0143
SULFATHIAZOLE U UROBILINOGEN INC N YIELDS GREENISH COLOR WITH EHPLICHS R01143
SULFONA MI DES U UROBILINOGEN INC N REACT WITH EHRLICH’S REAGENT 901436
SULFONAMIDES U UROBILINOGEN INC V HEMOLYTIC ANEMIA WITH G-6-PD DEFICIEIICY 90384
TRYPTOPHAN U UROBILINOGEN INC N PRODUCES AN ORANGE COLOR WITH EHRLICH’S REAGENT P01436
VITAMIN K U UROBILINOGEN INC V HEMOLYTIC ANEMIA IN G-6-PD DEFICIENCY P0384
5-HYDROXYINDOLEACET U UROBILINOGEN INC N REACTS WITH EHRLICH’S REAGENT 90436
THY MOL U UROBILINOGEN Z N NO EFFECT ON WALDENSTRON PROCEDURE 90779
PROTEINURIA U UPOKINASE INC V IF PENAL INFARCTION OR HYPOXIA 90758

PP!GNA NCY U UROPEPSINOGEN INC V MODERATE INCREASE OBSERVED P0291
VITAMIN F U UROPORPHYRIN DEC V REDUCE TO NORMAL LEVELS IN PORPHYRIA P06 88
DI!THYLSTILBESTROL F UROPORPHYPIN INC V NAY INDUCE PORPHYRIA CUTANEA TARDA P0 975
ESTROGENS F UROPORPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA P 0975
ETHINYLESTRADIOL F UROPOPPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA P0975
?RENARIN F UROPORPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TAPDA P0 987
ANTICONVULS ANTS U UROPOPPHYRIN INC V DRUG RELATED EFFECT REPORTED IN ONE CHILD 90657
BARBITURATES U UROPORPHYRIN INC V NAY PRECIPITATE ACUTE PORPHYRIA 90371
CHLOROQUINE U UPOPOPPRYRIN INC V TRANSIENT INC NAY OCCUR WITH CUTANEOUS PORPHYRIA P0 37 1
CHLORPROPANIDE U UPOPORPHYRIN INC V NAY PRECIPITATE CUTANEOUS PORPHYRIA 90371
DIETHYLSTILBESTR OL U UROPORPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA P0975
ESTPOGE NS U UPOPORPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA P0 975
ETHANOL U UROPORPHYBIN INC V MAY PRECIPITATE ATTACK OF PORPHYRIA P037 1
ETHINYLESTRADIOL U UROPORPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TARDA 90975
ORAL CONTRACEPTIVE U UROPORPHYRIN INC V NAY INDUCE PORPHYRIA CUTANEA TARDA P0792
PRENARIN U UPOPORPHYRIN INC V MAY INDUCE PORPHYRIA CUTANEA TAPDA 90987
S ULFO NE N ETH A N E U UBOPORPHYRIN INC V MAY PROVOKE ATTACK OF PORPHYRIA P03 71
TOLBUTAN IDE U UROPORPHYRIN INC V MAY PRECIPITATE PORPHYRIA ATTACK P0 371
GLUCOSE S VALINE DEC V PROBABLE MUSCLE UPTAKE P03 97
OPAL CONTRACEPTIVE S VALINE DEC V HORMONAL EFFECT (SECOND PART OF CYCLE) P0 226
ORGANOPHOS PHORU S S VITAMIN A DEC V METABOLISN IMPAIRED P0 302
STILBESTPOL S VITAMIN A DEC V HORMONAL EFFECT WHEN GIVEN TO LACTATING WOMEN 90352
ETHINYL!STRADIOL S VITAMIN A INC V DUE TO ALTERATION IN CONC OF BINDING GLOBULIN P0 3 52
NORETHISTEPONE S VITAMIN A INC V DUE TO ALTERATION IN CONC OF BINDING GLOBULIN P0352
VITAMIN A S VITAMIN A INC V INGESTED COMPOUND IN SERUM P03 84
CHOLESTYRAM INE S VITAMIN A Z V ABSORPTION NOT SIGNIFICANTLY IMPAIRED P0657
AMINOSALICYLIC AC S VITAMIN B12 DEC V IMPAIRS ABSORPTION P0976
ANTICONVULSANTS S VITAMIN 912 DEC V SIG LOWER THAN NORMAL CONTROLS P06 57
CHLORPRONAZINE S VITAMIN B12 DEC N POSSIBLE INHIB EFFECT ON SOME STRAINS E. GRACILIS P0657
COLCHICINE S VITAMIN 912 DEC V IMPAIRS ABSORPTION P0976
ETHANOL S VITAMIN B12 DEC V IMPAIRS ABSORPTION P0976
METFORMI N S VITAMIN B12 DEC V DUE TO IMPAIRED 912 ABSORPTION P0935
NEONYCIN S VITAMIN B12 DEC V IMPAIRS ABSORPTION P0976
ORAL CONTRACEPTIVE S VITAMIN P12 DEC V PROBABLE INTERFERENCE WITH G.I. ABSORPTION P0982
ANINOSALICYLIC AC U VITAMIN B12 DEC V OCCURS WITH VITAMIN B12 DEFICIENCY P0976
COLCHICINE U VITAMIN B12 DEC V OCCURS WITH IMPAIRED ABSORPTION OF B12 P0976
METFORMIN U VITAMIN B12 DEC V MAY CAUSE MEGALOBLASTIC ANEMIA P09 35
NEONYCIN U VITAMIN B12 DEC V WITH IMPAIRED ABSORPTION P0976
FOLIC ACID E VITAMIN 912 INC V DUPING TREATMENT OF FOLATE DEFICIENT ANEMIA P0425
IRON SALTS VITAMIN B12 INC V DURING TREATMENT OF IRON-DEFICIENT ANEMIA P0 425
VITAMIN 912 F VITAMIN B12 INC V DURING TREATMENT OF VITAMIN 312 DEFICIENCY R0425
ISONIA ZID U VITAMIN B6 INC V DOSE RELATED EFFECT P079 1
CLOFIBRATE U VMA DEC M DUE TO INTERFERING GLUCURONIDES OF DRUG P08 12
CLONIDINE U VMA DEC V DOSE RELATED EFFECT P01455
GUA NETHIDINE U VMA DEC V 30% REDUCTION SEEN IF GIVEN THERAPEUTICALLY P1006
HYDRAZINE U VNA DEC V MAY POTENTIATE ACTION OF DRUGS ON CNS P0596
IMIPRAMIN! U VNA DEC V APPPOX. 30% DECREASE, BLOCK OF UPTAKE INTO CELLS RO428
ISOCARBOXAZI D U VMA DEC V INHIBITION OF FORMATION P014 17
LEV000PA U VMA DEC V ?DOPAMINE AS N!UPOTRANSMITTEP SUPPRESSES NORMET P0 475
MAO INHIBITORS U VNA DEC V INHIBITION OF NOPMETANEPHRINE CONVERSION TO VMA P014 17
METHYLDOPA U VNA DEC V DEPLETION OF TISSUE STORES P0276
MORPHINE U VMA DEC V CLINICALLY SIGNIFICANT BUT SMALL EFFECT 90632
NIALANIDE U VMA DEC V EFFECT OBSERVED IN SCHIZOPHRENICS P0657
PHENOTHIAZI NES U VNA DEC V ALTERS BLOOD CONCENTRATION P0042
RESERPIN? U VNA DEC V DEPLETION OF CATECHOLAMINE STORES P06 54
ACETYLSALICYLIC AC U VNA INC N INTERFEPES WITH FLUORO-,COLORINETRIC PROCEDURES R0155
AJMALINE U VMA INC V RELEASE OF STORED NOREPINEPHRINE P0596
ANINOSALICYLIC AC U VMA INC N REACTS WITH DIAZO REAGENT IF USED 90030
ANIL!RI DI NE U VMA INC N INTERFERES WITH PISANO PROCEDURE 90299
BANANAS U VNA INC M METABOLITES INTERFERE WITH ANALYSIS P0 355
BROMSULFALEIN U VNA INC N OCCURS UNLESS COMPLETELY EXTRACTED P003 0
CAFFEINE U VNA INC N INTERFERENCE WITH METHOD REPORTED P0355
CHLOPPRONAZINE U VNA INC V INC METAB AND DEC ORGAN UPTAKE OF NOREPINEPHRINE P1 001
CHOCOL ATE U VNA INC N CATECHOLS IN CHOCOLATE 90355
COFFEE U VMA INC N INTERFERENCE WITH NONSPECIFIC METHODS P07 13
DI S UL F I P A N U VMA INC N ?INTERFEPENCE FROM ACETALDEHYDE FROM ETHANOL P014 17
EPINEPHRINE U VMA INC V MEASURED AS ENDOGENOUS COMPOUND P04 17
GLYCERYL GtJAIACOLAT U VNA INC N AFFECTS P-NITRONILINE IN INITIAL PART OF REACTION P0233
INSULIN U VNA INC V INCREASE AFTER INSULIN SHOCK, NONE WITH NORMAL DOSE P0908
LEVARTER!NOL U VNA INC V NORMAL NETABOLITE, EFFECT SLIGHT USUALLY P0908
LEVODOPA U VMA INC V SMALL INCREASE, LARGER INCREASE HVA P0 175
LITHIUM U VMA INC V SLIGHT INCREASE ONLY, MECHANISM NOT CLEAR P 04 17
MEPHENESIN U VNA INC N PURPLE OP RED COLOR IN INITIAL PART OF SCREEN TEST P0 178
METHENAMI NE U VMA INC N INTERFERES WITH FLUOPONETRIC PROCEDURES 90596
METHOCARBAMOL U VNA INC N FALSE P05 WITH SCREENING, NO EFFECT QUANT METH. 90299
METHYL DO PA U VMA INC N INTERFERENCE BY 5HIAA WITH NON SPEC. DIAZO REACTION 90839
NITBOGLYCER IN U VNA INC V EFFECT GREATER THAN THAT ON CATECHOLAMINES 90961
OXYTETRACYCLINE U VMA INC N PRODUCES INTERFERING COLOR P 100 1
PHENAZOPYPIDINE U VNA INC N YIELDS SIMILAR COLOR IN REACTION P0596
PROCHLORPERAZINE U VNA INC V INC METABOLISM, DEC ORGAN UPTAKE OF NOREPINEPHRINE P1001
PSP U VNA INC N NAY INTERFERE WITH COLORIMETRIC METHOD P0030
PAUWOLFIA U VNA INC V RELEASE OF STORED NOREPINEPHPINE P0 596
RESEPINE U VNA INC V RELEASE OF STORED NOREPINEPHRINE P0596
STIBOPHEN U VMA INC N AT NEUTRAL OR ALK PH AFFECT GITLOW PROCEDURE 90998
SYROSI NGOPINE U VNA INC V RELEASE OF STORED NOREPINEPHRINE P0596
TEA U VMA INC N NETABOLITES INTERFERE WITH ANALYSIS P0 909
VANILLA U VNA INC N NAY BE MEASURED BY COLORIMETRIC METHOD 90355
ANGIOT!NS IN U VMA Z V EPINEPHPINE DEC COMPENSATES FOR NOREPINEPHPINE INC P1030
STORAGE OF SAMPLE U VMA Z N ACIDIFIED SEVERAL DAYS ROOM TEMP, 1 WK AT 14 DEC P0998
DIURETICS B VOLUME DEC V MAY OCCUR IF RAPID DIURETIC ACTION 90 384

TESTOSTERONE B VOLUME DEC V PRODUCES POLYCYTHEMIC-LIKE STATE 90657
ANGIOTENSIN P VOLUME DEC V PROMOTES LOSS OF PROTEIN-FREE FILTRATE TO TISSUES 903814
EPINEPHRINE P VOLUME DEC V LOSS OF PROTEIN-FREE FLUID TO TISSUES R03814
LEVAPTEPENOL P VOLUME DEC V DUE TO LOSS OF PROTEIN-FREE FLUID TO TISSUES RO384
PROP RANOLOL P VOLUME DEC V DEC BY APPROX 8% USUALLY, ?MECHANISM 90917
THIAZI DES P VOLUME DEC V DUE TO DIURETIC ACTION RO38
ACETAMINOPHEN U VOLUME DEC V INC TRANSPORT OF WATER IN DIABETES INSIPIDUS RO 384
A NITRI PTYLI NE U VOLUME DEC V MAY CAUSE URINARY RETENTION 90026
ANGIOTENS IN U VOLUME DEC V VASOCONSTRICTIVE EFFECT IN KIDNEY 90384
ATROPINE U VOLUME DEC V VERY LARGE DOSES CAUSE RELEASE OF ADH 903814
BETA- ADRENERGIC U VOLUME DEC V ANTIDIURETIC EFFECT MEDIATED CENTRALLY R0835
CEPHALORIDINE U VOLUME DEC V SUGGESTIVE OF NEPHROTOXICITY R0298
CHLORPROPANIDE U VOLUME DEC V IN PATIENTS WITH DIABETES INSIPIDUS 908140
DIAZOXID! U VOLUME DEC V EFFECT OVER 2H OF 4MG/KG GIVEN I.V. R0501
EPINEPHRINE U VOLUME DEC V I.M. INJECTION CAUSES SHARP DEC P0657
ETHER U VOLUME DEC V DUE TO VASOCONSTRICTION 90026
GUANCYDINE U VOLUME DEC V PROBABLE ACTION ON RENAL TUBULES 90962
ISOPROT!RENOL U VOLUME DEC V ANTIDIURETIC EFFECT MEDIATED THROUGH ADH RELAEASE P09 35
KA NANYCIN U VOLUME DEC V NEPHROTOXICITY MAY OCCUR WITH OLIGUPIA, AZOTEMIA 901467
MEPERIDINE U VOLUME DEC V CAUSES RELEASE OF ADH 90384
MORPHINE U VOLUME DEC V MAY STIMULATE RELEASE OF ADH 90026
MUSCULAR EXERCISE U VOLUME DEC V WITH HEAVY EXERCISE 90505
NOREPINEPHRINE U VOLUME DEC V SLIGHT FALL AFTER I.V. INFUSION 90657
OX Y PH EN RU TAZON E U VOLUME DEC V NAY CAUSE MARKED WATER RETENTION 90384
PAIN U VOLUME DEC V SLIGHT CHANGES IN RESPONSE TO STRESS SITUATIONS 90549
PR E NY L RU TAZ ON E U VOLUME DEC V CAUSES SIGNIFICANT WATER RETENTION P03 84
PHOSPHORUS U VOLUME DEC V TOXICITY EFFECT 90384
PROLACTIN U VOLUME DEC V ACTION FOR UP TO 8 HOURS WHEN GIVEN I.!. R046L1
SPECT INOMYC IN U VOLUME DEC V MECHANISM NOT DISCUSSED 90045
SPINAL ANESTHESIA U VOLUME DEC V FOUND POST-OPERATIVELY, BUT NORMAL RENAL FUNCTION P0384
S UL FA 0 I A Z IN! U VOLUME DEC V ASSOCIATED WITH CRYSTALLURIA AND HENATURIA P07 36
VASOPRESSIN U VOLUME DEC V THERAPEUTIC INTENT P0026
5-HYDROXYTRYPTAMINE U VOLUME DEC V WITH DOSES LARGE ENOUGH TO AFFECT CVS 903814
DIATRIZOATE B VOLUME INC V HYPERTONICITY NAY OCCUR IN CHILDREN 90026
PREGNANCY B VOLUME INC V INC TO MAX OF PLUS 45% BY 32ND WEEK 90291
A NI NOPY PINE P VOLUME INC V FLUID RETENTION MAY OCCUR 90657
CORTICOST!ROIDS P VOLUME INC V EXPANSION OF ECF DUE TO WATER RETENTION P0 3814
CORTICOTROPIN P VOLUME INC V MOD DOSES CAN CAUSE SALT AND WATER RETENTION R0467
DEXTRAN P VOLUME INC V HEMODYNAMIC EFFECT, ALSO INCREASES URINE FLOW 90384
DIAZOXI DE P VOLUME INC V CAUSES SALT AND WATER RETENTION P0384
ESTROGENS P VOLUME INC V RETENTION OF SALT AND WATER COMMON 90657
OXYPHE NBtJTA ZONE P VOLUME INC V MAY CAUSE MARKED SALT AND WATER RETENTION P0 38 4
PH E NYL BUT AEON E P VOLUME INC V MAY INC BY 50% DUE TO SALT AND WATER RETENTION P038 4
PREGNANCY P VOLUME INC V INC BY PLUS 25 TO 55% BY 32ND WEEK P029 1
ACETYLSALICYLIC AC U VOLUME INC V DEC PENAL TUBULAR REABSORPTION P03 84
AMMONIUM SALTS U VOLUME INC V DIURETIC ACTION OF ACID FORMING SALT 90384
CAFFEINE U VOLUME INC V DIURETIC ACTION P0384
CHLORPROM AZINE U VOLUME INC V ?DEPPESSES ADH SECRETION OR WATER REABSORPTION P0 384
CHLORTHALIDONE U VOLUME INC V MAY PRODUCE MARKED DIUR!SIS 90657
CITRATES U VOLUME INC V WEAK DIURETIC EFFECT 90026
CLOPANIDE U VOLUME INC V DIURETIC ACTION P076 1
DEHYDFOCHOLIC ACID U VOLUME INC V MILD DIURETIC ACTION P0026
DEMETHYLC HLOPTET PAC U VOLUME INC V MAY CAUSE SYNDROME LIKE DIABETES INSIPIDUS 90736
DEXTRAN U VOLUME INC V HEMODYNAMIC EFFECT P0 3814
DIAPAMIDE U VOLUME INC V DIURETIC ACTION 90609
DIGITALIS U VOLUME INC V DIURETIC ACTION IN CARDIAC FAILURE 90384
DOCA U VOLUME INC V ASSOCIATED WITH POLYDIPSIA ALSO P0 384
ETHACPYNIC ACID U VOLUME INC V THERAPEUTIC INTENT P084 0
ETHANOL U VOLUME INC V DIURETIC ACTION, INHIBITS PITUITARY ADH SECRETION P0384
FUROSEMIDE U VOLUME INC V DIURETIC ACTION P0452
INULIN U VOLUME INC V MASSIVE DOSES PRODUCE MARKED DIURESIS P0026
ISOSORBITOL U VOLUME INC V ACTS AS OSMOTIC DIURETIC 90384
MEFRUSIDE U VOLUME INC V DIURETIC ACTION, LESS EFFECTIVE THAN THIAZIDES P006 1
MENSTRUATION U VOLUME INC V POST-MENSTRUAL DIUPESIS (DEC PREMENSTRUALLY) P0291
MERCURIAL DIURETICS U VOLUME INC V THERAPEUTIC INTENT R0384
MET HOX Y FLU PA NE U VOLUME INC V IMPAIRED DISTAL RENAL TUBULAR FUNCTION P0229
METOLAZONE U VOLUME INC V DIURETIC ACTION 90401
MUSCULAR EXERCISE U VOLUME INC V WITH MILD EXERCISE P0505
NITRATES U VOLUME INC V PENAL TUBULAR EPITHELIUM RELATIVELY IMPERMEABLE 90384
PARATHYROID EXTRACT U VOLUME INC V HORMONAL ACTION 90384
PREGNANCY U VOLUME INC V MAY INCREASE BY UP TO 25% IN LAST TRIMESTER P0143
SC-161 02 U VOLUME INC V DURATION OF DIURETIC ACTION SHORT P04 99
STREPTOZOTOCIN U VOLUME INC V NOTED TEN DAYS AFTER INFUSION (WITH POLYDIPSIA) 90686
TETRACYCLINE U VOLUME INC V NAY HAVE DIURETIC OR NEPHROTOXIC ACTION P0 153
UP E A U VOLUME INC V ACTS AS OSMOTIC DIURETIC P0630
XA NTHI NES U VOLUME INC V DIURETIC ACTION 90384
CHLORDIAZEPOXIDE P WARFARIN INC N SPECTROPHOTOMETRIC METHOD SHOWS INTERFERENCE P0787
HYDRALAZINE S WASSERMAN REACTION P05 V FALSE POSITIVE REACTION REPORTED 90657
DIGOXIN E WATER INC V SLIGHT EFFECT ONLY DUE TO ACTION ON MEMBRANE 90527
ACETA MINOPH!N B WHIT! CELL COUNT DEC V NAY AFFECT BONE NARROW FUNCTION/PANCYTOPENIA 90591
ACETANILID B WHITE CELL COUNT DEC V LEUKOPENIA ROSS 3
ACETAZOLA MID! B WHITE CELL COUNT DEC V LEUKOPENIA/ACRANULOCYTOSIS P0728
ACETOHEXAMI DE B WHITE CELL COUNT DEC V LEUKOPENIA AND APLASTIC ANEMIA REPORTED P062 0
ACETOP HENAZINE B WHITE CELL COUNT DEC V TRANSITORY LEUKOPENIA OR AGRANULOCYTOSIS P00 26
ACETOPHENETI DIN B WHITE CELL COUNT DEC V MAY CAUSE APLASTIC ANEMIA OP PANCYTOPENIA R06 20
ACETYLSALICYLIC AC B WHITE CELL COUNT DEC V DEPRESSES LEUKOCYTOSIS OF ACUTE RHEUMATIC FEVER P0989
A LLOPU 91 NOL B WHITE CELL COUNT DEC V HYPERSENSITIVITY REACTION (OFTEN TRANSIENT) P062 0
AMINOGLUTETHIMID! B WHITE CELL COUNT DEC V MAY CAUSE LEUKOPENIA R0620
AMINOPYRI NE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS,OCCtYPS WITHIN MINUTES 91023
AMINOSALICYLIC AC B WHITE CELL COUNT DEC V LEUKOPENIA BUT NO CASES OF AGRANULOCYTOSIS P0658

AMITRIPTYLINE B WHITE CELL COUNT DEC V LEUKOPENIA/AGRANULOCYTOSIS MAY OCCUR P0063
AMODIA QUI NE B WHITE CELL COUNT DEC V REPORTED EFFECT(AMA - BLOOD DYSCRASIA COMMITTEE) P0620
AMPICILLIN B WHITE CELL COUNT DEC V LEUKOPENIA P0390
ANTAZOLINE B WHITE CELL COUNT DEC V LEUKOPENIA 90932
ANTICONVULSANTS B WHITE CELL COUNT DEC V MAY OCCUR WITH SEVERE MECALOBLASTIC ANEMIA P0976
ANTINEOPLASTIC B WHITE CELL COUNT DEC V OFTEN THERAPEUTIC INTENT 90620
ANTI PY PINE B WHITE CELL COUNT DEC V LEUKOPENIA/AGPANULOCYTOSIS P0657
ARSENICALS B WHITE CELL COUNT DEC V PANCYTOPENIA P0 240
ASPARAGINASE B WHITE CELL COUNT DEC V MILD EFFECT IN UP TO 25% PATIENTS P0705
AZATHIOPPINE B WHITE CELL COUNT DEC N LOW COUNT BY COULTER 5, ?DUE TO FRAGILE CELLS P05 98
AZATHIOPPINE B WHITE CELL COUNT DEC V DRUG RELATED LEUKOPENIA (PROBABLE EFFECT) P0860
BARBI TURATES B WHITE CELL COUNT DEC V LEUKOPENIA P095 2
BE NZE NE B WHIT! CELL COUNT DEC V PROBABLE MYELOTOXIC EFFECT (USUALLY LATE) 90658
BI SHY DROXYCOUMARIN B WHITE CELL COUNT DEC V REPORTED EFFECT (AMA-BLOOD DYSCRASIAS COMMITTEE) P065 8
BISMUTH B WHITE CELL COUNT DEC V MAY CAUSE APLASTIC ANEMIA/AGRANULOCYTOSIS P0620
B US ULFA N B WHIT! CELL COUNT DEC V PANCYTOPENIA/LEUKOPENIA R0657
BUTAPEPAZINE B WHITE CELL COUNT DEC V TRANSITORY LEUKOPENIA P0026
CARBA NAZEPI NE B WHITE CELL COUNT DEC V PANCYTOPENIA (LEUKOPENIA IN 15% PATIENTS) P0278
CARBENICILLIN B WHITE CELL COUNT DEC V LEUKOPENIA MAY OCCUR INFREQUENTLY P04 67
CARBIMAZOLE B WRITE CELL COUNT DEC V AGPANULOCYTOSIS P0165
CARBON TETRACHLOR B WHITE CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCPASIAS) P0658
CARBUTAMIDE B WHITE CELL COUNT DEC V LEUKOPENIA/ACPANULOCYTOSIS P1000
CEPHALORI DINE B WHITE CELL COUNT DEC V NAY CAUSE NEUTROPENIA/LEUKOPENIA P0298
CEPHALOTHIN B WHITE CELL COUNT DEC V RAPE RESPONSE TO THERAPY P0620
CHLORA MBUC IL B WHITE CELL COUNT DEC V NEUTROPENIA (DOSE RELATED) P0 167
CHLOR AMPHENICOL B WHITE CELL COUNT DEC V PANCYTOPENIA/APLASTIC ANEMIA P0 272
CHLORDANE B WHITE CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0658
CHLO9DIAZEPOXIDE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS REPORTED (LEUKOPENIA MORE COMMON) P06 20
CHLOROPHENOTHANE B WHITE CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) R0658
CHLOROQUI NE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS/PANCYTOPENIA 90912
CHLOROTHIAZIDE B WHITE CELL COUNT DEC V LEUKOPENIA/PANCYTOPENIA R0024
CHLORPHENIPANINE B WHITE CELL COUNT DEC V LEUKOPENIA (AMA-BLOOD DYSCRASIAS) P065 8
CHLORPROMAZINE B WHITE CELL COUNT DEC V AGP ANULOCYTOS IS/LEU KOPENIA/GRA NULOCYTOPENIA P0602
CHLORPROPAMIDE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS P0 984
CHLORPROT HI XENE B WHITE CELL COUNT DEC V POSSIBLE HEMATOLOCICAL DISORDER P03 84
CHLOPT ETPACYCLINE B WHITE CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) 90658
CHLOP THALIDO NE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS R0537
CHOLESTYRAMINE B WHITE CELL COUNT DEC V POSSIBLE RELATIONSHIP TO DRUG ADMINISTRATION P0467
CINCHOPHEN B WHITE CELL COUNT DEC V LEUKOPENIA OP AGRANULOCYTOSIS MAY OCCUR R0658
CLINDA NYC IN B WHITE CELL COUNT DEC V MAY CAUSE AGRANULOCYTOSIS P0736
CLOFI BRAT! B WHITE CELL COUNT DEC V MAY CAUSE LEUKOPENIA 90784
CLOXACILLIN B WHIT! CELL COUNT DEC V MAY CAUSE LEUKOPENIA P0 620
COLCHICINE B WHITE CELL COUNT DEC V LEUKOPENIA P0656
COLISTINETHATE B WHITE CELL COUNT DEC V NEUTROPENIA/LEU KOPENIA/GRA NULOCYTOPENIA R0026
COLISTI N B WHITE CELL COUNT DEC V NAY CAUSE LEUKOPENIA/GPANULOCYTOPENIA P0620
CORTICOSTEROIDS B WHITE CELL COUNT DEC V MAY CAUSE LEUKOPENIA P0 620
CYCLOHEXI MID! B WHITE CELL COUNT DEC V LEUKOP!NIA (AMA-BLOOD DYSCRASIAS) P0658
CYCLOPHOSPHAMIDE B WHITE CELL COUNT DEC V BONE MARROW DEPRESSION (REVERSIBLE LEUKOPENIA) P0025
CYCLOSERI NE B WHITE CELL COUNT DEC V NAY OCCUR WITH MALOBLASTIC ANEMIA P0976
CYTAPABINE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS /LEUKOPENIA P0620
DACTINONYCIN B WHITE CELL COUNT DEC V LEUKOPENIA/PANCYTOPENIA P0026
DESIPR AMINE B WHITE CELL COUNT DEC V NAY CAUSE ACRANULOCYTOSIS P0620
DIAMINODIPMENYLSULF B WHITE CELL COUNT DEC V AGRANULOCYTOSIS P045 1
DIAPRIM B WHITE CELL COUNT DEC V LEUKOPENIA P0656
DIAZEPAN B WHITE CELL COUNT DEC V LEUKOPENIA P0789
DIAZOXI D! B WHITE CELL COUNT DEC V MAY CAUSE LEUKOPENIA P0967
DICHLORPHENAMIDE B WHITE CELL COUNT DEC V NAY CAUSE LEUKOPENIA 90620
DIETHIAZI NE B WHITE CELL COUNT DEC V MAY CAUSE LEUKOPENIA P062 0
DIETHYLPPOPION B WHITE CELL COUNT DEC V MARROW DEPRESSION WITH LEUKOPENIA/AGRANULOCYTOSIS P0650
DIGITALIS B WHITE CELL COUNT DEC V AGRANULOCYTOSIS/LEUKOPENIA P0620
DIIODOHYDROXYQUIN B WHITE CELL COUNT DEC V MAY CAUSE LEUKOPENIA P0 620
DI NITROPRENOL B WHITE CELL COUNT DEC V MAY CAUSE ACRANULOCYTOSIS/APLASTIC ANEMIA P0384
DIPHENYLHYDANTOIN B WHITE CELL COUNT DEC V MEGALOBLASTIC/H!MOLYTIC/APLASTIC ANEMIA/PANCYTOPEN 90025
DIPYRONE B WHITE CELL COUNT DEC V LEUKOPENIA OP ACPANULOCYTOSIS P014 68
DOXAPR AN B WHITE CELL COUNT DEC V FURTHER DEC NOTED IN PATIENT WITH LEUKOPENIA 90010
DOXEPIN B WHIT! CELL COUNT DEC V THEORETICAL POSSIBILITY DUE TO CLASS OF COMPOUND P0026
DOXYCY CL IN! B WHITE CELL COUNT DEC V NEUTROPENIA REPORTED P07 314
EDT A B WHITE CELL COUNT DEC V TRANSIENT BONE NARROW DEPRESSION 90026
EPYTHPONYCI N B WHITE CELL COUNT DEC V LEUKOPENIA OP NEUTROPENIA MAY OCCUR P0623
ETHACRYNIC ACID B WHITE CELL COUNT DEC V AGRANULOCYTOSIS P0970
ETHOSUXI MID! B WHITE CELL COUNT DEC V APLASTIC ANEMIA/PANCYTOPENIA/LEUKOPENIA IN 10% P0026
ETBOTOIN B WHITE CELL COUNT DEC V POSSIBLE BONE NARROW DEPRESSION RO026
ETHOXAZOLAMID! B WHITE CELL COUNT DEC V LEUKOPENIA 90620
FLUOROCYTOSINE B WHITE CELL COUNT DEC V REPORTED EFFECT 90898
FLUOROURACIL B WHITE CELL COUNT DEC V NAY CAUSE BONE NARROW DEPRESSION P0026
FLUPHENAZINE B WHITE CELL COUNT DEC V TRANSIENT LEUKOPENIA REPORTED P0026
FUMAGILLIN B WHITE CELL COUNT DEC V LEUKOPENIA (AMA-BLOOD DYSCRASIAS) P0 658
FUROSEMIDE B WHITE CELL COUNT DEC V MAY CAUSE LEUKOPENIA OR APLASTIC ANEMIA P0620
GLAUCAPUBIN B WHITE CELL COUNT DEC V LEUKOPENIA P06 20
GLUCOSU LFONE B WHITE CELL COUNT DEC V LEUKOPENIA 90620
GLUTETHINID! B WHITE CELL COUNT DEC V MAY CAUSE APLASTIC ANEMIA P0026
GOLD B WHITE CELL COUNT DEC V APLASTIC ANEMIA/LEUKOPENIA/ACRANULOCYTOSIS P0933
GRI SEOFULVI N B WHITE CELL COUNT DEC V MAY CAUSE LEUKOPENIA/NEUTROPENIA P0657
HAIR LACQUER B WHITE CELL COUNT DEC V SOME MAY CAUSE LEUKOPENIA (AMA-BLOOD DYSCRASIAS) P06 58
HALOPERIDOL B WHITE CELL COUNT DEC V MAY CAUSE ANEMIA 90620
HETACILLIN B WHITE CELL COUNT DEC V PROBABLY ALLEPGIC RESPONSE (RARE) P0467
HEXACHLOROB ENZENE B WHITE CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0658
HEXANETHYLMELANINE B WHITE CELL COUNT DEC V MODERATE EFFECT IN HALF OF PATIENTS 90995
HYDRALAZINE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS/PA NCYTOPENIA/LEUKOPENIA P0014
HYDROCHLOROTHIAZIDE B WHITE CELL COUNT DEC V NAY CAUSE LEUKOPENIA/AGRANULOCYTOSIS P0261

HYDRDFLUMETHIAZIDE B WHITE CELL COUNT DEC V PANCYTOPENIA, AGRANULOCYTOSIS OR APLASTIC ANEMIA RO991
HYDROXYCHLOROQUINE B WHITE CELL COUNT DEC V LEUKOPENIA 90620
HYDROXYUREA B WHITE CELL COUNT DEC V LEUKOPENIA MAY OCCUR 90657
IDOXURIDINE B WHITE CELL COUNT DEC V EFFECT OF HIGH CONCENTRATION ONLY 90620
INIPRAMINE B WHITE CELL COUNT DEC V MAY CAUSE LEUKOPENIA/AGRANULOCYTOS IS 90857
INDANDIONES B WHITE CELL COUNT DEC V WITH OTHER EVIDENCE OF HYPERSENSITIVITY P0 620
INDOMETHACIN B WHITE CELL COUNT DEC V AGPANULOCYTOSIS/PANCYTOPENIA P07 86
IODOTHIOURACIL B WHITE CELL COUNT DEC V AGRANULOCYTOSIS 90620
IPRONIAZID B WHITE CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0658
ISOCARBOXAZID B WHITE CELL COUNT DEC V AGRANULOCYTOSIS/LEUKOPENIA - RARE 90451
ISONIAZID B WHITE CELL COUNT DEC V AGRANULOCYTOSIS - RARE R0071
LEAD B WHITE CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCPASIAS) P0658
LEVODOPA B WHITE CELL COUNT DEC V TRANSITORY DEPRESSION IN A FEW PATIENTS P 0026
LINCONYCIN B WHITE CELL COUNT DEC V AGRANULOCYTO SIS/LEUKOPENIA/NEUTROPENIA P00 23
LOCAL ANESTHETICS B WHITE CELL COUNT DEC V RN DEPRESSION AND AGRANULOCYTOSIS REPORTED 90657
NAFENIDE B WHITE CELL COUNT DEC V PROBABLE EFFECT OBSERVED IN ONE CHILD 90048
MAO INHIBITORS B WHITE CELL COUNT DEC V OCCASIONAL LEUKOPENIA/AGRANULOCYTOSIS 90620
MEFENAMIC ACID B WHITE CELL COUNT DEC V PANCYTOPENIA (TEMP DEPRESSION MAY OCCUR OFTEN) RO62O
MELPHALAN B WHITE CELL COUNT DEC V NAY CAUSE BONE MARROW DEPRESSION (DOSE RELATED) ?0167
NEPACRINE B WHITE CELL COUNT DEC V LEUKOPENIA P0620
MEPAZINE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS 90329
MEPHENESIN B WHITE CELL COUNT DEC V MAY CAUSE LEUKOPENIA P0620
MEPHENOXALONE B WHITE CELL COUNT DEC V MILD AND TRANSITORY 90026
MEPHENYTOIN B WHITE CELL COUNT DEC V AGRANULOCYTOSIS/APLASTIC ANEMIA 90784
MEPROBAMATE B WHITE CELL COUNT DEC V PANCYTOPENIA (MAY BE AGRANULOCYTOSIS) 90025
MERCAPTOPURINE B WHITE CELL COUNT DEC V AGBANULOCYTOSIS 90656
MERCURIAL DIURETICS B WHITE CELL COUNT DEC V NEUTROPENIA/AGRANULOCYTOSIS REPOR1ED RO552
NESORIDAZINE B WHITE CELL COUNT DEC V TRANSIENT AGRANULOCYTOSIS REPORTED 90026
METHAZOLAMIDE B WHITE CELL COUNT DEC V PROBABLE EFFECT AS LIKE ACETAZOLAMIDE 90 620
NETHICILLIN B WHITE CELL COUNT DEC V MAY CAUSE BONE MARROW DEPRESSION P06 20
NETHIMAZOLE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS P0025
NETHOCARBAMOL B WHITE CELL COUNT DEC V NAY CAUSE LEUKOPENIA 90620
NETHOTREXATE B WHITE CELL COUNT DEC V AG RANULOCYTOSIS/LYNPHOCYTOPENIA 90656
NETHSUXIMIDE B WHITE CELL COUNT DEC V RAPE APLASTIC ANEMIA OR REVERSIBLE LEUKOPENIA 90620
METHYCLOTHIAZIDE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS OR APLASTIC ANEMIA NAY OCCUR ROLl 67
NETHYLDOPA B WHITE CELL COUNT DEC V VERY PARE, MAY CAUSE GRANULOCYTOPENIA 90532
METHYLPROMAZINE B WHITE CELL COUNT DEC V LEUKOPENIA (AMA-BLOOD DYSCRASIAS) P065 8
METHYLTHIOURACIL B WHITE CELL COUNT DEC V OCCASIONAL LEUKOPENIA OR AGPANULOCYTOSIS R0620
METHYPRYLON B WHITE CELL COUNT DEC V DUE TO TOXIC ACTION OF METABOLITE 90620
METHYSERGID! B WHITE CELL COUNT DEC V NEUTROPENIA REPORTED R0620
METPONIDAZOLE B WHITE CELL COUNT DEC V LEUKOPENIA AND REDUCTION OF POLYMOPPHS P0620
MITHPAMYCIN B WHITE CELL COUNT DEC V REVERSIBLE EFFECT R0O26
MITONYCIN C B WHITE CELL COUNT DEC V PANCYTOPENIA P0 589
NEOMYCIN B WHITE CELL COUNT DEC V IF SEVERE MEGALOBLASTIC ANEMIA P0976
NIALAMIDE B WHITE CELL COUNT DEC V LEUKOPENIA REPORTED R0026
NITROFURANS B WHITE CELL COUNT DEC V MAY OCCASIONALLY CAUSE AGRANULOCYTOSIS 90657
NITROFURANTOIN B WHITE CELL COUNT DEC V LEUKOPENIA/AGRANULOCYTOSIS NAY OCCUR P0293
NORTPIPTYLINE B WHITE CELL COUNT DEC V MAY CAUSE AGRANULOCYTOSIS R0026
NOVOBIOCIN B WHITE CELL COUNT DEC V MAY INDUCE BLOOD DYSCPASIAS P0 620
OXACILLIN B WHITE CELL COUNT DEC V MAY CAUSE BONE MARROW DEPRESSION 90620
OXAZ!PAM B WHITE CELL COUNT DEC V LEUKOPENIA OCCURS RARELY P06 20
OXYPHENBUTAZONE B WHITE CELL COUNT DEC V AGPANULOCYTOSIS/LEUKOPENIA 90620
PARANETHADIONE B WHITE CELL COUNT DEC V APLASTIC ANEMIA/NEUTROPENIA P0026
PARATHION B WHITE CELL COUNT DEC V LEUKOPENIA (AMA-BLOOD DYSCRASIAS) P0658
PENICILLAMINE B WHITE CELL COUNT DEC V LEUKOPENIA MAY OCCUR WITH RASH 90022
PENICILLIN B WHITE CELL COUNT DEC V AGRANULOCYTOSIS/LEUKOPENIA 90711
PERCHLOPATE B WHITE CELL COUNT DEC V MAY CAUSE FATAL APLASTIC ANEMIA P06 20
PEPPH!NAZINE B WHITE CELL COUNT DEC V SUSPECTED OF CAUSING AGRANULOCYTOSIS P0741
PHENACEMIDE B WHITE CELL COUNT DEC V APLASTIC ANEMIA (LEUKOPENIA REPORTED MOST OFTEN) P0 026
PH!NELZINE B WHITE CELL COUNT DEC V MAY CAUSE LEUKOPENIA 90026
PHENETHICILLIN B WHITE CELL COUNT DEC V THEORETICALLY LEUKOPENIA MAY OCCUR 90467
PHENETURIDE B WHITE CELL COUNT DEC V LEUKOPENIA REPORTED P0 384
PHENINDIONE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS/LEUKOPENIA 90620
PHENOBARBITAL B WHITE CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) 90658
PHENOTHIAZINES B WHITE CELL COUNT DEC V AGRANULOCYTOSIS/LEUKOPENIA ESP IF LOW INITIALLY P0574
PHENSUXINIDE B WHITE CELL COUNT DEC V POSSIBLE AGRANULOCYTOSIS (VERY RARE P0026
PHENYLBUTAZONE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS/APLASTIC ANENIA/LEUKOPENIA P0 764
PHOSPHORUS B WHITE CELL COUNT DEC V REPORTED EFFECT WITH POISONING RO368
PIPAMAZINE B WHITE CELL COUNT DEC V PANCYTOP!NIA (AMA-BLOOD DYSCRASIAS) P0658
PIPEPACETAZINE B WHITE CELL COUNT DEC V RARE LEUKOPENIA /AGPANULOCYTOSIS (REVERSIBLE) P00 26
PIPOBROMAN B WHITE CELL COUNT DEC V BONE MARROW DEPRESSION MAY OCCUR AFTER 4 WEEKS P0467
PREDNISOLONE B WHITE CELL COUNT DEC V LEUKOPENIA R062O
PREDNISONE B WHITE CELL COUNT DEC N LOW COUNT BY COULTER 5, ?DUE TO FRAGILE CELLS 90598
PRIMAQUINE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS/LEUKOPENIA P0620
PRINIDONE B WHIT! CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYCRASIAS) P065 8
PROCAINANIDE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS R09 15
PPOCAPBAZINE B WHITE CELL COUNT DEC V LEUKOPENIA AND BONE NARROW DEPRESSION 90026
PROCHLORPERAZIN! B WHITE CELL COUNT DEC V AGPANULOCYTOSIS DUE TO INTERFERENCE IN DEVELOPMENT P00 25
PROMAZINE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS 90329
PPOM!THAZINE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS/LEUKOPENIA P09 32
PROPYLTHIOUPACIL B WHITE CELL COUNT DEC V AGRANULOCYTOSIS (INCIDENCE 1 IN 200) P0212
PROTHIONAMIDE B WHITE CELL COUNT DEC V SINGLE CASE REPORTED P0 657
PROTRIPTYLINE B WHITE CELL COUNT DEC V TRANSIENT AGRANULOCYTOSIS OR LEUKOPNIA P 00 2 6
PYRATHIAZINE B WHITE CELL COUNT DEC V NAY OCCUR WITH PROLONGED USE P0620
PYPAZOLONES B WHITE CELL COUNT DEC V APLASTIC/HEMOLYTIC ANEMIA (NAY BE AGPANULOCYTOSIS) P 06 20
PYRIMETHAMINE B WHITE CELL COUNT DEC V MAY OCCUR WITH SEVERE MEGALOBLASTIC ANEMIA P1007
QUINACRINE B WHITE CELL COUNT DEC V LEUKOPENIA/AGRANULOCYTOSIS/APLASTIC ANEMIA P0656
QUINIDINE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS/LEUKOPENIA P062 0
QUININE B WHITE CELL COUNT DEC V LEUKOPENIA (AMA-BLOOD DYSCRASIAS) P06 58
RADIOACTIVE B WHITE CELL COUNT DEC V MAY CAUSE NARROW DEPRESSION R0620

PIFAMPIN B WHITE CELL COUNT DEC V TOXIC OR ALLERGIC RESPONSE (USUALLY TRANSIENT) 90740
PISTOCETIN B WHITE CELL COUNT DEC V LEUKOPENIA OP AGRANULOCYTOPENIA 90620
SODIUM PROS P32 B WHITE CELL COUNT DEC V LEUKOPENIA IF EXCESS USED R0026
STREPTOMYCIN B WHITE CELL COUNT DEC V AGRANULOCTYOSIS/LEUKOPENIA/NEUTPOPENIA P0620
SULFADIAZINE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS/LEUKOPENIA P0620
SULFAMETHIZOLE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS P0751
SULFAMETHOXAZOLE B WHITE CELL COUNT DEC V TOXIC REACTION TO DRUG P0542
SULFAMETHOXYPYRID B WHITE CELL COUNT DEC V LEUKOPENIA (AMA-BLOOD DYSCRASIAS) P0658
SULFISOXAZOLE B WHITE CELL COUNT DEC V AGPANULOCYTOSIS/APLASTIC ANEMIA P0751
SULFONAMIDES B WHITE CELL COUNT DEC V AGPANULOCYTOSIS/APLASTIC ANEMIA P0657
SULFONES B WHITE CELL COUNT DEC V AGRANULOCYTOSIS/LEUKOPENIA P0026
SULFONYLUREAS B WHITE CELL COUNT DEC V PANCYTOPENIA/AGRANULOCYTOSIS P0620
SULTHIAME B WRITE CELL COUNT DEC V LEUKOPENIA/ALSO INCS HALF LIFE OF DIPHENYLHYDANTOIN P0384
SURANIN B WHITE CELL COUNT DEC V AGRANULOCYTOSIS REPORTED P0026
TETRACYCLINE B WHITE CELL COUNT DEC V LEUKOPENIA (AMA-BLOOD DYSCRASIAS) P0658
THENALIDIN! B WHITE CELL COUNT DEC V LEUKOPENIA (AMA-BLOOD DYSCRASIAS) P0658
THIABENDAZOLE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS/LEUKOPENIA P0647
THIACETAZONE B WHITE CELL COUNT DEC V DRUG RELATED AGRANULOCYTOSIS (PARE) P0657
THIAMAZOL! B WHITE CELL COUNT DEC V RAPE AGRANULOCYTOSIS OP PANCYTOPENIA P0657
THIAZIDES B WHITE CELL COUNT DEC V REPORTED TO CAUSE AGRANULOCYTOPENIA P0723
THIOGLYCOLATE B WHITE CELL COUNT DEC V REPORTED EFFECT R0658
THIOGUANINE B WHITE CELL COUNT DEC V NAY CAUSE NARROW DEPRESSION P0167
THIOPROPAZATE B WHITE CELL COUNT DEC V RARE LEUKOPENIA P0026
THIORIDAZINE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS DUE TO INHIBITION OF DEVELOPMENT 90741
THIOSEMICARBAZONES B WHITE CELL COUNT DEC V LEUKOPENIA/AGRANULOCYTOSIS IN 0.5% P0384
THIOTEPA B WHITE CELL COUNT DEC V MAY CAUSE BONE NARROW DEPRESSION P0026
THIOTHIXENE B WHITE CELL COUNT DEC V TRANSITORY LEUKOPENIA P0620
THIOtIRACIL B WHITE CELL COUNT DEC V AGRANULOCYTOSIS (IN ABOUT 1% CASES) P0937
TIOCARLIDE B WHITE CELL COUNT DEC V ASSOC WITH PEL LYMPHOCYTOSIS AND NONOCYTOSIS P0657
TOLAZAMIDE B WRITE CELL COUNT DEC V LEUKOPENIA/AGRANULOCYTOSIS P0384
TOLAZOLINE B WHITE CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0658
TOLBUTANIDE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS/APLASTIC ANEMIA P0199
TPANYLCYPROMINE B WHITE CELL COUNT DEC V THEORETICAL EFFECT OF THIS TYPE OF DRUG P0026
TRIETHYLENEMELANINE B WHITE CELL COUNT DEC V MAY CAUSE BONE NARROW DEPRESSION P0026
TRIFLUOPEPAZINF B WHITE CELL COUNT DEC V PANCYTOPENIA (AMA-BLOOD DYSCRASIAS) P0657
TRIFLUPERIDOL B WHITE CELL COUNT DEC V PARE LEUKOPENIA/AGPANULOCYTOSIS P0384
TPIFLUPROMAZINE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS DUE TO INHIBITION OF DEVELOPMENT P0741
TRIMEPRAZINE B WHITE CELL COUNT DEC V NAY CAUSE LEUKOPENIA OP AGRANULOCYTOSIS P0026
TRINETHAOIONE B WHITE CELL COUNT DEC V APLASTIC ANEMIA 90784
TPIPELENNAMINE B WHITE CELL COUNT DEC V AGRANULOCYTOSIS/ LEUKOPENIA (RARE) P0932
UPACIL MUSTARD B WHITE CELL COUNT DEC V NAY CAUSE BONE MARROW DEPRESSION 90026
UPETHAN B WHITE CELL COUNT DEC V BONE NARROW APLASIA/PANCYTOPENIA 90026
VINBLASTINE B WHITE CELL COUNT DEC V LEUKOPENIA R0026
VINCRISTINE B WHITE CELL COUNT DEC V USUALLY REVERSIBLE LEUKOPENIA R0026
VITAMIN A B WHITE CELL COUNT DEC V LEUKOPENIA WITH HYPOPLASTIC ANEMIA REPORTED P1010
VITAMIN K B WHITE CELL COUNT DEC V PANCYTOPENIA REPORTED AFTER K3 AND K4 P0657
X-RAY THERAPY B WHITE CELL COUNT DEC V CELL DESTRUCTION IN LEUKEMICS P0930
ACIDS B WHITE CELL COUNT INC V RESPONSE TO INGESTION P0368
ALLOPURINOL B WHITE CELL COUNT INC V HYPERSENSITIVITY REACTION OCCURS WITH FEVER 90620
ANINOSALICYLIC AC B WHITE CELL COUNT INC V MAINLY DUE TO EOSINOPHILIA DUE TO HYPERSENSITIVITY 90620
AMPHETAMINES B WHITE CELL COUNT INC V MYELOBLASTIC LEUKEMIA P0100
AMPICILLIN B WHITE CELL COUNT INC V MAINLY DUE TO EOSINOPHILIA OF HYPERSENSITIVITY 90620
ATROPINE B WHITE CELL COUNT INC V MAY CAUSE LEUKOCYTOSIS (EFFECT IN CHILDREN) 90026
BELLADONNA B WHITE CELL COUNT INC V MAY CAUSE LEUKOCYTOSIS P0026
BENZENE B WHITE CELL COUNT INC V LYMPHOCYTIC OR POLYNORPHONUCLEAP EARLY 90384
CAPREOMYCIN B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA OF HYPERSENSITIVITY 90620
CEPHALOTHIN B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA OF HYPERSENSITIVITY P0620
CHLORANPHENICOL B WHITE CELL COUNT INC V LEUKEMIA MAY OCCUR AS SEQUEL TO MARROW DEPRESSION P0026
CHLOPPROPAMIDE B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA OF HYPERSENSITIVITY P0620
CLOXACILLIN B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA OF HYPERSENSITIVITY P0620
COLCHICINE B WHITE CELL COUNT INC V LEUKOCYTOSIS FOLLOWS INITIAL LEUKOPENIA P0384
COPPER B WHITE CELL COUNT INC V LEUKOCYTOSIS OBSERVED WITH POISONING R0657
CORTICOTROPIN B WHITE CELL COUNT INC V SIGNIFICANT NEUTROPHILIC CRANULOCYTOSIS P0657
DESIPRAMINE B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA OF HYPERSENSITIVITY P0620
DIELDPIN B WHITE CELL COUNT INC V NAY OCCUR IN ACUTE RESPONSE P0368
DIETHYLCARBANAZINE B WHITE CELL COUNT INC V OFTEN MARKED LEUKOCYTOSIS MAXIMAL ON FOURTH DAY P0384
DIGITALIS B WHITE CELL COUNT INC V PARE LEUKOCYTOSIS P0620
DIPHENYLHYDANTOIN B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA P0620
DYDROGESTERONE B WHITE CELL COUNT INC V MILD LEUKOCYTOSIS REPORTED P0026
EPINEPHRINE B WHITE CELL COUNT INC V INITIALLY DUE TO LYMPHOCYTOSIS LATER NEUTROPHILIA P08914
ERYTHROMYCIN B WHITE CELL COUNT INC V LEUKOCYTOSIS OBSERVED P0623
ETIOCHOLANOLONE B WHITE CELL COUNT INC V PYPOGEN - INCREASES NUMBER OF GRANULOCYTES P0657
FLOPANTYRONE B WHITE CELL COUNT INC V IN PATIENTS WITH PREEXISTING LIVER DISEASE P0620
GOLD B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA OF HYPERSENSITIVITY P0620
HALOPERIDOL B WHITE CELL COUNT INC V RARELY REPORTED LEUKOCYTOSIS R0026
HALOTHANE B WHITE CELL COUNT INC V ALLERGIC HYPERSENSITIVE RESPONSE P0384
IMIPPAMINE B WHITE CELL COUNT INC V (TRANSIENT 1-6 HOURS) (POSSIBLY LOEFFLER’S SYNDROME) P0857
IODID!S B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA P0620
IRON DEXTRAN B WHITE CELL COUNT INC V LEUKENOID REACTION REPORTED P0657
ISONIAZID B WHITE CELL COUNT INC V DUE TO EOSINO?HILIA P0620
KANANYCIN B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA P0620
LITHIUM B WHITE CELL COUNT INC V ?DRUG ASSOCIATED ENDOCRINE EFFECT (MAY DOUBLE) P0626
METHICILLIN B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA/LEUKOCYTOSIS 90620
METHYLDOPA B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA P0620
NETHYSERGIDE B WHITE CELL COUNT INC V DUE TO NEUTPOPHILIA P0620
MUSCULAR EXERCISE B WHITE CELL COUNT INC V MAINLY DUE TO NEUTROPHILIA AFTER EXERCISE 90291
NALIDIXIC ACID B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA P0620
NAPHTHALENE B WHITE CELL COUNT INC V LEUKOCYTOSIS NAY OCCUR FOLLOWING INGESTION P0368
NOVOBIOCIN B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA P0620
OXYPHENBUTAZONE B WHITE CELL COUNT INC V LEUKEMIA REPORTED TO DEVELOP IN 2 SUBJECTS P0657
1264 CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972#{149}

PAPA LCHY0E B WRITE CELL COUNT INC V LEUKOCYTOSIS IN STVRE ACUT OR CHRONIC POISONING 9C38L4
PH NINDIONE B WHITE CELL COUNT INC V OCCASIONAL LEUKOCYTOSIS MAY OCCUR 9C384
PHENOTRIAZINES B WHITI CELL COUNT INC V DUE TO EOSCNOPHILIA OR GENERALIZED LEUKOCYTOSIS 9C623
PHENYLUTA ZONE B WHITE CELL COUNT INC V LEUKEMIA-DRUG INDUCED R657
PHOSPHORUS B WH1aE CELL COUNT INC V PEPOPTED LSCKOCYTOS1S WITH PGISONING R368
PILOCAPPINE B WHITE CELL COUNT INC V PROBABLY DUE TO CONTLIICTION OF SPLEEN PC 384
POTASSIUM IODIDE B WHITE CELL COUNT INC V DUE TO :osINoPaILIA ?:62C
PREDNISOLONE B WHIT CELL COUNT INC V LEUCOCYTOSIS 0BSL?Vb OCCASIONALLY R620
PREGNANCY B WHITE CELL COUNT INC V IN LATE PREGNANCY AND AT LABOR P2291
QUININE B WHITE CELL COUNT INC V P?IIARY INC, iSP LY?!?HOCYTES (SPLENIC CONTRACTIONS) P C 384
RADIOACTIVE IODINE B WHITE CELL COUNT INC V INCIDENCE OF ACUTE LUK7MI? Ii1GHOE
RISTOCETIN B WHII CELL COUNT INC V DUE TO EOSINOPH1LIA P.262 0
SC-161C 2 B WHITE CELL COUNT INC V MECHANISM NOT EX?LAINi) P2 1499
SThEPTOKINAST B WHITE CELL COUNT INC V DUE TO LOSINOPHILIA R0620
STRYCHNINE B WHITE CELL COUNT INC V PROBABLY OUT TO RELEASE OF EPINEPBBINE FROM ADRENAL P2368
SULFONAMIDES B WHITE CELL COUNT INC V ASSOC WITH HEMOLYSIS (ISP WITH LONG-ACTING DRUGS) P.2#{149}
620
TETRACYCLINE B WHITE CELL COUNT INC V LEUKOCYTOSIS WITIl ATYPICAL LYMPHOCYTES 90384
TRIANTERENC B WHITh CELL COUNT INC V DUE TO EOSINO?HILIA P62C
TPIFLUPERIDOL B WHITE CELL COUNT INC V DUE 10 EOSINOPHILIA p0620
VANCOMYC IN B WHITE CELL COUNT INC V DUE TO ZOSINOPHILIA R0620
VIOMYCIN B WHITE CELL COUNT INC V DUE TO EOSINOPHILIA h062C
ALLOPUPINOL U XANTHINE CALCULI P05 V 9AE SIDE EFFECT P0395
A LLOPU?I NOL S XANTHINE INC V INHIBITS XANTHINE OXIDASL (SLIGHT INC ONLY) 14.2026
ALLOPURINOL U XANTHINE INC V INEIIBITS XANTHINP OXIDASE 93026
ORAL CONTRACEPTIVE U XANTHURENIC ACID INC V REVERSED BY PYPIDOXINE (INC TO NICOTINIC ACID) PC, 657
PENICILLAMI NE U XANTHURENIC ACID INC V INDUCES PYRIDOXINE ANTAGONIS1 P0384
ACETYLSALICYLIC AC U XYLOSE EXCRETION DEC V AFFECTS RENAL ELIMINATION 90523
AMINOSALICYLIC AC U XYLOSE EXCRETION DEC V 2X NORMAL DOSE PRODUCED REVERSIBLE EFFCT ON ABSORP 90993
COLC HICINE U XYLOSE EXCRETION DC V DEC ABSORP PROM GUT, DISTURBS EPITHEL CELL FUNCTION 90763
I NDONETHACIN U XYLOSE EXCRETION DEC V ?DJE TO INCPPASED MOTILITY OF GUT 9C523
ISOCARBOXAZ ID U XYLOSE EXCRETION DEC V DECREASEC G.I. TRACT ABSORPTION R2956
KANAMYCIN U XYLOSE EXCRETION DEC V BUE TO IMPAIRED GASTROINTESTINAL ABSORPTION 90467
MAO INHIBITORS U XYLOSE EXCRETION DEC V DECREASED G.I. TRACT ABSORPTION 90355
MTALS U XYLOSE ELCRETION DEC V LESS ABSOPPED IN NON-FASTING STATE P.0766
METFORMIN U XYLOSE EXCRETION DEC V PROBAI3LY DOSE RELATED MALABSORPTION 90935
NEOMYCIN U XYLOSL EXCRETION DEC V AFFECTS INTESTINAL ABSCRPTION iITH NUCOSAL DAMAGE P2486
PHENELEINE U XYIOSE EXCRETION DEC V DECBEASED ABSOBPTION 0? XYLOSE FROM G.I.TPACT PC 956
PHNFOPMIN U XYICSE EXCRETION DEC V AFFECTS INTESTINAL ABSOBPTION 9C9C3
3ALACTOS U XYLOSE EXCRETION INC N INTERFERES WITH BRONOANILINL PROC IF 0VR 2 G/103ML 90779
GLUCOSL U XYLOSE EXCRETION INC N INTERFERES WITH BROMOANILINE PROC IF OVER 2 G/100NL R0779
PHTNAZOPYRIDINE U XYLOSE EXCRETION INC M DUE TO INTERFERING BACKGROUND COLOR PC 766
THY NOL U XYLOSE EXC3ETION Z N NO EFFECT ON ANALYTICAL METHOD PC 779
CCRTICOSTEROIDS S ZINC DEC V RAPID-SUSTAINED DROP IN BURN AND SURGICAL PATIENTS 9 0335
ORAL CONTRACEPTIVE S ZINC DEC V DURATION OF OS UNRELATED TO ZN CONCENTRATION 90414
ESTROG ThS S ZINC INC V MEIABOLIC EFFECT RC148
EDTA U ZINC INC V I? POISONING DUE TO ZINC P0326
THANOL U ZINC INC V IN ABSENCE 01 EFFECT ON SLPLJ?1 CONCENTRATION P.C 187
PENICILLAMINE U ZINC INC V IF POISONING DUE TO ZINC PC 384
STORAGE OF SAMPLE S ZNSO4 TURBIDITY DEC N EFFECT OBSEPVLO AFTER I DAY AT 4 DEGREES RC36
HEPARIN S ZNSO4 TURBIDITY INC N AFFECTS ?HYSICO-CHCNICAL PROPLPTIES R236
LIPEMIA S ZNSO4 TURBIDITY INC N EFFECT LESS MARKED THAN hITH THYNOL TURBIDITY 90436
RIFAMPIN S ZNSOL3 TURBIDITY INC V HEPATOTOXIC EFFECT (CHOLESTASIS) R 074 C
BILIR UBIN S ZNSOLL TURBIDITY Z N PPOI3 SANE NON-INTERFERENCE AS WITH THYMOL TURBIDITY P.C 436
HEAT S ZNSO4 TURBIDITY Z N LITTLE CHANGE WITH TELIPERAIURE OBSERVED P 018 1
HEMOGLOBIN S ZNSO4 TURBIDITY Z N P905 SAME NON-INTERFERENCE AS WITH THYMOL TURBIDITY R0436
PENTAZOC INE U 11 OH CORTICOSTEROIDS DEC V ?DUE TO DEPPESSION OF ADRENOCORTICAL SECRETION PC 236
PPOPOXYPHENE U 11 OH CORTICOSTEPOIDS DEC V SLIGHT EFFECT ONLY (PROBABLY PHYSIOLOGICAL ACTION) PC 236
CHOLESTEROL P 11 OH CORTICOSTEROIDS INC N DUE TO NON-S?ECIPIC PLUORESENCE P0389
C OR I IC OT P OPI N P 11 OH CORTICOSTEPOIDS INC N DUE TO INC CHOLESTEPOL WITH NON-SPECIFIC FLUORES P C’389
NICOTINE P 11 OH CORTICOSTEPOIDS INC V UP TO 8C% INCREASE AFTER HEAVY SMOKING RC526
ATTA MINOPHEN U 11 OH CORTICOSTEROIDS Z V NO EFFECT WITH SHORT TERM INGESTION 2.6 G/DAY RC236
ACETYLSALICYLIC AC U 11 OH CORTICOSTEROIDS Z N NO EFFECT ON FLUOPONETBIC MATTINGLY METHOD P0236
ACETYLSALICYLIC AC U 11 OH CORTICOSTEROIDS V NO EFFECT WITH SHORT TERM INGESTION 2.6 G/DAY PC 236
CHLOR DIAZEPOXIDE U 11 OH CORTICOSTEROIDS Z V NO EFFECT SHORT TERN INGESTION 3C MG/DAY 90236
DIAZ EPAN U 1 OH CORTICOSTEROIDS Z V NO EFFECT SHORT TERM INGESTION OF 15 MG/DAY P C 236
DIPHENHYDR AMINE U 11 OH COPTICOSTEROIDS Z V NO EFFECT SHORT TERF INGESTION OF 150 MG/DAY 90236
PHENOBARBITAL U 11 OH COPTICOSTEROIDS Z V NO EFFECT SHORT TERN INGESTION OF 120 MG/DAY P0236
CHLO RDIAZEPOXI OF U 17 KETOGENIC STEROIDS DEC N INTERFERES WITH ZIMMERMAN REACTION R’29C7
D EX A MET HAS ONE U 17 KETOGENIC STEROIDS DEC V SUPPRESSION OF ACTH BC 653
GLUCOSE U 17 KETOGENIC STEROIDS DEC N INT1RFERZS WITH NORYMBEESKI REACTION P0907
IODIPANIDE U 17 KETOGENIC STEROIDS DEC N INTERFERES WITH REACTION P 3692
ZOTH ALAMATE U 17 KETOGENIC STEROIDS DEC M ACTS AS REDUCING SUBST (RUTHERFORD & NELSON METHOD) PC 6 92
NE PROBAM ATE U 17 KETOGENIC STEROIDS DEC N INTERFERES WITH ZIMMERMAN REACTION (HOLTOPFF-KOCH) 90816
METYRAPONE U 17 KETOGENIC STEROIDS DEC N INTER?ERES WITH ZIMMERMAN REACTION RC907
ORAL CONTRACEPTIVE U 17 KETOGENIC STEROIDS DEC V PROB DUE TO ESTROGEN DECREASING CORTISOL SECRETION 90695
ACET AZOLAMIDE U 17 KETOGENIC STEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION P0133
ACETOPHENONE U 17 KETOGENIC STEROIDS INC N INTERFERES IN MEASUREMENT BY ZIMMERMAN METHOD 90907
CHLORDIAZEPOXIDE U 17 KETOGENIC STEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION BC 692
CHLORPROMA ZI NE U 17 K ETOG !NIC STEROIDS INC N INTERFERES WITH ZIMMERPIAN REACTION P0907
CORTISONE U 17 KETOGENIC STEROIDS INC V METABOLIC PRODUCTS 90596
DIGITOXIN U 17 KETOGENIC STEROIDS INC N INTERFERES WITH hIMMERMAN REACTION IN VITRO P0133
ETPYT?MINE U 17 KETOGENIC STEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION 90133
HYDRALAZINE U 17 KETOGE NIC STEROIDS INC N GLUCURONIDE INTERFERES WITH ZIMMERMAN REACTION P C 907
HYDROXYZINE U 17 KETOGENIC STEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION PC 692
MEPROBAM ATE U 17 KETOGENIC STEROIDS INC N GLUCURONIDE INTERFERES WITH ZIMMERMAN REACTION PC 907
N El NY PRY LON U 17 KETOGENIC STEROIDS INC H INTZRFERLS WITH ZIMMERMAN REACTION RC9C7
N FT Y PA PONE U 17 KETOGENIC STEROIDS INC V NORMAL RESPONSE TO INJECTION IS DOUBLING Of OUTPUT PC 1467
NALIDIXIC ACID U 17 KETOGENIC STEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION 90590
OLEANDOMYCIN U 17 KETOGENIC STEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION 90907
PENICILLIN U 17 KETOGENIC STEROIDS INC N INTERFERES WITH ZIMMERMAN (NORYMELRSKI) REACTION RC9C7

PHENAGLYCODOL U 17 KETOGENIC STEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION P0907
PHENAZOPYRIDINE U 17 KETOGENIC STEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION 90907
PHENOTHIAZINES U 17 KETOGENIC STEROIDS INC N YIELD SIMILAR COLOR WITH ZIMMERMAN REACTION 90596
SPIRONOLACTONF U 17 KETOGENIC STEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION P0907
CHLOROTHIAZIDE U 17 KETOGENIC STEROIDS Z N PROB MIN INTERFERENCE WITH ZIMMERMAN REACTION 90907
GLUTETHIMIDE U 17 KETOGENIC STEROIDS Z N PROB MIN INTERFERENCE WITH ZIMMERMAN REACTION 90907
IOTHALANATE U 17 KETOGENIC STEROIDS Z V NO PHYSIOLOGICAL EFFECT OBSERVED P0692
MORPHINE P 17 KETOSTEROIDS DEC V INHIBITS ACTH AND PIT GONADOTPOPIN RELEASE 903814
AMINOGLUTETHIMIDE U 17 KETOSTEROIDS DEC V INHIBITS STEROID BIOSYNTHESIS P0359
BETAMETHASONE U 17 KETOSTEROIDS DEC V FEEDBACK PITUITARY SUPPRESSION OF ACTH 90356
CARBON DISULFIDE U 17 KETOSTEROIDS DEC V REDUCTION IN RELATION TO TINE OF EXPOSURE P0254
CHLORDIAZEPOXIDE U 17 KETOSTEROIDS DEC N INTERFERES WITH ZIMMERMAN PEACTION(IN VITRO, VIVO) P0 133
CHLORMEPODIN U 17 KETOSTEPOIDS DEC N POSSIBLE INTERFERENCE WITH ZIMMERMAN REACTION 90133
CHLORPROMAZINE U 17 KETOSTEROIDS DEC V INHIBIT OF HYPOTHALAMUS AND DEC ACTH SECRETION P0359
CORTICOTROPIN U 17 KETOSTEROIDS DEC V REDUCTION EVEN IF ORALLY OR TOPICALLY GIVEN 90138
CORTISONE U 17 KETOSTEPOIDS DEC V PITUITARY SUPPRESSION OF ACTH 91001
DIGOXIN U 17 KETOSTEROIDS DEC N SLIGHT EFFECT ON ZIMMERMAN REACTION IN VITRO P0133
DIPHENYLHYDANTOIN U 17 KETOSTEROIDS DEC V ALTERS STEROID METABOLISM P0 417
ESTROGENS U 17 KETOSTEPOIDS DEC N INTERFERES WITH ZI MMERMAN REACTIONS 90355
GLUCOSE U 17 KETOSTEROIDS DEC N INTERFERES WITH ZIMMERMAN REACTION P0907
MENOPAUSE U 17 KETOSTEPOIDS DEC V NORMAL RESPONSE R0291
MEPEPIDINE U 17 KETOSTEROIDS DEC V PROBABLE EFFECT (INHIBITS ACTH AND PGH RELEASE) P038 4
NEPROBAMATE U 17 KETOSTEPOIDS DEC N INTERFERES WITH ZIMMERMAN REACTION 90816
ETPONIDAZ0LE U 17 KETOSTEPOIDS DEC V IF PREVIOUSLY ELEVATED, ? DEPRESSES ADRENAL CORTEX 90384
METYPAPONE U 17 KETOSTEPOIDS DEC N INTERFERES WITH ZIMMERMAN REACTION 90907
MORPHINE U 17 KETOSTEROIDS DEC V INHIBITS ACTH AND PIT GONADOTROPIN RELEASE P0384
OPAL CONTRACEPTIVE U 17 KETOSTEROIDS DEC V PROBABLE DECREASE IN CORTISOL SECRETION P 0695
PHENOTHIAZINES U 17 KETOSTEROIDS DEC V INHIBIT RELEASE OF STEROID HORMONES 90596
PROBENECID U 17 KETOSTEROIDS DEC V DECREASE OF UP TO 50% REPORTED P0 344
PROMAZINE U 17 KETOSTEROIDS DEC N IN VITRO EFFECT AT LEAST ON ZIMMERMAN REACTION 90133
PROPOXYPHENE U 17 KETOSTEPOIDS DEC V PROBABLE ACTION ON HYPOTHALAMIC-PIT.ACTH SECRETION P0 236
PYPAZINAMIDE U 17 KETOSTEROIDS DEC V TEMP DECREASED EXCRETION REPORTED 90384
PESEPPINE U 17 KETOSTEROIDS DEC N INTERFERENCE WITH ZIMMERMAN PROCEDURE P0 133
SECOBARBITAL U 17 KETOSTEROIDS DEC N NEG INTERFERENCE ON ZIMMERMAN REACTION IN VITRO 90133
ACETOPHENONE U 17 KETOSTEPOIDS INC N INTERFERES IN MEASUREMENT BY ZIMMERMAN METHOD 90907
CHLORAMPHENICOL U 17 KETOSTEROIDS INC N AFFECTS SOME METHODS BUT NOT MODIFIED REDDY METHOD 90417
CHLORPROMAZINE U 17 KETOSTEROIDS INC V ALTERS STEROID METABOLISM 90133
CHLOPPPOMAZINE U 17 KETOSTEPOIDS INC N INTERFERES WITH ZIMMERMAN REACTION P0907
CHLORTHALIDONE U 17 KETOSTEPOIDS INC V ALLEGED INCREASED EXCRETION P0417
CLOXACILLIN U 17 KETOSTEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION P0907
CORTICOTROPIN U 17 KETOSTEROIDS INC V STIMULATION OF ADRENAL 901417
DEXAMETHASONE U 17 KETOSTEROIDS INC N AFFECTS METHOD OF REDDY (METABOLISM,1952) R0470
ERYTHRONYCIN U 17 KETOSTEROIDS INC N INTERFERENCE WITH MEASURING PROCEDURE 90417
ETHINAMATE U 17 KETOSTEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION P0 133
ETHINYLESTRADIOL U 17 KETOSTEROIDS INC V TEMPORARY ENHANCED EXCRETION ON STOPPING DRUG 90469
GONADOTROPIN U 17 KETOSTEROIDS INC V METABOLIC RESPONSE 90842
NEPROBAMATE U 17 KETOSTEROIDS INC N GLUCUPONIDE INTERFERES WITH ZIMMERMAN REACTION P08 16
METHYPRYLON U 17 KETOSTEROIDS INC M REPORTED EFFECT ON HOLTOPFF-KOCH MOD OF ZIMMERMAN 90133
NALIDIXIC ACID U 17 KETOSTEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION P0590
NANDROLONE U 17 KETOSTEPOIDS INC V ANABOLIC EFFECT 90708
OLEANDOMYCIN U 17 KETOSTEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION P07 03
PENICILLIN U 17 KETOSTEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION P0907
PHENAGLYC000L U 17 KETOSTEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION P0907
PHENAZOPYPIDINE U 17 KETOSTEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION P0 907
PHENOTHIAZINES U 17 KETOSTEROIDS INC M INC ABSORBANCE ABNORMAL COLOR ZIMMERMAN PROCEDURE P0 133
PIPERIDINES U 17 KETOSTEROIDS INC N INTERFERENCE WITH ZIMMERMAN REACTION IN VITRO R0133
PREGNANCY U 17 KETOSTEROIDS INC V UPPER LIMIT OF NORMAL AT TERM R0291
QUINIDINE U 17 KETOSTEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION P02 99
SECOBARBITAL U 17 KETOSTEPOIDS INC N INTERFERES WITH ZIMMERMAN PEACTION P0299
SPIRONOLACTONE U 17 KETOSTEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION P0907
TESTOLACTONE U 17 KETOSTEROIDS INC V REPORTED EFFECT P01417
ACETANINOPHEN U 17 KETOSTEROIDS Z V NO EFFECT WITH SHORT TERM INGESTION 2.6 G/DAY P0236
ACETAZOLAMIDE U 17 KETOSTEROIDS Z N MIN INTERFERENCE WITH ZIMMERMAN REACTION IN VITRO 90133
ACETYLSALICYLIC AC U 17 KETOSTEROIDS Z V NO EFFECT WITH SHORT TERM INGESTION 2.6 G/DAY P0 236
ACETYLSALICYLIC AC U 17 KETOSTEPOIDS Z N NO EFFECT ON ZIMMERMAN PROCEDURE P0236
AMPHETAMINES U 17 KETOSTEROIDS Z N NO EFFECT ON ZIMMERMAN REACTION 90133
BARBITURATES U 17 KETOSTEROIDS Z V SHORT TERM INGESTION PRODUCES NO EFFECT P0236
BARBITURATES U 17 KETOSTEROIDS Z N NO INTERFERENCE WITH ZIMMERMAN PROCEDURE P0 236
CHLORDIAZEPOXIDE U 17 KETOSTEROIDS Z V NO EFFECT SHORT TERM INGESTION OF 30 MG/DAY P0236
CHLORDIAZEPOXIDE U 17 KETOSTEPOIDS Z N NO EFFECT ON ZIMMERMAN REACTION IF ADDED IN VITRO 90236
CHLOROTHIAZIDE U 17 KETOSTEROIDS Z N NIN INTERFERENCE WITH ZIMMERMAN REACTION IN VITRO P0 133
DI.AZEPAM U 17 KETOSTEPOIDS Z V NO EFFECT SHORT TERN INGESTION OF 15 MG/DAY 90236
DIGITOXIN U 17 KETOSTEROIDS Z N NIN INTERFERENCE WITH ZIMMERMAN REACTION 90133
DIPHENHYDRANINE U 17 KETOSTEPOIDS Z V NO EFFECT SHORT TERM INGESTION OF 150 MG/DAY 90236
GLUTETHINIDE U 17 KETOSTEROIDS Z N MIN INTERFERENCE WITH ZIMMERMAN REACTION IN VITRO 90133
HYDRALAZINE U 17 KETOSTEROIDS Z N NO SIGNIFICANT EFFECT WITH ZIMMERMAN REACTION 90133
HYDROXYZINE U 17 KETOSTEROIDS Z N NO EFFECT REPORTED ON ZIMMERMAN REACTION 90133
IOTHALAMATE U 17 KETOSTEROIDS Z V NO PHYSIOLOGICAL EFFECT OBSERVED P0692
PERPHENAZINE U 17 KETOSTEROIDS Z N MINIMAL EFFECT ON ZIMMERMAN PEACTION P0 133
PHENOBARBITAL U 17 KETOSTEROIDS Z V NO EFFECT SHORT TERN INGESTION OF 120 MG/DAY P0236
PROCHLORPERAZINE U 17 KETOSTEPOIDS Z N NO SIGNIFICANT EFFECT WITH ZIMMERMAN REACTION P0133
PROPOXYPHENE U 17 KETOSTEPOIDS Z N ADDED IN VITRO NO EFFECT ON ZIMMERMAN REATION 90236
MORPHINE P 17 OH CORTICOSTEROIDS DEC V INHIBITS ACTH AND PIT GONADOTROPIN RELEASE P0 384
ACETYLSALICYLIC AC U 17 OH CORTICOSTEPOIDS DEC N CONJUGATE INHIBITS B-GLUCURONIDASE, DOSE> 4.8 G/DAY P0236
AMINOGLUTETHINIDE U 17 OH CORTICOSTEROIDS DEC V INHIBITS STEROID BIOSYNTHESIS P03 59
BARBITURATES U 17 OH CORTICOSTEROIDS DEC V CHRONIC INGESTION METAB DIVERTED TO 6-B-OH-CORTISOL 90236
CALCIUM GLUCONATE U 17 OH CORTICOSTEROIDS DEC N REDUCED VALUE REPORTED IN A SINGLE CASE P0 164
CARBON DISULFIDE U 17 OH CORTICOSTEROIDS DEC V REDUCTION IN RELATION TO TIME OF EXPOSURE 90254
CHLORPROMAZINE U 17 OH CORTICOSTEPOIDS DEC V INHIBIT OF HYPOTHALAMUS AND DEC ACTH SECRETION 90359
CORTICOTPOPIN U 17 OH CORTICOSTEROIDS DEC V REDUCTION EVEN IF GIVEN ORALLY OR TOPICALLY 90138

DEXA METHA SONE U 17 OH CORTICOSTEPOIDS DEC V PITUITARY FEEDBACK WITH SUPPRESSION OF ACTH P0584
DIPHENYLHYDANTOIN U 17 OH CORTICOSTEROIDS DEC V WITH CHRONIC INGESTION COPTISOL= 6-B-OH CORTISOL R0981
ESTROGENS U 17 OH COPTICOSTEROIDS DEC N INTERFERES WITH ZIMMERMAN REACTIONS P0654
ESTROGENS U 17 OH CORTICOSTEROIDS DEC V WITH CHRONIC INGESTION CORTISOL= 6-B-OH CORTISOL 90514
HYDRALAZINE U 17 OH CORTICOSTEPOIDS DEC N IN VITRO EFFECT REPORTED MODIFIED GLENN-NELSON P0133
MED P0 XY PROGE STEP ONE U 17 OH CORTICOSTEROIDS DEC V INHIBITION OF STEROID BIOSYNTHESIS IN ADRENALS 90942
MEPERIDINE U 17 OH CORTICOSTEPOIDS DEC V PROBABLE EFFECT (INHIBITS ACTH AND PGH RELEASE) 903814
MITOTA NE U 17 OH CORTICOSTEPOIDS DEC V STIMULATES EXTRA-ADRENAL HYDROXYATION OF CORTISOL P02 17
MORPHINE U 17 OH CORTICOSTEROIDS DEC V INHIBITS ACTH AND PIT GONADOTPOPIN RELEASE 90384
ORAL CONTRACEPTIVE U 17 OH CORTICOSTEROIDS DEC V P909 DUE TO ESTROGEN DECREASING CORTISOL SECRETION 90695
PENTAZOCINE U 17 OH CORTICOSTEPOIDS DEC V ?DUE TO DEPRESSION OF ADPENOCORTICAL SECRETION 90236
PERPHENAZINE U 17 OH CORTICOSTEROIDS DEC V ACTS ON HYPOTHALAMUS TO DEPRESS ACTH SECRETION R0133
PHENOBARB ITAL U 17 OH CORTICOSTEROIDS DEC V WITH CHRONIC INGESTION COPTISOL= 6-B-OH CORTISOL 90169
PHENOTHIAZI NES U 17 OH CORTICOSTEROIDS DEC V INHIBIT RELEASE OF STEROID HORMONES R0596
PHENYL BUTAZONE U 17 OH CORTICOSTEROIDS DEC V CORTISOL METABOLISM DIVERTED TO 6-B-OH CORTISOL 90558
PPOMAZINE U 17 OH COPTICOSTEROIDS DEC V ACTS ON HYPOTHALAMUS TO DECREASE ACTH SECRETION RO133
PROMETHAZINE U 17 OH CORTICOSTEPOIDS DEC N INTERFERENCE WITH PORTER-SILBER REACTION P0 907
PRO POX V PH ENE U 17 OH CORTICOSTEPOIDS DEC V PROBABLE ACTION ON HYPOTHALAMIC-PIT. ACTH SECRETION P0236
RESEPPINE U 17 OH CORTICOSTEROIDS DEC N INTERFERENCE WITH PORTER-SILBER REACTION P0907
ACETYLSALICYLIC AC P 17 OH CORTICOSTEPOIDS INC V LARGE DOSES STIMULATE ADRENOCOPTICAL ACTIVITY 90881
BET AM ETH A SONE P 17 OH CORTICOSTEROIDS INC V SLIGHT EFFECT, ABSOPBED THROUGH SKIN 90026
ESTROGENS P 17 OH CORTICOSTEROIDS INC V CAUSES STIMULATION OF PITUITARY ADRENAL AXIS R0971
METYR A PON! P 17 OH CORTICOSTEROIDS INC V INDIRECTLY STIMULATES ACTH PRODUCTION 90593
ACETAZOLA MID! U 17 011 CORTICOSTEPOIDS INC M IN VITRO INTERFERENCE WITH GLENN-NELSON METHOD 90299
ASCORBIC ACID U 17 OH COPTICOSTEROIDS INC N INTERFERES WITH METHOD OF PEDDY 90417
BETAMETHAS ONE U 17 OH COBTICOSTEROIDS INC V SLIGHT INC, NAY BE ABSORBED THROUGH SKIN 90026
CHLORAL HYDRATE U 17 OH CORTICOSTEROIDS INC N INTERFERES WITH PORTER-SILBER REACTION 90907
CHLORDIAZEPOXIDE U 17 OH CORTICOSTEROIDS INC N INTERFERES WITH PORTEP-SILBER PEACTION(VITPO, TIVO) P0133
CHLORNERODIN U 17 OH CORTICOSTEPOIDS INC N POSSIBLE INTERFERENCE WITH PORTER-SILVER REACTION 90133
CHLOROTHIAZIDE U 17 OH CORTICOSTEROIDS INC N INTERFERES WITH PORTER-SILBER REACTION IN VITRO R1001
CH LORPROMAZI NE U 17 OH COPTICOSTEROIDS INC N INTERFERES WITH PORTER-SILBEP REACTION P0133
CHLORTHALIDONE U 17 OH COPTICOSTEPOIDS INC V REPORTED EFFECT P0596
COLCHICINE U 17 OH CORTICOSTEPOIDS INC N INTERFERES WITH PORTEP-SILBER REACTION 90907
CORTI COTROP IN U 17 OH CORTICOSTEROIDS INC V MARKED RESPONSE TO I.V. INFUSION 90116
CORTISONE U 17 OH CORTICOSTEPOIDS INC V MEASURING EXCRETORY PRODUCTS OF CORTISONE 91001
DEX A METHA SO NE U 17 OH CORTICOSTEROIDS INC N MEASURED AS ENDOGENOUS STEROIDS BY REDDY METHOD P0653
D IGIT OXI N U 17 OH COETICOSTEROIDS INC M MODERATE EFFECT WITH IN VITRO TEST P014 17
DIGOXIN U 17 OH CORTICOSTEROIDS INC N MODERATE EFFECT WITH IN VITRO TEST P04 17
ERYTHROMYCIN U 17 OH CORTICOSTEROIDS INC N REPORTED INTERFERENCE WITH MEASURING PROCEDURE 90417
ETHI NA NATE U 17 OH CORTICOSTEROIDS INC N MINIMAL EFFECT WITH GLENN-NELSON METHOD P04 17
ETHINYLESTRADIOL U 17 OH CORTICOSTEROIDS INC V TEMPORARY ENHANCED EXCRETION ON STOPPING DRUG 90469
ETPYPTAMINE U 17 OH CORTICOSTEROIDS INC N GLUCUPONIDE INTERFERES WITH ZIMMERMAN REACTION 90133
FRUCTOSE U 17 OH CORTICOSTEROIDS INC N INTERFERES WITH PORTER-SILBER REACTION 90907
GLUTETHI MIDE U 17 OH COPTICOSTEROIDS INC N INTERFERES WITH MOD GLENN-NELSON PROCEDURE IN VITRO 90133
GONADOTROPIN U 17 OH CORTICOSTEROIDS INC V HORMONAL ACTION 90842
HYDROXYZINE U 17 OH COPTICOSTEROIDS INC N INTERFERES WITH POPTEP-SILBER REACTION 90654
HYDPOXYZINE U 17 09 CORTICOSTEROIDS INC N AFFECTS MODIFIED GLENN-NELSON METHOD P0133
100 IDES U 17 OH COBTICOSTEROIDS INC N INTERFERES WITH PORTER-SILBEP REACTION 90907
ME PR OB AM A TE U 17 OH COPTICOSTEROIDS INC N GLUCtIRONIDE INTERFERES WITH POPTER-SILBER REACTION 90596
NEPROBA MATE U 17 OH CORTICOSTEROIDS INC N SMALL EFFECT ON MODIFIED GLENN-NELSON METHOD P 1001
METHENAMINE U 17 OH CORTICOSTEROIDS INC N AFFECTS POPTER-SILBER AND REDDY METHODS P01142
METHYPR YLON U 17 OH CORTICOSTEROIDS INC N REPORTED EFFECT ON GLENN-NELSON PROCEDURE P0 133
METYRA PONE U 17 OH CORTICOSTEROIDS INC V NORMAL RESPONSE TO INJECTION IS 2-14 TIMES INCREASE P0593
MUSCULAR EXERCISE U 17 OH CORTICOSTEROIDS INC V RESPONSE TO STRESS OF EXERCISE 90184
OLEANDOMYCI N U 17 OH COBTICOSTEROIDS INC N INTERFERES WITH PORTER-SILBER REACTION R0703
P AR AL D ER YDE U 17 OH CORTICOSTEPOIDS INC N INTERFERES WITH POPTER-SILBER REACTION 90907
PENICILLI N U 17 OH CORTICOSTEROIDS INC M ? INTERFERES WITH PORTER-SILBER REACTION 90596
PERPHE NAZ IN! U 17 OH CORTICOSTEROIDS INC N ABNORMAL COLOR WITH GLENN-NELSON PROCEDURE P0 133
PHENAZOPYPI DINE U 17 OH COBTICOSTEROIDS INC N INTERFERES WITH MODIFIED GLENN-NELSON METHOD P0 133
PHENOTHIAZINES U 17 OH CORTICOSTEPOIDS INC N SLIGHT INC ABSORBANCE MOD GLENN-NELSON METHOD 90133
P1 PERI DINES U 17 OH CORTICOSTEROIDS INC N INTERFERES WITH PORTER-SILBER REACTION IN VITRO 90133
PPOCHLOPPERAZINE U 17 OH CORTICOSTEROIDS INC N INTERFERENCE WITH PORTER-SILBEP REACTION 90133
PRONAZI NE U 17 OH CORTICOSTEPOIDS INC N IN VITRO EFFECT AT LEAST ON GLENN-NELSON NETH 90133
QUINID IN! U 17 OH CORTICOSTEROIDS INC N INTERFERES WITH ZIMMERMAN REACTION P0356
QUININE U 17 OH CORTICOSTEPOIDS INC N PEDDY METHOD AFFECTED, NOT POPTER-SILBER 90907
SPIRONOLACTONE U 17 OH CORTICOSTEROIDS INC N INTERFERES WITH PORTER-SILBEP REACTION P0907
SULFAMERAZI NE U 17 OH CORTICOSTEPOIDS INC N ALLEGED EFFECT ON METHOD OF REDDY P0417
TESTOSTEPONE U 17 OH COPTICOSTEROIDS INC N COMMON KETO GROUP INVOLVED IN COLOR REACTION 90233
VITAMIN K U 17 OH COBTICOSTEROIDS INC M ALLEGED IN VITRO INTERFERENCE WITH REDDY METHOD 901417
ACETAMINOPHEN U 17 OH CORTICOSTEROIDS Z V NO EFFECT WITH SRT TERM INGESTION 2.6 G/DAY P0 236
ACETYLSALICYLIC AC U 17 OH CORTICOSTEROIDS Z V NO EFFECT WITH SHORT TERM INGESTION 2.6 G/DAY 90236
ACETYLSALICYLIC AC U 17 OH CORTICOSTEROIDS Z N NO EFFECT ON PORTEP-SILBER PROCEDURE 90236
AMPHETAMINES U 17 OH CORTICOSTEPOIDS Z N NO EFFECT ON GLENN-NELSON PROCEDURE 90133
BARBITURATES U 17 OH CORTICOSTEROIDS Z N NO INTERFERENCE WITH PORTER-SILBEP PROCEDURE P0 236
BARBITU PATES U 17 OH CORTICOSTEROIDS Z V NO EFFECT WITH SHORT TERM INGESTION 91001
CHLORDIAZEPOXI DE U 17 OH CORTICOSTEROIDS Z N NO EFFECT PORTEP-SILBER REACTION IF ADDED IN VITRO 90236
CHLOPDIAZEPOXIDE U 17 OH CORTICOSTEROIDS Z V NO EFFECT SHORT TERM INGESTION 30 MG/DAY P0236
DIAZEPAM U 17 011 COPTICOSTEROIDS Z V NO EFFECT SHORT TERM INGESTION OF 15 MG/DAY P0236
DIP HENHYDPA NINE U 17 OH COBTICOSTEROIDS Z V NO EFFECT SHORT TERM INGESTION OF 150 MG/DAY 90236
10TH ALA MA TE U 17 OR CORTICOSTEROIDS Z V NO PHYSIOLOGICAL EFFECT OBSERVED 90692
NALIDIXIC ACID El 17 OH CORTICOSTEROIDS Z N NO EFFECT WITH PORTEP-SILBER REACTION 90999
PHENOBARBITAL U 17 OH CORTICOSTEROIDS Z V NO EFFECT SHORT TERM INGESTION OF 120 MG/DAY 90236
PRO PD X VP HEN! U 17 OH CORTICOSTEROIDS Z N ADDED IN VITRO NO EFFECT PORTER-SILBER PROCEDUPE 90236
SECOBARBITAL U 17 OR CORTICOSTEROIDS Z N NO EFFECT GLENN-NELSON PROC WHEN ADDED IN VITRO 90133
AMINO ACIDS F 2-PG DEC V ASSOCIATED WITH LOW SERUM PHOSPHATE P09 38
AMINO ACIDS F 2,3 DPG DEC V ASSOCIATED WITH LOW SERUM PHOSPHATE 90938
ANTICONVULSANTS S 25 OH-VITAMIN D DEC V PROBABLY DUE TO INC METABOLISM OF VITAMIN D P0 1409
ORAL CONTRACEPTIVE U 3 OH ANTHRANILIC ACID INC V REVERSED BY PYPIDOXINE (INC TO NICOTINIC ACID) R0657
ORAL CONTRACEPTIVE U 3 OH KYNURENINE INC V REVERSED BY PYPIDOXINE (INC TO NICOTINIC ACID) P0657
GLUCOSE U 3-0-METHYL-D-GLUCOSE INC N SEVERAL METHODS WITHOUT REMOVAL OF GLUCOSE 90340
CLINICAL CHEMISTRY, Vol. 18, No. 10. 1972 1267

AMINO ACIDS E 3-PG DEC V ASSOCIATED WITH LOW SERUM PHOSPHATE 90938
CAFFEI NE P 3,5-AMP INC V INHIBITS PHOSPHODIESTERASE INCS LIPOLYSIS P01*29
BANANAS U 4-HYDROXYBENZOIC ACID INC V POSSIBLE EFFECT OF BACTERIAL METABOLISM 90858
COFFEE U 4-HYDROXYBENZOIC ACID INC V POSSIBLE EFFECT OF BACTERIAL METABOLISM P0858
CHLOPOPHENYLANINE U 5 OH INDOLEACETIC ACID DEC V INHIBITS BIOSYNTHESIS OF SEROTONIN P0 231
CHLORPROMAZINE U 5 OH INDOLEACETIC ACID DEC N INTERFERES WITH METHOD OF GOLDENBEPG 90374
CORTICOTROPIN U 5 OH INDOLEACETIC ACID DEC V MECHANISM NOT DESCRIBED P04 17
ETHANOL U 5 OH INDOLEACETIC ACID DEC V SEROTONIN METABOLISM DIVERTED TO 5 OH TRYPTOPHOL P0258
HEPARIN U 5 OH INDOLEACETIC ACID DEC V REDUCTION IN SINGLE CASE CARCINOID SYNDROME 90480
HYDRAZI NE U 5 OH INDOLEACETIC ACID DEC V MAY POTENTIATE ACTION OF DRUGS ON CNS 90596
IMIPRANINE U 5 OH INDOLEACETIC ACID DEC V MAY DECREASE UPTO 50%:DEC CELL PERMEABILITY TO 5HT 901428
ISOCARBOXAZID U 5 OH INDOLEACETIC ACID DEC V DUE TO INHIBITION OF CONVERSION OF 5 PT TO 5 HIAA 90417
ISONIAZID U 5 OH INDOLEACETIC ACID DEC V CAUSES DECARBOXYLASE INHIBITION WITH REDUCED 5HT P0 257
LEV 000 PA U 5 OH INDOLEACETIC ACID DEC V IN PARKINSON’S DISEASE ?INC TPYPT PYPR ACTIVITY P0158
MAO INHIBITORS U 5 OH INDOLEACETIC ACID DEC V INHIBITION OF CONVERSION OF SilT TO 5HIAA 90531
NETHENANINE U 5 OH INDOLEACETIC ACID DEC N SLIGHT FALSE NEG EFFECT WITH NITROSONAPHTHOL P0 86 7
MET HYLDOPA U 5 OH INDOLEACETIC ACID DEC V INHIBITION OF AROMATIC AMINO ACID DECARBOXYLATION P0257
PHENOTHIAZINES U 5 OH INDOLEACETIC ACID DEC N FALSE DECREASE IF NITROSONAPHTHOL USED 91 001
PPOCHLORPERAZINE U 5 OH INDOLEACETIC ACID DEC N INTERFERENCE WITH NITROSONAPHTHOL METHODS P0800
PRONAZI NE U 5 OH INDOLEACETIC ACID DEC N INTERFERES WITH METHOD OF GOLDENBEPG P03 74
PROMETHAZINE U 5 OH INDOLEACETIC ACID DEC N INTERFERENCE WIT H NITROSONA PHTHOL METHODS 90800
ACETANILID U 5 OH INDOLEACETIC ACID INC N FALSE P05 NITROSONAPHTHOL,N0 EFFECT QUANT TEST 90737
ACETOPHENETIDIN U 5 OH INDOLEACETIC ACID INC N FALSE POSITIVE WITH SCREENING PROCEDURES P04 17
BANANAS U 5 OH INDOLEACETIC ACID INC N INDOLES IN BANANAS 90234
EGGPL ANT U 5 OH INDOLEACETIC ACID INC V AS RESULT OF HIGH CONTENT IN FOOD 90417
FLUOROURACIL U 5 OH INDOLEACETIC ACID INC V IN PATIENTS WITH CARCINOID DUE TO CELL DESTRUCTION P0417
GLYCERYL GUAIACOLAT U 5 OH INDOLEACETIC ACID INC N INTERTERES WITH NITPOSONAPHTHOL METHOD P03 55
ME LPHA LA N U 5 OH INDOLEACETIC ACID INC V PROBABLY DUE TO TISSUE DESTRUCTION IF CARCINOID 905914
MEPHENESIN U 5 OH INDOLEACETIC ACID INC N INTERFERES WITH NITPOSONAPHTHOL REACTION 91001
NETHAMPHETA MINE U 5 OH INDOLEACETIC ACID INC V SINGLE INSTANCE REPORTED 90577
METHOCARBANOL U 5 OH INDOLEACETIC ACID INC N METABOLITE ALLEGEDLY REACTS WITH NITROSONAPHTHOL 90458
PHENNETRAZINE U 5 OH INDOLEACETIC ACID INC V REPORTED EFFECT 90577
PINEAPPLES U 5 OH INDOLEACETIC ACID INC V RICH IN SEROTONIN 90337
PLUMS U 5 OH INDOLEACETIC ACID INC V RICH IN SEROTONIN 90417
PREGNANCY U 5 OH INDOLEACETIC ACID INC V MODERATE INCREASE OBSERVED 90291
RAUWOLFIA U 5 OH INDOLEACETIC ACID INC V RESULT OF RELEASE OF 5 PT FROM BRAIN, TISSUES 90384
RESERPINE U 5 OH INDOLEACETIC ACID INC V RELEASE OF 5 HT FROM BRAIN AND TISSUES P06 54
WALNUTS U 5 OH INDOLEACETIC ACID INC V RICH IN SEROTONIN 90417
5-HYDROXYTRYPTA NINE U 5 OH INDOLEACETIC ACID INC V MAY BE INGESTED VIA FOOD IN LARGE AMOUNTS 90417
METHY SERGIDE P 5 OH TPYPTAMINE DEC V NOTED IN MIGRAINE SUBJECTS P02 38
RESERPINE P 5 OH TRYPTAMINE DEC V OBSERVED NORMAL RESPONSE TO THERAPY P0657
MAO INHIBITORS U 5 OH TRYPTAMINE GLUCUR INC V DUE TO INHIBITION OF CONVERSION OF 5 PT TO 5 HIAA P03 84
MAO INHIBITORS P 5 OH TRYPTAMINE INC V EFFECT OBSERVED AFTER SINGLE LARGE DOSE R03814
PLANTATNS U 5 OH TPYPTANINE INC N 5 OH TRYPTAMINE CONTAINED IN PLANTS 90355
ACETOHEXANIDE S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS 90492
ACETYLSALICYLIC AC S 5-NUCLEOTIDASE INC V REVERSIBLE HEPATOTOXICITY WITH PROLONGED ADMIN. P0806
ANABOLIC STEROIDS S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS P0492
A N DR OG ENS S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS 90492
ASPARAGINASE S 5-NUCLEOTIDASE INC V OBSERVED IN UP TO 25% PATIENTS 90705
CARBAMAZEPI NE S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS P04 92
CAR BEN OXOLONE S 5-NUCLEOTIDASF INC V POSSIBLE DIRECT HEPATOTOXICITY OF DRUG 90669
CHLORA MPH ENICOL S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS 90596
CHLOROTHI AZ IDE S 5-NUCLEOTIDASE INC V MAY CAUSE CHOLESTATIC JAUNDICE 90620
CHLORPPOPAMIDE S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS 90492
ESTPADIOL S 5-NUCLEOTIDASE INC V CHOLESTATIC EFFECT 90620
ESTROG? NS S 5-NUCLEOTIDASE INC V NAY CAUSE CHOLESTASIS 90620
IMIPPAMINE S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS 901492
INDOMETHACIN S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS P01492
LI NCONYCI N S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS P04 92
METHYLTESTOSTE RON! S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS P0 492
NALIDIXIC ACID S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS P04 92
NITROFUPA NTOIN S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS 90492
NORETHA NDROLONE S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS P04 92
NOR ETH YNO DR EL S 5-NUCLEOTIDAS! INC V DUE TO CHOLESTASIS P0492
OXACILLIN S 5-NUCLEOTIDAS! INC V DUE TO CHOLESTASIS 90492
PHENOTHIAZINES S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS 90492
PRO POX Y PH ENE S 5-NUCLEOTIDASE INC V DUE TO CROLESTASIS P0492
SULFONAMIDES S 5-NtJCLEOTIDASE INC V NAY CAUSE CHOLESTASIS P04 92
THIABENDAZOLE S 5-NUCLEOTIDAS! INC V RARE CHOLESTASIS P0492
THIAZIDES S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS 90492
TOLAZA MID! S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS P0 1492
TOLBUTA MID! S 5-NUCLEOTIDASE INC V DUE TO CHOLESTASIS POLl 92
DIPHENYLHYDANTOIN U 6 HYDROXYCORTISOL INC V ALTERS STEROID METABOLISM 90981
NITOTANE U 6 HYDROXYCORTISOL INC V ALTERED COPTISOL METABOLISM INDUCED BY DRUG 90675
PHENOBARBITAL U 6 HYDROXYCORTISOL INC V ALTERATION OF STEROID EXCRETORY PATTERN (LONG TERM) 90236
PH E NY LB UTAZ ONE U 6 HYDROXYCORTISOL INC V LONG TERM CHANGE IN STEROID EXCRETORY PATTERN 90558
ESTROGENS U 6-HYDROXYCORTISOL INC V ALTERATION OF STEROID EXCRETORY PATTERN (LONG TERN) P0 236
COPPER 9 6-PG DEHYDROGENASE DEC V STRONGLY INHIBITED BY ADDITION OF COPPER 90135
BOXIDINE S 7-DEHYDROCHOLESTEROL INC V INHIBITS TRANSFORMATION TO CHOLESTEROL 90351

201 AAITS E
D-GLUCAFIC ACID EXCRETION AS A TEST FOP HEPATIC ENZYME INDUCTION
LNCT 1, 859 (1971)
CC2 ABBRTTZZESC A, SWANS0 J
JADICE A?TP THERAPY WITH CHLORDIAZEPOXIDE HYDROCPLORIDE
NEW ?NGL 3 MED 273, 321 (1965)
00:3 ABUL_FADL MAN, KING 03
PRO9ERTIES OF THE PCID PHOSPHATASES OF EPYTHROCYTES AND OF THE HUMAN PROSTATE GLAND
!3IOCHEN 3 45, 51 (19L9)
co: ACLAND JD
THE INTERPRETATION OF TEE SERUM PROTEIN BOUND IODINE: A REVIEW
J CLIN PATHOL 24, 187 (1971)
CC5 ATOCELLA G, BILLING BN
EFFECT OF DRUGS ON THE HPATIC TRANSPORT OF BILIRUBIN
IN THEPAPEUTIC AGONTS AN) THE LIVER, MCINTYRE N, SHERLOCK S (LOS) BLACKWELL, OXFORD (1965)
C#{149}006
ADAMS PG, HARRISON OR, SCOTT P
THE DLVELOPNENT OF CADMIUM INDUCED PROTEINURIA, IMPARIED RENAL FUNCTION AND OSTEOMALACIA
QUART C MED 38, 1425 (1969)
CCC7 A3NITT 21
HYPOGLYCEMIC ACTION OF MONOAMINE OXIDASE INHIBITORS (NAOI’S)
DIABETES 17, 628 (19#{128}8)
0008 AGGELEP PM, O’REILLY PA, LEONG L ET AL
?OTENTIATION OF ANTICOAGULANT EFFECT OF WARFARIN BY PHENYLBUTAZONE
EW ENGL J NED 27#{128},496 (1967)
00:9 AUS ES, GOLDBERG N
PNAL MECHANISMS OF THE NATBIURETIC AND ANTIPHOSPHATURIC EFFECTS OF TRIFLOCIN - A NEW DIURETIC
J LAB CLIN MED 76, 283 (1970)
OC1C AH ROBINS
MANUFACTURER’ S LITERATURE ON DOPRAM
14C7 CUMMINGS DP, RICEMOND VA 23220
0011 AITKF.W 3M, HART D1, SMITH DA
TF EFFECT 02 LONG-TERM MESTRANOL ADMINISTRATION ON CALCIUM AND PHOSPHORUS HONEOSTASIS IN OOPHOPECTONIZED WOMEN
OLIN SCI 41, 233 (1971)
0012 AJTUNIEWICZ AB, GRAINGEP J, SCHEUER P3, SHERLOCK S
JAUNDICE DUE TO IPRINDOLE
GUT 12, 705 (1971)
C013 AL-HUJAJ N, SCHONTHAL H
HYPERUBICEMIA AND LEVODOPA
NEW ENGL J MED 285, 859 (1971)
OCILL ALPC0N-SEGOViA 0, WAKIM KG, WORTHINGTON 3W, WARD LI
CLINICAL AND EXPERIMENTAL STUDIES ON THE HYDRALAZINE SYNDROME
!EDICIN 46, 1 (1967)
0015 ALARCON-SEGOVIA D, FISHLEIN E, ALCALA H
ISONIAZIL ACETYLAIION RATE AND DEVELOPMENT OF ANTINUCLEAR ANTIBODIES UPON ISONIAZID TREATMENT
ANTH!ITIS PHEUM 14, 71.8 (1971)
316 ALBERT N, STANSELL MO
VASCULAR SYMPTOMATIC RELIEF DURING ADMINISTRATION OF ETHYLCHLOROPHENOXYISOBUTYRATE (CLOFIBRATE)
METJBOLISM 18, 635 (1969)
0017 ALEXANDER FL JR
EVALUION OF AN AUIOATIC CALCIUM TITPATOR
OLIN CHEN 17, 1171 (1971)
0018 ALLISON SP, CHAMBERLAIN NJ, MILLER JE, FERGUSON 9, GILLETT AP,BEMAND BV, SAUNDERS PA
LFFECTS OF PROPRANOLOL ON BLOOD SUGAR, INSULIN AND FREE FATTY ACIDS
DIABFTOLOGIA 5, 339 (1969)
0019 ALMEN I
A STEEPING DEVICE FOP SELECTIVE ANGIOGRAPHY AND SOME VASCULAR AND ENZYMATIC REACTIONS OBSERVED
ACTA RADIOL (SUPPL) 260, (1966)
‘OC2C ALMN T
TOXICITY OF RADIO CONTRAST AGENTS
IN INTERNATIONAL ENCYCLOPEDIA OF PHARMACOLOGY AND THERAPEUTICS VOL2, PERGAMON PRESS, NEW YORK (1971)
0021 AMA COUNCIL ON DRUGS
NEW DRUGS
1967 EDITION CHICAGO ANEBICAN MEDICAL ASSOCIATION (1967)
0222 AMA COUNCIL OF DRUGS
A COPPER-CHELATING AGENT: PENICILLANINE (CUPRIMINE)
3 AMER MED ASS 189, 847 (1964)
A NEW ANTIBIOTIC- LINCONYCIN
3 AFR !!FD ASS 194,545 (1965)
0C24 AMA COUNCIL ON DRUGS
REGISTRY ON ADVERSE REACTIONS
A’IER ‘ED ASSOC (1964)
FISTBY ON ADVERSE REACTIONS, TABULATION OF REPORTS - PANEL ON HEMATOLOGY
A’E9 MED ASSOC JULY (1964)
0C26 AMA COUNCIL ON DRUGS
A?IA DRUG EVALUATIONS
AMA 535 NORTH DEARBORN ST, CHICAGO, ILL 60610
2027 AVADO? E, SALVATOPE AC
SERUM GLUTAMIC OXALOACETIC TRANSAMINASE ACTIVITY, REVISED MANUAL AND AUTOMATED METHODS USING DIAZONIUM DYES
AMER 3 CLIN PATHOL 55, 686 (1971)
0028 AVBPUS JL, SCHINERT G, LAJOS TZ,ANBRUS CM, MINK IB, LASSNAN HB, MOORE PH, NELZER 3
EFFECT OF ANTIFIBSINOLYTIC AGENTS AND ESTROGENS ON BLOOD LOSS AND BLOOD COAGULATION FACTORS
3 MCD 2, 65 (1971)
0029 AMERICAN HOSPITAL FORMULARY SERVICE
AMERICAN HOSPITAL FORMULARY SERVICE,
AEERICAN SOCIETY OF HOSPIIAL PHARMACISTS, WASHINGTON, DC
OC3C AMERY A, CONWAY 3
A CRITICAL REVI!W OF DIAGNOSTIC TESTS FOR PHEOCHEOMOCYTOMA
AMER HFART 3 73, 129 (1967)

0031 ANAST CS
THE UNRELIABILITY OF THE TITAN YELLOW METHOD FOR THE DETERMINATION OF MAGNESIUM
CLIN CHEN 9, 544 (1963)
0032 ANDERSEN CJ, KEIDING NP, NEILSEN AB
FALSE ELEVATION OF SERUM PROTEIN-BOUND-IODINE CAUSED BY RED COLORED DRUGS OR FOODS
SCAND J CLIN LAB INVEST 16, 249 (1964)
Q233 ANDERSON 00, PERSSON I
CARBOHYDRATE METABOLISM DURING TREATMENT WITH CHLOPTHALIDONE AND ETHACRYNIC ACID
BRIT MED J 2, 798 (1968)
0C34 ANDERSON MS, BOWERS CY, KASTIN AJ, SCHALCH DS, SCHALLY AV, SNYDER P3, UTIGEP RD, WILBER JF, WISE AJ
SYNTHETIC THYROTROPIN-RELEASING HORMONE: A POTENT STIMULATOR OF THYROTROPIN SECRETION IN NAN
NEW ENGL 3 MED 285, 1279 (1971)
C35 ANDO Y, FUJII N, FUJITA J, UETE T
EFFECT OF ANTICOAGULANTS ON THE PH, PCO2 AND P02 OF BLOOD
KITANO BYOIN KIYO 15, 14 (1970)
0036 ANECKSTEIN AG, WEINGOLD AB
CHLOROTHIAZIDE-INDUCED HEPATIC COMA IN PREGNANCY
AMER 3 OBSTET GYNECOL 95, 136 (1966)
0037 ANNOTATION
LAXATIVE JAUNDICE
BRIT MED 3 1, 324 (1972)
0038 ANONYMOUS
DRUGS FOP PARASITIC INFECTIONS
MEDICAL LETTER 11, 21 (1969)
0039 ANONYMOUS
FALSE POSITIVE AND FALSE NEGATIVE REACTIONS WITH VARIOUS TESTS FOR PROTEINURIA
AMES COMPANY, ELKHART, IND
0040 ANONYMOUS
ALUMINUM NICOTINATE REDUCES LEVEL OF SERUM CHOLESTEROL
J AMER NED ASS 209, 353 (1969)
0C141 ANONYMOUS
AMICAR AND HYPERFIBRINOLYSIS
0042 ANONYMOUS
DRUGS AND OTHER FACTORS AFFECTING LABORATORY TESTS
0243 ANONYMOUS
FDA APPROVED NEW DRUG LITERATURE-SODIUM DICLOXACILLIN MONOHYDRATE
DRUG INTEL 2, 251 (1968)
0044 ANONYMOUS
FALSE POSITIVE AND FALSE NEGATIVE REACTIONS WITH VARIOUS TESTS FOR GLYCOSURIA
AMES COMPANY, ELKHART, IND
OC14S ANONYMOUS
FDA DRUG EFFICACY STUDY IMPLEMENTATION
DPUG THERAPY 1, 81 (1971)
0046 ANONYMOUS
USE OF PROBENECID IN ANTIMICROBIAL THERAPY
0C47 ANONYMOUS

0048 ANONYMOUS
MAFENIDE ACETATE CREAM: A REVIEW
DRUGS 1, 461 (1971)
0049 ANONYMOUS
DIAZOXIDE: A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC USE IN HYPERTENSIVE CRISIS
DRUGS 2, 78 (1971)
0052 ANTCLIFF AC, BEEVERS DG, HAMILTON N, HARPUR 3!
THE USE OF AMILORIDE HYDROCHLORIDE IN THE CORRECTION OF HYPOKALAEMIC ALKALOSIS INDUCED BY DIURETICS
POSTGRAD MED J 47, 644 (1971)
0051 ANTON AN
ETHANOL AND URINARY CATECHOLAMINES IN MAN
CLIN PHARMACOL THEB 6, 462 (1965)
0C52 ANUMONYE A, READING NW, KNIGHT F, ASHCPOFT GW
URIC ACID METABOLISM IN MANIC-DEPRESSIVE ILLNESS AND DURING LITHIUM THERAPY
IANCET 1, 1290 (1968)
0053 ARENA 3M
RHUBARB HYPERPHAGIA HAZARDS
J AMER MED ASS 219, 626 (1972)
0C54 ARIAS IN
EFFECTS OF PLANT ACID (ICTEROGENIN) S CERTAIN ANABOLIC STEROIDS ON HEPATIC METABOLISM OF BILIRUBIN AND BSP
ANN NY ACAD SCI 1C4, 1014 (1963)
0055 ARKY RA, ABRAMSON EA
INSULIN RESPONSE TO GLUCOSE IN THE PRESENCE OF ORAL HYPOGLYCEMICS
ANN NY ACAD SCI 148, 768 (1968)
0C56 ARNESON GA
PHENOTHIAZINE DERIVATIVES AND GLUCOSE METABOLISM
3 NEUPOPSYCHIAT 5, 181 (1964)
0057 ARTHUR .JB ET AL
TRIAL OF CLOFIBRATE IN THE TREATMENT OF ISCHAEMIC HEART DISEASE
BRIT MED 3 4, 767 (1971)
0C58 ASFELDI VP
PLASMA COPTICOSTEROIDS IN NORMAL INDIVIDUALS
0C59 ATUK NO, BLAYDES MC WESTERVELT FR OR, WOOD JE JR
EFFECT OF AMINOPHYLLLINE ON URINARY EXCRETION OF EPINEPHRINE AND NOREPINEPHRINE IN MAN
CIRCULATION 35, 745 (1967)
0060 AUBERTIN E AND SUDRE 3
PURPURA THROMBOCYTOPENIQUE HEMORRHAGIQUE DUE A L’ESIDREX
3 MED BORDEAUX 141, 1735 (1964)
1270 CL1NICAL CHEMISTRY, Vol. 18, No. 10, 1972

0061 AUL) WHP, MLJRDOCH WE
CLINICAL TRIAL OF N?RUSIDE, A NEW DIURETIC
BOlT NED 3 4, 786 (1971)
C062 AURELL N, VIKGREN P
PLASMA RENIN ACTIVITY IN SUPINE MUSCULAR EXERCISE
3 PPPL PHYSIOL 31, 839 (1971)
0063 AYD FJ
AMITFIPTYLINE REAPPRAISAL AFTER SIX YEARS EXPERIENCE
DIS NERV 26, 719 (1965)
OCSLL AYNSLEY-GREEN A, ALBFFTI KGNM
SERUM-INSULIN OR PLASMA-INSULIN?
LNCLT 1, 318 (1972)
0C65 BAGOADE 3D, PORTE D JR, BIEFMAN EL
STEROID-INDUCED LIPENIA. A COMPLICATION OF HIGH-DOSAGE CORTICOSTi(OID THOPAPY
ARCH INTERN MED 125, 129 (1970)
CC66 BAILEY CC, GEARY CG, ISRAELS MCG, WHITTAKEP JA, BROWN NJ, WEATHERALL 03
YTOSINE APABINOSICE IN TNT TREATMENT OF ACUTE NYILOBLASTIC LEUKEMIA
LANCET 1, 1268 (1971)
0C67 BAKER N, HUEBOTTEP RO
IMMOBILIZING AND HYPERGLYCEMIC EFFECTS OF BENZYL ALCOHOL
LIFE SCIENCES 10, 1193 (1971)
0C8 BALDWIN DS, LEVINE BB, NCCLUSKY PT, GALLO GE
RENAL FAILURE AND INTERSTITIAL NEPHRITIS DUE TO PENICILLIN AND MEIHICILLIN
NEW ENGL 3 MED 279, 1245 (1968)
0C69 BALL GV, SORENSEN LB
PATHOGENESIS OF HYERURICENIA IN SATURNINE GOUT
NEW ENGL 3 MED 280, 1199 (1969)
OC70 BANERJEE 5, KUNAR KS, BANDYOPADHYAY A
EFFECT OF OXYTETRACYCLINE AND TETRACYCLINE ON GLUCOSE TOLERANCE AND SERUM LIPIDS
PROC SOC EXP BIOL MED 125, 618 (1967)
0C71 BANSAL OP
AGRANULOCYTOSIS DURING UNITHEBEN THERAPY
IND PRACTITIONER 18, 616 (1965)
3072 EARBOSA 3, SEAL US, DOE PP
EFFECTS OF ANABOLIC STEROIDS ON HAPTOGLOBIN, OROSOMUCOID, PLASNINOGEN, FIRFINOGEN, TRANSFERRRIN, CERULOPLASMIN
3 CLIN ENDOCRINOL 33, 388 (1971)
0073 BARDIN CW, ROSS GT, LIPSETT MB
SITE OF ACTION OF CLOMIPHENE CITRATE IN NAN: A STUDY OF THE PIIUITARY-LEYDIG CELL AXIS
3 CLIN ENDOCRINOL METAB 27, 1558 (1967)
0074 BARNES PC, LEONARD JHC
HYPOKALEMIC MYOPATHY AND MYOGLOBINUPIA DUE TO CARBENOXOLON SODIUM
POSTGPAD MED 3 47, 813 (1S71)
0C75 BARON ON
CHLOPDIAZEPOXIDE (LIBRIUM) AND THYROID FUNCTION TESTS
BFIT MED J 1, 699 (1967)
0076 BARRETT PVD, THEIER SC
MENINGITIS AND PANCREATITIS ASSOCIATED WITH SULFAMETHIZOLE
NEW ENGL 3 MED 268, 36 (1963)
0C77 BARZEL US
THE ROLE OF BONE IN ACID RASE METABOLISM
IN OSTEOPOROSIS, BAPZEL US (ED) , GRUNE & STRATTON, NEW YORK (197C)
0078 BASSIP 0, HALL 3
PHOTO-ACTIVATION AS A SOURCE OF ERROR IN THE CEPHALIN CHOLESTEROL FLOCCULATION TEST
SCAND 3 CLIN LAB INVEST 7, 2714 (1955)
0C79 EATSAKIS JG, BRIERE P0
INTERPRETIVE ENZYMOLOGY
CC THOMAS, SPRINGFICLL ILL (1967)
CC8O BATSAKIS JG, PRESTON JA, BPIERE RO, GIESEN PC
IATPOGENIC ABERRATIONS OF SERUM ENZYME ACTIVITY
CLIN BIOCHEM 2, 125 (1968)
0081 BAUER 3D, ACKERMANN PG, TORO G
BRAYS’ CLINICAL LABORATORY METHODS 6TH ED
CV NOSBY CO, ST LOUIS (1962)
0C82 BAYLIS EN, GREENWOOD FC, JAMES VHT, JENKINS J, LANDON J, MARKS V, SAMOLS F
IN GROWTH HORMONE INTERNATIONAL CONGRESS SERIES NO 158
PFCILE A, MULLER ER (EDS) EXCEPPTA NEDICA FOUNDATION, AMSTERDAM (1968)
0C83 BAYSHORE P, HAMILTON A, LEWEY F, ERSKINE L, HAMMOND 0 ET AL
SURVEY OF CARBON DISULFIDE AND HYDROGEN SULFIDE HAZAHDS IN THE VISCOSE RAYON INDUSTRY
OCCUPATIONAL DISEASE PREVENTIVE DIVISION, DEPT OF LABOR & INDUSOPY, BULL 46 (1938)
0084 BECK RP, NORCOS F, FAWCETT D WATANABE N
ADPENOCORTICAL FUNCTION STUDIES DUPING THE NORMAL MENSTRUAL CYCLE AND IN WO3EN RECEIVING NOPETHINDRONE
AMER 3 OBSTET GYNTCOL 112, 364 (1972)
‘JC85 BECK PP, FAWCETT DM, NORCOS F
THYROID FUNCTION STUDIES IN DIFFERENT PHASES OF THE MENSTRUAL CYCLE AND IN WOMEN RECEIVING NORETHINDRONE
0C86 BECKER CE, GORDON P, ROBBINS 3
HEPATITIS FROM NETHIMAZOLE DURING ADRENAL STEROID THERAPY FOR MALIGNANT EXOPHTHALMOS
J AMER NED ASS 206, 1787 (1968)
0087 BEELEY L, KENDALL NJ
EFFECT OF ASPIRIN ON RENAL CLEARANCE OF 1-DIATEIZOATE
BRIT MED 3 1, 707 (1971)
0C88 BEERMAN B, ERICSSON OLE, HELLSTROM K, WENGLE B, WERNER B
TRANSIENT CHOLESTASIS DURING TREATMENT WITH AJMALINE AND CHRONIC XANTHOMATOUS CHOLESTASIS
ACTA MED SCAND l9L. 241 (1971)
0089 BEEVERS DG, HAMILTON M, HARPUR JE
THE LONG-TERN TREATMENT OF HYPERTENSION WITH THIAZIDE DIURETICS
0C90 BELKIN GA
AN UNUSUAL CASE OF QUININE SENSITIVITY
ANN INTERN NED 66, 583 (1967)

2091 B LLAMY WL OR, MAUCK Fl? JR, HINNIGAR GR, WIGOD N
JAUNDICE ASSOCIATTD iITH THF ADMINISTRACION OF SODIUM P-ANINOSALICYLIC ACID: REVIEW OF THE LITERATURE
:1*N INTERN MFD (44, ThL3 (1956)
092 ELLI!GR JE, BUIST N
OAP;: COLUMN-CHBOMATOGRA?HIC NEASUFEMENT OF OROTIC ACID
CL HEM 17, 1132 (1971)
0093 EILEON N
FiAEMCLTIC ANENIA DUE TO NALIDIXIC ACID
LANCTT 2, 591 (1965)
0294 BENKEF JP, STETSON OR, CUE NC

CITRIC ACID INTOXICATION
j AMEF MED ASS 157, 1361 (1955)
D095 BENNETT 3, HALL PA
BABITUATE ASSAY
LANCET 1, 298 (1971)
0096 BLN!ETT 0, HALL PA
BARBITUATE ASSAY
LANCET 1, 1191 (1971)
7097 BFI4G OH
IXOSANINE INTERFERENCE WITH TH DETERMINATION OF PROTEIN BY THE LOWRY PROCEDURE
ANAL BIOCHEM *2, 5C5 (1971)
0098 EFPNOWITZ 0, SPITZTR 3, LIKOFF WP
RACTICAL SIGNIFICANCE OF SERU1 TRIGLYCERIDES AND RADIOACTIVE FAT TOLERANCE: THEIR RELATION TO CURRENT THERAPY
AMP 3 CARDIOL 1 , 198 (1962)
0C99 BELKOWITE D
LONG-TERM TREATMENT OF HYPERLIPIDEMIC PATIENTS WITH CLOFIBRATE
3 AMER NED ASS 218, 1002 (1971)
0100 BERRY JN
ACUTE MYELOBLASTIC LEUKEMIA IN A BENZEDRINE ADDICT
SOUTH MED 0 59, 1169 (1966)
0101 FFRTHELOT P, BILLING RH,
?FFECT OF BUNAMIODYL ON HEPATIC UPTAKE OF SULPOBROMOPUTHALEIN IN THE RAT
AMER 3 PHYSIOL 211, 395 (1966)
0122 BESSER GM, BUTLER 21*, LANDON 3, HESS L
TNLUENCE OF ANPHLTAMINES ON PLASMA COFTICOSTEROID AND GROWTH HORMONE LEVELS IN NAN
EPIT MED 3 4, 528 (1969)
C103 BESSNAN AN, CHANDPASTKAR S
FFECT OF PENTYLENITETRAZOL (METRAZOL) ON BLOOD CHOLESTEROL CONCENTRATION IN MAN
‘3 AMER GERIAT SOC 17, 25 (1969)
0104 BEUTLFP E
DRUG-INDUCED AN!MIA
F) PROC 31, 141 (1972)
0105 :zos DI, MARGOMENOS 0, PAVLIDES P, MARAGOS N
EFFECT OF ADRENALINE ON THE PLASMA IRON LEVEL
ARCH INST PASTEUR HELLEN 15, 55 (1969)
0126 BICK PL, THOMPSON WB
FIBF:INOLYTIC ACTIVITY: CHANGES INDUCED WITH ORAL CONTRACEPTIVES
OBSTOT GYNECOL 39, 213 (1972)
0157 EIJVOET OLN
NATRIURETIC EFFECT OF CALCITONIN IN MAN
NE LNL 3 MED 284, 681 (1971)
Cl 8 BILLING BH, MAGGIORE Q, CAPTTER NA,
HEP?TTC TRANSPORT OF BILIRUBIN
?tNN NY ACAD SCI 111, 319 (1963)
01:9 BILLING RH, NAGGIORE QS, GOULIS G,
ACTION OF CHOLECYSTOGRAPHIC CONTRAST MEDIA & NOVOBIOCIN ON HEPATIC TRANSPORT OF BILIRUBIN
IN BILIARY SYSTEM, TAYLOR W (ED) , BLACKWELL OXFORD (1965)
Cli: BILLING RH, BLACK N
TE ACTION OF DRUGS ON BILIRUBIN METABOLISM IN MAN
ANN NY ACAD SCI 179, 403 (1971)
2,111 BIOCHEMEX LABORATORIES
DIAGNOSTIC INTERFERENCES. MATERIALS AFFECTING THE DIAGNOSTIC SPECIFICITY OF LABORATORY TESTS
BIOCHEMEX LABORATOFIES INC, ELNONT, NY, 11003
C 112 BIOSCIENCE HANDBOOK
SPECIALIZED DIAGNOSTIC LABORATORY TESTS 9TH ED
BIOSCIENCE LABORATORIES, VAN NUYS, CALIF 1971
113 BI’A? 5, TAL E
TFFCT OF BETA-BLOCKING DRUG PROPRANOLOL ON 1131 UTILIZATION IN EUTHYROID PATIENTS
J CLIN PHARM 12, 15 (1972)
2114 BTRH CA
JAUNDICE DUE TO PHENOBARBITAL
LANCET 1, 478 (1936)
0115 BTH GG
METABOLIC EFFECTS OF RARE FOOD SUGARS
LrJCE 2, 1419 (1971)
2116 BIRKO G, DICZFALUSY L, PLANTIN L-O
SSESSNENI OF THE FUNCTIONAL CAPACITY OF THE ADRENAL CORTEX II CLINICAL APPLICATION OF THE THE ACTH TEST
J OLIN ENDOCRINOL 20, 593 (1960)
2117 BIRNBAUM D, LEVY N
DIURETICS AND ADVIRSE GASTROINTESTINAL REACTION
DIGESTION 4, 362 (1971)
C118 BINNBAUM 0, KARMELI F, TEFERA N
THE EFFECT OF DIAZEPAM ON HUMAN GASTRIC SECRETION
GIlT 12, 616 (1971)
:119 BLITSTEIN I
INFLUENCE DES DIVERS ANTICOAGULANTS SUP LES DOSAGES DE CERTAINS ELEMETS DU SANG
RV BELG SCI MED 7, 69 (1935)
0122 BLOCH-NICHEL H, KYRIACO C, JUVIN I
NOTRE EXPERIENCE DI L’INDONETHACINE DANS LES RHUNATISMES INFLAMMATOIPES
THERAPIE 22, 45 (1967)

0121 BLOCK A
NOPE ON INFANTILE METHENOGLOBINENIA DUE TO BENZOCAINE SUPPOSITORY
3 PEDIAT 67, 509 (1965)
0122 BLOCK LH, LAMY PP
THESE DRUGS DISCOLOR THE FECES OR URINE
AMER PROF PHARN 34, 27 (1968)
0123 BLOCK MB, GENANT HK, KIRSNER JB
PANCREATITIS AS AN ADVERSE REACTION TO SALICYLAZOSULPAPYPIDINE
NEW ENGL 3 MED 282, 380 (1970)
01214 BLOMFIELD 3, DIXON,SR, MCCREDIE DA
POTENTIAL HEPATOTOXICITY OF COPPER IN RECURRENT HENODIALYSIS
0125 BLUNBERG AG, HEATON AM, VASSILIADES 3
THE INTERFERENCE OF CHLORPROMAZINE METABOLITES IN THE ANALYSIS OF URINARY METHOXY-CATECHOLAMINES
CLIN CHEM 12, 803 (1966)
0126 BOARDMAN PL, HART FD
SIDE-EFFECTS OF INDOMETHACIN
ANN RHEUN DIS 26, 127 (1967)
0127 BOCK ND, NEPGUET P, BRANDT T, MURATA T
EXPERIMENTAL STUDIES WITH CLONIDINE HYDROCHLORIDE IN NORMOTENSIVE AND HYPERTENSIVE SUBJECTS
IN CATAPPES IN HYPERTENSION, CONOLLY ME (ED) BUTTERWORTH, LONDON (1970)
0128 BODANSKY 0
METHEMOGLOBINEMIA AND METHENOGLOBIN-PRODUCING COMPOUNDS
PHARMACOL REV 3, 141* (1951)
0129 BOGER WP, STRICKLAND SC
GOUT
LANCET 1, 1420 (19514)
0130 BOGUSZ N
INFLUENCE OF INSECTICIDES ON THE ACTIVITY OF SOME ENZYMES CONTAINED IN HUMAN SERUM
CLIN CHIN ACTA 19, 367 (1968)
0131 BONKOWSKY HL, TSCHUDY DP, COLLINS A, DOHERTY 3, BOSSENMAIER I, CARDINAL 9, WATSON CJ
REPRESSION OF THE OVERPRODUCTION OF POPPHYRIN PRECURSORS IN ACUTE INTERMITTENT PORPHYRIA BY INTRAVENOUS INFUSION
PROC NAT ACAD SCI 68, 2725 (1971)
0132 BOPA 55, RADICHEVICH I, WERNER SC
APTIFACTUAL ELEVATION OF P81 FROM AN IODINATED DYE USED TO STAIN MEDICINAL CAPSULES PINK
0133 BOPUSHEK 5, GOLD 33
COMMONLY USED MEDICATIONS THAT INTERFERE WITH ROUTINE ENDOCRINOLOGY LABORATORY PROCEDURES
CLIN CHEM 10, 41 (1964)
0131* BOTTIGER LE, WESTERHOLM B
OPAL CONTRACEPTIVES AND THROMBOEMBOLIC DISEASE
ACTA NED SCAND 190, 455 (1971)
0135 BOULARD N, BLUME K-G, BEUTLER E
THE EFFECT OF COPPER ON RED CELL ENZYME ACTIVITIES
3 CLIN INVEST 51, 1459 (1972)
0136 BOWERS GN JR
LACTIC DEHYDROGENASE
STAND NETH CLIN CHEM 4, 163 (1963)
0137 BOYER TO, ROUFF SL
ACETAMINOPHEN-INDUCED HEPATIC NECROSIS AND RENAL FAILURE
3 AMER NED ASS 218, 4140 (1971)
0138 BRAINERD H
CURRENT DIAGNOSIS AND TREATMENT-1970
LANGE MEDICAL PUBLICATIONS, LOS ALTOS, CALIF (1 970)
0139 BRASCH RC, ROCKOFF SC, KUHN C, CHRAPLYVY N
CONTRAST MEDIA AS HISTAMINE LIBERATORS
INVEST RADIOL 6, 510 (1971)
0140 BRATLID D, WINSNES A
DETERMINATION OF CONJUGATED AND UNCONJUGATED BILIRUBIN BY METHODS BASED ON DIRECT SPECTROPHOTOMETPY
SCAND 3 CLIN LAB INVEST 28,41 (1971)
0141 BRAUNSTEINER H, HERBST M, SANDHOFER F ET AL
LONG-TERM THERAPY OF ADULT CASES OF PRIMARY HYPERTRIGLYCERIDAEMIA WITH CLOFIRPATE
GEP MED MONTHLY 13, 65 (1968)
0142 BRAVERMAN LE, PEINSTEIN H, LOAYZA H, PONFRET D
FORMALDEHYDE-FORMING DRUGS AND URINARY 17-HYDROXYCORTICOSTEROIDS
CLIN CHEM 14, 374 (1968)
0143 BRAY WE
CLINICAL LABORATORY METHODS 5TH ED
CV NOSBY COMPANY, ST LOUIS (1957)
0144 BRECKENRIDGE A, WELBORN TA, DOLLERY CT, FRAZER P
GLUCOSE TOLERANCE IN HYPERTENSIVE PATIENTS ON LONG-TERM DIURETIC THERAPY
LANCET 1, 61 (1967)
0145 BREST AN, HEIDE? C, MEHBOD H El AL
DRUG CONTROL OF DIURETIC-INDUCED HYPEPURICFMIA
3 AMER NED ASS 195, 42 (1966)
011*6 BPICKMAN AS, COBURN 3W, KOPPEL N, PEACOCK N, MASSRY SG
EFFECT OF HYDROCHLOROTHIAZIDE ON CALCIUM METABOLISM
3 CLIN INVEST 50, 13 (1971)
0147 BRICKNAN AS, ISENBERG 31
SECRETIN INCREASES SERUM CALCIUM IN NAN
CLIN RES 20, 236 (1972)
0148 BRIGGS NH, BRIGGS N, AUSTIN 3
EFFECTS OF STEROID PHARMACEUTICALS ON PLASMA ZINC
NATURE 232, 480 (1971)
0149 BPIGGS MN, BRIGGS N
EFFECTS OF ORAL ETHINYLESTRADIOL ON SERUM PROTEINS IN NORMAL WOMEN
CONTRACEPTION 3,381 (1971)
0150 BRODAL BP
THE INFLUENCE OF HAEMOLYSIS ON THE RADIO INMUNOASSAY OF INSULIN
SCAND 3 CLIN LAB INVEST 28, 287 (1971)

151 BROOKS FP
TESTING PANCREATIC FUNCTION
NEW ENGL J MED 286,.3DG (1972)
0152 BROWES DO
ASSESSMENT OF THE LABSTIX STRIP TEST COMMENTS ON DETECTION OF PARAPROTEINS IN URINE
J MED LAB TECHNOL 27, 533 (1970)
0153 BROWN CR
TETRACYCLINE AND RENAL FUNCTION
BRIT MED 0 4, 428 (1971)
154 BROWN RF
AIIIWOACIDURIA RESULTING FROM CYCLOLEUCINE ADMINISTRATION IN MAN
SCIENCE 157, 1432 (1967)
2155 BROWN KG, OWENS JR JR, BERSON AW, HENRY 5K
VANIL!IANDELIC ACID SCREENING TEST FOR PHEOCUROMOCYTOMA AND NEUROBLASTONA
AMER J CLIN PATHOL 46, 599 (1966)
)156 BROWNING RH, DONNERBEEG RL
CAPREOMYCIN EXPERIENCES IN PATIENT ACCEPTANCE AND TOXICITY
ANN NY ACAD SCI 135, 1057 (1966)
2157 BRUCKNER FE, PANDLE APH
THE USE OF INDONETHACIN IN RHEUMATOID ARTHRITIS
ANN PHYS MED 8, 1OC (1965)
1158 BRUNE GG, PFLUGHAUPT KW
EFFECTS OF L-DOPA TREATMENT ON INDOLE METABOLISM IN PARKINSON’S DISEASE
TXPERIENTIA 27, 516 (1971)
0159 BRYANT 3M, YU IF, BEEGER L, SCHVARTZ N FT AL
HYPERURICEMIA INDUCED BY TNT ADMINISTRATION OF CHLORTHALIDONE AND OTHER SULFONAMIDE DIURETICS
AMER 3 MED 33, 408 (1962)
0160 BRYSON G
BIOGENIC ANINES IN NORMAL AND ABNORMAL BEHAVIORAL STATES
CLIN CHEM 17, 5 (1971)
D161 BLITIST NRM, RAMBERG DA, STRANDHOLM 33, FERRY PC
COPPER POPPEPS: A BENIGN CAUSE OF BLUE DIAPERS
ARCH DIS CHILD 46, 873 (1971)
0162 BULBROOK RD, HAYWARD JL
EXCRETION OF URINARY 17-HYDROXYCORTICOSTEROIDS AND 11-DEOXY-17-OXOST3ROIDS BY WOMEN
LANCET 2, 1033 (1969)
0163 BUNNEY WE JR
A BEHAVIORAL-BIOCHEMICAL STUDY OF LITHIUM TREATMENT
AMER J PSYCHIAT 125, 499 (1968)
C16LI BURCH PG, MIGEON C
SYSTEMIC ABSORPTION 0? TOPICAL STEROIDS
ARCH OPHTHAL 79, 174 (1968)
0165 BUPRELL CD
FATAL NARROW APLASIA AFTER TREATMENT WITH CARBIMAZOLE
BRIT NED 3 1, 1456 (1956)
0166 BURROUGHS WF.LLCOME AND COMPANY
MANUFACTURER’S LITERATURE ON ZYLOPRIN
I SCARSDALE PD TUCKAHOE NY 10707
0167 BURROUGHS WELLCOME AND COMPANY
TREATMENT OF NEOPLASTIC DISEASES - MANUFACTURER’S BROCHURE 1971
1 SCARSDALE RD TUCKAHOE NY 1C7C7
0169 BURROW GN, BURKE WP, HIMMELHOCH 3M, SPENCER RP, HERSHAM 3M
EFFECT OF LITHIUM ON THYROID FUNCTION
3 OLIN ENDOCPINOL 32, 647 (1971)
0159 BURSTEIN 5, KLAIBER FL
PHENOBARBITOL-INDUCED INCREASE IN 6-BETA-HYDROXYCORTISOL:CLUE TO ITS SIGNIFICANCE IN HUMAN URINE
0170 BUTLER WT, BENNETT JE, HILL GO II, SZWED C?, COTLOVE E
ELECTROCARDIOGRAPHIC AND ELECTROLYTE ABNORMALITIES CAUSED BY AMPHOTEBICIN B IN DOG AND MAN
2171 BUTTNER H
QUESTION AND ANSWER SECTION
GER NED MONTHLY 13, 2147 (1968)
2172 BYNUM TE, SOLOMON TE, JOHNSON LR, JACOBSEN ED
INHIBITION OF PANCREATIC SECRETION IN NAN BY CIGARETTE SMOKING
CLIN RES 20, 39 (1972)
:173 CAIN CK, EDITOR
IN ANNUAL REPORTS IN MEDICINAL CHEMISTRY, 1970
ACADEMIC PRESS, NEW YORK (1971)
0174 CAIN ND, WALTERS WA, CATT KJ
EFFECTS OF ORAL CONTRACEPTIVE THERAPY ON THE RENIN ANGIOTENSIN SYSTEM
J CLIN ENDOCPINOL 33, 671 (1971)
175 CALNE DB
THE METABOLISM OF ORALLY ADMINISTERED L-DOPA IN PARKINSONISM
BRIT 3 PHARMACOL 37, 57 (1969)
0176 CAMERON 53
RIFANPICIN AND THFONBOCITOPENIA
LANCET 2, 167 (1971)
0177 CAMERON A, EISEN AA, NIRAN3AN LM
A?LASTIC ANEMIA DUE TO PHENYLBUTAZONE
POSTGRADUATE NED 3 142, 49 (1966)
0178 CAMPBELL DJ, SHERBANIUK, RIGBY 3
FALSE POSITIVE REACTION DUE TO METHOCARBAMOL IN THE SCREENING TEST FOR VANILNANDELIC ACID (VNA)
CLIN CHEN 10, 4147 (1964)
0179 CANNON P3, SVAHN OS, DENARTINI FE
INFLUENCE OF HYPERTONIC SALINE INFUSIONS FRACTIONAL REABSORPTION OF URATE AND OTHER IONS
018 CAPIZZI RL, BERTINO OR, HANDSCHUMACHLR RE
L-ASPARAGINASE
ANN REV MED 21, 1433 (1970)

0181 CARAWAY WT,
CHEMICAL AND DIAGNOSTIC SPECIFICITY OF LABORATORY TESTS
AMER 3 CLIN PATHOL 37, 445 (1962)
3182 CARAWAY WT
NON-URATE CHROMOGENS IN BODY FLUIDS
CLIN CHEM 15, 720 (1969)
0183 CARAWAY WT
ACCURACY IN CLINICAL CHEMISTRY
CLIN CHEN 17, 63 (1971)
0184 CARAWAY WT
SOURCES OF ERROR IN CLINICAL CHENISTY
STAND METH CLIN CHEM 5, 19 (1965)
0185 CAREN 9, CORBO L
DEPRESSION OF PLASMA LIPID FRACTIONS AND INHIBITION OF PLATELET AGGREGATION BY ACTION OF GLUCAGON
METABOLISM 20, 1057 (1971)
0186 CAREY PM
PRINCIPLES OF ORAL CONTRACEPTIVES: 2 SIDE EFFECTS OF ORAL CONTRACEPTIVES
NED 3 AUST 2, 12142 (1971)
0187 CAREY MA, JONES 3D, GASTINEAU CF
EFFECT OF MODERATE ALCOHOL INTAKE ON BLOOD CHEMISTRY VALUES
3 AMER NED ASS 216, 1766 (1971)
0188 CARRUTHERS M, TAGGAPT P. CONWAY N, BATES D, SOMERVILLE W
VALIDITY OF PLASNA-CATECHOLANINE ESTIMATIONS
LANCET 2, 62 (1970)
0189 CARSTAIPS NC, BRECKENRIDGE A, DOLLERY CT, WORRLEDGE SM
INCIDENCE OF A POSITIVE DIRECT COOMBS TEST IN PATIENTS ON ALPHA-NETHYLDOPA
LANCET 2, 133 (1966)
0190 CARTER SA
POTENTIATION OF THE EFFECT OF ORALLY ADMINISTERED ANTICOAGULANTS BY PHENYRAMIDOL HYDROCHLORIDE
NEW ENGL 3 MED 273, 423 (1965)
0191 CASSIDY CE
THE DURATION OF INCREASED SERUM IODINE CONCENTRATION AFTER INGESTION OF BUNAMIODYL (ORABILEX)
0192 CASTLEMAN B, MCNEELY RU
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL
NEW ENGL 3 MED 276, 167 (1967)
0193 CATHRO ON, SAEZ JN, BERTRAND 3
THE EFFECT OF CLONIPHENE ON THE PLASMA ANDROGENS OF PREPUBERTAL AND PUBERTAL BOYS
3 ENDOCRINOL 50, 387 (1971)
0194 CATTELL WR
EXCRETORY PATHWAYS FOR CONTRAST MEDIA
INVEST RADIOL 6, 1473, (1971)
C195 CHAKRABARTI R, FEARNLEY GB, EVANS JF
EFFECTS OF CLOPIBRATE ON FIBRINOLYSIS, PLATELET STICKINESS, PLASMA FIBRINOGEN AND SERUM CHOLESTEROL
LANCET 2, 1C07 (1968)
0196 CHALLIS TW, REID LC, HINTON JW
STUDY OF SOME FACTORS WHICH INFLUENCE THE LEVEL OF SERUM AMYLASE IN DOGS AND HUMANS
GASTROENTEROLOGY 33, 818 (1957)
0197 CHAN TK, MAK LW, NG PP
METHEMOGLOBINEMIA, HEINZ BODIES AND ACUTE MASSIVE INTRAVASCULAR HENOLYSIS IN LYSOL POISONING
BLOOD 38, 739 (1971)
0198 CHANG T-W
COLD UPTICARIA AND PHOTOSENSITIVITY DUE TO GRISEOFULVIN
J AMER MED ASS 193, 848 (1965)
0199 CHAPMAN I, CHEUNG US
PANCYTOPENIA ASSOCIATED WITH TOLBUTAMIDE THERAPY
J AMER MED ASS 186, 595 (1963)
0200 CHARLES MA, DANFORTH E JR
NONKETOACIDOTIC HYPERGLYCEMIA AND COMA DURING INTRAVENOUS DIAZOXIDE THERAPY IN UREMIA
DIABETES 20, 501 (1971)
0201 CHAUHUPI TK
MECHANISM OF HYPOCALCENIC EFFECT OF INORGANIC PHOSPHATE
NEW ENGL 3 NED 285, 691 (1971)
0202 CHEPASKIN E
EFFECT OF CAFFEINE VERSUS PLACEBO SUPPLEMENTATION ON BLOOD GLUCOSE CONCENTRATION
LANCET 1, 1299 (1967)
0203 CHINITZ 3L, KIM KE, ONESTI G, SWARTZ C
PATHOPHYSIOLOGY AND PREVENTION OF DEXTRAN-40-INDUCED ANURIA
3 LAB CLIN MED 77, 76 (1971)
02014 CHRISTIAN DG
DRUG INTERFERENCE WITH LABORATORY BLOOD CHEMISTRY DETERMINATIONS
AMER 3 CLIN PATROL 54, 118 (1970)
02C5 CLAGHORN JL
FALSE POSITIVE URINE GLUCOSE TEST IN TWO PATIENTS RECEIVING TRIOXAZINE
3 NEW DRUGS 6, 153 (1966)
0206 CLIFFORD NJ, WElL 3
CORTISOL METABOLISM IN PERSONS OCCUPATIONALLY EXPOSED TO DOT
ARCH ENVIRON HEALTH 214, 145 (1972)
0207 COFFEY VJ
MYXOEDEMA DURING CYCLOPHOSPHAMIDE THERAPY
BRIT MED 3 4, 682 (1971)
0208 COHEN LC
CPK TESTS - EFFECT OF INTRAMUSCULAR INJECTION IN MYOCARDIAL INFARCTION
3 AMER MED ASS 219, 625 (1972)
0209 COHEN MM, DEBAS HT, HOLUBITSKY IB, HARRISON RC
CAFFEINE AND PENTAGASTPIN STIMULATION OF HUMAN GASTRIC SECRETION
0210 COHN KE
THE EFFECT OF GLUCAGON ON ARRHYTHMIAS DUE TO DIGITALIS TOXICITY
AMER 3 CARDIOL 25, 683 (1970)

0211 COLLINS PD
ILLUSTRATED MANUAL OF LABORATORY DIAGNOSIS
JR LIPPINCOTT, PHILADELPHIA (1968)
0212 COLWELL AR JR, SANDO DE, LANG 53
PPO?YLTHIOURACIL-INDUCED AGRANULOCYTOSIS, TOXIC HEPATITIS, AND DEATH
3 AMER MED ASS 1148, 639 (1952)
0213 COMBS AB, GIRT SN, PEOPLES SA
A NEW NFTHOD FOR ANALYSIS OF PHENYLTHIOUREA IN BIOLOGICAL FLUIDS
ANAL BIOCHEN 411, 570 (1971)
021-1 CONOY E, BOHOUN C
ISO-HOMOVANILLIC ACID DETERMINATION IN HUMAN URINE
0215 CONN HO
BLOOD AMMONIA
0216 CONN 3W
HYPERTENSION, THE POTASSIUM ION AND INPAPIED CARBOHYDRATE TOLERANCE
NEW ENGL 3 MED 273, 1135 (1965)
0217 CONNEY AN
DRUG METABOLISM AND THERAPEUTICS
NEW ENGL 3 MED 280, 653 (1969)
0218 CONRAD ME, MARCEL E, KNOCHEL JP, CROSBY WH
NOVOBIOCIN JAUNDICE: DENONSTRATION OF A HEMOLYTIC STATE
ANTIBIOT MED 7, 382 (1960)
0219 COON UW, WILLIS III PW
SOME SIDE EFFECTS OF HEPARIN, HEPAPINOIDS, AND THEIR ANTAGONISTS
CLIN PHARMACOL THER 7, 379 (1966)
0220 COON WW, WILLIS III PW
SOME ASPECTS OF THE PHARMACOLOGY OF OPAL ANTICOAGULANTS
OLIN PHARNACOL THE? 11, 312 (1970)
0221 COOPER GR, MCDANIEL V
THE DETERMINATION OF GLUCOSE BY THE ORTHO-TOLUIDINE METHOD
0222 COOPEPBERG, LIDLOW
HAEMOLYTIC ANEMIA, JAUNDICE AND DIABETES NELLITUS FOLLOWING CHLORPROMAZINE THERAPY
CANAD NED ASS 3 75, 71*5 (1956)
0223 CORNISH AL, MCCLELLAN JT, JOHNSTON DH
EFFECTS OF CHLOPOTHIAZIDE ON THE PANCREAS
NNW ENGL 3 MED 265, 673 (1961)
0224 COURSIN DR
DISCUSSION OF PAPER
ANN NY ACAD SCI 80, 894 (1959)
0225 CRAFT IL, WISE I
PLASMA AMINO ACIDS AND ORAL CONTRACEPTIVES
LANCET 2, 1138 (1969)
0226 CRAFT IL, PETERS TJ
QUANTITATIVE CHANGES IN PLASMA AMINO ACIDS INDUCED BY ORAL CONTRACEPTIVES
OLIN SOT 41, 301 (1971)
0.227 CRAIG GM, CRANE CW
LACTIC ACIDOSIS COMPLICATING LIVER FAILURE AFTER INTRAVENOUS FRUCTOSE
BRIT MED J 4, 211 (1971)
0228 CRAMER JL, ELKES A
AGRANULOCYTOSIS AFTER DESIPRAMINE
LANCET 1, 105 (1967)
0229 CRANDELL WR, PAPPAS SG, MACDONALD A
NEPHPOTOXICITY ASSOCIATED WITH METHOXYFLURANE ANESTHESIA
ANESTHESIOLOGY 27, 591 (1966)
0230 CRAWFORD OR
METHEMOGLOBIN IN MAN FOLLOWING THE USE OF PRILOCAINE
ACTA ANAESTHESIOL SCAND SUPPL 16, 183 (1965)
0231 CREMATA VY JR, KOC BK
CLINICAL-PHARMACOLOGICAL EVALUATION OF P-CHLOROPHENYLALANINE: NEW SEROTONIN DEPLETING AGENT
OLIN PHARNACOL TIlER 7, 768 (1966)
0232 CROFT JO
COONBS’ - TEST POSITIVITY INDUCED BY DRUGS
ANN INTERN MED 68, 176 (1968)
0233 CROSS FC, CANADA AT, DAVIS NM
EFFECTS OF CERTAIN DRUGS ON THE RESULTS OF SOME COMMON LABORATORY DIAGNOSTIC PROCEDURES
AMER 3 HOSP PHARM 23, 235 (1966)
0234 CR001 33, SJOERDSMA A
THE CLINICAL AND LABORATORY SIGNIFICANCE OF SEROTONIN AND CATECHOLAMINES IN BANANAS
NEW ENGL 3 MED 261, 23 (1959)
0235 CROUT JR
CATECHOLANINES IN URINE
0235 CRYIR P1, SODE 3
DRUG INTERFERENCE WITH MEASUREMENT OF ADRENAL HORMONES IN URINE:ANALGESICS AND TRANQUILIZER-SEDATIVES
0237 CULLEN SI, CATALANO PM
GRISEOFULVIN-WARFARIN ANTAGONISM
3 AMER NED ASS 199, 582 (1967)
0238 CUMMINGS JN
MIGRAINE - A BIOCHEMICAL DISORDER?
FOURTH SYMPOSIUM OF THE MIGRAINE TRUST, LONDON 11 SEPT 1970
0239 CUNNINGHAM GC
P’ENYLKETONUPIA TESTING - ITS ROLE IN PEDIATRICS AND PUBLIC HEALTH
CPIT REV CLIN LAB SCI 2, 45 (1971)
0240 DACIE JV
THE HAEMOLYTIC ANAENIAS PART IV
GRTJNE S STRATTON INC. NEW YORK (1967)

0241 DAHL JR
DIPHENYLHYDANTOIN TOXIC PSYCHOSIS WITH ASSOCIATED HYPERGLYCEMIA
CALIF MED 107, 345 (1967)
0242 DALE E, SI!?SON G
SERUN MAGNESIUM LEVELS OF WOMEN TAKING AN ORAL OR LONG-TERM INJECTABLE PROGESTATIONAL CONTRACEPTIVE
OBSTET GYNECOL 39, 115 (1972)
021*3 DALE E, SPIVEY SN
SERUM PROTEINS OF WOMEN UTILIZING COMBINATION ORAL OR LONG-ACTING INJECTABLE PPOGESTATIONAL CONTRACEPTIVES
CONTRACEPTION 4, 241 (1971)
024(4 DALE PA
DEMONSTRATION OF ALDOLAS! IN HUMAN PLATELETS: THE RELATION TO PLASMA AND SERUM ALDOLASE
02145 DAMN NC (ED)
HANDBOOK OF CLINICAL LABCRATORY DATA
CHEMICAL RUBBER CO, CLEVELAND OHIO (1965)
0246 DANIELS AL, EVERSON GJ
INFLUENCE OF ACETYLSALICYLIC ACID (ASPIRIN) ON URINARY EXCRETION OF ASCORBIC ACID
0247 DANOWSKI TS, VESTER 3W, SUNDER JH, GONZALEZ AR, KHURANA RC, JUNG Y
ENDOCRINE AND METABOLIC INDICIES DURING ADMINISTRATION OF A LPO?HILIC HIS-PHENOL, PPOBUCOL
CLIN PHARNACOL THER 12, 929 (1971)
0248 DANZINGER PG, HOFMANN AF, SCHOENFIELD U, THISTLE 3L
DISSOLUTION OF CHOLESTEROL GALLSTONES BY CHENODEOXYCHOLIC ACID
NEW ENGL 3 NED 286, 1 (1972)
0249 DATEY KK, DESHMUKH SN, DALVI CP, PURANDOPE NM
HEPATOCELLULAR DAMAGE WITH ETHACRYNIC ACID
BRIT NED 3 2, 152 (1967)
0250 DAVIDSOHN I, WELLS BR
CLINICAL DIAGNOSIS BY LABORATOPY METHODS 13TH ED
WB SAUNDERS COMPANY, PHILADELPHIA (1962)
0251 DAVIDSON DGD, EASTHAM WN
ACUTE LIVER NECROSIS FOLLOWING OVERDOSE OF PARACETAMOL
BRIT NED 3 2, 497 (1966)
0252 DAVIDSON RJL
PHENACETIN-INDUCED HEMOLYTIC ANEMIA
3 CLIN PATHOL 24, 537 (1971)
0253 DAVIDSON MB, BERNSTEIN 3M
EFFECT OF NICOTINIC ACID ON GROWTH HORMONE INDUCED GLUCOSE INTOLERANCE AND LIPOLYSIS
CLIN RES 20, 237 (1972)
0254 DAVIDSON N, FEINLERB N
CARBON DISULFIDE POISONING: A REVIEW
AMER HEART 3 83, 100 (1972)
0255 DAVIS P3
FACTORS AFFECTING THE DETERMINATION OF THE SERUM PROTEIN-BOUND IODINE
AMER 3 NED 40, 918 (1966)
0256 DAVIS P3, HSU TB, BIANCHINE JR, MORGAN JP
EFFECTS OF A NEW HYPOLIPENIC AGENT, NK-185, ON SERUM THYROXINE BINDING GLOBULIN (TBG)
0257 DAVIS RB
METABOLIC STUDIES IN CAPCINOID SYNDROME: OBSERVATIONS ON USE OF ALPHA-METHYLDOPA, ISONICOTININC ACID HYDRAZIDE
METABOLISM 10, 1035 (1961)
0258 DAVIS yE, BROWN H, HUFF JE, CASHAW JL
THE ALTERATION OF SEROTONIN N!TABOLISM TO 5-HYDROXYIRYPTOPHOL BY ETHANOL INGESTION IN MAN
3 LAB CLIN MED 69, 132 (1967)
0259 DAYAN AD, LEWIS PD
IDOXURIDINE AND JAUNDICE
LANCET 2, 1073 (1970)
0260 DAYNOND T3
CHOLECYSTOGRAPHY AND RENAL FAILURE
LANCET 2, 5149 (1971)
0261 DE RITIS L
UN CASO DI NEUTROPENIA DA CHLOROTHIAZIDE
ARCISPED S ANNA FERPERA 16, 985 (1963)
0262 DEADMAN NM
EVALUATION OF CHROMOGENS SUITABLE FOP OCCULT BLOOD IN FAECES
0263 DEBLASI S
AZIONE DEL FARGAN SULLA GLICEMIA E SULLA CURVA GLICENICA DE CARICO NELL’UOMO E NEL CANE
MINERVA ANESTESIOLOGICA 19, 66 (1953)
0264 DEFELICE EA, MEHTA DJ, CAHN MM, LEVY E3
EVALUATION OF SAFETY, SERUM LEVELS AND URINARY EXCRETION OF HETACILLIN IN NORMAL VOLUNTEERS
TOXICOL APPL PHARNACOL 11, 20 (1967)
0265 DEMANET JC, BONNYNS N, BLEIBERG H, STEVENS-ROCMAN C
COMA DUE TO WATER INTOXICATION IN BEER DRINKERS
LANCET 2, 1115 (1971)
0266 DENAYER P, MALVAUX P, OSTYN N
SERUM FREE THYROXINE AND BINDING PROTEINS AFTER EXERCISE
0267 DENT CE
SOME PROBLEMS OF HYPEPPAPATHYROIDISM
BRIT NED 3 2, 11419 (1962)
0268 DI SANT-AGNESE PA
PERSONAL COMMUNICATION
NATIONAL INSTITUTES OF HEALTH, BETHESDA MD
0269 DESSPRIS A
INFLUENCE OF CHOLESTEROL, HENOLYSIS AND METALS ON TESTOSTERONE PROTEIN BINDING
3 STEROID BIOCHEM 1, 185 (1970)
0270 DEYKIN 0
WARFARIN THERAPY (SECOND OF TWO PARTS)
NEW ENGL 3 MED 283, 801 (1970)

0271 DICKES P,SCHENKER V, DEUTSCH C
SERIAL LIVER FUNCTION AND BLOOD STUDIES IN PATIENTS RECEIVING CHLORPROMAZINE
NEW ENGL 3 MED 256, 1 (1957)
0272 DILLON NC, BRIDGES PA, NULL WA, BENTLY HP
ERYTHROPOIETIC CHANGES ASSOCIATED WITH CHLORANPHENICOL THERAPY
ALA 3 MED SCI 1, 368 (19611)
0273 DIPPE 5, JONES P
NAPIHUANA, GLUCOSE AND INSULIN
CLIN RES 20, 237 (1972)
02714 DOIG A, GRAY W, MUNRO 3F, STREET HV
WATER INTOXICATION IN BEER DRINKERS
LANCET 2, 1318 (1971)
0275 DOLLERY CT, DUNCAN H, SCHUNER B
HYPEPURICEMIA RELATED TO TREATMENT OF HYPERTENSION
BRIT MED 3 2, 832 (1960)
0276 DOLLERY CT
METHYLDOPA IN HYPERTENSION
AMER HEART 3 65, 139 (1963)
0277 DONAHOE, JF, POWERS P0
BIOCHEMICAL ABNORMALITIES WITH XYLITOL
NEW ENGL 0 MED 282, 691 (1970)
0278 DONALDSON GWK, GRAHAM JG
APLASTIC ANAEMIA FOLLOWING THE ADMINISTRATION OF TEGRETOL
BRIT 3 CLIN PRACT 19, 699 (1965)
0279 DORNHOPST A, OUYANG A
EFFECT OF ALCOHOL ON GLUCOSE TOLERANCE
LANCET 2, 957 (1971)
0280 DOUGLASS JE
ATHEROSCLEROSIS
IN ANNUAL REPORTS IN MEDICINAL CHEMISTRY 1970, CAIN CK (ED), ACADEMIC PRESS, NY (1971)
0281 DOW CHEMICAL COMPANY
MANUFACTURER’S LITERATURE (1971)
90 BOX 1656 INDIANAPOLIS IND 116206
0282 DOWLING HF, LEPPER NH
HEPATIC REACTIONS TO TETRACYCLINE
3 AMER MED ASS 188, 307 (1964)
0283 DRASH A, WOLFF FW
DRUG THERAPY IN LEUCINE-SENSITIVE HYPOGLYCEMIA
METABOLISM 13, 487 (1964)
0284 DRUMMOND KN, MICHAEL AF
SPECIFICITY OF THE INHIBITION OF TUBULAR PHOSPHATE REABSORPTION BY CERTAIN AMINO ACIDS
NATURE 201, 1333 (1964)
0285 DRUTZ DO
HYPOKALENIC RHABDOMYOLYSIS AND MYOGLOBINURIA FOLLOWING AMPHOTERICIN B THERAPY
J AMER MED ASS 211, 824 (1970)
0286 DUDL RJ, LERNER P, ENSWICK OW, WILLIAMS RH
EFFECT OF SECRETIN ON RELEASE OF PANCREATIC GLUCAGON IN NAN
CLIN RES 20, 237 (1972)
0287 DUNEA G, FREEDMAN P
PHENOLSULFONPHTHALEIN EXCRETION TEST
3 AMER MED ASS 204, 621 (1968)
0288 DUTTERA MO
NATIONAL INSTITUTES OF HEALTH, BETHESDA ND
0299 DUVERNOY WC
POSITIVE PHENTOLAMINE TEST IN HYPERTENSION INDUCED BY A NASAL DECONGESTANT
NEW ENGL 3 MED 280, 877 (1969)
0290 DVORAK K, BLAZKOVA E
ACUTE THROMBOCYTOPENIC PURPUPA AFTER PHENYLBUTAZONE
VNITRNI LTK 11, 1000 (1965)
0291 EASTHAM RD
BIOCHEMICAL VALUES IN CLINICAL MEDICINE 4TH ED
WILLIAMS & WILKINS, BALTIMORE (1971)
0292 EASTHAM RD
LAB GUIDE TO CLINICAL DIAGNOSIS
0293 EDITORIAL
EDITORIAL
GENEESK NED T 109, 2046 (1965)
0294 EDITORIAL
HEMOLYTIC ANEMIA CAUSED BY PENICILLIN
NEW ENGL 0 MED 2714, 222 (1966)
0295 EDWARDS NS, CURTIS JR
DECREASED ANTICOAGULANT TOLERANCE WITH OXYMETHOLONE
LANCET 2, 221 (1971)
0296 EHRLICH EN
RECIPROCAL VARIATIONS IN URINARY CORTISOL AND ALDOSTERONE IN RESPONSE TO INCREASED SALT INTAKE IN HUMANS
0297 EKELUND L-G, EKLUND B, KAIJSEP L
TINE COURSE FOR THE CHANGE IN HEMOGLOBIN CONCENTRATION WITH CHANGE IN POSTURE
ACTA MED SCAND 190, 335 (1971)
0298 ELI LILLY AND COMPANY
MANUFACTURER’S LITERATURE ON DYMELOR, LORIDINE, KEFLIN, GLUCAGON
307 EAST MCCARTHY, INDIANAPOLIS, IND 46206
0299 ELKING NP, KARAT HF
DRUG INDUCED MODIFICATIONS OF LABORATORY TEST VALUES,
AMER J HOSP PHARN 25, 1485 (1968)
0300 ELKINTON SG
HEPATIC INJURY CAUSED BY L-ALPHA-MFTHYLDOPA

0301 ELLIOTT NC JR, MURDAUGH NV JR
FFECTS OF ACTYLSALICYLIC ACID ON EXCRETION OF ENDOGENOUS METABOLITES BY MAN
PROC SOC EXP BIOL NED 1C9, 333 (1962)
D3C2 EMBER M, NINDSZENTY L, PZNGEI B, CSASZAP L, CZINA N
SECONDARY VITAMIN A DEFICIENCY IN ORGANOPHOSPHATE FORMULATORS AND SPRAY WORKERS
?S COMM CHEM PATHCL PHARM 3, iLLS (1972)
0303 ENGELMAN K, HOBWITZ C, AMBROSE IF FT AL
FURTHR EVALUATION OF THE TYRAMINE TEST FOR PHEOCHROMOCYTOMA
NEW FNGL 3 NED 278, 705 (1968)
0304 ERAZ J AND HAUKNECHT P
DIMINISHED URINARY ESTPIOL DUE TO MANDELAMINE ADMINISTRATION DURING PREGNANCY
AMER 0 OBSTET GYNECOL 1CII, 921 (1969)
03C5 ERNAELSTEEN D, WILLIAMS 3
JAUNDICE DUE TO NITROFUPANTOIN
0306 EFYASA Y, CHANG PM, FITTINGER CR
SERUM IONIC CALCIUM CHANGES IN MAN FOLLOWING SUCCINYLCHOLINL ADMINISTRATION
Fl) PROC 29, 5148 (197C)
0307 ESPIRITU CR, KIM TS, LEVINE PA
GRANULOMATOUS HEPATITIS ASSOCIATED WITH SULFADIMETHOXINE HYPERSENSITIVITY
J AMER MED ASS 202, 965 (1967)
0308 ESPOSITO R, VITALI 0
RIFANPICIN AND THFOMBOCYTOPEFIA
LANCET 2, 1491 (1971)
03C9 EYKYN S
USE AND CONTROL OF CEPHALOSPORINS
0 OLIN PATHOL 214, 419 (1971)
0310 EYSSEN H, EVPARD E, VANDERHAEGHE H
CHOLESTEROL LOWERING LFFECTS OF N-NETHYLATED NEONYCIN AND BASIC ANTIBIOTICS
0 LAB CLIN MED 66, 753 (1966)
C311 FAJANS 55, FLOYD 30 OR, KNOPF RE, CONN 3W
EFFECT OF AMINO ACIDS AND PROTEINS ON INSULIN SECRETION IN MAN
RECENT PROGR NORM RES 23, 617 (1967)
0312 FALL’JCCA F, CARRATU F, TAMBUFRANO G, JAVICOLI, N MENEINGER G, ANDREANI D
EFFECTS OF CAEPULIN AND PANCREOZYMIN ON INSULIN SECRETION IN NORMAL SUBJECTS AND IN PATIENTS WITH INSULINONA
FOLIA ENDOCRINOL 2, 110 (1971)
r313 FARID NP, JOHNSON P3, LOW WT
HEMOLYTIC REACTION 10 MEFENAMIC ACID
LANCET 2, 382 (1971)
3114 FEARNLEY GEl, CHAKRABAPTI P, HOCKING ED
FIBRINOLYTIC EFFECTS OF DIGUANIDES PLUS ETHYLESTPZNOL IN OCCLUSIVE VASCULAR DISEASE
LANCFT 2, 1008 (1967)
0315 FEIKS FK
UBER LINE WEITEPE INDIKATION ZU PARENTERALER SCHWEFELTHERAPIE
WIENER MEDIZINISCHE WOCHENSCHR 117, 899 (1967)
0316 FEINBFRG U, SANDBERG, CECASTRO 0 IT AL
EFFECTS OF COFFEE INGESTION ON ORAL GLUCOSE TOLEBANCE CURVES IN NORMAL HUMAN SUBJECTS
0317 FELDMAN 3M, KELLEY IN, LEBOVIIZ HE
INHIBITION OF GLUCOSE OXIDASE PAPER TESTS BY REDUCING METABOLITES
DIABETES 19, 337 (197C)
0318 FELDMAN JE, LEBOVITZ HE
LEV000PA AND TESTS FOP URINARY GLUCOSE
NEW ENGL 0 MED 283, 1C53 (1973)
3319 FELDMAN 3M, LFBOVITZ HE
ENDOCRINE AND METABOLIC EFFECTS OF GLYBENCLAMIDE
DIABETES 20, 745 (1971)
C32C FENECH FE, BANNISTER WH, GRECH JL
HEPATITIS WITH BILIVEPOINEMIA IN ASSOCIATION WITH INDOPIETHACIN THERAPY
ERIT MED 3 3, 155 (1967)
0321 FERGUSON DR
EFFECTS OF LOW DOSES OF FLUORIDE ON SERUM PROTEINS AND A SERUM ENZYME IN NAN
NATURE NEW BIOL 231, 159 (1971)
0322 FERNANDEZ AA, JACOBS SE
PORPHYPINS, POPPHOEILNOGEN AND ANINOLEVULINIC ACID IN URINE
STAND METH OLIN CHEM 6, 57 (197C)
0323 FERRARA N, MIZRAHY 0, SAPOSHINIK A, FEINSTEIN
SERUM B-GLUCURONIDASE ACTIVITY DURING PREGNANCY IN NORMAL AND DIABETIC WOMEN AND ITS RELATION TO ESTROGEN LEVELS
ISRAEL 0 MED SCI 7, 1214 (1971)
03214 FERRIS TF, GORDEN P
EFFECT OF ANGIOTENSIN AND NOREPINEPHPINE UPON URATE CLEARANCE IN MAN
AMER 3 NED 44, 359 (1968)
0325 FICHMAN NP, VORHERR H, KLEENAN CR, TELFER N
DIURETIC - INDUCED HYPONATRENIA
0326 FIELDS WS, HASS WK (105)
ASPIRIN, PLATELETS AND STROKE: BACKGROUND FOR A CLINICAL TRIAL
GREEN, ST LOUIS MO (1971)
0327 FINE 0, SHFDROVILZKY H
HY?ONATREMIA DUE TO CHLOPPPOPANIDE, A SYNDROME RESEMBLING INAPPROPRIATE SECRETION OF ANTIDIURETIC HORMONE
3328 FINLAY GD, WHITSETT TH, CUCURCIL IA, GOLDBERG LI
AUGMENTATION OF SODIUM AND POTASSIUM EXCRETION, GLONERULAR FILTRATION PATE AND RENAL PLASMA FLOW BY LEVODOPA
NEW ENGL J MED 2814, 865 (1971)
0329 FIOPE 3M, NOONAN FM
AGRANULOCYTOSIS DUE TO MEPAZINE (PHENOTHIAZINE)
NEW ENGL 3 MED 260, 375 (1959)
0330 FISCHIR NW, HOAK JC
MIMICRY OF ACUTE CHOLECYSTITIS BY ERYTHPOMYCIN ESTOLATE REACTIONS. REPORT OF TWO CASES
AiIER 3 NED SCI 247, 283 (1964)

0331 IStI6P CE, WOO J, HORTON R
EF’ECT OF SPIRONOLACTONE ON ALDOSTEPONE AND PENIN IN NORMAL NAN AND IN PRIMARY ALDOSTERONISN
CLIN PES 20, 217 (1972)
C332 FLEISCHER N, BROWN H, GRAHAM DY ET AL
CH4ONIC LAXATIVE-INDUCED HYPERALDOSTERONISN AND HYPOKALEMIA SIMULATING BARTTER’S SYNDROME
C 333 FLEISHER WR
HNZYMATIC METHODS FOR LACTIC AND PYRUVIC ACIDS
334 FLOYD JC JR, FAJANS SS, KNOPF RE, CONN OW
PLASMA INSULIN IN HYPERINSULINISM: COMPARATIVE EFFECTS OF TOLBUTAMIDE, LEUCINE AND GLUCOSE
0335 FLYNN A, PORIES 110, STRAIN NH, HILL OA OR, FRATIANNE PB
RAPID SERUM-ZINC DEPLETION ASSOCIATED WITH CORTICOSTEROID THERAPY
LANCET 2, 1169 (1971)
0336 FORSHAW j
MUSCLE PARESIS AND HYPOKALAEMIA AFTER TREATMENT WITH DUOGASTRONE
BRIT MED 0 2, 674 (1969)
2337 FOY JM, PARRATT JR
5-HYDPOXYTRYPTAMINE IN PINEAPPLES
J PHARN PHARMACOL 13, 382 (1961)
0338 FRAJOLA WJ
IN FLUORINE AND DENTAL HEALTH
MUNLER JC, HINE MK (EDS) STAPLES PRESS, LONDON (1960)
0339 FRASCINO JA
EFFECT OF INORGANIC FLUORIDE ON THE PENAL CONCENTRATING MECHANISM
J LAB CLIN MED 79, 192 (1972)
031*0 FRAYN KN, ADNITT PT
ESTIMATION OF 3-O-NETHYL-D-GLUCOSE IN THE PRESENCE OF GLUCOSE
J CLIN PATROL 24, 671 (1971)
0341 FRAYN KN, ADNITT PT, TURNER P
TIlE HYPOGLYCAEMIC ACTION OF METFORNIN
POSTGRAD MED 3 47, 777 (1971)
0342 FPEIOEPISZICK FK, TOUSSAINT W
WIRKUNGEN VON PHENAZETIN UND NAPAP AUF DAS BLUTBILD DES SAUGLINGS
NED KLIN 61, 334 (1966)
C343 FRIEDMAN HS
TOTAL PROTEINS IN CEREBROSPINAL FLUID (COLORINETRIC)
3344 FRIEND DG
URICOSURIC DRUGS
PRACTITIONER 230, 153 (1968)
0345 FRIES,J, SIRAGANIAN F
SULFONAMIDE HEPATITIS REPORT OF A CASE DUE TO SULFAMETHOXAZOLE AND SULFISOXAZOLE
NEW ENGL 3 MED 274, 95 (1966)
0346 FRItIGS CS, QUEEN C, FOSTER LB
IMPROVED COLORINETFIC METHOD FOR ASSAY OF AMPHETAMINES IN URINE
CLIN CHEN 17, 1016 (1971)
0347 FRONLICH ED, DUSTAN HP, PAGE III
SOME CLINICAL EFFECTS OF GUANOXAN
OLIN PHARMACOL TilER 7 599 (1966)
0348 PROUD DJR
ESTIMATION OF SERUM GENTAMICICN LEVELS
LANCET 2, 1425 (1971)
C39 FTIRST P, GUANIERI G, HULTMAN E
THE EFFECT OF THE ADMINISTRATION OF L-TRYPTOPHAN ON SYNTHESIS OF UREA AND GLUCONEOGENESIS IN NAN
0350 GABRIEL H
RIFANPICIN JAUNDICE
BRIT MED 3 3, 182 (1971)
0351 GAILANI 5, HOLLAND JF, GLICK A
EFFECTS OF BOXIDINE ON HUMAN SERUM STEROLS AND NEOPLASMS
3352 GAL I, PARKINSON C, CRAFT I
EFFECT OF ORAL CONTRACEPTIVES ON HUMAN PLASMA VITAMIN A LEVELS
BRIT MED J 2, 436 (1971)
2’353 GALLANT ON, BISHOP NP
QUIDE VS MELLARIL IN CHRONIC SCHIZOPHRENIC PATIENTS
CUPH THER PES 14, 10 (1972)
0354 GANBINO SR
PH AND PCO2
0355 GARB S
CLINICAL GUIDE TO UNDESIRABLE DRUG INTERACTIONS AND INTERFERENCES
SPRINGER PUB CO, NEW YORK 1C003 (1971)
3356 GAR3 S
LABORATORY TESTS IN COMMON USE 14TH ED
SPRINGER PUB CO, NEW YORK 10003 (1966)
0357 GARCIA M, MILLER N, MOSES AM
CHLORPROPAMIDE-INDUCED WATER RETENTION IN PATIENTS WITH DIABETES MELLITUS
D358 GARETTSON LK, PEPEL ON, DAYTON PG
METHYLPHENIDATE INTERACTION WITH BOTH ANTICONVULSANTS AND ETHYL BISCOUMACETATE: A NEW ACTION OF NETH!LPHENIDATE
0 AMER NED ASS 207, 2053 (1969)
0359 GAUNT H, STEINETZ BG, CHART JJ
PHARMACOLOGIC ALTERATION OF STEROID HORMONE FUNCTIONS
CLIN PHARNACOL THER 9, 657 (1968)
036C GAUT ZN, POCELINKO N, SOLOMON NM, THOMAS GB
ORAL GLUCOSE TOLERANCE, PLASMA INSULIN, AND URIC ACID EXCRETION IN MAN DURING CHRONIC ADMINISTRATION
METABOLISM 20, 1031 (1971)

3361 GAWTHORNE 3M, WATSON 3, STOKSTAD ELR
AUTOMATED METHYLMALONIC ACID ASSAY
ANAL BIOCHEM 42, 555 (1971)
0362 GERTIG H, NOWACZYK N, GNIADEK N
EFFECT OF ALDRIN, DIELORIN AND LINDANE ON LACTIC ACID DEHYDROGENASE AND CHOLINESTERASE ACTIVITY
DISS PHARM PHARMACOL 22, 253 (1970)
0363 GESER CA, FELBER 3P, BRAND E, SCHULTIS K
UNTERSUCHUNGEN ZUR GLUCAGON-INDUZIERTEN SEKRETION
KLIN WOCHENSCHR 49, 1175 (1971)
0364 GHANEM NH, FAHMI MN, ABDEL MALEK AT
EOSINOPENIC EFFECT OF ANTISEROTONIN (METHYSERGIDE)
ALEXANDRIA MED 3 11, 400 (1965)
0365 GIFFOPD RW JR
CATAPRES (ST 155) IN THE MANAGEMENT OF HYPERTENSION
IN CATAPRES IN HYPERTENSION, CONOLLY ME (ED) BUTTERWOPTH, LONDON (1970)
3366 GILBERT EF, DASILVA AQ, QUEEN ON
INTRAHEPATIC CHOLESTASIS WITH FATAL TERMINATION FOLLOWING NORETHANDROLONE THERAPY
J AMER MED ASS 185, 538 (1963)
0367 GINSBERG DO, SAAD A, GABUZADA GJ
METABOLIC STUDIES WITH THE DIURETIC TRIAMTERENE IN PATIENTS WITH CIRRHOSIS ANLa ASCITES
NEW ENGL 3 MED 271, 1229 (19614)
0368 GLEASON MN, GOSSLEIN RE, HODGE NC
CLINICAL TOXICOLOGY OF COMMERCIAL PRODUCTS
0369 GLUECK CO
EFFECTS OF OXANDROLONE ON PLASMA TRIGLYCERIDES AND POSTHEPAPIN LIPOLYTIC ACTIVITY
0370 GOCHNAN N
0371 GOLDBERG A
POEPHYRINS AND PORPHYRIAS
IN RECENT ADVANCES IN HAEMATOLOGY, GOLDBERG A, BRAIN MC (EDS) CHURCHILL LIVINGSTONE, EDINBURGH 1971
0372 GOLDBERG ON, WATTS C
SERUM ENZYME CHANGES AS EVIDENCE OF LIVER REACTION TO ORAL ALCOHOL
0373 GOLDBERG LI
MONOAMINE OXIDASE INHIBITORS ADVERSE REACTIONS AND POSSIBLE MECHANISMS
J AMER MED ASS 190, 456 (1964)
0374 GOLDENBERG H
SPECIFIC PHOTOMETRIC DETERMINATION OF 5-HYDROXYINDOLEACETIC ACID IN URINE
CLIN CHEM 13, 697 (1967)
0375 GOLDENBERG H, DREWES PA
DIRECT PHOTOMETRIC DETERMINATION OF GLOBULIN IN SERUM
OLIN CHEM 17, 358 (1971)
0376 GOLDFARB 5, SINGER EJ, POPPER H
BILIARY DUCTULES AND BILE SECRETION
J LAB CLIN NED 62, 608 (1963)
0377 GOLDFINGEP 5, KLINENBERG JP, SEEGNILLER JE
RENAL RETENTION OF URIC ACID INDUCED BY INFUSION OF BETA-HYDROXYBUTYPATE AND ACETOACETATE
NEW ENGL 3 MED 272, 351 (1965)
3378 GOLDFINGEP SE
TREATMENT OF GOUT
NEW ENGL 0 MED 285, 1303 (1971)
0379 GOLDSMITH GA
THERAPY OF HYPERCHOLESTEROLEMIA
AMER 3 DIG DIS 9, 651 (1964)
0380 GOLDSMITH N, GOLDSMITH 3
EPIDEMIOLOGICAL ASPECT OF MAGNESIUM AND CALCIUM METABOLISM
0381 GOLDSTEIN G
SARCOID REACTION ASSOCIATED WITH PHENYLBUTAZONE HYPERSENSITIVITY
0382 GOLDZIEHER JW, KLEBER 3W, MOSES LE, RATHMACHER RP
A CROSS-SECTIONAL STUDY OF PLASMA FSH AND LH LEVELS IN WOMEN
0383 G000ALE PM
CLINICAL INTERPRETATION OF LABORATORY TESTS 5TH ED
DAVIS, PHILADELPHIA (1964)
0384 GOODMAN ES, GILMAN A
THE PHARMACOLOGICAL BASIS OF THERAPEUTICS 4TH ED
MACMILLAN CO, NEW YORK NY (1970)
0385 GOODWIN, OF
SPECTROPHOTOMETRIC QUANTITATION OF PLASMA AND URINARY NITROGEN WITH FLUORODINITROBENZENE
0386 GORDON PD, PAWSEY CGK, O’HALLORAN NW, ABBOTT NL, WILSON LL, SILVERSTONE H
USE OF HOME-BLOOD-PRESSURE MEASUREMENT TO COMPARE THE EFFICACY OF TWO DIURETICS
MED 3 AUST 2, 565 (1971)
0387 GOSS H, DICKHAUS OW
INCREASED BISHYDROXYCOUNARIN REQUIREMENTS IN PATIENTS RECEIVING PHENOBARBITAL
NEW ENGL 3 MED 273, 1094 (1965)
0388 GOUGOUX A, MICHAUD G, VINAY P ET AL
THE URICOSURIC ACTION OF BENZIODARONE IN MAN AND DOG
CLIN RES 18, 747 (1970)
0389 GRAPE V, STAUDINGER H
SPECIFICITY OF THE FLUOROMETRIC DETERMINATION OF PLASMA 11-HYDROXYCORTICOIDS
Z KLIN CHEM KLIN BIOCHEM 8, 368 (1970)
0390 GRAF N, TARLOV
AGRANULOCYTOSIS WITH MONOHISTIOCYTOSIS ASSOCIATED WITH ANPICILLIN THERAPY

0391 GRAISELY B, EMERY 3?, HUGUES FC, NARCHE 0
RITANPICINE ET ICTLRE OBSERVATIONS CHEZ L’HOMME
1-LIRAPIE 26, 655 (1971)
392 GFACY H3, ‘JRIGHT LD, MCGINNISS NH

C005;’ POSITIV FACTIONS ASSOCIATEA) WITH SODIUM CEPHALOTHIN THERAPY
0 ANT? MED ASS 199, 725 (1967)
3#{176}? GPAL”ICK HP, NCGINNISS N, ELTON W, MCCURDY P
E:OLYTIC ANENIC ASSCIkTED WITH CEPRALOTHIN
3 1ER N:!.) ASS 217, 1193 (1971)
03LL G0E’3JRC- SN
MO ON LEVODOPA - Ii1PLICATIONS TOE ADRENAL FUNCTION
N4 FNGL 0 MED 286, 375 (1972)
:395 GEENE XL, PUJINOTO WY, SEGMILLEF 31
JPINARY XANTHINE STONES, A RARE COMPLICATION OF ALLOPUPINOL THERAPY
NW FNGL J MD 28:, ‘+26 (1969)
:39 GEL.NLA4 3, PHYOR J, INNACKN J, HAHN T, HADJAD 3, ANAST C

OT.CMALACIA (ON) FROM ANTICONVULSANT DRUGS (ACV) : THERAPEUTIC IMPLICATIONS
CLN S 20, 56 (1972)
0397 Gl:BLE B?, WHITEHEAD RG
HE L??FCT OF N ORAL GLUCOSE LOAD ON SERUM FREE AMINO ACID CONCENTRATION IN CHILDREN BEFORE AND AFTER TREATMENT
E1IT 0 NUTR 25, 253 (1971)
0398 GtOSS L
OAYP’CNBUTAZONE-INCUOED PAROTITIS
0399 GNJ ‘N IC, FIVETT DI
SPECIfICITY C’? SPIES AND CHAMBERS REAGENT FOR COLORNETRIC ESTIMATION OF TRYPTOPHAN
ANAL BIOCHIM 44, 519 (1971)
c:c GU!PRA N
TOXICITY OF INDONETHACIN REPORT OF A CASE OF ACUTE PANCREATITIS
0 AMER MED ASS 23, 552 (1967)
C#{149} GUNSTONf RF, ‘IING AJ, SHANI HGP, NJENO 0, SABUKA ENW
CLINICAL 3X?ERIENC WITi ?IETOLAEONE IN FIFTY-TWO AFRICAN PATIENTS
POSTG?AD uT) 0 L7, 799 (1971)
C4:2 GUPTA KK
G1kNiTHIDINE AND GLUCOSE TOLERANCE IN DIABETICS
DPI: !LD 3 3, 679 (1968)
CL3 GUSTASON A, 3JORNTOEP 9, FAHLEN N
MJTFORMIN ADMINISTRATION IN HYPERLIPIDEMIC STATES
AOTA ED SCAND 190, 191 (1971)
0Ly:1 GUTMAN
u’?IcOSUR:o DRUGS, WITH SPECIAL REFERENCE TO PROBLNECID AND SULFINPYRAZONE
AOVAN PHARMACOL 1, 91 (1966)
4:#{149}3GDT1AN AB
LR’JG R1ACTIONS CHARACTEFIZED BY CHOLESTASIS ASSOCIATED WITH INTRAHEPATIC BILIARY TRACT OBSTRUCTION
;tP 3 MED 23, 841 (19c7)
04:6 HA?0 HG, DANBACH2 MA, GUNCAGA J, LAUFFENBERGER T
?NL EFFECTS OF CALCITONIN AND PARATHYROID EXTRACT IN MAN
3 OLIN INVOST 50, 2689 (1971)
047 HAD)N JW, NETZNR RJ
PSUDCKTTOSIS AND HY?ERACETALDEHYDEMIA IN PARALDEHYDE ACIDOSIS
AFF 3 MED 147, 6142 (1969)
0Cm HACEN HT
THYROID FUNCTION TESTS PHYSIOLOGIC BASIS AND CLINICAL INTERPRETATION
?OSTGPAD MED 129 (1966)
D’9 HAHN TO, HADOAD JG, HCNIIIN BA
EFFECT 3? CHRONIC ANTICONVULSANT THERAPY ON SERUM 25-OH VITAMIN D LEVELS
OLIN ELS 23, 238 (1972)
Q41 HAINMERL: UP, BIRCHLF. 3
‘RONG IDEA, GOOD RESULTS (THE LACTULOSE STORY)
N! ?NGL 3 MED 281, 14141 (1969)
01411 HAINLINE A
MEMZMOGLOBIN
STAND NITH CLIN CHFM 5, 143 (1965)
a12 HALLR J
A REVIEW OF THE LONG TERM EFFECTS OF HORMONAL CONTRACEPTIVES
OONTFACEPTION 1, 233 (1970)
3L113 iALLIDAY A, JAWETZ F
SODIUM NITROF’J?ANTOIN ADMINISTERED INTRAVENOUSLY
NW TNGL 3 MED 266, 27 (1962)
:L1L HALETE’) JA, HACKLEY DPI, SMITH JO JR
PLASMA ZINC AND COPPER IN PREGNANCY AND AFTER ORAL CONTRACEPTIVES
LWCT 2, 278 (1968)
:15 hANGS? IM, G’JTMAN Ak3
POSTASPHFNAMINE JAUNDICE
3 AMER MED ASS 115, 263 (1940)
01116 HANSTN or, SIEPSBOECK-NIELSEN K
St?Ut.: PROTEIN-BOUND IODINE AND SERUM THYROXINE DURING PEPPHENAZINE THERAPY
ACTA ENDOCRINOL 55, 136 (1967)
01117 HANSIEN PD
DRUG INTERACTIONS
LEA & FERIGER, PHILADELPHIA (1971)
OLL18 BANSTEN PD
0!GS IN THF PRODUCTION OF DIRECT COOMBS TEST POSITIVITY
A’4} 3 HOSP PHAP1 28, 629 (1971)
0419 HANTMAN A, DONALDSON CL, HULLEY SB
ABNORMAL URINARY SEDINNT DURING THERAPY WITH SYNTHETIC SODIUM CALCITONIN
a OLIN ENDOCRINOL 33, 5611 (1971)
042: HARGREAVES T, LATHE GB
INHIBITORY ASPECTS OF BILE SECRETION
NATURE 2CC, 1172 (1963)

3421 HARGREAVES T, LATHE GH
DRUGS AFFECTING BILIARY SECRETION
IN THERAPEUTIC AGEN’IS AND THE LIVER, MCINTYRE N & SHERLOCK S (lOS) BLACKWELL, OXFORD (1965)
0422 HARRIS 0, JESSOP 3D, CHAPUT DE SAINTONGE DM
FURTHER EXPERIENCE .WITH AZATHIOPRINE IN RHEUMATOID ARTHRITIS
BRIT MED 3 14, LL63 (1971)
423 HARRIS A
LONG TERM TREATMENT OF PAROXYSMAL CARDIAC ARRHYTHMIAS WITH PROPRANOLOL
ANIR J CARDIOL 18, 431 (1966)
0424 HARRISON TR
HARRISON’S PRINCIPLES OF INTERNAL MEDICINE 6TH ED
WINTROBE N (ED) MCGPAW-HILL, NY (1970)
0425 HARRISON P3
VITAMIN B12 LEVELS IN ERYTHROCYTES IN HYPOCHROMIC ANAEMIA
3 OLIN PATROL 24, 698 (1971)
0426 HARTSHORN EA
DRUG INTERACTIONS
DRUG INTEL 2, 174 (1968)
0427 HASKELL CM, CANELLOS GP LEVENTHAL HG, CARBONE PP, BLOCK JR, SERPICK AA, SELAWRY OS
L-ASPARAGINASE THERAPEUTIC AND TOXIC EFFECTS IN PATIENTS WITH NEOPLASTIC DISEASE
NE ENGL 3 MED 281, 1028 (1969)
0428 HASKOVEC L, PYSANEK K
EXCRETION OF 3-METHOXY-14HYDROXYMANDELIC ACID S 5-OH INDOLEACETIC ACID IN DEPRESSED PATIENTS
J PSYCHIAT P25 5, 213 (1967)
0429 HAVEL P3
THE AUTONOMIC NERVOUS SYSTEM AND INTERMEDIARY CARBOHYDRATE AND FAT METABOLISM
ANESTHESIOLOGY 29, 702 (1968)
0430 HEALEY LA, HARRISON N, DECKER JL
URICOSURIC EFFECT OF CHLORPROTHIXENE
NEW ENGL 3 NED 272, 526 (1965)
0431 HEANEY RI’, WHEDON GD,
IMPAIRMENT OF HEPATIC BROMSULPHTHALEIN CLEARANCE BY TWO 17-SUBSTITUTED TESTOSTERONES
3 LAB CLIN MED 52, 169 (1955)
0432 HELLSTROM P1, REPO UK, MATTSON K
NEW DRUGS IN TUBERCULOSIS
DRUGS 1, 349 (1971)
0433 HELLSTPOM PE, REPO UK
CAPREOMYCIN, ETHAMBUTOL, AND RIFAMPICIN IN APPARENTLY INCURABLE PULMONARY TUBERCULOSIS
SCAND 0 RESP DIS (SUPPL) 69, 69 (1969)
011311 HENDERSON AR
A SOURCE OF ERROR IN BLOOD PYRUVATE DETERMINATION
3 OLIN PATROL 24, 475 (1971)
01435 HENGSTNANN H
UBER VERBREITUNG UND FOLGEN DES PHENAZETIN - ABUSUS AUF DEN LANDE EIN BERICHT USER 7) FALLE
MUNCH MED WOCHENSCHR 1)8, 1489 (1966)
CL136 HENRY NJ
CLINICAL CHEMISTRY:PPINCIPLES AND TECHNICS
HOEBFR DIVISION, HARPER AND ROW NEW YORK NY (19614)
0437 HENRY RJ, SOBEL C, BEENMAN S
ON THE DETERMINATION OF ‘PANCREATIC LIPASE’ IN SERUM
CLIN CHEM 3, 77 (1957)
0438 HENRY P3, GOLUB OJ, BERKMAN 5, SEGALOVE M
CRITIQUE ON THE ICTERUS INDEX DETERMINATION
AMER 3 CLIN PATROL 23, 841 (1953)
0439 HENRY 33, BERKMAN S
ABSORBANCE OF VARIOUS PROTEIN-FREE FILTRATES OP SERUM
CLIN CHEN 3, 711 (1957)
C144C HERD OK
INTERFERENCE OF HEXOSAMINES IN THE LOWRY REACTION
ANAL BIOCHEM 144, LIC4 (1971)
01141 HEPSH EN, WONG VG, HENDERSON ES ET AL
HEPATOTOXIC EFFECT OP MEIHOTREXATE
CANCER 19, 6CC (1966)
01442 HERXHEINER A
PIE AMPICIN
DRUG THER BULL 8, 11 (1970)
01443 HESS 3W, MACDONALD PP
SERUM CREATINE PHOSPHOKINASE ACTIVITY: A NEW DIAGNOSTIC AID IN NYOCARDIAL AND SKELETAL MUSCLE DISEASE
0 NICH MED SOC 62, 1C95 (1963)
0444 HEYMANN W
NEPHROTIC SYNDROME AFTER USE OF TRINETBADIONE IN PETIT MAL
0 AMER MED ASS 2C2, 893 (1967)
0445 HEYNANN W. GROPE WE
INCREASE IN PROTEINURIA DUE TO STEROID MEDICATION IN CHRONIC PENAL DISEASE
3 PEDIAT 74, 356 (1969)
0446 HILlS BW
HYPERGLYCEMIA AND GLYCOSURIA FOLLOWING CHLORPROMAZINE THERAPY
0 AMER NED ASS 162, 1651 (1956)
0447 HILL 3M, ROBERTS 3, LOET E ET AL
L-ASPARAGINASE THERAPY FOR LEUKEMIA AND OTHER MALIGNANT NEOPLASMS
3 AMER NED ASS 202, 882 (1967)
04118 HILLMER T, FRERICHS H, CREUTZFELDT W, HALLER J
KOLENHYDRAT-UND FETTSTOFFWECHSZLVERANDERUNGEN WAHREND DER BEHANDLUNG MIT EINEM OVULATIONS-HEMMER (EUGYNON)
VERHANDL 3 KONGRESS 0 DEUTSCHEN DIABETESGESELLSCHA?T, GOTTINGEN (1968)
04119 HINMAN AR, WOLINSKY E
NEPHROTOXICITY ASSCCIATED WITH THE USE OF CEPHALORIDINE
0 AMER MED ASS 203, 724 (1967)
0450 HINSHAW JR
PENTAZOCINE: A POTENT, NON-ADDICTING ANALGESIC
AMER 3 MED SCI 251, 57 (1966)

0451 R3ELN. N, DEVERDIER OH
BIOCHEMICAL EFFECTS OF AROMATIC ANINES. 1 METHAENOGLOBINAEMIA, HIENOLYSIS AND HEINZ-BODY FORMATION
BIOCHEN PHAMACOL 14, 1119 (1965)
0452 HOECHST HARMACEUTICAL COMPANY
MANUFACTURER’S LITERATURE ON LASIX
1385 TENNESSEE AVE, CINCINNATI, OHIO 45229
01*53 HOEKENGA NT, BUNDE CA, CHO YW, KUZMA 30
DOUBLE BLIND NULTICENTEP EVALUATION OF A NEW ANTIANGINAL DRUG: PERHEXILINE MALEATE
0R5L1 HOFFMAN PS, NAPTINO JA, WAHL G, ARKY PA
FASTING AND REFEEDING 3 ANTINATUPETIC EFFECT OF ORAL AND INTRAVENOUS CARBOHYDRATE
METABOLISM 20, 1065 (1971)
0455 HOKFELT B, HEDELAND H, DYMLING OF
THE INFLUENCE OF CATAPPES ON CATECHOLAMINES, RENIN AND ALDOSTERONE IN MAN
IN CATAPRES IN HYPERTENSION, CONOLLY ME (ED) BUTTERWORTH, LONDON (1970)
0456 HOLDEN JMC, ITIL TM
LABORATORY CHANGES WITH CHLORDIAZEPOXIDE AND THIORDIAZINE, ALONE AND COMBINED
CANAD PSYCHIAT ASS 3 iLl, 299 (1969)
0457 HOLLANDEP CS, MITStJMA T, SHINKMAN L, WOOLF P, GOSHINGORN MC
THYROTROPIN-RELEASING HORMONE: EVIDENCE FOP THYROID RESPONSE TO INTRAVENOUS INJECTION IN NAN
SCIENCE 175, 209 (1972)
0458 HONET 3C
FALSE POSITIVE URINARY TEST FOP. 5-HIAA DUE TO METHOCARBOMAL AND MEPHENESIN CARBAMATE
NEW ENGL 3 MED 261, 188 (1959)
0459 HONGF PT, ROSSING N
ALBUMIN METABOLISM AND ORAL CONTRACEPTION
CLIN SCI 36, 41 (1969)
01*60 HONNA Y, NIMURA T
SERUM CREATINE PHOSPHOKINASE ACTIVITY IN CHRONIC ALCOHOLICS
JAP 3 STUD ALC 14, 87 (1969)
0461 HOOD 3W, lOCH WN
JAUNDICE CAUSED RY PHENAZOPYRIDINE HYDROCHLORIDE
0 AMER MED ASS 198, 1366 (1966)
0462 HORDE? K, HORDER N
PLASMA HAPTOGLOBIN AND ?HYSICAL EXERCISE: CHANGES IN HEALTHY INDIVIDUALS CONCOMITANT WITH A STRENUOUS MARCH
OLIN CHIN ACTA 30, 369 (1970)
01163 BORNE CHW, MALLINSON AC, FERGUSON J, GOUDIE RB
EFFECT OF ORSYROGEN AND PROGESTOGEN ON SERUM LEVELS OF ALPHA2 MACROGLOBULIN, TRANSFEPRIN AND IGG
3 OLIN PATROL 24, 464 (1971)
01464 HOPPOBIN DE, BURSTYN PG, LLOYD 13, DURKIN N, LIPTON A, MUIRUPI KL
ACTIONS OF PROLACTIN ON HUMAN RENAL FUNCTION
LANCET 2, 352 (1971)
01*65 HOWARD RP, BRUSCO 03, FURMAN RH
EFFECT OF CHOLESTYRANINE ADMINISTRATION ON SERUM LIPIDS & ON NITROGEN BALANCE IN FAMILIAL HYPERCHOLESTEROLEMIA
3 LAB OLIN MED 68, 12 (1966)
01*66 HOWITE PF
THE EFFECT OF APURIN (ALLOPURINOL) ON LIVER FUNCTION AND SEURM IRON
DAN MED BULL 17, 203 (1970)
01467 HU? B (ED)
PHYSICIAN’S DESK REFERENCE TO PHARMACEUTICAL SPECIALTIES AND BIOLOGICALS, 26ND ED
MEDICAL ECONOMICS INC, ORADELL NJ (1972)
01168 HUGULEY CM JR
AGRANULOCYTOSIS INDUCED BY DIPYPONE
3 AMER MED ASS 189, 938 (1964)
0469 HUIS IN’T VELD LG
DRUG INFORMATION SERVICE NOTE NO 5
IFCC COMMITTEE ON STANDARDS
01470 HUIS IN’T VELD LG
DRUG INFORMATION SERVICE NOTE NO 6
IFCC COMNITEE ON STANDARDS
0471 BULLET SB, NOGEL 3M, DONALDSON CL, BAYERS 3M, FRIEDMAN RJ, ROSEN SN
THE EFFECT OF SUPPLEMENTAL ORAL PHOSPHATE ON THE BONE MINERAL CHANGES DURING PROLONGED BED REST
3 CLIN INVEST 50, 2506 (1971)
0472 HUNTER E, RAIN E, GORDON S
INCIDENCE OF POSITIVE 000MBS TEST, LE CELLS AND ANTINUCLEAR FACTOR IN PATIENTS ON ALPHA-METHYLDOPA(ALDOMET)
MED 3 AUST 2, 810 (1971)
01473 HUNTER 3, MAXWELL 3D, STEWART DA, PARSONS V, WILLIAMS P
ALTERED CALCIUM METABOLISM IN EPILEPTIC CHILDREN ON ANTICONVULSANTS
BRIT MED 3 14, 202 (1971)
01474 HUNTER WM
IN GROWTH AND DEVELOPMENT OF MAMMALS
LODGE GA AND LAMMING GE (EDS), BUTTEPWOPTH, LONDON (1968)
0(175 HURT P
THE EFFECT OF RADIOGRAPHIC CONTRAST MEDIA ON URINALYSIS
AMER J MED TECHNOL 26, 122 (1960)
01476 HUTTUNEN 3K
FRUCTOSE IN MEDICINE: A REVIEW WITH PARTICULAR REFERENCE TO DIABETES MELLITUS
POSTGOIAD MED 3 47, 654 (1971)
0477 IBER FL
CHOLESTASI S
POSTGRAD NED 141, 30 (1967)
01478 IRIE N TSUSHINA T, SAKUNA N
EFFECT OF NICOTINIC ACID ADMINISTRATION ON PLASMA HGH, FFA AND GLUCOSE IN OBESE SUBJECTS
0479 ISHIBE T
ALTERATIONS IN SERUM LACTATE DEHYDPOGENASE ACTIVITY AND ITS ISOENZYNE PATTERN AFTER MASSAGE OF THE PROSTRATE
INVEST UROL 9, 104 (1971)
01480 IZAKOVIC V, IZAKOVICOVA A
HEPARIN AND PREDNISONE TO? CARCINOID SYNDROME
KLIN WOCHENSCHP 42, 8714 (1963)

0481 3ABLONSKI P, OWEN JA
THE CLINICAL CHEMISTRY OF BROMSULFOPHTHALEIN AND OTHER CHOLEPRILIC DYES
IN ADV IN OLIN CHIN 12, 209, BODANSKY 0, STEWART OP (EDS) ACADEMIC PRESS, NY (1969)
0482 3ACKSON CE, NEIER DW
ROUTINE SERUM MAGNESIUM ANALYSIS CORRELATION WITH CLINICAL STATE IN 5,100 PATIENTS
0483 JACKSON ST, RALLISON ML, BUNTIN WH, JOHNSON SB, FLYNN PR
USE OF OXANDROLONE FOR GROWTH STIMULATION
CLIN RES 20, 254 (1972)
0484 JACOBS LS, SNYDER P3, WILBER 3F, UTIGER RD, DAUGHADAY WH
INCREASED SERUM PROLACTIN AFTER ADMINISTRATION OF SYNTHETIC THYROTROPIN RELEASING HONRMONE IN MAN
3 OLIN ENDOCRINOL 33, 996 (1971)
0485 JACOBS SL, FERNANDEZ AA
HEMOGLOBIN IN PLASMA
STAND METH OLIN CHEN 6, 107 (1970)
0486 JACOBSON ED, PRIOR JT, FALOON WW
MALABSORPTIVE SYNDROME INDUCED BY NEOMYCIN: MORPHOLOGIC ALTERATIONS IN THE JE3UNAL MUCOSA
3 LAB OLIN MED 56, 2145 (1960)
01487 JAILLARD 3, SEZILLE G, SCHERPERCEL P, FRUCHART 30
ETUDE CLINIQUE ET EXPEPMENTALE DES MODIFICATIONS DES LIPIDES PLASMATIQUES INDUITES PAR L’ALCOOL
NUTR METABOL 13, 114 (1971)
0488 JAIN A, HOYT H
THE EARLY CLINICAL EVALUATION OF W-2354 IN GOUT
OLIN PHARMACOL THER 13, 11*1 (1972)
0489 3AKOWIAK ME, LEVIER PP
ELIMINATION OF PHOSPHORUS INTERFERENCE IN THE COLORIMETRIC DETERMINATION OF SILICON IN BIOLOGICAL MATERIAL
0490 JAMES VHT, NATTINGLY 0, DALY JR
RECOMMENDED METHOD FOR THE DETERMINATION OF PLASMA CORTICOSTEROIDS
BRIT NED 3 2, 310 (1971)
0491 3APRETT P3, GRAVES NJ, COHEN NM
THE EFFECTS OF INFUSIONS OF AMINO-ACIDS, SECRETIN AND PANCPEOZYNIN UPON LEVELS OF BLOOD SUGAR AND PLASMA INSULIN
DIABETOLOGIA 5, 1421 (1969)
0492 JAVITT NB
THE CHOLESTATIC SYNDROME - 1971
AMER 3 NED 51, 637 (1971)
01493 JENKINS 35, CONNOLLY 3
ADREN000RTICAL RESPONSE TO ETHANOL IN MAN
BPIT NED 3 2, 804 (1968)
0494 JENKINS GO, HUGHES DTD, HALL PC
A HAENATOLOGICAL STUDY OF PATIENTS RECEIVING LONG-TERM TREATMENT WITH TRIMETHOPRIM AND SULPHONAMIDE
3 OLIN PATHOL 23, 392 (1970)
0495 3ENNEKENS FGI, VAN VEELEN OWN
HYPERVITA NINOSE
PRESSE MED 714, 2925 (1966)
0496 JOATTELA A, NIKKI P, TAKKI 5, TANMISTO T
EFFECT OF DEXTROMORANIDE, FENTANYL, AND MORPHINE ON THE PLASMA CATECHOLANINE LEVELS
ANN OLIN RES 3, 107 (1971)
0497 3OHANNSON EDB, GEMZELL C
PLASMA LEVELS OF PROGESTERONE DURING THE LUTEAL PHASE IN NORMAL WOMEN TREATED WITH SYNTHETIC ESTROGENS
01498 JOHANSSON SA
APPARENT RESISTANCE TO ORAL ANTICOAGULANT THERAPY AND INFLUENCE OF HYPNOTICS ON SOME COAGULATION FACTORS
ACTA MED SCAND 1811, 297 (1968)
0499 JOHNSON BE
THE DIURETIC ACTION OF AN AZIDO PYRIMIDINE IN MAN
OLIN PHARMACOL THER 11, 77 (1970)
0500 JOHNSON PB JR
OSMOLALITY OF SERUM AND URINE
STAND METH OLIN CHEM 5, 159 (1965)
0501 JOHNSON B?
DIAZOXIDE AND PENAL FUNCTION IN MAN
0502 JONES CM
ALTERATION OF THYROID FUNCTION BY HENODIALYSIS - AN EFFECT OF HEPARIN
ALA 3 MED 501 8, 265 (1971)
0503 JONES MF, CALDWELL JR
ACUTE HEMORRHAGIC PANCREATITIS ASSOCIATED WITH ADMINISTRATION OF CHLORLTHALIDONE
NEW ENGL 3 MED 267, 1029 (1962)
0504 JONES P3, DOBPILOVIC L
LIPOPROTEIN LIPID ALTERATIONS WITH CHOLESTYRAMINE ADMINISTRATION
3 LAB OLIN MED 75, 953 (1970)
0505 KAOHADORIAN WA, JOHNSON RE
THE EFFECT OF EXERCISE ON SOME CLINICAL MEASURES OF RENAL FUNCTION
AMER HEART 3 82, 278 (1971)
0506 KALESH DG, NALLIKARJUNESWARA VR, CLEMETSON CAB
EFFECT OF ESTROGEN-CONTAINING OPAL CONTRACEPTIVES ON PLATLET AND PLASMA ASCORBIC ACID CONCENTRATIONS
0507 KALLIONAKI JL
A THERAPEUTIC TRIAL WITH A COMBINATION OF TRIMETHOPRIN-SULFAMETHOXIZOLE IN RHEUMATOID ARTHRITIS
CURB THER RES 14, 22 (1972)
0508 KANE FJ 3R, MOORE LP
HEPATOTOXICITY OCCURRING WITH THIORIDAZINE THERAPY
SOUTH NED 3 64, 573 (1971)
0509 KANSAL PC, RUSE 3, TALBERT OR, RUSE MG
THE EFFECT OF L-DOPA ON PLASMA GROWTH HORMONE, INSULIN AND THYROXINE
0510 KAPLAN A
UREA NITROGEN AND URINARY AMMONIA

0511 KARK PAP, POSKANZER DO, BULLOCK 3D, BOYLEN G
MERCURY POISONING AND ITS TREATMENT WITH N-ACETYL-D-L-PENICILLAMINE
NEW ENGL J MED 285, 10 (1971)
0512 KARKALAS Y, LAL H
JAUNDICE FOLLOWING THERAPY WITH IMIPRANINE AND CYPROHEPTADINE
OLIN TOXICOL 4, 47 (1971)
0513 KATER RMH
DOUBLE BLIND EVALUATION OF ANALGESIC & TOXIC EFFECTS OF FLUFENAMIC ACID & NEFENAMIC ACID
NED 3 AUST 1, 848 (1968)
0514 KATZ FR, LIPNAN MM, F?ANTZ AG ET AL
THE PHYSIOLOGIC SIGNIFICANCE OF 6-BETA-HYDROXYCORTISOL IN HUMAN CORTICOID METABOLISM
0 OLIN ENDOORINOL 22, 71 (1962)
0515 KAUFMAN F
A RARE COMPLICATION OF SULFADIMETHOXINE (MADRIBON) THERAPY
CALIF MED 107, 344 (1967)
0516 KEDRA M, POLESZAK 3, PITERA A
EFFECT OF CAFFEINE ON THE COMPOSITION OF BLOOD LIPIDS
POL TYG LEN 25, 125 (1970)
0517 KEENAN J, THOMPSON OR, CHAMBERLAIN NA, BESSEP GM
PROLONGED CORTICOTBOPHIC ACTION 0? A SYNTHETIC SUBSTITUTED 1-18 ACTH
BRIT MED 3 3, 71*2 (1971)
0518 KELLER D?
G-6-PD DEFICIENCY
CRC PRESS CLEVELAND OHIO 1971
0519 KELLEY WN, ROSENBLOON FM, SEEGNILLER JE
THE EFFECTS OF AZATHIOPRINE (IMURAN) ON PURINE SYNTHESIS IN CLINICAL DISORDERS OF PURINE METABOLISM
3 OLIN INVEST 46, 1518 (1967)
0520 KELLEY WN, GOLOFINGER SE, HARDY HL
HYPERURICEMIA IN CHRONIC BERYLLIUM DISEASE
0521 KELSEY WN, SCHARYJ N
FATAL HEPATITIS PPO3ABLY DUE TO INDOMETHACIN
J AMER MED ASS 199, 586 (1967)
0522 KEN DC, WEINBERGEP MN, MAYES ON, NUGENT CA
SALINE SUPPRESSION OF PLASMA ALDOSTERONE IN HYPERTENSION
0523 KENDALL N3, NUTTER 5, HAWKINS CF
XYLOSE TEST: EFFECT OF ASPIRIN AND INDOMETHACIN
BRIT NED 3 1, 532 (1971)
05214 KENDALL OW, EGANS ML, STOTT AK
FLUOROMETRIC DETERMINATION OF CORTICOSTEPOIDS: AN INTERFERING SUBSTANCE IN IMPURE DICHLORONETHANE
3 OLIN EN000RINOL 28, 1373 (1968)
0525 KENT JR, HILL N, PARLOW A?, BISCHOFF A
ESTPOGENIO SUPPESSION OF THE PITUITARY-GONADAL AXIS AND PROSTATIC FUNCTION
OLIN PHARNACOL THER 13, 1144 (1972)
0526 KEPSHBAUN A, PAPPAJOHN DO., BELLET S ET AL
EFFECT OF SMOKING AND NICOTINE ON ADREN000RTICAL SECRETION
3 AMER MED ASS 203, 275 (1968)
0527 KETTLEWELL N, NOWEPS A, WHITE P
EFFECT OF DIGOXIN ON HUMAN RED BLOOD CELL ELECTROLYTES
BRIT 3 PHAPNACOL 1414, 1 65 (1 972)
0529 KEW MC, SEFTEL NC, BLOOMBEEG BM
PREGNANCY TESTS AND PROTEINURIA
LANCET 1, 902 (1967)
0529 KING B, SPIKESMAN A, EMERY AEH
THE EFFECT OF PREGNANCY ON SERUM LEVELS OF CREATINE KINASE
0530 KINGSLEY GR, TAGER HS
ION-EXCHANGE METHOD FOP THE DETERMINATION OF PLASMA AMMONIA NITROGEN WITH THE BERTHELOT REACTION
STAND METH OLIN CHEN 6, 115 (1970)
0531 KIPBTRGER E
VARIABLE ACTION OF MAO INHIBITING HYDRAZINES ON SEBOTONIN METABOLISM
NATURE 197, 1211 (1963)
0532 KIRCKMAIB H, RUBER H
FIEBERHAPTE REAKTION (‘DRUG FEVER’) UNTER A-METHYLDOPA
WIEN KLIN WOCHENSCHR 77, 699 (1965)
0533 KIRSH MM, ABRANS B COON W, ZUIDENA G
DIPHENHYDRAMINE (BENADRYL) HYDROCHLORIDE IN THE TREATMENT OF AMMONIA INTOXICATION
ARCH SURG 91, 466 (1965)
0534 KISTAULDY 5, BUKI B, MESZAROS S
EFFFCT OF ORALLY ADNINISTERFD AMINO ACIDS ON PORTAL BLOOD AMMONIA
ACTA MED ACAD Sd HUNG 20, 365 (1964)
0535 KISTNEP RW
PRESENT STATUS OF ORAL CONTRACEPTIVES
DRUG THERAPY 1, 14 (1971)
0536 KLEIN GO, COOPER GP
ELECTROPHORETIC DETERMINATION OF SERUM LIPOPPOTEINS (PRESTAINING TECHNIQUE)
STAND METH OLIN OHEP! 6, 127 (1970)
0537 KLEIN N
AGRANULOCYTOSIS SECONDARY TO CHLORTHALIDONE THERAPY (REPORT OF A CASE)
J AMER MED ASS 184, 310 (1963)
0538 KLEIN NC, MAGIDA MG
PROPOXYPHENE (DARVON) HEPATOTOXICITY
AMER 3 DIG DIS 16, 467 (1971)
0539 KLOTZ M RICHTER H, MEUFFELS N
INTERTERENOE BY FORMALDEHYDE FORMING DRUGS IN THE DETERMINATION OF URINARY CATEOHOLAMINES
OLIN CHEM 10, 372 (1964)
0543 KNI”FIN JO, NOYES ND, PORTER FS
IRON AND OHOLESTYRMAINE IN ERYTHROPOIETIC PROTOPORPHYPIA
OLIN RES 18, 38 (1970)

0541 KNIPSOH AK, GRALLA EJ
ABNORMAL SERUM TPANSAMINASE LEVELS AFTER PARENTERAL AMPICILLIN AND CARBENICILLIN ADMINISTRATION
NEW ENGL 3 MED 282, 1081 (1970)
0542 KOCH-WESER 3, SIDEL VW, DEXTER N, PARISH C, FINER DC, KANAREK P
ADVERSE REACTIONS TO SULFISOXAZOLE, SULFANETHOXAZOLE, AND NITFOFURANTOIN
0543 KOCH-WESEB 3
POTENTIATION BY GLUCAGON OF THE HYPOPPOTHRONBINEMIC ACTION OF WARFARIN
0544 KOOH-WESER 3
QIJINIDINE-INDUCED HYPOPROTHRONBINEMIC HEMORRHAGE IN PATIENTS ON CHRONIC WAPEAPIN THERAPY
0545 KOCH-WESER 3, SELLERS EM
COUMARIN ANTICOAGULANTS
NEW ENGL 0 MED 285, 555 (1971)
0546 KOENEST MN, FRIER F?
AN EVALUATION OF TWO METHODS FOR THE DETERMINATION OF TRUE OPEATININE
AMER J NED TECHNOL 37, 473 (1971)
0547 KOHN RN, MONTES N
HEPATIC FIBROSIS FOLLOWING LONG ACTING NICOTINIC ACID THERAPY: A CASE REPORT
AMER 3 MED 501 258, 94 (1969)
0548 KONTUPEK 5, GABRYS B
INHIBITION OF GASTRIC SECRETION OF HYDROCHLORIC ACID BY SEOPETIN
POL TYG LEK 25, 95 (1970)
0549 KONZETT H, HORTNAGL H, ROPTNAGL H, WINKLER H
ON THE URINARY OUTPUT OF VASOPRESSIN, EPINEPHRINE AND NOREPINEPHRINE DUPING DIFFERENT STRESS SITUATIONS
PSYCHOPHARMACOLOGIA 21, 247 (1971)
0550 KORNAN MG, SOVENY C, HANSKY 3
THE EFFECT OF FOOD ON SERUM GASTRIN
AUST N Z 3 NED 3, 299 (1971)
0551 KOSSOVER ME, BECKHAN ME, THREEFOOT SA
INFLUENCE OF AN ORAL PEPISTALTIC STIMULANT, DANTHRON, ON THE PSP EXCRETION TEST
AMER J MED 501 247, 694 (1964)
0552 KOSZEWSKI P3, HUBBARD TE
IMMUNOLOGIC AGRANULOCYTOSIS DUE TO MERCUIAL DIURETICS
AMER 0 MED 20, 958 (1956)
0553 KRACKE PR
RELATION OF DRUG THERAPY TO NEUTROPENIC STATES
3 AMER NED ASS 111, 1255 (1938)
0554 KRANTZ JO, CARP 03
PHARMACOLOGIC PRINCIPLES OF MEDICAL PRACTICE 6TH ED
WILLIAMS N WILKINS, BALTIMORE (1965)
0555 KRISTINSSON A
FATAL REACTION TO AOETAZCLAMIDE
BRIT 0 OPHTHAL 51, 3148 (1967)
0556 KRUMHOLZ WV, OHIPPS HI, NERLIS S
CLINICAL EFFECTS OF TRIOXAZINE, WITH A CASE REPORT OF HYPERGLYCEMIA AS A SIDE EFFECT
3 OLIN PHARMACOL 7, 108 (1967)
0557 KUNTZ E, LIEHP H, PFINGST W
TOXISOHE LEBEPSOHADIGUNG DURCH ATHIONAMID
DEUTSCH MED WOOHENSOHR 92, 1718 (1967)
0558 KUNTZMAN R, JACOBSON N, CONNEY AN
EFFECT OF PHENYLBUTAZONE ON CORTISOL METABOLISM IN MAN
PHARMACOLOGIST 8, 195 (1966)
0559 KURZ N
DIAMOX UND MANIFESTIERUNG VON DIABETES MELLITUS
WIEN MED WOCHENSCHR 118, 239 (1968)
0560 KUTT M, NILHORAT TN, MCDOWELL F
THE EFFECT OF IODIZED CONTRAST MEDIA UPON BLOOD PROTEINS, ELECTROLYTES AND RED CELLS
NEUROLOGY 13, 492 (1963)
0561 KUZUYA T, KANAZAWA Y
STUDIES ON THE MECHANISM OF XYLITOL-IN000ED INSULIN SECRETION IN DOGS
DIABETOLOGIA 5, 248 (1969)
0562 LADD AT
PROCAINAMIDE- INDUCED LUPUS EPYTHEMATOSUS
NEW ENGL 3 MED 267, 1357 (1962)
0563 LANDON 3 (1969) CITED BY LORAINE JA, BELL ET
HORMONE ASSAYS AND THEIR CLINICAL APPLICATION 3RD ED
0564 LANGLOIS
DIANOX ET THROMBOCYTOPENIE
ARCH OPHTHAL (PARIS) 26, 701 (1966)
0565 LARSEN PR
INHIBITION OF TRIIODOTHYRONINE (T3) BINDING TO THYROXINE BINDING GLOBULIN BY SODIUM SALICYLATE
0566 LARSSON-COHN U
THE 2-HOUR SULFOBROMOPHTHALEIN RETENTION TEST AND THE TRANSAMINASE ACTIVITY DURING ORAL CONTRACEPTIVE THERAPY
0567 LASSER EC, LANG OH
INHIBITION OF AOETYLOHOLINESTERASE BY SOME ORGANIC CONTRAST MEDIA
INVEST RADIOL 1, 237 (1966)
0568 LAUNAY C, PABIANI P, GRENET P, ET AL
UN NOUVEAU CAS D’ACRODYNI AVEC PRESENCE DE MERCURE DANS LES URINES (DISCUSSION THEPAPEUTIQUE)
ARCH FR PEDIATR 7, 79 (1950)
0569 LAY WH
DRUG-INDUCED HAEMOLYTIC REACTIONS DUE TO ANTIBODIES AGAINST THE ERYTHROCYTE/DIPYRONE COMPLEX
VOX SANG 11, 601 (1966)
0570 LEAVELL PS, THORUP OA
FUNDAMENTALS OF CLINICAL HEMATOLOGY 3RD ED

0571 LEBACQ EG, TIFZMALIS A
METFORMN AND LACTIC ACIDOSIS
LANCET , 311* (1972)
0572 LEDEPLE LABORATORIES DIVISION
PRODUCT NFORMATION (DECLOMYCIN)
AMERICAN CYANANID COMPANY, PEARL RIVER NY 10965
0573 LEE-JONES N
SERUM TRANSAMINASES DURING SALICYLATE THERAPY
BRIT MED 3 2, 772 (1971)
0574 LEFEVRE NIP
INCIDENTS ET ACCIDENTS DES MEDICATIONS NEUROLEPTIQUES ET PSYCHOTROPES
3 MED BORDEAUX 1414, 139 (1967)
0575 LEHMANN J
LIGHT - A SOURCE OF ERROR IN THE FLUOROMETRIC DETERMINATION OF TRYPTOPHAN
SCAND 3 OLIN LAB INVEST 28, 49 (1971)
0576 LEONARD P3, PERSAUD 0, MOTWANI R
THE ESTIMATION OF PLASMA ALBUMIN BY BOG DYE BINDING ON THE TECHNICON SMA 12/60 ANALYZER
OLIN CHIN ACTA 35, 1*09 (1971)
0577 LEVI, L
THE EFFECT OF COFFEE ON THE FUNCTION OF THE SYMPATHOADRENO-MEDULLAPY SYSTEM IN MAN
ACTA MED SCAND 181, 1*31 (1967)
0578 LEVIN K, JOSEPHSON B, GRUNEWALD G
THE EFFECT OF IODOCULORO-OXYQUINOLINE AND IOPANOIC ACID ON THE DETERMINATION OF PBI AND BET
0579 LEVINE PA
STEATORPHOSA INDUCED BY PARA-AMINOSALICYLIC ACID
0580 LEVINSON SA, MACFATE B?,
CLINICAL LABORATORY DIAGNOSIS 6TH EDITION
LEA & FEBIGER, PHILADELPHIA (1961)
0581 LEVY N, ELIAKIM M
URINARY PRECIPITATE DURING OEPHLOTHIN - CEPHALORIDINE TREATMENT
J AMER NED ASS 219, 908 (1972)
0592 LEWIS SA, OSWALD I, DUNLEAVY DL?
CHRONIC FENFLURANINE ADMINISTRATION: SOME CEREBRAL EFFECTS
BRIT MED 3 3, 67 (1971)
0583 LEZA MA
AGRNULOCITOSIS MEDICAMENTOSSAS CON PLASMOOITOSIS MEDULAR F HIPERGANNA GLOBINENIA
REV OLIN ESP 103, 316 (1966)
0584 LIDDLE GW
TESTS OF PITUITARY-ADRENAL SUPRESSIBILITY IN THE DIAGNOSIS OF CUSHING’S SYNDROME
0 OLIN EN000RINOL 20, 1539 (1960)
0585 L1DSKY ND, SHARP 3T
JAUND:OE WITH THE USE OF 4-HYDROXYPYRAZOLE- (3,4-D) -PYRIMIDINE (U-HPP)
ARTHRITIS PHEUN 10, 294 (1967)
0586 LIEBER CS
HYPERURICENIA INDUCED BY ALCOHOL
ARTHRITIS PHEUM 8, 786 (1965)
0597 LINAS C, GUIHA NH, FRETS ED
TREATMENT OF SEVERE RESISTANT HYPERTENSION WITH MINOXIDIL
0583 LIPS3TT PIG, COMBS JW, CATT K, SEIGEL DG
PROBLEMS IN CONTRACEPTIVES
0589 LIU K, MITTELMAN A, SPROUL BE, ELIAS EG
PENAL TOXICITY IN MAN TREATED WITH MITOMYCIN C
CANCEP28, 1314 (1971)
0590 LLEPNA 3, PEARSON 0
INTERFERENCE OF NALIDIXIC ACID IN URINARY 17-KETOSTEROID DETERMINATIONS
NEW ENGL 3 MED 279, 893 (1968)
0591 LLOYD T
AG RANULOCYTO SI S ASSOCIATED WITH PAPACETA MOL
LANCET 1, 114 (1961)
0592 LONDONO OH, MCGEE 3H, SOBEL RE, ROSENBLOOM AC, SAVORY 3
VARIATIONS IN SERUM CALCIUM AND PHOSPHORUS CONCENTRATIONS DURING GLUCOSE TOLERANCE TESTS
OLIN CHEM 17, 648 (1971)
0593 LORAINE JA, BELL FT
HORMONE ASSAYS AND THEIR CLINICAL APPLICATION 3RD ED
0594 LOTITO CA, MENGEL CE
EFFECT OF NELPHALAN IN THE MALIGNANT CARCINOID SYNDROME
ARCH INTERN NED 124, 36 (1969)
0595 LOUBATIERES AL
CONFRONTATION OF EXPERIMENTAL AND CLINICAL PHARMACOLOGICAL OBSERVATIONS IN THE FIELD OF HYPOGLYCAEMIC
ARCH INTERN PHARN THERAP 192, 133 (1971) SUPPL
0596 LUBRAN N
THE EFFECTS OF DRUGS ON LABORATORY VALUES
MED OLIN N AMER 53, 211 (1969)
0597 LUBY ED, SCHWARTZ D, ROSENBAUM H
LITHIUM-CARBONATE-IN DUCED NYXEDEMA
3 AMER MED ASS 218, 1298 (1971)
0598 LUKE RG, KOEPKE JA, SIEGEL ?R
THE EFFECTS OF IMNUNOSUPPRSIVE DRUGS AND UREMIA ON AUTOMATED LE’JKOOYTE COUNTS
AMER 3 OLIN PATHOL 56, 503 (1971)
0599 LUND J, PEDERSEN HE, OLSEN PZ, HVIDBERG PP
EARLY HUMAN STUDIES OF A NE CARBONIC ANHYDRASE INHIBITOR (NSD 3004) WITH ANTICONVULSANT PROPERTIES
OLIN PHARMACOL THEP 12, 902 (1971)
0600 LUPOVITCH A,
PHENOTHIAZINE INTERFERENCE AND THE PORTER-SILBEP REACTION
OLIN CHEM iLl, 179 (1968)

0601 LUBIE AO
S?IRONOLAOTONE AND STEROID ASSAY
LANOET 2, 326 (1969)
0602 LUTZ EG
NONOCYTOSIS BLOOD DYSCRASIA AND CHLORPROMAZINE TOXICITY
INTERN 3 NEUROPSYOHIAT 1, 76 (1965)
0603 LYNGSOE 3, TRAP-JENSEN 3
PHENPORMIN-INDUCED HYPOGLYCEMIA IN NORMAL SUBJECTS
BRIT MED 0 2, 2213 (1969)
0604 NACAROL V, NORRIS 3Q, BAKER K3, BRADLEY SE
HYDR000RTISONE OHOLEBESIS IN THE DOG
J OLIN INVEST 49, 1714 (1970)
0605 MACBETH WA, KASS EN, MCDERMOTT WK
TB EATN ENT OF HEPATIO ENC EPHALOPATHY BY ALTERA TION OF I NTESTI NAL FLOP A WITH L ACTOBA CILLUS ACIDOPHI LU S
LANCET 1, 399 (1965)
0606 MACDONALD PP
SALICYLATE
STAND NETH OLIN OHEM 5, 237 (1965)
0607 MACGIBBON BH, LOUGHRIDGE LW, HOURIHANE DO, BOYD DW
AUTOINNUNE HAENOLYTIO ANAEMIA WITH ACUTE RENAL FAILURE DUE TO PHENACETIN AND P-AMINOSALICYLIC ACID
LANCET 1, 7 (1960)
0608 MACGREGOR GA, POOLE-WILSON PA, JONES N?
PHENFORNIN AND METABOLIC ACIDOSIS
LANCET 1, 69 (1972)
0609 MACKAY EV, KHOO 5K
CLINICAL AND LABORATORY STUDY OP A NEW DIURETIC AGENT (‘VECTREN’) IN PREGNANCY
NED 3 AUST 1, 607 (1969)
0610 MAJOHROWICZ F, NENDELSON 311
BLOOD METHANOL CONCENTRATIONS DURING EXPERIMENTALLY INDUCED ETHANOL INTOXICATION IN ALCOHOLICS
3 PHARMACOL EXP THEP 179, 293 (1971)
0611 MALARKEY WB, JACOBS LS, DAUGHADAY WH
LEV000PA SUPPRESSION OF PROLACTIN IN NONPUERPERAL GALACTORRHEA
NEW ENGL 3 NED 285, 1160 (1971)
0612 MALPTZKY B, BLAOHLY PH
THE USE OF LITHIUM IN PSYCHIATRY
CRIT REV OLIN LAB SCI 2, 279 (1971)
0613 NALHERBE C, BURRILL KO, LEVIN SR, KARAM JH, FORSHAM PH
EFFECT OF DIPHENYLHYDANTOIN ON INSULIN SECRETION IN MAN
NEW ENGL 3 NED 286, 339 (1972)
0614 MARCEL YL, NOEL SP
PLASTICIZE? IN LIPID EXTRACTS OF HUMAN BLOOD
CHEM PHYS LIPIDS 14, 1418 (1970)
0615 MARSHALL F?, TAIT AC, TODRIOK A
THE EFFECT OF RESERPINE ON THE BLOOD SUGAR LEVEL IN HUMAN SUBJECTS
BIOOHEM 3 69, 41 (1958)
0616 MARTIN WE
ADVERSE REACTIONS DURING TREATMENT OF PARKINSON’S DISEASE WITH LEV000PA
3 AMER NED ASS 216, 1979 (1971)
0617 MARTIN HE, JONES P
THE EFFECT OF AMMONIUN CHLORIDE AND SODIUM BICARBONATE ON EXCRETION OF MAGNESIUM, CALCIUM, AND PHOSPHATE
AMER HEART 3 62, 206 (1961)
0618 MARTIN HE
CLINICAL STUDIES OF MAGNESIUM METABOLISM
MED OLIN N AMER 36, 1157 (1952)
0619 MARTIN JH, GORDON N, WALLACE P
NETHOTREXATE IN PSORIASIS. PRECIPITATION OF GOUT
ARCH DERMATOL 96, 431 (1967)
0620 MARTIN EW
HAZARDS OF MEDtCATION, A MANUAL ON DRUG INTERACTIONS, INOONPATABILITIES, CONTRAINDICATIONS AND ADVERSE EFFECTS
LIPPINCOTT, PHILADELPHIA 1971
0621 MARTIN CM
MYELOGRAPHY WITH SODIUM DIATRIZOATE (HYPAQUE)
CALIF NED 115, 57 (1971)
0622 MASEL NA
A LUPUS-LIKE REACTION TO ANTITUBEROULOSIS DRUGS
MED 3 AUST 2, 738 (1967)
0623 MASEL MA
ERYTHROMYCIN HEPATO-SENSITIVITY: A PRELIMINARY REPORT OF TWO CASES
MED 3 AUST 49, 560 (1962)
0624 MATHER A, MACKIE NP
EFFECTS OF HENOLYSIS ON SERUM ELECTROLYTES VALUES
OLIN CHEM 6, 223 (1960)
0625 NATTHYSSE 5, LIPINSKI 3, 511TH V
L-DOPA AND S-ADENOSYLMETHIONINE
0626 MAYFIELD D, BROWN PG
THE CLINICAL LABORATORY AND ELEOTROENCEPHALOGRAPHIC EFFECTS OF LITHIUM
3 PSYOHIAT RES 4, 207 (1966)
0627 NAZZARD WP, SPEIGEP NJ, BAGDADE JP, BIERMAN EL
INCREASED PLASMA TRIGLYCERIDE LEVELS INDUCED BY ORAL CONTRACEPTIVES
NEW ENGL 3 MED 280, 471 (1969)
0628 MCALLISTER PA
INHIBITION OF THE CYSTEINE-SULFURIC ACID REACTION FOR SEDOHEPTULOSE BY FERRIC IRON
0629 MCBRIDE WG
OPAL CONTRACEPTIVES
NED 3 AUST 1, 525 (1965)
0630 MOCURDY PR, NAHN000 L
INTRAVENOUS UREA TREATMENT OF THE PAINFUL CRISIS OF SICKLE-CELL DISEASE A PRELIMINARY REPORT
NEW ENGL J MED 285, 992 (1971)

0631 MCDONALD PD
RENAL DYSFUNCTION WITH METHOXYFLURANE
J AMER tIED ASS 217, 79 (1971)
0632 MCDONALD BK, WEISE VK
THE EFFECT 0? CERTAIN PSYCHOTROPIC DRUGS ON THE URINARY EXCRETION OF 3-METHOXY-4-HYDROXYMANDELIC ACID IN MAN
3 PHARMACOL EXP THER 136, 26 (1962)
0633 MCDU??EE FO
BONE NARROW DEPRESSION AFTER DRUG THERAPY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHENATOSUS
ANN RHEUM DIS 24, 299 (1965)
0634 MOGANN 03, CARTER RE
THE EFFECT OF HENOLYSIS ON THE VAN DEN BERGH REACTION FOR SERUM BILIPUBIN
3 PEDIAT 57, 199 (1960)
0635 MCGEACHIN PL, DAUGHERTY HK, HARGAN LA, POTT2R BA
THE EFFECT OF BLOOD ANTICOAGULANTS ON SERUM AND PLASMA ANYLASE ACTIVITIES
OLIN CHIN ACTA 2 75 (1957)
0636 MOGINNISS N
0637 MCINTYRE PA
HYPOKALEMIA OCCURRING DURING PABA-AMINOSALICYLIC ACID THERAPY
DULL JOHNS HOPKINS HOSP 92, 210 (1953)
0638 NOKINNEY SE, PECK NM, BOCHEY B, BYHAN B, BEYER NH
BEN?MID, P(DI-N-PROPYLSUIYAMYL) -RENZOIO ACID
J PHARMACOL EXP THER 102, 208 (1951)
0639 MCQUEEN EG
HORMONAL STEROID CONTRACEPTIVES IV ADVERSE REACTIONS AND MANAGEMENT OF THE PATIENT
DRUGS 2, 138 (1971)
0640 MEANT A, CARTEl G
CONFRONTO TRA LA VARIZIONI DEL METABOLISNO TPYPTOFANO TO ACIDO NICOTINICO
ACTA VITAMINOL ENZY?IOL 24, 231 (1970)
O61 MEANS JH, DE GROOT U, STANBURY JR
THE THYROID AND ITS DISEASES 3RD ED
MCGRAW-HILL, NEW YORK NY (1963)
O6U2 MEHBOD H, SWARTZ CD, BREST AN
THE EFFECT OF PROLONGED THYROID ADMINISTRATION ON THYROID FUNCTION
0643 MEHTA S
THE INFLUENCE OF PREMEDICATION WITH DIAZEPAN ON THE BLOOD SUGAR LEVEL
ANAESTHESIA 26, 468 (1971)
06144 NEITES S
CALCIUM (FLUOPOMETRIC)
0645 MELTZEB H
INTRAMUSCULAR CHLORPRONAZINE AND OREATINE KINASE: ACUTE PSYCHOSIS OR LOCAL MUSCLE TRAUMA
SCIENCE 164, 726 (1969)
06146 MENCZEL 3, DREYFUSS F
IFFEOT OP PREDNISONE ON BLOOD COAGULATION TIME IN PATIENTS ON DICUMAROL THERAPY
0 LAB OLIN MED 56, 114 (1960)
0647 MEECN SHARP N DOHME
LITERATURE CONCERNING NINTEZOL, (THIABENDAZOLE, MSD)
DIVISION OF MERCK & 00 INC WEST POINT, PA 19486
0648 MERCK SHARP N DOHME
MANUFACTURER’S LITERATURE ON INDONETHACIN
DIVISION OF MERCK & 00, WEST POINT PA 19486
06149 MERIMEE TE, PINEBERG SE
STUDIES OF THE SEX-BASED VARIATION OF HUMAN GROWTH HORMONE SECRETION
0650 MERRELL-NATIONAL LABORATORIES, DIVISION OF RICHARDSON MEPRELL
MANUFACTURER’S LITERATURE ON TENUATE
CINCINNATI, OHIO 45215
0651 MERRIEL SL, DAVIS A, SMOLENS B, FINGOLD SM
CEPHALOTHIN IN SERIOUS BACTERIAL INFECTION
ANN INTERN MED 6L4, 1 (1966)
0652 NESTMAN JH, P0000K 05, KIRCHNER A
LACTIC ACIDOSIS WITH RECOVERY IN DIABETES MELLITUS ON PHENFORMIN THERAPY
CALIF NED 111, 181 (1969)
0653 METCALF MG
RAPID GAS CHRONATOGRAPHIC ASSAY FOR DEHYDROEPIANDROSTERONE IN URINE
OLIN BIOCHEM 4 241 (1971)
0654 MEYERS PH, JAWETZ E, GOLD?IEN A
REVIEW OF MEDICAL PHARMACOLOGY
LANGE, LOS ALTOS, CALIF (1968)
0655 ME!EBS BR, KAPLAN !c, WEINSTEIN L
CEPHALEXIN: MICROBIOLOGICAL EFFECTS AND PHARMACOLOGIC PARAMETERS IN MAN
0656 MEYLEP L ET AL, EDS
SID EFFECTS 0? DRUGS VOL 5 EXCERPTA MEDIOA FOUNDATION
MOUTON N 00, THE HAGUE (1966)
0657 MEYLER L, MEPXHEIMER A (EDS)
SIDE EFFECTS OF DRUGS VOL 6 EXCERPTA MEDIOA FOUNDATION
MOUTON & CO, THE HAGUE (1968)
0658 NIALE JB
LABORATORY MEDICINE - HEMATOLOGY 2ND ED
CV MOSSY CO, ST LOUIS (1962)
0659 MICHOTTE U, WAUTERS N
CLINICAL TEST OF INDONETHACIN
RHEUNATOL SCAND 10, 273 (1964)
0660 MIGEON 00
IN CIBA FOUNDATION COLLOQUIA ON ENDOCRINOLOGY VOL 8
CNU?CHILL, LONDON (1954)

0661 MIGNAULT G, LABEPQUE B, HANEL S
METHOXYFLURANE AND NEPHROTOXIOITY: A STUDY OF RENAL FUNCTION IN 22 PATIENTS ANESTHETIZED WITH NETHOXYFLURANE
CANAD ANAESTH SOC 3 17, 331 (1970)
0662 MILLAE( RA
THE FLUORINETRIC ESTIMATION OP EPINEPURINE IN PERIPHERAL VENOUS PLASMA DURING INSULIN HYPOGLYCEMIA
3 PHARMACOL EXP THEP 118, 453 (1956)
0663 MILLER SE,
A TEXTBOOK OF CLINICAL PATHOLOGY 6TH ED
06614 MILLER M
NEUPOPATHY, AGRANULOCYTOSIS AND HEPATIC TOXICITY FOLLOWING INIPRAMINE THERAPY
AMER 3 PSYCHIAT 12C, 185, (1963)
2665 MILLS PM JR
SEVERE HYPERSENSITIVITY REACTIONS ASSOCIATED WITH ALLOPURINOL
J AMER MED ASS 216, 799 (1971)
0666 MILNF MD
INFLUENCE OF ACID-BASE BALANCE ON EFFICACY AND TOXICITY OF DRUGS
PROC ROY SOC MED 58, 961 (1965)
0667 MITCHELL WD
A COMPARISON OF THE EFFECT OF OLOFIBRATE AND THYROXINE ON SERUM LIPIDS IN THREE HYPOTHYROID SUBJECTS
0668 MITCHELL WD, MUPOHINSON LE
THE EFFECT OF CLOFIBPATE ON SERUM AND FAECAL LIPIDS
0669 MITCHELL ABS
DUOGASTRONE-INDUCED HYPOKALAEMIC NEPHROPATHY AND MYOPATHY WITH MYOBLOBINURIA
0670 MIYADA DS, BAYSINGER V, NOTRICA 5, NAKAMURA PM
ALBUMIN QUANTITATION BY DYE BINDING AND SALT FRACTIONATION TECHNIQUES
OLIN OHEM 18, 52 (1972)
0671 MOROOS F, CROCKFORD PM, BECK PP
THE EFFECT OF NOPETHINDRONE WITH AND WITHOUT ESTROGEN ON SERUM INNUNOREACTIVE LUTEINIZING HORMONE SECRETION
0672 NORENO N, MURPHY C, GOLDSMITH C
INCREASE IN SERUM POTASSIUM RESULTING FROM THE ADMINISTRATION OF HYPERTONIC NANNITOL OR OTHER SOLUTIONS
J LAB OLIN MED 73, 291 (1969)
0673 MORGAN OH
JAUNDICE ASSOCIATED WITH AMITRIPTYLINE
BRIT J PSYCHIAT 115, 105 (1969)
0674 MORGAN JP, BIANOHINE OR, TAH-HSIUNG H, LASAGNA L
THE URICOSURIC AND THYROXIN (T4) DISPLACING EFFECT OF MK-185, A NEW HYPOLIPIDENIC AGENT
OLIN RES 19, 27(1971)
0675 NORSELLI PL, MARC V, GARATTINI 5, ZACCALA M
METABOLISM OF EXOGENOUS CORTISOL IN HUMANS INFLUENCE OF PHENOBARBITAL TREATMENT ON PLASMA CORTISOL
REV EUROP ETUDES OLIN BIOL 15, 195 (1970)
0676 MOSER RH
DISEASES OF MEDICAL PROGRESS 3RD ED
CC THOMAS, SPRINGFIELD ILL (1964)
0677 MOSER RH
DISEASES OF MEDICAL PROGRESS: A STUDY OF IATROGENIC DISEASE 3RD ED
CC THOMAS, SPRINGFIELD ILL (1969)
0678 MOSER RH
BIBLIOGRAPHIES ON DISEASES OF MEDICAL PROGRESS REACTIONS TO PHENOTHIAZINE AND RELATED DRUGS
0679 MOSER RH
DISORDERS PRODUCED BY PROGESTATIONAL AGENTS
OLIN PHARMAOOL TilER 7, 399 (1966)
0680 NUDGE GH
URICOSURIC ACTION OF CHOLECYSTOGRAPHIC AGENTS: A POSSIBLE FACTOR IN NEPHROTOXICITY
NEW ENGL 3 MED 284, 929 (1971)
0681 MUELLER MN, KAPPAS A
ESTROGEN PHARMACOLOGY: INFLUENCE OF ESTRADIOL AND ESTRIOL ON HEPATIC DISPOSAL OF SULFOBROMOPHTHALEIN (BSP)
3 OLIN INVEST 43, 1905 (1964)
0682 MULLER KH, HERPMANN K
VERTRAGT 51CR FINE GLEIOHZEITIGE BEHANDLUNG MIT ANTIKOAGULANTIEN UND INDOMETACIN?
MED WELT 17, 1553 (1966)
0683 NUNZENBERGER P, EMMANUEL S
THE INCIDENCE OF DRUG-DIAGNOSTIC TEST INTERFERENCES IN OUTPATIENTS
AMER 3 HOSP PHARM 28, 786 (1971)
0684 MURAKANI N, ODAKE K, MATSUDA T FT AL
EFFECTS OF ANABOLIC STEROIDS ON ANTICOAGULANT REQUIREMENTS
JAP CIRO 3 29, 243 (1965)
0685 MURPHY DL, GOODWIN FK, BUNNEY WE JR
ALDOSTERONE AND SODIUM RESPONSE TO LITHIUM ADMINISTRATION IN NAN
LANOET 2, 1458 (1969)
0686 MURRAY-LYON IN, CASSAR 3, COULSON R, WILLIAMS R, GANGULI PC, EDWARDS JO, TAYLOR KW
FURTHER STUDIES IN STREPTOZOTOCIN THERAPY FOR A MULTIPLE HORMONE-PRODUCING ISLET CELL CARCINOMA
GUT 12, 717 (1971)
0687 MUSCAT-BARON 3M, FREEMAN DM
TOXIC HEPATITIS FOLLOWING PHENYLBUTAZONE THERAPY
BRIT 3 OLIN PRACT 20, 437 (1966)
0688 NAIR PP, MEZEY E, MURTY H, QUARTNER J, NENDELOFF A
VITAMIN E AND PORPHYRIN METABOLISM IN MAN
0689 NASH 3
CURRENT THERAPEUTICS CCXLII GLYMIDINE
069C NAUMANN HN
PREVENTION OF PYRIDIUM INTERFERENCE IN URINALYSIS BY DITHIONATE REDUCTION OR BUTANOL EXTRACTION

0691 NEILL DW, CARRE 10, M000RY FL, THOMPSON PH
A POSSIBLE SOURCE OF ERROR IN THE DIAGNOSIS OF PHEOCHROMOCYTO?IA
0 OLIN PATHOL 14, Lt5 (1961)
0692 NFLSON JO, KRUEGER GG, WILCOX RB, THOMPSON WP
EFFECT OF RADI000NTEAST MEDIA ON THE NFASUPLNENI OF ADRENAL STEROIDS IN THE URINE
0693 NEWTON 3, DIXON P
SIlL OF ACTION OF OLOMIPHENE AND ITS USE AS A TEST OF PITUITARY FUNCTION
0 OBSTET GYNECOL SPIT COMM 78, 812 (1971)
694 NICHOLLS DG, HAMPTON JR MITCHELL JRA
CYCLICAL CHANGES IN PLASMA-LYSOLECITHIN INDUCED BY ORAL CONTPACPTIV2S
LANCET 2, 1428 (1971)
0695 NIELSEN MD, BINDER C, STARUP 0
LIRINARY EXCRETION OF DIFFERENT CORTIOOSTEPOID NETAROLIT2S IN ORAL CCNTRACPTION AND PREGNANCY
ACTA ONDOCRINOL 60, 473 (1969)
696 NILSSON KO, HOKFELT B
INFLUENCE OF NETYRAPONE ON PLASMA CONCENTRATIONS OF TESTOSTERONE AND ANDROSTERIDIONE IN MAN
0697 NIZET A
ANTAGONISTIC ACTION OF UPACIL, THIOURACIL AND THIOUPEA ON RETICULOCYTE RIPENING
SCIENCE 115, 290 (1952)
0698 N030IN PC, BRADFORD LG, OSMET LS
MONITORING NETHOTPEXATE THERAPY IN PSORIARIS
ARCH DERNATOL 101, 646 (1970)
0699 NORDIN BEC
THE EFFECT OF INTRAVENOUS PARATHYPOID EXTRACT ON URINARY PH, BICARBONATE AND ELECTROLYTE EXCRETION
CLIN 501 19, 311 (196C)
070C NOSAL I, KISER ML, ROBITAILLE ML, KING 3W
URINARY ALKALINE PHOSPHATASE AND LACTIC DEHYDROGENASE ACTIVITY IN THE DIAGNOSIS OF UROLOGIC NEOPLASMS
OLIN CHEM 12, 542 (1966)
0701 NOSSLIN B
BPOMSULPHTHALEIN RETENTION N JAUNDICE DUE TO UNCONJUGATED BILIRURIN FOLLOWING TREATMENT WITH MALE FERN EXTRACT
SCAND 3 OLIN LAB INVEST SUPPL 15, 69 (1963)
0702 NOUPOK DS
HYPOT HYROIDIS N FOLLOWI NG PROLONGED SODI UN NITORPRUSSIDE THERAPY
ANER 0 MED 501 2148, 129 (19614)
0703 NUMPROFF N, PERLNUTTPR N, SLATER S
FALSELY ELEVATED VALUES FOR URINARY 17-KETOSTEROIDS AND 17-HYDROXYCORTIOQIDS
3 OLIN EN000RINOL 19, 1350 (1959)
C74 O’SHEA NJ, FLUTE PT, PANNELL GM
LABORATORY CONTROL OF HEPAPIN THERAPY
3 OLI’ PATHOL 24, 542 (1971)
07D5 OETTGEN HF, STEPHENSON PA, SCHWARTZ MN, LEEPER RD, TALLAL L, TAN CC, CLARKSON RD IT AL
TOXICITY OF F COLI L-ASPARGINASE IN NAN
CANCER 25, 253 (1970)
07C6 OLIVA PB
LACTIC ACIDOSIS
AMER J NED 48, 2E9 (197C)
0727 OLIVER ME, ROBERTS SD, HAYES D FT AL
EFFECT OF ATROMID AND ETHYL CHLOPOPHENOXYISOBUTYRATE ON ANTICOAGULANT RQUIRENNTS
LANCET 1, 143 (1963)
07C8 OGANON INC
MANUFACTURER’S LITERATURE ON DURABOLIN
375 MOUNT PLEASANT AVE, WEST ORANGE NJ 07052
07:9 OPOSZ L, MICHAEL R, ZIEGLER N
SERUM-INSULIN OR PLASMA-INSULIN
LANCET 2, 119 (1971)
0710 OWEN WC, KBEISBERG RA, SIEGAL AM
CARBOHYDRATE INDUCED HYPERTRIGLYOERIDEMIA: INHIBITION 3Y PHENFORNIN
DIABETES 20, 739 (1971)
711 OYAKE H, ISONO 1, KUDO N
A CASE 0? AGRANULOCYTOSIS POSSIBLY DUE TO AMINOBENZYL PENICILLIN
IBYC 22, 676 (1968)
3712 OYAMA, T TAKAZAWA T
EFFECTS OF HALOTHANE ANESTHESIA AND SURGERY ON HUMAN GROWTH HORMONE AND INSULIN LEVELS IN PLASMA
B?IT J ANAESTH 43, 573 (1971)
0713 PACKMAN BC, O’NEAL LW, WESSLER 5, AVIOLI LV
PHEOCHROMOCYTOMA
J AMER NED ASS 212, 780 (1970)
714 PAGE LB, DESSAULLES, 3, LAGG 5, HABER E
INTERFERENCE WITH IMNUNOASSAYS OF ANGIOTENSIN I AND II BY PROTEINS IN HUMAN PLASNA
715 PAINE D
FATAL HEPATIC NECROSIS ASSOCIATED WITH ANINO-SALICtLIC ACID: REVIEW OF LITERATURE AND REPORT OF CASE
3 AMER MED ASS 167, 286 (1958)
0716 PALVA IP, HEINIVAARA 0, MATTILA N
DRUG INDUCED MALA3SOPPTION OF VITAMIN B12. III INTERFERENCE OF PAS AND OLIC ACID
ANN NED INTERN PENN 5, 37 (1965)
717 PAOLETTI F, JUAN A, VAZQUEZ J, WOLF PL
POSITIVE PREGNANCY TEST IN AN 82 YEAR-OLD-WOMAN.
AMER 0 MED 501 252, 57 (1966)
0718 PAPAVASILIOU PS, COTZIAS GO, DUBY SE, STICK A?, FEHLING C, BELL MA
LEVODOPA IN PARKINSONISM: POTENTIATION OF CENTRAL EFFECTS WITH A PERPHERAL INHIBITOR
NEW LNGL 0 NED 286, 8 (1972)
0719 PARDtJE WO
SEVERE LIVER DYSFUNCTION DURING NICOTINIC ACID THERAPY
0 AMER NED ASS 175, 137 (1961)
0720 PAPFITT AM
OHLOROTHIAZIDE INDUCED HYPERCALEMIA IN JUVENILE OSTEOPORESIS AND HYPERPARATHYBOIDISM
NEW ENGL 3 MED 281, 55 (1969)

0721 PkPSONS WU JR
EFFECT OF NICOTINIC ACID ON SERUM LEVELS OF cHOLESTEROL, TRIGLYCERIDES, GLUCOSE AND URIC ACID
OIECULATION 38, StJPPL 6 1513 (1968)
0722 PAS A, QUINN EL
CHOLESTATIO HEPATITIS TOLLOWING TH ADMINISTRATION OF SODIUM OXACILLIN
J AME? NED ASS 191, 674 (1965)
023 PATHY NS
THE USE, ACTION AND SIDE EFFECTS OF DIURETICS
GRONTOL OLIN 13, 261 (1971)
0724 PAIJLUS HE,COUTTS A, CALABRO JJ, KLINENBERG JR
CLINICAL SIGNIFICANCE C? HYPEPURICEMIA IN ROUTINELY SCREENED HOSPITALIZED MEN
J AMER MED ASS 211, 277 (1970)
0725 PAWAN GLS
METABOLIC EFFECTS OP 5992 IN MAN
S APR MED J SUPPL L&5, 23 (1971)
0726 PAYNE P
SERUM URIC ACID AND PHENOTHIAZINES
LANCET 2, 855 (1969)
0727 PEARSON AJG, GRAINGEP JM, SCHEUR P3, MCINTYRE N
JAUNDICE DUE TO OXYPHRNISATIN
LANCET 1, 9914 (1971)
0728 PEARSON JR, BINDER CI, NEBER 0
AGRANULOOYTOSIS FOLLOWING DIAMOX THERAPY
J AME? MED ASS 157, 339 (1955)
0729 PELLETIEP 0
SMoKING AND VITAMIN C LEVELS IN HUMANS
AMER J CLIN NUT? 21, 12514 (1968)
0730 PERKINS JR
EFFECTS O LIGHT ON THE DETERMINATION OF CITRULLINE
0731 PE?RY NM JP, SAKAMATO A, TAN EM
RELATIONSHIP OP AO?TYATING ENZYME TO HYDRALAZINE TOXICITY
0 LAB OLIN MED 70, 1020 (1967)
0732 PETRUCCI JV, DUNNE PA, CHAPMAN 00
SPURIOUS ERYTHROCYTE INDICES AS MEASURED BY THE MODEL S COULTE? COUNTER DUE TO COLD AGGLUTININS
0733 PFIZER INC
MANUFACTURER’S LITERATURE ON DIABINASE
235 EAST 42ND SF, NEW YORK NY 10017
0734 PFIZER INC
PRODUCT INFORMATION (VIBRANYCIN)
235 EAST 42ND ST, NEW YORK NY 10017
0735 PHILLIPS I
CLINICAL USES AND CONTROL O RIFANPICIN AND CLINDANYCIN
J OLIN PATHOL 24, 1410 (1971)
0736 PiIILP JR
UNTOWARD EFFECTS OF ANTIMICROBIAL DRUGS PREVENTION AND CONTROL
POSTGPAD NED 50, 193 (1971)
0737 PIFROP C
ASSAYS AND IMPORTANCE OF SEPOTININ AND ITS METABOLITES
AMER J OLIN PATHOL 30, 230 (1958)
0738 PILEGGI VJ, SFGAL HA, LANCHANTIN GF
THE EFFECT OF SULFORRONOPHTHALEIN ON SERUM PBI, BET AND THYROXINE IODINE
0739 PILEWSKI RN, SOHEIB PT, MISAGE OR, KESSLER F, KRIFCHER E, SHAPIRO AP
TECHNIQUE OF CONTROLLED DRUG ASSAY IN HYPERTENSION. V COMPARISION OP HYDROCHLOROTHIAZIDE WITH A NEW QUINETHAZON
0740 PINES A, PAA?AT N, SIDDIQUI GM
RIFAMPICIN AND ETHAMBUTOL IN THE TREATMENT OF DRUG RESISTANT AND PAP ADVANCED PULMONARY TUBERCULOSIS
0 IRISH NED ASSOC 63, 82 (1970)
0741 PISCIOTTA AV
GRANULOOYTOSIS INDUCED BY CERTAIN PHENOTHIAZINE DERIVATIVES
J AMER MED ASS 208, 1862 (1969)
0742 PITNEY W?, OAKLEY CM, GOODWIN OF
THERA?EUTIC DEFIBRINATION WITH ANCROD (ARVIN)
AMER UFART 0 80, 144 (1970)
0743 PITTINGER C, CHANG PM, FAULKNER W
S1RUM IONIZED OALCIUN:SOME FACTORS AFFECTING ITS LEVEL
SOUTH NED J 64, 1211 (1971)
0744 PLATNAN SF, FIEVE PR
LITHIUM CARBONATE AND PLASMA COPTISOL RESPONSE IN THE AFFECTIVE DISORDERS
ARCH GEN PSYCHIAT 18, 591 (1968)
0745 POILLFUX F, LENERCIER N
USE 0? THE NEW ANTIBIOTIC GENTANYOIN IN SURGERY
PRESSE NED 75, 611 (1967)
07146 POLLCP L, THOMSON ON, THOMAS W
OPSIROGEN/PROGESTOGEN ORAL CONTRACEPTION AND BLOOD CLOTTING: A LONG-TERM FOLLOW-UP
BRIT MED J 14, 648 (1971)
O74 PONIKOWSKA I
BLOOD PATTERNS OF FREE FATTY ACIDS IN HEALTHY SUBJECTS AND DIABETICS UNDER INSULIN, GLUCOSE AND TOLBUTAMIDE
POL ARCH MED WEWN 45, 71 (1970)
0748 POOLE G, STRADLING P, WORLLEDGE S
?OTENTIALLY SERIOUS SIDE-EFFECTS OF HIGH-DOSE TWICE-WEEKLY PIFANPIOIN
POSTGPAD MED 0 47, 7L2 (1971)
O79 POTTER JL, WEINBERG AG, WEST P
AMPICILLINURIA AND AMPICILLIN CRYSTALLUPIA
PEOIATPICS 48, 636 (1971)
0750 POWELL 33, DJUH YY

A CINPARISON OF AUTOMATED METHODS FOP GLUCOSE ANALYSIS IN PATIENTS WITH UREMIA BEFORE AND AFTER DIALYSIS
AMP? 0 OLIN PATHOL 56, 8 (1971)
CLINICAL”YF’ .#{149}
,
0751 PRETTY NM, GOSSELIN G, OOLPRON G, LONG LA
AGRANULOCYTOSIS: A REPORT OF 30 OASES
CANAD NED ASS 3 93, 1058 (1965)
0752 PRICE NL
CIPCULATING ADRENALINE AND NORADRENALINE DURING DIETHYL-ETHER ANAESTNSIA IN MAN
OLIN SOT 16, 377 (1957)
0753 PROCTOR FA, BARTON FL
POLYOBIC ACUTE RENAL FAILURE AFTER METHOXYFLURANE AND TETRACYCLINE
BRIT MED 3 4, 661 (1971)
0734 PRO?? RP, STILLMAN JS
AGRANULOCYTOSIS AND HYDROXYOHLOROQUINE
NEW ENGL J MED 277, 492 (1967)
0755 PUL’KINEN NO, WILLMAN K
SERUM INORGANIC PHOSPHATE DUPING OPAL CONTRACEPTIVE THERAPY
ANN CHIP GYNEC FENN 57, 172 (1968)
0756 PYBUS 3, BOWERS GN JR
SERUM LITHIUM DETERMINATION BY ATOMIC ABSORPTION SPECTROSCOPY
0757 QUAGLIANA 3M
EFFECT OF TOPICAL POVIDONE-IODINE (BETADINE) ON SERUM PROTEIN-BOUND IODINE
0758 RAAB WP
THE DIAGNOSTIC VALUE OF URINARY ENZYME DETERMINATIONS
OLIN 011KM 18, 5 (1972)
0759 PABINOWITZ D, MERINEF TO, NELSON 3K, SCHULTZ RB, BURGESS JA
IN GROWTH HORMONE INTERNATIONAL CONGRESS SERIES NO 158,
PECILE A, MULLER E! (EDS) EXCERPTA MEDICA FOUNDATION, AMSTERDAM (1968)
0760 RACE TT, PARS IC, FALOON WW
INTESTINAL MALABSORPTION INDUCED BY ORAL COLCHICINE COMPARISON WITH NEOMYCIN AND CATHARTIC AGENTS
AMER 3 NED Sd 259, 32 (1970)
0761 RADCLIFP P3, WILTON NM, DONNELLY GL
CLOPAMIDE (BRINALDIX), A NEW DIURETIC AGENT: DURATION OF ACTION AND DOSAGE RESPONSE
CURRENT THERAP RES 10, 103 (1968)
0762 PAMSAY ID
CARBAMAZEPINE-INDUOED JAUNDICE
BRIT MED 3 4, 155 (1967)
0763 PA?OPOPT S FT AL
HYPOPROTHROMBINEMIA AFTER SALICYLATE ADMINISTRATION IN NAN AND RABBITS
PROC SOC EXP BIOL NTD 53, 40 (1943)
0764 PECHENBERG MN
PHENYLBUTAZONE
EDWARD ARNOLD LTD LONDON (1962)
0765 REEVES DS
SULFAMETHOXAZOLE/TRIMETHOPRIM: THE FIRST TWO YEARS
3 OLIN PATHOL 24, 430 (1971)
0766 REINER N, CHEUNG HL
XYLOSE
0767 PEINHAPD’T DJ III, TAUSIG I, ALVAREZ B
SERUM CHOLESTEROL ELEVATION WITH TRIPLUORPERAZINE (STELAZINE) THERAPY
DELAWARE MED 3 34, 318 (1962)
0769 PEINKEN L, HOHENAUER L, ZIEGLER EE
ACTIVITY OF RED CELL GLUTAMIC OXALOACETIC TRANSAMINASE IN EPILEPTIC CHILDREN UNDER ANTIEPLETIC TREATMENT
CLIN CHIN AOTA 36, 270 (1972)
0769 REIO L, WETTERBEPG L
FALSE PORPHOBILINOGEN PEACTIONS IN THE URINE OF MENTAL PATIENTS
J AMER NED ASS 207, 148 (1969)
0770 REISS E, CANTERBURY 3M, BEPCOVITZ MA, KAPLAN EL
POLE OF PHOSPHATE IN THE SECRETION OF PARATHYROID HORMONE IN MAN
3 OLIN INVEST 49, 2146 (1970)
0771 REMP DG
URIC ACID (URICASE)
0772 RENNIF 1DB, KEEN H
EVALUATION OF CLINICAL METHODS FOR DETECTING PROTEINURIA
LANOET 2, 489 (1967)
0773 PEUBI PC, VORBUGER C, BUTIKOFER F
A COMPARISON OF THE SHORT-TERN AND LONG-TERM HAENODYNAMIC EFFECT OF ANTIHYPERTENSIVE DRUG THERAPY
IN CATAPRES IN HYPERTENSION, CONOLLY ME (ED) BUTTERWOPTH, LONDON (1970)
074 REYNOLDS TB, PELLE HO
EFFECTS OF A NEW DIURETIC ANIPRAMIDINE (MK 870) IN PATIENTS WITH CIRRHOSIS AND ASOITES
OLIN RES 14, 1814 (1966)
0775 REYNOLDS EN, MILNEP G, MATHEWS DM, CHANARIN I
ANTICONVULSANT THERAPY, MEGALOBLASTIC HAENOPOIESIS AND FOLIO ACID METABOLISM
QUART 3 MED 35, 521 (1966)
0776 REYNOLDS TB, PETERS RL, YAMADA S
CHRONIC ACTIVE AND LUPOID HEPATITIS CAUSED BY A LAXATIVE, OXYPHENISATIN
NEW ENGL 3 NED 285, 513 (1971)
0777 RICE EW, LUKASIEWICZ DR
INTERFERENCE OF BROMIDE IN ZAK FEOL3 SULFURIC ACID CHOLESTEROL METHOD AND MEANS OF ELIMINATING THIS INTERFERENCE
OLIN CHEM 3, 160 (1957)
0778 RICHARDS NO, BORGSTEDT HH
NEAR FATAL REACTION TO INGESTION OF THE HALLUCINOGENIC DRUG NDA
3 AMER MED ASS 218, 1826 (1971)
0779 RICMTERICH B
CLINICAL CHEMISTRY - THEORY AND PRACTICE
KARGER, BASEL 1969
0780 RIDDOCH D
GASTPITIS AND L-DOPA
SPIT lIED 3 1, 53 (1972)
- 1294 CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

0781 ROBBINS PC, HARBIN 3E JR
THE IN VITRO SENSITIVITY OP ERYTHROCYTE AGGREGATION TO QUININE
OLIN CHEN 17, 31 (1971)
0782 ROBERTSON NRC
APNOEA AFTER THAN ADMINISTRATION IN THE NEWBORN
ARCH 015 CHILD 145, 206 (1970)
0783 ROBERTSON DM, NESTER 3, KELLIE AE
THE MEASUREMENT OF OESTRADIOL AND PROGESTERONE IN PLASMA FROM NORMAL, INFERTILE AND OLOMIPHENE TESTED WOMEN
0784 ROBINS NM
APLASTIC ANEMIA SECONDARY TO ANTICONVULSANTS
AMER J 015 CHILD 104, 614 (1962)
0785 ROBINSON AG, LOEB JN
ETHANOL INGESTION- COMMONEST CAUSE OF ELEVATED PLASMA OSNOLALITY?
NEW ENGL 3 MED 284, 1253 (1971)
0786 ROBINSON PG
INDONETHACIN IN RHEUMATIC DISEASE - A RE-ASSESSMENT
MED 3 lUST 1, 971 (1966)
0787 ROBINSON OS, SYLVESTER D
INTERACTION OF COMMONLY PRESCRIBED DRUGS AND WAPEAPIN
0788 ROCHE LABORATORIES
ROCHE LABORATORIES ADVERTISEMENT: DATA ON FILE
MEDICAL DEPARTMENT, HOFFMAN-LAROCHE INC (1971)
DRUG INFORMATION CIRCULAR ON VALIUM (DIAZEPAM)
ROCHE LABORATORIES, NUTLEY NJ 07110
NANU FACTURER ‘ S LITERATURE ON GANTRISIN
DIVISION 0? HOFFMAN-LA RCOHE INC
0791 ROE DA
DRUG-INDUCED DEFICIENCY OF B VITAMINS
NEW YORK STATE 3 MED 71, 2770 (1971)
0792 ROENIGK NH, GOTTLOB ME
ESTROGEN-INDUOED PORPHYRIA CUTANEA TARDA
ARCH DERMATOL 102, 260 (1970)
0793 RONNOV-JESSEN V, TJEPNLUND A
HEPATOTOXICITY DUE TO TREATMENT WITH PAPAVEPINE REPORT OF FOUR CASES
NEW ENGL 3 MED 281, 1333 (1969)
0794 ROSALKI SB, RAU D, LEHMANN D, PRENTICE N
DETERMINATION OF SERUM GAMMA-GLUTAMYL TRANSPEPTIDASE ACTIVITY AND ITS CLINICAL APPLICATIONS
ANN OLIN BIOCHEN 7, 143 (1970)
0795 ROSALKI SB, TARLOW D, PAU D
PLASMA GANMA-GLUTAMYL TRANSPEPTIDASE ELEVATION IN PATIENTS RECEIVING ENZYME-INDUCING DRUGS
LANCET 2, 376 (1971)
0796 ROSE DP, CRAMP DG
REDUCTION OF PLASMA TYROSINE BY ORAL CONTRACEPTIVES AND ESTROGENS:A POSSIBLE CONSEQUENCE OP TYROSINE AMINO-TRANS
0797 ROSE PG
PARACETAMOL OVERDOSE AND LIVER DAMAGE
BRIT NED 3 1, 381 (1969)
0798 ROSNEB 3M, CONTE N?
EVALUATION OF TESTICULAR FUNCTION BY MEASUREMENT OF URINARY EXCRETION OF TESTOSTERONE
3 OLIN ENDOORINOL 26, 735 (1966)
0799 ROSS AR, SHERLOCK S
A CONTROLLED TRIAL 0? AZOTHIOPRINE IN PRIMARY BILIARY CIRRHOSIS
GUT 12, 770 (1971)
0800 ROSS G, WEINSTEIN I, KABAKOW B
THE INFLUENCE OF PHENOTHIAZINE AND SOME OF ITS DERIATIVES ON THE DETERMINATION OF 5-HYDROXYINDOLEAOETIO ACID
OLIN OHEM 4, 66 (1958)
0801 ROTHSTEIN E
WARFARIN EFFECT ENHANCED BY DISULFIPAM
3 AMER MED ASS 206, 1574 (1068)
0802 ROUTH 31, BANNOW RE
DEVELOPMENT OF A SCREENING TEST FOR L-DOPA AND ITS METABOLITES IN URINE
CLIN OHEM 17, 872 (1971)
0803 RUBENSTEIN AN, LOWY C, WELBORN TA, FRASER TR
URINE INSULIN IN NORMAL SUBJECTS
0804 RUBULIS A, RUBERT N, FALOON WW
CHOLESTEROL LOWERING, FECAL BILE ACID AND STEPOL CHANGES DURING NEOMYCIN AND COLOHICINE
AMER 3 OLIN NUTP 23, 1251 (1970)
0805 RUEDY 3, DAVIES P0
A COMPARATIVE CLINICAL TRIAL OF GUANOXAN AND GUANETHIDINE IN ESSENTIAL HYPERTENSION
OLIN PHAPMACOL THEP 8, 38 (1967)
0806 RUSSELL AS, STURGE RA, SMITH MA
SERUM TRANSANINASES DURING SALICYLATE THERAPY
BRIT NED 3 2, 1428 (1971)
0807 RYAN OF, KAGEN U, HYN” Al
NYOGLOBINEMIA AFTER A SINGLE DOSE OF SUCCINYLOHOLINE
NEW ENGL 3 MED 285, 824 (1971)
0808 RYAN OR, NAHA GE, NCNAHON FG, KYRIAKOPOULOS A
EFFECTS OF A NEW ORAL HYPOGLYCEMIC AGENT ON GLUCOSE AND INStILIN AFTER ORAL GLUCOSE LOADING
DIABETES 20, 734 (1971)
0809 RYAN JR, GOMEZ-PEREZ F, JAIN A, MAHA G, MOMAHON FG
METABOLIC AND EFFICACY STUDIES OF MK-27O, A NEW ORAL HYPOGLYCEMIC AGENT
OLIN PHARMACOL THEP 13, 151 (1972)
0810 RYLANOE NJ, MYHAL DR
TAURINE EXCRETION AND THE INFLUENCE OF DRUGS
CLINICAL CHEMISTRY. Vol. 18. Nn in 1Q79 14

0811 SABATER 3, FERRE C, MAYA A
p MISLEADING FINDING IN URINE ELECTROPHORESIS
LANCET 2, 316 (1971)
0812 SACRE NH, WALKER G
EPPROT OF CLOPIBRATE ADMINISTRATION ON THE URINARY VANILMANDELIC ACID METHOD OF PISANO ET AL
0813 SAPED-UZ-ZAFAR N, MILLER ON, BRENEMAN GM, MANSOW J
OBSERVATIONS ON THE EFFPCT OF HEPARINS ON FREE AND TOTAL THYROXINE
0814 SAGONE AL, LAWRENCE T, BALC?ZAK SP
SMOKING - A CAUS! OF ‘SPURIOUS’ POLYCYTHEMIA
BLOOD 38, 826 (1971)
0815 SAHEBJAMI H, SCALETTAR P
EFFECTS OF FRUCTOSE INFUSION ON LACTATE AND URIC ACID METABOLISM
LANCET 1, 366 (1971)
0816 SALVESEN 5, NISSEN-MEYER B
INPLUENCE OF NEPPOBANATE THERAPY ON THE ESTIMATION OF 17-KETOSTEROIDS AND 17-KETOGENIC STEROIDS
0817 SANOLS E, MAR.81 G, MARKS V
PROMOTION OF INSULIN SECRETION BY GLUCAGON
LANOET 2, 415 (1965)
0818 SAMUEL P, SHALOHI OR, HOLTZMAN CM
REDUCTION OF SE?UN CHOLESTEROL CONCENTRATIONS BY PAROMONYCIN IN PATIENTS WITH ARTERIOSCLEROSIS
0819 SANDLEB N, KAPOUN F, RUTHVEN OR
METABOLISM OF DOPA IN PARKINSONISM
NEW ENGL 3 MED 281, 1429 (1969)
0820 SANTEN RJ, LEONARD 3M, SHERINS P3, GANDY HN, PAULSEN CA
SHORT AND LONG-TERM EFFECTS OF CLONIPHENE CITRATE ON THE PITUITARY-TESTICULAR AXIS
0 OLIN ENDOOPINOL 33, 970 (1971)
0821 SAPIRA 3D, KLANIECKI T, RATNIN G
“NON-PHEOCHROMOCYTON A”
3 AMER MED ASS 212, 22143 (1970)
0822 SASAKI N, SHUNUPA N, HARIGUCHI T, NAKAJINA H
EFFECT OF CELLULOSE ACETATE RESIN USED AS A CONTAINER IN TRIOSORB AND TETRASORB TESTS
HORONAN TO PINSHO 18, 666 (1970)
0823 SAVEGE TM, FOLEY El, 000LTAS P3, WALTON B, STRUNIN L, SIMPSON BR, SCOTT DF
CT 1341: SOME EFFECTS IN NAN
ANAESTHESIA 26, 402 (1971)
0824 SAWIN CT
MEASUREMENT OF PLASMA COPTISOL IN THE DIAGNOSIS OF CUSHING’S SYNDROME
0825 SAX SM, MOORE JJ
GLUTAMIC OXALOAOETIO TRANSAMINASE (COLORINETRIC)
STAND NETH OLIN CHEM 6, 149 (1970)
0826 SOHA?FNEP F, POPPER H, CHESPOW E
c:WLESTASIS PRODUCED BY ADMINISTRATION OF NORETHANDPOLONE
AMER 3 MED 26, 2L9 (1959)
0827 SOHATZ , PALTER NC, RUSSELL OS
EFFECT OF ORAL CONTRACEPTIVES AND PREGNANCY ON THYROID FUNCTION
CANAD MET) ASS 3 99, 892 (1958)
0828 SCHATZ DL, SHEPPARD PH, STEIN?? G, CHANDARLAPATY CS
INFLUENCE OF HEPARIN ON SERUM FREE THYROXINE
0829 SCHENKER JG, REN-YOSEPH Y, SLiAPIRA E

ERYTHROCYTE CARBONIC ANHYDRASE B LEVELS DUPING PREGNANCY AND USE OF ORAL CONTRACEPTIVES
OBSTET GYNECOL 39, 237 (1972)
0830 SCHINDLER AR, RATANASOPA V, HERRMANN WL
ACID HYDROLYSIS OF URINARY ESTRIOL
CLIN CHEM 13, 136 (1967)
0831 SCHLENZKA , STRECKENBACH K
EFFECT OF WASHING AGENTS ON THE FEPRIC CHLORIDE TEST FOR PHENYLKETONUPIA
DEUT GESUNDHEITSW 25, 1497 (1970)
0832 SCHNTEWEISS 0, POOLE GW
HYPERURICEMIA DUE TO PYRAZINAMIDE
EPIT MED 3 2, 830 (1960)
0833 SOHOENFIELD U, MCGILL OR, FOULK WT
STUDIES OF RSP METABOLISM IN NAN, DEMONSTRATION OF A TRANSPORT MAXIMUM FOR BILIARY EXCRETION
J OLIN INVEST 43, 11424 (196U)
08311 SOHOENFIELD U
SUL?OBROMOPHTHALEIN TRANSPORT AND METABOLISM
0835 SOHRIER RW, LIEBERM-AN R, UFFERMAN PC
MNCHANISM OF ANTIDIURETIC EFFECT OF BETA ADRENEPGIC STIMULATION
0 OLIN INVEST 51, 97 (192)
0836 SOHROGIE JO, HOLT P, HARTLEY PC, BARTHOLOMEW G
“HISTAMINE INDUCED” PANCREATITIS
GASTROENTEPOLOGY 49, 672 (1965)
0837 SCNFOGIE JO, SOLOMON HM
THE HYPOCHOLESTEROLEMIC EFFECT OP PHENYRANIDOL
OLIN PHARMACOL ThER 7, 723 (1966)
0838 SCHULTZ AL
INFLUENCE OF DRUGS ON THYROID I 131 UPTAKE AND SERUM CHEMICAL PROTEIN-BOUND IODINE
POSTGRAD NFD 31, A-34 (1962)
0839 SCHWARTZ MN,
INTERFERENCES IN BIOCHFNICAL TESTS
MEN SLOAN-KETTERING OLIN BULL 1, 11 (1971)
0840 SCHWARTZ TO, PILLAY VKG, KASK RN
ETHACRYNIC ACID: ITS USEFULNESS AND UNTOWARD EFFECTS
AMER HEART 3 79, 42 (1970)

C841 SCHWAPZE R, KINTZEL HW, HINKEL GK
THE INFLUENCE OF OROTIC ACID ON THE SERUM BILIRUBIN LEVEL OF MATURE NEWBORN
ACTA PAED SCAND 60, 7C5 (1971)
0842 SCOMMEGNA A, LASH SR
OVARIAN OVEPSTINULATION, MASSIVE ASCITES, AND SINGLETON PREGNANCY AFTER CLOMIPHENE
3 AMER NED ASS 207, 753 (1969)
0843 SCOTT JT, HALL AP, GRAHAME R
ALLOPURINOL IN TREATMENT OF GOUT
BRIT MED 3 2, 321 (1966)
0844 SCOTT JT, PORTER TN, LEWIS SM, DIXON AS3
STUDIES OF GASTROINTESTINAL BLEEDING CAUSED BY CORTICOSTEROIDS, SALICYLATES AND OTHER ANALGESICS
QUART J MED 30, 167 (1961)
08145 SCURRY NT, BRUTON 3, BARRY KG
THE EFFECT OF OHORIONIC GONADOTROPIN ON STEROID EXCRETION
0846 SEANONDS B, TOWFIGHI 3, ARVAN DA
DETERMINATION OF IONIZED CALCIUM IN SERUM BY USE OF AN ION-SELECTIVE ELECTRODE
OLIN OHEM 18, 155 (1972)
0847 SEDDON P3
HORMONAL STEROID CONTRACEPTIVES, 1) PHYSIOLOGICAL AND PHARMACOLOGICAL CONSIDERATIONS
DRUGS 1, 399 (197C)
0848 SEINFELD F, STARR P
STUDIES OF THYROID FUNCTION IN PATIENTS TREATED WITH PARA-AMINOSALICYLIC ACID AND ISONIAZID
AMER REV RESP DIS 8C, 8145 (1959)
0849 SEITZ H, JAWORSKI ZF
EFFECT OF HYDROOMLOROTHIAZIDE ON SERUM AND URINARY CALCIUM AND URINARY CITRATE
CANAD MED ASS 3 90, 414 (1964)
0850 SELLERS EN, KOCH-WESER J
DISPLACEMENT OF WARFARIN FROM HUMAN ALBUMIN BY DIAZOXIDE AND ETHACRYNIC, MEFENAMIC AND NALIDIXIC ACIDS
OLIN PHARMACOL THEE 11, 5214 (1970)
3851 SELLERS EM, LANG ML, KOCH-WESER J
POTENTIATION BY TRIOHLOPOETHYLPHOSPHATE OF WARFARIN INDUCED HYPOPPOTHROMBINEMIA
OLIN PHARMACOL THEB 13, 152 (1972)
0852 SEN 5, MUKER3EE AB
HYPOGLYOAEMIO ACTION OF OXYTETRACYOLINE
J INDIAN MED ASSOO 52, 366 (1969)
0853 SETTLAGE DF, NAKAMURA RN, DAVAJAN V, KHARNA K, MISHELL DR
A QUANTITATIVE ANALYSIS OF SERUM PROTEINS DURING TREATMENT WITH OPAL CONTRACEPTIVE STEROIDS
CONTRACEPTION 1, 1C1 (1970)
08514 SHAFFNER F
DIAGNOSIS OF DRUG-INDUCED HEPATITIC DAMAGE
J AMER MED ASS 191, 466 (1965)
C855 SHAH S
HEPATOTOXICITY DUE TO PAPAVERINE HYDROCHLORIDE
NEW ENGL 3 MED 282, 1271 (1970)
0856 SHARP P, RILEY C, COOK JGH, PINK PJF
EFFECT OF TWO SULPHONYLUREAS ON GLUCOSE DETERMINATIONS BY ENZYMIC METHODS
0857 SHAW DM
ANTI-DEPRESSANT DRUGS
0858 SHAW KNF, TREVARTHEN 3
EXOGENOUS SOURCES OF URINARY PHENOL AND INDOLE ACIDS
NATURE 182, 797 (1958)
0859 SHAY H, SIPLET H
STUDY OF OULORPRONAZINE JAUNDICE: MECHANISM 6 PREVENT: SPEC REF TO SERUM ALK PHOSPHATASE & SGOT
0860 SHELP WD, BLOODWORTH 3MB JR, RIESELBACH RE
EFFECT OF AZATHIOPRINE ON RENAL HISTOLOGY AND FUNCTION IN LUPUS NEPHRITIS
0861 SHERLOCK S
HALOTHANE HEPATITIS
GUT 12, 324 (1971)
0862 SHERLOCK S
EFFECTS OF DRUGS ON THE LIVER
ANN OLIN BIOCHEM 7, 75 (1970)
0863 SHERMAN HO, OALDWELL ML, ADAMS N
A QUANTITATIVE COMPARISON OF THE INFLUENCE OF NEUTRAL SALTS ON THE ACTIVITY OF PANCREATIC AMYLASE
J AMER OHEM SOC 50, 2538 (1928)
0864 SHERMAN 3D LOVE DE, HARPINGTON OF
ANEMIA, POSiTIVE LUPUS AND RHEUMATOID FACTORS WITH METHYLDOPA! A REPORT OF THREE CASES
ARCH INTERN MED 12C, 321 (1967)
0865 SHERMAN L, KIM 5, BENJAMIN F, KOLODNY liD
EFFECT OF CHLORPROPIAZINE ON SERUM GROWTH HORMONE CONCENTRATION IN MAN
NEW FNGL 3 NED 284, 72 (1971)
0866 SHERWOOD LM
RYPERNATREMIA DUPING SODIUM SULFATE THERAPY
NEW ENGL J NED 277, 314 (1967)
0867 SHILS NE
INTERFERENCE BY FORNALDEHYDOGENIC DRUGS IN THE QUANTITATIVE DETERMINATION OF URINARY HYDROXYINDOLACETIC ACID
OLIN CHEM 13, 397 (1967)
0868 SHOJANIA AM, HORNADY GO, BARNES PH
THE EFFECT OF ORAL CONTRACEPTIVES ON FOLATE METABOLISM
0869 SHOPSIN B, FPIEDMANN R, GERSHON S
LITHIUM AND LEU000YTOSIS
OLIN PHARMACOL TilER 12, 923 (1971)
0870 SHOPSIN B
EFFECTS OF LITHIUM ON THYROID FUNCTION A REVIEW
DIS NERV SYST 31, 237 (1970)

0871 SHURTLEFF DR, HAYDEN PW
THE TREATMENT OF HYDROOEPHALUS WITH ISOSORBIDE, AN ORAL HYPEBOSMOTIC AGENT
J OLIN PHARM 12, 108 (1972)
2872 SHUSTER F, NAPIER EA, HENLEY KS
SERUM TRANSAMINASE ACTIVITY FOLLOWING MORPHINE, MEPEBIDINE, AND CODEINE IN NORMALS
AMER 3 MED 501 246, 71i4 (1963)
0873 SIMPSON W
SEVERE MEGALOBLASTIC ANEMIA INDUCED BY PHENYTOIN SODIUM
OPAL SURGERY 22, 302 (1966)
0874 SIMPSON NM JR
ORAL CONTRACEPTIVES AND UNTOWARD EFFECTS COINCIDENT WITH THEIR USE
SOUTH NED 3 64, 1184 (1971)
0875 SINGH GB
CLINICAL SIGNIFICANCE AND EXPERIMENTAL STUDIES ON ANYLASE A REVIEW
INDIAN 3 MED SOI 20, 181 (1966)
0876 SINGH HP, HEBERT MA, GAULT NH
EFFECT OF SOME DRUGS ON CLINICAL LABORATORY VALUES AS DETERMINED BY THE TECHNICON SNA 12/60
OLIN OHEM 18, 137 (1972)
0877 SKEITH MD, HEALEY LA, CUTLER RE
URATE EXCRETION DURING MANNITOL AND GLUCOSE DIURESIS
3 LAB OLIN MED 70, 213 (1967)
0878 SKEITH ND, HEALEY LA, CUTLER RE
EFFECT OF PHLORIDZIN ON URIC ACID EXCRETION IN MAN
AMER 3 PHYSIOL 219, 1080 (1970)
0879 SLAYTON RE, SHNIDER BI, ELIAS E, HORTON J, PERLIA OP
NEW APPROACH TO THE TREATMENT OF HYPEROALCEMIA: THE EFFECT OF SHORT-TERM TREATMENT WITH MITHRAMYCIN
OLIN PHARMAOOL THER 12, 833 (1971)
0880 SMITH 3W (ED)
MANUAL OF MEDICAL THERAPEUTICS 19TH ED
LITTLE BROWN S 00, BOSTON MASS (1969)
0881 SMITH NJH, SMITH PK
THE SALICYLATES. A CRITICAL BIBLIOGRAPHIC REVIEW
INTERSCIENCE, NEW YORK NY (1966)
0882 SMITH WO, KYPIAKOPOULOS AA, HAMMARSTEIN JF
MAGNESIUM DEPLETION INDUCED BY VARIOUS DiURETICS
J OKLAHOMA STATE NED ASSOC 55, 248 (1962)
0883 SMITH, KLINE AND FRENCH
MANUFACTURER’S LITERATURE ON DUCON
1500 SPRING GARDEN ST, PHILADELPHIA 191C1
0884 SOKOLOFF B, MIOHITERU H, SAELHOF 00, WRZOLEK T
AGING ATHEROSCLEROSIS AND ASCORBIC ACID METABOLISM
J AMER GERIAT SOC 14, 1239 (1966)
0885 SOLOMON NM, SCHROGIE 33
CHANGE IN RECEPTOR SITE AFFINITY: A PROPOSED EXPLANATION FOR THE POTENTIATING EFFECT OF D-THYROXINE
OLIN PHARMACOL THEF 8, 797 (1967)
0886 SOLOMON NM, BARAKAT NJ, ASHLEY CJ
MECHANISMS OF DRUG INTERACTION
J AMER MED ASS 216, 1997 (1971)
0887 SOPOINI G, SCIARPA F, DISILVERIO F, FRAIOLI F
FURTHER STUDIES ON PLASMA ANDROGENS AND GONADOTROPINS AFTER CYPROTERONE ACETATE (SN 714)
FOLIA ENDOCRINOL 24, 196 (1971)
0888 SORENSEN LB
SUPPRESSION OF THE SHUNT PATHWAY IN PRIMARY GOUT BY AZATHIOPRINE
PROC NAT ACAD 501 55, 571 (1966)
0889 SORRELL T, FORBES 13, BURNESS FR, RISCHBIETH RHO
DEPRESSION OF IMMUNOLOGICAL FUNCTION IN PATIENTS TREATED WITH PHENYTOIN SODIUM(SODIUM DIPHENYLHYDANTOIN)
LANCET 2, 1233 (1971)
0890 SPARKS LL, COPINSOHI G, DONALDSON CL ET AL
HYPERGLYCEMIC RESPONSE TO INTRAVENOUS ARGININE IN PREMATURITY-ONSET DIABETES
DIABETES 16, 268 (1967)
0891 SPELLACY WN, BUHI WO, BIRK SA, MCCREARY SA
STUDIES OF ETHYNODIOL ACETATE AND MESTRANOL ON BLOOD GLUCOSE AND PLASMA INSULIN
CONTRACEPTION 3,185 (1971)
3892 SPITTLE OP
ATHEROSCLEROSIS AND VITAMIN 0
LANOET 2, 1280 (1971)
0893 STARZL TE, PUTNAM OW, HALGRINSON OG, SCHROTER GT, MARTINEAU G, LAUNOIS B, CORMAN JL
CYCLOPHOSPHANIDE AND WHOLE ORGAN TRANSPLANTATION IN HUMAN BEINGS
SURG GYNECOL OBSTET i33, 981 (1971)
0894 STEEL CM, FRENCH EB, AITCHISON WRC
STUDIES ON ADRENALINE INDUCED LEU000YTOSIS IN NORMAL NAN
BRIT J HAEMATOL 21, 413 (1971)
0895 STEELE TN, OPPENHEIMER S
FACTORS AFFECTING UPATE EXCRETION FOLLOWING DIURETIC ADMINISTRATION IN NAN
AMER 3 MED 47, 5614 (1969)
0896 STEELE TN
CONTROL OF URIC ACID EXCRETION
NEW ENGL 3 MED 284, 1193 (1971)
0897 STEELE TB
EVIDENCE FOR ALTERED RENAL URATE REABSORPTION DURING CHANGES IN VOLUME OF THE EXTRACELLULAR FLUID
3 LAB OLIN MED 74, 288 (1969)
0898 STEER PU, MARKS MI, KLITE PD, EICKHOFF TO
5-FLUOROCYTOSINE: AN ORAL ANTIFUNGAL AGENT
0899 STEINBERG M, LEIFHEIT HO
EFFECT OF METRECAL ON SERUM-PRECIPITABLE IODINE VALUES
TEXAS REP BIOL MED 23, 122 (1965)
0900 STEVENS VC, GOLDZIEHER OW, VORYS N
EFFECT OF MESTRANOL AND OHLORMADINONE ACETATE ON URINARY EXCRETION OF ESH AND LII

1901 STONE ND
IDIOPATHIC HYPEPGLYCERIDEMIA TREATED WTIH ?IETHYLT2STOSTERON AND METHANDIENONE
LANCET 1, 1477 (1963)
092 STORM-MATHISN H
DI S CU 55 I ON
IN CATAPRES IN HYPERTENSION, CONOLLY NE (ED) BUTTEPWORTH, LONDON (1970)
09)3 STOWERS 3M, BREWSTER PD
STUDiES ON THE MECHANISM OF WEIGHT REDUCTION BY PHENFORMIN
POSTGRAD NED 3 NAY SUPPL, 13 (1969)
0904 SUKI WN, DAWOUD F, EKNOYAN G, MARTINEZ-MALDONADO M
EFFECTS OF NETOLAZONE ON RENAL FUNCTION IN NORMAL MAN
J PHARMACOL EXP THER 180, 6 (1972)
0905 SULLIVAN JF, LANKFORD HG, SCHWARTZ NJ, FARRELL 0
MAGNESIUM METABOLISM IN ALCOHOLISM
AMER 3 OLIN NUTR 13, 297 (1963)
39:6 SUMIEPSKILL WHO, THORSELL F, FEINBERG OH FT AL
FFECTS OF URFASE INHIBITION IN HYPERAMMONEMIA:OLINICAL AND EXPERIMENTAL STUDIES
GASTBOENTEROLOGY 54, 2C (1968)
0907 SUNDERMAN FW JR
DRUG INTERFERENCE IN CLINICAL BIOCHEMISTRY,
CRIT RFV OLIN LAB 501 1, 427 (1970)
D9B SUNDERNAN FW JR
MEASUREMENTS OF VANILMANDELIC ACID FOR THE DIAGNOSIS OF PHEOOHROMOOYTOMA AND NEUROBLASTOMA
‘:‘909 SUNDERMAN FW JR
COLOEMETRIC DETERMINATION OF VANILMANDELIC ACID IN URINE
2910 SUNDRMAN PW JR
sFFECTS OF DRUGS UPON HEMATOLOGICAL TESTS
ANN OF OLIN LAB 501 2, 1 (1972)
0911 SWAIMAN K?, FLAGLER DG
MERCURY POISONING WITH CENTRAL AND PERIPHERAL NERVOUS SYSTEM INVOLVEMENT TREATED WITH PENICILLAMINE
PEDIATRICS 48, 639 (1971)
912 SWEENEY GD, SAUNDERS 53, DOWDLE RB, EALES U
THE EFFECTS OF CHLOPOQUINE ON PATIENTS WITH CUTANEOUS PORPHYRIA ‘SYMPTOMATIC’ TYPE
BIT NED 0 1, 1281 (1965)
913 SWIDLER G
HANDBOOK OF DRUG INTERACTIONS
WILEY-INTERSOIENCE NEW YORK, NY 1971
0914 TAIl B
INTFRFERENCE IN IMMUNOLOGICAL METHODS OF PREGNANCY TESTING BY PRONETHAZINE
MrD 3 AUST 2, 126 (1971)
0915 TALMERS EN, TELMOS AJ
PROCAINE AMIDE HYDROCHLORIDE (PRONESTYL) INDUCED AGRANULOCYTOSIS
MICH MED 64, 655 (1965)
0916 TANNENBERG AM, WICHER KJ, ROSE NR
AMP[CILLIN NEPHROPATHY
0 AMER NED ASS 218, 449 (1971)
0917 TARAZI C, FROHLICH ED, DUSTAN HP
PLASMA VOLUME CHANGES WITH LONG-TERM BETA-ADRENERGIC BLOCKADE
AMER HEART 3 82, 770 (1971)
C918 TATRO DS
EFFECT OF ORAL CONTRACEPTIVES ON PLASMA MINERALS AND PROTEIN
HOSP FORM MANAGLIENT 6, 14 (1971)
2919 TAUBEPT HO, HASKINS AL, MOSZKOWSKI EF
THE INFLUENCE OF THIORIDAZINE UPON URINARY GONADOTROPIN EXCRETION
SOUTH MED 3 59, 13C1 (1966)
0920 TERRAGNA A, SPIRITO L
PORPORA TROMBOCITOPENICA IN LATTANTE DOPO SOMNINISTRAZIONE DI ACIDO ACETILSALICILICO ALLA NUTRICE
MINERVA PEDIAT 19, 613 (1967)
3921 TERRY SI
TRANSIENT DYSAESTHESIAE AND PERSISTENT LEU000YTOSIS AFTER CLIOQUINOL THERAPY
BRTI MED 3 3, 745 (1971)
7922 THENOT A
HYDROOHLOROTHIAZIDE CONTRE PANCREAS
PPESSE MED 71, 572 (1963)
0923 THIERS RE
MAGNESIUM (FLUORONETRIC)
STAND METH OLIN OHEM 5, 131 (1965)
1924 THOMAS DV, EDWARDS JB, EDWARDS PG
EXAMINATION OF XYLITOL
NEW ENGL 3 MED 283, 437 (1970)
D925 THOMAS S
EFFECTS OF CHANGE OF POSTURE ON THE DIURNAL RENAL EXCRETORY RHYTHM
0 PHYSIOL 148, 489 (1959)
0926 THOMPSON RHS, WOOTON lOP
BIOCHEMICAL DISORDERS IN HUMAN DISEASE 3RD ED
ACADEMIC PRESS, NEW YORK (1971)
0927 THORNTON GHM, ILLINGWORTH DG
AN EVALUATION OF THE BENZIDINE TEST FOR OCCULT BLOOD IN THE iAECES
GASTROENTEPOLOGY 28, 593 (1955)
0928 THRIFT CB
ACUTE SALIOYLATE INTOXICATION: EFFECT ON THE DIRECT EOSINOPHIL COUNT
ILLINOIS NED 3 128, 39 (1965)
0929 TIETZ NW ED
FUNDAMENTALS OF CLINICAL CHEMISTRY
0930 TISCHENDORF FW, LEDDEROSE G, MULLER D, WILMANNS V
HEAVY LYSOZYMUIA AFTER X-RADIATION OF THE SPLEEN IN HUMAN CHRONIC NYELOCYTIC LEUKAENIA
NATURE 235, 274 (1972)

0931 TO3E BA, GOLDMAN BS
THE METABOLISM OF THE VOLATILE AMINES: THE POLE OF DRUGS IN THE ?ATHOGENESIS OF HEPATIC ENCEPHALOPATHY
CANAD NED ASS 3 89, 8714 (1963)
0932 TODAY’S DRUGS
ANTIHISTAMINES, MECHANISM OF ACTION
RRIT MED 3 2, 1642 (1963)
0933 TODAY’ S ORUGS
TODAY’S DRUGS DRUGS FOR RHEUMATOID DISORDERS
BRIT MED 3 1, 545 (1964)
0934 TOKUYAMA I, LEACH RB, SHEINFELD 5, MADDOCK NO
DEPRESSION OF GONADOTPCPIN EXCRETION AS A METHOD FOR ASSAY OF ESTROGENS IN HUMAN SUBJECTS
0935 TOMKIN GH, IIADDEN DR, WEAVER JA, MONTGOMERY DAD
VITAMIN P12 STATUS OF PATIENTS ON LONG TERM METFORMIN THERAPY
BIT NED 3 2, 685 (197)
0936 TONPSETT SL
INTERFERENCE FROM THE PRESENCE OF OTHER SUBSTANCES IN DETECTING AND DETERMINING BARBITURATES
3 OLIN PATH 22, 291, (1969)
0937 TRASOFF A, WOHL MG, ?IINTZ 55
FATAL AGRANULOCYTOSIS WITH AUTOPSY FOLLOWING THE USE OF THIOUBACIL IN A CASE OF THYROTOXICOSIS
AMER 3 NED 501 211, 62 (1946)
0938 TRAVIS SF, SUGERMAN NJ, RUBERG RU, DUDRICK SO, DELIVORIA-PAPADOPOULOS N, MILLER LD, OSKI FA
ALTERATIONS OF RED-CELL GLYCOLYTIC INTERMEDIATES AND OXYGEN TRANSPORT AS A CONSEQUENCE OF HYPOPHOSPHATEMIA
NEW ENGL 3 NED 285, 763 (1971)
0939 TRYDING N, TUFVESSON G, NILSSON S
SERUM-NONOAMINE-OXIDASE LEVELS DURING LEVODOPA THERAPY
LANCET 1, 859 (1971)
0940 TUCCI OR, ESPINER EA, JAGGER P1 FT AL
VASOPRESSIN IN THE EVALUATION OF PITUITARY-ADRENAL FUNCTION
O9L&1 TUNMISTO T AIRAKSINEN MM
INCREASE OF OREATINE KINASE ACTIVITY IN SERUM CAUSED BY INTERMITTENTLY ADMINISTERED SUXAMETHONIUM
SPIT 3 ANAESTH 38, 510 (1966)
0942 TURKINGTON VE, NIXON JO, CAMPBELL 35, HURTEAU GD
EFFECT OF A LONG-ACTING STEROID CONTRACEPTIVE (MEDOXYPROGESTERONE ACETATE) ON HUMAN FEMALE SUBJECTS
CLIN CHEM 17, 667 (1971)
0943 TUPKINGTON RW
PHENOTHIAZINE STIMULATION TEST FOR PROLACTIN RESERVE: THE SYNDROME OF ISOLATED PROLACTIN DEFICIENCY
0944 TURTLE JT, BURGESS JA, BAUOKHAN S
THE METABOLIC EFFECTS OF FENFLUPANINE
S APR MED 3 SUPPL 44, 23 (1971)
0945 TYNES PS
THE CLINICAL USE OF AMPHOTERICIN B
G 32, 97 (1965)
0946 TYSELL JE OR, KNAUER ON
HEPATITIS INDUCED BY METHYLDOPA(ALDOMET) REPORT OF A CASE AND REVIEW OF THE LITERATURE
AMER 3 DIG DIS 16, 849 (1971)
0947 UDALL JA
DRUG INTERFERENCE WITH WARFARIN THERAPY
OLIN MED 77, 20 (1970)
09148 UPJOHN AC, GALBRAITH H-JB, SOLOMONS B
RAISED SERUM PROTEIN BOUND IODINE AFTER TOPICAL CLIOQUINOL
POSTGRAD MED 3 47, 515 (1971)
0949 UPJOHN COMPANY
LITERATURE ON OLEOCIN
7171 PORTAGE PD, KALAMAZOO, MICHIGAN 49001
0950 UTIGER RD
IN CURRENT TOPICS ON THYROID RESEARCH
CASSANO 0, ANDREOLI N (EDS) ACADEMIC PRESS NEW YORK (1965)
0951 VALDES OS, MAURER NM, SHUMWAY ON, DRAPER DA, HOSSAINI AA
CONTROLLED CLINICAL TRIAL OF PHENOBARBITAL AND/OR LIGHT IN REDUCING NEONATAL HYPERBILIRUBINEMIA
0 PEDIAT 79, 1015 (1971)
0952 VAN DAM FE, OVERKAMP N, HAANEN C
THE INTERACTION OF DRUGS
LANCET 2, 1027 (1966)
0953 VAN DER WEERDT ON
THPOMBOOYTOPENIA DUE TO QUINIDINE OP QUININE
VOX SANG (BASEL) 12, 265 (1967)
095L1 VAN DEE VELDE CD, GORDON MW
MANIC-DEPRESSIVE ILLNESS, DIABETES NELLITUS, AND LITHIUM CARBONATE
ARCH GEN PSYCHIAT 21, 478 (1969)
0955 VAN PEENEN MO, FILES 33
THE EFFECT OF MEDICATION ON LABORATORY TEST RESULTS
AMER 3 OLIN PATH 52, 666 (1969)
0956 VAN PRAAG HM, LEIJNSE B
THE XYLOSE METABOLISM IN DEPRESSED PATIENTS ANDITS ALTERATION UNDER THE INFLUENCE OF ANTIDEPRESSIVE HYDRAZINES
0957 VANDAM LD
ANALGETIC DRUGS - THE MILD ANALGETICS
NEW ENGL 3 MED 286, 20 (1972)
0958 VERSONUPE 3CM
CLINICAL USE OF MEASUREMENTS OF CLEARANCE AND MAXIMUM CAPACITY OF THE LIVER
ACTA MED SCAND 142, 409 (1952)
0959 VEBSTER FDEB, GAROUTTE 3, ICHINOSA H, GUERRERO-?IGUEROA P
MODE OF ACTION OF DIPHENYLHYDANTOIN
FED PROC 24, 390 (1965)
0960 VESELL ES, PASSANANTI GT, GREENE FE
IMPAIRMENT OF DRUG METABOLISM IN MAN BY ALLOPURINOL AND NORTRIPTYLINE
NEW ENGL 3 MED 283, 1484 (1970)

0961 VIGLIANI EC
BIOLOGICAL EFFECTS OF NITROGLYOOL ON THE METABOLISM OF CATECHOLANINES
0962 VILLAPPEAL H, APOILA H, RAMIREZ NA, SIERRA P
EFFECT OF GUANCYDINE ON SYSTEMIC AND RENAL HEMODYNAMICS IN ARTERIAL HYPERTENSION
0963 VORYS N, ULLERY JO, STEVENS V
THE EFFECTS OF SEX STEROIDS ON GONADOTROPINS
0964 WACHTER 3P, SMEBY PR, FREE AH
URINALYSIS AND ORAL HYPOGLYCEMIC AGENTS.
AMER 3 NED TECHNOL 26, 125 (1960)
0965 WACKER WEC, PAPIST A?
MAGNESIUM METABOLISM
NEW ENGL 3 NED 278, 712 (1968)
0966 WAISBREN BA, EVANI SV, ZIEBEPT A?
CARBENCILLIN AND BLEEDING
J AMER MED ASS 217, 1243 (1971)
0967 WALES JE, WOLFF F
HEMATOLOGICAL SIDE-EFFECTS OF DIAZOXIDE
LANCET 1, 53 (1967)
0968 WALKER FA
AMMONIA IN FIBRIN HYOROLYSATES
NEW ENGL 3 MED 285, 1324 (1971)
0969 WALKER BA, EZE LO, TWEEDIE MCK, PRICE EVANS DA
THE INFLUENCE OF ABO BLOOD GROUPS, SECRETOR STATUS AND FAT INGESTION ON SERUM ALKALINE PHOSPHATASE
0970 WALKER, 3G
FATAL AGRANULOCYTOSIS COMPLICATING TREATMENT WITH ETHACRYNIC ACID
0971 WALLACE FE, SILVERBERG HI, CARTER AC
EFFECT OF ETHINYL ESTRADIOL ON PLASMA 17-OH COBTICOSTEBOIDS, ACTH RESPONSIVENESS AND HYDR000?TISONE CLEARANCE
PROC 500 EXPTL BIOL MED 95, 805 (1957)
0972 WALLACE SL, NISSEN AN
GRISEOFULVIN IN ACUTE GOUT
NEW ENGL 3 NED 266, 1099 (1962)
0973 WALLACH 3
INTERPRETATION OF DIAGNOSTIC TESTS
LITTLE BROWN 8 00, BOSTON MASS (1970)
0974 WANKA 3, JONES LI, WOOD PHN, DIXON ASJ
INDONETHACIN IN RHEUMATIC DISEASES
ANN RHEUN DIS 23, 218 (19614)
0975 WATSON 03
THE PROBLEM OF PORPHYRIA - SOME FACTS AND QUESTIONS
NEW ENGL 3 MED 263, 1205 (1960)
0976 WAXMAN 5, CORCINO JJ, HERBERT V
DRUGS, TOXINS AND DIETARY AMINO ACIDS AFFECTING VITAMIN 612 OR FOLIO ACID ABSORPTION OR UTILIZATION
AMER 3 MED 148, 599 (1970)
0977 WEBSTER PD, ZIEVE U
ALTERATIONS IN SERUM CONTENT OF PANCREATIC ENZYMES
NEW ENGL 3 MED 267, 604 (1962)
0978 WEISS P, BIANOHINE JR
THE EFFECT ON SERUM T000PHEROL LEVELS ON DRUG-INDUCED DECREASE IN SERUM LIPIDS
AMER J NED SOT 258, 275 (1971)
0979 WEISSMAN PH, SHERKNAN L GREGERMAN RI
CHLORPROPAMIDE HYPONATRENIA
NEW ENGL J MED 284, 65 (1971)
0980 WENNBERG OF, OKUN, R, HINMAN E3, NORTHOUTT PC, GRIEP P0, WALKER WG
RENAL TOXICITY OF ORAL OHOLECYSTOGRAPHIC MEDIA
3 AMER MED ASS 186, 461 (1963)
0981 WERK ER OR, MACGEE 3, SHOLITON U
EFFECT OF DIPHENYLHYDANTOIN ON CORTISOL METABOLISM IN MAN
3 OLIN INVEST 43, 18214 (1964)
0982 WERTALIK LF, METZ EN, LOBUGLIO A?, BALCERZAK SP
DECREASED SERUM B12 LEVELS SECONDARY TO ORAL CONTRACEPTIVE AGENTS
AMER J OLIN NUTR 24, 603 (1971)
0983 WEST CD, DAMAST BL, SARRO SD, PEARSON ON
CONVERSION OF TESTOSTERONE TO ESTROGENS IN CASTRATED, ADRENALECTOMIZED HUMAN FEMALES
3 BIOL CHEM 218, 409 (1956)
0984 WHILE LUR
FATAL MARROW APLASIA DUPING CHLORPROPAMIDE THERAPY
BRIT MED 3 1, 69 (1962)
0985 WHITE MG, ASCH NJ
ACID-BASE EFFECTS OF TOPICAL MAFENIDE ACETATE IN THE BURNED PATIENT
NEW ENGU 3 MED 284, 1281 (1971)
0986 WIEDEPHOLT IC, GENCO N, FOLEY 3M
RECURRENT EPISODES OF HYPOGLYCEMIA INDUCED BY PROPOXYPHENE
NEUROLOGY 17, 703 (1967)
0987 NIEGAND SE, OOPENAN PW?I, PERRY HO
METABOLIC ALKALINIZATION IN PORPHYRIA CUTANEA TARDA
ARCH DERNATOL 100, 544 (1969)
0988 WIGLEY RD
ASPIRIN AND THE KIDNEY
N Z MED 3 74, 301 (1971)
0989 WIJNJA U L, SNIJDER JA, NIEWIG HO
ACETYLSALICYLIC ACID AS A CAUSE OF PANCYTOPENIA FROM BONE MARROW DAMAGE
LANCET 2, 768 (1966)
0990 WILKINSON JR
AN INTRODUCTION TO DIAGNOSTIC ENZYNOLOGY
ARNOLD LONDON (1962)

:991 WILLIAMSON 3M, GIBBS WN
HYPOPLASTIC ANAEMIA AND HYDROFLUMETHIAZIDE
SCOT NED 3 11, 19 (1966)
0992 WiLSON IC, GAMBILL 3M, SANDIFIER MG JR
A DOUBLE BLIND STUDY COMPARING IMIPRAMINE (TOFRANIL) WITH DESNETHYLINIPRANINE (PEPTOFRANE)
PSYCHOSOMATICS 5, 88 (1964)
:993 WILSON PA, DIETSCHY JM
DIFFERENTIAL DIAGNOSTIC APPROACH TO CLINICAL PROBLEMS OF MALABSORPTION
0994 WILSON OS, KIRKENDALL NM
THE ACUTE EFFECTS OF MEFRUSIDE IN MAN: A NEW DIURETIC COMPOUND
J PHAPMACOL EXP THER 173, 288 (1970)
C995 WILSON WL, BISEL HF, COLE 0, ROCHLIN D, RAMIREZ G, MADDEN P
PROLONGED LOW-DOSAGE ADMINISTRATION OF HEXAMETHYLMELAMINE (NC 13875)
CANCER 25, 568 (1970)
0996 WINEK CL, SCHWEIGHARDT FK, FOCHTMAN PS, COLLAN ND
QUININE IN URINALYSIS FOR HEROIN
3 AMER MED ASS 217, 1243 (1971)
0997 WINIKOFF 0
ORAL CONTRACEPTIVES AND THYROID FUNCTION TESTS, THE DIAGNOSiS OF THYROID DISEASE
NED 3 AUST 1, 1059 (1971)
998 WINSTEN S
COLLECTION AND PRESERVATION OF SPECIMENS
0999 WINTHROP LABORATORIES
MANUFACTURER’S LITERATURE ON NEGGRAN
90 PARK AVENUE, NEW YORK NY 10016
1000 WINTROBF MM
CLINICAL HEMATOLOGY 6TH ED
LEA & FEBIGER, PHILADELPHIA (1967)
ic:’i WIRTH WA, THOMPSON RL
THE EFFECT 0? VARIOUS CONDITIONS AND SUBSTANCES ON THE RESULTS OF LABORATORY PROCEDURES
AMER 3 OLIN PATROL 43, 579 (1965)
1002 WISE PH
OLOPAMIDE AND CARBOHYDRATE METABOLISM
MED 3 AUST 2, 795 (1969)
1C3 WOLCOTT GO, HACKETT TN JR
LEV000PA AND TESTS FOR KETONURIA
NEW ENGL 3 NED 283, 1522 (1970)
1024 WOLPERT E, PHILLIPS SF, SUMMERSKILL WH
AMMONIA PRODUCTION IN THE HUMAN COLON: EFFECTS OF CLEANSING, NEOMYCIN AND ACETOHYDROXANIC ACID (AHA)
NEW ENGL 3 MED 283, 159 (1970)
10C.5 WOOD PC, CAHILL GE
MANNOSE UTILIZATION IN MAN
3 OLIN INVEST 42, 13CC (1963)
1006 WOODS 3W, AJZEN H
EFFECT OF RESERPINE AND GUANETHIDINE ON EXCRETION OF 3-METHOXY-4-HYDROXYMANDELIO ACID IN MAN
10T7 WORLD HEALTH ORG
EXPPRT COMMITTEE ON MALARIA - REPORT
WLD HLTH ORG TEOHN REP SER 324, 38 (1966)
ic:s WRIGHT N, OLARKSON AR, BROWN 55, FUSTER V
EFFECTS OF POiSONING ON SERUM ENZYME ACTIVITIES, COAGULATION AND FIBRINOLYSIS
BRIT MED 3 3, 347 (1971)
1009 WRIGHT NP, RAINWATER JO, TOLLE LD
GLUCOSE ASSSAY SYSTEMS: EVALUATION OF A COLORIMETPIO HEXOKINASE PROCEDURE
OLIN CHEM 17, 1010 (1971)
1010 YAFFE SO, FILER U JR
THE USE AND ABUSE OF VITAMIN A
1011 YALOW PS, BERSON SA
IMMUNOASSAY OF ENDOGENOUS PLASMA INSULIN IN MAN
3 OLIN INVEST 39, 1157 (1960)
1012 YEN 550, TSAI 00
THE BIPHASIC PATTERN IN THE FEEDBACK ACTION OF ETHINYL ESTRADIOL ON THE RELEASE OF PITUITARY FSH AND LH
0 OLIN EN000RINOL 33, 882 (1971)
1013 YEUNG CY, YU VYH
PHENOBARBITONE ENHANOEME NT OF BRON SULFALEI N CLEARANCE IN NEONATAL HYPERBILIRUBINEMIA
1C14 YOSHINURA N, KODANA K, YOSHITAKE 0
CARBOHYDRATE METABOLISM AND INSULIN RELEASE DURING ETHER AND HALOTHANE ANAESTHSIA
BRIT J ANAESTH 43, 1022 (1971)
1015 YOUNG DS
PERSONAL OBSERVATION
1016 YOUNG MM, JASANI C, SMITH DA ET AL

SOME EFFECTS OF ETHINYL ESTRADIOL ON CALCIUM AND PHOSPHORUS METABOLISM IN OSTEOPOROSIS
OLIN 501 34, 411 (1968)
1017 YOUNG PC, NACHNAN RI, HOROWITZ HI
THROMBOCYTOPENIA DUE TO DIGITOXIN
AMER 3 MED 41, 605 (1966)
1C18 YU TF, BERGER U, GUTMAN AB
HYPOGLYCEMIC AND URICOSURIC PROPERTIES OF ACETOHEXAMIDE AND HYDROXYHEXAMIDE
1019 YU T, SIPOTA 3M, BERGER L FT AL
EFFECT OF SODIUM LACTATE INFUSION ON URATE CLEARANCE IN MAN
1020 YU TF, KAUNG C, GUTMAN AR
EFFECT OF GLYOINE LOADING ON PLASMA AND URINARY URIC ACID AND AMINOACIDS IN NORMAL AND GOUTY SUBJECTS
AMER 3 MED 49, 352 (1970)

1021 ZAK B, WILLARD HH, MYERS GB, BOYLE A3
OHLORIC ACID METHOD FOR DETERMINATION OF PROTEIN-BOUND IODINE
ANAL CHEM 24, 1345 (1952)
1022 ZAREMBSKI PM, HODGKINSON A, COCHRAN N
TREATMENT OF PRIMARY HYPEROXALURIA WITH CALCIUM CARBIMIDE
NEW ENGL 3 MED 277, 1000 (1967)
1C23 ZERNECHEL CF
AMINOPYRINE AND AGRANULOCYTOSIS: REVIEW AND REPORT OF SIX CASES
N C MED 3 28, 91 (1967)
1024 ZIPORIN ZZ, CHAMBERS OS, TAYLOR PR, WIER JA
THE EFFECT Oi ISONIAZID ADMINISTRATION ON THE BLOOD AMMONIA IN TUBERCULOUS PATIENTS
AMER REV RESP DIS 86, 21 (1962)
1025 ZIR LN, PARKE3 DO, SMITH PA, ROSSNAN LG
THE RELATIONSHIP OF HUMAN GROWTH HORMONE AND PLASMA TYROSINE DURING SLEEP
1026 ZONDAG HA, VAN BOETZELAER GL
DETERMINATION OF PROTEIN IN CEREBROSPINAL FLUID SOURCES OF ERROR IN THE LOWRY METHOD
1027 ZSIGMOID EK, ROBINS G
THE EFFECT OF A SERIES OF ANTI-CANCER DRUGS ON PLASMA CHOLINESTERASE ACTIVITY
CANAD ANAESTH SOC 3 19, 75 (1972)
1028 ZUOK TP, BERGIN JO, RAYMOND 3M, DIVYPE NB
IMPLICATIONS OF DEPRESSED ANTITHROMBIN III ACTIVITY ASSOCIATED WITH ORAL CONTRACEPTIVES
SURG GYNECOL OBSTET 133, 609 (1971)
1029 ZUOKER MB
SOME EFFECTS OF DISODIUM ETHYLENEDIAMINE TETRAACETATE ON BLOOD COAGULATION
1030 ZUSPAN FP, TALLEDO 01, CHESLEY LO
ANGIOTENSIN AND NOREPINEPHRINE INFUSIONS DUPING PREGNANCY: ALTERATIONS IN PLASMA EPINEPURINE AND NOREPINEPHRINE

Effects of Drugs On Clinical Laboratory Tests DS Young

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Effects of Drugs On Clinical Laboratory Tests DS Young

Uploaded by

Copyright:

Available Formats

Effects of

CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972 1041

1042 CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972 1043

1044 CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972 1045

BELLADONNA* (BELLADONNA ALKALOIDS) (BELLADONNA EXTRACT) (BELLADONNA LEAF) (HYOSCYANINE) (ATROPINE*)

1046 CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972 1047

1048 CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972 1049

GALLAMINE*(GALLAMINE TRIETHIODIDE) (FLAXEDIL)

1050 CLINiCAL CHEMISTRY, Vol. 18, No. 10, 1972

IODOPYRAET*(DIODRAST) (PYLtJNBRINE) (PYELOMBRINE) (DIODONE) (PERIODIL) (PYELOSIL) (UROGRAF) (VASIODONE)

LAXATIVES* (BISACODYL*) (CASCARA*) (CASTOR OIL*) (DANTHRONt) (GLYCERIN SUPPOSITORIES) (OXYPHENISATIN*)

CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972 1051

1052 CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972 1053

1054 CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

PROMAZINEt (PROMAZINE HYDROCHLORIDE) (SPARINE)

CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972 1055

RAUWOLFIA*(AJMALINEt) (RESERPILINE) (SERPENTINE)

1056 CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972 1057

105$ CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972 1059

1060 CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972 1061

1062 CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972 1063

1064 CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972 1065

1066 CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972 1067

1068 CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

CLINICAL CHEMISTRY, Volt 18, No. 10, 1972 1069

1070 CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972 1071

1072 CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972 1073

1074 CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972 1075

1076 CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972 1077

1078 CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972 1079

1080 CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

CLiNICAL CHEMISTRY, Vol. 18, No. 10, 1972 1081

1082 CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972 1083

1084 CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972 1085

1086 CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972 1087

1088 CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972 1089

1090 CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972 1091

1092 CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972 1093

1094 CLINICAL CHEM1STRY, Vol. 18, No. 10, 1972

CLINIcAL CHEMISTRY, Vol. 18, No. 10, 1972 1095

1096 CLINICAL CHEMISTRY, Vol. 18, No. 10, 1972

LAXATIVES* (BISACODYL) (CASCARA) (CASTOR OIL) (DANTHRONt) (GLYCERIN SUPPOSITORIES) (OXYPHENISATIN)